### NN 143/2022 (8.12.2022.), Odluka o utvrđivanju Osnovne liste lijekova Hrvatskog zavoda za zdravstveno osiguranje

Hrvatski zavod za zdravstveno osiguranje

2176

Na osnovi članka 20. stavka 7. Zakona o obveznom zdravstvenom osiguranju (»Narodne novine«, broj 80/13., 137/13. i 98/19.) i članka 26. točke 10. Statuta Hrvatskog zavoda za zdravstveno osiguranje (»Narodne novine«, broj 18/09., 33/10., 8/11., 18/13., 1/14., 83/15. i 108/21.), Upravno vijeće Hrvatskog zavoda za zdravstveno osiguranje na 64. sjednici održanoj 30. studenoga 2022. godine, uz prethodno pribavljeno mišljenje Hrvatske liječničke komore, donijelo je

ODLUKU

O UTVRĐIVANJU OSNOVNE LISTE LIJEKOVA HRVATSKOG ZAVODA ZA ZDRAVSTVENO OSIGURANJE

Članak 1.

(1) Ovom Odlukom utvrđuje se Osnovna lista lijekova Hrvatskog zavoda za zdravstveno osiguranje (u daljnjem tekstu: Osnovna lista lijekova) koja, u skladu s člankom 20. stavkom 3. Zakona o obveznom zdravstvenom osiguranju (»Narodne novine«, broj 80/13., 137/13. i 98/19.) sadrži popis lijekova koji se osiguranim osobama Hrvatskog zavoda za zdravstveno osiguranje (u daljnjem tekstu: Zavod) u cijelosti osiguravaju u okviru prava na zdravstvenu zaštitu iz obveznoga zdravstvenog osiguranja.

(2) Ovom Odlukom utvrđuje se i Osnovna lista magistralnih pripravaka.

Članak 2.

(1) Lijekovi utvrđeni Osnovnom listom lijekova primjenjuju se u okviru zdravstvene zaštite iz obveznoga zdravstvenog osiguranja koja se provodi u djelatnosti na primarnoj, sekundarnoj i tercijarnoj razini te na razini zdravstvenih zavoda.

(2) Osnovna lista lijekova sadrži sljedeće podatke: šifru anatomsko-terapijsko-kemijske (ATK) klasifikacije lijekova Svjetske zdravstvene organizacije, oznake, nezaštićeno ime lijeka (INN), definiranu dnevnu dozu (DDD) i jedinicu mjere, cijenu lijeka za definiranu dnevnu dozu, način primjene lijeka, naziv nositelja odobrenja, naziv proizvođača, zaštićeno ime lijeka, oblik, jačinu i količinu prema pakiranju lijeka, cijenu za jedinicu oblika lijeka, cijenu za originalno pakiranje lijeka, oznaku »R« i »RS« te stopu poreza na dodanu vrijednost (u daljnjem tekstu: PDV).

(3) Oznaka uz nezaštićeno ime lijeka označava medicinske indikacije osnovom kojih osigurana osoba ima pravo na korištenje pojedinog lijeka iz Osnovne liste lijekova na teret sredstava obveznoga zdravstvenog osiguranja te pravila njihove primjene prilikom korištenja zdravstvene zaštite na svim razinama zdravstvene djelatnosti.

(4) Oznaka uz »R« i »RS« označava smjernicu propisivanja lijeka osnovom kojih osigurana osoba ima pravo na korištenje pojedinog lijeka iz Osnovne liste lijekova na teret sredstava obveznoga zdravstvenog osiguranja te pravila njihovog propisivanja na recept.

(5) Osnovna lista lijekova sastavni je dio ove Odluke.

Članak 3.

(1) Osnovna lista magistralnih pripravaka sadrži sljedeće podatke: šifru anatomsko-terapijsko-kemijske (ATK) klasifikacije lijekova Svjetske zdravstvene organizacije, naziv pripravka, cijenu za originalno pakiranje lijeka, oznaku »R« ili »RS« te stopu PDV-a.

(2) Osnovna lista magistralnih pripravaka sastavni je dio ove Odluke.

Članak 4.

(1) Na lijekove utvrđene Osnovnom listom lijekova i Osnovnom listom magistralnih pripravaka obračunava se i plaća PDV po stopi od 5 %, u skladu s propisima kojima se uređuje PDV.

(2) Iznimno od stavka 1. ovoga članka PDV se ne obračunava i plaća na punu krv pod ATK šifrom »V07AC01 911« i na punu krv za autolognu transfuziju pod ATK šifrom »V07AC01 912«.

Članak 5.

(1) Danom stupanja na snagu ove Odluke prestaje važiti Odluka o utvrđivanju Osnovne liste lijekova Hrvatskog zavoda za zdravstveno osiguranje (»Narodne novine«, broj 77/22. i 82/22. – ispravak, 90/22., 112/22., 115/22. – ispravak i 132/22.).

(2) Na dan uvođenja eura kao službene valute u Republici Hrvatskoj prestaju važiti »Osnovna lista lijekova s cijenama u kunama – 1. dio«, »Osnovna lista lijekova s cijenama u kunama – 2. dio«, »Osnovna lista lijekova s cijenama u kunama – 3. dio«, »Osnovna lista lijekova s cijenama u kunama – 4. dio« iz članka 2. stavka 5. ove Odluke i »Osnovna lista magistralnih pripravaka s cijenama u kunama« iz članka 3. stavka 2. ove Odluke.

Članak 6.

Ova Odluka stupa na snagu petnaestoga dana od dana objave u »Narodnim novinama«, osim »Osnovna lista lijekova s cijenama u eurima – 1. dio«, » Osnovna lista lijekova s cijenama u eurima – 2. dio«, »Osnovna lista lijekova s cijenama u eurima – 3. dio«, »Osnovna lista lijekova s cijenama u eurima – 4. dio« iz članka 2. stavka 5 ove Odluke i »Osnovna lista magistralnih pripravaka s cijenama u eurima« iz članka 3. stavka 2. ove Odluke koje stupaju na snagu na dan uvođenja eura kao službene valute u Republici Hrvatskoj.

Klasa: 025-04/22-01/268

Urbroj: 338-01-01-22-01

Zagreb, 30. studenoga 2022.

Predsjednik
 Upravnog vijeća Hrvatskog zavoda
 za zdravstveno osiguranje
 prof. dr. sc. Drago Prgomet, dr. med. spec., v. r.

Osnovna lista lijekova s cijenama u kunama – 1. dio

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena u kn za DDD (bez PDV-a) | Način primjene | Nositelj  odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena u kn za jed, obl. (bez PDV-a) | Cijena u kn za orig. pak. (bez PDV-a) | R/RS | Stopa PDV-a |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. |
| A01AB12 451 | DS | heksetidin |  |  | O |  |  |  |  |  |  |  | 5% |
| A01AD11 263 |  | polivinil-pirolidon + natrij-hijalurat + gliciretinična kiselinaNA101 |  |  | L | Helsinn Birex Pharmaceuticals Ltd. | Helsinn Healthcare SA | Gelclair | gel oralni konc., boč. 1x180 ml | 226,65 | 226,65 | RSRA01 | 5% |
| A02BA02 051 | DS | ranitidin | 0,3 g |  | P |  |  |  |  |  |  |  | 5% |
| A02BA03 141 |  | famotidin | 40 mg | 1,86 | O | Alkaloid d.o.o. | Alkaloid | Famosan | tbl. 20x20 mg | 0,93 | 18,60 | R | 5% |
| A02BA03 142 |  | famotidin | 40 mg | 1,81 | O | Alkaloid d.o.o. | Alkaloid | Famosan | tbl. 10x40 mg | 1,81 | 18,07 | R | 5% |
| A02BC01 112 |  | omeprazol | 20 mg | 1,01 | O | Belupo d.d. | Belupo | Target plus | caps. 28x20 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC01 118 |  | omeprazol | 20 mg | 1,01 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ortalox | caps. 28x20 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC01 131 |  | omeprazol | 20 mg | 1,01 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ultop | caps. 14x20 mg | 1,01 | 14,16 | RRA02 | 5% |
| A02BC01 134 |  | omeprazol | 20 mg | 0,77 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ultop | caps. 28x40 mg | 1,53 | 42,93 | RRA02 | 5% |
| A02BC01 135 |  | omeprazol | 20 mg | 1,01 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ultop | caps. 28x20 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC02 011 | DS | pantoprazolNA201 | 40 mg | 18,04 | P | Belupo d.d. | Belupo | Zoltex | praš. za otop. za inj., boč. stakl. 1x40 mg | 18,04 | 18,04 |  | 5% |
| A02BC02 021 | DS | pantoprazolNA201 | 40 mg | 24,74 | P | Sandoz d.o.o. | Sandoz-Lek | Pantoprazol Sandoz | praš. za otop. za inj., boč. stakl. 1x40 mg | 24,74 | 24,74 |  | 5% |
| A02BC02 030 | DS | pantoprazolNA201 | 40 mg | 24,74 | P | KRKA-FARMA d.o.o. | Krka d.d. | Nolpaza | praš. za otop. za inj., boč. 1x40 mg | 24,74 | 24,74 |  | 5% |
| A02BC02 072 | DS | pantoprazolNA201 | 40 mg | 14,61 | P | Apta Medica International d.o.o. | Sofarimex Indústria Quimica e Farmaceutica S.A. | Pantoprazol AptaPharma | praš. za otop. za inj., boč. stakl. 10x40 mg | 14,61 | 146,12 |  | 5% |
| A02BC02 101 |  | pantoprazol | 40 mg | 1,05 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zipantola | tbl. 28x20 mg | 0,52 | 14,63 | RRA02 | 5% |
| A02BC02 102 |  | pantoprazol | 40 mg | 0,94 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zipantola | tbl. 56x20 mg | 0,47 | 26,34 | RRA02 | 5% |
| A02BC02 103 |  | pantoprazol | 40 mg | 1,01 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zipantola | tbl. 14x40 mg | 1,01 | 14,16 | RRA02 | 5% |
| A02BC02 104 |  | pantoprazol | 40 mg | 1,01 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zipantola | tbl. 28x40 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC02 111 |  | pantoprazol | 40 mg | 1,05 | O | Belupo d.d. | Belupo | Zoltex | tbl. 28x20 mg | 0,52 | 14,63 | RRA02 | 5% |
| A02BC02 112 |  | pantoprazol | 40 mg | 0,94 | O | Belupo d.d. | Belupo | Zoltex | tbl. 56x20 mg | 0,47 | 26,34 | RRA02 | 5% |
| A02BC02 114 |  | pantoprazol | 40 mg | 1,01 | O | Belupo d.d. | Belupo | Zoltex | tbl. 28x40 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC02 121 |  | pantoprazol | 40 mg | 1,05 | O | Sandoz d.o.o. | Sandoz-Lek | Acipan | tbl. žel. otp. 28x20 mg | 0,52 | 14,63 | RRA02 | 5% |
| A02BC02 122 |  | pantoprazol | 40 mg | 0,94 | O | Sandoz d.o.o. | Sandoz-Lek | Acipan | tbl. žel. otp. 56x20 mg | 0,47 | 26,34 | RRA02 | 5% |
| A02BC02 123 |  | pantoprazol | 40 mg | 1,01 | O | Sandoz d.o.o. | Sandoz-Lek | Acipan | tbl. žel. otp. 14x40 mg | 1,01 | 14,16 | RRA02 | 5% |
| A02BC02 124 |  | pantoprazol | 40 mg | 1,01 | O | Sandoz d.o.o. | Sandoz-Lek | Acipan | tbl. žel. otp. 28x40 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC02 126 |  | pantoprazol | 40 mg | 1,05 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Zoprax | tbl. žel. otp. 28x20 mg | 0,52 | 14,63 | RRA02 | 5% |
| A02BC02 127 |  | pantoprazol | 40 mg | 0,94 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Zoprax | tbl. žel. otp. 56x20 mg | 0,47 | 26,34 | RRA02 | 5% |
| A02BC02 128 |  | pantoprazol | 40 mg | 1,01 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Zoprax | tbl. žel. otp. 28x40 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC02 129 |  | pantoprazol | 40 mg | 0,91 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Zoprax | tbl. žel. otp. 56x40 mg | 0,91 | 50,96 | RRA02 | 5% |
| A02BC02 131 |  | pantoprazol | 40 mg | 1,05 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 28x20 mg | 0,52 | 14,63 | RRA02 | 5% |
| A02BC02 132 |  | pantoprazol | 40 mg | 0,94 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 56x20 mg | 0,47 | 26,34 | RRA02 | 5% |
| A02BC02 133 |  | pantoprazol | 40 mg | 1,05 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 30x20 mg | 0,52 | 15,68 | RRA02 | 5% |
| A02BC02 134 |  | pantoprazol | 40 mg | 0,94 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 60x20 mg | 0,47 | 28,22 | RRA02 | 5% |
| A02BC02 135 |  | pantoprazol | 40 mg | 1,01 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 14x40 mg | 1,01 | 14,16 | RRA02 | 5% |
| A02BC02 136 |  | pantoprazol | 40 mg | 1,01 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 28x40 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC02 137 |  | pantoprazol | 40 mg | 1,05 | O | Alkaloid d.o.o. | Atlantic Pharma – Produçoes Farmaceuticas, S.A. | Pantoprazol Alkaloid | tbl. žel. otp. 28x20 mg | 0,52 | 14,63 | RRA02 | 5% |
| A02BC02 138 |  | pantoprazol | 40 mg | 0,98 | O | Alkaloid d.o.o. | West Pharma, Atlantic Pharma | Pantoprazol Alkaloid | tbl. žel. otp. 28x40 mg | 0,98 | 27,44 | RRA02 | 5% |
| A02BC02 141 |  | pantoprazol | 40 mg | 1,05 | O | PharmaS d.o.o. | PharmaS d.o.o. | Pantoprazol PharmaS | tbl. žel. otp. 28x20 mg | 0,52 | 14,63 | RRA02 | 5% |
| A02BC02 142 |  | pantoprazol | 40 mg | 0,86 | O | PharmaS d.o.o. | PharmaS d.o.o. | Pantoprazol PharmaS | tbl. žel. otp. 56x20 mg | 0,43 | 24,04 | RRA02 | 5% |
| A02BC02 144 |  | pantoprazol | 40 mg | 0,89 | O | PharmaS d.o.o. | PharmaS d.o.o. | Pantoprazol PharmaS | tbl. žel. otp. 28x40 mg | 0,89 | 25,04 | RRA02 | 5% |
| A02BC02 162 |  | pantoprazol | 40 mg | 1,01 | O | Takeda Pharmaceuticals Croatia d.o.o. | Takeda | Controloc | tbl. 28x40 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC02 181 |  | pantoprazol | 40 mg | 0,94 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Apazol A | tbl. žel. otp. 28x20 mg | 0,47 | 13,17 | RRA02 | 5% |
| A02BC02 182 |  | pantoprazol | 40 mg | 0,89 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Apazol A | tbl. žel. otp. 56x20 mg | 0,44 | 24,80 | RRA02 | 5% |
| A02BC02 183 |  | pantoprazol | 40 mg | 0,91 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Apazol A | tbl. žel. otp. 28x40 mg | 0,91 | 25,48 | RRA02 | 5% |
| A02BC03 111 |  | lanzoprazol | 30 mg | 1,05 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Larona | caps. žel. otp. tvrde 28x15 mg | 0,52 | 14,63 | RRA02 | 5% |
| A02BC03 112 |  | lanzoprazol | 30 mg | 1,01 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Larona | caps. žel. otp. tvrde 28x30 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC03 131 |  | lanzoprazol | 30 mg | 1,01 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lanzul | caps. 14x30 mg | 1,01 | 14,16 | RRA02 | 5% |
| A02BC03 132 |  | lanzoprazol | 30 mg | 1,05 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lanzul S | caps. 28x15 mg | 0,52 | 14,63 | RRA02 | 5% |
| A02BC03 133 |  | lanzoprazol | 30 mg | 1,01 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lanzul | caps. 28x30 mg | 1,01 | 28,31 | RRA02 | 5% |
| A02BC05 061 | DS | esomeprazolNA201 | 30 mg | 22,39 | P | AstraZeneca d.o.o. | AstraZeneca | Nexium | boč. 10x40 mg | 29,11 | 291,05 |  | 5% |
| A02BC05 131 |  | esomeprazol | 30 mg | 0,70 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 14x20 mg | 0,70 | 9,75 | RRA02 | 5% |
| A02BC05 132 |  | esomeprazol | 30 mg | 0,70 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 28x20 mg | 0,70 | 19,51 | RRA02 | 5% |
| A02BC05 133 |  | esomeprazol | 30 mg | 0,67 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 14x40 mg | 1,35 | 18,87 | RRA02 | 5% |
| A02BC05 134 |  | esomeprazol | 30 mg | 0,67 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 28x40 mg | 1,35 | 37,75 | RRA02 | 5% |
| A02BC05 135 |  | esomeprazol | 30 mg | 0,94 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 56x20 mg | 0,63 | 35,12 | RRA02 | 5% |
| A02BC05 136 |  | esomeprazol | 30 mg | 0,91 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 56x40 mg | 1,21 | 67,95 | RRA02 | 5% |
| A02BC05 163 |  | esomeprazol | 30 mg | 0,70 | O | AstraZeneca d.o.o. | AstraZeneca | Nexium | tbl. 28x20 mg | 0,70 | 19,51 | RRA02 | 5% |
| A02BX05 131 |  | bizmut oksid | 0,48 g | 4,04 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ulcamed | tbl. film obl. 56x120 mg | 1,01 | 56,56 | RRA16 | 5% |
| A03AA04 111 |  | mebeverin | 0,3 g | 22,46 | O | Belupo d.d. | Belupo | Rudakol | obl. tbl. 50x135 mg | 0,53 | 26,50 | R | 5% |
| A03AX04 161 |  | pinaverij bromid | 0,15 g | 1,14 | O | Mylan Hrvatska d.o.o. | Mylan Laboratories SAS | Dicetel | tbl. film obl. 30x100 mg | 0,76 | 22,80 | R | 5% |
| A03BA01 051 | PR | atropin | 1,5 mg |  | P |  |  |  |  |  |  |  | 5% |
| A03BB01 051 | DS | hioscin-butilbromid | 60 mg |  | P |  |  |  |  |  |  |  | 5% |
| A03BB01 551 |  | hioscin-butilbromid | 60 mg |  | R |  |  |  |  |  |  | R | 5% |
| A03BB01 563 | DS | hioscin-butilbromid | 60 mg |  | O |  |  |  |  |  |  |  | 5% |
| A03FA01 051 | PR | metoklopramid | 30 mg |  | P |  |  |  |  |  |  |  | 5% |
| A03FA01 111 |  | metoklopramid | 30 mg | 1,35 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Metopran | tbl. 40x10 mg | 0,45 | 18,01 | R | 5% |
| A03FA01 142 |  | metoklopramid | 30 mg | 1,35 | O | Alkaloid d.o.o. | Alkaloid | Reglan | tbl. 40x10 mg | 0,45 | 18,01 | R | 5% |
| A03FA01 241 |  | metoklopramid | 30 mg | 2,48 | O | Alkaloid d.o.o. | Alkaloid | Reglan | otop. oral. 120 ml (5mg/5ml) | 9,92 | 9,92 | R | 5% |
| A04AA01 071 | DS | ondansetronNA401 | 16 mg | 119,20 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro | Ondanzetron Kabi | otop. za inj., boč. stakl. 5x2 ml (2 mg/ml) | 23,84 | 119,20 |  | 5% |
| A04AA01 072 | DS | ondansetronNA401 | 16 mg | 112,35 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro | Ondanzetron Kabi | otop. za inj., boč. stakl. 5x4 ml (2 mg/ml) | 44,94 | 224,70 |  | 5% |
| A04AA01 122 |  | ondansetron | 16 mg | 30,21 | O | Sandoz d.o.o. | Sandoz-Salutas | Ondantor | tbl. film obl. 10x8 mg | 15,11 | 151,05 | RSRA17 | 5% |
| A04AA02 086 | DS | granisetronNA401 | 3 mg | 83,12 | P | Fresenius Kabi d.o.o. | Labesfal – Laboratorios Almiro S.A. | Granizetron Kabi | otop. za inj., amp. 5x1 mg/ml | 27,71 | 138,53 |  | 5% |
| A04AA02 087 | DS | granisetronNA401 | 3 mg | 43,86 | P | Fresenius Kabi d.o.o. | Labesfal – Laboratorios Almiro S.A. | Granizetron Kabi | otop. za inj., amp. 5x3 mg/3 ml | 43,86 | 219,28 |  | 5% |
| A04AA05 041 | DS | palonosetronNA402 | 0,25 mg | 294,55 | P | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Palonosetron Accord | otop. za inj. boč. stakl. 1x250 mcg/5 ml | 294,55 | 294,55 |  | 5% |
| A04AA05 071 | DS | palonosetronNA402 | 0,25 mg | 294,55 | P | Medochemie Ltd. | Medochemie Ltd. | Ferant | otop. za inj., amp. 1x250 mcg/5 ml | 294,55 | 294,55 |  | 5% |
| A04AA55 131 | DS | netupitant + palonozetronNA402 |  |  | O | Helsinn Birex Pharmaceuticals Ltd. | Helsinn Birex Pharmaceuticals Ltd. | Akynzeo | caps. tvrda 1x(300 mg + 0,5 mg) | 546,05 | 546,05 |  | 5% |
| A04AD12 101 | DS | aprepitantNA402 | 165 mg | 155,92 | O | Teva B.V. | Merckle GmbH | Aprepitant Teva | caps. tvrda 1x125 mg + 2x80 mg | 89,77 | 269,32 |  | 5% |
| A04AD12 161 | DS | aprepitantNA402 | 165 mg | 155,92 | O | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | Emend | caps. tvrda 1x125 mg + 2x80 mg | 89,77 | 269,32 |  | 5% |
| A04AD12 171 | DS | aprepitantNA402 | 165 mg | 155,92 | O | ALPHA-MEDICAL d.o.o. | Pharmathen International S.A., Pharmathen S.A. | Aprepitant Alpha-Medical | caps. tvrda 1x125 mg + 2x80 mg | 89,77 | 269,32 |  | 5% |
| A05AA02 161 |  | ursodeoksikolna kiselina | 0,75 g | 5,84 | O | Dr. Falk Pharma GmbH | Dr. Falk Pharma GmbH | Ursofalk | caps. 100x250 mg | 1,95 | 194,67 | RSRA03 | 5% |
| A05AA02 171 |  | ursodeoksikolna kiselina | 0,75 g | 4,52 | O | AS GRINDEKS | AS Grindeks | Ursogrix | caps. 100x250 mg | 1,51 | 150,62 | RSRA03 | 5% |
| A06AD11 361 |  | laktuloza | 6,7 g | 0,57 | O | Mylan Hrvatska d.o.o. | Abbott | Duphalac sirup | boč. plast. s čaš. mjern. plast. 1x500 ml (66,7 g/100 ml) | 28,33 | 28,33 | RRA12 | 5% |
| A06AD11 365 |  | laktuloza | 6,7 g | 0,58 | O | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Lactulose-MIP sirup | boč. plast. 1x500 ml (65 g/100 ml) | 28,33 | 28,33 | RRA12 | 5% |
| A07AA12 161 | DS | fidaksomicinNA700 | 0,4 g | 1.113,49 | O | Tillotts Pharma GmbH | Tillotts Pharma GmbH | Dificlir | tbl. film obl. 20x200 mg | 556,75 | 11.134,93 |  | 5% |
| A07BA01 111 | DS | aktivni (medicinski) ugljen | 5 g | 30,56 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Carbomed | tbl. 30x150 mg | 0,92 | 27,50 |  | 5% |
| A07BA01 312 | DS | aktivni (medicinski) ugljen | 5 g | 12,83 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Carbomed | granule 1x50 g (19,25 g u 50 g) | 49,40 | 49,40 |  | 5% |
| A07CA01 351 |  | natrij-klorid + kalij-klorid + natrij-citrat |  |  | O |  |  |  |  |  |  | R | 5% |
| A07EC01 131 |  | sulfasalazin | 2 g | 2,64 | O | KRKA-FARMA d.o.o. | Krka d.d. | Sulfasalazin Krka EN | tbl. žel. otp. 50x500 mg | 0,66 | 32,94 | R | 5% |
| A07EC01 182 |  | sulfasalazin | 2 g | 2,63 | O | Pfizer Croatia d.o.o. | Kemwell | Salazopyrin | tbl. 100x500 mg | 0,66 | 65,87 | R | 5% |
| A07EC02 172 |  | mesalazin | 1,5 g | 5,62 | O | Dr. Falk Pharma GmbH | Dr. Falk Pharma GmbH | Salofalk | tbl. 100x500 mg | 1,87 | 187,49 | RSpa03 | 5% |
| A09AA02 172 |  | enzimi gušterače (visoko dozirani) |  |  | O | Mylan Hrvatska d.o.o. | Abbott | Kreon 10.000 | caps. 100x1 kom. | 0,76 | 75,93 | RSRA15 | 5% |
| A09AA02 173 |  | enzimi gušterače (visoko dozirani) |  |  | O | Mylan Hrvatska d.o.o. | Abbott | Kreon 25.000 | caps. 100x1 kom. | 2,02 | 202,00 | RSRA15 | 5% |
| A09AA02 175 |  | enzimi gušterače (visoko dozirani) |  |  | O | Mylan Hrvatska d.o.o. | Abbott Laboratories GmbH | Kreon 35.000 | caps. 50x1 kom. | 3,46 | 172,90 | RSRA15 | 5% |
| A10AB01 061 |  | inzulin | 40 IU | 4,45 | P | Eli Lilly Hrvatska d.o.o. | Lilly France | Humulin R | otop. za inj., uložak 5x3 ml (100 IU/ml), susp. | 33,34 | 166,70 | R | 5% |
| A10AB01 072 |  | inzulin | 40 IU | 3,51 | P | Novo Nordisk A/S | Novo Nordisk | Actrapid | otop. za inj., boč. 1x10 ml (100 IU/ml) | 87,64 | 87,64 | R | 5% |
| A10AB04 082 |  | inzulin lispro | 40 U | 6,44 | P | Eli Lilly Nederland B.V. | Lilly France S.A.S. | Humalog | otop. za inj., brizg. napunj. Junior KwikPen 5x3 ml (100 U/ml) | 48,29 | 241,45 | R | 5% |
| A10AB04 083 |  | inzulin lispro | 40 U | 5,89 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog | otop. za inj., uložak 5x3 ml (100 U/ml) | 44,20 | 221,00 | R | 5% |
| A10AB04 084 |  | inzulin lispro | 40 U | 6,44 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog | otop. za inj., brizg. napunj. KwikPen 5x3 ml (100 U/ml) | 48,29 | 241,45 | R | 5% |
| A10AB04 085 |  | inzulin lispro | 40 U | 6,44 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog | otop. za inj., brizg. napunj. KwikPen 5x3 ml (200 U/ml) | 96,58 | 482,90 | R | 5% |
| A10AB05 071 |  | inzulin aspart | 40 U | 6,44 | P | Novo Nordisk A/S | Novo Nordisk | NovoRapid | otop. za inj., brizg. napunj. FlexPen 5x3 ml (100 U/ml) | 48,29 | 241,45 | R | 5% |
| A10AB05 072 |  | inzulin aspart | 40 U | 5,89 | P | Novo Nordisk A/S | Novo Nordisk | NovoRapid | otop. za inj., uložak stakl. Penfil 5x3 ml (100 U/ml) | 44,20 | 221,00 | R | 5% |
| A10AB05 076 |  | inzulin aspartNA912 | 40 U | 5,16 | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoRapid | otop. za inj., boč. 1x10 ml (100 U/ml) | 129,06 | 129,06 | RPA29 | 5% |
| A10AB05 077 |  | inzulin aspart | 40 U | 5,89 | P | Novo Nordisk A/S | Novo Nordisk A/S | Fiasp | otop. za inj., uložak stakl. Penfil 5x3 ml (100 U/ml) | 44,20 | 221,00 | R | 5% |
| A10AB06 061 |  | inzulin glulizin | 40 U | 6,08 | P | Sanofi-Aventis Deutschland GmbH | Sanofi-Aventis GmbH | Apidra | otop. za inj., brizg. napunj. SoloStar 5x3 ml (100 U/ml) | 45,58 | 227,88 | R | 5% |
| A10AC01 066 |  | inzulin | 40 IU | 4,45 | P | Eli Lilly Hrvatska d.o.o. | Lilly France | Humulin N | susp. za inj. uložak 5x3 ml (100 IU/ml) | 33,34 | 166,70 | R | 5% |
| A10AC01 077 |  | inzulin human | 40 IU | 4,86 | P | Sanofi-Aventis Deutschland GmbH | Sanofi-Aventis Deutchland GmbH | Insuman Basal | susp. za inj., brizg. napunj. SoloStar 5x3 ml (100 IU/ml) | 36,47 | 182,37 | R | 5% |
| A10AD01 083 |  | inzulin | 40 IU | 4,45 | P | Eli Lilly Hrvatska d.o.o. | Lilly France | Humulin M3 | susp. za inj., uložak 5x3 ml (100 IU/ml) | 33,34 | 166,70 | R | 5% |
| A10AD04 081 |  | inzulin lispro | 40 U | 5,89 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog Mix 25 | susp. za inj., uložak 5x3 ml (100 U/ml) | 44,20 | 221,00 | R | 5% |
| A10AD04 083 |  | inzulin lispro | 40 U | 5,89 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog Mix 50 | susp. za inj., uložak 5x3 ml (100 U/ml) | 44,20 | 221,00 | R | 5% |
| A10AD04 085 |  | inzulin lispro | 40 U | 6,62 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog Mix 25 | susp. za inj., brizg, napunj. KwikPen 5x3 ml (100 U/ml) | 49,63 | 248,13 | R | 5% |
| A10AD04 086 |  | inzulin lispro | 40 U | 6,59 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog Mix 50 | susp. za inj., brizg. napunj. KwikPen 5x3 ml (100 U/ml) | 49,42 | 247,08 | R | 5% |
| A10AD05 073 |  | inzulin aspart | 40 U | 6,60 | P | Novo Nordisk A/S | Novo Nordisk | NovoMix 30 | susp. za inj., brizg. napunj. FlexPen 5x3 ml (100 U/ml) | 49,50 | 247,50 | R | 5% |
| A10AD06 071 |  | inzulin degludek + inzulin aspart | 40 U | 7,70 | P | Novo Nordisk A/S | Novo Nordisk A/S | Ryzodeg | otop. za inj., brizg. napunj. 5x3 mL (100 U/mL) | 57,77 | 288,86 | R | 5% |
| A10AE04 062 |  | inzulin glargin | 40 U | 8,41 | P | Sanofi-Aventis Deutschland GmbH | Sanofi-Aventis GmbH | Lantus | otop. za inj., brizg. napunj. SoloStar 5x3 ml (100 U/ml) | 63,06 | 315,30 | RRA08 | 5% |
| A10AE04 082 |  | inzulin glargin | 40 U | 7,04 | P | Eli Lilly Nederland B.V. | Lilly France S.A.S. | Abasaglar | otop. za inj., brizg. napunj. KwikPen 5x3 ml (100 U/ml) | 52,77 | 263,87 | RRA08 | 5% |
| A10AE04 091 |  | inzulin glargin | 40 U | 7,04 | P | Viatris Limited | McDermott Laboratories t/a Mylan Dublin Biologics | Semglee | otop. za inj., brizg. napunj. 5x3 ml (100 U/ml) | 52,77 | 263,87 | RRA08 | 5% |
| A10AE05 071 |  | inzulin detemir | 40 U | 9,95 | P | Novo Nordisk A/S | Novo Nordisk | Levemir | otop. za inj., brizg. napunj. FlexPen 5x3 ml (100 U/ml) | 74,60 | 373,00 | RRA08 | 5% |
| A10AE06 061 |  | degludek inzulin | 40 U | 10,40 | P | Novo Nordisk A/S | Novo Nordisk | Tresiba | otop. za inj., brizg. napunj. FlexTouch 5x3 ml (100 U/ml) | 78,00 | 390,00 | RRA08 | 5% |
| A10BA02 101 |  | metformin | 2 g | 0,56 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gluformin | tbl. film obl. 80x850 mg | 0,24 | 19,20 | R | 5% |
| A10BA02 102 |  | metformin | 2 g | 0,54 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gluformin | tbl. film obl. 80x1000 mg | 0,27 | 21,46 | R | 5% |
| A10BA02 103 |  | metformin | 2 g | 0,56 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gluformin | tbl. film obl. 30x850 mg | 0,24 | 7,20 | R | 5% |
| A10BA02 104 |  | metformin | 2 g | 0,58 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gluformin | tbl. film obl. 30x1000 mg | 0,29 | 8,64 | R | 5% |
| A10BA02 111 |  | metformin | 2 g | 0,71 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 100x500 mg | 0,18 | 17,72 | R | 5% |
| A10BA02 112 |  | metformin | 2 g | 0,56 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 30x850 mg | 0,24 | 7,20 | R | 5% |
| A10BA02 113 |  | metformin | 2 g | 0,58 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 30x1000 mg | 0,29 | 8,64 | R | 5% |
| A10BA02 114 |  | metformin | 2 g | 0,56 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 120x850 mg | 0,24 | 28,80 | R | 5% |
| A10BA02 115 |  | metformin | 2 g | 0,54 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 120x1000 mg | 0,27 | 32,19 | R | 5% |
| A10BA02 122 |  | metformin | 2 g | 0,71 | O | Sandoz d.o.o. | Sandoz-Lek | Meglucon | tbl. film obl. 120x500 mg | 0,18 | 21,26 | R | 5% |
| A10BA02 124 |  | metformin | 2 g | 0,56 | O | Sandoz d.o.o. | Sandoz-Lek | Meglucon | tbl. film obl. 120x850 mg | 0,24 | 28,80 | R | 5% |
| A10BA02 125 |  | metformin | 2 g | 0,54 | O | Sandoz d.o.o. | Sandoz-Lek | Meglucon | tbl. film obl. 120x1000 mg | 0,27 | 32,19 | R | 5% |
| A10BA02 173 |  | metformin | 2 g | 0,71 | O | Medis Adria d.o.o. | Weifa | Aglurab | tbl. film obl. 100x500 mg | 0,18 | 17,72 | R | 5% |
| A10BA02 174 |  | metformin | 2 g | 0,56 | O | Medis Adria d.o.o. | Weifa | Aglurab | tbl. film obl. 100x850 mg | 0,24 | 24,00 | R | 5% |
| A10BA02 175 |  | metformin | 2 g | 0,54 | O | Medis Adria d.o.o. | Weifa | Aglurab | tbl. film obl. 60x1000 mg | 0,27 | 16,10 | R | 5% |
| A10BA02 181 |  | metformin | 2 g | 0,71 | O | Berlin-Chemie Menarini Hrvatska d.o.o. | Berlin-Chemie AG | Siofor 500 | tbl. film obl. 120x500 mg | 0,18 | 21,26 | R | 5% |
| A10BB01 161 |  | glibenklamid-mikrokrist. | 7 mg | 1,05 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Glibenclamid Genericon | tbl. 30x3,5 mg | 0,53 | 15,75 | R | 5% |
| A10BB09 111 |  | gliklazid | 60 mg | 0,76 | O | Belupo d.d. | Belupo d.d. | Glika | tbl. s prod. oslob. 60x30 mg | 0,38 | 22,91 | R | 5% |
| A10BB09 112 |  | gliklazid | 60 mg | 0,55 | O | Belupo d.d. | Belupo d.d. | Glika | tbl. s prilag. oslob. 30x60 mg | 0,55 | 16,61 | R | 5% |
| A10BB09 113 |  | gliklazid | 60 mg | 0,55 | O | Belupo d.d. | Belupo d.d. | Glika | tbl. s prilag. oslob. 60x60 mg | 0,55 | 33,22 | R | 5% |
| A10BB09 114 |  | gliklazid | 60 mg | 0,55 | O | Belupo d.d. | Belupo d.d. | Glika | tbl. s prilag. oslob. 90x60 mg | 0,55 | 49,83 | R | 5% |
| A10BB09 131 |  | gliklazid | 60 mg | 0,76 | O | KRKA-FARMA d.o.o. | Krka d.d. | Gliclada | tbl. s prilag. osl. 60x30 mg | 0,38 | 22,91 | R | 5% |
| A10BB09 134 |  | gliklazid | 60 mg | 0,50 | O | KRKA-FARMA d.o.o. | Krka d.d. | Gliclada | tbl. s prilag. osl. 30x90 mg | 0,74 | 22,28 | R | 5% |
| A10BB12 111 |  | glimepirid | 2 mg | 0,55 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Betaglid | tbl. 30x2 mg | 0,55 | 16,61 | R | 5% |
| A10BB12 112 |  | glimepirid | 2 mg | 0,50 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Betaglid | tbl. 30x3 mg | 0,74 | 22,28 | R | 5% |
| A10BB12 145 |  | glimepirid | 2 mg | 0,55 | O | PharmaS d.o.o. | PharmaS d.o.o. | Glimepirid PharmaS | tbl. 30x2 mg | 0,55 | 16,50 | R | 5% |
| A10BB12 146 |  | glimepirid | 2 mg | 0,55 | O | PharmaS d.o.o. | PharmaS d.o.o. | Glimepirid PharmaS | tbl. 60x2 mg | 0,55 | 33,22 | R | 5% |
| A10BB12 147 |  | glimepirid | 2 mg | 0,49 | O | PharmaS d.o.o. | PharmaS d.o.o. | Glimepirid PharmaS | tbl. 30x3 mg | 0,73 | 21,98 | R | 5% |
| A10BB12 148 |  | glimepirid | 2 mg | 0,50 | O | PharmaS d.o.o. | PharmaS d.o.o. | Glimepirid PharmaS | tbl. 60x3 mg | 0,74 | 44,56 | R | 5% |
| A10BB12 161 |  | glimepirid | 2 mg | 0,55 | O | sanofi-aventis groupe | Sanofi-Aventis GmbH, Sanofi-Aventis S.p.A., Sanofi Winthrop Tours | Amaryl | tbl. 30x2 mg | 0,55 | 16,61 | R | 5% |
| A10BB12 162 |  | glimepirid | 2 mg | 0,50 | O | sanofi-aventis groupe | Sanofi-Aventis GmbHSanofi-Aventis S.p.A.Sanofi Winthrop Tours | Amaryl | tbl. 30x3 mg | 0,74 | 22,28 | R | 5% |
| A10BD02 171 |  | metformin + glibenklamid |  |  | O | MERCK d.o.o. | Merck | Glucovance | tbl. film obl. 30x(500 mg + 5 mg) | 0,60 | 17,85 | R | 5% |
| A10BD05 161 |  | pioglitazon + metformin |  |  | O | Cheplapharm Arzneimittel GmbH | Takeda | Competact | tbl. film obl. 56x(15 mg + 850 mg) | 2,50 | 139,86 | R | 5% |
| A10BD07 101 |  | sitagliptin + metformin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Adamed Pharma S.A. | Gluformin Combi | tbl. s prod. oslob. 56x(50 mg + 1000 mg) | 1,47 | 82,49 | R | 5% |
| A10BD07 111 |  | sitagliptin + metformin |  |  | O | Teva GmbH | Laboratorios Liconsa S.A. | Sitagliptin/metforminklorid Teva | tbl. film obl. 56x(50 mg + 1000 mg) | 1,47 | 82,26 | R | 5% |
| A10BD07 125 |  | sitagliptin + metformin |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Eprocliv | tbl. film obl. 56x(50 mg + 1000 mg) | 1,47 | 82,26 | R | 5% |
| A10BD07 131 |  | sitagliptin + metformin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Maymetsi | tbl. film obl. 56x(50 mg + 1000 mg) | 1,47 | 82,26 | R | 5% |
| A10BD07 171 |  | sitagliptin + metformin |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Fordiab | tbl. film obl. 56x(50 mg + 1000 mg) | 1,47 | 82,26 | R | 5% |
| A10BD07 181 |  | sitagliptin + metformin |  |  | O | Viatris Limited | Mylan Hungary Kft, Medis International A.S. | Glerova | tbl. film obl. 56x(50 mg + 1000 mg) | 1,39 | 78,00 | R | 5% |
| A10BD07 182 |  | sitagliptin + metformin |  |  | O | Zentiva k.s. | Laboratorios Liconsa S.A. | Jamesi | tbl. film obl. 56x(50 mg + 1000 mg) | 1,40 | 78,36 | R | 5% |
| A10BD07 183 |  | sitagliptin + metformin |  |  | O | Novatin Limited | SAG Manufacturing S.L.U. | Zaxoran | tbl. film obl. 56x(50 mg + 850 mg) | 1,32 | 74,10 | R | 5% |
| A10BD07 184 |  | sitagliptin + metformin |  |  | O | Novatin Limited | SAG Manufacturing S.L.U. | Zaxoran | tbl. film obl. 56x(50 mg + 1000 mg) | 1,32 | 74,10 | R | 5% |
| A10BD07 185 |  | sitagliptin + metformin |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o., Accord Healthcare B.V. | Sitagliptin/metforminklorid Accord | tbl. film obl. 56x(50 mg + 1000 mg) | 1,26 | 70,40 | R | 5% |
| A10BD08 111 |  | vildagliptin + metformin |  |  | O | Belupo d.d. | Belupo | Agnis Combi | tbl. film obl. 60x(50 mg + 850 mg) | 1,40 | 83,73 | R | 5% |
| A10BD08 112 |  | vildagliptin + metformin |  |  | O | Belupo d.d. | Belupo | Agnis Combi | tbl. film obl. 60x(50 mg + 1000 mg) | 1,40 | 83,73 | R | 5% |
| A10BD08 121 |  | vildagliptin + metformin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Vilspox | tbl. film obl. 60x(50 mg + 1000 mg) | 1,47 | 88,14 | R | 5% |
| A10BD08 141 |  | vildagliptin + metformin |  |  | O | Accord Healthcare S.L.U. | LABORATORI FUNDACIÓ DAU, Pharmadox Healthcare Ltd. | Vildagliptin/metforminklorid Accord | tbl. film obl. 60x(50 mg + 1000 mg) | 1,26 | 75,56 | R | 5% |
| A10BD08 171 |  | vildagliptin + metformin |  |  | O | Medochemie Ltd. | Medochemie Ltd. | Daltex | tbl. film obl. 60x(50 mg + 1000 mg) | 1,47 | 88,14 | R | 5% |
| A10BD08 181 |  | vildagliptin + metformin |  |  | O | Zentiva k.s. | Pharmathen S.A., Pharmathen International S.A. | Ipinzan | tbl. film obl. 60x(50 mg + 1000 mg) | 1,33 | 79,54 | R | 5% |
| A10BD08 191 |  | vildagliptin + metformin |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Vilbaco | tbl. film obl. 60x(50 mg + 1000 mg) | 1,33 | 79,54 | R | 5% |
| A10BD08 192 |  | vildagliptin + metformin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | SAG Manufacturing S.L.U., Galenicum Health S.L. | Vildagliptin/metforminklorid Genericon | tbl. film obl. 60x(50 mg + 1000 mg) | 1,20 | 71,78 | R | 5% |
| A10BG03 101 |  | pioglitazon | 30 mg | 4,87 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Pioglitazon Pliva tbl. 15 mg | tbl. 30x15 mg | 2,44 | 73,05 | R | 5% |
| A10BG03 102 |  | pioglitazon | 30 mg | 3,66 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Pioglitazon Pliva tbl. 30 mg | tbl. 30x30 mg | 3,66 | 109,70 | R | 5% |
| A10BG03 133 |  | pioglitazon | 30 mg | 3,66 | O | ACTAVIS GROUP PTC ehf. | Actavis Ltd. | Pioglitazon Actavis | tbl. 28x45 mg | 5,49 | 153,59 | R | 5% |
| A10BG03 181 |  | pioglitazon | 30 mg | 4,87 | O | Cheplapharm Arzneimittel GmbH | Takeda | Actos | tbl. 28x15 mg | 2,44 | 68,18 | R | 5% |
| A10BG03 182 |  | pioglitazon | 30 mg | 3,66 | O | Cheplapharm Arzneimittel GmbH | Takeda | Actos | tbl. 28x30 mg | 3,66 | 102,39 | R | 5% |
| A10BG03 183 |  | pioglitazon | 30 mg | 4,63 | O | Novatin Limited | Laboratori Fundacio Dau | Novapio | tbl. 30x15 mg | 2,31 | 69,40 | R | 5% |
| A10BG03 184 |  | pioglitazon | 30 mg | 3,47 | O | Novatin Limited | Laboratori Fundacio Dau | Novapio | tbl. 30x30 mg | 3,47 | 104,22 | R | 5% |
| A10BG03 185 |  | pioglitazon | 30 mg | 3,47 | O | Novatin Limited | Laboratori Fundacio Dau | Novapio | tbl. 30x45 mg | 5,21 | 156,33 | R | 5% |
| A10BH01 101 |  | sitagliptin | 0,1 g | 2,38 | O | Teva B.V. | Teva Gyogyszergyar Zrt., Teva Operations Poland Sp. z o.o. | Sitagliptin Teva | tbl. film obl. 28x100 mg | 2,38 | 66,64 | R | 5% |
| A10BH01 122 |  | sitagliptin | 0,1 g | 4,30 | O | Jadran – Galenski Laboratorij d.d. | Zakłady Farmaceutyczne Polpharma S.A., Pharmacare Premium Ltd. | Sigazix | tbl. film obl. 28x50 mg | 2,15 | 60,14 | R | 5% |
| A10BH01 123 |  | sitagliptin | 0,1 g | 2,15 | O | Jadran – Galenski Laboratorij d.d. | Zakłady Farmaceutyczne Polpharma S.A., Pharmacare Premium Ltd. | Sigazix | tbl. film obl. 28x100 mg | 2,15 | 60,14 | R | 5% |
| A10BH01 124 |  | sitagliptin | 0,1 g | 8,59 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Adimuplan | tbl. film obl. 28x25 mg | 2,15 | 60,14 | R | 5% |
| A10BH01 125 |  | sitagliptin | 0,1 g | 4,30 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Adimuplan | tbl. film obl. 28x50 mg | 2,15 | 60,14 | R | 5% |
| A10BH01 126 |  | sitagliptin | 0,1 g | 2,15 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Adimuplan | tbl. film obl. 28x100 mg | 2,15 | 60,14 | R | 5% |
| A10BH01 131 |  | sitagliptin | 0,1 g | 9,52 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Maysiglu | tbl. film obl. 28x25 mg | 2,38 | 66,64 | R | 5% |
| A10BH01 132 |  | sitagliptin | 0,1 g | 4,76 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Maysiglu | tbl. film obl. 28x50 mg | 2,38 | 66,64 | R | 5% |
| A10BH01 133 |  | sitagliptin | 0,1 g | 2,38 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Maysiglu | tbl. film obl. 28x100 mg | 2,38 | 66,64 | R | 5% |
| A10BH01 164 |  | sitagliptin | 0,1 g | 8,59 | O | ALPHA-MEDICAL d.o.o. | Adamed Pharma S.A. | Dowim | tbl. film obl. 28x25 mg | 2,15 | 60,14 | R | 5% |
| A10BH01 165 |  | sitagliptin | 0,1 g | 4,30 | O | ALPHA-MEDICAL d.o.o. | Adamed Pharma S.A. | Dowim | tbl. film obl. 28x50 mg | 2,15 | 60,14 | R | 5% |
| A10BH01 166 |  | sitagliptin | 0,1 g | 2,15 | O | ALPHA-MEDICAL d.o.o. | Adamed Pharma S.A. | Dowim | tbl. film obl. 28x100 mg | 2,15 | 60,14 | R | 5% |
| A10BH01 167 |  | sitagliptin | 0,1 g | 8,16 | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o. | Sitagliptin Accord | tbl. film obl. 28x25 mg | 2,04 | 57,13 | R | 5% |
| A10BH01 168 |  | sitagliptin | 0,1 g | 4,08 | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o. | Sitagliptin Accord | tbl. film obl. 28x50 mg | 2,04 | 57,13 | R | 5% |
| A10BH01 169 |  | sitagliptin | 0,1 g | 2,04 | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o. | Sitagliptin Accord | tbl. film obl. 28x100 mg | 2,04 | 57,13 | R | 5% |
| A10BH01 175 |  | sitagliptin | 0,1 g | 2,04 | O | Novatin Limited | SAG Manufacturing S.L.U. | Zaxivia | tbl. film obl. 28x100 mg | 2,04 | 57,13 | R | 5% |
| A10BH01 181 |  | sitagliptin | 0,1 g | 7,75 | O | Mylan Ireland Limited | Mylan Hungary Kft, Medis International A.S. | Jaglix | tbl. film obl. 28x25 mg | 1,94 | 54,27 | R | 5% |
| A10BH01 182 |  | sitagliptin | 0,1 g | 3,88 | O | Mylan Ireland Limited | Mylan Hungary Kft, Medis International A.S. | Jaglix | tbl. film obl. 28x50 mg | 1,94 | 54,27 | R | 5% |
| A10BH01 183 |  | sitagliptin | 0,1 g | 1,94 | O | Mylan Ireland Limited | Mylan Hungary Kft, Medis International A.S. | Jaglix | tbl. film obl. 28x100 mg | 1,94 | 54,27 | R | 5% |
| A10BH02 111 |  | vildagliptin | 0,1 g | 2,38 | O | Belupo d.d. | Belupo d.d. | Agnis | tbl. 60x50 mg | 1,19 | 71,40 | R | 5% |
| A10BH02 121 |  | vildagliptin | 0,1 g | 2,38 | O | Sandoz d.o.o. | Sandoz-Lek | Saxotin | tbl. 56x50 mg | 1,19 | 66,64 | R | 5% |
| A10BH02 131 |  | vildagliptin | 0,1 g | 2,38 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma Gmbh | Glypvilo | tbl. 60x50 mg | 1,19 | 71,28 | R | 5% |
| A10BJ01 062 |  | eksenatid | 15 mcg | 13,31 | P | AstraZeneca AB | AstraZeneca AB | Byetta | otop. za inj., brizg. napunj. 1x2,4 ml, 10 mcg/40 mcl, (0,25 mg/ml) | 532,48 | 532,48 | RSRA11 | 5% |
| A10BJ03 061 |  | liksisenatid | 20 mcg | 38,03 | P | sanofi-aventis groupe | Sanofi-Aventis Deutchland GmbH | Lyxumia | otop. za inj., brizg. napunj. 1x3 ml (10 mcg/doza) | 266,24 | 266,24 | RSRA11 | 5% |
| A10BJ03 062 |  | liksisenatid | 20 mcg | 19,02 | P | sanofi-aventis groupe | Sanofi-Aventis Deutchland GmbH | Lyxumia | otop. za inj., brizg. napunj. 2x3 ml (20 mcg/doza) | 266,24 | 532,48 | RSRA11 | 5% |
| A10BJ05 061 |  | dulaglutid | 0.16 mg | 28,40 | P | Eli Lilly Nederland B.V. | Eli Lilly Italia S.p.A. | Trulicity | otop. za inj., brizg. napunj. 2x0,75 mg/0,5 ml | 133,12 | 266,24 | RSRA11 | 5% |
| A10BJ05 062 |  | dulaglutid | 0.16 mg | 14,20 | P | Eli Lilly Nederland B.V. | Eli Lilly Italia S.p.A. | Trulicity | otop. za inj., brizg. napunj. 2x1,5 mg/0,5 ml | 133,12 | 266,24 | RSRA11 | 5% |
| A10BJ05 063 |  | dulaglutid | 0.16 mg | 7,10 | P | Eli Lilly Nederland B.V. | Eli Lilly Italia S.p.A. | Trulicity | otop. za inj., brizg. napunj. 2x3,0 mg/0,5 ml | 133,12 | 266,24 | RSRA11 | 5% |
| A10BJ05 064 |  | dulaglutid | 0.16 mg | 4,73 | P | Eli Lilly Nederland B.V. | Eli Lilly Italia S.p.A. | Trulicity | otop. za inj., brizg. napunj. 2x4,5 mg/0,5 ml | 133,12 | 266,24 | RSRA11 | 5% |
| A10BJ06 071 |  | semaglutid | 0.11 mg | 58,57 | P | Novo Nordisk A/S | Novo Nordisk A/S | Ozempic | otop. za inj., brizg. napunj., 1x1,5 ml (0,25 mg/doza) | 532,48 | 532,48 | RSRA11 | 5% |
| A10BJ06 072 |  | semaglutid | 0.11 mg | 29,29 | P | Novo Nordisk A/S | Novo Nordisk A/S | Ozempic | otop. za inj., brizg. napunj., 1x1,5 ml (0,5 mg/doza) | 532,48 | 532,48 | RSRA11 | 5% |
| A10BJ06 073 |  | semaglutid | 0.11 mg | 14,64 | P | Novo Nordisk A/S | Novo Nordisk A/S | Ozempic | otop. za inj., brizg. napunj., 1x3 ml (1 mg/doza) | 532,48 | 532,48 | RSRA11 | 5% |
| A10BX02 101 |  | repaglinid | 4 mg | 0,97 | O | DOUBLE-E-PHARMA Limited | Pliva Hrvatska d.o.o. | Reodon | tbl. 90x0,5 mg | 0,12 | 10,88 | R | 5% |
| A10BX02 102 |  | repaglinid | 4 mg | 0,97 | O | DOUBLE-E-PHARMA Limited | Pliva Hrvatska d.o.o. | Reodon | tbl. 90x1 mg | 0,24 | 21,75 | R | 5% |
| A10BX02 103 |  | repaglinid | 4 mg | 0,92 | O | DOUBLE-E-PHARMA Limited | Pliva Hrvatska d.o.o. | Reodon | tbl. 90x2 mg | 0,46 | 41,21 | R | 5% |
| A10BX02 112 |  | repaglinid | 4 mg | 0,97 | O | Belupo d.d. | Belupo | Reglinid | tbl. 90x1 mg | 0,24 | 21,75 | R | 5% |
| A10BX02 113 |  | repaglinid | 4 mg | 0,92 | O | Belupo d.d. | Belupo | Reglinid | tbl. 90x2 mg | 0,46 | 41,21 | R | 5% |
| A10BX02 127 |  | repaglinid | 4 mg | 0,92 | O | PharmaS d.o.o. | PharmaS d.o.o. | Repaglinid PharmaS | tbl. 90x2 mg | 0,46 | 41,21 | R | 5% |
| A11CC02 251 |  | dihidrotahisterol | 1 mg |  | O |  |  |  |  |  |  | R | 5% |
| A11CC04 051 | DS | kalcitriol | 1 mcg |  | P |  |  |  |  |  |  |  | 5% |
| A11CC05 161 |  | kolekalciferol | 20 mcg | 0,19 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Dekristol | caps. meka 14x20 000 IU (0,5 mg) | 4,74 | 66,40 | R | 5% |
| A11CC05 201 |  | kolekalciferol | 20 mcg | 0,33 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivit D3 | boč. 1x10 ml (4.000 i.j./ml) | 16,73 | 16,73 | R | 5% |
| A11CC05 261 |  | kolekalciferol | 20 mcg | 0,23 | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Oleovit D3 | oralne kapi, boč. 1x12,5 ml (14400 i.j./ml) | 52,70 | 52,70 | R | 5% |
| A11CC05 271 |  | kolekalciferol | 20 mcg | 0,21 | O | PROXIMUM d.o.o. | SMB Technology S.A. | D-VITAL | oralna otop., amp. 4x1 ml (25 000 IU/ml) | 6,59 | 26,35 | R | 5% |
| A11CC05 272 |  | kolekalciferol | 20 mcg | 0,20 | O | PROXIMUM d.o.o. | SMB Technology S.A. | D-VITAL | oralna otop., amp. 3x1 ml (100 000 IU/ml) | 25,03 | 75,10 | RSRA31 | 5% |
| A11EA01 051 | DS | vitamini B kompleksa |  |  | P |  |  |  |  |  |  |  | 5% |
| A12AA02 051 | PR | kalcij-glukobionat |  |  | P |  |  |  |  |  |  |  | 5% |
| A12AA04 131 |  | kalcij-karbonat | 3 g | 2,94 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kalcijev karbonat | tbl. 50x1 g | 0,98 | 49,00 | R | 5% |
| A12BA01 111 |  | kalij-klorid | 3 g | 4,56 | O | Belupo d.d. | Belupo | Kalijev klorid Belupo | tbl. za oral. otop. 30x500 mg | 0,76 | 22,81 | R | 5% |
| A12BA01 112 |  | kalij-klorid | 3 g | 4,56 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Kalijev klorid Jadran | tbl. 30x500 mg | 0,76 | 22,81 | R | 5% |
| A12BA02 321 |  | kalijev citrat |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Kalijev citrat JGL | praš. za oral. otop., vreć. 15x1 (20,5 mg/ml) | 1,80 | 27,00 | R | 5% |
| A12BA30 161 |  | kalij-citrat + kalij-hidrogenkarbonat |  |  | O | Desma GmbH | E-Pharma Trento S.p.A. | Kalinor | tbl. šum. 15x1 tbl. (2,17 g + 2 g/tbl.) | 2,00 | 30,00 | R | 5% |
| A16AA01 051 | DS | levokarnitin | 2 g |  | P |  |  |  |  |  |  |  | 5% |
| A16AA01 151 | DS | levokarnitin | 2 g |  | O |  |  |  |  |  |  |  | 5% |
| A16AA05 161 | DS | karglumatna kiselinaNA501 | 200 mg | 453,32 | O | Recordati Rare Diseases | Recordati Rare Diseases | Carbaglu | tbl. za oral. susp. 60x200 mg | 453,32 | 27.199,40 |  | 5% |
| A16AB02 062 | KS | imiglucerazaNA903 | 300 j. | 7.568,43 | P | Genzyme Europe B.V. | Genzyme | Cerezyme | praš. za konc. za otop. za inf., stakl. boč. 1x400 j. | 10.090,99 | 10.090,99 |  | 5% |
| A16AB03 062 | KS | agalzidaza alfaNA904 | 1 mg | 3.413,30 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Replagal | konc. za inf., boč. 1x3,5 mg/3,5 ml | 11.946,54 | 11.946,54 |  | 5% |
| A16AB04 061 | KS | agalzidaza betaNA904 | 5 mg | 3.322,30 | P | Genzyme Europe B.V. | Genzyme | Fabrazyme | praš. za konc. za otop. za inf., boč. stakl. 1x35 mg | 23.256,07 | 23.256,07 |  | 5% |
| A16AB04 062 | KS | agalzidaza betaNA904 | 5 mg | 3.630,96 | P | Genzyme Europe B.V. | Genzyme | Fabrazyme | praš. za konc. za otop. za inf., boč. stakl. 1x5 mg | 3.630,96 | 3.630,96 |  | 5% |
| A16AB05 061 | KS | laronidazaNA906 | 1 T j. | 9.688,66 | P | Genzyme Europe B.V. | Genzyme | Aldurazyme | praš. za konc. za otop. za inf., boč. stakl. 1x500 j./5 ml (100j./ml) | 4.844,33 | 4.844,33 |  | 5% |
| A16AB07 061 | KS | alglukozidaza alfaNA907 | 0,1 g | 7.406,96 | P | Genzyme Europe B.V. | Genzyme | Myozyme | praš. za konc. za otop. za inf., boč. 1x50 mg | 3.703,48 | 3.703,48 |  | 5% |
| A16AB08 061 | KS | galsulfazaNA908 |  |  | P | BioMarin International Limited | BioMarin International Limited | Naglazyme | konc. otop. za inf., boč. 1x5 mg/5 ml | 10.350,06 | 10.350,06 |  | 5% |
| A16AB09 071 | KS | idursulfaza NA909 |  |  | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Elaprase | boč. stakl. 1x6 mg/3 ml (2 mg/ml) | 20.005,65 | 20.005,65 |  | 5% |
| A16AB10 061 | KS | velagluceraza alfaNA903 | 300 U | 7.823,94 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Vpriv | praš. za otop. za inf., boč. stakl. 1x400 U/20 ml (nakon rekonstitucije 100 U/1ml) | 10.431,66 | 10.431,66 |  | 5% |
| A16AB12 071 | KS | elosulfaza alfaNA913 | 20 mg | 25.067,32 | P | BioMarin International Limited | BioMarin International Ltd. | Vimizim | konc. za otop. za inf., boč. stakl. 1x5 ml (1 mg/ml) | 6.266,83 | 6.266,83 |  | 5% |
| A16AB17 071 | KL | cerliponaza alfaNA915 | 21 mg | 12.858,21 | P | BioMarin International Limited | BioMarin International Limited | Brineura | otop. za inf., boč. 2x150 mg/5 ml (30mg/ml) | 91.844,24 | 183.688,48 |  | 5% |
| A16AX04 151 | KS | nitizinonNA905 | 20 mg |  | O |  |  |  |  |  |  |  | 5% |
| A16AX08 072 | KL | teduglutidNA914 | 5 mg | 8.726,06 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Revestive | praš. boč. 28x1,25 mg + 0,5 ml otap. za otop. za inj. u štrc. napunj. (2,5 mg/ml) | 2.181,52 | 61.082,42 |  | 5% |
| A16AX08 073 | KL | teduglutidNA914 | 5 mg | 4.492,52 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Revestive | praš. boč. 28x5 mg + 0,5 ml otap. za otop. za inj. u štrc. napunj. (10 mg/ml) | 4.492,52 | 125.790,65 |  | 5% |
| A16AX10 161 | KS | eliglustatNA910 |  |  | O | Genzyme Europe B.V. | Genzyme Ireland Ltd. | Cerdelga | caps. tvrda 56x84 mg | 2.569,54 | 143.894,43 |  | 5% |
| A16AX14 161 | KS | migalastatNA911 |  |  | O | Amicus Therapeutics Europe Limited | Almac Pharma Services (Ireland) Limited | Galafold | caps. tvrde 14x123 mg | 7.809,29 | 109.330,00 |  | 5% |
| B01AA03 162 |  | varfarin | 7,5 mg | 1,04 | O | Orion Corporation | Orion | Martefarin | tbl. 100x3 mg | 0,42 | 41,67 | R | 5% |
| B01AB01 011 | DS | heparin | 10 T i.j. | 14,60 | P | Belupo d.d. | Belupo | Heparin Belupo | otop. za inj., lio amp. 10x25.000 i.j./5 ml | 36,50 | 365,00 |  | 5% |
| B01AB01 061 | DS | heparinnatrij | 10 T i.j. | 13,23 | P | Panpharma | Panpharma GmbH | Heparin Panpharma | otop. za inj./inf., 5.000 i.j./ml (10x5 ml) | 33,07 | 330,67 |  | 5% |
| B01AB02 061 | DS | antitrombin IIINB101 | 2.1 T i.j. | 3.968,92 | P | CSL Behring GmbH | CSL Behring GmbH | Kybernin | lio boč. 1x500 i.j./10ml | 945,00 | 945,00 |  | 5% |
| B01AB02 071 | DS | antitrombin IIINB101 | 2.1 T i.j. | 3.969,00 | P | Jana Pharm d.o.o. | Octapharma | ATenativ | lio boč. 1x500 i.j./10ml | 945,00 | 945,00 |  | 5% |
| B01AB02 082 | DS | antitrombin IIINB101 | 2.1 T i.j. | 3.969,00 | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Antithrombin III Baxalta 50 IU/ml | praš. i otap. za otop. za inj./inf., boč. 1x500 IU/10 ml (50 IU/ml) | 945,00 | 945,00 |  | 5% |
| B01AB04 071 | DSPO | dalteparinNB102 | 2.5 T i.j. | 68,02 | P | Pfizer Croatia d.o.o. | Pfizer | Fragmin | štrc. 10x2.500 i.j./0,2ml | 13,60 | 136,03 |  | 5% |
| B01AB04 072 | DSPO | dalteparinNB102 | 2.5 T i.j. | 64,78 | P | Pfizer Croatia d.o.o. | Pfizer | Fragmin | štrc. 10x5.000 i.j./0,2ml | 25,91 | 259,13 |  | 5% |
| B01AB04 073 | DSPO | dalteparinNB102 | 2.5 T i.j. | 10,52 | P | Pfizer Croatia d.o.o. | Pfizer | Fragmin | štrc. 10x7.500 i.j./0,3ml | 31,55 | 315,50 | RSRB10 | 5% |
| B01AB04 080 |  | dalteparin | 2.5 T i.j. | 10,07 | P | Pfizer Croatia d.o.o. | Pfizer Manufacturing Belgium N.V. | Fragmin | otop. za inj., štrc. napunj. 5x10.000 i.j./0,4 ml | 40,26 | 201,32 | RSRB10 | 5% |
| B01AB04 081 |  | dalteparin | 2.5 T i.j. | 9,12 | P | Pfizer Croatia d.o.o. | Pfizer Manufacturing Belgium N.V. | Fragmin | otop. za inj., štrc. napunj. 5x12.500 i.j./0,5 ml | 45,60 | 228,02 | RSRB10 | 5% |
| B01AB04 082 |  | dalteparin | 2.5 T i.j. | 8,54 | P | Pfizer Croatia d.o.o. | Pfizer Manufacturing Belgium N.V. | Fragmin | otop. za inj., štrc. napunj. 5x15.000 i.j./0,6 ml | 51,26 | 256,28 | RSRB10 | 5% |
| B01AB05 061 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 10,51 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x20 mg/0,2 ml | 10,51 | 105,10 | RSRB11 | 5% |
| B01AB05 062 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 9,89 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 6x40 mg/0,4 ml | 19,78 | 118,70 | RSRB11 | 5% |
| B01AB05 063 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 9,89 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x40 mg/0,4 ml | 19,78 | 197,84 | RSRB11 | 5% |
| B01AB05 064 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 8,74 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 6x60 mg/0,6 ml | 26,22 | 157,30 |  | 5% |
| B01AB05 065 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 8,74 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x60 mg/0,6 ml | 26,22 | 262,16 |  | 5% |
| B01AB05 066 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 7,74 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x80 mg/0,8 ml | 30,95 | 309,53 |  | 5% |
| B01AB05 067 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 6,33 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x100 mg/1 ml | 31,67 | 316,73 |  | 5% |
| B01AB05 085 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 1,13 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x20 mg/0,2 ml | 11,32 | 113,17 | RSRB11 | 5% |
| B01AB05 086 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 1,09 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x40 mg/0,4 ml | 21,83 | 218,33 | RSRB11 | 5% |
| B01AB05 087 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 1,00 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x60 mg/0,6 ml | 29,97 | 299,70 |  | 5% |
| B01AB05 088 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 0,89 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x80 mg/0,8 ml | 35,43 | 354,33 |  | 5% |
| B01AB05 089 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 0,79 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x100 mg/1 ml | 39,59 | 395,91 |  | 5% |
| B01AB06 021 | DSPO | nadroparinNB102 | 2.85 T i.j. | 14,25 | P | Mylan Hrvatska d.o.o. | Aspen Notre Dame de Bondeville | Fraxiparine | štrc. 10x2850 i.j. anti Xa/0,3 ml | 14,25 | 142,47 | RSRB11 | 5% |
| B01AB06 022 | DSPO | nadroparinNB102 | 2.85 T i.j. | 12,94 | P | Mylan Hrvatska d.o.o. | Aspen Notre Dame de Bondeville | Fraxiparine | štrc. 10x5.700 i.j. anti Xa/0,6 ml | 25,89 | 258,85 | RSRB11 | 5% |
| B01AB06 023 | DSPO | nadroparinNB102 | 2.85 T i.j. | 9,39 | P | Mylan Hrvatska d.o.o. | Aspen Notre Dame de Bondeville | Fraxiparine | štrc. 10x7.600 i.j. anti Xa/0,8 ml | 25,04 | 250,35 |  | 5% |
| B01AB06 024 | DSPO | nadroparinNB102 | 2.85 T i.j. | 14,30 | P | Mylan Hrvatska d.o.o. | Aspen Notre Dame de Bondeville | Fraxiparine | štrc. 10x3.800 i.j. anti Xa/0,4 ml | 19,06 | 190,60 | RSRB11 | 5% |
| B01AC04 111 |  | klopidogrel | 75 mg | 2,26 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Pigrel | tbl. film obl. 28x75 mg | 2,26 | 63,40 | RSRB01 | 5% |
| B01AC04 115 |  | klopidogrel | 75 mg | 2,16 | O | Belupo d.d. | Belupo | Klopidex | tbl. film obl. 30x75 mg | 2,16 | 64,90 | RSRB01 | 5% |
| B01AC04 125 |  | klopidogrel | 75 mg | 2,16 | O | Sandoz d.o.o. | Sandoz-Lek | Kogrel | tbl. film obl. 30x75 mg | 2,16 | 64,90 | RSRB01 | 5% |
| B01AC04 126 |  | klopidogrel | 75 mg | 1,99 | O | Sandoz d.o.o. | Sandoz-Lek | Kogrel | tbl. film obl. 60x75 mg | 1,99 | 119,20 | RSRB01 | 5% |
| B01AC04 131 |  | klopidogrel | 75 mg | 2,26 | O | Krka d.d., Novo mesto | KRKA-FARMA d.o.o. | Zyllt | tbl. film obl. 28x75 mg | 2,26 | 63,40 | RSRB01 | 5% |
| B01AC04 135 |  | klopidogrel | 75 mg | 2,26 | O | Mylan Hrvatska d.o.o. | Phamathen International SA | Gardin | tbl. film obl. 28x75 mg | 2,26 | 63,40 | RSRB01 | 5% |
| B01AC04 145 |  | klopidogrel | 75 mg | 2,26 | O | PharmaS d.o.o. | PharmaS d.o.o. | Klopidogrel PharmaS | tbl. film obl. 28x75 mg | 2,26 | 63,40 | RSRB01 | 5% |
| B01AC04 163 | DS | klopidogrelNB103 | 75 mg | 3,42 | O | sanofi-aventis groupe | Sanofi Winthrop Industrie | Plavix | tbl. film obl. 30x300 mg | 13,68 | 410,40 |  | 5% |
| B01AC06 151 | DS | acetilsalicilna kiselina | 100 mg |  | O |  |  |  |  |  |  |  | 5% |
| B01AC07 051 | DS | dipiridamolNB104 | 0,2 g |  | P |  |  |  |  |  |  |  | 5% |
| B01AC11 062 | KS | iloprostNB105 | 0,15 mg | 1.386,10 | I | Bayer AG | Berlimed S.A. | Ventavis | otop. za atomizator, amp. stakl. 90x2 ml (10 mcg/ml) | 184,81 | 16.633,20 |  | 5% |
| B01AC16 062 | DS | eptifibatidNB106 |  |  | P | GlaxoSmithKline (Ireland) Limited | Glaxo Operations UK Ltd., GlaxoSmithKline Manufacturing S.P.A. | Integrilin | boč. 1x100 ml (0,75 mg/ml) | 420,24 | 420,24 |  | 5% |
| B01AC16 071 | DS | eptifibatidNB106 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Eptifibatid Accord | otop. za inj., boč. stakl. 1x10 ml (2 mg/ml) | 95,61 | 95,61 |  | 5% |
| B01AC16 072 | DS | eptifibatidNB106 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Eptifibatid Accord | otop. za inj., boč. stakl. 1x100 ml (0,75 mg/ml) | 301,05 | 301,05 |  | 5% |
| B01AC22 101 |  | prasugrel | 10 mg | 7,59 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prasugrel Pliva | tbl. film obl. 28x10 mg | 7,59 | 212,61 | RS RB02 | 5% |
| B01AC22 131 |  | prasugrel | 10 mg | 7,40 | O | KRKA-FARMA d.o.o. | Krka d.d. | Eliskardia | tbl. film obl. 28x10 mg | 7,40 | 207,24 | RS RB02 | 5% |
| B01AC22 141 |  | prasugrel | 10 mg | 7,17 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Tosynal | tbl. film obl. 30x10 mg | 7,17 | 215,20 | RS RB02 | 5% |
| B01AC22 171 |  | prasugrel | 10 mg | 7,03 | O | Mylan Pharmaceuticals Limited | McDermott Laboratories t/a Gerard Laboratories t/a Mylan Dublin, Mylan Hungary Kft./Mylan Hungary Ltd. | Prasugrel Mylan | tbl. film obl. 28x10 mg | 7,03 | 196,88 | RS RB02 | 5% |
| B01AC24 111 |  | tikagrelor | 0,18 g | 7,59 | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Greccas | tbl. film obl. 56x90 mg | 3,80 | 212,61 | RS RB02 | 5% |
| B01AC24 171 |  | tikagrelor | 0,18 g | 7,59 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Tilobrastil | tbl. film obl. 56x90 mg | 3,80 | 212,61 | RS RB02 | 5% |
| B01AC24 174 |  | tikagrelor | 0,18 g | 7,59 | O | PharmaS d.o.o. | S.C Labormed – Pharma SA, AdAlvo Limited | Tikagrelor PharmaS | tbl. film obl. 56x90 mg | 3,80 | 212,61 | RS RB02 | 5% |
| B01AC24 181 |  | tikagrelor | 0,18 g | 7,59 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atixarso | tbl. film obl. 56x90 mg | 3,80 | 212,61 | RS RB02 | 5% |
| B01AC24 182 |  | tikagrelor | 0,18 g | 7,59 | O | Abdi Farma Unipessoal Ltd. | Interpharma Services Ltd., Pharmadox Healthcare Limited | Tikagrelor Abdi | tbl. film obl. 56x90 mg | 3,80 | 212,61 | RS RB02 | 5% |
| B01AC24 191 |  | tikagrelor | 0,18 g | 7,59 | O | Mylan Ireland Limited | PharOS MT Ltd | Igzelym | tbl. film obl. 56x90 mg | 3,80 | 212,61 | RS RB02 | 5% |
| B01AC24 192 |  | tikagrelor | 0,18 g | 7,59 | O | STADA d.o.o. | STADA Arzneimittel AG | Tigrix | tbl. film obl. 60x90 mg | 3,80 | 227,80 | RS RB02 | 5% |
| B01AD02 061 | DS | alteplazaNB107 | 0,1 g | 6.210,30 | P | Boehringer Ingelheim Zagreb d.o.o. | Boehringer Ingelheim | Actilyse | lio boč. 1x50 mg | 3.105,15 | 3.105,15 |  | 5% |
| B01AE07 162 | DS | dabigatran eteksilat NB108 | 0,22 g | 22,67 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Pradaxa | caps. tvrda 30x75 mg | 7,73 | 231,90 |  | 5% |
| B01AE07 164 | DS | dabigatran eteksilat NB108 | 0,22 g | 15,41 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Pradaxa | caps. tvrda 30x110 mg | 7,70 | 231,10 |  | 5% |
| B01AF01 161 | DS | rivaroksaban NB108 | 20 mg | 31,95 | O | Bayer AG | Bayer AG | Xarelto | tbl. film obl. 10x10 mg | 15,97 | 159,73 |  | 5% |
| B01AF01 162 | DS | rivaroksaban NB108 | 20 mg | 30,28 | O | Bayer AG | Bayer AG | Xarelto | tbl. film obl. 30x10 mg | 15,14 | 454,14 |  | 5% |
| B01AF01 361 |  | rivaroksaban | 20 mg | 16,50 | O | Bayer AG | Bayer AG | Xarelto | gran. za oral. susp. 1 mg/ml, 100 ml boca | 82,50 | 82,50 | RSRB13 | 5% |
| B01AF01 362 |  | rivaroksaban | 20 mg | 13,20 | O | Bayer AG | Bayer AG | Xarelto | gran. za oral. susp. 1 mg/ml, 250 ml boca | 165,00 | 165,00 | RSRB13 | 5% |
| B01AF01 964 |  | rivaroksaban | 20 mg | 20,18 | O | Bayer AG | Bayer AG | Xarelto | film obl. tbl. 28x15 mg | 15,14 | 423,86 | RSRB14 | 5% |
| B01AF01 965 |  | rivaroksaban | 20 mg | 20,18 | O | Bayer AG | Bayer AG | Xarelto | film obl.tbl. 42x15 mg | 15,14 | 635,80 | RSRB14 | 5% |
| B01AF01 966 |  | rivaroksaban | 20 mg | 15,14 | O | Bayer AG | Bayer AG | Xarelto | film obl.tbl. 28x20 mg | 15,14 | 423,86 | RSRB15 | 5% |
| B01AF02 161 | DS | apiksabanNB108 | 10 mg | 30,28 | O | Bristol-Myers Squibb/Pfizer EEIG | Bristol-Myers Squibb S.r.l. | Eliquis | tbl. film obl. 20x2,5 mg | 7,57 | 151,38 |  | 5% |
| B01AX05 061 | DS | fondaparinuksNB109 | 2,5 mg | 32,53 | P | Mylan IRE Healthcare Ltd | Aspen Notre Dame de Bondeville | Arixtra | otop. za inj., štrc. napunj. 10x2,5 mg/0,5 ml | 32,53 | 325,33 |  | 5% |
| B02AA01 052 | DS | aminokapronska kiselina | 16 g |  | P |  |  |  |  |  |  |  | 5% |
| B02AA02 051 | DS | traneksamična kiselinaNB201 | 2 g |  | P |  |  |  |  |  |  |  | 5% |
| B02AA02 061 | DS | traneksamatna kiselina | 2 g | 53,01 | P | Makpharm d.o.o. | Bioindustria Lim SPA | Trenolk | amp. 5x5 ml (100 mg/ml) | 13,25 | 66,26 |  | 5% |
| B02AA02 151 | DS | traneksamična kiselinaNB201 | 2 g |  | O |  |  |  |  |  |  |  | 5% |
| B02AB01 051 | DS | aprotinin NB202 | 500 T i.j. |  | P |  |  |  |  |  |  |  | 5% |
| B02BA01 062 | PR | fitomenadion | 20 mg | 7,76 | P | Cheplapharm Arzneimittel GmbH | Cheplapharm Arzneimittel GmbH | Konakion | amp. 5x10 mg/ml | 3,88 | 19,40 |  | 5% |
| B02BA01 151 |  | fitomenadion | 20 mg |  | O |  |  |  |  |  |  | R | 5% |
| B02BB01 071 | DS | fibrinogen | 5 g | 14.690,00 | P | Jana Pharm d.o.o. | Octapharma Pharmazeutika Produktionsges.m.b.H., Octapharma AB | Fibryga | praš. i otap. za otop. za inj./inf., stak. boč. 1x1 g | 2.938,00 | 2.938,00 |  | 5% |
| B02BC30 962 | DS | ljudski fibrinogen, ljudski trombin |  |  | L | Corza Medical GmbH | Takeda | TachoSil | 1 matrica tkivnog ljepila 9,5 cm x 4,8 cm | 1.866,18 | 1.866,18 |  | 5% |
| B02BC30 963 | DS | ljudski fibrinogen, ljudski trombin |  |  | L | Corza Medical GmbH | Takeda | TachoSil | 1 matrica tkivnog ljepila 3,0 cm x 2,5 cm | 355,62 | 355,62 |  | 5% |
| B02BC30 964 | DS | ljudski fibrinogen, ljudski trombin |  |  | L | Corza Medical GmbH | Takeda Austria GmbH | TachoSil | 2 matrice tkivnog ljepila od 4,8 x 4,8 cm | 1.270,44 | 2.540,88 |  | 5% |
| B02BC30 965 | DS | ljudski fibrinogen, ljudski trombin |  |  | L | Corza Medical GmbH | Takeda Austria GmbH | TachoSil | 1 prethodno zarolana matrica tkivnog ljepila od 4,8 x 4,8 cm | 1.544,75 | 1.544,75 |  | 5% |
| B02BD01 071 | DS | ljudski protrombinski kompleksNB203 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octaplex 500 IU | praš. i otap. za otop. za inf. boč. stakl. boč. s praš., boč. stakl. 1x500 i.j., s 20 ml otap. i 1 set za prijenos (igla za filtraciju i dvostrana igla) | 1.584,78 | 1.584,78 |  | 5% |
| B02BD01 081 | DS | ljudski protrombinski kompleksNB203 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Beriplex | praš. i otap. za otop. za inf. boč. stakl. boč. s praš., boč. stakl. 1x500 i.j., s 20 ml otap. i 1 set za prijenos s filterom | 1.651,06 | 1.651,06 |  | 5% |
| B02BD01 082 | DS | ljudski protrombinski kompleksNB203 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Beriplex | praš. i otap. za otop. za inf. boč. stakl. boč. s praš., boč. stakl. 1x1000 i.j., s 40 ml otap. i 1 set za prijenos s filterom | 3.333,41 | 3.333,41 |  | 5% |
| B02BD02 001 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 1.264,02 | 1.264,02 |  | 5% |
| B02BD02 002 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 2.528,05 | 2.528,05 |  | 5% |
| B02BD02 003 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x750 i.j. | 3.792,08 | 3.792,08 |  | 5% |
| B02BD02 004 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 5.056,10 | 5.056,10 |  | 5% |
| B02BD02 005 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x1500 i.j. | 7.584,15 | 7.584,15 |  | 5% |
| B02BD02 006 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 10.112,20 | 10.112,20 |  | 5% |
| B02BD02 007 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x3000 i.j. | 15.168,31 | 15.168,31 |  | 5% |
| B02BD02 008 | DS | rekombinantni čimbenik VIII (lonoktokog alfa)NB205 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Afstyla | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 1.157,50 | 1.157,50 |  | 5% |
| B02BD02 009 | DS | rekombinantni čimbenik VIII (lonoktokog alfa)NB205 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Afstyla | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 2.315,00 | 2.315,00 |  | 5% |
| B02BD02 010 | DS | rekombinantni čimbenik VIII (lonoktokog alfa)NB205 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Afstyla | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 4.630,00 | 4.630,00 |  | 5% |
| B02BD02 011 | DS | rekombinantni čimbenik VIII (damoktokog alfa pegol)NB207 |  |  | P | Bayer AG | Bayer AG | Jivi 500 IU | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 3.045,00 | 3.045,00 |  | 5% |
| B02BD02 012 | DS | rekombinantni čimbenik VIII (damoktokog alfa pegol)NB207 |  |  | P | Bayer AG | Bayer AG | Jivi 1000 IU | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 6.090,00 | 6.090,00 |  | 5% |
| B02BD02 013 | DS | rekombinantni čimbenik VIII (damoktokog alfa pegol)NB207 |  |  | P | Bayer AG | Bayer AG | Jivi 2000 IU | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 12.180,00 | 12.180,00 |  | 5% |
| B02BD02 014 | DS | rekombinantni čimbenik VIII (damoktokog alfa pegol)NB207 |  |  | P | Bayer AG | Bayer AG | Jivi 3000 IU | praš. i otap. za otop. za inj., boč. stakl. 1x3000 i.j. | 18.270,00 | 18.270,00 |  | 5% |
| B02BD02 021 | DS | rekombinantni čimbenik VIII (rurioktokog alfa pegol)NB207 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | Adynovi | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 2.821,20 | 2.821,20 |  | 5% |
| B02BD02 022 | DS | rekombinantni čimbenik VIII (rurioktokog alfa pegol)NB207 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | Adynovi | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 5.550,46 | 5.550,46 |  | 5% |
| B02BD02 023 | DS | rekombinantni čimbenik VIII (turoktokog alfa pegol)NB207 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Esperoct | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 2.470,00 | 2.470,00 |  | 5% |
| B02BD02 024 | DS | rekombinantni čimbenik VIII (turoktokog alfa pegol)NB207 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Esperoct | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 4.940,00 | 4.940,00 |  | 5% |
| B02BD02 025 | DS | rekombinantni čimbenik VIII (turoktokog alfa pegol)NB207 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Esperoct | praš. i otap. za otop. za inj., boč. stakl. 1x3000 i.j. | 14.820,00 | 14.820,00 |  | 5% |
| B02BD02 031 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 1.189,59 | 1.189,59 |  | 5% |
| B02BD02 033 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 i.j. | 4.670,49 | 4.670,49 |  | 5% |
| B02BD02 034 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x1.500 i.j. | 6.923,77 | 6.923,77 |  | 5% |
| B02BD02 035 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x2.000 i.j. | 9.340,98 | 9.340,98 |  | 5% |
| B02BD02 036 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x3.000 i.j. | 13.847,54 | 13.847,54 |  | 5% |
| B02BD02 061 | DS | čimbenik VIIINB204 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Emoclot | praš. i otap. za otop. za inf., boč. stakl. 1x500 i.j. (50 IU/ml) | 1.284,88 | 1.284,88 |  | 5% |
| B02BD02 062 | DS | čimbenik VIIINB204 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Emoclot | praš. i otap. za otop. za inf., boč. stakl. 1x1000 i.j. (100 IU/ml) | 2.373,50 | 2.373,50 |  | 5% |
| B02BD02 072 | DS | čimbenik VIIINB204 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octanate | lio. boč. 500 i.j. | 1.427,65 | 1.427,65 |  | 5% |
| B02BD02 073 | DS | čimbenik VIIINB204 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octanate | lio. boč. 1.000 i.j. | 2.637,23 | 2.637,23 |  | 5% |
| B02BD02 079 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Advate | praš. i otap. za otop. za inj., boč. stakl. 1x500 IU/5 ml | 2.555,52 | 2.555,52 |  | 5% |
| B02BD02 080 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Advate | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 IU/5 ml | 5.114,98 | 5.114,98 |  | 5% |
| B02BD02 082 | DS | rekombinantni čimbenik VIII (moroktokog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | ReFacto AF | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 1.214,24 | 1.214,24 |  | 5% |
| B02BD02 083 | DS | rekombinantni čimbenik VIII (moroktokog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | ReFacto AF | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 2.299,97 | 2.299,97 |  | 5% |
| B02BD02 084 | DS | rekombinantni čimbenik VIII (moroktokog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | ReFacto AF | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 i.j. | 4.767,27 | 4.767,27 |  | 5% |
| B02BD02 085 | DS | rekombinantni čimbenik VIII (moroktokog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | ReFacto AF | praš. i otap. za otop. za inj., boč. stakl. 1x2.000 i.j. | 9.534,54 | 9.534,54 |  | 5% |
| B02BD02 086 | DS | rekombinantni čimbenik VIII (simoktokog alfa)NB205 |  |  | P | Octapharma AB | Octapharma AB | Nuwiq | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 1.189,59 | 1.189,59 |  | 5% |
| B02BD02 087 | DS | rekombinantni čimbenik VIII (simoktokog alfa)NB205 |  |  | P | Octapharma AB | Octapharma AB | Nuwiq | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 2.253,28 | 2.253,28 |  | 5% |
| B02BD02 088 | DS | rekombinantni čimbenik VIII (simoktokog alfa)NB205 |  |  | P | Octapharma AB | Octapharma AB | Nuwiq | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 i.j. | 4.670,49 | 4.670,49 |  | 5% |
| B02BD02 095 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Bayer AG | Bayer AG | Kovaltry | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 2.528,05 | 2.528,05 |  | 5% |
| B02BD02 096 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Bayer AG | Bayer AG | Kovaltry | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 5.056,10 | 5.056,10 |  | 5% |
| B02BD02 097 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Bayer AG | Bayer AG | Kovaltry | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 10.112,20 | 10.112,20 |  | 5% |
| B02BD03 063 | DS | aktivirani koncentrat čimbenika protrombinskog kompleksaNB204 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Feiba 50 U/ml | praš. i otap. za otop. za inf., boč. 1x500 U/10 ml (50 U/ml) | 2.911,36 | 2.911,36 |  | 5% |
| B02BD04 063 | DS | čimbenik IX NB204 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octanine F | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. + 5 ml otap. + set | 1.401,29 | 1.401,29 |  | 5% |
| B02BD04 072 | DS | čimbenik IX NB204 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Immunine 600 IU | praš. i otap. za otop. za inj./inf., boč. 1x600 IU/5 ml | 1.601,00 | 1.601,00 |  | 5% |
| B02BD04 074 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 1.898,75 | 1.898,75 |  | 5% |
| B02BD04 075 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 3.797,50 | 3.797,50 |  | 5% |
| B02BD04 076 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 7.595,00 | 7.595,00 |  | 5% |
| B02BD04 077 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 15.190,00 | 15.190,00 |  | 5% |
| B02BD04 078 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x3000 i.j. | 22.785,00 | 22.785,00 |  | 5% |
| B02BD04 091 | DS | rekombinantni humani faktor IX (nonakog beta pegol)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Refixia | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 4.745,00 | 4.745,00 |  | 5% |
| B02BD04 092 | DS | rekombinantni humani faktor IX (nonakog beta pegol)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Refixia | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 9.490,00 | 9.490,00 |  | 5% |
| B02BD04 093 | DS | rekombinantni humani faktor IX (nonakog beta pegol)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Refixia | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 18.980,00 | 18.980,00 |  | 5% |
| B02BD04 095 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 891,19 | 891,19 |  | 5% |
| B02BD04 096 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 1.782,38 | 1.782,38 |  | 5% |
| B02BD04 097 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 i.j. | 3.564,76 | 3.564,76 |  | 5% |
| B02BD04 098 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x2.000 i.j. | 7.129,52 | 7.129,52 |  | 5% |
| B02BD06 075 | DS | koagulacijski faktor VIII, ljudski, von Willebrandov faktor, ljudskiNB206 |  |  | P | Jana Pharm d.o.o. | Octapharma | Wilate 500, 500 IU FVIII i 500 IU vWF | praš. i otap. za otop. za inj., boč. 1x500 IU i 500 IU | 2.014,48 | 2.014,48 |  | 5% |
| B02BD06 076 | DS | konc. čimbenik VIII s von Willebrandovim čimbenikomNB204 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Immunate 500 IU FVIII/375 IU vWF | praš. i otap. za otop. za inj., boč. 1x500 IU FVIII/375 IU vWF/5 ml | 1.468,23 | 1.468,23 |  | 5% |
| B02BD06 077 | DS | koagulacijski faktor VIII, ljudski, von Willebrandov faktor, ljudskiNB206 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Haemate P 1200 IU VWF/500 IU FVIII | praš. i otap. za otop. za inj., boč. 1x1.200 IU vWF/500 IU FVIII | 1.822,33 | 1.822,33 |  | 5% |
| B02BD07 051 | DS | čimbenik ugrušavanja krvi XIIINB204 |  |  | P |  |  |  |  |  |  |  | 5% |
| B02BD08 084 | DS | aktivirani rekombinantni čimbenik VII A NB204 |  |  | P | Novo Nordisk A/S | Novo Nordisk | NovoSeven | praš. i otap. za otop. za inj., 1x1 mg (50 KIU) | 4.454,72 | 4.454,72 |  | 5% |
| B02BD08 088 | DS | aktivirani rekombinantni čimbenik VII A NB204 |  |  | P | Novo Nordisk A/S | Novo Nordisk | NovoSeven | praš. i otap. za otop. za inj., 1x2 mg (100 KIU) | 8.826,29 | 8.826,29 |  | 5% |
| B02BD08 089 | DS | aktivirani rekombinantni čimbenik VII A NB204 |  |  | P | Novo Nordisk A/S | Novo Nordisk | NovoSeven | praš. i otap. za otop. za inj., 1x5 mg (250 KIU) | 21.931,17 | 21.931,17 |  | 5% |
| B02BX04 063 | KS | romiplostimNB504 | 30 mcg | 494,28 | P | Amgen Europe B.V. | Amgen Europe B.V. | Nplate | praš. i otap. za otop. za inj., štrc. napunj. 1x250 mcg | 4.119,02 | 4.119,02 |  | 5% |
| B02BX04 064 | KS | romiplostimNB504 | 30 mcg | 497,55 | P | Amgen Europe B.V. | Amgen Europe B.V. | Nplate | praš. i otap. za otop. za inj., štrc. napunj. 1x500 mcg | 8.292,46 | 8.292,46 |  | 5% |
| B02BX05 161 | KS | eltrombopagNB504 | 50 mg | 484,83 | O | Novartis Europharm Limited Irska | Lek d.d., Novartis Pharma GmbH | Revolade | tbl. film obl. 28x25 mg | 242,41 | 6.787,56 |  | 5% |
| B02BX05 162 | KS | eltrombopagNB504 | 50 mg | 484,83 | O | Novartis Europharm Limited Irska | Lek d.d., Novartis Pharma GmbH | Revolade | tbl. film obl. 28x50 mg | 484,83 | 13.575,13 |  | 5% |
| B02BX06 071 | DS | emicizumabNB507 | 15 mg | 8.055,45 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x1 ml (30 mg/ml) | 16.110,89 | 16.110,89 |  | 5% |
| B02BX06 072 | DS | emicizumabNB507 | 15 mg | 8.025,84 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x0,4 ml (150 mg/ml) | 32.103,36 | 32.103,36 |  | 5% |
| B02BX06 073 | DS | emicizumabNB507 | 15 mg | 8.010,10 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x0,7 ml (150 mg/ml) | 56.070,69 | 56.070,69 |  | 5% |
| B02BX06 074 | DS | emicizumabNB507 | 15 mg | 8.003,81 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x1 ml (150 mg/ml) | 80.038,07 | 80.038,07 |  | 5% |
| B02BX06 971 | DS | emicizumabNB510 | 15 mg | 8.055,45 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x1 ml (30 mg/ml) | 16.110,89 | 16.110,89 |  | 5% |
| B02BX06 972 | DS | emicizumabNB510 | 15 mg | 8.025,84 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x0,4 ml (150 mg/ml) | 32.103,36 | 32.103,36 |  | 5% |
| B02BX06 973 | DS | emicizumabNB510 | 15 mg | 8.010,10 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x0,7 ml (150 mg/ml) | 56.070,69 | 56.070,69 |  | 5% |
| B02BX06 974 | DS | emicizumabNB510 | 15 mg | 8.003,81 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x1 ml (150 mg/ml) | 80.038,07 | 80.038,07 |  | 5% |
| B02BX08 171 | KS | avatrombopagNB504 | 20 mg | 484,83 | O | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Doptelet | tbl. film obl. 10x20 mg | 484,83 | 4.848,30 |  | 5% |
| B02BX08 172 | KS | avatrombopagNB504 | 20 mg | 484,83 | O | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Doptelet | tbl. film obl. 15x20 mg | 484,83 | 7.272,45 |  | 5% |
| B02BX08 173 | KS | avatrombopagNB504 | 20 mg | 484,83 | O | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Doptelet | tbl. film obl. 30x20 mg | 484,83 | 14.544,90 |  | 5% |
| B03AA02 141 |  | željezo II -fumarat | 0,2 g | 0,49 | O | Alkaloid d.o.o. | Alkaloid | Heferol | caps. 30x350 mg | 0,86 | 25,82 | R | 5% |
| B03AC01 021 | DS | željezo karboksimaltoza | 100 mg | 149,04 | P | Vifor France S.A. | Vifor France S.A. | Ferinject | otop. za inj. ili inf. , boč. 1x10 ml (50 mg/ml) | 745,21 | 745,21 |  | 5% |
| B03AC01 022 | DS | željezo karboksimaltoza | 100 mg | 141,59 | P | Vifor France S.A. | Vifor France S.A. | Ferinject | otop. za inj. ili inf. , boč. 1x20 ml (50 mg/ml) | 1.415,89 | 1.415,89 |  | 5% |
| B03AC02 051 | DS | željezo III-oksid saharat | 100 mg | 44,36 | P |  |  |  | 1x100 mg | 44,36 |  |  | 5% |
| B03AC05 051 | PO | željezo III-sorbitol glukonska kiselina |  |  | P |  |  |  |  |  |  |  | 5% |
| B03AC06 062 | DS | željezova(III) derizomaltoza | 100 mg | 149,04 | P | Pharmacosmos A/S | Pharmacosmos A/S | Monofer | otop. za inj./inf., amp./boč. 5x5 ml (100 mg/ml) | 745,21 | 3.726,05 |  | 5% |
| B03BA01 051 | PR | cijanokobalamin | 20 mcg |  | P |  |  |  |  |  |  |  | 5% |
| B03BB01 161 |  | folatna kiselina | 10 mg | 1,63 | O | Makpharm d.o.o. | G.L. Pharma GmbH | Folbella | tbl. 30x5 mg | 0,82 | 24,48 | R | 5% |
| B03XA01 001 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 37,85 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj., štrc. napunj. 6x2.000 i.j./0,5 ml | 75,69 | 454,16 |  | 5% |
| B03XA01 002 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 37,82 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj., štrc. napunj. 6x3.000 i.j./0,5 ml | 113,46 | 680,74 |  | 5% |
| B03XA01 003 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 37,51 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj. štrc. napunj. 6x4.000 i.j./0,5 ml | 150,05 | 900,28 |  | 5% |
| B03XA01 004 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 34,99 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj., štrc. napunj. 6x10.000 i.j./ml | 349,89 | 2.099,36 |  | 5% |
| B03XA01 005 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 34,77 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj., štrc. napunj. 1x20.000 i.j./ml | 695,46 | 695,46 |  | 5% |
| B03XA01 021 | DSPO | epoetin alfaNB301 | 1 T i.j. | 34,06 | P | Sandoz GmbH | Sandoz | Binocrit | otop. za inj., štrc. napunj. 6x2.000 i.j/ml | 68,12 | 408,74 |  | 5% |
| B03XA01 023 | DSPO | epoetin alfaNB301 | 1 T i.j. | 33,76 | P | Sandoz GmbH | Sandoz | Binocrit | otop. za inj., štrc. napunj. 6x4.000 i.j/0,4 ml | 135,04 | 810,25 |  | 5% |
| B03XA01 075 | DSPO | epoetin betaNB301 | 1 T i.j. | 34,22 | P | Roche Registration GmbH | Roche | NeoRecormon | šprica 6x2.000 i.j/0,3 ml | 68,44 | 410,64 |  | 5% |
| B03XA01 077 | DSPO | epoetin betaNB301 | 1 T i.j. | 33,26 | P | Roche Registration GmbH | Roche | NeoRecormon | šprica 6x4.000 i.j/0,3 ml | 133,02 | 798,12 |  | 5% |
| B03XA01 078 | DSPO | epoetin betaNB301 | 1 T i.j. | 32,72 | P | Roche Registration GmbH | Roche | NeoRecormon | šprica 6x10.000 i.j/0,6 ml | 327,22 | 1.963,34 |  | 5% |
| B03XA01 081 | DSPO | eritropoetin zetaNB301 | 1 T i.j. | 37,85 | P | Pfizer Europe MA EEIG | STADA Arzneimittel AG, Hospira Enterprises B.V. | Retacrit | otop. za inj., štrc. napunj. 6x2.000 i.j/0,6 ml | 75,69 | 454,16 |  | 5% |
| B03XA01 082 | DSPO | eritropoetin zetaNB301 | 1 T i.j. | 37,51 | P | Pfizer Europe MA EEIG | STADA Arzneimittel AG, Hospira Enterprises B.V. | Retacrit | otop. za inj., štrc. napunj. 6x4.000 i.j/0,4 ml | 150,05 | 900,28 |  | 5% |
| B03XA01 083 | DSPO | eritropoetin zetaNB301 | 1 T i.j. | 33,49 | P | Pfizer Europe MA EEIG | STADA Arzneimittel AG, Hospira Enterprises B.V. | Retacrit | otop. za inj., štrc. napunj. 6x10.000 i.j/ml | 334,89 | 2.009,36 |  | 5% |
| B03XA02 061 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 52,98 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x10 mcg/0,4 ml (25 mcg/ml) | 117,73 | 117,73 |  | 5% |
| B03XA02 062 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 51,64 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x30 mcg/0,3ml (100 mcg/ml) | 344,30 | 344,30 |  | 5% |
| B03XA02 063 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 57,73 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x20 mcg/0,5 ml (40 mcg/ml) | 230,93 | 230,93 |  | 5% |
| B03XA02 064 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 51,96 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x40 mcg/0,4 ml (100 mcg/ml) | 461,84 | 461,84 |  | 5% |
| B03XA02 065 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 51,96 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x50 mcg/0,5 ml (100 mcg/ml) | 577,30 | 577,30 |  | 5% |
| B03XA02 066 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 51,96 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x60 mcg/0,3 ml (200 mcg/ml) | 692,76 | 692,76 |  | 5% |
| B03XA02 067 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 51,96 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x80 mcg/0,4 ml (200 mcg/ml) | 923,68 | 923,68 |  | 5% |
| B03XA03 062 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 46,46 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x50 mcg/0,3 ml | 580,79 | 580,79 |  | 5% |
| B03XA03 063 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 45,56 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x75 mcg/0,3 ml | 854,19 | 854,19 |  | 5% |
| B03XA03 064 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 45,56 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x100 mcg/0,3ml | 1.138,91 | 1.138,91 |  | 5% |
| B03XA03 065 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 45,56 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x120 mcg/0,3ml | 1.366,69 | 1.366,69 |  | 5% |
| B03XA03 066 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 45,56 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x150 mcg/0,3ml | 1.708,36 | 1.708,36 |  | 5% |
| B03XA03 067 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 45,56 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj. štrc. napunj. 1x200 mcg/0,3ml | 2.277,82 | 2.277,82 |  | 5% |
| B05AA01 011 | DS | ljudski albumin 5%NB501 |  |  | P | Imunološki zavod | Imunološki zavod | Albumin ljudski 50 g/l | otop. za inf., boca stakl. 1x250 ml | 258,00 | 258,00 |  | 5% |
| B05AA01 012 | DS | ljudski albumin 20%NB502 |  |  | P | Imunološki zavod | Imunološki zavod | Albumin (ljudski) 20% | otop. za inf., boca stakl. 1x50 ml | 200,77 | 200,77 |  | 5% |
| B05AA01 013 | DS | ljudski albumin 20%NB502 |  |  | P | Imunološki zavod | Imunološki zavod | Albumin (ljudski) 20% | otop. za inf., boca stakl. 1x100 ml | 408,59 | 408,59 |  | 5% |
| B05AA01 064 | DS | ljudski albumin 20%NB502 |  |  | P | Jana Pharm d.o.o. | Octapharma | Albunorm 20% (non HR) | otop. za inf., boč. stakl. 1x100 ml | 408,59 | 408,59 |  | 5% |
| B05AA01 065 | DS | ljudski albumin 5%NB501 |  |  | P | Jana Pharm d.o.o. | Octapharma Pharmazeutika Octapharma S.A.S., Octapharma AB, Octapharma Produktionsgesellschaft, Octapharma GmbH | Albunorm 5% | otop. za inf., boca stakl. 1x250 ml | 258,00 | 258,00 |  | 5% |
| B05AA01 066 | DS | ljudski albumin 20%NB502 |  |  | P | Jana Pharm d.o.o. | Octapharma | Albunorm 20% | otop. za inf., boca stakl. 1x50 ml | 200,77 | 200,77 |  | 5% |
| B05AA01 067 | DS | ljudski albumin 5%NB501 |  |  | P | Jana Pharm d.o.o. | Octapharma Pharmazeutika Octapharma S.A.S., Octapharma AB, Octapharma Produktionsgesellschaft, Octapharma GmbH | Albunorm 5% | otop. za inf., boca stakl. 1x100 ml | 122,35 | 122,35 |  | 5% |
| B05AA01 075 | DS | ljudski albumin 20%NB502 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Human albumin Kedrion | otop. za inf., stakl. boč. 1x50 ml (200 g/l) | 200,77 | 200,77 |  | 5% |
| B05AA01 076 | DS | ljudski albumin 20%NB502 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Human albumin Kedrion | otop. za inf., stakl. boč. 1x100 ml (200 g/l) | 408,59 | 408,59 |  | 5% |
| B05AA01 081 | DS | ljudski albumin 20%NB502 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Albumeon 200 g/l | boč. 1x50 ml | 200,77 | 200,77 |  | 5% |
| B05AA01 083 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 1x50 ml/kutija | 200,77 | 200,77 |  | 5% |
| B05AA01 084 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 12x50 ml/kutija, 2 kutije | 200,77 | 4.818,48 |  | 5% |
| B05AA01 085 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 1x50 ml/kutija, 24 kutije | 200,77 | 4.818,48 |  | 5% |
| B05AA01 086 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 1x100 ml/kutija | 408,59 | 408,59 |  | 5% |
| B05AA01 087 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 6x100 ml/kutija, 2 kutije | 408,59 | 4.903,08 |  | 5% |
| B05AA01 088 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 1x100 ml/kutija, 12 kutija | 408,59 | 4.903,08 |  | 5% |
| B05AA01 089 | DS | ljudski albumin 20%NB502 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Albumeon 200 g/l | boč. 1x100 ml | 388,16 | 388,16 |  | 5% |
| B05AA01 964 | DS | ljudski albumin 20%NB502 |  |  | P | Jana Pharm d.o.o. | Octapharma | Albunorm 20% (HR) | otop. za inf., boč. stakl. 1x100 ml | 326,87 | 326,87 |  | 5% |
| B05AA02 061 | DS | proteini ljudske plazmeNV701 |  |  | P | Octapharma (IP) SPRL | Octapharma Pharmazeutika Produktionsges.m.b.H., Octapharma AB | octaplasLG | otop. za inf., vreć. 1x200 ml (45-70 mg/ml) | 647,97 | 647,97 |  | 5% |
| B05AA05 002 | PR | dekstran 40 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Soludeks 40 | otop. za inf., boca stakl. 10x500 ml (100 mg/ml) | 42,65 | 426,50 |  | 5% |
| B05AA06 051 | DS | želatina |  |  | P |  |  |  |  |  |  |  | 5% |
| B05AA07 063 | DS | hidroksietil škrob |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Voluven 6% | boca 10x500 ml | 49,41 | 494,10 |  | 5% |
| B05AA07 064 | DS | hidroksietil škrob |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Voluven 6% | vreć. plast. 20x500 ml | 49,41 | 988,20 |  | 5% |
| B05AA07 081 | DS | hidroksietil škrob (poli-o-2-hidroksietil škrob) |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Volulyte 6% | otop. za inf., vreć. poliolef. 20x500 ml | 40,02 | 800,44 |  | 5% |
| B05BA01 081 | DS | infuzije aminokiselina (N (2)-L-alanin-L-glutamin) |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Dipeptiven | boč. 10x100 ml | 233,94 | 2.339,36 |  | 5% |
| B05BA01 091 | DS | infuzije aminokiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Nephrotect 10% | boč. 10x500 ml | 110,85 | 1.108,50 |  | 5% |
| B05BA02 065 | DS | otopine masti i masnih kiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SMOFlipid 20% emulzija za infuziju | boca stakl. 10x100 ml | 35,24 | 352,40 |  | 5% |
| B05BA02 066 | DS | otopine masti i masnih kiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SMOFlipid 20% emulzija za infuziju | boca stakl. 10x500 ml | 93,77 | 937,70 |  | 5% |
| B05BA03 008 | PO | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 5% otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (50 mg/ml) | 6,85 | 68,50 |  | 5% |
| B05BA03 010 | PO | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 10% otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (100 mg/ml) | 8,86 | 88,60 |  | 5% |
| B05BA03 012 | DS | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 10% otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (100 mg/ml) | 7,59 | 75,90 |  | 5% |
| B05BA03 021 | PO | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza 5% | otop. za inf., boca stakl. 10x500 ml (50 mg/ml) | 6,85 | 68,50 |  | 5% |
| B05BA03 022 | PR | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 5% otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (50 mg/ml) | 6,20 | 62,00 |  | 5% |
| B05BA03 023 | DS | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 5% otopina za infuziju | otop. za inf., boč. stakl. 20x100 ml (50 mg/ml) | 5,86 | 117,20 |  | 5% |
| B05BA03 024 | PO | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza 10% | otop. za inf., boca stakl. 10x500 ml (100 mg/ml) | 8,86 | 88,60 |  | 5% |
| B05BA03 026 | DS | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 10% otopina za infuziju | otop. za inf., boč. stakl. 20x100 ml (100 mg/ml) | 6,47 | 129,40 |  | 5% |
| B05BA03 061 | DS | glukoza |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Glukoza 5% Viaflo | otop. za inf.,vreć. plast. 50x100 ml (50mg/ml) | 6,53 | 326,50 |  | 5% |
| B05BA03 062 | PR | glukoza |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Glukoza 5% Viaflo | otop. za inf., vreć. plast. 30x250 ml (50mg/ml) | 6,93 | 207,90 |  | 5% |
| B05BA03 063 | PO | glukoza |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Glukoza 5% Viaflo | otop. za inf., vreć. plast. 20x500 ml (50mg/ml) | 7,65 | 153,00 |  | 5% |
| B05BA03 067 | DS | glukoza |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Glukoza 5% Viaflo | otop. za inf., vreć. plast. 60x100 ml (50mg/ml) | 5,58 | 334,80 |  | 5% |
| B05BA03 071 | DS | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 50 mg/ml | otop. za inf., 50 mg/ml, polietil. Ecoflac plus boca, 20x100 ml | 5,88 | 117,54 |  | 5% |
| B05BA03 072 | PR | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 50 mg/ml | otop. za inf., 50 mg/ml, polietil. Ecoflac plus boca, 10x250 ml | 6,24 | 62,37 |  | 5% |
| B05BA03 073 | PO | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 50 mg/ml | otop. za inf., 50 mg/ml, polietil. Ecoflac plus boca, 10x500 ml | 6,89 | 68,85 |  | 5% |
| B05BA03 074 | DS | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 50 mg/ml | otop. za inf., 50 mg/ml, polietil. Ecoflac plus boca, 10x1000 ml | 11,92 | 119,17 |  | 5% |
| B05BA03 075 | PO | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 100 mg/ml | otop. za inf., 100 mg/ml, polietil. Ecoflac plus boca, 10x500 ml | 8,89 | 88,90 |  | 5% |
| B05BA03 076 | DS | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 100 mg/ml | otop. za inf., 100 mg/ml, polietil. Ecoflac plus boca, 10x1000 ml | 12,33 | 123,28 |  | 5% |
| B05BA03 077 | DS | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., boca plast. 40x100 ml | 5,29 | 211,60 |  | 5% |
| B05BA03 078 | PO | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 10% | otop. za inf., boca plast. 10x500 ml | 8,00 | 80,00 |  | 5% |
| B05BA03 079 | PR | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., boca plast. 20x250 ml | 5,62 | 112,32 |  | 5% |
| B05BA03 080 | PO | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., boca plast. 10x500 ml | 6,20 | 61,97 |  | 5% |
| B05BA03 081 | DS | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 60x50 ml | 5,30 | 318,06 |  | 5% |
| B05BA03 084 | PO | glukoza |  |  | P | Baxter d.o.o. | Bieffe Medital S.A. | Glukoza 10% Viaflo | otop. za inf., vreć. plast. 20x500 ml, (100 mg/ml) | 7,20 | 144,00 |  | 5% |
| B05BA03 086 | DS | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 50x100 ml | 5,88 | 293,85 |  | 5% |
| B05BA03 087 | PR | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 30x250 ml | 6,24 | 187,11 |  | 5% |
| B05BA03 088 | PO | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 20x500 ml | 6,89 | 137,70 |  | 5% |
| B05BA03 089 | DS | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 10x1000 ml | 13,08 | 130,82 |  | 5% |
| B05BA10 025 | DS | otopina aminokiselina s elektrolitima + otopina glukoze + lipidna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven Nutribase | vreć. plast. 4x1026 ml | 192,13 | 768,52 |  | 5% |
| B05BA10 026 | DS | otopina aminokiselina s elektrolitima + otopina glukoze + lipidna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven Nutribase | vreć. plast. 4x1539 ml | 242,04 | 968,16 |  | 5% |
| B05BA10 031 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega peri | emulzija za infuziju, vreć. 5x1250 ml | 206,30 | 1.031,50 |  | 5% |
| B05BA10 032 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega peri | emulzija za infuziju, vreć. 5x1875 ml | 259,81 | 1.299,05 |  | 5% |
| B05BA10 033 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 56/144 specijal | emulzija za infuziju, vreć. 5x625 ml | 117,99 | 589,95 |  | 5% |
| B05BA10 034 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 38/120 plus | emulzija za infuziju, vreć. 5x1250 ml | 174,82 | 874,10 |  | 5% |
| B05BA10 047 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 56/144 specijal | emulzija za infuziju, vreć. 5x1250 ml | 203,88 | 1.019,40 |  | 5% |
| B05BA10 048 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 56/144 specijal | emulzija za infuziju, vreć. 5x1875 ml | 278,18 | 1.390,90 |  | 5% |
| B05BA10 049 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 38/120 plus | emulzija za infuziju, vreć. 5x1875 ml | 238,72 | 1.193,60 |  | 5% |
| B05BA10 060 | DS | glukoza + otopina aminokiselina + emulzija lipidaNB400 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven extra Nitrogen bez elektrolita | emulz. za inf., vreć. 4x2025 ml | 608,33 | 2.433,32 |  | 5% |
| B05BA10 061 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | OliClinomel N4-550E | emulz. za inf., vreć. plast. 6x1000 ml | 161,16 | 966,93 |  | 5% |
| B05BA10 062 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | OliClinomel N4-550E | emulz. za inf., vreć. plast. 4x2000 ml | 219,43 | 877,70 |  | 5% |
| B05BA10 064 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | OliClinomel N7-1000E | emulz. za inf., vreć. plast. 6x1000 ml | 169,27 | 1.015,62 |  | 5% |
| B05BA10 065 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | OliClinomel N7-1000E | emulz. za inf., vreć. plast. 4x2000 ml | 253,52 | 1.014,09 |  | 5% |
| B05BA10 066 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Kabiven | vreć. plast. 4x1026 ml | 167,84 | 671,37 |  | 5% |
| B05BA10 067 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Kabiven | vreć. plast. 4x1540 ml | 185,78 | 743,11 |  | 5% |
| B05BA10 068 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Kabiven Peripheral | vreć. plast. 4x1440 ml | 184,07 | 736,28 |  | 5% |
| B05BA10 069 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Kabiven Peripheral | vreć. plast. 4x1920 ml | 194,88 | 779,52 |  | 5% |
| B05BA10 070 | DS | glukoza + otopina aminokiselina s elektrolitima + emulzija lipidaNB400 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven extra Nitrogen | emulz. za inf., vreć. 4x1518 ml | 492,84 | 1.971,36 |  | 5% |
| B05BA10 075 | DS | infuzije aminokiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Aminoven Infant 10% | boč. 10x250 ml | 55,55 | 555,50 |  | 5% |
| B05BA10 076 | DS | infuzije aminokiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Aminosteril N hepa 8% | boca 10x500 ml | 69,76 | 697,60 |  | 5% |
| B05BA10 079 | DS | infuzije aminokiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Aminoven 10% | boca 10x500 ml | 56,35 | 563,50 |  | 5% |
| B05BA10 080 | DS | glukoza + otopina aminokiselina s elektrolitima + emulzija lipidaNB400 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven extra Nitrogen | emulz. za inf., vreć. 4x2025 ml | 669,30 | 2.677,20 |  | 5% |
| B05BA10 084 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Periolimel N4E | emulz. za inf., vreć. plast. 6x1000 ml | 285,00 | 1.710,00 |  | 5% |
| B05BA10 085 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Periolimel N4E | emulz. za inf., vreć. plast. 4x2000 ml | 367,31 | 1.469,24 |  | 5% |
| B05BA10 086 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Olimel N7E | emulz. za inf., vreć. plast. 4x2000 ml | 380,00 | 1.520,00 |  | 5% |
| B05BA10 087 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Olimel N9E | emulz. za inf., vreć. plast. 6x1000 ml | 330,52 | 1.983,14 |  | 5% |
| B05BA10 088 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Olimel N9E | emulz. za inf., vreć. plast. 4x2000 ml | 411,70 | 1.646,80 |  | 5% |
| B05BA10 089 | DS | glukoza + otopina aminokiselina s elektrolitima + emulzija lipida |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven Low Osmo Peripheral | emulz. za inf., vreć. 4x1400 ml | 399,00 | 1.596,00 |  | 5% |
| B05BA10 090 | DS | glukoza + otopina aminokiselina + emulzija lipidaNB400 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven extra Nitrogen bez elektrolita | emulz. za inf., vreć. 4x1518 ml | 488,00 | 1.952,00 |  | 5% |
| B05BA10 092 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven Peripheral | emulzija za infuziju, vreć. 4x1206 ml | 211,35 | 845,40 |  | 5% |
| B05BA10 093 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven Peripheral | emulzija za infuziju, vreć. 4x1448 ml | 227,39 | 909,56 |  | 5% |
| B05BA10 094 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven Peripheral | emulzija za infuziju, vreć. 4x1904 ml | 247,76 | 991,04 |  | 5% |
| B05BA10 095 | DS | emulzija lipida + aminokiselina + glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven bez elektrolita | emulz. za inf., plast. vreć. (Excel) 4x986 ml | 184,64 | 738,56 |  | 5% |
| B05BA10 096 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven | emulz. za inf., plast. vreć. (Excel) 4x986 ml | 184,64 | 738,56 |  | 5% |
| B05BA10 097 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven | emulz. za inf., plast. vreć. (Excel) 4x1477 ml | 232,80 | 931,20 |  | 5% |
| B05BA10 098 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven | emulz. za inf., plast. vreć. (Excel) 4x1970 ml | 290,97 | 1.163,88 |  | 5% |
| B05BA10 099 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven | emulz. za inf., plast. vreć. (Excel) 3x2463 ml | 338,16 | 1.014,48 |  | 5% |
| B05BB01 014 | PO | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (9 mg/ml) | 7,60 | 76,00 |  | 5% |
| B05BB01 018 | PO | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (9 mg/ml) | 6,60 | 66,00 |  | 5% |
| B05BB01 029 | PO | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf., boca polietil. 20x500 ml (9 mg/ml) | 7,62 | 152,40 |  | 5% |
| B05BB01 031 | PO | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf., boč. stakl. 20x100 ml (9 mg/ml) | 6,40 | 128,00 |  | 5% |
| B05BB01 032 | DS | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 10% koncentrat za otopinu za infuziju | konc. za otop. za inf. 10%, boč. stakl. 40x50 ml (100 mg/ml) | 7,08 | 283,20 |  | 5% |
| B05BB01 033 | DS | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf. 0,9%, vreć. PP 12x1000 ml | 12,40 | 148,80 |  | 5% |
| B05BB01 034 | DS | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf. 0,9%, vreć. PP 6x2000 ml | 19,83 | 118,98 |  | 5% |
| B05BB01 042 | PO | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter/Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf., 9 mg/ml, vreć. plast. 30x250 ml | 6,65 | 199,50 |  | 5% |
| B05BB01 043 | PO | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter/Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf., 9 mg/ml, vreć. plast. 20x500 ml | 7,65 | 153,00 |  | 5% |
| B05BB01 044 | DS | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter/Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf., 9 mg/ml, vreć. plast. 10x1000 ml | 13,78 | 137,80 |  | 5% |
| B05BB01 046 | PO | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf., 9 mg/ml, vreć. plast. 60x100 ml | 5,49 | 329,40 |  | 5% |
| B05BB01 047 | PO | natrij-klorid |  |  | P | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Natrijev klorid Alkaloid 9 mg/ml | otop. za inf., boca plast. 20x500 ml (9 mg/ml) | 6,55 | 130,91 |  | 5% |
| B05BB01 051 | DS | natrij-klorid |  |  | P |  |  |  | amp. 10%, 1x10 ml |  |  |  | 5% |
| B05BB01 052 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Ringerova otopina HZTM otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (8,6 mg/ml + 0,34 mg/ml + 0,30 mg/ml) | 7,62 | 76,20 |  | 5% |
| B05BB01 053 | DS | natrij-klorid + natrij-acetat + natrij-laktat + kalcij-klorid + kalij-klorid + magnezij klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Infusol | otop. za inf., boca stakl. 10x500 ml (5,723 mg/ml + 5,305 mg/ml + 0,56 mg/ml + 0,294 mg/ml + 0,372 mg/ml + 0,305 mg/ml)) | 8,65 | 86,50 |  | 5% |
| B05BB01 054 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Ringerova otopina | otop. za inf., boca stakl. 10x500 ml (8,6 mg/ml + 0,33 mg/ml + 0,30 mg/ml) | 7,62 | 76,20 |  | 5% |
| B05BB01 055 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Ringerova otopina Viaflo | otop. za inf., vreć. plast. 20x500 ml | 7,65 | 153,00 |  | 5% |
| B05BB01 056 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Ringerova otopina B. Braun | otop. za inf., polietil. Ecoflac plus boca, 10x500 ml | 7,65 | 76,50 |  | 5% |
| B05BB01 057 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Ringerova otopina B.Braun | otop. za inf., polietil. Ecoflac plus boca, 10x1000 ml | 11,85 | 118,50 |  | 5% |
| B05BB01 058 | DS | natrij-klorid + kalij-klorid + kalcij-klorid-dihidrat + natrij-laktat |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Slož. otop. natrijevog laktata (Hartmannova otopina) | otop. za inf., polietil. Ecoflac plus boca, 10x500 ml | 6,78 | 67,84 |  | 5% |
| B05BB01 059 | DS | natrij-klorid + kalij-klorid + kalcij-klorid-dihidrat + natrij-laktat |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Slož. otop. natrijevog laktata (Hartmannova otopina) otopina za infuziju | otop. za inf., polietil. Ecoflac plus boca, 10x1000 ml | 9,47 | 94,72 |  | 5% |
| B05BB01 060 | DS | natrij-klorid + kalij – klorid + kalcij-klorid-dihidrat + natrij-laktat |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ringerov laktat Fresenius Kabi | otop. za inf., boca plast. 10x500 ml | 6,10 | 61,00 |  | 5% |
| B05BB01 068 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ringerova otopina Fresenius Kabi | otop. za inf., boca plast. 10x500 ml | 6,89 | 68,85 |  | 5% |
| B05BB01 071 | PO | natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid B. Braun 9 mg/ml | otop. za inf., 9 mg/ml, polietil. Ecoflac plus boca, 20x100 ml | 6,43 | 128,60 |  | 5% |
| B05BB01 072 | PO | natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid B. Braun 9 mg/ml | otop. za inf., 9 mg/ml, polietil. Ecoflac plus boca, 10x250 ml | 6,65 | 66,50 |  | 5% |
| B05BB01 073 | PO | natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid B. Braun 9 mg/ml | otop. za inf., 9 mg/ml, polietil. Ecoflac plus boca, 10x500 ml | 7,65 | 76,50 |  | 5% |
| B05BB01 074 | DS | natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid B. Braun 9 mg/ml | otop. za inf., 9 mg/ml, polietil. Ecoflac plus boca, 10x1000 ml | 13,78 | 137,80 |  | 5% |
| B05BB01 077 | DS | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., PE boca, 10x1000 ml (9 mg/ml) | 12,40 | 124,00 |  | 5% |
| B05BB01 078 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 50x100 ml (9 mg/ml) | 5,79 | 289,35 |  | 5% |
| B05BB01 079 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 30x250 ml (9 mg/ml) | 5,99 | 179,55 |  | 5% |
| B05BB01 085 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + kalcij-klorid dihidrat + natrij-acetat trihidrat + L-malatna kiselina |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Sterofundin Iso B. Braun | otop. za inf., polietil. Ecoflac plus boca, 10x500 ml | 10,19 | 101,90 |  | 5% |
| B05BB01 086 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + kalcij-klorid dihidrat + natrij-acetat trihidrat + L-malatna kiselina |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Sterofundin Iso B. Braun | otop. za inf., polietil. Ecoflac plus boca, 10x1000 ml | 12,54 | 125,41 |  | 5% |
| B05BB01 087 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + natrij-acetat trihidrat |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ionolyte | otop. za inf., vreć. plast. 20x500 ml | 9,17 | 183,42 |  | 5% |
| B05BB01 088 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + natrij-acetat trihidrat |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ionolyte | otop. za inf., vreć. plast. 10x1000 ml | 11,29 | 112,87 |  | 5% |
| B05BB01 091 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + natrij-acetat-trihidrat + natrij-glukonat |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Plasma-Lyte 148 Viaflo | otop. za inf., vreć. plast. 20x500 ml | 11,33 | 226,60 |  | 5% |
| B05BB01 092 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + natrij-acetat-trihidrat + natrij-glukonat |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Plasma-Lyte 148 Viaflo | otop. za inf., vreć. plast. 10x1000 ml | 13,94 | 139,40 |  | 5% |
| B05BB01 093 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 20x500 ml (9 mg/ml) | 6,89 | 137,70 |  | 5% |
| B05BB01 094 | DS | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 60x50 ml (9 mg/ml) | 5,22 | 313,20 |  | 5% |
| B05BB01 095 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., boca plast. 40x100 ml (9 mg/ml) | 5,79 | 231,48 |  | 5% |
| B05BB01 096 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., boca plast. 20x250 ml (9 mg/ml) | 5,99 | 119,70 |  | 5% |
| B05BB01 097 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., boca plast. 10x500 ml (9 mg/ml) | 6,89 | 68,85 |  | 5% |
| B05BB01 098 | DS | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 10x1000 ml (9 mg/ml) | 11,16 | 111,60 |  | 5% |
| B05BB01 099 | DS | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf. 9 mg/ml, vreć. plast. 75x50 ml | 5,22 | 391,50 |  | 5% |
| B05BB02 021 | DS | glukoza + natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukosalina I 50 mg/ml + 9 mg/ml otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (50 mg/ml + 9 mg/ml) | 8,76 | 87,60 |  | 5% |
| B05BB02 022 | DS | glukoza + natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukosalina I 50 mg/ml + 9 mg/ml otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (50 mg/ml + 9 mg/ml) | 7,74 | 77,40 |  | 5% |
| B05BB02 024 | DS | glukoza + natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukosalina III 25 mg/ml + 4,5 mg/ml otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (25 mg/ml + 4,5 mg/ml) | 9,20 | 92,00 |  | 5% |
| B05BB02 061 | DS | glukoza + natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid 9 mg/ml + Glukoza 50 mg/ml B. Braun | otop. za inf., (9 mg/ml + 50 mg/ml), polietil. Ecoflac plus boca, 10x500 ml | 7,88 | 78,80 |  | 5% |
| B05BB02 062 | DS | glukoza + natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid 9 mg/ml + Glukoza 50 mg/ml B. Braun | otop. za inf., (9 mg/ml + 50 mg/ml), polietil. Ecoflac plus boca, 10x1000 ml | 13,75 | 137,50 |  | 5% |
| B05BB02 071 | DS | glukoza (kao hidrat) + natrij-klorid + natrij-acetat-trihidrat + kalij-klorid + magnezij-klorid heksahidrat |  |  | P | Baxter d.o.o. | Bieffe Medital S.A. | GNAK 50 mg/ml | otop. za inf., vreć. plast. 10x1000 ml | 13,24 | 132,40 |  | 5% |
| B05BC01 006 | DS | manitol + natrij-klorid + natrij-acetat |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Manitol 10% + elektroliti HZTM otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (100 mg/ml + 2,6 mg/ml + 2,7 mg/ml) | 13,52 | 135,18 |  | 5% |
| B05BC01 007 | DS | manitol |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Manitol HZTM 20% otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (200 mg/ml) | 13,23 | 132,30 |  | 5% |
| B05CX10 961 | DS | otopine za ispiranje mokraćnog mjehura |  |  | L | Fresenius Kabi d.o.o. | Fresenius Kabi | Purisole SM | vreć. plast. 1x3000 ml | 55,79 | 55,79 |  | 5% |
| B05CX10 963 | DS | otopina za ispiranje kod endoskopskih pretraga i operativnih zahvata |  |  | L | B. Braun Adria d.o.o. | B.Braun | Sorbitol/Manitol 3% B. Braun | ecobag/ecobag Click 4x3.000 ml | 50,21 | 200,84 |  | 5% |
| B05CX10 964 | DS | otopina za ispiranje |  |  | L | Agmar d.o.o. | Baxter, Bieffe Medital | Manitol i sorbitol | otop. za ispir., vreć. Clear-Flex 4x3.000 ml | 45,18 | 180,72 |  | 5% |
| B05XA01 027 | DS | kalij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | 1 M Kalijev klorid HZTM 7,45% koncentrat za otopinu za infuziju | konc. za otop. za inf., boč. stakl. 40x50 ml (74,5 mg/ml) | 6,79 | 271,60 |  | 5% |
| B05XA01 061 | DS | kalij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Kalijev klorid B. Braun 74,5 mg/ml | konc. za otop. za inf., 74,5 mg/ml, boca stakl. 20x100 ml | 11,06 | 221,20 |  | 5% |
| B05XA02 052 | DS | natrij-hidrogenkarbonat |  |  | P |  |  |  |  |  |  |  | 5% |
| B05XA05 051 | DS | magnezij-sulfat |  |  | P |  |  |  |  |  |  |  | 5% |
| B05XA07 017 | DS | kalcij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Kalcijev klorid 100 mg/ml (10%) HZTM otopina za injekciju | otop. za inj., boč. stakl. 40x30 ml (100 mg/ml) | 8,02 | 320,80 |  | 5% |
| B06AC02 001 | DS | ikatibantNB509 | 30 mg | 8.233,41 | P | Teva B.V. | Merckle GmbH | Ikatibant Teva | štrc. napunj. 1x30 mg | 8.233,41 | 8.233,41 |  | 5% |
| B06AC02 041 | DS | ikatibantNB509 | 30 mg | 8.233,41 | P | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp.z.o.o., Accord Healthcare B.V. | Icatibant Accord | štrc. napunj. 1x30 mg | 8.233,41 | 8.233,41 |  | 5% |
| B06AC02 061 | DS | ikatibantNB509 | 30 mg | 9.168,16 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Firazyr | štrc. napunj. 1x30 mg | 9.168,16 | 9.168,16 |  | 5% |
| B06AC02 071 | DS | ikatibantNB509 | 30 mg | 7.821,74 | P | Fresenius Kabi d.o.o. | Fresenius Kabi Austria GmbH | Ikatibant Fresenius | štrc. napunj. 1x30 mg | 7.821,74 | 7.821,74 |  | 5% |
| B06AC04 061 | DS | konestat alfaNB509 | 3500 U | 9.333,33 | P | Pharming Group N.V. | Pharming Technologies B.V. | Ruconest | praš. za otop. za inj., boč. stakl. 1x2100 U | 5.600,00 | 5.600,00 |  | 5% |
| C01AA08 051 | PR | metildigoksin | 0,2 mg |  | P |  |  |  |  |  |  |  | 5% |
| C01AA08 101 |  | metildigoksin | 0,2 mg | 0,99 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Lanitop | tbl. 50x0,1 mg | 0,50 | 24,75 | R | 5% |
| C01BB01 051 | PR | lidokain | 3 g |  | P |  |  |  |  |  |  |  | 5% |
| C01BC03 073 | PR | propafenon | 0,3 g | 39,44 | P | Mylan Hrvatska d.o.o. | Famar Health Care Services Madrid S.A.U. | Rytmonorm | amp. 5x70 mg/20 ml | 7,89 | 39,44 |  | 5% |
| C01BC03 142 |  | propafenon | 0,3 g | 0,99 | O | Alkaloid d.o.o. | Alkaloid | Propafenon Alkaloid | tbl. 50x150 mg | 0,49 | 24,70 | R | 5% |
| C01BD01 022 | DS | amjodaron | 0,2 g | 11,82 | P | sanofi-aventis groupe | Sanofi Winthrop Ambares | Cordarone | amp. 6x150 mg/3 ml | 8,87 | 53,20 |  | 5% |
| C01BD01 061 | DS | amjodaron | 0,2 g | 8,28 | P | hameln pharma gmbh | HBM Pharma s.r.o. | Amiodaronklorid Hameln | amp. 10x150 mg/3 ml | 6,21 | 62,09 |  | 5% |
| C01BD01 112 |  | amjodaron | 0,2 g | 1,22 | O | Belupo d.d. | Belupo | Amiodaronklorid Belupo | tbl. 60x200 mg | 1,22 | 73,20 | R | 5% |
| C01BD01 121 |  | amjodaron | 0,2 g | 1,22 | O | sanofi-aventis groupe | Sanofi Winthrop Ambares | Cordarone | tbl. 60x200 mg | 1,22 | 73,20 | R | 5% |
| C01BD01 133 |  | amjodaron | 0,2 g | 1,22 | O | KRKA-FARMA d.o.o. | Krka d.d. | Amiokordin | tbl. 60x200 mg | 1,22 | 73,20 | R | 5% |
| C01CA01 052 | DS | etiladrianolNC101 | 50 mg |  | P |  |  |  |  |  |  |  | 5% |
| C01CA03 071 | PR | norepinefrin | 6 mg | 46,92 | P | Sintetica GmbH | Sirton Pharmaceuticals S.p.A., Sintetica GmbH | Sinora | konc. za otop. za inf., 1 mg/ml, amp. 10x1 ml | 7,82 | 78,20 |  | 5% |
| C01CA03 072 | PR | norepinefrin | 6 mg | 16,16 | P | Sintetica GmbH | Sirton Pharmaceuticals S.p.A., Sintetica GmbH | Sinora | konc. za otop. za inf., 1 mg/ml, amp. 10x10 ml | 26,93 | 269,30 |  | 5% |
| C01CA03 073 | PR | norepinefrin | 6 mg | 15,35 | P | Sintetica GmbH | Sirton Pharmaceuticals S.p.A., Sintetica GmbH | Sinora | konc. za otop. za inf., 1 mg/ml, amp. 10x5 ml | 12,79 | 127,92 |  | 5% |
| C01CA03 081 | PR | norepinefrin | 6 mg | 17,36 | P | Ligula Pharma d.o.o. | Laboratorios Normon S.A. | Noradrenalin Ligula Pharma | konc. za otop. za inf., 0,5 mg/ml, amp. 100x10 ml | 14,47 | 1.446,55 |  | 5% |
| C01CA04 061 | DS | dopamin | 0,5 g | 74,46 | P | Medicuspharma d.o.o. | Wuelfing Pharma | Dopamin Admeda | amp. 5x50 mg/5 ml | 7,45 | 37,23 |  | 5% |
| C01CA07 061 | DS | dobutamin | 0,5 g | 58,00 | P | Panpharma | Panpharma GmbH | Dobutamin Panpharma | konc. za otop. za inf., boč. stakl. 10x250 mg/20 ml | 29,00 | 290,00 |  | 5% |
| C01CA07 071 | DS | dobutamin | 0,5 g | 63,50 | P | Medicuspharma d.o.o. | Haupt Pharma Wülfing GmbH | Dobutamin Admeda | otop. za inf., amp. 1x250 mg/50 ml | 31,75 | 31,75 |  | 5% |
| C01CA07 082 | DS | dobutamin | 0,5 g | 60,32 | P | hameln pharma gmbh | Siegfried Hameln GmbH, Hameln rds | Dobutamin Hameln | otop. za inf., boč. 1x250 mg/50 ml | 30,16 | 30,16 |  | 5% |
| C01CA07 083 | DS | dobutamin | 0,5 g | 60,32 | P | hameln pharma gmbh | Siegfried Hameln GmbH, Hameln rds | Dobutamin Hameln | konc. za otop. za inf., amp. 5x250 mg/20 ml | 30,16 | 150,80 |  | 5% |
| C01CA24 051 | PR | adrenalin (epinefrin) | 0,5 mg |  | P |  |  |  |  |  |  |  | 5% |
| C01CA24 071 |  | adrenalin (epinefrin) | 0,5 mg | 130,07 | P | Mylan Hrvatska d.o.o. | Meda Pharma GmbH | EpiPen Jr | otop. za inj., autoinjektor 1x1 mg/2 ml (doza 0,15 mg/0,3 ml) | 260,14 | 260,14 | RSRC09 | 5% |
| C01CA24 072 |  | adrenalin (epinefrin) | 0,5 mg | 65,04 | P | Mylan Hrvatska d.o.o. | Meda Pharma GmbH | EpiPen | otop. za inj., autoinjektor 1x2 mg/2 ml (doza 0,3 mg/0,3 ml) | 260,14 | 260,14 | RSRC09 | 5% |
| C01CX08 061 | DS | levosimendanNC102 | 11 mg | 4.955,39 | P | Orion Corporation | Orion | Simdax | konc. otop. za inf., boč. stak. 1x5ml (2,5mg/1ml) | 5.631,30 | 5.631,30 |  | 5% |
| C01CX08 071 | DS | levosimendanNC102 | 11 mg | 3.562,99 | P | ALPHA-MEDICAL d.o.o. | Sabiedriba Ar Ierobezotu Atbildibu «Pharmidea” | Levosimendan Alpha-Medical | konc. otop. za inf., boč. stak. 1x5ml (2,5mg/1ml) | 4.048,98 | 4.048,98 |  | 5% |
| C01DA02 764 |  | gliceriltrinitrat | 2,5 mg | 1,15 | O | Medis Adria d.o.o. | G. Pohl-Boskamp | Nitrolingual | rasprš. oral. boč. 1x14,4 ml (0,4 mg/doza, 200 doza) | 36,73 | 36,73 | R | 5% |
| C01DA08 101 |  | izosorbid-dinitrat | 20 mg | 0,69 | SL | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Tinidil | tbl. sublingv. 40x5 mg | 0,17 | 6,85 | R | 5% |
| C01DA14 111 |  | izosorbid-5-mononitrat | 40 mg | 0,60 | O | Mylan Hrvatska d.o.o. | Temmler Pharma | Olicard 40 | caps. retard 50x40 mg | 0,60 | 30,00 | R | 5% |
| C01DA14 112 |  | izosorbid-5-mononitrat | 40 mg | 0,63 | O | Mylan Hrvatska d.o.o. | Temmler Pharma | Olicard 60 | caps. retard 50x60 mg | 0,95 | 47,45 | R | 5% |
| C01DA14 113 |  | izosorbid-5-mononitrat | 40 mg | 0,60 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Cardox retard | tbl. retard 50x40 mg | 0,60 | 30,00 | R | 5% |
| C01DA14 115 |  | izosorbid mononitrat | 40 mg | 0,60 | O | Belupo d.d. | Belupo | Isocard 40 mg | tbl. s prod. oslob. 50x40 mg | 0,60 | 30,00 | R | 5% |
| C01DA14 116 |  | izosorbid mononitrat | 40 mg | 0,63 | O | Belupo d.d. | Belupo | Isocard 60 mg | tbl. s prod. osl. 50x60 mg | 0,95 | 47,45 | R | 5% |
| C01DA14 121 |  | izosorbid-5-mononitrat | 40 mg | 0,63 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | ISMN Jadran 20 | tbl. 60x20 mg | 0,32 | 19,01 | R | 5% |
| C01DA14 122 |  | izosorbid-5-mononitrat | 40 mg | 0,60 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | ISMN Jadran 40 | tbl. 60x40 mg | 0,60 | 36,00 | R | 5% |
| C01DA14 161 |  | izosorbid-5-mononitrat | 40 mg | 0,63 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | ISMN Genericon | tbl. 60x20 mg | 0,32 | 19,01 | R | 5% |
| C01DA14 162 |  | izosorbid-5-mononitrat | 40 mg | 0,60 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | ISMN Genericon | tbl. 60x40 mg | 0,60 | 36,00 | R | 5% |
| C01EA01 061 | DS | alprostadilNC103 | 0,5 mg | 152,14 | P | Pfizer Croatia d.o.o. | Pfizer | Prostin VR | amp. 5x1 ml (0,5 mg/ml) | 304,28 | 1.521,39 |  | 5% |
| C01EB15 145 |  | trimetazidin | 40 mg | 0,48 | O | PharmaS d.o.o. | PharmaS d.o.o. | Trimetazidin PharmaS | tbl. s prilag. oslob. 60x35 mg | 0,42 | 25,23 | RS | 5% |
| C02AB01 151 |  | l-metildopa | 1g |  | O |  |  |  |  |  |  | R | 5% |
| C02AC05 112 |  | moksonidin | 0,3 mg | 1,40 | O | Belupo d.d. | Belupo d.d. | Moksonidin Belupo | tbl. film obl. 28x0,2 mg | 0,94 | 26,20 | RRC07 | 5% |
| C02AC05 113 |  | moksonidin | 0,3 mg | 1,24 | O | Belupo d.d. | Belupo d.d. | Moksonidin Belupo | tbl. film obl. 28x0,4 mg | 1,65 | 46,20 | RRC07 | 5% |
| C02AC05 121 |  | moksonidin | 0,3 mg | 1,40 | O | Sandoz d.o.o. | Sandoz-Salutas | Moxaviv | tbl. film obl. 28x0,2 mg | 0,94 | 26,20 | RRC07 | 5% |
| C02AC05 122 |  | moksonidin | 0,3 mg | 1,24 | O | Sandoz d.o.o. | Sandoz-Salutas | Moxaviv | tbl. film obl. 28x0,4 mg | 1,65 | 46,20 | RRC07 | 5% |
| C02AC05 123 |  | moksonidin | 0,3 mg | 1,27 | O | Sandoz d.o.o. | Salutas Pharma | Moxaviv | tbl. film obl. 60x0,2 mg | 0,84 | 50,66 | RRC07 | 5% |
| C02AC05 124 |  | moksonidin | 0,3 mg | 1,12 | O | Sandoz d.o.o. | Salutas Pharma | Moxaviv | tbl. film obl. 60x0,4 mg | 1,49 | 89,35 | RRC07 | 5% |
| C02AC05 162 |  | moksonidin | 0,3 mg | 1,24 | O | Mylan Hrvatska d.o.o. | Mylan Laboratories SAS | Physiotens | tbl. film obl. 28x0,4 mg | 1,65 | 46,20 | RRC07 | 5% |
| C02AC05 163 |  | moksonidin | 0,3 mg | 1,24 | O | Mylan Hrvatska d.o.o. | Mylan Laboratories SAS | Cynt | tbl. film obl. 28x0,2 mg | 0,83 | 23,24 | RRC07 | 5% |
| C02AC05 164 |  | moksonidin | 0,3 mg | 1,11 | O | Mylan Hrvatska d.o.o. | Mylan Laboratories SAS | Cynt | tbl. film obl. 28x0,4 mg | 1,48 | 41,44 | RRC07 | 5% |
| C02CA04 111 |  | doksazosin | 4 mg | 1,50 | O | Belupo d.d. | Belupo | Doxa | tbl. 20x2 mg | 0,75 | 15,00 | R | 5% |
| C02CA04 112 |  | doksazosin | 4 mg | 1,31 | O | Belupo d.d. | Belupo | Doxa | tbl. 20x4 mg | 1,31 | 26,20 | R | 5% |
| C02CA04 123 |  | doksazosin | 4 mg | 1,50 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Doxazin | tbl. 30x2 mg | 0,75 | 22,50 | R | 5% |
| C02CA04 124 |  | doksazosin | 4 mg | 1,31 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Doxazin | tbl. 30x4 mg | 1,31 | 39,30 | R | 5% |
| C02CA04 131 |  | doksazosin | 4 mg | 1,50 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kamiren | tbl. 20x2 mg | 0,75 | 15,00 | R | 5% |
| C02CA04 134 |  | doksazosin | 4 mg | 1,31 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kamiren | tbl. 20x4 mg | 1,31 | 26,20 | R | 5% |
| C02CA04 137 |  | doksazosin | 4 mg | 1,31 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kamiren XL | tbl. s prilag. osl. 30x4 mg | 1,31 | 39,30 | R | 5% |
| C02CA04 138 |  | doksazosin | 4 mg | 1,32 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kamiren XL | tbl. s prilag. osl. 60x4 mg | 1,32 | 79,40 | R | 5% |
| C02CA06 064 | PO | urapidil | 50 mg | 33,56 | P | Cheplapharm Arzneimittel GmbH | Takeda | Ebrantil | amp. 5x50 mg/10 ml | 33,56 | 167,78 |  | 5% |
| C02CA06 065 | PO | urapidil | 50 mg | 46,18 | P | Cheplapharm Arzneimittel GmbH | Takeda | Ebrantil | amp. 5x25 mg/5 ml | 23,09 | 115,45 |  | 5% |
| C02DA01 051 | DS | diazoksid | 0,3g |  | P |  |  |  |  |  |  |  | 5% |
| C02DC01 151 | DS | minoksidilNC991 | 20 mg |  | O |  |  |  |  |  |  | RSRC91 | 5% |
| C02DD01 051 | DS | nitroprusid-natrij | 50 mg |  | P |  |  |  |  |  |  |  | 5% |
| C02KX01 131 | KS | bosentanNC201 | 0,25 g | 344,88 | O | Makpharm d.o.o. | Pharmascience International Limited, Kern Pharma S.L. | Bosentan Makpharm | tbl. film obl. 56x62,5 mg | 86,22 | 4.828,32 |  | 5% |
| C02KX01 132 | KS | bosentanNC201 | 0,25 g | 237,67 | O | Makpharm d.o.o. | Pharmascience International Limited, Kern Pharma S.L. | Bosentan Makpharm | tbl. film obl. 56x125 mg | 118,84 | 6.654,85 |  | 5% |
| C02KX01 141 | KS | bosentanNC201 | 0,25 g | 344,88 | O | Cipla Europe NV | Cipla (EU) Limited, Cipla Europe NV | Bosentan Cipla | tbl. film obl. 56x62,5 mg | 86,22 | 4.828,32 |  | 5% |
| C02KX01 142 | KS | bosentanNC201 | 0,25 g | 237,67 | O | Cipla Europe NV | Cipla (EU) Limited, Cipla Europe NV | Bosentan Cipla | tbl. film obl. 56x125 mg | 118,84 | 6.654,85 |  | 5% |
| C02KX01 181 | KS | bosentanNC201 | 0,25 g | 344,88 | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Phan | tbl. film obl. 56x62,5 mg | 86,22 | 4.828,32 |  | 5% |
| C02KX01 182 | KS | bosentanNC201 | 0,25 g | 237,67 | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Phan | tbl. film obl. 56x125 mg | 118,84 | 6.654,85 |  | 5% |
| C02KX02 061 | KS | ambrisentanNC201 | 7,5 mg | 524,39 | O | GlaxoSmithKline (Ireland) Limited | Aspen Bad Oldesloe, GlaxoSmithKline Trading Services Limited | Volibris | tbl. film obl. 30x5 mg | 349,59 | 10.487,70 |  | 5% |
| C02KX02 062 | KS | ambrisentanNC201 | 7,5 mg | 209,45 | O | GlaxoSmithKline (Ireland) Limited | Aspen Bad Oldesloe, GlaxoSmithKline Trading Services Limited | Volibris | tbl. film obl. 30x10 mg | 279,27 | 8.378,00 |  | 5% |
| C02KX02 101 | KS | ambrisentanNC201 | 7,5 mg | 524,39 | O | Teva B.V. | Teva UK Ltd. | Ambrisentan Teva | tbl. film obl. 30x5 mg | 349,59 | 10.487,70 |  | 5% |
| C02KX02 102 | KS | ambrisentanNC201 | 7,5 mg | 209,45 | O | Teva B.V. | Teva UK Ltd. | Ambrisentan Teva | tbl. film obl. 30x10 mg | 279,27 | 8.378,00 |  | 5% |
| C03BA04 151 |  | klortalidon | 25 mg |  | O |  |  |  |  |  |  | R | 5% |
| C03BA11 101 |  | indapamid | 2,5 mg | 1,13 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Indapamid SR Pliva | drag. 30x1,5 mg | 0,68 | 20,41 | R | 5% |
| C03BA11 111 |  | indapamid | 2,5 mg | 1,13 | O | Belupo d.d. | Belupo | Indamid SR | drag. 30x1,5 mg | 0,68 | 20,41 | R | 5% |
| C03BA11 131 |  | indapamid | 2,5 mg | 1,13 | O | KRKA-FARMA d.o.o. | Krka d.d. | Rawel SR | tbl. film obl. 30x1,5 mg | 0,68 | 20,41 | R | 5% |
| C03BA11 132 |  | indapamid | 2,5 mg | 1,13 | O | KRKA-FARMA d.o.o. | Krka d.d. | Rawel SR | tbl. film obl. 60x1,5 mg | 0,68 | 40,82 | R | 5% |
| C03BA11 145 |  | indapamid | 2,5 mg | 0,91 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Dipam retard | tbl. s prod. oslob. 30x1,5 mg | 0,54 | 16,31 | R | 5% |
| C03BA11 172 |  | indapamid | 2,5 mg | 1,13 | O | Servier Pharma d.o.o. | LLS, SII, Anpharm | Tertensif SR | tbl. 30x1,5 mg | 0,68 | 20,41 | R | 5% |
| C03CA01 014 | PR | furosemid | 40 mg | 5,37 | P | Belupo d.d. | Belupo | Fursemid | amp. 5x20 mg/2 ml | 2,69 | 13,43 |  | 5% |
| C03CA01 023 | PR | furosemid | 40 mg | 4,09 | P | Sandoz d.o.o. | Sandoz-Salutas | Edemid | otop. za inj., amp. 5x40 mg/4 ml | 4,09 | 20,43 |  | 5% |
| C03CA01 061 | PR | furosemid | 40 mg | 5,10 | P | hameln pharma gmbh | Hameln rds, Siegfried Hameln GmbH | Furosemid Hameln | amp. 10x20 mg/2 ml | 2,55 | 25,52 |  | 5% |
| C03CA01 112 |  | furosemid | 40 mg |  | O | Belupo d.d. | Belupo | Fursemid forte | tbl. 20x500 mg | 2,80 | 55,98 | R | 5% |
| C03CA01 122 |  | furosemid | 40 mg |  | O | Sandoz d.o.o. | Sandoz-Lek | Edemid forte | tbl. 30x500 mg | 2,80 | 83,97 | R | 5% |
| C03CA01 171 |  | furosemid | 40 mg | 0,44 | O | sanofi-aventis groupe | Sanofi Winthrop Industrie | Lasix | tbl. 20x40 mg | 0,44 | 8,80 | R | 5% |
| C04AB01 051 | DS | fentolamin | 1 mg |  | P |  |  |  |  |  |  |  | 5% |
| C05BA01 404 | DS | heparin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Heparin krema | krema 30g (250 i.j./g) | 28,06 | 28,06 |  | 5% |
| C07AA05 121 |  | propranolol | 0,16 g | 1,67 | O | Sandoz d.o.o. | Sandoz-Lek | Propranolol Sandoz | tbl. 50x40 mg | 0,42 | 20,89 | R | 5% |
| C07AA05 270 |  | propranolol | 0,16 g | 458,21 | O | Pierre Fabre Dermatologie | Farmea, PIERRE FABRE MEDICAMENT PRODUCTION – CHATEAURENARD | Hemangiol | oral. otop., boca 1x120 ml (3,75 mg/ml) | 1.288,71 | 1.288,71 | RSRC10 | 5% |
| C07AB03 101 |  | atenolol | 75 mg | 0,65 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atenolol | tbl. 30x50 mg | 0,43 | 12,95 | R | 5% |
| C07AB03 112 |  | atenolol | 75 mg | 0,65 | O | Belupo d.d. | Belupo | Ormidol | tbl. 30x50 mg | 0,43 | 12,95 | R | 5% |
| C07AB03 113 |  | atenolol | 75 mg | 0,65 | O | Belupo d.d. | Belupo | Ormidol | tbl. 28x100 mg | 0,86 | 24,16 | R | 5% |
| C07AB07 101 |  | bisoprolol | 10 mg | 1,76 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kordobis | tbl. 20x1,25 mg | 0,22 | 4,40 | R | 5% |
| C07AB07 102 |  | bisoprolol | 10 mg | 1,51 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kordobis | tbl. 30x2,5 mg | 0,38 | 11,33 | R | 5% |
| C07AB07 103 |  | bisoprolol | 10 mg | 0,83 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kordobis | tbl. 30x5 mg | 0,41 | 12,42 | R | 5% |
| C07AB07 111 |  | bisoprolol | 10 mg | 0,83 | O | Belupo d.d. | Belupo | Bisobel | tbl. 30x5 mg | 0,41 | 12,42 | R | 5% |
| C07AB07 112 |  | bisoprolol | 10 mg | 0,54 | O | Belupo d.d. | Belupo | Bisobel | tbl. 30x10 mg | 0,54 | 16,20 | R | 5% |
| C07AB07 114 |  | bisoprolol | 10 mg | 0,83 | O | Belupo d.d. | Belupo | Bisobel | tbl. 60x5 mg | 0,41 | 24,84 | R | 5% |
| C07AB07 115 |  | bisoprolol | 10 mg | 0,83 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Biprol | tbl. 30x5 mg | 0,41 | 12,42 | R | 5% |
| C07AB07 117 |  | bisoprolol | 10 mg | 1,51 | O | Belupo d.d. | Belupo | Bisobel | tbl. 30x2,5 mg | 0,38 | 11,33 | R | 5% |
| C07AB07 118 |  | bisoprolol | 10 mg | 1,51 | O | Belupo d.d. | Belupo | Bisobel | tbl. 60x2,5 mg | 0,38 | 22,66 | R | 5% |
| C07AB07 119 |  | bisoprolol | 10 mg | 1,51 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Biprol | tbl. 30x2,5 mg | 0,38 | 11,33 | R | 5% |
| C07AB07 121 |  | bisoprolol | 10 mg | 0,83 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol | tbl. film obl. 30x5 mg | 0,41 | 12,42 | R | 5% |
| C07AB07 122 |  | bisoprolol | 10 mg | 0,54 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol | tbl. film obl. 30x10 mg | 0,54 | 16,20 | R | 5% |
| C07AB07 125 |  | bisoprolol | 10 mg | 1,51 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol Cor | tbl. film obl. 30x2,5 mg | 0,38 | 11,33 | R | 5% |
| C07AB07 126 |  | bisoprolol | 10 mg | 1,51 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol Cor | tbl. film obl. 50x2,5 mg | 0,38 | 18,88 | R | 5% |
| C07AB07 127 |  | bisoprolol | 10 mg | 1,76 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol Cor | tbl. film obl. 30x1,25 mg | 0,22 | 6,60 | R | 5% |
| C07AB07 128 |  | bisoprolol | 10 mg | 0,83 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol | tbl. film obl. 60x5 mg | 0,41 | 24,84 | R | 5% |
| C07AB07 136 |  | bisoprolol | 10 mg | 1,51 | O | Alkaloid d.o.o. | Alkaloid | Tyrez | tbl. film obl. 30x2,5 mg | 0,38 | 11,33 | R | 5% |
| C07AB07 137 |  | bisoprolol | 10 mg | 0,83 | O | Alkaloid d.o.o. | Alkaloid | Tyrez | tbl. film obl. 30x5 mg | 0,41 | 12,42 | R | 5% |
| C07AB07 138 |  | bisoprolol | 10 mg | 0,54 | O | Alkaloid d.o.o. | Alkaloid | Tyrez | tbl. film obl. 30x10 mg | 0,54 | 16,20 | R | 5% |
| C07AB07 141 |  | bisoprolol | 10 mg | 1,76 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Lybrol | tbl. 20x1,25 mg | 0,22 | 4,40 | R | 5% |
| C07AB07 142 |  | bisoprolol | 10 mg | 1,51 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Lybrol | tbl. 30x2,5 mg | 0,38 | 11,33 | R | 5% |
| C07AB07 144 |  | bisoprolol | 10 mg | 0,83 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Lybrol | tbl. 30x5 mg | 0,41 | 12,42 | R | 5% |
| C07AB07 163 |  | bisoprolol | 10 mg | 0,93 | O | MERCK d.o.o. | Merck | Concor | tbl. 30x10 mg | 0,93 | 27,80 | R | 5% |
| C07AB07 181 |  | bisoprolol | 10 mg | 1,51 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 30x2,5 mg | 0,38 | 11,33 | R | 5% |
| C07AB07 182 |  | bisoprolol | 10 mg | 0,83 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 30x5 mg | 0,41 | 12,42 | R | 5% |
| C07AB07 183 |  | bisoprolol | 10 mg | 0,54 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 30x10 mg | 0,54 | 16,20 | R | 5% |
| C07AB07 184 |  | bisoprolol | 10 mg | 1,36 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 60x2,5 mg | 0,34 | 20,39 | R | 5% |
| C07AB07 185 |  | bisoprolol | 10 mg | 0,75 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 60x5 mg | 0,37 | 22,36 | R | 5% |
| C07AB07 186 |  | bisoprolol | 10 mg | 0,49 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 60x10 mg | 0,49 | 29,16 | R | 5% |
| C07AB12 101 |  | nebivolol | 5 mg | 0,93 | O | PLIVA HRVATSKA d.o.o. | Balkanpharma – Dupnitsa AD, Actavis Limited | Nebivolol Pliva | tbl. 28x5 mg | 0,93 | 26,04 | R | 5% |
| C07AB12 111 |  | nebivolol | 5 mg | 0,90 | O | Belupo d.d. | Belupo | Nibel | tbl. 14x5 mg | 0,90 | 12,55 | R | 5% |
| C07AB12 112 |  | nebivolol | 5 mg | 0,93 | O | Belupo d.d. | Belupo | Nibel | tbl. 28x5 mg | 0,93 | 26,04 | R | 5% |
| C07AB12 121 |  | nebivolol | 5 mg | 0,93 | O | Sandoz d.o.o. | Sandoz-Salutas | Nebyol | tbl. 30x5 mg | 0,93 | 27,90 | R | 5% |
| C07AB12 122 |  | nebivolol | 5 mg | 0,84 | O | Sandoz d.o.o. | Sandoz-Salutas | Nebyol | tbl. 60x5 mg | 0,84 | 50,54 | R | 5% |
| C07AB12 141 |  | nebivolol | 5 mg | 0,84 | O | Alkaloid-INT d.o.o. | Alkaloid – int d.o.o. | Massido | tbl. 28x5 mg | 0,84 | 23,44 | R | 5% |
| C07AG02 101 |  | karvedilol | 37,5 mg | 1,40 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Carvetrend | tbl. 28x25 mg | 0,94 | 26,20 | R | 5% |
| C07AG02 102 |  | karvedilol | 37,5 mg | 1,87 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Carvetrend | tbl. 28x12,5mg | 0,62 | 17,46 | R | 5% |
| C07AG02 103 |  | karvedilol | 37,5 mg | 3,45 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Carvetrend | tbl. 28x6,25 mg | 0,58 | 16,11 | R | 5% |
| C07AG02 104 |  | karvedilol | 37,5 mg | 3,60 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Carvetrend | tbl. 28x3,125 mg | 0,30 | 8,40 | R | 5% |
| C07AG02 114 |  | karvedilol | 37,5 mg | 3,60 | O | Belupo d.d. | Belupo | Carvelol | tbl. 30x3,125 mg | 0,30 | 9,00 | R | 5% |
| C07AG02 115 |  | karvedilol | 37,5 mg | 3,45 | O | Belupo d.d. | Belupo | Carvelol | tbl. 30x6,25 mg | 0,58 | 17,26 | R | 5% |
| C07AG02 116 |  | karvedilol | 37,5 mg | 1,87 | O | Belupo d.d. | Belupo | Carvelol | tbl. 30x12,5 mg | 0,62 | 18,71 | R | 5% |
| C07AG02 117 |  | karvedilol | 37,5 mg | 1,40 | O | Belupo d.d. | Belupo | Carvelol | tbl. 30x25 mg | 0,94 | 28,07 | R | 5% |
| C07AG02 131 |  | karvedilol | 37,5 mg | 3,60 | O | KRKA-FARMA d.o.o. | Krka d.d. | Coryol | tbl. 28x3,125 mg | 0,30 | 8,40 | R | 5% |
| C07AG02 132 |  | karvedilol | 37,5 mg | 3,45 | O | KRKA-FARMA d.o.o. | Krka d.d. | Coryol | tbl. 28x6,25 mg | 0,58 | 16,11 | R | 5% |
| C07AG02 133 |  | karvedilol | 37,5 mg | 1,87 | O | KRKA-FARMA d.o.o. | Krka d.d. | Coryol | tbl. 28x12,5 mg | 0,62 | 17,46 | R | 5% |
| C07AG02 134 |  | karvedilol | 37,5 mg | 1,40 | O | KRKA-FARMA d.o.o. | Krka d.d. | Coryol | tbl. 28x25 mg | 0,94 | 26,20 | R | 5% |
| C08CA01 101 |  | amlodipin | 5 mg | 0,48 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Vilpin | tbl. 30x5 mg | 0,48 | 14,54 | R | 5% |
| C08CA01 102 |  | amlodipin | 5 mg | 0,29 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Vilpin | tbl. 30x10 mg | 0,58 | 17,26 | R | 5% |
| C08CA01 111 |  | amlodipin | 5 mg | 0,48 | O | Belupo d.d. | Belupo | Amonex | tbl. 30x5 mg | 0,48 | 14,54 | R | 5% |
| C08CA01 112 |  | amlodipin | 5 mg | 0,29 | O | Belupo d.d. | Belupo | Amonex | tbl. 30x10 mg | 0,58 | 17,26 | R | 5% |
| C08CA01 113 |  | amlodipin | 5 mg | 0,36 | O | Belupo d.d. | Belupo | Amonex | tbl. 60x5 mg | 0,36 | 21,60 | R | 5% |
| C08CA01 114 |  | amlodipin | 5 mg | 0,36 | O | Belupo d.d. | Belupo | Amonex | tbl. 90x5 mg | 0,36 | 32,40 | R | 5% |
| C08CA01 115 |  | amlodipin | 5 mg | 0,27 | O | Belupo d.d. | Belupo | Amonex | tbl. 60x10 mg | 0,54 | 32,40 | R | 5% |
| C08CA01 116 |  | amlodipin | 5 mg | 0,27 | O | Belupo d.d. | Belupo | Amonex | tbl. 90x10 mg | 0,54 | 48,60 | R | 5% |
| C08CA01 123 |  | amlodipin | 5 mg | 0,48 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 30x5 mg | 0,48 | 14,54 | R | 5% |
| C08CA01 124 |  | amlodipin | 5 mg | 0,36 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 60x5 mg | 0,36 | 21,60 | R | 5% |
| C08CA01 125 |  | amlodipin | 5 mg | 0,36 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 90x5 mg | 0,36 | 32,40 | R | 5% |
| C08CA01 126 |  | amlodipin | 5 mg | 0,29 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 30x10 mg | 0,58 | 17,26 | R | 5% |
| C08CA01 127 |  | amlodipin | 5 mg | 0,27 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 60x10 mg | 0,54 | 32,40 | R | 5% |
| C08CA01 128 |  | amlodipin | 5 mg | 0,27 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 90x10 mg | 0,54 | 48,60 | R | 5% |
| C08CA01 131 |  | amlodipin | 5 mg | 0,48 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Tenox | tbl. 30x5 mg | 0,48 | 14,54 | R | 5% |
| C08CA01 132 |  | amlodipin | 5 mg | 0,29 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Tenox | tbl. 30x10 mg | 0,58 | 17,26 | R | 5% |
| C08CA01 133 |  | amlodipin | 5 mg | 0,36 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Tenox | tbl. 60x5 mg | 0,36 | 21,60 | R | 5% |
| C08CA01 134 |  | amlodipin | 5 mg | 0,27 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Tenox | tbl. 60x10 mg | 0,54 | 32,40 | R | 5% |
| C08CA01 141 |  | amlodipin | 5 mg | 0,48 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Lopin | tbl. 30x5 mg | 0,48 | 14,54 | R | 5% |
| C08CA01 142 |  | amlodipin | 5 mg | 0,29 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Lopin | tbl. 30x10 mg | 0,58 | 17,26 | R | 5% |
| C08CA01 143 |  | amlodipin | 5 mg | 0,27 | O | PharmaS d.o.o. | PharmaS d.o.o. | Amlodipin PharmaS | tbl. 30x10 mg | 0,54 | 16,18 | R | 5% |
| C08CA01 145 |  | amlodipin | 5 mg | 0,45 | O | PharmaS d.o.o. | PharmaS d.o.o. | Amlodipin PharmaS | tbl. 30x5 mg | 0,45 | 13,49 | R | 5% |
| C08CA01 146 |  | amlodipin | 5 mg | 0,35 | O | PharmaS d.o.o. | PharmaS d.o.o. | Amlodipin PharmaS | tbl. 60x5 mg | 0,35 | 20,79 | R | 5% |
| C08CA01 147 |  | amlodipin | 5 mg | 0,48 | O | Alkaloid d.o.o. | Alkaloid | Caprez | tbl. 30x5 mg | 0,48 | 14,54 | R | 5% |
| C08CA01 148 |  | amlodipin | 5 mg | 0,29 | O | Alkaloid d.o.o. | Alkaloid | Caprez | tbl. 30x10 mg | 0,58 | 17,26 | R | 5% |
| C08CA01 149 |  | amlodipin | 5 mg | 0,24 | O | PharmaS d.o.o. | PharmaS d.o.o. | Amlodipin PharmaS | tbl. 60x10 mg | 0,49 | 29,21 | R | 5% |
| C08CA01 171 |  | amlodipin | 5 mg | 0,48 | O | Upjohn EESV | Heinrich Mack | Norvasc | tbl. 30x5 mg | 0,48 | 14,54 | R | 5% |
| C08CA01 172 |  | amlodipin | 5 mg | 0,29 | O | Upjohn EESV | Heinrich Mack | Norvasc | tbl. 30x10 mg | 0,58 | 17,26 | R | 5% |
| C08CA01 181 |  | amlodipin | 5 mg | 0,43 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Amlodipin Genericon | tbl. 30x5 mg | 0,43 | 13,00 | R | 5% |
| C08CA01 182 |  | amlodipin | 5 mg | 0,25 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Amlodipin Genericon | tbl. 30x10 mg | 0,51 | 15,25 | R | 5% |
| C08CA01 183 |  | amlodipin | 5 mg | 0,32 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Amlodipin Genericon | tbl. 90x5 mg | 0,32 | 29,16 | R | 5% |
| C08CA05 132 |  | nifedipin dugodjelujući | 30 mg | 0,85 | O | KRKA-FARMA d.o.o. | Krka d.d. | Cordipin XL | tbl. 20x40 mg | 1,13 | 22,60 | R | 5% |
| C08CA06 041 | DS | nimodipinNC801 | 50 mg | 427,60 | P | Bayer d.o.o. | Bayer AG | Nimotop S | boč. inf. 1x10 mg/50 ml | 85,52 | 85,52 |  | 5% |
| C08CA13 111 |  | lerkanidipin | 10 mg | 0,48 | O | Belupo d.d. | Belupo | Pinox | tbl. film obl. 28x10 mg | 0,48 | 13,57 | R | 5% |
| C08CA13 112 |  | lerkanidipin | 10 mg | 0,36 | O | Belupo d.d. | Belupo | Pinox | tbl. film obl. 56x10 mg | 0,36 | 20,16 | R | 5% |
| C08DA01 105 |  | verapamil | 0,24 g | 1,40 | O | Mylan Hrvatska d.o.o. | AbbVie Deutschland GmbH & Co.KG | Isoptin RR | tbl. s prod. oslob. 30x240 mg | 1,40 | 42,10 | R | 5% |
| C09AA02 131 |  | enalapril | 10 mg | 0,40 | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap | tbl. 20x5 mg | 0,20 | 4,00 | R | 5% |
| C09AA02 132 |  | enalapril | 10 mg | 0,35 | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap | tbl. 20x10 mg | 0,35 | 7,00 | R | 5% |
| C09AA03 101 |  | lizinopril | 10 mg | 0,38 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Optimon | tbl. 30x5 mg | 0,19 | 5,70 | R | 5% |
| C09AA03 102 |  | lizinopril | 10 mg | 0,29 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Optimon | tbl. 30x10 mg | 0,29 | 8,70 | R | 5% |
| C09AA03 103 |  | lizinopril | 10 mg | 0,32 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Optimon | tbl. 30x20 mg | 0,63 | 19,00 | R | 5% |
| C09AA03 104 |  | lizinopril | 10 mg | 0,40 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor | tbl. 30x5 mg | 0,20 | 6,00 | R | 5% |
| C09AA03 113 |  | lizinopril | 10 mg | 0,40 | O | Belupo d.d. | Belupo | Irumed | tbl. 60x5 mg | 0,20 | 12,00 | R | 5% |
| C09AA03 114 |  | lizinopril | 10 mg | 0,40 | O | Belupo d.d. | Belupo | Irumed | tbl. 30x5 mg | 0,20 | 6,00 | R | 5% |
| C09AA03 115 |  | lizinopril | 10 mg | 0,35 | O | Belupo d.d. | Belupo | Irumed | tbl. 30x10 mg | 0,35 | 10,50 | R | 5% |
| C09AA03 116 |  | lizinopril | 10 mg | 0,32 | O | Belupo d.d. | Belupo | Irumed | tbl. 30x20 mg | 0,63 | 19,00 | R | 5% |
| C09AA03 124 |  | lizinopril | 10 mg | 0,35 | O | Belupo d.d. | Belupo | Irumed | tbl. 60x10 mg | 0,35 | 21,00 | R | 5% |
| C09AA03 125 |  | lizinopril | 10 mg | 0,25 | O | Belupo d.d. | Belupo | Irumed | tbl. 60x20 mg | 0,50 | 30,00 | R | 5% |
| C09AA03 127 |  | lizinopril | 10 mg | 0,35 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor | tbl. 30x10 mg | 0,35 | 10,50 | R | 5% |
| C09AA03 129 |  | lizinopril | 10 mg | 0,32 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor | tbl. 30x20 mg | 0,63 | 19,00 | R | 5% |
| C09AA03 130 |  | lizinopril | 10 mg | 0,25 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor | tbl. 60x20 mg | 0,50 | 30,00 | R | 5% |
| C09AA03 143 |  | lizinopril | 10 mg | 0,29 | O | Alkaloid d.o.o. | Alkaloid | Skopryl | tbl. 30x10 mg | 0,29 | 8,70 | R | 5% |
| C09AA03 144 |  | lizinopril | 10 mg | 0,32 | O | Alkaloid d.o.o. | Alkaloid | Skopryl | tbl. 30x20 mg | 0,63 | 19,00 | R | 5% |
| C09AA04 130 |  | perindopril | 4 mg | 0,40 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Perineva | tbl. 30x2 mg | 0,20 | 6,00 | R | 5% |
| C09AA04 131 |  | perindopril | 4 mg | 0,35 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Perineva | tbl. 30x4 mg | 0,35 | 10,50 | R | 5% |
| C09AA04 132 |  | perindopril | 4 mg | 0,35 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Perineva | tbl. 60x4 mg | 0,35 | 21,00 | R | 5% |
| C09AA04 133 |  | perindopril | 4 mg | 0,32 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Perineva | tbl. 30x8 mg | 0,63 | 19,00 | R | 5% |
| C09AA05 104 |  | ramipril | 2,5 mg | 0,35 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 30x2,5 mg | 0,35 | 10,50 | R | 5% |
| C09AA05 105 |  | ramipril | 2,5 mg | 0,32 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 30x5 mg | 0,63 | 19,00 | R | 5% |
| C09AA05 106 |  | ramipril | 2,5 mg | 0,24 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 30x10 mg | 0,97 | 29,10 | R | 5% |
| C09AA05 107 |  | ramipril | 2,5 mg | 0,35 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 60x2,5 mg | 0,35 | 21,00 | R | 5% |
| C09AA05 108 |  | ramipril | 2,5 mg | 0,25 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 60x5 mg | 0,50 | 30,00 | R | 5% |
| C09AA05 109 |  | ramipril | 2,5 mg | 0,24 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 60x10 mg | 0,97 | 58,20 | R | 5% |
| C09AA05 111 |  | ramipril | 2,5 mg | 0,40 | O | Belupo d.d. | Belupo | Ramed | tbl. 28x1,25 mg | 0,20 | 5,60 | R | 5% |
| C09AA05 112 |  | ramipril | 2,5 mg | 0,35 | O | Belupo d.d. | Belupo | Ramed | tbl. 28x2,5 mg | 0,35 | 9,80 | R | 5% |
| C09AA05 113 |  | ramipril | 2,5 mg | 0,32 | O | Belupo d.d. | Belupo | Ramed | tbl. 28x5 mg | 0,63 | 17,73 | R | 5% |
| C09AA05 114 |  | ramipril | 2,5 mg | 0,24 | O | Belupo d.d. | Belupo | Ramed | tbl. 28x10 mg | 0,97 | 27,16 | R | 5% |
| C09AA05 115 |  | ramipril | 2,5 mg | 0,35 | O | Belupo d.d. | Belupo | Ramed | tbl. 56x2,5 mg | 0,35 | 19,60 | R | 5% |
| C09AA05 116 |  | ramipril | 2,5 mg | 0,25 | O | Belupo d.d. | Belupo | Ramed | tbl. 56x5 mg | 0,50 | 28,00 | R | 5% |
| C09AA05 117 |  | ramipril | 2,5 mg | 0,35 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar | tbl. 28x2,5 mg | 0,35 | 9,80 | R | 5% |
| C09AA05 118 |  | ramipril | 2,5 mg | 0,32 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar | tbl. 28x5 mg | 0,63 | 17,73 | R | 5% |
| C09AA05 119 |  | ramipril | 2,5 mg | 0,24 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar | tbl. 28x10 mg | 0,97 | 27,16 | R | 5% |
| C09AA05 121 |  | ramipril | 2,5 mg | 0,40 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 28x1,25 mg | 0,20 | 5,60 | R | 5% |
| C09AA05 122 |  | ramipril | 2,5 mg | 0,35 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 28x2,5 mg | 0,35 | 9,80 | R | 5% |
| C09AA05 123 |  | ramipril | 2,5 mg | 0,35 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 50x2,5 mg | 0,35 | 17,50 | R | 5% |
| C09AA05 124 |  | ramipril | 2,5 mg | 0,32 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 28x5 mg | 0,63 | 17,73 | R | 5% |
| C09AA05 125 |  | ramipril | 2,5 mg | 0,25 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 50x5 mg | 0,50 | 25,00 | R | 5% |
| C09AA05 126 |  | ramipril | 2,5 mg | 0,24 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 28x10 mg | 0,97 | 27,16 | R | 5% |
| C09AA05 127 |  | ramipril | 2,5 mg | 0,24 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 50x10 mg | 0,97 | 48,50 | R | 5% |
| C09AA05 131 |  | ramipril | 2,5 mg | 0,40 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 30x1,25 mg | 0,20 | 6,00 | R | 5% |
| C09AA05 133 |  | ramipril | 2,5 mg | 0,35 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 30x2,5 mg | 0,35 | 10,50 | R | 5% |
| C09AA05 134 |  | ramipril | 2,5 mg | 0,35 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 60x2,5 mg | 0,35 | 21,00 | R | 5% |
| C09AA05 135 |  | ramipril | 2,5 mg | 0,32 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 30x5 mg | 0,63 | 19,00 | R | 5% |
| C09AA05 136 |  | ramipril | 2,5 mg | 0,25 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 60x5 mg | 0,50 | 30,00 | R | 5% |
| C09AA05 137 |  | ramipril | 2,5 mg | 0,24 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 30x10 mg | 0,97 | 29,10 | R | 5% |
| C09AA05 138 |  | ramipril | 2,5 mg | 0,24 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 60x10 mg | 0,97 | 58,20 | R | 5% |
| C09AA05 141 |  | ramipril | 2,5 mg | 0,35 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril Mibe | tbl. 28x2,5 mg | 0,35 | 9,80 | R | 5% |
| C09AA05 142 |  | ramipril | 2,5 mg | 0,32 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril Mibe | tbl. 28x5 mg | 0,63 | 17,73 | R | 5% |
| C09AA05 143 |  | ramipril | 2,5 mg | 0,24 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril Mibe | tbl. 28x10 mg | 0,97 | 27,16 | R | 5% |
| C09AA05 161 |  | ramipril | 2,5 mg | 0,32 | O | sanofi-aventis groupe | Sanofi-Aventis S.p.A., Sanofi-Aventis GmbH, Sanofi Winthrop Quetigny | Tritace | tbl. 28x5 mg | 0,63 | 17,73 | R | 5% |
| C09AA05 164 |  | ramipril | 2,5 mg | 0,24 | O | sanofi-aventis groupe | Sanofi-Aventis S.p.A., Sanofi-Aventis GmbH, Sanofi Winthrop Quetigny | Tritace | tbl. 28x10 mg | 0,97 | 27,16 | R | 5% |
| C09AA05 171 |  | ramipril | 2,5 mg | 0,35 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramipril Genericon | tbl. 30x2,5 mg | 0,35 | 10,50 | R | 5% |
| C09AA05 172 |  | ramipril | 2,5 mg | 0,32 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramipril Genericon | tbl. 30x5 mg | 0,63 | 19,00 | R | 5% |
| C09AA05 173 |  | ramipril | 2,5 mg | 0,24 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramipril Genericon | tbl. 30x10 mg | 0,97 | 29,10 | R | 5% |
| C09AA05 175 |  | ramipril | 2,5 mg | 0,25 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramipril Genericon | tbl. 90x5 mg | 0,50 | 45,00 | R | 5% |
| C09BA02 132 |  | enalapril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap H | tbl. 20x(10 mg + 25 mg) | 0,60 | 11,90 | R | 5% |
| C09BA02 134 |  | enalapril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap HL 20 | tbl. 30x(20 mg + 12,5 mg) | 0,89 | 26,80 | R | 5% |
| C09BA02 135 |  | enalapril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap HL 20 | tbl. 60x(20 mg + 12,5 mg) | 0,84 | 50,60 | R | 5% |
| C09BA03 101 |  | lizinopril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Optimon Plus | tbl. 30x(20 mg + 12,5 mg) | 0,93 | 27,80 | R | 5% |
| C09BA03 112 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 30x(20 mg + 12,5 mg) | 0,93 | 27,80 | R | 5% |
| C09BA03 113 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 60x(20 mg + 12,5 mg) | 0,93 | 55,60 | R | 5% |
| C09BA03 114 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 30x(10 mg + 12,5 mg) | 0,64 | 19,10 | R | 5% |
| C09BA03 115 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 60x(10 mg + 12,5 mg) | 0,64 | 38,20 | R | 5% |
| C09BA03 116 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 30x(20 mg + 25 mg) | 0,93 | 27,80 | R | 5% |
| C09BA03 117 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 60x(20 mg + 25 mg) | 0,84 | 50,20 | R | 5% |
| C09BA03 122 |  | lizinopril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor H | tbl. 20x(20 mg + 12,5 mg) | 0,93 | 18,53 | R | 5% |
| C09BA03 123 |  | lizinopril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor H | tbl. 30x(10 mg + 12,5 mg) | 0,64 | 19,10 | R | 5% |
| C09BA03 124 |  | lizinopril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor H | tbl. 30x(20 mg + 12,5 mg) | 0,93 | 27,80 | R | 5% |
| C09BA03 141 |  | lizinopril + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Lizinopril H Mibe | tbl. 30x(10 mg + 12,5 mg) | 0,64 | 19,10 | R | 5% |
| C09BA03 142 |  | lizinopril + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Lizinopril H Mibe | tbl. 30x(20 mg + 12,5 mg) | 0,93 | 27,80 | R | 5% |
| C09BA03 145 |  | lizinopril + hidroklorotiazid |  |  | O | Alkaloid d.o.o. | Alkaloid | Skopryl Plus | tbl. 30x(20 mg + 12,5 mg) | 0,93 | 27,80 | R | 5% |
| C09BA03 146 |  | lizinopril + hidroklorotiazid |  |  | O | Alkaloid d.o.o. | Alkaloid | Skopryl Plus | tbl. 60x(20 mg + 12,5 mg) | 0,87 | 52,00 | R | 5% |
| C09BA04 102 |  | perindopril + indapamid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Co-Articel | tbl. film obl. 30x(5 mg + 1,25 mg) | 0,67 | 20,21 | R | 5% |
| C09BA04 131 |  | perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Co-Perineva | tbl. 60x(2 mg + 0,625 mg) | 0,34 | 20,22 | R | 5% |
| C09BA04 132 |  | perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Co-Perineva | tbl. 30x(4 mg + 1,25 mg) | 0,67 | 20,21 | R | 5% |
| C09BA04 134 |  | perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Co-Perineva | tbl. 30x(8 mg + 2,5 mg) | 1,09 | 32,75 | R | 5% |
| C09BA04 136 |  | perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Co-Perineva | tbl. 30x(2 mg + 0,625 mg) | 0,34 | 10,11 | R | 5% |
| C09BA05 103 |  | ramipril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen Plus | tbl. 30x(2,5 mg + 12,5 mg) | 0,64 | 19,10 | R | 5% |
| C09BA05 104 |  | ramipril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen Plus | tbl. 30x(5 mg + 25 mg) | 0,93 | 27,80 | R | 5% |
| C09BA05 105 |  | ramipril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen Plus | tbl. 60x(2,5 mg + 12,5 mg) | 0,64 | 38,20 | R | 5% |
| C09BA05 106 |  | ramipril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen Plus | tbl. 60x(5 mg + 25 mg) | 0,84 | 50,20 | R | 5% |
| C09BA05 111 |  | ramipril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Ramzid | tbl. 28x(2,5mg + 12,5 mg) | 0,64 | 17,83 | R | 5% |
| C09BA05 112 |  | ramipril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Ramzid | tbl. 28x(5 mg + 25 mg) | 0,93 | 25,95 | R | 5% |
| C09BA05 113 |  | ramipril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Ramzid | tbl. 56x(2,5 mg + 12,5 mg) | 0,64 | 35,65 | R | 5% |
| C09BA05 114 |  | ramipril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Ramzid | tbl. 56x(5 mg + 25 mg) mg | 0,84 | 46,85 | R | 5% |
| C09BA05 121 |  | ramipril + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Salutas | Piramil HL | tbl. 28x(2,5 mg + 12,5 mg) | 0,64 | 17,83 | R | 5% |
| C09BA05 123 |  | ramipril + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Salutas | Piramil H | tbl. 28x(5mg + 25 mg) | 0,93 | 25,95 | R | 5% |
| C09BA05 128 |  | ramipril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar Plus | tbl. 28x(2,5mg + 12,5 mg) | 0,56 | 15,62 | R | 5% |
| C09BA05 129 |  | ramipril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar Plus | tbl. 28x(5 mg + 25 mg) | 0,91 | 25,45 | R | 5% |
| C09BA05 131 |  | ramipril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril HL | tbl. 30x(2,5 mg + 12,5 mg) | 0,64 | 19,10 | R | 5% |
| C09BA05 132 |  | ramipril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril HL | tbl. 60x(2,5 mg + 12,5 mg) | 0,64 | 38,20 | R | 5% |
| C09BA05 133 |  | ramipril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril HD | tbl. 30x(5 mg + 25 mg) | 0,93 | 27,80 | R | 5% |
| C09BA05 134 |  | ramipril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril HD | tbl. 60x(5 mg + 25 mg) | 0,84 | 50,20 | R | 5% |
| C09BA05 141 |  | ramipril + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril H Mibe | tbl. 28x(2,5 mg + 12,5 mg) | 0,64 | 17,83 | R | 5% |
| C09BA05 142 |  | ramipril + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril H Mibe | tbl. 28x(5 mg + 25 mg) | 0,93 | 25,95 | R | 5% |
| C09BA05 161 |  | ramipril + hidroklorotiazid |  |  | O | sanofi-aventis groupe | Aventis Pharma S.p.A | Tritazide | tbl. 28x(2,5 mg + 12,5 mg) | 0,64 | 17,83 | R | 5% |
| C09BA05 171 |  | ramipril + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramicomp Genericon 2,5 mg/12,5 mg | tbl. 30x(2,5 mg + 12,5 mg) | 0,62 | 18,60 | R | 5% |
| C09BA05 172 |  | ramipril + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramicomp Genericon 5 mg/25 mg | tbl. 30x(5 mg + 25 mg) | 0,93 | 27,80 | R | 5% |
| C09BB04 101 |  | perindopril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Teva Czech Industries s.r.o., Teva Pharma S.L.U., Teva UK Ltd., Teva Operations Poland Sp. z o.o., Teva Pharmaceuticals, Teva Pharma B.V. | Articel-Am | tbl. 30x(5 mg + 5 mg) | 0,67 | 20,21 | R | 5% |
| C09BB04 111 |  | perindopril + amlodipin |  |  | O | Jadran – Galenski Laboratorij d.d. | Adamed Pharma S.A., Jadran Galenski laboratorij d.d. | Almirincomb | tbl. 30x(4 mg + 5 mg) | 0,47 | 14,15 | R | 5% |
| C09BB04 112 |  | perindopril + amlodipin |  |  | O | Jadran – Galenski Laboratorij d.d. | Adamed Pharma S.A., Jadran Galenski laboratorij d.d. | Almirincomb | tbl. 30x(4 mg + 10 mg) | 0,47 | 14,15 | R | 5% |
| C09BB04 113 |  | perindopril + amlodipin |  |  | O | Jadran – Galenski Laboratorij d.d. | Adamed Pharma S.A., Jadran Galenski laboratorij d.d. | Almirincomb | tbl. 30x(8 mg + 5 mg) | 0,78 | 23,31 | R | 5% |
| C09BB04 114 |  | perindopril + amlodipin |  |  | O | Jadran – Galenski Laboratorij d.d. | Adamed Pharma S.A., Jadran Galenski laboratorij d.d. | Almirincomb | tbl. 30x(8 mg + 10 mg) | 0,82 | 24,72 | R | 5% |
| C09BB04 131 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Dalneva | tbl. 30x(4 mg + 5 mg) | 0,67 | 20,21 | R | 5% |
| C09BB04 132 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Dalneva | tbl. 30x(4 mg + 10 mg) | 0,67 | 20,21 | R | 5% |
| C09BB04 133 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Dalneva | tbl. 30x(8 mg + 5 mg) | 1,11 | 33,30 | R | 5% |
| C09BB04 134 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Dalneva | tbl. 30x(8 mg + 10 mg) | 1,18 | 35,32 | R | 5% |
| C09BB04 135 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Predalneva | tbl. 30x(2,85 mg + 2,5 mg) | 0,39 | 11,56 | R | 5% |
| C09BB07 101 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 30x(5 mg + 5 mg) | 0,95 | 28,61 | R | 5% |
| C09BB07 102 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 60x(5 mg + 5 mg) | 0,86 | 51,50 | R | 5% |
| C09BB07 103 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 30x(5 mg + 10 mg) | 0,95 | 28,61 | R | 5% |
| C09BB07 104 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 60x(5 mg + 10 mg) | 0,86 | 51,50 | R | 5% |
| C09BB07 105 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 30x(10 mg + 5 mg) | 1,13 | 33,96 | R | 5% |
| C09BB07 106 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 30x(10 mg + 10 mg) | 1,13 | 33,96 | R | 5% |
| C09BB07 110 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(10 mg + 10 mg) | 1,02 | 61,13 | R | 5% |
| C09BB07 111 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(2,5 mg + 5 mg) | 0,71 | 21,15 | R | 5% |
| C09BB07 112 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(2,5 mg + 5 mg) | 0,63 | 38,07 | R | 5% |
| C09BB07 113 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(5 mg + 5 mg) | 0,95 | 28,61 | R | 5% |
| C09BB07 114 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(5 mg + 5 mg) | 0,86 | 51,50 | R | 5% |
| C09BB07 115 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(5 mg + 10 mg) | 0,95 | 28,61 | R | 5% |
| C09BB07 116 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(5 mg + 10 mg) | 0,86 | 51,50 | R | 5% |
| C09BB07 117 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(10 mg + 5 mg) | 1,13 | 33,96 | R | 5% |
| C09BB07 118 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(10 mg + 5 mg) | 1,02 | 61,13 | R | 5% |
| C09BB07 119 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(10 mg + 10 mg) | 1,13 | 33,96 | R | 5% |
| C09BB07 122 |  | ramipril + amlodipin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Prylar | caps. tvrda 30x(5 mg + 5 mg) | 0,95 | 28,61 | R | 5% |
| C09BB07 123 |  | ramipril + amlodipin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Prylar | caps. tvrda 30x(10 mg + 5 mg) | 1,13 | 33,96 | R | 5% |
| C09BB07 124 |  | ramipril + amlodipin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Prylar | caps. tvrda 30x(5 mg + 10 mg) | 0,95 | 28,61 | R | 5% |
| C09BB07 125 |  | ramipril + amlodipin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Prylar | caps. tvrda 30x(10 mg + 10 mg) | 1,13 | 33,96 | R | 5% |
| C09BB07 131 |  | ramipril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Rameam | caps. tvrda 30x(5 mg + 5 mg) | 0,95 | 28,61 | R | 5% |
| C09BB07 181 |  | ramipril + amlodipin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol | caps. tvrda 30x(5 mg + 5 mg) | 0,91 | 27,18 | R | 5% |
| C09BB07 182 |  | ramipril + amlodipin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol | caps. tvrda 30x(5 mg + 10 mg) | 0,91 | 27,18 | R | 5% |
| C09BB07 183 |  | ramipril + amlodipin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol | caps. tvrda 30x(10 mg + 5 mg) | 1,08 | 32,26 | R | 5% |
| C09BB07 184 |  | ramipril + amlodipin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol | caps. tvrda 30x(10 mg + 10 mg) | 1,08 | 32,26 | R | 5% |
| C09BX01 131 |  | perindopril + indapamid + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Dalneva | tbl. film obl. 30x(4 mg + 1,25 mg + 5 mg) | 0,83 | 24,85 | R | 5% |
| C09BX01 132 |  | perindopril + indapamid + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Dalneva | tbl. film obl. 30x(4 mg + 1,25 mg + 10 mg) | 0,88 | 26,50 | R | 5% |
| C09BX01 133 |  | perindopril + indapamid + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Dalneva | tbl. film obl. 30x(8 mg + 2,5 mg + 5 mg) | 1,65 | 49,39 | R | 5% |
| C09BX01 134 |  | perindopril + indapamid + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Dalneva | tbl. film obl. 30x(8 mg + 2,5 mg + 10 mg) | 1,70 | 51,05 | R | 5% |
| C09BX03 121 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Prylar H | caps. tvrda 30x(5 mg + 5 mg + 12,5 mg) | 0,75 | 22,40 | R | 5% |
| C09BX03 122 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Prylar H | caps. tvrda 30x(5 mg + 5 mg + 25 mg) | 0,75 | 22,40 | R | 5% |
| C09BX03 123 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Prylar H | caps. tvrda 30x(10 mg + 5 mg + 25 mg) | 1,00 | 29,89 | R | 5% |
| C09BX03 124 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Prylar H | caps. tvrda 30x(10 mg + 10 mg + 25 mg) | 1,05 | 31,47 | R | 5% |
| C09BX03 171 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol Plus | caps. tvrda 30x(5 mg + 5 mg + 12,5 mg) | 0,75 | 22,40 | R | 5% |
| C09BX03 172 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol Plus | caps. tvrda 30x(5 mg + 5 mg + 25 mg) | 0,75 | 22,40 | R | 5% |
| C09BX03 173 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol Plus | caps. tvrda 30x(10 mg + 5 mg + 25 mg) | 1,00 | 29,89 | R | 5% |
| C09BX03 174 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol Plus | caps. tvrda 30x(10 mg + 10 mg + 25 mg) | 1,05 | 31,47 | R | 5% |
| C09CA01 101 |  | losartan | 50 mg | 0,55 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Losartic | tbl. 28x50 mg | 0,55 | 15,40 | RRC02 | 5% |
| C09CA01 121 |  | losartan | 50 mg | 0,55 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Lotan | tbl. film obl. 28x50 mg | 0,55 | 15,40 | RRC02 | 5% |
| C09CA01 125 |  | losartan | 50 mg | 0,55 | O | Alkaloid d.o.o. | Alkaloid | Lotar | tbl. film obl. 30x50 mg | 0,55 | 16,50 | RRC02 | 5% |
| C09CA01 126 |  | losartan | 50 mg | 0,58 | O | Alkaloid d.o.o. | Alkaloid | Lotar | tbl. film obl. 30x100 mg | 1,15 | 34,60 | RRC02 | 5% |
| C09CA01 131 |  | losartan | 50 mg | 0,55 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lorista | tbl. 28 x 50 mg | 0,55 | 15,40 | RRC02 | 5% |
| C09CA01 132 |  | losartan | 50 mg | 0,58 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lorista | tbl. 28x100 mg | 1,15 | 32,29 | RRC02 | 5% |
| C09CA03 111 |  | valsartan | 80 mg | 0,55 | O | Belupo d.d. | Belupo | Val | tbl. film obl. 28x80 mg | 0,55 | 15,40 | RRC02 | 5% |
| C09CA03 112 |  | valsartan | 80 mg | 0,58 | O | Belupo d.d. | Belupo | Val | tbl. film obl. 28x160 mg | 1,15 | 32,29 | RRC02 | 5% |
| C09CA03 113 |  | valsartan | 80 mg | 0,55 | O | Belupo d.d. | Belupo | Val | tbl. film obl. 56x80 mg | 0,55 | 30,80 | RRC02 | 5% |
| C09CA03 114 |  | valsartan | 80 mg | 0,58 | O | Belupo d.d. | Belupo | Val | tbl. film obl. 56x160 mg | 1,16 | 64,77 | RRC02 | 5% |
| C09CA03 121 |  | valsartan | 80 mg | 0,55 | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm | tbl. film obl. 30x80 mg | 0,55 | 16,50 | RRC02 | 5% |
| C09CA03 122 |  | valsartan | 80 mg | 0,58 | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm | tbl. film obl. 30x160 mg | 1,15 | 34,60 | RRC02 | 5% |
| C09CA03 124 |  | valsartan | 80 mg | 0,53 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Desart | tbl. film obl. 28x80 mg | 0,53 | 14,80 | RRC02 | 5% |
| C09CA03 125 |  | valsartan | 80 mg | 0,58 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Desart | tbl. film obl. 28x160 mg | 1,15 | 32,29 | RRC02 | 5% |
| C09CA03 132 |  | valsartan | 80 mg | 0,55 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Valsacor | tbl. film obl. 28x80 mg | 0,55 | 15,40 | RRC02 | 5% |
| C09CA03 133 |  | valsartan | 80 mg | 0,58 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Valsacor | tbl. film obl. 28x160 mg | 1,15 | 32,29 | RRC02 | 5% |
| C09CA03 134 |  | valsartan | 80 mg | 0,58 | O | KRKA-FARMA d.o.o. | Krka d.d. | Valsacor | tbl. film obl. 28x320 mg | 2,33 | 65,24 | RRC02 | 5% |
| C09CA06 122 |  | kandesartan | 8 mg | 0,58 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Kandepres | tbl. 28x16 mg | 1,15 | 32,29 | RRC02 | 5% |
| C09CA07 131 |  | telmisartan | 40 mg | 0,55 | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska | Tolura | tbl. 30x40 mg | 0,55 | 16,50 | RRC02 | 5% |
| C09CA07 132 |  | telmisartan | 40 mg | 0,58 | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska | Tolura | tbl. 30x80 mg | 1,15 | 34,60 | RRC02 | 5% |
| C09DA01 101 |  | losartan + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Losartic plus | tbl. 28x(50 mg + 12,5 mg) | 0,95 | 26,60 | RRC02 | 5% |
| C09DA01 121 |  | losartan + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Lotan H | tbl. 28x(50 mg + 12,5 mg) | 0,95 | 26,60 | RRC02 | 5% |
| C09DA01 131 |  | losartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Lorista H | tbl. film obl. 28x(50 mg + 12,5 mg) | 0,95 | 26,60 | RRC02 | 5% |
| C09DA01 132 |  | losartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Lorista HD | tbl. film obl. 30x(100 mg + 25 mg) | 1,15 | 34,60 | RRC02 | 5% |
| C09DA01 134 |  | losartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | KRKA d.d. | Lorista H | tbl. film obl. 28x(100 mg + 12,5 mg) | 1,23 | 34,44 | RRC02 | 5% |
| C09DA01 161 |  | losartan + hidroklorotiazid |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Hyzaar | tbl. 28x(50 mg + 12,5 mg) | 0,95 | 26,60 | RRC02 | 5% |
| C09DA01 162 |  | losartan + hidroklorotiazid |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Fortzaar | tbl. 28x(100 mg + 25 mg) | 1,25 | 35,00 | RRC02 | 5% |
| C09DA01 163 |  | losartan + hidroklorotiazid |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Hyzaar | tbl. film obl. 28x(100 mg + 12,5 mg) | 1,23 | 34,44 | RRC02 | 5% |
| C09DA03 111 |  | valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Val Plus | tbl. film obl. 28x(80 mg + 12,5 mg) | 0,95 | 26,60 | RRC02 | 5% |
| C09DA03 112 |  | valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Val Plus | tbl. film obl. 28x(160 mg + 12,5 mg) | 1,28 | 35,75 | RRC02 | 5% |
| C09DA03 113 |  | valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Val Plus | tbl. film obl. 56x(80 mg + 12,5 mg) | 0,95 | 53,20 | RRC02 | 5% |
| C09DA03 114 |  | valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Val Plus | tbl. film obl. 56x(160 mg + 12,5 mg) | 1,28 | 71,50 | RRC02 | 5% |
| C09DA03 121 |  | valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm H | tbl. film obl. 30x(80 mg + 12,5 mg) | 0,95 | 28,50 | RRC02 | 5% |
| C09DA03 122 |  | valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm H | tbl. film obl. 30x(160 mg + 12,5 mg) | 1,28 | 38,30 | RRC02 | 5% |
| C09DA03 124 |  | valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm H | tbl. film obl. 30x(160 mg + 25 mg) | 1,28 | 38,30 | RRC02 | 5% |
| C09DA03 131 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 28x(80 mg + 12,5 mg) | 0,95 | 26,60 | RRC02 | 5% |
| C09DA03 132 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 56x(80 mg + 12,5 mg) | 0,95 | 53,20 | RRC02 | 5% |
| C09DA03 133 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 28x(160 mg + 12,5 mg) | 1,28 | 35,75 | RRC02 | 5% |
| C09DA03 134 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 56x(160 mg + 12,5 mg) | 1,28 | 71,50 | RRC02 | 5% |
| C09DA03 135 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 28x(160 mg + 25 mg) | 1,28 | 35,75 | RRC02 | 5% |
| C09DA03 136 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 56x(160 mg + 25 mg) | 1,28 | 71,50 | RRC02 | 5% |
| C09DA03 137 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Valsacombi | tbl. film obl. 28x(320 mg + 12,5 mg) | 2,72 | 76,25 | RRC02 | 5% |
| C09DA03 139 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Valsacombi | tbl. film obl. 28x(320 mg + 25 mg) | 2,72 | 76,25 | RRC02 | 5% |
| C09DA03 163 |  | valsartan + hidroklorotiazid |  |  | O | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Co-Diovan | tbl. film obl. 28x(160 mg + 25 mg) | 1,28 | 35,75 | RRC02 | 5% |
| C09DA03 164 |  | valsartan + hidroklorotiazid |  |  | O | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Co-Diovan | tbl. film obl. 28x(320 mg + 12,5 mg) | 2,72 | 76,25 | RRC02 | 5% |
| C09DA07 137 |  | telmisartan + hidroklorotiazid |  |  | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska Sp. zo. o., TAD Pharma GmbH | Tolucombi | tbl. 28x(40 mg + 12,5 mg) | 0,95 | 26,60 | RRC02 | 5% |
| C09DA07 138 |  | telmisartan + hidroklorotiazid |  |  | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska Sp. zo. o., TAD Pharma GmbH | Tolucombi | tbl. 28x(80 mg + 12,5 mg) | 1,28 | 35,75 | RRC02 | 5% |
| C09DA07 139 |  | telmisartan + hidroklorotiazid |  |  | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska Sp. zo. o., TAD Pharma GmbH | Tolucombi | tbl. 28x(80 mg + 25 mg) | 1,28 | 35,75 | RRC02 | 5% |
| C09DB01 111 |  | amlodipin + valsartan |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas | tbl. film obl. 30x(5 mg + 80 mg) | 0,52 | 15,65 | RRC02 | 5% |
| C09DB01 112 |  | amlodipin + valsartan |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas | tbl. film obl. 30x(5 mg + 160 mg) | 1,01 | 30,39 | RRC02 | 5% |
| C09DB01 113 |  | amlodipin + valsartan |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas | tbl. film obl. 30x(10 mg + 160 mg) | 1,01 | 30,39 | RRC02 | 5% |
| C09DB01 121 |  | amlodipin + valsartan |  |  | O | Sandoz d.o.o. | Novartis Pharma GmbH | Amlodipin/valsartan Sandoz | tbl. film obl. 28x(5 mg + 80 mg) | 0,55 | 15,37 | RRC02 | 5% |
| C09DB01 122 |  | amlodipin + valsartan |  |  | O | Sandoz d.o.o. | Novartis Pharma GmbH | Amlodipin/valsartan Sandoz | tbl. film obl. 28x(5 mg + 160 mg) | 1,01 | 28,36 | RRC02 | 5% |
| C09DB01 123 |  | amlodipin + valsartan |  |  | O | Sandoz d.o.o. | Novartis Pharma GmbH | Amlodipin/valsartan Sandoz | tbl. film obl. 28x(10 mg + 160 mg) | 1,07 | 29,86 | RRC02 | 5% |
| C09DB01 141 |  | amlodipin + valsartan |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., Krka-farma d.o.o. | Wamlox | tbl. film obl. 30x(5 mg + 160 mg) | 1,01 | 30,39 | RRC02 | 5% |
| C09DB01 142 |  | amlodipin + valsartan |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., Krka-farma d.o.o. | Wamlox | tbl. film obl. 30x(10 mg + 160 mg) | 1,07 | 31,99 | RRC02 | 5% |
| C09DB01 143 |  | amlodipin + valsartan |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma Gmbh | Wamlox | tbl. film obl. 30x(5 mg + 80 mg) | 0,55 | 16,47 | RRC02 | 5% |
| C09DX01 111 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas HCT | tbl. film obl. 30x(5 mg + 160 mg + 12,5 mg) | 1,11 | 33,32 | RRC02 | 5% |
| C09DX01 112 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas HCT | tbl. film obl. 30x(5 mg + 160 mg + 25 mg) | 1,11 | 33,32 | RRC02 | 5% |
| C09DX01 113 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas HCT | tbl. film obl. 30x(10 mg + 160 mg + 12,5 mg) | 1,18 | 35,31 | RRC02 | 5% |
| C09DX01 114 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas HCT | tbl. film obl. 30x(10 mg + 160 mg + 25 mg) | 1,18 | 35,31 | RRC02 | 5% |
| C09DX01 124 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Salutas Pharma GmbH | Dipperam HCT | tbl. film obl. 28x(5 mg + 160 mg + 12,5 mg) | 1,17 | 32,73 | RRC02 | 5% |
| C09DX01 125 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Salutas Pharma GmbH | Dipperam HCT | tbl. film obl. 28x(5 mg + 160 mg + 25 mg) | 1,17 | 32,73 | RRC02 | 5% |
| C09DX01 126 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Salutas Pharma GmbH | Dipperam HCT | tbl. film obl. 28x(10 mg + 160 mg + 12,5 mg) | 1,18 | 32,96 | RRC02 | 5% |
| C09DX01 131 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GMBH | Valtricom | tbl. film obl. 30x(5 mg + 160 mg + 12,5 mg) | 1,17 | 35,07 | RRC02 | 5% |
| C09DX01 132 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GMBH | Valtricom | tbl. film obl. 30x(10 mg + 160 mg + 12,5 mg) | 1,18 | 35,31 | RRC02 | 5% |
| C09DX01 133 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GMBH | Valtricom | tbl. film obl. 30x(5 mg + 160 mg + 25 mg) | 1,17 | 35,07 | RRC02 | 5% |
| C09DX01 134 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GMBH | Valtricom | tbl. film obl. 30x(10 mg + 320 mg + 25 mg) | 2,22 | 66,63 | RRC02 | 5% |
| C10AA01 106 |  | simvastatin | 30 mg | 1,14 | O | Alkaloid d.o.o. | Alkaloid | Lipterra | tbl. film obl. 28x10 mg | 0,38 | 10,64 | RRC03 | 5% |
| C10AA01 108 |  | simvastatin | 30 mg | 0,75 | O | Alkaloid d.o.o. | Alkaloid | Lipterra | tbl. film obl. 28x20 mg | 0,50 | 14,03 | RRC03 | 5% |
| C10AA01 109 |  | simvastatin | 30 mg | 0,79 | O | Alkaloid d.o.o. | Alkaloid | Lipterra | tbl. film obl. 28x40 mg | 1,05 | 29,33 | RRC03 | 5% |
| C10AA01 112 |  | simvastatin | 30 mg | 1,14 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Simvax | tbl. film obl. 28x10 mg | 0,38 | 10,64 | RRC03 | 5% |
| C10AA01 114 |  | simvastatin | 30 mg | 0,75 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Simvax | tbl. film obl. 28x20 mg | 0,50 | 14,03 | RRC03 | 5% |
| C10AA01 116 |  | simvastatin | 30 mg | 0,79 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Simvax | tbl. film obl. 28x40 mg | 1,05 | 29,33 | RRC03 | 5% |
| C10AA01 131 |  | simvastatin | 30 mg | 1,14 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 20x10 mg | 0,38 | 7,60 | RRC03 | 5% |
| C10AA01 132 |  | simvastatin | 30 mg | 1,14 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 28x10 mg | 0,38 | 10,64 | RRC03 | 5% |
| C10AA01 133 |  | simvastatin | 30 mg | 0,75 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 20x20 mg | 0,50 | 10,02 | RRC03 | 5% |
| C10AA01 134 |  | simvastatin | 30 mg | 0,75 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 28x20 mg | 0,50 | 14,03 | RRC03 | 5% |
| C10AA01 135 |  | simvastatin | 30 mg | 0,79 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 28x40 mg | 1,05 | 29,33 | RRC03 | 5% |
| C10AA01 136 |  | simvastatin | 30 mg | 1,14 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 60x10 mg | 0,38 | 22,80 | RRC03 | 5% |
| C10AA01 137 |  | simvastatin | 30 mg | 0,75 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 60x20 mg | 0,50 | 30,06 | RRC03 | 5% |
| C10AA01 138 |  | simvastatin | 30 mg | 0,79 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 60x40 mg | 1,05 | 62,80 | RRC03 | 5% |
| C10AA01 141 |  | simvastatin | 30 mg | 1,14 | O | Belupo d.d. | Belupo | Protecta | tbl. film obl. 28x10 mg | 0,38 | 10,64 | RRC03 | 5% |
| C10AA01 142 |  | simvastatin | 30 mg | 0,75 | O | Belupo d.d. | Belupo | Protecta | tbl. film obl. 28x20 mg | 0,50 | 14,03 | RRC03 | 5% |
| C10AA01 143 |  | simvastatin | 30 mg | 0,79 | O | Belupo d.d. | Belupo | Protecta | tbl. film obl. 28x40 mg | 1,05 | 29,33 | RRC03 | 5% |
| C10AA01 144 |  | simvastatin | 30 mg | 0,75 | O | Belupo d.d. | Belupo | Protecta | tbl. film obl. 56x20 mg | 0,50 | 28,06 | RRC03 | 5% |
| C10AA01 166 |  | simvastatin | 30 mg | 0,75 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Simvastatin Genericon | tbl. film obl. 30x20 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA01 167 |  | simvastatin | 30 mg | 0,79 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Simvastatin Genericon | tbl. film obl. 30x40 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 101 |  | atorvastatin | 20 mg | 1,00 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 30x10 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA05 102 |  | atorvastatin | 20 mg | 1,00 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 60x10 mg | 0,50 | 30,06 | RRC03 | 5% |
| C10AA05 103 |  | atorvastatin | 20 mg | 1,05 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 30x20 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 104 |  | atorvastatin | 20 mg | 1,05 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 60x20 mg | 1,05 | 62,84 | RRC03 | 5% |
| C10AA05 105 |  | atorvastatin | 20 mg | 0,67 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 30x40 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA05 106 |  | atorvastatin | 20 mg | 0,67 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 60x40 mg | 1,34 | 80,60 | RRC03 | 5% |
| C10AA05 107 |  | atorvastatin | 20 mg | 0,53 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 30x80 mg | 2,10 | 63,00 | RRC03 | 5% |
| C10AA05 111 |  | atorvastatin | 20 mg | 1,00 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 30x10 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA05 112 |  | atorvastatin | 20 mg | 1,00 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 60x10 mg | 0,50 | 30,06 | RRC03 | 5% |
| C10AA05 113 |  | atorvastatin | 20 mg | 1,05 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 30x20 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 114 |  | atorvastatin | 20 mg | 1,05 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 60x20 mg | 1,05 | 62,84 | RRC03 | 5% |
| C10AA05 115 |  | atorvastatin | 20 mg | 0,67 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 30x40 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA05 121 |  | atorvastatin | 20 mg | 1,00 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 30x10 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA05 122 |  | atorvastatin | 20 mg | 1,05 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 30x20 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 123 |  | atorvastatin | 20 mg | 1,00 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 60x10 mg | 0,50 | 30,06 | RRC03 | 5% |
| C10AA05 124 |  | atorvastatin | 20 mg | 1,05 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 60x20 mg | 1,05 | 62,84 | RRC03 | 5% |
| C10AA05 125 |  | atorvastatin | 20 mg | 0,67 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 30x40 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA05 126 |  | atorvastatin | 20 mg | 0,67 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 60x40 mg | 1,34 | 80,60 | RRC03 | 5% |
| C10AA05 127 |  | atorvastatin | 20 mg | 1,00 | O | Mylan Hrvatska d.o.o. | Pharmathen International SA | Synordia | tbl. film obl. 30x10 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA05 129 |  | atorvastatin | 20 mg | 1,05 | O | Mylan Hrvatska d.o.o. | Pharmathen International SA | Synordia | tbl. film obl. 30x20 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 131 |  | atorvastatin | 20 mg | 1,00 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 30x10 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA05 132 |  | atorvastatin | 20 mg | 1,05 | O | KRKA-FARMA d.o.o. | Krka d.d.,KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 30x20 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 133 |  | atorvastatin | 20 mg | 0,67 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 30x40 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA05 134 |  | atorvastatin | 20 mg | 0,67 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 60x40 mg | 1,34 | 80,60 | RRC03 | 5% |
| C10AA05 136 |  | atorvastatin | 20 mg | 1,00 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 60x10 mg | 0,50 | 30,06 | RRC03 | 5% |
| C10AA05 137 |  | atorvastatin | 20 mg | 1,05 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 60x20 mg | 1,05 | 62,84 | RRC03 | 5% |
| C10AA05 138 |  | atorvastatin | 20 mg | 0,67 | O | Mylan Hrvatska d.o.o. | Pharmathen International SA | Synordia | tbl. film obl. 30x40 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA05 139 |  | atorvastatin | 20 mg | 0,53 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atoris | tbl. film obl. 30x80 mg | 2,10 | 63,00 | RRC03 | 5% |
| C10AA05 141 |  | atorvastatin | 20 mg | 1,00 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 30x10 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA05 142 |  | atorvastatin | 20 mg | 1,00 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 60x10 mg | 0,50 | 30,06 | RRC03 | 5% |
| C10AA05 143 |  | atorvastatin | 20 mg | 1,05 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 30x20 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 144 |  | atorvastatin | 20 mg | 1,05 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 60x20 mg | 1,05 | 62,84 | RRC03 | 5% |
| C10AA05 145 |  | atorvastatin | 20 mg | 0,67 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 30x40 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA05 146 |  | atorvastatin | 20 mg | 0,67 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 60x40 mg | 1,34 | 80,60 | RRC03 | 5% |
| C10AA05 171 |  | atorvastatin | 20 mg | 1,00 | O | Upjohn EESV | Goedecke GmbH za Pfizer | Sortis | tbl. film obl. 30x10 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA05 172 |  | atorvastatin | 20 mg | 1,05 | O | Upjohn EESV | Goedecke GmbH za Pfizer | Sortis | tbl. film obl. 30x20 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 173 |  | atorvastatin | 20 mg | 0,67 | O | Upjohn EESV | Goedecke GmbH za Pfizer | Sortis | tbl. film obl. 30x40 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA05 174 |  | atorvastatin | 20 mg | 0,53 | O | Upjohn EESV | Goedecke GmbH za Pfizer | Sortis | tbl. film obl. 30x80 mg | 2,10 | 63,00 | RRC03 | 5% |
| C10AA05 175 |  | atorvastatin | 20 mg | 1,00 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 30x10 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA05 176 |  | atorvastatin | 20 mg | 1,00 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 60x10 mg | 0,50 | 30,06 | RRC03 | 5% |
| C10AA05 177 |  | atorvastatin | 20 mg | 1,05 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 30x20 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 178 |  | atorvastatin | 20 mg | 1,05 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 60x20 mg | 1,05 | 62,84 | RRC03 | 5% |
| C10AA05 179 |  | atorvastatin | 20 mg | 0,67 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 30x40 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA05 180 |  | atorvastatin | 20 mg | 0,86 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 60x40 mg | 1,34 | 80,60 | RRC03 | 5% |
| C10AA05 181 |  | atorvastatin | 20 mg | 1,00 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Artas | tbl. film obl. 28x10 mg | 0,50 | 14,03 | RRC03 | 5% |
| C10AA05 183 |  | atorvastatin | 20 mg | 0,92 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Artas | tbl. film obl. 28x20 mg | 0,92 | 25,85 | RRC03 | 5% |
| C10AA05 184 |  | atorvastatin | 20 mg | 1,05 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Artas | tbl. film obl. 56x20 mg | 1,05 | 58,65 | RRC03 | 5% |
| C10AA05 185 |  | atorvastatin | 20 mg | 0,64 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Artas | tbl. film obl. 28x40 mg | 1,27 | 35,56 | RRC03 | 5% |
| C10AA05 191 |  | atorvastatin | 20 mg | 0,76 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atoris | tbl. film obl. 30x30 mg | 1,15 | 34,40 | RRC03 | 5% |
| C10AA05 192 |  | atorvastatin | 20 mg | 0,76 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atoris | tbl. film obl. 60x30 mg | 1,15 | 68,81 | RRC03 | 5% |
| C10AA05 193 |  | atorvastatin | 20 mg | 0,52 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atoris | tbl. film obl. 30x60 mg | 1,56 | 46,80 | RRC03 | 5% |
| C10AA05 195 |  | atorvastatin | 20 mg | 1,00 | O | Alkaloid d.o.o. | Alkaloid | Calipra | tbl. film obl. 30x10 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA05 196 |  | atorvastatin | 20 mg | 1,05 | O | Alkaloid d.o.o. | Alkaloid | Calipra | tbl. film obl. 30x20 mg | 1,05 | 31,42 | RRC03 | 5% |
| C10AA05 197 |  | atorvastatin | 20 mg | 0,67 | O | Alkaloid d.o.o. | Alkaloid | Calipra | tbl. film obl. 30x40 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA05 198 |  | atorvastatin | 20 mg | 0,53 | O | Alkaloid d.o.o. | Alkaloid | Calipra | tbl. film obl. 30x80 mg | 2,10 | 63,00 | RRC03 | 5% |
| C10AA07 105 |  | rosuvastatin | 10 mg | 0,76 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o.; Merckle GmbH; HBM Pharma s.r.o.; Teva Pharma B.V.; Teva Operations Poland | Epri | tbl. film obl. 30x15 mg | 1,15 | 34,40 | RRC03 | 5% |
| C10AA07 106 |  | rosuvastatin | 10 mg | 0,52 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o.; Merckle GmbH; HBM Pharma s.r.o.; Teva Pharma B.V.; Teva Operations Poland | Epri | tbl. film obl. 30x30 mg | 1,56 | 46,80 | RRC03 | 5% |
| C10AA07 107 |  | rosuvastatin | 10 mg | 1,00 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Epri | tbl. film obl. 30x5 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA07 108 |  | rosuvastatin | 10 mg | 1,02 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Epri | tbl. film obl. 30x10 mg | 1,02 | 30,60 | RRC03 | 5% |
| C10AA07 109 |  | rosuvastatin | 10 mg | 0,67 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Epri | tbl. film obl. 30x20 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA07 110 |  | rosuvastatin | 10 mg | 0,43 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Epri | tbl. film obl. 30x40 mg | 1,74 | 52,10 | RRC03 | 5% |
| C10AA07 112 |  | rosuvastatin | 10 mg | 1,05 | O | Belupo d.d. | Belupo | Rosix | tbl. film obl. 28x10 mg | 1,05 | 29,33 | RRC03 | 5% |
| C10AA07 113 |  | rosuvastatin | 10 mg | 0,67 | O | Belupo d.d. | Belupo | Rosix | tbl. film obl. 28x20 mg | 1,34 | 37,61 | RRC03 | 5% |
| C10AA07 114 |  | rosuvastatin | 10 mg | 0,53 | O | Belupo d.d. | Belupo | Rosix | tbl. film obl. 28x40 mg | 2,10 | 58,80 | RRC03 | 5% |
| C10AA07 121 |  | rosuvastatin | 10 mg | 1,05 | O | Sandoz d.o.o. | Sandoz-Lek | Coupet | tbl. film obl. 28x10 mg | 1,05 | 29,33 | RRC03 | 5% |
| C10AA07 122 |  | rosuvastatin | 10 mg | 0,67 | O | Sandoz d.o.o. | Sandoz-Lek | Coupet | tbl. film obl. 28x20 mg | 1,34 | 37,61 | RRC03 | 5% |
| C10AA07 123 |  | rosuvastatin | 10 mg | 0,53 | O | Sandoz d.o.o. | Sandoz-Lek | Coupet | tbl. film obl. 28x40 mg | 2,10 | 58,80 | RRC03 | 5% |
| C10AA07 128 |  | rosuvastatin | 10 mg | 0,87 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Coupet | tbl. film obl. 60x10 mg | 0,87 | 51,93 | RRC03 | 5% |
| C10AA07 129 |  | rosuvastatin | 10 mg | 0,67 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Coupet | tbl. film obl. 60x20 mg | 1,34 | 80,60 | RRC03 | 5% |
| C10AA07 130 |  | rosuvastatin | 10 mg | 0,40 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Coupet | tbl. film obl. 60x40 mg | 1,61 | 96,60 | RRC03 | 5% |
| C10AA07 131 |  | rosuvastatin | 10 mg | 1,00 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Roswera | tbl. film obl. 28x5 mg | 0,50 | 14,03 | RRC03 | 5% |
| C10AA07 132 |  | rosuvastatin | 10 mg | 1,05 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Roswera | tbl. film obl. 28x10 mg | 1,05 | 29,33 | RRC03 | 5% |
| C10AA07 133 |  | rosuvastatin | 10 mg | 0,67 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Roswera | tbl. film obl. 28x20 mg | 1,34 | 37,61 | RRC03 | 5% |
| C10AA07 134 |  | rosuvastatin | 10 mg | 0,53 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Roswera | tbl. film obl. 28x40 mg | 2,10 | 58,80 | RRC03 | 5% |
| C10AA07 135 |  | rosuvastatin | 10 mg | 0,76 | O | KRKA-FARMA d.o.o. | Krka d.d. | Roswera | tbl. film obl. 28x15 mg | 1,15 | 32,11 | RRC03 | 5% |
| C10AA07 136 |  | rosuvastatin | 10 mg | 0,52 | O | KRKA-FARMA d.o.o. | Krka d.d. | Roswera | tbl. film obl. 28x30 mg | 1,56 | 43,68 | RRC03 | 5% |
| C10AA07 141 |  | rosuvastatin | 10 mg | 0,67 | O | Genericon Pharma Gesellschaft m.b.H. | Pharmaceutical Works Polpharma S.A.; Genericon Pharma Gesellschaft m.b.H. | Rosuvastatin Genericon | tbl. film obl. 30x20 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA07 142 |  | rosuvastatin | 10 mg | 1,01 | O | Genericon Pharma Gesellschaft m.b.H. | Pharmaceutical Works Polpharma S.A.; Genericon Pharma Gesellschaft m.b.H. | Rosuvastatin Genericon | tbl. film obl. 30x10 mg | 1,01 | 30,28 | RRC03 | 5% |
| C10AA07 143 |  | rosuvastatin | 10 mg | 0,43 | O | Genericon Pharma Gesellschaft m.b.H. | Pharmaceutical Works Polpharma S.A.; Genericon Pharma Gesellschaft m.b.H. | Rosuvastatin Genericon | tbl. film obl. 30x40 mg | 1,74 | 52,10 | RRC03 | 5% |
| C10AA07 144 |  | rosuvastatin | 10 mg | 1,00 | O | Alkaloid-INT d.o.o. | Alkaloid – INT | Ropuido | tbl. film obl. 30x5 mg | 0,50 | 15,03 | RRC03 | 5% |
| C10AA07 145 |  | rosuvastatin | 10 mg | 0,96 | O | Alkaloid-INT d.o.o. | Alkaloid – INT | Ropuido | tbl. film obl. 30x10 mg | 0,96 | 28,77 | RRC03 | 5% |
| C10AA07 146 |  | rosuvastatin | 10 mg | 0,67 | O | Alkaloid-INT d.o.o. | Alkaloid – INT | Ropuido | tbl. film obl. 30x20 mg | 1,34 | 40,30 | RRC03 | 5% |
| C10AA07 147 |  | rosuvastatin | 10 mg | 0,43 | O | Alkaloid-INT d.o.o. | Alkaloid – INT | Ropuido | tbl. film obl. 30x40 mg | 1,74 | 52,10 | RRC03 | 5% |
| C10AA07 165 |  | rosuvastatin | 10 mg | 0,97 | O | Jadran – Galenski Laboratorij d.d. | Teva Pharma S.L.U. | Rosuvastatin JGL | tbl. film obl. 28x5 mg | 0,48 | 13,56 | RRC03 | 5% |
| C10AA07 166 |  | rosuvastatin | 10 mg | 0,91 | O | Jadran – Galenski Laboratorij d.d. | Teva Pharma S.L.U. | Rosuvastatin JGL | tbl. film obl. 28x10 mg | 0,91 | 25,51 | RRC03 | 5% |
| C10AA07 167 |  | rosuvastatin | 10 mg | 0,67 | O | Jadran – Galenski Laboratorij d.d. | Teva Pharma S.L.U. | Rosuvastatin JGL | tbl. film obl. 28x20 mg | 1,34 | 37,61 | RRC03 | 5% |
| C10AA07 168 |  | rosuvastatin | 10 mg | 0,50 | O | Jadran – Galenski Laboratorij d.d. | Teva Pharma S.L.U. | Rosuvastatin JGL | tbl. film obl. 28x40 mg | 1,98 | 55,51 | RRC03 | 5% |
| C10AA07 181 |  | rosuvastatin | 10 mg | 1,00 | O | Viatris Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Generics [UK] Limited | Rosacol | tbl. film obl. 28x5 mg | 0,50 | 14,03 | RRC03 | 5% |
| C10AA07 182 |  | rosuvastatin | 10 mg | 0,96 | O | Viatris Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Generics [UK] Limited | Rosacol | tbl. film obl. 28x10 mg | 0,96 | 26,85 | RRC03 | 5% |
| C10AA07 183 |  | rosuvastatin | 10 mg | 0,67 | O | Viatris Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Generics [UK] Limited | Rosacol | tbl. film obl. 28x20 mg | 1,34 | 37,61 | RRC03 | 5% |
| C10AA07 184 |  | rosuvastatin | 10 mg | 0,53 | O | Viatris Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Generics [UK] Limited | Rosacol | tbl. film obl. 28x40 mg | 2,10 | 58,80 | RRC03 | 5% |
| C10AB05 101 |  | fenofibrat | 200 mg | 1,47 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp.z.o.o. | Zigotrig | tbl. film obl. 30x160 mg | 1,17 | 35,23 | RRC04 | 5% |
| C10AB05 141 |  | fenofibrat | 200 mg | 1,47 | O | Alkaloid d.o.o. | Alkaloid | Ziglip | tbl. 30x145 mg | 1,06 | 31,93 | RRC04 | 5% |
| C10AB05 171 |  | fenofibrat | 200 mg | 1,47 | O | Bausch Health Ireland Limited | SMB Technology S.A. | Fenolip | caps. 30x160 mg | 1,17 | 35,23 | RRC04 | 5% |
| C10AC01 354 |  | kolestiramin | 14 g |  | O |  |  |  |  |  |  | R | 5% |
| C10AX09 161 |  | ezetimib | 10 mg | 2,50 | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Ezetrol | tbl. 28x10 mg | 2,50 | 69,96 | RSRC08 | 5% |
| C10AX13 061 |  | evolokumab |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Repatha | otop. za inj., brizg. napunj. 2x1 ml (140 mg/ml) | 1.434,51 | 2.869,02 | RS RC11 | 5% |
| C10AX14 061 |  | alirokumab | 5,4 mg | 103,28 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Praluent | otop. za inj., brizg. napunj. 2x1 ml (75 mg/ml) | 1.434,51 | 2.869,02 | RSRC11 | 5% |
| C10AX14 062 |  | alirokumab | 5,4 mg | 51,64 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Praluent | otop. za inj., brizg. napunj. 2x1 ml (150 mg/ml) | 1.434,51 | 2.869,02 | RSRC11 | 5% |
| C10AX14 063 |  | alirokumab | 5,4 mg | 51,64 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Praluent | otop. za inj., brizg. napunj. 1x2 ml (150 mg/ml) | 2.869,02 | 2.869,02 | RSRC11 | 5% |
| C10AX16 071 |  | inklisiran |  |  | P | Novartis Europharm Limited Irska | APO-CARE Pharma GmbH | Leqvio | otop. za inj., štrc. napunj. 1,5 ml (189 mg/ml) | 15.820,93 | 15.820,93 | RSRC11 | 5% |
| C10BA05 121 |  | ezetimib + atorvastatin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Tulip Combi | tbl. film obl. 30x(10 mg + 10 mg) | 2,37 | 71,21 | RSpc08 | 5% |
| C10BA05 122 |  | ezetimib + atorvastatin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Tulip Combi | tbl. film obl. 30x(10 mg + 20 mg) | 2,55 | 76,61 | RSpc08 | 5% |
| C10BA05 123 |  | ezetimib + atorvastatin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Tulip Combi | tbl. film obl. 30x(10 mg + 40 mg) | 2,89 | 86,74 | RSpc08 | 5% |
| C10BA05 124 |  | ezetimib + atorvastatin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Tulip Combi | tbl. film obl. 30x(10 mg + 80 mg) | 4,36 | 130,69 | RSpc08 | 5% |
| C10BA05 161 |  | ezetimib + atorvastatin |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme B.V. | Atozet | tbl. film obl. 30x(10 mg + 10 mg) | 2,50 | 74,96 | RSpc08 | 5% |
| C10BA05 162 |  | ezetimib + atorvastatin |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme B.V. | Atozet | tbl. film obl. 30x(10 mg + 20 mg) | 2,69 | 80,64 | RSpc08 | 5% |
| C10BA05 163 |  | ezetimib + atorvastatin |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme B.V. | Atozet | tbl. film obl. 30x(10 mg + 40 mg) | 3,04 | 91,30 | RSpc08 | 5% |
| C10BA05 171 |  | ezetimib + atorvastatin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Elpen Pharmaceutical Co. Inc. | Co-Atorvox | tbl. film obl. 30x(10 mg + 10 mg) | 2,50 | 74,96 | RSpc08 | 5% |
| C10BA05 172 |  | ezetimib + atorvastatin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Elpen Pharmaceutical Co. Inc. | Co-Atorvox | tbl. film obl. 30x(10 mg + 20 mg) | 2,69 | 80,64 | RSpc08 | 5% |
| C10BA05 173 |  | ezetimib + atorvastatin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Elpen Pharmaceutical Co. Inc. | Co-Atorvox | tbl. film obl. 30x(10 mg + 40 mg) | 3,04 | 91,30 | RSpc08 | 5% |
| C10BA05 174 |  | ezetimib + atorvastatin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Elpen Pharmaceutical Co. Inc. | Co-Atorvox | tbl. film obl. 30x(10 mg + 80 mg) | 4,60 | 138,00 | RSpc08 | 5% |
| C10BA06 101 |  | rosuvastatin + ezetimib |  |  | O | PLIVA HRVATSKA d.o.o. | Teva Operations Poland Sp. z o.o. | Eprizet | tbl. 30x(10 mg + 10 mg) | 2,69 | 80,64 | RSpc08 | 5% |
| C10BA06 102 |  | rosuvastatin + ezetimib |  |  | O | PLIVA HRVATSKA d.o.o. | Teva Operations Poland Sp. z o.o. | Eprizet | tbl. 30x(20 mg + 10 mg) | 3,04 | 91,30 | RSpc08 | 5% |
| C10BA06 111 |  | rosuvastatin + ezetimib |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix Combi | tbl. 30x(5 mg + 10 mg) | 2,50 | 74,96 | RSpc08 | 5% |
| C10BA06 112 |  | rosuvastatin + ezetimib |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix Combi | tbl. 30x(10 mg + 10 mg) | 2,69 | 80,64 | RSpc08 | 5% |
| C10BA06 113 |  | rosuvastatin + ezetimib |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix Combi | tbl. 30x(20 mg + 10 mg) | 3,04 | 91,30 | RSpc08 | 5% |
| C10BA06 122 |  | rosuvastatin + ezetimib |  |  | O | Jadran – Galenski Laboratorij d.d. | Pabianickie Zaklady Farmaceutyczne Polfa S.A., JGL d.d. | Ezotera | tbl. 28x(10 mg + 10 mg) | 2,69 | 75,26 | RSpc08 | 5% |
| C10BA06 123 |  | rosuvastatin + ezetimib |  |  | O | Jadran – Galenski Laboratorij d.d. | Pabianickie Zaklady Farmaceutyczne Polfa S.A., JGL d.d. | Ezotera | tbl. 28x(20 mg + 10 mg) | 3,04 | 85,21 | RSpc08 | 5% |
| C10BA06 131 |  | rosuvastatin + ezetimib |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Roswera | tbl. 30x(10 mg + 10 mg) | 2,69 | 80,64 | RSpc08 | 5% |
| C10BA06 132 |  | rosuvastatin + ezetimib |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Roswera | tbl. 30x(20 mg + 10 mg) | 3,04 | 91,30 | RSpc08 | 5% |
| C10BA06 133 |  | rosuvastatin + ezetimib |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Roswera | tbl. 30x(40 mg + 10 mg) | 4,60 | 138,00 | RSpc08 | 5% |
| C10BA06 171 |  | rosuvastatin + ezetimib |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma Gesellschaft m.b.H., Pabianickie Zaklady Farmaceutyczne Polfa S.A. | Rosuvastatin/Ezetimib Genericon | tbl. 30x(5 mg + 10 mg) | 2,50 | 74,96 | RSpc08 | 5% |
| C10BA06 172 |  | rosuvastatin + ezetimib |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma Gesellschaft m.b.H., Pabianickie Zaklady Farmaceutyczne Polfa S.A. | Rosuvastatin/Ezetimib Genericon | tbl. 30x(10 mg + 10 mg) | 2,69 | 80,64 | RSpc08 | 5% |
| C10BA06 173 |  | rosuvastatin + ezetimib |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma Gesellschaft m.b.H., Pabianickie Zaklady Farmaceutyczne Polfa S.A. | Rosuvastatin/Ezetimib Genericon | tbl. 30x(20 mg + 10 mg) | 3,04 | 91,30 | RSpc08 | 5% |
| C10BX03 131 |  | amlodipin + atorvastatin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atordapin | tbl. film obl. 30x(5 mg + 10 mg) | 0,54 | 16,09 | RRC03 | 5% |
| C10BX03 133 |  | amlodipin + atorvastatin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atordapin | tbl. film obl. 30x(10 mg + 10 mg) | 0,54 | 16,09 | RRC03 | 5% |
| C10BX09 111 |  | rosuvastatin + amlodipin |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix-Am | caps. tvrda 30x(10 mg + 5 mg) | 1,40 | 41,98 | RRC03 | 5% |
| C10BX09 112 |  | rosuvastatin + amlodipin |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix-Am | caps. tvrda 30x(10 mg + 10 mg) | 1,47 | 44,01 | RRC03 | 5% |
| C10BX09 113 |  | rosuvastatin + amlodipin |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix-Am | caps. tvrda 30x(20 mg + 5 mg) | 1,65 | 49,35 | RRC03 | 5% |
| C10BX09 114 |  | rosuvastatin + amlodipin |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix-Am | caps. tvrda 30x(20 mg + 10 mg) | 1,80 | 53,85 | RRC03 | 5% |
| C10BX13 131 |  | rosuvastatin + perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Roxiper | tbl. 30 x (10 mg + 4 mg + 1.25 mg) | 1,63 | 48,98 | RRC03 | 5% |
| C10BX13 132 |  | rosuvastatin + perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Roxiper | tbl. 30 x (10 mg + 8 mg + 2.5 mg) | 2,05 | 61,52 | RRC03 | 5% |
| C10BX13 133 |  | rosuvastatin + perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Roxiper | tbl. 30 x (20 mg + 4 mg + 1.25 mg) | 2,26 | 67,73 | RRC03 | 5% |
| C10BX13 134 |  | rosuvastatin + perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Roxiper | tbl. 30 x (20 mg + 8 mg + 2.5 mg) | 2,68 | 80,27 | RRC03 | 5% |
| D01BA02 111 |  | terbinafin | 0,25 g | 4,64 | O | Belupo d.d. | Belupo | Terbinax | tbl. 14x250 mg | 4,64 | 64,98 | RRD01 | 5% |
| D01BA02 112 |  | terbinafin | 0,25 g | 4,64 | O | Belupo d.d. | Belupo | Terbinax | tbl. 42x250 mg | 4,64 | 194,94 | RRD01 | 5% |
| D01BA02 162 |  | terbinafin | 0,25 g | 4,64 | O | Novartis Hrvatska d.o.o. | Lek d.d, PE PROIZVODNJA LENDAVA, Novartis Pharma GmbH | Lamisil | tbl. 14x250 mg | 4,64 | 64,98 | Rpd01 | 5% |
| D05AX52 444 |  | kalcipotriol + betametazon |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Psotriol | mast 60 g (50 mcg/g + 0,5 mg/g) | 145,23 | 145,23 | R | 5% |
| D05AX52 445 |  | kalcipotriol + betametazon |  |  | L | LEO Pharma A/S | Colep Laupheim GmbH & Co. KG, LEO Laboratories Ltd. | Enstilar | pjena za kožu 60 g (50 mcg/g + 0,5 mg/g) | 305,40 | 305,40 | RSRD03 | 5% |
| D05BA02 151 | DS | metoksalen (metoksipsoralen)ND991 | 10 mg |  | O |  |  |  |  |  |  |  | 5% |
| D05BB02 161 |  | acitretin | 35 mg | 12,73 | O | ACTAVIS GROUP PTC ehf. | Cenexi | Neotigason | caps. 30x10 mg | 3,64 | 109,10 | RSpd03 | 5% |
| D05BB02 162 |  | acitretin | 35 mg | 10,79 | O | ACTAVIS GROUP PTC ehf. | Cenexi | Neotigason | caps. 30x25 mg | 7,71 | 231,30 | RSpd03 | 5% |
| D06AX01 461 |  | fusidatna kiselina |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Fusicutan | krema 15 g (20 mg/g) | 20,74 | 20,74 | R | 5% |
| D06AX01 462 |  | fusidatna kiselina |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Fusicutan | mast 15 g (20 mg/g) | 20,74 | 20,74 | R | 5% |
| D06AX02 451 | DS | kloramfenikol |  |  | L |  |  |  |  |  |  |  | 5% |
| D06AX09 402 |  | mupirocin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Betrion | mast 2%, 1x15 g | 29,03 | 29,03 | R | 5% |
| D06AX09 411 |  | mupirocin |  |  | L | Belupo d.d. | Belupo | Mirobact | mast 2%, 1x15 g | 29,03 | 29,03 | R | 5% |
| D06AX09 415 |  | mupirocin |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Mupiron | mast 1x15 g (20 mg/1g) | 29,03 | 29,03 | R | 5% |
| D07AB10 411 |  | alklometazon |  |  | L | Belupo d.d. | Belupo | Afloderm | mast 1x20 g (0,5 mg/g) | 21,60 | 21,60 | R | 5% |
| D07AB10 413 |  | alklometazon |  |  | L | Belupo d.d. | Belupo | Afloderm | krema 1x20 g (0,5 mg/g) | 21,60 | 21,60 | R | 5% |
| D07AB10 414 |  | alklometazon |  |  | L | Belupo d.d. | Belupo | Afloderm | krema 1x40 g (0,5 mg/g) | 41,80 | 41,80 | R | 5% |
| D07AC01 412 |  | betametazon |  |  | L | Belupo d.d. | Belupo | Beloderm | mast 1x30 g (0,5 mg/g) | 17,72 | 17,72 | R | 5% |
| D07AC01 414 |  | betametazon |  |  | L | Belupo d.d. | Belupo | Beloderm | krema 1x30 g (0,5 mg/g) | 17,72 | 17,72 | R | 5% |
| D07AC01 418 |  | betametazon |  |  | L | Belupo d.d. | Belupo | Beloderm losion | boč. polietil. 1x50 ml (0,5 mg/1g) | 33,21 | 33,21 | R | 5% |
| D07AC01 431 |  | betametazon |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Betazon | krema 1x25 g (0,5 mg/g) | 14,77 | 14,77 | R | 5% |
| D07AC01 432 |  | betametazon |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Betazon | mast 1x25 g (0,5 mg/g) | 14,77 | 14,77 | R | 5% |
| D07CC01 401 |  | betametazon + gentamicin |  |  | L | Belupo d.d. | Belupo | Belogent | mast 1x15 g (0,5 + 1 mg/g) | 15,99 | 15,99 | R | 5% |
| D07CC01 402 |  | betametazon + gentamicin |  |  | L | Belupo d.d. | Belupo | Belogent | krema 1x15 g (0,5 + 1 mg/g) | 15,99 | 15,99 | R | 5% |
| D07CC01 441 |  | betametazon + gentamicin |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Cazal | mast 1x20 g (0,5 + 1 mg/g) | 20,25 | 20,25 | R | 5% |
| D07CC01 442 |  | betametazon + gentamicin |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Cazal | krema 1x20 g (0,5 + 1 mg/g) | 20,25 | 20,25 | R | 5% |
| D07CC01 461 |  | betametazon + gentamicin |  |  | L | Organon Pharma d.o.o. | Schering – Plough | Diprogenta | krema 1x15 g (0,5 + 1 mg/g) | 15,99 | 15,99 | R | 5% |
| D07CC01 462 |  | betametazon + gentamicin |  |  | L | Organon Pharma d.o.o. | Schering – Plough | Diprogenta | mast 1x15 g (0,5 + 1 mg/g) | 15,99 | 15,99 | R | 5% |
| D07XC01 411 |  | betametazon + salicilna kiselina |  |  | L | Belupo d.d. | Belupo | Belosalic | mast 1x30 g (0,5 mg/g + 30 mg/g) | 28,96 | 28,96 | R | 5% |
| D07XC01 712 |  | betametazon + salicilna kiselina |  |  | L | Belupo d.d. | Belupo | Belosalic | losion 1x100 ml (0,5 mg/g + 20 mg/g) | 87,75 | 87,75 | R | 5% |
| D07XC01 761 |  | betametazon + salicilna kiselina |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Soderm plus | otop. za kožu 1x50 ml (0,64 mg/g + 20 mg/g) | 39,49 | 39,49 | R | 5% |
| D07XC01 762 |  | betametazon + salicilna kiselina |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Soderm plus | otop. za kožu 1x100 ml (0,64 mg/g + 20 mg/g) | 78,98 | 78,98 | R | 5% |
| D08AC02 901 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept pjenušavi 4,5% | boca 1x500 ml | 56,87 | 56,87 |  | 5% |
| D08AC02 902 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept glukonat 5% | boca 1x1000 ml | 61,81 | 61,81 |  | 5% |
| D08AC02 903 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept pjenušavi 4,5% | boca 1x3.000 ml | 223,42 | 223,42 |  | 5% |
| D08AC02 905 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept blue 0,8% | boca 1x200 ml | 18,40 | 18,40 |  | 5% |
| D08AC02 906 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept blue 0,8% | boca 1x500 ml | 27,60 | 27,60 |  | 5% |
| D08AC02 907 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept blue 0,8% | boca 1x3.000 ml | 110,40 | 110,40 |  | 5% |
| D08AC02 909 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept tinkt. 0,5% | boca 1x1.000 ml | 29,90 | 29,90 |  | 5% |
| D08AC02 910 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept tinkt. 0,5% | boca 1x3.000 ml | 82,80 | 82,80 |  | 5% |
| D08AG02 943 |  | povidon-jod |  |  | L | Alkaloid d.o.o. | Alkaloid | Betadine | otop. 10%, 1x100 ml | 22,05 | 22,05 | R | 5% |
| D08AG02 944 | DS | povidon-jod |  |  | L | Alkaloid d.o.o. | Alkaloid | Betadine | otop. 10%, 1x1000 ml | 62,04 | 62,04 |  | 5% |
| D08AG02 946 | DS | povidon-jod |  |  | L | Alkaloid d.o.o. | Alkaloid | Betadine | otop. 7,5%, 1x1000 ml | 59,98 | 59,98 |  | 5% |
| D08AJ57 961 | DS | oktenidin + fenoksietanol |  |  | L | Schülke & Mayr GmbH | Schulke | Octenisept otopina | boca plast. 1x1000 ml (0,1% + 2%) | 57,40 | 57,40 |  | 5% |
| D08AX08 963 | DS | etanol + bifenilol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman pure | boca 1x500 ml | 21,74 | 21,74 |  | 5% |
| D08AX08 964 | DS | etanol + bifenilol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman pure | boca 1x1000 ml | 39,51 | 39,51 |  | 5% |
| D08AX08 965 | DS | etanol + bifenilol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman pure | kanister 1x5000 ml | 137,66 | 137,66 |  | 5% |
| D08AX08 966 | DS | etanol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman Care | boca 1x500 ml | 21,74 | 21,74 |  | 5% |
| D08AX08 967 | DS | etanol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman Care | boca 1x1000 ml | 39,51 | 39,51 |  | 5% |
| D08AX54 901 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Manorapid rfu | boč. 1x150 ml | 13,60 | 13,60 |  | 5% |
| D08AX54 902 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Manorapid rfu | boca 1x500 ml | 26,99 | 26,99 |  | 5% |
| D08AX54 903 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Manorapid rfu | kanister 1x5 L | 179,50 | 179,50 |  | 5% |
| D08AX54 904 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Skindes obojeni | boč. rasprš. 1x200 ml | 25,90 | 25,90 |  | 5% |
| D08AX54 905 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Skindes obojeni | boca 1x1000 ml | 49,90 | 49,90 |  | 5% |
| D08AX54 906 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Skindes neobojeni | boč. rasprš. 1x200 ml | 24,90 | 24,90 |  | 5% |
| D08AX54 907 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Skindes neobojeni | boca 1x1000 ml | 39,90 | 39,90 |  | 5% |
| D08AX54 911 | DS | izopropanol + etanol |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept lucid | boca 1x200 ml | 18,14 | 18,14 |  | 5% |
| D08AX54 912 | DS | izopropanol + etanol |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept lucid | boca 1x500 ml | 24,29 | 24,29 |  | 5% |
| D08AX54 913 | DS | izopropanol + etanol |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept lucid | boca 1x3000 ml | 107,70 | 107,70 |  | 5% |
| D11AH01 962 |  | takrolimus hidrat |  |  | L | LEO Pharma A/S | Astellas Ireland Co. Ltd. | Protopic 0,03% | mast, 1x30 g | 169,60 | 169,60 | RSRD02 | 5% |
| D11AH05 061 | DS | dupilumabNR509 | 21,4 mg | 463,79 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Dupixent | otop. za inj., štrc. napunj. 2x200 mg/1,14 ml | 4.334,51 | 8.669,02 |  | 5% |
| D11AH05 062 | DS | dupilumabNR509 | 21,4 mg | 309,19 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Dupixent | otop. za inj., brizg. napunj. 2x300 mg/2 ml | 4.334,51 | 8.669,02 |  | 5% |
| G01AA01 651 |  | nistatin | 0,1 M i.j. |  | V |  |  |  |  |  |  | R | 5% |
| G02AB01 051 | PR | metilergometrin | 0,2 mg |  | P |  |  |  |  |  |  |  | 5% |
| G02AB01 251 |  | metilergometrin | 0,2 mg |  | O |  |  |  |  |  |  | R | 5% |
| G02AB03 051 | PR | ergometrin | 0,2 mg |  | P |  |  |  |  |  |  |  | 5% |
| G02AD02 664 | DS | dinoproston | 0,5 mg | 68,31 | V | Pfizer Croatia d.o.o. | Pfizer | Prostin E2 | vag. gel 1x2 mg/3 g | 273,23 | 273,23 |  | 5% |
| G02AD02 665 | DS | dinoproston | 0,5 mg | 127,99 | V | Pfizer Croatia d.o.o. | Pfizer | Prepidil | gel 1x0,5 mg/3 g | 127,99 | 127,99 |  | 5% |
| G02AD02 671 | DS | dinoprostonNG306 | 0,5 mg | 31,49 | V | Ferring GmbH | Ferring GmbH | Propess | sust. za isporuku u rodnicu, vreć. 5x10 mg | 629,86 | 3.149,32 |  | 5% |
| G02AD04 066 | DS | karboprost | 2,5 mg | 1.104,80 | P | Pfizer Croatia d.o.o. | Pfizer | Prostin 15M | amp. 1x0,25 mg/ml | 110,48 | 110,48 |  | 5% |
| G02AD06 161 | DS | mizoprostolNG307 | 0,2 mg | 696,32 | O | Norgine B.V. | Azanta Danmark A/S, Norgine B.V. | Angusta | tbl. 8x25 mcg | 87,04 | 696,32 |  | 5% |
| G02BA03 671 | PO | levonorgestrelNG301 |  |  | V | Gedeon Richter Plc. | Odyssea Pharma S.P.R.L. | Levosert | sustav intrauter. 1x52 mg (20 mcg/24h) | 589,41 | 589,41 |  | 5% |
| G02BA03 861 | PO | levonorgestrelNG301 |  |  | V | Bayer d.o.o. | Bayer Oy | Mirena | sustav intrauter. 1x52 mg (20 mcg/24h) | 764,53 | 764,53 |  | 5% |
| G02CA03 051 | DS | fenoterol |  |  | P |  |  |  |  |  |  |  | 5% |
| G02CB01 151 |  | bromokriptin | 5 mg |  | O |  |  |  |  |  |  | R | 5% |
| G02CB03 171 |  | kabergolin | 0.5 mg | 21,10 | O | Pfizer Croatia d.o.o. | Pfizer Italia S.r.l. | Dostinex | tbl. 8x0,5 mg | 21,10 | 168,83 | RSRG08 | 5% |
| G02CX01 061 | DS | atosibanNG201 | 165 mg | 4.342,30 | P | Ferring Pharmaceuticals A/S | Ferring | Tractocile | boč. 1x6,75 mg/0,9 ml (7,5 mg/ml) | 177,60 | 177,60 |  | 5% |
| G02CX01 062 | DS | atosibanNG201 | 165 mg | 2.377,87 | P | Ferring Pharmaceuticals A/S | Ferring | Tractocile | boč. 1x37,5 mg/5 ml (7,5 mg /ml) | 540,49 | 540,49 |  | 5% |
| G02CX01 071 | DS | atosibanNG201 | 165 mg | 3.039,61 | P | ALPHA-MEDICAL d.o.o. | PharmIdea SIA | Atosiban Alpha-Medical | boč. 1x6,75 mg/0,9 ml | 124,32 | 124,32 |  | 5% |
| G02CX01 072 | DS | atosibanNG201 | 165 mg | 1.858,91 | P | ALPHA-MEDICAL d.o.o. | PharmIdea SIA | Atosiban Alpha-Medical | boč. 1x37,5 mg/5 ml | 422,53 | 422,53 |  | 5% |
| G03BA03 052 | PR | testosteron | 18 mg |  | P |  |  |  |  |  |  |  | 5% |
| G03BA03 071 | PO | testosteronNG302 | 18 mg | 13,32 | P | Bayer d.o.o. | Bayer AG | Nebido | otop. za inj., boč.1x1000 mg/4 ml | 739,93 | 739,93 |  | 5% |
| G03BA03 151 |  | testosteron | 0,12 g |  | O |  |  |  |  |  |  | R | 5% |
| G03BA03 961 |  | testosteron | 50 mg | 10,86 | TD | Besins Healthcare S.A. | Besins Manufacturing Belgium | Androgel gel | vreć. 30x50 mg/5 g | 10,86 | 325,90 | RSRG01 | 5% |
| G03CA03 051 | DS | estradiol | 1 mg |  | P |  |  |  |  |  |  |  | 5% |
| G03CA03 171 |  | estradiol | 2 mg | 0,96 | O | Novo Nordisk A/S | Novo Nordisk | Estrofem | tbl. 1x28/2 mg | 0,96 | 26,88 | R | 5% |
| G03CA03 172 |  | estradiol | 2 mg | 2,11 | O | Novo Nordisk A/S | Novo Nordisk | Estrofem | tbl. 1x28/1 mg | 1,05 | 29,50 | R | 5% |
| G03DA02 161 |  | medroksiprogesteron | 5 mg | 0,60 | O | Pfizer Croatia d.o.o. | Pfizer | Provera | tbl. 24x5 mg | 0,60 | 14,40 | R | 5% |
| G03DA02 162 |  | medroksiprogesteron | 5 mg | 0,37 | O | Pfizer Croatia d.o.o. | Pfizer | Provera | tbl. 30x10 mg | 0,74 | 22,20 | R | 5% |
| G03DA04 051 | DS | progesteron | 5 mg |  | P |  |  |  |  |  |  |  | 5% |
| G03DA04 161 |  | progesteron | 0,3 g | 3,99 | O | Besins Healthcare S.A. | Cyndea Pharma S.L., Besins Manufacturing Belgium | Utrogestan | caps. 30x100 mg | 1,33 | 39,90 | R | 5% |
| G03DA04 671 |  | progesteron | 90 mg | 1,39 | V | Besins Healthcare Ireland Limited | Cyndea Pharma S.L., Besins Manufacturing Belgium | Utrogestan | meke caps. za rodnicu 15x200 mg | 3,08 | 46,20 | R | 5% |
| G03DA04 861 |  | progesteron | 90 mg | 20,20 | V | MERCK d.o.o. | Central Pharma | Crinone | gel za rodnicu 8%, aplik. plast. napunj. 15x1 doza (90 mg/1,125g) | 20,20 | 303,03 | R | 5% |
| G03DA04 871 |  | progesteron | 90 mg | 1,41 | V | Gedeon Richter Plc. | Actavis UK Limited, Gedeon Richter Plc. | Cyclogest | vag. 15x400 mg | 6,26 | 93,95 | R | 5% |
| G03GA01 051 | DS | koriogonadotropinNG303 | 250 i.j. |  | P |  |  |  |  |  |  |  | 5% |
| G03GA02 063 | DS | menotropin (FSH + LH)NG304 | 75 i.j. | 152,10 | P | Ferring GmbH | Ferring | Menopur | praš. i otap. za otop. za inj., boč. 1x1200 IU | 2.433,67 | 2.433,67 |  | 5% |
| G03GA02 064 | DS | menotropin (FSH + LH)NG304 | 75 i.j. | 130,33 | P | Ferring GmbH | Ferring | Menopur | praš. i otap. za otop. za inj., boč. 10x75 IU | 130,33 | 1.303,30 |  | 5% |
| G03GA02 065 | DS | menotropin (FSH + LH)NG304 | 75 i.j. | 131,95 | P | Ferring GmbH | Ferring GmbH | Menopur | praš. i otap. za otop. za inj., boč. 1x600 IU | 1.055,57 | 1.055,57 |  | 5% |
| G03GA05 001 | DS | folitropin alfaNG304 | 75 i.j. | 157,52 | P | Theramex Ireland Limited | Merckle Biotec GmbH, Teva Pharmaceuticals Europe B.V. | Ovaleap | otop. za inj., pen-štrcaljka 1x300 IU (22 mcg)/0,5 ml | 630,07 | 630,07 |  | 5% |
| G03GA05 002 | DS | folitropin alfaNG304 | 75 i.j. | 148,46 | P | Theramex Ireland Limited | Merckle Biotec GmbH, Teva Pharmaceuticals Europe B.V. | Ovaleap | otop. za inj., pen-štrcaljka 1x450 IU (33 mcg)/0,75 ml | 890,73 | 890,73 |  | 5% |
| G03GA05 003 | DS | folitropin alfaNG304 | 75 i.j. | 156,01 | P | Theramex Ireland Limited | Merckle Biotec GmbH, Teva Pharmaceuticals Europe B.V. | Ovaleap | otop. za inj., pen-štrcaljka 1x900 IU (66 mcg)/1,5 ml | 1.872,12 | 1.872,12 |  | 5% |
| G03GA05 071 | DS | folitropin alfaNG304 | 75 i.j. | 176,96 | P | Merck Europe B.V. | Merck | Gonal-f | amp. 1x75 i.j. | 176,96 | 176,96 |  | 5% |
| G03GA05 072 | DS | folitropin alfaNG304 | 75 i.j. | 159,85 | P | Merck Europe B.V. | Merck | Gonal-f | otop. za inj., pen-štrcaljka 1x300 IU (22 mcg)/0,5 ml | 639,40 | 639,40 |  | 5% |
| G03GA05 073 | DS | folitropin alfaNG304 | 75 i.j. | 152,37 | P | Merck Europe B.V. | Merck | Gonal-f | otop. za inj., pen-štrcaljka 1x450 IU (33 mcg)/0,75 ml | 914,20 | 914,20 |  | 5% |
| G03GA05 074 | DS | folitropin alfaNG304 | 75 i.j. | 167,46 | P | Merck Europe B.V. | Merck | Gonal-f | otop. za inj., pen-štrcaljka 1x900 IU (66 mcg)/1,5 ml | 2.009,54 | 2.009,54 |  | 5% |
| G03GA05 081 | DS | folitropin alfaNG304 | 75 i.j. | 141,60 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brizg. napunj.1x75 IU/0,125 ml | 141,60 | 141,60 |  | 5% |
| G03GA05 082 | DS | folitropin alfaNG304 | 75 i.j. | 142,44 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brizg. napunj. 1x150 IU/0,25 ml | 284,88 | 284,88 |  | 5% |
| G03GA05 083 | DS | folitropin alfaNG304 | 75 i.j. | 137,14 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brizg. napunj. 1x225 IU/0,375 ml | 411,41 | 411,41 |  | 5% |
| G03GA05 084 | DS | folitropin alfaNG304 | 75 i.j. | 159,85 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brizg. napunj. 1x300 IU/0,50 ml | 639,40 | 639,40 |  | 5% |
| G03GA05 085 | DS | folitropin alfaNG304 | 75 i.j. | 152,37 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brozg. napunj. 1x450 IU/0,75 ml | 914,20 | 914,20 |  | 5% |
| G03GA06 076 | DS | folitropin betaNG304 | 75 i.j. | 174,74 | P | Organon N.V. | N.V. Organon | Puregon | otop. za inj. 1x300 IU/0,36 ml, uložak i 6 igala | 698,94 | 698,94 |  | 5% |
| G03GA06 077 | DS | folitropin betaNG304 | 75 i.j. | 178,12 | P | Organon N.V. | N.V. Organon | Puregon | otop. za inj. u ulošku i 9 igala (1 uložak, 900 IU/1,08 ml) | 2.137,40 | 2.137,40 |  | 5% |
| G03GA08 073 | DS | koriogonadotropinNG303 | 250 mcg | 204,43 | P | Merck Europe B.V. | Serono | Ovitrelle | otop. za inj., brizg. napunj. 1x250 mcg | 204,43 | 204,43 |  | 5% |
| G03GA09 061 | DS | korifolitropin alfaNG304 | 0,15 mg | 4.804,68 | P | Organon N.V. | Organon | Elonva | otop. za inj., štrc. napunj. 1x100 mcg/0,5 ml | 3.203,28 | 3.203,28 |  | 5% |
| G03GA09 062 | DS | korifolitropin alfaNG304 | 0,15 mg | 3.516,53 | P | Organon N.V. | Organon | Elonva | otop. za inj., štrc. napunj. 1x150 mcg/0,5 ml | 3.516,53 | 3.516,53 |  | 5% |
| G03GA10 074 | DS | folitropin deltaNG304 | 12 mcg | 606,41 | P | Ferring Pharmaceuticals A/S | Ferring GmbH | Rekovelle | otop. za inj. 1x12 mcg/0,36 ml, napunjena brizgalica i 3 igle | 606,41 | 606,41 |  | 5% |
| G03GA10 075 | DS | folitropin deltaNG304 | 12 mcg | 611,42 | P | Ferring Pharmaceuticals A/S | Ferring GmbH | Rekovelle | otop. za inj. 1x36 mcg/1,08 ml, napunjena brizgalica i 6 igala | 1.834,25 | 1.834,25 |  | 5% |
| G03GA10 076 | DS | folitropin deltaNG304 | 12 mcg | 583,69 | P | Ferring Pharmaceuticals A/S | Ferring GmbH | Rekovelle | otop. za inj. 1x72 mcg/2,16 ml, napunjena brizgalica i 9 igala | 3.502,14 | 3.502,14 |  | 5% |
| G03GA30 061 | DS | folitropin alfa + lutropin alfaNG305 |  |  | P | Merck Europe B.V. | Merck Serono S.p.A. | Pergoveris | praš. i otap. za otop. za inj., 1 x (150 IU + 75 IU) | 515,18 | 515,18 |  | 5% |
| G03GA30 062 | DS | folitropin alfa + lutropin alfaNG305 |  |  | P | Merck Europe B.V. | Merck Serono S.A. | Pergoveris | otop. za inj., brizg. napunj., (300 IU + 150 IU)/0,48 ml | 1.034,69 | 1.034,69 |  | 5% |
| G03GA30 063 | DS | folitropin alfa + lutropin alfaNG305 |  |  | P | Merck Europe B.V. | Merck Serono S.A. | Pergoveris | otop. za inj., brizg. napunj., (450 IU + 225 IU)/0,72 ml | 1.539,05 | 1.539,05 |  | 5% |
| G03GA30 064 | DS | folitropin alfa + lutropin alfaNG305 |  |  | P | Merck Europe B.V. | Merck Serono S.A. | Pergoveris | otop. za inj., brizg. napunj., (900 IU + 450 IU)/1,44 ml | 3.008,30 | 3.008,30 |  | 5% |
| G03GB02 151 |  | klomifen | 9 mg |  | O |  |  |  |  |  |  | R | 5% |
| G03HA01 161 |  | ciproteron-acetat | 0,1 g | 7,05 | O | Bayer d.o.o. | Delpharm Lille SAS., Bayer Weimar GmbH und Co. KG. | Androcur | tbl. 50x50 mg | 3,53 | 176,33 | R | 5% |
| G03HB01 141 |  | ciproteron-acetat + etinilestradiol |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Axira 35 | tbl. film obl. 63x(2 mg + 0,035 mg) | 1,06 | 66,71 | RSRG02 | 5% |
| G03XA01 151 |  | danazol | 0,6 g |  | O |  |  |  |  |  |  | RSRG91 | 5% |
| G03XC01 161 |  | raloksifen | 60 mg | 3,48 | O | DAIICHI SANKYO EUROPE GmbH | Lilly S.A. | Evista | tbl. 28x60 mg | 3,48 | 97,35 | RSRG03 | 5% |
| G04BD04 151 |  | oksibutinin | 15 mg |  | O |  |  |  |  |  |  | RRG09 | 5% |
| G04BD08 101 |  | solifenacin | 5 mg | 2,22 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Urotrim | tbl. film obl. 30x5 mg | 2,22 | 66,47 | RRG04 | 5% |
| G04BD08 102 |  | solifenacin | 5 mg | 2,43 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Urotrim | tbl. film obl. 30x10 mg | 4,87 | 146,00 | RRG04 | 5% |
| G04BD08 111 |  | solifenacin | 5 mg | 2,22 | O | Belupo d.d. | Belupo d.d. | Beloflux | tbl. film obl. 30x5 mg | 2,22 | 66,47 | RRG04 | 5% |
| G04BD08 112 |  | solifenacin | 5 mg | 1,81 | O | Belupo d.d. | Belupo d.d. | Beloflux | tbl. film obl. 30x10 mg | 3,62 | 108,50 | RRG04 | 5% |
| G04BD08 121 |  | solifenacin | 5 mg | 2,22 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Spazur | tbl. film obl. 30x5 mg | 2,22 | 66,47 | RRG04 | 5% |
| G04BD08 122 |  | solifenacin | 5 mg | 2,12 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Spazur | tbl. film obl. 30x10 mg | 4,23 | 126,90 | RRG04 | 5% |
| G04BD08 141 |  | solifenacin | 5 mg | 2,22 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Soline | tbl. film obl. 30x5 mg | 2,22 | 66,47 | RRG04 | 5% |
| G04BD08 142 |  | solifenacin | 5 mg | 2,43 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Soline | tbl. film obl. 30x10 mg | 4,87 | 146,00 | RRG04 | 5% |
| G04BD08 161 |  | solifenacin | 5 mg | 2,22 | O | Astellas d.o.o. | Astellas Pharma Europe B.V. | Vesicare | tbl. film obl. 30x5 mg | 2,22 | 66,47 | RRG04 | 5% |
| G04BD08 162 |  | solifenacin | 5 mg | 2,43 | O | Astellas d.o.o. | Astellas Pharma Europe B.V. | Vesicare | tbl. film obl. 30x10 mg | 4,87 | 146,00 | RRG04 | 5% |
| G04BD08 181 |  | solifenacin | 5 mg | 2,22 | O | Viatris Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories, Mylan Dublin B.V. | Solven | tbl. film obl. 30x5 mg | 2,22 | 66,47 | RRG04 | 5% |
| G04BD08 182 |  | solifenacin | 5 mg | 2,35 | O | Viatris Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories, Mylan B.V. | Solven | tbl. film obl. 30x10 mg | 4,70 | 141,09 | RRG04 | 5% |
| G04BD08 183 |  | solifenacin | 5 mg | 2,22 | O | STADA d.o.o. | STADA Arzneimittel GmbH | Solifenacin STADA | tbl. film obl. 30x5 mg | 2,22 | 66,47 | RRG04 | 5% |
| G04BD08 184 |  | solifenacin | 5 mg | 1,90 | O | STADA d.o.o. | STADA Arzneimittel GmbH | Solifenacin STADA | tbl. film obl. 30x10 mg | 3,81 | 114,21 | RRG04 | 5% |
| G04BD08 185 |  | solifenacin | 5 mg | 2,11 | O | BE Pharma d.o.o. | Genepharm S.A. | Solifenacin Be Pharma | tbl. film obl. 30x5 mg | 2,11 | 63,15 | RRG04 | 5% |
| G04BD08 186 |  | solifenacin | 5 mg | 1,72 | O | BE Pharma d.o.o. | Genepharm S.A. | Solifenacin Be Pharma | tbl. film obl. 30x10 mg | 3,44 | 103,08 | RRG04 | 5% |
| G04BD09 022 | PR | trospij |  |  | P | Sandoz d.o.o. | Sandoz-Lek | Spasmex | amp. 50x0,2 mg/5 ml | 2,71 | 135,50 |  | 5% |
| G04BD12 161 |  | mirabegron | 50 mg | 16,85 | O | Astellas Pharma Europe B.V. | Astellas Pharma Europe B.V. | Betmiga | tbl. s prod. otpušt. 30x25 mg | 8,42 | 252,70 | RSRG07 | 5% |
| G04BD12 162 |  | mirabegron | 50 mg | 8,42 | O | Astellas Pharma Europe B.V. | Astellas Pharma Europe B.V. | Betmiga | tbl. s prod. otpušt. 30x50 mg | 8,42 | 252,70 | RSRG07 | 5% |
| G04BD13 101 |  | desfesoterodin | 3.5 mg | 2,22 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Tovedeso | tbl. s prod. oslob. 28x3,5 mg | 2,22 | 62,04 | RRG04 | 5% |
| G04BD13 102 |  | desfesoterodin | 3.5 mg | 2,12 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Tovedeso | tbl. s prod. oslob. 28x7 mg | 4,23 | 118,51 | RRG04 | 5% |
| G04BE03 101 | DS | sildenafilNG401 | 50 mg | 59,73 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sildenafil Pliva | tbl. film obl. 90x20 mg | 23,89 | 2.150,40 |  | 5% |
| G04BE03 161 | DS | sildenafilNG401 | 50 mg | 59,73 | O | Pfizer Europe MA EEIG | Pfizer | Revatio | tbl. film obl. 90x20 mg | 23,89 | 2.150,40 |  | 5% |
| G04BE03 171 | DS | sildenafilNG401 | 50 mg | 59,73 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Granpidam | tbl. film obl. 90x20 mg | 23,89 | 2.150,40 |  | 5% |
| G04BE03 172 | DS | sildenafilNG401 | 50 mg | 59,73 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Granpidam | tbl. film obl. 300x20 mg | 23,89 | 7.168,00 |  | 5% |
| G04BE03 173 | DS | sildenafilNG401 | 50 mg | 59,73 | O | ALPHA-MEDICAL d.o.o. | Mawdsley Brooks & Co. Ltd. | Sildenafil Alpha-Medical | tbl. film obl. 90x20 mg | 23,89 | 2.150,40 |  | 5% |
| G04CA02 103 |  | tamsulozin | 0,4 mg | 1,05 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Bazetham | tbl. s prod. oslob. 30x0,4 mg | 1,05 | 31,49 | RSRG05 | 5% |
| G04CA02 111 |  | tamsulozin | 0,4 mg | 1,05 | O | Belupo d.d. | Belupo | Tamosin | caps. s prod. oslob. tvrda 30x0,4 mg | 1,05 | 31,49 | RSRG05 | 5% |
| G04CA02 112 |  | tamsulozin | 0,4 mg | 0,69 | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Tamosin | caps. s prilag. oslob. tvrda 100x0,4 mg | 0,69 | 68,89 | RSRG05 | 5% |
| G04CA02 131 |  | tamsulozin | 0,4 mg | 1,05 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tanyz | caps. s prod. oslob. tvrda 30x0,4 mg | 1,05 | 31,49 | RSRG05 | 5% |
| G04CA02 132 |  | tamsulozin | 0,4 mg | 0,85 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tanyz | caps. s prod. oslob. tvrda 60x0,4 mg | 0,85 | 51,01 | RSRG05 | 5% |
| G04CA02 133 |  | tamsulozin | 0,4 mg | 0,94 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tanyz ERAS | tbl. s prod. oslob. 30x0,4 mg | 0,94 | 28,34 | RSRG05 | 5% |
| G04CA02 134 |  | tamsulozin | 0,4 mg | 0,85 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tanyz ERAS | tbl. s prod. oslob. 60x0,4 mg | 0,85 | 51,01 | RSRG05 | 5% |
| G04CA02 145 |  | tamsulozin | 0,4 mg | 1,05 | O | PharmaS d.o.o. | PharmaS d.o.o. | Tamsulozin PharmaS | caps. s prod. oslob. tvrda 30x0,4 mg | 1,05 | 31,49 | RSRG05 | 5% |
| G04CA02 146 |  | tamsulozin | 0,4 mg | 0,85 | O | PharmaS d.o.o. | PharmaS d.o.o. | Tamsulozin PharmaS | caps. tvrda s prod. oslob. 60x0,4 mg | 0,85 | 51,01 | RSRG05 | 5% |
| G04CA02 147 |  | tamsulozin | 0,4 mg | 0,77 | O | Alkaloid-INT d.o.o. | Alkaloid-INT d.o.o. | Tamaliz | caps. s prilag. oslob., tvrda 30x0,4 mg | 0,77 | 22,95 | RSRG05 | 5% |
| G04CA02 148 |  | tamsulozin | 0,4 mg | 0,73 | O | Alkaloid-INT d.o.o. | Alkaloid-INT d.o.o. | Tamaliz | caps. s prilag. oslob., tvrda 100x0,4 mg | 0,73 | 72,52 | RSRG05 | 5% |
| G04CA02 161 |  | tamsulozin | 0,4 mg | 1,05 | O | Astellas d.o.o. | Astellas Pharma Europe B.V. | Omnic | caps. s prod. otp. 30x0,4 mg | 1,05 | 31,49 | RSRG05 | 5% |
| G04CA02 163 |  | tamsulozin | 0,4 mg | 1,05 | O | Menarini International Operations Luxembourg S.A. | Menarini-Von Heyden GmbH; Synthon Hispania S.L. | Flosin | caps. s prilag. oslob. tvrda 30x0,4 mg | 1,05 | 31,49 | RSRG05 | 5% |
| G04CA02 164 |  | tamsulozin | 0,4 mg | 0,85 | O | Menarini International Operations Luxembourg S.A. | Menarini-Von Heyden GmbH; Synthon Hispania S.L. | Flosin | caps. s prilag. oslob. tvrda 100x0,4 mg | 0,85 | 85,02 | RSRG05 | 5% |
| G04CA02 172 |  | tamsulozin | 0,4 mg | 1,05 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Tamsu Genericon | caps. s prod. oslob. tvrda 30x0,4 mg | 1,05 | 31,49 | RSRG05 | 5% |
| G04CA02 181 |  | tamsulozin | 0,4 mg | 0,97 | O | Zentiva k.s. | Synthon BV, Synthon Hispania S.L. | Tamsich | caps. s prilag. oslob. tvrda 30x0,4 mg | 0,97 | 29,02 | RSRG05 | 5% |
| G04CA52 101 |  | dutasterid + tamsulozin |  |  | O | PLIVA HRVATSKA d.o.o. | Laboratorios Leon Farma S.A. | Duster Duo | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CA52 102 |  | dutasterid + tamsulozin |  |  | O | PLIVA HRVATSKA d.o.o. | Laboratorios Leon Farma S.A. | Duster Duo | caps. tvrda 90x(0,5 mg + 0,4 mg) | 1,65 | 148,15 | RSpg03 | 5% |
| G04CA52 111 |  | dutasterid + tamsulozin |  |  | O | Belupo d.d. | Belupo | Kllotas | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CA52 121 |  | dutasterid + tamsulozin |  |  | O | Jadran – Galenski Laboratorij d.d. | Laboratorios Leon Farma S.A. | Dulmod | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CA52 141 |  | dutasterid + tamsulozin |  |  | O | PharmaS d.o.o. | Laboratorios Leon Farma S.A. | Atekago | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CA52 142 |  | dutasterid + tamsulozin |  |  | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Tamaliz Duo | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CA52 162 |  | dutasterid + tamsulozin |  |  | O | Mylan Ireland Limited | Laboratorios Leon Farma S.A. | Vasgar | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CA52 163 |  | dutasterid + tamsulozin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma Gesellschaft m.b.H., Laboratorios Leon Farma S.A. | Duitam | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CA52 171 |  | dutasterid + tamsulozin |  |  | O | ALPHA-MEDICAL d.o.o. | Laboratorios Leon Farma S.A. | Duostin | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CA52 181 |  | dutasterid + tamsulozin |  |  | O | Zentiva k.s. | Laboratorios Leon Farma S.A. | Dupro plus | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CA52 191 |  | dutasterid + tamsulozin |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Dutasterid/tamsulozin Stada | caps. tvrda 30x(0,5 mg + 0,4 mg) | 1,82 | 54,72 | RSpg03 | 5% |
| G04CB01 141 |  | finasterid | 5 mg | 0,86 | O | PharmaS d.o.o. | PharmaS d.o.o. | Finasterid PharmaS | tbl. film obl. 28x5 mg | 0,86 | 24,00 | RSRG06 | 5% |
| G04CB01 171 |  | finasterid | 5 mg | 0,86 | O | PharmaS d.o.o. | Cipla | Fincar | tbl. film obl. 28x5 mg | 0,86 | 24,00 | RSRG06 | 5% |
| G04CB01 181 |  | finasterid | 5 mg | 0,86 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH | Finasterid Genericon | tbl. film obl. 30x5 mg | 0,86 | 25,71 | RSRG06 | 5% |
| H01AA02 051 | KL | tetrakozaktid (tetracosactrin) | 0,25 mg |  | P |  |  |  |  |  |  |  | 5% |
| H01AB01 061 | KL | tirotropin alfaNH101 | 0,9 mg | 2.424,01 | P | Genzyme Europe B.V. | Genzyme | Thyrogen | praš. za otop. za inj., boč. 2x0,9 mg | 2.424,01 | 4.848,02 |  | 5% |
| H01AC01 021 |  | somatropinNH505 | 2 i.j. | 74,37 | P | Sandoz GmbH | Sandoz | Omnitrope | uložak stakl. 1x5 mg/1,5 ml (1 mg =3 i.j.) | 557,78 | 557,78 | RSRH06 | 5% |
| H01AC01 022 |  | somatropinNH505 | 2 i.j. | 74,37 | P | Sandoz GmbH | Sandoz | Omnitrope | uložak stakl. 1x10 mg/1,5 ml (1 mg =3 i.j.) | 1.115,55 | 1.115,55 | RSRH06 | 5% |
| H01AC01 023 |  | somatropinNH505 | 2 i.j. | 74,37 | P | Sandoz GmbH | Sandoz | Omnitrope | uložak stakl. 1x15 mg/1,5 ml (1 mg =3 i.j.) | 1.673,33 | 1.673,33 | RSRH06 | 5% |
| H01AC01 062 |  | somatropinNH505 | 2 i.j. | 74,37 | P | Pfizer Croatia d.o.o. | Pfizer | Genotropin | praš. i otap. za otop. za inj., uložak dvodijelni stakl. 5x5,3 mg/ml (5x16 i.j.) | 594,96 | 2.974,80 | RSRH06 | 5% |
| H01AC01 065 |  | somatropinNH505 | 2 i.j. | 669,33 | P | Pfizer Croatia d.o.o. | Pfizer | Genotropin | praš. i otap. za otop. za inj., uložak dvodijelni stakl. 5x12 mg/ml (5x36 i.j.) | 1.338,66 | 6.693,30 | RSRH06 | 5% |
| H01AC01 066 |  | somatropinNH505 | 2 i.j. | 74,37 | P | Pfizer Croatia d.o.o. | Pfizer | Genotropin | praš. i otap. za otop. za inj., uložak dvodijelni stakl. u višedoznoj napunj. brizg. GoQuick 5x5,3 mg/ml (5x16 i.j.) | 594,96 | 2.974,80 | RSRH06 | 5% |
| H01AC01 067 |  | somatropinNH505 | 2 i.j. | 74,37 | P | Pfizer Croatia d.o.o. | Pfizer | Genotropin | praš. i otap. za otop. za inj., uložak dvodijelni stakl. u višedoznoj napunj. brizg. GoQuick 5x12 mg/ml (5x36 i.j.) | 1.338,66 | 6.693,30 | RSRH06 | 5% |
| H01AC01 086 |  | somatropinNH506 | 2 i.j. | 119,97 | P | Novo Nordisk A/S | Novo Nordisk A/S | Norditropin NordiFlex | otop. za inj., napunj. brizg. 1x5 mg/1,5 ml (1 mg =3 i.j.) | 899,81 | 899,81 | RSRH06 | 5% |
| H01AC01 087 |  | somatropinNH506 | 2 i.j. | 119,44 | P | Novo Nordisk A/S | Novo Nordisk A/S | Norditropin NordiFlex | otop. za inj., napunj. brizg. 1x10 mg/1,5 ml (1 mg =3 i.j.) | 1.791,56 | 1.791,56 | RSRH06 | 5% |
| H01AC01 088 |  | somatropinNH506 | 2 i.j. | 120,89 | P | Novo Nordisk A/S | Novo Nordisk A/S | Norditropin NordiFlex | otop. za inj., napunj. brizg. 1x15 mg/1,5 ml (1 mg =3 i.j.) | 2.720,13 | 2.720,13 | RSRH06 | 5% |
| H01AX01 081 | DS | pegvisomantNH507 |  |  | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Somavert | praš. i otap. za otop. za inj., 30x10 mg | 485,42 | 14.562,70 |  | 5% |
| H01AX01 082 | DS | pegvisomantNH507 |  |  | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Somavert | praš. i otap. za otop. za inj., 30x20 mg | 967,61 | 29.028,40 |  | 5% |
| H01BA02 052 | PR | dezmopresin | 4 mcg |  | P |  |  |  |  |  |  |  | 5% |
| H01BA02 163 |  | dezmopresin | 0,4 mg | 29,33 | O | Ferring GmbH | Ferring | Minirin Melt | liofilizat oral. 30x60 mcg | 4,40 | 132,04 | RSRH01 | 5% |
| H01BA02 164 |  | dezmopresin | 0,4 mg | 29,33 | O | Ferring GmbH | Ferring | Minirin Melt | liofilizat oral. 30x120 mcg | 8,80 | 264,08 | RSRH01 | 5% |
| H01BA02 751 |  | dezmopresin | 25 mcg | 7,95 | N |  |  |  |  | 158,98 | 158,98 | RSRH02 | 5% |
| H01BA02 761 |  | dezmopresin | 25 mcg | 7,95 | N | Ferring GmbH | Ferring | Minirin | rasprš. za nos 1x5 ml (0,1 mg/ml, 50 doza) | 158,98 | 158,98 | RSRH02 | 5% |
| H01BA04 071 | DS | terlipresinNH106 | 12 mg | 2.577,99 | P | Ferring GmbH | Ferring GmbH | Glypressin | praš. i otap. za otop. za inj. štrc. 5x1 mg | 214,85 | 1.074,25 |  | 5% |
| H01BB02 062 | PR | oksitocin | 15 i.j. | 8,05 | P | Mylan Hrvatska d.o.o. | Mylan S.A.S. | Syntocinon | amp. 10x5 i.j./ ml. | 2,68 | 26,83 |  | 5% |
| H01BB02 763 | PR | oksitocin | 15 i.j. | 2,51 | N | Mylan Hrvatska d.o.o. | Delpharm Huningue S. A. S. | Syntocinon | rasprš. 1x5 ml (40 i.j./ml) | 33,50 | 33,50 |  | 5% |
| H01CA01 751 |  | gonadorelin |  |  | N |  |  |  |  |  |  | RSRH91 | 5% |
| H01CB02 001 | DS | oktreotidNH105 | 0,7 mg | 162,99 | P | Teva B.V. | Pliva Hrvatska d.o.o., Merckle GmbH | Oktreotid Teva | boč. 1x20 mg | 4.656,84 | 4.656,84 |  | 5% |
| H01CB02 002 | DS | oktreotidNH105 | 0,7 mg | 139,07 | P | Teva B.V. | Pliva Hrvatska d.o.o., Merckle GmbH | Oktreotid Teva | boč. 1x30 mg | 5.960,30 | 5.960,30 |  | 5% |
| H01CB02 065 | DS | oktreotidNH104 | 0,7 mg | 266,48 | P | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Sandostatin | amp. 5x0,10 mg | 38,07 | 190,35 |  | 5% |
| H01CB02 066 | DS | oktreotidNH104 | 0,7 mg | 240,87 | P | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Sandostatin | amp. 5x0,50 mg | 172,05 | 860,23 |  | 5% |
| H01CB02 068 | DS | oktreotidNH105 | 0,7 mg | 179,78 | P | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Sandostatin Lar | boč. 1x20 mg | 5.213,58 | 5.213,58 |  | 5% |
| H01CB02 069 | DS | oktreotidNH105 | 0,7 mg | 153,30 | P | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Sandostatin Lar | boč. 1x30 mg | 6.591,74 | 6.591,74 |  | 5% |
| H01CB05 061 | DS | pasireotidNH507 | 1,2 mg | 658,84 | P | Recordati Rare Diseases | Novartis Pharma GmbH | Signifor | praš. i otap. za susp. za inj., 1x40 mg | 21.961,26 | 21.961,26 |  | 5% |
| H01CB05 062 | DS | pasireotidNH507 | 1,2 mg | 485,02 | P | Recordati Rare Diseases | Novartis Pharma GmbH | Signifor | praš. i otap. za susp. za inj., 1x60 mg | 24.250,93 | 24.250,93 |  | 5% |
| H01CC01 061 | DS | ganireliks | 0.25 mg | 201,51 | P | Organon N.V. | Organon | Orgalutran | otop. za inj., štrc. napunj. 1x0,25 mg/0,5 ml | 201,51 | 201,51 |  | 5% |
| H01CC02 071 | DS | cetroreliks | 0,25 mg | 261,64 | P | Merck Europe B.V. | Baxter | Cetrotide | praš. i otap. za otop. za inj. boč. 1x0,25 mg + napunj. štrc. | 261,64 | 261,64 |  | 5% |
| H02AA02 151 |  | fludrokortizon | 0,1 mg |  | O |  |  |  |  |  |  | R | 5% |
| H02AB02 021 | PR | deksametazon | 1,5 mg | 1,30 | P | Sandoz d.o.o. | Sandoz-Salutas | Deksametazon Sandoz | otop. za inj., amp. 10x4 mg/ml | 3,47 | 34,65 |  | 5% |
| H02AB02 032 | PR | deksametazon | 1,5 mg | 2,00 | P | KRKA-FARMA d.o.o. | Krka d.d. | Dexamethason/Deksametazon Krka | amp. 25x4 mg/ml / otop. za inj./inf., 25x4 mg/ml | 5,37 | 134,25 |  | 5% |
| H02AB02 071 | PR | deksametazon | 1,5 mg | 1,23 | P | hameln pharma gmbh | hameln rds s.r.o., Siegfried Hameln GmbH | Deksametazon hameln | otop. za inj., amp. 10x4 mg/1 ml | 3,29 | 32,92 |  | 5% |
| H02AB02 101 |  | deksametazon | 1,5 mg | 1,52 | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH | Deksametazon Pliva | tbl. 20x4 mg | 4,04 | 80,86 | R | 5% |
| H02AB02 102 |  | deksametazon | 1,5 mg | 1,00 | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH | Deksametazon Pliva | tbl. 20x8 mg | 5,32 | 106,30 | R | 5% |
| H02AB02 131 |  | deksametazon | 1,5 mg | 4,44 | O | KRKA-FARMA d.o.o. | Krka d.d. | Dexamethason/Deksametazon Krka | tbl. 10x0,5 mg | 1,48 | 14,80 | R | 5% |
| H02AB02 132 |  | deksametazon | 1,5 mg | 1,60 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Deksametazon Krka | tbl. 20x4 mg | 4,26 | 85,13 | R | 5% |
| H02AB02 133 |  | deksametazon | 1,5 mg | 1,16 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Deksametazon Krka | tbl. 20x20 mg | 15,49 | 309,85 | RSRV03 | 5% |
| H02AB04 064 | PO | metilprednizolon-sukcinat-natrij | 20 mg | 5,50 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x40 mg/ml | 10,99 | 10,99 |  | 5% |
| H02AB04 065 | DS | metilprednizolon-acetat | 20 mg | 4,49 | P | Pfizer Croatia d.o.o. | Pfizer | Depo Medrol | amp. 1x40 mg/ml | 8,97 | 8,97 |  | 5% |
| H02AB04 066 | PO | metilprednizolon-sukcinat-natrij | 20 mg | 3,66 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x125 mg/2 ml | 21,95 | 21,95 |  | 5% |
| H02AB04 067 | DS | metilprednizolon-sukcinat-natrij | 20 mg | 2,77 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x500 mg/8 ml | 69,34 | 69,34 |  | 5% |
| H02AB04 068 | DS | metilprednizolon-sukcinat-natrij | 20 mg | 2,52 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x250 mg | 31,55 | 31,55 |  | 5% |
| H02AB04 069 | DS | metilprednizolon-sukcinat-natrij | 20 mg | 1,49 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x1.000 mg/16 ml | 74,62 | 74,62 |  | 5% |
| H02AB04 161 |  | metilprednizolon-acetat | 7,5 mg | 0,64 | O | Pfizer Croatia d.o.o. | Pfizer | Medrol | tbl. 50x16 mg | 1,37 | 68,33 | R | 5% |
| H02AB07 172 |  | prednizon | 10 mg | 0,62 | O | MERCK d.o.o. | Merck | Decortin | tbl. 10x20 mg | 1,24 | 12,40 | R | 5% |
| H02AB07 174 |  | prednizon | 10 mg | 0,58 | O | MERCK d.o.o. | Merck | Decortin | tbl. 50x20 mg | 1,16 | 58,00 | R | 5% |
| H02AB07 551 | DS | prednizon |  |  | R |  |  |  |  |  |  |  | 5% |
| H02AB09 083 | PR | hidrokortizon | 30 mg | 3,73 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Cortef | amp. 1x100 mg /2 ml | 11,19 | 11,19 |  | 5% |
| H02AB09 161 |  | hidrokortizon | 30 mg | 349,21 | O | Diurnal Europe B.V. | Delpharm Lille SAS | Alkindi | gran. u caps. za otvaranje 50x0,5 mg | 5,82 | 291,00 | RSRH92 | 5% |
| H02AB09 162 |  | hidrokortizon | 30 mg | 349,19 | O | Diurnal Europe B.V. | Delpharm Lille SAS | Alkindi | gran. u caps. za otvaranje 50x1 mg | 11,64 | 582,00 | RSRH92 | 5% |
| H02AB09 163 |  | hidrokortizon | 30 mg | 264,60 | O | Diurnal Europe B.V. | Delpharm Lille SAS | Alkindi | gran. u caps. za otvaranje 50x2 mg | 17,64 | 882,00 | RSRH92 | 5% |
| H02AB09 182 |  | hidrokortizon | 30 mg | 1,68 | O | Pfizer Croatia d.o.o. | Pharmacia & Upjohn | Cortef | tbl. 100x10 mg | 0,56 | 56,00 | R | 5% |
| H03AA01 051 | DS | levotiroksin | 0,15 mg |  | P |  |  |  |  |  |  |  | 5% |
| H03AA01 171 |  | levotiroksin | 0,15 mg | 0,41 | O | Berlin Chemie AG | Berlin-Chemie AG | Letrox 50 | tbl. 100x50 mcg | 0,14 | 13,74 | R | 5% |
| H03AA01 172 |  | levotiroksin | 0,15 mg | 0,28 | O | Berlin Chemie AG | Berlin-Chemie AG | Letrox 100 | tbl. 100x100 mcg | 0,19 | 18,57 | R | 5% |
| H03AA01 173 |  | levotiroksin | 0,15 mg | 0,23 | O | Berlin Chemie AG | Berlin-Chemie AG | Letrox 150 | tbl. 100x150 mcg | 0,23 | 23,38 | R | 5% |
| H03AA02 051 | DS | liotironin | 60 mcg |  | P |  |  |  |  |  |  |  | 5% |
| H03BA02 142 |  | propiltiouracil | 0,1 g | 2,80 | O | Alkaloid d.o.o. | Alkaloid | Propiltiouracil Alkaloid | tbl. 60x50 mg | 1,40 | 84,00 | R | 5% |
| H03BB02 051 | DS | tiamazol |  |  | P |  |  |  |  |  |  |  | 5% |
| H03BB02 111 |  | tiamazol | 10 mg | 1,40 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Athyrazol | tbl. 30x10 mg | 1,40 | 42,00 | R | 5% |
| H04AA01 061 | PR | glukagon | 1 mg | 108,00 | P | Novo Nordisk A/S | Novo Nordisk | GlucaGen Hypokit | lio boč. 1x1 mg + štrcaljka | 108,00 | 108,00 | R | 5% |
| H04AA01 761 |  | glukagon | 3 mg | 435,30 | N | Eli Lilly Nederland B.V. | Lilly France S.A.S. | Baqsimi | praš. za nos, 3 mg (1 monodoza) | 435,30 | 435,30 | RRH08 | 5% |
| H05AA02 001 | RL | teriparatid | 20 mcg | 49,77 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V. | Teriparatid Pliva | otop. za inj., brizg. napunj. 1x600 mcg/2,4 ml (250 mcg/ml) | 1.493,17 | 1.493,17 | RSRH07 | 5% |
| H05AA02 071 | RL | teriparatid | 20 mcg | 49,77 | P | Eli Lilly Nederland B.V. | Lilly France | Forsteo | otop. za inj., brizg. napunj. 1x600 mcg/2,4 ml (250 mcg/ml) | 1.493,17 | 1.493,17 | RSRH07 | 5% |
| H05AA02 072 | RL | teriparatid | 20 mcg | 44,90 | P | STADA Arzneimittel AG | Gedeon Richter Plc. | Movymia | otop. za inj., uložak 1x600 mcg/2,4 ml (250 mcg/ml) | 1.347,13 | 1.347,13 | RSRH07 | 5% |
| H05AA02 073 | RL | teriparatid | 20 mcg | 49,77 | P | STADA Arzneimittel AG | Gedeon Richter Plc | Movymia starter kit | otop. za inj., brizgalica i uložak 1x600 mcg/2,4 ml (250 mcg/ml) | 1.493,17 | 1.493,17 | RSRH07 | 5% |
| H05AA02 074 | RL | teriparatid | 20 mcg | 42,16 | P | STADA Arzneimittel AG | Gedeon Richter Plc. | Movymia | otop. za inj., uložak 3x600 mcg/2,4 ml (250 mcg/ml) | 1.264,77 | 3.794,31 | RSRH07 | 5% |
| H05AA02 081 | RL | teriparatid | 20 mcg | 49,77 | P | Gedeon Richter Plc. | Richter-Helm BioLogics GmbH & Co. KG | Terrosa | otop. za inj., brizgalica Terrosa Pen i uložak 1x600 mcg/2,4 ml (250 mcg/ml) | 1.493,17 | 1.493,17 | RSRH07 | 5% |
| H05AA02 082 | RL | teriparatid | 20 mcg | 44,90 | P | Gedeon Richter Plc. | Richter-Helm BioLogics GmbH & Co. KG | Terrosa | otop. za inj., uložak 1x600 mcg/2,4 ml (250 mcg/ml) | 1.347,13 | 1.347,13 | RSRH07 | 5% |
| H05AA02 083 | RL | teriparatid | 20 mcg | 49,77 | P | Zentiva k.s. | GP Pharm S.A. | Teriparatid Zentiva | otop. za inj., brizg. napunj. 1x600 mcg/2,4 ml (250 mcg/ml) | 1.493,17 | 1.493,17 | RSRH07 | 5% |
| H05AA02 084 | RL | teriparatid | 20 mcg | 49,77 | P | Accord Healthcare S.L.U. | Accord Healthcare BV, Accord Healthcare Polska Sp. z o.o. | Sondelbay | otop. za inj., brizg. napunj. 1x600 mcg/2,4 ml (250 mcg/ml) | 1.493,17 | 1.493,17 | RSRH07 | 5% |
| H05BX01 141 | DS | sinakalcetNH502 | 60 mg | 47,90 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Laboratori Fundacio Dau | Cinakalcet Accordpharma | tbl. film obl. 28x30 mg | 23,95 | 670,60 |  | 5% |
| H05BX01 142 | DS | sinakalcetNH502 | 60 mg | 47,90 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Laboratori Fundacio Dau | Cinakalcet Accordpharma | tbl. film obl. 28x60 mg | 47,90 | 1.341,20 |  | 5% |
| H05BX01 161 | DS | sinakalcetNH502 | 60 mg | 56,08 | O | Amgen Europe B.V. | Amgen Europe B.V. | Mimpara | tbl. film obl. 28x30 mg | 28,04 | 785,18 |  | 5% |
| H05BX01 162 | DS | sinakalcetNH502 | 60 mg | 52,39 | O | Amgen Europe B.V. | Amgen Europe B.V. | Mimpara | tbl. film obl. 28x60 mg | 52,39 | 1.467,01 |  | 5% |
| H05BX01 181 | DS | sinakalcetNH502 | 60 mg | 50,48 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Cinet | tbl. film obl. 28x30 mg | 25,24 | 706,66 |  | 5% |
| H05BX01 182 | DS | sinakalcetNH502 | 60 mg | 50,48 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Cinet | tbl. film obl. 28x60 mg | 50,48 | 1.413,32 |  | 5% |
| H05BX02 061 | DS | parikalcitolNH503 | 2 mcg | 41,27 | P | AbbVie d.o.o. | AbbVie S.r.l. | Zemplar | boč. 5x5 mcg/ml | 103,18 | 515,88 |  | 5% |
| H05BX02 161 |  | parikalcitol | 2 mcg | 39,12 | O | AbbVie d.o.o. | Aesica Queenborough Limited, AbbVie Deutschland GmbH & Co.KG | Zemplar | caps. meke 28x1 mcg | 19,56 | 547,69 | RSRH05 | 5% |
| H05BX02 162 |  | parikalcitol | 2 mcg | 40,89 | O | AbbVie d.o.o. | Aesica Queenborough Limited, AbbVie Deutschland GmbH & Co.KG | Zemplar | caps. meke 28x2 mcg | 40,89 | 1.144,86 | RSRH05 | 5% |
| H05BX02 171 |  | parikalcitol | 2 mcg | 27,38 | O | ALPHA-MEDICAL d.o.o. | Yasenka d.o.o. | Parkol | caps. meke 28x1 mcg | 13,69 | 383,38 | RSRH05 | 5% |
| H05BX02 172 |  | parikalcitol | 2 mcg | 28,62 | O | ALPHA-MEDICAL d.o.o. | Yasenka d.o.o. | Parkol | caps. meke 28x2 mcg | 28,62 | 801,40 | RSRH05 | 5% |
| H05BX04 061 | DS | etelkalcetidNH504 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Parsabiv | otop. za inj., boč. stakl. 6x2,5 mg/0,5 ml (5 mg/ml) | 122,81 | 736,83 |  | 5% |
| H05BX04 062 | DS | etelkalcetidNH504 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Parsabiv | otop. za inj., boč. stakl. 6x5 mg/1 ml (5 mg/ml) | 245,12 | 1.470,69 |  | 5% |
| J01AA02 112 |  | doksiciklin | 0,1 g | 1,00 | O | Belupo d.d. | Belupo | Doksiciklin Belupo | caps. 25x100 mg | 1,00 | 25,00 | R | 5% |
| J01AA12 061 | DS | tigeciklinNJ101 | 0,1 g | 585,28 | P | Pfizer Europe MA EEIG | Wyeth | Tygacil | praš. za otop. za inf., boč. stakl. 10x50 mg (10 mg/ml) | 292,64 | 2.926,40 |  | 5% |
| J01AA12 071 | DS | tigeciklinNJ101 | 0,1 g | 409,68 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Tigeciklin Accord | praš. za otop. za inf., boč. stakl. 10x50 mg (10 mg/ml) | 204,84 | 2.048,40 |  | 5% |
| J01BA01 052 | DS | kloramfenikolNJ101 | 3 g |  | P |  |  |  |  |  |  |  | 5% |
| J01CA01 051 | PR | ampicilin | 6 g |  | P |  |  |  | 500 mg |  |  |  | 5% |
| J01CA01 052 | DS | ampicilin | 6 g |  | P |  |  |  | 1 g |  |  |  | 5% |
| J01CA04 118 |  | amoksicilin | 1.5 g | 1,71 | O | Belupo d.d. | Belupo | Amoksicilin Belupo | tbl. za oral. susp. 16x500 mg | 0,57 | 9,12 | RRJ01 | 5% |
| J01CA04 119 |  | amoksicilin | 1.5 g | 1,73 | O | Belupo d.d. | Belupo | Amoksicilin Belupo | tbl. za oral. susp. 16x1000 mg | 1,16 | 18,50 | RRJ01 | 5% |
| J01CA04 121 |  | amoksicilin | 1.5 g | 1,73 | O | Sandoz d.o.o. | Sandoz GmbH | Ospamox | tbl. za oral. susp. 16x1 g | 1,16 | 18,50 | RRJ01 | 5% |
| J01CA04 141 |  | amoksicilin | 1.5 g | 1,71 | O | Alkaloid d.o.o. | Alkaloid | Almacin | caps. 16x500 mg | 0,57 | 9,12 | RRJ01 | 5% |
| J01CA04 311 |  | amoksicilin | 1.5 g | 3,60 | O | Belupo d.d. | Belupo | Amoksicilin Belupo | sirup 1x100 ml (250 mg/5 ml) | 12,00 | 12,00 | RRJ01 | 5% |
| J01CA04 342 |  | amoksicilin | 1.5 g | 3,60 | O | Alkaloid d.o.o. | Alkaloid | Almacin | praš. za oral susp. 100 ml (250 mg/5 ml) | 12,00 | 12,00 | RRJ01 | 5% |
| J01CE01 051 | PO | benzilpenicilin | 3,6 g |  | P |  |  |  |  |  |  |  | 5% |
| J01CE02 116 |  | fenoksimetilpenicilin | 2 g | 4,37 | O | Belupo d.d. | Belupo d.d. | Silapen K | tbl. film obl. 30x1.500.000 i.j. | 1,96 | 58,94 | RRJ02 | 5% |
| J01CE02 117 |  | fenoksimetilpenicilin | 2 g | 4,55 | O | Sandoz d.o.o. | Sandoz | Ospen K | tbl. film obl. 30x1.000.000 i.j. | 1,37 | 40,99 | RRJ02 | 5% |
| J01CE02 118 |  | fenoksimetilpenicilin | 2 g | 4,37 | O | Sandoz d.o.o. | Sandoz | Ospen K | tbl. film obl. 30x1.500.000 i.j. | 1,96 | 58,94 | RRJ02 | 5% |
| J01CE02 171 |  | fenoksimetilpenicilin | 2 g | 4,63 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Penon | tbl. film obl. 30x800 mg | 1,85 | 55,58 | RRJ02 | 5% |
| J01CE02 172 |  | fenoksimetilpenicilin | 2 g | 4,44 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Penon | tbl. film obl. 30x1000 mg | 2,22 | 66,60 | RRJ02 | 5% |
| J01CE02 313 |  | fenoksimetilpenicilin | 2 g | 40,89 | O | Belupo d.d. | Belupo | Silapen K | praš. za oral. otop. 1x100 ml (250 mg/5 ml) | 102,22 | 102,22 | RRJ02 | 5% |
| J01CE02 363 |  | fenoksimetilpenicilin | 2 g | 38,84 | O | ALPHA-MEDICAL d.o.o. | Laboratorios Atral S.A. | Penon | praš. za oral. otop. 1x100 ml (250 mg/5 ml) | 97,11 | 97,11 | RRJ02 | 5% |
| J01CE08 051 | PO | benzatin benzilpenicilin | 3,6 g |  | P |  |  |  |  |  |  |  | 5% |
| J01CE09 051 | PO | prokain benzilpenicilin |  |  | P |  |  |  |  |  |  |  | 5% |
| J01CE30 051 | PO | benzilpenicilin prokainpenicilin (depo-bipenicilin) |  |  | P |  |  |  |  |  |  |  | 5% |
| J01CF05 061 | DS | flukloksacilinnatrij | 2 g | 35,72 | P | Altamedics d.o.o. | MITIM S.r.l. | Flukloksacilin Altamedics | praš. za otop. za inj./inf., boč. stakl. 10x1 g | 17,86 | 178,60 |  | 5% |
| J01CF05 063 | DS | flukloksacilin | 2 g | 37,38 | P | Altamedics d.o.o. | MITIM S.r.l. | Flukloksacilin Altamedics | praš. za otop. za inj. ili inf., boč. stakl. 10x2 g | 37,38 | 373,80 |  | 5% |
| J01CF05 171 |  | flukloksacilin | 2 g | 15,38 | O | Altamedics d.o.o. | Athlone Laboratories Limited, Co. Roscommon | Flukloksacilin Altamedics | caps. tvrda 20x500 mg | 3,85 | 76,90 | R | 5% |
| J01CR01 051 | DS | ampicilin + sulbaktamNJ101 | 6 g |  | P |  |  |  |  |  |  |  | 5% |
| J01CR01 071 | DS | ampicilin + sulbaktamNJ101 | 6 g | 86,70 | P | Apta Medica International d.o.o. | MITIM S.r.l. | Ampicilin/sulbaktam AptaPharma | praš. za otop. za inj./inf., boč. 10x(1 g + 0,5 g) | 14,45 | 144,50 |  | 5% |
| J01CR01 072 | DS | ampicilin + sulbaktamNJ101 | 6 g | 86,70 | P | Apta Medica International d.o.o. | MITIM S.r.l. | Ampicilin/sulbaktam AptaPharma | praš. za otop. za inj./inf., boč. 10x(2 g + 1 g) | 28,90 | 289,00 |  | 5% |
| J01CR02 005 | PO | amoksicilin + klavulanska kiselina | 3 g | 150,10 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Klavocin | boč. 5x(500 + 100 mg) | 25,02 | 125,08 |  | 5% |
| J01CR02 006 | PR | amoksicilin + klavulanska kiselina | 3 g | 73,93 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Klavocin | boč. 5x(1.000 + 200 mg) | 24,64 | 123,22 |  | 5% |
| J01CR02 061 | PR | amoksicilin + klavulanska kiselina | 3 g | 51,75 | P | Medochemie Ltd. | Medochemie Ltd. | Medoclav | boč. 10x(1.000 mg + 200 mg) | 17,25 | 172,50 |  | 5% |
| J01CR02 071 | PR | amoksicilin + klavulanska kiselina | 3 g | 49,02 | P | Apta Medica International d.o.o. | Laboratorio Reig Jofre S.A. | Amoksicilin/klavulanska kiselina AptaPharma | boč. 10x(1.000 mg + 200 mg) | 16,34 | 163,40 |  | 5% |
| J01CR02 108 |  | amoksicilin + klavulanska kiselina | 1.5 g | 4,04 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Klavocin bid | tbl. film obl. 14x1 g (875 mg + 125 mg) | 2,36 | 33,00 | RRJ04 | 5% |
| J01CR02 111 |  | amoksicilin + klavulanska kiselina | 1.5 g | 3,09 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Klavax bid | tbl. film obl. 14x1 g (875 mg + 125 mg) | 1,80 | 25,20 | RRJ04 | 5% |
| J01CR02 115 |  | amoksicilin + klavulanska kiselina | 1.5 g | 4,04 | O | Belupo d.d. | Belupo | Klavobel BID | tbl. film obl. 14x1 g (875 mg + 125 mg) | 2,36 | 33,00 | RRJ04 | 5% |
| J01CR02 131 |  | amoksicilin + klavulanska kiselina | 1.5 g | 2,78 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Betaklav | tbl. film obl. 14x1 g (875 mg + 125 mg) | 1,62 | 22,68 | RRJ04 | 5% |
| J01CR02 141 |  | amoksicilin + klavulanska kiselina | 1.5 g | 2,72 | O | PharmaS d.o.o. | PharmaS d.o.o. | KlavoPhar | tbl. film obl. 14x1 g (875 mg + 125 mg) | 1,58 | 22,18 | RRJ04 | 5% |
| J01CR02 161 |  | amoksicilin + klavulanska kiselina | 1.5 g | 2,71 | O | Medochemie Ltd. | Medochemie Ltd. | Medoclav | tbl. film obl. 14x1 g (875 mg + 125 mg) | 1,58 | 22,17 | RRJ04 | 5% |
| J01CR02 171 |  | amoksicilin + klavulanska kiselina | 1.5 g | 4,04 | O | GlaxoSmithKline Trading Services Limited | SmithKline Beecham Pharmaceuticals, Glaxo Wellcome Production | Augmentin | tbl. film obl. 14x1 g (875 mg + 125 mg) | 2,36 | 33,00 | RRJ04 | 5% |
| J01CR02 209 |  | amoksicilin + klavulanska kiselina | 1.5 g | 6,01 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Klavocin bid sirup | susp. 70 ml (400 mg + 57 mg)/5 ml | 22,45 | 22,45 | RRJ04 | 5% |
| J01CR02 212 |  | amoksicilin + klavulanska kiselina | 1.5 g | 6,01 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Klavax bid sirup | susp. 70 ml (400 mg + 57 mg)/5 ml | 22,45 | 22,45 | RRJ04 | 5% |
| J01CR02 231 |  | amoksicilin + klavulanska kiselina | 1.5 g | 5,41 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Betaklav | praš. za oral. susp. 1x70 ml (400 mg + 57 mg/5 ml) | 20,21 | 20,21 | RRJ04 | 5% |
| J01CR02 273 |  | amoksicilin + klavulanska kiselina | 1.5 g | 6,01 | O | GlaxoSmithKline Trading Services Limited | SmithKline Beecham Pharmaceuticals, Glaxo Wellcome Production | Augmentin | susp. 70 ml(400 mg + 57 mg)/5 ml | 22,45 | 22,45 | RRJ04 | 5% |
| J01CR05 001 | DS | piperacilin + tazobaktamNJ101 | 14 g | 212,84 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Acipirin | praš. za inj. ili inf. 10x4,5 g | 60,81 | 608,10 |  | 5% |
| J01CR05 041 | DS | piperacilin + tazobaktamNJ101 | 14 g | 216,38 | P | Sandoz d.o.o. | Sandoz | Piperacilin/tazobaktam Sandoz | praš. za otop. za inf., boč. 10x(4,0 g + 0,5 g)/100ml | 61,82 | 618,23 |  | 5% |
| J01CR05 074 | DS | piperacilin + tazobaktamNJ101 | 14 g | 433,65 | P | Fresenius Kabi d.o.o. | Laboratorio Farmaceutico, Labesfal-Laboratorios Almiro | Piperacilin/Tazobactam Fresenius Kabi | praš. za otop. za inf., boč. 10x(2,0 g + 0,25 g)/50 ml | 43,37 | 433,65 |  | 5% |
| J01CR05 075 | DS | piperacilin + tazobaktamNJ101 | 14 g | 212,84 | P | Fresenius Kabi d.o.o. | Laboratorio Farmaceutico, Labesfal-Laboratorios Almiro | Piperacilin/Tazobactam Fresenius Kabi | praš. za otop. za inf., boč. 10x(4,0 g + 0,5 g)/50 ml | 60,81 | 608,10 |  | 5% |
| J01DB01 111 |  | cefaleksin | 2 g | 5,24 | O | Belupo d.d. | Belupo | Cefaleksin Belupo | caps. 16x500 mg | 1,31 | 20,96 | RRJ05 | 5% |
| J01DB01 142 |  | cefaleksin | 2 g | 5,24 | O | Alkaloid d.o.o. | Alkaloid | Cefalexin Alkaloid | caps. 16x500 mg | 1,31 | 20,96 | RRJ05 | 5% |
| J01DB01 313 |  | cefaleksin | 2 g | 8,02 | O | Belupo d.d. | Belupo | Cefaleksin Belupo | praš. za oral. susp. 1x100 ml (250 mg/5 ml) | 20,04 | 20,04 | RRJ05 | 5% |
| J01DB01 343 |  | cefaleksin | 2 g | 8,02 | O | Alkaloid d.o.o. | Alkaloid | Cefalexin Alkaloid | praš. za oral. susp. 1x100 ml (250 mg/5 ml) | 20,04 | 20,04 | RRJ05 | 5% |
| J01DB04 061 | PR | cefazolin | 3 g | 25,47 | P | Medochemie Ltd. | Medochemie Ltd | Zepilen | praš. za otop. za inj. ili inf. boč. stakl. 10x1 g/10 ml | 7,64 | 76,40 |  | 5% |
| J01DB04 082 | PR | cefazolin | 3 g | 21,78 | P | ALPHA-MEDICAL d.o.o. | PJSC SIC Borshchahivskiy CPP | Cefazolin Alpha-Medical | praš. za otop. za inj. ili inf., boč. stakl. 1x1 g/10 ml | 7,26 | 7,26 |  | 5% |
| J01DB04 083 | PR | cefazolin | 3 g | 20,69 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefazolin AptaPharma | praš. za otop. za inj. ili inf. boč. 10x1 g/10 ml | 6,90 | 68,97 |  | 5% |
| J01DC02 061 | DS | cefuroksim NJ102 | 3 g | 26,00 | P | Medochemie Ltd. | Medochemie Ltd. | Axetine | praš. za otop. za inj. ili inf. boč. 10x750 mg | 6,50 | 65,00 |  | 5% |
| J01DC02 062 | DS | cefuroksim NJ102 | 3 g | 20,00 | P | Medochemie Ltd. | Medochemie Ltd. | Axetine | praš. za otop. za inj. ili inf. boč. 10x1,5 g | 10,00 | 100,00 |  | 5% |
| J01DC02 076 | DS | cefuroksim NJ102 | 3 g | 26,00 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefuroksim AptaPharma | praš. za otop. za inj. ili inf., boč. stakl. 10x750 mg | 6,50 | 65,00 |  | 5% |
| J01DC02 077 | DS | cefuroksim NJ102 | 3 g | 19,00 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefuroksim AptaPharma | praš. za otop. za inj. ili inf., boč. stakl. 10x1500 mg | 9,50 | 95,00 |  | 5% |
| J01DC02 081 | DS | cefuroksim NJ102 | 3 g | 43,64 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chemisch-pharmazeutische Fabrik GmbH | Cefuroxim-MIP | praš. za otop. za inj., boč. stakl. 10x750 mg | 10,91 | 109,11 |  | 5% |
| J01DC02 082 | DS | cefuroksimNJ102 | 3 g | 26,05 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chemisch-pharmazeutische Fabrik GmbH | Cefuroxim-MIP | praš. za otop. za inj. ili inf., boč. stakl. 10x1500 mg | 13,03 | 130,25 |  | 5% |
| J01DC02 111 |  | cefuroksimNJ102 | 0,5 g | 2,67 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Efox | tbl. film obl. 10x500 mg | 2,67 | 26,70 | RRJ06 | 5% |
| J01DC02 113 |  | cefuroksimNJ102 | 0,5 g | 4,18 | O | Belupo d.d. | Belupo d.d. | Beloxim | tbl. film obl. 10x250 mg | 2,09 | 20,88 | RRJ06 | 5% |
| J01DC02 114 |  | cefuroksimNJ102 | 0,5 g | 2,67 | O | Belupo d.d. | Belupo d.d. | Beloxim | tbl. film obl. 10x500 mg | 2,67 | 26,70 | RRJ06 | 5% |
| J01DC02 123 |  | cefuroksimNJ102 | 0,5 g | 2,67 | O | Sandoz d.o.o. | Sandoz | Xorimax | tbl. film obl. 10x500 mg | 2,67 | 26,70 | RRJ06 | 5% |
| J01DC02 124 |  | cefuroksimNJ102 | 0,5 g | 2,67 | O | Sandoz d.o.o. | Sandoz | Xorimax | tbl. film obl. 16x500 mg | 2,67 | 42,72 | RRJ06 | 5% |
| J01DC02 144 |  | cefuroksimNJ102 | 0,5 g | 2,67 | O | KRKA-FARMA d.o.o. | Krka d.d. | Furocef | tbl. film obl. 14x500 mg | 2,67 | 37,38 | RRJ06 | 5% |
| J01DC02 162 |  | cefuroksimNJ102 | 0,5 g | 4,18 | O | GlaxoSmithKline d.o.o. | Glaxo Operations UK Ltd., GlaxoSmithKline Trading Services Limited | Zinnat | tbl. film obl. 10x250 mg | 2,09 | 20,88 | RRJ06 | 5% |
| J01DC02 163 |  | cefuroksimNJ102 | 0,5 g | 2,67 | O | GlaxoSmithKline d.o.o. | Glaxo Operations UK Ltd., GlaxoSmithKline Trading Services Limited | Zinnat | tbl. film obl. 10x500 mg | 2,67 | 26,70 | RRJ06 | 5% |
| J01DC02 262 |  | cefuroksimNJ102 | 0,5 g | 12,40 | O | GlaxoSmithKline d.o.o. | Glaxo Operations UK Ltd., GlaxoSmithKline Trading Services Limited | Zinnat | suspenzija 1x100 ml (125 mg/5 ml) | 62,00 | 62,00 | RRJ06 | 5% |
| J01DD01 051 | DS | cefotaksimNJ101 | 4 g |  | P |  |  |  |  |  |  |  | 5% |
| J01DD01 061 | DS | cefotaksimNJ101 | 4 g | 87,44 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefotaksim AptaPharma | praš. za otop. za inj/inf., boč. 10x1 g | 21,86 | 218,60 |  | 5% |
| J01DD01 062 | DS | cefotaksimNJ101 | 4 g | 87,28 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefotaksim AptaPharma | praš. za otop. za inj/inf., boč. 10x2 g | 43,64 | 436,41 |  | 5% |
| J01DD02 042 | DS | ceftazidimNJ101 | 4 g | 138,02 | P | Alkaloid d.o.o. | Alkaloid | Cefaz | praš. za otop. za inj., boč. 5x1000 mg/10 ml | 34,51 | 172,53 |  | 5% |
| J01DD02 043 | DS | ceftazidimNJ101 | 4 g | 117,46 | P | Alkaloid d.o.o. | Alkaloid – INT d.o.o. | Cefaz | praš. za otop. za inj./inf., boč. 10x1000 mg/10 ml | 29,37 | 293,65 |  | 5% |
| J01DD02 071 | DS | ceftazidimNJ101 | 4 g | 150,96 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro S.A | Ceftazidim Kabi | praš. za otop. za inj., boč. 1x500 mg/10 ml | 18,87 | 18,87 |  | 5% |
| J01DD02 072 | DS | ceftazidimNJ101 | 4 g | 150,96 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro S.A | Ceftazidim Kabi | praš. za otop. za inj., boč. 10x500 mg/10 ml | 18,87 | 188,70 |  | 5% |
| J01DD02 073 | DS | ceftazidimNJ101 | 4 g | 172,88 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro S.A | Ceftazidim Kabi | praš. za otop. za inj., boč. 1x1000 mg/10 ml | 43,22 | 43,22 |  | 5% |
| J01DD02 074 | DS | ceftazidimNJ101 | 4 g | 123,64 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro S.A | Ceftazidim Kabi | praš. za otop. za inj., boč. 10x1000 mg/10 ml | 30,91 | 309,10 |  | 5% |
| J01DD02 077 | DS | ceftazidimNJ101 | 4 g | 123,64 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Ceftazidim AptaPharma | praš. za otop. za inj./inf., boč. 10x1000 mg/10 ml | 30,91 | 309,10 |  | 5% |
| J01DD02 078 | DS | ceftazidimNJ101 | 4 g | 117,46 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Ceftazidim AptaPharma | praš. za otop. za inj./inf., boč. 10x2000 mg/10 ml | 58,73 | 587,29 |  | 5% |
| J01DD04 065 | DSPO | ceftriakson NJ110 | 2 g | 35,93 | P | Fresenius Kabi d.o.o. | Labesfal, Laboratorios Almiro, S.A. | Ceftriaxone Kabi | praš. za otop. za inj., boč 10x1 g | 17,96 | 179,64 |  | 5% |
| J01DD04 066 | DSPO | ceftriaksonNJ110 | 2 g | 54,00 | P | Fresenius Kabi d.o.o. | Labesfal, Laboratorios Almiro, S.A. | Ceftriaxone Kabi | praš. za otop. za inj., boč 10x2 g | 54,00 | 540,00 |  | 5% |
| J01DD04 071 | DSPO | ceftriaksonNJ110 | 2 g | 23,89 | P | Medochemie Ltd. | Medochemie Ltd. | Medaxone | praš. za otop. za inj. ili inf. boč. 10x1 g | 11,95 | 119,45 |  | 5% |
| J01DD04 075 | DSPO | ceftriaksonNJ110 | 2 g | 35,93 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Ceftriaxon MIP | praš. za otop. za inj. ili inf., boč. stakl. 10x1 g | 17,96 | 179,64 |  | 5% |
| J01DD04 076 | DSPO | ceftriaksonNJ110 | 2 g | 37,80 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Ceftriaxon MIP | praš. za otop. za inj. ili inf., boč. stakl. 10x2 g | 37,80 | 378,00 |  | 5% |
| J01DD04 085 | DSPO | ceftriaksonNJ110 | 2 g | 23,89 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A | Ceftriakson AptaPharma | praš. za otop. za inj./inf. boč. 10x1 g | 11,95 | 119,45 |  | 5% |
| J01DD04 086 | DSPO | ceftriaksonNJ110 | 2 g | 35,91 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A | Ceftriakson AptaPharma | praš. za otop. za inj./inf. boč. 5x2 g | 35,91 | 179,55 |  | 5% |
| J01DD04 087 | DSPO | ceftriaksonNJ110 | 2 g | 34,12 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A | Ceftriakson AptaPharma | praš. za otop. za inj./inf. boč. 10x2 g | 34,12 | 341,15 |  | 5% |
| J01DD08 141 |  | cefiksim | 0,4 g | 4,38 | O | ALPHA-MEDICAL d.o.o. | Medika d.d. | Cefiksim CLN | tbl. film obl. 10x400 mg | 4,38 | 43,77 | RRJ07 | 5% |
| J01DD08 142 |  | cefiksim | 0,4 g | 4,38 | O | ALPHA-MEDICAL d.o.o. | Medika d.d. | Cefiksim CLN | tbl. film obl. 5x400 mg | 4,38 | 21,89 | RRJ07 | 5% |
| J01DD08 241 |  | cefiksim | 0,4 g | 15,80 | O | Alkaloid d.o.o. | Alkaloid | Cefiksim Alkaloid | praš. za oral. susp. 1x60 ml (100 mg/5 ml) | 47,40 | 47,40 | RRJ07 | 5% |
| J01DD08 242 |  | cefiksim | 0,4 g | 15,80 | O | Alkaloid d.o.o. | Alkaloid | Cefiksim Alkaloid | praš. za oral. susp. 1x100 ml (100 mg/5 ml) | 79,00 | 79,00 | RRJ07 | 5% |
| J01DD52 071 | DS | ceftazidim + avibaktamNJ107 |  |  | P | Pfizer Ireland Pharmaceuticals | GlaxoSmithKline Manufacturing S.p.A | Zavicefta | praš. za konc. za otop. za inf., boč. stakl. 10x(2 g + 0,5 g) | 784,27 | 7.842,68 |  | 5% |
| J01DE01 041 | DS | cefepimNJ101 | 4 g | 102,08 | P | Accord Healthcare Polska Sp. z o.o. | Laboratorio Farmaceutico C.T. S.r.l. | Cefepim Accord | praš. za otop. za inj. ili inf., boč. stakl. 1x1 g | 25,52 | 25,52 |  | 5% |
| J01DE01 042 | DS | cefepimNJ101 | 4 g | 107,76 | P | Accord Healthcare Polska Sp. z o.o. | Laboratorio Farmaceutico C.T. S.r.l. | Cefepim Accord | praš. za otop. za inj. ili inf., boč. stakl. 1x2 g | 53,88 | 53,88 |  | 5% |
| J01DE01 071 | DS | cefepimNJ101 | 4 g | 145,84 | P | Fresenius Kabi d.o.o. | Labesfal – Laboratorios Almiro S.A. | Cefepime Kabi | praš. za otop. za inj. ili inf., boč. stakl. 10x1 g | 36,46 | 364,59 |  | 5% |
| J01DE01 072 | DS | cefepimNJ101 | 4 g | 153,94 | P | Fresenius Kabi d.o.o. | Labesfal – Laboratorios Almiro S.A. | Cefepime Kabi | praš. za otop. za inj. ili inf., boč. stakl. 10x2 g | 76,97 | 769,68 |  | 5% |
| J01DH02 073 | DS | meropenemNJ101 | 3 g | 263,45 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Meropenem AptaPharma | praš. za otop. za inj. ili inf., boč. 10x500 mg | 43,91 | 439,10 |  | 5% |
| J01DH02 074 | DS | meropenemNJ101 | 3 g | 240,45 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Meropenem AptaPharma | praš. za otop. za inj. ili inf., boč. 10x1000 mg | 80,15 | 801,50 |  | 5% |
| J01DH02 075 | DS | meropenemNJ101 | 3 g | 217,00 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Meropenem AptaPharma | praš. za otop. za inf., boč. 6x2000 mg | 144,67 | 868,00 |  | 5% |
| J01DH02 081 | DS | meropenemNJ101 | 3 g | 277,31 | P | Fresenius Kabi d.o.o. | ACS Dobfar S.p.A. | Meropenem Kabi | praš. za otop. za inj. ili inf., boč. 10x500 mg/20 ml | 46,22 | 462,19 |  | 5% |
| J01DH02 082 | DS | meropenemNJ101 | 3 g | 253,11 | P | Fresenius Kabi d.o.o. | ACS Dobfar S.p.A. | Meropenem Kabi | praš. za otop. za inj. ili inf., boč. 10x1000 mg/20 ml | 84,37 | 843,70 |  | 5% |
| J01DH02 083 | DS | meropenemNJ101 | 3 g | 277,31 | P | Medochemie Ltd. | Medochemie Ltd | Archifar | praš. za otop. za inj. ili inf., boč. stakl. 10x500 mg/20 ml | 46,22 | 462,19 |  | 5% |
| J01DH02 084 | DS | meropenemNJ101 | 3 g | 253,11 | P | Medochemie Ltd. | Medochemie Ltd | Archifar | praš. za otop. za inj. ili inf., boč. stakl. 10x1000 mg/30 ml | 84,37 | 843,70 |  | 5% |
| J01DH02 085 | DS | meropenemNJ101 | 3 g | 250,25 | P | Ligula Pharma d.o.o. | Venus Pharma GmbH | Meropenem Ligula Pharma | praš. za otop. za inj. ili inf., boč. 10x500 mg | 41,71 | 417,10 |  | 5% |
| J01DH02 086 | DS | meropenemNJ101 | 3 g | 228,42 | P | Ligula Pharma d.o.o. | Venus Pharma GmbH | Meropenem Ligula Pharma | praš. za otop. za inj. ili inf., boč. 10x1000 mg | 76,14 | 761,40 |  | 5% |
| J01DH03 061 | DS | ertapenemNJ101 | 1 g | 254,97 | P | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | Invanz | praš. za konc.za otop. za inf., boč. stakl. 1x1g/20ml | 254,97 | 254,97 |  | 5% |
| J01DH03 071 | DS | ertapenemNJ101 | 1 g | 228,66 | P | Fresenius Kabi d.o.o. | ACS Dobfar S.p.A. | Ertapenem Fresenius Kabi | praš. za konc.za otop. za inf., boč. stakl. 10x1g/20 ml | 228,66 | 2.286,60 |  | 5% |
| J01DH03 072 | DS | ertapenemNJ101 | 1 g | 205,79 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Ertapenem AptaPharma | praš. za konc.za otop. za inf., boč. 10x1g | 205,79 | 2.057,94 |  | 5% |
| J01DH51 068 | DS | imipenem + cilastatinNJ101 | 2 g | 137,86 | P | Fresenius Kabi d.o.o. | Facta Farmaceutici | Imipenem/Cilastatin Kabi | praš. za otop. za inf., boč. stakl. 10x(500 mg + 500 mg) | 34,47 | 344,66 |  | 5% |
| J01DH51 072 | DS | imipenem + cilastatinNJ101 | 2 g | 111,20 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Imipenem/cilastatin AptaPharma | praš. za otop. za inf., boč. 10x(500 mg + 500 mg) | 27,80 | 278,00 |  | 5% |
| J01DH56 061 | DS | imipenem + cilastatin + relebaktamNJ111 | 2 g | 5.222,20 | P | Merck Sharp & Dohme B.V. | FAREVA Mirabel | Recarbrio | praš. za otop. za inf., boč. 25x(500 mg + 500 mg + 250 mg) | 1.305,55 | 32.638,75 |  | 5% |
| J01DI02 061 | DS | ceftarolin fosamilNJ108 | 1,2 g | 813,12 | P | Pfizer Ireland Pharmaceuticals | Facta Farmaceutici S.p.A | Zinforo | praš. za konc. za otop. za inf., boč. stakl. 10x600 mg | 406,56 | 4.065,61 |  | 5% |
| J01DI54 061 | DS | ceftolozan + tazobaktamNJ712 |  |  | P | Merck Sharp & Dohme B.V. | Cubist Pharmaceuticals Italia s.r.l. | Zerbaxa | praš. za konc. za otop. za inf., boč. 10x1 g/0,5 g | 690,04 | 6.900,40 |  | 5% |
| J01EA01 151 |  | trimetoprim | 0,4 g |  | O |  |  |  |  |  |  | R | 5% |
| J01EE01 051 | DS | sulfametoksazol + trimetoprim |  |  | P |  |  |  |  |  |  |  | 5% |
| J01EE01 111 |  | sulfametoksazol + trimetoprim |  |  | O | Belupo d.d. | Belupo | Sulotrim | tbl. 20x120 mg | 0,28 | 5,61 | RRJ09 | 5% |
| J01EE01 112 |  | sulfametoksazol + trimetoprim |  |  | O | Belupo d.d. | Belupo | Sulotrim | tbl. 20x480 mg | 0,84 | 16,82 | RRJ09 | 5% |
| J01EE01 114 |  | sulfametoksazol + trimetoprim |  |  | O | Belupo d.d. | Belupo | Sulotrim forte | tbl. 20x960 mg | 1,27 | 25,46 | RRJ09 | 5% |
| J01FA01 051 | DS | eritromicin | 1 g |  | P |  |  |  |  |  |  |  | 5% |
| J01FA01 111 |  | eritromicin | 1 g | 7,32 | O | Belupo d.d. | Belupo | Eritromicin | caps. 16x250 mg | 1,83 | 29,28 | RRJ10 | 5% |
| J01FA09 112 |  | klaritromicin | 0,5 g | 3,60 | O | Belupo d.d. | Belupo | Makcin SR | tbl. 7x500 mg | 3,60 | 25,17 | RRJ11 | 5% |
| J01FA09 114 |  | klaritromicin | 0,5 g | 3,60 | O | Belupo d.d. | Belupo | Makcin | tbl. 14x500 mg | 3,60 | 50,34 | RRJ11 | 5% |
| J01FA09 131 |  | klaritromicin | 0,5 g | 3,49 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid | tbl. film obl. 14x250 mg | 1,74 | 24,41 | RRJ11 | 5% |
| J01FA09 132 |  | klaritromicin | 0,5 g | 3,60 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid | tbl. film obl. 14x500 mg | 3,60 | 50,34 | RRJ11 | 5% |
| J01FA09 133 |  | klaritromicin | 0,5 g | 3,60 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid uno | tbl. s prod. otp. 7x500 mg | 3,60 | 25,17 | RRJ11 | 5% |
| J01FA09 134 |  | klaritromicin | 0,5 g | 3,60 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid uno | tbl. s prod. otp. 14x500 mg | 3,60 | 50,34 | RRJ11 | 5% |
| J01FA09 143 |  | klaritromicin | 0,5 g | 3,60 | O | Sandoz d.o.o. | Sandoz | Lekoklar XL | tbl. film obl. 7x500 mg | 3,60 | 25,17 | RRJ11 | 5% |
| J01FA09 144 |  | klaritromicin | 0,5 g | 3,60 | O | Sandoz d.o.o. | Sandoz | Lekoklar XL | tbl. film obl. 14x500 mg | 3,60 | 50,34 | RRJ11 | 5% |
| J01FA09 335 |  | klaritromicin | 0,5 g | 8,22 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid | susp. oral. 60 ml (125 mg/5 ml) | 24,65 | 24,65 | RRJ11 | 5% |
| J01FA10 007 | DS | azitromicinNJ103 | 0,5 g | 103,69 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed | praš. za inf. otop. boč. 5x500 mg | 103,69 | 518,44 |  | 5% |
| J01FA10 041 | DS | azitromicinNJ103 | 0,5 g | 72,58 | P | PharmaS d.o.o. | Anfarm Hellas S.A. | Azitromicin PharmaS | praš. za konc. za inf. otop; boč. 1x500 mg | 72,58 | 72,58 |  | 5% |
| J01FA10 101 |  | azitromicin | 0,3 g | 13,22 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed | tbl. 6x125 mg | 5,51 | 33,06 | RRJ12 | 5% |
| J01FA10 111 |  | azitromicin | 0,3 g | 2,54 | O | Belupo d.d. | Belupo | Azitromicin Belupo | tbl. film obl. 6x250 mg | 2,12 | 12,70 | RRJ12 | 5% |
| J01FA10 112 |  | azitromicin | 0,3 g | 2,54 | O | Belupo d.d. | Belupo | Azitromicin Belupo | tbl. film obl. 3x500 mg | 4,23 | 12,70 | RRJ12 | 5% |
| J01FA10 125 |  | azitromicin | 0,3 g | 2,54 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Makromicin | tbl. film obl. 3x500 mg | 4,23 | 12,70 | RRJ12 | 5% |
| J01FA10 131 |  | azitromicin | 0,3 g | 2,54 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Azimed | caps. 6x250 mg | 2,12 | 12,70 | RRJ12 | 5% |
| J01FA10 132 |  | azitromicin | 0,3 g | 2,54 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Azimed | tbl. film obl. 3x500 mg | 4,23 | 12,70 | RRJ12 | 5% |
| J01FA10 133 |  | azitromicin | 0,3 g | 2,54 | O | KRKA-FARMA d.o.o. | Krka d.d. | Azibiot | tbl. film obl. 3x500 mg | 4,23 | 12,70 | RRJ12 | 5% |
| J01FA10 141 |  | azitromicin | 0,3 g | 2,54 | O | Sandoz d.o.o. | Sandoz | Azitromicin Sandoz | tbl. film obl. 6x250 mg | 2,12 | 12,70 | RRJ12 | 5% |
| J01FA10 142 |  | azitromicin | 0,3 g | 2,54 | O | Sandoz d.o.o. | Sandoz | Azitromicin Sandoz | tbl. film obl. 3x500 mg | 4,23 | 12,70 | RRJ12 | 5% |
| J01FA10 143 |  | azitromicin | 0,3 g | 2,54 | O | PharmaS d.o.o. | PharmaS d.o.o. | Azitromicin PharmaS | tbl. film obl. 3x500 mg | 4,23 | 12,70 | RRJ12 | 5% |
| J01FA10 304 |  | azitromicin | 0,3 g | 15,83 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed | praš. za oral. susp., 1x20 ml (100 mg/5 ml) | 21,10 | 21,10 | RRJ18 | 5% |
| J01FA10 306 |  | azitromicin | 0,3 g | 11,03 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed 1.200 | praš. za oral. susp., 1x30 ml (200 mg/5 ml) | 44,10 | 44,10 | RRJ12 | 5% |
| J01FA10 308 |  | azitromicin | 0,3 g | 11,03 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed forte | praš. za oral. susp., 1x15 ml (200 mg/5 ml) | 22,05 | 22,05 | RRJ12 | 5% |
| J01FA10 309 |  | azitromicin | 0,3 g | 11,03 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed 1.500 | praš. za oral. susp., 1x37,5 ml (200 mg/5 ml) | 55,13 | 55,13 | RRJ12 | 5% |
| J01FA10 343 |  | azitromicin | 0,3 g | 10,07 | O | Sandoz d.o.o. | Sandoz | Azitromicin Sandoz forte | praš. za oral. susp., boč. 1x15 ml (200 mg/5 ml) | 20,14 | 20,14 | RRJ12 | 5% |
| J01FF01 022 | DS | klindamicin | 1,8 g | 59,64 | P | Sandoz d.o.o. | Sandoz-Lek | Klimicin | amp. 10x300 mg/2 ml | 11,93 | 119,28 |  | 5% |
| J01FF01 065 | DS | klindamicin | 1,8 g | 34,81 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Clindamycin MIP/Klindamicin-MIP | otop. za inj., amp. 5x900 mg/6 ml | 17,41 | 87,03 |  | 5% |
| J01FF01 071 | DS | klindamicin | 1,8 g | 40,96 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Clindamycin MIP/Klindamicin-MIP | otop. za inj., amp. 5x600 mg/4 ml | 13,65 | 68,27 |  | 5% |
| J01FF01 081 | DS | klindamicin | 1,8 g | 67,99 | P | hameln pharma gmbh | hameln rds, Siegfried Hameln GmbH | Klindamicin hameln | otop. za inj./inf., amp. 10x300 mg/2 ml | 11,33 | 113,32 |  | 5% |
| J01FF01 082 | DS | klindamicin | 1,8 g | 38,90 | P | hameln pharma gmbh | hameln rds, Siegfried Hameln GmbH | Klindamicin hameln | otop. za inj./inf., amp. 10x600 mg/4 ml | 12,97 | 129,68 |  | 5% |
| J01FF01 121 |  | klindamicin | 1,2 g | 8,22 | O | Sandoz d.o.o. | Sandoz-Lek | Klimicin | caps. 16x150 mg | 1,03 | 16,43 | R | 5% |
| J01FF01 122 |  | klindamicin | 1,2 g | 6,00 | O | Sandoz d.o.o. | Sandoz-Lek | Klimicin | caps. 16x300 mg | 1,50 | 24,00 | R | 5% |
| J01FF01 162 |  | klindamicin | 1,2 g | 6,00 | O | Pfizer Croatia d.o.o. | Pfizer | Dalacin C | caps. 16x300 mg | 1,50 | 24,00 | R | 5% |
| J01GA01 051 | DS | streptomicin | 1 g |  | P |  |  |  |  |  |  |  | 5% |
| J01GB01 961 | DS | tobramicinNJ104 | 0,3 g | 227,47 | I | Chiesi Pharmaceuticals GmbH | Chiesi | Bramitob | otop. za nebulizator, spremnik jednodozni, 56x300 mg/4 ml | 227,47 | 12.738,13 |  | 5% |
| J01GB01 962 | DS | tobramicinNJ104 | 0.112g | 263,94 | I | Mylan IRE Healthcare Ltd | Novartis Pharma GmbH | Tobi Podhaler | prašak inhalata, caps. tvrde 4x56x28 mg | 65,98 | 14.780,55 |  | 5% |
| J01GB03 013 | PO | gentamicin | 0,24 g | 18,70 | P | Belupo d.d. | Belupo | Gentamicin Belupo | amp. 10x80 mg | 6,23 | 62,32 |  | 5% |
| J01GB03 014 | PO | gentamicin | 0,24 g | 16,74 | P | Belupo d.d. | Belupo | Gentamicin Belupo | amp. 10x120 mg | 8,37 | 83,70 |  | 5% |
| J01GB03 032 | PO | gentamicin | 0,24 g | 18,70 | P | KRKA-FARMA d.o.o. | Krka d.d. | Garamycin | amp. 10x80 mg | 6,23 | 62,32 |  | 5% |
| J01GB03 033 | PO | gentamicin | 0,24 g | 16,74 | P | KRKA-FARMA d.o.o. | Krka d.d. | Garamycin | amp. 10x120 mg | 8,37 | 83,70 |  | 5% |
| J01GB06 051 | DS | amikacinNJ101 | 1 g |  | P |  |  |  |  |  |  |  | 5% |
| J01GB07 051 | DS | netilmicin | 0,35 g |  | P |  |  |  |  |  |  |  | 5% |
| J01MA01 052 | DS | ofloksacin | 0,4 g |  | P |  |  |  |  |  |  |  | 5% |
| J01MA02 022 | DS | ciprofloksacinNJ105 | 0.8 g | 179,57 | P | Sandoz d.o.o. | Sandoz-Salutas | Ciprofloksacin Lek | otop. za inf., boč. stakl. 5x200 mg/100 ml | 44,89 | 224,46 |  | 5% |
| J01MA02 031 | DS | ciprofloksacinNJ105 | 0.8 g | 179,56 | P | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | boč. inf. 1x200 mg/100 ml | 44,89 | 44,89 |  | 5% |
| J01MA02 033 | DS | ciprofloksacinNJ105 | 0.8 g | 165,65 | P | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | boč. inf. 5x10 ml (100 mg/10 ml) | 20,71 | 103,53 |  | 5% |
| J01MA02 034 | DS | ciprofloksacinNJ105 | 0.8 g | 161,62 | P | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | boč. inf. 1x400 mg/200 ml | 80,81 | 80,81 |  | 5% |
| J01MA02 061 | DS | ciprofloksacinNJ105 | 0.8 g | 165,65 | P | Alkaloid d.o.o. | Alkaloid | Citeral | konc. otop. za inf., amp. 5x10 ml (100 mg/10 ml) | 20,71 | 103,53 |  | 5% |
| J01MA02 066 | DS | ciprofloksacin NJ105 | 0.8 g | 161,60 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ciprofloxacin Kabi | otop. za inf., boč. 1x200 mg/100 ml | 40,40 | 40,40 |  | 5% |
| J01MA02 067 | DS | ciprofloksacin NJ105 | 0.8 g | 145,44 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ciprofloxacin Kabi | otop. za inf., boč. 10x200 mg/100 ml | 36,36 | 363,60 |  | 5% |
| J01MA02 068 | DS | ciprofloksacin NJ105 | 0.8 g | 145,46 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ciprofloxacin Kabi | otop. za inf., boč. 1x400 mg/200 ml | 72,73 | 72,73 |  | 5% |
| J01MA02 069 | DS | ciprofloksacin NJ105 | 0.8 g | 130,91 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ciprofloxacin Kabi | otop. za inf., boč. 10x400 mg/200 ml | 65,46 | 654,57 |  | 5% |
| J01MA02 102 |  | ciprofloksacin | 1 g | 8,55 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Cipromed | tbl. 10x500 mg | 4,27 | 42,73 | RSRV03 | 5% |
| J01MA02 111 |  | ciprofloksacin | 1 g | 8,03 | O | Belupo d.d. | Belupo | Ciflox | tbl. film obl. 10x250 mg | 2,01 | 20,07 | RSRV03 | 5% |
| J01MA02 112 |  | ciprofloksacin | 1 g | 8,55 | O | Belupo d.d. | Belupo | Ciflox | tbl. film obl. 10x500 mg | 4,27 | 42,73 | RSRV03 | 5% |
| J01MA02 116 |  | ciprofloksacin | 1 g | 8,55 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ciprofloksacin JGL | tbl. film obl. 10x500 mg | 4,27 | 42,73 | RSRV03 | 5% |
| J01MA02 122 |  | ciprofloksacin | 1 g | 8,55 | O | Sandoz d.o.o. | Sandoz-Salutas | Ciprofloksacin Sandoz | tbl. film obl. 10x500 mg | 4,27 | 42,73 | RSRV03 | 5% |
| J01MA02 131 |  | ciprofloksacin | 1 g | 8,03 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | tbl. 10x250 mg | 2,01 | 20,07 | RSRV03 | 5% |
| J01MA02 132 |  | ciprofloksacin | 1 g | 8,55 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | tbl. 10x500 mg | 4,27 | 42,73 | RSRV03 | 5% |
| J01MA02 161 |  | ciprofloksacin | 1 g | 8,03 | O | Alkaloid d.o.o. | Alkaloid | Citeral | tbl. 10x250 mg | 2,01 | 20,07 | RSRV03 | 5% |
| J01MA02 162 |  | ciprofloksacin | 1 g | 8,55 | O | Alkaloid d.o.o. | Alkaloid | Citeral | tbl. 10x500 mg | 4,27 | 42,73 | RSRV03 | 5% |
| J01MA03 051 | DS | pefloksacin | 0,8 mg |  | P |  |  |  |  |  |  |  | 5% |
| J01MA03 151 | DS | pefloksacin | 0,8 mg |  | O |  |  |  |  |  |  |  | 5% |
| J01MA06 111 |  | norfloksacin | 0,8 g | 3,07 | O | Belupo d.d. | Belupo | Noflox | tbl. film obl. 20x400 mg | 1,54 | 30,70 | RRJ14 | 5% |
| J01MA06 134 |  | norfloksacin | 0,8 g | 3,07 | O | KRKA-FARMA d.o.o. | Krka d.d. | Nolicin | tbl. 20x400 mg | 1,54 | 30,70 | RRJ14 | 5% |
| J01MA06 161 |  | norfloksacin | 0,8 g | 3,07 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Trizolin URO | tbl. film obl. 20x400 mg | 1,54 | 30,70 | RRJ14 | 5% |
| J01MA12 021 | DS | levofloksacinNJ105 | 0,5 g | 132,53 | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Levofloksacin Sandoz | otop. za inf., vreć. 1x100 ml (5 mg/ml) | 132,53 | 132,53 |  | 5% |
| J01MA12 031 | DS | levofloksacinNJ105 | 0,5 g | 92,77 | P | KRKA-FARMA d.o.o. | Pharmathen S.A., Krka d.d., Anfarm Hellas S.A. | Levalox | otop. za inf., boč. 1x100 ml (5 mg/ml) | 92,77 | 92,77 |  | 5% |
| J01MA12 032 | DS | levofloksacinNJ105 | 0,5 g | 92,77 | P | KRKA-FARMA d.o.o. | Pharmathen S.A., Krka d.d., Anfarm Hellas S.A. | Levalox | otop. za inf., boč. 5x100 ml (5 mg/ml) | 92,77 | 463,85 |  | 5% |
| J01MA12 132 |  | levofloksacin | 0,5 g | 5,26 | O | KRKA-FARMA d.o.o. | Pharmathen S.A., Krka d.d. | Levalox | tbl. film obl. 10x500 mg | 5,26 | 52,60 | RSRJ15 | 5% |
| J01MA12 133 |  | levofloksacin | 0,5 g | 5,26 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Fovelid | tbl. film obl. 10x500 mg | 5,26 | 52,60 | RSRJ15 | 5% |
| J01MA14 031 | DS | moksifloksacinNJ105 | 400 mg | 109,40 | P | KRKA-FARMA d.o.o. | Krka dd, TAD Pharma GmbH | Moloxin | otop. za inf., boca 1x400 mg/250 ml | 109,40 | 109,40 |  | 5% |
| J01MA14 044 | DS | moksifloksacinNJ105 | 400 mg | 121,56 | P | PharmaS d.o.o. | Pharmathen S.A. | Moksifloksacin PharmaS | otop. za inf., boč. 1x400 mg/250 ml | 121,56 | 121,56 |  | 5% |
| J01MA14 061 | DS | moksifloksacinNJ105 | 400 mg | 121,56 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Moxifloxacin Kabi | otop. za inf., boč. (KabiPac) 10x400 mg/250 ml | 121,56 | 1.215,60 |  | 5% |
| J01MA14 072 | DS | moksifloksacinNJ105 | 400 mg | 103,93 | P | Zentiva k.s. | Pharmathen S.A. | Moksifloksacin Zentiva | otop. za inf., boč. 1x400 mg/250 ml | 103,93 | 103,93 |  | 5% |
| J01MA14 131 |  | moksifloksacin | 0,4 g | 5,26 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH, KRKA-FARMA d.o.o. | Moloxin | tbl. film obl. 5x400 mg | 5,26 | 26,30 | RSRJ16 | 5% |
| J01MA14 132 |  | moksifloksacin | 0,4 g | 5,26 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH, KRKA-FARMA d.o.o. | Moloxin | tbl. film obl. 7x400 mg | 5,26 | 36,82 | RSRJ16 | 5% |
| J01XA01 021 | DS | vankomicinNJ101 | 2 g | 178,20 | P | Sandoz d.o.o. | Sandoz-Lek | Edicin | boč. 1x500 mg | 44,55 | 44,55 |  | 5% |
| J01XA01 022 | DS | vankomicinNJ101 | 2 g | 165,44 | P | Sandoz d.o.o. | Sandoz-Lek | Edicin | boč. 1x1.000 mg | 82,72 | 82,72 |  | 5% |
| J01XA01 071 | DS | vankomicinNJ101 | 2 g | 101,04 | P | Fresenius Kabi d.o.o. | Xellia Pharmaceuticals ApS | Vancomycin Kabi | praš. za konc. za otop. za inf., boč. stakl. 1x500 mg | 25,26 | 25,26 |  | 5% |
| J01XA01 072 | DS | vankomicinNJ101 | 2 g | 93,80 | P | Fresenius Kabi d.o.o. | Xellia Pharmaceuticals ApS | Vancomycin Kabi | praš. za konc. za otop. za inf., boč. stakl. 1x1000 mg | 46,90 | 46,90 |  | 5% |
| J01XA01 081 | DS | vankomicinNJ101 | 2 g | 95,99 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-Pharm. Fabrik GmbH | Vankomicin MIP 500 mg | praš. za otop. za inf., boč. 5x500 mg | 24,00 | 119,99 |  | 5% |
| J01XA01 082 | DS | vankomicinNJ101 | 2 g | 89,11 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-Pharm. Fabrik GmbH | Vankomicin MIP 1000 mg | praš. za otop. za inf., boč. 5x1000 mg | 44,56 | 222,78 |  | 5% |
| J01XA01 083 | DS | vankomicinNJ101 | 2 g | 91,20 | P | Apta Medica International d.o.o. | Laboratorio Reig Jofre S.A. | Vankomicin AptaPharma | praš. za otop. za inf., boč. 10x500 mg | 22,80 | 228,00 |  | 5% |
| J01XA01 084 | DS | vankomicinNJ101 | 2 g | 84,66 | P | Apta Medica International d.o.o. | Laboratorio Reig Jofre S.A. | Vankomicin AptaPharma | praš. za otop. za inf., boč. 10x1000 mg | 42,33 | 423,32 |  | 5% |
| J01XA01 151 | DS | vankomicinNJ101 | 2 g |  | O |  |  |  |  |  |  |  | 5% |
| J01XA02 061 | DS | teikoplaninNJ101 | 0,4g | 259,42 | P | sanofi-aventis groupe | Gruppo Lepetit | Targocid | boč. 1x200 mg + otap. | 129,71 | 129,71 |  | 5% |
| J01XA02 062 | DS | teikoplaninNJ101 | 0,4g | 254,50 | P | sanofi-aventis groupe | Gruppo Lepetit | Targocid | boč. 1x400 mg + otap. | 254,50 | 254,50 |  | 5% |
| J01XB01 001 | DS | kolistimetat-natrijNJ104 | 3 MU | 234,71 | I | Teva B.V. | Penn Pharmaceutical Services Ltd, Forest-Tosara Ltd | Colobreathe | praš. za inh., caps. tvrda 56x125 mg (1,662,500 IU) + inhalator Turbospin | 130,07 | 7.283,76 |  | 5% |
| J01XB01 071 | DS | kolistinNJ101 | 9 MU | 399,15 | P | Altamedics d.o.o. | Xellia Pharmaceuticals ApS | Colixin | praš. za otop. za inj./inf., boč. stakl. 30x1.000.000 IU (80 mg) | 44,35 | 1.330,50 |  | 5% |
| J01XB01 072 | DS | kolistinNJ101 | 9 MU | 399,15 | P | Zentiva k.s. | Xellia Pharmaceuticals ApS | Kolistin Zentiva | praš. za otop. za inj., inf. ili inh., boč. 10x1.000.000 IU (80 mg) | 44,35 | 443,50 |  | 5% |
| J01XB01 073 | DS | kolistinNJ101 | 9 MU | 399,15 | P | Zentiva k.s. | Xellia Pharmaceuticals ApS | Kolistin Zentiva | praš. za otop. za inj., inf. ili inh., boč. 10x2.000.000 IU (160 mg) | 88,70 | 887,00 |  | 5% |
| J01XB01 074 | DS | kolistinNJ101 | 9 MU | 379,19 | P | Altamedics d.o.o. | Xellia Pharmaceuticals ApS | Colixin | praš. za otop. za inj./inf., boč. stakl. 30x2.000.000 IU (160 mg) | 84,27 | 2.527,95 |  | 5% |
| J01XD01 031 | DS | metronidazol | 1,5 g | 49,35 | P | KRKA-FARMA d.o.o. | Krka d.d. | Efloran | boč. inf. 0,5% 100 ml | 16,45 | 16,45 |  | 5% |
| J01XD01 065 | DS | metronidazol | 1.5 g | 36,54 | P | B. Braun Adria d.o.o. | Braun Melsungen AG, Braun Medical S.A. | Metronidazol B. Braun 5 mg/ml | otop. za inf., 5 mg/ml, polietil. Ecoflac plus boca, 20x100 ml | 12,18 | 243,60 |  | 5% |
| J01XD01 071 | DS | metronidazol | 1.5 g | 39,99 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Metronidazol Fresenius | otop. za inf., boč. plast. (KabiPac) 10x100 ml (5 mg/ml) | 13,33 | 133,29 |  | 5% |
| J01XE01 111 |  | nitrofurantoin | 0,2 g | 4,92 | O | Belupo d.d. | Belupo | Ninur | caps. 30x50 mg | 1,23 | 36,90 | R | 5% |
| J01XE01 171 |  | nitrofurantoin | 0,2 g | 3,44 | O | Mylan Ireland Limited | IASIS Pharmaceticals Hellas S.A. | Prevuro | caps. 30x50 mg | 0,86 | 25,83 | R | 5% |
| J01XX01 051 | DS | fosfomicinNJ101 | 8 g |  | P |  |  |  |  |  |  |  | 5% |
| J01XX08 041 | DS | linezolidNJ106 | 1,2 g | 302,04 | P | KRKA-FARMA d.o.o. | Krka d.d. | Linezolid Krka | otop. za inf., vreć. 1x600 mg/300 ml | 151,02 | 151,02 |  | 5% |
| J01XX08 060 | DS | linezolidNJ106 | 1,2 g | 372,89 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Linezolid Kabi | otop. za inf., vreć. 10x600 mg/300 ml | 186,45 | 1.864,46 |  | 5% |
| J01XX08 061 | DS | linezolidNJ106 | 1,2 g | 372,89 | P | Pfizer Croatia d.o.o. | Fresenius Kabi | Zyvoxid | otop. za inf., vreć. plast. 10x600 mg/300 ml | 186,45 | 1.864,46 |  | 5% |
| J01XX08 062 | DS | linezolidNJ106 | 1,2 g | 372,90 | P | Sandoz d.o.o. | Synthon Hispania S.L., Synthon BV | Linezolid Sandoz | otop. za inf., vreć. 1x600 mg/300 ml | 186,45 | 186,45 |  | 5% |
| J01XX08 063 | DS | linezolidNJ106 | 1,2 g | 372,89 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Linezolid Kabi | otop. za inf., boč. 10x600 mg/300 ml | 186,45 | 1.864,46 |  | 5% |
| J01XX08 091 | DS | linezolidNJ106 | 1,2 g | 271,84 | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Demo S.A. Pharmaceutical Industry | Linezolid Accord | otop. za inf., vreć. plast. 10x600 mg/300 ml | 135,92 | 1.359,20 |  | 5% |
| J01XX08 101 | DS | linezolidNJ106 | 1,2 g | 458,43 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Linezolid Pliva | tbl. film obl. 10x600 mg | 229,21 | 2.292,14 |  | 5% |
| J01XX08 121 | DS | linezolidNJ106 | 1,2 g | 492,07 | O | Sandoz d.o.o. | Sandoz | Lynz | tbl. film obl. 10x600 mg | 246,04 | 2.460,37 |  | 5% |
| J01XX08 131 | DS | linezolidNJ106 | 1,2 g | 412,58 | O | KRKA-FARMA d.o.o. | Krka dd, TAD Pharma GmbH | Linezolid Krka | tbl. film obl. 10x600 mg | 206,29 | 2.062,89 |  | 5% |
| J01XX08 161 | DS | linezolidNJ106 | 1,2 g | 492,07 | O | Pfizer Croatia d.o.o. | Pharmacia & Upjohn | Zyvoxid | tbl. film obl. 10x600 mg | 246,04 | 2.460,37 |  | 5% |
| J02AA01 051 | DS | amfotericin B | 35 mg |  | P |  |  |  |  |  |  |  | 5% |
| J02AC01 066 | DS | flukonazol | 0,2 g | 60,98 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Flukonazol Kabi | otop. za inf., boč. 10x100 ml (2 mg/ml) | 60,98 | 609,79 |  | 5% |
| J02AC01 113 |  | flukonazol | 0,2 g | 9,90 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Fluconax | caps. 7x100 mg | 4,95 | 34,65 | R | 5% |
| J02AC01 114 |  | flukonazol | 0,2 g | 22,87 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Fluconax | caps. 1x150 mg | 17,15 | 17,15 | R | 5% |
| J02AC01 161 |  | flukonazol | 0,2 g | 10,03 | O | Pfizer Croatia d.o.o. | Pfizer | Diflucan | caps. 7x50 mg | 2,51 | 17,55 | R | 5% |
| J02AC01 162 |  | flukonazol | 0,2 g | 9,90 | O | Pfizer Croatia d.o.o. | Pfizer | Diflucan | caps. 7x100 mg | 4,95 | 34,65 | R | 5% |
| J02AC01 163 |  | flukonazol | 0,2 g | 22,87 | O | Pfizer Croatia d.o.o. | Pfizer | Diflucan | caps. 1x150 mg | 17,15 | 17,15 | R | 5% |
| J02AC01 205 |  | flukonazol | 0,2 g | 36,11 | O | Pfizer Croatia d.o.o. | Pfizer | Diflucan | sirup 1x35 ml (50 mg/5 ml) | 63,20 | 63,20 | R | 5% |
| J02AC02 131 |  | itrakonazol | 0,2 g | 10,51 | O | Belupo d.d. | Belupo | Itrac 3 | caps. 4x100 mg | 5,25 | 21,01 | R | 5% |
| J02AC02 132 |  | itrakonazol | 0,2 g | 9,90 | O | Belupo d.d. | Belupo | Itrac 3 | caps. 28x100 mg | 4,95 | 138,60 | R | 5% |
| J02AC03 041 | DS | vorikonazolNJ201 | 0,4 g | 1.164,10 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Vorikonazol Pliva | praš. za otop. za inf., boč. 1x200 mg | 582,05 | 582,05 |  | 5% |
| J02AC03 042 | DS | vorikonazolNJ201 | 0,4 g | 1.164,10 | P | PharmaS d.o.o. | Anfarm Hellas S.A., Pharmathen S.A. | Vorikonazol PharmaS | praš. za otop. za inf., boč. 1x200 mg | 582,05 | 582,05 |  | 5% |
| J02AC03 061 | DS | vorikonazolNJ201 | 0,4 g | 1.164,10 | P | Pfizer Europe MA EEIG | Pfizer | Vfend | praš. za otop. za inf. boč. 1x200 mg/20 ml (10 mg/1ml) | 582,05 | 582,05 |  | 5% |
| J02AC03 071 | DS | vorikonazolNJ201 | 0,4 g | 1.047,70 | P | Zentiva k.s. | Anfarm Hellas S.A., Pharmathen S.A., Pharmathen International S.A. | Voramol | praš. za otop. za inf., boč. 1x200 mg/20 ml (10 mg/ml) | 523,85 | 523,85 |  | 5% |
| J02AC03 081 | DS | vorikonazolNJ201 | 0,4 g | 942,94 | P | Fresenius Kabi d.o.o. | Fresenius Kabi Deutschland GmbH | Vorikonazol Fresenius Kabi | praš. za otop. za inf., boč. 1x200 mg | 471,47 | 471,47 |  | 5% |
| J02AC03 101 | DS | vorikonazolNJ201 | 0,4 g | 293,78 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Vorikonazol Pliva | tbl. film obl. 28x200 mg | 146,89 | 4.112,92 |  | 5% |
| J02AC03 131 | DS | vorikonazolNJ201 | 0,4 g | 264,40 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Vorikonazol Accord | tbl. film obl. 28x200 mg | 132,20 | 3.701,63 |  | 5% |
| J02AC03 142 | DS | vorikonazolNJ201 | 0,4 g | 237,96 | O | Medochemie Ltd. | Medochemie Ltd. | Verria | tbl. film obl. 28x200 mg | 118,98 | 3.331,47 |  | 5% |
| J02AC03 161 | DS | vorikonazolNJ201 | 0,4 g | 268,40 | O | Pfizer Europe MA EEIG | Pfizer | Vfend | tbl. film obl. 28x50 mg | 33,55 | 939,40 |  | 5% |
| J02AC03 162 | DS | vorikonazolNJ201 | 0,4 g | 293,78 | O | Pfizer Europe MA EEIG | Pfizer | Vfend | tbl. film obl. 28x200 mg | 146,89 | 4.112,92 |  | 5% |
| J02AC03 171 | DS | vorikonazolNJ201 | 0,4 g | 293,78 | O | Zentiva k.s. | Pharmathen S.A., Pharmathen International S.A. | Voramol | tbl. film obl. 30x200 mg | 146,89 | 4.406,70 |  | 5% |
| J02AC03 361 | DS | vorikonazolNJ201 | 0,4 g | 518,16 | O | Pfizer Europe MA EEIG | Pfizer | Vfend | praš. za oral. susp. 1x70 ml (40 mg/ml) | 3.627,12 | 3.627,12 |  | 5% |
| J02AC04 101 | KS | posakonazolNJ202 | 0,3 g | 408,26 | O | Teva B.V. | Delorbis Pharmaceuticals Ltd | Posakonazol Teva | tbl. žel. otp. 24x100 mg | 136,09 | 3.266,10 |  | 5% |
| J02AC04 141 | KS | posakonazolNJ202 | 0,3 g | 408,26 | O | Mylan Pharmaceuticals Limited | Medis International A.S., Delorbis Pharmaceuticals Ltd | Posakonazol Mylan | tbl. žel. otp. 24x100 mg | 136,09 | 3.266,10 |  | 5% |
| J02AC04 171 | KS | posakonazolNJ202 | 0,3 g | 450,95 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Delorbis Pharmaceutical Ltd. | Posakonazol Accord | tbl. žel. otp. 24x100 mg | 150,32 | 3.607,60 |  | 5% |
| J02AC04 172 | KS | posakonazolNJ202 | 0,3 g | 387,85 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Delorbis Pharmaceuticals Ltd. | Posakonazol Accord | tbl. žel. otp. 96x100 mg | 129,28 | 12.411,18 |  | 5% |
| J02AC04 181 | KS | posakonazolNJ202 | 0,3 g | 429,75 | O | Abdi Farma Unipessoal Ltd. | Interpharma Services Ltd. | Posakonazol Abdi | tbl. žel. otp. 24x100 mg | 143,25 | 3.438,00 |  | 5% |
| J02AC04 191 | KS | posakonazolNJ202 | 0,3 g | 429,75 | O | Zentiva k.s. | Delorbis Pharmaceuticals Ltd | Posakonazol Zentiva | tbl. žel. otp. 24x100 mg | 143,25 | 3.438,00 |  | 5% |
| J02AC04 192 | KS | posakonazolNJ202 | 0,3 g | 387,85 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Posakonazol STADA | tbl. žel. otp. 24x100 mg | 129,28 | 3.102,80 |  | 5% |
| J02AC04 361 | KS | posakonazolNJ202 | 0,3 g | 241,13 | O | Merck Sharp & Dohme B.V. | Schering – Plough | Noxafil | susp. oral., boč. stakl. 1x105 ml (40 mg/ml) | 3.375,75 | 3.375,75 |  | 5% |
| J02AC05 071 | DS | izavukonazolNJ719 | 0,2 g | 2.692,20 | P | Basilea Pharmaceutica Deutschland GmbH | Almac Pharma Services (Ireland) Limited | Cresemba | praš. za otop. za inf., boč. 1x200 mg | 2.692,20 | 2.692,20 |  | 5% |
| J02AC05 171 | DS | izavukonazolNJ719 | 0,2 g | 657,84 | O | Basilea Pharmaceutica Deutschland GmbH | Almac Pharma Services (Ireland) Limited | Cresemba | caps. tvrda 14x100 mg | 328,92 | 4.604,88 |  | 5% |
| J02AX04 011 | DS | kaspofunginNJ201 | 50 mg | 1.822,01 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kaspofungin Pliva | praš. za konc. za otop. za inf., boč. stakl. 1x50 mg | 1.822,01 | 1.822,01 |  | 5% |
| J02AX04 012 | DS | kaspofunginNJ201 | 50 mg | 1.942,33 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kaspofungin Pliva | praš. za konc. za otop. za inf., boč. stakl. 1x70 mg | 2.719,26 | 2.719,26 |  | 5% |
| J02AX04 041 | DS | kaspofunginNJ201 | 50 mg | 1.822,01 | P | PharmaS d.o.o. | Pharmadox Healthcare Ltd., Galenicum Health S.L. | Kaspofungin PharmaS | praš. za konc. za otop. za inf., boč. 1x50 mg | 1.822,01 | 1.822,01 |  | 5% |
| J02AX04 042 | DS | kaspofunginNJ201 | 50 mg | 1.475,82 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Xellia Pharmaceuticals ApS | Caspofungin Accord | praš. za konc. za otop. za inf., boč. 1x50 mg | 1.475,82 | 1.475,82 |  | 5% |
| J02AX04 071 | DS | kaspofunginNJ201 | 50 mg | 1.639,81 | P | Zentiva k.s. | Pharmaten S.A., Pharmadox Healthcare Ltd | Dalvocans | praš. za konc. za otop. za inf., boč. stakl. 1x50 mg | 1.639,81 | 1.639,81 |  | 5% |
| J02AX04 072 | DS | kaspofunginNJ201 | 50 mg | 1.942,33 | P | Zentiva k.s. | Pharmaten S.A., Pharmadox Healthcare Ltd | Dalvocans | praš. za konc. za otop. za inf., boč. stakl. 1x70 mg | 2.719,26 | 2.719,26 |  | 5% |
| J02AX04 082 | DS | kaspofunginNJ201 | 50 mg | 1.942,33 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Xellia Pharmaceuticals ApS | Caspofungin Accord | praš. za konc. za otop. za inf., boč. 1x70 mg | 2.719,26 | 2.719,26 |  | 5% |
| J02AX05 001 | DS | mikafunginNJ201 | 0,1 g | 2.211,48 | P | Teva B.V. | S.C. Sindan-Pharma S.R.L. | Mikafungin Teva | praš. za otop. za inf., boč. stakl. 1x50 mg | 1.105,74 | 1.105,74 |  | 5% |
| J02AX05 002 | DS | mikafunginNJ201 | 0,1 g | 1.996,77 | P | Teva B.V. | S.C. Sindan-Pharma S.R.L. | Mikafungin Teva | praš. za otop. za inf., boč. stakl. 1x100 mg | 1.996,77 | 1.996,77 |  | 5% |
| J02AX05 021 | DS | mikafunginNJ201 | 0,1 g | 2.211,48 | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Mikafungin Sandoz | praš. za otop. za inf., boč. stakl. 1x50 mg | 1.105,74 | 1.105,74 |  | 5% |
| J02AX05 022 | DS | mikafunginNJ201 | 0,1 g | 1.896,93 | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Mikafungin Sandoz | praš. za otop. za inf., boč. stakl. 1x100 mg | 1.896,93 | 1.896,93 |  | 5% |
| J02AX05 061 | DS | mikafunginNJ201 | 0,1 g | 2.211,48 | P | Astellas Pharma Europe B.V. | Astellas Ireland Co. Ltd | Mycamine | praš. za otop. za inf., boč. stakl. 1x50 mg | 1.105,74 | 1.105,74 |  | 5% |
| J02AX05 062 | DS | mikafunginNJ201 | 0,1 g | 2.453,53 | P | Astellas Pharma Europe B.V. | Astellas Ireland Co. Ltd | Mycamine | praš. za otop. za inf., boč. stakl. 1x100 mg | 2.453,53 | 2.453,53 |  | 5% |
| J02AX06 001 | DS | anidulafunginNJ201 | 0,1 g | 1.997,28 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Anidulafungin Pliva | praš. i otap. za konc. za otop. za inf., boč. 1×100 mg | 1.997,28 | 1.997,28 |  | 5% |
| J02AX06 041 | DS | anidulafunginNJ201 | 0,1 g | 1.897,42 | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Anidulafungin Accord | praš. za konc. za otop. za inf., stakl. boč. 1×100 mg | 1.897,42 | 1.897,42 |  | 5% |
| J02AX06 061 | DS | anidulafunginNJ201 | 0,1 g | 74,60 | P | Pfizer Europe MA EEIG | Pfizer | Ecalta | praš. i otap. za konc. za otop. za inf., boč. 1×100 mg/30 ml | 2.238,10 | 2.238,10 |  | 5% |
| J02AX06 071 | DS | anidulafunginNJ201 | 0,1 g | 1.802,55 | P | Fresenius Kabi d.o.o. | Laboratori Fundacio Dau | Anidulafungin Fresenius Kabi | praš. za konc. za otop. za inf., stakl. boč. 1×100 mg | 1.802,55 | 1.802,55 |  | 5% |
| J04AB02 051 | DS | rifampicin | 0,6 g |  | P |  |  |  |  |  |  |  | 5% |
| J04AB02 101 |  | rifampicin | 0,6 g | 6,36 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Rimactan | caps. 16x300 mg | 3,18 | 50,88 | R | 5% |
| J04AB02 102 |  | rifampicin | 0,6 g | 5,90 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Rimactan | caps. 100x300 mg | 2,95 | 295,00 | R | 5% |
| J04AB04 151 | DS | rifabutinNJ401 | 0,15 g |  | O |  |  |  |  |  |  |  | 5% |
| J04AC51 052 | DS | izoniazid + piridoksin |  |  | P |  |  |  |  |  |  |  | 5% |
| J04AC51 151 |  | izoniazid + piridoksin |  |  | O |  |  |  |  |  |  | R | 5% |
| J04AD01 151 | DS | protionamidNJ401 | 0,75 g |  | O |  |  |  |  |  |  |  | 5% |
| J04AK01 131 |  | pirazinamid | 1,5 g | 5,53 | O | KRKA-FARMA d.o.o. | Krka d.d. | Pyrazinamid | tbl. 100x500 mg | 1,84 | 184,33 | R | 5% |
| J04AK02 051 | DS | etambutol | 1,2 g |  | P |  |  |  |  |  |  |  | 5% |
| J04AK02 151 |  | etambutol | 1,2 g |  | O |  |  |  |  |  |  | R | 5% |
| J05AB01 032 | DS | aciklovir | 4 g | 858,34 | P | KRKA-FARMA d.o.o. | Krka d.d. | Virolex | boč. inf. 5x250 mg | 53,65 | 268,23 |  | 5% |
| J05AB01 071 | DS | aciklovir | 4 g | 617,44 | P | ALPHA-MEDICAL d.o.o. | Laboratorio Reig Jofre S.A., Alpha-Medical d.o.o. | Aciklovir Alpha-Medical | boč. inf. 5x250 mg | 38,59 | 192,95 |  | 5% |
| J05AB01 113 |  | aciklovir | 4 g | 37,70 | O | Belupo d.d. | Belupo | Herplexim | tbl. film obl. 35x400 mg | 3,77 | 131,95 | R | 5% |
| J05AB01 131 |  | aciklovir | 4 g | 54,60 | O | KRKA-FARMA d.o.o. | Krka d.d. | Virolex | tbl. film obl. 20x200 mg | 2,73 | 54,60 | R | 5% |
| J05AB06 071 | KS | ganciklovir | 0,5 g | 225,94 | P | Cheplapharm Arzneimittel GmbH | Cheplapharm Arzneimittel GmbH, Prestige Promotion Verkaufsförderung & Werbeservice GmbH | Cymevene | boč. 1x500 mg/10 ml | 225,94 | 225,94 |  | 5% |
| J05AB14 101 |  | valganciklovir | 0,9 g | 166,24 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Valganciklovir Pliva | tbl. film obl. 60x450 mg | 83,12 | 4.987,20 | RRJ51 | 5% |
| J05AB14 181 |  | valganciklovir | 0,9 g | 166,24 | O | Zentiva k.s. | Pharmadox Healthcare Ltd., SC Labormed – Pharma SA | Alvanocyt | tbl. film obl. 60x450 mg | 83,12 | 4.987,20 | RRJ51 | 5% |
| J05AB14 182 |  | valganciklovir | 0,9 g | 150,90 | O | STADA d.o.o. | Stada Arzneimittel AG, Pharmadox Healthcare Ltd, Centrafarm Services BV | Valganciklovir Stada | tbl. film obl. 60x450 mg | 75,45 | 4.527,07 | RRJ51 | 5% |
| J05AE03 151 | KL | ritonavirNJ501 | 1,2 g |  | O |  |  |  |  |  |  |  | 5% |
| J05AE10 121 | KL | darunavirNJ501 | 1,2 g | 88,21 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d., Salutas Pharma GmbH | Darunavir Sandoz | tbl. film obl. 30x800 mg | 58,80 | 1.764,10 |  | 5% |
| J05AE10 131 | KL | darunavirNJ501 | 1,2 g | 81,57 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma Gmbh | Darunavir Krka | tbl. film obl. 30x800 mg | 54,38 | 1.631,34 |  | 5% |
| J05AE10 141 | KL | darunavirNJ501 | 1,2 g | 77,49 | O | Accord Healthcare Polska Sp. z o.o. | Pharmathen International S.A. | Darunavir Accord | tbl. film obl. 30x800 mg | 51,66 | 1.549,77 |  | 5% |
| J05AF01 252 | KL | zidovudinNJ501 | 0,6 g |  | O |  |  |  |  |  |  |  | 5% |
| J05AF05 101 | KL | lamivudinNJ501 | 0,3 g | 17,28 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, TEVA UK Ltd | Lamivudin Teva Pharma B.V. | tbl. film obl. 30x300 mg | 17,28 | 518,40 |  | 5% |
| J05AF05 161 | KL | lamivudinNJ501 | 0,3 g | 16,93 | O | ViiV Healthcare B.V. | Glaxo Operations UK Ltd., GlaxoSmithKline Pharmaceuticals S.A. | Epivir | tbl. film obl. 60x150 mg | 8,47 | 508,00 |  | 5% |
| J05AF05 163 | DS | lamivudinNJ503 | 0,3 g | 33,77 | O | GlaxoSmithKline (Ireland) Limited | GlaxoWellcome Operations UK Limited, GlaxoSmithKline Pharmaceuticals S.A. | Zeffix | tbl. film obl. 28x100 mg | 11,26 | 315,19 |  | 5% |
| J05AF05 165 | DS | lamivudinNJ503 | 0,3 g | 24,95 | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Lamivudin Alpha-Medical | tbl. film obl. 28x100 mg | 8,32 | 232,91 |  | 5% |
| J05AF05 262 | KL | lamivudinNJ501 | 0,3 g | 22,67 | O | ViiV Healthcare B.V. | Aspen Bad Oldesloe GmbH, Glaxo Operations UK Ltd | Epivir | otop. za oral. primj. 240 ml (10 mg/1 ml) | 181,33 | 181,33 |  | 5% |
| J05AF06 161 | KL | abakavirNJ501 | 0,6 g | 48,03 | O | ViiV Healthcare B.V. | Glaxo Operations UK Ltd., GlaxoSmithKline Pharmaceuticals S.A. | Ziagen | tbl. film obl. 60x300 mg | 24,01 | 1.440,80 |  | 5% |
| J05AF07 101 | DS | tenofovirNJ504 | 0,245 g | 36,93 | O | PLIVA HRVATSKA d.o.o. | Teva Pharmaceutical Works, Teva UK Ltd., Pharmachemie B.V., Teva Operations, Merckle GmbH, Teva Pharma B.V. | Tenofovirdizoproksil Pliva | tbl. film obl. 30x245 mg | 36,93 | 1.107,90 |  | 5% |
| J05AF07 161 | DS | tenofovirNJ504 | 0,245 g | 36,93 | O | Gilead Sciences Ireland UC | Nycomed, Gilead | Viread | tbl. film obl. 30x245 mg | 36,93 | 1.107,90 |  | 5% |
| J05AF07 171 | DS | tenofovirNJ504 | 0,245 g | 36,93 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Tenofovirdizoproksil Alpha-Medical | tbl. film obl. 30x245 mg | 36,93 | 1.107,90 |  | 5% |
| J05AF07 181 | DS | tenofovirNJ504 | 0,245 g | 36,93 | O | Mylan Pharmaceuticals Limited | McDermott Laboratories Limited, Mylan Hungary Kft | Tenofovirdizoproksil Mylan | tbl. film obl. 30x245 mg | 36,93 | 1.107,90 |  | 5% |
| J05AF10 171 | DS | entekavirNJ510 | 0,5 mg | 40,96 | O | Mylan Pharmaceuticals Limited | Mylan Hungary Kft., McDermott Laboratories Limited trading as Gerard Laboratories | Entekavir Mylan | tbl. film obl. 30x0,5 mg | 40,96 | 1.228,90 |  | 5% |
| J05AF10 172 | DS | entekavirNJ510 | 0,5 mg | 20,48 | O | Mylan Pharmaceuticals Limited | Mylan Hungary Kft., McDermott Laboratories Limited trading as Gerard Laboratories | Entekavir Mylan | tbl. film obl. 30x1 mg | 40,96 | 1.228,90 |  | 5% |
| J05AF10 181 | DS | entekavirNJ510 | 0,5 mg | 28,67 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Entekavir Accord | tbl. film obl. 30x0,5 mg | 28,67 | 860,10 |  | 5% |
| J05AF10 182 | DS | entekavirNJ510 | 0,5 mg | 14,34 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Entekavir Accord | tbl. film obl. 30x1 mg | 28,67 | 860,10 |  | 5% |
| J05AF13 161 | DS | tenofovir alafenamidNJ511 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Vemlidy | tbl. film obl. 30x25 mg | 72,40 | 2.171,90 |  | 5% |
| J05AG01 171 | KL | nevirapinNJ501 | 0,4 g | 18,90 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Viramune | tbl. 60x200 mg | 9,45 | 567,00 |  | 5% |
| J05AG03 101 | KL | efavirenzNJ501 | 0,6 g | 30,75 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Efavirenz Teva | tbl. film obl. 30x600 mg | 30,75 | 922,60 |  | 5% |
| J05AG03 171 | KL | efavirenzNJ501 | 0,6 g | 30,75 | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Ltd. | Efavirenz Alpha-Medical | tbl. film obl. 30x600 mg | 30,75 | 922,60 |  | 5% |
| J05AG24 161 | KL | doravirin + lamivudin + tenofovir dizoproksilNJ501 |  |  | O | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme B.V. | Delstrigo | tbl. film obl. 30 x (100 mg + 300 mg + 245 mg) | 145,56 | 4.366,90 |  | 5% |
| J05AH01 771 | DS | zanamivirNJ506 | 20 mg | 22,99 | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Limited | Relenza | praš. za inhal. 20x5 mg (5 rotadisk blist. po 4 doze + diskhaler) | 5,75 | 114,93 |  | 5% |
| J05AH02 101 |  | oseltamivir | 0,15 g | 25,33 | O | ACTAVIS GROUP PTC ehf. | Balkanpharma-Dupnitsa AD | Ebilfumin | tvrde caps. 10x30 mg | 5,07 | 50,65 | R RJ52 | 5% |
| J05AH02 102 |  | oseltamivir | 0,15 g | 23,22 | O | ACTAVIS GROUP PTC ehf. | Balkanpharma-Dupnitsa AD | Ebilfumin | tvrde caps. 10x45 mg | 6,97 | 69,65 | R RJ52 | 5% |
| J05AH02 103 |  | oseltamivir | 0,15 g | 20,24 | O | ACTAVIS GROUP PTC ehf. | Balkanpharma-Dupnitsa AD | Ebilfumin | tvrde caps. 10x75 mg | 10,12 | 101,20 | R RJ52 | 5% |
| J05AH02 161 |  | oseltamivir | 0,15 g | 25,59 | O | Roche Registration GmbH | Roche | Tamiflu | caps. 10x75 mg | 12,79 | 127,93 | RRJ52 | 5% |
| J05AJ01 161 | KL | raltegravirNJ501 | 800 mg | 135,93 | O | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | Isentress | tbl. film obl. 60x400 mg | 67,97 | 4.078,00 |  | 5% |
| J05AJ01 162 | KL | raltegravirNJ501 | 800 mg | 90,62 | O | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | Isentress | tbl. film obl. 60x600 mg | 67,97 | 4.078,00 |  | 5% |
| J05AJ03 161 | KL | dolutegravirNJ501 | 50 mg | 144,60 | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A., GlaxoSmithKline Pharmaceuticals S.A. | Tivicay | tbl. film obl. 30x50 mg | 144,60 | 4.338,10 |  | 5% |
| J05AJ03 162 | KL | dolutegravirNJ501 | 50 mg | 140,75 | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A., GlaxoSmithKline Pharmaceuticals S.A. | Tivicay | tbl. film obl. 30x10 mg | 28,15 | 844,50 |  | 5% |
| J05AJ03 163 | KL | dolutegravirNJ501 | 50 mg | 139,85 | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A., GlaxoSmithKline Pharmaceuticals S.A. | Tivicay | tbl. film obl. 30x25 mg | 69,92 | 2.097,70 |  | 5% |
| J05AP51 161 | DS | ledipasvir + sofosbuvirNJ711 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ltd. | Harvoni | tbl. film obl. 28x(90 mg + 400 mg) | 3.991,85 | 111.771,89 |  | 5% |
| J05AP51 162 | DS | ledipasvir + sofosbuvirNJ711 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ltd. | Harvoni | tbl. film obl. 28x(90 mg + 400 mg) | 3.991,85 | 111.771,89 |  | 5% |
| J05AP54 161 | DS | elbasvir + grazoprevirNJ711 |  |  | O | Merck Sharp & Dohme B.V. | Schering-Plough Labo N.V. | Zepatier | tbl. film obl. 28x(50 mg + 100 mg) | 2.488,60 | 69.680,89 |  | 5% |
| J05AP54 162 | DS | elbasvir + grazoprevirNJ711 |  |  | O | Merck Sharp & Dohme B.V. | Schering-Plough Labo N.V. | Zepatier | tbl. film obl. 28x(50 mg + 100 mg) | 2.488,60 | 69.680,89 |  | 5% |
| J05AP55 161 | DS | sofosbuvir + velpatasvirNJ711 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Epclusa | tbl film obl. 28x(400 mg + 100 mg) | 2.977,31 | 83.364,68 |  | 5% |
| J05AP55 162 | DS | sofosbuvir + velpatasvirNJ711 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Epclusa | tbl film obl. 28x(400 mg + 100 mg) | 2.977,31 | 83.364,68 |  | 5% |
| J05AP56 161 | DS | sofosbuvir + velpatasvir + voksilaprevirNJ714 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Vosevi | tbl. film obl. 28x(400 mg + 100 mg + 100 mg) | 3.743,24 | 104.810,81 |  | 5% |
| J05AP57 161 | DS | glekaprevir + pibrentasvirNJ711 |  |  | O | AbbVie Deutschland GmbH & Co. KG | Abbvie Deutschland GmBH & Co. KG | Maviret | tbl. film obl. 84x(100 mg + 40 mg) | 1.139,88 | 95.749,64 |  | 5% |
| J05AP57 162 | DS | glekaprevir + pibrentasvirNJ711 |  |  | O | AbbVie Deutschland GmbH & Co. KG | Abbvie Deutschland GmBH & Co. KG | Maviret | tbl. film obl. 84x(100 mg + 40 mg) | 1.139,88 | 95.749,64 |  | 5% |
| J05AR02 001 | KL | abakavir + lamivudinNJ501 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Merckle GmbH | Abakavir/lamivudin Pliva | tbl. film obl. 30x(600 mg + 300 mg) | 37,64 | 1.129,10 |  | 5% |
| J05AR02 121 | KL | abakavir + lamivudinNJ501 |  |  | O | Sandoz d.o.o. | Lupin (Europe) Ltd | Abakavir/lamivudin Sandoz | tbl. film obl. 30x(600 mg + 300 mg) | 37,64 | 1.129,10 |  | 5% |
| J05AR02 171 | KL | abakavir + lamivudinNJ501 |  |  | O | Remedica Ltd. | Remedica Ltd. | Abakavir/Lamivudin Remedica | tbl. film obl. 30x(600 mg + 300 mg) | 37,64 | 1.129,10 |  | 5% |
| J05AR02 181 | KL | abakavir + lamivudinNJ501 |  |  | O | Mylan Pharmaceuticals Limited | Mylan S.A.S., Gerard Laboratories | Abakavir/Lamivudin Mylan | tbl. film obl. 30x(600 mg + 300 mg) | 37,64 | 1.129,10 |  | 5% |
| J05AR03 101 | KL | emtricitabin + tenofovir NJ501 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Emtricitabin/tenofovirdizoproksil Pliva | tbl. film obl. 30x(200 mg + 245 mg) | 30,54 | 916,20 |  | 5% |
| J05AR03 121 | KL | emtricitabin + tenofovir NJ501 |  |  | O | Krka d.d., Novo mesto | Krka d.d. | Emtricitabine/Tenofovir disoproxil Krka | tbl. film obl. 30x(200 mg + 245 mg) | 30,54 | 916,20 |  | 5% |
| J05AR03 171 | KL | emtricitabin + tenofovir NJ501 |  |  | O | Remedica Ltd. | Remedica Ltd. | Emtricitabin/tenofovirdizoproksil Remedica | tbl. film obl. 30x(200 mg + 245 mg) | 30,54 | 916,20 |  | 5% |
| J05AR03 181 | KL | emtricitabin + tenofovir NJ501 |  |  | O | Mylan Pharmaceuticals Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories t/a Mylan Dublin | Emtricitabin/tenofovirdizoproksil Mylan | tbl. film obl. 30x(200 mg + 245 mg) | 30,54 | 916,20 |  | 5% |
| J05AR06 171 | KL | efavirenz + emtricitabin + tenofovir dizoproksilNJ501 |  |  | O | Mylan Pharmaceuticals Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories t/a Mylan Dublin | Efavirenz/emtricitabin/tenofovirdizoproksil Mylan | tbl. film obl. 30 x (600 mg + 200 mg + 245 mg) | 81,88 | 2.456,46 |  | 5% |
| J05AR06 172 | KL | efavirenz + emtricitabin + tenofovir dizoproksilNJ501 |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Emtenef | tbl. film obl. 30 x (600 mg + 200 mg + 245 mg) | 57,32 | 1.719,52 |  | 5% |
| J05AR10 141 | KL | lopinavir + ritonavirNJ501 |  |  | O | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lopinavir/Ritonavir Accord | tbl. film obl. 120x(200 mg + 50 mg) | 16,20 | 1.943,76 |  | 5% |
| J05AR10 171 | KL | lopinavir + ritonavirNJ501 |  |  | O | Mylan Pharmaceuticals Limited | McDermott Laboratories Limited trading as Gerard Laboratories, Mylan Hungary Kft | Lopinavir/Ritonavir Mylan | tbl. film obl. 120x(200 mg + 50 mg) | 14,58 | 1.749,38 |  | 5% |
| J05AR10 284 | KL | lopinavir + ritonavirNJ501 |  |  | O | AbbVie Deutschland GmbH & Co. KG | Aesica Queenborough Limited, AbbVie Logistics B.V. | Kaletra | otop. boč. plast. 5x60 ml + 5 štrc. 5 ml | 495,20 | 2.476,00 |  | 5% |
| J05AR13 161 | KL | dolutegravir + abakavir + lamivudinNJ501 |  |  | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A., GlaxoSmithKline Pharmaceuticals S.A. | Triumeq | tbl. film obl. 30x(50 mg + 600 mg + 300 mg) | 186,13 | 5.584,00 |  | 5% |
| J05AR14 161 | KL | darunavir + kobicistatNJ501 |  |  | O | Janssen-Cilag International N.V. | Janssen – Cilag SpA | Rezolsta | tbl. film obl. 30x(800 mg + 150 mg) | 114,98 | 3.449,32 |  | 5% |
| J05AR17 161 | KL | emtricitabin + tenofovir alafenamidNJ713 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Descovy | tbl. film obl. 30x(200 mg + 10 mg) | 110,77 | 3.323,00 |  | 5% |
| J05AR17 162 | KL | emtricitabin + tenofovir alafenamidNJ713 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Descovy | tbl. film obl. 30x(200 mg + 25 mg) | 110,77 | 3.323,00 |  | 5% |
| J05AR19 161 | KL | emtricitabin + rilpivirin + tenofovir alafenamidNJ507 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Odefsey | tbl. film obl. 30x(200 mg + 25 mg + 25 mg) | 138,56 | 4.156,90 |  | 5% |
| J05AR20 171 | KL | biktegravir + emtricitabin + tenofovir alafenamidNJ717 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Biktarvy | tbl. film obl. 30x(50 mg + 200 mg + 25 mg) | 177,68 | 5.330,40 |  | 5% |
| J05AR21 171 | KL | dolutegravir + rilpivirinNJ718 |  |  | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A. | Juluca | tbl. film obl. 30x(50 mg + 25 mg) | 192,57 | 5.777,20 |  | 5% |
| J05AR25 171 | KL | dolutegravir + lamivudinNJ501 |  |  | O | ViiV Healthcare B.V. | Glaxo Wellcome, S.A. | Dovato | tbl. film obl. 30x(50 mg + 300 mg) | 153,79 | 4.613,68 |  | 5% |
| J05AX18 071 | KL | letermovirNJ720 | 480 mg | 2.521,38 | P | Merck Sharp & Dohme B.V. | Schering-Plough Labo NV | Prevymis | konc. za otop. za inf., boč. 1x240 mg/12 ml | 1.260,69 | 1.260,69 |  | 5% |
| J05AX18 171 | KL | letermovirNJ720 | 480 mg | 2.317,43 | O | Merck Sharp & Dohme B.V. | Schering-Plough Labo NV | Prevymis | tbl. film obl. 28x240 mg | 1.158,72 | 32.444,07 |  | 5% |
| J06AA03 013 | PO | imunoglobulin-antitoksin protiv otrova zmija (purificiran i koncentriran) |  |  | P | Imunološki zavod | Imunološki zavod | Antitoksin za otrov europskih zmija (konjski) | boč. 1x10 ml | 750,00 | 750,00 |  | 5% |
| J06AA03 051 | PO | imunoglobulin-antitoksin protiv otrova zmija (purificiran i koncentriran) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06AA04 051 | DS | imunoglobulin-antitoksin botulinum |  |  | P |  |  |  |  |  |  |  | 5% |
| J06AA05 052 | DS | imunoglobulin-antitoksin protiv plinske gangrene |  |  | P |  |  |  |  |  |  |  | 5% |
| J06AA07 053 | PR | imunoglobulin-antitoksin protiv otrova pauka (crna udovica) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BA01 061 |  | imunoglobulin, ljudskiNJ708 |  |  | P | Jana Pharm d.o.o. | Octapharma AB | Gammanorm | otop. za inj., boč. 1x10 ml (165 mg/ml) | 727,77 | 727,77 | RSRJ53 | 5% |
| J06BA01 063 |  | imunoglobulin, ljudskiNJ708 |  |  | P | Jana Pharm d.o.o. | Octapharma AB | Gammanorm | otop. za inj., boč. 1x12 ml (165 mg/ml) | 873,30 | 873,30 | RSRJ53 | 5% |
| J06BA01 071 |  | imunoglobulin za subkutanu primjenu NJ715 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | HyQvia | otop. za inf. za potkožnu primjenu, boč. 1x25 ml (100 mg/ml) + 1,25 ml (rHuPH20) | 1.060,19 | 1.060,19 | RSRJ54 | 5% |
| J06BA01 072 |  | imunoglobulin za subkutanu primjenu NJ715 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | HyQvia | otop. za inf. za potkožnu primjenu, boč. 1x50 ml (100 mg/ml) + 2,5 ml (rHuPH20) | 2.150,18 | 2.150,18 | RSRJ54 | 5% |
| J06BA01 073 |  | imunoglobulin za subkutanu primjenu NJ715 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | HyQvia | otop. za inf. za potkožnu primjenu, boč. 1x100 ml (100 mg/ml) + 5 ml (rHuPH20) | 4.228,51 | 4.228,51 | RSRJ54 | 5% |
| J06BA01 081 |  | imunoglobulin, ljudskiNJ708 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Hizentra | otop. za inj., boč. 1x5 ml (200 mg/ml) | 402,91 | 402,91 | RSRJ53 | 5% |
| J06BA01 082 |  | imunoglobulin, ljudskiNJ708 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Hizentra | otop. za inj., boč. 1x10 ml (200 mg/ml) | 805,82 | 805,82 | RSRJ53 | 5% |
| J06BA02 016 | DS | imunoglobulin za intraven. primjenu 7 SNJ601 |  |  | P | Imunološki zavod | Imunološki zavod | IZ IVIG 50 mg/ml | boč. 1x2,5 g/50 ml | 634,01 | 634,01 |  | 5% |
| J06BA02 017 | DS | imunoglobulin za intraven. primjenu 7 SNJ601 |  |  | P | Imunološki zavod | Imunološki zavod | IZ IVIG 50 mg/ml | boč. 1x5 g/100 ml | 1.200,12 | 1.200,12 |  | 5% |
| J06BA02 018 | DS | imunoglobulin za intraven. primjenu7 SNJ601 |  |  | P | Imunološki zavod | Imunološki zavod | IZ IVIG 50 mg/ml | boč. 1x500 mg/10 ml | 102,79 | 102,79 |  | 5% |
| J06BA02 051 | DS | imunoglobulin za intraven. primjenu 5 SNJ602 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BA02 060 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam (HR) | boč. 1x10 g/200 ml | 3.365,10 | 3.365,10 |  | 5% |
| J06BA02 061 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam | boč. 1x2,5 g/50 ml | 907,61 | 907,61 |  | 5% |
| J06BA02 062 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam (HR) | boč. 1x5 g/100 ml | 1.742,10 | 1.742,10 |  | 5% |
| J06BA02 065 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Ig Vena | otop. za inf., boč. stakl. 1x20 ml (50 g/l) | 373,45 | 373,45 |  | 5% |
| J06BA02 066 | DS | imunoglobulin za intraven. primjenu 7 S NJ716 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Ig Vena | otop. za inf., boč. stakl. 1x50 ml (50 g/l) | 1.102,68 | 1.102,68 |  | 5% |
| J06BA02 067 | DS | imunoglobulin za intraven. primjenu 7 S NJ716 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Ig Vena | otop. za inf., boč. stakl. 1x100 ml (50 g/l) | 2.341,70 | 2.341,70 |  | 5% |
| J06BA02 068 | DS | imunoglobulin za intraven. primjenu 7 S NJ716 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Ig Vena | otop. za inf., boč. stakl. 1x200 ml (50 g/l) | 4.324,46 | 4.324,46 |  | 5% |
| J06BA02 076 | DS | imunoglobulin za intraven. primjenu 7 S NJ601 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Kiovig | otop. za inf., boč. 1x2,5 g/25 ml (100 mg/ml) | 922,31 | 922,31 |  | 5% |
| J06BA02 077 | DS | imunoglobulin za intraven. primjenu 7 S NJ601 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Kiovig | otop. za inf., boč. 1x5 g/50 ml (100 mg/ml) | 1.902,17 | 1.902,17 |  | 5% |
| J06BA02 078 | DS | imunoglobulin za intraven. primjenu 7 S NJ601 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Kiovig | otop. za inf., boč. 1x10 g/100 ml (100 mg/ml) | 3.616,71 | 3.616,71 |  | 5% |
| J06BA02 091 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | CSL Behring GmbH | CSL Behring AG, CSL Behring GmbH | Privigen | otop. za inf., boč. stakl. 1x25 ml (100 mg/ml) | 1.102,68 | 1.102,68 |  | 5% |
| J06BA02 092 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | CSL Behring GmbH | CSL Behring AG, CSL Behring GmbH | Privigen | otop. za inf., boč. stakl. 1x50 ml (100 mg/ml) | 2.143,63 | 2.143,63 |  | 5% |
| J06BA02 093 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | CSL Behring GmbH | CSL Behring AG, CSL Behring GmbH | Privigen | otop. za inf., boč. stakl. 1x100 ml (100 mg/ml) | 4.214,45 | 4.214,45 |  | 5% |
| J06BA02 094 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | CSL Behring GmbH | CSL Behring AG, CSL Behring GmbH | Privigen | otop. za inf., boč. stakl. 1x200 ml (100 mg/ml) | 8.346,79 | 8.346,79 |  | 5% |
| J06BA02 960 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam (non HR) | boč. 1x10 g/200 ml | 4.683,40 | 4.683,40 |  | 5% |
| J06BA02 962 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam (non HR) | boč. 1x5 g/100 ml | 2.341,70 | 2.341,70 |  | 5% |
| J06BB01 081 | DS | imunoglobulin anti-D-(Rho) (ljudski)NJ603 |  |  | P | Jana Pharm d.o.o. | Octapharma | Rhesonativ | otop. za inj. amp. 1x2 ml (625 IU/125 mcg/ml) | 338,52 | 338,52 |  | 5% |
| J06BB02 018 | PO | imunoglobulin antitetanus – TIG (ljudski) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Imunoglobulin protiv tetanusa, ljudski | otop. za inj. amp. 1x250 IU | 67,96 | 67,96 |  | 5% |
| J06BB02 051 | PO | imunoglobulin antitetanus – TIG (ljudski)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB02 054 | DS | imunoglobulin antitetanus hiperimuni (5000i.j.) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB03 051 | DS | imunoglobulin Varicella/zosterNJ604 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB04 019 | DS | imunoglobulin anti-HBs (ljudski) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Imunoglobulin protiv hepatitisa B, ljudski | boč. stakl. 250 IU | 350,00 | 350,00 |  | 5% |
| J06BB04 051 | DS | imunoglobulin anti-HBs (ljudski)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB04 061 | KL | imunoglobulin protiv hepatitisa B (ljudski)NJ606 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Venbig | praš. i otap. za otop. za inf., boč. stakl. 1x500 i.j. | 1.482,00 | 1.482,00 |  | 5% |
| J06BB04 062 | KL | imunoglobulin protiv hepatitisa B (ljudski)NJ606 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Venbig | praš. i otap. za otop. za inf., boč. stakl. 1x2500 i.j. | 7.329,54 | 7.329,54 |  | 5% |
| J06BB05 020 | PR | imunoglobulin protiv bjesnoće (ljudski) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | IZ HRIG 500 Imunoglobulin protiv bjesnoće, ljudski | otop. za inj., boč. stakl. 500 IU | 759,84 | 759,84 |  | 5% |
| J06BB05 051 | PR | imunoglobulin protiv bjesnoće (ljudski)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB09 051 | KL | hiperimuni anti-citomegalo virus (ljudski) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB12 051 | DS | imunoglobulin protiv krpeljnog meningoencefalitisa (ljudski) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BD01 051 | DS | palivizumabNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BD01 084 | DS | palivizumabNJ707 |  |  | P | AstraZeneca AB | AbbVie S.r.l. | Synagis | otop. za inj., boč. stakl. 1x1 ml (100 mg/mL) | 6.068,36 | 6.068,36 |  | 5% |
| J07AG01 051 | PR | cjepivo protiv Haemophilusa influenzae tipa BNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AG51 051 | PR | cjepivo protiv Haemophilus influenzae tipBNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AH04 051 |  | cjepivo protiv meningokokne bolesti, tetravalentno (A, C, W-135, Y)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AH08 051 |  | cjepivo protiv meningokokne bolesti, tetravalentno (A, C, W-135, Y)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AH09 051 |  | cjepivo protiv meningokoka grupe B (rDNK, komponentno, adsorbirano)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AJ51 051 | PR | cjepivo protiv difterije, tetanusa i pertusisa NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AJ52 051 | PR | cjepivo protiv difterije, tetanusa i pertusisa NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AL01 051 | PR | cjepivo protiv pneumokokne bolestiNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AL01 071 | PR | cjepivo protiv pneumokokne bolesti, polisaharidno, 23-valentnoNJ707 |  |  | P | Merck Sharp & Dohme d.o.o. | Merck Sharp & Dohme B.V. | Pneumovax 23 | štrc. napunj. 1x0,5 ml | 166,36 | 166,36 |  | 5% |
| J07AL02 051 | PR | cjepivo protiv pneumokokne bolestiNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AL02 062 | PR | cjepivo protiv pneumokoka, polisaharidno, konjugirano, 13-valentno, adsorbiranoNJ707 |  |  | P | Pfizer Europe MA EEIG | John Wyeth & Brother Ltd. | Prevenar 13 | štrc. napunj. 1x1 doza (0,5 ml), susp. | 358,79 | 358,79 |  | 5% |
| J07AL52 071 | PR | cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbiranoNJ707 |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Synflorix | štrc. napunj. 1x0,5 ml, susp. | 339,57 | 339,57 |  | 5% |
| J07AL52 072 | PR | cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbiranoNJ707 |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Synflorix | štrc. napunj. 10x0,5 ml, susp. | 339,57 | 3.395,67 |  | 5% |
| J07AM01 013 | PO | tetanus anatoksin (ANA-TE) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv tetanusa, adsorbirano, Imunološki zavod | susp. za inj., boč. stakl. 1x10 doza | 22,20 | 22,20 |  | 5% |
| J07AM01 014 | PO | tetanus anatoksin (ANA-TE) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv tetanusa, adsorbirano, Imunološki zavod | susp. za inj., amp 10x1 doza | 8,68 | 86,83 |  | 5% |
| J07AM01 051 | PO | tetanus anatoksin NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AM51 015 | PR | cjepivo protiv difterije-tetanusa pro adultis (ANA-DI-TE pro adultis) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv difterije i tetanusa sa smanjenim sadržajem antigena, adsorbirano, Imunološki zavod | susp. za inj., amp. stakl. 10x1 doza | 8,00 | 80,00 |  | 5% |
| J07AM51 016 | PR | cjepivo protiv difterije-tetanusa pro adultis (ANA-DI-TE pro adultis) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv difterije i tetanusa sa smanjenim sadržajem antigena, adsorbirano, Imunološki zavod | susp. za inj., boč. stakl. 1x10 doza | 54,26 | 54,26 |  | 5% |
| J07AM51 051 | PR | cjepivo protiv difterije i tetanusa NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AN01 051 | PR | BCG-cjepivo protiv tuberkuloze-živo, atenuiranoNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AP03 051 | PR | cjepivo protiv tifusa, polisaharidno |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BB01 051 | PR | cjepivo protiv gripeNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BB02 051 | PR | cjepivo protiv gripeNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BB03 051 | PR | cjepivo protiv gripeNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BC01 051 | DS | cjepivo protiv hepatitisa BNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BC01 074 | DS | cjepivo protiv hepatitisa B |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Engerix -B dosis adulta | 1x20 mcg/1 ml susp. za inj. u napunj. štrc. | 78,87 | 78,87 |  | 5% |
| J07BC01 075 | DS | cjepivo protiv hepatitisa B |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Engerix -B dosis pediatrica | 1x10 mcg/0,5 ml susp. za inj. u napunj. štrc. | 48,00 | 48,00 |  | 5% |
| J07BC02 051 |  | cjepivo protiv hepatitisa ANJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BD01 011 | PR | cjepivo protiv morbila (MO) |  |  | P | Imunološki zavod | Imunološki zavod | Cjepivo protiv morbila, živo, liofilizirano, Edmonston-Zagreb, HDS | praš. boč. + otap. za susp. za inj. boč. 0,5 ml | 23,03 | 23,03 |  | 5% |
| J07BD01 051 | PR | cjepivo protiv ospicaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BD52 018 | PR | cjepivo protiv morbila-parotitisa-rubele (MO-PA-RU) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv morbila, rubele i parotitisa, živo, liofilizirano «Edmonston-Zgb” | lio boč. 1x1 doza | 67,47 | 67,47 |  | 5% |
| J07BD52 051 | PR | cjepivo protiv ospica, mumpsa i rubeleNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BD52 061 | PR | cjepivo protiv morbila-parotitisa-rubele (MO-PA-RU) |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Priorix | cjepivo kombinirano, liof., boč. 1x1 doza + štrc. napunj. s 0,5 ml vode za injekcije + 2 igle sa zaštitom | 66,32 | 66,32 |  | 5% |
| J07BD52 062 | PR | cjepivo protiv morbila-parotitisa-rubele, živo |  |  | P | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | M-M-RVAXPRO | štrc. napunj. 1x0,5 ml + 1 boč. stakl. s praškom, + 2 priložene igle, susp. | 59,66 | 59,66 |  | 5% |
| J07BE01 012 | PR | cjepivo protiv parotitisa (PA) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv parotitisa živo, liofil. «L-Zgb” | lio boč. 1x1 doza | 37,03 | 37,03 |  | 5% |
| J07BF03 051 | PR | cjepivo protiv dječje paralize, inaktiviranoNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BG01 051 | DS | cjepivo protiv bjesnoćeNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BH01 051 | PR | monovalentno cjepivo protiv rotavirusaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BH02 051 | PR | 5 – valentno cjepivo protiv rotavirusaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BJ01 019 | PR | cjepivo protiv rubele (RU ) |  |  | P | Imunološki zavod | Imunološki zavod | Cjepivo protiv rubele, živo, Imunološki zavod | praš. boč. + otap. za susp. za inj. boč. 0,5 ml | 24,74 | 24,74 |  | 5% |
| J07BJ01 051 | PR | cjepivo protiv rubele NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BK01 051 |  | cjepivo protiv varičelaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BK01 061 |  | cjepivo protiv varičelaNJ707 |  |  | P | Merck Sharp & Dohme d.o.o. | Merck Sharp & Dohme B.V. | Varivax | štrc. napunj. 1x0,5 ml + 1 boč. s praškom | 323,74 | 323,74 |  | 5% |
| J07BM01 051 |  | cjepivo protiv humanog papilomavirusaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BM02 051 |  | 2 – valentno cjepivo protiv humanog papilomavirusaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BM03 051 |  | 9-valentno cjepivo protiv humanog papilomavirusa (rekombinantno, adsorbirano)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BM03 061 |  | 9-valentno cjepivo protiv humanog papilomavirusa (rekombinantno, adsorbirano)NJ707 |  |  | P | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme B.V. | Gardasil 9 | susp. za inj., štrc. napunj. 1×0,5 ml | 903,08 | 903,08 |  | 5% |
| J07CA01 051 | PR | cjepivo protiv difterije, tetanusa i dječje paralize (Td-IPV)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07CA06 051 | PR | cjepivo protiv difterije, tetanusa, pertusisa, dječje paralize i Haemophilusa influenzae tipa BNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07CA06 071 | PR | cjepivo protiv difterije, tetanusa-DT, pertusisa-(acelularno), poliomijelitisa-IPV (inaktivirano), adsorbirano i Haemophilus influenzae tip b (konjugirano)NJ707 |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Infanrix-IPV + Hib | štrc. stakl. 1x0,5 ml + 1 stakl.boč. s praškom + 2 igle sa zaštitom, susp. | 141,29 | 141,29 |  | 5% |
| J07CA09 051 | PR | cjepivo protiv difterije, tetanusa, pertusisa (acelularno), dječje paralize (inaktivirano),H. influenzae tipa B i hepatitisa BNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA01 051 | DS | ciklofosfamid |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA01 161 |  | ciklofosfamid |  |  | O | Baxter d.o.o. | Baxter Oncology GmbH | Endoxan | tbl. obl. 50x50 mg | 1,63 | 81,50 | RSRL01 | 5% |
| L01AA02 151 |  | klorambucil |  |  | O |  |  |  |  |  |  | RSRL01 | 5% |
| L01AA03 051 | DS | melfalan |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA03 151 |  | melfalan |  |  | O |  |  |  |  |  |  | RSRL01 | 5% |
| L01AA05 052 | DS | klormetin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA06 051 | DS | ifosfamid |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA09 001 | DS | bendamustinNL441 |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L. | Bendamustin Teva | praš. za konc. za otop. za inf., boč. 5x25 mg (2,5 mg/ml) | 275,60 | 1.377,99 |  | 5% |
| L01AA09 002 | DS | bendamustinNL441 |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L. | Bendamustin Teva | praš. za konc. za otop. za inf., boč. 5x100 mg (2,5 mg/ml) | 1.219,03 | 6.095,16 |  | 5% |
| L01AA09 040 | DS | bendamustinNL441 |  |  | P | PharmaS d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Bendamustin PharmaS | praš. za konc. za otop. za inf., boč. 5x25 mg (2,5 mg/ml) | 340,24 | 1.701,21 |  | 5% |
| L01AA09 041 | DS | bendamustinNL441 |  |  | P | PharmaS d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Bendamustin PharmaS | praš. za konc. za otop. za inf., boč. 5x100 mg (2,5 mg/ml) | 1.504,98 | 7.524,91 |  | 5% |
| L01AA09 061 | DS | bendamustinNL441 |  |  | P | Makpharm d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Benmak | praš. za konc. za otop. za inf., boč. 5x100 mg (2,5 mg/ml) | 1.504,98 | 7.524,91 |  | 5% |
| L01AA09 062 | DS | bendamustinNL441 |  |  | P | Makpharm d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Benmak | praš. za konc. za otop. za inf., boč. 5x25 mg (2,5 mg/ml) | 340,24 | 1.701,21 |  | 5% |
| L01AA09 071 | DS | bendamustinNL441 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc. | Bendamustin Kabi | praš. za konc. za otop. za inf., boč. 1x25 mg (2,5 mg/ml) | 306,22 | 306,22 |  | 5% |
| L01AA09 072 | DS | bendamustinNL441 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc. | Bendamustin Kabi | praš. za konc. za otop. za inf., boč. 1x100 mg (2,5 mg/ml) | 1.354,48 | 1.354,48 |  | 5% |
| L01AB01 051 | DS | busulfan |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AB01 151 |  | busulfan |  |  | O |  |  |  |  |  |  | RSRL01 | 5% |
| L01AD01 051 | DS | karmustin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AD02 151 | DS | lomustin |  |  | O |  |  |  |  |  |  |  | 5% |
| L01AX03 101 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x5 mg | 15,99 | 79,93 |  | 5% |
| L01AX03 102 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x20 mg | 64,65 | 323,25 |  | 5% |
| L01AX03 103 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x100 mg | 319,85 | 1.599,25 |  | 5% |
| L01AX03 104 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x140 mg | 458,10 | 2.290,50 |  | 5% |
| L01AX03 105 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x180 mg | 588,15 | 2.940,73 |  | 5% |
| L01AX03 106 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x250 mg | 789,70 | 3.948,50 |  | 5% |
| L01AX03 181 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x5 mg | 14,39 | 71,94 |  | 5% |
| L01AX03 182 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x20 mg | 61,47 | 307,33 |  | 5% |
| L01AX03 183 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x100 mg | 291,41 | 1.457,06 |  | 5% |
| L01AX03 184 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x140 mg | 413,07 | 2.065,35 |  | 5% |
| L01AX03 185 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x180 mg | 529,33 | 2.646,64 |  | 5% |
| L01AX03 186 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x250 mg | 737,63 | 3.688,14 |  | 5% |
| L01AX04 051 | DS | dakarbazin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01BA01 006 | DS | metotreksat |  |  | P | Zentiva k.s. | Pliva Hrvatska d.o.o. | Metotreksat Zentiva | otop. za inj., boč. stakl. 1x50 mg/2 ml (25 mg/1 ml) | 27,03 | 27,03 |  | 5% |
| L01BA01 007 | DS | metotreksat |  |  | P | Zentiva k.s. | Pliva Hrvatska d.o.o. | Metotreksat Zentiva | otop. za inj., boč. stakl. 1x1000 mg/10 ml (100 mg/1 ml) | 258,83 | 258,83 |  | 5% |
| L01BA01 012 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x7,5 mg/0,30 ml | 30,23 | 30,23 | RSRL50 | 5% |
| L01BA01 013 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x10 mg/0,40 ml | 56,12 | 56,12 | RSRL50 | 5% |
| L01BA01 014 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x15 mg/0,38 ml | 84,18 | 84,18 | RSRL50 | 5% |
| L01BA01 015 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x20 mg/0,50 ml | 100,22 | 100,22 | RSRL50 | 5% |
| L01BA01 016 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x25 mg/0,63 ml | 114,14 | 114,14 | RSRL50 | 5% |
| L01BA01 018 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A., S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x12,5 mg/0,31 ml | 70,15 | 70,15 | RSRL50 | 5% |
| L01BA01 019 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x17,5 mg/0,44 ml | 86,35 | 86,35 | RSRL50 | 5% |
| L01BA01 081 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x7,5 mg/0,375 ml (20 mg/ml) | 30,23 | 30,23 | RSRL50 | 5% |
| L01BA01 082 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x10 mg/0,5 ml (20 mg/ml) | 56,12 | 56,12 | RSRL50 | 5% |
| L01BA01 083 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x15 mg/0,75 ml (20 mg/ml) | 84,18 | 84,18 | RSRL50 | 5% |
| L01BA01 084 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x20 mg/1 ml (20 mg/ml) | 100,22 | 100,22 | RSRL50 | 5% |
| L01BA01 085 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x25 mg/1,25 ml (20 mg/ml) | 114,14 | 114,14 | RSRL50 | 5% |
| L01BA04 001 | DS | pemetreksedNL102 |  |  | P | PLIVA HRVATSKA d.o.o. | Pharmachemie B.V., Teva Pharmaceutical Works, Pliva Hrvatska d.o.o., Teva Operations | Pemetreksed Pliva | praš. za konc. za otop. za inf., boč. 1x500 mg | 3.067,55 | 3.067,55 |  | 5% |
| L01BA04 002 | DS | pemetreksedNL102 |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharmaceutical Works | Pemetreksed Pliva | praš. za konc. za otop. za inf., boč. 1x1000 mg | 6.135,10 | 6.135,10 |  | 5% |
| L01BA04 003 | DS | pemetreksedNL102 |  |  | P | ACTAVIS GROUP PTC ehf. | Pliva Hrvatska d.o.o., S.C. Sindan-Pharma S.R.L. | Armisarte | konc. za otop. za inf., boč. 1x20 ml (25 mg/ml) | 2.768,47 | 2.768,47 |  | 5% |
| L01BA04 004 | DS | pemetreksedNL102 |  |  | P | ACTAVIS GROUP PTC ehf. | Pliva Hrvatska d.o.o., S.C. Sindan-Pharma S.R.L. | Armisarte | konc. za otop. za inf., boč. 1x40 ml (25 mg/ml) | 5.536,93 | 5.536,93 |  | 5% |
| L01BA04 023 | DS | pemetreksedNL102 |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Pemetreksed Sandoz | konc. otop. za inf., boč. 1x20 ml (25 mg/ml) | 3.067,55 | 3.067,55 |  | 5% |
| L01BA04 024 | DS | pemetreksedNL102 |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Pemetreksed Sandoz | konc. otop. za inf., boč. 1x40 ml (25 mg/ml) | 6.135,10 | 6.135,10 |  | 5% |
| L01BA04 031 | DS | pemetreksedNL102 |  |  | P | Krka d.d., Novo mesto | KRKA d.d. | Pemetrexed Krka | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 613,51 | 613,51 |  | 5% |
| L01BA04 032 | DS | pemetreksedNL102 |  |  | P | Krka d.d., Novo mesto | KRKA d.d. | Pemetrexed Krka | praš. za konc. za otop. za inf., boč. stakl. 1x500 mg | 3.067,55 | 3.067,55 |  | 5% |
| L01BA04 041 | DS | pemetreksedNL102 |  |  | P | PharmaS d.o.o. | Synthon Hispania S.L., Synthon s.r.o., Adamed Sp. z.o.o. | Pemetreksed PharmaS | praš. za konc. za otop. za inf., boč. 1x500 mg | 3.067,55 | 3.067,55 |  | 5% |
| L01BA04 044 | DS | pemetreksedNL102 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Wessling Hungary Kft. | Pemetrexed Accord | praš. za konc. za otop. za inf., boč. 1x500 mg | 2.914,18 | 2.914,18 |  | 5% |
| L01BA04 045 | DS | pemetreksedNL102 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Wessling Hungary Kft | Pemetrexed Accord | konc. za otop. za inf., boč. 1x1000 mg | 5.828,35 | 5.828,35 |  | 5% |
| L01BA04 071 | DS | pemetreksedNL102 |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Oncology Plc., Fresenius Kabi Deutschland GmbH | Pemetrexed Fresenius Kabi | praš. za konc. za otop. za inf., boč. 1x500 mg | 3.067,55 | 3.067,55 |  | 5% |
| L01BA04 081 | DS | pemetreksedNL102 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Pemetrexed EVER Pharma | konc. za otop. za inf., boč. 1x4 ml (25 mg/ml) | 613,51 | 613,51 |  | 5% |
| L01BA04 082 | DS | pemetreksedNL102 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Pemetrexed EVER Pharma | konc. za otop. za inf., boč. 1x20 ml (25 mg/ml) | 3.067,55 | 3.067,55 |  | 5% |
| L01BA04 083 | DS | pemetreksedNL102 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Pemetrexed EVER Pharma | konc. za otop. za inf., boč. 1x40 ml (25 mg/ml) | 6.135,10 | 6.135,10 |  | 5% |
| L01BB02 151 |  | merkaptopurin |  |  | O |  |  |  |  |  |  | RSRL92 | 5% |
| L01BB03 151 |  | tioguanin |  |  | O |  |  |  |  |  |  | RSRL92 | 5% |
| L01BB04 061 | DS | kladribinNL103 |  |  | P | Lipomed GmbH | Lipomed | Litak | otop. za inj. boč. 1x5 ml (2 mg /ml) | 2.228,91 | 2.228,91 |  | 5% |
| L01BB05 071 | DS | fludarabinNL104 |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fludarabine Pliva | konc. otop. za inj. ili inf., boč. stakl. 1x2 ml | 565,21 | 565,21 |  | 5% |
| L01BB05 081 | DS | fludarabinNL104 |  |  | P | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma S.R.L. | Sindarabin | praš. za otop. za inj. ili inf., boč. stakl. 1x50 mg | 543,00 | 543,00 |  | 5% |
| L01BB05 091 | DS | fludarabinNL104 |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Fludarabin Accord | konc. za otop.za inj.ili inf., boč. stakl. 1x50 mg/2 mL | 488,70 | 488,70 |  | 5% |
| L01BB05 092 | DS | fludarabinNL104 |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Fludarabin Accord | konc. za otop.za inj.ili inf., boč. stakl. 5x50 mg/2 mL | 488,70 | 2.443,50 |  | 5% |
| L01BB06 061 | KL | klofarabinNL417 |  |  | P | Genzyme Europe B.V. | Pharmachemie B.V., Genzyme Limited | Evoltra | konc. za otop. za inf., boč. stakl. 1x20 mg/20 ml | 7.105,14 | 7.105,14 |  | 5% |
| L01BB06 071 | KL | klofarabinNL417 |  |  | P | Makpharm d.o.o. | Synthon Hispania S.L., Synthon BV | Klofarabin Makpharm | konc. za otop. za inf., boč. stakl. 1x20 mg/20 ml | 7.105,14 | 7.105,14 |  | 5% |
| L01BC01 063 | DS | citarabin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Cytosar | amp. 1x1.000 mg/10 ml | 165,77 | 165,77 |  | 5% |
| L01BC02 002 | DS | 5-fluorouracil |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fluorouracil Pliva | otop. za inj./inf., boč. stak. 1x500 mg/10 ml (50 mg/ml) | 16,77 | 16,77 |  | 5% |
| L01BC02 022 | DS | 5-fluorouracil |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Fluorouracil Sandoz | otop. za inj. ili inf., boč. stakl. 1x50 mg/ml (20 ml) | 36,19 | 36,19 |  | 5% |
| L01BC02 023 | DS | 5-fluorouracil |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Fluorouracil Sandoz | otop. za inj. ili inf., boč. stakl. 1x50 mg/ml (100 ml) | 119,02 | 119,02 |  | 5% |
| L01BC02 451 |  | 5-fluorouracil |  |  | L |  |  |  |  |  |  | R | 5% |
| L01BC05 011 | DS | gemcitabin |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Gitrabin | praš. za otop. za inf., boč. 1x2000 mg | 468,18 | 468,18 |  | 5% |
| L01BC05 041 | DS | gemcitabin |  |  | P | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Gemcitabin Accord | konc. za otop. za inf., boč. 1x200 mg/2 ml | 44,56 | 44,56 |  | 5% |
| L01BC05 042 | DS | gemcitabin |  |  | P | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Gemcitabin Accord | konc. za otop. za inf., boč. 1x1000 mg/10 ml | 234,09 | 234,09 |  | 5% |
| L01BC05 043 | DS | gemcitabin |  |  | P | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Gemcitabin Accord | konc. za otop. za inf., boč. 1x2000 mg/20 ml | 444,77 | 444,77 |  | 5% |
| L01BC05 068 | DS | gemcitabin |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH | Gemcitabin Sandoz | konc. za otop. za inf., boč. 1x200 mg/5 ml | 46,91 | 46,91 |  | 5% |
| L01BC05 069 | DS | gemcitabin |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Gemcitabin Sandoz | konc. za otop. za inf., boč. 1x1000 mg/25 ml | 246,41 | 246,41 |  | 5% |
| L01BC05 073 | DS | gemcitabin |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Gemcitabin Sandoz | konc. za otop. za inf., boč. 1x2000 mg/50 ml | 422,53 | 422,53 |  | 5% |
| L01BC05 081 | DS | gemcitabin |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Gitrabin | praš. za otop. za inf., boč. 1x200 mg | 57,91 | 57,91 |  | 5% |
| L01BC05 082 | DS | gemcitabin |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Gitrabin | praš. za otop. za inf., boč. 1x1 g | 273,79 | 273,79 |  | 5% |
| L01BC05 083 | DS | gemcitabin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc. | Gemcitabin Kabi | praš. za otop. za inf., boč. 1x200 mg/10 ml | 57,91 | 57,91 |  | 5% |
| L01BC05 084 | DS | gemcitabin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc. | Gemcitabin Kabi | praš. za otop. za inf., boč. 1x1000 mg/50 ml | 273,79 | 273,79 |  | 5% |
| L01BC06 101 |  | kapecitabin |  |  | O | Teva B.V. | Teva Czech Industries s.r.o., Pharmachemie B.V., Merckle GmbH | Kapecitabin Teva | tbl. film obl. 60x150 mg | 1,95 | 117,12 | RSRL02 | 5% |
| L01BC06 102 |  | kapecitabin |  |  | O | Teva B.V. | Teva Czech Industries s.r.o., Pharmachemie B.V., Merckle GmbH | Kapecitabin Teva | tbl. film obl. 120x500 mg | 5,13 | 615,60 | RSRL02 | 5% |
| L01BC06 122 |  | kapecitabin |  |  | O | Sandoz d.o.o. | Sandoz-Salutas | Kapecitabin Sandoz | tbl. film obl. 120x500 mg | 5,13 | 615,60 | RSRL02 | 5% |
| L01BC06 142 |  | kapecitabin |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Kapecitabin JGL | tbl. film obl. 120x500 mg | 5,13 | 615,60 | RSRL02 | 5% |
| L01BC06 143 |  | kapecitabin |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmacare Premium Ltd | Kapecitabin Accord | tbl. film obl. 60x150 mg | 1,95 | 117,12 | RSRL02 | 5% |
| L01BC06 144 |  | kapecitabin |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmacare Premium Ltd | Kapecitabin Accord | tbl. film obl. 60x300 mg | 3,90 | 234,24 | RSRL02 | 5% |
| L01BC06 172 |  | kapecitabin |  |  | O | Zentiva k.s. | Remedica Ltd. | Xalvobin | tbl. film obl. 120x500 mg | 5,13 | 615,60 | RSRL02 | 5% |
| L01BC06 173 |  | kapecitabin |  |  | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Kapetral | tbl. film obl. 60x150 mg | 1,95 | 117,12 | RSRL02 | 5% |
| L01BC06 174 |  | kapecitabin |  |  | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Kapetral | tbl. film obl. 120x500 mg | 5,13 | 615,60 | RSRL02 | 5% |
| L01BC06 175 |  | kapecitabin |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Kapecitabin Accord | tbl. film obl. 120x500 mg | 5,13 | 615,60 | RSRL02 | 5% |
| L01BC06 176 |  | kapecitabin |  |  | O | Krka d.d., Novo mesto | Accord Healthcare Ltd., Pharmacare Premium Ltd | Ecansya | tbl. film obl. 120x500 mg | 5,13 | 615,60 | RSRL02 | 5% |
| L01BC07 061 | DS | azacitidinNL106 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Celgene Distribution B.V. | Vidaza | praš. za susp. za inj., boč. stakl. 1x100 mg | 1.663,96 | 1.663,96 |  | 5% |
| L01BC07 071 | DS | azacitidinNL106 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Azacitidin Accord | praš. za susp. za inj., boč. stakl. 1x100 mg | 1.663,96 | 1.663,96 |  | 5% |
| L01BC07 081 | DS | azacitidinNL106 |  |  | P | Mylan Ireland Limited | Drehm Pharma GmbH | Azacitidin Mylan | praš. za susp. za inj., boč. stakl. 1x100 mg | 1.663,96 | 1.663,96 |  | 5% |
| L01BC07 092 | DS | azacitidinNL106 |  |  | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Azacitidin Sandoz | praš. za susp. za inj., boč. stakl. 1x100 mg | 1.590,02 | 1.590,02 |  | 5% |
| L01BC07 093 | DS | azacitidinNL106 |  |  | P | Zentiva k.s. | AqVida GmbH | Zassida | praš. za susp. za inj., boč. stakl. 1x100 mg | 1.510,52 | 1.510,52 |  | 5% |
| L01BC59 161 | DS | trifluridin + tipiracilNL466 |  |  | O | Les Laboratoires Servier | Les Laboratoires Servier Industrie | Lonsurf | tbl. film obl. 20x(15 mg + 6,14 mg) | 222,68 | 4.453,60 |  | 5% |
| L01BC59 162 | DS | trifluridin + tipiracilNL466 |  |  | O | Les Laboratoires Servier | Les Laboratoires Servier Industrie | Lonsurf | tbl. film obl. 20x(20 mg + 8,19 mg) | 263,87 | 5.277,47 |  | 5% |
| L01CA01 051 | DS | vinblastin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01CA02 061 | DS | vinkristin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Vincristine | amp. 1x1 mg | 39,80 | 39,80 |  | 5% |
| L01CA03 051 | KL | vindesin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01CA04 061 | DS | vinorelbin |  |  | P | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma | Vinorelsin | konc. za otop. za inf., boč. stakl. 10x1 ml (10 mg/ml) | 93,30 | 933,00 |  | 5% |
| L01CA04 161 | DS | vinorelbin |  |  | O | Zentiva k.s. | Pharmadox Healthcare Limited | Lavib | caps. meka 4x20 mg | 118,00 | 472,00 |  | 5% |
| L01CA04 162 | DS | vinorelbin |  |  | O | Zentiva k.s. | Pharmadox Healthcare Limited | Lavib | caps. meka 4x80 mg | 354,00 | 1.416,00 |  | 5% |
| L01CB01 022 | DS | etopozid |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Etoposide Sandoz | konc. otop. za inf., boč. 1x100 mg/5 ml | 54,07 | 54,07 |  | 5% |
| L01CB01 025 | DS | etopozid |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Etoposide Sandoz | konc. za otop. za inf., boč. stakl. 1x1000 mg/50 ml | 438,02 | 438,02 |  | 5% |
| L01CB01 151 |  | etopozid |  |  | O |  |  |  |  |  |  | RSRL03 | 5% |
| L01CD01 006 | DS | paklitaksel |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paklitaksel Kabi | konc. za otop.za inf., boč. stakl. 1x5 ml (6 mg/ml) | 170,10 | 170,10 |  | 5% |
| L01CD01 007 | DS | paklitaksel |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paklitaksel Kabi | konc. za otop. za inf., boč. stakl. 1x16,7 ml (6 mg/ml) | 538,65 | 538,65 |  | 5% |
| L01CD01 008 | DS | paklitaksel |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paklitaksel Kabi | konc. za otop. za inf., boč. stakl. 1x25 ml (6 mg/ml) | 797,64 | 797,64 |  | 5% |
| L01CD01 009 | DS | paklitaksel |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paklitaksel Kabi | konc. za otop. za inf., boč. stakl. 1x50 ml (6 mg/ml) | 1.563,92 | 1.563,92 |  | 5% |
| L01CD01 071 | DS | paklitaksel |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Paklitaksel Sandoz | boč. 1x30 mg/5 ml | 234,37 | 234,37 |  | 5% |
| L01CD01 072 | DS | paklitaksel |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Paklitaksel Sandoz | boč. 1x150 mg/25 ml | 1.094,15 | 1.094,15 |  | 5% |
| L01CD01 074 | DS | paklitaksel |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Paklitaksel Sandoz | konc. za otop. za inf., boč. 1x100 mg/16,7 ml (6 mg/ml) | 745,10 | 745,10 |  | 5% |
| L01CD01 075 | DS | paklitaksel |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Paklitaksel Sandoz | konc. za otop. za inf., boč. 1x300 mg/50 ml (6 mg/ml) | 2.145,30 | 2.145,30 |  | 5% |
| L01CD01 081 | DS | paklitaksel |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Paclitaxel Pliva | konc. za otop. za inf., boč. stakl. 1x30 mg/5 ml (6 mg/ml) | 379,73 | 379,73 |  | 5% |
| L01CD01 082 | DS | paklitaksel |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Paclitaxel Pliva | konc. za otop. za inf., boč. stak. 1x100 mg/16,7 ml (6 mg/ml) | 1.219,93 | 1.219,93 |  | 5% |
| L01CD01 083 | DS | paklitaksel |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Paclitaxel Pliva | konc. otop. za inf., boč. stakl. 1x150 mg/25 ml (6 mg/ml) | 2.188,30 | 2.188,30 |  | 5% |
| L01CD01 084 | DS | paklitaksel |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Paclitaxel Pliva | konc. za otop. za inf., boč. stak. 1x300 mg/50 ml (6 mg/ml) | 3.804,04 | 3.804,04 |  | 5% |
| L01CD01 086 | DS | paklitaksel |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis/ Sindan-Pharma | Sindaxel | konc. otop. za inf., boč. 1x5 ml (30 mg/5 ml) | 210,00 | 210,00 |  | 5% |
| L01CD01 087 | DS | paklitaksel |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis/ Sindan-Pharma | Sindaxel | konc. otop. za inf., boč. 1x16,7 ml (100 mg/16,7 ml) | 665,00 | 665,00 |  | 5% |
| L01CD01 088 | DS | paklitaksel |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis/ Sindan-Pharma | Sindaxel | konc. otop. za inf., boč. 1x25 ml (150 mg/25 ml) | 984,74 | 984,74 |  | 5% |
| L01CD01 089 | DS | paklitaksel |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis/ Sindan-Pharma | Sindaxel | konc. otop. za inf., boč. 1x50 ml (300 mg/50 ml) | 1.930,77 | 1.930,77 |  | 5% |
| L01CD01 095 | DS | paklitaksel (nab)NL436 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Abraxane | praš. za susp. za inf., boč. stakl. 1x100 mg (5 mg/ml) | 1.958,01 | 1.958,01 |  | 5% |
| L01CD01 096 | DS | paklitaksel (nab)NL436 |  |  | P | ratiopharm GmbH | Pharmachemie B.V., Merckle GmbH | Pazenir | praš. za disp. za inf., boč. stakl. 1x100 mg (5 mg/ml) | 1.469,95 | 1.469,95 |  | 5% |
| L01CD02 031 | DS | docetaksel |  |  | P | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tolnexa | konc. za otop. za inf., boč. stakl. 1x20 mg/ml | 396,09 | 396,09 |  | 5% |
| L01CD02 032 | DS | docetaksel |  |  | P | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tolnexa | konc. za otop. za inf., boč. stakl. 1x80 mg/4 ml | 1.381,50 | 1.381,50 |  | 5% |
| L01CD02 033 | DS | docetaksel |  |  | P | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tolnexa | konc. za otop. za inf., boč. stakl. 1x160 mg/8 ml | 2.488,32 | 2.488,32 |  | 5% |
| L01CD02 061 | DS | docetaksel |  |  | P | Aventis Pharma S.A. | Aventis Pharma Dagenham | Taxotere | konc. otop. za inf., boč. 1x20 mg/1 ml | 396,09 | 396,09 |  | 5% |
| L01CD02 062 | DS | docetaksel |  |  | P | Aventis Pharma S.A. | Aventis Pharma Dagenham | Taxotere | konc. za otop. za inf., boč. 1x80 mg/4 ml | 1.381,50 | 1.381,50 |  | 5% |
| L01CD02 063 | DS | docetaksel |  |  | P | Aventis Pharma S.A. | Aventis Pharma Dagenham | Taxotere | konc. otop. za inf., boč. 1x160 mg/8 ml | 2.488,32 | 2.488,32 |  | 5% |
| L01CD02 077 | DS | docetaksel |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Oncology Plc., Fresenius Kabi Deutschland GmbH | Docetaxel Kabi | konc. za otop. za inf., boč. stakl. 1x80 mg/4 ml | 1.381,50 | 1.381,50 |  | 5% |
| L01CD02 078 | DS | docetaksel |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Oncology Plc., Fresenius Kabi Deutschland GmbH | Docetaxel Kabi | konc. za otop. za inf., boč. stakl. 1x160 mg/8 ml | 2.488,32 | 2.488,32 |  | 5% |
| L01CD02 079 | DS | docetaksel |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Oncology Plc., Fresenius Kabi Deutschland GmbH | Docetaxel Kabi | konc. za otop. za inf., boč. stakl. 1x20 mg/ml | 396,09 | 396,09 |  | 5% |
| L01CD02 081 | DS | docetaksel |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Docetaksel Teva | konc. za otop. za inf., boč. 1x20 mg/ml | 396,09 | 396,09 |  | 5% |
| L01CD02 082 | DS | docetaksel |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Docetaksel Teva | konc. za otop. za inf., boč. 1x80 mg/4 ml | 1.381,50 | 1.381,50 |  | 5% |
| L01CD02 083 | DS | docetaksel |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Docetaksel Teva | konc. za otop. za inf., boč. 1x140 mg/7 ml | 1.850,04 | 1.850,04 |  | 5% |
| L01CD02 084 | DS | docetaksel |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Docetaxel Accord | konc. za otop. za inf., boč. stakl. 1x20 mg/ml | 320,83 | 320,83 |  | 5% |
| L01CD02 085 | DS | docetaksel |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Docetaxel Accord | konc. za otop. za inf., boč. stakl. 1x80 mg/4 ml | 1.119,02 | 1.119,02 |  | 5% |
| L01CD02 086 | DS | docetaksel |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Docetaxel Accord | konc. za otop. za inf., boč. stakl. 1x160 mg/8 ml | 2.015,54 | 2.015,54 |  | 5% |
| L01CD04 011 | DS | kabazitakselNL438 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o., S.C. Sindan-Pharma S.R.L. | Kabazitaksel Teva | konc. za otop. za inf., boč. stakl. 1x60 mg | 17.147,77 | 17.147,77 |  | 5% |
| L01CD04 061 | DS | kabazitakselNL438 |  |  | P | sanofi-aventis groupe | Aventis Pharma, Sanofi-Aventis Deutschland GmbH | Jevtana | konc. i otap. za otop. za inf., boč. stakl. 1x60 mg | 19.000,29 | 19.000,29 |  | 5% |
| L01CD04 071 | DS | kabazitakselNL438 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Kabazitaksel Accord | konc. za otop. za inf., boč. stakl. 1x60 mg | 19.000,29 | 19.000,29 |  | 5% |
| L01CD04 081 | DS | kabazitakselNL438 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Kabazitaksel EVER Pharma | konc. za otop. za inf., boč. stakl. 1x60 mg | 19.000,29 | 19.000,29 |  | 5% |
| L01CD04 082 | DS | kabazitakselNL438 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Kabazitaksel EVER Pharma | konc. za otop. za inf., boč. stakl. 1x50 mg | 13.737,00 | 13.737,00 |  | 5% |
| L01CD04 083 | DS | kabazitakselNL438 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Kabazitaksel EVER Pharma | konc. za otop. za inf., boč. stakl. 1x45 mg | 12.363,69 | 12.363,69 |  | 5% |
| L01CD04 084 | DS | kabazitakselNL438 |  |  | P | Zentiva k.s. | Pharmadox Healthcare Limited | Eleber | konc. i otap. za otop. za inf., boč. stakl. 1x60 mg | 19.000,29 | 19.000,29 |  | 5% |
| L01CD04 085 | DS | kabazitakselNL438 |  |  | P | Viatris Limited | AqVida GmbH | Kabazitaksel Viatris | konc. za otop. za inf., boč. stakl. 1x60 mg | 18.050,28 | 18.050,28 |  | 5% |
| L01CE01 061 | DS | topotekanNL123 |  |  | O | Novartis Europharm Limited Irska | GlaxoSmithKline Manufacturing S.p.A. | Hycamtin | caps. tvrda 10x0,25 mg | 69,71 | 697,10 |  | 5% |
| L01CE01 062 | DS | topotekanNL123 |  |  | O | Novartis Europharm Limited Irska | GlaxoSmithKline Manufacturing S.p.A. | Hycamtin | caps. tvrda 10x1 mg | 267,81 | 2.678,07 |  | 5% |
| L01CE01 081 | DS | topotekanNL124 |  |  | P | ALPHA-MEDICAL d.o.o. | Venus Pharma GmbH | Topotecan Alpha-medical | praš. za konc. za otop. za inf., boč. stakl. 5x4 mg | 990,49 | 4.952,45 |  | 5% |
| L01CE01 083 | DS | topotekanNL124 |  |  | P | Pfizer Europe MA EEIG | Hospira UK Limited, Hospira Enterprises B.V. | Topotecan Hospira | konc. za otop. za inf., boč. stakl. 5x4 mg/4 ml | 826,76 | 4.133,79 |  | 5% |
| L01CE01 091 | DS | topotekanNL425 |  |  | P | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma S.R.L. | Potactasol | praš. za konc. za otop. za inf., boč. stakl. 1x4 mg | 744,08 | 744,08 |  | 5% |
| L01CE02 041 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Irinotekan Accord | konc. za otop. za inf., boč. 1x40 mg/2 ml | 174,23 | 174,23 |  | 5% |
| L01CE02 042 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Irinotekan Accord | konc. za otop. za inf, boč. 1x1000 mg/50 ml | 3.552,50 | 3.552,50 |  | 5% |
| L01CE02 063 | DS | irinotekan |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc, Fresenius Kabi Deutschland GmbH | Irinotekan Kabi | konc. za otop. za inf., boč. stakl. 1x40 mg/2 ml | 193,59 | 193,59 |  | 5% |
| L01CE02 064 | DS | irinotekan |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc, Fresenius Kabi Deutschland GmbH | Irinotekan Kabi | konc. za otop. za inf, boč. stakl. 1x100 mg/5 ml | 437,40 | 437,40 |  | 5% |
| L01CE02 065 | DS | irinotekan |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc, Fresenius Kabi Deutschland GmbH | Irinotekan Kabi | konc. za otop. za inf, boč. stakl. 1x300 mg/15 ml | 1.312,20 | 1.312,20 |  | 5% |
| L01CE02 066 | DS | irinotekan |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc, Fresenius Kabi Deutschland GmbH | Irinotekan Kabi | konc. za otop. za inf, boč. stakl. 1x500 mg/25 ml | 2.187,00 | 2.187,00 |  | 5% |
| L01CE02 067 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Irinotekan Accord | konc. za otop. za inf, boč. 1x100 mg/5 ml | 393,66 | 393,66 |  | 5% |
| L01CE02 068 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Irinotekan Accord | konc. za otop. za inf, boč. 1x300 mg/15 ml | 1.180,98 | 1.180,98 |  | 5% |
| L01CE02 069 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Irinotekan Accord | konc. za otop. za inf, boč. 1x500 mg/25 ml | 1.968,30 | 1.968,30 |  | 5% |
| L01CE02 071 | DS | irinotekan |  |  | P | Teva B.V. | Actavis/ Sindan-Pharma | Irinotesin | konc. otop. za inf., boč. stakl. 1x2 ml (20 mg/ml) | 239,00 | 239,00 |  | 5% |
| L01CE02 072 | DS | irinotekan |  |  | P | Teva B.V. | Actavis/ Sindan-Pharma | Irinotesin | konc. otop. za inf. boč. stakl. 1x5 ml (20 mg/ml) | 540,00 | 540,00 |  | 5% |
| L01CE02 073 | DS | irinotekan |  |  | P | Teva B.V. | Actavis Italy S.p.A., S.C. Sindan-Pharma S.R.L. | Irinotesin | konc. za otop. za inf, boč. 1x300 mg/15 ml | 1.121,93 | 1.121,93 |  | 5% |
| L01CE02 074 | DS | irinotekan |  |  | P | Teva B.V. | Actavis Italy S.p.A., S.C. Sindan-Pharma S.R.L. | Irinotesin | konc. za otop. za inf, boč. 1x500 mg/25 ml | 1.869,89 | 1.869,89 |  | 5% |
| L01CE02 091 | DS | irinotekan |  |  | P | Pfizer Croatia d.o.o. | Aventis Pharma, Actavis , Pfizer | Campto | boč. inf. 1x100 mg/5 ml | 540,00 | 540,00 |  | 5% |
| L01CX01 001 | KL | trabektedinNL418 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o. | Trabektedin Teva | praš. za konc. za otop. za inf., boč. stakl. 1x0,25 mg | 2.493,99 | 2.493,99 |  | 5% |
| L01CX01 002 | KL | trabektedinNL418 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o. | Trabektedin Teva | praš. za konc. za otop. za inf., boč. stakl. 1x1 mg | 9.975,97 | 9.975,97 |  | 5% |
| L01CX01 061 | KL | trabektedinNL418 |  |  | P | PHARMA MAR, S.A. | Pharma Mar S.A. | Yondelis | praš. za konc. za otop. za inf., boč. stakl. 1x0,25 mg | 3.841,66 | 3.841,66 |  | 5% |
| L01CX01 062 | KL | trabektedinNL418 |  |  | P | PHARMA MAR, S.A. | Pharma Mar S.A. | Yondelis | praš. za konc. za otop. za inf., boč. stakl. 1x1 mg | 14.251,39 | 14.251,39 |  | 5% |
| L01DA01 051 | KL | daktinomicin (aktinomicin-D) |  |  | P |  |  |  |  |  |  |  | 5% |
| L01DB01 008 | DS | doksorubicin liposomalniNL446 |  |  | P | Teva B.V. | GP-Pharm, Teva Operations Poland Sp. z o.o. | Myocet | praš., disp. i otap. za konc. za disp. za inf. 2x50 mg | 3.423,77 | 6.847,53 |  | 5% |
| L01DB01 063 | DS | doksorubicin |  |  | P | ACTAVIS GROUP PTC ehf. | Sindan-Pharma | Sindroxocin | praš. za otop. za inj. ili inf., boč. 1x10 mg | 39,37 | 39,37 |  | 5% |
| L01DB01 064 | DS | doksorubicin |  |  | P | ACTAVIS GROUP PTC ehf. | Sindan-Pharma | Sindroxocin | praš. za otop. za inj. ili inf., boč. 1x50 mg | 196,83 | 196,83 |  | 5% |
| L01DB01 081 | DS | doksorubicin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Doxorubicin Pliva | boč. 1x10 mg/5 ml | 43,74 | 43,74 |  | 5% |
| L01DB01 082 | DS | doksorubicin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Doxorubicin Pliva | boč. 1x50 mg/25 ml | 218,70 | 218,70 |  | 5% |
| L01DB01 091 | DS | doksorubicin pegilirani liposomalni NL539 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z o.o. | Zolsketil | konc. za disp. za inf., boč. 1x25 ml (2 mg/ml) | 2.396,64 | 2.396,64 |  | 5% |
| L01DB01 092 | DS | doksorubicin pegilirani liposomalni NL539 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z o.o. | Zolsketil | konc. za disp. za inf., boč. 1x10 ml (2 mg/ml) | 958,66 | 958,66 |  | 5% |
| L01DB02 063 | DS | daunorubicin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Daunoblastina | amp. 1x20 mg | 71,07 | 71,07 |  | 5% |
| L01DB03 064 | DS | epirubicin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Farmorubicin PFS | amp. 1x10 mg | 90,30 | 90,30 |  | 5% |
| L01DB03 065 | DS | epirubicin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Farmorubicin PFS | amp. 1x50 mg | 380,00 | 380,00 |  | 5% |
| L01DB03 081 | DS | epirubicin |  |  | P | Teva B.V. | Sindan-Pharma | Episindan | praš. za otop. za inj., boč. 1x10 mg | 80,05 | 80,05 |  | 5% |
| L01DB03 082 | DS | epirubicin |  |  | P | Teva B.V. | Sindan-Pharma | Episindan | praš. za otop. za inj., boč. 1x50 mg | 438,21 | 438,21 |  | 5% |
| L01DB06 067 | DS | idarubicin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Zavedos | lio amp. 1x10 mg | 875,12 | 875,12 |  | 5% |
| L01DB07 051 | DS | mitoksantron |  |  | P |  |  |  |  |  |  |  | 5% |
| L01DB11 061 | DS | piksantronNL480 |  |  | P | Les Laboratoires Servier | Les Laboratoires Servier Industrie | Pixuvri | praš. za konc. za otop. za inf., boč. stakl. 1x29 mg | 5.221,81 | 5.221,81 |  | 5% |
| L01DC01 051 | DS | bleomicin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01DC03 051 | DS | mitomicin-D |  |  | P |  |  |  |  |  |  |  | 5% |
| L01EA01 101 | DS | imatinibNL115 | 400 mg | 210,85 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivatinib | tbl. film obl. 60x100 mg | 52,71 | 3.162,80 |  | 5% |
| L01EA01 102 | DS | imatinibNL115 | 400 mg | 190,95 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivatinib | tbl. film obl. 30x400 mg | 190,95 | 5.728,60 |  | 5% |
| L01EA01 135 | DS | imatinib NL115 | 400 mg | 210,85 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 60x100 mg | 52,71 | 3.162,80 |  | 5% |
| L01EA01 136 | DS | imatinib NL115 | 400 mg | 215,29 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 90x100 mg | 53,82 | 4.844,10 |  | 5% |
| L01EA01 137 | DS | imatinibNL115 | 400 mg | 190,95 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 30x400 mg | 190,95 | 5.728,60 |  | 5% |
| L01EA01 138 | DS | imatinib NL115 | 400 mg | 187,35 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 60x400 mg | 187,35 | 11.240,80 |  | 5% |
| L01EA01 141 | DS | imatinibNL115 | 400 mg | 162,67 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Imatinib Alkaloid-INT | tbl. film obl. 60x100 mg | 40,67 | 2.440,08 |  | 5% |
| L01EA01 142 | DS | imatinibNL115 | 400 mg | 161,36 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Imatinib Alkaloid-INT | tbl. film obl. 30x400 mg | 161,36 | 4.840,92 |  | 5% |
| L01EA01 161 | DS | imatinibNL115 | 400 mg | 210,85 | O | Zentiva k.s. | Remedica Ltd., Pharmadox Healthcare Ltd. | Imakrebin | tbl. film obl. 60x100 mg | 52,71 | 3.162,80 |  | 5% |
| L01EA01 162 | DS | imatinibNL115 | 400 mg | 190,95 | O | Zentiva k.s. | Remedica Ltd., Pharmadox Healthcare Ltd. | Imakrebin | tbl. film obl. 30x400 mg | 190,95 | 5.728,60 |  | 5% |
| L01EA01 193 | DS | imatinibNL115 | 400 mg | 190,26 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Imatinib Accord | tbl. film obl. 60x100 mg | 47,57 | 2.853,90 |  | 5% |
| L01EA01 194 | DS | imatinibNL115 | 400 mg | 188,73 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Imatinib Accord | tbl. film obl. 30x400 mg | 188,73 | 5.661,90 |  | 5% |
| L01EA02 101 | DS | dasatinibNL119 | 100 mg | 633,33 | O | Teva B.V. | Merckle GmbH, Pliva Hrvatska d.o.o. | Dasatinib Teva | tbl. film obl. 60x20 mg | 126,67 | 7.599,95 |  | 5% |
| L01EA02 102 | DS | dasatinibNL119 | 100 mg | 381,21 | O | Teva B.V. | Merckle GmbH, Pliva Hrvatska d.o.o. | Dasatinib Teva | tbl. film obl. 30x100 mg | 381,21 | 11.436,21 |  | 5% |
| L01EA02 141 | DS | dasatinibNL119 | 100 mg | 666,66 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Nodriga | tbl. film obl. 60x20 mg | 133,33 | 7.999,95 |  | 5% |
| L01EA02 142 | DS | dasatinibNL119 | 100 mg | 401,27 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Nodriga | tbl. film obl. 30x100 mg | 401,27 | 12.038,12 |  | 5% |
| L01EA02 161 | DS | dasatinibNL119 | 100 mg | 1.002,50 | O | Bristol-Myers Squibb Pharma EEIG | Bristol-Myers Squibb | Sprycel | tbl. film obl. 60x20 mg | 200,50 | 12.030,00 |  | 5% |
| L01EA02 163 | DS | dasatinibNL119 | 100 mg | 603,42 | O | Bristol-Myers Squibb Pharma EEIG | Bristol-Myers Squibb | Sprycel | tbl. film obl. 30x100 mg | 603,42 | 18.102,60 |  | 5% |
| L01EA02 173 | DS | dasatinibNL119 | 100 mg | 601,66 | O | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Dasatinib Zentiva | tbl. film obl. 60x20 mg | 120,33 | 7.219,95 |  | 5% |
| L01EA02 174 | DS | dasatinibNL119 | 100 mg | 362,15 | O | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Dasatinib Zentiva | tbl. film obl. 30x100 mg | 362,15 | 10.864,40 |  | 5% |
| L01EA02 181 | DS | dasatinibNL119 | 100 mg | 633,33 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Dasatinib Alpha-Medical | tbl. film obl. 60x20 mg | 126,67 | 7.599,95 |  | 5% |
| L01EA02 182 | DS | dasatinibNL119 | 100 mg | 381,21 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Dasatinib Alpha-Medical | tbl. film obl. 30x100 mg | 381,21 | 11.436,21 |  | 5% |
| L01EA03 171 | DS | nilotinibNL121 | 600 mg | 655,85 | O | Novartis Europharm Limited Irska | Lek d.d, PE PROIZVODNJA LENDAVA, Novartis Pharma GmbH | Tasigna | caps. tvrda 112x200 mg | 218,62 | 24.485,07 |  | 5% |
| L01EA04 161 | DS | bosutinibNL119 | 400 mg | 704,91 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Bosulif | tbl. film obl. 28x100 mg | 176,23 | 4.934,40 |  | 5% |
| L01EA04 162 | DS | bosutinibNL119 | 400 mg | 706,20 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Bosulif | tbl. film obl. 28x500 mg | 882,75 | 24.717,00 |  | 5% |
| L01EA05 161 | DS | ponatinibNL526 | 45 mg | 2.093,90 | O | Incyte Biosciences Distribution B.V. | Incyte Biosciences Distribution B.V. | Iclusig | tbl. film obl. 60x15 mg | 697,97 | 41.878,00 |  | 5% |
| L01EA05 162 | DS | ponatinibNL526 | 45 mg | 1.272,33 | O | Incyte Biosciences Distribution B.V. | Incyte Biosciences Distribution B.V. | Iclusig | tbl. film obl. 30x45 mg | 1.272,33 | 38.170,00 |  | 5% |
| L01EB01 101 | DS | gefitinibNL419 | 250 mg | 248,34 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gefitinib Pliva | tbl. film obl. 30x250 mg | 248,34 | 7.450,20 |  | 5% |
| L01EB01 141 | DS | gefitinibNL419 | 250 mg | 235,92 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Phrompo | tbl. film obl. 30x250 mg | 235,92 | 7.077,69 |  | 5% |
| L01EB01 191 | DS | gefitinibNL419 | 250 mg | 275,94 | O | Zentiva k.s. | Pharmadox Healthcare Limited, S.C Labormed – Pharma SA | Gefitinib Zentiva | tbl. film obl. 30x250 mg | 275,94 | 8.278,20 |  | 5% |
| L01EB02 161 | DS | erlotinib | 150 mg | 196,87 | O | Roche Registration GmbH | Roche | Tarceva | tbl. film obl. 30x150 mg | 196,87 | 5.906,08 |  | 5% |
| L01EB02 162 | DS | erlotinib | 150 mg | 196,87 | O | Zentiva k.s. | Remedica Ltd. | Varlota | tbl. film obl. 30x150 mg | 196,87 | 5.906,08 |  | 5% |
| L01EB02 163 | DS | erlotinib | 150 mg | 196,87 | O | Remedica Ltd. | Remedica Ltd. | Erlotinib Remedica | tbl. film obl. 30x150 mg | 196,87 | 5.906,08 |  | 5% |
| L01EB02 164 | DS | erlotinib | 150 mg | 196,87 | O | PharmaS d.o.o. | Remedica Ltd. | Erlotinib PharmaS | tbl. film obl. 30x150 mg | 196,87 | 5.906,08 |  | 5% |
| L01EB02 165 | DS | erlotinib | 150 mg | 196,87 | O | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma S.R.L. | Erlotinib Actavis | tbl. film obl. 30x150 mg | 196,87 | 5.906,08 |  | 5% |
| L01EB02 166 | DS | erlotinib | 150 mg | 196,87 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d., Remedica Ltd. | Erlotinib Sandoz | tbl. film obl. 30x150 mg | 196,87 | 5.906,08 |  | 5% |
| L01EB02 167 | DS | erlotinib | 150 mg | 196,87 | O | Mylan Pharmaceuticals Limited | Remedica Ltd. | Erlotinib Mylan | tbl. film obl. 30x150 mg | 196,87 | 5.906,08 |  | 5% |
| L01EB02 168 | DS | erlotinib | 150 mg | 187,03 | O | KRKA-FARMA d.o.o. | Krka d.d. | Erlotinib Krka | tbl. film obl. 30x150 mg | 187,03 | 5.610,78 |  | 5% |
| L01EB02 169 | DS | erlotinib | 150 mg | 177,67 | O | Alkaloid-INT d.o.o. | Alkaloid-INT d.o.o. | Fokleros | tbl. film obl. 30x150 mg | 177,67 | 5.330,24 |  | 5% |
| L01EB03 161 | DS | afatinibNL419 | 40 mg | 998,28 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Giotrif | tbl. film obl. 28x20 mg | 499,14 | 13.975,92 |  | 5% |
| L01EB03 162 | DS | afatinibNL419 | 40 mg | 660,30 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Giotrif | tbl. film obl. 28x30 mg | 495,22 | 13.866,25 |  | 5% |
| L01EB03 163 | DS | afatinibNL419 | 40 mg | 495,22 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Giotrif | tbl. film obl. 28x40 mg | 495,22 | 13.866,25 |  | 5% |
| L01EB04 161 | KS | osimertinibNL473 | 80 mg | 3.037,70 | O | AstraZeneca AB | AstraZeneca AB | Tagrisso | tbl. film obl. 28x40 mg | 1.518,85 | 42.527,80 |  | 5% |
| L01EB04 162 | KS | osimertinibNL473 | 80 mg | 1.518,85 | O | AstraZeneca AB | AstraZeneca AB | Tagrisso | tbl. film obl. 28x80 mg | 1.518,85 | 42.527,80 |  | 5% |
| L01EC01 061 | KS | vemurafenibNL422 | 1920 mg | 1.711,09 | O | Roche Registration GmbH | Roche Pharma AG | Zelboraf | tbl. film obl. 56x240 mg | 213,89 | 11.977,65 |  | 5% |
| L01EC02 162 | KS | dabrafenibNL422 | 300 mg | 1.576,26 | O | Novartis Europharm Limited Irska | Glaxo Wellcome S.A. | Tafinlar | caps. tvrda 120x50 mg | 262,71 | 31.525,20 |  | 5% |
| L01EC02 163 | KS | dabrafenibNL422 | 300 mg | 1.584,39 | O | Novartis Europharm Limited Irska | Glaxo Wellcome S.A. | Tafinlar | caps. tvrda 120x75 mg | 396,10 | 47.531,60 |  | 5% |
| L01ED01 161 | DS | krizotinibNL444 | 500 mg | 1.366,22 | O | Pfizer Europe MA EEIG | Pfizer | Xalkori | caps. tvrda 60x200 mg | 546,49 | 32.789,29 |  | 5% |
| L01ED01 162 | DS | krizotinibNL444 | 500 mg | 1.092,98 | O | Pfizer Europe MA EEIG | Pfizer | Xalkori | caps. tvrda 60x250 mg | 546,49 | 32.789,29 |  | 5% |
| L01ED03 161 | DS | alektinibNL474 | 1200 mg | 1.418,75 | O | Roche Registration GmbH | Roche Pharma AG | Alecensa | caps. tvrda 224x150 mg | 177,34 | 39.724,91 |  | 5% |
| L01ED04 071 | DS | brigatinibNL501 | 180 mg | 1.377,95 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. 28x30 mg | 229,66 | 6.430,48 |  | 5% |
| L01ED04 072 | DS | brigatinibNL501 | 180 mg | 1.356,29 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. 28x90 mg | 678,15 | 18.988,11 |  | 5% |
| L01ED04 073 | DS | brigatinibNL501 | 180 mg | 1.124,83 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. 28x180 mg | 1.124,83 | 31.495,33 |  | 5% |
| L01ED04 074 | DS | brigatinibNL501 | 180 mg | 1.285,52 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. (7x90 mg + 21x180 mg) | 1.124,83 | 31.495,33 |  | 5% |
| L01ED05 161 | DS | lorlatinibNL511 | 100 mg | 1.422,46 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Lorviqua | tbl. film obl. 90x25 mg | 355,62 | 32.005,35 |  | 5% |
| L01ED05 162 | DS | lorlatinibNL511 | 100 mg | 1.423,27 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Lorviqua | tbl. film obl. 120x25 mg | 355,82 | 42.698,09 |  | 5% |
| L01ED05 163 | DS | lorlatinibNL511 | 100 mg | 1.053,37 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Lorviqua | tbl. film obl. 30x100 mg | 1.053,37 | 31.601,00 |  | 5% |
| L01EE01 161 | KS | trametinibNL422 | 2 mg | 1.078,85 | O | Novartis Europharm Limited Irska | Lek Pharmaceuticals d.d., Novartis Pharma GmbH | Mekinist | tbl. film obl. 30x0,5 mg | 269,71 | 8.091,40 |  | 5% |
| L01EE01 162 | KS | trametinibNL422 | 2 mg | 1.064,73 | O | Novartis Europharm Limited Irska | Lek Pharmaceuticals d.d., Novartis Pharma GmbH | Mekinist | tbl. film obl. 30x2 mg | 1.064,73 | 31.941,90 |  | 5% |
| L01EE02 161 | KS | kobimetinibNL422 | 45 mg | 1.362,64 | O | Roche Registration GmbH | Roche Pharma AG | Cotellic | tbl. film obl. 63x20 mg | 605,62 | 38.153,85 |  | 5% |
| L01EF01 161 | DS | palbociklibNL478 | 94 mg | 1.219,09 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | caps. tvrda 21x75 mg | 972,68 | 20.426,21 |  | 5% |
| L01EF01 162 | DS | palbociklibNL478 | 94 mg | 919,47 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | caps. tvrda 21x100 mg | 978,16 | 20.541,29 |  | 5% |
| L01EF01 163 | DS | palbociklibNL478 | 94 mg | 735,57 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | caps. tvrda 21x125 mg | 978,16 | 20.541,29 |  | 5% |
| L01EF01 164 | DS | palbociklibNL478 | 94 mg | 1.211,49 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | tbl. film obl. 21x75 mg | 966,62 | 20.298,95 |  | 5% |
| L01EF01 165 | DS | palbociklibNL478 | 94 mg | 908,62 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | tbl. film obl. 21x100 mg | 966,62 | 20.298,95 |  | 5% |
| L01EF01 166 | DS | palbociklibNL478 | 94 mg | 726,90 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | tbl. film obl. 21x125 mg | 966,62 | 20.298,95 |  | 5% |
| L01EF02 161 | DS | ribociklibNL479 | 450 mg | 805,95 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Kisqali | tbl. film obl. 63x200 mg | 358,20 | 22.566,60 |  | 5% |
| L01EF03 171 | DS | abemaciklibNL498 | 300 mg | 1.988,30 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Verzenios | tbl. film obl. 28x50 mg | 331,39 | 9.278,78 |  | 5% |
| L01EF03 172 | DS | abemaciklibNL498 | 300 mg | 994,16 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Verzenios | tbl. film obl. 28x100 mg | 331,39 | 9.278,78 |  | 5% |
| L01EF03 173 | DS | abemaciklibNL498 | 300 mg | 662,77 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Verzenios | tbl. film obl. 28x150 mg | 331,39 | 9.278,78 |  | 5% |
| L01EG01 071 | DS | temsirolimusNL122 | 3.57 mg | 764,60 | P | Pfizer Europe MA EEIG | Wyeth | Torisel | konc. i otap. za inf. boč. stakl. 1x30 mg/1,2 ml + boč. stakl. 1x2,2 ml | 6.425,25 | 6.425,25 |  | 5% |
| L01EG01 081 | DS | temsirolimusNL122 | 3.57 mg | 535,22 | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Polska Sp. z o.o., Accord Healthcare B.V. | Temsirolimus Accord | konc. i otap. za otop. za inf. boč. stakl. 30 mg, 1 boč. s konc. i 1 boč. s otap. | 4.497,68 | 4.497,68 |  | 5% |
| L01EG02 101 | DS | everolimusNL420 | 10 mg | 568,49 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Everolimus Pliva | tbl. 30x5 mg | 284,25 | 8.527,39 |  | 5% |
| L01EG02 102 | DS | everolimusNL420 | 10 mg | 388,32 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Everolimus Pliva | tbl. 30x10 mg | 388,32 | 11.649,47 |  | 5% |
| L01EG02 131 | DS | everolimusNL420 | 10 mg | 511,64 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 30x2,5 mg | 127,91 | 3.837,33 |  | 5% |
| L01EG02 132 | DS | everolimusNL420 | 10 mg | 460,48 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 90x2,5 mg | 115,12 | 10.360,78 |  | 5% |
| L01EG02 133 | DS | everolimusNL420 | 10 mg | 511,64 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 30x5 mg | 255,82 | 7.674,65 |  | 5% |
| L01EG02 134 | DS | everolimusNL420 | 10 mg | 460,48 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 90x5 mg | 230,24 | 20.721,56 |  | 5% |
| L01EG02 135 | DS | everolimusNL420 | 10 mg | 349,48 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 30x10 mg | 349,48 | 10.484,52 |  | 5% |
| L01EG02 136 | DS | everolimusNL420 | 10 mg | 314,54 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 90x10 mg | 314,54 | 28.308,20 |  | 5% |
| L01EG02 171 | DS | everolimusNL420 | 10 mg | 568,49 | O | Zentiva k.s. | Genepharm S.A., Pharmadox Healthcare Limited | Everolimus Zentiva | tbl. 30x5 mg | 284,25 | 8.527,39 |  | 5% |
| L01EG02 172 | DS | everolimusNL420 | 10 mg | 388,32 | O | Zentiva k.s. | Genepharm S.A., Pharmadox Healthcare Limited | Everolimus Zentiva | tbl. 30x10 mg | 388,32 | 11.649,47 |  | 5% |
| L01EG02 181 | DS | everolimusNL420 | 10 mg | 568,49 | O | STADA d.o.o. | Stada Arzneimittel | Everolimus STADA | tbl. 30x5 mg | 284,25 | 8.527,39 |  | 5% |
| L01EG02 182 | DS | everolimusNL420 | 10 mg | 388,32 | O | STADA d.o.o. | Stada Arzneimittel | Everolimus STADA | tbl. 30x10 mg | 388,32 | 11.649,47 |  | 5% |
| L01EG02 183 | DS | everolimusNL420 | 10 mg | 568,49 | O | Mylan Pharmaceuticals Limited | Synthon Hispania S.L., Synthon BV | Everolimus Mylan | tbl. 30x5 mg | 284,25 | 8.527,39 |  | 5% |
| L01EG02 184 | DS | everolimusNL420 | 10 mg | 388,32 | O | Mylan Pharmaceuticals Limited | Synthon Hispania S.L., Synthon BV | Everolimus Mylan | tbl. 30x10 mg | 388,32 | 11.649,47 |  | 5% |
| L01EG02 185 | DS | everolimusNL420 | 10 mg | 568,49 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Alpha-Medical | tbl. 30x5 mg | 284,25 | 8.527,39 |  | 5% |
| L01EG02 186 | DS | everolimusNL420 | 10 mg | 388,32 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Alpha-Medical | tbl. 30x10 mg | 388,32 | 11.649,47 |  | 5% |
| L01EH01 161 | DS | lapatinibNL120 | 1250 mg | 581,80 | O | Novartis Europharm Limited Irska | Glaxo Wellcome S.A., Novartis Pharma GmbH | Tyverb | tbl. film obl. 70x250 mg | 116,36 | 8.145,20 |  | 5% |
| L01EJ01 161 | DS | ruksolitinibNL453 | 30 mg | 1.470,87 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Jakavi | tbl. 56x5 mg | 245,14 | 13.728,03 |  | 5% |
| L01EJ01 162 | DS | ruksolitinibNL453 | 30 mg | 972,99 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Jakavi | tbl. 56x15 mg | 486,50 | 27.243,81 |  | 5% |
| L01EJ01 163 | DS | ruksolitinibNL453 | 30 mg | 729,75 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Jakavi | tbl. 56x20 mg | 486,50 | 27.243,81 |  | 5% |
| L01EK01 161 | DS | aksitinibNL430 | 10 mg | 799,20 | O | Pfizer Europe MA EEIG | Pfizer | Inlyta | tbl. film obl. 56x1 mg | 79,92 | 4.475,52 |  | 5% |
| L01EK01 162 | DS | aksitinibNL430 | 10 mg | 799,20 | O | Pfizer Europe MA EEIG | Pfizer | Inlyta | tbl. film obl. 56x5 mg | 399,60 | 22.377,60 |  | 5% |
| L01EL01 161 | DS | ibrutinibNL502 | 420 mg | 1.350,39 | O | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Imbruvica | caps. tvrda 90x140 mg | 450,13 | 40.511,70 |  | 5% |
| L01EL01 162 | DS | ibrutinibNL471 | 420 mg | 1.349,80 | O | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Imbruvica | caps. tvrda 120x140 mg | 449,93 | 53.992,00 |  | 5% |
| L01EL01 163 | DS | ibrutinibNL527 | 420 mg | 1.349,80 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x140 mg | 449,93 | 12.598,13 |  | 5% |
| L01EL01 164 | DS | ibrutinibNL527 | 420 mg | 1.349,80 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x280 mg | 899,87 | 25.196,27 |  | 5% |
| L01EL01 165 | DS | ibrutinibNL527 | 420 mg | 1.349,80 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x420 mg | 1.349,80 | 37.794,40 |  | 5% |
| L01EL01 166 | DS | ibrutinibNL471 | 420 mg | 1.349,80 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x560 mg | 1.799,73 | 50.392,53 |  | 5% |
| L01EL02 161 | DS | akalabrutinib NL533 | 0.2 g | 1.282,31 | O | AstraZeneca AB | AstraZeneca AB | Calquence | caps. tvrda 56x100 mg | 641,16 | 35.904,68 |  | 5% |
| L01EM01 161 | DS | idelalisibNL454 | 300 mg | 1.371,48 | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Zydelig | tbl. film obl. 60x100 mg | 457,16 | 27.429,60 |  | 5% |
| L01EM01 162 | DS | idelalisibNL454 | 300 mg | 914,32 | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Zydelig | tbl. film obl. 60x150 mg | 457,16 | 27.429,60 |  | 5% |
| L01EM03 171 | DS | alpelisibNL531 | 300 mg | 1.045,35 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Piqray | tbl. film obl. 28x50 mg + 28x200 mg | 435,56 | 24.391,36 |  | 5% |
| L01EM03 172 | DS | alpelisibNL531 | 300 mg | 871,12 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Piqray | tbl. film obl. 56x150 mg | 435,56 | 24.391,36 |  | 5% |
| L01EM03 173 | DS | alpelisibNL531 | 300 mg | 1.306,68 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Piqray | tbl. film obl. 28x200 mg | 871,12 | 24.391,36 |  | 5% |
| L01EX01 101 | DS | sunitinibNL117 | 33 mg | 478,17 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sunitinib Pliva | caps. tvrda 28x12,5 mg | 181,13 | 5.071,57 |  | 5% |
| L01EX01 102 | DS | sunitinibNL117 | 33 mg | 475,99 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sunitinib Pliva | caps. tvrda 28x25 mg | 360,60 | 10.096,79 |  | 5% |
| L01EX01 103 | DS | sunitinibNL117 | 33 mg | 474,06 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sunitinib Pliva | caps. tvrda 28x50 mg | 718,28 | 20.111,79 |  | 5% |
| L01EX01 131 | DS | sunitinibNL117 | 33 mg | 478,18 | O | KRKA-FARMA d.o.o. | Krka d.d, Krka – farma d.o.o. | Sunitinib Krka | caps. tvrda 30x12,5 mg | 181,13 | 5.433,90 |  | 5% |
| L01EX01 132 | DS | sunitinibNL117 | 33 mg | 475,99 | O | KRKA-FARMA d.o.o. | Krka d.d, Krka – farma d.o.o. | Sunitinib Krka | caps. tvrda 30x25 mg | 360,60 | 10.818,00 |  | 5% |
| L01EX01 133 | DS | sunitinibNL117 | 33 mg | 474,07 | O | KRKA-FARMA d.o.o. | Krka d.d, Krka – farma d.o.o. | Sunitinib Krka | caps. tvrda 30x50 mg | 718,28 | 21.548,40 |  | 5% |
| L01EX01 141 | DS | sunitinibNL117 | 33 mg | 454,27 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Sunitinib Alkaloid-INT | caps. tvrda 28x12,5 mg | 172,07 | 4.817,99 |  | 5% |
| L01EX01 142 | DS | sunitinibNL117 | 33 mg | 452,19 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Sunitinib Alkaloid-INT | caps. tvrda 28x25 mg | 342,57 | 9.591,95 |  | 5% |
| L01EX01 143 | DS | sunitinibNL117 | 33 mg | 450,36 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Sunitinib Alkaloid-INT | caps. tvrda 28x50 mg | 682,36 | 19.106,20 |  | 5% |
| L01EX01 164 | DS | sunitinibNL117 | 33 mg | 478,17 | O | Pfizer Europe MA EEIG | Pfizer | Sutent | caps. tvrda 28x12,5 mg | 181,13 | 5.071,57 |  | 5% |
| L01EX01 165 | DS | sunitinibNL117 | 33 mg | 475,99 | O | Pfizer Europe MA EEIG | Pfizer | Sutent | caps. tvrda 28x25 mg | 360,60 | 10.096,79 |  | 5% |
| L01EX01 166 | DS | sunitinibNL117 | 33 mg | 474,06 | O | Pfizer Europe MA EEIG | Pfizer | Sutent | caps. tvrda 28x50 mg | 718,28 | 20.111,79 |  | 5% |
| L01EX01 171 | DS | sunitinibNL117 | 33 mg | 478,17 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sunitinib Stada | caps. tvrda 28x12,5 mg | 181,13 | 5.071,57 |  | 5% |
| L01EX01 172 | DS | sunitinibNL117 | 33 mg | 475,99 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sunitinib Stada | caps. tvrda 28x25 mg | 360,60 | 10.096,79 |  | 5% |
| L01EX01 173 | DS | sunitinibNL117 | 33 mg | 474,06 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sunitinib Stada | caps. tvrda 28x50 mg | 718,28 | 20.111,79 |  | 5% |
| L01EX01 174 | DS | sunitinibNL117 | 33 mg | 478,18 | O | Accord Healthcare S.L.U. | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Accord | caps. tvrda 30x12,5 mg | 181,13 | 5.433,90 |  | 5% |
| L01EX01 175 | DS | sunitinibNL117 | 33 mg | 475,99 | O | Accord Healthcare S.L.U. | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Accord | caps. tvrda 30x25 mg | 360,60 | 10.818,00 |  | 5% |
| L01EX01 176 | DS | sunitinibNL117 | 33 mg | 474,07 | O | Accord Healthcare S.L.U. | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Accord | caps. tvrda 30x50 mg | 718,28 | 21.548,40 |  | 5% |
| L01EX01 177 | DS | sunitinibNL117 | 33 mg | 478,17 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sunitinib Sandoz | caps. tvrda 28x12,5 mg | 181,13 | 5.071,57 |  | 5% |
| L01EX01 178 | DS | sunitinibNL117 | 33 mg | 475,99 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sunitinib Sandoz | caps. tvrda 28x25 mg | 360,60 | 10.096,79 |  | 5% |
| L01EX01 179 | DS | sunitinibNL117 | 33 mg | 474,06 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sunitinib Sandoz | caps. tvrda 28x50 mg | 718,28 | 20.111,79 |  | 5% |
| L01EX01 181 | DS | sunitinibNL117 | 33 mg | 478,17 | O | Mylan Ireland Limited | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Mylan | caps. tvrda 28x12,5 mg | 181,13 | 5.071,57 |  | 5% |
| L01EX01 182 | DS | sunitinibNL117 | 33 mg | 475,99 | O | Mylan Ireland Limited | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Mylan | caps. tvrda 28x25 mg | 360,60 | 10.096,79 |  | 5% |
| L01EX01 183 | DS | sunitinibNL117 | 33 mg | 474,06 | O | Mylan Ireland Limited | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Mylan | caps. tvrda 28x50 mg | 718,28 | 20.111,79 |  | 5% |
| L01EX01 184 | DS | sunitinibNL117 | 33 mg | 478,17 | O | ALPHA-MEDICAL d.o.o. | Synthon s.r.o., Synthon BV | Sunitinib Alpha-Medical | caps. tvrda 28x12,5 mg | 181,13 | 5.071,57 |  | 5% |
| L01EX01 185 | DS | sunitinibNL117 | 33 mg | 475,99 | O | ALPHA-MEDICAL d.o.o. | Synthon s.r.o., Synthon BV | Sunitinib Alpha-Medical | caps. tvrda 28x25 mg | 360,60 | 10.096,79 |  | 5% |
| L01EX01 186 | DS | sunitinibNL117 | 33 mg | 474,06 | O | ALPHA-MEDICAL d.o.o. | Synthon s.r.o., Synthon BV | Sunitinib Alpha-Medical | caps. tvrda 28x50 mg | 718,28 | 20.111,79 |  | 5% |
| L01EX01 187 | DS | sunitinibNL117 | 33 mg | 478,17 | O | Zentiva k.s. | Remedica Ltd., Pharmacare Premium Ltd. | Zesuva | caps. tvrda 28x12,5 mg | 181,13 | 5.071,57 |  | 5% |
| L01EX01 188 | DS | sunitinibNL117 | 33 mg | 475,99 | O | Zentiva k.s. | Remedica Ltd., Pharmacare Premium Ltd. | Zesuva | caps. tvrda 28x25 mg | 360,60 | 10.096,79 |  | 5% |
| L01EX01 189 | DS | sunitinibNL117 | 33 mg | 474,06 | O | Zentiva k.s. | Remedica Ltd., Pharmacare Premium Ltd. | Zesuva | caps. tvrda 28x50 mg | 718,28 | 20.111,79 |  | 5% |
| L01EX01 191 | DS | sunitinibNL117 | 33 mg | 454,27 | O | Pharmascience International Limited | Bluepharma Industria Farmaceutica S.A. | Sunitinib Pharmascience | caps. tvrda 28x12,5 mg | 172,07 | 4.817,99 |  | 5% |
| L01EX01 192 | DS | sunitinibNL117 | 33 mg | 452,19 | O | Pharmascience International Limited | Bluepharma Industria Farmaceutica S.A. | Sunitinib Pharmascience | caps. tvrda 28x25 mg | 342,57 | 9.591,95 |  | 5% |
| L01EX01 193 | DS | sunitinibNL117 | 33 mg | 450,36 | O | Pharmascience International Limited | Bluepharma Industria Farmaceutica S.A. | Sunitinib Pharmascience | caps. tvrda 28x50 mg | 682,36 | 19.106,20 |  | 5% |
| L01EX01 194 | DS | sunitinibNL117 | 33 mg | 431,55 | O | Farmex d.o.o. | Genepharm S.A., Pharmacare Premium Ltd. | Nibufar | caps. tvrda 28x12,5 mg | 163,47 | 4.577,09 |  | 5% |
| L01EX01 195 | DS | sunitinibNL117 | 33 mg | 429,58 | O | Farmex d.o.o. | Genepharm S.A., Pharmacare Premium Ltd. | Nibufar | caps. tvrda 28x25 mg | 325,44 | 9.112,32 |  | 5% |
| L01EX01 196 | DS | sunitinibNL117 | 33 mg | 427,84 | O | Farmex d.o.o. | Genepharm S.A., Pharmacare Premium Ltd. | Nibufar | caps. tvrda 28x50 mg | 648,24 | 18.150,72 |  | 5% |
| L01EX02 171 | KLDS | sorafenibNL118 | 800 mg | 586,06 | O | Bayer AG | Bayer AG | Nexavar | tbl. film obl. 112x200 mg | 146,51 | 16.409,65 |  | 5% |
| L01EX02 172 | KLDS | sorafenibNL517 | 800 mg | 528,92 | O | Mylan Ireland Limited | Remedica Ltd. | Sorafenib Mylan | tbl. film obl. 112x200 mg | 132,23 | 14.809,71 |  | 5% |
| L01EX02 173 | KLDS | sorafenibNL517 | 800 mg | 586,06 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sorafenib Stada | tbl. film obl. 112x200 mg | 146,51 | 16.409,65 |  | 5% |
| L01EX02 174 | KLDS | sorafenibNL517 | 800 mg | 586,06 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sorafenib Teva | tbl. film obl. 112x200 mg | 146,51 | 16.409,65 |  | 5% |
| L01EX02 175 | KLDS | sorafenibNL517 | 800 mg | 556,76 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sorafenib Sandoz | tbl. film obl. 112x200 mg | 139,19 | 15.589,17 |  | 5% |
| L01EX02 176 | KLDS | sorafenibNL517 | 800 mg | 556,76 | O | Zentiva k.s. | Remedica Ltd. | Fenesa | tbl. film obl. 112x200 mg | 139,19 | 15.589,17 |  | 5% |
| L01EX02 177 | KLDS | sorafenibNL517 | 800 mg | 528,92 | O | Pharmascience International Limited | Remedica Ltd., PharOS MT Ltd. | Sorafenib Pharmascience | tbl. film obl. 112x200 mg | 132,23 | 14.809,71 |  | 5% |
| L01EX02 178 | KLDS | sorafenibNL517 | 800 mg | 528,92 | O | STADA d.o.o. | STADA Arzneimittel AG | Sorafenib Stada | tbl. film obl. 56x400 mg | 264,46 | 14.809,71 |  | 5% |
| L01EX03 101 | KLDS | pazopanibNL421 | 800 mg | 482,17 | O | Teva B.V. | PharOS MT Ltd, Remedica Ltd. | Pazopanib Teva | tbl. film obl. 30x200 mg | 120,54 | 3.616,24 |  | 5% |
| L01EX03 102 | KLDS | pazopanibNL421 | 800 mg | 482,16 | O | Teva B.V. | PharOS MT Ltd, Remedica Ltd. | Pazopanib Teva | tbl. film obl. 30x400 mg | 241,08 | 7.232,47 |  | 5% |
| L01EX03 161 | KLDS | pazopanibNL421 | 800 mg | 699,71 | O | Novartis Europharm Limited Irska | Lek Pharmaceuticals d.d., Novartis Pharma GmbH | Votrient | tbl. film obl. 30x200 mg | 174,93 | 5.247,80 |  | 5% |
| L01EX03 162 | KLDS | pazopanibNL421 | 800 mg | 688,81 | O | Novartis Europharm Limited Irska | Lek Pharmaceuticals d.d., Novartis Pharma GmbH | Votrient | tbl. film obl. 30x400 mg | 344,40 | 10.332,10 |  | 5% |
| L01EX03 171 | KLDS | pazopanibNL421 | 800 mg | 482,17 | O | Zentiva k.s. | PharOS MT Ltd, Remedica Ltd. | Pazopanib Zentiva | tbl. film obl. 30x200 mg | 120,54 | 3.616,24 |  | 5% |
| L01EX03 172 | KLDS | pazopanibNL421 | 800 mg | 482,16 | O | Zentiva k.s. | PharOS MT Ltd, Remedica Ltd. | Pazopanib Zentiva | tbl. film obl. 30x400 mg | 241,08 | 7.232,47 |  | 5% |
| L01EX03 181 | KLDS | pazopanibNL421 | 800 mg | 482,17 | O | STADA d.o.o. | STADA Arzneimittel AG | Pyzypi | tbl. film obl. 30x200 mg | 120,54 | 3.616,24 |  | 5% |
| L01EX03 182 | KLDS | pazopanibNL421 | 800 mg | 482,16 | O | STADA d.o.o. | STADA Arzneimittel AG | Pyzypi | tbl. film obl. 30x400 mg | 241,08 | 7.232,47 |  | 5% |
| L01EX03 191 | KLDS | pazopanibNL421 | 800 mg | 458,06 | O | Pharmascience International Limited | Remedica Ltd., PharOS MT Ltd | Pazopanib Pharmascience | tbl. film obl. 30x200 mg | 114,51 | 3.435,43 |  | 5% |
| L01EX03 192 | KLDS | pazopanibNL421 | 800 mg | 435,15 | O | Pharmascience International Limited | Remedica Ltd., PharOS MT Ltd | Pazopanib Pharmascience | tbl. film obl. 60x400 mg | 217,58 | 13.054,61 |  | 5% |
| L01EX04 161 | KS | vandetanibNL481 |  |  | O | Genzyme Europe B.V. | AstraZeneca UK Ltd. | Caprelsa | tbl. film obl. 30x100 mg | 414,42 | 12.432,45 |  | 5% |
| L01EX04 162 | KS | vandetanibNL481 |  |  | O | Genzyme Europe B.V. | AstraZeneca UK Ltd. | Caprelsa | tbl. film obl. 30x300 mg | 1.177,00 | 35.310,00 |  | 5% |
| L01EX05 161 | DS | regorafenibNL470 | 120 mg | 596,56 | O | Bayer AG | Bayer AG | Stivarga | tbl. film obl. 84x40 mg | 198,85 | 16.703,68 |  | 5% |
| L01EX08 161 | KL | lenvatinibNL542 | 18 mg | 1.679,69 | O | Eisai GmbH | Eisai GmbH | Lenvima | caps. tvrda 30x4 mg | 373,27 | 11.198,00 |  | 5% |
| L01EX08 162 | KL | lenvatinibNL542 | 18 mg | 695,40 | O | Eisai GmbH | Eisai GmbH | Lenvima | caps. tvrda 30x10 mg | 386,33 | 11.590,00 |  | 5% |
| L01EX09 161 | KS | nintedanibNL455 | 380 mg | 800,98 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim Pharma GmbH | Ofev | caps. meka 60x100 mg | 210,78 | 12.647,00 |  | 5% |
| L01EX09 162 | KS | nintedanibNL455 | 380 mg | 738,81 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim Pharma GmbH | Ofev | caps. meka 60x150 mg | 291,64 | 17.498,20 |  | 5% |
| L01EX09 171 | DS | nintedanibNL472 | 380 mg | 538,88 | O | Boehringer Ingelheim International GmbH | Boerhinger Ingelheim | Vargatef | caps. meka 120x100 mg | 141,81 | 17.017,24 |  | 5% |
| L01EX09 172 | DS | nintedanibNL472 | 380 mg | 718,51 | O | Boehringer Ingelheim International GmbH | Boerhinger Ingelheim | Vargatef | caps. meka 60x150 mg | 283,62 | 17.017,24 |  | 5% |
| L01EX10 171 | KL | midostaurinNL489 | 100 mg | 3.405,80 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Rydapt | caps. meka 112x25 mg | 851,45 | 95.362,40 |  | 5% |
| L01EX13 161 | DS | gilteritinibNL541 | 120 mg | 4.700,03 | O | Astellas Pharma Europe B.V. | Astellas Pharma Europe B.V. | Xospata | tbl. film obl. 84x40 mg | 1.566,68 | 131.600,84 |  | 5% |
| L01EX14 161 | DS | entrektinibNL528 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Rozlytrek | caps. tvrda 90x200 mg | 596,80 | 53.711,70 |  | 5% |
| L01FA01 061 | DS | rituksimabNL518 |  |  | P | Roche Registration GmbH | Roche | Mabthera | boč. 2x100 mg/10 ml | 1.385,23 | 2.770,45 |  | 5% |
| L01FA01 062 | DS | rituksimabNL518 |  |  | P | Roche Registration GmbH | Roche | Mabthera | boč. 1x500 mg/50 ml | 6.757,43 | 6.757,43 |  | 5% |
| L01FA01 063 | DS | rituksimabNL429 |  |  | P | Roche Registration GmbH | Roche | Mabthera | otop. za supkut. inj., boč. 1x1400 mg | 10.504,25 | 10.504,25 |  | 5% |
| L01FA01 071 | DS | rituksimabNL518 |  |  | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd. | Truxima | konc. za otop. za inf., boč. stakl. 1x500 mg/50 ml | 6.757,43 | 6.757,43 |  | 5% |
| L01FA01 072 | DS | rituksimabNL518 |  |  | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd. | Truxima | konc. za otop. za inf., boč. stakl. 2x100 mg/10 ml | 1.385,23 | 2.770,45 |  | 5% |
| L01FA01 081 | DS | rituksimabNL518 |  |  | P | Sandoz GmbH | Sandoz GmbH | Rixathon | konc. za otop. za inf., boč. stakl. 2x100 mg/10 ml | 1.368,07 | 2.736,14 |  | 5% |
| L01FA01 082 | DS | rituksimabNL518 |  |  | P | Sandoz GmbH | Sandoz GmbH | Rixathon | konc. za otop. za inf., boč. stakl. 1x500 mg/50 ml | 6.717,68 | 6.717,68 |  | 5% |
| L01FA01 083 | DS | rituksimabNL111 |  |  | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Ruxience | konc. za otop. za inf., boč. stakl. 1x100 mg/10 ml | 1.299,67 | 1.299,67 |  | 5% |
| L01FA01 084 | DS | rituksimabNL111 |  |  | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Ruxience | konc. za otop. za inf., boč. stakl. 1x500 mg/50 ml | 6.381,80 | 6.381,80 |  | 5% |
| L01FA03 061 | DS | obinutuzumabNL451 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Gazyvaro | konc. za otop. za inf., boč. stakl. 1x1000 mg/40 ml | 22.557,25 | 22.557,25 |  | 5% |
| L01FC01 071 | KS | daratumumabNL492 |  |  | P | Janssen-Cilag International N.V. | Janssen Biologics B.V | Darzalex | konc. za otop. za inf., boč. stakl. 1x100 mg/5 ml | 3.173,38 | 3.173,38 |  | 5% |
| L01FC01 072 | KS | daratumumabNL492 |  |  | P | Janssen-Cilag International N.V. | Janssen Biologics B.V | Darzalex | konc. za otop. za inf., boč. stakl. 1x400 mg/20 ml | 12.445,18 | 12.445,18 |  | 5% |
| L01FC01 073 | KS | daratumumabNL492 |  |  | P | Janssen-Cilag International N.V. | Janssen Biologics B.V | Darzalex | otop. za supkut. inj., boč. 1x1800 mg/15 ml | 38.207,30 | 38.207,30 |  | 5% |
| L01FD01 061 | DS | trastuzumab NL112 |  |  | P | Roche Registration GmbH | Roche | Herceptin | boč. 1x150 mg | 2.935,41 | 2.935,41 |  | 5% |
| L01FD01 062 | DS | trastuzumab NL487 |  |  | P | Roche Registration GmbH | Roche | Herceptin | otop. za supkut. inj., boč. 1x600 mg/5 ml | 8.806,23 | 8.806,23 |  | 5% |
| L01FD01 071 | DS | trastuzumab NL112 |  |  | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd | Herzuma | boč. 1x150 mg | 2.935,41 | 2.935,41 |  | 5% |
| L01FD01 072 | DS | trastuzumab NL112 |  |  | P | Viatris Limited | McDermott Laboratories Limited T/A Mylan Dublin Biologics | Ogivri | boč. 1x150 mg | 2.788,64 | 2.788,64 |  | 5% |
| L01FD01 081 | DS | trastuzumab NL112 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kanjinti | boč. 1x150 mg | 2.935,41 | 2.935,41 |  | 5% |
| L01FD01 082 | DS | trastuzumab NL112 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kanjinti | boč. 1x420 mg | 7.953,98 | 7.953,98 |  | 5% |
| L01FD01 083 | DS | trastuzumab NL112 |  |  | P | Pfizer Europe MA EEIG | Wyeth Pharmaceuticals, Pfizer Manufacturing Belgium NV | Trazimera | boč. 1x150 mg | 2.935,41 | 2.935,41 |  | 5% |
| L01FD01 084 | DS | trastuzumab NL112 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Zercepac | boč. 1x150 mg | 2.649,21 | 2.649,21 |  | 5% |
| L01FD01 085 | DS | trastuzumab NL112 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Zercepac | boč. 1x60 mg | 1.006,70 | 1.006,70 |  | 5% |
| L01FD01 086 | DS | trastuzumab NL112 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Zercepac | boč. 1x420 mg | 7.311,82 | 7.311,82 |  | 5% |
| L01FD02 061 | DS | pertuzumabNL443 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Perjeta | konc. za otop. za inf., boč. stakl. 1x420 mg | 19.122,98 | 19.122,98 |  | 5% |
| L01FD03 061 | DS | trastuzumab emtanzinNL450 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Kadcyla | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 12.739,00 | 12.739,00 |  | 5% |
| L01FD03 062 | DS | trastuzumab emtanzinNL450 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Kadcyla | praš. za konc. za otop. za inf., boč. stakl. 1x160 mg | 20.376,00 | 20.376,00 |  | 5% |
| L01FE01 061 | DS | cetuksimabNL113 |  |  | P | Merck Europe B.V. | Merck Healthcare KGaA | Erbitux | otop. za inf., boč. 1x20 ml (5 mg/ml) | 1.343,58 | 1.343,58 |  | 5% |
| L01FE02 061 | DS | panitumumabNL431 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Vectibix | konc. za otop. za inf., boč. 1x5 ml (20 mg/ml) | 2.763,47 | 2.763,47 |  | 5% |
| L01FF01 061 | KS | nivolumabNL467 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Bristol – Myers Squibb S.r.l. | Opdivo | konc. za otop. za inf., boč. stakl. 1x4 ml (10 mg/ml) | 3.746,33 | 3.746,33 |  | 5% |
| L01FF01 062 | KS | nivolumabNL467 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Bristol – Myers Squibb S.r.l. | Opdivo | konc. za otop. za inf., boč. stakl. 1x10 ml (10 mg/ml) | 9.231,75 | 9.231,75 |  | 5% |
| L01FF01 063 | KS | nivolumabNL467 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Bristol – Myers Squibb S.r.l. | Opdivo | konc. za otop. za inf., boč. stakl. 1x24 ml (10 mg/ml) | 22.040,95 | 22.040,95 |  | 5% |
| L01FF02 062 | KS | pembrolizumabNL452 |  |  | P | Merck Sharp & Dohme B.V. | Schering – Plough Labo NV | Keytruda | konc. za otop. za inf., boč. stakl. 1x100 mg/4 ml (25 mg/ml) | 22.683,16 | 22.683,16 |  | 5% |
| L01FF03 061 | KS | durvalumabNL515 |  |  | P | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | Imfinzi | konc. za otop. za inf., boč. stakl. 1x120 mg/2,4 ml (50mg/ml) | 4.927,37 | 4.927,37 |  | 5% |
| L01FF03 062 | KS | durvalumabNL515 |  |  | P | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | Imfinzi | konc. za otop. za inf., boč. stakl. 1x500 mg/10 ml (50mg/ml) | 20.224,46 | 20.224,46 |  | 5% |
| L01FF04 061 | KLKS | avelumabNL519 |  |  | P | Merck Europe B.V. | Merck Serono S.p.A. | Bavencio | konc. za otop. za inf. 10 ml, boč. stakl. 1x20 mg/ml | 6.651,55 | 6.651,55 |  | 5% |
| L01FF05 071 | KS | atezolizumabNL529 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Tecentriq | konc. otop. za inf., boč. 1x1200 mg/20 ml | 30.512,78 | 30.512,78 |  | 5% |
| L01FF05 072 | KS | atezolizumabNL529 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Tecentriq | konc. otop. za inf., boč. 1x840 mg/14 ml | 21.388,99 | 21.388,99 |  | 5% |
| L01FF06 071 | KS | cemiplimabNL537 |  |  | P | Regeneron Ireland Designed Activity Company (DAC) | Regeneron Ireland DAC | Libtayo | konc. za otop. za inf., boč. 1x350 mg/7 ml | 45.289,87 | 45.289,87 |  | 5% |
| L01FG01 061 | DS | bevacizumab NL128 |  |  | P | Roche Registration GmbH | Roche | Avastin | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.716,39 | 1.716,39 |  | 5% |
| L01FG01 062 | DS | bevacizumabNL128 |  |  | P | Roche Registration GmbH | Roche | Avastin | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 6.473,89 | 6.473,89 |  | 5% |
| L01FG01 071 | DS | bevacizumab NL128 |  |  | P | Amgen Technology (Ireland) UC | Amgen Technology (Ireland) UC | Mvasi | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.716,39 | 1.716,39 |  | 5% |
| L01FG01 072 | DS | bevacizumab NL128 |  |  | P | Amgen Technology (Ireland) UC | Amgen Technology (Ireland) UC | Mvasi | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 6.473,89 | 6.473,89 |  | 5% |
| L01FG01 073 | DS | bevacizumab NL128 |  |  | P | Mabxience Research S.L. | GH Genhelix S.A. | Alymsys | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.716,39 | 1.716,39 |  | 5% |
| L01FG01 074 | DS | bevacizumab NL128 |  |  | P | Mabxience Research S.L. | GH Genhelix S.A. | Alymsys | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 6.473,89 | 6.473,89 |  | 5% |
| L01FG01 075 | DS | bevacizumab NL128 |  |  | P | STADA Arzneimittel AG | GH GENHELIX S.A. | Oyavas | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.716,39 | 1.716,39 |  | 5% |
| L01FG01 076 | DS | bevacizumab NL128 |  |  | P | STADA Arzneimittel AG | GH GENHELIX S.A. | Oyavas | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 6.473,89 | 6.473,89 |  | 5% |
| L01FG01 077 | DS | bevacizumab NL128 |  |  | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Limited t/a Mylan Dublin Biologics, Mylan Germany GmbH | Abevmy | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.656,69 | 1.656,69 |  | 5% |
| L01FG01 078 | DS | bevacizumab NL128 |  |  | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Limited t/a Mylan Dublin Biologics, Mylan Germany GmbH | Abevmy | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 6.331,58 | 6.331,58 |  | 5% |
| L01FG02 061 | KS | ramucirumabNL469 |  |  | P | Eli Lilly Nederland B.V. | Lilly, S.A. | Cyramza | konc. za otop. za inf., boč. stakl. 2x10 ml (10 mg/ml) | 3.822,69 | 7.645,38 |  | 5% |
| L01FX02 061 | KS | gemtuzumab ozogamicinNL525 |  |  | P | Pfizer Europe MA EEIG | Pfizer Ireland Pharmaceuticals | Mylotarg | praš. za konc. za otop. za inf., boč. stakl. 1x5 mg | 57.699,86 | 57.699,86 |  | 5% |
| L01FX04 061 | KS | ipilimumabNL523 |  |  | P | Bristol-Myers Squibb Pharma EEIG | CATALENT ANAGNI S.R.L., Swords Laboratories T/A Bristol-Myers Squibb Cruiserath Biologics | Yervoy | konc. za otop. za inf., boč. stakl. 1x10 ml (5 mg/ml) | 25.981,65 | 25.981,65 |  | 5% |
| L01FX05 061 | DS | brentuksimab vedotinNL442 |  |  | P | Takeda Pharma A/S | Takeda Italia S.p.A. | Adcetris | praš. za konc. za otop. za inf., boč. stakl. 1x50 mg | 22.143,91 | 22.143,91 |  | 5% |
| L01FX06 061 | KL | dinutuksimab betaNL508 |  |  | P | EUSA Pharma (Netherlands) B.V. | Millmount Healthcare Ltd | Qarziba | konc. za otop. za inf., boč. stakl. 1x20 mg (4,5 mg/ml) | 69.464,16 | 69.464,16 |  | 5% |
| L01XA01 001 | DS | cisplatin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Cisplatin | boč. 1x10 mg/20 ml | 22,83 | 22,83 |  | 5% |
| L01XA01 002 | DS | cisplatin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Cisplatin | boč. 1x50 mg/100 ml | 110,50 | 110,50 |  | 5% |
| L01XA01 063 | DS | cisplatin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Cisplatin | amp. 1x50 mg/50 ml | 106,10 | 106,10 |  | 5% |
| L01XA02 072 | DS | karboplatin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Carboplatin | amp. 1x150 mg/15 ml | 190,50 | 190,50 |  | 5% |
| L01XA03 066 | DS | oksaliplatin |  |  | P | ACTAVIS GROUP PTC ehf. | Sindan-Pharma | Sinoxal | praš. za otop. za inf., boč. 1x50 mg/10 ml | 671,71 | 671,71 |  | 5% |
| L01XA03 067 | DS | oksaliplatin |  |  | P | ACTAVIS GROUP PTC ehf. | Sindan-Pharma | Sinoxal | praš. za otop. za inf., boč. 1x100 mg/20 ml | 1.409,56 | 1.409,56 |  | 5% |
| L01XA03 075 | DS | oksaliplatin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Oxaliplatin Kabi | konc. za otop. za inf., boč. stakl. 1x10 ml (5 mg/ml) | 494,02 | 494,02 |  | 5% |
| L01XA03 076 | DS | oksaliplatin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Oxaliplatin Kabi | konc. za otop. za inf., boč. stakl. 1x20 ml (5 mg/ml) | 969,03 | 969,03 |  | 5% |
| L01XA03 077 | DS | oksaliplatin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Oxaliplatin Kabi | konc. za otop. za inf., boč. stakl. 1x40 ml (5 mg/ml) | 1.938,06 | 1.938,06 |  | 5% |
| L01XA03 081 | DS | oksaliplatin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Oxaliplatin Pliva | konc. otop. za inf., boč. stakl. 1x50 mg/10 ml | 737,10 | 737,10 |  | 5% |
| L01XA03 082 | DS | oksaliplatin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Oxaliplatin Pliva | konc. otop. za inf., boč. stakl. 1x100 mg/20 ml | 1.445,85 | 1.445,85 |  | 5% |
| L01XB01 151 |  | prokarbazin |  |  | O |  |  |  |  |  |  | RSRL04 | 5% |
| L01XG01 002 | DS | bortezomibNL126 |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o., Teva Gyogyszergyar Zrt. | Bortezomib Pliva | praš. za otop. za inj., boč. 1x3,5 mg | 3.541,99 | 3.541,99 |  | 5% |
| L01XG01 003 | DS | bortezomibNL126 |  |  | P | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma S.R.L. | Bortezomib Actavis | praš. za otop. za inj., boč. 1x3,5 mg | 3.187,79 | 3.187,79 |  | 5% |
| L01XG01 032 | DS | bortezomibNL126 |  |  | P | KRKA-FARMA d.o.o. | Krka d.d. | Bortezomib Krka | praš. za otop. za inj., boč. 1x3,5 mg | 3.028,40 | 3.028,40 |  | 5% |
| L01XG01 041 | DS | bortezomibNL126 |  |  | P | PharmaS d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Bortezomib PharmaS | praš. za otop. za inj., boč. 1x3,5 mg/10 ml | 3.541,99 | 3.541,99 |  | 5% |
| L01XG01 042 | DS | bortezomibNL126 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, WESSLING Hungary Kft. | Bortezomib Accord | praš. za otop. za inj., boč. 1x3,5 mg | 3.541,99 | 3.541,99 |  | 5% |
| L01XG01 043 | DS | bortezomibNL126 |  |  | P | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Gloftrinid | praš. za otop. za inj., boč. 1x3,5 mg | 2.733,13 | 2.733,13 |  | 5% |
| L01XG01 061 | DS | bortezomibNL126 |  |  | P | Zentiva k.s. | Synthon Hispania S.L., Synthon s.r.o. | Vortemyel | praš. za otop. za inj., boč. 1x3,5 mg/10 ml | 4.622,29 | 4.622,29 |  | 5% |
| L01XG01 062 | DS | bortezomibNL126 |  |  | P | ALPHA-MEDICAL d.o.o. | Pharmidea LLC | Bortezomib Alpha-Medical | praš. za otop. za inj., boč. 1x3,5 mg | 3.541,99 | 3.541,99 |  | 5% |
| L01XG01 081 | DS | bortezomibNL126 |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Deutchland GmbH | Bortezomib Fresenius Kabi | praš. za otop. za inj., boč. 1x3,5 mg | 2.876,98 | 2.876,98 |  | 5% |
| L01XG02 071 | KS | karfilzomibNL493 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kyprolis | praš. za otop. za inf., boč. stakl. 1x10 mg/5 ml (2 mg/ml) | 1.445,44 | 1.445,44 |  | 5% |
| L01XG02 072 | KS | karfilzomibNL493 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kyprolis | praš. za otop. za inf., boč. stakl. 1x30 mg/15 ml (2 mg/ml) | 4.336,32 | 4.336,32 |  | 5% |
| L01XG02 073 | KS | karfilzomibNL493 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kyprolis | praš. za otop. za inf., boč. stakl. 1x60 mg/30 ml (2 mg/ml) | 8.088,73 | 8.088,73 |  | 5% |
| L01XG03 171 | KS | iksazomibNL494 |  |  | O | Takeda Pharma A/S | Takeda Pharma A/S | Ninlaro | caps. tvrde 3x2,3 mg | 12.130,43 | 36.391,28 |  | 5% |
| L01XG03 172 | KS | iksazomibNL494 |  |  | O | Takeda Pharma A/S | Takeda Pharma A/S | Ninlaro | caps. tvrde 3x3 mg | 12.130,43 | 36.391,28 |  | 5% |
| L01XG03 173 | KS | iksazomibNL494 |  |  | O | Takeda Pharma A/S | Takeda Pharma A/S | Ninlaro | caps. tvrde 3x4 mg | 12.130,43 | 36.391,28 |  | 5% |
| L01XK01 162 | KSDS | olaparibNL521 |  |  | O | AstraZeneca AB | AstraZeneca AB | Lynparza | tbl. film obl. 56x100 mg | 326,95 | 18.309,01 |  | 5% |
| L01XK01 163 | KSDS | olaparibNL521 |  |  | O | AstraZeneca AB | AstraZeneca AB | Lynparza | tbl. film obl. 56x150 mg | 326,95 | 18.309,01 |  | 5% |
| L01XK04 161 | DS | talazoparibNL530 |  |  | O | Pfizer Europe MA EEIG | Excella GmbH & Co. KG | Talzenna | caps. 30x0,25 mg | 421,80 | 12.653,90 |  | 5% |
| L01XK04 162 | DS | talazoparibNL530 |  |  | O | Pfizer Europe MA EEIG | Excella GmbH & Co. KG | Talzenna | caps. 30x1 mg | 1.248,12 | 37.443,50 |  | 5% |
| L01XX01 051 | KS | amsakrin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01XX02 051 | KS | L-asparaginaza |  |  | P |  |  |  |  |  |  |  | 5% |
| L01XX05 183 |  | hidroksikarbamid |  |  | O | Cheplapharm Arzneimittel GmbH | Corden Pharma Latina S.p.A., | Litalir | caps. 100x500 mg | 2,28 | 228,00 | RSRL04 | 5% |
| L01XX05 184 |  | hidroksikarbamid |  |  | O | Makpharm d.o.o. | PharmaS d.o.o. | Xybaid | caps. 100x500 mg | 2,28 | 228,00 | RSRL04 | 5% |
| L01XX24 071 | KS | pegaspergazaNL497 |  |  | P | Les Laboratoires Servier | Les Laboratoires Servier Industrie | Oncaspar | praš. za otop. za inf., boč. stakl. 1x3750 U (750 U/ml) | 12.471,67 | 12.471,67 |  | 5% |
| L01XX27 011 | DS | arsenov trioksidNL543 |  |  | P | Teva B.V. | Almac Pharma Services (Ireland) Limited, Almac Pharma Services Limited | Trisenox | konc. za otop. za inf., 10x6 ml (2 mg/ml) | 2.490,00 | 24.900,00 |  | 5% |
| L01XX35 171 | DS | anagrelidNL459 |  |  | O | AOP Orphan Pharmaceuticals AG | AOP Orphan Pharmaceuticals AG | Thromboreductin | caps. tvrda 100x0,5 mg | 18,27 | 1.826,67 |  | 5% |
| L01XX35 172 | DS | anagrelidNL459 |  |  | O | Zentiva k.s. | Synthon BV, Synthon Hispania S.L. | Grenalvon | caps. tvrda 100x0,5 mg | 18,27 | 1.826,67 |  | 5% |
| L01XX35 173 | DS | anagrelidNL459 |  |  | O | PLIVA HRVATSKA d.o.o. | Synthon Hispania S.L. | Atremia | caps. tvrda 100x0,5 mg | 17,38 | 1.737,61 |  | 5% |
| L01XX35 174 | DS | anagrelidNL459 |  |  | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania, Synthon BV | Anagrelid Alpha-Medical | caps. tvrda 100x0,5 mg | 18,27 | 1.826,67 |  | 5% |
| L01XX35 175 | DS | anagrelidNL459 |  |  | O | STADA d.o.o. | Stada Arzneimittel AG | Anagrelid Stada | caps. tvrda 100x0,5 mg | 18,27 | 1.826,67 |  | 5% |
| L01XX44 061 | DS | afliberceptNL475 |  |  | P | sanofi-aventis groupe | Sanofi – aventis Deutschland GmbH | Zaltrap | konc. za otop. za inf., boč. stakl. 1x100 mg/4 ml (25 mg/ml) | 2.545,50 | 2.545,50 |  | 5% |
| L01XX44 062 | DS | afliberceptNL475 |  |  | P | sanofi-aventis groupe | Sanofi – aventis Deutschland GmbH | Zaltrap | konc. za otop. za inf., boč. stakl. 1x200 mg/8 ml (25 mg/ml) | 5.018,93 | 5.018,93 |  | 5% |
| L01XX52 161 | DS | venetoklaksNL544 |  |  | O | AbbVie Deutschland GmbH & Co. KG | AbbVie Deutschland GmbH | Venclyxto | tbl. film obl. 14x10 mg | 39,72 | 556,03 |  | 5% |
| L01XX52 162 | DS | venetoklaksNL544 |  |  | O | AbbVie Deutschland GmbH & Co. KG | AbbVie Deutschland GmbH | Venclyxto | tbl. film obl. 7x50 mg | 197,49 | 1.382,43 |  | 5% |
| L01XX52 163 | DS | venetoklaksNL544 |  |  | O | AbbVie Deutschland GmbH & Co. KG | AbbVie Deutschland GmbH | Venclyxto | tbl. film obl. 7x100 mg | 390,17 | 2.731,19 |  | 5% |
| L01XX52 164 | DS | venetoklaksNL544 |  |  | O | AbbVie Deutschland GmbH & Co. KG | AbbVie Deutschland GmbH | Venclyxto | tbl. film obl. 112x100 mg | 380,79 | 42.648,85 |  | 5% |
| L01XX71 071 | KL | tisagenlekleucelNL499 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Kymriah | 1,2 x 106 – 6 x 108 stanica disperzija za infuziju, 1-3 vrećice za infuziju | 2.371.141,33 | 2.371.141,33 |  | 5% |
| L01XY02 061 | DS | pertuzumab + trastuzumabNL520 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Phesgo | otop. za inj., boč. stakl. 1x(600 mg + 600 mg)/10 ml | 28.995,23 | 28.995,23 |  | 5% |
| L01XY02 062 | DS | pertuzumab + trastuzumabNL520 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Phesgo | otop. za inj., boč. stakl. 1x(1200 mg + 600 mg)/15 ml | 49.184,23 | 49.184,23 |  | 5% |
| L02AB01 161 |  | megestrol-acetat | 0,16 g | 10,30 | O | Bausch Health Ireland Limited | Haupt Pharma Amareg GmbH | Megace | tbl. 30x160 mg | 10,30 | 309,06 | RSRL02 | 5% |
| L02AE02 041 | DS | leuprorelinNL201 | 0,134 mg | 9,85 | P | PharmaS d.o.o. | GP-PHARM, S.A. | Lutrate depo | praš. i otap. za susp. za inj. s prod. osl. 1x22,5 mg | 1.653,73 | 1.653,73 |  | 5% |
| L02AE02 042 | DS | leuprorelinNL201 | 0,134 mg | 20,09 | P | PharmaS d.o.o. | GP-PHARM, S.A. | Lutrate depo | praš. i otap. za susp. za inj. s prod. osl. 1x3,75 mg | 562,20 | 562,20 |  | 5% |
| L02AE02 043 | DS | leuprorelinNL201 | 0,134 mg | 9,36 | P | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o. | Camcevi | susp. za inj. s prod. osl., štrc. napunj. 1x42 mg | 2.932,61 | 2.932,61 |  | 5% |
| L02AE02 062 | DS | leuprorelinNL201 | 0,134 mg | 10,86 | P | Recordati Industria Chimica e Farmaceutica S.p.A. | Astellas Pharma Europe B.V. | Eligard | praš. i otap. za otop. za inj. štrc. 1x22,5 mg | 1.822,96 | 1.822,96 |  | 5% |
| L02AE02 063 | DS | leuprorelinNL201 | 0,134 mg | 10,19 | P | Recordati Industria Chimica e Farmaceutica S.p.A. | Astellas Pharma Europe B.V. | Eligard | praš. i otap. za otop. za inj., štrc. napunj. 1x45 mg | 3.421,01 | 3.421,01 |  | 5% |
| L02AE02 802 | DS | leuprorelinNL201 | 60 mcg | 16,90 | P | Sandoz d.o.o. | Sandoz – Ever Pharma | Lerin | implantat 1x5 mg | 1.408,43 | 1.408,43 |  | 5% |
| L02AE03 061 | DS | goserelin | 0,129 mg | 23,02 | P | AstraZeneca d.o.o. | AstraZeneca | Zoladex | implantat 1x3,6 mg, štap. u plast. aplik. | 642,41 | 642,41 |  | 5% |
| L02AE03 062 | DS | goserelin | 0,129 mg | 23,37 | P | AstraZeneca d.o.o. | AstraZeneca | Zoladex LA | implantat 1x10,8 mg, štap. u plast. aplik. | 1.956,75 | 1.956,75 |  | 5% |
| L02AE03 071 | DS | goserelin | 0,129 mg | 20,57 | P | Alvogen IPCo S.ar.l. | AMW GmbH | Reseligo | implantat u štrc. napunj. 1x3,6 mg | 574,10 | 574,10 |  | 5% |
| L02AE03 072 | DS | goserelin | 0,129 mg | 20,80 | P | Alvogen IPCo S.ar.l. | AMW GmbH | Reseligo | implantat u štrc. napunj. 1x10,8 mg | 1.741,00 | 1.741,00 |  | 5% |
| L02AE04 072 | DS | triptorelin | 0,134 mg | 59,31 | P | Ferring GmbH | Ferring | Decapeptyl | amp. 7x0,1 mg/ml | 42,36 | 296,54 |  | 5% |
| L02AE04 073 | DS | triptorelin | 0,134 mg | 25,87 | P | Ferring GmbH | Ferring | Decapeptyl Depot | prašak i otap. za susp. za inj., štrc. 1x3,75 mg/2 ml | 723,98 | 723,98 |  | 5% |
| L02BA01 161 |  | tamoksifen | 20 mg | 1,47 | O | AstraZeneca d.o.o. | AstraZeneca | Nolvadex | tbl. 30x10 mg | 0,74 | 22,10 | RS RL02 | 5% |
| L02BA03 001 | DS | fulvestrantNL202 | 8,3 mg | 45,40 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fulvestrant Pliva | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 1.367,42 | 2.734,84 |  | 5% |
| L02BA03 022 | DS | fulvestrantNL202 | 8,3 mg | 45,40 | P | Sandoz d.o.o. | Sandoz-Lek, Ebewe Pharma GmbH | Fulvestrant Sandoz | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 1.367,42 | 2.734,84 |  | 5% |
| L02BA03 073 | DS | fulvestrantNL202 | 8,3 mg | 45,40 | P | Mylan Pharmaceuticals Limited | Mylan Teoranta | Fulvestrant Mylan | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 1.367,43 | 2.734,85 |  | 5% |
| L02BA03 081 | DS | fulvestrantNL202 | 8,3 mg | 43,13 | P | Accord Healthcare Polska Sp. z o.o. | Actavis Italy S.p.A. | Fulvestrant Accord | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 1.299,05 | 2.598,10 |  | 5% |
| L02BA03 082 | DS | fulvestrantNL202 | 8,3 mg | 38,92 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Fulvestrant EVER Pharma | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 1.172,32 | 2.344,64 |  | 5% |
| L02BA03 091 | DS | fulvestrantNL202 | 8,3 mg | 40,97 | P | Apta Medica International d.o.o. | Laboratorios Farmalán | Fulvestrant AptaPharma | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 1.234,02 | 2.468,04 |  | 5% |
| L02BB01 101 |  | flutamid | 0,75 g | 7,73 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prostandril | tbl. 100x250 mg | 2,58 | 257,67 | RSRL05 | 5% |
| L02BB03 103 |  | bikalutamid | 50 mg | 5,62 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Bilumid | tbl. film obl. 28x50 mg | 5,62 | 157,27 | RSRL23 | 5% |
| L02BB03 104 |  | bikalutamid | 50 mg | 7,02 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Bilumid | tbl. film obl. 28x150 mg | 21,05 | 589,40 | RSRL23 | 5% |
| L02BB03 111 |  | bikalutamid | 50 mg | 5,62 | O | Belupo d.d. | Belupo | Bixalan | tbl. film obl. 28x50 mg | 5,62 | 157,27 | RSRL23 | 5% |
| L02BB03 112 |  | bikalutamid | 50 mg | 7,02 | O | Belupo d.d. | Belupo | Bixalan | tbl. film obl. 28x150 mg | 21,05 | 589,40 | RSRL23 | 5% |
| L02BB03 115 |  | bikalutamid | 50 mg | 5,62 | O | Farmex d.o.o. | Genepharm S.A. | Kalufar | tbl. film obl. 28x50 mg | 5,62 | 157,27 | RSRL23 | 5% |
| L02BB03 116 |  | bikalutamid | 50 mg | 7,02 | O | Farmex d.o.o. | Genepharm S.A. | Kalufar | tbl. film obl. 28x150 mg | 21,05 | 589,40 | RSRL23 | 5% |
| L02BB03 117 |  | bikalutamid | 50 mg | 5,62 | O | STADA d.o.o. | Genepharm S.A. | Bikalis | tbl. film obl. 28x50 mg | 5,62 | 157,27 | RSRL23 | 5% |
| L02BB03 118 |  | bikalutamid | 50 mg | 7,02 | O | STADA d.o.o. | Genepharm S.A. | Bikalis | tbl. film obl. 28x150 mg | 21,05 | 589,40 | RSRL23 | 5% |
| L02BB03 121 |  | bikalutamid | 50 mg | 5,62 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Bikalutamid JGL | tbl. film obl. 28x50 mg | 5,62 | 157,27 | RSRL23 | 5% |
| L02BB03 122 |  | bikalutamid | 50 mg | 7,02 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Bikalutamid JGL | tbl. film obl. 28x150 mg | 21,05 | 589,40 | RSRL23 | 5% |
| L02BB03 161 |  | bikalutamid | 50 mg | 5,62 | O | Laboratoires Juvisé Pharmaceuticals | AstraZeneca | Casodex | tbl. 28x50 mg | 5,62 | 157,27 | RSRL23 | 5% |
| L02BB03 162 |  | bikalutamid | 50 mg | 7,02 | O | Laboratoires Juvisé Pharmaceuticals | AstraZeneca | Casodex | tbl. film obl. 28x150 mg | 21,05 | 589,40 | RSRL23 | 5% |
| L02BB03 163 |  | bikalutamid | 50 mg | 5,42 | O | Altamedics d.o.o. | Genepharm S.A. | Bicaprox | tbl. film obl. 28x50 mg | 5,42 | 151,83 | RSRL23 | 5% |
| L02BB03 164 |  | bikalutamid | 50 mg | 6,53 | O | Altamedics d.o.o. | Genepharm S.A. | Bicaprox | tbl. film obl. 28x150 mg | 19,59 | 548,63 | RSRL23 | 5% |
| L02BB04 162 | DS | enzalutamidNL439 | 0,16 g | 828,48 | O | Astellas Pharma Europe B.V. | Astellas Pharma Europe B.V. | Xtandi | tbl. film obl. 112x40 mg | 207,12 | 23.197,44 |  | 5% |
| L02BB05 161 | DS | apalutamidNL532 | 0,24 g | 796,29 | O | Janssen-Cilag International N.V. | Janssen-Cilag S.p.A. | Erleada | tbl. film obl. 112x60 mg | 199,07 | 22.296,21 |  | 5% |
| L02BB06 161 | DS | darolutamidNL514 | 120 mg | 80,64 | O | Bayer AG | Orion Corporation, Orion Pharma | Nubeqa | tbl. film obl. 112x300 mg | 201,59 | 22.578,08 |  | 5% |
| L02BG03 101 |  | anastrozol | 1 mg | 5,07 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Anastrozol Pliva | tbl. film obl. 28x1 mg | 5,07 | 142,00 | RSRL24 | 5% |
| L02BG03 111 |  | anastrozol | 1 mg | 5,07 | O | Farmex d.o.o. | Genepharm S.A., Rottendorf Pharma GmbH | Anastris | tbl. film obl. 28x1 mg | 5,07 | 142,00 | RSRL24 | 5% |
| L02BG03 113 |  | anastrozol | 1 mg | 5,07 | O | Belupo d.d. | Genepharm S.A. | Strazolan | tbl. film obl. 28x1 mg | 5,07 | 142,00 | RSRL24 | 5% |
| L02BG03 121 |  | anastrozol | 1 mg | 5,07 | O | Sandoz d.o.o. | Sandoz-Salutas | Anastrozol Sandoz | tbl. film obl. 28x1 mg | 5,07 | 142,00 | RSRL24 | 5% |
| L02BG03 122 |  | anastrozol | 1 mg | 5,07 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Anastrozol JGL | tbl. film obl. 28x1 mg | 5,07 | 142,00 | RSRL24 | 5% |
| L02BG03 142 |  | anastrozol | 1 mg | 5,07 | O | Mylan Hrvatska d.o.o. | McDermott Laboratories Limited t/a Gerard | Ivel | tbl. film obl. 28x1 mg | 5,07 | 142,00 | RSRL24 | 5% |
| L02BG03 161 |  | anastrozol | 1 mg | 4,88 | O | PharmaS d.o.o. | Cipla | Armotraz | tbl. film obl. 30x1 mg | 4,88 | 146,50 | RSRL24 | 5% |
| L02BG03 163 |  | anastrozol | 1 mg | 5,07 | O | STADA d.o.o. | Genepharm S.A. | Astralis | tbl. film obl. 28x1 mg | 5,07 | 142,00 | RSRL24 | 5% |
| L02BG03 171 |  | anastrozol | 1 mg | 5,07 | O | Laboratoires Juvisé Pharmaceuticals | AstraZeneca | Arimidex | tbl. film obl. 28x1 mg | 5,07 | 142,00 | RSRL24 | 5% |
| L02BG03 181 |  | anastrozol | 1 mg | 5,07 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Aremed | tbl. film obl. 28x1 mg | 5,07 | 142,00 | RSRL24 | 5% |
| L02BG04 101 |  | letrozol | 2,5 mg | 5,07 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Avomit | tbl. film obl. 30x2,5 mg | 5,07 | 152,14 | RSRL25 | 5% |
| L02BG04 111 |  | letrozol | 2,5 mg | 5,07 | O | Belupo d.d. | Genepharm S.A. | Letrilan | tbl. film obl. 30x2,5 mg | 5,07 | 152,14 | RSRL25 | 5% |
| L02BG04 122 |  | letrozol | 2,5 mg | 5,07 | O | Sandoz d.o.o. | Sandoz-Salutas | Letrozol Sandoz | tbl. film obl. 30x2,5 mg | 5,07 | 152,14 | RSRL25 | 5% |
| L02BG04 124 |  | letrozol | 2,5 mg | 5,07 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Letrozol JGL | tbl. film obl. 30x2,5 mg | 5,07 | 152,14 | RSRL25 | 5% |
| L02BG04 161 |  | letrozol | 2,5 mg | 5,07 | O | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Femara | tbl. film obl. 30x2,5 mg | 5,07 | 152,14 | RSRL25 | 5% |
| L02BG04 164 |  | letrozol | 2,5 mg | 5,07 | O | Zentiva k.s. | Vipharm S.A. | Lametta | tbl. film obl. 30x2,5 mg | 5,07 | 152,14 | RSRL25 | 5% |
| L02BG04 165 |  | letrozol | 2,5 mg | 5,07 | O | STADA d.o.o. | Genepharm S.A. | Siletris | tbl. film obl. 30x2,5 mg | 5,07 | 152,14 | RSRL25 | 5% |
| L02BG04 171 |  | letrozol | 2,5 mg | 5,07 | O | Farmex d.o.o. | Genepharm S.A. | Letrofar | tbl. film obl. 30x2,5 mg | 5,07 | 152,14 | RSRL25 | 5% |
| L02BX03 111 | DS | abirateronNL440 | 1 g | 479,59 | O | Teva B.V. | Teva Operations Poland Sp. z o.o., Merckle GmbH | Abirateron Teva | tbl. film obl. 60x500 mg | 239,79 | 14.387,69 |  | 5% |
| L02BX03 121 | DS | abirateronNL440 | 1 g | 504,83 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Abirateron Sandoz | tbl. film obl. 60x500 mg | 252,42 | 15.144,94 |  | 5% |
| L02BX03 131 | DS | abirateronNL440 | 1 g | 504,83 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, TAD Pharma GmbH | Abiraterone Krka | tbl. film obl. 60x500 mg | 252,42 | 15.144,94 |  | 5% |
| L02BX03 141 | DS | abirateronNL440 | 1 g | 504,83 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Abirateron Alpha-Medical | tbl. film obl. 60x500 mg | 252,42 | 15.144,94 |  | 5% |
| L02BX03 142 | DS | abirateronNL440 | 1 g | 504,83 | O | Accord Healthcare S.L.U. | Synthon Hispania S.L., Accord Healthcare Polska Sp. z.o.o. | Abiraterone Accord | tbl. film obl. 60x500 mg | 252,42 | 15.144,94 |  | 5% |
| L02BX03 162 | DS | abirateronNL440 | 1 g | 504,83 | O | Janssen-Cilag International N.V. | Janssen-Cilag S.p.A. | Zytiga | tbl. film obl. 60x500 mg | 252,42 | 15.144,94 |  | 5% |
| L02BX03 171 | DS | abirateronNL440 | 1 g | 504,83 | O | STADA d.o.o. | Remedica Ltd. | Abirateron STADA | tbl. film obl. 60x500 mg | 252,42 | 15.144,94 |  | 5% |
| L02BX03 181 | DS | abirateronNL440 | 1 g | 504,83 | O | Zentiva k.s. | Synthon BV, Synthon Hispania S.L. | Abirateron Zentiva | tbl. film obl. 60x500 mg | 252,42 | 15.144,94 |  | 5% |
| L02BX03 191 | DS | abirateronNL440 | 1 g | 504,83 | O | Mylan Ireland Limited | Remedica Ltd. | Abirateron Mylan | tbl. film obl. 60x500 mg | 252,42 | 15.144,94 |  | 5% |
| L02BX03 192 | DS | abirateronNL440 | 1 g | 455,61 | O | Pharmascience International Limited | Bluepharma Industria Farmaceutica S.A. | Abirateron Pharmascience | tbl. film obl. 60x500 mg | 227,81 | 13.668,31 |  | 5% |
| L03AA02 001 | DS | filgrastim | 0,35 mg | 368,42 | P | Teva GmbH | Pliva Hrvatska d.o.o. | Tevagrastim | otop. za inj. ili inf., štrc. stakl. napunj. 1x300 mcg/0,5 ml | 315,77 | 315,77 |  | 5% |
| L03AA02 002 | DS | filgrastim | 0,35 mg | 373,74 | P | Teva GmbH | Pliva Hrvatska d.o.o. | Tevagrastim | otop. za inj. ili inf., štrc. stakl. napunj. 1x480 mcg/0,8 ml | 512,55 | 512,55 |  | 5% |
| L03AA02 071 | DS | filgrastim | 0,35 mg | 355,35 | P | Pfizer Europe MA EEIG | Hospira Zagreb, Hospira Enterprises | Nivestim | otop. za inj. i inf., napunj. stakl. štrc. 12 MU, 5x0,2 ml (0,6 mg/ml) | 121,83 | 609,17 |  | 5% |
| L03AA02 072 | DS | filgrastim | 0,35 mg | 368,40 | P | Pfizer Europe MA EEIG | Hospira Zagreb d.o.o., Hospira Enterprises B.V. | Nivestim | otop. za inj. i inf., napunj. stakl. štrc. 30 MU, 5x0,5 ml (0,6 mg/ml) | 315,77 | 1.578,86 |  | 5% |
| L03AA02 081 | DS | filgrastim | 0,35 mg | 368,42 | P | Sandoz GmbH | Sandoz | Zarzio | otop. za inj. ili inf., štrc. stakl. napunj. 1x30 MU/0,5 ml | 315,77 | 315,77 |  | 5% |
| L03AA02 082 | DS | filgrastim | 0,35 mg | 377,54 | P | Sandoz GmbH | Sandoz | Zarzio | otop. za inj. ili inf., štrc. stakl. napunj. 1x48 MU/0,5 ml | 517,76 | 517,76 |  | 5% |
| L03AA02 085 | DS | filgrastim | 0,35 mg | 305,80 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Accofil | otop. za inj. ili inf., štrc. stakl. napunj. 5x30 MU/0,5 ml (0,6 mg/ml) | 262,12 | 1.310,58 |  | 5% |
| L03AA02 086 | DS | filgrastim | 0,35 mg | 305,80 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Accofil | otop. za inj. ili inf., štrc. stakl. napunj. 5x48 MU/0,5 ml (0,96 mg/ml) | 419,39 | 2.096,93 |  | 5% |
| L03AA02 087 | DS | filgrastim | 0,35 mg | 355,35 | P | Accord Healthcare S.L.U. | Accord Healthcare Ltd., Accord Healthcare Polska Sp.z o.o. | Accofil | otop. za inj. ili inf., štrc. stakl. napunj. 5x12 MU/0,2 ml (0,6 mg/ml) | 121,83 | 609,17 |  | 5% |
| L03AA03 051 | DS | molgramostim | 0,35 mg |  | P |  |  |  |  |  |  |  | 5% |
| L03AA13 021 | DS | pegfilgrastimNL301 | 0,3 mg | 212,33 | P | Sandoz GmbH | Sandoz GmbH | Ziextenzo | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 4.246,52 | 4.246,52 |  | 5% |
| L03AA13 071 | DS | pegfilgrastimNL301 | 0,3 mg | 212,33 | P | Amgen Europe B.V. | Amgen Europe B.V. | Neulasta | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 4.246,52 | 4.246,52 |  | 5% |
| L03AA13 072 | DS | pegfilgrastimNL301 | 0,3 mg | 219,50 | P | Amgen Europe B.V. | Amgen Europe B.V. | Neulasta | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml s on-body injektorom (Onpro pribor) | 4.389,93 | 4.389,93 |  | 5% |
| L03AA13 073 | DS | pegfilgrastimNL301 | 0,3 mg | 212,33 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Pelgraz | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 4.246,52 | 4.246,52 |  | 5% |
| L03AA13 074 | DS | pegfilgrastimNL301 | 0,3 mg | 212,33 | P | Viatris Limited | McDermott Laboratories t/a Mylan Dublin Biologics | Fulphila | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 4.246,52 | 4.246,52 |  | 5% |
| L03AA13 075 | DS | pegfilgrastimNL301 | 0,3 mg | 208,52 | P | Juta Pharma GmbH | Juta Pharma GmbH | Grasustek | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 4.170,43 | 4.170,43 |  | 5% |
| L03AA13 081 | DS | pegfilgrastimNL301 | 0,3 mg | 212,33 | P | Mundipharma Corporation (Ireland) Limited | 3P BIOPHARMACEUTICALS SL | Pelmeg | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 4.246,52 | 4.246,52 |  | 5% |
| L03AA13 085 | DS | pegfilgrastimNL301 | 0,3 mg | 146,23 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Pelgraz | otop. za inj., napunj. injektor 1x6 mg/0,6 ml | 2.924,69 | 2.924,69 |  | 5% |
| L03AA14 001 | DS | lipegfilgrastimNL301 | 0,3 mg | 229,08 | P | Teva Pharma B.V. | Merckle Biotec GmbH, Teva Pharmaceuticals Europe B.V. | Lonquex | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 4.581,52 | 4.581,52 |  | 5% |
| L03AA14 002 | DS | lipegfilgrastimNL301 | 0,3 mg | 217,62 | P | Teva B.V. | Merckle GmbH, Teva Biotec GmbH | Lonquex | otop. za inj., boč. stakl. 6x6 mg/0,6 ml | 4.352,44 | 26.114,66 |  | 5% |
| L03AB07 062 |  | interferon beta-1aNL303 | 4,3 mcg | 182,91 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Avonex | otop. za inj., 4x0,5 ml (30 mcg/0,5 ml), štrc. napunj. i 4 igle | 1.276,14 | 5.104,54 | RSRL94 | 5% |
| L03AB07 072 |  | interferon beta-1aNL303 | 4,3 mcg | 76,32 | P | Merck Europe B.V. | Merck | Rebif | šprica 3x22 mcg (6 mil. i.j.)/0,5 ml | 390,45 | 1.171,36 | RSRL94 | 5% |
| L03AB07 073 |  | interferon beta-1aNL303 | 4,3 mcg | 48,92 | P | Merck Europe B.V. | Merck | Rebif | štrc. napunj. 12x44 mcg/0,5 ml | 500,60 | 6.007,16 | RSRL94 | 5% |
| L03AB07 074 |  | interferon beta-1aNL303 | 4,3 mcg | 48,63 | P | Merck Europe B.V. | Merck | Rebif | otop. za inj. u ulošku, 4x132 mcg/1,5 ml (44 mcg/0,5 ml) | 1.492,83 | 5.971,30 | RSRL94 | 5% |
| L03AB08 092 |  | interferon beta-1bNL303 | 4 M i.j. |  | P | Bayer AG | Bayer AG | Betaferon | praš. i otap. štrc. napunj. 15x1,2 ml/300 mcg (250 mcg/ml) | 322,40 | 4.835,95 | RSRL94 | 5% |
| L03AB11 061 | DS | peginterferon alfa-2aNL305 | 26 mcg | 194,85 | P | Roche Registration GmbH | Roche | Pegasys | štrc. 1x135 mcg/0,5 ml i igla | 1.011,71 | 1.011,71 |  | 5% |
| L03AB11 065 | DS | peginterferon alfa-2aNL305 | 26 mcg | 174,03 | P | Roche Registration GmbH | Roche Pharma AG | Pegasys | štrc. 1x180 mcg/0,5 ml i igla | 1.204,86 | 1.204,86 |  | 5% |
| L03AB13 071 |  | peginterferon beta-1aNL303 | 8.9 mcg | 117,32 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Plegridy | otop. za inj., napunj. brizg. 1x63 mcg/0,5 ml + 1x94 mcg/0,5 ml | 2.069,58 | 4.139,16 | RSRL94 | 5% |
| L03AB13 072 |  | peginterferon beta-1aNL303 | 8.9 mcg | 190,72 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Plegridy | otop. za inj., napunj. brizg. 2x125 mcg/0,5 ml | 2.678,69 | 5.357,37 | RSRL94 | 5% |
| L03AX03 051 | DS | BCG vaccinum | 1,8 mg |  | P |  |  |  |  |  |  |  | 5% |
| L03AX13 062 |  | glatiramer acetat (kopolimer-1)NL303 | 20 mg | 174,81 | P | PLIVA HRVATSKA d.o.o. | Teva Pharmaceuticals Europe B.V. | Copaxone | otop. za inj., štrc. napunj. 28x20 mg/ml | 174,81 | 4.894,59 | RSRL94 | 5% |
| L03AX13 063 |  | glatiramer acetat (kopolimer-1)NL303 | 20 mg | 176,10 | P | PLIVA HRVATSKA d.o.o. | Teva Pharmaceuticals Europe B.V. | Copaxone | otop. za inj., štrc. napunj. 12x40 mg/ml | 352,20 | 4.226,44 | RSRL94 | 5% |
| L03AX13 071 |  | glatirameracetatNL303 | 20 mg | 131,53 | P | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Remurel | otop. za inj., štrc. napunj. 28x20 mg/ml | 131,53 | 3.682,97 | RSRL94 | 5% |
| L03AX13 072 |  | glatirameracetatNL303 | 20 mg | 176,10 | P | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Remurel | otop. za inj., štrc. napunj. 12x40 mg/ml | 352,20 | 4.226,44 | RSRL94 | 5% |
| L03AX16 061 | KL | pleriksaforNL423 | 16,8 mg | 29.434,46 | P | Genzyme Europe B.V. | Genzyme Ltd. | Mozobil | otop. za inj., boč. stakl. 1x24 mg/1,2 ml (20 mg/ml) | 42.050,07 | 42.050,07 |  | 5% |
| L03AX21 051 | KL | elapegademaza-lvlrNL306 |  |  | P |  |  |  |  |  |  |  | 5% |
| L04AA02 051 | KL | muromonab (CD3) | 5 mg |  | P |  |  |  |  |  |  |  | 5% |
| L04AA03 051 | KL | imunoglobulin-antilimfocitniALGNL401 |  |  | P |  |  |  |  |  |  |  | 5% |
| L04AA04 073 | KL | imunoglobulin protiv T limfocita, kunićiji za humanu primj.NL402 |  |  | P | Neovii Biotech GmbH | Neovii Biotech GmbH | Grafalon | boč. 1x5 ml (20 mg/ml) | 1.933,80 | 1.933,80 |  | 5% |
| L04AA04 074 | KL | imunoglobulin protiv T limfocita, kunićiji za humanu primj.NL402 |  |  | P | Neovii Biotech GmbH | Neovii Biotech GmbH | Grafalon | boč. 10x5 ml (20 mg/ml) | 1.933,80 | 19.338,00 |  | 5% |
| L04AA04 161 | KL | kunićji imunoglobulin protiv timocita, za ljudeNL403 |  |  | P | sanofi-aventis groupe | Genzyme Polyclonals S.A.S. | Thymoglobuline | praš. za otop. za inf., boč. stakl. 1x25 mg | 1.375,29 | 1.375,29 |  | 5% |
| L04AA06 062 | DS | mikofenolat mofetilNL404 | 2 g | 296,18 | P | Roche Registration GmbH | Roche | CellCept | praš. za konc. za otop. za inf. boč. stakl. 4x500 mg/20 ml | 74,05 | 296,18 |  | 5% |
| L04AA06 101 |  | mikofenolat mofetilNL404 | 2 g | 37,88 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Trixin | tbl. film obl. 50x500 mg | 9,47 | 473,50 | RSRL41 | 5% |
| L04AA06 102 |  | mikofenolat mofetilNL404 | 2 g | 39,51 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Trixin | caps. tvrda 100x250 mg | 4,94 | 493,86 | RSRL41 | 5% |
| L04AA06 161 |  | mikofenolat mofetilNL404 | 2 g | 42,29 | O | Roche Registration GmbH | Roche | CellCept | caps. 100x250 mg | 5,29 | 528,67 | RSRL41 | 5% |
| L04AA06 162 |  | mikofenolat mofetilNL404 | 2 g | 37,88 | O | Roche Registration GmbH | Roche | CellCept | tbl. 50x500 mg | 9,47 | 473,50 | RSRL41 | 5% |
| L04AA06 171 |  | mikofenolat-natrijNL405 | 2 g | 77,63 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek d.d., PE PROIZVODNJA LENDAVA | Myfortic | tbl. žel. otp. 120x180 mg | 6,99 | 838,40 | RSRL42 | 5% |
| L04AA06 172 |  | mikofenolat-natrijNL405 | 2 g | 74,89 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek d.d., PE PROIZVODNJA LENDAVA | Myfortic | tbl. žel. otp. 120x360 mg | 13,48 | 1.617,60 | RSRL42 | 5% |
| L04AA06 181 |  | mikofenolat-natrijNL405 | 2 g | 60,04 | O | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Mikofenolatna kiselina Accord | tbl. žel. otp. 120x180 mg | 5,40 | 648,38 | RSRL42 | 5% |
| L04AA06 182 |  | mikofenolat-natrijNL405 | 2 g | 60,03 | O | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Mikofenolatna kiselina Accord | tbl. žel. otp. 120x360 mg | 10,81 | 1.296,75 | RSRL42 | 5% |
| L04AA10 161 |  | sirolimus | 3 mg | 80,61 | O | Pfizer Europe MA EEIG | Wyeth | Rapamune | tbl. obl. 30x1 mg | 26,87 | 806,10 | RSRL43 | 5% |
| L04AA13 161 |  | leflunomid | 20 mg | 14,02 | O | Sanofi-Aventis Deutschland GmbH | Aventis Intercontinental | Arava | tbl. film obl. 30x10 mg | 7,01 | 210,30 | RSRL48 | 5% |
| L04AA13 162 |  | leflunomid | 20 mg | 8,46 | O | Sanofi-Aventis Deutschland GmbH | Aventis Intercontinental | Arava | tbl. film obl. 30x20 mg | 8,46 | 253,70 | RSRL48 | 5% |
| L04AA18 161 |  | everolimus | 1,5 mg | 72,28 | O | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Certican | tbl. 60x0,25 mg | 12,05 | 722,80 | RSRL44 | 5% |
| L04AA18 162 |  | everolimus | 1,5 mg | 64,14 | O | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Certican | tbl. 60x0,50 mg | 21,38 | 1.282,80 | RSRL44 | 5% |
| L04AA23 061 | DS | natalizumabNL406 | 10 mg | 373,32 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Tysabri | konc. otop. za inf., boč. stakl. 1x15 ml (20 mg/1 ml) | 11.199,47 | 11.199,47 |  | 5% |
| L04AA23 062 | DS | natalizumabNL406 | 10 mg | 380,71 | P | Biogen Netherlands B.V. | FUJIFILM Diosynth Biotechnologies Denmark ApS, Biogen Netherlands B.V | Tysabri | otop. za inj., štrc. napunj. 2x150 mg | 5.710,61 | 11.421,22 |  | 5% |
| L04AA25 061 | KL | ekulizumabNL482 | 64 mg | 6.913,72 | P | Alexion Europe SAS | Almac Pharma Services, Patheon Italia S.p.A | Soliris | konc. za otop. za inf., boč. stakl. 1x300 mg (30 ml, 10 mg/ml) | 32.408,07 | 32.408,07 |  | 5% |
| L04AA27 161 | DS | fingolimodNL457 | 0,5 mg | 266,96 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Gilenya | caps. tvrda 28x0,5 mg | 266,96 | 7.474,96 |  | 5% |
| L04AA27 162 | DS | fingolimodNL457 | 0,5 mg | 266,96 | O | KRKA-FARMA d.o.o. | Idifarma Desarrollo Farmaceutico S.L., Krka d.d. | Efigalo | caps. tvrda 28x0,5 mg | 266,96 | 7.474,96 |  | 5% |
| L04AA27 163 | DS | fingolimodNL457 | 0,5 mg | 266,96 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Fingolimod Alpha-Medical | caps. tvrda 28x0,5 mg | 266,96 | 7.474,96 |  | 5% |
| L04AA27 164 | DS | fingolimodNL457 | 0,5 mg | 266,96 | O | Teva GmbH | Teva Operations Poland Sp. z o.o., Merckle GmbH | Fingolimod Teva | caps. tvrda 28x0,5 mg | 266,96 | 7.474,96 |  | 5% |
| L04AA27 165 | DS | fingolimodNL457 | 0,5 mg | 266,96 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Fingolimod Stada | caps. tvrda 28x0,5 mg | 266,96 | 7.474,96 |  | 5% |
| L04AA27 166 | DS | fingolimodNL457 | 0,5 mg | 266,96 | O | Sandoz d.o.o. | Novartis Pharma GmbH | Inzolfi | caps. tvrda 28x0,5 mg | 266,96 | 7.474,96 |  | 5% |
| L04AA27 167 | DS | fingolimodNL457 | 0,5 mg | 266,96 | O | Accord Healthcare S.L.U. | LABORATORI FUNDACIÓ DAU, Accord Healthcare Polska Sp. z.o.o. | Fingolimod Accord | caps. tvrda 28x0,5 mg | 266,96 | 7.474,96 |  | 5% |
| L04AA27 168 | DS | fingolimodNL457 | 0,5 mg | 266,96 | O | Mylan Ireland Limited | Mylan Hungary Kft | Fingolimod Mylan | caps. tvrda 28x0,5 mg | 266,96 | 7.474,96 |  | 5% |
| L04AA27 169 | DS | fingolimodNL457 | 0,5 mg | 253,61 | O | Pharmascience International Limited | Pharmascience International Limited | Fingolimod Pharmascience | caps. tvrda 28x0,5 mg | 253,61 | 7.101,21 |  | 5% |
| L04AA27 171 | DS | fingolimodNL457 | 0,5 mg | 240,93 | O | Jadran – Galenski Laboratorij d.d. | Genepharm S.A. | Arlesias | caps. tvrda 28x0,5 mg | 240,93 | 6.746,15 |  | 5% |
| L04AA29 171 |  | tofacitinibNL506 | 10 mg | 9,43 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Xeljanz | tbl. film obl. 56x5 mg | 94,28 | 5.279,49 | RSRL105 | 5% |
| L04AA29 172 |  | tofacitinibNL507 | 10 mg | 8,95 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Xeljanz | tbl. film obl. 56x10 mg | 179,09 | 10.029,23 | RSRL106 | 5% |
| L04AA29 173 |  | tofacitinibNL509 | 10 mg | 8,37 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Xeljanz | tbl. s prod. oslob. 28x11 mg | 184,06 | 5.153,68 | RSRL109 | 5% |
| L04AA31 161 |  | teriflunomidNL538 | 14 mg | 179,09 | O | sanofi-aventis groupe | Sanofi Winthrop Industrie | Aubagio | tbl. film obl. 28x14 mg | 179,09 | 5.014,53 | RSRL114 | 5% |
| L04AA32 161 |  | apremilastNL505 |  |  | O | Amgen Europe B.V. | Celgene Distribution B.V. | Otezla | tbl. film obl. (4x10 mg) + (4x20 mg) + (19x30 mg) | 98,96 | 2.671,83 | RSRL75 | 5% |
| L04AA32 162 |  | apremilastNL505 |  |  | O | Amgen Europe B.V. | Celgene Distribution B.V. | Otezla | tbl. film obl. 56x30 mg | 98,58 | 5.520,29 | RSRL75 | 5% |
| L04AA33 061 | DS | vedolizumabNL437 |  |  | P | Takeda Pharma A/S | Takeda Italia S.p.A. | Entyvio | praš. za konc. za otop. za inf., boč. stakl. 1x300 mg | 14.295,19 | 14.295,19 |  | 5% |
| L04AA33 064 |  | vedolizumabNL522 |  |  | P | Takeda Pharma A/S | Takeda Austria GmbH | Entyvio | otop. za inj., štrc. napunj. 2x108 mg | 3.329,13 | 6.658,26 | RSRL110 | 5% |
| L04AA33 065 |  | vedolizumabNL522 |  |  | P | Takeda Pharma A/S | Takeda Austria GmbH | Entyvio | otop. za inj., brizg. napunj. 2x108 mg | 3.329,13 | 6.658,26 | RSRL110 | 5% |
| L04AA34 061 | DS | alemtuzumabNL432 | 0,13 mg | 634,03 | P | Sanofi Belgium | Genzyme Limited | Lemtrada | konc. za otop. za inf., boč. stakl. 1x12 mg/1,2 ml | 58.526,10 | 58.526,10 |  | 5% |
| L04AA36 061 | DS | okrelizumabNL484 | 3.29 mg | 438,48 | P | Roche Registration GmbH | Roche Pharma AG | Ocrevus | konc. za otop. za inf., boč. stakl. 1x300 mg/10 ml (30 mg/ml) | 39.983,08 | 39.983,08 |  | 5% |
| L04AA37 161 |  | baricitinibNL503 | 4 mg | 407,37 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Olumiant | tbl. film obl. 35x2 mg | 203,69 | 7.129,03 | RSRL96 | 5% |
| L04AA37 162 |  | baricitinibNL504 | 4 mg | 186,58 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Olumiant | tbl. film obl. 35x4 mg | 186,58 | 6.530,18 | RSRL97 | 5% |
| L04AA40 161 | DS | kladribinNL308 | 0.34 mg | 467,12 | O | Merck Europe B.V. | NerPharMa S.R.L., R-Pharm Germany GmbH | Mavenclad | tbl. 1x10 mg | 13.738,95 | 13.738,95 |  | 5% |
| L04AA40 162 | DS | kladribinNL308 | 0.34 mg | 463,82 | O | Merck Europe B.V. | NerPharMa S.R.L., R-Pharm Germany GmbH | Mavenclad | tbl. 4x10 mg | 13.641,68 | 54.566,71 |  | 5% |
| L04AA42 161 | DS | siponimodNL513 |  |  | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Mayzent | tbl. film obl. 12x0,25 mg | 123,26 | 1.479,12 |  | 5% |
| L04AA42 162 | DS | siponimodNL513 |  |  | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Mayzent | tbl. film obl. 120x0,25 mg | 94,13 | 11.295,60 |  | 5% |
| L04AA42 163 | DS | siponimodNL513 |  |  | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Mayzent | tbl. film obl. 28x2 mg | 436,04 | 12.209,21 |  | 5% |
| L04AA43 061 | KL | ravulizumab NL524 | 58.9 mg | 6.372,82 | P | Alexion Europe SAS | Alexion Pharma International Operations Unlimited Company | Ultomiris | konc. za otop. za inf., boč. stakl. 1x300 mg (30 ml, 10 mg/ml) | 32.459,30 | 32.459,30 |  | 5% |
| L04AA43 062 | KL | ravulizumab NL524 | 58.9 mg | 6.372,82 | P | Alexion Europe SAS | Alexion Pharma International Operations Unlimited Company | Ultomiris | konc. za otop. za inf., boč. stakl. 1x300 mg (3 ml, 100 mg/ml) | 32.459,30 | 32.459,30 |  | 5% |
| L04AA43 063 | KL | ravulizumab NL524 | 58.9 mg | 6.372,85 | P | Alexion Europe SAS | Alexion Pharma International Operations Unlimited Company | Ultomiris | konc. za otop. za inf., boč. stakl. 1x1100 mg (11 ml, 100 mg/ml) | 119.017,43 | 119.017,43 |  | 5% |
| L04AA44 161 |  | upadacitinibNL512 | 15 mg | 180,25 | O | AbbVie Deutschland GmbH & Co. KG | AbbVie S.r.l. | Rinvoq | tbl. s prod. oslob. 28x15 mg | 180,25 | 5.047,08 | RSRL107 | 5% |
| L04AA44 162 |  | upadacitinibNL535 | 15 mg | 108,15 | O | AbbVie Deutschland GmbH & Co. KG | AbbVie S.r.l. | Rinvoq | tbl. s prod. oslob. 28x30 mg | 216,30 | 6.056,50 | RSRL112 | 5% |
| L04AA52 071 | DS | ofatumumabNL534 |  |  | P | Novartis Ireland Limited | Novartis Pharma GmbH | Kesimpta | otop. za inj., brizg. napunj. 1x20 mg | 10.115,64 | 10.115,64 | RSRL111 | 5% |
| L04AB01 060 |  | etanerceptNL408 | 7 mg | 195,49 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel | praš. i otap. za otop. za inj., boč. 4x25 mg + 4 napunj. štrc. s otap. | 698,17 | 2.792,69 | RSRL93 | 5% |
| L04AB01 061 |  | etanerceptNL408 | 7 mg | 165,89 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel | otop. za inj., štrc. napunj. 4x50 mg/ml + 4 jast. | 1.184,92 | 4.739,67 | RSRL93 | 5% |
| L04AB01 063 |  | etanerceptNL408 | 7 mg | 164,86 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel (MyClick) | otop. za inj., brizg. napunj. 4x50 mg/ml + 4 jast. natop. alkoholom | 1.177,59 | 4.710,37 | RSRL93 | 5% |
| L04AB01 064 |  | etanerceptNL434 | 7 mg | 202,50 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel | praš. i otap. za otop. za inj. za ped. upor., boč. 4x10 mg + 4 štrc. napunj. s otap. + 8 jast. | 289,28 | 1.157,13 | RSRL93 | 5% |
| L04AB01 065 |  | etanerceptNL408 | 7 mg | 165,89 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Benepali | otop. za inj., štrc. napunj. 4x50 mg/ml | 1.184,92 | 4.739,67 | RSRL93 | 5% |
| L04AB01 066 |  | etanerceptNL408 | 7 mg | 164,86 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Benepali | otop. za inj., brizg. napunj. 4x50 mg/ml | 1.177,59 | 4.710,37 | RSRL93 | 5% |
| L04AB01 067 |  | etanerceptNL408 | 7 mg | 179,12 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel (MyClick) | otop. za inj., brizg. napunj. 4x25 mg/ml + 4 jast. natop. alkoholom | 639,72 | 2.558,88 | RSRL93 | 5% |
| L04AB01 073 |  | etanerceptNL408 | 7 mg | 164,86 | P | Sandoz GmbH | Sandoz GmbH | Erelzi | otop. za inj., brizg. napunj. 4x50 mg/ml | 1.177,59 | 4.710,37 | RSRL93 | 5% |
| L04AB01 074 |  | etanerceptNL408 | 7 mg | 180,50 | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Ltd T/A Mylan Dublin Biologics | Nepexto | otop. za inj., štrc. napunj. 4x25 mg/0.5 ml | 644,66 | 2.578,63 | RSRL93 | 5% |
| L04AB01 075 |  | etanerceptNL408 | 7 mg | 165,89 | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Ltd T/A Mylan Dublin Biologics | Nepexto | otop. za inj., štrc. napunj. 4x50 mg/ml | 1.184,92 | 4.739,67 | RSRL93 | 5% |
| L04AB01 076 |  | etanerceptNL408 | 7 mg | 164,86 | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Ltd T/A Mylan Dublin Biologics | Nepexto | otop. za inj., brizg. napunj. 4x50 mg/ml | 1.177,59 | 4.710,37 | RSRL93 | 5% |
| L04AB02 021 | DS | infliksimabNL409 | 3,75 mg | 93,05 | P | Sandoz GmbH | Sandoz GmbH | Zessly | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 2.481,23 | 2.481,23 |  | 5% |
| L04AB02 061 | DS | infliksimabNL409 | 3,75 mg | 94,27 | P | Janssen Biologics B.V. | Janssen Biologics B.V. | Remicade | lio boč. za inf. 1x100 mg | 2.513,77 | 2.513,77 |  | 5% |
| L04AB02 071 | DS | infliksimabNL409 | 3,75 mg | 94,27 | P | Pfizer Europe MA EEIG | HOSPIRA Enterprises B.V. | Inflectra | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 2.513,77 | 2.513,77 |  | 5% |
| L04AB02 079 |  | infliksimabNL536 | 3,75 mg | 72,66 | P | Celltrion Healthcare Hungary Kft. | Millmount Healthcare Ltd., Nuvisan GmbH | Remsima | otop. za inj., brizg. napunj. 2x120 mg | 2.325,00 | 4.650,00 | RSRL113 | 5% |
| L04AB02 081 | DS | infliksimabNL409 | 3,75 mg | 94,27 | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd. | Remsima | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 2.513,77 | 2.513,77 |  | 5% |
| L04AB02 082 | DS | infliksimabNL409 | 3,75 mg | 94,27 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Flixabi | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 2.513,77 | 2.513,77 |  | 5% |
| L04AB04 063 |  | adalimumabNL510 | 2,9 mg | 158,85 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie Biotechnology GmbH | Humira | otop. za inj., štrc. stakl. 2x40 mg/0,4 ml | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 064 |  | adalimumabNL510 | 2,9 mg | 158,85 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie Biotechnology GmbH | Humira | otop. za inj., brizg. napunj. 2x40 mg/0,4 ml | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 066 |  | adalimumabNL411 | 2,9 mg | 158,85 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie Biotechnology GmbH | Humira | otop. za inj., štrc. stakl. 2x20 mg/0,2 ml | 1.095,52 | 2.191,04 | RSRL93 | 5% |
| L04AB04 067 |  | adalimumabNL510 | 2,9 mg | 158,85 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie Biotechnology GmbH | Humira | otop. za inj., brizg. napunj. 1x80 mg/0,8 ml | 4.382,07 | 4.382,07 | RSRL93 | 5% |
| L04AB04 071 |  | adalimumabNL411 | 2.9 mg | 158,85 | P | Amgen Europe B.V. | Amgen Europe B.V. | Amgevita | otop. za inj. štrc. stakl., 1x20 mg/0,4 ml (50 mg/ml) | 1.095,52 | 1.095,52 | RSRL93 | 5% |
| L04AB04 072 |  | adalimumabNL410 | 2,9 mg | 158,85 | P | Amgen Europe B.V. | Amgen Europe B.V. | Amgevita | otop. za inj., štrc. stakl. 2x40 mg/0,8 ml (50 mg/ml) | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 073 |  | adalimumabNL410 | 2,9 mg | 158,85 | P | Amgen Europe B.V. | Amgen Europe B.V. | Amgevita | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 074 |  | adalimumabNL410 | 2,9 mg | 158,85 | P | Fresenius Kabi Deutschland GmbH | Merck Serono S.p.a. | Idacio | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 081 |  | adalimumabNL410 | 2,9 mg | 158,85 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Imraldi | otop. za inj., štrc. stakl. 2x40 mg/0,8 ml (50 mg/ml) | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 082 |  | adalimumabNL410 | 2,9 mg | 158,85 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Imraldi | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 085 |  | adalimumabNL410 | 2,9 mg | 158,85 | P | Sandoz GmbH | Sandoz GmbH | Hyrimoz | otop. za inj., štrc. stakl. 2x40 mg/0,8 ml (50 mg/ml) | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 086 |  | adalimumabNL410 | 2,9 mg | 158,85 | P | Sandoz GmbH | Sandoz GmbH | Hyrimoz | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 090 |  | adalimumabNL510 | 2,9 mg | 158,85 | P | Viatris Limited | McDermott laboratories T/A Mylan Dublin Biologics, Mylan Germany GmbH | Hulio | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 2.191,04 | 4.382,07 | RSRL93 | 5% |
| L04AB04 091 |  | adalimumabNL510 | 2,9 mg | 150,91 | P | STADA Arzneimittel AG | Ivers-Lee CSM | Hukyndra | otop. za inj., brizg. napunj. 2x40 mg/0,4 ml | 2.081,49 | 4.162,97 | RSRL93 | 5% |
| L04AB05 061 |  | certolizumab pegolNL428 | 14 mg | 218,45 | P | UCB Pharma S.A. | UCB Pharma S.A. | Cimzia | otop. za inj., štrc. napunj. 2x200 mg/ml | 3.120,65 | 6.241,30 | RSRL93 | 5% |
| L04AB06 061 |  | golimumabNL412 |  |  | P | Janssen Biologics B.V. | Janssen Biologics B.V. | Simponi | otop. za inj., brzig. napunj. 1x50 mg/0,5 ml | 6.474,12 | 6.474,12 | RSRL93 | 5% |
| L04AB06 062 |  | golimumabNL412 |  |  | P | Janssen Biologics B.V. | Janssen Biologics B.V. | Simponi | otop. za inj., brizg. napunj. 1x100 mg/ml | 10.236,00 | 10.236,00 | RSRL93 | 5% |
| L04AC02 061 | KS | baziliksimabNL413 | 40 mg | 16.385,32 | P | Novartis Europharm Limited Irska | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Simulect | praš. za inj. boč. 1x20 mg/5 ml | 8.192,66 | 8.192,66 |  | 5% |
| L04AC05 061 |  | ustekinumabNL424 | 0,54 mg | 227,98 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V. | Stelara | otop. za inj. štrc. napunj. 1x45 mg/0,5 ml | 18.998,72 | 18.998,72 | RSRL99 | 5% |
| L04AC05 062 |  | ustekinumabNL463 | 0,54 mg | 114,32 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V. | Stelara | otop. za inj. štrc. napunj. 1x90 mg/1 ml | 19.052,52 | 19.052,52 | RSRL100 | 5% |
| L04AC05 063 | DS | ustekinumabNL464 | 0,54 mg | 79,14 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V. | Stelara | konc. za otop. za inf., boč. stakl. 1x130 mg/26 ml | 19.052,52 | 19.052,52 |  | 5% |
| L04AC07 061 | DS | tocilizumab NL414 |  |  | P | Roche Registration GmbH | Roche | RoActemra | konc. otop. za inf., boč. 1x80 mg/4 ml | 985,41 | 985,41 |  | 5% |
| L04AC07 062 | DS | tocilizumabNL414 |  |  | P | Roche Registration GmbH | Roche | RoActemra | konc. otop. za inf., boč. 1x200 mg/10 ml | 2.464,00 | 2.464,00 |  | 5% |
| L04AC07 063 | DS | tocilizumabNL414 |  |  | P | Roche Registration GmbH | Roche | RoActemra | konc. otop. za inf., boč. 1x400 mg/20 ml | 4.508,04 | 4.508,04 |  | 5% |
| L04AC07 064 |  | tocilizumabNL486 | 20 mg | 197,01 | P | Roche Registration GmbH | Roche | RoActemra | otop. za inj., štrc. napunj. 4x162 mg/0,9 ml | 1.595,78 | 6.383,13 | RSRL93 | 5% |
| L04AC07 065 |  | tocilizumabNL485 | 20 mg | 197,01 | P | Roche Registration GmbH | Roche Pharma AG | RoActemra | otop. za inj., brizg. napunj. 4x162 mg/0,9 ml (ACTPen) | 1.595,78 | 6.383,13 | RSRL93 | 5% |
| L04AC10 061 |  | sekukinumabNL449 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Cosentyx | otop. za inj., brizg. napunj. 2x150 mg | 3.592,10 | 7.184,19 | RSRL103 | 5% |
| L04AC10 062 |  | sekukinumabNL449 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Cosentyx | otop. za inj., brizg. napunj. 1x300 mg | 7.184,19 | 7.184,19 | RSRL103 | 5% |
| L04AC13 061 |  | iksekizumabNL456 |  |  | P | Eli Lilly and Company (Ireland) Limited | Eli Lilly Italia S.p.A. | Taltz | otop. za inj., brizg. napunj. 1x80 mg/ml | 7.436,13 | 7.436,13 | RSRL95 | 5% |
| L04AC14 071 |  | sarilumabNL433 | 14.3 mg | 316,52 | P | sanofi-aventis groupe | Sanofi Winthrop Industrie | Kevzara | otop. za inj., štrc. napunj. 2x150 mg | 3.320,13 | 6.640,25 | RSRL93 | 5% |
| L04AC14 072 |  | sarilumabNL433 | 14.3 mg | 307,25 | P | sanofi-aventis groupe | Sanofi Winthrop Industrie | Kevzara | otop. za inj., brizg. napunj. 2x150 mg | 3.222,93 | 6.445,85 | RSRL93 | 5% |
| L04AC14 073 |  | sarilumabNL433 | 14.3 mg | 234,10 | P | sanofi-aventis groupe | Sanofi Winthrop Industrie | Kevzara | otop. za inj., štrc. napunj. 2x200 mg | 3.274,11 | 6.548,21 | RSRL93 | 5% |
| L04AC14 074 |  | sarilumabNL433 | 14.3 mg | 230,44 | P | sanofi-aventis groupe | Sanofi Winthrop Industrie | Kevzara | otop. za inj., brizg. napunj. 2x200 mg | 3.222,93 | 6.445,85 | RSRL93 | 5% |
| L04AC16 062 |  | guselkumabNL483 | 1.79 mg | 256,33 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V. | Tremfya | otop. za inj., brizg. napunj. 1x100 mg/ml | 14.319,96 | 14.319,96 | RSRL102 | 5% |
| L04AC18 071 |  | risankizumabNL500 | 1,67 mg | 238,66 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie S.r.l. | Skyrizi | otop. za inj., štrc. napunj. 2x75 mg/0,83 ml | 10.718,35 | 21.436,70 | RSRL104 | 5% |
| L04AC18 072 |  | risankizumabNL500 | 1,67 mg | 238,66 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie S.r.l. | Skyrizi | otop. za inj., brizg. napunj. 1x150 mg | 21.436,70 | 21.436,70 | RSRL104 | 5% |
| L04AD01 065 | KS | ciklosporinNL415 | 0,25 g | 66,10 | P | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH | Sandimmun | amp. 10x250 mg/5 ml | 66,10 | 661,03 |  | 5% |
| L04AD01 141 |  | ciklosporinNL415 | 0,25 g | 39,97 | O | Alkaloid d.o.o. | Alkaloid | Ciklosporin Alkaloid | caps. meke 50x25 mg | 4,00 | 199,83 | RSRL45 | 5% |
| L04AD01 142 |  | ciklosporinNL415 | 0,25 g | 36,04 | O | Alkaloid d.o.o. | Alkaloid | Ciklosporin Alkaloid | caps. 50x50 mg | 7,21 | 360,38 | RSRL45 | 5% |
| L04AD01 143 |  | ciklosporinNL415 | 0,25 g | 35,75 | O | Alkaloid d.o.o. | Alkaloid | Ciklosporin Alkaloid | caps. meke 50x100 mg | 14,30 | 715,00 | RSRL45 | 5% |
| L04AD01 161 |  | ciklosporinNL415 | 0,25 g | 39,97 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek Pharmaceuticals d.d. | Sandimmun Neoral | caps. 50x25 mg | 4,00 | 199,83 | RSRL45 | 5% |
| L04AD01 162 |  | ciklosporinNL415 | 0,25 g | 38,27 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek Pharmaceuticals d.d. | Sandimmun Neoral | caps. 50x50 mg | 7,65 | 382,67 | RSRL45 | 5% |
| L04AD01 163 |  | ciklosporinNL415 | 0,25 g | 35,75 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek Pharmaceuticals d.d. | Sandimmun Neoral | caps. 50x100 mg | 14,30 | 715,00 | RSRL45 | 5% |
| L04AD01 171 |  | ciklosporinNL415 | 0,25 g | 39,97 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Equoral | caps. 50x25 mg | 4,00 | 199,83 | RSRL45 | 5% |
| L04AD01 172 |  | ciklosporinNL415 | 0,25 g | 36,04 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Equoral | caps. 50x50 mg | 7,21 | 360,38 | RSRL45 | 5% |
| L04AD01 173 |  | ciklosporinNL415 | 0,25 g | 35,75 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Equoral | caps. 50x100 mg | 14,30 | 715,00 | RSRL45 | 5% |
| L04AD01 264 |  | ciklosporinNL415 | 0,25 g | 42,39 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH | Sandimmun Neoral | otop. 10% 1x50 ml (100 mg/ml) | 847,88 | 847,88 | RSRL45 | 5% |
| L04AD02 052 | KS | takrolimusNL416 | 5 mg |  | P |  |  |  |  |  |  |  | 5% |
| L04AD02 104 |  | takrolimusNL416 | 5 mg | 47,67 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Tacforius | caps. s prod. oslob. tvrda 30x0,5 mg | 4,77 | 143,01 | RSRL46 | 5% |
| L04AD02 105 |  | takrolimusNL416 | 5 mg | 49,70 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Tacforius | caps. s prod. oslob. tvrda 30x1 mg | 9,94 | 298,20 | RSRL46 | 5% |
| L04AD02 106 |  | takrolimusNL416 | 5 mg | 45,24 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Tacforius | caps. s prod. oslob. tvrda 30x3 mg | 27,14 | 814,24 | RSRL46 | 5% |
| L04AD02 107 |  | takrolimusNL416 | 5 mg | 44,17 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Tacforius | caps. s prod. oslob. tvrda 30x5 mg | 44,17 | 1.325,24 | RSRL46 | 5% |
| L04AD02 121 |  | takrolimusNL416 | 5 mg | 45,50 | O | Sandoz d.o.o. | Sandoz-Lek | Tacrocel | caps. tvrda 30x0,5 mg | 4,55 | 136,50 | RSRL46 | 5% |
| L04AD02 122 |  | takrolimusNL416 | 5 mg | 50,10 | O | Sandoz d.o.o. | Sandoz-Lek | Tacrocel | caps. tvrda 60x1 mg | 10,02 | 601,20 | RSRL46 | 5% |
| L04AD02 161 |  | takrolimusNL416 | 5 mg | 50,10 | O | Astellas d.o.o. | Astellas Ireland Co. Ltd. | Prograf | caps. 60x1 mg | 10,02 | 601,20 | RSRL46 | 5% |
| L04AD02 162 |  | takrolimusNL416 | 5 mg | 40,68 | O | Astellas d.o.o. | Astellas Ireland Co. Ltd. | Prograf | caps. 30x5 mg | 40,68 | 1.220,30 | RSRL46 | 5% |
| L04AD02 163 |  | takrolimusNL416 | 5 mg | 53,63 | O | Astellas d.o.o. | Astellas Ireland Co. Ltd. | Prograf | caps. 30x0,5 mg | 5,36 | 160,90 | RSRL46 | 5% |
| L04AD02 165 |  | takrolimusNL416 | 5 mg | 55,87 | O | Astellas Pharma Europe B.V. | Astellas Ireland Co., Ltd. | Advagraf | caps. s prod. oslob. tvrda 30x0,5 mg | 5,59 | 167,60 | RSRL46 | 5% |
| L04AD02 166 |  | takrolimusNL416 | 5 mg | 55,07 | O | Astellas Pharma Europe B.V. | Astellas Ireland Co., Ltd. | Advagraf | caps. s prod. oslob. tvrda 30x1 mg | 11,01 | 330,40 | RSRL46 | 5% |
| L04AD02 167 |  | takrolimusNL416 | 5 mg | 46,62 | O | Astellas Pharma Europe B.V. | Astellas Ireland Co., Ltd. | Advagraf | caps. s prod. oslob. tvrda 30x3 mg | 27,97 | 839,20 | RSRL46 | 5% |
| L04AD02 168 |  | takrolimusNL416 | 5 mg | 49,11 | O | Astellas Pharma Europe B.V. | Astellas Ireland Co., Ltd. | Advagraf | caps. s prod. oslob. tvrda 30x5 mg | 49,11 | 1.473,30 | RSRL46 | 5% |
| L04AD02 181 |  | takrolimusNL416 |  |  | O | Chiesi Faramaceutici S.p.A. | Chiesi Farmaceutici S.p.A. | Envarsus | tbl. s prod. oslob. 30x0,75 mg | 12,23 | 366,90 | RSRL46 | 5% |
| L04AD02 182 |  | takrolimusNL416 |  |  | O | Chiesi Faramaceutici S.p.A. | Chiesi Farmaceutici S.p.A. | Envarsus | tbl. s prod. oslob. 60x1 mg | 15,33 | 919,60 | RSRL46 | 5% |
| L04AD02 183 |  | takrolimusNL416 |  |  | O | Chiesi Faramaceutici S.p.A. | Chiesi Farmaceutici S.p.A. | Envarsus | tbl. s prod. oslob. 30x4 mg | 63,95 | 1.918,50 | RSRL46 | 5% |
| L04AX01 195 |  | azatioprin | 0,15 g | 3,91 | O | Aspen Pharma Trading Limited | Excella | Imuran | tbl. film obl. 100x50 mg | 1,30 | 130,33 | R | 5% |
| L04AX03 131 |  | metotreksat | 2,5 mg | 0,78 | O | Sandoz d.o.o. | Salutas Pharma GmbH | Metotreksat Sandoz | tbl. 30x2,5 mg | 0,78 | 23,31 | RSRL48 | 5% |
| L04AX04 101 | DS | lenalidomidNL490 | 10 mg | 2.202,12 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Lenalidomid Teva | caps. tvrda 21x5 mg | 1.101,06 | 23.122,21 |  | 5% |
| L04AX04 102 | DS | lenalidomidNL490 | 10 mg | 1.139,14 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Lenalidomid Teva | caps. tvrda 21x10 mg | 1.139,14 | 23.922,00 |  | 5% |
| L04AX04 103 | DS | lenalidomidNL427 | 10 mg | 799,37 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Lenalidomid Teva | caps. tvrda 21x15 mg | 1.199,05 | 25.180,07 |  | 5% |
| L04AX04 104 | DS | lenalidomidNL427 | 10 mg | 525,35 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Lenalidomid Teva | caps. tvrda 21x25 mg | 1.313,38 | 27.580,91 |  | 5% |
| L04AX04 121 | DS | lenalidomidNL427 | 10 mg | 1.783,71 | O | Sandoz d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Sandoz | caps. tvrda 21x5 mg | 891,86 | 18.728,99 |  | 5% |
| L04AX04 122 | DS | lenalidomidNL427 | 10 mg | 922,71 | O | Sandoz d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Sandoz | caps. tvrda 21x10 mg | 922,71 | 19.376,82 |  | 5% |
| L04AX04 124 | DS | lenalidomidNL427 | 10 mg | 425,53 | O | Sandoz d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Sandoz | caps. tvrda 21x25 mg | 1.063,84 | 22.340,54 |  | 5% |
| L04AX04 141 | DS | lenalidomidNL490 | 10 mg | 1.529,30 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Lenalidomid Alkaloid-INT | caps. tvrda 21x5 mg | 764,65 | 16.057,70 |  | 5% |
| L04AX04 142 | DS | lenalidomidNL490 | 10 mg | 791,10 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Lenalidomid Alkaloid-INT | caps. tvrda 21x10 mg | 791,10 | 16.613,12 |  | 5% |
| L04AX04 143 | DS | lenalidomidNL427 | 10 mg | 555,14 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Lenalidomid Alkaloid-INT | caps. tvrda 21x15 mg | 832,71 | 17.486,90 |  | 5% |
| L04AX04 144 | DS | lenalidomidNL427 | 10 mg | 364,84 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Lenalidomid Alkaloid-INT | caps. tvrda 21x25 mg | 912,09 | 19.153,97 |  | 5% |
| L04AX04 161 | DS | lenalidomidNL490 | 10 mg | 2.241,95 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Revlimid | caps. tvrda 21x5 mg | 1.120,98 | 23.540,51 |  | 5% |
| L04AX04 162 | DS | lenalidomidNL490 | 10 mg | 1.164,16 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Revlimid | caps. tvrda 21x10 mg | 1.164,16 | 24.447,36 |  | 5% |
| L04AX04 163 | DS | lenalidomidNL427 | 10 mg | 820,23 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Revlimid | caps. tvrda 21x15 mg | 1.230,35 | 25.837,28 |  | 5% |
| L04AX04 164 | DS | lenalidomidNL427 | 10 mg | 539,40 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Revlimid | caps. tvrda 21x25 mg | 1.348,50 | 28.318,43 |  | 5% |
| L04AX04 165 | DS | lenalidomidNL490 | 10 mg | 1.609,79 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, KRKA – FARMA d.o.o. | Lenalidomid Krka | caps. tvrda 21x5 mg | 804,90 | 16.902,84 |  | 5% |
| L04AX04 166 | DS | lenalidomidNL490 | 10 mg | 832,74 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, KRKA – FARMA d.o.o. | Lenalidomid Krka | caps. tvrda 21x10 mg | 832,74 | 17.487,57 |  | 5% |
| L04AX04 167 | DS | lenalidomidNL427 | 10 mg | 584,36 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, KRKA – FARMA d.o.o. | Lenalidomid Krka | caps. tvrda 21x15 mg | 876,54 | 18.407,26 |  | 5% |
| L04AX04 168 | DS | lenalidomidNL427 | 10 mg | 384,04 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, KRKA – FARMA d.o.o. | Lenalidomid Krka | caps. tvrda 21x25 mg | 960,10 | 20.162,07 |  | 5% |
| L04AX04 171 | DS | lenalidomidNL427 | 10 mg | 2.241,95 | O | Zentiva k.s. | Pharmadox Healthcare Limited, Pharmacare Premium Ltd. | Lenalidomid Zentiva | caps. tvrda 21x5 mg | 1.120,98 | 23.540,51 |  | 5% |
| L04AX04 172 | DS | lenalidomidNL427 | 10 mg | 1.164,16 | O | Zentiva k.s. | Pharmadox Healthcare Limited, Pharmacare Premium Ltd. | Lenalidomid Zentiva | caps. tvrda 21x10 mg | 1.164,16 | 24.447,36 |  | 5% |
| L04AX04 173 | DS | lenalidomidNL427 | 10 mg | 820,23 | O | Zentiva k.s. | Pharmadox Healthcare Limited, Pharmacare Premium Ltd. | Lenalidomid Zentiva | caps. tvrda 21x15 mg | 1.230,35 | 25.837,28 |  | 5% |
| L04AX04 174 | DS | lenalidomidNL427 | 10 mg | 539,40 | O | Zentiva k.s. | Pharmadox Healthcare Limited, Pharmacare Premium Ltd. | Lenalidomid Zentiva | caps. tvrda 21x25 mg | 1.348,50 | 28.318,43 |  | 5% |
| L04AX04 175 | DS | lenalidomidNL427 | 10 mg | 1.694,52 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x5 mg | 847,26 | 17.792,46 |  | 5% |
| L04AX04 176 | DS | lenalidomidNL427 | 10 mg | 355,36 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x7,5 mg | 266,52 | 5.596,92 |  | 5% |
| L04AX04 177 | DS | lenalidomidNL427 | 10 mg | 876,57 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x10 mg | 876,57 | 18.407,97 |  | 5% |
| L04AX04 178 | DS | lenalidomidNL427 | 10 mg | 615,11 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x15 mg | 922,67 | 19.376,06 |  | 5% |
| L04AX04 179 | DS | lenalidomidNL427 | 10 mg | 483,33 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x20 mg | 966,66 | 20.299,79 |  | 5% |
| L04AX04 180 | DS | lenalidomidNL427 | 10 mg | 404,25 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x25 mg | 1.010,63 | 21.223,23 |  | 5% |
| L04AX04 181 | DS | lenalidomidNL427 | 10 mg | 1.025,23 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Alpha-Medical | caps. tvrda 21x10 mg | 1.025,23 | 21.529,80 |  | 5% |
| L04AX04 182 | DS | lenalidomidNL427 | 10 mg | 472,82 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Alpha-Medical | caps. tvrda 21x25 mg | 1.182,04 | 24.822,82 |  | 5% |
| L04AX04 183 | DS | lenalidomidNL427 | 10 mg | 1.783,71 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x2,5 mg | 445,93 | 9.364,50 |  | 5% |
| L04AX04 184 | DS | lenalidomidNL490 | 10 mg | 1.783,71 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x5 mg | 891,86 | 18.728,99 |  | 5% |
| L04AX04 185 | DS | lenalidomidNL427 | 10 mg | 355,36 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x7,5 mg | 266,52 | 5.596,92 |  | 5% |
| L04AX04 186 | DS | lenalidomidNL490 | 10 mg | 922,71 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x10 mg | 922,71 | 19.376,82 |  | 5% |
| L04AX04 187 | DS | lenalidomidNL427 | 10 mg | 647,49 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x15 mg | 971,23 | 20.395,85 |  | 5% |
| L04AX04 188 | DS | lenalidomidNL427 | 10 mg | 508,77 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x20 mg | 1.017,53 | 21.368,20 |  | 5% |
| L04AX04 189 | DS | lenalidomidNL427 | 10 mg | 425,53 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x25 mg | 1.063,84 | 22.340,54 |  | 5% |
| L04AX04 191 | DS | lenalidomidNL427 | 10 mg | 1.694,53 | O | Pharmascience International Limited | Pharmadox Healthcare Limited, Alvogen Malta (Out-Licensing) Ltd. | Lenalidomid Pharmascience | caps. tvrda 21x5 mg | 847,26 | 17.792,54 |  | 5% |
| L04AX04 192 | DS | lenalidomidNL427 | 10 mg | 876,57 | O | Pharmascience International Limited | Pharmadox Healthcare Limited, Alvogen Malta (Out-Licensing) Ltd. | Lenalidomid Pharmascience | caps. tvrda 21x10 mg | 876,57 | 18.407,98 |  | 5% |
| L04AX04 193 | DS | lenalidomidNL427 | 10 mg | 615,11 | O | Pharmascience International Limited | Pharmadox Healthcare Limited, Alvogen Malta (Out-Licensing) Ltd. | Lenalidomid Pharmascience | caps. tvrda 21x15 mg | 922,67 | 19.376,06 |  | 5% |
| L04AX04 194 | DS | lenalidomidNL427 | 10 mg | 404,26 | O | Pharmascience International Limited | Pharmadox Healthcare Limited, Alvogen Malta (Out-Licensing) Ltd. | Lenalidomid Pharmascience | caps. tvrda 21x25 mg | 1.010,64 | 21.223,51 |  | 5% |
| L04AX04 195 | DS | lenalidomidNL427 | 10 mg | 1.609,80 | O | Mylan Ireland Limited | McDermott Laboratories Ltd trading as Gerard Laboratories, Mylan Hungary Kft | Lenalidomid Mylan | caps. tvrda 21x5 mg | 804,90 | 16.902,91 |  | 5% |
| L04AX04 196 | DS | lenalidomidNL427 | 10 mg | 832,74 | O | Mylan Ireland Limited | McDermott Laboratories Ltd trading as Gerard Laboratories, Mylan Hungary Kft | Lenalidomid Mylan | caps. tvrda 21x10 mg | 832,74 | 17.487,58 |  | 5% |
| L04AX04 197 | DS | lenalidomidNL427 | 10 mg | 584,36 | O | Mylan Ireland Limited | McDermott Laboratories Ltd trading as Gerard Laboratories, Mylan Hungary Kft | Lenalidomid Mylan | caps. tvrda 21x15 mg | 876,54 | 18.407,26 |  | 5% |
| L04AX04 198 | DS | lenalidomidNL427 | 10 mg | 384,04 | O | Mylan Ireland Limited | McDermott Laboratories Ltd trading as Gerard Laboratories, Mylan Hungary Kft | Lenalidomid Mylan | caps. tvrda 21x25 mg | 960,11 | 20.162,33 |  | 5% |
| L04AX05 111 | KS | pirfenidonNL455 | 2,4 g | 378,97 | O | Teva GmbH | Actavis Limited | Pirfenidon Teva | tbl. film obl. 252x267 mg | 42,16 | 10.624,32 |  | 5% |
| L04AX05 112 | KS | pirfenidonNL455 | 2,4 g | 378,97 | O | Teva GmbH | Actavis Limited | Pirfenidon Teva | tbl. film obl. 84x801 mg | 126,48 | 10.624,32 |  | 5% |
| L04AX05 121 | KS | pirfenidonNL455 | 2,4 g | 398,93 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Pirfenidon Sandoz | tbl. film obl. 252x267 mg | 44,38 | 11.183,96 |  | 5% |
| L04AX05 122 | KS | pirfenidonNL455 | 2,4 g | 398,93 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Pirfenidon Sandoz | tbl. film obl. 84x801 mg | 133,14 | 11.183,96 |  | 5% |
| L04AX05 162 | KS | pirfenidonNL455 | 2,4 g | 569,90 | O | Roche Registration GmbH | Roche Pharma AG | Esbriet | tbl. film obl. 252x267 mg | 63,40 | 15.977,08 |  | 5% |
| L04AX05 163 | KS | pirfenidonNL455 | 2,4 g | 569,90 | O | Roche Registration GmbH | Roche Pharma AG | Esbriet | tbl. film obl. 84x801 mg | 190,20 | 15.977,08 |  | 5% |
| L04AX05 164 | KS | pirfenidonNL455 | 2,4 g | 378,98 | O | Zentiva k.s. | PharOS MT Ltd, Rontis Hellas Medical and Pharmaceutical Products S.A. | Pirfenidon Zentiva | tbl. film obl. 252x267 mg | 42,16 | 10.624,76 |  | 5% |
| L04AX05 165 | KS | pirfenidonNL455 | 2,4 g | 378,98 | O | Zentiva k.s. | PharOS MT Ltd, Rontis Hellas Medical and Pharmaceutical Products S.A. | Pirfenidon Zentiva | tbl. film obl. 84x801 mg | 126,49 | 10.624,76 |  | 5% |
| L04AX06 161 | KS | pomalidomidNL477 | 3 mg | 2.925,17 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Distribution B.V. | Imnovid | caps. tvrda 21x3 mg | 2.925,17 | 61.428,50 |  | 5% |
| L04AX06 162 | KS | pomalidomidNL477 | 3 mg | 2.221,07 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Distribution B.V. | Imnovid | caps. tvrda 21x4 mg | 2.961,43 | 62.189,96 |  | 5% |
| L04AX07 161 | DS | dimetil fumaratNL538 | 0,48 g | 261,49 | O | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Tecfidera | caps. žel. otp. tvrda 14x120 mg | 65,37 | 915,23 |  | 5% |
| L04AX07 162 |  | dimetil fumaratNL538 | 0,48 g | 243,57 | O | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Tecfidera | caps. žel. otp. tvrda 56x240 mg | 121,79 | 6.820,05 | RSRL114 | 5% |
| L04AX07 171 | DS | dimetil fumaratNL538 | 0,48 g | 183,05 | O | Mylan Ireland Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories | Dimetilfumarat Mylan | caps. žel. otp. tvrda 14x120 mg | 45,76 | 640,66 |  | 5% |
| L04AX07 172 |  | dimetil fumaratNL538 | 0,48 g | 170,50 | O | Mylan Ireland Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories | Dimetilfumarat Mylan | caps. žel. otp. tvrda 56x240 mg | 85,25 | 4.774,04 | RSRL114 | 5% |
| M01AB01 051 | DS | indometacin | 0,1 g |  | P |  |  |  |  |  |  |  | 5% |
| M01AB01 111 |  | indometacin | 0,1 g | 1,39 | O | Belupo d.d. | Belupo | Indometacin Belupo | caps. tvrda 30x25 mg | 0,35 | 10,40 | R | 5% |
| M01AB05 021 | PR | diklofenak | 0,1 g | 1,91 | P | Sandoz d.o.o. | Sandoz-Salutas | Diclac | otop. za inj., amp. 5x75 mg/3 ml | 1,44 | 7,18 |  | 5% |
| M01AB05 033 | PR | diklofenak | 0,1 g | 2,00 | P | KRKA-FARMA d.o.o. | Krka d.d. | Naklofen | amp. 5x75 mg/3 ml | 1,60 | 7,98 |  | 5% |
| M01AB05 111 |  | diklofenak | 0,1 g | 0,78 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Diklofenak Mibe | tbl. retard 20x100 mg | 0,78 | 15,53 | R | 5% |
| M01AB05 121 |  | diklofenak | 0,1 g | 0,80 | O | Sandoz d.o.o. | Sandoz-Salutas | Diclac DUO | tbl. s prilag. oslob. 20x75 mg | 0,60 | 12,00 | R | 5% |
| M01AB05 122 |  | diklofenak | 0,1 g | 0,80 | O | Sandoz d.o.o. | Sandoz-Salutas | Diclac DUO | tbl. s prilag. oslob. 30x75 mg | 0,60 | 18,00 | R | 5% |
| M01AB05 505 |  | diklofenak | 0,1 g | 16,24 | R | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH | Voltaren | supp. 10x12,5 mg | 2,03 | 20,30 | R | 5% |
| M01AB05 506 |  | diklofenak | 0,1 g | 11,04 | R | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH | Voltaren | supp. 10x25 mg | 2,76 | 27,59 | R | 5% |
| M01AC06 141 |  | meloksikam | 15 mg | 0,78 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Meliam | tbl. 20x15 mg | 0,78 | 15,53 | R | 5% |
| M01AE01 118 |  | ibuprofen | 1,2 g | 0,80 | O | Belupo d.d. | Belupo | Ibuprofen Belupo | tbl. film obl. 30x800 mg | 0,53 | 16,00 | R | 5% |
| M01AE01 274 |  | ibuprofen | 1,2 g | 7,28 | O | Mylan Hrvatska d.o.o. | AbbVie S.r.L. | Dalsy | sirup 1x100 ml (100 mg/5 ml) | 12,13 | 12,13 | R | 5% |
| M01AE01 314 |  | ibuprofen | 1,2 g | 7,28 | O | Belupo d.d. | Belupo | Ibuprofen Belupo | oral. susp. 1x100 ml (20 mg/ml) | 12,13 | 12,13 | R | 5% |
| M01AE01 342 |  | ibuprofen | 1,2 g | 5,91 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Ibuprofen Alkaloid | oral. susp. 1x100 ml (20 mg/ml) | 9,85 | 9,85 | R | 5% |
| M01AE01 361 |  | ibuprofen | 1,2 g | 5,70 | O | Mylan Hrvatska d.o.o. | Farmasierra Manufacturing S.L. | Dalsy forte | oral. susp. 1x200 ml (40 mg/ml) | 38,00 | 38,00 | R | 5% |
| M01AE01 371 |  | ibuprofen | 1,2 g | 6,22 | O | Jadran – Galenski Laboratorij d.d. | Farmasierra Manufacturing S.L., JGL d.d. | Ibuprofen JGL | oral. susp. 1x100 ml (20 mg/ml) | 10,37 | 10,37 | R | 5% |
| M01AE01 372 |  | ibuprofen | 1,2 g | 3,99 | O | Jadran – Galenski Laboratorij d.d. | Farmasierra Manufacturing S.L., JGL d.d. | Ibuprofen JGL | oral. susp. 1x100 ml (40 mg/ml) | 13,30 | 13,30 | R | 5% |
| M01AE03 021 | PR | ketoprofen | 0,15 g | 5,43 | P | Sandoz d.o.o. | Sandoz-Lek | Ketonal | amp. 10x100 mg/2ml | 3,80 | 38,00 |  | 5% |
| M01AE03 111 |  | ketoprofen | 0,15 g | 0,82 | O | Belupo d.d. | Belupo | Knavon | caps. 25x50 mg | 0,27 | 6,81 | R | 5% |
| M01AE03 112 |  | ketoprofen | 0,15 g | 0,80 | O | Belupo d.d. | Belupo | Knavon forte | tbl. 20x100 mg | 0,53 | 10,67 | R | 5% |
| M01AE03 113 |  | ketoprofen | 0,15 g | 0,78 | O | Belupo d.d. | Belupo | Knavon | tbl. retard 20x150 mg | 0,78 | 15,53 | R | 5% |
| M01AE03 122 |  | ketoprofen | 0,15 g | 0,80 | O | Sandoz d.o.o. | Sandoz-Lek | Ketonal forte | tbl. film obl. 20x100 mg | 0,53 | 10,67 | R | 5% |
| M01AE03 128 |  | ketoprofen | 0,15 g | 0,78 | O | Sandoz d.o.o. | Sandoz-Lek | Ketonal DUO | caps. s prilag. oslob. tvrda 30x150 mg | 0,78 | 23,30 | R | 5% |
| M01CB01 051 | DS | natrij-aurotiomalat | 2,4 mg |  | P |  |  |  |  |  |  |  | 5% |
| M01CC01 151 |  | penicilamin | 0,5 g |  | O |  |  |  |  |  |  | R | 5% |
| M03AB01 051 | DS | suksametonij |  |  | P |  |  |  |  |  |  |  | 5% |
| M03AC01 051 | DS | pankuronij |  |  | P |  |  |  |  |  |  |  | 5% |
| M03AC03 051 | DS | vekuronij |  |  | P |  |  |  |  |  |  |  | 5% |
| M03AC04 051 | DS | atrakurij |  |  | P |  |  |  |  |  |  |  | 5% |
| M03AC09 063 | DS | rokuronij |  |  | P | Merck Sharp & Dohme d.o.o. | Organon i Schering-Plough | Esmeron | boč. 10x50 mg/5 ml | 21,40 | 213,96 |  | 5% |
| M03AC09 069 | DS | rokuronij |  |  | P | hameln pharma gmbh | Hameln rds, Siegfried Hameln GmbH | Rokuronijev bromid Hameln | otop za inj./inf., amp. 10x50 mg/5 ml | 18,34 | 183,40 |  | 5% |
| M03AC09 071 | DS | rokuronij |  |  | P | hameln pharma gmbh | Hameln rds, Hameln Pharmaceuticals GmbH | Rokuronijev bromid Hameln | otop za inj./inf., boč. 10x50 mg/5 ml | 21,40 | 213,96 |  | 5% |
| M03AC09 072 | DS | rokuronij |  |  | P | AS Kalceks | AS Kalceks | Rokuronijev bromid Kalceks 10 mg/ml | otop za inj./inf., boč. 10x50 mg/5 ml | 20,33 | 203,26 |  | 5% |
| M03AC09 073 | DS | rokuronij |  |  | P | Mylan Pharmaceuticals Limited | Mylan S.A.S. | Rokuronijev bromid Mylan | otop za inj./inf., boč. 10x50 mg/5 ml | 20,33 | 203,26 |  | 5% |
| M03AC09 074 | DS | rokuronij |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Austria GmbH | Rokuronijev bromid Fresenius Kabi | otop za inj./inf., boč. 10x50 mg/5 ml | 19,31 | 193,10 |  | 5% |
| M03AC09 075 | DS | rokuronij |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Rokuronijev bromid B. Braun | otop za inj./inf., amp. 20x50 mg/5 ml | 18,34 | 366,80 |  | 5% |
| M03AC11 061 | DS | cisatrakurij |  |  | P | Accord Healthcare Polska Sp. z o.o. | B. Braun Medical S.A. | Cisatrakurij Accordpharma | otop za inj./inf., boč. 5x5 ml (2 mg/ml) | 23,40 | 117,00 |  | 5% |
| M03AC11 062 | DS | cisatrakurij |  |  | P | Accord Healthcare Polska Sp. z o.o. | B. Braun Medical S.A. | Cisatrakurij Accordpharma | otop za inj./inf., boč. 1x30 ml (5 mg/ml) | 351,00 | 351,00 |  | 5% |
| M03AX01 061 | KSDS | C. botulinum toxin tip A-hemaglutinin kompleksNM301 |  |  | P | Allergan Pharm. Ireland | Allergan | Botox | lio. boč. 10 ml (1,4 mg/100 i.j.) | 1.396,64 | 1.396,64 |  | 5% |
| M03AX01 071 | KS | clostridium botulinum neurotoksin tip A (150 kD)NM504 |  |  | P | Merz Pharmaceuticals Gmbh | Merz Pharma GmbH & Co. KgaA | Xeomin | praš. za otop. za inj., boč. 1x50 IU | 617,84 | 617,84 |  | 5% |
| M03AX01 072 | KS | clostridium botulinum neurotoksin tip A (150 kD)NM504 |  |  | P | Merz Pharmaceuticals Gmbh | Merz Pharma GmbH & Co. KgaA | Xeomin | praš. za otop. za inj., boč. 1x100 IU | 1.235,67 | 1.235,67 |  | 5% |
| M03BX01 051 | DS | baklofen | 0,55 mg |  | P |  |  |  |  |  |  |  | 5% |
| M03BX02 162 |  | tizanidin | 12 mg | 6,15 | O | Altamedics d.o.o. | Niche Generics Ltd. | Tizanidin Altamedics | tbl 30x4 mg | 2,05 | 61,51 | RSRM03 | 5% |
| M03CA01 151 | DS | dantrolenNM302 |  |  | OP |  |  |  |  |  |  |  | 5% |
| M04AA01 111 |  | alopurinol | 0,4 g | 0,99 | O | Belupo d.d. | Belupo | Alopurinol Belupo | tbl. 100x100mg | 0,25 | 24,87 | R | 5% |
| M04AA01 112 |  | alopurinol | 0,4 g | 0,79 | O | Belupo d.d. | Belupo d.d. | Alopurinol Belupo | tbl. 100x200 mg | 0,40 | 39,60 | R | 5% |
| M04AA01 121 |  | alopurinol | 0,4 g | 0,99 | O | Sandoz d.o.o. | Sandoz-Salutas | Alopurinol Sandoz | tbl. 100x100 mg | 0,25 | 24,87 | R | 5% |
| M04AA01 141 |  | alopurinol | 0,4 g | 0,99 | O | PharmaS d.o.o. | PharmaS d.o.o. | Alopurinol PharmaS | tbl. 100x100 mg | 0,25 | 24,87 | R | 5% |
| M04AC01 152 |  | kolhicin | 1 mg |  | O |  |  |  |  |  |  | R | 5% |
| M05BA04 121 |  | alendronat natrij | 10 mg | 2,15 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma S.L.U., | Alendor | tbl. 4x70 mg | 15,03 | 60,13 | RSRM02 | 5% |
| M05BA04 141 |  | alendronat natrij | 10 mg | 2,15 | O | Sandoz d.o.o. | Sandoz-Lek | Forosa | tbl. film obl. 4x70 mg | 15,03 | 60,13 | RSRM02 | 5% |
| M05BA04 162 |  | alendronat natrij | 10 mg | 2,15 | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Fosamax T | tbl. 4x70 mg | 15,03 | 60,13 | RSRM02 | 5% |
| M05BA06 121 |  | ibandronatna kiselina | 5 mg | 1,47 | O | Sandoz d.o.o. | Sandoz-Pharmaten | Ibandronat Sandoz | tbl. film obl. 1x150 mg | 44,00 | 44,00 | RSRM02 | 5% |
| M05BA06 122 |  | ibandronatna kiselina | 5 mg | 1,49 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ostea | tbl. film obl. 1x150 mg | 44,79 | 44,79 | RSRM02 | 5% |
| M05BA06 141 |  | ibandronatna kiselina | 5 mg | 1,49 | O | PharmaS d.o.o. | PharmaS d.o.o. | Ibandronat PharmaS | tbl. film obl. 1x150 mg | 44,79 | 44,79 | RSRM02 | 5% |
| M05BA06 161 |  | ibandronatna kiselina | 5 mg | 1,49 | O | Atnahs Pharma Netherlands B.V. | Roche | Bonviva | tbl. film obl. 1x150 mg | 44,79 | 44,79 | RSRM02 | 5% |
| M05BA06 162 |  | ibandronatna kiselinaNM502 | 5 mg | 2,90 | O | Atnahs Pharma Netherlands B.V. | Roche | Bondronat | tbl. film obl. 28x50 mg | 29,05 | 813,33 | RS RM01 | 5% |
| M05BA06 163 |  | ibandronatna kiselina | 5 mg | 1,32 | O | Atnahs Pharma Netherlands B.V. | Waymade PLC | Bonviva | tbl. film obl. 3x150 mg | 39,71 | 119,13 | RSRM02 | 5% |
| M05BA06 165 |  | ibandronatna kiselinaNM502 | 5 mg | 2,90 | O | Makpharm d.o.o. | Synthon BV, Synthon Hispania | Ibadron | tbl. film obl. 30x50 mg | 29,05 | 871,43 | RS RM01 | 5% |
| M05BA06 171 |  | ibandronatna kiselina | 5 mg | 1,49 | O | Makpharm d.o.o. | Synthon BV, Synthon Hispania SL | Bonosta | tbl. film obl. 1x150 mg | 44,79 | 44,79 | RSRM02 | 5% |
| M05BA06 172 |  | ibandronatna kiselinaNM502 | 5 mg | 2,90 | O | Zentiva k.s. | Synthon Hispania, Synthon BV | Ibat | tbl. film obl. 30x50 mg | 29,05 | 871,43 | RS RM01 | 5% |
| M05BA06 181 |  | ibandronatna kiselinaNM502 | 5 mg | 2,90 | O | Pharmathen S.A. | Pharmathen S.A. | Iasibon | tbl. film obl. 28x50 mg | 29,05 | 813,33 | RS RM01 | 5% |
| M05BA07 101 |  | risedronat natrij | 5 mg | 1,87 | O | Accord Healthcare Polska Sp. z o.o. | Pliva Hrvatska d.o.o. | Risbon | tbl. film obl. 2x75 mg | 28,07 | 56,13 | RSRM02 | 5% |
| M05BA07 112 |  | risedronat natrij | 5mg | 2,15 | O | Belupo d.d. | Belupo | Bonna | tbl. film obl. 4x35 mg | 15,03 | 60,13 | RSRM02 | 5% |
| M05BA07 113 |  | risedronat natrij | 5 mg | 1,87 | O | Belupo d.d. | Belupo | Bonna | tbl. film obl. 2x75 mg | 28,07 | 56,13 | RSRM02 | 5% |
| M05BA07 114 |  | risedronat natrij | 5 mg | 1,68 | O | Belupo d.d. | Belupo | Bonna | tbl. film obl. 6x75 mg | 25,26 | 151,56 | RSRM02 | 5% |
| M05BA07 145 |  | risedronat natrij | 5 mg | 2,15 | O | PharmaS d.o.o. | PharmaS d.o.o. | Risedronat PharmaS | tbl. film obl. 4x35 mg | 15,03 | 60,13 | RSRM02 | 5% |
| M05BA08 001 | DS | zoledronatna kiselina | 4 mg | 656,01 | P | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Pharmachemie B.V., Teva Operations Poland Sp. Z.o.o. | Zoledronatna kiselina Teva | konc. za otop. za inf., boč. 1x4 mg/5 ml | 656,01 | 656,01 |  | 5% |
| M05BA08 062 | DS | zoledronatna kiselina | 4 mg | 656,01 | P | ALPHA-MEDICAL d.o.o. | Pharmidea LLC | Zolenat | konc. za otop. za inf., boč. 1x4 mg/5 ml | 656,01 | 656,01 |  | 5% |
| M05BA08 071 | DS | zoledronatna kiselina | 4 mg | 654,05 | P | Pfizer Europe MA EEIG | Hospira UK Limited, Hospira Enterprises B.V. | Zoledronatna kiselina Hospira | konc. za otop. za inf., boč. 1x4 mg/5 ml | 654,05 | 654,05 |  | 5% |
| M05BA08 081 | DS | zoledronatna kiselina | 4 mg | 656,01 | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A | Zoledronatna kiselina Actavis | konc. za otop. za inf., boč. 1x4 mg/5 ml | 656,01 | 656,01 |  | 5% |
| M05BA08 082 | DS | zoledronatna kiselina | 4 mg | 656,01 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Zoledronatna kiselina Accord | konc. za otop. za inf., boč. 1x4 mg/5 ml | 656,01 | 656,01 |  | 5% |
| M05BX04 071 | DS | denosumabNM503 | 0,33 mg | 5,72 | P | Amgen Europe B.V. | Amgen Europe B.V. | Xgeva | otop. za inj., boč. stakl. 1x120 mg/1,7 ml (70 mg/ml) | 2.079,15 | 2.079,15 |  | 5% |
| M05BX04 961 | DS/RL | denosumab | 0,33 mg | 7,59 | P | Amgen Europe B.V. | Amgen Europe B.V. | Prolia | otop. za inj., štrc. napunj. 1x60 mg | 1.379,84 | 1.379,84 | RSRM04 | 5% |
| M09AX03 171 | KL | atalurenNM601 | 2.8 g | 17,63 | P | PTC Therapeutics International Limited | PTC Therapeutics International Limited, Almac Pharma Services Ltd. | Translarna | gran. za oral. susp., 30x125 mg | 787,03 | 23.610,75 |  | 5% |
| M09AX03 172 | KL | atalurenNM601 | 2.8 g | 17,58 | P | PTC Therapeutics International Limited | PTC Therapeutics International Limited, Almac Pharma Services Ltd. | Translarna | gran. za oral. susp., 30x250 mg | 1.569,87 | 47.095,95 |  | 5% |
| M09AX03 173 | KL | atalurenNM601 | 2.8 g | 17,55 | P | PTC Therapeutics International Limited | PTC Therapeutics International Limited, Almac Pharma Services Ltd. | Translarna | gran. za oral. susp., 30x1000 mg | 6.266,77 | 188.003,10 |  | 5% |
| M09AX07 061 | KL | nusinersenNM600 | 0.1 mg | 4.417,34 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Spinraza | otop. za inj., boč. stakl. 1x12 mg/5 ml (2,4 mg/ml) | 530.080,94 | 530.080,94 |  | 5% |
| M09AX09 061 | KL | onasemnogen abeparvovekNM602 |  |  | P | Novartis Gene Therapies EU Limited | Almac Pharma Services (Ireland) Limited | Zolgensma | otop. za inf., 1 doza | 14.669.840,87 | 14.669.840,87 |  | 5% |
| M09AX10 371 | KL | risdiplamNM603 |  |  | O | Roche Registration GmbH | Roche Pharma AG | Evrysdi | praš. za oral. otop. 1x60 mg | 52.473,17 | 52.473,17 |  | 5% |
| N01AB08 061 | DS | sevofluran |  |  | I | Piramal Critical Care B.V. | Piramal Healthcare UK Ltd. | Sojourn | para inhalata, tekućina, boca 1x250 ml | 861,79 | 861,79 |  | 5% |
| N01AB08 063 | DS | sevofluran |  |  | P | Baxter d.o.o. | Baxter S.A. | Sevofluran Baxter | para inhalata, tekućina, boca 1x250 ml | 828,00 | 828,00 |  | 5% |
| N01AB08 064 | DS | sevofluran |  |  | P | Baxter d.o.o. | Baxter S.A. | Sevofluran Baxter | para inhalata, tekućina, boca 6x250 ml | 745,20 | 4.471,20 |  | 5% |
| N01AB08 072 | DS | sevofluran |  |  | P | AbbVie d.o.o. | AbbVie S.r.L. | Sevorane | boč. 1x250 ml | 861,79 | 861,79 |  | 5% |
| N01AF03 051 | DS | tiopental-natrij |  |  | P |  |  |  |  |  |  |  | 5% |
| N01AH01 082 | DS | fentanil |  |  | P | Piramal Critical Care B.V. | Piramal Critical Care B.V. | Fentanyl | amp. 50x10 ml (0,05 mg/ml) | 10,43 | 521,60 |  | 5% |
| N01AH02 051 | DS | alfentanil |  |  | P |  |  |  |  |  |  |  | 5% |
| N01AH03 061 | DS | sufentanil |  |  | P | Altamedics d.o.o. | Laboratoire Renaudin | Sufentanil Altamedics | otop. za inj./inf., 5 mcg/ml, amp., 10x10 ml | 8,85 | 88,45 |  | 5% |
| N01AH03 071 | DS | sufentanil |  |  | P | hameln pharma gmbh | hameln rds a.s., Siegfried Hameln GmbH | Sufentanil hameln | otop. za inj./inf., 5 mcg/ml, amp., 10x10 ml | 6,19 | 61,92 |  | 5% |
| N01AH51 051 | DS | fentanil + droperidol |  |  | P |  |  |  |  |  |  |  | 5% |
| N01AX03 051 | DS | ketamin-klorid |  |  | P |  |  |  |  |  |  |  | 5% |
| N01AX07 089 | DS | etomidat |  |  | P | Piramal Critical Care B.V. | Piramal Critical Care B.V. | Hypnomidate | amp. 5x10 ml | 7,04 | 35,18 |  | 5% |
| N01AX10 071 | DS | propofol |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Propofol-Lipuro 10 mg/ml | emulz. za inj. ili inf., 10 mg/ml, amp., 5x20 ml | 19,31 | 96,57 |  | 5% |
| N01AX10 072 | DS | propofol |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Propofol-Lipuro 10 mg/ml | emulz. za inj. ili inf., 10 mg/ml, boč., 10x50 ml | 48,76 | 487,60 |  | 5% |
| N01AX10 074 | DS | propofol |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Propofol-Lipuro 20 mg/ml | emulz. za inj. ili inf., 20 mg/ml, boč., 10x50 ml | 78,61 | 786,12 |  | 5% |
| N01AX10 083 | DS | propofol |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Propofol 1% MCT Fresenius | emulz. za inj./inf., amp. 1%, 5x20 ml (10 mg/ml) | 17,38 | 86,91 |  | 5% |
| N01AX10 084 | DS | propofol |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Propofol 1% MCT Fresenius | emulz. za inj./inf., boč. 1%, 10x50 ml (10 mg/ml) | 48,76 | 487,60 |  | 5% |
| N01AX10 085 | DS | propofol |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Propofol 1% MCT Fresenius | emulz. za inj./inf., boč. 1%, 10x100 ml (10 mg/ml) | 76,53 | 765,25 |  | 5% |
| N01AX10 086 | DS | propofol |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Propofol 2% MCT Fresenius | emulz. za inj./inf., boč. 2%, 10x50 ml (20 mg/ml) | 70,75 | 707,51 |  | 5% |
| N01AX13 951 | DS | dušik-oksidul |  |  | I |  |  |  |  |  |  |  | 5% |
| N01AX14 061 | DS | esketaminklorid |  |  | P | Makpharm d.o.o. | G.L. Pharma GmbH | Esgamda | otop. za inj. ili inf., amp., 10x25 mg/ml (2 ml) | 25,80 | 258,00 |  | 5% |
| N01BB01 051 | DS | bupivakain |  |  | P |  |  |  |  |  |  |  | 5% |
| N01BB02 012 | PR | lidokain |  |  | P | Belupo d.d. | Belupo | Lidokainklorid Belupo | amp. 100x40 mg/2 ml | 2,08 | 208,10 |  | 5% |
| N01BB02 013 | PR | lidokain |  |  | P | Belupo d.d. | Belupo | Lidokainklorid Belupo | amp. 5x100 mg/5 ml | 5,90 | 29,51 |  | 5% |
| N01BB02 071 | PR | lidokain |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Lidokainklorid B. Braun 20 mg/ml | otop. za inj./inf., 20 mg/ml, polietil. amp. 20x5 ml | 2,50 | 49,90 |  | 5% |
| N01BB02 072 | PR | lidokain |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Lidokainklorid B. Braun 20 mg/ml | otop. za inj./inf., 20 mg/ml, polietil. amp. 20x10 ml | 4,40 | 88,00 |  | 5% |
| N01BB02 411 | DS | lidokain |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Dolokain gel | gel 1x25 g (20 mg/1 g) | 43,13 | 43,13 |  | 5% |
| N01BB02 714 | PR | lidokain |  |  | L | Belupo d.d. | Belupo | Lidokain Belupo | otop. za rasprš. 50 ml (100 mg/1 ml) | 95,00 | 95,00 |  | 5% |
| N01BB02 941 |  | lidokain |  |  | L | Grünenthal GmbH | Grünenthal GmbH | Versatis | flaster med. 5%, 5x(10 cmx14 cm)/700 mg | 17,45 | 87,25 | RRN16 | 5% |
| N01BB02 942 |  | lidokain |  |  | L | Grünenthal GmbH | Grünenthal GmbH | Versatis | flaster med. 5%, 10x(10 cmx14 cm)/700 mg | 17,45 | 174,50 | RRN16 | 5% |
| N01BB02 943 |  | lidokain |  |  | L | Grünenthal GmbH | Grünenthal GmbH | Versatis | flaster med. 5%, 30x(10 cmx14 cm)/700 mg | 17,45 | 523,50 | RRN16 | 5% |
| N01BB08 051 | DS | artikain |  |  | P |  |  |  |  |  |  |  | 5% |
| N01BB09 061 | DS | ropivakain |  |  | P | L.Molteni & C. dei F.lli Alitti Soc. di Esercizio S.p.A. | L. Molteni | Ropivacaine Molteni | otop. za inf., 5x100 ml (2 mg/ml) | 68,00 | 340,00 |  | 5% |
| N01BB09 062 | DS | ropivakain |  |  | P | L.Molteni & C. dei F.lli Alitti Soc. di Esercizio S.p.A. | L. Molteni | Ropivacaine Molteni | otop. za inj., amp. 5x10 ml (7,5 mg/ml) | 25,20 | 126,00 |  | 5% |
| N01BB10 061 | DS | levobupivakain |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Levobupivakain Kabi | otop. za inj ili inf., amp. 5x10 ml (5 mg/ml) | 19,60 | 98,00 |  | 5% |
| N01BB52 014 | PR | lidokain + adrenalin |  |  | P | Belupo d.d. | Belupo | Lidokainklorid – adrenalin Belupo | amp. 100x2 ml (40 mg + 0,025 mg) | 2,08 | 208,10 |  | 5% |
| N01BB55 052 | DS | butanilkain + noradrenalin |  |  | P |  |  |  |  |  |  |  | 5% |
| N01BB58 053 | DS | artikain + adrenalin |  |  | P |  |  |  |  |  |  |  | 5% |
| N01BX01 454 | DS | kloretil (etil-klorid) |  |  | L |  |  |  |  |  |  |  | 5% |
| N02AA01 041 | PO | morfin | 30 mg | 8,39 | P | Alkaloid d.o.o. | Alkaloid | Morfinklorid Alkaloid | otop. za inj./inf. 10x20 mg/ml | 5,60 | 55,95 |  | 5% |
| N02AA01 161 |  | morfin | 0,1 g | 14,25 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | Sevredol | tbl. film obl. 60x10 mg | 1,43 | 85,50 | RRN01 | 5% |
| N02AA01 162 |  | morfin | 0,1 g | 12,82 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | Sevredol | tbl. film obl. 60x20 mg | 2,56 | 153,80 | RRN01 | 5% |
| N02AA01 173 |  | morfin | 0,1 g | 8,22 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | MST Continus | tbl. obl. s post. oslob. 60x60 mg | 4,93 | 295,80 | R | 5% |
| N02AA01 174 |  | morfin | 0,1 g | 7,83 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | MST Continus | tbl. obl. s post. oslob. 60x100 mg | 7,83 | 469,80 | R | 5% |
| N02AA05 173 |  | oksikodon | 75 mg | 16,13 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | OxyContin | tbl. s prod. oslob. 60x10 mg | 1,57 | 94,08 | RRN02 | 5% |
| N02AA05 174 |  | oksikodon | 75 mg | 14,90 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | OxyContin | tbl. s prod. oslob. 60x20 mg | 3,97 | 238,40 | RRN02 | 5% |
| N02AA05 181 |  | oksikodon | 75 mg | 11,76 | O | ALPHA-MEDICAL d.o.o. | G.L. Pharma GmbH | Oxygerolan | tbl. s prod. oslob. 60x10 mg | 1,57 | 94,08 | RRN02 | 5% |
| N02AA05 182 |  | oksikodon | 75 mg | 11,02 | O | ALPHA-MEDICAL d.o.o. | G.L. Pharma GmbH | Oxygerolan | tbl. s prod. oslob. 60x20 mg | 2,94 | 176,26 | RRN02 | 5% |
| N02AA55 101 |  | oksikodon + nalokson | 75 mg | 22,50 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 50x(5 mg + 2,5 mg) | 1,50 | 75,00 | R | 5% |
| N02AA55 102 |  | oksikodon + nalokson | 75 mg | 22,50 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 50x(10 mg + 5 mg) | 3,00 | 150,00 | R | 5% |
| N02AA55 103 |  | oksikodon + nalokson | 75 mg | 22,54 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 50x(20 mg + 10 mg) | 6,01 | 300,50 | R | 5% |
| N02AA55 104 | DS | oksikodon + nalokson | 75 mg | 22,52 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 50x(40 mg + 20 mg) | 12,01 | 600,50 |  | 5% |
| N02AA55 105 |  | oksikodon + nalokson | 75 mg | 19,25 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 30x(40 mg + 20 mg) | 10,27 | 308,06 | R | 5% |
| N02AA55 163 |  | oksikodon + nalokson | 75 mg | 22,54 | O | Mundipharma Gesellschaft m.b.H | Bard Pharmaceuticals Ltd., Mundipharma GmbH | Targinact | tbl. s prod. oslob. 30x(20 mg + 10 mg) | 6,01 | 180,30 | R | 5% |
| N02AA55 164 |  | oksikodon + nalokson | 75 mg | 20,27 | O | Mundipharma Gesellschaft m.b.H | Bard Pharmaceuticals Ltd., Mundipharma GmbH | Targinact | tbl. s prod. oslob. 30x(40 mg + 20 mg) | 10,81 | 324,27 | R | 5% |
| N02AB02 051 | DS | petidin | 0,4 g |  | P |  |  |  |  |  |  |  | 5% |
| N02AB03 901 |  | fentanil | 1,2 mg | 11,16 | TD | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fentagesic | flaster transd. 5x 4,125 mg (25 mcg/h) | 11,16 | 55,80 | RRN02 | 5% |
| N02AB03 902 |  | fentanil | 1,2 mg | 22,32 | TD | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fentagesic | flaster transd. 5x 8,25 mg (50 mcg/h) | 22,32 | 111,60 | RRN02 | 5% |
| N02AB03 903 |  | fentanil | 1,2 mg | 44,64 | TD | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fentagesic | flaster transd. 5x 16,50 mg (100 mcg/h) | 44,64 | 223,20 | RRN02 | 5% |
| N02AB03 904 |  | fentanil | 1,2 mg | 3,25 | TD | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fentagesic | flaster transd. 5x 12,375 mg (75 mcg/h) | 33,48 | 167,40 | RRN02 | 5% |
| N02AB03 961 |  | fentanil | 1,2 mg | 3,19 | TD | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Durogesic | flaster transd. 5x4,2 mg (25 mcg/h) | 11,16 | 55,80 | RRN02 | 5% |
| N02AB03 962 |  | fentanil | 1,2 mg | 3,19 | TD | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Durogesic | flaster transd. 5x8,4 mg (50 mcg/h) | 22,32 | 111,60 | RRN02 | 5% |
| N02AB03 963 |  | fentanil | 1,2 mg | 44,64 | TD | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Durogesic | flaster transd. 5x16,8 mg (100 mcg/h) | 44,64 | 223,20 | RRN02 | 5% |
| N02AB03 965 |  | fentanil | 1,2 mg | 33,48 | TD | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Durogesic | flaster transd. 5x12,6 mg (75 mcg/h) | 33,48 | 167,40 | RRN02 | 5% |
| N02AE01 901 |  | buprenorfin | 1,2 mg | 1,66 | TD | PLIVA HRVATSKA d.o.o. | Tesa Labtec GmbH | Laribon | flaster transd. 4x20 mg (35 mcg/h) | 27,64 | 110,57 | RRN02 | 5% |
| N02AE01 902 |  | buprenorfin | 1,2 mg | 1,61 | TD | PLIVA HRVATSKA d.o.o. | Tesa Labtec GmbH | Laribon | flaster transd. 4x30 mg (52,50 mcg/h) | 40,24 | 160,97 | RRN02 | 5% |
| N02AE01 903 |  | buprenorfin | 1,2 mg | 1,52 | TD | PLIVA HRVATSKA d.o.o. | Tesa Labtec GmbH | Laribon | flaster transd. 4x40 mg (70 mcg/h) | 50,63 | 202,51 | RRN02 | 5% |
| N02AE01 941 |  | buprenorfin | 1,2 mg | 1,71 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 4x20 mg (35 mcg/h) | 28,58 | 114,30 | RRN02 | 5% |
| N02AE01 942 |  | buprenorfin | 1,2 mg | 1,71 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 8x20 mg (35 mcg/h) | 28,58 | 228,61 | RRN02 | 5% |
| N02AE01 943 |  | buprenorfin | 1,2 mg | 1,63 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 4x30 mg (52,50 mcg/h) | 40,71 | 162,82 | RRN02 | 5% |
| N02AE01 944 |  | buprenorfin | 1,2 mg | 1,63 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 8x30 mg (52,50 mcg/h) | 40,70 | 325,63 | RRN02 | 5% |
| N02AE01 945 |  | buprenorfin | 1,2 mg | 1,52 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 4x40 mg (70 mcg/h) | 50,63 | 202,51 | RRN02 | 5% |
| N02AE01 946 |  | buprenorfin | 1,2 mg | 1,52 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 8x40 mg (70 mcg/h) | 50,63 | 405,01 | RRN02 | 5% |
| N02AJ13 102 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. film obl. 60x(37,5 mg + 325 mg) | 0,40 | 23,72 | R | 5% |
| N02AJ13 103 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,40 | 11,86 | R | 5% |
| N02AJ13 104 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. film obl. 50x(37,5 mg + 325 mg) | 0,36 | 18,23 | R | 5% |
| N02AJ13 105 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. 30x(75 mg + 650 mg) | 1,02 | 30,62 | R | 5% |
| N02AJ13 106 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. 50x(75 mg + 650 mg) | 0,75 | 37,26 | R | 5% |
| N02AJ13 111 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo | Zaracet | tbl. film obl. 10x(37,5 mg + 325 mg) | 0,40 | 3,95 | R | 5% |
| N02AJ13 112 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo | Zaracet | tbl. film obl. 20x(37,5 mg + 325 mg) | 0,40 | 7,91 | R | 5% |
| N02AJ13 113 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo | Zaracet | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,40 | 11,86 | R | 5% |
| N02AJ13 114 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo | Zaracet | tbl. film obl. 100x(37,5 mg + 325 mg) | 0,40 | 39,53 | R | 5% |
| N02AJ13 126 |  | tramadol + paracetamol |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Tramadox | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,40 | 11,86 | R | 5% |
| N02AJ13 127 |  | tramadol + paracetamol |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Tramadox | tbl. film obl. 60x(37,5 mg + 325 mg) | 0,40 | 23,72 | R | 5% |
| N02AJ13 132 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Doreta | tbl. film obl. 20x(37,5 mg + 325 mg) | 0,40 | 7,91 | R | 5% |
| N02AJ13 133 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Doreta | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,40 | 11,86 | R | 5% |
| N02AJ13 134 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Doreta | tbl. film obl. 50x(37,5 mg + 325 mg) | 0,40 | 19,77 | R | 5% |
| N02AJ13 135 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Doreta | tbl. film obl. 30x(75 mg + 650 mg) | 1,02 | 30,62 | R | 5% |
| N02AJ13 136 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Doreta | tbl. film obl. 50x(75 mg + 650 mg) | 0,83 | 41,40 | R | 5% |
| N02AJ13 142 |  | tramadol + paracetamol |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Zaldiar | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,40 | 11,86 | R | 5% |
| N02AJ13 181 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo d.d. | Zaracet | tbl. film obl. 30x(75 mg + 650 mg) | 1,02 | 30,62 | R | 5% |
| N02AJ13 182 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo d.d. | Zaracet | tbl. film obl. 50x(75 mg + 650 mg) | 0,83 | 41,40 | R | 5% |
| N02AX02 013 | PR | tramadol | 0,3 g | 14,92 | P | Belupo d.d. | Belupo | Lumidol | amp. 5x50 mg/ml | 2,98 | 14,92 |  | 5% |
| N02AX02 014 | PR | tramadol | 0,3 g | 9,33 | P | Belupo d.d. | Belupo | Lumidol | amp. 5x100 mg/2 ml | 3,73 | 18,66 |  | 5% |
| N02AX02 023 | PR | tramadol | 0,3 g | 13,02 | P | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | amp. 5x50 mg/ml | 2,17 | 10,85 |  | 5% |
| N02AX02 024 | PR | tramadol | 0,3 g | 8,13 | P | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | amp. 5x100 mg/2 ml | 2,71 | 13,55 |  | 5% |
| N02AX02 043 | PR | tramadol | 0,3 g | 17,90 | P | STADA d.o.o. | STADA Arzneimittel AG | Tramal | amp. 5x50 mg/ml | 2,98 | 14,92 |  | 5% |
| N02AX02 044 | PR | tramadol | 0,3 g | 11,19 | P | STADA d.o.o. | STADA Arzneimittel AG | Tramal | amp. 5x100 mg/2 ml | 3,73 | 18,66 |  | 5% |
| N02AX02 111 |  | tramadol | 0,3 g | 4,92 | O | Belupo d.d. | Belupo | Lumidol | caps. 20x50 mg | 0,82 | 16,40 | R | 5% |
| N02AX02 112 |  | tramadol | 0,3 g | 3,58 | O | Belupo d.d. | Belupo | Lumidol retard | tbl. s prod. oslob. 30x100 mg | 1,19 | 35,76 | R | 5% |
| N02AX02 113 |  | tramadol | 0,3 g | 3,58 | O | Belupo d.d. | Belupo | Lumidol retard | tbl. s prod. oslob. 50x100 mg | 1,19 | 59,60 | R | 5% |
| N02AX02 116 |  | tramadol | 0,3 g | 3,65 | O | Belupo d.d. | Belupo | Lumidol retard | tbl. 30x200 mg | 2,43 | 72,98 | R | 5% |
| N02AX02 117 |  | tramadol | 0,3 g | 3,58 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Tramadol Mibe | tbl. s prod. oslob. 30x100 mg | 1,19 | 35,76 | R | 5% |
| N02AX02 121 |  | tramadol | 0,3 g | 3,58 | O | Sandoz d.o.o. | Sandoz-Salutas | Tramadolor retard | tbl. s prod. oslob. 30x100 mg | 1,19 | 35,76 | R | 5% |
| N02AX02 123 |  | tramadol | 0,3 g | 3,22 | O | Sandoz d.o.o. | Sandoz-Salutas | Tramadolor retard | tbl. s prod. oslob. 30x150 mg | 1,61 | 48,30 | R | 5% |
| N02AX02 125 |  | tramadol | 0,3 g | 3,65 | O | Sandoz d.o.o. | Sandoz-Salutas | Tramadolor retard | tbl. s prod. oslob. 30x200 mg | 2,43 | 72,98 | R | 5% |
| N02AX02 131 |  | tramadol | 0,3 g | 3,35 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | caps. tvrda 20x50 mg | 0,56 | 11,16 | R | 5% |
| N02AX02 132 |  | tramadol | 0,3 g | 3,40 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | tbl. s prod. oslob. 30x100 mg | 1,13 | 33,97 | R | 5% |
| N02AX02 133 |  | tramadol | 0,3 g | 3,06 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | tbl. s prod. oslob. 30x150 mg | 1,53 | 45,89 | R | 5% |
| N02AX02 134 |  | tramadol | 0,3 g | 3,47 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | tbl. s prod. oslob. 30x200 mg | 2,31 | 69,33 | R | 5% |
| N02AX02 140 |  | tramadol | 0,3 g | 4,92 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Toram | caps. 20x50 mg | 0,82 | 16,40 | R | 5% |
| N02AX02 141 |  | tramadol | 0,3 g | 4,92 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal | caps. 20x50 mg | 0,82 | 16,40 | R | 5% |
| N02AX02 142 |  | tramadol | 0,3 g | 3,70 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 30x50 mg | 0,62 | 18,50 | R | 5% |
| N02AX02 143 |  | tramadol | 0,3 g | 3,70 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 50x50 mg | 0,62 | 30,83 | R | 5% |
| N02AX02 146 |  | tramadol | 0,3 g | 3,58 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 30x100 mg | 1,19 | 35,76 | R | 5% |
| N02AX02 148 |  | tramadol | 0,3 g | 3,58 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 50x100 mg | 1,19 | 59,60 | R | 5% |
| N02AX02 149 |  | tramadol | 0,3 g | 3,22 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 30x150 mg | 1,61 | 48,30 | R | 5% |
| N02AX02 161 |  | tramadol | 0,3 g | 3,58 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | Tramundin retard | tbl. film obl. 50x100 mg | 1,19 | 59,60 | R | 5% |
| N02AX02 162 |  | tramadol | 0,3 g | 3,22 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 50x150 mg | 1,61 | 80,50 | R | 5% |
| N02AX02 163 |  | tramadol | 0,3 g | 3,65 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 30x200 mg | 2,43 | 72,98 | R | 5% |
| N02AX02 164 |  | tramadol | 0,3 g | 3,60 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 50x200 mg | 2,40 | 120,02 | R | 5% |
| N02AX02 212 |  | tramadol | 0,3 g | 5,45 | O | Belupo d.d. | Belupo | Lumidol | kapi, oralne, boč. 1x10 ml (100 mg/ml) | 18,18 | 18,18 | R | 5% |
| N02AX02 242 |  | tramadol | 0,3 g | 5,45 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal | kapi, oralne, boč. 1x10 ml (100 mg/ml) | 18,18 | 18,18 | R | 5% |
| N02AX02 247 |  | tramadol | 0,3 g | 4,14 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal | kapi, oralne,boč. 1x96 ml (100 mg/ml) | 132,48 | 132,48 | R | 5% |
| N02AX06 164 |  | tapentadol | 0,4 g | 32,42 | O | Grünenthal GmbH | Grünenthal GmbH | Palexia | tbl. film obl. 30x50 mg | 4,05 | 121,59 | RRN02 | 5% |
| N02AX06 165 |  | tapentadol | 0,4 g | 29,87 | O | Grünenthal GmbH | Grünenthal GmbH | Palexia | tbl. film obl. 30x75 mg | 5,60 | 168,00 | RRN02 | 5% |
| N02AX06 166 |  | tapentadol | 0,4 g | 28,67 | O | Grünenthal GmbH | Grünenthal GmbH | Palexia | tbl. film obl. 30x100 mg | 7,17 | 215,00 | RRN02 | 5% |
| N02AX06 267 |  | tapentadol | 0,4 g | 29,88 | O | Grünenthal GmbH | Grünenthal GmbH | Palexia | oralna otop., boč. 1x100 ml (20 mg/ml) | 149,40 | 149,40 | RRN02 | 5% |
| N02BA01 151 | DS | acetilsalicilna kiselina | 3 g |  | O |  |  |  |  |  |  |  | 5% |
| N02BB02 042 | PR | metamizol | 3 g | 3,81 | P | Alkaloid d.o.o. | Alkaloid | Alkagin | otop. za inj. 50x2,5 g/5 ml | 3,20 | 159,92 |  | 5% |
| N02BE01 042 | DSPR | paracetamolNN101 | 3 g | 31,05 | P | Accord Healthcare Polska Sp. z o.o. | Industria Farmaceutica Galenica Senese S.r.l. | Paracetamol Accord | otop. za inf., boč. stakl. 20x100 ml (10 mg/ml) | 10,35 | 207,00 |  | 5% |
| N02BE01 061 | DSPR | paracetamolNN101 | 3 g | 38,35 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paracetamol Kabi | otop. za inf., boč. stakl. 10x100 ml (10 mg/ml) | 12,78 | 127,83 |  | 5% |
| N02BE01 071 | DSPR | paracetamolNN101 | 3 g | 34,50 | P | B. Braun Adria d.o.o. | B. Braun Medical S.A. | Paracetamol B. Braun 10 mg/ml | otop. za inf., 10 mg/ml, polietil. Ecoflac plus boca, 10x100 ml | 11,50 | 115,00 |  | 5% |
| N02BE01 151 | DS | paracetamol | 3 g |  | O |  |  |  |  |  |  |  | 5% |
| N02BE01 312 |  | paracetamol | 3 g | 14,00 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Paracetamol JGL | sirup 1x150 ml (120 mg/5 ml) | 16,80 | 16,80 | R | 5% |
| N02BE01 551 | DS | paracetamol | 3 g |  | R |  |  |  |  |  |  |  | 5% |
| N02CC01 122 |  | sumatriptan | 50 mg | 9,35 | O | Sandoz d.o.o. | Sandoz-Salutas | Sumigra | tbl. 6x50 mg | 9,35 | 56,12 | RSRN03 | 5% |
| N02CC01 162 |  | sumatriptan | 50 mg | 9,36 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Imigran | tbl. 2x50 mg | 9,36 | 18,71 | RSRN03 | 5% |
| N02CC04 171 |  | rizatriptan | 10 mg | 9,35 | O | ALPHA-MEDICAL d.o.o. | Glenmark Pharmaceuticals s.r.o. | Emalt | tbl. rasp. za usta 6x10 mg | 9,35 | 56,12 | RSRN03 | 5% |
| N03AA01 102 |  | metilfenobarbital | 0,5 g | 7,19 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Phemiton | tbl. 50x200 mg | 2,88 | 143,85 | R | 5% |
| N03AA02 051 | PR | fenobarbiton-natrij | 0,1 g |  | P |  |  |  |  |  |  |  | 5% |
| N03AA02 103 |  | fenobarbital | 0,1 g | 4,61 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Phenobarbiton | tbl. 30x15 mg | 0,69 | 20,73 | R | 5% |
| N03AA02 104 |  | fenobarbital | 0,1 g | 2,05 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Phenobarbiton | tbl. 10x100 mg | 2,05 | 20,53 | R | 5% |
| N03AA03 151 |  | primidon | 1,25 g |  | O |  |  |  |  |  |  | R | 5% |
| N03AB02 051 | DS | fenitoin | 0,3 g |  | P |  |  |  |  |  |  |  | 5% |
| N03AB02 151 |  | fenitoin | 0,3 g |  | O |  |  |  |  |  |  | R | 5% |
| N03AD01 351 |  | etosuksimid | 1,25 g |  | O |  |  |  |  |  |  | R | 5% |
| N03AE01 052 | PR | klonazepam | 8 mg |  | P |  |  |  |  |  |  |  | 5% |
| N03AE01 161 |  | klonazepam | 8 mg | 4,91 | O | Cheplapharm Arzneimittel GmbH | Roche | Rivotril | tbl. 50x0,5 mg | 0,31 | 15,33 | R | 5% |
| N03AE01 162 |  | klonazepam | 8 mg | 2,64 | O | Cheplapharm Arzneimittel GmbH | Roche | Rivotril | tbl. 30x2 mg | 0,66 | 19,80 | R | 5% |
| N03AF01 109 |  | karbamazepin | 1 g | 1,91 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Novartis Farma S.p.A. | Tegretol | tbl. 50x200 mg | 0,38 | 19,05 | R | 5% |
| N03AF01 110 |  | karbamazepin | 1 g | 2,22 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Novartis Farma S.p.A. | Tegretol CR | tbl. 30x400 mg | 0,89 | 26,67 | R | 5% |
| N03AF02 163 |  | okskarbazepin | 1g | 3,82 | O | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Trileptal | tbl. film obl. 50x600 mg | 2,29 | 114,66 | R | 5% |
| N03AF02 364 |  | okskarbazepin | 1g | 7,89 | O | Novartis Hrvatska d.o.o. | Novartis Farmaceutica S.A., Novartis Pharma GmbH | Trileptal | boč. 1x250 ml (60 mg/ml), susp. | 118,37 | 118,37 | R | 5% |
| N03AG01 121 |  | natrij-valproat | 1,5 g | 3,12 | O | sanofi-aventis groupe | Sanofi Winthrop Ambares | Depakine Chrono | tbl. 100x300 mg | 0,62 | 62,40 | R | 5% |
| N03AG01 122 |  | natrij-valproat | 1,5 g | 3,64 | O | sanofi-aventis groupe | Sanofi Winthrop Ambares | Depakine Chrono | tbl. 30x500 mg | 1,21 | 36,40 | R | 5% |
| N03AG01 251 |  | natrij-valproat | 1,5 g |  | O |  |  |  | oralna otopina/granule |  |  | R | 5% |
| N03AG04 151 |  | vigabatrin | 2 g |  | O |  |  |  |  |  |  | RSRN23 | 5% |
| N03AX09 111 |  | lamotrigin | 0,3 g | 6,84 | O | Belupo d.d. | Belupo | Arvind | tbl. 30x25 mg | 0,57 | 17,10 | RSRN22 | 5% |
| N03AX09 112 |  | lamotrigin | 0,3 g | 7,58 | O | Belupo d.d. | Belupo | Arvind | tbl. 30x50 mg | 1,26 | 37,90 | RSRN22 | 5% |
| N03AX09 113 |  | lamotrigin | 0,3 g | 6,47 | O | Belupo d.d. | Belupo | Arvind | tbl. 30x100 mg | 2,16 | 64,70 | RSRN22 | 5% |
| N03AX09 121 |  | lamotrigin | 0,3 g | 6,84 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 30x25 mg | 0,57 | 17,10 | RSRN22 | 5% |
| N03AX09 122 |  | lamotrigin | 0,3 g | 7,58 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 30x50 mg | 1,26 | 37,90 | RSRN22 | 5% |
| N03AX09 123 |  | lamotrigin | 0,3 g | 6,47 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 30x100 mg | 2,16 | 64,70 | RSRN22 | 5% |
| N03AX09 124 |  | lamotrigin | 0,3 g | 5,52 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 30x200 mg | 3,68 | 110,30 | RSRN22 | 5% |
| N03AX09 144 |  | lamotrigin | 0,3 g | 6,70 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 60x50 mg | 1,12 | 66,96 | RSRN22 | 5% |
| N03AX09 145 |  | lamotrigin | 0,3 g | 5,85 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 60x100 mg | 1,95 | 117,00 | RSRN22 | 5% |
| N03AX09 162 |  | lamotrigin | 0,3 g | 6,84 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, Specifar S.A. | Lamotrigin Genericon | tbl. za žvak./oral. susp. 30x50 mg | 1,14 | 34,20 | RSRN22 | 5% |
| N03AX09 163 |  | lamotrigin | 0,3 g | 5,85 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, Specifar S.A. | Lamotrigin Genericon | tbl. za žvak./oral. susp. 60x100 mg | 1,95 | 117,00 | RSRN22 | 5% |
| N03AX09 175 |  | lamotrigin | 0,3 g | 4,31 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. 56x25 mg | 0,36 | 20,11 | RSRN22 | 5% |
| N03AX09 176 |  | lamotrigin | 0,3 g | 6,70 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. 56x50 mg | 1,12 | 62,50 | RSRN22 | 5% |
| N03AX09 177 |  | lamotrigin | 0,3 g | 5,85 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. 56x100 mg | 1,95 | 109,20 | RSRN22 | 5% |
| N03AX09 180 |  | lamotrigin | 0,3 g | 55,20 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. za žvak./oral. susp. 60x5 mg | 0,92 | 55,20 | RSRN22 | 5% |
| N03AX11 111 |  | topiramat | 0,3 g | 4,31 | O | Belupo d.d. | Belupo | Tiramat | tbl. film obl. 60x25 mg | 0,36 | 21,55 | RSRN15 | 5% |
| N03AX11 112 |  | topiramat | 0,3 g | 9,00 | O | Belupo d.d. | Belupo | Tiramat | tbl. film obl. 60x50 mg | 1,50 | 90,00 | RSRN15 | 5% |
| N03AX11 113 |  | topiramat | 0,3 g | 6,50 | O | Belupo d.d. | Belupo | Tiramat | tbl. film obl. 60x100 mg | 2,17 | 130,00 | RSRN15 | 5% |
| N03AX11 181 |  | topiramat | 0,3 g | 4,31 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV, Lusomedicamenta-Sociedade Tecnica, Farmaceutica S.A. | Topamax | tbl. 60x25 mg | 0,36 | 21,55 | RSRN15 | 5% |
| N03AX11 182 |  | topiramat | 0,3 g | 9,00 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV, Lusomedicamenta-Sociedade Tecnica, Farmaceutica S.A. | Topamax | tbl. 60x50 mg | 1,50 | 90,00 | RSRN15 | 5% |
| N03AX11 183 |  | topiramat | 0,3 g | 6,50 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV, Lusomedicamenta-Sociedade Tecnica, Farmaceutica S.A. | Topamax | tbl. 60x100 mg | 2,17 | 130,00 | RSRN15 | 5% |
| N03AX11 184 |  | topiramat | 0,3 g | 5,52 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV, Lusomedicamenta-Sociedade Tecnica, Farmaceutica S.A. | Topamax | tbl. 60x200 mg | 3,68 | 220,60 | RSRN15 | 5% |
| N03AX12 111 |  | gabapentin | 1,8 g | 7,68 | O | Belupo d.d. | Belupo | Katena | caps. 20x100 mg | 0,43 | 8,53 | RSRN04 | 5% |
| N03AX12 112 |  | gabapentin | 1,8 g | 9,00 | O | Belupo d.d. | Belupo | Katena | caps. 50x300 mg | 1,50 | 75,00 | RSRN04 | 5% |
| N03AX12 113 |  | gabapentin | 1,8 g | 7,49 | O | Belupo d.d. | Belupo | Katena | caps. 50x400 mg | 1,66 | 83,18 | RSRN04 | 5% |
| N03AX12 162 |  | gabapentin | 1,8 g | 9,00 | O | Upjohn EESV | Pfizer Manufacturing Deutschland GmbH, Genera d.d. | Neurontin | caps. 50x300 mg | 1,50 | 75,00 | RSRN04 | 5% |
| N03AX12 163 |  | gabapentin | 1,8 g | 7,49 | O | Upjohn EESV | Pfizer Manufacturing Deutschland GmbH, Genera d.d. | Neurontin | caps. 50x400 mg | 1,66 | 83,18 | RSRN04 | 5% |
| N03AX14 061 | DS | levetiracetam | 1,5 g | 165,00 | P | Pharmathen S.A. | Pharmathen S.A. | Matever | konc. za otop. za inf., boč. 10x5 ml (100 mg/ml) | 55,00 | 550,00 |  | 5% |
| N03AX14 071 | DS | levetiracetam | 1,5 g | 115,50 | P | Sun Pharmaceutical Industries Europe BV | Sun Pharmaceutical Industries Europe B.V | Levetiracetam Sun | konc. za otop. za inf., boč. 10x5 ml (100 mg/ml) | 38,50 | 385,00 |  | 5% |
| N03AX14 101 |  | levetiracetam | 1,5 g | 3,75 | O | ACTAVIS GROUP PTC ehf. | Teva Operations Poland Sp. z o.o | Levetiracetam Actavis | tbl. film obl. 60x250 mg | 0,63 | 37,50 | RSRN15 | 5% |
| N03AX14 102 |  | levetiracetam | 1,5 g | 3,71 | O | ACTAVIS GROUP PTC ehf. | Teva Operations Poland Sp. z o.o | Levetiracetam Actavis | tbl. film obl. 60x500 mg | 1,24 | 74,11 | RSRN15 | 5% |
| N03AX14 103 |  | levetiracetam | 1,5 g | 4,58 | O | ACTAVIS GROUP PTC ehf. | Teva Operations Poland Sp. z o.o | Levetiracetam Actavis | tbl. film obl. 60x1000 mg | 3,05 | 183,25 | RSRN15 | 5% |
| N03AX14 112 |  | levetiracetam | 1,5 g | 3,71 | O | Belupo d.d. | Belupo d.d. | Levetiracetam Belupo | tbl. film obl. 60x500 mg | 1,24 | 74,11 | RSRN15 | 5% |
| N03AX14 113 |  | levetiracetam | 1,5 g | 5,09 | O | Belupo d.d. | Belupo d.d. | Levetiracetam Belupo | tbl. film obl. 60x1000 mg | 3,39 | 203,61 | RSRN15 | 5% |
| N03AX14 121 |  | levetiracetam | 1,5 g | 3,75 | O | Alkaloid d.o.o. | Alkaloid | Lyvam | tbl. film obl. 60x250 mg | 0,63 | 37,50 | RSRN15 | 5% |
| N03AX14 123 |  | levetiracetam | 1,5 g | 5,67 | O | Alkaloid d.o.o. | Alkaloid | Lyvam | tbl. film obl. 60x750 mg | 2,84 | 170,10 | RSRN15 | 5% |
| N03AX14 124 |  | levetiracetam | 1,5 g | 5,09 | O | Alkaloid d.o.o. | Alkaloid | Lyvam | tbl. film obl. 60x1000 mg | 3,39 | 203,61 | RSRN15 | 5% |
| N03AX14 184 |  | levetiracetam | 1,5 g | 3,75 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Levetiracetam Accord | tbl. film obl. 60x250 mg | 0,63 | 37,50 | RSRN15 | 5% |
| N03AX14 185 |  | levetiracetam | 1,5 g | 3,71 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Levetiracetam Accord | tbl. film obl. 60x500 mg | 1,24 | 74,11 | RSRN15 | 5% |
| N03AX14 186 |  | levetiracetam | 1,5 g | 4,12 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Levetiracetam Accord | tbl. film obl. 60x1000 mg | 2,75 | 164,92 | RSRN15 | 5% |
| N03AX15 161 |  | zonisamid | 0,2 g | 12,23 | O | Makpharm d.o.o. | Chanelle Medical | Zonisamid Makpharm | caps. tvrda 28x25 mg | 1,53 | 42,79 | RSRN15 | 5% |
| N03AX15 162 |  | zonisamid | 0,2 g | 12,23 | O | Makpharm d.o.o. | Chanelle Medical | Zonisamid Makpharm | caps. tvrda 28x50 mg | 3,06 | 85,61 | RSRN15 | 5% |
| N03AX15 163 |  | zonisamid | 0,2 g | 10,14 | O | Makpharm d.o.o. | Chanelle Medical | Zonisamid Makpharm | caps. tvrda 98x100 mg | 5,07 | 496,86 | RSRN15 | 5% |
| N03AX16 101 |  | pregabalin | 0,3 g | 4,31 | O | PLIVA HRVATSKA d.o.o. | Teva UK Ltd., Merckle GmbH, Pliva Hrvatska d.o.o. | Pregabalin Pliva | caps. tvrda 56x25 mg | 0,36 | 20,11 | RSpn21 | 5% |
| N03AX16 102 |  | pregabalin | 0,3 g | 3,44 | O | PLIVA HRVATSKA d.o.o. | Teva UK Ltd., Merckle GmbH, Pliva Hrvatska d.o.o. | Pregabalin Pliva | caps. tvrda 56x75 mg | 0,86 | 48,13 | RSpn21 | 5% |
| N03AX16 103 |  | pregabalin | 0,3 g | 2,64 | O | PLIVA HRVATSKA d.o.o. | Teva UK Ltd., Merckle GmbH, Pliva Hrvatska d.o.o. | Pregabalin Pliva | caps. tvrda 56x150 mg | 1,32 | 73,89 | RSpn21 | 5% |
| N03AX16 104 |  | pregabalin | 0,3 g | 2,93 | O | PLIVA HRVATSKA d.o.o. | Teva UK Ltd., Merckle GmbH, Pliva Hrvatska d.o.o. | Pregabalin Pliva | caps. tvrda 56x300 mg | 2,93 | 164,20 | RSpn21 | 5% |
| N03AX16 121 |  | pregabalin | 0,3 g | 3,44 | O | Sandoz GmbH | Sandoz-Kundl | Pregabalin Sandoz | caps. tvrda 56x75 mg | 0,86 | 48,13 | RSpn21 | 5% |
| N03AX16 122 |  | pregabalin | 0,3 g | 2,64 | O | Sandoz GmbH | Sandoz-Kundl | Pregabalin Sandoz | caps. tvrda 56x150 mg | 1,32 | 73,89 | RSpn21 | 5% |
| N03AX16 125 |  | pregabalin | 0,3 g | 3,44 | O | Belupo d.d. | Belupo | Pregabalin Belupo | caps. tvrda 56x75 mg | 0,86 | 48,13 | RSpn21 | 5% |
| N03AX16 126 |  | pregabalin | 0,3 g | 2,64 | O | Belupo d.d. | Belupo | Pregabalin Belupo | caps. tvrda 56x150 mg | 1,32 | 73,89 | RSpn21 | 5% |
| N03AX16 127 |  | pregabalin | 0,3 g | 2,93 | O | Belupo d.d. | Belupo | Pregabalin Belupo | caps. tvrda 56x300 mg | 2,93 | 164,20 | RSpn21 | 5% |
| N03AX16 132 |  | pregabalin | 0,3 g | 3,44 | O | KRKA-FARMA d.o.o. | KRKA d.d., TAD Pharma GmbH | Pragiola | caps. tvrda 56x75 mg | 0,86 | 48,13 | RSpn21 | 5% |
| N03AX16 133 |  | pregabalin | 0,3 g | 2,64 | O | KRKA-FARMA d.o.o. | KRKA d.d., TAD Pharma GmbH | Pragiola | caps. tvrda 56x150 mg | 1,32 | 73,89 | RSpn21 | 5% |
| N03AX16 134 |  | pregabalin | 0,3 g | 2,93 | O | KRKA-FARMA d.o.o. | KRKA d.d., TAD Pharma GmbH | Pragiola | caps. tvrda 56x300 mg | 2,93 | 164,20 | RSpn21 | 5% |
| N03AX16 141 |  | pregabalin | 0,3 g | 3,09 | O | Medochemie Ltd. | Medochemie Ltd. | Siranalen | caps. tvrda 56x75 mg | 0,77 | 43,32 | RSpn21 | 5% |
| N03AX16 142 |  | pregabalin | 0,3 g | 2,38 | O | Medochemie Ltd. | Medochemie Ltd. | Siranalen | caps. tvrda 56x150 mg | 1,19 | 66,50 | RSpn21 | 5% |
| N03AX16 143 |  | pregabalin | 0,3 g | 2,64 | O | Medochemie Ltd. | Medochemie Ltd. | Siranalen | caps. tvrda 56x300 mg | 2,64 | 147,78 | RSpn21 | 5% |
| N03AX16 164 |  | pregabalin | 0,3 g | 2,93 | O | Pfizer Europe MA EEIG | Pfizer | Lyrica | caps. 56x300 mg | 2,93 | 164,20 | RSpn21 | 5% |
| N03AX16 182 |  | pregabalin | 0,3 g | 3,08 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, GE Pharmaceuticals Ltd., Bluepharma Industria Farmaceutica S.A. | Pregabalin Genericon | caps. tvrda 60x75 mg | 0,77 | 46,20 | RSpn21 | 5% |
| N03AX16 183 |  | pregabalin | 0,3 g | 2,64 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, GE Pharmaceuticals Ltd., Bluepharma Industria Farmaceutica S.A. | Pregabalin Genericon | caps. tvrda 60x150 mg | 1,32 | 79,17 | RSpn21 | 5% |
| N03AX16 184 |  | pregabalin | 0,3 g | 2,93 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, GE Pharmaceuticals Ltd., Bluepharma Industria Farmaceutica S.A. | Pregabalin Genericon | caps. tvrda 60x300 mg | 2,93 | 175,93 | RSpn21 | 5% |
| N03AX16 185 |  | pregabalin | 0,3 g | 2,81 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Pregabalin Accord | caps. tvrda 56x25 mg | 0,23 | 13,10 | RSpn21 | 5% |
| N03AX16 186 |  | pregabalin | 0,3 g | 3,09 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Pregabalin Accord | caps. tvrda 56x75 mg | 0,77 | 43,31 | RSpn21 | 5% |
| N03AX16 187 |  | pregabalin | 0,3 g | 2,37 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Pregabalin Accord | caps. tvrda 56x150 mg | 1,19 | 66,49 | RSpn21 | 5% |
| N03AX18 101 |  | lakozamid | 0,3 g | 6,17 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Lakozamid Pliva | tbl. film obl. 56x50 mg | 1,03 | 57,59 | RSpn22 | 5% |
| N03AX18 102 |  | lakozamid | 0,3 g | 6,93 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Lakozamid Pliva | tbl. film obl. 56x100 mg | 2,31 | 129,43 | RSpn22 | 5% |
| N03AX18 103 |  | lakozamid | 0,3 g | 6,93 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Lakozamid Pliva | tbl. film obl. 56x150 mg | 3,47 | 194,14 | RSpn22 | 5% |
| N03AX18 104 |  | lakozamid | 0,3 g | 6,93 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Lakozamid Pliva | tbl. film obl. 56x200 mg | 4,62 | 258,85 | RSpn22 | 5% |
| N03AX18 111 |  | lakozamid | 0,3 g | 6,17 | O | Belupo d.d. | Belupo d.d. | Midza | tbl. film obl. 56x50 mg | 1,03 | 57,59 | RSpn22 | 5% |
| N03AX18 112 |  | lakozamid | 0,3 g | 6,93 | O | Belupo d.d. | Belupo d.d. | Midza | tbl. film obl. 56x100 mg | 2,31 | 129,43 | RSpn22 | 5% |
| N03AX18 113 |  | lakozamid | 0,3 g | 6,93 | O | Belupo d.d. | Belupo d.d. | Midza | tbl. film obl. 56x150 mg | 3,47 | 194,14 | RSpn22 | 5% |
| N03AX18 114 |  | lakozamid | 0,3 g | 6,93 | O | Belupo d.d. | Belupo d.d. | Midza | tbl. film obl. 56x200 mg | 4,62 | 258,85 | RSpn22 | 5% |
| N03AX18 141 |  | lakozamid | 0,3 g | 6,17 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd, Wessling Hungary Kft. | Lakozamid Accord | tbl. film obl. 56x50 mg | 1,03 | 57,59 | RSpn22 | 5% |
| N03AX18 142 |  | lakozamid | 0,3 g | 6,93 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd, Wessling Hungary Kft. | Lakozamid Accord | tbl. film obl. 56x100 mg | 2,31 | 129,43 | RSpn22 | 5% |
| N03AX18 143 |  | lakozamid | 0,3 g | 6,93 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd, Wessling Hungary Kft. | Lakozamid Accord | tbl. film obl. 56x150 mg | 3,47 | 194,14 | RSpn22 | 5% |
| N03AX18 144 |  | lakozamid | 0,3 g | 6,93 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd, Wessling Hungary Kft. | Lakozamid Accord | tbl. film obl. 56x200 mg | 4,62 | 258,85 | RSpn22 | 5% |
| N03AX18 172 |  | lakozamid | 0,3 g | 6,93 | O | Mylan Ireland Limited | HBM Pharma s.r.o., Mylan Hungary Kft | Seizpat | tbl. film obl. 56x100 mg | 2,31 | 129,43 | RSpn22 | 5% |
| N03AX18 173 |  | lakozamid | 0,3 g | 6,93 | O | Mylan Ireland Limited | HBM Pharma s.r.o., Mylan Hungary Kft | Seizpat | tbl. film obl. 56x200 mg | 4,62 | 258,85 | RSpn22 | 5% |
| N03AX23 171 |  | brivaracetam | 0.1 g | 21,04 | O | UCB Pharma S.A. | UCB Pharma S.A. | Briviact | tbl. film obl. 56x50 mg | 10,52 | 589,00 | RSRN26 | 5% |
| N03AX23 172 |  | brivaracetam | 0.1 g | 10,52 | O | UCB Pharma S.A. | UCB Pharma S.A. | Briviact | tbl. film obl. 56x100 mg | 10,52 | 589,00 | RSRN26 | 5% |
| N03AX23 271 |  | brivaracetam | 0.1 g | 21,03 | O | UCB Pharma S.A. | UCB Pharma S.A. | Briviact | otop. oral. 300 ml (10 mg/ml) | 630,80 | 630,80 | RSRN26 | 5% |
| N04AA01 151 | DS | triheksifenidil | 10 mg |  | O |  |  |  |  |  |  |  | 5% |
| N04AA02 072 | PR | biperiden | 10 mg | 7,59 | P | Desma GmbH | Sirton Pharmaceuticals S.p.A. | Akineton | amp. 5x5 mg/ml | 3,79 | 18,97 |  | 5% |
| N04AA02 171 |  | biperiden | 10 mg | 1,16 | O | Desma GmbH | Laboratorio Farmaceutico S.I.T. Srl | Akineton | tbl. 50x2 mg | 0,23 | 11,59 | R | 5% |
| N04BA02 121 |  | levodopa + karbidopa | 0,6 g | 3,26 | O | Sandoz d.o.o. | Sandoz-Lek | Nakom | tbl. 100x(250 mg + 25 mg) | 1,36 | 135,67 | R | 5% |
| N04BA02 571 | DS | levodopa + karbidopaNN401 |  |  | P | AbbVie d.o.o. | Fresenius Kabi Norge AS, AbbVie Logistics B.V. | Duodopa intestinalni gel | vreć. plast., kazeta 7x100 ml (20 mg/ml levodope + 5 mg/ml karbidope) | 721,68 | 5.051,74 |  | 5% |
| N04BA03 061 | DS | levodopa + karbidopa + entakaponNN401 |  |  | P | LobSor Pharmaceuticals AB | Bioglan AB | Lecigon | intestinalni gel u ulošku, 7x47 ml (20 mg/ml levodope + 5 mg/ml karbidope + 20mg/ml entakapona) | 725,67 | 5.079,72 |  | 5% |
| N04BA03 161 |  | levodopa + karbidopa + entakapon | 0,45 g | 26,97 | O | Orion Corporation | Orion Pharma | Stalevo | tbl. film obl. 100x(50 mg + 12,5 mg + 200 mg) | 3,00 | 299,67 | Rpn05 | 5% |
| N04BA03 162 |  | levodopa + karbidopa + entakapon | 0,45 g | 13,49 | O | Orion Corporation | Orion Pharma | Stalevo | tbl. film obl. 100x(100 mg + 25 mg + 200 mg) | 3,00 | 299,67 | Rpn05 | 5% |
| N04BA03 163 |  | levodopa + karbidopa + entakapon | 0,45 g | 8,99 | O | Orion Corporation | Orion Pharma | Stalevo | tbl. film obl. 100x(150 mg + 37,5 mg + 200 mg) | 3,00 | 299,67 | Rpn05 | 5% |
| N04BA03 164 |  | levodopa + karbidopa + entakapon | 0,45 g | 6,74 | O | Orion Corporation | Orion Pharma | Stalevo | tbl. film obl. 100x(200mg + 50 mg + 200 mg) | 3,00 | 299,67 | Rpn05 | 5% |
| N04BB01 161 |  | amantadin | 200 mg | 2,16 | O | Merz Pharmaceuticals Gmbh | Merz | PK-Merz | tbl. film obl. 30x100 mg | 1,08 | 32,34 | R | 5% |
| N04BC04 101 |  | ropinirol | 6 mg | 6,87 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Lirona XL | tbl. s prod. oslob. 28x2 mg | 2,29 | 64,12 | R | 5% |
| N04BC04 102 |  | ropinirol | 6 mg | 6,71 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Lirona XL | tbl. s prod. oslob. 28x4 mg | 4,48 | 125,31 | R | 5% |
| N04BC04 103 |  | ropinirol | 6 mg | 6,38 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Lirona XL | tbl. s prod. oslob. 28x8 mg | 8,51 | 238,28 | R | 5% |
| N04BC04 115 |  | ropinirol | 6 mg | 6,87 | O | Belupo d.d. | Belupo | Eminens SR | tbl. s prod. oslob. 28x2 mg | 2,29 | 64,12 | R | 5% |
| N04BC04 116 |  | ropinirol | 6 mg | 6,71 | O | Belupo d.d. | Belupo | Eminens SR | tbl. s prod. oslob. 28x4 mg | 4,48 | 125,31 | R | 5% |
| N04BC04 117 |  | ropinirol | 6 mg | 6,38 | O | Belupo d.d. | Belupo | Eminens SR | tbl. s prod. oslob. 28x8 mg | 8,51 | 238,28 | R | 5% |
| N04BC04 131 |  | ropinirol | 6 mg | 6,87 | O | KRKA-FARMA d.o.o. | KRKA d.d. | Rolpryna SR | tbl. s prod. oslob. 28x2 mg | 2,29 | 64,12 | R | 5% |
| N04BC04 132 |  | ropinirol | 6 mg | 6,71 | O | KRKA-FARMA d.o.o. | KRKA d.d. | Rolpryna SR | tbl. s prod. oslob. 28x4 mg | 4,48 | 125,31 | R | 5% |
| N04BC04 133 |  | ropinirol | 6 mg | 6,38 | O | KRKA-FARMA d.o.o. | KRKA d.d. | Rolpryna SR | tbl. s prod. oslob. 28x8 mg | 8,51 | 238,28 | R | 5% |
| N04BC04 176 |  | ropinirol | 6 mg | 6,87 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A., Glaxo Wellcome GmbH & Co.KG, Glaxo Wellcome S.A., SmithKline Beecham Plc | Requip Modutab | tbl. s prod. oslob. 28x2 mg | 2,29 | 64,12 | R | 5% |
| N04BC04 177 |  | ropinirol | 6 mg | 6,71 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A., Glaxo Wellcome GmbH & Co.KG, Glaxo Wellcome S.A., SmithKline Beecham Plc | Requip Modutab | tbl. s prod. oslob. 28x4 mg | 4,48 | 125,31 | R | 5% |
| N04BC04 178 |  | ropinirol | 6 mg | 6,38 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A., Glaxo Wellcome GmbH & Co.KG, Glaxo Wellcome S.A., SmithKline Beecham Plc | Requip Modutab | tbl. s prod. oslob. 28x8 mg | 8,51 | 238,28 | R | 5% |
| N04BC05 103 |  | pramipeksol | 2,5 mg | 9,91 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x0,26 mg | 1,03 | 30,92 | R | 5% |
| N04BC05 104 |  | pramipeksol | 2,5 mg | 9,91 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x0,52 mg | 2,06 | 61,83 | R | 5% |
| N04BC05 105 |  | pramipeksol | 2,5 mg | 9,59 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x1,05 mg | 4,03 | 120,83 | R | 5% |
| N04BC05 106 |  | pramipeksol | 2,5 mg | 9,12 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x2,1 mg | 7,66 | 229,77 | R | 5% |
| N04BC05 107 |  | pramipeksol | 2,5 mg | 9,12 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x3,15 mg | 11,49 | 344,66 | R | 5% |
| N04BC05 187 |  | pramipeksol | 2,5 mg | 9,59 | O | Krka d.d., Novo mesto | Krka d.d., TAD Pharma GmbH | Oprymea | tbl. 30x0,7 mg | 2,69 | 80,56 | R | 5% |
| N04BD02 111 |  | razagilin | 1 mg | 5,64 | O | Belupo d.d. | Belupo d.d. | Razagilin Belupo | tbl. 28x1 mg | 5,64 | 158,00 | Rpn06 | 5% |
| N04BD02 112 |  | razagilin | 1 mg | 5,11 | O | Belupo d.d. | Belupo d.d. | Razagilin Belupo | tbl. 56x1 mg | 5,11 | 286,18 | Rpn06 | 5% |
| N04BD02 161 |  | razagilin | 1 mg | 5,64 | O | Teva B.V. | Teva Pharmaceuticals | Azilect | tbl. 28x1 mg | 5,64 | 158,00 | Rpn06 | 5% |
| N04BD02 162 |  | razagilin | 1 mg | 5,64 | O | PLIVA HRVATSKA d.o.o. | Teva Pharmaceuticals Europe B.V. | Razagilin Teva | tbl. 28x1 mg | 5,64 | 158,00 | Rpn06 | 5% |
| N04BD02 171 |  | razagilin | 1 mg | 5,64 | O | Medochemie Ltd. | Medochemie Ltd. | Sagilia | tbl. 28x1 mg | 5,64 | 158,00 | Rpn06 | 5% |
| N04BD02 181 |  | razagilin | 1 mg | 5,64 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Azipron | tbl. 28x1 mg | 5,64 | 158,00 | Rpn06 | 5% |
| N04BD02 191 |  | razagilin | 1 mg | 5,64 | O | Makpharm d.o.o. | Synthon Hispania S.L., Synthon s.r.o., Synthon BV, | Razagilin Makpharm | tbl. 28x1 mg | 5,64 | 158,00 | Rpn06 | 5% |
| N04BD02 192 |  | razagilin | 1 mg | 5,64 | O | STADA d.o.o. | STADA Arzneimittel GmbH | Razagilin Stada | tbl. 28x1 mg | 5,64 | 158,00 | Rpn06 | 5% |
| N04BX02 171 |  | entakapon | 1 g | 11,45 | O | HEC Pharma GmbH | Formula Pharmazeutische und chemische Entwicklungs GmbH | Entakapon HEC | tbl. film obl. 30x200 mg | 2,29 | 68,67 | Rpn05 | 5% |
| N05AA02 191 |  | levomepromazin | 0,3 g | 7,68 | O | sanofi-aventis groupe | Sanofi S.p.A | Nozinan | tbl. film obl. 20x25 mg | 0,64 | 12,80 | R | 5% |
| N05AA02 192 |  | levomepromazin | 0,3 g | 4,07 | O | sanofi-aventis groupe | Sanofi S.p.A | Nozinan | tbl. film obl. 20x100 mg | 1,36 | 27,13 | R | 5% |
| N05AA03 051 | PR | promazin | 0,1 g |  | P |  |  |  |  |  |  |  | 5% |
| N05AA03 101 |  | promazin | 0,3 g | 11,16 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prazine | drag. 50x25 mg | 0,93 | 46,49 | R | 5% |
| N05AA03 102 |  | promazin | 0,3 g | 4,88 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prazine | drag. 50x100 mg | 1,63 | 81,41 | R | 5% |
| N05AA03 111 |  | promazin | 0,3 g | 11,16 | O | Belupo d.d. | Belupo | Promazin Belupo | tbl. obl. 50x25 mg | 0,93 | 46,49 | R | 5% |
| N05AA03 112 |  | promazin | 0,3 g | 4,88 | O | Belupo d.d. | Belupo | Promazin Belupo | tbl. obl. 50x100 mg | 1,63 | 81,41 | R | 5% |
| N05AB02 035 | PO | flufenazin-dekanoat | 1 mg | 1,13 | P | KRKA-FARMA d.o.o. | Krka d.d. | Moditen depo | amp. 5x25 mg/ml | 28,20 | 140,98 |  | 5% |
| N05AB02 131 |  | flufenazin | 10 mg | 9,65 | O | KRKA-FARMA d.o.o. | Krka d.d. | Moditen | drag. 25x1 mg | 0,97 | 24,13 | R | 5% |
| N05AB02 132 |  | flufenazin | 10 mg | 3,36 | O | KRKA-FARMA d.o.o. | Krka d.d. | Moditen | drag. 100x2,5 mg | 0,84 | 84,00 | R | 5% |
| N05AB02 133 |  | flufenazin | 10 mg | 3,36 | O | KRKA-FARMA d.o.o. | Krka d.d. | Moditen | drag. 100x5 mg | 1,68 | 168,00 | R | 5% |
| N05AD01 031 | PR | haloperidol | 8 mg | 6,63 | P | KRKA-FARMA d.o.o. | Krka d.d. | Haldol/Haloperidol Krka | amp. 10x5 mg/ml / otop. za inj., 10x5 mg/ml | 3,98 | 39,75 |  | 5% |
| N05AD01 032 | PO | haloperidol-dekanoat | 3,3 mg | 2,04 | P | KRKA-FARMA d.o.o. | Krka d.d. | Haldol depo/Haloperidol depo Krka | amp. 5x50 mg/ml / otop. za inj. s prod. oslob., 5x50 mg/ml | 30,95 | 154,73 |  | 5% |
| N05AD01 137 |  | haloperidol | 8 mg | 1,14 | O | KRKA-FARMA d.o.o. | Krka d.d. | Haldol/Haloperidol Krka | tbl. 30x10 mg | 1,43 | 42,83 | R | 5% |
| N05AD01 251 |  | haloperidol | 8 mg |  | O |  |  |  | oralne kapi |  |  | R | 5% |
| N05AE03 171 |  | sertindol | 16 mg | 20,35 | O | Lundbeck Croatia d.o.o. | H. Lundbeck A/S | Serdolect | tbl. film obl. 30x4 mg | 5,09 | 152,63 | RSRN06 | 5% |
| N05AE03 172 |  | sertindol | 16 mg | 20,35 | O | Lundbeck Croatia d.o.o. | H. Lundbeck A/S | Serdolect | tbl. film obl. 28x12 mg | 15,26 | 427,35 | RSRN06 | 5% |
| N05AE04 161 |  | ziprazidon | 80 mg | 13,74 | O | Upjohn EESV | Pfizer | Zeldox | caps. 30x40 mg | 6,87 | 206,10 | RSRN06 | 5% |
| N05AE04 162 |  | ziprazidon | 80 mg | 10,19 | O | Upjohn EESV | Pfizer | Zeldox | caps. 30x60 mg | 7,64 | 229,20 | RSRN06 | 5% |
| N05AE04 163 |  | ziprazidon | 80 mg | 12,11 | O | Upjohn EESV | Pfizer | Zeldox | caps. 30x80 mg | 12,11 | 363,29 | RSRN06 | 5% |
| N05AE05 161 |  | lurasidon | 60 mg | 21,50 | O | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | Aziende Chimiche Riunite Angelini Francesco ACRAF SPA, Millmount Healthcare Ltd. | Latuda | tbl. film obl. 28x37 mg | 13,26 | 371,28 | RSRN06 | 5% |
| N05AE05 162 |  | lurasidon | 60 mg | 10,75 | O | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | Aziende Chimiche Riunite Angelini Francesco ACRAF SPA, Millmount Healthcare Ltd. | Latuda | tbl. film obl. 28x74 mg | 13,26 | 371,28 | RSRN06 | 5% |
| N05AH02 051 | DS | klozapin | 0,3 g |  | P |  |  |  |  |  |  |  | 5% |
| N05AH02 101 |  | klozapin | 0,3 g | 6,96 | O | PLIVA HRVATSKA d.o.o. | Accord Healthcare Limited | Sanosen | tbl. 50x25 mg | 0,58 | 28,98 | RSRN06 | 5% |
| N05AH02 161 |  | klozapin | 0,3 g | 6,19 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Klozapin Alpha-Medical | tbl. 50x100 mg | 2,06 | 103,10 | RSRN06 | 5% |
| N05AH02 162 |  | klozapin | 0,3 g | 7,73 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Klozapin Alpha-Medical | tbl. 50x25 mg | 0,64 | 32,20 | RSRN06 | 5% |
| N05AH02 163 |  | klozapin | 0,3 g | 6,27 | O | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Wessling Hungary Kft. | Klozapin Accord | tbl. 50x25 mg | 0,52 | 26,13 | RSRN06 | 5% |
| N05AH02 164 |  | klozapin | 0,3 g | 5,02 | O | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Wessling Hungary Kft. | Klozapin Accord | tbl. 50x100 mg | 1,67 | 83,60 | RSRN06 | 5% |
| N05AH02 171 |  | klozapin | 0,3 g | 7,27 | O | Makpharm d.o.o. | Synthon Hispania S.L., Synthon BV | Zaniq | tbl. rasp. za usta 100x12,5 mg | 0,30 | 30,28 | RSRN06 | 5% |
| N05AH02 172 |  | klozapin | 0,3 g | 6,61 | O | Makpharm d.o.o. | Synthon Hispania S.L., Synthon BV | Zaniq | tbl. rasp. za usta 100x25 mg | 0,55 | 55,06 | RSRN06 | 5% |
| N05AH02 173 |  | klozapin | 0,3 g | 5,29 | O | Makpharm d.o.o. | Synthon Hispania S.L., Synthon BV | Zaniq | tbl. rasp. za usta 100x100 mg | 1,76 | 176,30 | RSRN06 | 5% |
| N05AH02 174 |  | klozapin | 0,3 g | 7,73 | O | Mylan Hrvatska d.o.o. | Novartis Pharma | Leponex | tbl. 50x25 mg | 0,64 | 32,20 | RSRN06 | 5% |
| N05AH02 175 |  | klozapin | 0,3 g | 6,19 | O | Mylan Hrvatska d.o.o. | Novartis Pharma | Leponex | tbl. 50x100 mg | 2,06 | 103,10 | RSRN06 | 5% |
| N05AH03 061 | RL | olanzapinNN502 | 10 mg | 63,80 | P | Eli Lilly Nederland B.V. | Lilly S.A. | Zypadhera | praš. i otap. za susp. za inj. s prod. osl. 1x210 mg | 1.339,76 | 1.339,76 | RSRN08 | 5% |
| N05AH03 062 | RL | olanzapinNN502 | 10 mg | 55,81 | P | Eli Lilly Nederland B.V. | Lilly S.A. | Zypadhera | praš. i otap. za susp. za inj. s prod. osl. 1x300 mg | 1.674,28 | 1.674,28 | RSRN08 | 5% |
| N05AH03 063 | RL | olanzapinNN502 | 10 mg | 52,15 | P | Eli Lilly Nederland B.V. | Lilly S.A. | Zypadhera | praš. i otap. za susp. za inj. s prod. osl. 1x405 mg | 2.112,04 | 2.112,04 | RSRN08 | 5% |
| N05AH03 065 | DS | olanzapinNN503 | 10 mg | 26,30 | P | Eli Lilly Nederland B.V. | Lilly S.A. | Zyprexa | praš. za otop. za inj. boč. 1x10 mg | 26,30 | 26,30 |  | 5% |
| N05AH03 101 |  | olanzapin | 10 mg | 4,04 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Olandix | tbl. rasp. za usta 28x5 mg | 2,02 | 56,55 | RSRN06 | 5% |
| N05AH03 102 |  | olanzapin | 10 mg | 3,90 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Olandix | tbl. rasp. za usta 28x10 mg | 3,90 | 109,20 | RSRN06 | 5% |
| N05AH03 111 |  | olanzapin | 10 mg | 4,04 | O | Belupo d.d. | Belupo | Vaira | tbl. film obl. 28x5 mg | 2,02 | 56,55 | RSRN06 | 5% |
| N05AH03 112 |  | olanzapin | 10 mg | 3,90 | O | Belupo d.d. | Belupo | Vaira | tbl. film obl. 28x10 mg | 3,90 | 109,20 | RSRN06 | 5% |
| N05AH03 113 |  | olanzapin | 10 mg | 4,04 | O | Belupo d.d. | Belupo | Vaira -V | tbl. rasp. za usta 28x5 mg | 2,02 | 56,55 | RSRN06 | 5% |
| N05AH03 114 |  | olanzapin | 10 mg | 3,90 | O | Belupo d.d. | Belupo | Vaira -V | tbl. rasp. za usta 28x10 mg | 3,90 | 109,20 | RSRN06 | 5% |
| N05AH03 123 |  | olanzapin | 10 mg | 4,02 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ziora | tbl. rasp. za usta 30x5 mg | 2,01 | 60,30 | RSRN06 | 5% |
| N05AH03 124 |  | olanzapin | 10 mg | 3,89 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ziora | tbl. rasp. za usta 30x10 mg | 3,89 | 116,70 | RSRN06 | 5% |
| N05AH03 126 |  | olanzapin | 10 mg | 4,04 | O | Sandoz d.o.o. | Sandoz-Salutas | Olanzalux | tbl. film obl. 28x5 mg | 2,02 | 56,55 | RSRN06 | 5% |
| N05AH03 127 |  | olanzapin | 10 mg | 3,83 | O | Sandoz d.o.o. | Sandoz-Salutas | Olanzalux | tbl. film obl. 28x10 mg | 3,83 | 107,14 | RSRN06 | 5% |
| N05AH03 131 |  | olanzapin | 10 mg | 4,04 | O | Krka d.d., Novo mesto | Krka d.d. | Zalasta | tbl. rasp. za usta 28x5 mg | 2,02 | 56,55 | RSRN06 | 5% |
| N05AH03 132 |  | olanzapin | 10 mg | 3,90 | O | Krka d.d., Novo mesto | Krka d.d. | Zalasta | tbl. rasp. za usta 28x10 mg | 3,90 | 109,20 | RSRN06 | 5% |
| N05AH03 133 |  | olanzapin | 10 mg | 7,31 | O | Krka d.d., Novo mesto | Krka d.d. | Zalasta | tbl. rasp. za usta 28x15 mg | 10,97 | 307,13 | RSRN06 | 5% |
| N05AH03 145 |  | olanzapin | 10 mg | 3,98 | O | PharmaS d.o.o. | PharmaS d.o.o. | Olanzapin PharmaS | tbl. rasp. za usta 28x5 mg | 1,99 | 55,67 | RSRN06 | 5% |
| N05AH03 146 |  | olanzapin | 10 mg | 3,75 | O | PharmaS d.o.o. | PharmaS d.o.o. | Olanzapin PharmaS | tbl. rasp. za usta 28x10 mg | 3,75 | 104,90 | RSRN06 | 5% |
| N05AH03 163 |  | olanzapin | 10 mg | 4,04 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Zyprexa Velotab | tbl. rasp. za usta 28x5 mg | 2,02 | 56,55 | RSRN06 | 5% |
| N05AH03 164 |  | olanzapin | 10 mg | 3,90 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Zyprexa Velotab | tbl. rasp. za usta 28x10 mg | 3,90 | 109,20 | RSRN06 | 5% |
| N05AH04 100 |  | kvetiapin | 0,4 g | 16,91 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Loquen | tbl. film obl. 60x25 mg | 1,06 | 63,40 | RSRN06 | 5% |
| N05AH04 101 |  | kvetiapin | 0,4 g | 6,65 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Loquen | tbl. film obl. 60x100 mg | 1,66 | 99,69 | RSRN06 | 5% |
| N05AH04 102 |  | kvetiapin | 0,4 g | 5,81 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Loquen | tbl. film obl. 60x200 mg | 2,91 | 174,35 | RSRN06 | 5% |
| N05AH04 103 |  | kvetiapin | 0,4 g | 7,62 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Loquen XR | tbl. film obl. s prod. oslob. 60x200 mg | 3,81 | 228,45 | RSRN06 | 5% |
| N05AH04 104 |  | kvetiapin | 0,4 g | 7,16 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Loquen XR | tbl. film obl. s prod. oslob. 60x300 mg | 5,37 | 322,00 | RSRN06 | 5% |
| N05AH04 105 |  | kvetiapin | 0,4 g | 7,30 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Loquen XR | tbl. film obl. s prod. oslob. 60x400 mg | 7,30 | 438,20 | RSRN06 | 5% |
| N05AH04 106 |  | kvetiapin | 0,4 g | 8,01 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma S.L.U. | Loquen XR | tbl. film obl. s prod. oslob. 60x150 mg | 3,01 | 180,31 | RSRN06 | 5% |
| N05AH04 111 |  | kvetiapin | 0,4 g | 16,91 | O | Belupo d.d. | Belupo | Q-pin | tbl. film obl. 60x25 mg | 1,06 | 63,40 | RSRN06 | 5% |
| N05AH04 112 |  | kvetiapin | 0,4 g | 6,65 | O | Belupo d.d. | Belupo | Q-pin | tbl. film obl. 60x100 mg | 1,66 | 99,69 | RSRN06 | 5% |
| N05AH04 113 |  | kvetiapin | 0,4 g | 5,81 | O | Belupo d.d. | Belupo | Q-pin | tbl. film obl. 60x200 mg | 2,91 | 174,35 | RSRN06 | 5% |
| N05AH04 114 |  | kvetiapin | 0,4 g | 6,79 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x50 mg | 0,85 | 50,95 | RSRN06 | 5% |
| N05AH04 115 |  | kvetiapin | 0,4 g | 8,01 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x150 mg | 3,01 | 180,31 | RSRN06 | 5% |
| N05AH04 121 |  | kvetiapin | 0,4 g | 16,91 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Quelapin | tbl. film obl. 60x25 mg | 1,06 | 63,40 | RSRN06 | 5% |
| N05AH04 122 |  | kvetiapin | 0,4 g | 6,65 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Quelapin | tbl. film obl. 60x100 mg | 1,66 | 99,69 | RSRN06 | 5% |
| N05AH04 124 |  | kvetiapin | 0,4 g | 5,81 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Quelapin | tbl. film obl. 60x200 mg | 2,91 | 174,35 | RSRN06 | 5% |
| N05AH04 129 |  | kvetiapin | 0,4 g | 6,63 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x400 mg | 6,63 | 397,80 | RSRN06 | 5% |
| N05AH04 130 |  | kvetiapin | 0,4 g | 6,79 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x50 mg | 0,85 | 50,95 | RSRN06 | 5% |
| N05AH04 131 |  | kvetiapin | 0,4 g | 16,91 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Kventiax | tbl. film obl. 60x25 mg | 1,06 | 63,40 | RSRN06 | 5% |
| N05AH04 132 |  | kvetiapin | 0,4 g | 6,65 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Kventiax | tbl. film obl. 60x100 mg | 1,66 | 99,69 | RSRN06 | 5% |
| N05AH04 133 |  | kvetiapin | 0,4 g | 5,81 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Kventiax | tbl. film obl. 60x200 mg | 2,91 | 174,35 | RSRN06 | 5% |
| N05AH04 134 |  | kvetiapin | 0,4 g | 6,66 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Kventiax | tbl. film obl. 60x300 mg | 4,99 | 299,60 | RSRN06 | 5% |
| N05AH04 135 |  | kvetiapin | 0,4 g | 7,62 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin XR PharmaS | tbl. s prod. oslob. 60x200 mg | 3,81 | 228,45 | RSRN06 | 5% |
| N05AH04 136 |  | kvetiapin | 0,4 g | 7,16 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin XR PharmaS | tbl. s prod. oslob. 60x300 mg | 5,37 | 322,00 | RSRN06 | 5% |
| N05AH04 137 |  | kvetiapin | 0,4 g | 7,30 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin XR PharmaS | tbl. s prod. oslob. 60x400 mg | 7,30 | 438,20 | RSRN06 | 5% |
| N05AH04 138 |  | kvetiapin | 0,4 g | 6,79 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin XR PharmaS | tbl. s prod. oslob. 60x50 mg | 0,85 | 50,95 | RSRN06 | 5% |
| N05AH04 146 |  | kvetiapin | 0,4 g | 16,91 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin PharmaS | tbl. film obl. 60x25 mg | 1,06 | 63,40 | RSRN06 | 5% |
| N05AH04 147 |  | kvetiapin | 0,4 g | 6,65 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin PharmaS | tbl. film obl. 60x100 mg | 1,66 | 99,69 | RSRN06 | 5% |
| N05AH04 148 |  | kvetiapin | 0,4 g | 5,81 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin PharmaS | tbl. film obl. 60x200 mg | 2,91 | 174,35 | RSRN06 | 5% |
| N05AH04 164 |  | kvetiapin | 0,4 g | 7,16 | O | AstraZeneca d.o.o. | AstraZeneca | Seroquel XR | tbl. s prod. oslob. 60x300 mg | 5,37 | 322,00 | RSRN06 | 5% |
| N05AH04 165 |  | kvetiapin | 0,4 g | 7,30 | O | AstraZeneca d.o.o. | AstraZeneca | Seroquel XR | tbl. s prod. oslob. 60x400 mg | 7,30 | 438,20 | RSRN06 | 5% |
| N05AH04 181 |  | kvetiapin | 0,4 g | 7,62 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x200 mg | 3,81 | 228,45 | RSRN06 | 5% |
| N05AH04 182 |  | kvetiapin | 0,4 g | 7,16 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x300 mg | 5,37 | 322,00 | RSRN06 | 5% |
| N05AH04 183 |  | kvetiapin | 0,4 g | 7,30 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x400 mg | 7,30 | 438,20 | RSRN06 | 5% |
| N05AH04 184 |  | kvetiapin | 0,4 g | 8,01 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x150 mg | 3,01 | 180,31 | RSRN06 | 5% |
| N05AH04 185 |  | kvetiapin | 0,4 g | 7,62 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x200 mg | 3,81 | 228,45 | RSRN06 | 5% |
| N05AH04 186 |  | kvetiapin | 0,4 g | 7,16 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x300 mg | 5,37 | 322,00 | RSRN06 | 5% |
| N05AL01 112 |  | sulpirid | 0,8 g | 6,31 | O | Belupo d.d. | Belupo | Sulpirid Belupo | caps. tvrda 12x200 mg | 1,58 | 18,93 | R | 5% |
| N05AL01 143 |  | sulpirid | 0,8 g | 6,31 | O | Alkaloid d.o.o. | Alkaloid-int d.o.o. | Eglonyl forte | tbl. 10x200 mg | 1,58 | 15,78 | R | 5% |
| N05AL01 144 |  | sulpirid | 0,8 g | 5,55 | O | Alkaloid d.o.o. | Alkaloid-int d.o.o. | Eglonyl forte | tbl. 30x200 mg | 1,39 | 41,60 | R | 5% |
| N05AL05 162 |  | amisulprid | 0,4 g | 6,60 | O | sanofi-aventis groupe | Sanofi Winthrop Quetigny | Solian | tbl. 30x200 mg | 3,30 | 99,04 | RSRN09 | 5% |
| N05AL05 172 |  | amisulprid | 0,4 g | 6,60 | O | Medochemie Ltd. | Medochemie Ltd. | Aktiprol | tbl. 30x200 mg | 3,30 | 99,04 | RSRN09 | 5% |
| N05AL05 173 |  | amisulprid | 0,4 g | 6,60 | O | Medochemie Ltd. | Medochemie Ltd. | Aktiprol | tbl. 30x400 mg | 6,60 | 198,08 | RSRN09 | 5% |
| N05AN01 115 |  | litij-karbonat | 24 mmol |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Litijev karbonat Jadran | tbl. 100x300 mg | 0,75 | 75,38 | R | 5% |
| N05AX08 081 | RL | risperidonNN504 | 2,7 mg | 65,80 | P | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Rispolept Consta | susp. s prod. djel. za i.m. primj. 1x25 mg | 609,26 | 609,26 | RSRN10 | 5% |
| N05AX08 082 | RL | risperidonNN504 | 2,7 mg | 57,90 | P | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Rispolept Consta | susp. s prod. djel. za i.m. primj. 1x37,5 mg | 804,18 | 804,18 | RSRN10 | 5% |
| N05AX08 083 | RL | risperidonNN504 | 2,7 mg | 53,31 | P | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Rispolept Consta | susp. s prod. djel. za i.m. primj. 1x50 mg | 987,23 | 987,23 | RSRN10 | 5% |
| N05AX08 101 |  | risperidon | 5 mg | 6,03 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Merckle GmbH | Risset | tbl. film obl. 20x1 mg | 1,21 | 24,13 | RSRN06 | 5% |
| N05AX08 102 |  | risperidon | 5 mg | 4,79 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Merckle GmbH | Risset | tbl. film obl. 60x2 mg | 1,92 | 115,00 | RSRN06 | 5% |
| N05AX08 103 |  | risperidon | 5 mg | 4,92 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Merckle GmbH | Risset | tbl. film obl. 60x3 mg | 2,95 | 177,00 | RSRN06 | 5% |
| N05AX08 104 |  | risperidon | 5 mg | 6,57 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Merckle GmbH | Risset | tbl. film obl. 60x4 mg | 5,26 | 315,40 | RSRN06 | 5% |
| N05AX08 111 |  | risperidon | 5 mg | 6,03 | O | Belupo d.d. | Belupo | Prospera | tbl. film obl. 20x1 mg | 1,21 | 24,13 | RSRN06 | 5% |
| N05AX08 112 |  | risperidon | 5 mg | 4,79 | O | Belupo d.d. | Belupo | Prospera | tbl. film obl. 60x2 mg | 1,92 | 115,00 | RSRN06 | 5% |
| N05AX08 122 |  | risperidon | 5 mg | 4,79 | O | Sandoz d.o.o. | Sandoz-Lek | Rispolux | tbl. film obl. 60x2 mg | 1,92 | 115,00 | RSRN06 | 5% |
| N05AX08 131 |  | risperidon | 5 mg | 6,03 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Torendo | tbl. film obl. 20x1 mg | 1,21 | 24,13 | RSRN06 | 5% |
| N05AX08 141 |  | risperidon | 5 mg | 6,03 | O | Alkaloid d.o.o. | Alkaloid | Risdonal | tbl. film obl. 20x1 mg | 1,21 | 24,13 | RSRN06 | 5% |
| N05AX08 142 |  | risperidon | 5 mg | 4,79 | O | Alkaloid d.o.o. | Alkaloid | Risdonal | tbl. film obl. 60x2 mg | 1,92 | 115,00 | RSRN06 | 5% |
| N05AX08 143 |  | risperidon | 5 mg | 4,92 | O | Alkaloid d.o.o. | Alkaloid | Risdonal | tbl. film obl. 60x3 mg | 2,95 | 177,00 | RSRN06 | 5% |
| N05AX08 185 |  | risperidon | 5 mg | 4,79 | O | Johnson & Johnson S.E.d.o.o. | Janssen-Cilag S.p.A. | Rispolept | tbl. film obl. 60x2 mg | 1,92 | 115,00 | RSRN06 | 5% |
| N05AX08 186 |  | risperidon | 5 mg | 4,92 | O | Johnson & Johnson S.E.d.o.o. | Janssen-Cilag S.p.A. | Rispolept | tbl. film obl. 60x3 mg | 2,95 | 177,00 | RSRN06 | 5% |
| N05AX08 187 |  | risperidon | 5 mg | 6,57 | O | Johnson & Johnson S.E.d.o.o. | Janssen-Cilag S.p.A. | Rispolept | tbl. film obl. 60x4 mg | 5,26 | 315,40 | RSRN06 | 5% |
| N05AX08 288 |  | risperidon | 5 mg | 9,28 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Rispolept | otop. oral. 100 ml (1 mg/ml) | 185,67 | 185,67 | RSRN06 | 5% |
| N05AX12 061 | RL | aripiprazol | 15 mg | 73,18 | P | Otsuka Pharmaceutical Netherlands B.V. | H. Lundbeck A/S | Abilify Maintena | praš. i otap. za susp. za inj. s prod. oslob. za i.m. primj. 1x400 mg | 1.951,39 | 1.951,39 | RSRN17 | 5% |
| N05AX12 101 |  | aripiprazol | 15 mg | 8,02 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Teva Operations Poland, Merckle GmbH | Aripiprazol Pliva | tbl. 30x5 mg | 2,67 | 80,15 | RSRN06 | 5% |
| N05AX12 102 |  | aripiprazol | 15 mg | 6,49 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Teva Operations Poland, Merckle GmbH | Aripiprazol Pliva | tbl. 30x10 mg | 4,33 | 129,84 | RSRN06 | 5% |
| N05AX12 103 |  | aripiprazol | 15 mg | 6,87 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Teva Operations Poland, Merckle GmbH | Aripiprazol Pliva | tbl. 30x15 mg | 6,87 | 205,99 | RSRN06 | 5% |
| N05AX12 104 |  | aripiprazol | 15 mg | 5,13 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Teva Operations Poland, Merckle GmbH | Aripiprazol Pliva | tbl. 30x30 mg | 10,26 | 307,80 | RSRN06 | 5% |
| N05AX12 131 |  | aripiprazol | 15 mg | 6,49 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Arisppa | tbl. 30x10 mg | 4,33 | 129,84 | RSRN06 | 5% |
| N05AX12 132 |  | aripiprazol | 15 mg | 6,18 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Arisppa | tbl. 30x15 mg | 6,18 | 185,39 | RSRN06 | 5% |
| N05AX12 133 |  | aripiprazol | 15 mg | 5,13 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Arisppa | tbl. 30x30 mg | 10,26 | 307,80 | RSRN06 | 5% |
| N05AX12 141 |  | aripiprazol | 15 mg | 4,26 | O | Mylan Pharmaceuticals Limited | Pharmathen | Aripiprazole Mylan Pharma | tbl. 28x10 mg | 2,84 | 79,61 | RSRN06 | 5% |
| N05AX12 142 |  | aripiprazol | 15 mg | 4,05 | O | Mylan Pharmaceuticals Limited | Pharmathen | Aripiprazole Mylan Pharma | tbl. 28x15 mg | 4,05 | 113,40 | RSRN06 | 5% |
| N05AX12 143 |  | aripiprazol | 15 mg | 4,15 | O | Mylan Pharmaceuticals Limited | Pharmathen | Aripiprazole Mylan Pharma | tbl. 28x30 mg | 8,31 | 232,60 | RSRN06 | 5% |
| N05AX12 161 |  | aripiprazol | 15 mg | 5,26 | O | Medochemie Ltd. | Medochemie Ltd. | Zykalor | tbl. 30x10 mg | 3,50 | 105,14 | RSRN06 | 5% |
| N05AX12 162 |  | aripiprazol | 15 mg | 4,99 | O | Medochemie Ltd. | Medochemie Ltd. | Zykalor | tbl. 30x15 mg | 4,99 | 149,84 | RSRN06 | 5% |
| N05AX12 171 |  | aripiprazol | 15 mg | 5,26 | O | STADA d.o.o. | STADA Arzneimittel AG, Centrafarm Services BV, STADA Arzneimittel GmbH | Aripiprazol STADA | tbl. 28x10 mg | 3,51 | 98,28 | RSRN06 | 5% |
| N05AX12 172 |  | aripiprazol | 15 mg | 5,00 | O | STADA d.o.o. | STADA Arzneimittel AG, Centrafarm Services BV, STADA Arzneimittel GmbH | Aripiprazol STADA | tbl. 28x15 mg | 5,00 | 140,11 | RSRN06 | 5% |
| N05AX12 173 |  | aripiprazol | 15 mg | 5,13 | O | STADA d.o.o. | STADA Arzneimittel AG, Centrafarm Services BV, STADA Arzneimittel GmbH | Aripiprazol STADA | tbl. 28x30 mg | 10,26 | 287,28 | RSRN06 | 5% |
| N05AX12 181 |  | aripiprazol | 15 mg | 4,74 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Aripiprazole Accord | tbl. 28x10 mg | 3,16 | 88,45 | RSRN06 | 5% |
| N05AX12 183 |  | aripiprazol | 15 mg | 4,62 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Aripiprazole Accord | tbl. 28x30 mg | 9,23 | 258,55 | RSRN06 | 5% |
| N05AX13 001 | RL | paliperidon | 2,5 mg | 48,42 | P | Teva B.V. | Actavis Group PTC ehf. | Paliperidon Teva | susp. za inj. s prod. oslob. za i.m. primj. 1x50 mg | 968,37 | 968,37 | RSRN11 | 5% |
| N05AX13 002 | RL | paliperidon | 2,5 mg | 41,46 | P | Teva B.V. | Actavis Group PTC ehf. | Paliperidon Teva | susp. za inj. s prod. oslob. za i.m. primj. 1x75 mg | 1.243,80 | 1.243,80 | RSRN11 | 5% |
| N05AX13 003 | RL | paliperidon | 2,5 mg | 38,34 | P | Teva B.V. | Actavis Group PTC ehf. | Paliperidon Teva | susp. za inj. s prod. oslob. za i.m. primj. 1x100 mg | 1.533,43 | 1.533,43 | RSRN11 | 5% |
| N05AX13 004 | RL | paliperidon | 2,5 mg | 35,25 | P | Teva B.V. | Actavis Group PTC ehf. | Paliperidon Teva | susp. za inj. s prod. oslob. za i.m. primj. 1x150 mg | 2.114,81 | 2.114,81 | RSRN11 | 5% |
| N05AX13 061 | RL | paliperidon | 2,5 mg | 69,17 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Xeplion | susp. za inj. s prod. oslob. za i.m. primj. 1x50 mg | 1.383,39 | 1.383,39 | RSRN11 | 5% |
| N05AX13 062 | RL | paliperidon | 2,5 mg | 59,23 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Xeplion | susp. za inj. s prod. oslob. za i.m. primj. 1x75 mg | 1.776,86 | 1.776,86 | RSRN11 | 5% |
| N05AX13 063 | RL | paliperidon | 2,5 mg | 54,77 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Xeplion | susp. za inj. s prod. oslob. za i.m. primj. 1x100 mg | 2.190,62 | 2.190,62 | RSRN11 | 5% |
| N05AX13 064 | RL | paliperidon | 2,5 mg | 50,35 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Xeplion | susp. za inj. s prod. oslob. za i.m. primj. 1x150 mg | 3.021,15 | 3.021,15 | RSRN11 | 5% |
| N05AX13 065 | RL | paliperidon | 2,5 mg | 57,66 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Trevicta | susp. za inj. s prod. oslob. za i.m. primj. 1x175 mg | 4.036,05 | 4.036,05 | RSRN20 | 5% |
| N05AX13 066 | RL | paliperidon | 2,5 mg | 49,48 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Trevicta | susp. za inj. s prod. oslob. za i.m. primj. 1x263 mg | 5.205,42 | 5.205,42 | RSRN20 | 5% |
| N05AX13 067 | RL | paliperidon | 2,5 mg | 45,94 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Trevicta | susp. za inj. s prod. oslob. za i.m. primj. 1x350 mg | 6.432,08 | 6.432,08 | RSRN20 | 5% |
| N05AX13 068 | RL | paliperidon | 2,5 mg | 42,41 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Trevicta | susp. za inj. s prod. oslob. za i.m. primj. 1x525 mg | 8.905,73 | 8.905,73 | RSRN20 | 5% |
| N05BA01 011 | PR | diazepam | 10 mg | 1,86 | P | Belupo d.d. | Belupo | Normabel | amp. 10x10 mg/2 ml | 1,86 | 18,64 |  | 5% |
| N05BA01 031 | PR | diazepam | 10 mg | 1,86 | P | KRKA-FARMA d.o.o. | Krka d.d. | Apaurin | amp. 10x10 mg/2 ml | 1,86 | 18,64 |  | 5% |
| N05BA01 043 | PR | diazepam | 10 mg | 1,86 | P | Alkaloid d.o.o. | Alkaloid | Diazepam Alkaloid | otop. za inj. 10x10 mg/2 ml | 1,86 | 18,64 |  | 5% |
| N05BA01 111 |  | diazepam | 10 mg | 1,15 | O | Belupo d.d. | Belupo | Normabel | tbl. 30x2 mg | 0,23 | 6,87 | R | 5% |
| N05BA01 113 |  | diazepam | 10 mg | 0,56 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Diazepam JGL | tbl. 30x5 mg | 0,28 | 8,40 | R | 5% |
| N05BA01 114 |  | diazepam | 10 mg | 0,48 | O | Belupo d.d. | Belupo | Normabel | tbl. 30x10 mg | 0,48 | 14,31 | R | 5% |
| N05BA01 117 |  | diazepam | 10 mg | 1,15 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Diazepam JGL | tbl. 30x2 mg | 0,23 | 6,87 | R | 5% |
| N05BA01 118 |  | diazepam | 10 mg | 0,48 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Diazepam JGL | tbl. 30x10 mg | 0,48 | 14,31 | R | 5% |
| N05BA01 141 |  | diazepam | 10 mg | 1,15 | O | Alkaloid d.o.o. | Alkaloid | Diazepam Alkaloid | tbl. obl. 30x2 mg | 0,23 | 6,87 | R | 5% |
| N05BA01 142 |  | diazepam | 10 mg | 0,56 | O | Alkaloid d.o.o. | Alkaloid | Diazepam Alkaloid | tbl. obl. 30x5 mg | 0,28 | 8,40 | R | 5% |
| N05BA01 551 |  | diazepam | 10 mg |  | R |  |  |  |  |  |  | R | 5% |
| N05BA06 071 | DS | lorazepam | 20 mg | 36,30 | P | Medochemie Ltd. | Medochemie Ltd. | Temelor | otop. za inj., amp. 10 x 4 mg/ml | 7,26 | 72,60 |  | 5% |
| N05BA09 151 | DS | klobazam | 20 mg |  | O |  |  |  |  |  |  |  | 5% |
| N05BA12 111 |  | alprazolam | 1 mg | 0,76 | O | Belupo d.d. | Belupo | Misar | tbl. 30x0,25 mg | 0,19 | 5,70 | R | 5% |
| N05BA12 132 |  | alprazolam | 1 mg | 0,76 | O | KRKA-FARMA d.o.o. | Krka d.d. | Helex | tbl. 30x0,25 mg | 0,19 | 5,70 | R | 5% |
| N05BA12 141 |  | alprazolam | 1 mg | 0,68 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Maprazax | tbl. 30x0,25 mg | 0,17 | 5,13 | R | 5% |
| N05BA12 142 |  | alprazolam | 1 mg | 0,62 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Maprazax | tbl. 90x0,25 mg | 0,15 | 13,85 | R | 5% |
| N05BC01 151 |  | meprobamat | 1,2 g |  | O |  |  |  |  |  |  | RRN91 | 5% |
| N05CD01 131 | DS | flurazepam | 30 mg | 3,31 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fluzepam | caps. 10x15 mg | 1,66 | 16,55 |  | 5% |
| N05CD01 132 | DS | flurazepam | 30 mg | 1,94 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fluzepam | caps. 10x30 mg | 1,94 | 19,43 |  | 5% |
| N05CD02 111 |  | nitrazepam | 5 mg | 0,88 | O | Belupo d.d. | Belupo | Cerson | tbl. 10x5 mg | 0,88 | 8,82 | R | 5% |
| N05CD02 112 |  | nitrazepam | 5 mg | 0,88 | O | Belupo d.d. | Belupo | Cerson | tbl. 30x5 mg | 0,88 | 26,46 | R | 5% |
| N05CD02 161 |  | nitrazepam | 5 mg | 0,62 | O | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Nitrazepam Accord | tbl. 30x5 mg | 0,62 | 18,52 | R | 5% |
| N05CD08 062 | DS | midazolam | 15 mg | 12,24 | P | Cheplapharm Arzneimittel GmbH | Cenexi | Dormicum | amp. 5x15 mg/3 ml | 12,24 | 61,20 |  | 5% |
| N05CD08 075 | DS | midazolam | 15 mg | 9,01 | P | AS Kalceks | AS Kalceks | Midazolam Kalceks 5 mg/ml | otop. za inj./inf., 5 mg/ml, amp., 10x3 ml | 9,01 | 90,06 |  | 5% |
| N05CD08 076 | DS | midazolam | 15 mg | 8,56 | P | hameln pharma gmbh | hameln rds a.s., Siegfried Hameln GmbH | Midazolam hameln | otop. za inj./inf., 5 mg/ml, amp., 10x3 ml | 8,56 | 85,56 |  | 5% |
| N05CD08 077 | DS | midazolam | 15 mg | 8,27 | P | hameln pharma gmbh | hameln rds a.s., Siegfried Hameln GmbH | Midazolam hameln | otop. za inj./inf., 5 mg/ml, amp., 10x10 ml | 27,55 | 275,50 |  | 5% |
| N05CD08 081 | DS | midazolam | 15 mg | 7,58 | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Midazolam B. Braun 1 mg/ml | otop. za inj./inf., 1 mg/ml, polietil. Ecoflac plus boca, 10x100 ml | 50,56 | 505,60 |  | 5% |
| N05CD08 082 | DS | midazolam | 15 mg | 9,48 | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Midazolam B. Braun 5 mg/ml | otop. za inj./inf., 5 mg/ml, amp., 10x3 ml | 9,48 | 94,80 |  | 5% |
| N05CD08 083 | DS | midazolam | 15 mg | 8,70 | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Midazolam B. Braun 5 mg/ml | otop. za inj./inf., 5 mg/ml, polietil. amp., 10x10 ml | 29,00 | 290,00 |  | 5% |
| N05CD08 161 | DS | midazolam | 15 mg | 1,90 | O | Cheplapharm Arzneimittel GmbH | Recipharm Leganés S.L.U. | Dormicum | tbl. 10x15 mg | 1,90 | 18,98 |  | 5% |
| N05CF02 141 |  | zolpidem | 10 mg | 0,54 | O | Alkaloid d.o.o. | Alkaloid | Lunata | tbl. film obl. 20x5 mg | 0,27 | 5,40 | R | 5% |
| N05CF02 142 |  | zolpidem | 10 mg | 0,50 | O | Alkaloid d.o.o. | Alkaloid | Lunata | tbl. film obl. 20x10 mg | 0,50 | 10,00 | R | 5% |
| N05CF02 143 |  | zolpidem | 10 mg | 0,54 | O | Alkaloid d.o.o. | ALKALOID-INT d.o.o. | Lunata | tbl. film obl. 30x5 mg | 0,27 | 8,10 | R | 5% |
| N05CF02 144 |  | zolpidem | 10 mg | 0,50 | O | Alkaloid d.o.o. | ALKALOID-INT d.o.o. | Lunata | tbl. film obl. 30x10 mg | 0,50 | 15,00 | R | 5% |
| N05CM18 001 | DS | deksmedetomidinNN506 | 1 mg | 587,89 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Deksmedetomidin Pliva | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 117,58 | 2.939,47 |  | 5% |
| N05CM18 002 | DS | deksmedetomidinNN506 | 1 mg | 50,40 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V. | Deksmedetomidin Pliva | konc. za otop. za inf., boč. 4x4 ml (100 mcg/ml) | 201,62 | 806,47 |  | 5% |
| N05CM18 003 | DS | deksmedetomidinNN506 | 1 mg | 50,40 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V. | Deksmedetomidin Pliva | konc. za otop. za inf., boč. 4x10 ml (100 mcg/ml) | 504,05 | 2.016,19 |  | 5% |
| N05CM18 041 | DS | deksmedetomidinNN506 | 1 mg | 558,50 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Dexmedetomidine Accord | konc. za otop. za inf., boč. 5x10 ml (100 mcg/ml) | 558,50 | 2.792,50 |  | 5% |
| N05CM18 061 | DS | deksmedetomidin NN506 | 1 mg | 587,89 | P | Mylan Ireland Limited | Mylan Teoranta | Deksmedetomidin Mylan | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 117,58 | 2.939,47 |  | 5% |
| N05CM18 062 | DS | deksmedetomidinNN506 | 1 mg | 587,89 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Dexmedetomidine Accord | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 117,58 | 2.939,47 |  | 5% |
| N05CM18 071 | DS | deksmedetomidin NN506 | 1 mg | 587,89 | P | Orion Corporation | Orion Corporation | Dexdor | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 117,58 | 2.939,47 |  | 5% |
| N05CM18 082 | DS | deksmedetomidinNN506 | 1 mg | 530,58 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., amp. 25x2 ml (100 mcg/ml) | 106,12 | 2.652,88 |  | 5% |
| N05CM18 083 | DS | deksmedetomidinNN506 | 1 mg | 530,58 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., boč. 4x4 ml (100 mcg/ml) | 212,23 | 848,92 |  | 5% |
| N05CM18 084 | DS | deksmedetomidinNN506 | 1 mg | 530,58 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., boč. 4x10 ml (100 mcg/ml) | 530,58 | 2.122,30 |  | 5% |
| N05CM18 085 | DS | deksmedetomidin NN506 | 1 mg | 478,84 | P | AS Kalceks | AS Kalceks | Deksmedetomidin Kalceks | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 95,77 | 2.394,22 |  | 5% |
| N05CM18 086 | DS | deksmedetomidinNN506 | 1 mg | 454,90 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., amp. 5x4 ml (100 mcg/ml) | 181,96 | 909,80 |  | 5% |
| N05CM18 087 | DS | deksmedetomidinNN506 | 1 mg | 454,90 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., amp. 5x10 ml (100 mcg/ml) | 454,90 | 2.274,51 |  | 5% |
| N05CM18 088 | DS | deksmedetomidinNN506 | 1 mg | 454,90 | P | Fresenius Kabi d.o.o. | Fresenius Kabi Austria GmbH | Deksmedetomidin Kabi | konc. za otop. za inf., boč. 10x2 ml (100 mcg/ml) | 90,98 | 909,80 |  | 5% |
| N06AA04 051 | DS | klomipramin | 0,1 g |  | P |  |  |  |  |  |  |  | 5% |
| N06AA04 151 |  | klomipramin | 0,1 g |  | O |  |  |  |  |  |  | R | 5% |
| N06AA09 051 | DS | amitriptilin | 75 mg |  | P |  |  |  |  |  |  |  | 5% |
| N06AA21 103 |  | maprotilin | 0,1 g | 2,92 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Ladiomil | tbl. 30x25 mg | 0,73 | 21,90 | R | 5% |
| N06AB05 111 |  | paroksetin | 20 mg | 0,64 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Seroxat | tbl. 30x20 mg | 0,64 | 19,29 | R | 5% |
| N06AB05 115 |  | paroksetin | 20 mg | 0,64 | O | PharmaS d.o.o. | PharmaS d.o.o. | Paroksetin PharmaS | tbl. film obl. 30x20 mg | 0,64 | 19,25 | R | 5% |
| N06AB05 116 |  | paroksetin | 20 mg | 1,28 | O | PharmaS d.o.o. | PharmaS d.o.o. | Paroksetin PharmaS | tbl. film obl. 30x30 mg | 1,92 | 57,61 | R | 5% |
| N06AB06 102 |  | sertralin | 50 mg | 0,64 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Luxeta | tbl. 30x50 mg | 0,64 | 19,29 | R | 5% |
| N06AB06 121 |  | sertralin | 50 mg | 0,64 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Sonalia | tbl. film obl. 28x50 mg | 0,64 | 18,00 | R | 5% |
| N06AB06 131 |  | sertralin | 50 mg | 0,64 | O | KRKA-FARMA d.o.o. | Krka d.d. | Asentra | tbl. 28x50 mg | 0,64 | 18,00 | R | 5% |
| N06AB06 132 |  | sertralin | 50 mg | 0,84 | O | KRKA-FARMA d.o.o. | Krka d.d. | Asentra | tbl. 28x100 mg | 1,67 | 46,87 | R | 5% |
| N06AB06 171 |  | sertralin | 50 mg | 0,64 | O | Upjohn EESV | Haupt Pharma | Zoloft | tbl. 28x50 mg | 0,64 | 18,00 | R | 5% |
| N06AB10 101 |  | escitalopram | 10 mg | 0,64 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Serpentil | tbl. film obl. 28x10 mg | 0,64 | 18,00 | R | 5% |
| N06AB10 111 |  | escitalopram | 10 mg | 0,64 | O | Belupo d.d. | Belupo | Citram | tbl. film obl. 28x10 mg | 0,64 | 18,00 | R | 5% |
| N06AB10 128 |  | escitalopram | 10 mg | 0,64 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Escital | tbl. rasp. za usta 28x10 mg | 0,64 | 18,00 | R | 5% |
| N06AB10 132 |  | escitalopram | 10 mg | 0,64 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea | tbl. film obl. 28x10 mg | 0,64 | 18,00 | R | 5% |
| N06AB10 133 |  | escitalopram | 10 mg | 0,84 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea | tbl. film obl. 28x20 mg | 1,67 | 46,87 | R | 5% |
| N06AB10 136 |  | escitalopram | 10 mg | 0,97 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea Q-Tab | tbl. rasp. za usta 28x5 mg | 0,49 | 13,61 | R | 5% |
| N06AB10 137 |  | escitalopram | 10 mg | 0,61 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea Q-Tab | tbl. rasp. za usta 28x10 mg | 0,61 | 17,15 | R | 5% |
| N06AB10 138 |  | escitalopram | 10 mg | 0,84 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea Q-Tab | tbl. rasp. za usta. 28x20 mg | 1,67 | 46,87 | R | 5% |
| N06AX11 111 |  | mirtazapin | 30 mg | 1,36 | O | Belupo d.d. | Belupo | Calixta | tbl. film obl. 30x15 mg | 0,68 | 20,41 | R | 5% |
| N06AX11 112 |  | mirtazapin | 30 mg | 1,51 | O | Belupo d.d. | Belupo | Calixta | tbl. film obl. 30x30 mg | 1,51 | 45,20 | R | 5% |
| N06AX11 113 |  | mirtazapin | 30 mg | 1,36 | O | Belupo d.d. | Belupo | Calixta | tbl. film obl. 30x45 mg | 2,04 | 61,23 | R | 5% |
| N06AX11 131 |  | mirtazapin | 30 mg | 1,51 | O | KRKA-FARMA d.o.o. | Krka d.d. | Mirzaten | tbl. film obl. 30x30 mg | 1,51 | 45,20 | R | 5% |
| N06AX11 132 |  | mirtazapin | 30 mg | 1,36 | O | KRKA-FARMA d.o.o. | Krka d.d. | Mirzaten | tbl. film obl. 30x45 mg | 2,04 | 61,23 | R | 5% |
| N06AX11 137 |  | mirtazapin | 30 mg | 1,36 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Mirzaten Q-Tab | tbl. rasp. za usta 30x15 mg | 0,68 | 20,41 | R | 5% |
| N06AX11 138 |  | mirtazapin | 30 mg | 1,51 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Mirzaten Q-Tab | tbl. rasp. za usta 30x30 mg | 1,51 | 45,20 | R | 5% |
| N06AX11 139 |  | mirtazapin | 30 mg | 1,36 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Mirzaten Q-Tab | tbl. rasp. za usta 30x45 mg | 2,04 | 61,23 | R | 5% |
| N06AX16 101 |  | venlafaksin | 0,1 g | 1,51 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Velafax | tbl. 28x37,5 mg | 0,57 | 15,88 | R | 5% |
| N06AX16 102 |  | venlafaksin | 0,1 g | 1,51 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Velafax | tbl. 28x75 mg | 1,13 | 31,75 | R | 5% |
| N06AX16 103 |  | venlafaksin | 0,1 g | 1,78 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Velafax XL | caps. s prod. oslob. 28x75 mg | 1,33 | 37,29 | R | 5% |
| N06AX16 104 |  | venlafaksin | 0,1 g | 1,36 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Velafax XL | caps. s prod. oslob. 28x150 mg | 2,04 | 57,15 | R | 5% |
| N06AX16 126 |  | venlafaksin | 0,1 g | 1,36 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Faxiven | caps. s prod. oslob., tvrda 28x150 mg | 2,04 | 57,15 | R | 5% |
| N06AX16 131 |  | venlafaksin | 0,1 g | 1,97 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Alventa | caps. s prilag. oslob. 28x37,5 mg | 0,74 | 20,66 | R | 5% |
| N06AX16 132 |  | venlafaksin | 0,1 g | 1,78 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Alventa | caps. s prilag. oslob. 28x75 mg | 1,33 | 37,29 | R | 5% |
| N06AX16 133 |  | venlafaksin | 0,1 g | 1,78 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Alventa | caps. s prilag. oslob. 60x75 mg | 1,33 | 79,91 | R | 5% |
| N06AX16 134 |  | venlafaksin | 0,1 g | 1,36 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Alventa | caps. s prilag. oslob. 28x150 mg | 2,04 | 57,15 | R | 5% |
| N06AX21 101 |  | duloksetin | 60 mg | 4,11 | O | PLIVA HRVATSKA d.o.o. | Balkanpharma – Dupnitsa AD | Duloksetin Pliva | caps. žel. otp. tvrda 28x30 mg | 2,06 | 57,56 | RRN18 | 5% |
| N06AX21 102 |  | duloksetin | 60 mg | 3,73 | O | PLIVA HRVATSKA d.o.o. | Balkanpharma – Dupnitsa AD | Duloksetin Pliva | caps. žel. otp. tvrda 28x60 mg | 3,73 | 104,53 | RRN18 | 5% |
| N06AX21 111 |  | duloksetin | 60 mg | 3,16 | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Dolyxan | caps. žel. otp. tvrda 28x30 mg | 1,58 | 44,29 | RRN18 | 5% |
| N06AX21 112 |  | duloksetin | 60 mg | 3,16 | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Dolyxan | caps. žel. otp. tvrda 28x60 mg | 3,16 | 88,57 | RRN18 | 5% |
| N06AX21 131 |  | duloksetin | 60 mg | 4,11 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Dulsevia | caps. žel. otp. tvrda 28x30 mg | 2,06 | 57,56 | RRN18 | 5% |
| N06AX21 132 |  | duloksetin | 60 mg | 3,73 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Dulsevia | caps. žel. otp. tvrda 28x60 mg | 3,73 | 104,53 | RRN18 | 5% |
| N06AX21 133 |  | duloksetin | 60 mg | 2,13 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Dulsevia | caps. žel. otp. tvrda 28x90 mg | 3,19 | 89,32 | RRN18 | 5% |
| N06AX21 161 |  | duloksetin | 60 mg | 4,11 | O | Mylan Pharmaceuticals Limited | McDermott Laboratories Ltd t/a Gerard Laboratories t/a Mylan, Mylan Hungary Kft | Duloxetine Mylan | caps. žel. otp. tvrda 28x30 mg | 2,06 | 57,56 | RRN18 | 5% |
| N06AX21 162 |  | duloksetin | 60 mg | 3,73 | O | Mylan Pharmaceuticals Limited | McDermott Laboratories Ltd t/a Gerard Laboratories t/a Mylan, Mylan Hungary Kft | Duloxetine Mylan | caps. žel. otp. tvrda 28x60 mg | 3,73 | 104,53 | RRN18 | 5% |
| N06AX21 171 |  | duloksetin | 60 mg | 4,11 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Cymbalta | caps. žel. otp. tvrda 28x30 mg | 2,06 | 57,56 | RRN18 | 5% |
| N06AX21 172 |  | duloksetin | 60 mg | 3,73 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Cymbalta | caps. žel. otp. tvrda 28x60 mg | 3,73 | 104,53 | RRN18 | 5% |
| N06AX21 181 |  | duloksetin | 60 mg | 3,70 | O | STADA d.o.o. | Stada Arzneimittel AG; Centrafarm Services BV, Stada Arzneimittel GmbH, Clonmel Healthcare Ltd., Stada Nordic ApS | Duloksetin STADA | caps. žel. otp. tvrda 28x30 mg | 1,85 | 51,80 | RRN18 | 5% |
| N06AX21 182 |  | duloksetin | 60 mg | 3,70 | O | STADA d.o.o. | Stada Arzneimittel AG; Centrafarm Services BV, Stada Arzneimittel GmbH, Clonmel Healthcare Ltd., Stada Nordic ApS | Duloksetin STADA | caps. žel. otp. tvrda 28x60 mg | 3,70 | 103,59 | RRN18 | 5% |
| N06AX21 183 |  | duloksetin | 60 mg | 3,33 | O | Medochemie Ltd. | Medochemie Ltd. | Onelar | caps. žel. otp. tvrda 28x30 mg | 1,67 | 46,62 | RRN18 | 5% |
| N06AX21 184 |  | duloksetin | 60 mg | 3,33 | O | Medochemie Ltd. | Medochemie Ltd. | Onelar | caps. žel. otp. tvrda 28x60 mg | 3,33 | 93,23 | RRN18 | 5% |
| N06AX26 161 |  | vortioksetin | 10 mg | 6,36 | O | H. Lundbeck A/S | H. Lundbeck A/S | Brintellix | tbl. film obl. 28x5 mg | 3,18 | 89,04 | R | 5% |
| N06AX26 162 |  | vortioksetin | 10 mg | 6,22 | O | H. Lundbeck A/S | H. Lundbeck A/S | Brintellix | tbl. film obl. 28x10 mg | 6,22 | 174,07 | R | 5% |
| N06AX27 761 | DS | esketaminNN507 | 8 mg | 492,35 | N | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Spravato | sprej za nos, 1x28 mg | 1.723,22 | 1.723,22 |  | 5% |
| N06BA07 151 | DS | modafinilNN991 | 0,3 g |  | O |  |  |  |  |  |  |  | 5% |
| N06BA07 161 |  | modafinil | 0,3 g | 33,13 | O | Makpharm d.o.o. | Chanelle Medical | Vigifinil | tbl. 30x100 mg | 11,04 | 331,30 | RSRN21 | 5% |
| N06BC01 051 | DS | kofein citratNN992 | 0,4 g |  | P |  |  |  |  |  |  |  | 5% |
| N06BX13 161 | KL | idebenonNN300 | 900 mg | 1.053,49 | O | Santhera Pharmaceuticals GmbH | Santhera Pharmaceuticals (Deutschland) GmbH | Raxone | tbl. film obl. 180x150 mg | 175,58 | 31.604,83 |  | 5% |
| N07AA01 051 | DS | neostigminij | 2 mg |  | P |  |  |  |  |  |  |  | 5% |
| N07AA01 151 |  | neostigminij | 60 mg |  | O |  |  |  |  |  |  | R | 5% |
| N07AA02 052 | DS | piridostigminij | 10 mg |  | P |  |  |  |  |  |  |  | 5% |
| N07AA02 152 |  | piridostigminij | 0,18 g |  | O |  |  |  | 100x10 mg |  |  | R | 5% |
| N07AA02 161 |  | piridostigminij | 0,18 g | 4,56 | O | Mylan Hrvatska d.o.o. | ICN Polfa Rzeszow S.A, Labiana Pharmaceuticals | Mestinon | tbl. obl. 150x60 mg | 1,52 | 228,00 | R | 5% |
| N07BB01 151 |  | disulfiram | 0,2 g |  | O |  |  |  |  |  |  | R | 5% |
| N07BC01 121 |  | buprenorfin | 8 mg | 12,67 | SL | Sandoz d.o.o. | Sandoz-Salutas | Buprenorfin Sandoz | tbl. sublingv. 7x2 mg | 3,17 | 22,17 | RSRN13 | 5% |
| N07BC01 122 |  | buprenorfin | 8 mg | 11,12 | SL | Sandoz d.o.o. | Sandoz-Salutas | Buprenorfin Sandoz | tbl. subllingv. 7x8 mg | 11,12 | 77,86 | RSRN13 | 5% |
| N07BC01 142 |  | buprenorfin | 8 mg | 12,67 | SL | Alkaloid d.o.o. | Alkaloid | Buprenorfin Alkaloid | tbl. sublingv. 7x2 mg | 3,17 | 22,17 | RSRN13 | 5% |
| N07BC01 143 |  | buprenorfin | 8 mg | 11,12 | SL | Alkaloid d.o.o. | Alkaloid | Buprenorfin Alkaloid | tbl. subllingv. 7x8 mg | 11,12 | 77,86 | RSRN13 | 5% |
| N07BC01 162 |  | buprenorfin | 8 mg | 12,67 | SL | INDIVIOR EUROPE LIMITED | RB | Subutex | tbl. sublingv. 7x2 mg | 3,17 | 22,17 | RSRN13 | 5% |
| N07BC01 163 |  | buprenorfin | 8 mg | 11,12 | SL | INDIVIOR EUROPE LIMITED | RB | Subutex | tbl. sublingv. 7x8 mg | 11,12 | 77,86 | RSRN13 | 5% |
| N07BC02 101 | XX | metadon | 25 mg | 4,85 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Heptanon | tbl. 20x5 mg | 0,97 | 19,40 | RSRN14 | 5% |
| N07BC02 202 | XX | metadon | 25 mg | 4,08 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Heptanon | otop. 1x10 ml (10 mg/ml) | 16,30 | 16,30 | RSRN14 | 5% |
| N07BC02 241 | XX | metadon | 25 mg | 4,08 | O | Alkaloid d.o.o. | Alkaloid | Metadon Alkaloid | otop. oral. 10 ml (10 mg/1ml) | 16,30 | 16,30 | RSRN14 | 5% |
| N07BC02 242 | DS | metadon | 25 mg | 2,16 | O | Alkaloid d.o.o. | Alkaloid | Metadon Alkaloid | otop. oral. 100 ml (10 mg/1ml) | 86,41 | 86,41 |  | 5% |
| N07BC02 262 | XX | metadon | 25 mg | 4,08 | O | L.Molteni & C. dei F.lli Alitti Soc. di Esercizio S.p.A. | L. Molteni | Metadon Molteni | otop. oral., boč. plast. 1x20 ml (5 mg/ml) | 16,30 | 16,30 | RSRN14 | 5% |
| N07BC02 263 | DS | metadon | 25 mg | 1,94 | O | L.Molteni & C. dei F.lli Alitti Soc. di Esercizio S.p.A. | L. Molteni | Metadon Molteni | otop. oral., boca plast. 1x1000 ml (5 mg/ml) | 388,85 | 388,85 |  | 5% |
| N07BC51 141 |  | buprenorfin + nalokson | 8 mg | 11,69 | SL | Alkaloid-INT d.o.o. | Ethypharm | Bulnexo | tbl. sublingv. 7x(2 mg + 0,5 mg) | 2,92 | 20,46 | RSRN13 | 5% |
| N07BC51 142 |  | buprenorfin + nalokson | 8 mg | 12,29 | SL | Alkaloid-INT d.o.o. | Ethypharm | Bulnexo | tbl. sublingv. 7x(8 mg + 2 mg) | 12,29 | 86,01 | RSRN13 | 5% |
| N07BC51 161 |  | buprenorfin + nalokson | 8 mg | 11,69 | SL | INDIVIOR EUROPE LIMITED | RB | Suboxone | tbl. sublingv. 7x(2 mg + 0,5mg) | 2,92 | 20,46 | RSRN13 | 5% |
| N07BC51 162 |  | buprenorfin + nalokson | 8 mg | 14,22 | SL | INDIVIOR EUROPE LIMITED | RB | Suboxone | tbl. sublingv. 7x(8 mg + 2mg) | 14,22 | 99,52 | RSRN13 | 5% |
| N07BC51 171 |  | buprenorfin + nalokson | 8 mg | 11,69 | SL | G.L. Pharma GmbH | G.L. Pharma GmbH | Bupensanduo | tbl. sublingv. 7x(2 mg + 0,5mg) | 2,92 | 20,46 | RSRN13 | 5% |
| N07BC51 172 |  | buprenorfin + nalokson | 8 mg | 11,32 | SL | G.L. Pharma GmbH | G.L. Pharma GmbH | Bupensanduo | tbl. sublingv. 7x(4 mg + 1 mg) | 5,66 | 39,63 | RSRN13 | 5% |
| N07BC51 173 |  | buprenorfin + nalokson | 8 mg | 9,96 | SL | G.L. Pharma GmbH | G.L. Pharma GmbH | Bupensanduo | tbl. sublingv. 7x(8 mg + 2 mg) | 9,96 | 69,74 | RSRN13 | 5% |
| N07XX02 171 | DS | riluzolNN994 | 100mg | 33,95 | O | Makpharm d.o.o. | Glenmark Pharmaceuticals Europe Ltd., Glenmark Pharmaceuticals s.r.o. | Alsemol | tbl. film obl. 56x50 mg | 16,97 | 950,51 | RSRN25 | 5% |
| N07XX02 181 | DS | riluzolNN994 | 100mg | 24,53 | O | ALPHA-MEDICAL d.o.o. | Glenmark Pharmaceuticals s.r.o. | Yulir | tbl. film obl. 56x50 mg | 12,27 | 686,92 | RSRN25 | 5% |
| N07XX04 361 | DS | natrijev oksibatNN700 | 7,5 g | 180,70 | O | UCB Pharma S.A. | UCB Pharma Ltd. | Xyrem | otop. oral. 180 ml (500 mg/ml) | 2.168,40 | 2.168,40 |  | 5% |
| N07XX08 161 | KL | tafamidisNN995 | 20 mg | 936,88 | O | Pfizer Europe MA EEIG | Millmount Healthcare Limited | Vyndaqel | caps. meka 30x61 mg | 2.857,47 | 85.724,10 |  | 5% |
| P01AB01 111 |  | metronidazol | 2 g | 9,09 | O | Belupo d.d. | Belupo | Medazol | tbl. 20x250 mg | 1,14 | 22,73 | R | 5% |
| P01AB01 112 |  | metronidazol | 2 g | 10,04 | O | Belupo d.d. | Belupo | Medazol | tbl. 10x400 mg | 2,01 | 20,07 | R | 5% |
| P01AB01 113 |  | metronidazol | 2 g | 9,95 | O | Belupo d.d. | Belupo | Medazol | tbl. 20x400 mg | 1,99 | 39,78 | R | 5% |
| P01BA01 151 |  | klorokin | 0,5 g |  | O |  |  |  |  |  |  | R | 5% |
| P01BA02 161 |  | hidroksiklorokin | 0,516 g | 3,83 | O | Makpharm d.o.o. | PharmaS d.o.o. | Hyplaxy | tbl. film obl. 30x200 mg | 1,48 | 44,50 | RSRV03 | 5% |
| P01BC01 151 |  | kinin-sulfat | 1,5 g |  | O |  |  |  |  |  |  | R | 5% |
| P01BD01 152 | DS | pirimetamin | 75 mg |  | O |  |  |  |  |  |  |  | 5% |
| P02BA01 151 | DS | prazikvantel | 3 g |  | O |  |  |  |  |  |  |  | 5% |
| P02CA01 151 |  | mebendazol | 0,2 g |  | O |  |  |  |  |  |  | R | 5% |
| P02CA03 151 |  | albendazol | 0,4 g |  | O |  |  |  |  |  |  | R | 5% |
| P03AC01 451 |  | piretrin |  |  | L |  |  |  |  |  |  | R | 5% |
| P03AX05 451 |  | krotamiton (krema) |  |  | L |  |  |  |  |  |  | R | 5% |
| P03AX05 752 |  | krotamiton (losion) |  |  | L |  |  |  |  |  |  | R | 5% |
| R02AA15 442 |  | povidon-jod |  |  | L | Alkaloid d.o.o. | Alkaloid | Betadine | grgljača 1%, 1x100 ml | 17,38 | 17,38 | R | 5% |
| R03AC02 701 |  | salbutamol | 10 mg | 5,95 | I | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Salbutamol Pliva | otop. 10 ml (5 mg/ml) | 29,73 | 29,73 | R | 5% |
| R03AC02 705 |  | salbutamol | 0,8 mg | 1,84 | I | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Ventolin | aerosol za inhal. 200x100 mcg | 0,23 | 46,12 | R | 5% |
| R03AC12 763 |  | salmeterol | 0,1 mg | 4,60 | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production | Serevent inhaler | stlač. inhalat, susp., 120x25 mcg | 1,15 | 138,00 | R | 5% |
| R03AC18 771 |  | indakaterol | 0,15 mg | 4,60 | I | Novartis Europharm Limited Irska | Novartis Pharma GmbH, Novartis Farmaceutica S.A. | Onbrez Breezhaler | prašak inhalata, caps. tvrde 30x150 mcg + 1 inhalator | 4,60 | 138,00 | R | 5% |
| R03AK06 321 |  | salmeterol + flutikazon |  |  | I | Sandoz d.o.o. | Sandoz – Aeropharm | AirFluSal Forspiro | praš. za inhal. 60x(50 + 250 mcg)/doza | 2,42 | 144,90 | RRR02 | 5% |
| R03AK06 322 |  | salmeterol + flutikazon |  |  | I | Sandoz d.o.o. | Sandoz – Aeropharm | AirFluSal Forspiro | praš. za inhal. 60x(50 + 500 mcg)/doza | 3,18 | 190,68 | RRR03 | 5% |
| R03AK06 361 |  | salmeterol + flutikazon |  |  | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Seretide 100 Diskus | praš. za inhal. 60x(50 + 100 mcg)/doza | 1,86 | 111,72 | RRR02 | 5% |
| R03AK06 362 |  | salmeterol + flutikazon |  |  | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Seretide 250 Diskus | praš. za inhal. 60x(50 + 250 mcg)/doza | 2,42 | 144,90 | RRR02 | 5% |
| R03AK06 363 |  | salmeterol + flutikazon |  |  | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Seretide 500 Diskus | praš. za inhal. 60x(50 + 500 mcg)/doza | 3,18 | 190,68 | RRR03 | 5% |
| R03AK06 371 |  | salmeterol + flutikazon |  |  | I | Salvus d.o.o. | Celon Pharma S.A. | Saldisk | praš. za inhal. 60x(50 + 100 mcg)/doza | 1,86 | 111,72 | RRR02 | 5% |
| R03AK06 372 |  | salmeterol + flutikazon |  |  | I | Salvus d.o.o. | Celon Pharma S.A. | Saldisk | praš. za inhal. 60x(50 + 250 mcg)/doza | 2,42 | 144,90 | RRR02 | 5% |
| R03AK06 373 |  | salmeterol + flutikazon |  |  | I | Salvus d.o.o. | Celon Pharma S.A. | Saldisk | praš. za inhal. 60x(50 + 500 mcg)/doza | 3,18 | 190,68 | RRR03 | 5% |
| R03AK06 781 |  | salmeterol + flutikazon |  |  | I | Cipla Europe NV | S & D Pharma CZ, Cipla (EU) Limited | Salmeterol/flutikazon Cipla | inhalat stlač. susp. 120x(25 mcg + 125 mcg) | 1,21 | 144,90 | RRR02 | 5% |
| R03AK06 782 |  | salmeterol + flutikazon |  |  | I | Cipla Europe NV | S & D Pharma CZ, Cipla (EU) Limited | Salmeterol/flutikazon Cipla | inhalat stlač. susp. 120x(25 mcg + 250 mcg) | 1,43 | 171,61 | RRR02 | 5% |
| R03AK06 791 |  | salmeterol + flutikazon |  |  | I | Mylan Hrvatska d.o.o. | 3M Health Care Limited, McDermott Laboratories Limited trading as Gerard Laboratories | Serzyl | inhalat stlač. susp. 120x(25 mcg + 125 mcg) | 1,11 | 132,61 | RRR02 | 5% |
| R03AK06 792 |  | salmeterol + flutikazon |  |  | I | Mylan Hrvatska d.o.o. | 3M Health Care Limited, McDermott Laboratories Limited trading as Gerard Laboratories | Serzyl | inhalat stlač. susp. 120x(25 mcg + 250 mcg) | 1,43 | 171,61 | RRR02 | 5% |
| R03AK07 301 |  | budesonid + formoterol |  |  | I | Teva Pharma B.V. | Norton (Waterford) Limited T/A Teva Pharmaceuticals Ireland, Teva Pharmaceuticals Europe B.V. | DuoResp Spiromax | praš. za inhal. 120x(160 + 4,5 mcg)/doza | 2,04 | 245,16 | RRR02 | 5% |
| R03AK07 302 |  | budesonid + formoterol |  |  | I | Teva Pharma B.V. | Norton (Waterford) Limited T/A Teva Pharmaceuticals Ireland, Teva Pharmaceuticals Europe B.V. | DuoResp Spiromax | praš. za inhal. 60x(320 + 9 mcg)/doza | 3,61 | 216,43 | R RR05 | 5% |
| R03AK07 321 |  | budesonid + formoterol |  |  | I | Sandoz d.o.o. | Lek Pharmaceuticals d.d.; Salutas Pharma GmbH | AirBuFo Forspiro | praš. za inhal. 120x(160 + 4,5 mcg) | 1,84 | 220,64 | RRR02 | 5% |
| R03AK07 322 |  | budesonid + formoterol |  |  | I | Sandoz d.o.o. | Lek Pharmaceuticals d.d., Salutas Pharma GmbH | AirBuFo Forspiro | praš. za inhal. 60x(320 + 9 mcg) | 3,43 | 205,61 | R RR05 | 5% |
| R03AK07 373 |  | budesonid + formoterol |  |  | I | AstraZeneca d.o.o. | AstraZeneca | Symbicort Turbuhaler | praš. za inhal. 60x(320 + 9 mcg) + nastavak za usta | 3,61 | 216,43 | R RR05 | 5% |
| R03AK07 375 |  | budesonid + formoterol |  |  | I | AstraZeneca d.o.o. | AstraZeneca | Symbicort Turbuhaler | praš. za inhal. 120x(160 + 4,5 mcg) + nastavak za usta | 2,04 | 245,16 | RRR02 | 5% |
| R03AK07 376 |  | budesonid + formoterol |  |  | I | AstraZeneca d.o.o. | AstraZeneca | Symbicort | inhal. stlač., susp., 120x(160 + 4,5 mcg) | 2,04 | 245,16 | RRR10 | 5% |
| R03AK08 362 |  | beklometazon + formoterol |  |  | I | Chiesi Pharmaceuticals GmbH | Chiesi | Foster | inhalat stlač. 180x(100 mcg + 6mcg) | 1,80 | 324,65 | RRR05 | 5% |
| R03AK08 363 |  | beklometazon + formoterol |  |  | I | Chiesi Pharmaceuticals GmbH | Chiesi Pharmaceuticals GmbH | Foster NEXThaler | praš. inh. 180x(100 mcg + 6 mcg) | 1,80 | 324,65 | RRR05 | 5% |
| R03AK10 362 |  | flutikazonfuorat + vilanterol |  |  | I | GlaxoSmithKline (Ireland) Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Relvar Ellipta | prašak inhalata 30x(184 + 22 mcg)/doza | 8,17 | 245,16 | Rpr06 | 5% |
| R03AK11 761 |  | flutikazon + formoterol |  |  | I | Mundipharma Gesellschaft m.b.H | Bard Pharmaceuticals Ltd., Mundipharma DC B.V. | Flutiform | inhalat stlač. susp. 120x(50 mcg + 5 mcg) | 1,39 | 166,20 | R | 5% |
| R03AL09 761 |  | beklometazon + formoterol + glikopironij |  |  | I | Chiesi Faramaceutici S.p.A. | Chiesi Farmaceutici S.p.A., Chiesi SAS | Trimbow | inhalat stlač., otop. 180x(87 mcg + 5 mcg + 9 mcg) | 2,34 | 421,14 | RRR12 | 5% |
| R03BA01 704 |  | beklometazon | 1,5 mg | 7,58 | I | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Qvar Autohaler | inhal. stlač. 1x10 ml, 200 doza (100 mcg/doza) | 0,51 | 101,00 | R | 5% |
| R03BA02 761 |  | budesonid | 0,8 mg | 4,06 | I | AstraZeneca d.o.o. | AstraZeneca | Pulmicort Respules | susp. za atomizator 0,5 mg/ml (20x2 ml) | 5,08 | 101,60 | Rpr07 | 5% |
| R03BA05 773 |  | flutikazon | 0,6 mg | 6,00 | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, GlaxoWellcome S.A. | Flixotide inhaler | stlač. inhalat, susp. 120x50 mcg | 0,50 | 60,00 | RRR07 | 5% |
| R03BA08 362 |  | ciklezonid | 160 mcg | 2,24 | I | Covis Pharma Europe B.V. | Takeda GmbH, AstraZeneca AB | Alvesco | aerosol za inhal. 120x160 mcg | 2,24 | 268,80 | R | 5% |
| R03BB01 761 |  | ipratropij-bromid | 0,12 mg | 0,87 | I | Boehringer Ingelheim Zagreb d.o.o. | Instituto De Angeli S.r.l. | Atrovent N | aerosol za inhal. 200x20 mcg | 0,15 | 29,00 | R | 5% |
| R03BB01 962 |  | ipratropij-bromid | 0,3 mg | 1,41 | I | Boehringer Ingelheim Zagreb d.o.o. | Instituto De Angeli S.r.l. | Atrovent | otop. za atomizator 1x20 ml (0,25 mg/1 ml) | 23,47 | 23,47 | R | 5% |
| R03BB04 701 |  | tiotropij bromid | 10 mcg | 5,10 | I | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Braltus | prašak inhal., caps. tvrda 30x10 mcg (isporučena doza) + Zonda uređaj za inhal. | 5,10 | 153,09 | Rpr03 | 5% |
| R03BB04 764 |  | tiotropij bromid | 10 mcg | 2,84 | I | Zentiva k.s. | Helm AG | Plubir | prašak za inhal. u caps. tvrdoj, 30x18 mcg + uređaj za inhal. | 5,10 | 153,09 | Rpr03 | 5% |
| R03BB04 771 |  | tiotropij bromid | 10 mcg | 2,84 | I | Viatris Limited | Ferrer Internacional S.A. | Acopair | prašak za inhal. u caps. tvrdoj, 30x18 mcg + uređaj za inhal. (NeumoHaler) | 5,10 | 153,09 | Rpr03 | 5% |
| R03CB03 083 | PR | orciprenalinNR301 | 60 mg |  | P |  |  |  |  |  |  |  | 5% |
| R03CB04 952 | DS | kisik |  |  | N |  |  |  |  |  |  |  | 5% |
| R03DA05 051 | PO | aminofilin | 0,6 g |  | P |  |  |  |  |  |  |  | 5% |
| R03DC03 101 |  | montelukast | 10 mg | 1,78 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Melarth | tbl. film obl. 28x10 mg | 1,78 | 49,94 | RRR08 | 5% |
| R03DC03 102 |  | montelukast | 10 mg | 3,43 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Melarth | tbl. za žvak. 28x5 mg | 1,71 | 48,00 | RRR08 | 5% |
| R03DC03 103 |  | montelukast | 10 mg | 7,86 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Melarth | vreć. alum. 28x4 mg (u 500 mg granula) | 3,14 | 88,01 | RSRR09 | 5% |
| R03DC03 112 |  | montelukast | 10 mg | 1,78 | O | Belupo d.d. | Belupo | Monlast | tbl. film obl. 28x10 mg | 1,78 | 49,94 | RRR08 | 5% |
| R03DC03 122 |  | montelukast | 10 mg | 1,78 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Montelux | tbl. film obl. 28x10 mg | 1,78 | 49,94 | RRR08 | 5% |
| R03DC03 131 |  | montelukast | 10 mg | 5,67 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Monkasta | tbl. za žvak. 28x4 mg | 2,27 | 63,47 | RRR08 | 5% |
| R03DC03 133 |  | montelukast | 10 mg | 3,43 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Monkasta | tbl. za žvak. 28x5 mg | 1,71 | 48,00 | RRR08 | 5% |
| R03DC03 135 |  | montelukast | 10 mg | 1,78 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Monkasta | tbl. film obl. 28x10 mg | 1,78 | 49,94 | RRR08 | 5% |
| R03DC03 183 |  | montelukast | 10 mg | 7,86 | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Singulair mini | vreć. alum. 28x4 mg (u 500 mg granula) | 3,14 | 88,01 | RSRR09 | 5% |
| R03DX05 061 | DS | omalizumabNR502 | 16 mg | 263,10 | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Xolair | otop. za inj., štrc. napunj. 1x150 mg/ml | 2.466,58 | 2.466,58 |  | 5% |
| R03DX08 061 | DS | reslizumabNR503 | 7.1 mg | 277,54 | P | Teva B.V. | Sicor Biotech UAB | Cinqaero | konc. za otop. za inf., boč. stakl. 1x2,5 ml (10 mg/ml) | 977,25 | 977,25 |  | 5% |
| R03DX08 062 | DS | reslizumabNR503 | 7.1 mg | 257,00 | P | Teva B.V. | Sicor Biotech UAB | Cinqaero | konc. za otop. za inf., boč. stakl. 1x10 ml (10 mg/ml) | 3.619,78 | 3.619,78 |  | 5% |
| R03DX09 071 | DS | mepolizumabNR504 | 3,6 mg | 276,45 | P | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Manufacturing S.P.A., Glaxo Operations UK Ltd | Nucala | praš. za otop. za supkut. inj., boč. stakl. 1x100 mg | 7.679,22 | 7.679,22 |  | 5% |
| R03DX09 072 | DS | mepolizumabNR505 | 3,6 mg | 266,85 | P | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Manufacturing S.P.A | Nucala | otop. za inj., brizg. napunj. 1x100 mg | 7.412,45 | 7.412,45 |  | 5% |
| R03DX10 061 | DS | benralizumabNR503 | 0.54 mg | 297,46 | P | AstraZeneca AB | MedImmune UK Ltd, MedImmune Pharma B.V. | Fasenra | otop. za inj., štrc. napunj. 1x30 mg | 16.525,63 | 16.525,63 |  | 5% |
| R03DX10 062 | DS | benralizumabNR503 | 0.54 mg | 297,46 | P | AstraZeneca AB | MedImmune Pharma B.V. | Fasenra | otop. za inj., brizg. napunj. 1x30 mg | 16.525,63 | 16.525,63 |  | 5% |
| R05CB13 961 |  | dornaze alfa (dezoksiribonukleaza)NR501 | 2,5 mg | 133,41 | I | Roche d.o.o. | Roche | Pulmozyme | amp. za inhal. 6x2,5 mg/2,5 ml | 133,41 | 800,45 | R | 5% |
| R05DA04 141 |  | kodein | 0,1 g | 7,52 | O | Alkaloid d.o.o. | Alkaloid | Kodeinfosfat Alkaloid | tbl. 10x30 mg | 2,26 | 22,56 | RSRR51 | 5% |
| R06AB03 271 |  | dimetinden | 4 mg | 3,71 | O | GlaxoSmithKline Dungarvan Ltd. | GlaxoSmithKline Consumer Healtcare GmbH & Co. | Fenistil 0,1% | kapi za oral. primj. 1x20 ml (1mg/ml) | 18,56 | 18,56 | R | 5% |
| R06AC03 003 | PO | kloropiramin | 20 mg | 9,44 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Synopen | amp. 10x20mg/2 ml | 9,44 | 94,36 |  | 5% |
| R06AD03 032 | PR | tietilperazin | 13 mg | 7,76 | P | KRKA-FARMA d.o.o. | Krka d.d. | Torecan | amp. 50x6,5 mg | 3,88 | 194,03 |  | 5% |
| R06AE07 132 |  | cetirizin | 10 mg | 0,68 | O | KRKA-FARMA d.o.o. | Krka d.d. | Letizen | tbl. 20x10 mg | 0,68 | 13,59 | R | 5% |
| R06AX13 102 |  | loratadin | 10 mg | 0,68 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Rinolan | tbl. 30x10 mg | 0,68 | 20,38 | R | 5% |
| R06AX13 111 |  | loratadin | 10 mg | 0,68 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Contral | tbl. 10x10 mg | 0,68 | 6,79 | R | 5% |
| R06AX13 112 |  | loratadin | 10 mg | 0,68 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Contral | tbl. 30x10 mg | 0,68 | 20,38 | R | 5% |
| R06AX13 116 |  | loratadin | 10 mg | 0,68 | O | Belupo d.d. | Belupo | Belodin | tbl. 30x10 mg | 0,68 | 20,38 | R | 5% |
| R06AX13 303 |  | loratadin | 10 mg | 1,39 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Rinolan | sirup 1x100 ml (5 mg/5 ml) | 13,85 | 13,85 | R | 5% |
| R06AX26 161 |  | feksofenadin | 0,12 g | 0,45 | O | Cipla Europe NV | S & D Pharma CZ,spol. s.r.o., Cipla (EU) Limited | Feksofenadinklorid Cipla | tbl. film obl. 30x180 mg | 0,68 | 20,38 | R | 5% |
| R06AX27 113 |  | desloratadin | 5 mg | 0,68 | O | Belupo d.d. | Belupo | Alerdin | tbl. rasp. za usta 30x5 mg | 0,68 | 20,38 | R | 5% |
| R06AX27 122 |  | desloratadin | 5 mg | 0,68 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Escontral direkt | tbl. rasp. za usta 30x5 mg | 0,68 | 20,38 | R | 5% |
| R06AX27 123 |  | desloratadin | 5 mg | 0,58 | O | Jadran – Galenski Laboratorij d.d. | Genepharm S.A., Jadran Galenski laboratorij d.d. | Escontral | tbl. film obl. 30x5 mg | 0,58 | 17,38 | R | 5% |
| R06AX27 131 |  | desloratadin | 5 mg | 0,68 | O | Krka d.d., Novo mesto | KRKA-FARMA d.o.o., Krka d.d. | Dasselta | tbl. film obl. 30x5 mg | 0,68 | 20,38 | R | 5% |
| R06AX27 132 |  | desloratadin | 5 mg | 0,68 | O | Krka d.d., Novo mesto | KRKA-FARMA d.o.o., Krka d.d. | Dasselta | tbl. film obl. 10x5 mg | 0,68 | 6,79 | R | 5% |
| R06AX27 165 |  | desloratadin | 5 mg | 0,61 | O | Teva B.V. | TEVA Pharmaceutical Works Private Limited Company | Desloratadin Teva | tbl. film obl. 10x5 mg | 0,61 | 6,11 | R | 5% |
| R06AX27 171 |  | desloratadin | 5 mg | 0,61 | O | Teva B.V. | TEVA Pharmaceutical Works Private Limited Company | Desloratadin Teva | tbl. film obl. 30x5 mg | 0,61 | 18,34 | R | 5% |
| R07AA02 051 | DS | surfaktant, prirodni (goveđi) |  |  | I |  |  |  |  |  |  |  | 5% |
| R07AA02 361 | DS | surfaktant, prirodni (svinjski) | 0,16 g | 3.898,79 | I | Chiesi Pharmaceuticals GmbH | Chiesi Farmaceutici S.p.A., Chiesi Pharmaceuticals GmbH | Curosurf | ukapna tekuć. za dušnik i pluća, susp., boč. stakl. 2x120 mg/1,5 ml | 2.924,10 | 5.848,19 |  | 5% |
| R07AA02 362 | DS | surfaktant, prirodni (svinjski) | 0,16 g | 3.980,40 | I | Chiesi Pharmaceuticals GmbH | Chiesi Farmaceutici S.p.A., Chiesi Pharmaceuticals GmbH | Curosurf | ukapna tekuć. za dušnik i pluća, susp., boč. stakl. 1x120 mg/1,5 ml | 2.985,30 | 2.985,30 |  | 5% |
| R07AX02 171 | KS | ivakaftorNR508 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Kalydeco | film. obl. tbl., 28x150 mg | 1.996,20 | 55.893,60 |  | 5% |
| R07AX30 171 | KS | lumakaftor + ivakaftorNR506 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Orkambi | granule 56x(100 mg + 125 mg) | 1.472,75 | 82.474,19 |  | 5% |
| R07AX30 172 | KS | lumakaftor + ivakaftorNR506 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Orkambi | granule 56x(150 mg + 188 mg) | 1.472,75 | 82.474,19 |  | 5% |
| R07AX30 173 | KS | lumakaftor + ivakaftorNR506 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Orkambi | film. obl. tbl., 112x(100 mg + 125 mg) | 824,32 | 92.323,47 |  | 5% |
| R07AX30 174 | KS | lumakaftor + ivakaftorNR506 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Orkambi | film. obl. tbl., 112x(200 mg + 125 mg) | 736,35 | 82.471,57 |  | 5% |
| R07AX32 171 | KS | ivakaftor + tezakaftor + eleksakaftorNR507 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Kaftrio | film. obl. tbl., 56 x (75 mg + 50 mg + 100 mg) | 1.377,60 | 77.145,41 |  | 5% |
| S01BA01 071 | DS | deksametazonNS101 |  |  | P | AbbVie Deutschland GmbH & Co. KG | Allergan Pharmaceuticals Ireland | Ozurdex | intravitrealni implantat u aplikatoru 1x700 mcg | 6.902,87 | 6.902,87 |  | 5% |
| S01EA05 772 |  | brimonidin |  |  | L | Allergan Pharm. Ireland | Allergan | Alphagan | kapi za oči 1x5 ml | 33,50 | 33,50 | RSRS03 | 5% |
| S01EA05 775 |  | brimonidin |  |  | L | Bausch + Lomb Ireland Limited | Pharma Stulln GmbH, UAB Santonika | Luxfen | kapi za oči, otop. 1x5 ml (2 mg/ml) | 33,50 | 33,50 | RSRS03 | 5% |
| S01EA05 777 |  | brimonidin |  |  | L | Jadran – Galenski Laboratorij d.d. | Jadran Galenski laboratorij d.d. | Bimanox | kapi za oči, otop. 1x5 ml (2 mg/ml) | 30,15 | 30,15 | RSRS03 | 5% |
| S01EB02 751 | DS | karbakol |  |  | L |  |  |  |  |  |  |  | 5% |
| S01EC01 051 | DS | acetazolamid | 0,75 g |  | P |  |  |  |  |  |  |  | 5% |
| S01EC03 721 |  | dorzolamid | 0,3 ml | 6,70 | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Dorzol | kapi za oči 1x5 ml (20 mg/ml) | 33,50 | 33,50 | RSRS03 | 5% |
| S01EC03 761 |  | dorzolamid | 0,3 ml | 2,01 | L | Santen Oy | Merck Sharp & Dohme B.V., Laboratories Merck Sharp & Dohme – Chibret | Trusopt | kapi za oči 1x5 ml (20 mg/ml) | 33,50 | 33,50 | RSRS03 | 5% |
| S01EC03 771 |  | dorzolamid | 0,3 ml | 2,01 | L | Bausch + Lomb Ireland Limited | S.C. Rompharm | Oftidor | kapi za oči 1x5 ml (20 mg/ml) | 33,50 | 33,50 | RSRS03 | 5% |
| S01EC03 781 |  | dorzolamid | 0,3 ml | 2,01 | L | Zentiva k.s. | Rafarm S.A. | Dorvis | kapi za oči 1x5 ml (20 mg/ml) | 33,50 | 33,50 | RSRS03 | 5% |
| S01EC04 763 |  | brinzolamid |  |  | L | Zentiva k.s. | Famar S.A., Balkanpharma-Razgrad AD | Bravis | kapi za oči 1x5 ml | 32,88 | 32,88 | RSRS03 | 5% |
| S01ED01 711 |  | timolol |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Timalen 0,25% | kapi za oči 1x5 ml (2,5 mg/ml) | 22,72 | 22,72 | R | 5% |
| S01ED01 712 |  | timolol |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Timalen 0,5% | kapi za oči 1x5 ml (5 mg/ml) | 26,49 | 26,49 | R | 5% |
| S01ED51 721 |  | timolol + dorzolamid |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Glaumax | kapi za oči 1x5 ml (5 mg + 20 mg/ml) | 36,20 | 36,20 | RSRS03 | 5% |
| S01ED51 725 |  | timolol + dorzolamid |  |  | L | Bausch + Lomb Ireland Limited | FAMAR S.A., PHARMATHEN S.A. | Oftidorix | kapi za oči, otop. 1x5 ml (5 mg + 20 mg/ml) | 36,20 | 36,20 | RSRS03 | 5% |
| S01ED51 771 |  | timolol + dorzolamid |  |  | L | Zentiva k.s. | Rafarm S.A. | Dorvis plus | kapi za oči, 1x5 ml (5 mg + 20 mg/ml) | 36,20 | 36,20 | RSRS03 | 5% |
| S01ED51 772 |  | latanoprost + timolol |  |  | L | Bausch + Lomb Ireland Limited | S.C. Rompharm | Timlatan | kapi za oči boč. 1x2,5 ml (50 mcg/ml + 5 mg/ml) | 36,24 | 36,24 | RSRS03 | 5% |
| S01ED51 782 |  | latanoprost + timolol |  |  | L | Zentiva k.s. | Rafarm S.A. | Lapovis plus | kapi za oči, boč. 1x2,5 ml (50 mcg/ml + 5 mg/ml) | 36,24 | 36,24 | RSRS03 | 5% |
| S01ED51 783 |  | latanoprost + timolol |  |  | L | Upjohn EESV | Pfizer | Xalacom | kapi za oči boč. 1x2,5 ml (50 mcg/ml + 5 mg/ml) | 36,24 | 36,24 | RSRS03 | 5% |
| S01EE01 721 |  | latanoprost |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Latanox | kapi za oči 1x2,5 ml (50 mcg/ml) | 40,27 | 40,27 | RSRS03 | 5% |
| S01EE01 722 |  | latanoprost |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Latanox | kapi za oči, boč. plast. 3x2,5 ml | 40,27 | 120,81 | RSRS03 | 5% |
| S01EE01 761 |  | latanoprost |  |  | L | Upjohn EESV | Pfizer | Xalatan | kapi za oči 1x2,5 ml (50 mcg/ml) | 40,27 | 40,27 | RSRS03 | 5% |
| S01EE01 771 |  | latanoprost |  |  | L | Bausch + Lomb Ireland Limited | S.C. Rompharm | Latapres | kapi za oči 1x2,5 ml (50 mcg/ml) | 40,27 | 40,27 | RSRS03 | 5% |
| S01EE01 772 |  | latanoprost |  |  | L | Zentiva k.s. | Bruschettini S.R.L. | Lapovis | kapi za oči 1x2,5 ml (50 mcg/ml) | 38,40 | 38,40 | RSRS03 | 5% |
| S01EE01 791 |  | latanoprost |  |  | L | UNIMED PHARMA spol s.r.o. | Unimed Pharma spol s.r.o. | Unilat | kapi za oči, boč. 1x2,5 ml (50 mcg/ml) | 34,56 | 34,56 | RSRS03 | 5% |
| S01FB01 751 | DS | fenilefrin |  |  | L |  |  |  |  |  |  |  | 5% |
| S01JA01 751 | DS | fluorescein |  |  | L |  |  |  |  |  |  |  | 5% |
| S01KA02 751 | DS | hipromeloza |  |  | L |  |  |  |  |  |  |  | 5% |
| S01LA04 061 | DS | ranibizumabNS101 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Lucentis | otop. za inj., boč. stak. 1x2,3 mg/0,23 ml (10 mg/ml) | 4.750,51 | 4.750,51 |  | 5% |
| S01LA04 062 | DS | ranibizumabNS101 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Lucentis | otop. za inj., štrc. napunj. 1x1,65 mg/0,165 ml (10 mg/ml) | 4.727,41 | 4.727,41 |  | 5% |
| S01LA04 063 | DS | ranibizumabNS101 |  |  | P | Midas Pharma GmbH | Midas Pharma GmbH | Ranivisio | otop. za inj., boč. stak. 1x2,3 mg/0,23 ml (10 mg/ml) | 3.800,41 | 3.800,41 |  | 5% |
| S01LA05 061 | DS | afliberceptNS101 |  |  | P | Bayer AG | Bayer AG | Eylea | otop. za inj., boč. stak. 1x40 mg/ml | 4.824,96 | 4.824,96 |  | 5% |
| S01LA05 062 | DS | afliberceptNS101 |  |  | P | Bayer AG | Bayer AG | Eylea | otop. za inj., štrc. napunj. 1x40 mg/ml | 4.824,96 | 4.824,96 |  | 5% |
| S01LA06 061 | DS | brolucizumabNS101 |  |  | P | Novartis Europharm Limited Irska | S.A. Alcon-Couvreur N.V. | Beovu | otop. za inj., štrc. napunj. 1x0,165 ml (120 mg/ml) | 4.642,71 | 4.642,71 |  | 5% |
| S01XA20 762 |  | hipromeloza |  |  | L | Alcon Farmaceutika d.o.o. | Alcon | Isopto Tears | kapi za oči 1x15 ml (5 mg/ml) | 13,60 | 13,60 | RRS02 | 5% |
| S01XA27 071 | KL | voretigen neparvovekNS104 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Luxturna | 1x boč. konc. (5x1012 vg/ml) + 2x boč. otap. | 2.556.246,80 | 2.556.246,80 |  | 5% |
| V01AA01 011 | DS | alergeni za specifičnu imunoterapijuNV101 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za specifičnu imunoterapiju | boč. 1x10 ml | 67,00 | 67,00 |  | 5% |
| V01AA01 012 | DS | alergeni za specifičnu imunoterapijuNV101 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za specifičnu imunoterapiju | boč. 1x10 ml | 67,00 | 67,00 |  | 5% |
| V01AA01 013 | DS | alergeni za specifičnu imunoterapijuNV101 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za specifičnu imunoterapiju | boč. 1x10 ml | 67,00 | 67,00 |  | 5% |
| V01AA01 014 | DS | alergeni za specifičnu imunoterapijuNV101 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za specifičnu imunoterapiju | boč. 1x10 ml | 94,05 | 94,05 |  | 5% |
| V03AB03 052 | DS | natrij-kalcij-edetatNV301 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB04 054 | PR | pralidoksim NV301 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB04 153 | DS | pralidoksim NV301 |  |  | O |  |  |  |  |  |  |  | 5% |
| V03AB14 051 | DS | protamin-sulfatNV301 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB15 055 | PR | nalokson |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB23 051 | PR | acetilcisteinNV302 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB25 061 | PR | flumazenilNV301 |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Flumazenil B. Braun 0,1 mg/ml | otopina za inj./inf., 0,1 mg/ml, amp. 5x5 ml | 41,22 | 206,12 |  | 5% |
| V03AB25 062 | PR | flumazenilNV301 |  |  | P | Cheplapharm Arzneimittel GmbH | Cheplapharm Arzneimittel GmbH | Anexate | amp. 5x0,5 mg/5 ml | 58,89 | 294,46 |  | 5% |
| V03AB35 001 | DS | sugamadeksNV303 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o. | Sugamadeks Teva | otop. za inj., boč. stakl. 10x200 mg/2 ml (100 mg/ml) | 382,29 | 3.822,90 |  | 5% |
| V03AB35 002 | DS | sugamadeksNV303 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o. | Sugamadeks Teva | otop. za inj., boč. stakl. 10x500 mg/5 ml (100 mg/ml) | 955,73 | 9.557,25 |  | 5% |
| V03AB35 041 | DS | sugamadeksNV303 |  |  | P | Pharmazac S.A. | Medichem S.A., Sant Joan Despí, Barcelona, Španjolska | Sugamadeks Pharmazac 100 mg/ml otopina za injekciju | otop. za inj., boč. stakl. 10x200 mg/2 ml (100 mg/ml) | 423,59 | 4.235,89 |  | 5% |
| V03AB35 042 | DS | sugamadeksNV303 |  |  | P | Pharmazac S.A. | Medichem S.A., Sant Joan Despí, Barcelona, Španjolska | Sugamadeks Pharmazac 100 mg/ml otopina za injekciju | otop. za inj., boč. stakl. 10x500 mg/5 ml (100 mg/ml) | 1.058,97 | 10.589,73 |  | 5% |
| V03AB35 081 | DS | sugamadeksNV303 |  |  | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Sugamadeks Sandoz | otop. za inj., boč. stakl. 10x200 mg/2 ml (100 mg/ml) | 402,41 | 4.024,10 |  | 5% |
| V03AB37 061 | DS | idarucizumab |  |  | P | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Praxbind | otop. za inj./inf., boč. stakl. 2x2,5 g/50 ml | 9.945,00 | 19.890,00 |  | 5% |
| V03AC01 051 | PR | deferoksaminNV301 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AC03 101 |  | deferasiroks |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Deferasiroks Pliva | tbl. za oral. susp. 30x500 mg | 87,83 | 2.634,94 | RSRV25 | 5% |
| V03AC03 161 |  | deferasiroks |  |  | O | Makpharm d.o.o. | Pharmascience International Limited | Zilart | tbl. za oral. susp. 28x125 mg | 24,35 | 681,73 | RSRV25 | 5% |
| V03AC03 163 |  | deferasiroks |  |  | O | Makpharm d.o.o. | Pharmascience International Limited | Zilart | tbl. za oral. susp. 28x500 mg | 87,83 | 2.459,28 | RSRV25 | 5% |
| V03AC03 171 |  | deferasiroks |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp.z.o.o., Pharmadox Healthcare Limited | Deferasiroks Accord | tbl. film obl. 30x90 mg | 23,13 | 693,90 | RSRV25 | 5% |
| V03AC03 172 |  | deferasiroks |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp.z.o.o., Pharmadox Healthcare Limited | Deferasiroks Accord | tbl. film obl. 30x180 mg | 43,89 | 1.316,65 | RSRV25 | 5% |
| V03AC03 173 |  | deferasiroks |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp.z.o.o., Pharmadox Healthcare Limited | Deferasiroks Accord | tbl. film obl. 30x360 mg | 87,82 | 2.634,60 | RSRV25 | 5% |
| V03AC03 174 |  | deferasiroks |  |  | O | PLIVA HRVATSKA d.o.o. | PharOS MT Ltd, Teva UK Ltd. | Deferasiroks Pliva | tbl. film obl. 30x180 mg | 43,89 | 1.316,65 | RSRV25 | 5% |
| V03AC03 175 |  | deferasiroks |  |  | O | PLIVA HRVATSKA d.o.o. | PharOS MT Ltd, Teva UK Ltd. | Deferasiroks Pliva | tbl. film obl. 30x360 mg | 87,83 | 2.634,94 | RSRV25 | 5% |
| V03AC03 181 |  | deferasiroks |  |  | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Deferasiroks Alpha-Medical | tbl. film obl. 30x180 mg | 43,89 | 1.316,65 | RSRV25 | 5% |
| V03AC03 182 |  | deferasiroks |  |  | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Deferasiroks Alpha-Medical | tbl. film obl. 30x360 mg | 87,83 | 2.634,94 | RSRV25 | 5% |
| V03AC03 191 |  | deferasiroks |  |  | O | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Zeoks | tbl. film obl. 30x360 mg | 87,83 | 2.634,94 | RSRV25 | 5% |
| V03AE01 361 |  | kalcijev polistirensulfonat | 45 g | 21,84 | O | Makpharm d.o.o. | Laboratorios Rubió, S.A. | Xaviox | praš. za oral. susp., vreć. 26x14,96 g | 7,26 | 188,76 | RSRV03 | 5% |
| V03AE02 101 |  | sevelamer-karbonat | 6,4 g | 24,64 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o.; Synthon Hispania S.L.; Merckle GmbH | Sevelamerkarbonat Pliva | tbl. film obl. 180x800 mg | 3,08 | 554,40 | RSRV01 | 5% |
| V03AE02 121 |  | sevelamer-karbonat | 6,4 g | 24,64 | O | Sandoz d.o.o. | Synthon Hispania S.L. | Sevelamer Sandoz | tbl. film obl. 180x800 mg | 3,08 | 554,40 | RSRV01 | 5% |
| V03AE02 162 |  | sevelamer-karbonat | 6,4 g | 24,64 | O | Genzyme Europe B.V. | Genzyme | Renvela | tbl. film obl. 180x800 mg | 3,08 | 554,40 | RSRV01 | 5% |
| V03AE02 163 |  | sevelamer-karbonat | 6,4 g | 31,97 | O | Genzyme Europe B.V. | Genzyme | Renvela | praš. za oral. susp. 60x2,4 g | 11,99 | 719,40 | RSRV01 | 5% |
| V03AE03 171 |  | lantan | 2,25 g | 24,64 | O | Mylan Ireland Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Mylan Hungary Kft | Lantan Mylan | tbl. za žvak. 90x500 mg | 5,48 | 492,80 | RSRV01 | 5% |
| V03AE03 172 |  | lantan | 2,25 g | 24,64 | O | Mylan Ireland Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Mylan Hungary Kft | Lantan Mylan | tbl. za žvak. 90x750 mg | 8,21 | 739,20 | RSRV01 | 5% |
| V03AE03 173 |  | lantan | 2,25 g | 24,64 | O | Mylan Ireland Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Mylan Hungary Kft | Lantan Mylan | tbl. za žvak. 90x1000 mg | 10,95 | 985,60 | RSRV01 | 5% |
| V03AE04 161 |  | kalcijev acetat + magnezijev subkarbonat teški |  |  | O | Fresenius Medical Care Hrvatska d.o.o. | Fresenius Medical Care Deutschland GmbH | OsvaRen | tbl. film obl. 180x(435 mg + 235 mg) | 0,87 | 156,60 | RSRV12 | 5% |
| V03AE05 171 |  | saharoželjezov (III) oksihidroksid | 1.5 g | 39,03 | O | Vifor Fresenius Medical Care Renal Pharma France | Vifor France | Velphoro | tbl. za žvak. 90x500 mg | 13,01 | 1.170,90 | RSRV24 | 5% |
| V03AF01 051 | DS | mesna (merkaptoetan-sulfonska kiselina) |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AF03 001 | DS | kalcij-folinat | 60 mg | 32,27 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kalcijev folinat Pliva | otop. za inj./inf., boč. stakl. 1x100 mg/10 ml (10 mg/ml) | 64,54 | 64,54 |  | 5% |
| V03AF03 003 | DS | kalcij-folinat | 60 mg | 25,86 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kalcijev folinat Pliva | otop. za inj./inf., boč. stakl. 1x500 mg/50 ml (10 mg/1 ml) | 206,87 | 206,87 |  | 5% |
| V03AF03 004 | DS | kalcij-folinat | 60 mg | 37,45 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kalcijev folinat Pliva | otop. za inj., boč. stakl. 1x50 mg/5 ml (10 mg/1 ml) | 31,21 | 31,21 |  | 5% |
| V03AF03 005 | DS | kalcij-folinat | 60 mg | 26,82 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kalcijev folinat Pliva | otop. za inj., boč. stakl. boč. 1x300 mg/30 ml (10 mg/1 ml) | 134,12 | 134,12 |  | 5% |
| V03AF03 064 | DS | kalcij-folinat | 60 mg | 33,94 | P | Sandoz d.o.o. | Ebewe Pharma | Kalcijev folinat Sandoz | otop. za inj. ili inf., boč. stakl. 1x20 ml (10 mg/ml) | 113,12 | 113,12 |  | 5% |
| V03AF03 065 | DS | kalcij-folinat | 60 mg | 26,72 | P | Sandoz d.o.o. | Ebewe Pharma | Kalcijev folinat Sandoz | otop. za inj. ili inf., boč. stakl. 1x35 ml (10 mg/ml) | 155,88 | 155,88 |  | 5% |
| V03AF03 067 | DS | kalcij-folinat | 60 mg | 38,72 | P | Sandoz d.o.o. | Ebewe Pharma | Kalcijev folinat Sandoz | otop. za inj. ili inf., boč. stakl. 1x10 ml (10 mg/ml) | 64,54 | 64,54 |  | 5% |
| V03AF03 069 | DS | kalcij-folinat | 60 mg | 50,51 | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Kalcijev folinat Sandoz | otop. za inj./inf., boč. stakl. 1x1000 mg/100 ml (10 mg/1 ml) | 841,91 | 841,91 |  | 5% |
| V03AF03 151 | DS | kalcij-folinat | 60 mg |  | O |  |  |  |  |  |  |  | 5% |
| V04CD01 051 | KL | metirapon |  |  | P |  |  |  |  |  |  |  | 5% |
| V04CF01 051 | PR | tuberkulinNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| V04CJ02 051 | KL | protirelin (TRH) |  |  | P |  |  |  |  |  |  |  | 5% |
| V04CL01 011 | DS | alergeni grupni za testiranje |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za PRICK test | boč. 1x2 ml | 53,45 | 53,45 |  | 5% |
| V04CL01 012 | DS | alergeni grupni za testiranje |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za intradermalno testiranje-ID test | boč. 1x10 ml | 53,45 | 53,45 |  | 5% |
| V04CL02 011 | DS | alergeni pojedinačni za testiranje |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za PRICK test | boč. 1x2 ml | 53,45 | 53,45 |  | 5% |
| V04CL02 012 | DS | alergeni pojedinačni za testiranje |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za intradermalno testiranje-ID test | boč. 1x10 ml | 53,45 | 53,45 |  | 5% |
| V06DC01 024 | PR | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza 20% HZTM otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (200 mg/ml) | 10,11 | 101,10 |  | 5% |
| V06DC01 051 | PR | glukoza (amp. 37 %) |  |  | P |  |  |  |  |  |  |  | 5% |
| V06DC01 052 | PR | glukoza (amp. 50 %) |  |  | P |  |  |  |  |  |  |  | 5% |
| V07AB01 911 | PR | voda redestilirana |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Aqua pro injectione HZTM | otap. za parent. upor., boca stakl. 20x100 ml | 5,62 | 112,40 |  | 5% |
| V07AB01 912 | PR | voda redestilirana |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Aqua pro injectione HZTM | otap. za parent. upor., boca stakl. 10x500 ml | 6,48 | 64,80 |  | 5% |
| V07AB01 941 | PR | voda redestilirana |  |  | P | Alkaloid d.o.o. | Alkaloid | Voda za injekcije Alkaloid | otap. za parent. upor., amp. stakl. 50x5 ml | 1,02 | 51,00 |  | 5% |
| V07AB01 962 | PR | voda redestilirana |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Voda za injekcije Viaflo | otop. za parent. prim., vreć. plast. 20x500 ml | 6,81 | 136,27 |  | 5% |
| V07AB01 963 | PR | voda redestilirana |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Voda za injekcije B.Braun | otap. za parent. prim., polietil. Ecoflac plus boca, 20x100 ml | 5,62 | 112,40 |  | 5% |
| V07AB01 964 | PR | voda redestilirana |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Voda za injekcije B. Braun | otap. za parent. prim., polietil. Ecoflac plus boca, 10x500 ml | 6,50 | 64,97 |  | 5% |
| V07AB01 965 | PR | voda redestilirana |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Voda za injekcije Fresenius Kabi | otap. za parent. upor., amp. polietil. 20x5 ml | 1,27 | 25,30 |  | 5% |
| V07AB01 966 | PR | voda redestilirana |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Voda za injekcije Fresenius Kabi | otap. za parent. upor., amp. polietil. 20x10 ml | 1,25 | 25,07 |  | 5% |
| V07AB02 971 | DS | irigacijske otopine |  |  | L | B. Braun Adria d.o.o. | B.Braun | Izotonična otopina NaCl 0,9% B.Braun | ecotainer 1x1.000 ml | 12,71 | 12,71 |  | 5% |
| V07AB02 972 | DS | irigacijske otopine |  |  | L | B. Braun Adria d.o.o. | B.Braun | Izotonična otopina NaCl 0,9% B.Braun | ecobag 1x3.000 ml | 36,32 | 36,32 |  | 5% |
| V07AB02 973 | DS | irigacijske otopine |  |  | L | Agmar d.o.o. | Baxter S.A. | Natrijev klorid 0,9 % | otop. za ispir., vreć. Clear-Flex 4x3.000 ml | 32,69 | 130,75 |  | 5% |
| V07AB02 974 | DS | irigacijske otopine |  |  | L | Fresenius Kabi d.o.o. | Fresenius Kabi France S.A.S. | NaCl 0,9% Fresenius 1000 ml | boca plast. Plastipur 6x1000 ml | 11,44 | 68,63 |  | 5% |
| V07AB02 975 | DS | irigacijske otopine |  |  | L | Fresenius Kabi d.o.o. | Fresenius Kabi AG | NaCl 0,9% Fresenius 3000 ml | vreć. plast. 4x3000 ml | 29,42 | 117,68 |  | 5% |
| V07AZ01 421 | DS | gel za ultrazvuk |  |  | L | CERACARTA S.p.a. | CERACARTA | Eko gel | boca plast. 1x250 ml | 8,00 | 8,00 |  | 5% |
| V07AZ01 422 | DS | gel za EKG, EEG, EMG i defibrilator |  |  | L | CERACARTA S.p.a. | CERACARTA | Zero gel | boca plast. 1x260 g, gel | 8,00 | 8,00 |  | 5% |
| V07AZ01 423 | DS | gel za ultrazvuk |  |  | L | CERACARTA S.p.a. | CERACARTA | Eko gel | ecotainer 1x5.000 ml | 85,00 | 85,00 |  | 5% |
| V07AZ01 424 | DS | gel za ultrazvuk |  |  | L | CERACARTA S.p.a. | CERACARTA | Eko gel | boč. plast. 1x300 ml | 9,00 | 9,00 |  | 5% |
| V08AA11 051 | DS | meglumin-amidotrizoat-65%NV801 |  |  | P |  |  |  |  |  |  |  | 5% |
| V08AA12 076 | DS | natrijev amidotrizoat + meglumin amidotrizoat |  |  | P | Bayer d.o.o. | Berlimed S.A. | Gastrografin 0,1 g/ml + 0,66 g/ml oralna/rektalna otopina | oralna/rektalna otopina, boč. stakl. 1x100 ml (10 g natrijevog amidotrizoata + 66 g meglumin amidotrizoata) | 61,23 | 61,23 |  | 5% |
| V08AB02 089 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 300 | boč. polipropil. 10x50 ml (300 mg I/ml) | 95,93 | 959,32 |  | 5% |
| V08AB02 090 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 300 | boč. polipropil. 10x100 ml (300 mg I/ml) | 210,79 | 2.107,89 |  | 5% |
| V08AB02 092 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 350 | boč. polipropil. 10x50 ml (350 mg I/ml) | 121,40 | 1.213,99 |  | 5% |
| V08AB02 093 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 350 | boč. polipropil. 10x100 ml (350 mg I/ml) | 213,09 | 2.130,91 |  | 5% |
| V08AB02 094 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 350 | boč. polipropil. 10x200 ml (350 mg I/ml) | 377,28 | 3.772,80 |  | 5% |
| V08AB02 095 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 350 | boč. polipropil. 6x500 ml (350 mg I/ml) | 965,43 | 5.792,58 |  | 5% |
| V08AB03 052 | DS | joksaglikanska kiselinaNV803 |  |  | P |  |  |  |  |  |  |  | 5% |
| V08AB04 063 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 300 | boč. 1x30 ml | 74,49 | 74,49 |  | 5% |
| V08AB04 064 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 300 | boč. 1x50 ml (300 mg I/ml) | 111,04 | 111,04 |  | 5% |
| V08AB04 065 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 300 | boč. 1x100 ml (300 mg I/ml) | 228,67 | 228,67 |  | 5% |
| V08AB04 066 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 370 | boč. 1x30 ml (370 mg/ml) | 74,16 | 74,16 |  | 5% |
| V08AB04 067 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 370 | boč. 1x50 ml (370 mg/ml) | 126,63 | 126,63 |  | 5% |
| V08AB04 068 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 370 | boč. 1x100 ml (370 mg/ml) | 246,79 | 246,79 |  | 5% |
| V08AB04 069 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 370 | boč. 1x200 ml (370 mg/ml) | 469,90 | 469,90 |  | 5% |
| V08AB05 073 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 300 | amp. 10x50 ml | 127,32 | 1.273,18 |  | 5% |
| V08AB05 074 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 300 | amp. 10x100 ml | 250,08 | 2.500,81 |  | 5% |
| V08AB05 076 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 370 | amp. 10x50 ml | 142,78 | 1.427,84 |  | 5% |
| V08AB05 077 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 370 | amp. 10x100 ml | 284,82 | 2.848,21 |  | 5% |
| V08AB05 078 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 370 | amp. 10x200 ml | 551,03 | 5.510,34 |  | 5% |
| V08AB05 079 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 370 | boca 8x500 ml | 1.391,12 | 11.128,99 |  | 5% |
| V08AB07 061 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf., boč. stakl. 10x50 ml (300 mg/ml) | 97,17 | 971,69 |  | 5% |
| V08AB07 062 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x100 ml (300 mg/ml) | 190,16 | 1.901,60 |  | 5% |
| V08AB07 063 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x100 ml (320 mg/ml) | 236,10 | 2.360,97 |  | 5% |
| V08AB07 064 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf., boč. stakl. 10x50 ml (350 mg/ml) | 112,06 | 1.120,58 |  | 5% |
| V08AB07 065 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x100 ml (350 mg/ml) | 216,49 | 2.164,85 |  | 5% |
| V08AB07 066 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x200 ml (350 mg/ml) | 346,58 | 3.465,80 |  | 5% |
| V08AB07 067 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 5x500 ml (350 mg/ml) | 1.046,72 | 5.233,60 |  | 5% |
| V08AB07 069 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf., boč. stakl. 25x50 ml (350 mg/ml) | 112,06 | 2.801,50 |  | 5% |
| V08AB07 070 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x500 ml (350 mg/ml) | 1.046,72 | 10.467,20 |  | 5% |
| V08AB07 071 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x500 ml (320 mg/ml) | 1.062,00 | 10.620,00 |  | 5% |
| V08AB09 082 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 270 | boč. plast. 10x100 ml (270 mgI/ml) | 232,57 | 2.325,69 |  | 5% |
| V08AB09 083 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 320 | boč. plast. 10x50 ml (320 mgI/ml) | 141,38 | 1.413,75 |  | 5% |
| V08AB09 084 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 320 | boč. plast. 10x100 ml (320 mgI/ml) | 282,71 | 2.827,14 |  | 5% |
| V08AB09 085 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 320 | boč. 10x200 ml (320 mgI/ml) | 532,10 | 5.321,00 |  | 5% |
| V08AB09 087 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 320 | boč. plast. 6x500 ml (320 mgI/ml) | 1.262,21 | 7.573,27 |  | 5% |
| V08AB10 061 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 300 | otop. za inj., stakl. boca 1x50 ml (300 mg I/ml) | 104,32 | 104,32 |  | 5% |
| V08AB10 062 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 300 | otop. za inj., boca stakl. 1x100 ml (300 mg I/ml) | 205,80 | 205,80 |  | 5% |
| V08AB10 063 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 300 | otop. za inj., stakl. boca 1x200 ml (300 mg I/ml) | 374,76 | 374,76 |  | 5% |
| V08AB10 064 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 300 | otop. za inj., stakl. boca 1x500 ml (300 mg I/ml) | 955,32 | 955,32 |  | 5% |
| V08AB10 065 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 350 | otop. za inj., stakl. boca 1x50 ml (350 mg I/ml) | 121,50 | 121,50 |  | 5% |
| V08AB10 066 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 350 | otop. za inj., boca stakl. 1x100 ml (350 mg I/ml) | 238,50 | 238,50 |  | 5% |
| V08AB10 067 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 350 | otop. za inj., stakl. boca 1x200 ml (350 mg I/ml) | 419,76 | 419,76 |  | 5% |
| V08AB10 068 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 350 | otop. za inj., stakl. boca 1x500 ml (350 mg I/ml) | 1.078,02 | 1.078,02 |  | 5% |
| V08AB10 069 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 400 | otop. za inj., stakl. boca 1x50 ml (400 mg I/ml) | 149,00 | 149,00 |  | 5% |
| V08AB10 070 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 400 | otop. za inj., stakl. boca 1x100 ml (400 mg I/ml) | 282,00 | 282,00 |  | 5% |
| V08AB10 071 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 400 | otop. za inj., stakl. boca 1x200 ml (400 mg I/ml) | 560,00 | 560,00 |  | 5% |
| V08AB10 072 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 400 | otop. za inj., stakl. boca 1x500 ml (400 mg I/ml) | 1.390,00 | 1.390,00 |  | 5% |
| V08AB11 062 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 300 | boč. 1x50 ml (300 mgI/ml) | 106,88 | 106,88 |  | 5% |
| V08AB11 063 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 300 | boč. 1x100 ml (300 mgI/ml) | 216,46 | 216,46 |  | 5% |
| V08AB11 064 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 350 | boč. 1x50 ml (350 mgI/ml) | 115,42 | 115,42 |  | 5% |
| V08AB11 065 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 350 | boč. 1x100 ml (350 mgI/ml) | 226,57 | 226,57 |  | 5% |
| V08AB11 066 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 300 | otop. za inj., boč. 1x200 ml (300 mgI/ml) | 416,40 | 416,40 |  | 5% |
| V08AB11 067 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 350 | otop. za inj., boč. 1x200 ml (350 mgI/ml) | 466,40 | 466,40 |  | 5% |
| V08AC01 053 | DS | jodoksaminska kiselina meglumin-jodoksamat |  |  | P |  |  |  |  |  |  |  | 5% |
| V08AD02 055 | DS | smjesa etilnih estera jodiranih masnih kiselina (lipiodol-ultrafluid) |  |  | P |  |  |  |  |  |  |  | 5% |
| V08BA01 251 | DS | barij-sulfat |  |  | O |  |  |  |  |  |  |  | 5% |
| V08CA02 061 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč.stakl. 1x15 ml (279,32 mg/ml) | 249,74 | 249,74 |  | 5% |
| V08CA02 062 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč.stakl. 1x20 ml (279,32 mg/ml) | 311,96 | 311,96 |  | 5% |
| V08CA02 063 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., štrc. napunj. 1x10 ml (279,32 mg/ml) | 161,49 | 161,49 |  | 5% |
| V08CA02 064 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., štrc. napunj. 1x15 ml (279,32 mg/ml) | 240,92 | 240,92 |  | 5% |
| V08CA02 065 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., štrc. napunj. 1x20 ml (279,32 mg/ml) | 311,96 | 311,96 |  | 5% |
| V08CA02 066 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč. stakl. 1x10 ml (279,32 mg/ml) | 161,49 | 161,49 |  | 5% |
| V08CA02 067 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč. stakl. 1x60 ml (279,32 mg/ml) | 622,36 | 622,36 |  | 5% |
| V08CA02 068 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč. stakl. 1x100 ml (279,32 mg/ml) | 1.037,27 | 1.037,27 |  | 5% |
| V08CA02 071 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x10 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 113,04 | 1.130,40 |  | 5% |
| V08CA02 072 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x15 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 174,82 | 1.748,18 |  | 5% |
| V08CA02 073 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x20 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 218,37 | 2.183,72 |  | 5% |
| V08CA02 074 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x50 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 545,93 | 5.459,30 |  | 5% |
| V08CA02 075 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x100 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 1.091,86 | 10.918,60 |  | 5% |
| V08CA02 076 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., štrc. napunj. 10x10 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 113,04 | 1.130,40 |  | 5% |
| V08CA02 077 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., štrc. napunj. 10x15 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 168,64 | 1.686,44 |  | 5% |
| V08CA02 078 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., štrc. napunj. 10x20 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 218,37 | 2.183,72 |  | 5% |
| V08CA02 081 | DS | gadoteratna kiselina |  |  | P | Bayer d.o.o. | Sanochemia Pharmazeutika GmbH | Dotagraf | otop. za inj., boč. 1x10 ml (0,5 mmol/ml) | 101,74 | 101,74 |  | 5% |
| V08CA02 082 | DS | gadoteratna kiselina |  |  | P | Bayer d.o.o. | Sanochemia Pharmazeutika GmbH | Dotagraf | otop. za inj., boč.1x15 ml (0,5 mmol/ml) | 157,34 | 157,34 |  | 5% |
| V08CA02 083 | DS | gadoteratna kiselina |  |  | P | Bayer d.o.o. | Sanochemia Pharmazeutika GmbH | Dotagraf | otop. za inj., boč. 1x20 ml (0,5 mmol/ml) | 196,53 | 196,53 |  | 5% |
| V08CA04 061 | DS | gadoteridol |  |  | P | Bracco Imaging s.p.a. | Bipso GmbH, Bracco Imaging s.p.a. | ProHance | otop. za inj., boč. stakl. 1x20 ml (0,5 mmol/ml) | 295,00 | 295,00 |  | 5% |
| V08CA08 061 | DS | gadobenična kiselina |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | MultiHance | otop. za inj., boč. stakl. 1x10 ml (0,5 mmol/ml) | 245,18 | 245,18 |  | 5% |
| V08CA08 062 | DS | gadobenična kiselina |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | MultiHance | otop. za inj., boč. stakl. 1x15 ml (0,5 mmol/ml) | 333,34 | 333,34 |  | 5% |
| V08CA08 063 | DS | gadobenična kiselina |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | MultiHance | otop. za inj., boč. stakl. 1x20 ml (0,5 mmol/ml) | 401,74 | 401,74 |  | 5% |
| V08CA09 071 | DS | gadobutrol |  |  | P | Bayer d.o.o. | Bayer AG | Gadovist | otop. za inj. u napunj. štrc./ulošku 5x7,5 ml (604,72 mg/1 mmol/ml) | 368,84 | 1.844,18 |  | 5% |
| V08CA09 073 | DS | gadobutrol |  |  | P | Bayer d.o.o. | Bayer AG | Gadovist | otop. za inj., boč. 1x15 ml (604,72 mg/1 mmol/ml) | 722,00 | 722,00 |  | 5% |
| V08CA10 074 | DS | gadoksetična kiselinaNV805 |  |  | P | Bayer d.o.o. | Bayer AG | Primovist | otop. za inj., štrc. napunj. 1x10 ml (0,25 mmol/ml) | 1.265,41 | 1.265,41 |  | 5% |
| V09AB03 061 | DS | ioflupanNV806 |  |  | P | GE Healthcare B.V. | GE Healthcare B.V. | DaTSCAN | otop. za inj., boč. stakl. 1x10 ml s 2,5 ml otop. (74 MBq/ml) | 6.128,54 | 6.128,54 |  | 5% |
| V09AB03 062 | DS | ioflupanNV806 |  |  | P | GE Healthcare B.V. | GE Healthcare B.V. | DaTSCAN | otop. za inj., boč. stakl. 1x10 ml s 5 ml otop. (74 MBq/ml) | 6.399,94 | 6.399,94 |  | 5% |
| V09IX04 051 | DS | fludeoksiglukoza (18F) |  |  | P |  |  |  |  |  |  |  | 5% |
| V10XX03 061 | KL | radij-223 dikloridNV808 |  |  | P | Bayer AG | Bayer AS | Xofigo | otop. za inj., boč. stakl. 1x6 ml (1000 kBq/ml) | 33.973,87 | 33.973,87 |  | 5% |

Osnovna lista lijekova s cijenama u kunama – 2. dio

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena u kn za DDD (bez PDV-a) | Način primjene | Nositelj  odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena u kn za jed, obl. (bez PDV-a) | Cijena u kn za orig. pak. (bez PDV-a) | R/RS | Stopa PDV-a |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. |
| V06CA01 362 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Anamix Infant | prašak 1x400 g | 249,34 | 249,34 | RSRV02 | 5% |
| V06CA01 363 |  | dijetetski preparat |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Start | prašak 4x400 g | 258,55 | 1.034,18 | RSRV02 | 5% |
| V06CA01 371 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Cooler 10 | napitak, 30 vreć.x87 ml/kutija | 43,72 | 1.311,71 | RSfRV17 | 5% |
| V06CA01 372 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Cooler 15 | napitak, 30 vreć.x130 ml/kutija | 65,59 | 1.967,57 | RSfRV17 | 5% |
| V06CA01 373 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Cooler 20 | napitak, 30 vreć.x174 ml/kutija | 87,45 | 2.623,43 | RSfRV17 | 5% |
| V06CA01 383 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Express | prah, 30x25 g | 58,95 | 1.768,50 | RSfRV17 | 5% |
| V06CA01 384 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Express | prah, 30x34 g | 78,60 | 2.358,00 | RSfRV17 | 5% |
| V06CA01 391 |  | dijetetski preparatNV601 |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Lophlex LQ 20 | tetrapak 30x125 ml | 92,05 | 2.761,50 | RSfRV17 | 5% |
| V06CA01 392 |  | dijetetski preparatNV601 |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Lophlex | prah, vreć. 30x27,8 g | 82,85 | 2.485,35 | RSfRV17 | 5% |
| V06CA01 394 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Nutri 2 | prašak 1x500 g | 751,73 | 751,73 | RSRV21 | 5% |
| V06CA01 395 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Nutri 3 | prašak 1x500 g | 877,01 | 877,01 | RSRV22 | 5% |
| V06CA01 396 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Anamix First Spoon | prašak 30x12,5 g | 23,79 | 713,76 | RSRV18 | 5% |
| V06CA01 397 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Anamix Junior | prašak 30x36 g | 47,58 | 1.427,52 | RSRV19 | 5% |
| V06CA01 398 |  | dijetetski preparat |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Gel | prašak 30x24 g | 45,20 | 1.356,00 | RSRV28 | 5% |
| V06DX01 381 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | Neocate LCP | limenka 1x400 g | 207,65 | 207,65 | RSVP02 | 5% |
| V06DX01 383 |  | dijetetski preparatNV611 |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | Zamjena za mlijeko PKU Loprofin | tetrepak 1x200 ml | 7,10 | 7,10 | RSfRV17 | 5% |
| V06DX01 389 |  | dijetetski preparatNV611 |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | Zamjena za rižu Loprofin | kutija 1x500 g | 54,00 | 54,00 | RSfRV17 | 5% |
| V06DX01 391 |  | dijetetski preparat |  |  | O | Medis Adria d.o.o. | UP Medi-Europa SA | Novalac Aminova | limenka 1x400 g | 205,55 | 205,55 | RSVP02 | 5% |
| V06DX01 392 |  | dijetetski preparat |  |  | O | Abbott Laboratories d.o.o. | Abbott | Similac Elecare | limenka 1x400 g | 200,07 | 200,07 | RSVP02 | 5% |
| V06DX01 466 |  | dijetetski preparat |  |  | O | Oktal Pharma d.o.o. | Nestle Suisse S.A. | Alfamino | limenka 1x400 g | 210,60 | 210,60 | RSVP02 | 5% |
| V06DX03 345 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Two Cal | boca 1x200 ml | 8,81 | 8,81 | RSVO06a | 5% |
| V06DX03 350 | DS | namirnice za enteralnu primjenuNV605 |  |  | O | Abbott Laboratories d.o.o. | Abbott | Oxepa | boca 1x500 ml | 75,00 | 75,00 |  | 5% |
| V06DX03 357 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Nutrison | vreć. plast./kolapsibilna boca 1x1000 ml | 31,88 | 31,88 | RSVO01b | 5% |
| V06DX03 360 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle | Modulen IBD | kutija 1x400 g/1800 ml | 107,69 | 107,69 | RSVS10a | 5% |
| V06DX03 361 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Glucerna | limenka 1x250 ml | 8,51 | 8,51 | RSVS13b | 5% |
| V06DX03 362 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Glucerna SR | tetrapak 1x230 ml | 9,15 | 9,15 | RSVS12a | 5% |
| V06DX03 372 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Diben | vreć. plast. 1x500 ml | 17,70 | 17,70 | RSVS13b | 5% |
| V06DX03 380 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle | Peptamen Junior | kutija 1x400 g/1800 ml | 64,17 | 64,17 | RSVP12 | 5% |
| V06DX03 384 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Nutrini Drink Multi Fibre | boca. plast. 1x200 ml | 8,24 | 8,24 | RSVP11 | 5% |
| V06DX03 387 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Plus Fiber | boca 1x200 ml | 8,15 | 8,15 | RSVO04a | 5% |
| V06DX03 389 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Jevity | spremnik plast. 1x1.000 ml | 24,50 | 24,50 | RSVO02b | 5% |
| V06DX03 390 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Osmolite | spremnik plast. 1x1.000 ml | 24,50 | 24,50 | RSVO01b | 5% |
| V06DX03 391 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Pulmocare RTH | boca 1x250 ml | 8,92 | 8,92 | RSVS11a | 5% |
| V06DX03 394 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Fresubin HP Energy | vreć. plast. 1x500 ml | 18,00 | 18,00 | RSVO03b | 5% |
| V06DX03 395 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Supportan | vreć. plast. 1x500 ml | 29,98 | 29,98 | RSVS01b | 5% |
| V06DX03 396 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Pediasure | tetrapak/boca 1x200 ml | 6,57 | 6,57 | RSVP10 | 5% |
| V06DX03 399 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Survimed OPD | vreć. plast. 1x500 ml | 26,98 | 26,98 | RSVS09b | 5% |
| V06DX03 400 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutrison Energy Multi Fibre | vreć. plast. 1x1000 ml | 36,68 | 36,68 | RSVO04b | 5% |
| V06DX03 421 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Nutrison Advanced Diason | vreć. plast. 1x1000 ml | 36,90 | 36,90 | RSVS12b | 5% |
| V06DX03 432 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Nepro HP | boca 1x220 ml | 17,09 | 17,09 | RSVS08a | 5% |
| V06DX03 437 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Nepro LP | boč. 1x220 ml | 15,38 | 15,38 | RSVS07a | 5% |
| V06DX03 438 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi Deutschland GmbH | FRESUBIN 2 kcal HP | vreć. plast. 1x500 ml | 19,24 | 19,24 | RSVO05b | 5% |
| V06DX03 439 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi Deutschland GmbH | FRESUBIN 2 kcal HP fibre | vreć. plast. 1x500 ml | 19,90 | 19,90 | RSVO06b | 5% |
| V06DX03 440 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Intestamin | vreć. plast. 1x500 ml | 188,00 | 188,00 | RSVS02b | 5% |
| V06DX03 443 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Vital 1,5 kcal | boč. 1x200 ml | 13,85 | 13,85 | RSVS09a | 5% |
| V06DX03 444 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutridrink Multi Fibre | boca plast. 4x200 ml | 8,15 | 32,60 | RSVO04a | 5% |
| V06DX03 445 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Renilon 7,5 | boč. 4x125 ml | 10,74 | 42,94 | RSVS08a | 5% |
| V06DX03 446 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N. V. Nutricia | Forticare | boč. 4x125 ml | 11,27 | 45,07 | RSVS01a | 5% |
| V06DX03 447 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Diasip | boca plast. 4x200 ml | 7,56 | 30,24 | RSVS12a | 5% |
| V06DX03 451 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Fresubin Protein Energy Drink | boč. plast. 4x200 ml | 7,88 | 31,52 | RSVO03a | 5% |
| V06DX03 452 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Diben drink | boč. plast. 4x200 ml | 7,17 | 28,66 | RSVS13a | 5% |
| V06DX03 453 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Fresubin Energy Drink | boč. plast. 4x200 ml | 7,88 | 31,52 | RSVO03a | 5% |
| V06DX03 454 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Supportan | boč. plast. 4x200 ml | 16,90 | 67,60 | RSVS01a | 5% |
| V06DX03 455 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Frebini Energy Drink | plast. boč. 4x200 ml | 8,13 | 32,53 | RSVP11 | 5% |
| V06DX03 456 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN 2 kcal fibre DRINK | boč. plast. 4x200 ml | 8,83 | 35,32 | RSVO06a | 5% |
| V06DX03 457 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN 2 kcal DRINK | boč. plast. 4x200 ml | 8,55 | 34,20 | RSVO05a | 5% |
| V06DX03 458 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN HEPA DRINK | boč. plast. 4x200 ml | 10,79 | 43,16 | RSVS06a | 5% |
| V06DX03 460 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN RENAL | boč. plast. 4x200 ml | 15,54 | 62,14 | RSVS07a | 5% |
| V06DX03 461 | DS | namirnice za enteralnu primjenu NV612 |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | ProvideXtra Drink | plast. boč. 4x200 ml | 13,50 | 54,00 |  | 5% |
| V06DX03 462 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Frebini Energy fibre Drink | plast. boč. 4x200 ml | 8,08 | 32,31 | RSVP11 | 5% |
| V06DX03 463 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN 2 kcal CREME | krema, plast. posudica 4x125 g | 12,39 | 49,54 | RSVS15 | 5% |
| V06DX03 464 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Fresubin DB Creme | krema, plast. posudica 4x125 g | 12,39 | 49,54 | RSVS15 | 5% |
| V06DX03 465 |  | namirnice za enteralnu primjenu |  |  | O | Belupo d.d. | Belupo d.d. | Nutrixa | tetrapak 1x200 ml | 7,34 | 7,34 | RSVO01a | 5% |
| V06DX03 467 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Plus Advance | boca 4x220 ml | 17,10 | 68,40 | RSVS04a | 5% |
| V06DX03 469 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Milupa GmbH | FortiFit | limenka, prah 1x280 g | 119,70 | 119,70 | RSVS04a | 5% |
| V06DX03 470 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Prosure | boca 4x220 ml | 16,90 | 67,60 | RSVS01a | 5% |
| V06DX03 472 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN 3,2 kcal DRINK | boč. plast. 4x125 ml | 17,10 | 68,40 | RSVS04a | 5% |
| V06DX03 473 |  | namirnice za enteralnu primjenu |  |  | O | Belupo d.d. | Immergut GmbH&Co.KG | Nutribel Complex | tetrapak 1x200 ml | 16,90 | 16,90 | RSVS01a | 5% |
| V06DX03 474 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Compact | boca 4x125 ml | 8,81 | 35,23 | RSVO07a | 5% |
| V06DX03 475 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle Health Science | Resource Senior Active/Resource Active | boca 4x200 ml | 17,10 | 68,40 | RSVS04a | 5% |
| V06DX03 476 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle Clinical Nutrition France | Nestle Resource 2.0.+fibre | boč. 4x200 ml | 8,83 | 35,32 | RSVO06a | 5% |
| V06DX03 478 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Even Sante Industrie | Nestle Resource Junior | boč. 4x200 ml | 8,24 | 32,96 | RSVP11 | 5% |
| V06DX03 479 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle Clinical Nutrition France | Nestle Resource 2.0. | boč. 4x200 ml | 8,55 | 34,20 | RSVO05a | 5% |
| V06DX03 480 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Plus Advance RTH | spremnik plast. 1x500 ml | 38,86 | 38,86 | RSVS04b | 5% |
| V06DX03 481 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Glucerna 1,5 kcal/500 ml | spremnik plast. 1x500 ml | 25,28 | 25,28 | RSVS13b | 5% |
| V06DX03 483 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Jevity Plus HP | spremnik plast. 1x500 ml | 15,00 | 15,00 | RSVO02b | 5% |
| V06DX03 484 |  | namirnice za enteralnu primjenu |  |  | O | Belupo d.d. | Belupo d.d. | Nutribel Diabet | tetrapak 1x200 ml | 7,56 | 7,56 | RSVS12a | 5% |
| V06DX03 485 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutrison Advanced Cubison | vreć. plast./ kolapsibilna boca 1x1000 ml | 48,09 | 48,09 | RSVS05b | 5% |
| V06DX03 486 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Cubitan | boca plast. 4x200 mL | 15,51 | 62,04 | RSVS05a | 5% |
| V06DX03 487 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Abound | kutija 30x24 g | 15,51 | 465,30 | RSVS05a | 5% |
| V06DX03 488 |  | namirnice za enteralnu primjenu |  |  | O | PROXIMUM d.o.o. | Biodue S.p.A. | PRONUTIM | vrećice, 30x20g | 16,81 | 504,41 | RSVS04a | 5% |
| V06DX03 490 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi Deutschland GmbH | Survimed OPD 1.5 kcal DRINK | plast. boč. 4x200 ml | 13,85 | 55,40 | RSVS09a | 5% |
| V06DX03 491 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Plus | boca 4x220 ml | 8,67 | 34,68 | RSVO03a | 5% |
| V06DX03 492 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutridrink Compact Protein | boca 4x125 ml | 16,25 | 65,00 | RSVS04a | 5% |
| V06DX03 493 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Compact Protein HMB | boca 4x125 ml | 16,25 | 64,98 | RSVS04a | 5% |
| V06DX03 494 | DS | namirnica za enteralnu primjenuNV613 |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutrison Protein Intense | kolapsibilna boca 1x500 ml | 62,67 | 62,67 |  | 5% |

Osnovna lista lijekova s cijenama u kunama – 3. dio

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena u kn za DDD (bez PDV-a) | Način primjene | Nositelj  odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena u kn za jed, obl. (bez PDV-a) | Cijena u kn za orig. pak. (bez PDV-a) | R/RS | Stopa PDV-a |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. |
| V20AA01 916 | RZ | sterilna gaza |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care sterilna gaza 1/4 m | 1 x 1/4 m | 1,39 | 1,39 | RRZ01 | 5% |
| V20AA01 925 | RZ | sterilna gaza |  |  | L | Lohmann & Rauscher d.o.o. | Lohmann&Rauscher | Gaza Swab 1/2 m L&R | 1 x 1/2 m | 1,84 | 1,84 | RRZ01 | 5% |
| V20AA01 926 | RZ | sterilna gaza |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care sterilna gaza 1/2 m | 1 x 1/2 m | 1,84 | 1,84 | RRZ01 | 5% |
| V20AA01 935 | RZ | sterilna gaza |  |  | L | Lohmann & Rauscher d.o.o. | Lohmann&Rauscher | Gaza Swab 1/1 m L&R | 1 x 1 m | 3,09 | 3,09 | RRZ01 | 5% |
| V20AA01 936 | RZ | sterilna gaza |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care sterilna gaza 1 m | 1 x 1 m | 3,09 | 3,09 | RRZ01 | 5% |
| V20AA01 947 | RZ | sterilna gaza |  |  | L | InMEDIC d.o.o. | Tosama | Upojna gaza 1/4 m Tosama | 1 x 1/4 m | 1,40 | 1,40 | RRZ01 | 5% |
| V20AA01 957 | RZ | sterilna gaza |  |  | L | InMEDIC d.o.o. | Tosama | Upojna gaza 1/2 m Tosama | 1 x 1/2 m | 1,84 | 1,84 | RRZ01 | 5% |
| V20AA01 967 | RZ | sterilna gaza |  |  | L | InMEDIC d.o.o. | Tosama | Upojna gaza 1/1 m Tosama | 1 x 1 m | 3,09 | 3,09 | RRZ01 | 5% |
| V20AB02 926 | RZ | komprese |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care Loli gauze komprese sterilne 5 cm x 8 cm, 16 sl a1 | 1 vr. (8 x 5) cm, 1 kom., 16 sl. | 0,40 | 0,40 | RRZ01 | 5% |
| V20AB02 928 | RZ | komprese |  |  | L | Lola Ribar d.d. | Lola Ribar d.d. | Lola care Loli gauze komprese sterilne 5 cm x 8 cm, 16 sl a5 | 1 vr. (8 x 5) cm, 5 kom., 16 sl. | 0,36 | 1,80 | RRZ01 | 5% |
| V20AB02 935 | RZ | komprese |  |  | L | Lohmann & Rauscher d.o.o. | Lohmann&Rauscher | Gazin | 1 vr. x (7,5 x 7,5) cm, 2 kom., 8 sl. | 0,41 | 0,41 | RRZ01 | 5% |
| V20AB02 936 | RZ | komprese |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care Loli gauze komprese sterilne 7,5 cm x 7,5 cm, 8 sl a2 | 1 vr. x (7,5 x 7,5) cm, 2 kom., 8 sl. | 0,41 | 0,41 | RRZ01 | 5% |
| V20AB02 945 | RZ | komprese |  |  | L | Lohmann & Rauscher d.o.o. | Lohmann&Rauscher | Gazin | 1 vr. x (10 x 10) cm, 2 kom., 8 sl. | 0,75 | 0,75 | RRZ01 | 5% |
| V20AB02 946 | RZ | komprese |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care Loli gauze komprese sterilne 10 cm x 10 cm, 8 sl a2 | 1 vr. x (10 x 10) cm, 2 kom., 8 sl. | 0,75 | 0,75 | RRZ01 | 5% |
| V20AD04 916 | RZ | mikropore |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care lolapora medicinska / kirurška traka 1,25 cm x 9,1 m | 1x (1,25 cm x 9,1 m) | 1,39 | 1,39 | RRZ01 | 5% |
| V20AD04 917 | RZ | mikropore |  |  | L | InMEDIC d.o.o. | Tosama | Microtape | 1x (2,5 cm x 9,1m) | 2,57 | 2,57 | RRZ01 | 5% |
| V20AD04 926 | RZ | mikropore |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care lolapora medicinska / kirurška traka 2,5 cm x 9,1 m | 1x (2,5 cm x 9,1m) | 2,56 | 2,56 | RRZ01 | 5% |
| V20AD04 936 | RZ | mikropore |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care lolapora medicinska / kirurška traka 5 cm x 9,1 m | 1x (5 cm x 9,1 m) | 5,02 | 5,02 | RRZ01 | 5% |
| V20AD04 947 | RZ | mikropore |  |  | L | InMEDIC d.o.o. | Tosama | Microtape | 1x (5 cm x 9,1 m) | 5,03 | 5,03 | RRZ01 | 5% |
| V20AD04 949 | RZ | mikropore |  |  | L | Lohmann & Rauscher d.o.o. | Jiangsu Nanfang Medical Co., Ltd. | Microporous Tape | 1x (1,25 cm x 9,15 m) | 1,39 | 1,39 | RRZ01 | 5% |
| V20AD04 959 | RZ | mikropore |  |  | L | Lohmann & Rauscher d.o.o. | Jiangsu Nanfang Medical Co., Ltd. | Microporous Tape | 1x (2,5 cm x 9,15m) | 2,58 | 2,58 | RRZ01 | 5% |
| V20AD04 969 | RZ | mikropore |  |  | L | Lohmann & Rauscher d.o.o. | Jiangsu Nanfang Medical Co., Ltd. | Microporous Tape | 1x (5 cm x 9,15 m) | 5,03 | 5,03 | RRZ01 | 5% |
| V20AE05 916 | RZ | staničevina |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola celulozna vata 1 kg | 1 x 1 kg | 22,00 | 22,00 | RRZ01 | 5% |
| V20AF06 916 | RZ | vata |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola sensitive vata za osjetljivu kožu 50 g | 1 x 50 g | 3,35 | 3,35 | RRZ01 | 5% |
| V20AF06 917 | RZ | vata |  |  | L | InMEDIC d.o.o. | Tosama | Cik cak vata Tosama | 1 x 50 g | 3,35 | 3,35 | RRZ01 | 5% |

Osnovna lista lijekova s cijenama u kunama – 4. dio

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena u kn za DDD (bez PDV-a) | Način primjene | Nositelj  odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena u kn za jed, obl. (bez PDV-a) | Cijena u kn za orig. pak. (bez PDV-a) | R/RS | Stopa PDV-a |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. |
| V07AC01 911 | DS | puna krv NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (525 ml) | 320,25 | 320,25 |  | 0% |
| V07AC01 912 | DS | + puna krv za autolognu transfuzijuNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 521,97 | 521,97 |  | 0% |
| V07AC03 912 | DS | puna krv sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (500 ml) | 545,00 | 545,00 |  | 5% |
| V07AC04 913 | DS | svježe zamrznuta plazmaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (260 ml) | 184,60 | 184,60 |  | 5% |
| V07AC04 915 | DS | Svježe zamrznuta plazma – COVID-19 kovalenscentna plazmaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 184,60 | 184,60 |  | 5% |
| V07AC04 930 | DS | svježe zamrznuta plazma dobivena aferezom NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (480 ml) | 528,00 | 528,00 |  | 5% |
| V07AC04 931 | DS | + svježe zamrznuta plazma – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 568,57 | 568,57 |  | 5% |
| V07AC04 932 | DS | + svježe zamrznuta plazma dobivena aferezom – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 911,97 | 911,97 |  | 5% |
| V07AC04 933 | DS | + svježe zamrznuta plazma dobivena aferezom sa smanjenim sadržajem krioprecipitataNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 755,66 | 755,66 |  | 5% |
| V07AC04 934 | DS | + svježe zamrznuta plazma sa smanjenim brojem leukocita – filtrirana plazmaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 499,09 | 499,09 |  | 5% |
| V07AC04 935 | DS | + svježe zamrznuta plazma za autolognu transfuzijuNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 428,37 | 428,37 |  | 5% |
| V07AC04 936 | DS | + svježe zamrznuta plazma dobivena aferezom – COVID-19 kovalenscentna plazmaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 528,00 | 528,00 |  | 5% |
| V07AC04 937 | DS | + svježe zamrznuta plazma sa smanjenim sadržajem krioprecipitataNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 412,26 | 412,26 |  | 5% |
| V07AC06 915 | DS | koncentrat eritrocitaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 365,42 | 365,42 |  | 5% |
| V07AC06 931 | DS | koncentrat eritrocita u hranjivoj otopiniNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 365,42 | 365,42 |  | 5% |
| V07AC06 932 | DS | koncentrat eritrocita bez sloja leukocita i trombocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 365,42 | 365,42 |  | 5% |
| V07AC06 933 | DS | koncentrat eritrocita bez sloja leukocita i trombocita, u hranjivoj otopiniNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 365,42 | 365,42 |  | 5% |
| V07AC06 934 | DS | + koncentrat eritrocita bez sloja leukocita i trombocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 456,73 | 456,73 |  | 5% |
| V07AC06 935 | DS | +koncentrat eritrocita za autolognu transfuzijuNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 559,23 | 559,23 |  | 5% |
| V07AC07 916 | DS | koncentrat eritrocita sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (265 ml) | 574,42 | 574,42 |  | 5% |
| V07AC07 934 | DS | koncentrat eritrocita sa smanjenim brojem leukocita, u hranjivoj otopini NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (265 ml) | 574,42 | 574,42 |  | 5% |
| V07AC07 935 | DS | koncentrat eritocita sa smanjenim brojem leukocita, u hranjivoj otopini – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 665,73 | 665,73 |  | 5% |
| V07AC07 936 | DS | + koncentrat eritrocita sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 665,73 | 665,73 |  | 5% |
| V07AC08 917 | DS | koncentrat opranih eritrocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 319,20 | 319,20 |  | 5% |
| V07AC09 918 | DS | koncentrat opranih eritrocita sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (250 ml) | 545,00 | 545,00 |  | 5% |
| V07AC09 919 | DS | + koncentrat opranih eritrocita sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 636,31 | 636,31 |  | 5% |
| V07AC10 919 | DS | koncentrat eritrocita u plazmi NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (550 ml) | 434,50 | 434,50 |  | 5% |
| V07AC10 920 | DS | + koncentrat eritrocita u plazmi sa smanjenim brijem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 948,19 | 948,19 |  | 5% |
| V07AC10 921 | DS | + koncentrat eritrocita u plazmi sa smanjenim brojem leukocitaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 856,88 | 856,88 |  | 5% |
| V07AC11 920 | DS | koncentrat trombocita dobiven trombaferezom NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 339,37 | 339,37 |  | 5% |
| V07AC12 922 | DS | koncentrat trombocita dobiven tromboferezom, sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 485,78 | 485,78 |  | 5% |
| V07AC12 923 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 611,61 | 611,61 |  | 5% |
| V07AC12 924 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita u smanjenom volumenu plazme – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 619,49 | 619,49 |  | 5% |
| V07AC12 925 | DS | + koncentrat opranih trombocita dobiven trombaferezom sa smanjenim brojem leukocita – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 654,57 | 654,57 |  | 5% |
| V07AC12 926 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 501,00 | 501,00 |  | 5% |
| V07AC12 927 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita u smanjenom volumenu plazme – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 508,88 | 508,88 |  | 5% |
| V07AC12 928 | DS | + koncentrat opranih trombocita dobiven trombaferezom sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 543,96 | 543,96 |  | 5% |
| V07AC12 929 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita u smanjenom volumenu plazmeNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 493,66 | 493,66 |  | 5% |
| V07AC12 930 | DS | + koncentrat opranih trombocita sa smanjenim brojem leukocita – trombaferezaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 528,75 | 528,75 |  | 5% |
| V07AC12 931 | DS | koncentrat trombocita dobiven tromboferezom u hranjivoj otopini sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 485,78 | 485,78 |  | 5% |
| V07AC12 932 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 501,00 | 501,00 |  | 5% |
| V07AC12 934 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 611,61 | 611,61 |  | 5% |
| V07AC12 935 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita u smanjenom volumenu – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 508,88 | 508,88 |  | 5% |
| V07AC12 936 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita u smanjenom volumenuNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 493,66 | 493,66 |  | 5% |
| V07AC12 937 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita u smanjenom volumenu – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 611,61 | 611,61 |  | 5% |
| V07AC13 923 | DS | koncentrat trombocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 223,43 | 223,43 |  | 5% |
| V07AC13 935 | DS | koncentrat trombocita-više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 253,28 | 253,28 |  | 5% |
| V07AC13 936 | DS | koncentrat trombocita iz sloja leukocita i trombocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 223,43 | 223,43 |  | 5% |
| V07AC13 937 | DS | koncentrat trombocita iz sloja leukocita i trombocita-više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 253,28 | 253,28 |  | 5% |
| V07AC13 938 | DS | + koncentrat trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza u smanjenom volumenu plazme – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 516,34 | 516,34 |  | 5% |
| V07AC13 939 | DS | +koncentrat trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza u smanjenom volumenu plazme – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 350,43 | 350,43 |  | 5% |
| V07AC13 940 | DS | + koncentrat trombocita u smanjenom volumenu plazme – 1 dozaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 270,73 | 270,73 |  | 5% |
| V07AC13 941 | DS | + koncentrat trombocita u smanjenom volumenu plazme – više dozaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 270,75 | 270,75 |  | 5% |
| V07AC13 942 | DS | + koncentrat trombocita sa smanjenim brojem leukocita u smanjenom volumenu plazme – više davateljaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 327,60 | 327,60 |  | 5% |
| V07AC13 943 | DS | +koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita pool više doza u smanjenom volumenu – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 350,43 | 350,43 |  | 5% |
| V07AC13 944 | DS | + koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita, pool više doza u smanjenom volumenu NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 327,60 | 327,60 |  | 5% |
| V07AC14 925 | DS | koncentrat trombocita sa smanjenim brojem leukocita više davatelja NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 315,77 | 315,77 |  | 5% |
| V07AC14 938 | DS | koncentrat trombocita sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 565,37 | 565,37 |  | 5% |
| V07AC14 940 | DS | + koncentrat trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 504,51 | 504,51 |  | 5% |
| V07AC14 941 | DS | + koncentrat opranih trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 568,96 | 568,96 |  | 5% |
| V07AC14 942 | DS | + koncentrat trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više davatelja – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 407,08 | 407,08 |  | 5% |
| V07AC14 943 | DS | + koncentrat opranih trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 444,67 | 444,67 |  | 5% |
| V07AC14 944 | DS | + koncentrat opranih trombocita sa smanjenim brojem leukocita – više dozaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 380,22 | 380,22 |  | 5% |
| V07AC14 945 | DS | koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita, pool više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 315,77 | 315,77 |  | 5% |
| V07AC14 946 | DS | + koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita pool više doza – inaktivacija patogena NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 504,51 | 504,51 |  | 5% |
| V07AC14 947 | DS | + koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita pool više davatelja – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 407,08 | 407,08 |  | 5% |
| V07AC14 948 | DS | + koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita pool više doza u smanjenom volumenu – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 504,51 | 504,51 |  | 5% |
| V07AC15 926 | DS | koncentrat leukocita dobiven leukoforezom NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 339,37 | 339,37 |  | 5% |
| V07AC16 927 | DS | koncentrat leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 223,43 | 223,43 |  | 5% |
| V07AC16 939 | DS | koncentrat leukocitia-više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 253,28 | 253,28 |  | 5% |
| V07AC16 940 | DS | koncentrat trombocita i leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 223,43 | 223,43 |  | 5% |
| V07AC16 941 | DS | koncentrat trombocita i leukocita-više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 253,28 | 253,28 |  | 5% |
| V07AC16 942 | DS | + koncentrat leukocita i trombocita pool više doza – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 344,59 | 344,59 |  | 5% |
| V07AC16 943 | DS | + koncentrat leukocita i trombocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 314,74 | 314,74 |  | 5% |
| V07AC17 928 | DS | krioprecipitat univerzalni-deset dozaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (200 ml) | 2.515,24 | 2.515,24 |  | 5% |
| V07AC17 929 | DS | krioprecipitat liofiliziran iz 1500 ml plazme NV701 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Krioprecipitat | boč. 1x50 ml (550-650 i.j F-VIII) s priborom za infuziju | 1.080,00 | 1.080,00 |  | 5% |

Osnovna lista lijekova s cijenama u eurima – 1. dio

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena u EUR za DDD (bez PDV-a) | Način primjene | Nositelj  odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena u EUR za jed. obl. (bez PDV-a) | Cijena u EUR za orig. pak. (bez PDV-a) | R/RS | Stopa PDV-a |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. |
| A01AB12 451 | DS | heksetidin |  |  | O |  |  |  |  |  |  |  | 5% |
| A01AD11 263 |  | polivinil-pirolidon + natrij-hijalurat + gliciretinična kiselinaNA101 |  |  | L | Helsinn Birex Pharmaceuticals Ltd. | Helsinn Healthcare SA | Gelclair | gel oralni konc., boč. 1x180 ml | 30,0816 | 30,08 | RSRA01 | 5% |
| A02BA02 051 | DS | ranitidin | 0,3 g |  | P |  |  |  |  |  |  |  | 5% |
| A02BA03 141 |  | famotidin | 40 mg | 0,2470 | O | Alkaloid d.o.o. | Alkaloid | Famosan | tbl. 20x20 mg | 0,1234 | 2,47 | R | 5% |
| A02BA03 142 |  | famotidin | 40 mg | 0,2400 | O | Alkaloid d.o.o. | Alkaloid | Famosan | tbl. 10x40 mg | 0,2398 | 2,40 | R | 5% |
| A02BC01 112 |  | omeprazol | 20 mg | 0,1343 | O | Belupo d.d. | Belupo | Target plus | caps. 28x20 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC01 118 |  | omeprazol | 20 mg | 0,1343 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ortalox | caps. 28x20 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC01 131 |  | omeprazol | 20 mg | 0,1343 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ultop | caps. 14x20 mg | 0,1342 | 1,88 | RRA02 | 5% |
| A02BC01 134 |  | omeprazol | 20 mg | 0,1018 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ultop | caps. 28x40 mg | 0,2035 | 5,70 | RRA02 | 5% |
| A02BC01 135 |  | omeprazol | 20 mg | 0,1343 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ultop | caps. 28x20 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC02 011 | DS | pantoprazolNA201 | 40 mg | 2,3900 | P | Belupo d.d. | Belupo | Zoltex | praš. za otop. za inj., boč. stakl. 1x40 mg | 2,3943 | 2,39 |  | 5% |
| A02BC02 021 | DS | pantoprazolNA201 | 40 mg | 3,2800 | P | Sandoz d.o.o. | Sandoz-Lek | Pantoprazol Sandoz | praš. za otop. za inj., boč. stakl. 1x40 mg | 3,2836 | 3,28 |  | 5% |
| A02BC02 030 | DS | pantoprazolNA201 | 40 mg | 3,2800 | P | KRKA-FARMA d.o.o. | Krka d.d. | Nolpaza | praš. za otop. za inj., boč. 1x40 mg | 3,2836 | 3,28 |  | 5% |
| A02BC02 072 | DS | pantoprazolNA201 | 40 mg | 1,9390 | P | Apta Medica International d.o.o. | Sofarimex Indústria Quimica e Farmaceutica S.A. | Pantoprazol AptaPharma | praš. za otop. za inj., boč. stakl. 10x40 mg | 1,9393 | 19,39 |  | 5% |
| A02BC02 101 |  | pantoprazol | 40 mg | 0,1386 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zipantola | tbl. 28x20 mg | 0,0693 | 1,94 | RRA02 | 5% |
| A02BC02 102 |  | pantoprazol | 40 mg | 0,1250 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zipantola | tbl. 56x20 mg | 0,0624 | 3,50 | RRA02 | 5% |
| A02BC02 103 |  | pantoprazol | 40 mg | 0,1343 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zipantola | tbl. 14x40 mg | 0,1342 | 1,88 | RRA02 | 5% |
| A02BC02 104 |  | pantoprazol | 40 mg | 0,1343 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zipantola | tbl. 28x40 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC02 111 |  | pantoprazol | 40 mg | 0,1386 | O | Belupo d.d. | Belupo | Zoltex | tbl. 28x20 mg | 0,0693 | 1,94 | RRA02 | 5% |
| A02BC02 112 |  | pantoprazol | 40 mg | 0,1250 | O | Belupo d.d. | Belupo | Zoltex | tbl. 56x20 mg | 0,0624 | 3,50 | RRA02 | 5% |
| A02BC02 114 |  | pantoprazol | 40 mg | 0,1343 | O | Belupo d.d. | Belupo | Zoltex | tbl. 28x40 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC02 121 |  | pantoprazol | 40 mg | 0,1386 | O | Sandoz d.o.o. | Sandoz-Lek | Acipan | tbl. žel. otp. 28x20 mg | 0,0693 | 1,94 | RRA02 | 5% |
| A02BC02 122 |  | pantoprazol | 40 mg | 0,1250 | O | Sandoz d.o.o. | Sandoz-Lek | Acipan | tbl. žel. otp. 56x20 mg | 0,0624 | 3,50 | RRA02 | 5% |
| A02BC02 123 |  | pantoprazol | 40 mg | 0,1343 | O | Sandoz d.o.o. | Sandoz-Lek | Acipan | tbl. žel. otp. 14x40 mg | 0,1342 | 1,88 | RRA02 | 5% |
| A02BC02 124 |  | pantoprazol | 40 mg | 0,1343 | O | Sandoz d.o.o. | Sandoz-Lek | Acipan | tbl. žel. otp. 28x40 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC02 126 |  | pantoprazol | 40 mg | 0,1386 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Zoprax | tbl. žel. otp. 28x20 mg | 0,0693 | 1,94 | RRA02 | 5% |
| A02BC02 127 |  | pantoprazol | 40 mg | 0,1250 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Zoprax | tbl. žel. otp. 56x20 mg | 0,0624 | 3,50 | RRA02 | 5% |
| A02BC02 128 |  | pantoprazol | 40 mg | 0,1343 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Zoprax | tbl. žel. otp. 28x40 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC02 129 |  | pantoprazol | 40 mg | 0,1207 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Zoprax | tbl. žel. otp. 56x40 mg | 0,1208 | 6,76 | RRA02 | 5% |
| A02BC02 131 |  | pantoprazol | 40 mg | 0,1386 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 28x20 mg | 0,0693 | 1,94 | RRA02 | 5% |
| A02BC02 132 |  | pantoprazol | 40 mg | 0,1250 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 56x20 mg | 0,0624 | 3,50 | RRA02 | 5% |
| A02BC02 133 |  | pantoprazol | 40 mg | 0,1387 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 30x20 mg | 0,0694 | 2,08 | RRA02 | 5% |
| A02BC02 134 |  | pantoprazol | 40 mg | 0,1250 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 60x20 mg | 0,0624 | 3,75 | RRA02 | 5% |
| A02BC02 135 |  | pantoprazol | 40 mg | 0,1343 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 14x40 mg | 0,1342 | 1,88 | RRA02 | 5% |
| A02BC02 136 |  | pantoprazol | 40 mg | 0,1343 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Nolpaza | tbl. film obl. žel. otp. 28x40 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC02 137 |  | pantoprazol | 40 mg | 0,1386 | O | Alkaloid d.o.o. | Atlantic Pharma – Produçoes Farmaceuticas, S.A. | Pantoprazol Alkaloid | tbl. žel. otp. 28x20 mg | 0,0693 | 1,94 | RRA02 | 5% |
| A02BC02 138 |  | pantoprazol | 40 mg | 0,1300 | O | Alkaloid d.o.o. | West Pharma, Atlantic Pharma | Pantoprazol Alkaloid | tbl. žel. otp. 28x40 mg | 0,1301 | 3,64 | RRA02 | 5% |
| A02BC02 141 |  | pantoprazol | 40 mg | 0,1386 | O | PharmaS d.o.o. | PharmaS d.o.o. | Pantoprazol PharmaS | tbl. žel. otp. 28x20 mg | 0,0693 | 1,94 | RRA02 | 5% |
| A02BC02 142 |  | pantoprazol | 40 mg | 0,1139 | O | PharmaS d.o.o. | PharmaS d.o.o. | Pantoprazol PharmaS | tbl. žel. otp. 56x20 mg | 0,0570 | 3,19 | RRA02 | 5% |
| A02BC02 144 |  | pantoprazol | 40 mg | 0,1186 | O | PharmaS d.o.o. | PharmaS d.o.o. | Pantoprazol PharmaS | tbl. žel. otp. 28x40 mg | 0,1187 | 3,32 | RRA02 | 5% |
| A02BC02 162 |  | pantoprazol | 40 mg | 0,1343 | O | Takeda Pharmaceuticals Croatia d.o.o. | Takeda | Controloc | tbl. 28x40 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC02 181 |  | pantoprazol | 40 mg | 0,1250 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Apazol A | tbl. žel. otp. 28x20 mg | 0,0624 | 1,75 | RRA02 | 5% |
| A02BC02 182 |  | pantoprazol | 40 mg | 0,1175 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Apazol A | tbl. žel. otp. 56x20 mg | 0,0588 | 3,29 | RRA02 | 5% |
| A02BC02 183 |  | pantoprazol | 40 mg | 0,1207 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Apazol A | tbl. žel. otp. 28x40 mg | 0,1208 | 3,38 | RRA02 | 5% |
| A02BC03 111 |  | lanzoprazol | 30 mg | 0,1386 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Larona | caps. žel. otp. tvrde 28x15 mg | 0,0693 | 1,94 | RRA02 | 5% |
| A02BC03 112 |  | lanzoprazol | 30 mg | 0,1343 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Larona | caps. žel. otp. tvrde 28x30 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC03 131 |  | lanzoprazol | 30 mg | 0,1343 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lanzul | caps. 14x30 mg | 0,1342 | 1,88 | RRA02 | 5% |
| A02BC03 132 |  | lanzoprazol | 30 mg | 0,1386 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lanzul S | caps. 28x15 mg | 0,0693 | 1,94 | RRA02 | 5% |
| A02BC03 133 |  | lanzoprazol | 30 mg | 0,1343 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lanzul | caps. 28x30 mg | 0,1342 | 3,76 | RRA02 | 5% |
| A02BC05 061 | DS | esomeprazolNA201 | 30 mg | 2,9715 | P | AstraZeneca d.o.o. | AstraZeneca | Nexium | boč. 10x40 mg | 3,8629 | 38,63 |  | 5% |
| A02BC05 131 |  | esomeprazol | 30 mg | 0,0921 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 14x20 mg | 0,0924 | 1,29 | RRA02 | 5% |
| A02BC05 132 |  | esomeprazol | 30 mg | 0,0925 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 28x20 mg | 0,0925 | 2,59 | RRA02 | 5% |
| A02BC05 133 |  | esomeprazol | 30 mg | 0,0893 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 14x40 mg | 0,1789 | 2,50 | RRA02 | 5% |
| A02BC05 134 |  | esomeprazol | 30 mg | 0,0895 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 28x40 mg | 0,1789 | 5,01 | RRA02 | 5% |
| A02BC05 135 |  | esomeprazol | 30 mg | 0,1248 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 56x20 mg | 0,0832 | 4,66 | RRA02 | 5% |
| A02BC05 136 |  | esomeprazol | 30 mg | 0,1208 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Emanera | caps. žel. otp. 56x40 mg | 0,1610 | 9,02 | RRA02 | 5% |
| A02BC05 163 |  | esomeprazol | 30 mg | 0,0925 | O | AstraZeneca d.o.o. | AstraZeneca | Nexium | tbl. 28x20 mg | 0,0925 | 2,59 | RRA02 | 5% |
| A02BX05 131 |  | bizmut oksid | 0,48 g | 0,5364 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ulcamed | tbl. film obl. 56x120 mg | 0,1341 | 7,51 | RRA16 | 5% |
| A03AA04 111 |  | mebeverin | 0,3 g | 2,9831 | O | Belupo d.d. | Belupo | Rudakol | obl. tbl. 50x135 mg | 0,0703 | 3,52 | R | 5% |
| A03AX04 161 |  | pinaverij bromid | 0,15 g | 0,1515 | O | Mylan Hrvatska d.o.o. | Mylan Laboratories SAS | Dicetel | tbl. film obl. 30x100 mg | 0,1009 | 3,03 | R | 5% |
| A03BA01 051 | PR | atropin | 1,5 mg |  | P |  |  |  |  |  |  |  | 5% |
| A03BB01 051 | DS | hioscin-butilbromid | 60 mg |  | P |  |  |  |  |  |  |  | 5% |
| A03BB01 551 |  | hioscin-butilbromid | 60 mg |  | R |  |  |  |  |  |  | R | 5% |
| A03BB01 563 | DS | hioscin-butilbromid | 60 mg |  | O |  |  |  |  |  |  |  | 5% |
| A03FA01 051 | PR | metoklopramid | 30 mg |  | P |  |  |  |  |  |  |  | 5% |
| A03FA01 111 |  | metoklopramid | 30 mg | 0,1793 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Metopran | tbl. 40x10 mg | 0,0598 | 2,39 | R | 5% |
| A03FA01 142 |  | metoklopramid | 30 mg | 0,1793 | O | Alkaloid d.o.o. | Alkaloid | Reglan | tbl. 40x10 mg | 0,0598 | 2,39 | R | 5% |
| A03FA01 241 |  | metoklopramid | 30 mg |  | O | Alkaloid d.o.o. | Alkaloid | Reglan | otop. oral. 120 ml (5mg/5ml) | 1,3166 | 1,32 | R | 5% |
| A04AA01 071 | DS | ondansetronNA401 | 16 mg | 15,8200 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro | Ondanzetron Kabi | otop. za inj., boč. stakl. 5x2 ml (2 mg/ml) | 3,1641 | 15,82 |  | 5% |
| A04AA01 072 | DS | ondansetronNA401 | 16 mg | 14,9100 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro | Ondanzetron Kabi | otop. za inj., boč. stakl. 5x4 ml (2 mg/ml) | 5,9646 | 29,82 |  | 5% |
| A04AA01 122 |  | ondansetron | 16 mg | 4,0100 | O | Sandoz d.o.o. | Sandoz-Salutas | Ondantor | tbl. film obl. 10x8 mg | 2,0048 | 20,05 | RSRA17 | 5% |
| A04AA02 086 | DS | granisetronNA401 | 3 mg | 11,0338 | P | Fresenius Kabi d.o.o. | Labesfal – Laboratorios Almiro S.A. | Granizetron Kabi | otop. za inj., amp. 5x1 mg/ml | 3,6772 | 18,39 |  | 5% |
| A04AA02 087 | DS | granisetronNA401 | 3 mg | 5,8200 | P | Fresenius Kabi d.o.o. | Labesfal – Laboratorios Almiro S.A. | Granizetron Kabi | otop. za inj., amp. 5x3 mg/3 ml | 5,8207 | 29,10 |  | 5% |
| A04AA05 041 | DS | palonosetronNA402 | 0,25 mg | 39,0900 | P | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Palonosetron Accord | otop. za inj. boč. stakl. 1x250 mcg/5 ml | 39,0935 | 39,09 |  | 5% |
| A04AA05 071 | DS | palonosetronNA402 | 0,25 mg | 39,0900 | P | Medochemie Ltd. | Medochemie Ltd. | Ferant | otop. za inj., amp. 1x250 mcg/5 ml | 39,0935 | 39,09 |  | 5% |
| A04AA55 131 | DS | netupitant + palonozetronNA402 |  |  | O | Helsinn Birex Pharmaceuticals Ltd. | Helsinn Birex Pharmaceuticals Ltd. | Akynzeo | caps. tvrda 1x(300 mg+0,5 mg) | 72,4733 | 72,47 |  | 5% |
| A04AD12 101 | DS | aprepitantNA402 | 165 mg | 20,6913 | O | Teva B.V. | Merckle GmbH | Aprepitant Teva | caps. tvrda 1x125 mg +2x80 mg | 11,9150 | 35,74 |  | 5% |
| A04AD12 161 | DS | aprepitantNA402 | 165 mg | 20,6913 | O | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | Emend | caps. tvrda 1x125 mg +2x80 mg | 11,9150 | 35,74 |  | 5% |
| A04AD12 171 | DS | aprepitantNA402 | 165 mg | 20,6913 | O | ALPHA-MEDICAL d.o.o. | Pharmathen International S.A., Pharmathen S.A. | Aprepitant Alpha-Medical | caps. tvrda 1x125 mg +2x80 mg | 11,9150 | 35,74 |  | 5% |
| A05AA02 161 |  | ursodeoksikolna kiselina | 0,75 g | 0,7752 | O | Dr. Falk Pharma GmbH | Dr. Falk Pharma GmbH | Ursofalk | caps. 100x250 mg | 0,2584 | 25,84 | RSRA03 | 5% |
| A05AA02 171 |  | ursodeoksikolna kiselina | 0,75 g | 0,5997 | O | AS GRINDEKS | AS Grindeks | Ursogrix | caps. 100x250 mg | 0,1999 | 19,99 | RSRA03 | 5% |
| A06AD11 361 |  | laktuloza | 6,7 g | 0,0755 | O | Mylan Hrvatska d.o.o. | Abbott | Duphalac sirup | boč. plast. s čaš. mjern. plast. 1x500 ml (66,7 g/100 ml) | 3,7600 | 3,76 | RRA12 | 5% |
| A06AD11 365 |  | laktuloza | 6,7 g | 0,0775 | O | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Lactulose-MIP sirup | boč. plast. 1x500 ml (65 g/100 ml) | 3,7600 | 3,76 | RRA12 | 5% |
| A07AA12 161 | DS | fidaksomicinNA700 | 0,4 g | 147,7860 | O | Tillotts Pharma GmbH | Tillotts Pharma GmbH | Dificlir | tbl. film obl. 20x200 mg | 73,8930 | 1.477,86 |  | 5% |
| A07BA01 111 | DS | aktivni (medicinski) ugljen | 5 g | 4,0556 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Carbomed | tbl. 30x150 mg | 0,1217 | 3,65 |  | 5% |
| A07BA01 312 | DS | aktivni (medicinski) ugljen | 5 g | 1,7039 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Carbomed | granule 1x50 g (19,25 g u 50 g) | 6,5565 | 6,56 |  | 5% |
| A07CA01 351 |  | natrij-klorid + kalij-klorid + natrij-citrat |  |  | O |  |  |  |  |  |  | R | 5% |
| A07EC01 131 |  | sulfasalazin | 2 g | 0,3496 | O | KRKA-FARMA d.o.o. | Krka d.d. | Sulfasalazin Krka EN | tbl. žel. otp. 50x500 mg | 0,0874 | 4,37 | R | 5% |
| A07EC01 182 |  | sulfasalazin | 2 g | 0,3496 | O | Pfizer Croatia d.o.o. | Kemwell | Salazopyrin | tbl. 100x500 mg | 0,0874 | 8,74 | R | 5% |
| A07EC02 172 |  | mesalazin | 1,5 g | 0,7464 | O | Dr. Falk Pharma GmbH | Dr. Falk Pharma GmbH | Salofalk | tbl. 100x500 mg | 0,2488 | 24,88 | RSpa03 | 5% |
| A09AA02 172 |  | enzimi gušterače (visoko dozirani) |  |  | O | Mylan Hrvatska d.o.o. | Abbott | Kreon 10.000 | caps. 100x1 kom. | 0,1008 | 10,08 | RSRA15 | 5% |
| A09AA02 173 |  | enzimi gušterače (visoko dozirani) |  |  | O | Mylan Hrvatska d.o.o. | Abbott | Kreon 25.000 | caps. 100x1 kom. | 0,2681 | 26,81 | RSRA15 | 5% |
| A09AA02 175 |  | enzimi gušterače (visoko dozirani) |  |  | O | Mylan Hrvatska d.o.o. | Abbott Laboratories GmbH | Kreon 35.000 | caps. 50x1 kom. | 0,4590 | 22,95 | RSRA15 | 5% |
| A10AB01 061 |  | inzulin | 40 IU | 0,5899 | P | Eli Lilly Hrvatska d.o.o. | Lilly France | Humulin R | otop. za inj., uložak 5x3 ml (100 IU/ml), susp. | 4,4250 | 22,12 | R | 5% |
| A10AB01 072 |  | inzulin | 40 IU | 0,4652 | P | Novo Nordisk A/S | Novo Nordisk | Actrapid | otop. za inj., boč. 1x10 ml (100 IU/ml) | 11,6318 | 11,63 | R | 5% |
| A10AB04 082 |  | inzulin lispro | 40 U | 0,8547 | P | Eli Lilly Nederland B.V. | Lilly France S.A.S. | Humalog | otop. za inj., brizg. napunj. Junior KwikPen 5x3 ml (100 U/ml) | 6,4092 | 32,05 | R | 5% |
| A10AB04 083 |  | inzulin lispro | 40 U | 0,7821 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog | otop. za inj., uložak 5x3 ml (100 U/ml) | 5,8663 | 29,33 | R | 5% |
| A10AB04 084 |  | inzulin lispro | 40 U | 0,8547 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog | otop. za inj., brizg. napunj. KwikPen 5x3 ml (100 U/ml) | 6,4092 | 32,05 | R | 5% |
| A10AB04 085 |  | inzulin lispro | 40 U | 0,8545 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog | otop. za inj., brizg. napunj. KwikPen 5x3 ml (200 U/ml) | 12,8184 | 64,09 | R | 5% |
| A10AB05 071 |  | inzulin aspart | 40 U | 0,8547 | P | Novo Nordisk A/S | Novo Nordisk | NovoRapid | otop. za inj., brizg. napunj. FlexPen 5x3 ml (100 U/ml) | 6,4092 | 32,05 | R | 5% |
| A10AB05 072 |  | inzulin aspart | 40 U | 0,7821 | P | Novo Nordisk A/S | Novo Nordisk | NovoRapid | otop. za inj., uložak stakl. Penfil 5x3 ml (100 U/ml) | 5,8663 | 29,33 | R | 5% |
| A10AB05 076 |  | inzulin aspartNA912 | 40 U | 0,6852 | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoRapid | otop. za inj., boč. 1x10 ml (100 U/ml) | 17,1292 | 17,13 | RPA29 | 5% |
| A10AB05 077 |  | inzulin aspart | 40 U | 0,7821 | P | Novo Nordisk A/S | Novo Nordisk A/S | Fiasp | otop. za inj., uložak stakl. Penfil 5x3 ml (100 U/ml) | 5,8663 | 29,33 | R | 5% |
| A10AB06 061 |  | inzulin glulizin | 40 U | 0,8064 | P | Sanofi-Aventis Deutschland GmbH | Sanofi-Aventis GmbH | Apidra | otop. za inj., brizg. napunj. SoloStar 5x3 ml (100 U/ml) | 6,0490 | 30,24 | R | 5% |
| A10AC01 066 |  | inzulin | 40 IU | 0,5899 | P | Eli Lilly Hrvatska d.o.o. | Lilly France | Humulin N | susp. za inj. uložak 5x3 ml (100 IU/ml) | 4,4250 | 22,12 | R | 5% |
| A10AC01 077 |  | inzulin human | 40 IU | 0,6453 | P | Sanofi-Aventis Deutschland GmbH | Sanofi-Aventis Deutchland GmbH | Insuman Basal | susp. za inj., brizg. napunj. SoloStar 5x3 ml (100 IU/ml) | 4,8409 | 24,20 | R | 5% |
| A10AD01 083 |  | inzulin | 40 IU | 0,5899 | P | Eli Lilly Hrvatska d.o.o. | Lilly France | Humulin M3 | susp. za inj., uložak 5x3 ml (100 IU/ml) | 4,4250 | 22,12 | R | 5% |
| A10AD04 081 |  | inzulin lispro | 40 U | 0,7821 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog Mix 25 | susp. za inj., uložak 5x3 ml (100 U/ml) | 5,8663 | 29,33 | R | 5% |
| A10AD04 083 |  | inzulin lispro | 40 U | 0,7821 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog Mix 50 | susp. za inj., uložak 5x3 ml (100 U/ml) | 5,8663 | 29,33 | R | 5% |
| A10AD04 085 |  | inzulin lispro | 40 U | 0,8781 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog Mix 25 | susp. za inj., brizg, napunj. KwikPen 5x3 ml (100 U/ml) | 6,5865 | 32,93 | R | 5% |
| A10AD04 086 |  | inzulin lispro | 40 U | 0,8744 | P | Eli Lilly Nederland B.V. | Lilly France | Humalog Mix 50 | susp. za inj., brizg. napunj. KwikPen 5x3 ml (100 U/ml) | 6,5586 | 32,79 | R | 5% |
| A10AD05 073 |  | inzulin aspart | 40 U | 0,8760 | P | Novo Nordisk A/S | Novo Nordisk | NovoMix 30 | susp. za inj., brizg. napunj. FlexPen 5x3 ml (100 U/ml) | 6,5698 | 32,85 | R | 5% |
| A10AD06 071 |  | inzulin degludek + inzulin aspart | 40 U | 1,0224 | P | Novo Nordisk A/S | Novo Nordisk A/S | Ryzodeg | otop. za inj., brizg. napunj. 5x3 mL (100 U/mL) | 7,6677 | 38,34 | R | 5% |
| A10AE04 062 |  | inzulin glargin | 40 U | 1,1160 | P | Sanofi-Aventis Deutschland GmbH | Sanofi-Aventis GmbH | Lantus | otop. za inj., brizg. napunj. SoloStar 5x3 ml (100 U/ml) | 8,3695 | 41,85 | RRA08 | 5% |
| A10AE04 082 |  | inzulin glargin | 40 U | 0,9339 | P | Eli Lilly Nederland B.V. | Lilly France S.A.S. | Abasaglar | otop. za inj., brizg. napunj. KwikPen 5x3 ml (100 U/ml) | 7,0043 | 35,02 | RRA08 | 5% |
| A10AE04 091 |  | inzulin glargin | 40 U | 0,9339 | P | Viatris Limited | McDermott Laboratories t/a Mylan Dublin Biologics | Semglee | otop. za inj., brizg. napunj. 5x3 ml (100 U/ml) | 7,0043 | 35,02 | RRA08 | 5% |
| A10AE05 071 |  | inzulin detemir | 40 U | 1,3203 | P | Novo Nordisk A/S | Novo Nordisk | Levemir | otop. za inj., brizg. napunj. FlexPen 5x3 ml (100 U/ml) | 9,9011 | 49,51 | RRA08 | 5% |
| A10AE06 061 |  | degludek inzulin | 40 U | 1,3803 | P | Novo Nordisk A/S | Novo Nordisk | Tresiba | otop. za inj., brizg. napunj. FlexTouch 5x3 ml (100 U/ml) | 10,3524 | 51,76 | RRA08 | 5% |
| A10BA02 101 |  | metformin | 2 g | 0,0750 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gluformin | tbl. film obl. 80x850 mg | 0,0319 | 2,55 | R | 5% |
| A10BA02 102 |  | metformin | 2 g | 0,0713 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gluformin | tbl. film obl. 80x1000 mg | 0,0356 | 2,85 | R | 5% |
| A10BA02 103 |  | metformin | 2 g | 0,0753 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gluformin | tbl. film obl. 30x850 mg | 0,0319 | 0,96 | R | 5% |
| A10BA02 104 |  | metformin | 2 g | 0,0767 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gluformin | tbl. film obl. 30x1000 mg | 0,0382 | 1,15 | R | 5% |
| A10BA02 111 |  | metformin | 2 g | 0,0940 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 100x500 mg | 0,0235 | 2,35 | R | 5% |
| A10BA02 112 |  | metformin | 2 g | 0,0753 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 30x850 mg | 0,0319 | 0,96 | R | 5% |
| A10BA02 113 |  | metformin | 2 g | 0,0767 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 30x1000 mg | 0,0382 | 1,15 | R | 5% |
| A10BA02 114 |  | metformin | 2 g | 0,0749 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 120x850 mg | 0,0319 | 3,82 | R | 5% |
| A10BA02 115 |  | metformin | 2 g | 0,0712 | O | Belupo d.d. | Belupo | Belformin | tbl. film obl. 120x1000 mg | 0,0356 | 4,27 | R | 5% |
| A10BA02 122 |  | metformin | 2 g | 0,0940 | O | Sandoz d.o.o. | Sandoz-Lek | Meglucon | tbl. film obl. 120x500 mg | 0,0235 | 2,82 | R | 5% |
| A10BA02 124 |  | metformin | 2 g | 0,0749 | O | Sandoz d.o.o. | Sandoz-Lek | Meglucon | tbl. film obl. 120x850 mg | 0,0319 | 3,82 | R | 5% |
| A10BA02 125 |  | metformin | 2 g | 0,0712 | O | Sandoz d.o.o. | Sandoz-Lek | Meglucon | tbl. film obl. 120x1000 mg | 0,0356 | 4,27 | R | 5% |
| A10BA02 173 |  | metformin | 2 g | 0,0940 | O | Medis Adria d.o.o. | Weifa | Aglurab | tbl. film obl. 100x500 mg | 0,0235 | 2,35 | R | 5% |
| A10BA02 174 |  | metformin | 2 g | 0,0751 | O | Medis Adria d.o.o. | Weifa | Aglurab | tbl. film obl. 100x850 mg | 0,0319 | 3,19 | R | 5% |
| A10BA02 175 |  | metformin | 2 g | 0,0713 | O | Medis Adria d.o.o. | Weifa | Aglurab | tbl. film obl. 60x1000 mg | 0,0356 | 2,14 | R | 5% |
| A10BA02 181 |  | metformin | 2 g | 0,0940 | O | Berlin-Chemie Menarini Hrvatska d.o.o. | Berlin-Chemie AG | Siofor 500 | tbl. film obl. 120x500 mg | 0,0235 | 2,82 | R | 5% |
| A10BB01 161 |  | glibenklamid-mikrokrist. | 7 mg | 0,1393 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Glibenclamid Genericon | tbl. 30x3,5 mg | 0,0697 | 2,09 | R | 5% |
| A10BB09 111 |  | gliklazid | 60 mg | 0,1013 | O | Belupo d.d. | Belupo d.d. | Glika | tbl. s prod. oslob. 60x30 mg | 0,0507 | 3,04 | R | 5% |
| A10BB09 112 |  | gliklazid | 60 mg | 0,0733 | O | Belupo d.d. | Belupo d.d. | Glika | tbl. s prilag. oslob. 30x60 mg | 0,0735 | 2,20 | R | 5% |
| A10BB09 113 |  | gliklazid | 60 mg | 0,0735 | O | Belupo d.d. | Belupo d.d. | Glika | tbl. s prilag. oslob. 60x60 mg | 0,0735 | 4,41 | R | 5% |
| A10BB09 114 |  | gliklazid | 60 mg | 0,0734 | O | Belupo d.d. | Belupo d.d. | Glika | tbl. s prilag. oslob. 90x60 mg | 0,0735 | 6,61 | R | 5% |
| A10BB09 131 |  | gliklazid | 60 mg | 0,1013 | O | KRKA-FARMA d.o.o. | Krka d.d. | Gliclada | tbl. s prilag. osl. 60x30 mg | 0,0507 | 3,04 | R | 5% |
| A10BB09 134 |  | gliklazid | 60 mg | 0,0658 | O | KRKA-FARMA d.o.o. | Krka d.d. | Gliclada | tbl. s prilag. osl. 30x90 mg | 0,0986 | 2,96 | R | 5% |
| A10BB12 111 |  | glimepirid | 2 mg | 0,0733 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Betaglid | tbl. 30x2 mg | 0,0735 | 2,20 | R | 5% |
| A10BB12 112 |  | glimepirid | 2 mg | 0,0658 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Betaglid | tbl. 30x3 mg | 0,0986 | 2,96 | R | 5% |
| A10BB12 145 |  | glimepirid | 2 mg | 0,0730 | O | PharmaS d.o.o. | PharmaS d.o.o. | Glimepirid PharmaS | tbl. 30x2 mg | 0,0730 | 2,19 | R | 5% |
| A10BB12 146 |  | glimepirid | 2 mg | 0,0735 | O | PharmaS d.o.o. | PharmaS d.o.o. | Glimepirid PharmaS | tbl. 60x2 mg | 0,0735 | 4,41 | R | 5% |
| A10BB12 147 |  | glimepirid | 2 mg | 0,0649 | O | PharmaS d.o.o. | PharmaS d.o.o. | Glimepirid PharmaS | tbl. 30x3 mg | 0,0972 | 2,92 | R | 5% |
| A10BB12 148 |  | glimepirid | 2 mg | 0,0657 | O | PharmaS d.o.o. | PharmaS d.o.o. | Glimepirid PharmaS | tbl. 60x3 mg | 0,0986 | 5,91 | R | 5% |
| A10BB12 161 |  | glimepirid | 2 mg | 0,0733 | O | sanofi-aventis groupe | Sanofi-Aventis GmbH, Sanofi-Aventis S.p.A., Sanofi Winthrop Tours | Amaryl | tbl. 30x2 mg | 0,0735 | 2,20 | R | 5% |
| A10BB12 162 |  | glimepirid | 2 mg | 0,0658 | O | sanofi-aventis groupe | Sanofi-Aventis GmbHSanofi-Aventis S.p.A.Sanofi Winthrop Tours | Amaryl | tbl. 30x3 mg | 0,0986 | 2,96 | R | 5% |
| A10BD02 171 |  | metformin + glibenklamid |  |  | O | MERCK d.o.o. | Merck | Glucovance | tbl. film obl. 30x(500 mg +5 mg) | 0,0790 | 2,37 | R | 5% |
| A10BD05 161 |  | pioglitazon + metformin |  |  | O | Cheplapharm Arzneimittel GmbH | Takeda | Competact | tbl. film obl. 56x(15 mg+850 mg) | 0,3315 | 18,56 | R | 5% |
| A10BD07 101 |  | sitagliptin + metformin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Adamed Pharma S.A. | Gluformin Combi | tbl. s prod. oslob. 56x(50 mg +1000 mg) | 0,1955 | 10,95 | R | 5% |
| A10BD07 111 |  | sitagliptin + metformin |  |  | O | Teva GmbH | Laboratorios Liconsa S.A. | Sitagliptin/metforminklorid Teva | tbl. film obl. 56x(50 mg +1000 mg) | 0,1950 | 10,92 | R | 5% |
| A10BD07 125 |  | sitagliptin + metformin |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Eprocliv | tbl. film obl. 56x(50 mg +1000 mg) | 0,1950 | 10,92 | R | 5% |
| A10BD07 131 |  | sitagliptin + metformin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Maymetsi | tbl. film obl. 56x(50 mg +1000 mg) | 0,1950 | 10,92 | R | 5% |
| A10BD07 171 |  | sitagliptin + metformin |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Fordiab | tbl. film obl. 56x(50 mg +1000 mg) | 0,1950 | 10,92 | R | 5% |
| A10BD07 181 |  | sitagliptin + metformin |  |  | O | Viatris Limited | Mylan Hungary Kft, Medis International A.S. | Glerova | tbl. film obl. 56x(50 mg +1000 mg) | 0,1849 | 10,35 | R | 5% |
| A10BD07 182 |  | sitagliptin + metformin |  |  | O | Zentiva k.s. | Laboratorios Liconsa S.A. | Jamesi | tbl. film obl. 56x(50 mg +1000 mg) | 0,1857 | 10,40 | R | 5% |
| A10BD07 183 |  | sitagliptin + metformin |  |  | O | Novatin Limited | SAG Manufacturing S.L.U. | Zaxoran | tbl. film obl. 56x(50 mg +850 mg) | 0,1756 | 9,83 | R | 5% |
| A10BD07 184 |  | sitagliptin + metformin |  |  | O | Novatin Limited | SAG Manufacturing S.L.U. | Zaxoran | tbl. film obl. 56x(50 mg +1000 mg) | 0,1756 | 9,83 | R | 5% |
| A10BD07 185 |  | sitagliptin + metformin |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o., Accord Healthcare B.V. | Sitagliptin/metforminklorid Accord | tbl. film obl. 56x(50 mg +1000 mg) | 0,1669 | 9,34 | R | 5% |
| A10BD08 111 |  | vildagliptin + metformin |  |  | O | Belupo d.d. | Belupo | Agnis Combi | tbl. film obl. 60x(50 mg+850 mg) | 0,1852 | 11,11 | R | 5% |
| A10BD08 112 |  | vildagliptin + metformin |  |  | O | Belupo d.d. | Belupo | Agnis Combi | tbl. film obl. 60x(50 mg+1000 mg) | 0,1852 | 11,11 | R | 5% |
| A10BD08 121 |  | vildagliptin + metformin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Vilspox | tbl. film obl. 60x(50 mg +1000 mg) | 0,1950 | 11,70 | R | 5% |
| A10BD08 141 |  | vildagliptin + metformin |  |  | O | Accord Healthcare S.L.U. | LABORATORI FUNDACIÓ DAU, Pharmadox Healthcare Ltd. | Vildagliptin/metforminklorid Accord | tbl. film obl. 60x(50 mg+1000 mg) | 0,1671 | 10,03 | R | 5% |
| A10BD08 171 |  | vildagliptin + metformin |  |  | O | Medochemie Ltd. | Medochemie Ltd. | Daltex | tbl. film obl. 60x(50 mg +1000 mg) | 0,1950 | 11,70 | R | 5% |
| A10BD08 181 |  | vildagliptin + metformin |  |  | O | Zentiva k.s. | Pharmathen S.A., Pharmathen International S.A. | Ipinzan | tbl. film obl. 60x(50 mg+1000 mg) | 0,1759 | 10,56 | R | 5% |
| A10BD08 191 |  | vildagliptin + metformin |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Vilbaco | tbl. film obl. 60x(50 mg+1000 mg) | 0,1759 | 10,56 | R | 5% |
| A10BD08 192 |  | vildagliptin + metformin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | SAG Manufacturing S.L.U., Galenicum Health S.L. | Vildagliptin/metforminklorid Genericon | tbl. film obl. 60x(50 mg+1000 mg) | 0,1588 | 9,53 | R | 5% |
| A10BG03 101 |  | pioglitazon | 30 mg | 0,6467 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Pioglitazon Pliva tbl. 15 mg | tbl. 30x15 mg | 0,3232 | 9,70 | R | 5% |
| A10BG03 102 |  | pioglitazon | 30 mg | 0,4853 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Pioglitazon Pliva tbl. 30 mg | tbl. 30x30 mg | 0,4853 | 14,56 | R | 5% |
| A10BG03 133 |  | pioglitazon | 30 mg | 0,4852 | O | ACTAVIS GROUP PTC ehf. | Actavis Ltd. | Pioglitazon Actavis | tbl. 28x45 mg | 0,7280 | 20,38 | R | 5% |
| A10BG03 181 |  | pioglitazon | 30 mg | 0,6464 | O | Cheplapharm Arzneimittel GmbH | Takeda | Actos | tbl. 28x15 mg | 0,3232 | 9,05 | R | 5% |
| A10BG03 182 |  | pioglitazon | 30 mg | 0,4854 | O | Cheplapharm Arzneimittel GmbH | Takeda | Actos | tbl. 28x30 mg | 0,4853 | 13,59 | R | 5% |
| A10BG03 183 |  | pioglitazon | 30 mg | 0,6140 | O | Novatin Limited | Laboratori Fundacio Dau | Novapio | tbl. 30x15 mg | 0,3070 | 9,21 | R | 5% |
| A10BG03 184 |  | pioglitazon | 30 mg | 0,4610 | O | Novatin Limited | Laboratori Fundacio Dau | Novapio | tbl. 30x30 mg | 0,4611 | 13,83 | R | 5% |
| A10BG03 185 |  | pioglitazon | 30 mg | 0,4611 | O | Novatin Limited | Laboratori Fundacio Dau | Novapio | tbl. 30x45 mg | 0,6916 | 20,75 | R | 5% |
| A10BH01 101 |  | sitagliptin | 0,1 g | 0,3157 | O | Teva B.V. | Teva Gyogyszergyar Zrt., Teva Operations Poland Sp. z o.o. | Sitagliptin Teva | tbl. film obl. 28x100 mg | 0,3159 | 8,84 | R | 5% |
| A10BH01 122 |  | sitagliptin | 0,1 g | 0,5700 | O | Jadran – Galenski Laboratorij d.d. | Zakłady Farmaceutyczne Polpharma S.A., Pharmacare Premium Ltd. | Sigazix | tbl. film obl. 28x50 mg | 0,2851 | 7,98 | R | 5% |
| A10BH01 123 |  | sitagliptin | 0,1 g | 0,2850 | O | Jadran – Galenski Laboratorij d.d. | Zakłady Farmaceutyczne Polpharma S.A., Pharmacare Premium Ltd. | Sigazix | tbl. film obl. 28x100 mg | 0,2851 | 7,98 | R | 5% |
| A10BH01 124 |  | sitagliptin | 0,1 g | 1,1400 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Adimuplan | tbl. film obl. 28x25 mg | 0,2851 | 7,98 | R | 5% |
| A10BH01 125 |  | sitagliptin | 0,1 g | 0,5700 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Adimuplan | tbl. film obl. 28x50 mg | 0,2851 | 7,98 | R | 5% |
| A10BH01 126 |  | sitagliptin | 0,1 g | 0,2850 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Adimuplan | tbl. film obl. 28x100 mg | 0,2851 | 7,98 | R | 5% |
| A10BH01 131 |  | sitagliptin | 0,1 g | 1,2629 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Maysiglu | tbl. film obl. 28x25 mg | 0,3159 | 8,84 | R | 5% |
| A10BH01 132 |  | sitagliptin | 0,1 g | 0,6314 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Maysiglu | tbl. film obl. 28x50 mg | 0,3159 | 8,84 | R | 5% |
| A10BH01 133 |  | sitagliptin | 0,1 g | 0,3157 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Maysiglu | tbl. film obl. 28x100 mg | 0,3159 | 8,84 | R | 5% |
| A10BH01 164 |  | sitagliptin | 0,1 g | 1,1400 | O | ALPHA-MEDICAL d.o.o. | Adamed Pharma S.A. | Dowim | tbl. film obl. 28x25 mg | 0,2851 | 7,98 | R | 5% |
| A10BH01 165 |  | sitagliptin | 0,1 g | 0,5700 | O | ALPHA-MEDICAL d.o.o. | Adamed Pharma S.A. | Dowim | tbl. film obl. 28x50 mg | 0,2851 | 7,98 | R | 5% |
| A10BH01 166 |  | sitagliptin | 0,1 g | 0,2850 | O | ALPHA-MEDICAL d.o.o. | Adamed Pharma S.A. | Dowim | tbl. film obl. 28x100 mg | 0,2851 | 7,98 | R | 5% |
| A10BH01 167 |  | sitagliptin | 0,1 g | 1,0829 | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o. | Sitagliptin Accord | tbl. film obl. 28x25 mg | 0,2708 | 7,58 | R | 5% |
| A10BH01 168 |  | sitagliptin | 0,1 g | 0,5414 | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o. | Sitagliptin Accord | tbl. film obl. 28x50 mg | 0,2708 | 7,58 | R | 5% |
| A10BH01 169 |  | sitagliptin | 0,1 g | 0,2707 | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o. | Sitagliptin Accord | tbl. film obl. 28x100 mg | 0,2708 | 7,58 | R | 5% |
| A10BH01 175 |  | sitagliptin | 0,1 g | 0,2707 | O | Novatin Limited | SAG Manufacturing S.L.U. | Zaxivia | tbl. film obl. 28x100 mg | 0,2708 | 7,58 | R | 5% |
| A10BH01 181 |  | sitagliptin | 0,1 g | 1,0286 | O | Mylan Ireland Limited | Mylan Hungary Kft, Medis International A.S. | Jaglix | tbl. film obl. 28x25 mg | 0,2572 | 7,20 | R | 5% |
| A10BH01 182 |  | sitagliptin | 0,1 g | 0,5143 | O | Mylan Ireland Limited | Mylan Hungary Kft, Medis International A.S. | Jaglix | tbl. film obl. 28x50 mg | 0,2572 | 7,20 | R | 5% |
| A10BH01 183 |  | sitagliptin | 0,1 g | 0,2571 | O | Mylan Ireland Limited | Mylan Hungary Kft, Medis International A.S. | Jaglix | tbl. film obl. 28x100 mg | 0,2572 | 7,20 | R | 5% |
| A10BH02 111 |  | vildagliptin | 0,1 g | 0,3160 | O | Belupo d.d. | Belupo d.d. | Agnis | tbl. 60x50 mg | 0,1579 | 9,48 | R | 5% |
| A10BH02 121 |  | vildagliptin | 0,1 g | 0,3157 | O | Sandoz d.o.o. | Sandoz-Lek | Saxotin | tbl. 56x50 mg | 0,1579 | 8,84 | R | 5% |
| A10BH02 131 |  | vildagliptin | 0,1 g | 0,3153 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma Gmbh | Glypvilo | tbl. 60x50 mg | 0,1577 | 9,46 | R | 5% |
| A10BJ01 062 |  | eksenatid | 15 mcg | 1,7668 | P | AstraZeneca AB | AstraZeneca AB | Byetta | otop. za inj., brizg. napunj. 1x2,4 ml, 10 mcg/40 mcl, (0,25 mg/ml) | 70,6722 | 70,67 | RSRA11 | 5% |
| A10BJ03 061 |  | liksisenatid | 20 mcg | 5,0486 | P | sanofi-aventis groupe | Sanofi-Aventis Deutchland GmbH | Lyxumia | otop. za inj., brizg. napunj. 1x3 ml (10 mcg/doza) | 2,5240 | 35,34 | RSRA11 | 5% |
| A10BJ03 062 |  | liksisenatid | 20 mcg | 2,5239 | P | sanofi-aventis groupe | Sanofi-Aventis Deutchland GmbH | Lyxumia | otop. za inj., brizg. napunj. 2x3 ml (20 mcg/doza) | 2,5240 | 70,67 | RSRA11 | 5% |
| A10BJ05 061 |  | dulaglutid | 0.16 mg | 3,7696 | P | Eli Lilly Nederland B.V. | Eli Lilly Italia S.p.A. | Trulicity | otop. za inj., brizg. napunj. 2x0,75 mg/0,5 ml | 17,6681 | 35,34 | RSRA11 | 5% |
| A10BJ05 062 |  | dulaglutid | 0.16 mg | 1,8848 | P | Eli Lilly Nederland B.V. | Eli Lilly Italia S.p.A. | Trulicity | otop. za inj., brizg. napunj. 2x1,5 mg/0,5 ml | 17,6681 | 35,34 | RSRA11 | 5% |
| A10BJ05 063 |  | dulaglutid | 0.16 mg | 0,9424 | P | Eli Lilly Nederland B.V. | Eli Lilly Italia S.p.A. | Trulicity | otop. za inj., brizg. napunj. 2x3,0 mg/0,5 ml | 17,6681 | 35,34 | RSRA11 | 5% |
| A10BJ05 064 |  | dulaglutid | 0.16 mg | 0,6283 | P | Eli Lilly Nederland B.V. | Eli Lilly Italia S.p.A. | Trulicity | otop. za inj., brizg. napunj. 2x4,5 mg/0,5 ml | 17,6681 | 35,34 | RSRA11 | 5% |
| A10BJ06 071 |  | semaglutid | 0.11 mg | 7,7737 | P | Novo Nordisk A/S | Novo Nordisk A/S | Ozempic | otop. za inj., brizg. napunj., 1x1,5 ml (0,25 mg/doza) | 70,6722 | 70,67 | RSRA11 | 5% |
| A10BJ06 072 |  | semaglutid | 0.11 mg | 3,8869 | P | Novo Nordisk A/S | Novo Nordisk A/S | Ozempic | otop. za inj., brizg. napunj., 1x1,5 ml (0,5 mg/doza) | 70,6722 | 70,67 | RSRA11 | 5% |
| A10BJ06 073 |  | semaglutid | 0.11 mg | 1,9434 | P | Novo Nordisk A/S | Novo Nordisk A/S | Ozempic | otop. za inj., brizg. napunj., 1x3 ml (1 mg/doza) | 70,6722 | 70,67 | RSRA11 | 5% |
| A10BX02 101 |  | repaglinid | 4 mg | 0,1280 | O | DOUBLE-E-PHARMA Limited | Pliva Hrvatska d.o.o. | Reodon | tbl. 90x0,5 mg | 0,0160 | 1,44 | R | 5% |
| A10BX02 102 |  | repaglinid | 4 mg | 0,1284 | O | DOUBLE-E-PHARMA Limited | Pliva Hrvatska d.o.o. | Reodon | tbl. 90x1 mg | 0,0321 | 2,89 | R | 5% |
| A10BX02 103 |  | repaglinid | 4 mg | 0,1216 | O | DOUBLE-E-PHARMA Limited | Pliva Hrvatska d.o.o. | Reodon | tbl. 90x2 mg | 0,0608 | 5,47 | R | 5% |
| A10BX02 112 |  | repaglinid | 4 mg | 0,1284 | O | Belupo d.d. | Belupo | Reglinid | tbl. 90x1 mg | 0,0321 | 2,89 | R | 5% |
| A10BX02 113 |  | repaglinid | 4 mg | 0,1216 | O | Belupo d.d. | Belupo | Reglinid | tbl. 90x2 mg | 0,0608 | 5,47 | R | 5% |
| A10BX02 127 |  | repaglinid | 4 mg | 0,1216 | O | PharmaS d.o.o. | PharmaS d.o.o. | Repaglinid PharmaS | tbl. 90x2 mg | 0,0608 | 5,47 | R | 5% |
| A11CC02 251 |  | dihidrotahisterol | 1 mg |  | O |  |  |  |  |  |  | R | 5% |
| A11CC04 051 | DS | kalcitriol | 1 mcg |  | P |  |  |  |  |  |  |  | 5% |
| A11CC05 161 |  | kolekalciferol | 20 mcg | 0,0252 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Dekristol | caps. meka 14x20 000 IU (0,5 mg) | 0,6295 | 8,81 | R | 5% |
| A11CC05 201 |  | kolekalciferol | 20 mcg | 0,0444 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivit D3 | boč. 1x10 ml (4.000 i.j./ml) | 2,2205 | 2,22 | R | 5% |
| A11CC05 261 |  | kolekalciferol | 20 mcg | 0,0311 | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Oleovit D3 | oralne kapi, boč. 1x12,5 ml (14400 i.j./ml) | 6,9945 | 6,99 | R | 5% |
| A11CC05 271 |  | kolekalciferol | 20 mcg | 0,0280 | O | PROXIMUM d.o.o. | SMB Technology S.A. | D-VITAL | oralna otop., amp. 4x1 ml (25 000 IU/ml) | 0,8743 | 3,50 | R | 5% |
| A11CC05 272 |  | kolekalciferol | 20 mcg | 0,0266 | O | PROXIMUM d.o.o. | SMB Technology S.A. | D-VITAL | oralna otop., amp. 3x1 ml (100 000 IU/ml) | 3,3225 | 9,97 | RSRA31 | 5% |
| A11EA01 051 | DS | vitamini B kompleksa |  |  | P |  |  |  |  |  |  |  | 5% |
| A12AA02 051 | PR | kalcij-glukobionat |  |  | P |  |  |  |  |  |  |  | 5% |
| A12AA04 131 |  | kalcij-karbonat | 3 g | 0,3900 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kalcijev karbonat | tbl. 50x1 g | 0,1301 | 6,50 | R | 5% |
| A12BA01 111 |  | kalij-klorid | 3 g | 0,6060 | O | Belupo d.d. | Belupo | Kalijev klorid Belupo | tbl. za oral. otop. 30x500 mg | 0,1009 | 3,03 | R | 5% |
| A12BA01 112 |  | kalij-klorid | 3 g | 0,6060 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Kalijev klorid Jadran | tbl. 30x500 mg | 0,1009 | 3,03 | R | 5% |
| A12BA02 321 |  | kalijev citrat |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Kalijev citrat JGL | praš. za oral. otop., vreć. 15x1 (20,5 mg/ml) | 0,2389 | 3,58 | R | 5% |
| A12BA30 161 |  | kalij-citrat + kalij-hidrogenkarbonat |  |  | O | Desma GmbH | E-Pharma Trento S.p.A. | Kalinor | tbl. šum. 15x1 tbl. (2,17 g+2 g/tbl.) | 0,2654 | 3,98 | R | 5% |
| A16AA01 051 | DS | levokarnitin | 2 g |  | P |  |  |  |  |  |  |  | 5% |
| A16AA01 151 | DS | levokarnitin | 2 g |  | O |  |  |  |  |  |  |  | 5% |
| A16AA05 161 | DS | karglumatna kiselinaNA501 | 200 mg | 60,1663 | O | Recordati Rare Diseases | Recordati Rare Diseases | Carbaglu | tbl. za oral. susp. 60x200 mg | 60,1663 | 3.609,98 |  | 5% |
| A16AB02 062 | KS | imiglucerazaNA903 | 300 j. | 1.004,5001 | P | Genzyme Europe B.V. | Genzyme | Cerezyme | praš. za konc. za otop. za inf., stakl. boč. 1x400 j. | 1.339,3045 | 1.339,30 |  | 5% |
| A16AB03 062 | KS | agalzidaza alfaNA904 | 1 mg | 453,0229 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Replagal | konc. za inf., boč. 1x3,5 mg/3,5 ml | 1.585,5783 | 1.585,58 |  | 5% |
| A16AB04 061 | KS | agalzidaza betaNA904 | 5 mg | 440,9443 | P | Genzyme Europe B.V. | Genzyme | Fabrazyme | praš. za konc. za otop. za inf., boč. stakl. 1x35 mg | 3.086,6109 | 3.086,61 |  | 5% |
| A16AB04 062 | KS | agalzidaza betaNA904 | 5 mg | 481,9100 | P | Genzyme Europe B.V. | Genzyme | Fabrazyme | praš. za konc. za otop. za inf., boč. stakl. 1x5 mg | 481,9112 | 481,91 |  | 5% |
| A16AB05 061 | KS | laronidazaNA906 | 1 T j. | 1.285,9000 | P | Genzyme Europe B.V. | Genzyme | Aldurazyme | praš. za konc. za otop. za inf., boč. stakl. 1x500 j./5 ml (100j./ml) | 642,9531 | 642,95 |  | 5% |
| A16AB07 061 | KS | alglukozidaza alfaNA907 | 0,1 g | 983,0800 | P | Genzyme Europe B.V. | Genzyme | Myozyme | praš. za konc. za otop. za inf., boč. 1x50 mg | 491,5363 | 491,54 |  | 5% |
| A16AB08 061 | KS | galsulfazaNA908 |  |  | P | BioMarin International Limited | BioMarin International Limited | Naglazyme | konc. otop. za inf., boč. 1x5 mg/5 ml | 1.373,6890 | 1.373,69 |  | 5% |
| A16AB09 071 | KS | idursulfaza NA909 |  |  | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Elaprase | boč. stakl. 1x6 mg/3 ml (2 mg/ml) | 2.655,2061 | 2.655,21 |  | 5% |
| A16AB10 061 | KS | velagluceraza alfaNA903 | 300 U | 1.038,4160 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Vpriv | praš. za otop. za inf., boč. stakl. 1x400 U/20 ml (nakon rekonstitucije 100 U/1ml) | 1.384,5192 | 1.384,52 |  | 5% |
| A16AB12 071 | KS | elosulfaza alfaNA913 | 20 mg | 3.327,0000 | P | BioMarin International Limited | BioMarin International Ltd. | Vimizim | konc. za otop. za inf., boč. stakl. 1x5 ml (1 mg/ml) | 831,7513 | 831,75 |  | 5% |
| A16AB17 071 | KL | cerliponaza alfaNA915 | 21 mg | 1.706,5772 | P | BioMarin International Limited | BioMarin International Limited | Brineura | otop. za inf., boč. 2x150 mg/5 ml (30mg/ml) | 12.189,8255 | 24.379,65 |  | 5% |
| A16AX04 151 | KS | nitizinonNA905 | 20 mg |  | O |  |  |  |  |  |  |  | 5% |
| A16AX08 072 | KL | teduglutidNA914 | 5 mg | 1.158,1471 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Revestive | praš. boč. 28x1,25 mg+0,5 ml otap. za otop. za inj. u štrc. napunj. (2,5 mg/ml) | 289,5368 | 8.107,03 |  | 5% |
| A16AX08 073 | KL | teduglutidNA914 | 5 mg | 596,2604 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Revestive | praš. boč. 28x5 mg+0,5 ml otap. za otop. za inj. u štrc. napunj. (10 mg/ml) | 596,2603 | 16.695,29 |  | 5% |
| A16AX10 161 | KS | eliglustatNA910 |  |  | O | Genzyme Europe B.V. | Genzyme Ireland Ltd. | Cerdelga | caps. tvrda 56x84 mg | 341,0370 | 19.098,07 |  | 5% |
| A16AX14 161 | KS | migalastatNA911 |  |  | O | Amicus Therapeutics Europe Limited | Almac Pharma Services (Ireland) Limited | Galafold | caps. tvrde 14x123 mg | 1.036,4703 | 14.510,58 |  | 5% |
| B01AA03 162 |  | varfarin | 7,5 mg | 0,1383 | O | Orion Corporation | Orion | Martefarin | tbl. 100x3 mg | 0,0553 | 5,53 | R | 5% |
| B01AB01 011 | DS | heparin | 10 T i.j. | 1,9376 | P | Belupo d.d. | Belupo | Heparin Belupo | otop. za inj., lio amp. 10x25.000 i.j./5 ml | 4,8444 | 48,44 |  | 5% |
| B01AB01 061 | DS | heparinnatrij | 10 T i.j. | 1,7556 | P | Panpharma | Panpharma GmbH | Heparin Panpharma | otop. za inj./inf., 5.000 i.j./ml (10x5 ml) | 4,3887 | 43,89 |  | 5% |
| B01AB02 061 | DS | antitrombin IIINB101 | 2.1 T i.j. | 526,7535 | P | CSL Behring GmbH | CSL Behring GmbH | Kybernin | lio boč. 1x500 i.j./10ml | 125,4231 | 125,42 |  | 5% |
| B01AB02 071 | DS | antitrombin IIINB101 | 2.1 T i.j. |  | P | Jana Pharm d.o.o. | Octapharma | ATenativ | lio boč. 1x500 i.j./10ml | 125,4231 | 125,42 |  | 5% |
| B01AB02 082 | DS | antitrombin IIINB101 | 2.1 T i.j. | 526,7535 | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Antithrombin III Baxalta 50 IU/ml | praš. i otap. za otop. za inj./inf., boč. 1x500 IU/10 ml (50 IU/ml) | 125,4231 | 125,42 |  | 5% |
| B01AB04 071 | DSPO | dalteparinNB102 | 2.5 T i.j. | 9,0250 | P | Pfizer Croatia d.o.o. | Pfizer | Fragmin | štrc. 10x2.500 i.j./0,2ml | 1,8054 | 18,05 |  | 5% |
| B01AB04 072 | DSPO | dalteparinNB102 | 2.5 T i.j. | 8,5975 | P | Pfizer Croatia d.o.o. | Pfizer | Fragmin | štrc. 10x5.000 i.j./0,2ml | 3,4392 | 34,39 |  | 5% |
| B01AB04 073 | DSPO | dalteparinNB102 | 2.5 T i.j. | 1,3957 | P | Pfizer Croatia d.o.o. | Pfizer | Fragmin | štrc. 10x7.500 i.j./0,3ml | 4,1874 | 41,87 | RSRB10 | 5% |
| B01AB04 080 |  | dalteparin | 2.5 T i.j. | 1,3360 | P | Pfizer Croatia d.o.o. | Pfizer Manufacturing Belgium N.V. | Fragmin | otop. za inj., štrc. napunj. 5x10.000 i.j./0,4 ml | 5,3440 | 26,72 | RSRB10 | 5% |
| B01AB04 081 |  | dalteparin | 2.5 T i.j. | 1,2104 | P | Pfizer Croatia d.o.o. | Pfizer Manufacturing Belgium N.V. | Fragmin | otop. za inj., štrc. napunj. 5x12.500 i.j./0,5 ml | 6,0527 | 30,26 | RSRB10 | 5% |
| B01AB04 082 |  | dalteparin | 2.5 T i.j. | 1,1337 | P | Pfizer Croatia d.o.o. | Pfizer Manufacturing Belgium N.V. | Fragmin | otop. za inj., štrc. napunj. 5x15.000 i.j./0,6 ml | 6,8028 | 34,01 | RSRB10 | 5% |
| B01AB05 061 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 1,3950 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x20 mg/0,2 ml | 1,3949 | 13,95 | RSRB11 | 5% |
| B01AB05 062 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 1,3125 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 6x40 mg/0,4 ml | 2,6257 | 15,75 | RSRB11 | 5% |
| B01AB05 063 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 1,3130 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x40 mg/0,4 ml | 2,6258 | 26,26 | RSRB11 | 5% |
| B01AB05 064 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 1,1600 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 6x60 mg/0,6 ml | 3,4795 | 20,88 |  | 5% |
| B01AB05 065 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 1,1597 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x60 mg/0,6 ml | 3,4795 | 34,79 |  | 5% |
| B01AB05 066 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 1,0270 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x80 mg/0,8 ml | 4,1082 | 41,08 |  | 5% |
| B01AB05 067 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 0,8408 | P | Techdow Europe AB | Health-Med spółka z ograniczoną odpowiedzialnością sp.k. | Inhixa | šprica 10x100 mg/1 ml | 4,2037 | 42,04 |  | 5% |
| B01AB05 085 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 0,1502 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x20 mg/0,2 ml | 1,5020 | 15,02 | RSRB11 | 5% |
| B01AB05 086 | DSPO | enoksaparinNB506 | 2.0 T i.j. | 0,1449 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x40 mg/0,4 ml | 2,8977 | 28,98 | RSRB11 | 5% |
| B01AB05 087 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 0,1326 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x60 mg/0,6 ml | 3,9777 | 39,78 |  | 5% |
| B01AB05 088 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 0,1176 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x80 mg/0,8 ml | 4,7028 | 47,03 |  | 5% |
| B01AB05 089 | DSPO | enoksaparinNB102 | 2.0 T i.j. | 1,0510 | P | sanofi-aventis groupe | Sanofi Winthrop Maisons Alfort, Sanofi Winthrop Le Trait, Sanofi Aventis Alcorcon | Clexane | šprica 10x100 mg/1 ml | 5,2546 | 52,55 |  | 5% |
| B01AB06 021 | DSPO | nadroparinNB102 | 2.85 T i.j. | 1,8910 | P | Mylan Hrvatska d.o.o. | Aspen Notre Dame de Bondeville | Fraxiparine | štrc. 10x2850 i.j. anti Xa/0,3 ml | 1,8909 | 18,91 | RSRB11 | 5% |
| B01AB06 022 | DSPO | nadroparinNB102 | 2.85 T i.j. | 1,7180 | P | Mylan Hrvatska d.o.o. | Aspen Notre Dame de Bondeville | Fraxiparine | štrc. 10x5.700 i.j. anti Xa/0,6 ml | 3,4355 | 34,36 | RSRB11 | 5% |
| B01AB06 023 | DSPO | nadroparinNB102 | 2.85 T i.j. | 1,2461 | P | Mylan Hrvatska d.o.o. | Aspen Notre Dame de Bondeville | Fraxiparine | štrc. 10x7.600 i.j. anti Xa/0,8 ml | 3,3227 | 33,23 |  | 5% |
| B01AB06 024 | DSPO | nadroparinNB102 | 2.85 T i.j. | 1,8975 | P | Mylan Hrvatska d.o.o. | Aspen Notre Dame de Bondeville | Fraxiparine | štrc. 10x3.800 i.j. anti Xa/0,4 ml | 2,5297 | 25,30 | RSRB11 | 5% |
| B01AC04 111 |  | klopidogrel | 75 mg | 0,3004 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Pigrel | tbl. film obl. 28x75 mg | 0,3005 | 8,41 | RSRB01 | 5% |
| B01AC04 115 |  | klopidogrel | 75 mg | 0,2870 | O | Belupo d.d. | Belupo | Klopidex | tbl. film obl. 30x75 mg | 0,2871 | 8,61 | RSRB01 | 5% |
| B01AC04 125 |  | klopidogrel | 75 mg | 0,2870 | O | Sandoz d.o.o. | Sandoz-Lek | Kogrel | tbl. film obl. 30x75 mg | 0,2871 | 8,61 | RSRB01 | 5% |
| B01AC04 126 |  | klopidogrel | 75 mg | 0,2637 | O | Sandoz d.o.o. | Sandoz-Lek | Kogrel | tbl. film obl. 60x75 mg | 0,2637 | 15,82 | RSRB01 | 5% |
| B01AC04 131 |  | klopidogrel | 75 mg | 0,3004 | O | Krka d.d., Novo mesto | KRKA-FARMA d.o.o. | Zyllt | tbl. film obl. 28x75 mg | 0,3005 | 8,41 | RSRB01 | 5% |
| B01AC04 135 |  | klopidogrel | 75 mg | 0,3004 | O | Mylan Hrvatska d.o.o. | Phamathen International SA | Gardin | tbl. film obl. 28x75 mg | 0,3005 | 8,41 | RSRB01 | 5% |
| B01AC04 145 |  | klopidogrel | 75 mg | 0,3004 | O | PharmaS d.o.o. | PharmaS d.o.o. | Klopidogrel PharmaS | tbl. film obl. 28x75 mg | 0,3005 | 8,41 | RSRB01 | 5% |
| B01AC04 163 | DS | klopidogrelNB103 | 75 mg | 0,4539 | O | sanofi-aventis groupe | Sanofi Winthrop Industrie | Plavix | tbl. film obl. 30x300 mg | 1,8156 | 54,47 |  | 5% |
| B01AC06 151 | DS | acetilsalicilna kiselina | 100 mg |  | O |  |  |  |  |  |  |  | 5% |
| B01AC07 051 | DS | dipiridamolNB104 | 0,2 g |  | P |  |  |  |  |  |  |  | 5% |
| B01AC11 062 | KS | iloprostNB105 | 0,15 mg | 183,9675 | I | Bayer AG | Berlimed S.A. | Ventavis | otop. za atomizator, amp. stakl. 90x2 ml (10 mcg/ml) | 24,5289 | 2.207,61 |  | 5% |
| B01AC16 062 | DS | eptifibatidNB106 |  |  | P | GlaxoSmithKline (Ireland) Limited | Glaxo Operations UK Ltd., GlaxoSmithKline Manufacturing S.P.A. | Integrilin | boč. 1x100 ml (0,75 mg/ml) | 55,7754 | 55,78 |  | 5% |
| B01AC16 071 | DS | eptifibatidNB106 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Eptifibatid Accord | otop. za inj., boč. stakl. 1x10 ml (2 mg/ml) | 12,6896 | 12,69 |  | 5% |
| B01AC16 072 | DS | eptifibatidNB106 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Eptifibatid Accord | otop. za inj., boč. stakl. 1x100 ml (0,75 mg/ml) | 39,9562 | 39,96 |  | 5% |
| B01AC22 101 |  | prasugrel | 10 mg | 1,0079 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prasugrel Pliva | tbl. film obl. 28x10 mg | 1,0078 | 28,22 | RS RB02 | 5% |
| B01AC22 131 |  | prasugrel | 10 mg | 0,9825 | O | KRKA-FARMA d.o.o. | Krka d.d. | Eliskardia | tbl. film obl. 28x10 mg | 0,9823 | 27,51 | RS RB02 | 5% |
| B01AC22 141 |  | prasugrel | 10 mg | 0,9520 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Tosynal | tbl. film obl. 30x10 mg | 0,9521 | 28,56 | RS RB02 | 5% |
| B01AC22 171 |  | prasugrel | 10 mg | 0,9332 | O | Mylan Pharmaceuticals Limited | McDermott Laboratories t/a Gerard Laboratories t/a Mylan Dublin, Mylan Hungary Kft./Mylan Hungary Ltd. | Prasugrel Mylan | tbl. film obl. 28x10 mg | 0,9332 | 26,13 | RS RB02 | 5% |
| B01AC24 111 |  | tikagrelor | 0,18 g | 1,0079 | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Greccas | tbl. film obl. 56x90 mg | 0,5039 | 28,22 | RS RB02 | 5% |
| B01AC24 171 |  | tikagrelor | 0,18 g | 1,0079 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Tilobrastil | tbl. film obl. 56x90 mg | 0,5039 | 28,22 | RS RB02 | 5% |
| B01AC24 174 |  | tikagrelor | 0,18 g | 1,0079 | O | PharmaS d.o.o. | S.C Labormed – Pharma SA, AdAlvo Limited | Tikagrelor PharmaS | tbl. film obl. 56x90 mg | 0,5039 | 28,22 | RS RB02 | 5% |
| B01AC24 181 |  | tikagrelor | 0,18 g | 1,0079 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atixarso | tbl. film obl. 56x90 mg | 0,5039 | 28,22 | RS RB02 | 5% |
| B01AC24 182 |  | tikagrelor | 0,18 g | 1,0079 | O | Abdi Farma Unipessoal Ltd. | Interpharma Services Ltd., Pharmadox Healthcare Limited | Tikagrelor Abdi | tbl. film obl. 56x90 mg | 0,5039 | 28,22 | RS RB02 | 5% |
| B01AC24 191 |  | tikagrelor | 0,18 g | 1,0079 | O | Mylan Ireland Limited | PharOS MT Ltd | Igzelym | tbl. film obl. 56x90 mg | 0,5039 | 28,22 | RS RB02 | 5% |
| B01AC24 192 |  | tikagrelor | 0,18 g | 1,0077 | O | STADA d.o.o. | STADA Arzneimittel AG | Tigrix | tbl. film obl. 60x90 mg | 0,5039 | 30,23 | RS RB02 | 5% |
| B01AD02 061 | DS | alteplazaNB107 | 0,1 g | 824,2400 | P | Boehringer Ingelheim Zagreb d.o.o. | Boehringer Ingelheim | Actilyse | lio boč. 1x50 mg | 412,1242 | 412,12 |  | 5% |
| B01AE07 162 | DS | dabigatran eteksilat NB108 | 0,22 g | 3,0096 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Pradaxa | caps. tvrda 30x75 mg | 1,0259 | 30,78 |  | 5% |
| B01AE07 164 | DS | dabigatran eteksilat NB108 | 0,22 g | 2,0447 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Pradaxa | caps. tvrda 30x110 mg | 1,0224 | 30,67 |  | 5% |
| B01AF01 161 | DS | rivaroksaban NB108 | 20 mg | 4,2400 | O | Bayer AG | Bayer AG | Xarelto | tbl. film obl. 10x10 mg | 2,1200 | 21,20 |  | 5% |
| B01AF01 162 | DS | rivaroksaban NB108 | 20 mg | 4,0180 | O | Bayer AG | Bayer AG | Xarelto | tbl. film obl. 30x10 mg | 2,0092 | 60,27 |  | 5% |
| B01AF01 361 |  | rivaroksaban | 20 mg | 2,1900 | O | Bayer AG | Bayer AG | Xarelto | gran. za oral. susp. 1 mg/ml, 100 ml boca | 10,9496 | 10,95 | RSRB13 | 5% |
| B01AF01 362 |  | rivaroksaban | 20 mg | 1,7520 | O | Bayer AG | Bayer AG | Xarelto | gran. za oral. susp. 1 mg/ml, 250 ml boca | 21,8993 | 21,90 | RSRB13 | 5% |
| B01AF01 964 |  | rivaroksaban | 20 mg | 2,6790 | O | Bayer AG | Bayer AG | Xarelto | film obl. tbl. 28x15 mg | 2,0091 | 56,26 | RSRB14 | 5% |
| B01AF01 965 |  | rivaroksaban | 20 mg | 2,6790 | O | Bayer AG | Bayer AG | Xarelto | film obl.tbl. 42x15 mg | 2,0092 | 84,39 | RSRB14 | 5% |
| B01AF01 966 |  | rivaroksaban | 20 mg | 2,0093 | O | Bayer AG | Bayer AG | Xarelto | film obl.tbl. 28x20 mg | 2,0091 | 56,26 | RSRB15 | 5% |
| B01AF02 161 | DS | apiksabanNB108 | 10 mg | 4,0180 | O | Bristol-Myers Squibb/Pfizer EEIG | Bristol-Myers Squibb S.r.l. | Eliquis | tbl. film obl. 20x2,5 mg | 1,0046 | 20,09 |  | 5% |
| B01AX05 061 | DS | fondaparinuksNB109 | 2,5 mg | 4,3180 | P | Mylan IRE Healthcare Ltd | Aspen Notre Dame de Bondeville | Arixtra | otop. za inj., štrc. napunj. 10x2,5 mg/0,5 ml | 4,3179 | 43,18 |  | 5% |
| B02AA01 052 | DS | aminokapronska kiselina | 16 g |  | P |  |  |  |  |  |  |  | 5% |
| B02AA02 051 | DS | traneksamična kiselinaNB201 | 2 g |  | P |  |  |  |  |  |  |  | 5% |
| B02AA02 061 | DS | traneksamatna kiselina | 2 g | 7,0320 | P | Makpharm d.o.o. | Bioindustria Lim SPA | Trenolk | amp. 5x5 ml (100 mg/ml) | 1,7588 | 8,79 |  | 5% |
| B02AA02 151 | DS | traneksamična kiselinaNB201 | 2 g |  | O |  |  |  |  |  |  |  | 5% |
| B02AB01 051 | DS | aprotinin NB202 | 500 T i.j. |  | P |  |  |  |  |  |  |  | 5% |
| B02BA01 062 | PR | fitomenadion | 20 mg | 1,0280 | P | Cheplapharm Arzneimittel GmbH | Cheplapharm Arzneimittel GmbH | Konakion | amp. 5x10 mg/ml | 0,5150 | 2,57 |  | 5% |
| B02BA01 151 |  | fitomenadion | 20 mg |  | O |  |  |  |  |  |  | R | 5% |
| B02BB01 071 | DS | fibrinogen | 5 g | 1.949,7000 | P | Jana Pharm d.o.o. | Octapharma Pharmazeutika Produktionsges.m.b.H., Octapharma AB | Fibryga | praš. i otap. za otop. za inj./inf., stak. boč. 1x1 g | 389,9396 | 389,94 |  | 5% |
| B02BC30 962 | DS | ljudski fibrinogen, ljudski trombin |  |  | L | Corza Medical GmbH | Takeda | TachoSil | 1 matrica tkivnog ljepila 9,5 cm x 4,8 cm | 247,6847 | 247,68 |  | 5% |
| B02BC30 963 | DS | ljudski fibrinogen, ljudski trombin |  |  | L | Corza Medical GmbH | Takeda | TachoSil | 1 matrica tkivnog ljepila 3,0 cm x 2,5 cm | 47,1989 | 47,20 |  | 5% |
| B02BC30 964 | DS | ljudski fibrinogen, ljudski trombin |  |  | L | Corza Medical GmbH | Takeda Austria GmbH | TachoSil | 2 matrice tkivnog ljepila od 4,8 x 4,8 cm | 168,6164 | 337,23 |  | 5% |
| B02BC30 965 | DS | ljudski fibrinogen, ljudski trombin |  |  | L | Corza Medical GmbH | Takeda Austria GmbH | TachoSil | 1 prethodno zarolana matrica tkivnog ljepila od 4,8 x 4,8 cm | 205,0236 | 205,02 |  | 5% |
| B02BD01 071 | DS | ljudski protrombinski kompleksNB203 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octaplex 500 IU | praš. i otap. za otop. za inf. boč. stakl. boč. s praš., boč. stakl. 1x500 i.j., s 20 ml otap. i 1 set za prijenos (igla za filtraciju i dvostrana igla) | 210,3365 | 210,34 |  | 5% |
| B02BD01 081 | DS | ljudski protrombinski kompleksNB203 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Beriplex | praš. i otap. za otop. za inf. boč. stakl. boč. s praš., boč. stakl. 1x500 i.j., s 20 ml otap. i 1 set za prijenos s filterom | 219,1333 | 219,13 |  | 5% |
| B02BD01 082 | DS | ljudski protrombinski kompleksNB203 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Beriplex | praš. i otap. za otop. za inf. boč. stakl. boč. s praš., boč. stakl. 1x1000 i.j., s 40 ml otap. i 1 set za prijenos s filterom | 442,4195 | 442,42 |  | 5% |
| B02BD02 001 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 167,7643 | 167,76 |  | 5% |
| B02BD02 002 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 335,5299 | 335,53 |  | 5% |
| B02BD02 003 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x750 i.j. | 503,2955 | 503,30 |  | 5% |
| B02BD02 004 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 671,0598 | 671,06 |  | 5% |
| B02BD02 005 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x1500 i.j. | 1.006,5897 | 1.006,59 |  | 5% |
| B02BD02 006 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 1.342,1196 | 1.342,12 |  | 5% |
| B02BD02 007 | DS | rekombinantni čimbenik VIIIFc (efmoroktokog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB | Elocta | praš. i otap. za otop. za inj., boč. stakl. 1x3000 i.j. | 2.013,1807 | 2.013,18 |  | 5% |
| B02BD02 008 | DS | rekombinantni čimbenik VIII (lonoktokog alfa)NB205 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Afstyla | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 153,6267 | 153,63 |  | 5% |
| B02BD02 009 | DS | rekombinantni čimbenik VIII (lonoktokog alfa)NB205 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Afstyla | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 307,2533 | 307,25 |  | 5% |
| B02BD02 010 | DS | rekombinantni čimbenik VIII (lonoktokog alfa)NB205 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Afstyla | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 614,5066 | 614,51 |  | 5% |
| B02BD02 011 | DS | rekombinantni čimbenik VIII (damoktokog alfa pegol)NB207 |  |  | P | Bayer AG | Bayer AG | Jivi 500 IU | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 404,1410 | 404,14 |  | 5% |
| B02BD02 012 | DS | rekombinantni čimbenik VIII (damoktokog alfa pegol)NB207 |  |  | P | Bayer AG | Bayer AG | Jivi 1000 IU | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 808,2819 | 808,28 |  | 5% |
| B02BD02 013 | DS | rekombinantni čimbenik VIII (damoktokog alfa pegol)NB207 |  |  | P | Bayer AG | Bayer AG | Jivi 2000 IU | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 1.616,5638 | 1.616,56 |  | 5% |
| B02BD02 014 | DS | rekombinantni čimbenik VIII (damoktokog alfa pegol)NB207 |  |  | P | Bayer AG | Bayer AG | Jivi 3000 IU | praš. i otap. za otop. za inj., boč. stakl. 1x3000 i.j. | 2.424,8457 | 2.424,85 |  | 5% |
| B02BD02 021 | DS | rekombinantni čimbenik VIII (rurioktokog alfa pegol)NB207 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | Adynovi | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 374,4376 | 374,44 |  | 5% |
| B02BD02 022 | DS | rekombinantni čimbenik VIII (rurioktokog alfa pegol)NB207 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | Adynovi | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 736,6726 | 736,67 |  | 5% |
| B02BD02 023 | DS | rekombinantni čimbenik VIII (turoktokog alfa pegol)NB207 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Esperoct | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 327,8253 | 327,83 |  | 5% |
| B02BD02 024 | DS | rekombinantni čimbenik VIII (turoktokog alfa pegol)NB207 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Esperoct | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 655,6507 | 655,65 |  | 5% |
| B02BD02 025 | DS | rekombinantni čimbenik VIII (turoktokog alfa pegol)NB207 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Esperoct | praš. i otap. za otop. za inj., boč. stakl. 1x3000 i.j. | 1.966,9520 | 1.966,95 |  | 5% |
| B02BD02 031 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 157,8857 | 157,89 |  | 5% |
| B02BD02 033 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 i.j. | 619,8805 | 619,88 |  | 5% |
| B02BD02 034 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x1.500 i.j. | 918,9422 | 918,94 |  | 5% |
| B02BD02 035 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x2.000 i.j. | 1.239,7611 | 1.239,76 |  | 5% |
| B02BD02 036 | DS | rekombinantni čimbenik VIII (turoktokog alfa)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | NovoEight | praš. i otap. za otop. za inj., boč. stakl. 1x3.000 i.j. | 1.837,8844 | 1.837,88 |  | 5% |
| B02BD02 061 | DS | čimbenik VIIINB204 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Emoclot | praš. i otap. za otop. za inf., boč. stakl. 1x500 i.j. (50 IU/ml) | 170,5329 | 170,53 |  | 5% |
| B02BD02 062 | DS | čimbenik VIIINB204 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Emoclot | praš. i otap. za otop. za inf., boč. stakl. 1x1000 i.j. (100 IU/ml) | 315,0176 | 315,02 |  | 5% |
| B02BD02 072 | DS | čimbenik VIIINB204 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octanate | lio. boč. 500 i.j. | 189,4817 | 189,48 |  | 5% |
| B02BD02 073 | DS | čimbenik VIIINB204 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octanate | lio. boč. 1.000 i.j. | 350,0206 | 350,02 |  | 5% |
| B02BD02 079 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Advate | praš. i otap. za otop. za inj., boč. stakl. 1x500 IU/5 ml | 339,1758 | 339,18 |  | 5% |
| B02BD02 080 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Advate | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 IU/5 ml | 678,8745 | 678,87 |  | 5% |
| B02BD02 082 | DS | rekombinantni čimbenik VIII (moroktokog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | ReFacto AF | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 161,1573 | 161,16 |  | 5% |
| B02BD02 083 | DS | rekombinantni čimbenik VIII (moroktokog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | ReFacto AF | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 305,2585 | 305,26 |  | 5% |
| B02BD02 084 | DS | rekombinantni čimbenik VIII (moroktokog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | ReFacto AF | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 i.j. | 632,7255 | 632,73 |  | 5% |
| B02BD02 085 | DS | rekombinantni čimbenik VIII (moroktokog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | ReFacto AF | praš. i otap. za otop. za inj., boč. stakl. 1x2.000 i.j. | 1.265,4509 | 1.265,45 |  | 5% |
| B02BD02 086 | DS | rekombinantni čimbenik VIII (simoktokog alfa)NB205 |  |  | P | Octapharma AB | Octapharma AB | Nuwiq | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 157,8857 | 157,89 |  | 5% |
| B02BD02 087 | DS | rekombinantni čimbenik VIII (simoktokog alfa)NB205 |  |  | P | Octapharma AB | Octapharma AB | Nuwiq | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 299,0616 | 299,06 |  | 5% |
| B02BD02 088 | DS | rekombinantni čimbenik VIII (simoktokog alfa)NB205 |  |  | P | Octapharma AB | Octapharma AB | Nuwiq | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 i.j. | 619,8805 | 619,88 |  | 5% |
| B02BD02 095 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Bayer AG | Bayer AG | Kovaltry | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 335,5299 | 335,53 |  | 5% |
| B02BD02 096 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Bayer AG | Bayer AG | Kovaltry | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 671,0598 | 671,06 |  | 5% |
| B02BD02 097 | DS | rekombinantni čimbenik VIII (oktokog alfa)NB205 |  |  | P | Bayer AG | Bayer AG | Kovaltry | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 1.342,1196 | 1.342,12 |  | 5% |
| B02BD03 063 | DS | aktivirani koncentrat čimbenika protrombinskog kompleksaNB204 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Feiba 50 U/ml | praš. i otap. za otop. za inf., boč. 1x500 U/10 ml (50 U/ml) | 386,4039 | 386,40 |  | 5% |
| B02BD04 063 | DS | čimbenik IX NB204 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octanine F | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j.+5 ml otap.+set | 185,9831 | 185,98 |  | 5% |
| B02BD04 072 | DS | čimbenik IX NB204 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Immunine 600 IU | praš. i otap. za otop. za inj./inf., boč. 1x600 IU/5 ml | 212,4892 | 212,49 |  | 5% |
| B02BD04 074 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 252,0074 | 252,01 |  | 5% |
| B02BD04 075 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 504,0149 | 504,01 |  | 5% |
| B02BD04 076 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 1.008,0297 | 1.008,03 |  | 5% |
| B02BD04 077 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 2.016,0595 | 2.016,06 |  | 5% |
| B02BD04 078 | DS | rekombinantni čimbenik IXFc (eftrenonakog alfa)NB205 |  |  | P | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Alprolix | praš. i otap. za otop. za inj., boč. stakl. 1x3000 i.j. | 3.024,0892 | 3.024,09 |  | 5% |
| B02BD04 091 | DS | rekombinantni humani faktor IX (nonakog beta pegol)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Refixia | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 629,7697 | 629,77 |  | 5% |
| B02BD04 092 | DS | rekombinantni humani faktor IX (nonakog beta pegol)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Refixia | praš. i otap. za otop. za inj., boč. stakl. 1x1000 i.j. | 1.259,5395 | 1.259,54 |  | 5% |
| B02BD04 093 | DS | rekombinantni humani faktor IX (nonakog beta pegol)NB205 |  |  | P | Novo Nordisk A/S | Novo Nordisk A/S | Refixia | praš. i otap. za otop. za inj., boč. stakl. 1x2000 i.j. | 2.519,0789 | 2.519,08 |  | 5% |
| B02BD04 095 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 118,2812 | 118,28 |  | 5% |
| B02BD04 096 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 236,5625 | 236,56 |  | 5% |
| B02BD04 097 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 i.j. | 473,1250 | 473,12 |  | 5% |
| B02BD04 098 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 |  |  | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x2.000 i.j. | 946,2499 | 946,25 |  | 5% |
| B02BD06 075 | DS | koagulacijski faktor VIII, ljudski, von Willebrandov faktor, ljudskiNB206 |  |  | P | Jana Pharm d.o.o. | Octapharma | Wilate 500, 500 IU FVIII i 500 IU vWF | praš. i otap. za otop. za inj., boč. 1x500 IU i 500 IU | 267,3674 | 267,37 |  | 5% |
| B02BD06 076 | DS | konc. čimbenik VIII s von Willebrandovim čimbenikomNB204 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Immunate 500 IU FVIII/375 IU vWF | praš. i otap. za otop. za inj., boč. 1x500 IU FVIII/375 IU vWF/5 ml | 194,8676 | 194,87 |  | 5% |
| B02BD06 077 | DS | koagulacijski faktor VIII, ljudski, von Willebrandov faktor, ljudskiNB206 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Haemate P 1200 IU VWF/500 IU FVIII | praš. i otap. za otop. za inj., boč. 1x1.200 IU vWF/500 IU FVIII | 241,8648 | 241,86 |  | 5% |
| B02BD07 051 | DS | čimbenik ugrušavanja krvi XIIINB204 |  |  | P |  |  |  |  |  |  |  | 5% |
| B02BD08 084 | DS | aktivirani rekombinantni čimbenik VII A NB204 |  |  | P | Novo Nordisk A/S | Novo Nordisk | NovoSeven | praš. i otap. za otop. za inj., 1x1 mg (50 KIU) | 591,2429 | 591,24 |  | 5% |
| B02BD08 088 | DS | aktivirani rekombinantni čimbenik VII A NB204 |  |  | P | Novo Nordisk A/S | Novo Nordisk | NovoSeven | praš. i otap. za otop. za inj., 1x2 mg (100 KIU) | 1.171,4500 | 1.171,45 |  | 5% |
| B02BD08 089 | DS | aktivirani rekombinantni čimbenik VII A NB204 |  |  | P | Novo Nordisk A/S | Novo Nordisk | NovoSeven | praš. i otap. za otop. za inj., 1x5 mg (250 KIU) | 2.910,7665 | 2.910,77 |  | 5% |
| B02BX04 063 | KS | romiplostimNB504 | 30 mcg | 65,6031 | P | Amgen Europe B.V. | Amgen Europe B.V. | Nplate | praš. i otap. za otop. za inj., štrc. napunj. 1x250 mcg | 546,6879 | 546,69 |  | 5% |
| B02BX04 064 | KS | romiplostimNB504 | 30 mcg | 66,0359 | P | Amgen Europe B.V. | Amgen Europe B.V. | Nplate | praš. i otap. za otop. za inj., štrc. napunj. 1x500 mcg | 1.100,5986 | 1.100,60 |  | 5% |
| B02BX05 161 | KS | eltrombopagNB504 | 50 mg | 64,3471 | O | Novartis Europharm Limited Irska | Lek d.d., Novartis Pharma GmbH | Revolade | tbl. film obl. 28x25 mg | 32,1737 | 900,86 |  | 5% |
| B02BX05 162 | KS | eltrombopagNB504 | 50 mg | 64,3475 | O | Novartis Europharm Limited Irska | Lek d.d., Novartis Pharma GmbH | Revolade | tbl. film obl. 28x50 mg | 64,3475 | 1.801,73 |  | 5% |
| B02BX06 071 | DS | emicizumabNB507 | 15 mg | 1.069,1400 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x1 ml (30 mg/ml) | 2.138,2826 | 2.138,28 |  | 5% |
| B02BX06 072 | DS | emicizumabNB507 | 15 mg | 1.065,2125 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x0,4 ml (150 mg/ml) | 4.260,8481 | 4.260,85 |  | 5% |
| B02BX06 073 | DS | emicizumabNB507 | 15 mg | 1.063,1229 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x0,7 ml (150 mg/ml) | 7.441,8594 | 7.441,86 |  | 5% |
| B02BX06 074 | DS | emicizumabNB507 | 15 mg | 1.062,2880 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x1 ml (150 mg/ml) | 10.622,8774 | 10.622,88 |  | 5% |
| B02BX06 971 | DS | emicizumabNB510 | 15 mg | 1.069,1400 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x1 ml (30 mg/ml) | 2.138,2826 | 2.138,28 |  | 5% |
| B02BX06 972 | DS | emicizumabNB510 | 15 mg | 1.065,2125 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x0,4 ml (150 mg/ml) | 4.260,8481 | 4.260,85 |  | 5% |
| B02BX06 973 | DS | emicizumabNB510 | 15 mg | 1.063,1229 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x0,7 ml (150 mg/ml) | 7.441,8594 | 7.441,86 |  | 5% |
| B02BX06 974 | DS | emicizumabNB510 | 15 mg | 1.062,2880 | P | Roche Registration GmbH | Roche Austria GmbH | Hemlibra | otop. za inj., boč. stakl. 1x1 ml (150 mg/ml) | 10.622,8774 | 10.622,88 |  | 5% |
| B02BX08 171 | KS | avatrombopagNB504 | 20 mg | 64,3480 | O | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Doptelet | tbl. film obl. 10x20 mg | 64,3480 | 643,48 |  | 5% |
| B02BX08 172 | KS | avatrombopagNB504 | 20 mg | 64,3480 | O | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Doptelet | tbl. film obl. 15x20 mg | 64,3480 | 965,22 |  | 5% |
| B02BX08 173 | KS | avatrombopagNB504 | 20 mg | 64,3480 | O | Swedish Orphan Biovitrum AB (publ) | Swedish Orphan Biovitrum AB (publ) | Doptelet | tbl. film obl. 30x20 mg | 64,3480 | 1.930,44 |  | 5% |
| B03AA02 141 |  | željezo II -fumarat | 0,2 g | 0,0653 | O | Alkaloid d.o.o. | Alkaloid | Heferol | caps. 30x350 mg | 0,1142 | 3,43 | R | 5% |
| B03AC01 021 | DS | željezo karboksimaltoza | 100 mg | 19,7820 | P | Vifor France S.A. | Vifor France S.A. | Ferinject | otop. za inj. ili inf. , boč. 1x10 ml (50 mg/ml) | 98,9064 | 98,91 |  | 5% |
| B03AC01 022 | DS | željezo karboksimaltoza | 100 mg | 18,7920 | P | Vifor France S.A. | Vifor France S.A. | Ferinject | otop. za inj. ili inf. , boč. 1x20 ml (50 mg/ml) | 187,9209 | 187,92 |  | 5% |
| B03AC02 051 | DS | željezo III-oksid saharat | 100 mg | #N/A | P |  |  |  | 1x100 mg | #N/A | #N/A |  | 5% |
| B03AC05 051 | PO | željezo III-sorbitol glukonska kiselina |  |  | P |  |  |  |  |  |  |  | 5% |
| B03AC06 062 | DS | željezova(III) derizomaltoza | 100 mg | 19,7812 | P | Pharmacosmos A/S | Pharmacosmos A/S | Monofer | otop. za inj./inf., amp./boč. 5x5 ml (100 mg/ml) | 98,9064 | 494,53 |  | 5% |
| B03BA01 051 | PR | cijanokobalamin | 20 mcg |  | P |  |  |  |  |  |  |  | 5% |
| B03BB01 161 |  | folatna kiselina | 10 mg | 0,2167 | O | Makpharm d.o.o. | G.L. Pharma GmbH | Folbella | tbl. 30x5 mg | 0,1083 | 3,25 | R | 5% |
| B03XA01 001 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 5,0233 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj., štrc. napunj. 6x2.000 i.j./0,5 ml | 10,0462 | 60,28 |  | 5% |
| B03XA01 002 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 5,0194 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj., štrc. napunj. 6x3.000 i.j./0,5 ml | 15,0583 | 90,35 |  | 5% |
| B03XA01 003 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 4,9788 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj. štrc. napunj. 6x4.000 i.j./0,5 ml | 19,9146 | 119,49 |  | 5% |
| B03XA01 004 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 4,6438 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj., štrc. napunj. 6x10.000 i.j./ml | 46,4388 | 278,63 |  | 5% |
| B03XA01 005 | DSPO | eritropoetin thetaNB301 | 1 T i.j. | 4,6150 | P | ratiopharm GmbH | Pliva Hrvatska d.o.o | Eporatio | otop. za inj., štrc. napunj. 1x20.000 i.j./ml | 92,3034 | 92,30 |  | 5% |
| B03XA01 021 | DSPO | epoetin alfaNB301 | 1 T i.j. | 4,5208 | P | Sandoz GmbH | Sandoz | Binocrit | otop. za inj., štrc. napunj. 6x2.000 i.j/ml | 9,0415 | 54,25 |  | 5% |
| B03XA01 023 | DSPO | epoetin alfaNB301 | 1 T i.j. | 4,4808 | P | Sandoz GmbH | Sandoz | Binocrit | otop. za inj., štrc. napunj. 6x4.000 i.j/0,4 ml | 17,9231 | 107,54 |  | 5% |
| B03XA01 075 | DSPO | epoetin betaNB301 | 1 T i.j. | 4,5417 | P | Roche Registration GmbH | Roche | NeoRecormon | šprica 6x2.000 i.j/0,3 ml | 9,0835 | 54,50 |  | 5% |
| B03XA01 077 | DSPO | epoetin betaNB301 | 1 T i.j. | 4,4138 | P | Roche Registration GmbH | Roche | NeoRecormon | šprica 6x4.000 i.j/0,3 ml | 17,6548 | 105,93 |  | 5% |
| B03XA01 078 | DSPO | epoetin betaNB301 | 1 T i.j. | 4,3430 | P | Roche Registration GmbH | Roche | NeoRecormon | šprica 6x10.000 i.j/0,6 ml | 43,4300 | 260,58 |  | 5% |
| B03XA01 081 | DSPO | eritropoetin zetaNB301 | 1 T i.j. | 5,0233 | P | Pfizer Europe MA EEIG | STADA Arzneimittel AG, Hospira Enterprises B.V. | Retacrit | otop. za inj., štrc. napunj. 6x2.000 i.j/0,6 ml | 10,0462 | 60,28 |  | 5% |
| B03XA01 082 | DSPO | eritropoetin zetaNB301 | 1 T i.j. | 4,9788 | P | Pfizer Europe MA EEIG | STADA Arzneimittel AG, Hospira Enterprises B.V. | Retacrit | otop. za inj., štrc. napunj. 6x4.000 i.j/0,4 ml | 19,9146 | 119,49 |  | 5% |
| B03XA01 083 | DSPO | eritropoetin zetaNB301 | 1 T i.j. | 4,4448 | P | Pfizer Europe MA EEIG | STADA Arzneimittel AG, Hospira Enterprises B.V. | Retacrit | otop. za inj., štrc. napunj. 6x10.000 i.j/ml | 44,4480 | 266,69 |  | 5% |
| B03XA02 061 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 7,0336 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x10 mcg/0,4 ml (25 mcg/ml) | 15,6255 | 15,63 |  | 5% |
| B03XA02 062 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 6,8550 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x30 mcg/0,3ml (100 mcg/ml) | 45,6965 | 45,70 |  | 5% |
| B03XA02 063 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 7,6625 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x20 mcg/0,5 ml (40 mcg/ml) | 30,6497 | 30,65 |  | 5% |
| B03XA02 064 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 6,8962 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x40 mcg/0,4 ml (100 mcg/ml) | 61,2967 | 61,30 |  | 5% |
| B03XA02 065 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 6,8958 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x50 mcg/0,5 ml (100 mcg/ml) | 76,6209 | 76,62 |  | 5% |
| B03XA02 066 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 6,8963 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x60 mcg/0,3 ml (200 mcg/ml) | 91,9451 | 91,95 |  | 5% |
| B03XA02 067 | DSPO | darbepoetin alfaNB301 | 4,5 mcg | 6,8957 | P | Amgen Europe B.V. | Amgen Europe B.V. | Aranesp | otop. za inj., štrc. stakl. 1x80 mcg/0,4 ml (200 mcg/ml) | 122,5934 | 122,59 |  | 5% |
| B03XA03 062 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 6,1664 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x50 mcg/0,3 ml | 77,0841 | 77,08 |  | 5% |
| B03XA03 063 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 6,0464 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x75 mcg/0,3 ml | 113,3705 | 113,37 |  | 5% |
| B03XA03 064 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 6,0464 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x100 mcg/0,3ml | 151,1593 | 151,16 |  | 5% |
| B03XA03 065 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 6,0463 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x120 mcg/0,3ml | 181,3909 | 181,39 |  | 5% |
| B03XA03 066 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 6,0464 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj., štrc. napunj. 1x150 mcg/0,3ml | 226,7383 | 226,74 |  | 5% |
| B03XA03 067 | DSPO | metoksi polietilenglikol-epoetin betaNB301 | 4 mcg | 6,0464 | P | Roche Registration GmbH | Roche | Mircera | otop. za inj. štrc. napunj. 1x200 mcg/0,3ml | 302,3187 | 302,32 |  | 5% |
| B05AA01 011 | DS | ljudski albumin 5%NB501 |  |  | P | Imunološki zavod | Imunološki zavod | Albumin ljudski 50 g/l | otop. za inf., boca stakl. 1x250 ml | 34,2425 | 34,24 |  | 5% |
| B05AA01 012 | DS | ljudski albumin 20%NB502 |  |  | P | Imunološki zavod | Imunološki zavod | Albumin (ljudski) 20% | otop. za inf., boca stakl. 1x50 ml | 26,6468 | 26,65 |  | 5% |
| B05AA01 013 | DS | ljudski albumin 20%NB502 |  |  | P | Imunološki zavod | Imunološki zavod | Albumin (ljudski) 20% | otop. za inf., boca stakl. 1x100 ml | 54,2292 | 54,23 |  | 5% |
| B05AA01 064 | DS | ljudski albumin 20%NB502 |  |  | P | Jana Pharm d.o.o. | Octapharma | Albunorm 20% (non HR) | otop. za inf., boč. stakl. 1x100 ml | 54,2292 | 54,23 |  | 5% |
| B05AA01 065 | DS | ljudski albumin 5%NB501 |  |  | P | Jana Pharm d.o.o. | Octapharma Pharmazeutika Octapharma S.A.S., Octapharma AB, Octapharma Produktionsgesellschaft, Octapharma GmbH | Albunorm 5% | otop. za inf., boca stakl. 1x250 ml | 34,2425 | 34,24 |  | 5% |
| B05AA01 066 | DS | ljudski albumin 20%NB502 |  |  | P | Jana Pharm d.o.o. | Octapharma | Albunorm 20% | otop. za inf., boca stakl. 1x50 ml | 26,6468 | 26,65 |  | 5% |
| B05AA01 067 | DS | ljudski albumin 5%NB501 |  |  | P | Jana Pharm d.o.o. | Octapharma Pharmazeutika Octapharma S.A.S., Octapharma AB, Octapharma Produktionsgesellschaft, Octapharma GmbH | Albunorm 5% | otop. za inf., boca stakl. 1x100 ml | 16,2386 | 16,24 |  | 5% |
| B05AA01 075 | DS | ljudski albumin 20%NB502 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Human albumin Kedrion | otop. za inf., stakl. boč. 1x50 ml (200 g/l) | 26,6468 | 26,65 |  | 5% |
| B05AA01 076 | DS | ljudski albumin 20%NB502 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Human albumin Kedrion | otop. za inf., stakl. boč. 1x100 ml (200 g/l) | 54,2292 | 54,23 |  | 5% |
| B05AA01 081 | DS | ljudski albumin 20%NB502 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Albumeon 200 g/l | boč. 1x50 ml | 26,6468 | 26,65 |  | 5% |
| B05AA01 083 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 1x50 ml/kutija | 26,6468 | 26,65 |  | 5% |
| B05AA01 084 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 12x50 ml/kutija, 2 kutije | 26,6468 | 639,52 |  | 5% |
| B05AA01 085 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 1x50 ml/kutija, 24 kutije | 26,6468 | 639,52 |  | 5% |
| B05AA01 086 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 1x100 ml/kutija | 54,2292 | 54,23 |  | 5% |
| B05AA01 087 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 6x100 ml/kutija, 2 kutije | 54,2292 | 650,75 |  | 5% |
| B05AA01 088 | DS | ljudski albumin 20%NB502 |  |  | P | Baxalta Innovations GmbH | Takeda Manufacturing Austria AG | Flexbumin | otop. za inf. (200 g/l), vreć. 1x100 ml/kutija, 12 kutija | 54,2292 | 650,75 |  | 5% |
| B05AA01 089 | DS | ljudski albumin 20%NB502 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Albumeon 200 g/l | boč. 1x100 ml | 51,5177 | 51,52 |  | 5% |
| B05AA01 964 | DS | ljudski albumin 20%NB502 |  |  | P | Jana Pharm d.o.o. | Octapharma | Albunorm 20% (HR) | otop. za inf., boč. stakl. 1x100 ml | 43,3831 | 43,38 |  | 5% |
| B05AA02 061 | DS | proteini ljudske plazmeNV701 |  |  | P | Octapharma (IP) SPRL | Octapharma Pharmazeutika Produktionsges.m.b.H., Octapharma AB | octaplasLG | otop. za inf., vreć. 1x200 ml (45-70 mg/ml) | 86,0004 | 86,00 |  | 5% |
| B05AA05 002 | PR | dekstran 40 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Soludeks 40 | otop. za inf., boca stakl. 10x500 ml (100 mg/ml) | 5,6606 | 56,61 |  | 5% |
| B05AA06 051 | DS | želatina |  |  | P |  |  |  |  |  |  |  | 5% |
| B05AA07 063 | DS | hidroksietil škrob |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Voluven 6% | boca 10x500 ml | 6,5578 | 65,58 |  | 5% |
| B05AA07 064 | DS | hidroksietil škrob |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Voluven 6% | vreć. plast. 20x500 ml | 6,5578 | 131,16 |  | 5% |
| B05AA07 081 | DS | hidroksietil škrob (poli-o-2-hidroksietil škrob) |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Volulyte 6% | otop. za inf., vreć. poliolef. 20x500 ml | 5,3118 | 106,24 |  | 5% |
| B05BA01 081 | DS | infuzije aminokiselina (N (2)-L-alanin-L-glutamin) |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Dipeptiven | boč. 10x100 ml | 31,0486 | 310,49 |  | 5% |
| B05BA01 091 | DS | infuzije aminokiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Nephrotect 10% | boč. 10x500 ml | 14,7123 | 147,12 |  | 5% |
| B05BA02 065 | DS | otopine masti i masnih kiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SMOFlipid 20% emulzija za infuziju | boca stakl. 10x100 ml | 4,6772 | 46,77 |  | 5% |
| B05BA02 066 | DS | otopine masti i masnih kiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SMOFlipid 20% emulzija za infuziju | boca stakl. 10x500 ml | 12,4454 | 124,45 |  | 5% |
| B05BA03 008 | PO | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 5% otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (50 mg/ml) | 0,9092 | 9,09 |  | 5% |
| B05BA03 010 | PO | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 10% otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (100 mg/ml) | 1,1759 | 11,76 |  | 5% |
| B05BA03 012 | DS | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 10% otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (100 mg/ml) | 1,0074 | 10,07 |  | 5% |
| B05BA03 021 | PO | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza 5% | otop. za inf., boca stakl. 10x500 ml (50 mg/ml) | 0,9092 | 9,09 |  | 5% |
| B05BA03 022 | PR | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 5% otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (50 mg/ml) | 0,8229 | 8,23 |  | 5% |
| B05BA03 023 | DS | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 5% otopina za infuziju | otop. za inf., boč. stakl. 20x100 ml (50 mg/ml) | 0,7778 | 15,56 |  | 5% |
| B05BA03 024 | PO | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza 10% | otop. za inf., boca stakl. 10x500 ml (100 mg/ml) | 1,1759 | 11,76 |  | 5% |
| B05BA03 026 | DS | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza HZTM 10% otopina za infuziju | otop. za inf., boč. stakl. 20x100 ml (100 mg/ml) | 0,8587 | 17,17 |  | 5% |
| B05BA03 061 | DS | glukoza |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Glukoza 5% Viaflo | otop. za inf.,vreć. plast. 50x100 ml (50mg/ml) | 0,8667 | 43,33 |  | 5% |
| B05BA03 062 | PR | glukoza |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Glukoza 5% Viaflo | otop. za inf., vreć. plast. 30x250 ml (50mg/ml) | 0,9198 | 27,59 |  | 5% |
| B05BA03 063 | PO | glukoza |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Glukoza 5% Viaflo | otop. za inf., vreć. plast. 20x500 ml (50mg/ml) | 1,0153 | 20,31 |  | 5% |
| B05BA03 067 | DS | glukoza |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Glukoza 5% Viaflo | otop. za inf., vreć. plast. 60x100 ml (50mg/ml) | 0,7406 | 44,44 |  | 5% |
| B05BA03 071 | DS | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 50 mg/ml | otop. za inf., 50 mg/ml, polietil. Ecoflac plus boca, 20x100 ml | 0,7800 | 15,60 |  | 5% |
| B05BA03 072 | PR | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 50 mg/ml | otop. za inf., 50 mg/ml, polietil. Ecoflac plus boca, 10x250 ml | 0,8278 | 8,28 |  | 5% |
| B05BA03 073 | PO | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 50 mg/ml | otop. za inf., 50 mg/ml, polietil. Ecoflac plus boca, 10x500 ml | 0,9138 | 9,14 |  | 5% |
| B05BA03 074 | DS | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 50 mg/ml | otop. za inf., 50 mg/ml, polietil. Ecoflac plus boca, 10x1000 ml | 1,5817 | 15,82 |  | 5% |
| B05BA03 075 | PO | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 100 mg/ml | otop. za inf., 100 mg/ml, polietil. Ecoflac plus boca, 10x500 ml | 1,1799 | 11,80 |  | 5% |
| B05BA03 076 | DS | glukoza |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Glukoza B. Braun 100 mg/ml | otop. za inf., 100 mg/ml, polietil. Ecoflac plus boca, 10x1000 ml | 1,6362 | 16,36 |  | 5% |
| B05BA03 077 | DS | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., boca plast. 40x100 ml | 0,7021 | 28,08 |  | 5% |
| B05BA03 078 | PO | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 10% | otop. za inf., boca plast. 10x500 ml | 1,0618 | 10,62 |  | 5% |
| B05BA03 079 | PR | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., boca plast. 20x250 ml | 0,7454 | 14,91 |  | 5% |
| B05BA03 080 | PO | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., boca plast. 10x500 ml | 0,8225 | 8,22 |  | 5% |
| B05BA03 081 | DS | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 60x50 ml | 0,7036 | 42,21 |  | 5% |
| B05BA03 084 | PO | glukoza |  |  | P | Baxter d.o.o. | Bieffe Medital S.A. | Glukoza 10% Viaflo | otop. za inf., vreć. plast. 20x500 ml, (100 mg/ml) | 0,9556 | 19,11 |  | 5% |
| B05BA03 086 | DS | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 50x100 ml | 0,7800 | 39,00 |  | 5% |
| B05BA03 087 | PR | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 30x250 ml | 0,8278 | 24,83 |  | 5% |
| B05BA03 088 | PO | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 20x500 ml | 0,9138 | 18,28 |  | 5% |
| B05BA03 089 | DS | glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Glukoza Fresenius Kabi 5% | otop. za inf., vreć. plast. 10x1000 ml | 1,7363 | 17,36 |  | 5% |
| B05BA10 025 | DS | otopina aminokiselina s elektrolitima + otopina glukoze + lipidna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven Nutribase | vreć. plast. 4x1026 ml | 25,5000 | 102,00 |  | 5% |
| B05BA10 026 | DS | otopina aminokiselina s elektrolitima + otopina glukoze + lipidna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven Nutribase | vreć. plast. 4x1539 ml | 32,1242 | 128,50 |  | 5% |
| B05BA10 031 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega peri | emulzija za infuziju, vreć. 5x1250 ml | 27,3807 | 136,90 |  | 5% |
| B05BA10 032 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega peri | emulzija za infuziju, vreć. 5x1875 ml | 34,4827 | 172,41 |  | 5% |
| B05BA10 033 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 56/144 specijal | emulzija za infuziju, vreć. 5x625 ml | 15,6600 | 78,30 |  | 5% |
| B05BA10 034 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 38/120 plus | emulzija za infuziju, vreć. 5x1250 ml | 23,2026 | 116,01 |  | 5% |
| B05BA10 047 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 56/144 specijal | emulzija za infuziju, vreć. 5x1250 ml | 27,0595 | 135,30 |  | 5% |
| B05BA10 048 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 56/144 specijal | emulzija za infuziju, vreć. 5x1875 ml | 36,9208 | 184,60 |  | 5% |
| B05BA10 049 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Nutriflex Omega 38/120 plus | emulzija za infuziju, vreć. 5x1875 ml | 31,6836 | 158,42 |  | 5% |
| B05BA10 060 | DS | glukoza + otopina aminokiselina + emulzija lipidaNB400 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven extra Nitrogen bez elektrolita | emulz. za inf., vreć. 4x2025 ml | 80,7393 | 322,96 |  | 5% |
| B05BA10 061 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | OliClinomel N4-550E | emulz. za inf., vreć. plast. 6x1000 ml | 21,3889 | 128,33 |  | 5% |
| B05BA10 062 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | OliClinomel N4-550E | emulz. za inf., vreć. plast. 4x2000 ml | 29,1227 | 116,49 |  | 5% |
| B05BA10 064 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | OliClinomel N7-1000E | emulz. za inf., vreć. plast. 6x1000 ml | 22,4660 | 134,80 |  | 5% |
| B05BA10 065 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | OliClinomel N7-1000E | emulz. za inf., vreć. plast. 4x2000 ml | 33,6482 | 134,59 |  | 5% |
| B05BA10 066 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Kabiven | vreć. plast. 4x1026 ml | 22,2765 | 89,11 |  | 5% |
| B05BA10 067 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Kabiven | vreć. plast. 4x1540 ml | 24,6569 | 98,63 |  | 5% |
| B05BA10 068 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Kabiven Peripheral | vreć. plast. 4x1440 ml | 24,4303 | 97,72 |  | 5% |
| B05BA10 069 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Kabiven Peripheral | vreć. plast. 4x1920 ml | 25,8650 | 103,46 |  | 5% |
| B05BA10 070 | DS | glukoza + otopina aminokiselina s elektrolitima + emulzija lipidaNB400 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven extra Nitrogen | emulz. za inf., vreć. 4x1518 ml | 65,4111 | 261,64 |  | 5% |
| B05BA10 075 | DS | infuzije aminokiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Aminoven Infant 10% | boč. 10x250 ml | 7,3728 | 73,73 |  | 5% |
| B05BA10 076 | DS | infuzije aminokiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Aminosteril N hepa 8% | boca 10x500 ml | 9,2587 | 92,59 |  | 5% |
| B05BA10 079 | DS | infuzije aminokiselina |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Aminoven 10% | boca 10x500 ml | 7,4789 | 74,79 |  | 5% |
| B05BA10 080 | DS | glukoza + otopina aminokiselina s elektrolitima + emulzija lipidaNB400 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven extra Nitrogen | emulz. za inf., vreć. 4x2025 ml | 88,8314 | 355,33 |  | 5% |
| B05BA10 084 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Periolimel N4E | emulz. za inf., vreć. plast. 6x1000 ml | 37,8260 | 226,96 |  | 5% |
| B05BA10 085 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Periolimel N4E | emulz. za inf., vreć. plast. 4x2000 ml | 48,7504 | 195,00 |  | 5% |
| B05BA10 086 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Olimel N7E | emulz. za inf., vreć. plast. 4x2000 ml | 50,4347 | 201,74 |  | 5% |
| B05BA10 087 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Olimel N9E | emulz. za inf., vreć. plast. 6x1000 ml | 43,8680 | 263,21 |  | 5% |
| B05BA10 088 | DS | emulzija lipida + aminokiselina + glukoza + kalcij – klorid |  |  | P | Baxter d.o.o. | Baxter S.A. | Olimel N9E | emulz. za inf., vreć. plast. 4x2000 ml | 54,6420 | 218,57 |  | 5% |
| B05BA10 089 | DS | glukoza + otopina aminokiselina s elektrolitima + emulzija lipida |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven Low Osmo Peripheral | emulz. za inf., vreć. 4x1400 ml | 52,9564 | 211,83 |  | 5% |
| B05BA10 090 | DS | glukoza + otopina aminokiselina + emulzija lipidaNB400 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi AB | SmofKabiven extra Nitrogen bez elektrolita | emulz. za inf., vreć. 4x1518 ml | 64,7687 | 259,07 |  | 5% |
| B05BA10 092 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven Peripheral | emulzija za infuziju, vreć. 4x1206 ml | #N/A | #N/A |  | 5% |
| B05BA10 093 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven Peripheral | emulzija za infuziju, vreć. 4x1448 ml | #N/A | #N/A |  | 5% |
| B05BA10 094 | DS | glukoza + otopina aminokiselina s elektrolitima + masna emulzija |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven Peripheral | emulzija za infuziju, vreć. 4x1904 ml | #N/A | #N/A |  | 5% |
| B05BA10 095 | DS | emulzija lipida + aminokiselina + glukoza |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven bez elektrolita | emulz. za inf., plast. vreć. (Excel) 4x986 ml | 24,5059 | 98,02 |  | 5% |
| B05BA10 096 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven | emulz. za inf., plast. vreć. (Excel) 4x986 ml | 24,5059 | 98,02 |  | 5% |
| B05BA10 097 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven | emulz. za inf., plast. vreć. (Excel) 4x1477 ml | 30,8979 | 123,59 |  | 5% |
| B05BA10 098 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven | emulz. za inf., plast. vreć. (Excel) 4x1970 ml | 38,6184 | 154,47 |  | 5% |
| B05BA10 099 | DS | emulzija lipida + aminokiselina + glukoza + kalcij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | SmofKabiven | emulz. za inf., plast. vreć. (Excel) 3x2463 ml | 44,8815 | 134,64 |  | 5% |
| B05BB01 014 | PO | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (9 mg/ml) | 1,0087 | 10,09 |  | 5% |
| B05BB01 018 | PO | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (9 mg/ml) | 0,8760 | 8,76 |  | 5% |
| B05BB01 029 | PO | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf., boca polietil. 20x500 ml (9 mg/ml) | 1,0113 | 20,23 |  | 5% |
| B05BB01 031 | PO | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf., boč. stakl. 20x100 ml (9 mg/ml) | 0,8494 | 16,99 |  | 5% |
| B05BB01 032 | DS | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 10% koncentrat za otopinu za infuziju | konc. za otop. za inf. 10%, boč. stakl. 40x50 ml (100 mg/ml) | 0,9397 | 37,59 |  | 5% |
| B05BB01 033 | DS | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf. 0,9%, vreć. PP 12x1000 ml | 1,6458 | 19,75 |  | 5% |
| B05BB01 034 | DS | natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Natrijev klorid HZTM 9 mg/ml (0,9%) otopina za infuziju | otop. za inf. 0,9%, vreć. PP 6x2000 ml | 2,6319 | 15,79 |  | 5% |
| B05BB01 042 | PO | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter/Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf., 9 mg/ml, vreć. plast. 30x250 ml | 0,8826 | 26,48 |  | 5% |
| B05BB01 043 | PO | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter/Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf., 9 mg/ml, vreć. plast. 20x500 ml | 1,0153 | 20,31 |  | 5% |
| B05BB01 044 | DS | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter/Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf., 9 mg/ml, vreć. plast. 10x1000 ml | 1,8289 | 18,29 |  | 5% |
| B05BB01 046 | PO | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf., 9 mg/ml, vreć. plast. 60x100 ml | 0,7286 | 43,72 |  | 5% |
| B05BB01 047 | PO | natrij-klorid |  |  | P | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Natrijev klorid Alkaloid 9 mg/ml | otop. za inf., boca plast. 20x500 ml (9 mg/ml) | 0,8687 | 17,37 |  | 5% |
| B05BB01 051 | DS | natrij-klorid |  |  | P |  |  |  | amp. 10%, 1x10 ml |  |  |  | 5% |
| B05BB01 052 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Ringerova otopina HZTM otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (8,6 mg/ml + 0,34 mg/ml + 0,30 mg/ml) | 1,0113 | 10,11 |  | 5% |
| B05BB01 053 | DS | natrij-klorid + natrij-acetat + natrij-laktat + kalcij-klorid + kalij-klorid + magnezij klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Infusol | otop. za inf., boca stakl. 10x500 ml (5,723 mg/ml + 5,305 mg/ml + 0,56 mg/ml + 0,294 mg/ml + 0,372 mg/ml + 0,305 mg/ml)) | 1,1481 | 11,48 |  | 5% |
| B05BB01 054 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Ringerova otopina | otop. za inf., boca stakl. 10x500 ml (8,6 mg/ml + 0,33 mg/ml + 0,30 mg/ml) | 1,0113 | 10,11 |  | 5% |
| B05BB01 055 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Ringerova otopina Viaflo | otop. za inf., vreć. plast. 20x500 ml | 1,0153 | 20,31 |  | 5% |
| B05BB01 056 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Ringerova otopina B. Braun | otop. za inf., polietil. Ecoflac plus boca, 10x500 ml | 1,0153 | 10,15 |  | 5% |
| B05BB01 057 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Ringerova otopina B.Braun | otop. za inf., polietil. Ecoflac plus boca, 10x1000 ml | 1,5728 | 15,73 |  | 5% |
| B05BB01 058 | DS | natrij-klorid + kalij-klorid + kalcij-klorid-dihidrat + natrij-laktat |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Slož. otop. natrijevog laktata (Hartmannova otopina) | otop. za inf., polietil. Ecoflac plus boca, 10x500 ml | 0,9004 | 9,00 |  | 5% |
| B05BB01 059 | DS | natrij-klorid + kalij-klorid + kalcij-klorid-dihidrat + natrij-laktat |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Slož. otop. natrijevog laktata (Hartmannova otopina) otopina za infuziju | otop. za inf., polietil. Ecoflac plus boca, 10x1000 ml | 1,2572 | 12,57 |  | 5% |
| B05BB01 060 | DS | natrij-klorid + kalij – klorid + kalcij-klorid-dihidrat + natrij-laktat |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ringerov laktat Fresenius Kabi | otop. za inf., boca plast. 10x500 ml | 0,8096 | 8,10 |  | 5% |
| B05BB01 068 | DS | natrij-klorid + kalcij-klorid + kalij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ringerova otopina Fresenius Kabi | otop. za inf., boca plast. 10x500 ml | 0,9138 | 9,14 |  | 5% |
| B05BB01 071 | PO | natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid B. Braun 9 mg/ml | otop. za inf., 9 mg/ml, polietil. Ecoflac plus boca, 20x100 ml | 0,8534 | 17,07 |  | 5% |
| B05BB01 072 | PO | natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid B. Braun 9 mg/ml | otop. za inf., 9 mg/ml, polietil. Ecoflac plus boca, 10x250 ml | 0,8826 | 8,83 |  | 5% |
| B05BB01 073 | PO | natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid B. Braun 9 mg/ml | otop. za inf., 9 mg/ml, polietil. Ecoflac plus boca, 10x500 ml | 1,0153 | 10,15 |  | 5% |
| B05BB01 074 | DS | natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid B. Braun 9 mg/ml | otop. za inf., 9 mg/ml, polietil. Ecoflac plus boca, 10x1000 ml | 1,8289 | 18,29 |  | 5% |
| B05BB01 077 | DS | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., PE boca, 10x1000 ml (9 mg/ml) | 1,6458 | 16,46 |  | 5% |
| B05BB01 078 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 50x100 ml (9 mg/ml) | 0,7681 | 38,40 |  | 5% |
| B05BB01 079 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 30x250 ml (9 mg/ml) | 0,7943 | 23,83 |  | 5% |
| B05BB01 085 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + kalcij-klorid dihidrat + natrij-acetat trihidrat + L-malatna kiselina |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Sterofundin Iso B. Braun | otop. za inf., polietil. Ecoflac plus boca, 10x500 ml | 1,3524 | 13,52 |  | 5% |
| B05BB01 086 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + kalcij-klorid dihidrat + natrij-acetat trihidrat + L-malatna kiselina |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Sterofundin Iso B. Braun | otop. za inf., polietil. Ecoflac plus boca, 10x1000 ml | 1,6645 | 16,64 |  | 5% |
| B05BB01 087 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + natrij-acetat trihidrat |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ionolyte | otop. za inf., vreć. plast. 20x500 ml | 1,2172 | 24,34 |  | 5% |
| B05BB01 088 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + natrij-acetat trihidrat |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ionolyte | otop. za inf., vreć. plast. 10x1000 ml | 1,4980 | 14,98 |  | 5% |
| B05BB01 091 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + natrij-acetat-trihidrat + natrij-glukonat |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Plasma-Lyte 148 Viaflo | otop. za inf., vreć. plast. 20x500 ml | 1,5037 | 30,07 |  | 5% |
| B05BB01 092 | DS | natrij-klorid + kalij-klorid + magnezij-klorid heksahidrat + natrij-acetat-trihidrat + natrij-glukonat |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Plasma-Lyte 148 Viaflo | otop. za inf., vreć. plast. 10x1000 ml | 1,8502 | 18,50 |  | 5% |
| B05BB01 093 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 20x500 ml (9 mg/ml) | 0,9138 | 18,28 |  | 5% |
| B05BB01 094 | DS | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 60x50 ml (9 mg/ml) | 0,6928 | 41,57 |  | 5% |
| B05BB01 095 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., boca plast. 40x100 ml (9 mg/ml) | 0,7681 | 30,72 |  | 5% |
| B05BB01 096 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., boca plast. 20x250 ml (9 mg/ml) | 0,7943 | 15,89 |  | 5% |
| B05BB01 097 | PO | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., boca plast. 10x500 ml (9 mg/ml) | 0,9138 | 9,14 |  | 5% |
| B05BB01 098 | DS | natrij-klorid |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Natrijev klorid Fresenius Kabi 9 mg/ml | otop. za inf., vreć. plast. 10x1000 ml (9 mg/ml) | 1,4812 | 14,81 |  | 5% |
| B05BB01 099 | DS | natrij-klorid |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Natrijev klorid Viaflo 9 mg/ml | otop. za inf. 9 mg/ml, vreć. plast. 75x50 ml | 0,6928 | 51,96 |  | 5% |
| B05BB02 021 | DS | glukoza + natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukosalina I 50 mg/ml + 9 mg/ml otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (50 mg/ml + 9 mg/ml) | 1,1627 | 11,63 |  | 5% |
| B05BB02 022 | DS | glukoza + natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukosalina I 50 mg/ml + 9 mg/ml otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (50 mg/ml + 9 mg/ml) | 1,0273 | 10,27 |  | 5% |
| B05BB02 024 | DS | glukoza + natrij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukosalina III 25 mg/ml + 4,5 mg/ml otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (25 mg/ml + 4,5 mg/ml) | 1,2210 | 12,21 |  | 5% |
| B05BB02 061 | DS | glukoza + natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid 9 mg/ml + Glukoza 50 mg/ml B. Braun | otop. za inf., (9 mg/ml + 50 mg/ml), polietil. Ecoflac plus boca, 10x500 ml | 1,0459 | 10,46 |  | 5% |
| B05BB02 062 | DS | glukoza + natrij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Natrijev klorid 9 mg/ml + Glukoza 50 mg/ml B. Braun | otop. za inf., (9 mg/ml + 50 mg/ml), polietil. Ecoflac plus boca, 10x1000 ml | 1,8249 | 18,25 |  | 5% |
| B05BB02 071 | DS | glukoza (kao hidrat) + natrij-klorid + natrij-acetat-trihidrat + kalij-klorid + magnezij-klorid heksahidrat |  |  | P | Baxter d.o.o. | Bieffe Medital S.A. | GNAK 50 mg/ml | otop. za inf., vreć. plast. 10x1000 ml | 1,7572 | 17,57 |  | 5% |
| B05BC01 006 | DS | manitol + natrij-klorid + natrij-acetat |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Manitol 10% + elektroliti HZTM otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (100 mg/ml + 2,6 mg/ml + 2,7 mg/ml) | 1,7941 | 17,94 |  | 5% |
| B05BC01 007 | DS | manitol |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Manitol HZTM 20% otopina za infuziju | otop. za inf., boca stakl. 10x250 ml (200 mg/ml) | 1,7559 | 17,56 |  | 5% |
| B05CX10 961 | DS | otopine za ispiranje mokraćnog mjehura |  |  | L | Fresenius Kabi d.o.o. | Fresenius Kabi | Purisole SM | vreć. plast. 1x3000 ml | 7,4046 | 7,40 |  | 5% |
| B05CX10 963 | DS | otopina za ispiranje kod endoskopskih pretraga i operativnih zahvata |  |  | L | B. Braun Adria d.o.o. | B.Braun | Sorbitol/Manitol 3% B. Braun | ecobag/ecobag Click 4x3.000 ml | 6,6640 | 26,66 |  | 5% |
| B05CX10 964 | DS | otopina za ispiranje |  |  | L | Agmar d.o.o. | Baxter, Bieffe Medital | Manitol i sorbitol | otop. za ispir., vreć. Clear-Flex 4x3.000 ml | 5,9964 | 23,99 |  | 5% |
| B05XA01 027 | DS | kalij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | 1 M Kalijev klorid HZTM 7,45% koncentrat za otopinu za infuziju | konc. za otop. za inf., boč. stakl. 40x50 ml (74,5 mg/ml) | 0,9012 | 36,05 |  | 5% |
| B05XA01 061 | DS | kalij-klorid |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Kalijev klorid B. Braun 74,5 mg/ml | konc. za otop. za inf., 74,5 mg/ml, boca stakl. 20x100 ml | 1,4679 | 29,36 |  | 5% |
| B05XA02 052 | DS | natrij-hidrogenkarbonat |  |  | P |  |  |  |  |  |  |  | 5% |
| B05XA05 051 | DS | magnezij-sulfat |  |  | P |  |  |  |  |  |  |  | 5% |
| B05XA07 017 | DS | kalcij-klorid |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Kalcijev klorid 100 mg/ml (10%) HZTM otopina za injekciju | otop. za inj., boč. stakl. 40x30 ml (100 mg/ml) | 1,0644 | 42,58 |  | 5% |
| B06AC02 001 | DS | ikatibantNB509 | 30 mg | 1.092,7600 | P | Teva B.V. | Merckle GmbH | Ikatibant Teva | štrc. napunj. 1x30 mg | 1.092,7613 | 1.092,76 |  | 5% |
| B06AC02 041 | DS | ikatibantNB509 | 30 mg | 1.092,7600 | P | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp.z.o.o., Accord Healthcare B.V. | Icatibant Accord | štrc. napunj. 1x30 mg | 1.092,7613 | 1.092,76 |  | 5% |
| B06AC02 061 | DS | ikatibantNB509 | 30 mg | 1.216,8200 | P | Takeda Pharmaceuticals International AG Ireland Branch | Shire Pharmaceuticals Ireland Limited | Firazyr | štrc. napunj. 1x30 mg | 1.216,8239 | 1.216,82 |  | 5% |
| B06AC02 071 | DS | ikatibantNB509 | 30 mg | 1.038,1200 | P | Fresenius Kabi d.o.o. | Fresenius Kabi Austria GmbH | Ikatibant Fresenius | štrc. napunj. 1x30 mg | 1.038,1233 | 1.038,12 |  | 5% |
| B06AC04 061 | DS | konestat alfaNB509 | 3500 U | 1,2388 | P | Pharming Group N.V. | Pharming Technologies B.V. | Ruconest | praš. za otop. za inj., boč. stakl. 1x2100 U | 743,2477 | 743,25 |  | 5% |
| C01AA08 051 | PR | metildigoksin | 0,2 mg |  | P |  |  |  |  |  |  |  | 5% |
| C01AA08 101 |  | metildigoksin | 0,2 mg | 0,1312 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Lanitop | tbl. 50x0,1 mg | 0,0657 | 3,28 | R | 5% |
| C01BB01 051 | PR | lidokain | 3 g |  | P |  |  |  |  |  |  |  | 5% |
| C01BC03 073 | PR | propafenon | 0,3 g | 5,2300 | P | Mylan Hrvatska d.o.o. | Famar Health Care Services Madrid S.A.U. | Rytmonorm | amp. 5x70 mg/20 ml | 1,0469 | 5,23 |  | 5% |
| C01BC03 142 |  | propafenon | 0,3 g | 0,1312 | O | Alkaloid d.o.o. | Alkaloid | Propafenon Alkaloid | tbl. 50x150 mg | 0,0656 | 3,28 | R | 5% |
| C01BD01 022 | DS | amjodaron | 0,2 g | 1,7650 | P | sanofi-aventis groupe | Sanofi Winthrop Ambares | Cordarone | amp. 6x150 mg/3 ml | 1,1768 | 7,06 |  | 5% |
| C01BD01 061 | DS | amjodaron | 0,2 g | 1,0987 | P | hameln pharma gmbh | HBM Pharma s.r.o. | Amiodaronklorid Hameln | amp. 10x150 mg/3 ml | 0,8241 | 8,24 |  | 5% |
| C01BD01 112 |  | amjodaron | 0,2 g | 0,1620 | O | Belupo d.d. | Belupo | Amiodaronklorid Belupo | tbl. 60x200 mg | 0,1619 | 9,72 | R | 5% |
| C01BD01 121 |  | amjodaron | 0,2 g | 0,1620 | O | sanofi-aventis groupe | Sanofi Winthrop Ambares | Cordarone | tbl. 60x200 mg | 0,1619 | 9,72 | R | 5% |
| C01BD01 133 |  | amjodaron | 0,2 g | 0,1620 | O | KRKA-FARMA d.o.o. | Krka d.d. | Amiokordin | tbl. 60x200 mg | 0,1619 | 9,72 | R | 5% |
| C01CA01 052 | DS | etiladrianolNC101 | 50 mg |  | P |  |  |  |  |  |  |  | 5% |
| C01CA03 071 | PR | norepinefrin | 6 mg | 6,2279 | P | Sintetica GmbH | Sirton Pharmaceuticals S.p.A., Sintetica GmbH | Sinora | konc. za otop. za inf., 1 mg/ml, amp. 10x1 ml | 1,0379 | 10,38 |  | 5% |
| C01CA03 072 | PR | norepinefrin | 6 mg | 2,1444 | P | Sintetica GmbH | Sirton Pharmaceuticals S.p.A., Sintetica GmbH | Sinora | konc. za otop. za inf., 1 mg/ml, amp. 10x10 ml | 3,5742 | 35,74 |  | 5% |
| C01CA03 073 | PR | norepinefrin | 6 mg | 2,0376 | P | Sintetica GmbH | Sirton Pharmaceuticals S.p.A., Sintetica GmbH | Sinora | konc. za otop. za inf., 1 mg/ml, amp. 10x5 ml | 1,6978 | 16,98 |  | 5% |
| C01CA03 081 | PR | norepinefrin | 6 mg | 2,3039 | P | Ligula Pharma d.o.o. | Laboratorios Normon S.A. | Noradrenalin Ligula Pharma | konc. za otop. za inf., 0,5 mg/ml, amp. 100x10 ml | 1,9199 | 191,99 |  | 5% |
| C01CA04 061 | DS | dopamin | 0,5 g | 9,8800 | P | Medicuspharma d.o.o. | Wuelfing Pharma | Dopamin Admeda | amp. 5x50 mg/5 ml | 0,9883 | 4,94 |  | 5% |
| C01CA07 061 | DS | dobutamin | 0,5 g | 7,6980 | P | Panpharma | Panpharma GmbH | Dobutamin Panpharma | konc. za otop. za inf., boč. stakl. 10x250 mg/20 ml | 3,8490 | 38,49 |  | 5% |
| C01CA07 071 | DS | dobutamin | 0,5 g | 8,4200 | P | Medicuspharma d.o.o. | Haupt Pharma Wülfing GmbH | Dobutamin Admeda | otop. za inf., amp. 1x250 mg/50 ml | 4,2139 | 4,21 |  | 5% |
| C01CA07 082 | DS | dobutamin | 0,5 g | 8,0000 | P | hameln pharma gmbh | Siegfried Hameln GmbH, Hameln rds | Dobutamin Hameln | otop. za inf., boč. 1x250 mg/50 ml | 4,0029 | 4,00 |  | 5% |
| C01CA07 083 | DS | dobutamin | 0,5 g | 8,0040 | P | hameln pharma gmbh | Siegfried Hameln GmbH, Hameln rds | Dobutamin Hameln | konc. za otop. za inf., amp. 5x250 mg/20 ml | 4,0029 | 20,01 |  | 5% |
| C01CA24 051 | PR | adrenalin (epinefrin) | 0,5 mg |  | P |  |  |  |  |  |  |  | 5% |
| C01CA24 071 |  | adrenalin (epinefrin) | 0,5 mg | 17,2650 | P | Mylan Hrvatska d.o.o. | Meda Pharma GmbH | EpiPen Jr | otop. za inj., autoinjektor 1x1 mg/2 ml (doza 0,15 mg/0,3 ml) | 34,5265 | 34,53 | RSRC09 | 5% |
| C01CA24 072 |  | adrenalin (epinefrin) | 0,5 mg | 8,6325 | P | Mylan Hrvatska d.o.o. | Meda Pharma GmbH | EpiPen | otop. za inj., autoinjektor 1x2 mg/2 ml (doza 0,3 mg/0,3 ml) | 34,5265 | 34,53 | RSRC09 | 5% |
| C01CX08 061 | DS | levosimendanNC102 | 11 mg | 657,6910 | P | Orion Corporation | Orion | Simdax | konc. otop. za inf., boč. stak. 1x5ml (2,5mg/1ml) | 747,4020 | 747,40 |  | 5% |
| C01CX08 071 | DS | levosimendanNC102 | 11 mg | 472,8881 | P | ALPHA-MEDICAL d.o.o. | Sabiedriba Ar Ierobezotu Atbildibu “Pharmidea” | Levosimendan Alpha-Medical | konc. otop. za inf., boč. stak. 1x5ml (2,5mg/1ml) | 537,3920 | 537,39 |  | 5% |
| C01DA02 764 |  | gliceriltrinitrat | 2,5 mg | 0,1522 | O | Medis Adria d.o.o. | G. Pohl-Boskamp | Nitrolingual | rasprš. oral. boč. 1x14,4 ml (0,4 mg/doza, 200 doza) | 4,8749 | 4,87 | R | 5% |
| C01DA08 101 |  | izosorbid-dinitrat | 20 mg | 0,0910 | SL | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Tinidil | tbl. sublingv. 40x5 mg | 0,0227 | 0,91 | R | 5% |
| C01DA14 111 |  | izosorbid-5-mononitrat | 40 mg | 0,0796 | O | Mylan Hrvatska d.o.o. | Temmler Pharma | Olicard 40 | caps. retard 50x40 mg | 0,0796 | 3,98 | R | 5% |
| C01DA14 112 |  | izosorbid-5-mononitrat | 40 mg | 0,0840 | O | Mylan Hrvatska d.o.o. | Temmler Pharma | Olicard 60 | caps. retard 50x60 mg | 0,1260 | 6,30 | R | 5% |
| C01DA14 113 |  | izosorbid-5-mononitrat | 40 mg | 0,0796 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Cardox retard | tbl. retard 50x40 mg | 0,0796 | 3,98 | R | 5% |
| C01DA14 115 |  | izosorbid mononitrat | 40 mg | 0,0796 | O | Belupo d.d. | Belupo | Isocard 40 mg | tbl. s prod. oslob. 50x40 mg | 0,0796 | 3,98 | R | 5% |
| C01DA14 116 |  | izosorbid mononitrat | 40 mg | 0,0840 | O | Belupo d.d. | Belupo | Isocard 60 mg | tbl. s prod. osl. 50x60 mg | 0,1260 | 6,30 | R | 5% |
| C01DA14 121 |  | izosorbid-5-mononitrat | 40 mg | 0,0840 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | ISMN Jadran 20 | tbl. 60x20 mg | 0,0421 | 2,52 | R | 5% |
| C01DA14 122 |  | izosorbid-5-mononitrat | 40 mg | 0,0797 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | ISMN Jadran 40 | tbl. 60x40 mg | 0,0796 | 4,78 | R | 5% |
| C01DA14 161 |  | izosorbid-5-mononitrat | 40 mg | 0,0840 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | ISMN Genericon | tbl. 60x20 mg | 0,0421 | 2,52 | R | 5% |
| C01DA14 162 |  | izosorbid-5-mononitrat | 40 mg | 0,0797 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | ISMN Genericon | tbl. 60x40 mg | 0,0796 | 4,78 | R | 5% |
| C01EA01 061 | DS | alprostadilNC103 | 0,5 mg | 20,1920 | P | Pfizer Croatia d.o.o. | Pfizer | Prostin VR | amp. 5x1 ml (0,5 mg/ml) | 40,3846 | 201,92 |  | 5% |
| C01EB15 145 |  | trimetazidin | 40 mg | 0,0638 | O | PharmaS d.o.o. | PharmaS d.o.o. | Trimetazidin PharmaS | tbl. s prilag. oslob. 60x35 mg | 0,0558 | 3,35 | RS | 5% |
| C02AB01 151 |  | l-metildopa | 1g |  | O |  |  |  |  |  |  | R | 5% |
| C02AC05 112 |  | moksonidin | 0,3 mg | 0,1864 | O | Belupo d.d. | Belupo d.d. | Moksonidin Belupo | tbl. film obl. 28x0,2 mg | 0,1242 | 3,48 | RRC07 | 5% |
| C02AC05 113 |  | moksonidin | 0,3 mg | 0,1642 | O | Belupo d.d. | Belupo d.d. | Moksonidin Belupo | tbl. film obl. 28x0,4 mg | 0,2190 | 6,13 | RRC07 | 5% |
| C02AC05 121 |  | moksonidin | 0,3 mg | 0,1864 | O | Sandoz d.o.o. | Sandoz-Salutas | Moxaviv | tbl. film obl. 28x0,2 mg | 0,1242 | 3,48 | RRC07 | 5% |
| C02AC05 122 |  | moksonidin | 0,3 mg | 0,1642 | O | Sandoz d.o.o. | Sandoz-Salutas | Moxaviv | tbl. film obl. 28x0,4 mg | 0,2190 | 6,13 | RRC07 | 5% |
| C02AC05 123 |  | moksonidin | 0,3 mg | 0,1680 | O | Sandoz d.o.o. | Salutas Pharma | Moxaviv | tbl. film obl. 60x0,2 mg | 0,1121 | 6,72 | RRC07 | 5% |
| C02AC05 124 |  | moksonidin | 0,3 mg | 0,1483 | O | Sandoz d.o.o. | Salutas Pharma | Moxaviv | tbl. film obl. 60x0,4 mg | 0,1976 | 11,86 | RRC07 | 5% |
| C02AC05 162 |  | moksonidin | 0,3 mg | 0,1642 | O | Mylan Hrvatska d.o.o. | Mylan Laboratories SAS | Physiotens | tbl. film obl. 28x0,4 mg | 0,2190 | 6,13 | RRC07 | 5% |
| C02AC05 163 |  | moksonidin | 0,3 mg | 0,1650 | O | Mylan Hrvatska d.o.o. | Mylan Laboratories SAS | Cynt | tbl. film obl. 28x0,2 mg | 0,1102 | 3,08 | RRC07 | 5% |
| C02AC05 164 |  | moksonidin | 0,3 mg | 0,1473 | O | Mylan Hrvatska d.o.o. | Mylan Laboratories SAS | Cynt | tbl. film obl. 28x0,4 mg | 0,1964 | 5,50 | RRC07 | 5% |
| C02CA04 111 |  | doksazosin | 4 mg | 0,1990 | O | Belupo d.d. | Belupo | Doxa | tbl. 20x2 mg | 0,0995 | 1,99 | R | 5% |
| C02CA04 112 |  | doksazosin | 4 mg | 0,1740 | O | Belupo d.d. | Belupo | Doxa | tbl. 20x4 mg | 0,1739 | 3,48 | R | 5% |
| C02CA04 123 |  | doksazosin | 4 mg | 0,1993 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Doxazin | tbl. 30x2 mg | 0,0995 | 2,99 | R | 5% |
| C02CA04 124 |  | doksazosin | 4 mg | 0,1740 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Doxazin | tbl. 30x4 mg | 0,1739 | 5,22 | R | 5% |
| C02CA04 131 |  | doksazosin | 4 mg | 0,1990 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kamiren | tbl. 20x2 mg | 0,0995 | 1,99 | R | 5% |
| C02CA04 134 |  | doksazosin | 4 mg | 0,1740 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kamiren | tbl. 20x4 mg | 0,1739 | 3,48 | R | 5% |
| C02CA04 137 |  | doksazosin | 4 mg | 0,1740 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kamiren XL | tbl. s prilag. osl. 30x4 mg | 0,1739 | 5,22 | R | 5% |
| C02CA04 138 |  | doksazosin | 4 mg | 0,1757 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kamiren XL | tbl. s prilag. osl. 60x4 mg | 0,1756 | 10,54 | R | 5% |
| C02CA06 064 | PO | urapidil | 50 mg | 4,4540 | P | Cheplapharm Arzneimittel GmbH | Takeda | Ebrantil | amp. 5x50 mg/10 ml | 4,4536 | 22,27 |  | 5% |
| C02CA06 065 | PO | urapidil | 50 mg | 6,1280 | P | Cheplapharm Arzneimittel GmbH | Takeda | Ebrantil | amp. 5x25 mg/5 ml | 3,0646 | 15,32 |  | 5% |
| C02DA01 051 | DS | diazoksid | 0,3g |  | P |  |  |  |  |  |  |  | 5% |
| C02DC01 151 | DS | minoksidilNC991 | 20 mg |  | O |  |  |  |  |  |  | RSRC91 | 5% |
| C02DD01 051 | DS | nitroprusid-natrij | 50 mg |  | P |  |  |  |  |  |  |  | 5% |
| C02KX01 131 | KS | bosentanNC201 | 0,25 g | 45,7736 | O | Makpharm d.o.o. | Pharmascience International Limited, Kern Pharma S.L. | Bosentan Makpharm | tbl. film obl. 56x62,5 mg | 11,4434 | 640,83 |  | 5% |
| C02KX01 132 | KS | bosentanNC201 | 0,25 g | 31,5446 | O | Makpharm d.o.o. | Pharmascience International Limited, Kern Pharma S.L. | Bosentan Makpharm | tbl. film obl. 56x125 mg | 15,7723 | 883,25 |  | 5% |
| C02KX01 141 | KS | bosentanNC201 | 0,25 g | 45,7736 | O | Cipla Europe NV | Cipla (EU) Limited, Cipla Europe NV | Bosentan Cipla | tbl. film obl. 56x62,5 mg | 11,4434 | 640,83 |  | 5% |
| C02KX01 142 | KS | bosentanNC201 | 0,25 g | 31,5446 | O | Cipla Europe NV | Cipla (EU) Limited, Cipla Europe NV | Bosentan Cipla | tbl. film obl. 56x125 mg | 15,7723 | 883,25 |  | 5% |
| C02KX01 181 | KS | bosentanNC201 | 0,25 g | 45,7736 | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Phan | tbl. film obl. 56x62,5 mg | 11,4434 | 640,83 |  | 5% |
| C02KX01 182 | KS | bosentanNC201 | 0,25 g | 31,5446 | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Phan | tbl. film obl. 56x125 mg | 15,7723 | 883,25 |  | 5% |
| C02KX02 061 | KS | ambrisentanNC201 | 7,5 mg | 69,5980 | O | GlaxoSmithKline (Ireland) Limited | Aspen Bad Oldesloe, GlaxoSmithKline Trading Services Limited | Volibris | tbl. film obl. 30x5 mg | 46,3986 | 1.391,96 |  | 5% |
| C02KX02 062 | KS | ambrisentanNC201 | 7,5 mg | 27,7988 | O | GlaxoSmithKline (Ireland) Limited | Aspen Bad Oldesloe, GlaxoSmithKline Trading Services Limited | Volibris | tbl. film obl. 30x10 mg | 37,0651 | 1.111,95 |  | 5% |
| C02KX02 101 | KS | ambrisentanNC201 | 7,5 mg | 69,5980 | O | Teva B.V. | Teva UK Ltd. | Ambrisentan Teva | tbl. film obl. 30x5 mg | 46,3986 | 1.391,96 |  | 5% |
| C02KX02 102 | KS | ambrisentanNC201 | 7,5 mg | 27,7988 | O | Teva B.V. | Teva UK Ltd. | Ambrisentan Teva | tbl. film obl. 30x10 mg | 37,0651 | 1.111,95 |  | 5% |
| C03BA04 151 |  | klortalidon | 25 mg |  | O |  |  |  |  |  |  | R | 5% |
| C03BA11 101 |  | indapamid | 2,5 mg | 0,1506 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Indapamid SR Pliva | drag. 30x1,5 mg | 0,0903 | 2,71 | R | 5% |
| C03BA11 111 |  | indapamid | 2,5 mg | 0,1506 | O | Belupo d.d. | Belupo | Indamid SR | drag. 30x1,5 mg | 0,0903 | 2,71 | R | 5% |
| C03BA11 131 |  | indapamid | 2,5 mg | 0,1506 | O | KRKA-FARMA d.o.o. | Krka d.d. | Rawel SR | tbl. film obl. 30x1,5 mg | 0,0903 | 2,71 | R | 5% |
| C03BA11 132 |  | indapamid | 2,5 mg | 0,1506 | O | KRKA-FARMA d.o.o. | Krka d.d. | Rawel SR | tbl. film obl. 60x1,5 mg | 0,0903 | 5,42 | R | 5% |
| C03BA11 145 |  | indapamid | 2,5 mg | 0,1200 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Dipam retard | tbl. s prod. oslob. 30x1,5 mg | 0,0722 | 2,16 | R | 5% |
| C03BA11 172 |  | indapamid | 2,5 mg | 0,1506 | O | Servier Pharma d.o.o. | LLS, SII, Anpharm | Tertensif SR | tbl. 30x1,5 mg | 0,0903 | 2,71 | R | 5% |
| C03CA01 014 | PR | furosemid | 40 mg | 0,7120 | P | Belupo d.d. | Belupo | Fursemid | amp. 5x20 mg/2 ml | 0,3565 | 1,78 |  | 5% |
| C03CA01 023 | PR | furosemid | 40 mg | 0,5420 | P | Sandoz d.o.o. | Sandoz-Salutas | Edemid | otop. za inj., amp. 5x40 mg/4 ml | 0,5423 | 2,71 |  | 5% |
| C03CA01 061 | PR | furosemid | 40 mg | 0,6780 | P | hameln pharma gmbh | Hameln rds, Siegfried Hameln GmbH | Furosemid Hameln | amp. 10x20 mg/2 ml | 0,3387 | 3,39 |  | 5% |
| C03CA01 112 |  | furosemid | 40 mg | 0,0297 | O | Belupo d.d. | Belupo | Fursemid forte | tbl. 20x500 mg | 0,3715 | 7,43 | R | 5% |
| C03CA01 122 |  | furosemid | 40 mg | 0,0297 | O | Sandoz d.o.o. | Sandoz-Lek | Edemid forte | tbl. 30x500 mg | 0,3715 | 11,14 | R | 5% |
| C03CA01 171 |  | furosemid | 40 mg | 0,0585 | O | sanofi-aventis groupe | Sanofi Winthrop Industrie | Lasix | tbl. 20x40 mg | 0,0584 | 1,17 | R | 5% |
| C04AB01 051 | DS | fentolamin | 1 mg |  | P |  |  |  |  |  |  |  | 5% |
| C05BA01 404 | DS | heparin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Heparin krema | krema 30g (250 i.j./g) | 3,7242 | 3,72 |  | 5% |
| C07AA05 121 |  | propranolol | 0,16 g | 0,2216 | O | Sandoz d.o.o. | Sandoz-Lek | Propranolol Sandoz | tbl. 50x40 mg | 0,0555 | 2,77 | R | 5% |
| C07AA05 270 |  | propranolol | 0,16 g | 60,8142 | O | Pierre Fabre Dermatologie | Farmea, PIERRE FABRE MEDICAMENT PRODUCTION – CHATEAURENARD | Hemangiol | oral. otop., boca 1x120 ml (3,75 mg/ml) | 171,0412 | 171,04 | RSRC10 | 5% |
| C07AB03 101 |  | atenolol | 75 mg | 0,0860 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atenolol | tbl. 30x50 mg | 0,0573 | 1,72 | R | 5% |
| C07AB03 112 |  | atenolol | 75 mg | 0,0860 | O | Belupo d.d. | Belupo | Ormidol | tbl. 30x50 mg | 0,0573 | 1,72 | R | 5% |
| C07AB03 113 |  | atenolol | 75 mg | 0,0860 | O | Belupo d.d. | Belupo | Ormidol | tbl. 28x100 mg | 0,1145 | 3,21 | R | 5% |
| C07AB07 101 |  | bisoprolol | 10 mg | 0,2320 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kordobis | tbl. 20x1,25 mg | 0,0292 | 0,58 | R | 5% |
| C07AB07 102 |  | bisoprolol | 10 mg | 0,2000 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kordobis | tbl. 30x2,5 mg | 0,0501 | 1,50 | R | 5% |
| C07AB07 103 |  | bisoprolol | 10 mg | 0,1100 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kordobis | tbl. 30x5 mg | 0,0549 | 1,65 | R | 5% |
| C07AB07 111 |  | bisoprolol | 10 mg | 0,1100 | O | Belupo d.d. | Belupo | Bisobel | tbl. 30x5 mg | 0,0549 | 1,65 | R | 5% |
| C07AB07 112 |  | bisoprolol | 10 mg | 0,0717 | O | Belupo d.d. | Belupo | Bisobel | tbl. 30x10 mg | 0,0717 | 2,15 | R | 5% |
| C07AB07 114 |  | bisoprolol | 10 mg | 0,1100 | O | Belupo d.d. | Belupo | Bisobel | tbl. 60x5 mg | 0,0549 | 3,30 | R | 5% |
| C07AB07 115 |  | bisoprolol | 10 mg | 0,1100 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Biprol | tbl. 30x5 mg | 0,0549 | 1,65 | R | 5% |
| C07AB07 117 |  | bisoprolol | 10 mg | 0,2000 | O | Belupo d.d. | Belupo | Bisobel | tbl. 30x2,5 mg | 0,0501 | 1,50 | R | 5% |
| C07AB07 118 |  | bisoprolol | 10 mg | 0,2007 | O | Belupo d.d. | Belupo | Bisobel | tbl. 60x2,5 mg | 0,0501 | 3,01 | R | 5% |
| C07AB07 119 |  | bisoprolol | 10 mg | 0,2000 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Biprol | tbl. 30x2,5 mg | 0,0501 | 1,50 | R | 5% |
| C07AB07 121 |  | bisoprolol | 10 mg | 0,1100 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol | tbl. film obl. 30x5 mg | 0,0549 | 1,65 | R | 5% |
| C07AB07 122 |  | bisoprolol | 10 mg | 0,0717 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol | tbl. film obl. 30x10 mg | 0,0717 | 2,15 | R | 5% |
| C07AB07 125 |  | bisoprolol | 10 mg | 0,2000 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol Cor | tbl. film obl. 30x2,5 mg | 0,0501 | 1,50 | R | 5% |
| C07AB07 126 |  | bisoprolol | 10 mg | 0,2008 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol Cor | tbl. film obl. 50x2,5 mg | 0,0501 | 2,51 | R | 5% |
| C07AB07 127 |  | bisoprolol | 10 mg | 0,2347 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol Cor | tbl. film obl. 30x1,25 mg | 0,0292 | 0,88 | R | 5% |
| C07AB07 128 |  | bisoprolol | 10 mg | 0,1100 | O | Sandoz d.o.o. | Sandoz-Salutas | Byol | tbl. film obl. 60x5 mg | 0,0549 | 3,30 | R | 5% |
| C07AB07 136 |  | bisoprolol | 10 mg | 0,2000 | O | Alkaloid d.o.o. | Alkaloid | Tyrez | tbl. film obl. 30x2,5 mg | 0,0501 | 1,50 | R | 5% |
| C07AB07 137 |  | bisoprolol | 10 mg | 0,1100 | O | Alkaloid d.o.o. | Alkaloid | Tyrez | tbl. film obl. 30x5 mg | 0,0549 | 1,65 | R | 5% |
| C07AB07 138 |  | bisoprolol | 10 mg | 0,0717 | O | Alkaloid d.o.o. | Alkaloid | Tyrez | tbl. film obl. 30x10 mg | 0,0717 | 2,15 | R | 5% |
| C07AB07 141 |  | bisoprolol | 10 mg | 0,2320 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Lybrol | tbl. 20x1,25 mg | 0,0292 | 0,58 | R | 5% |
| C07AB07 142 |  | bisoprolol | 10 mg | 0,2000 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Lybrol | tbl. 30x2,5 mg | 0,0501 | 1,50 | R | 5% |
| C07AB07 144 |  | bisoprolol | 10 mg | 0,1100 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Lybrol | tbl. 30x5 mg | 0,0549 | 1,65 | R | 5% |
| C07AB07 163 |  | bisoprolol | 10 mg | 0,1230 | O | MERCK d.o.o. | Merck | Concor | tbl. 30x10 mg | 0,1230 | 3,69 | R | 5% |
| C07AB07 181 |  | bisoprolol | 10 mg | 0,2000 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 30x2,5 mg | 0,0501 | 1,50 | R | 5% |
| C07AB07 182 |  | bisoprolol | 10 mg | 0,1100 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 30x5 mg | 0,0549 | 1,65 | R | 5% |
| C07AB07 183 |  | bisoprolol | 10 mg | 0,0717 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 30x10 mg | 0,0717 | 2,15 | R | 5% |
| C07AB07 184 |  | bisoprolol | 10 mg | 0,1807 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 60x2,5 mg | 0,0451 | 2,71 | R | 5% |
| C07AB07 185 |  | bisoprolol | 10 mg | 0,0990 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 60x5 mg | 0,0495 | 2,97 | R | 5% |
| C07AB07 186 |  | bisoprolol | 10 mg | 0,0645 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Sobycor | tbl. film obl. 60x10 mg | 0,0645 | 3,87 | R | 5% |
| C07AB12 101 |  | nebivolol | 5 mg | 0,1236 | O | PLIVA HRVATSKA d.o.o. | Balkanpharma – Dupnitsa AD, Actavis Limited | Nebivolol Pliva | tbl. 28x5 mg | 0,1234 | 3,46 | R | 5% |
| C07AB12 111 |  | nebivolol | 5 mg | 0,1193 | O | Belupo d.d. | Belupo | Nibel | tbl. 14x5 mg | 0,1190 | 1,67 | R | 5% |
| C07AB12 112 |  | nebivolol | 5 mg | 0,1236 | O | Belupo d.d. | Belupo | Nibel | tbl. 28x5 mg | 0,1234 | 3,46 | R | 5% |
| C07AB12 121 |  | nebivolol | 5 mg | 0,1233 | O | Sandoz d.o.o. | Sandoz-Salutas | Nebyol | tbl. 30x5 mg | 0,1234 | 3,70 | R | 5% |
| C07AB12 122 |  | nebivolol | 5 mg | 0,1118 | O | Sandoz d.o.o. | Sandoz-Salutas | Nebyol | tbl. 60x5 mg | 0,1118 | 6,71 | R | 5% |
| C07AB12 141 |  | nebivolol | 5 mg | 0,1111 | O | Alkaloid-INT d.o.o. | Alkaloid – int d.o.o. | Massido | tbl. 28x5 mg | 0,1111 | 3,11 | R | 5% |
| C07AG02 101 |  | karvedilol | 37,5 mg | 0,1864 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Carvetrend | tbl. 28x25 mg | 0,1242 | 3,48 | R | 5% |
| C07AG02 102 |  | karvedilol | 37,5 mg | 0,2486 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Carvetrend | tbl. 28x12,5mg | 0,0828 | 2,32 | R | 5% |
| C07AG02 103 |  | karvedilol | 37,5 mg | 0,4586 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Carvetrend | tbl. 28x6,25 mg | 0,0764 | 2,14 | R | 5% |
| C07AG02 104 |  | karvedilol | 37,5 mg | 0,4757 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Carvetrend | tbl. 28x3,125 mg | 0,0398 | 1,11 | R | 5% |
| C07AG02 114 |  | karvedilol | 37,5 mg | 0,4760 | O | Belupo d.d. | Belupo | Carvelol | tbl. 30x3,125 mg | 0,0398 | 1,19 | R | 5% |
| C07AG02 115 |  | karvedilol | 37,5 mg | 0,4580 | O | Belupo d.d. | Belupo | Carvelol | tbl. 30x6,25 mg | 0,0764 | 2,29 | R | 5% |
| C07AG02 116 |  | karvedilol | 37,5 mg | 0,2480 | O | Belupo d.d. | Belupo | Carvelol | tbl. 30x12,5 mg | 0,0828 | 2,48 | R | 5% |
| C07AG02 117 |  | karvedilol | 37,5 mg | 0,1865 | O | Belupo d.d. | Belupo | Carvelol | tbl. 30x25 mg | 0,1242 | 3,73 | R | 5% |
| C07AG02 131 |  | karvedilol | 37,5 mg | 0,4757 | O | KRKA-FARMA d.o.o. | Krka d.d. | Coryol | tbl. 28x3,125 mg | 0,0398 | 1,11 | R | 5% |
| C07AG02 132 |  | karvedilol | 37,5 mg | 0,4586 | O | KRKA-FARMA d.o.o. | Krka d.d. | Coryol | tbl. 28x6,25 mg | 0,0764 | 2,14 | R | 5% |
| C07AG02 133 |  | karvedilol | 37,5 mg | 0,2486 | O | KRKA-FARMA d.o.o. | Krka d.d. | Coryol | tbl. 28x12,5 mg | 0,0828 | 2,32 | R | 5% |
| C07AG02 134 |  | karvedilol | 37,5 mg | 0,1864 | O | KRKA-FARMA d.o.o. | Krka d.d. | Coryol | tbl. 28x25 mg | 0,1242 | 3,48 | R | 5% |
| C08CA01 101 |  | amlodipin | 5 mg | 0,0643 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Vilpin | tbl. 30x5 mg | 0,0643 | 1,93 | R | 5% |
| C08CA01 102 |  | amlodipin | 5 mg | 0,0382 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Vilpin | tbl. 30x10 mg | 0,0764 | 2,29 | R | 5% |
| C08CA01 111 |  | amlodipin | 5 mg | 0,0643 | O | Belupo d.d. | Belupo | Amonex | tbl. 30x5 mg | 0,0643 | 1,93 | R | 5% |
| C08CA01 112 |  | amlodipin | 5 mg | 0,0382 | O | Belupo d.d. | Belupo | Amonex | tbl. 30x10 mg | 0,0764 | 2,29 | R | 5% |
| C08CA01 113 |  | amlodipin | 5 mg | 0,0478 | O | Belupo d.d. | Belupo | Amonex | tbl. 60x5 mg | 0,0478 | 2,87 | R | 5% |
| C08CA01 114 |  | amlodipin | 5 mg | 0,0478 | O | Belupo d.d. | Belupo | Amonex | tbl. 90x5 mg | 0,0478 | 4,30 | R | 5% |
| C08CA01 115 |  | amlodipin | 5 mg | 0,0358 | O | Belupo d.d. | Belupo | Amonex | tbl. 60x10 mg | 0,0717 | 4,30 | R | 5% |
| C08CA01 116 |  | amlodipin | 5 mg | 0,0358 | O | Belupo d.d. | Belupo | Amonex | tbl. 90x10 mg | 0,0717 | 6,45 | R | 5% |
| C08CA01 123 |  | amlodipin | 5 mg | 0,0643 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 30x5 mg | 0,0643 | 1,93 | R | 5% |
| C08CA01 124 |  | amlodipin | 5 mg | 0,0478 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 60x5 mg | 0,0478 | 2,87 | R | 5% |
| C08CA01 125 |  | amlodipin | 5 mg | 0,0478 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 90x5 mg | 0,0478 | 4,30 | R | 5% |
| C08CA01 126 |  | amlodipin | 5 mg | 0,0382 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 30x10 mg | 0,0764 | 2,29 | R | 5% |
| C08CA01 127 |  | amlodipin | 5 mg | 0,0358 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 60x10 mg | 0,0717 | 4,30 | R | 5% |
| C08CA01 128 |  | amlodipin | 5 mg | 0,0358 | O | Sandoz d.o.o. | Sandoz-Lek | Amlopin | tbl. 90x10 mg | 0,0717 | 6,45 | R | 5% |
| C08CA01 131 |  | amlodipin | 5 mg | 0,0643 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Tenox | tbl. 30x5 mg | 0,0643 | 1,93 | R | 5% |
| C08CA01 132 |  | amlodipin | 5 mg | 0,0382 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Tenox | tbl. 30x10 mg | 0,0764 | 2,29 | R | 5% |
| C08CA01 133 |  | amlodipin | 5 mg | 0,0478 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Tenox | tbl. 60x5 mg | 0,0478 | 2,87 | R | 5% |
| C08CA01 134 |  | amlodipin | 5 mg | 0,0358 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Tenox | tbl. 60x10 mg | 0,0717 | 4,30 | R | 5% |
| C08CA01 141 |  | amlodipin | 5 mg | 0,0643 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Lopin | tbl. 30x5 mg | 0,0643 | 1,93 | R | 5% |
| C08CA01 142 |  | amlodipin | 5 mg | 0,0382 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Lopin | tbl. 30x10 mg | 0,0764 | 2,29 | R | 5% |
| C08CA01 143 |  | amlodipin | 5 mg | 0,0358 | O | PharmaS d.o.o. | PharmaS d.o.o. | Amlodipin PharmaS | tbl. 30x10 mg | 0,0716 | 2,15 | R | 5% |
| C08CA01 145 |  | amlodipin | 5 mg | 0,0597 | O | PharmaS d.o.o. | PharmaS d.o.o. | Amlodipin PharmaS | tbl. 30x5 mg | 0,0597 | 1,79 | R | 5% |
| C08CA01 146 |  | amlodipin | 5 mg | 0,0460 | O | PharmaS d.o.o. | PharmaS d.o.o. | Amlodipin PharmaS | tbl. 60x5 mg | 0,0460 | 2,76 | R | 5% |
| C08CA01 147 |  | amlodipin | 5 mg | 0,0643 | O | Alkaloid d.o.o. | Alkaloid | Caprez | tbl. 30x5 mg | 0,0643 | 1,93 | R | 5% |
| C08CA01 148 |  | amlodipin | 5 mg | 0,0382 | O | Alkaloid d.o.o. | Alkaloid | Caprez | tbl. 30x10 mg | 0,0764 | 2,29 | R | 5% |
| C08CA01 149 |  | amlodipin | 5 mg | 0,0323 | O | PharmaS d.o.o. | PharmaS d.o.o. | Amlodipin PharmaS | tbl. 60x10 mg | 0,0646 | 3,88 | R | 5% |
| C08CA01 171 |  | amlodipin | 5 mg | 0,0643 | O | Upjohn EESV | Heinrich Mack | Norvasc | tbl. 30x5 mg | 0,0643 | 1,93 | R | 5% |
| C08CA01 172 |  | amlodipin | 5 mg | 0,0382 | O | Upjohn EESV | Heinrich Mack | Norvasc | tbl. 30x10 mg | 0,0764 | 2,29 | R | 5% |
| C08CA01 181 |  | amlodipin | 5 mg | 0,0577 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Amlodipin Genericon | tbl. 30x5 mg | 0,0575 | 1,73 | R | 5% |
| C08CA01 182 |  | amlodipin | 5 mg | 0,0337 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Amlodipin Genericon | tbl. 30x10 mg | 0,0675 | 2,02 | R | 5% |
| C08CA01 183 |  | amlodipin | 5 mg | 0,0430 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Amlodipin Genericon | tbl. 90x5 mg | 0,0430 | 3,87 | R | 5% |
| C08CA05 132 |  | nifedipin dugodjelujući | 30 mg | 0,1125 | O | KRKA-FARMA d.o.o. | Krka d.d. | Cordipin XL | tbl. 20x40 mg | 0,1500 | 3,00 | R | 5% |
| C08CA06 041 | DS | nimodipinNC801 | 50 mg | 56,7500 | P | Bayer d.o.o. | Bayer AG | Nimotop S | boč. inf. 1x10 mg/50 ml | 11,3505 | 11,35 |  | 5% |
| C08CA13 111 |  | lerkanidipin | 10 mg | 0,0643 | O | Belupo d.d. | Belupo | Pinox | tbl. film obl. 28x10 mg | 0,0643 | 1,80 | R | 5% |
| C08CA13 112 |  | lerkanidipin | 10 mg | 0,0479 | O | Belupo d.d. | Belupo | Pinox | tbl. film obl. 56x10 mg | 0,0478 | 2,68 | R | 5% |
| C08DA01 105 |  | verapamil | 0,24 g | 0,1863 | O | Mylan Hrvatska d.o.o. | AbbVie Deutschland GmbH & Co.KG | Isoptin RR | tbl. s prod. oslob. 30x240 mg | 0,1863 | 5,59 | R | 5% |
| C09AA02 131 |  | enalapril | 10 mg | 0,0530 | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap | tbl. 20x5 mg | 0,0265 | 0,53 | R | 5% |
| C09AA02 132 |  | enalapril | 10 mg | 0,0465 | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap | tbl. 20x10 mg | 0,0465 | 0,93 | R | 5% |
| C09AA03 101 |  | lizinopril | 10 mg | 0,0507 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Optimon | tbl. 30x5 mg | 0,0252 | 0,76 | R | 5% |
| C09AA03 102 |  | lizinopril | 10 mg | 0,0383 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Optimon | tbl. 30x10 mg | 0,0385 | 1,15 | R | 5% |
| C09AA03 103 |  | lizinopril | 10 mg | 0,0420 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Optimon | tbl. 30x20 mg | 0,0841 | 2,52 | R | 5% |
| C09AA03 104 |  | lizinopril | 10 mg | 0,0533 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor | tbl. 30x5 mg | 0,0265 | 0,80 | R | 5% |
| C09AA03 113 |  | lizinopril | 10 mg | 0,0530 | O | Belupo d.d. | Belupo | Irumed | tbl. 60x5 mg | 0,0265 | 1,59 | R | 5% |
| C09AA03 114 |  | lizinopril | 10 mg | 0,0533 | O | Belupo d.d. | Belupo | Irumed | tbl. 30x5 mg | 0,0265 | 0,80 | R | 5% |
| C09AA03 115 |  | lizinopril | 10 mg | 0,0463 | O | Belupo d.d. | Belupo | Irumed | tbl. 30x10 mg | 0,0465 | 1,39 | R | 5% |
| C09AA03 116 |  | lizinopril | 10 mg | 0,0420 | O | Belupo d.d. | Belupo | Irumed | tbl. 30x20 mg | 0,0841 | 2,52 | R | 5% |
| C09AA03 124 |  | lizinopril | 10 mg | 0,0465 | O | Belupo d.d. | Belupo | Irumed | tbl. 60x10 mg | 0,0465 | 2,79 | R | 5% |
| C09AA03 125 |  | lizinopril | 10 mg | 0,0332 | O | Belupo d.d. | Belupo | Irumed | tbl. 60x20 mg | 0,0664 | 3,98 | R | 5% |
| C09AA03 127 |  | lizinopril | 10 mg | 0,0463 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor | tbl. 30x10 mg | 0,0465 | 1,39 | R | 5% |
| C09AA03 129 |  | lizinopril | 10 mg | 0,0420 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor | tbl. 30x20 mg | 0,0841 | 2,52 | R | 5% |
| C09AA03 130 |  | lizinopril | 10 mg | 0,0332 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor | tbl. 60x20 mg | 0,0664 | 3,98 | R | 5% |
| C09AA03 143 |  | lizinopril | 10 mg | 0,0383 | O | Alkaloid d.o.o. | Alkaloid | Skopryl | tbl. 30x10 mg | 0,0385 | 1,15 | R | 5% |
| C09AA03 144 |  | lizinopril | 10 mg | 0,0420 | O | Alkaloid d.o.o. | Alkaloid | Skopryl | tbl. 30x20 mg | 0,0841 | 2,52 | R | 5% |
| C09AA04 130 |  | perindopril | 4 mg | 0,0533 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Perineva | tbl. 30x2 mg | 0,0265 | 0,80 | R | 5% |
| C09AA04 131 |  | perindopril | 4 mg | 0,0463 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Perineva | tbl. 30x4 mg | 0,0465 | 1,39 | R | 5% |
| C09AA04 132 |  | perindopril | 4 mg | 0,0465 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Perineva | tbl. 60x4 mg | 0,0465 | 2,79 | R | 5% |
| C09AA04 133 |  | perindopril | 4 mg | 0,0420 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Perineva | tbl. 30x8 mg | 0,0841 | 2,52 | R | 5% |
| C09AA05 104 |  | ramipril | 2,5 mg | 0,0463 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 30x2,5 mg | 0,0465 | 1,39 | R | 5% |
| C09AA05 105 |  | ramipril | 2,5 mg | 0,0420 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 30x5 mg | 0,0841 | 2,52 | R | 5% |
| C09AA05 106 |  | ramipril | 2,5 mg | 0,0322 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 30x10 mg | 0,1287 | 3,86 | R | 5% |
| C09AA05 107 |  | ramipril | 2,5 mg | 0,0465 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 60x2,5 mg | 0,0465 | 2,79 | R | 5% |
| C09AA05 108 |  | ramipril | 2,5 mg | 0,0332 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 60x5 mg | 0,0664 | 3,98 | R | 5% |
| C09AA05 109 |  | ramipril | 2,5 mg | 0,0322 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen | tbl. 60x10 mg | 0,1287 | 7,72 | R | 5% |
| C09AA05 111 |  | ramipril | 2,5 mg | 0,0529 | O | Belupo d.d. | Belupo | Ramed | tbl. 28x1,25 mg | 0,0265 | 0,74 | R | 5% |
| C09AA05 112 |  | ramipril | 2,5 mg | 0,0464 | O | Belupo d.d. | Belupo | Ramed | tbl. 28x2,5 mg | 0,0465 | 1,30 | R | 5% |
| C09AA05 113 |  | ramipril | 2,5 mg | 0,0420 | O | Belupo d.d. | Belupo | Ramed | tbl. 28x5 mg | 0,0840 | 2,35 | R | 5% |
| C09AA05 114 |  | ramipril | 2,5 mg | 0,0321 | O | Belupo d.d. | Belupo | Ramed | tbl. 28x10 mg | 0,1287 | 3,60 | R | 5% |
| C09AA05 115 |  | ramipril | 2,5 mg | 0,0464 | O | Belupo d.d. | Belupo | Ramed | tbl. 56x2,5 mg | 0,0465 | 2,60 | R | 5% |
| C09AA05 116 |  | ramipril | 2,5 mg | 0,0332 | O | Belupo d.d. | Belupo | Ramed | tbl. 56x5 mg | 0,0664 | 3,72 | R | 5% |
| C09AA05 117 |  | ramipril | 2,5 mg | 0,0464 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar | tbl. 28x2,5 mg | 0,0465 | 1,30 | R | 5% |
| C09AA05 118 |  | ramipril | 2,5 mg | 0,0420 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar | tbl. 28x5 mg | 0,0840 | 2,35 | R | 5% |
| C09AA05 119 |  | ramipril | 2,5 mg | 0,0321 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar | tbl. 28x10 mg | 0,1287 | 3,60 | R | 5% |
| C09AA05 121 |  | ramipril | 2,5 mg | 0,0529 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 28x1,25 mg | 0,0265 | 0,74 | R | 5% |
| C09AA05 122 |  | ramipril | 2,5 mg | 0,0464 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 28x2,5 mg | 0,0465 | 1,30 | R | 5% |
| C09AA05 123 |  | ramipril | 2,5 mg | 0,0464 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 50x2,5 mg | 0,0465 | 2,32 | R | 5% |
| C09AA05 124 |  | ramipril | 2,5 mg | 0,0420 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 28x5 mg | 0,0840 | 2,35 | R | 5% |
| C09AA05 125 |  | ramipril | 2,5 mg | 0,0332 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 50x5 mg | 0,0664 | 3,32 | R | 5% |
| C09AA05 126 |  | ramipril | 2,5 mg | 0,0321 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 28x10 mg | 0,1287 | 3,60 | R | 5% |
| C09AA05 127 |  | ramipril | 2,5 mg | 0,0322 | O | Sandoz d.o.o. | Sandoz-Lek | Piramil | tbl. 50x10 mg | 0,1287 | 6,44 | R | 5% |
| C09AA05 131 |  | ramipril | 2,5 mg | 0,0533 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 30x1,25 mg | 0,0265 | 0,80 | R | 5% |
| C09AA05 133 |  | ramipril | 2,5 mg | 0,0463 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 30x2,5 mg | 0,0465 | 1,39 | R | 5% |
| C09AA05 134 |  | ramipril | 2,5 mg | 0,0465 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 60x2,5 mg | 0,0465 | 2,79 | R | 5% |
| C09AA05 135 |  | ramipril | 2,5 mg | 0,0420 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 30x5 mg | 0,0841 | 2,52 | R | 5% |
| C09AA05 136 |  | ramipril | 2,5 mg | 0,0332 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 60x5 mg | 0,0664 | 3,98 | R | 5% |
| C09AA05 137 |  | ramipril | 2,5 mg | 0,0322 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 30x10 mg | 0,1287 | 3,86 | R | 5% |
| C09AA05 138 |  | ramipril | 2,5 mg | 0,0322 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril | tbl. 60x10 mg | 0,1287 | 7,72 | R | 5% |
| C09AA05 141 |  | ramipril | 2,5 mg | 0,0464 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril Mibe | tbl. 28x2,5 mg | 0,0465 | 1,30 | R | 5% |
| C09AA05 142 |  | ramipril | 2,5 mg | 0,0420 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril Mibe | tbl. 28x5 mg | 0,0840 | 2,35 | R | 5% |
| C09AA05 143 |  | ramipril | 2,5 mg | 0,0321 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril Mibe | tbl. 28x10 mg | 0,1287 | 3,60 | R | 5% |
| C09AA05 161 |  | ramipril | 2,5 mg | 0,0420 | O | sanofi-aventis groupe | Sanofi-Aventis S.p.A., Sanofi-Aventis GmbH, Sanofi Winthrop Quetigny | Tritace | tbl. 28x5 mg | 0,0840 | 2,35 | R | 5% |
| C09AA05 164 |  | ramipril | 2,5 mg | 0,0321 | O | sanofi-aventis groupe | Sanofi-Aventis S.p.A., Sanofi-Aventis GmbH, Sanofi Winthrop Quetigny | Tritace | tbl. 28x10 mg | 0,1287 | 3,60 | R | 5% |
| C09AA05 171 |  | ramipril | 2,5 mg | 0,0463 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramipril Genericon | tbl. 30x2,5 mg | 0,0465 | 1,39 | R | 5% |
| C09AA05 172 |  | ramipril | 2,5 mg | 0,0420 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramipril Genericon | tbl. 30x5 mg | 0,0841 | 2,52 | R | 5% |
| C09AA05 173 |  | ramipril | 2,5 mg | 0,0322 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramipril Genericon | tbl. 30x10 mg | 0,1287 | 3,86 | R | 5% |
| C09AA05 175 |  | ramipril | 2,5 mg | 0,0332 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramipril Genericon | tbl. 90x5 mg | 0,0664 | 5,97 | R | 5% |
| C09BA02 132 |  | enalapril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap H | tbl. 20x(10 mg + 25 mg) | 0,0790 | 1,58 | R | 5% |
| C09BA02 134 |  | enalapril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap HL 20 | tbl. 30x(20 mg + 12,5 mg) | 0,1186 | 3,56 | R | 5% |
| C09BA02 135 |  | enalapril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Enap HL 20 | tbl. 60x(20 mg + 12,5 mg) | 0,1119 | 6,72 | R | 5% |
| C09BA03 101 |  | lizinopril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Optimon Plus | tbl. 30x(20 mg + 12,5 mg) | 0,1230 | 3,69 | R | 5% |
| C09BA03 112 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 30x(20 mg + 12,5 mg) | 0,1230 | 3,69 | R | 5% |
| C09BA03 113 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 60x(20 mg + 12,5 mg) | 0,1230 | 7,38 | R | 5% |
| C09BA03 114 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 30x(10 mg + 12,5 mg) | 0,0845 | 2,54 | R | 5% |
| C09BA03 115 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 60x(10 mg + 12,5 mg) | 0,0845 | 5,07 | R | 5% |
| C09BA03 116 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 30x(20 mg + 25 mg) | 0,1230 | 3,69 | R | 5% |
| C09BA03 117 |  | lizinopril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Iruzid | tbl. 60x(20 mg + 25 mg) | 0,1110 | 6,66 | R | 5% |
| C09BA03 122 |  | lizinopril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor H | tbl. 20x(20 mg + 12,5 mg) | 0,1230 | 2,46 | R | 5% |
| C09BA03 123 |  | lizinopril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor H | tbl. 30x(10 mg + 12,5 mg) | 0,0845 | 2,54 | R | 5% |
| C09BA03 124 |  | lizinopril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Amicor H | tbl. 30x(20 mg + 12,5 mg) | 0,1230 | 3,69 | R | 5% |
| C09BA03 141 |  | lizinopril + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Lizinopril H Mibe | tbl. 30x(10 mg + 12,5 mg) | 0,0845 | 2,54 | R | 5% |
| C09BA03 142 |  | lizinopril + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Lizinopril H Mibe | tbl. 30x(20 mg + 12,5 mg) | 0,1230 | 3,69 | R | 5% |
| C09BA03 145 |  | lizinopril + hidroklorotiazid |  |  | O | Alkaloid d.o.o. | Alkaloid | Skopryl Plus | tbl. 30x(20 mg + 12,5 mg) | 0,1230 | 3,69 | R | 5% |
| C09BA03 146 |  | lizinopril + hidroklorotiazid |  |  | O | Alkaloid d.o.o. | Alkaloid | Skopryl Plus | tbl. 60x(20 mg + 12,5 mg) | 0,1150 | 6,90 | R | 5% |
| C09BA04 102 |  | perindopril + indapamid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Co-Articel | tbl. film obl. 30x(5 mg + 1,25 mg) | 0,0894 | 2,68 | R | 5% |
| C09BA04 131 |  | perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Co-Perineva | tbl. 60x(2 mg + 0,625 mg) | 0,0447 | 2,68 | R | 5% |
| C09BA04 132 |  | perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Co-Perineva | tbl. 30x(4 mg + 1,25 mg) | 0,0894 | 2,68 | R | 5% |
| C09BA04 134 |  | perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Co-Perineva | tbl. 30x(8 mg + 2,5 mg) | 0,1449 | 4,35 | R | 5% |
| C09BA04 136 |  | perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Co-Perineva | tbl. 30x(2 mg + 0,625 mg) | 0,0447 | 1,34 | R | 5% |
| C09BA05 103 |  | ramipril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen Plus | tbl. 30x(2,5 mg + 12,5 mg) | 0,0845 | 2,54 | R | 5% |
| C09BA05 104 |  | ramipril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen Plus | tbl. 30x(5 mg + 25 mg) | 0,1230 | 3,69 | R | 5% |
| C09BA05 105 |  | ramipril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen Plus | tbl. 60x(2,5 mg + 12,5 mg) | 0,0845 | 5,07 | R | 5% |
| C09BA05 106 |  | ramipril + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prilen Plus | tbl. 60x(5 mg + 25 mg) | 0,1110 | 6,66 | R | 5% |
| C09BA05 111 |  | ramipril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Ramzid | tbl. 28x(2,5mg + 12,5 mg) | 0,0845 | 2,37 | R | 5% |
| C09BA05 112 |  | ramipril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Ramzid | tbl. 28x(5 mg + 25 mg) | 0,1230 | 3,44 | R | 5% |
| C09BA05 113 |  | ramipril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Ramzid | tbl. 56x(2,5 mg + 12,5 mg) | 0,0845 | 4,73 | R | 5% |
| C09BA05 114 |  | ramipril + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Ramzid | tbl. 56x(5 mg + 25 mg) mg | 0,1110 | 6,22 | R | 5% |
| C09BA05 121 |  | ramipril + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Salutas | Piramil HL | tbl. 28x(2,5 mg + 12,5 mg) | 0,0845 | 2,37 | R | 5% |
| C09BA05 123 |  | ramipril + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Salutas | Piramil H | tbl. 28x(5mg + 25 mg) | 0,1230 | 3,44 | R | 5% |
| C09BA05 128 |  | ramipril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar Plus | tbl. 28x(2,5mg + 12,5 mg) | 0,0740 | 2,07 | R | 5% |
| C09BA05 129 |  | ramipril + hidroklorotiazid |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Blocar Plus | tbl. 28x(5 mg + 25 mg) | 0,1206 | 3,38 | R | 5% |
| C09BA05 131 |  | ramipril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril HL | tbl. 30x(2,5 mg + 12,5 mg) | 0,0845 | 2,54 | R | 5% |
| C09BA05 132 |  | ramipril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril HL | tbl. 60x(2,5 mg + 12,5 mg) | 0,0845 | 5,07 | R | 5% |
| C09BA05 133 |  | ramipril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril HD | tbl. 30x(5 mg + 25 mg) | 0,1230 | 3,69 | R | 5% |
| C09BA05 134 |  | ramipril + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Ampril HD | tbl. 60x(5 mg + 25 mg) | 0,1110 | 6,66 | R | 5% |
| C09BA05 141 |  | ramipril + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril H Mibe | tbl. 28x(2,5 mg + 12,5 mg) | 0,0845 | 2,37 | R | 5% |
| C09BA05 142 |  | ramipril + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Ramipril H Mibe | tbl. 28x(5 mg + 25 mg) | 0,1230 | 3,44 | R | 5% |
| C09BA05 161 |  | ramipril + hidroklorotiazid |  |  | O | sanofi-aventis groupe | Aventis Pharma S.p.A | Tritazide | tbl. 28x(2,5 mg + 12,5 mg) | 0,0845 | 2,37 | R | 5% |
| C09BA05 171 |  | ramipril + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramicomp Genericon 2,5 mg/12,5 mg | tbl. 30x(2,5 mg + 12,5 mg) | 0,0823 | 2,47 | R | 5% |
| C09BA05 172 |  | ramipril + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Ramicomp Genericon 5 mg/25 mg | tbl. 30x(5 mg + 25 mg) | 0,1230 | 3,69 | R | 5% |
| C09BB04 101 |  | perindopril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Teva Czech Industries s.r.o., Teva Pharma S.L.U., Teva UK Ltd., Teva Operations Poland Sp. z o.o., Teva Pharmaceuticals, Teva Pharma B.V. | Articel-Am | tbl. 30x(5 mg + 5 mg) | 0,0894 | 2,68 | R | 5% |
| C09BB04 111 |  | perindopril + amlodipin |  |  | O | Jadran – Galenski Laboratorij d.d. | Adamed Pharma S.A., Jadran Galenski laboratorij d.d. | Almirincomb | tbl. 30x(4 mg + 5 mg) | 0,0626 | 1,88 | R | 5% |
| C09BB04 112 |  | perindopril + amlodipin |  |  | O | Jadran – Galenski Laboratorij d.d. | Adamed Pharma S.A., Jadran Galenski laboratorij d.d. | Almirincomb | tbl. 30x(4 mg + 10 mg) | 0,0626 | 1,88 | R | 5% |
| C09BB04 113 |  | perindopril + amlodipin |  |  | O | Jadran – Galenski Laboratorij d.d. | Adamed Pharma S.A., Jadran Galenski laboratorij d.d. | Almirincomb | tbl. 30x(8 mg + 5 mg) | 0,1031 | 3,09 | R | 5% |
| C09BB04 114 |  | perindopril + amlodipin |  |  | O | Jadran – Galenski Laboratorij d.d. | Adamed Pharma S.A., Jadran Galenski laboratorij d.d. | Almirincomb | tbl. 30x(8 mg + 10 mg) | 0,1094 | 3,28 | R | 5% |
| C09BB04 131 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Dalneva | tbl. 30x(4 mg + 5 mg) | 0,0894 | 2,68 | R | 5% |
| C09BB04 132 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Dalneva | tbl. 30x(4 mg + 10 mg) | 0,0894 | 2,68 | R | 5% |
| C09BB04 133 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Dalneva | tbl. 30x(8 mg + 5 mg) | 0,1473 | 4,42 | R | 5% |
| C09BB04 134 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Dalneva | tbl. 30x(8 mg + 10 mg) | 0,1563 | 4,69 | R | 5% |
| C09BB04 135 |  | perindopril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Predalneva | tbl. 30x(2,85 mg + 2,5 mg) | 0,0511 | 1,53 | R | 5% |
| C09BB07 101 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 30x(5 mg + 5 mg) | 0,1266 | 3,80 | R | 5% |
| C09BB07 102 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 60x(5 mg + 5 mg) | 0,1139 | 6,84 | R | 5% |
| C09BB07 103 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 30x(5 mg + 10 mg) | 0,1266 | 3,80 | R | 5% |
| C09BB07 104 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 60x(5 mg + 10 mg) | 0,1139 | 6,84 | R | 5% |
| C09BB07 105 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 30x(10 mg + 5 mg) | 0,1502 | 4,51 | R | 5% |
| C09BB07 106 |  | ramipril + amlodipin |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva-Hrvatska d.o.o. | Prilen-Am | caps. tvrda 30x(10 mg + 10 mg) | 0,1502 | 4,51 | R | 5% |
| C09BB07 110 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(10 mg + 10 mg) | 0,1352 | 8,11 | R | 5% |
| C09BB07 111 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(2,5 mg + 5 mg) | 0,0936 | 2,81 | R | 5% |
| C09BB07 112 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(2,5 mg + 5 mg) | 0,0842 | 5,05 | R | 5% |
| C09BB07 113 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(5 mg + 5 mg) | 0,1266 | 3,80 | R | 5% |
| C09BB07 114 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(5 mg + 5 mg) | 0,1139 | 6,84 | R | 5% |
| C09BB07 115 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(5 mg + 10 mg) | 0,1266 | 3,80 | R | 5% |
| C09BB07 116 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(5 mg + 10 mg) | 0,1139 | 6,84 | R | 5% |
| C09BB07 117 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(10 mg + 5 mg) | 0,1502 | 4,51 | R | 5% |
| C09BB07 118 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 60x(10 mg + 5 mg) | 0,1352 | 8,11 | R | 5% |
| C09BB07 119 |  | ramipril + amlodipin |  |  | O | Belupo d.d. | Belupo | Amora | caps. tvrda 30x(10 mg + 10 mg) | 0,1502 | 4,51 | R | 5% |
| C09BB07 122 |  | ramipril + amlodipin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Prylar | caps. tvrda 30x(5 mg + 5 mg) | 0,1266 | 3,80 | R | 5% |
| C09BB07 123 |  | ramipril + amlodipin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Prylar | caps. tvrda 30x(10 mg + 5 mg) | 0,1502 | 4,51 | R | 5% |
| C09BB07 124 |  | ramipril + amlodipin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Prylar | caps. tvrda 30x(5 mg + 10 mg) | 0,1266 | 3,80 | R | 5% |
| C09BB07 125 |  | ramipril + amlodipin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Prylar | caps. tvrda 30x(10 mg + 10 mg) | 0,1502 | 4,51 | R | 5% |
| C09BB07 131 |  | ramipril + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Rameam | caps. tvrda 30x(5 mg + 5 mg) | 0,1266 | 3,80 | R | 5% |
| C09BB07 181 |  | ramipril + amlodipin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol | caps. tvrda 30x(5 mg + 5 mg) | 0,1202 | 3,61 | R | 5% |
| C09BB07 182 |  | ramipril + amlodipin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol | caps. tvrda 30x(5 mg + 10 mg) | 0,1202 | 3,61 | R | 5% |
| C09BB07 183 |  | ramipril + amlodipin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol | caps. tvrda 30x(10 mg + 5 mg) | 0,1427 | 4,28 | R | 5% |
| C09BB07 184 |  | ramipril + amlodipin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol | caps. tvrda 30x(10 mg + 10 mg) | 0,1427 | 4,28 | R | 5% |
| C09BX01 131 |  | perindopril + indapamid + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Dalneva | tbl. film obl. 30x(4 mg + 1,25 mg + 5 mg) | 0,1099 | 3,30 | R | 5% |
| C09BX01 132 |  | perindopril + indapamid + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Dalneva | tbl. film obl. 30x(4 mg + 1,25 mg + 10 mg) | 0,1172 | 3,52 | R | 5% |
| C09BX01 133 |  | perindopril + indapamid + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Dalneva | tbl. film obl. 30x(8 mg + 2,5 mg + 5 mg) | 0,2185 | 6,56 | R | 5% |
| C09BX01 134 |  | perindopril + indapamid + amlodipin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Dalneva | tbl. film obl. 30x(8 mg + 2,5 mg + 10 mg) | 0,2258 | 6,78 | R | 5% |
| C09BX03 121 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Prylar H | caps. tvrda 30x(5 mg + 5 mg + 12,5 mg) | 0,0991 | 2,97 | R | 5% |
| C09BX03 122 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Prylar H | caps. tvrda 30x(5 mg + 5 mg + 25 mg) | 0,0991 | 2,97 | R | 5% |
| C09BX03 123 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Prylar H | caps. tvrda 30x(10 mg + 5 mg + 25 mg) | 0,1322 | 3,97 | R | 5% |
| C09BX03 124 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Prylar H | caps. tvrda 30x(10 mg + 10 mg + 25 mg) | 0,1392 | 4,18 | R | 5% |
| C09BX03 171 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol Plus | caps. tvrda 30x(5 mg + 5 mg + 12,5 mg) | 0,0991 | 2,97 | R | 5% |
| C09BX03 172 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol Plus | caps. tvrda 30x(5 mg + 5 mg + 25 mg) | 0,0991 | 2,97 | R | 5% |
| C09BX03 173 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol Plus | caps. tvrda 30x(10 mg + 5 mg + 25 mg) | 0,1322 | 3,97 | R | 5% |
| C09BX03 174 |  | ramipril + amlodipin + hidroklorotiazid |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Adamed Pharma S.A. | Pinmirol Plus | caps. tvrda 30x(10 mg + 10 mg + 25 mg) | 0,1392 | 4,18 | R | 5% |
| C09CA01 101 |  | losartan | 50 mg | 0,0729 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Losartic | tbl. 28x50 mg | 0,0730 | 2,04 | RRC02 | 5% |
| C09CA01 121 |  | losartan | 50 mg | 0,0729 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Lotan | tbl. film obl. 28x50 mg | 0,0730 | 2,04 | RRC02 | 5% |
| C09CA01 125 |  | losartan | 50 mg | 0,0730 | O | Alkaloid d.o.o. | Alkaloid | Lotar | tbl. film obl. 30x50 mg | 0,0730 | 2,19 | RRC02 | 5% |
| C09CA01 126 |  | losartan | 50 mg | 0,0765 | O | Alkaloid d.o.o. | Alkaloid | Lotar | tbl. film obl. 30x100 mg | 0,1531 | 4,59 | RRC02 | 5% |
| C09CA01 131 |  | losartan | 50 mg | 0,0729 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lorista | tbl. 28 x 50 mg | 0,0730 | 2,04 | RRC02 | 5% |
| C09CA01 132 |  | losartan | 50 mg | 0,0766 | O | KRKA-FARMA d.o.o. | Krka d.d. | Lorista | tbl. 28x100 mg | 0,1531 | 4,29 | RRC02 | 5% |
| C09CA03 111 |  | valsartan | 80 mg | 0,0729 | O | Belupo d.d. | Belupo | Val | tbl. film obl. 28x80 mg | 0,0730 | 2,04 | RRC02 | 5% |
| C09CA03 112 |  | valsartan | 80 mg | 0,0766 | O | Belupo d.d. | Belupo | Val | tbl. film obl. 28x160 mg | 0,1531 | 4,29 | RRC02 | 5% |
| C09CA03 113 |  | valsartan | 80 mg | 0,0730 | O | Belupo d.d. | Belupo | Val | tbl. film obl. 56x80 mg | 0,0730 | 4,09 | RRC02 | 5% |
| C09CA03 114 |  | valsartan | 80 mg | 0,0768 | O | Belupo d.d. | Belupo | Val | tbl. film obl. 56x160 mg | 0,1535 | 8,60 | RRC02 | 5% |
| C09CA03 121 |  | valsartan | 80 mg | 0,0730 | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm | tbl. film obl. 30x80 mg | 0,0730 | 2,19 | RRC02 | 5% |
| C09CA03 122 |  | valsartan | 80 mg | 0,0765 | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm | tbl. film obl. 30x160 mg | 0,1531 | 4,59 | RRC02 | 5% |
| C09CA03 124 |  | valsartan | 80 mg | 0,0700 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Desart | tbl. film obl. 28x80 mg | 0,0702 | 1,96 | RRC02 | 5% |
| C09CA03 125 |  | valsartan | 80 mg | 0,0766 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Desart | tbl. film obl. 28x160 mg | 0,1531 | 4,29 | RRC02 | 5% |
| C09CA03 132 |  | valsartan | 80 mg | 0,0729 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Valsacor | tbl. film obl. 28x80 mg | 0,0730 | 2,04 | RRC02 | 5% |
| C09CA03 133 |  | valsartan | 80 mg | 0,0766 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Valsacor | tbl. film obl. 28x160 mg | 0,1531 | 4,29 | RRC02 | 5% |
| C09CA03 134 |  | valsartan | 80 mg | 0,0773 | O | KRKA-FARMA d.o.o. | Krka d.d. | Valsacor | tbl. film obl. 28x320 mg | 0,3092 | 8,66 | RRC02 | 5% |
| C09CA06 122 |  | kandesartan | 8 mg | 0,0766 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Kandepres | tbl. 28x16 mg | 0,1531 | 4,29 | RRC02 | 5% |
| C09CA07 131 |  | telmisartan | 40 mg | 0,0730 | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska | Tolura | tbl. 30x40 mg | 0,0730 | 2,19 | RRC02 | 5% |
| C09CA07 132 |  | telmisartan | 40 mg | 0,0765 | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska | Tolura | tbl. 30x80 mg | 0,1531 | 4,59 | RRC02 | 5% |
| C09DA01 101 |  | losartan + hidroklorotiazid |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Losartic plus | tbl. 28x(50 mg + 12,5 mg) | 0,1261 | 3,53 | RRC02 | 5% |
| C09DA01 121 |  | losartan + hidroklorotiazid |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Lotan H | tbl. 28x(50 mg + 12,5 mg) | 0,1261 | 3,53 | RRC02 | 5% |
| C09DA01 131 |  | losartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Lorista H | tbl. film obl. 28x(50 mg + 12,5 mg) | 0,1261 | 3,53 | RRC02 | 5% |
| C09DA01 132 |  | losartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Lorista HD | tbl. film obl. 30x(100 mg + 25 mg) | 0,1531 | 4,59 | RRC02 | 5% |
| C09DA01 134 |  | losartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | KRKA d.d. | Lorista H | tbl. film obl. 28x(100 mg + 12,5 mg) | 0,1632 | 4,57 | RRC02 | 5% |
| C09DA01 161 |  | losartan + hidroklorotiazid |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Hyzaar | tbl. 28x(50 mg + 12,5 mg) | 0,1261 | 3,53 | RRC02 | 5% |
| C09DA01 162 |  | losartan + hidroklorotiazid |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Fortzaar | tbl. 28x(100 mg + 25 mg) | 0,1659 | 4,65 | RRC02 | 5% |
| C09DA01 163 |  | losartan + hidroklorotiazid |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Hyzaar | tbl. film obl. 28x(100 mg + 12,5 mg) | 0,1632 | 4,57 | RRC02 | 5% |
| C09DA03 111 |  | valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Val Plus | tbl. film obl. 28x(80 mg + 12,5 mg) | 0,1261 | 3,53 | RRC02 | 5% |
| C09DA03 112 |  | valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Val Plus | tbl. film obl. 28x(160 mg + 12,5 mg) | 0,1695 | 4,74 | RRC02 | 5% |
| C09DA03 113 |  | valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Val Plus | tbl. film obl. 56x(80 mg + 12,5 mg) | 0,1261 | 7,06 | RRC02 | 5% |
| C09DA03 114 |  | valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo | Val Plus | tbl. film obl. 56x(160 mg + 12,5 mg) | 0,1695 | 9,49 | RRC02 | 5% |
| C09DA03 121 |  | valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm H | tbl. film obl. 30x(80 mg + 12,5 mg) | 0,1261 | 3,78 | RRC02 | 5% |
| C09DA03 122 |  | valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm H | tbl. film obl. 30x(160 mg + 12,5 mg) | 0,1694 | 5,08 | RRC02 | 5% |
| C09DA03 124 |  | valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Valnorm H | tbl. film obl. 30x(160 mg + 25 mg) | 0,1694 | 5,08 | RRC02 | 5% |
| C09DA03 131 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 28x(80 mg + 12,5 mg) | 0,1261 | 3,53 | RRC02 | 5% |
| C09DA03 132 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 56x(80 mg + 12,5 mg) | 0,1261 | 7,06 | RRC02 | 5% |
| C09DA03 133 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 28x(160 mg + 12,5 mg) | 0,1695 | 4,74 | RRC02 | 5% |
| C09DA03 134 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 56x(160 mg + 12,5 mg) | 0,1695 | 9,49 | RRC02 | 5% |
| C09DA03 135 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 28x(160 mg + 25 mg) | 0,1695 | 4,74 | RRC02 | 5% |
| C09DA03 136 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Valsacombi | tbl. film obl. 56x(160 mg + 25 mg) | 0,1695 | 9,49 | RRC02 | 5% |
| C09DA03 137 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Valsacombi | tbl. film obl. 28x(320 mg + 12,5 mg) | 0,3614 | 10,12 | RRC02 | 5% |
| C09DA03 139 |  | valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Valsacombi | tbl. film obl. 28x(320 mg + 25 mg) | 0,3614 | 10,12 | RRC02 | 5% |
| C09DA03 163 |  | valsartan + hidroklorotiazid |  |  | O | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Co-Diovan | tbl. film obl. 28x(160 mg + 25 mg) | 0,1695 | 4,74 | RRC02 | 5% |
| C09DA03 164 |  | valsartan + hidroklorotiazid |  |  | O | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Co-Diovan | tbl. film obl. 28x(320 mg + 12,5 mg) | 0,3614 | 10,12 | RRC02 | 5% |
| C09DA07 137 |  | telmisartan + hidroklorotiazid |  |  | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska Sp. zo. o., TAD Pharma GmbH | Tolucombi | tbl. 28x(40 mg + 12,5 mg) | 0,1261 | 3,53 | RRC02 | 5% |
| C09DA07 138 |  | telmisartan + hidroklorotiazid |  |  | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska Sp. zo. o., TAD Pharma GmbH | Tolucombi | tbl. 28x(80 mg + 12,5 mg) | 0,1695 | 4,74 | RRC02 | 5% |
| C09DA07 139 |  | telmisartan + hidroklorotiazid |  |  | O | Krka d.d., Novo mesto | Krka d.d., Krka Polska Sp. zo. o., TAD Pharma GmbH | Tolucombi | tbl. 28x(80 mg + 25 mg) | 0,1695 | 4,74 | RRC02 | 5% |
| C09DB01 111 |  | amlodipin + valsartan |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas | tbl. film obl. 30x(5 mg + 80 mg) | 0,0692 | 2,08 | RRC02 | 5% |
| C09DB01 112 |  | amlodipin + valsartan |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas | tbl. film obl. 30x(5 mg + 160 mg) | 0,1344 | 4,03 | RRC02 | 5% |
| C09DB01 113 |  | amlodipin + valsartan |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas | tbl. film obl. 30x(10 mg + 160 mg) | 0,1344 | 4,03 | RRC02 | 5% |
| C09DB01 121 |  | amlodipin + valsartan |  |  | O | Sandoz d.o.o. | Novartis Pharma GmbH | Amlodipin/valsartan Sandoz | tbl. film obl. 28x(5 mg + 80 mg) | 0,0729 | 2,04 | RRC02 | 5% |
| C09DB01 122 |  | amlodipin + valsartan |  |  | O | Sandoz d.o.o. | Novartis Pharma GmbH | Amlodipin/valsartan Sandoz | tbl. film obl. 28x(5 mg + 160 mg) | 0,1344 | 3,76 | RRC02 | 5% |
| C09DB01 123 |  | amlodipin + valsartan |  |  | O | Sandoz d.o.o. | Novartis Pharma GmbH | Amlodipin/valsartan Sandoz | tbl. film obl. 28x(10 mg + 160 mg) | 0,1415 | 3,96 | RRC02 | 5% |
| C09DB01 141 |  | amlodipin + valsartan |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., Krka-farma d.o.o. | Wamlox | tbl. film obl. 30x(5 mg + 160 mg) | 0,1344 | 4,03 | RRC02 | 5% |
| C09DB01 142 |  | amlodipin + valsartan |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., Krka-farma d.o.o. | Wamlox | tbl. film obl. 30x(10 mg + 160 mg) | 0,1415 | 4,25 | RRC02 | 5% |
| C09DB01 143 |  | amlodipin + valsartan |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma Gmbh | Wamlox | tbl. film obl. 30x(5 mg + 80 mg) | 0,0729 | 2,19 | RRC02 | 5% |
| C09DX01 111 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas HCT | tbl. film obl. 30x(5 mg + 160 mg + 12,5 mg) | 0,1474 | 4,42 | RRC02 | 5% |
| C09DX01 112 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas HCT | tbl. film obl. 30x(5 mg + 160 mg + 25 mg) | 0,1474 | 4,42 | RRC02 | 5% |
| C09DX01 113 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas HCT | tbl. film obl. 30x(10 mg + 160 mg + 12,5 mg) | 0,1562 | 4,69 | RRC02 | 5% |
| C09DX01 114 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Vainas HCT | tbl. film obl. 30x(10 mg + 160 mg + 25 mg) | 0,1562 | 4,69 | RRC02 | 5% |
| C09DX01 124 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Salutas Pharma GmbH | Dipperam HCT | tbl. film obl. 28x(5 mg + 160 mg + 12,5 mg) | 0,1551 | 4,34 | RRC02 | 5% |
| C09DX01 125 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Salutas Pharma GmbH | Dipperam HCT | tbl. film obl. 28x(5 mg + 160 mg + 25 mg) | 0,1551 | 4,34 | RRC02 | 5% |
| C09DX01 126 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | Sandoz d.o.o. | Salutas Pharma GmbH | Dipperam HCT | tbl. film obl. 28x(10 mg + 160 mg + 12,5 mg) | 0,1562 | 4,37 | RRC02 | 5% |
| C09DX01 131 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GMBH | Valtricom | tbl. film obl. 30x(5 mg + 160 mg + 12,5 mg) | 0,1552 | 4,65 | RRC02 | 5% |
| C09DX01 132 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GMBH | Valtricom | tbl. film obl. 30x(10 mg + 160 mg + 12,5 mg) | 0,1562 | 4,69 | RRC02 | 5% |
| C09DX01 133 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GMBH | Valtricom | tbl. film obl. 30x(5 mg + 160 mg + 25 mg) | 0,1552 | 4,65 | RRC02 | 5% |
| C09DX01 134 |  | amlodipin + valsartan + hidroklorotiazid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GMBH | Valtricom | tbl. film obl. 30x(10 mg + 320 mg + 25 mg) | 0,2948 | 8,84 | RRC02 | 5% |
| C10AA01 106 |  | simvastatin | 30 mg | 0,1511 | O | Alkaloid d.o.o. | Alkaloid | Lipterra | tbl. film obl. 28x10 mg | 0,0504 | 1,41 | RRC03 | 5% |
| C10AA01 108 |  | simvastatin | 30 mg | 0,0996 | O | Alkaloid d.o.o. | Alkaloid | Lipterra | tbl. film obl. 28x20 mg | 0,0665 | 1,86 | RRC03 | 5% |
| C10AA01 109 |  | simvastatin | 30 mg | 0,1042 | O | Alkaloid d.o.o. | Alkaloid | Lipterra | tbl. film obl. 28x40 mg | 0,1390 | 3,89 | RRC03 | 5% |
| C10AA01 112 |  | simvastatin | 30 mg | 0,1511 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Simvax | tbl. film obl. 28x10 mg | 0,0504 | 1,41 | RRC03 | 5% |
| C10AA01 114 |  | simvastatin | 30 mg | 0,0996 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Simvax | tbl. film obl. 28x20 mg | 0,0665 | 1,86 | RRC03 | 5% |
| C10AA01 116 |  | simvastatin | 30 mg | 0,1042 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Simvax | tbl. film obl. 28x40 mg | 0,1390 | 3,89 | RRC03 | 5% |
| C10AA01 131 |  | simvastatin | 30 mg | 0,1515 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 20x10 mg | 0,0504 | 1,01 | RRC03 | 5% |
| C10AA01 132 |  | simvastatin | 30 mg | 0,1511 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 28x10 mg | 0,0504 | 1,41 | RRC03 | 5% |
| C10AA01 133 |  | simvastatin | 30 mg | 0,0998 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 20x20 mg | 0,0665 | 1,33 | RRC03 | 5% |
| C10AA01 134 |  | simvastatin | 30 mg | 0,0996 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 28x20 mg | 0,0665 | 1,86 | RRC03 | 5% |
| C10AA01 135 |  | simvastatin | 30 mg | 0,1042 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 28x40 mg | 0,1390 | 3,89 | RRC03 | 5% |
| C10AA01 136 |  | simvastatin | 30 mg | 0,1515 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 60x10 mg | 0,0504 | 3,03 | RRC03 | 5% |
| C10AA01 137 |  | simvastatin | 30 mg | 0,0998 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 60x20 mg | 0,0665 | 3,99 | RRC03 | 5% |
| C10AA01 138 |  | simvastatin | 30 mg | 0,1041 | O | KRKA-FARMA d.o.o. | Krka d.d. | Vasilip | tbl. film obl. 60x40 mg | 0,1389 | 8,33 | RRC03 | 5% |
| C10AA01 141 |  | simvastatin | 30 mg | 0,1511 | O | Belupo d.d. | Belupo | Protecta | tbl. film obl. 28x10 mg | 0,0504 | 1,41 | RRC03 | 5% |
| C10AA01 142 |  | simvastatin | 30 mg | 0,0996 | O | Belupo d.d. | Belupo | Protecta | tbl. film obl. 28x20 mg | 0,0665 | 1,86 | RRC03 | 5% |
| C10AA01 143 |  | simvastatin | 30 mg | 0,1042 | O | Belupo d.d. | Belupo | Protecta | tbl. film obl. 28x40 mg | 0,1390 | 3,89 | RRC03 | 5% |
| C10AA01 144 |  | simvastatin | 30 mg | 0,0996 | O | Belupo d.d. | Belupo | Protecta | tbl. film obl. 56x20 mg | 0,0665 | 3,72 | RRC03 | 5% |
| C10AA01 166 |  | simvastatin | 30 mg | 0,0995 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Simvastatin Genericon | tbl. film obl. 30x20 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA01 167 |  | simvastatin | 30 mg | 0,1043 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Simvastatin Genericon | tbl. film obl. 30x40 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 101 |  | atorvastatin | 20 mg | 0,1327 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 30x10 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA05 102 |  | atorvastatin | 20 mg | 0,1330 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 60x10 mg | 0,0665 | 3,99 | RRC03 | 5% |
| C10AA05 103 |  | atorvastatin | 20 mg | 0,1390 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 30x20 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 104 |  | atorvastatin | 20 mg | 0,1390 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 60x20 mg | 0,1390 | 8,34 | RRC03 | 5% |
| C10AA05 105 |  | atorvastatin | 20 mg | 0,0892 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 30x40 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA05 106 |  | atorvastatin | 20 mg | 0,0892 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 60x40 mg | 0,1783 | 10,70 | RRC03 | 5% |
| C10AA05 107 |  | atorvastatin | 20 mg | 0,0697 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Atorvox | tbl. film obl. 30x80 mg | 0,2787 | 8,36 | RRC03 | 5% |
| C10AA05 111 |  | atorvastatin | 20 mg | 0,1327 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 30x10 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA05 112 |  | atorvastatin | 20 mg | 0,1330 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 60x10 mg | 0,0665 | 3,99 | RRC03 | 5% |
| C10AA05 113 |  | atorvastatin | 20 mg | 0,1390 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 30x20 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 114 |  | atorvastatin | 20 mg | 0,1390 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 60x20 mg | 0,1390 | 8,34 | RRC03 | 5% |
| C10AA05 115 |  | atorvastatin | 20 mg | 0,0892 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Liptin | tbl. film obl. 30x40 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA05 121 |  | atorvastatin | 20 mg | 0,1327 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 30x10 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA05 122 |  | atorvastatin | 20 mg | 0,1390 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 30x20 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 123 |  | atorvastatin | 20 mg | 0,1330 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 60x10 mg | 0,0665 | 3,99 | RRC03 | 5% |
| C10AA05 124 |  | atorvastatin | 20 mg | 0,1390 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 60x20 mg | 0,1390 | 8,34 | RRC03 | 5% |
| C10AA05 125 |  | atorvastatin | 20 mg | 0,0892 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 30x40 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA05 126 |  | atorvastatin | 20 mg | 0,0892 | O | Sandoz d.o.o. | Sandoz-Lek | Tulip | tbl. film obl. 60x40 mg | 0,1783 | 10,70 | RRC03 | 5% |
| C10AA05 127 |  | atorvastatin | 20 mg | 0,1327 | O | Mylan Hrvatska d.o.o. | Pharmathen International SA | Synordia | tbl. film obl. 30x10 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA05 129 |  | atorvastatin | 20 mg | 0,1390 | O | Mylan Hrvatska d.o.o. | Pharmathen International SA | Synordia | tbl. film obl. 30x20 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 131 |  | atorvastatin | 20 mg | 0,1327 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 30x10 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA05 132 |  | atorvastatin | 20 mg | 0,1390 | O | KRKA-FARMA d.o.o. | Krka d.d.,KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 30x20 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 133 |  | atorvastatin | 20 mg | 0,0892 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 30x40 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA05 134 |  | atorvastatin | 20 mg | 0,0892 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 60x40 mg | 0,1783 | 10,70 | RRC03 | 5% |
| C10AA05 136 |  | atorvastatin | 20 mg | 0,1330 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 60x10 mg | 0,0665 | 3,99 | RRC03 | 5% |
| C10AA05 137 |  | atorvastatin | 20 mg | 0,1390 | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atoris | tbl. film obl. 60x20 mg | 0,1390 | 8,34 | RRC03 | 5% |
| C10AA05 138 |  | atorvastatin | 20 mg | 0,0892 | O | Mylan Hrvatska d.o.o. | Pharmathen International SA | Synordia | tbl. film obl. 30x40 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA05 139 |  | atorvastatin | 20 mg | 0,0697 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atoris | tbl. film obl. 30x80 mg | 0,2787 | 8,36 | RRC03 | 5% |
| C10AA05 141 |  | atorvastatin | 20 mg | 0,1327 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 30x10 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA05 142 |  | atorvastatin | 20 mg | 0,1330 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 60x10 mg | 0,0665 | 3,99 | RRC03 | 5% |
| C10AA05 143 |  | atorvastatin | 20 mg | 0,1390 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 30x20 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 144 |  | atorvastatin | 20 mg | 0,1390 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 60x20 mg | 0,1390 | 8,34 | RRC03 | 5% |
| C10AA05 145 |  | atorvastatin | 20 mg | 0,0892 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 30x40 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA05 146 |  | atorvastatin | 20 mg | 0,0892 | O | Belupo d.d. | Belupo | Torvas | tbl. film obl. 60x40 mg | 0,1783 | 10,70 | RRC03 | 5% |
| C10AA05 171 |  | atorvastatin | 20 mg | 0,1327 | O | Upjohn EESV | Goedecke GmbH za Pfizer | Sortis | tbl. film obl. 30x10 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA05 172 |  | atorvastatin | 20 mg | 0,1390 | O | Upjohn EESV | Goedecke GmbH za Pfizer | Sortis | tbl. film obl. 30x20 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 173 |  | atorvastatin | 20 mg | 0,0892 | O | Upjohn EESV | Goedecke GmbH za Pfizer | Sortis | tbl. film obl. 30x40 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA05 174 |  | atorvastatin | 20 mg | 0,0697 | O | Upjohn EESV | Goedecke GmbH za Pfizer | Sortis | tbl. film obl. 30x80 mg | 0,2787 | 8,36 | RRC03 | 5% |
| C10AA05 175 |  | atorvastatin | 20 mg | 0,1327 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 30x10 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA05 176 |  | atorvastatin | 20 mg | 0,1330 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 60x10 mg | 0,0665 | 3,99 | RRC03 | 5% |
| C10AA05 177 |  | atorvastatin | 20 mg | 0,1390 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 30x20 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 178 |  | atorvastatin | 20 mg | 0,1390 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 60x20 mg | 0,1390 | 8,34 | RRC03 | 5% |
| C10AA05 179 |  | atorvastatin | 20 mg | 0,0892 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 30x40 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA05 180 |  | atorvastatin | 20 mg | 0,0892 | O | PharmaS d.o.o. | PharmaS d.o.o. | Atorvastatin PharmaS | tbl. film obl. 60x40 mg | 0,1783 | 10,70 | RRC03 | 5% |
| C10AA05 181 |  | atorvastatin | 20 mg | 0,1329 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Artas | tbl. film obl. 28x10 mg | 0,0665 | 1,86 | RRC03 | 5% |
| C10AA05 183 |  | atorvastatin | 20 mg | 0,1225 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Artas | tbl. film obl. 28x20 mg | 0,1225 | 3,43 | RRC03 | 5% |
| C10AA05 184 |  | atorvastatin | 20 mg | 0,1389 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Artas | tbl. film obl. 56x20 mg | 0,1390 | 7,78 | RRC03 | 5% |
| C10AA05 185 |  | atorvastatin | 20 mg | 0,0843 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Artas | tbl. film obl. 28x40 mg | 0,1686 | 4,72 | RRC03 | 5% |
| C10AA05 191 |  | atorvastatin | 20 mg | 0,1016 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atoris | tbl. film obl. 30x30 mg | 0,1522 | 4,57 | RRC03 | 5% |
| C10AA05 192 |  | atorvastatin | 20 mg | 0,1014 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atoris | tbl. film obl. 60x30 mg | 0,1522 | 9,13 | RRC03 | 5% |
| C10AA05 193 |  | atorvastatin | 20 mg | 0,0690 | O | KRKA-FARMA d.o.o. | Krka d.d. | Atoris | tbl. film obl. 30x60 mg | 0,2070 | 6,21 | RRC03 | 5% |
| C10AA05 195 |  | atorvastatin | 20 mg | 0,1327 | O | Alkaloid d.o.o. | Alkaloid | Calipra | tbl. film obl. 30x10 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA05 196 |  | atorvastatin | 20 mg | 0,1390 | O | Alkaloid d.o.o. | Alkaloid | Calipra | tbl. film obl. 30x20 mg | 0,1390 | 4,17 | RRC03 | 5% |
| C10AA05 197 |  | atorvastatin | 20 mg | 0,0892 | O | Alkaloid d.o.o. | Alkaloid | Calipra | tbl. film obl. 30x40 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA05 198 |  | atorvastatin | 20 mg | 0,0697 | O | Alkaloid d.o.o. | Alkaloid | Calipra | tbl. film obl. 30x80 mg | 0,2787 | 8,36 | RRC03 | 5% |
| C10AA07 105 |  | rosuvastatin | 10 mg | 0,1016 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o.; Merckle GmbH; HBM Pharma s.r.o.; Teva Pharma B.V.; Teva Operations Poland | Epri | tbl. film obl. 30x15 mg | 0,1522 | 4,57 | RRC03 | 5% |
| C10AA07 106 |  | rosuvastatin | 10 mg | 0,0690 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o.; Merckle GmbH; HBM Pharma s.r.o.; Teva Pharma B.V.; Teva Operations Poland | Epri | tbl. film obl. 30x30 mg | 0,2070 | 6,21 | RRC03 | 5% |
| C10AA07 107 |  | rosuvastatin | 10 mg | 0,1327 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Epri | tbl. film obl. 30x5 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA07 108 |  | rosuvastatin | 10 mg | 0,1353 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Epri | tbl. film obl. 30x10 mg | 0,1354 | 4,06 | RRC03 | 5% |
| C10AA07 109 |  | rosuvastatin | 10 mg | 0,0892 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Epri | tbl. film obl. 30x20 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA07 110 |  | rosuvastatin | 10 mg | 0,0576 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Epri | tbl. film obl. 30x40 mg | 0,2305 | 6,91 | RRC03 | 5% |
| C10AA07 112 |  | rosuvastatin | 10 mg | 0,1389 | O | Belupo d.d. | Belupo | Rosix | tbl. film obl. 28x10 mg | 0,1390 | 3,89 | RRC03 | 5% |
| C10AA07 113 |  | rosuvastatin | 10 mg | 0,0891 | O | Belupo d.d. | Belupo | Rosix | tbl. film obl. 28x20 mg | 0,1783 | 4,99 | RRC03 | 5% |
| C10AA07 114 |  | rosuvastatin | 10 mg | 0,0696 | O | Belupo d.d. | Belupo | Rosix | tbl. film obl. 28x40 mg | 0,2787 | 7,80 | RRC03 | 5% |
| C10AA07 121 |  | rosuvastatin | 10 mg | 0,1389 | O | Sandoz d.o.o. | Sandoz-Lek | Coupet | tbl. film obl. 28x10 mg | 0,1390 | 3,89 | RRC03 | 5% |
| C10AA07 122 |  | rosuvastatin | 10 mg | 0,0891 | O | Sandoz d.o.o. | Sandoz-Lek | Coupet | tbl. film obl. 28x20 mg | 0,1783 | 4,99 | RRC03 | 5% |
| C10AA07 123 |  | rosuvastatin | 10 mg | 0,0696 | O | Sandoz d.o.o. | Sandoz-Lek | Coupet | tbl. film obl. 28x40 mg | 0,2787 | 7,80 | RRC03 | 5% |
| C10AA07 128 |  | rosuvastatin | 10 mg | 0,1148 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Coupet | tbl. film obl. 60x10 mg | 0,1149 | 6,89 | RRC03 | 5% |
| C10AA07 129 |  | rosuvastatin | 10 mg | 0,0892 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Coupet | tbl. film obl. 60x20 mg | 0,1783 | 10,70 | RRC03 | 5% |
| C10AA07 130 |  | rosuvastatin | 10 mg | 0,0534 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Coupet | tbl. film obl. 60x40 mg | 0,2137 | 12,82 | RRC03 | 5% |
| C10AA07 131 |  | rosuvastatin | 10 mg | 0,1329 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Roswera | tbl. film obl. 28x5 mg | 0,0665 | 1,86 | RRC03 | 5% |
| C10AA07 132 |  | rosuvastatin | 10 mg | 0,1389 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Roswera | tbl. film obl. 28x10 mg | 0,1390 | 3,89 | RRC03 | 5% |
| C10AA07 133 |  | rosuvastatin | 10 mg | 0,0891 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Roswera | tbl. film obl. 28x20 mg | 0,1783 | 4,99 | RRC03 | 5% |
| C10AA07 134 |  | rosuvastatin | 10 mg | 0,0696 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Roswera | tbl. film obl. 28x40 mg | 0,2787 | 7,80 | RRC03 | 5% |
| C10AA07 135 |  | rosuvastatin | 10 mg | 0,1014 | O | KRKA-FARMA d.o.o. | Krka d.d. | Roswera | tbl. film obl. 28x15 mg | 0,1522 | 4,26 | RRC03 | 5% |
| C10AA07 136 |  | rosuvastatin | 10 mg | 0,0690 | O | KRKA-FARMA d.o.o. | Krka d.d. | Roswera | tbl. film obl. 28x30 mg | 0,2070 | 5,80 | RRC03 | 5% |
| C10AA07 141 |  | rosuvastatin | 10 mg | 0,0892 | O | Genericon Pharma Gesellschaft m.b.H. | Pharmaceutical Works Polpharma S.A.; Genericon Pharma Gesellschaft m.b.H. | Rosuvastatin Genericon | tbl. film obl. 30x20 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA07 142 |  | rosuvastatin | 10 mg | 0,1340 | O | Genericon Pharma Gesellschaft m.b.H. | Pharmaceutical Works Polpharma S.A.; Genericon Pharma Gesellschaft m.b.H. | Rosuvastatin Genericon | tbl. film obl. 30x10 mg | 0,1340 | 4,02 | RRC03 | 5% |
| C10AA07 143 |  | rosuvastatin | 10 mg | 0,0576 | O | Genericon Pharma Gesellschaft m.b.H. | Pharmaceutical Works Polpharma S.A.; Genericon Pharma Gesellschaft m.b.H. | Rosuvastatin Genericon | tbl. film obl. 30x40 mg | 0,2305 | 6,91 | RRC03 | 5% |
| C10AA07 144 |  | rosuvastatin | 10 mg | 0,1327 | O | Alkaloid-INT d.o.o. | Alkaloid – INT | Ropuido | tbl. film obl. 30x5 mg | 0,0665 | 1,99 | RRC03 | 5% |
| C10AA07 145 |  | rosuvastatin | 10 mg | 0,1273 | O | Alkaloid-INT d.o.o. | Alkaloid – INT | Ropuido | tbl. film obl. 30x10 mg | 0,1273 | 3,82 | RRC03 | 5% |
| C10AA07 146 |  | rosuvastatin | 10 mg | 0,0892 | O | Alkaloid-INT d.o.o. | Alkaloid – INT | Ropuido | tbl. film obl. 30x20 mg | 0,1783 | 5,35 | RRC03 | 5% |
| C10AA07 147 |  | rosuvastatin | 10 mg | 0,0576 | O | Alkaloid-INT d.o.o. | Alkaloid – INT | Ropuido | tbl. film obl. 30x40 mg | 0,2305 | 6,91 | RRC03 | 5% |
| C10AA07 165 |  | rosuvastatin | 10 mg | 0,1286 | O | Jadran – Galenski Laboratorij d.d. | Teva Pharma S.L.U. | Rosuvastatin JGL | tbl. film obl. 28x5 mg | 0,0643 | 1,80 | RRC03 | 5% |
| C10AA07 166 |  | rosuvastatin | 10 mg | 0,1211 | O | Jadran – Galenski Laboratorij d.d. | Teva Pharma S.L.U. | Rosuvastatin JGL | tbl. film obl. 28x10 mg | 0,1209 | 3,39 | RRC03 | 5% |
| C10AA07 167 |  | rosuvastatin | 10 mg | 0,0891 | O | Jadran – Galenski Laboratorij d.d. | Teva Pharma S.L.U. | Rosuvastatin JGL | tbl. film obl. 28x20 mg | 0,1783 | 4,99 | RRC03 | 5% |
| C10AA07 168 |  | rosuvastatin | 10 mg | 0,0658 | O | Jadran – Galenski Laboratorij d.d. | Teva Pharma S.L.U. | Rosuvastatin JGL | tbl. film obl. 28x40 mg | 0,2631 | 7,37 | RRC03 | 5% |
| C10AA07 181 |  | rosuvastatin | 10 mg | 0,1329 | O | Viatris Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Generics [UK] Limited | Rosacol | tbl. film obl. 28x5 mg | 0,0665 | 1,86 | RRC03 | 5% |
| C10AA07 182 |  | rosuvastatin | 10 mg | 0,1271 | O | Viatris Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Generics [UK] Limited | Rosacol | tbl. film obl. 28x10 mg | 0,1273 | 3,56 | RRC03 | 5% |
| C10AA07 183 |  | rosuvastatin | 10 mg | 0,0891 | O | Viatris Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Generics [UK] Limited | Rosacol | tbl. film obl. 28x20 mg | 0,1783 | 4,99 | RRC03 | 5% |
| C10AA07 184 |  | rosuvastatin | 10 mg | 0,0696 | O | Viatris Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Generics [UK] Limited | Rosacol | tbl. film obl. 28x40 mg | 0,2787 | 7,80 | RRC03 | 5% |
| C10AB05 101 |  | fenofibrat | 200 mg | 0,1950 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp.z.o.o. | Zigotrig | tbl. film obl. 30x160 mg | 0,1559 | 4,68 | RRC04 | 5% |
| C10AB05 141 |  | fenofibrat | 200 mg | 0,1949 | O | Alkaloid d.o.o. | Alkaloid | Ziglip | tbl. 30x145 mg | 0,1413 | 4,24 | RRC04 | 5% |
| C10AB05 171 |  | fenofibrat | 200 mg | 0,1950 | O | Bausch Health Ireland Limited | SMB Technology S.A. | Fenolip | caps. 30x160 mg | 0,1559 | 4,68 | RRC04 | 5% |
| C10AC01 354 |  | kolestiramin | 14 g |  | O |  |  |  |  |  |  | R | 5% |
| C10AX09 161 |  | ezetimib | 10 mg | 0,3318 | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Ezetrol | tbl. 28x10 mg | 0,3316 | 9,29 | RSRC08 | 5% |
| C10AX13 061 |  | evolokumab |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Repatha | otop. za inj., brizg. napunj. 2x1 ml (140 mg/ml) | 190,3922 | 380,78 | RS RC11 | 5% |
| C10AX14 061 |  | alirokumab | 5,4 mg | 13,7081 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Praluent | otop. za inj., brizg. napunj. 2x1 ml (75 mg/ml) | 190,3922 | 380,78 | RSRC11 | 5% |
| C10AX14 062 |  | alirokumab | 5,4 mg | 6,8540 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Praluent | otop. za inj., brizg. napunj. 2x1 ml (150 mg/ml) | 190,3922 | 380,78 | RSRC11 | 5% |
| C10AX14 063 |  | alirokumab | 5,4 mg | 6,8540 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Praluent | otop. za inj., brizg. napunj. 1x2 ml (150 mg/ml) | 380,7844 | 380,78 | RSRC11 | 5% |
| C10AX16 071 |  | inklisiran |  |  | P | Novartis Europharm Limited Irska | APO-CARE Pharma GmbH | Leqvio | otop. za inj., štrc. napunj. 1,5 ml (189 mg/ml) | 2.099,7983 | 2.099,80 | RSRC11 | 5% |
| C10BA05 121 |  | ezetimib + atorvastatin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Tulip Combi | tbl. film obl. 30x(10 mg + 10 mg) | 0,3150 | 9,45 | RSpc08 | 5% |
| C10BA05 122 |  | ezetimib + atorvastatin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Tulip Combi | tbl. film obl. 30x(10 mg + 20 mg) | 0,3389 | 10,17 | RSpc08 | 5% |
| C10BA05 123 |  | ezetimib + atorvastatin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Tulip Combi | tbl. film obl. 30x(10 mg + 40 mg) | 0,3837 | 11,51 | RSpc08 | 5% |
| C10BA05 124 |  | ezetimib + atorvastatin |  |  | O | Sandoz d.o.o. | Sandoz-Lek | Tulip Combi | tbl. film obl. 30x(10 mg + 80 mg) | 0,5782 | 17,35 | RSpc08 | 5% |
| C10BA05 161 |  | ezetimib + atorvastatin |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme B.V. | Atozet | tbl. film obl. 30x(10 mg + 10 mg) | 0,3316 | 9,95 | RSpc08 | 5% |
| C10BA05 162 |  | ezetimib + atorvastatin |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme B.V. | Atozet | tbl. film obl. 30x(10 mg + 20 mg) | 0,3568 | 10,70 | RSpc08 | 5% |
| C10BA05 163 |  | ezetimib + atorvastatin |  |  | O | Organon Pharma d.o.o. | Merck Sharp & Dohme B.V. | Atozet | tbl. film obl. 30x(10 mg + 40 mg) | 0,4039 | 12,12 | RSpc08 | 5% |
| C10BA05 171 |  | ezetimib + atorvastatin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Elpen Pharmaceutical Co. Inc. | Co-Atorvox | tbl. film obl. 30x(10 mg + 10 mg) | 0,3316 | 9,95 | RSpc08 | 5% |
| C10BA05 172 |  | ezetimib + atorvastatin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Elpen Pharmaceutical Co. Inc. | Co-Atorvox | tbl. film obl. 30x(10 mg + 20 mg) | 0,3568 | 10,70 | RSpc08 | 5% |
| C10BA05 173 |  | ezetimib + atorvastatin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Elpen Pharmaceutical Co. Inc. | Co-Atorvox | tbl. film obl. 30x(10 mg + 40 mg) | 0,4039 | 12,12 | RSpc08 | 5% |
| C10BA05 174 |  | ezetimib + atorvastatin |  |  | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH, Elpen Pharmaceutical Co. Inc. | Co-Atorvox | tbl. film obl. 30x(10 mg + 80 mg) | 0,6105 | 18,32 | RSpc08 | 5% |
| C10BA06 101 |  | rosuvastatin + ezetimib |  |  | O | PLIVA HRVATSKA d.o.o. | Teva Operations Poland Sp. z o.o. | Eprizet | tbl. 30x(10 mg + 10 mg) | 0,3568 | 10,70 | RSpc08 | 5% |
| C10BA06 102 |  | rosuvastatin + ezetimib |  |  | O | PLIVA HRVATSKA d.o.o. | Teva Operations Poland Sp. z o.o. | Eprizet | tbl. 30x(20 mg + 10 mg) | 0,4039 | 12,12 | RSpc08 | 5% |
| C10BA06 111 |  | rosuvastatin + ezetimib |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix Combi | tbl. 30x(5 mg + 10 mg) | 0,3316 | 9,95 | RSpc08 | 5% |
| C10BA06 112 |  | rosuvastatin + ezetimib |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix Combi | tbl. 30x(10 mg + 10 mg) | 0,3568 | 10,70 | RSpc08 | 5% |
| C10BA06 113 |  | rosuvastatin + ezetimib |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix Combi | tbl. 30x(20 mg + 10 mg) | 0,4039 | 12,12 | RSpc08 | 5% |
| C10BA06 122 |  | rosuvastatin + ezetimib |  |  | O | Jadran – Galenski Laboratorij d.d. | Pabianickie Zaklady Farmaceutyczne Polfa S.A., JGL d.d. | Ezotera | tbl. 28x(10 mg + 10 mg) | 0,3567 | 9,99 | RSpc08 | 5% |
| C10BA06 123 |  | rosuvastatin + ezetimib |  |  | O | Jadran – Galenski Laboratorij d.d. | Pabianickie Zaklady Farmaceutyczne Polfa S.A., JGL d.d. | Ezotera | tbl. 28x(20 mg + 10 mg) | 0,4039 | 11,31 | RSpc08 | 5% |
| C10BA06 131 |  | rosuvastatin + ezetimib |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Roswera | tbl. 30x(10 mg + 10 mg) | 0,3568 | 10,70 | RSpc08 | 5% |
| C10BA06 132 |  | rosuvastatin + ezetimib |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Roswera | tbl. 30x(20 mg + 10 mg) | 0,4039 | 12,12 | RSpc08 | 5% |
| C10BA06 133 |  | rosuvastatin + ezetimib |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Co-Roswera | tbl. 30x(40 mg + 10 mg) | 0,6105 | 18,32 | RSpc08 | 5% |
| C10BA06 171 |  | rosuvastatin + ezetimib |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma Gesellschaft m.b.H., Pabianickie Zaklady Farmaceutyczne Polfa S.A. | Rosuvastatin/Ezetimib Genericon | tbl. 30x(5 mg + 10 mg) | 0,3316 | 9,95 | RSpc08 | 5% |
| C10BA06 172 |  | rosuvastatin + ezetimib |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma Gesellschaft m.b.H., Pabianickie Zaklady Farmaceutyczne Polfa S.A. | Rosuvastatin/Ezetimib Genericon | tbl. 30x(10 mg + 10 mg) | 0,3568 | 10,70 | RSpc08 | 5% |
| C10BA06 173 |  | rosuvastatin + ezetimib |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma Gesellschaft m.b.H., Pabianickie Zaklady Farmaceutyczne Polfa S.A. | Rosuvastatin/Ezetimib Genericon | tbl. 30x(20 mg + 10 mg) | 0,4039 | 12,12 | RSpc08 | 5% |
| C10BX03 131 |  | amlodipin + atorvastatin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atordapin | tbl. film obl. 30x(5 mg + 10 mg) | 0,0712 | 2,14 | RRC03 | 5% |
| C10BX03 133 |  | amlodipin + atorvastatin |  |  | O | KRKA-FARMA d.o.o. | Krka d.d., KRKA-FARMA d.o.o. | Atordapin | tbl. film obl. 30x(10 mg + 10 mg) | 0,0712 | 2,14 | RRC03 | 5% |
| C10BX09 111 |  | rosuvastatin + amlodipin |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix-Am | caps. tvrda 30x(10 mg + 5 mg) | 0,1857 | 5,57 | RRC03 | 5% |
| C10BX09 112 |  | rosuvastatin + amlodipin |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix-Am | caps. tvrda 30x(10 mg + 10 mg) | 0,1947 | 5,84 | RRC03 | 5% |
| C10BX09 113 |  | rosuvastatin + amlodipin |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix-Am | caps. tvrda 30x(20 mg + 5 mg) | 0,2183 | 6,55 | RRC03 | 5% |
| C10BX09 114 |  | rosuvastatin + amlodipin |  |  | O | Belupo d.d. | Adamed Sp. z o.o. | Rosix-Am | caps. tvrda 30x(20 mg + 10 mg) | 0,2382 | 7,15 | RRC03 | 5% |
| C10BX13 131 |  | rosuvastatin + perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Roxiper | tbl. 30 x (10 mg + 4 mg + 1.25 mg) | 0,2167 | 6,50 | RRC03 | 5% |
| C10BX13 132 |  | rosuvastatin + perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Roxiper | tbl. 30 x (10 mg + 8 mg + 2.5 mg) | 0,2722 | 8,17 | RRC03 | 5% |
| C10BX13 133 |  | rosuvastatin + perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Roxiper | tbl. 30 x (20 mg + 4 mg + 1.25 mg) | 0,2996 | 8,99 | RRC03 | 5% |
| C10BX13 134 |  | rosuvastatin + perindopril + indapamid |  |  | O | KRKA-FARMA d.o.o. | Krka d.d. | Roxiper | tbl. 30 x (20 mg + 8 mg + 2.5 mg) | 0,3551 | 10,65 | RRC03 | 5% |
| D01BA02 111 |  | terbinafin | 0,25 g | 0,6157 | O | Belupo d.d. | Belupo | Terbinax | tbl. 14x250 mg | 0,6160 | 8,62 | RRD01 | 5% |
| D01BA02 112 |  | terbinafin | 0,25 g | 0,6160 | O | Belupo d.d. | Belupo | Terbinax | tbl. 42x250 mg | 0,6160 | 25,87 | RRD01 | 5% |
| D01BA02 162 |  | terbinafin | 0,25 g | 0,6157 | O | Novartis Hrvatska d.o.o. | Lek d.d, PE PROIZVODNJA LENDAVA, Novartis Pharma GmbH | Lamisil | tbl. 14x250 mg | 0,6160 | 8,62 | Rpd01 | 5% |
| D05AX52 444 |  | kalcipotriol + betametazon |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Psotriol | mast 60 g (50 mcg/g + 0,5 mg/g) | 19,2753 | 19,28 | R | 5% |
| D05AX52 445 |  | kalcipotriol + betametazon |  |  | L | LEO Pharma A/S | Colep Laupheim GmbH & Co. KG, LEO Laboratories Ltd. | Enstilar | pjena za kožu 60 g (50 mcg/g + 0,5 mg/g) | 40,5335 | 40,53 | RSRD03 | 5% |
| D05BA02 151 | DS | metoksalen (metoksipsoralen)ND991 | 10 mg |  | O |  |  |  |  |  |  |  | 5% |
| D05BB02 161 |  | acitretin | 35 mg | 1,6893 | O | ACTAVIS GROUP PTC ehf. | Cenexi | Neotigason | caps. 30x10 mg | 0,4827 | 14,48 | RSpd03 | 5% |
| D05BB02 162 |  | acitretin | 35 mg | 1,4327 | O | ACTAVIS GROUP PTC ehf. | Cenexi | Neotigason | caps. 30x25 mg | 1,0233 | 30,70 | RSpd03 | 5% |
| D06AX01 461 |  | fusidatna kiselina |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Fusicutan | krema 15 g (20 mg/g) | 2,7527 | 2,75 | R | 5% |
| D06AX01 462 |  | fusidatna kiselina |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Fusicutan | mast 15 g (20 mg/g) | 2,7527 | 2,75 | R | 5% |
| D06AX02 451 | DS | kloramfenikol |  |  | L |  |  |  |  |  |  |  | 5% |
| D06AX09 402 |  | mupirocin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Betrion | mast 2%, 1x15 g | 3,8529 | 3,85 | R | 5% |
| D06AX09 411 |  | mupirocin |  |  | L | Belupo d.d. | Belupo | Mirobact | mast 2%, 1x15 g | 3,8529 | 3,85 | R | 5% |
| D06AX09 415 |  | mupirocin |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Mupiron | mast 1x15 g (20 mg/1g) | 3,8529 | 3,85 | R | 5% |
| D07AB10 411 |  | alklometazon |  |  | L | Belupo d.d. | Belupo | Afloderm | mast 1x20 g (0,5 mg/g) | 2,8668 | 2,87 | R | 5% |
| D07AB10 413 |  | alklometazon |  |  | L | Belupo d.d. | Belupo | Afloderm | krema 1x20 g (0,5 mg/g) | 2,8668 | 2,87 | R | 5% |
| D07AB10 414 |  | alklometazon |  |  | L | Belupo d.d. | Belupo | Afloderm | krema 1x40 g (0,5 mg/g) | 5,5478 | 5,55 | R | 5% |
| D07AC01 412 |  | betametazon |  |  | L | Belupo d.d. | Belupo | Beloderm | mast 1x30 g (0,5 mg/g) | 2,3518 | 2,35 | R | 5% |
| D07AC01 414 |  | betametazon |  |  | L | Belupo d.d. | Belupo | Beloderm | krema 1x30 g (0,5 mg/g) | 2,3518 | 2,35 | R | 5% |
| D07AC01 418 |  | betametazon |  |  | L | Belupo d.d. | Belupo | Beloderm losion | boč. polietil. 1x50 ml (0,5 mg/1g) | 4,4077 | 4,41 | R | 5% |
| D07AC01 431 |  | betametazon |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Betazon | krema 1x25 g (0,5 mg/g) | 1,9603 | 1,96 | R | 5% |
| D07AC01 432 |  | betametazon |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Betazon | mast 1x25 g (0,5 mg/g) | 1,9603 | 1,96 | R | 5% |
| D07CC01 401 |  | betametazon + gentamicin |  |  | L | Belupo d.d. | Belupo | Belogent | mast 1x15 g (0,5 + 1 mg/g) | 2,1222 | 2,12 | R | 5% |
| D07CC01 402 |  | betametazon + gentamicin |  |  | L | Belupo d.d. | Belupo | Belogent | krema 1x15 g (0,5 + 1 mg/g) | 2,1222 | 2,12 | R | 5% |
| D07CC01 441 |  | betametazon + gentamicin |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Cazal | mast 1x20 g (0,5 + 1 mg/g) | 2,6876 | 2,69 | R | 5% |
| D07CC01 442 |  | betametazon + gentamicin |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Cazal | krema 1x20 g (0,5 + 1 mg/g) | 2,6876 | 2,69 | R | 5% |
| D07CC01 461 |  | betametazon + gentamicin |  |  | L | Organon Pharma d.o.o. | Schering – Plough | Diprogenta | krema 1x15 g (0,5 + 1 mg/g) | 2,1222 | 2,12 | R | 5% |
| D07CC01 462 |  | betametazon + gentamicin |  |  | L | Organon Pharma d.o.o. | Schering – Plough | Diprogenta | mast 1x15 g (0,5 + 1 mg/g) | 2,1222 | 2,12 | R | 5% |
| D07XC01 411 |  | betametazon + salicilna kiselina |  |  | L | Belupo d.d. | Belupo | Belosalic | mast 1x30 g (0,5 mg/g + 30 mg/g) | 3,8437 | 3,84 | R | 5% |
| D07XC01 712 |  | betametazon + salicilna kiselina |  |  | L | Belupo d.d. | Belupo | Belosalic | losion 1x100 ml (0,5 mg/g + 20 mg/g) | 11,6464 | 11,65 | R | 5% |
| D07XC01 761 |  | betametazon + salicilna kiselina |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Soderm plus | otop. za kožu 1x50 ml (0,64 mg/g + 20 mg/g) | 5,2412 | 5,24 | R | 5% |
| D07XC01 762 |  | betametazon + salicilna kiselina |  |  | L | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Soderm plus | otop. za kožu 1x100 ml (0,64 mg/g + 20 mg/g) | 10,4824 | 10,48 | R | 5% |
| D08AC02 901 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept pjenušavi 4,5% | boca 1x500 ml | 7,5479 | 7,55 |  | 5% |
| D08AC02 902 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept glukonat 5% | boca 1x1000 ml | 8,2036 | 8,20 |  | 5% |
| D08AC02 903 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept pjenušavi 4,5% | boca 1x3.000 ml | 29,6529 | 29,65 |  | 5% |
| D08AC02 905 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept blue 0,8% | boca 1x200 ml | 2,4421 | 2,44 |  | 5% |
| D08AC02 906 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept blue 0,8% | boca 1x500 ml | 3,6631 | 3,66 |  | 5% |
| D08AC02 907 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept blue 0,8% | boca 1x3.000 ml | 14,6526 | 14,65 |  | 5% |
| D08AC02 909 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept tinkt. 0,5% | boca 1x1.000 ml | 3,9684 | 3,97 |  | 5% |
| D08AC02 910 | DS | klorheksidin |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept tinkt. 0,5% | boca 1x3.000 ml | 10,9894 | 10,99 |  | 5% |
| D08AG02 943 |  | povidon-jod |  |  | L | Alkaloid d.o.o. | Alkaloid | Betadine | otop. 10%, 1x100 ml | 2,9265 | 2,93 | R | 5% |
| D08AG02 944 | DS | povidon-jod |  |  | L | Alkaloid d.o.o. | Alkaloid | Betadine | otop. 10%, 1x1000 ml | 8,2341 | 8,23 |  | 5% |
| D08AG02 946 | DS | povidon-jod |  |  | L | Alkaloid d.o.o. | Alkaloid | Betadine | otop. 7,5%, 1x1000 ml | 7,9607 | 7,96 |  | 5% |
| D08AJ57 961 | DS | oktenidin + fenoksietanol |  |  | L | Schülke & Mayr GmbH | Schulke | Octenisept otopina | boca plast. 1x1000 ml (0,1% + 2%) | 7,6183 | 7,62 |  | 5% |
| D08AX08 963 | DS | etanol + bifenilol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman pure | boca 1x500 ml | 2,8854 | 2,89 |  | 5% |
| D08AX08 964 | DS | etanol + bifenilol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman pure | boca 1x1000 ml | 5,2439 | 5,24 |  | 5% |
| D08AX08 965 | DS | etanol + bifenilol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman pure | kanister 1x5000 ml | 18,2706 | 18,27 |  | 5% |
| D08AX08 966 | DS | etanol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman Care | boca 1x500 ml | 2,8854 | 2,89 |  | 5% |
| D08AX08 967 | DS | etanol |  |  | L | Oktal Pharma d.o.o. | Schulke | Desderman Care | boca 1x1000 ml | 5,2439 | 5,24 |  | 5% |
| D08AX54 901 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Manorapid rfu | boč. 1x150 ml | 1,8050 | 1,81 |  | 5% |
| D08AX54 902 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Manorapid rfu | boca 1x500 ml | 3,5822 | 3,58 |  | 5% |
| D08AX54 903 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Manorapid rfu | kanister 1x5 L | 23,8237 | 23,82 |  | 5% |
| D08AX54 904 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Skindes obojeni | boč. rasprš. 1x200 ml | 3,4375 | 3,44 |  | 5% |
| D08AX54 905 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Skindes obojeni | boca 1x1000 ml | 6,6229 | 6,62 |  | 5% |
| D08AX54 906 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Skindes neobojeni | boč. rasprš. 1x200 ml | 3,3048 | 3,30 |  | 5% |
| D08AX54 907 | DS | izopropanol + butandiol |  |  | L | Antiseptica d.o.o. | Antiseptica Pulheim | Skindes neobojeni | boca 1x1000 ml | 5,2956 | 5,30 |  | 5% |
| D08AX54 911 | DS | izopropanol + etanol |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept lucid | boca 1x200 ml | 2,4076 | 2,41 |  | 5% |
| D08AX54 912 | DS | izopropanol + etanol |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept lucid | boca 1x500 ml | 3,2238 | 3,22 |  | 5% |
| D08AX54 913 | DS | izopropanol + etanol |  |  | L | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivasept lucid | boca 1x3000 ml | 14,2942 | 14,29 |  | 5% |
| D11AH01 962 |  | takrolimus hidrat |  |  | L | LEO Pharma A/S | Astellas Ireland Co. Ltd. | Protopic 0,03% | mast, 1x30 g | 22,5098 | 22,51 | RSRD02 | 5% |
| D11AH05 061 | DS | dupilumabNR509 | 21,4 mg | 61,5560 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Dupixent | otop. za inj., štrc. napunj. 2x200 mg/1,14 ml | 575,2883 | 1.150,58 |  | 5% |
| D11AH05 062 | DS | dupilumabNR509 | 21,4 mg | 41,0373 | P | sanofi-aventis groupe | Sanofi-Aventis Deutschland GmbH | Dupixent | otop. za inj., brizg. napunj. 2x300 mg/2 ml | 575,2883 | 1.150,58 |  | 5% |
| G01AA01 651 |  | nistatin | 0,1 M i.j. |  | V |  |  |  |  |  |  | R | 5% |
| G02AB01 051 | PR | metilergometrin | 0,2 mg |  | P |  |  |  |  |  |  |  | 5% |
| G02AB01 251 |  | metilergometrin | 0,2 mg |  | O |  |  |  |  |  |  | R | 5% |
| G02AB03 051 | PR | ergometrin | 0,2 mg |  | P |  |  |  |  |  |  |  | 5% |
| G02AD02 664 | DS | dinoproston | 0,5 mg | 9,0650 | V | Pfizer Croatia d.o.o. | Pfizer | Prostin E2 | vag. gel 1x2 mg/3 g | 36,2639 | 36,26 |  | 5% |
| G02AD02 665 | DS | dinoproston | 0,5 mg | 16,9900 | V | Pfizer Croatia d.o.o. | Pfizer | Prepidil | gel 1x0,5 mg/3 g | 16,9872 | 16,99 |  | 5% |
| G02AD02 671 | DS | dinoprostonNG306 | 0,5 mg | 4,1799 | V | Ferring GmbH | Ferring GmbH | Propess | sust. za isporuku u rodnicu, vreć. 5x10 mg | 83,5973 | 417,99 |  | 5% |
| G02AD04 066 | DS | karboprost | 2,5 mg |  | P | Pfizer Croatia d.o.o. | Pfizer | Prostin 15M | amp. 1x0,25 mg/ml | 14,6632 | 14,66 |  | 5% |
| G02AD06 161 | DS | mizoprostolNG307 | 0,2 mg | 92,4200 | O | Norgine B.V. | Azanta Danmark A/S, Norgine B.V. | Angusta | tbl. 8x25 mcg | 11,5522 | 92,42 |  | 5% |
| G02BA03 671 | PO | levonorgestrelNG301 |  |  | V | Gedeon Richter Plc. | Odyssea Pharma S.P.R.L. | Levosert | sustav intrauter. 1x52 mg (20 mcg/24h) | 78,2282 | 78,23 |  | 5% |
| G02BA03 861 | PO | levonorgestrelNG301 |  |  | V | Bayer d.o.o. | Bayer Oy | Mirena | sustav intrauter. 1x52 mg (20 mcg/24h) | 101,4706 | 101,47 |  | 5% |
| G02CA03 051 | DS | fenoterol |  |  | P |  |  |  |  |  |  |  | 5% |
| G02CB01 151 |  | bromokriptin | 5 mg |  | O |  |  |  |  |  |  | R | 5% |
| G02CB03 171 |  | kabergolin | 0.5 mg | 2,8013 | O | Pfizer Croatia d.o.o. | Pfizer Italia S.r.l. | Dostinex | tbl. 8x0,5 mg | 2,8009 | 22,41 | RSRG08 | 5% |
| G02CX01 061 | DS | atosibanNG201 | 165 mg | 576,2836 | P | Ferring Pharmaceuticals A/S | Ferring | Tractocile | boč. 1x6,75 mg/0,9 ml (7,5 mg/ml) | 23,5716 | 23,57 |  | 5% |
| G02CX01 062 | DS | atosibanNG201 | 165 mg | 315,6181 | P | Ferring Pharmaceuticals A/S | Ferring | Tractocile | boč. 1x37,5 mg/5 ml (7,5 mg /ml) | 71,7354 | 71,74 |  | 5% |
| G02CX01 071 | DS | atosibanNG201 | 165 mg | 403,4230 | P | ALPHA-MEDICAL d.o.o. | PharmIdea SIA | Atosiban Alpha-Medical | boč. 1x6,75 mg/0,9 ml | 16,5001 | 16,50 |  | 5% |
| G02CX01 072 | DS | atosibanNG201 | 165 mg | 246,7224 | P | ALPHA-MEDICAL d.o.o. | PharmIdea SIA | Atosiban Alpha-Medical | boč. 1x37,5 mg/5 ml | 56,0794 | 56,08 |  | 5% |
| G03BA03 052 | PR | testosteron | 18 mg |  | P |  |  |  |  |  |  |  | 5% |
| G03BA03 071 | PO | testosteronNG302 | 18 mg | 1,7678 | P | Bayer d.o.o. | Bayer AG | Nebido | otop. za inj., boč.1x1000 mg/4 ml | 98,2056 | 98,21 |  | 5% |
| G03BA03 151 |  | testosteron | 0,12 g |  | O |  |  |  |  |  |  | R | 5% |
| G03BA03 961 |  | testosteron | 50 mg | 1,4417 | TD | Besins Healthcare S.A. | Besins Manufacturing Belgium | Androgel gel | vreć. 30x50 mg/5 g | 1,4418 | 43,25 | RSRG01 | 5% |
| G03CA03 051 | DS | estradiol | 1 mg |  | P |  |  |  |  |  |  |  | 5% |
| G03CA03 171 |  | estradiol | 2 mg | 0,1275 | O | Novo Nordisk A/S | Novo Nordisk | Estrofem | tbl. 1x28/2 mg | 0,1274 | 3,57 | R | 5% |
| G03CA03 172 |  | estradiol | 2 mg | 0,2800 | O | Novo Nordisk A/S | Novo Nordisk | Estrofem | tbl. 1x28/1 mg | 0,1398 | 3,92 | R | 5% |
| G03DA02 161 |  | medroksiprogesteron | 5 mg | 0,0796 | O | Pfizer Croatia d.o.o. | Pfizer | Provera | tbl. 24x5 mg | 0,0796 | 1,91 | R | 5% |
| G03DA02 162 |  | medroksiprogesteron | 5 mg | 0,0492 | O | Pfizer Croatia d.o.o. | Pfizer | Provera | tbl. 30x10 mg | 0,0982 | 2,95 | R | 5% |
| G03DA04 051 | DS | progesteron | 5 mg |  | P |  |  |  |  |  |  |  | 5% |
| G03DA04 161 |  | progesteron | 0,3 g | 0,5300 | O | Besins Healthcare S.A. | Cyndea Pharma S.L., Besins Manufacturing Belgium | Utrogestan | caps. 30x100 mg | 0,1765 | 5,30 | R | 5% |
| G03DA04 671 |  | progesteron | 90 mg | 0,1839 | V | Besins Healthcare Ireland Limited | Cyndea Pharma S.L., Besins Manufacturing Belgium | Utrogestan | meke caps. za rodnicu 15x200 mg | 0,4088 | 6,13 | R | 5% |
| G03DA04 861 |  | progesteron | 90 mg | 2,6813 | V | MERCK d.o.o. | Central Pharma | Crinone | gel za rodnicu 8%, aplik. plast. napunj. 15x1 doza (90 mg/1,125g) | 2,6813 | 40,22 | R | 5% |
| G03DA04 871 |  | progesteron | 90 mg | 0,1870 | V | Gedeon Richter Plc. | Actavis UK Limited, Gedeon Richter Plc. | Cyclogest | vag. 15x400 mg | 0,8313 | 12,47 | R | 5% |
| G03GA01 051 | DS | koriogonadotropinNG303 | 250 i.j. |  | P |  |  |  |  |  |  |  | 5% |
| G03GA02 063 | DS | menotropin (FSH + LH)NG304 | 75 i.j. | 20,1875 | P | Ferring GmbH | Ferring | Menopur | praš. i otap. za otop. za inj., boč. 1x1200 IU | 323,0035 | 323,00 |  | 5% |
| G03GA02 064 | DS | menotropin (FSH + LH)NG304 | 75 i.j. | 17,2980 | P | Ferring GmbH | Ferring | Menopur | praš. i otap. za otop. za inj., boč. 10x75 IU | 17,2978 | 172,98 |  | 5% |
| G03GA02 065 | DS | menotropin (FSH + LH)NG304 | 75 i.j. | 17,5125 | P | Ferring GmbH | Ferring GmbH | Menopur | praš. i otap. za otop. za inj., boč. 1x600 IU | 140,0982 | 140,10 |  | 5% |
| G03GA05 001 | DS | folitropin alfaNG304 | 75 i.j. | 20,9050 | P | Theramex Ireland Limited | Merckle Biotec GmbH, Teva Pharmaceuticals Europe B.V. | Ovaleap | otop. za inj., pen-štrcaljka 1x300 IU (22 mcg)/0,5 ml | 83,6247 | 83,62 |  | 5% |
| G03GA05 002 | DS | folitropin alfaNG304 | 75 i.j. | 19,7033 | P | Theramex Ireland Limited | Merckle Biotec GmbH, Teva Pharmaceuticals Europe B.V. | Ovaleap | otop. za inj., pen-štrcaljka 1x450 IU (33 mcg)/0,75 ml | 118,2202 | 118,22 |  | 5% |
| G03GA05 003 | DS | folitropin alfaNG304 | 75 i.j. | 20,7058 | P | Theramex Ireland Limited | Merckle Biotec GmbH, Teva Pharmaceuticals Europe B.V. | Ovaleap | otop. za inj., pen-štrcaljka 1x900 IU (66 mcg)/1,5 ml | 248,4730 | 248,47 |  | 5% |
| G03GA05 071 | DS | folitropin alfaNG304 | 75 i.j. | 23,4900 | P | Merck Europe B.V. | Merck | Gonal-f | amp. 1x75 i.j. | 23,4866 | 23,49 |  | 5% |
| G03GA05 072 | DS | folitropin alfaNG304 | 75 i.j. | 21,2150 | P | Merck Europe B.V. | Merck | Gonal-f | otop. za inj., pen-štrcaljka 1x300 IU (22 mcg)/0,5 ml | 84,8630 | 84,86 |  | 5% |
| G03GA05 073 | DS | folitropin alfaNG304 | 75 i.j. | 20,2233 | P | Merck Europe B.V. | Merck | Gonal-f | otop. za inj., pen-štrcaljka 1x450 IU (33 mcg)/0,75 ml | 121,3352 | 121,34 |  | 5% |
| G03GA05 074 | DS | folitropin alfaNG304 | 75 i.j. | 22,2258 | P | Merck Europe B.V. | Merck | Gonal-f | otop. za inj., pen-štrcaljka 1x900 IU (66 mcg)/1,5 ml | 266,7118 | 266,71 |  | 5% |
| G03GA05 081 | DS | folitropin alfaNG304 | 75 i.j. | 18,7900 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brizg. napunj.1x75 IU/0,125 ml | 18,7935 | 18,79 |  | 5% |
| G03GA05 082 | DS | folitropin alfaNG304 | 75 i.j. | 18,9050 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brizg. napunj. 1x150 IU/0,25 ml | 37,8101 | 37,81 |  | 5% |
| G03GA05 083 | DS | folitropin alfaNG304 | 75 i.j. | 18,2000 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brizg. napunj. 1x225 IU/0,375 ml | 54,6035 | 54,60 |  | 5% |
| G03GA05 084 | DS | folitropin alfaNG304 | 75 i.j. | 21,2150 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brizg. napunj. 1x300 IU/0,50 ml | 84,8630 | 84,86 |  | 5% |
| G03GA05 085 | DS | folitropin alfaNG304 | 75 i.j. | 20,2233 | P | Gedeon Richter Plc. | Finox Biotech AG | Bemfola | otop. za inj., brozg. napunj. 1x450 IU/0,75 ml | 121,3352 | 121,34 |  | 5% |
| G03GA06 076 | DS | folitropin betaNG304 | 75 i.j. | 23,1925 | P | Organon N.V. | N.V. Organon | Puregon | otop. za inj. 1x300 IU/0,36 ml, uložak i 6 igala | 92,7653 | 92,77 |  | 5% |
| G03GA06 077 | DS | folitropin betaNG304 | 75 i.j. | 23,6400 | P | Organon N.V. | N.V. Organon | Puregon | otop. za inj. u ulošku i 9 igala (1 uložak, 900 IU/1,08 ml) | 283,6817 | 283,68 |  | 5% |
| G03GA08 073 | DS | koriogonadotropinNG303 | 250 mcg | 27,1300 | P | Merck Europe B.V. | Serono | Ovitrelle | otop. za inj., brizg. napunj. 1x250 mcg | 27,1325 | 27,13 |  | 5% |
| G03GA09 061 | DS | korifolitropin alfaNG304 | 0,15 mg | 637,6931 | P | Organon N.V. | Organon | Elonva | otop. za inj., štrc. napunj. 1x100 mcg/0,5 ml | 425,1483 | 425,15 |  | 5% |
| G03GA09 062 | DS | korifolitropin alfaNG304 | 0,15 mg | 466,7200 | P | Organon N.V. | Organon | Elonva | otop. za inj., štrc. napunj. 1x150 mcg/0,5 ml | 466,7237 | 466,72 |  | 5% |
| G03GA10 074 | DS | folitropin deltaNG304 | 12 mcg | 80,4800 | P | Ferring Pharmaceuticals A/S | Ferring GmbH | Rekovelle | otop. za inj. 1x12 mcg/0,36 ml, napunjena brizgalica i 3 igle | 80,4844 | 80,48 |  | 5% |
| G03GA10 075 | DS | folitropin deltaNG304 | 12 mcg | 81,1500 | P | Ferring Pharmaceuticals A/S | Ferring GmbH | Rekovelle | otop. za inj. 1x36 mcg/1,08 ml, napunjena brizgalica i 6 igala | 243,4468 | 243,45 |  | 5% |
| G03GA10 076 | DS | folitropin deltaNG304 | 12 mcg | 77,4683 | P | Ferring Pharmaceuticals A/S | Ferring GmbH | Rekovelle | otop. za inj. 1x72 mcg/2,16 ml, napunjena brizgalica i 9 igala | 464,8139 | 464,81 |  | 5% |
| G03GA30 061 | DS | folitropin alfa + lutropin alfaNG305 |  |  | P | Merck Europe B.V. | Merck Serono S.p.A. | Pergoveris | praš. i otap. za otop. za inj., 1 x (150 IU + 75 IU) | 68,3761 | 68,38 |  | 5% |
| G03GA30 062 | DS | folitropin alfa + lutropin alfaNG305 |  |  | P | Merck Europe B.V. | Merck Serono S.A. | Pergoveris | otop. za inj., brizg. napunj., (300 IU + 150 IU)/0,48 ml | 137,3270 | 137,33 |  | 5% |
| G03GA30 063 | DS | folitropin alfa + lutropin alfaNG305 |  |  | P | Merck Europe B.V. | Merck Serono S.A. | Pergoveris | otop. za inj., brizg. napunj., (450 IU + 225 IU)/0,72 ml | 204,2670 | 204,27 |  | 5% |
| G03GA30 064 | DS | folitropin alfa + lutropin alfaNG305 |  |  | P | Merck Europe B.V. | Merck Serono S.A. | Pergoveris | otop. za inj., brizg. napunj., (900 IU + 450 IU)/1,44 ml | 399,2700 | 399,27 |  | 5% |
| G03GB02 151 |  | klomifen | 9 mg |  | O |  |  |  |  |  |  | R | 5% |
| G03HA01 161 |  | ciproteron-acetat | 0,1 g | 0,9360 | O | Bayer d.o.o. | Delpharm Lille SAS., Bayer Weimar GmbH und Co. KG. | Androcur | tbl. 50x50 mg | 0,4681 | 23,40 | R | 5% |
| G03HB01 141 |  | ciproteron-acetat + etinilestradiol |  |  | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Axira 35 | tbl. film obl. 63x(2 mg + 0,035 mg) | 0,1405 | 8,85 | RSRG02 | 5% |
| G03XA01 151 |  | danazol | 0,6 g |  | O |  |  |  |  |  |  | RSRG91 | 5% |
| G03XC01 161 |  | raloksifen | 60 mg | 0,4614 | O | DAIICHI SANKYO EUROPE GmbH | Lilly S.A. | Evista | tbl. 28x60 mg | 0,4614 | 12,92 | RSRG03 | 5% |
| G04BD04 151 |  | oksibutinin | 15 mg |  | O |  |  |  |  |  |  | RRG09 | 5% |
| G04BD08 101 |  | solifenacin | 5 mg | 0,2940 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Urotrim | tbl. film obl. 30x5 mg | 0,2941 | 8,82 | RRG04 | 5% |
| G04BD08 102 |  | solifenacin | 5 mg | 0,3230 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Urotrim | tbl. film obl. 30x10 mg | 0,6459 | 19,38 | RRG04 | 5% |
| G04BD08 111 |  | solifenacin | 5 mg | 0,2940 | O | Belupo d.d. | Belupo d.d. | Beloflux | tbl. film obl. 30x5 mg | 0,2941 | 8,82 | RRG04 | 5% |
| G04BD08 112 |  | solifenacin | 5 mg | 0,2400 | O | Belupo d.d. | Belupo d.d. | Beloflux | tbl. film obl. 30x10 mg | 0,4800 | 14,40 | RRG04 | 5% |
| G04BD08 121 |  | solifenacin | 5 mg | 0,2940 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Spazur | tbl. film obl. 30x5 mg | 0,2941 | 8,82 | RRG04 | 5% |
| G04BD08 122 |  | solifenacin | 5 mg | 0,2807 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Spazur | tbl. film obl. 30x10 mg | 0,5614 | 16,84 | RRG04 | 5% |
| G04BD08 141 |  | solifenacin | 5 mg | 0,2940 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Soline | tbl. film obl. 30x5 mg | 0,2941 | 8,82 | RRG04 | 5% |
| G04BD08 142 |  | solifenacin | 5 mg | 0,3230 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Soline | tbl. film obl. 30x10 mg | 0,6459 | 19,38 | RRG04 | 5% |
| G04BD08 161 |  | solifenacin | 5 mg | 0,2940 | O | Astellas d.o.o. | Astellas Pharma Europe B.V. | Vesicare | tbl. film obl. 30x5 mg | 0,2941 | 8,82 | RRG04 | 5% |
| G04BD08 162 |  | solifenacin | 5 mg | 0,3230 | O | Astellas d.o.o. | Astellas Pharma Europe B.V. | Vesicare | tbl. film obl. 30x10 mg | 0,6459 | 19,38 | RRG04 | 5% |
| G04BD08 181 |  | solifenacin | 5 mg | 0,2940 | O | Viatris Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories, Mylan Dublin B.V. | Solven | tbl. film obl. 30x5 mg | 0,2941 | 8,82 | RRG04 | 5% |
| G04BD08 182 |  | solifenacin | 5 mg | 0,3122 | O | Viatris Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories, Mylan B.V. | Solven | tbl. film obl. 30x10 mg | 0,6242 | 18,73 | RRG04 | 5% |
| G04BD08 183 |  | solifenacin | 5 mg | 0,2940 | O | STADA d.o.o. | STADA Arzneimittel GmbH | Solifenacin STADA | tbl. film obl. 30x5 mg | 0,2941 | 8,82 | RRG04 | 5% |
| G04BD08 184 |  | solifenacin | 5 mg | 0,2527 | O | STADA d.o.o. | STADA Arzneimittel GmbH | Solifenacin STADA | tbl. film obl. 30x10 mg | 0,5053 | 15,16 | RRG04 | 5% |
| G04BD08 185 |  | solifenacin | 5 mg | 0,2793 | O | BE Pharma d.o.o. | Genepharm S.A. | Solifenacin Be Pharma | tbl. film obl. 30x5 mg | 0,2794 | 8,38 | RRG04 | 5% |
| G04BD08 186 |  | solifenacin | 5 mg | 0,2280 | O | BE Pharma d.o.o. | Genepharm S.A. | Solifenacin Be Pharma | tbl. film obl. 30x10 mg | 0,4560 | 13,68 | RRG04 | 5% |
| G04BD09 022 | PR | trospij |  |  | P | Sandoz d.o.o. | Sandoz-Lek | Spasmex | amp. 50x0,2 mg/5 ml | 0,3597 | 17,98 |  | 5% |
| G04BD12 161 |  | mirabegron | 50 mg | 2,2360 | O | Astellas Pharma Europe B.V. | Astellas Pharma Europe B.V. | Betmiga | tbl. s prod. otpušt. 30x25 mg | 1,1180 | 33,54 | RSRG07 | 5% |
| G04BD12 162 |  | mirabegron | 50 mg | 1,1180 | O | Astellas Pharma Europe B.V. | Astellas Pharma Europe B.V. | Betmiga | tbl. s prod. otpušt. 30x50 mg | 1,1180 | 33,54 | RSRG07 | 5% |
| G04BD13 101 |  | desfesoterodin | 3.5 mg | 0,2939 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Tovedeso | tbl. s prod. oslob. 28x3,5 mg | 0,2941 | 8,23 | RRG04 | 5% |
| G04BD13 102 |  | desfesoterodin | 3.5 mg | 0,2809 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Tovedeso | tbl. s prod. oslob. 28x7 mg | 0,5617 | 15,73 | RRG04 | 5% |
| G04BE03 101 | DS | sildenafilNG401 | 50 mg | 7,9281 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sildenafil Pliva | tbl. film obl. 90x20 mg | 3,1712 | 285,41 |  | 5% |
| G04BE03 161 | DS | sildenafilNG401 | 50 mg | 7,9281 | O | Pfizer Europe MA EEIG | Pfizer | Revatio | tbl. film obl. 90x20 mg | 3,1712 | 285,41 |  | 5% |
| G04BE03 171 | DS | sildenafilNG401 | 50 mg | 7,9281 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Granpidam | tbl. film obl. 90x20 mg | 3,1712 | 285,41 |  | 5% |
| G04BE03 172 | DS | sildenafilNG401 | 50 mg | 7,9280 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Granpidam | tbl. film obl. 300x20 mg | 3,1712 | 951,36 |  | 5% |
| G04BE03 173 | DS | sildenafilNG401 | 50 mg | 7,9281 | O | ALPHA-MEDICAL d.o.o. | Mawdsley Brooks & Co. Ltd. | Sildenafil Alpha-Medical | tbl. film obl. 90x20 mg | 3,1712 | 285,41 |  | 5% |
| G04CA02 103 |  | tamsulozin | 0,4 mg | 0,1393 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Bazetham | tbl. s prod. oslob. 30x0,4 mg | 0,1393 | 4,18 | RSRG05 | 5% |
| G04CA02 111 |  | tamsulozin | 0,4 mg | 0,1393 | O | Belupo d.d. | Belupo | Tamosin | caps. s prod. oslob. tvrda 30x0,4 mg | 0,1393 | 4,18 | RSRG05 | 5% |
| G04CA02 112 |  | tamsulozin | 0,4 mg | 0,0914 | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Tamosin | caps. s prilag. oslob. tvrda 100x0,4 mg | 0,0914 | 9,14 | RSRG05 | 5% |
| G04CA02 131 |  | tamsulozin | 0,4 mg | 0,1393 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tanyz | caps. s prod. oslob. tvrda 30x0,4 mg | 0,1393 | 4,18 | RSRG05 | 5% |
| G04CA02 132 |  | tamsulozin | 0,4 mg | 0,1128 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tanyz | caps. s prod. oslob. tvrda 60x0,4 mg | 0,1128 | 6,77 | RSRG05 | 5% |
| G04CA02 133 |  | tamsulozin | 0,4 mg | 0,1253 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tanyz ERAS | tbl. s prod. oslob. 30x0,4 mg | 0,1254 | 3,76 | RSRG05 | 5% |
| G04CA02 134 |  | tamsulozin | 0,4 mg | 0,1128 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tanyz ERAS | tbl. s prod. oslob. 60x0,4 mg | 0,1128 | 6,77 | RSRG05 | 5% |
| G04CA02 145 |  | tamsulozin | 0,4 mg | 0,1393 | O | PharmaS d.o.o. | PharmaS d.o.o. | Tamsulozin PharmaS | caps. s prod. oslob. tvrda 30x0,4 mg | 0,1393 | 4,18 | RSRG05 | 5% |
| G04CA02 146 |  | tamsulozin | 0,4 mg | 0,1128 | O | PharmaS d.o.o. | PharmaS d.o.o. | Tamsulozin PharmaS | caps. tvrda s prod. oslob. 60x0,4 mg | 0,1128 | 6,77 | RSRG05 | 5% |
| G04CA02 147 |  | tamsulozin | 0,4 mg | 0,1017 | O | Alkaloid-INT d.o.o. | Alkaloid-INT d.o.o. | Tamaliz | caps. s prilag. oslob., tvrda 30x0,4 mg | 0,1015 | 3,05 | RSRG05 | 5% |
| G04CA02 148 |  | tamsulozin | 0,4 mg | 0,0963 | O | Alkaloid-INT d.o.o. | Alkaloid-INT d.o.o. | Tamaliz | caps. s prilag. oslob., tvrda 100x0,4 mg | 0,0963 | 9,63 | RSRG05 | 5% |
| G04CA02 161 |  | tamsulozin | 0,4 mg | 0,1393 | O | Astellas d.o.o. | Astellas Pharma Europe B.V. | Omnic | caps. s prod. otp. 30x0,4 mg | 0,1393 | 4,18 | RSRG05 | 5% |
| G04CA02 163 |  | tamsulozin | 0,4 mg | 0,1393 | O | Menarini International Operations Luxembourg S.A. | Menarini-Von Heyden GmbH; Synthon Hispania S.L. | Flosin | caps. s prilag. oslob. tvrda 30x0,4 mg | 0,1393 | 4,18 | RSRG05 | 5% |
| G04CA02 164 |  | tamsulozin | 0,4 mg | 0,1128 | O | Menarini International Operations Luxembourg S.A. | Menarini-Von Heyden GmbH; Synthon Hispania S.L. | Flosin | caps. s prilag. oslob. tvrda 100x0,4 mg | 0,1128 | 11,28 | RSRG05 | 5% |
| G04CA02 172 |  | tamsulozin | 0,4 mg | 0,1393 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma G.m.b.H | Tamsu Genericon | caps. s prod. oslob. tvrda 30x0,4 mg | 0,1393 | 4,18 | RSRG05 | 5% |
| G04CA02 181 |  | tamsulozin | 0,4 mg | 0,1283 | O | Zentiva k.s. | Synthon BV, Synthon Hispania S.L. | Tamsich | caps. s prilag. oslob. tvrda 30x0,4 mg | 0,1284 | 3,85 | RSRG05 | 5% |
| G04CA52 101 |  | dutasterid + tamsulozin |  |  | O | PLIVA HRVATSKA d.o.o. | Laboratorios Leon Farma S.A. | Duster Duo | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CA52 102 |  | dutasterid + tamsulozin |  |  | O | PLIVA HRVATSKA d.o.o. | Laboratorios Leon Farma S.A. | Duster Duo | caps. tvrda 90x(0,5 mg + 0,4 mg) | 0,2185 | 19,66 | RSpg03 | 5% |
| G04CA52 111 |  | dutasterid + tamsulozin |  |  | O | Belupo d.d. | Belupo | Kllotas | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CA52 121 |  | dutasterid + tamsulozin |  |  | O | Jadran – Galenski Laboratorij d.d. | Laboratorios Leon Farma S.A. | Dulmod | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CA52 141 |  | dutasterid + tamsulozin |  |  | O | PharmaS d.o.o. | Laboratorios Leon Farma S.A. | Atekago | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CA52 142 |  | dutasterid + tamsulozin |  |  | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Tamaliz Duo | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CA52 162 |  | dutasterid + tamsulozin |  |  | O | Mylan Ireland Limited | Laboratorios Leon Farma S.A. | Vasgar | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CA52 163 |  | dutasterid + tamsulozin |  |  | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma Gesellschaft m.b.H., Laboratorios Leon Farma S.A. | Duitam | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CA52 171 |  | dutasterid + tamsulozin |  |  | O | ALPHA-MEDICAL d.o.o. | Laboratorios Leon Farma S.A. | Duostin | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CA52 181 |  | dutasterid + tamsulozin |  |  | O | Zentiva k.s. | Laboratorios Leon Farma S.A. | Dupro plus | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CA52 191 |  | dutasterid + tamsulozin |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Dutasterid/tamsulozin Stada | caps. tvrda 30x(0,5 mg + 0,4 mg) | 0,2421 | 7,26 | RSpg03 | 5% |
| G04CB01 141 |  | finasterid | 5 mg | 0,1139 | O | PharmaS d.o.o. | PharmaS d.o.o. | Finasterid PharmaS | tbl. film obl. 28x5 mg | 0,1138 | 3,19 | RSRG06 | 5% |
| G04CB01 171 |  | finasterid | 5 mg | 0,1139 | O | PharmaS d.o.o. | Cipla | Fincar | tbl. film obl. 28x5 mg | 0,1138 | 3,19 | RSRG06 | 5% |
| G04CB01 181 |  | finasterid | 5 mg | 0,1137 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH | Finasterid Genericon | tbl. film obl. 30x5 mg | 0,1137 | 3,41 | RSRG06 | 5% |
| H01AA02 051 | KL | tetrakozaktid (tetracosactrin) | 0,25 mg |  | P |  |  |  |  |  |  |  | 5% |
| H01AB01 061 | KL | tirotropin alfaNH101 | 0,9 mg | 321,7200 | P | Genzyme Europe B.V. | Genzyme | Thyrogen | praš. za otop. za inj., boč. 2x0,9 mg | 321,7214 | 643,44 |  | 5% |
| H01AC01 021 |  | somatropinNH505 | 2 i.j. | 9,8707 | P | Sandoz GmbH | Sandoz | Omnitrope | uložak stakl. 1x5 mg/1,5 ml (1 mg =3 i.j.) | 74,0301 | 74,03 | RSRH06 | 5% |
| H01AC01 022 |  | somatropinNH505 | 2 i.j. | 9,8707 | P | Sandoz GmbH | Sandoz | Omnitrope | uložak stakl. 1x10 mg/1,5 ml (1 mg =3 i.j.) | 148,0589 | 148,06 | RSRH06 | 5% |
| H01AC01 023 |  | somatropinNH505 | 2 i.j. | 9,8707 | P | Sandoz GmbH | Sandoz | Omnitrope | uložak stakl. 1x15 mg/1,5 ml (1 mg =3 i.j.) | 222,0891 | 222,09 | RSRH06 | 5% |
| H01AC01 062 |  | somatropinNH505 | 2 i.j. | 9,8705 | P | Pfizer Croatia d.o.o. | Pfizer | Genotropin | praš. i otap. za otop. za inj., uložak dvodijelni stakl. 5x5,3 mg/ml (5x16 i.j.) | 78,9648 | 394,82 | RSRH06 | 5% |
| H01AC01 065 |  | somatropinNH505 | 2 i.j. | 88,8350 | P | Pfizer Croatia d.o.o. | Pfizer | Genotropin | praš. i otap. za otop. za inj., uložak dvodijelni stakl. 5x12 mg/ml (5x36 i.j.) | 177,6707 | 888,35 | RSRH06 | 5% |
| H01AC01 066 |  | somatropinNH505 | 2 i.j. | 9,8705 | P | Pfizer Croatia d.o.o. | Pfizer | Genotropin | praš. i otap. za otop. za inj., uložak dvodijelni stakl. u višedoznoj napunj. brizg. GoQuick 5x5,3 mg/ml (5x16 i.j.) | 78,9648 | 394,82 | RSRH06 | 5% |
| H01AC01 067 |  | somatropinNH505 | 2 i.j. | 9,8706 | P | Pfizer Croatia d.o.o. | Pfizer | Genotropin | praš. i otap. za otop. za inj., uložak dvodijelni stakl. u višedoznoj napunj. brizg. GoQuick 5x12 mg/ml (5x36 i.j.) | 177,6707 | 888,35 | RSRH06 | 5% |
| H01AC01 086 |  | somatropinNH506 | 2 i.j. | 15,9240 | P | Novo Nordisk A/S | Novo Nordisk A/S | Norditropin NordiFlex | otop. za inj., napunj. brizg. 1x5 mg/1,5 ml (1 mg =3 i.j.) | 119,4253 | 119,43 | RSRH06 | 5% |
| H01AC01 087 |  | somatropinNH506 | 2 i.j. | 15,8520 | P | Novo Nordisk A/S | Novo Nordisk A/S | Norditropin NordiFlex | otop. za inj., napunj. brizg. 1x10 mg/1,5 ml (1 mg =3 i.j.) | 237,7809 | 237,78 | RSRH06 | 5% |
| H01AC01 088 |  | somatropinNH506 | 2 i.j. | 16,0453 | P | Novo Nordisk A/S | Novo Nordisk A/S | Norditropin NordiFlex | otop. za inj., napunj. brizg. 1x15 mg/1,5 ml (1 mg =3 i.j.) | 361,0233 | 361,02 | RSRH06 | 5% |
| H01AX01 081 | DS | pegvisomantNH507 |  |  | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Somavert | praš. i otap. za otop. za inj., 30x10 mg | 64,4267 | 1.932,80 |  | 5% |
| H01AX01 082 | DS | pegvisomantNH507 |  |  | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Somavert | praš. i otap. za otop. za inj., 30x20 mg | 128,4244 | 3.852,73 |  | 5% |
| H01BA02 052 | PR | dezmopresin | 4 mcg |  | P |  |  |  |  |  |  |  | 5% |
| H01BA02 163 |  | dezmopresin | 0,4 mg |  | O | Ferring GmbH | Ferring | Minirin Melt | liofilizat oral. 30x60 mcg | 0,5842 | 17,52 | RSRH01 | 5% |
| H01BA02 164 |  | dezmopresin | 0,4 mg |  | O | Ferring GmbH | Ferring | Minirin Melt | liofilizat oral. 30x120 mcg | 1,1683 | 35,05 | RSRH01 | 5% |
| H01BA02 751 |  | dezmopresin | 25 mcg | 1,0550 | N |  |  |  |  | 21,1003 | 21,10 | RSRH02 | 5% |
| H01BA02 761 |  | dezmopresin | 25 mcg | 1,0550 | N | Ferring GmbH | Ferring | Minirin | rasprš. za nos 1x5 ml (0,1 mg/ml, 50 doza) | 21,1003 | 21,10 | RSRH02 | 5% |
| H01BA04 071 | DS | terlipresinNH106 | 12 mg | 342,1646 | P | Ferring GmbH | Ferring GmbH | Glypressin | praš. i otap. za otop. za inj. štrc. 5x1 mg | 28,5155 | 142,58 |  | 5% |
| H01BB02 062 | PR | oksitocin | 15 i.j. | 1,0680 | P | Mylan Hrvatska d.o.o. | Mylan S.A.S. | Syntocinon | amp. 10x5 i.j./ ml. | 0,3561 | 3,56 |  | 5% |
| H01BB02 763 | PR | oksitocin | 15 i.j. | 0,3338 | N | Mylan Hrvatska d.o.o. | Delpharm Huningue S. A. S. | Syntocinon | rasprš. 1x5 ml (40 i.j./ml) | 4,4462 | 4,45 |  | 5% |
| H01CA01 751 |  | gonadorelin |  |  | N |  |  |  |  |  |  | RSRH91 | 5% |
| H01CB02 001 | DS | oktreotidNH105 | 0,7 mg | 21,6325 | P | Teva B.V. | Pliva Hrvatska d.o.o., Merckle GmbH | Oktreotid Teva | boč. 1x20 mg | 618,0689 | 618,07 |  | 5% |
| H01CB02 002 | DS | oktreotidNH105 | 0,7 mg | 18,4583 | P | Teva B.V. | Pliva Hrvatska d.o.o., Merckle GmbH | Oktreotid Teva | boč. 1x30 mg | 791,0678 | 791,07 |  | 5% |
| H01CB02 065 | DS | oktreotidNH104 | 0,7 mg | 35,3633 | P | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Sandostatin | amp. 5x0,10 mg | 5,0528 | 25,26 |  | 5% |
| H01CB02 066 | DS | oktreotidNH104 | 0,7 mg | 31,9679 | P | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Sandostatin | amp. 5x0,50 mg | 22,8344 | 114,17 |  | 5% |
| H01CB02 068 | DS | oktreotidNH105 | 0,7 mg | 23,8607 | P | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Sandostatin Lar | boč. 1x20 mg | 691,9610 | 691,96 |  | 5% |
| H01CB02 069 | DS | oktreotidNH105 | 0,7 mg | 20,3458 | P | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Sandostatin Lar | boč. 1x30 mg | 874,8742 | 874,87 |  | 5% |
| H01CB05 061 | DS | pasireotidNH507 | 1,2 mg | 87,4429 | P | Recordati Rare Diseases | Novartis Pharma GmbH | Signifor | praš. i otap. za susp. za inj., 1x40 mg | 2.914,7601 | 2.914,76 |  | 5% |
| H01CB05 062 | DS | pasireotidNH507 | 1,2 mg | 64,3730 | P | Recordati Rare Diseases | Novartis Pharma GmbH | Signifor | praš. i otap. za susp. za inj., 1x60 mg | 3.218,6515 | 3.218,65 |  | 5% |
| H01CC01 061 | DS | ganireliks | 0.25 mg | 26,7400 | P | Organon N.V. | Organon | Orgalutran | otop. za inj., štrc. napunj. 1x0,25 mg/0,5 ml | 26,7450 | 26,74 |  | 5% |
| H01CC02 071 | DS | cetroreliks | 0,25 mg | 34,7300 | P | Merck Europe B.V. | Baxter | Cetrotide | praš. i otap. za otop. za inj. boč. 1x0,25 mg + napunj. štrc. | 34,7256 | 34,73 |  | 5% |
| H02AA02 151 |  | fludrokortizon | 0,1 mg |  | O |  |  |  |  |  |  | R | 5% |
| H02AB02 021 | PR | deksametazon | 1,5 mg | 0,1725 | P | Sandoz d.o.o. | Sandoz-Salutas | Deksametazon Sandoz | otop. za inj., amp. 10x4 mg/ml | 0,4599 | 4,60 |  | 5% |
| H02AB02 032 | PR | deksametazon | 1,5 mg | 0,2660 | P | KRKA-FARMA d.o.o. | Krka d.d. | Dexamethason/Deksametazon Krka | amp. 25x4 mg/ml / otop. za inj./inf., 25x4 mg/ml | 0,7127 | 17,82 |  | 5% |
| H02AB02 071 | PR | deksametazon | 1,5 mg | 0,1639 | P | hameln pharma gmbh | hameln rds s.r.o., Siegfried Hameln GmbH | Deksametazon hameln | otop. za inj., amp. 10x4 mg/1 ml | 0,4369 | 4,37 |  | 5% |
| H02AB02 101 |  | deksametazon | 1,5 mg | 0,2012 | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH | Deksametazon Pliva | tbl. 20x4 mg | 0,5366 | 10,73 | R | 5% |
| H02AB02 102 |  | deksametazon | 1,5 mg | 0,1323 | O | PLIVA HRVATSKA d.o.o. | Merckle GmbH | Deksametazon Pliva | tbl. 20x8 mg | 0,7054 | 14,11 | R | 5% |
| H02AB02 131 |  | deksametazon | 1,5 mg | 0,5880 | O | KRKA-FARMA d.o.o. | Krka d.d. | Dexamethason/Deksametazon Krka | tbl. 10x0,5 mg | 0,1964 | 1,96 | R | 5% |
| H02AB02 132 |  | deksametazon | 1,5 mg | 0,2119 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Deksametazon Krka | tbl. 20x4 mg | 0,5649 | 11,30 | R | 5% |
| H02AB02 133 |  | deksametazon | 1,5 mg | 0,1542 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Deksametazon Krka | tbl. 20x20 mg | 2,0562 | 41,12 | RSRV03 | 5% |
| H02AB04 064 | PO | metilprednizolon-sukcinat-natrij | 20 mg | 0,7300 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x40 mg/ml | 1,4586 | 1,46 |  | 5% |
| H02AB04 065 | DS | metilprednizolon-acetat | 20 mg | 0,5950 | P | Pfizer Croatia d.o.o. | Pfizer | Depo Medrol | amp. 1x40 mg/ml | 1,1905 | 1,19 |  | 5% |
| H02AB04 066 | PO | metilprednizolon-sukcinat-natrij | 20 mg | 0,4850 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x125 mg/2 ml | 2,9133 | 2,91 |  | 5% |
| H02AB04 067 | DS | metilprednizolon-sukcinat-natrij | 20 mg | 0,3680 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x500 mg/8 ml | 9,2030 | 9,20 |  | 5% |
| H02AB04 068 | DS | metilprednizolon-sukcinat-natrij | 20 mg | 0,3352 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x250 mg | 4,1874 | 4,19 |  | 5% |
| H02AB04 069 | DS | metilprednizolon-sukcinat-natrij | 20 mg | 0,1980 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Medrol | amp. 1x1.000 mg/16 ml | 9,9038 | 9,90 |  | 5% |
| H02AB04 161 |  | metilprednizolon-acetat | 7,5 mg | 0,0850 | O | Pfizer Croatia d.o.o. | Pfizer | Medrol | tbl. 50x16 mg | 0,1814 | 9,07 | R | 5% |
| H02AB07 172 |  | prednizon | 10 mg | 0,0825 | O | MERCK d.o.o. | Merck | Decortin | tbl. 10x20 mg | 0,1646 | 1,65 | R | 5% |
| H02AB07 174 |  | prednizon | 10 mg | 0,0770 | O | MERCK d.o.o. | Merck | Decortin | tbl. 50x20 mg | 0,1540 | 7,70 | R | 5% |
| H02AB07 551 | DS | prednizon |  |  | R |  |  |  |  |  |  |  | 5% |
| H02AB09 083 | PR | hidrokortizon | 30 mg | 0,4967 | P | Pfizer Croatia d.o.o. | Pfizer | Solu Cortef | amp. 1x100 mg /2 ml | 1,4852 | 1,49 |  | 5% |
| H02AB09 161 |  | hidrokortizon | 30 mg | 46,3459 | O | Diurnal Europe B.V. | Delpharm Lille SAS | Alkindi | gran. u caps. za otvaranje 50x0,5 mg | 0,7724 | 38,62 | RSRH92 | 5% |
| H02AB09 162 |  | hidrokortizon | 30 mg | 46,3431 | O | Diurnal Europe B.V. | Delpharm Lille SAS | Alkindi | gran. u caps. za otvaranje 50x1 mg | 1,5449 | 77,24 | RSRH92 | 5% |
| H02AB09 163 |  | hidrokortizon | 30 mg | 35,1184 | O | Diurnal Europe B.V. | Delpharm Lille SAS | Alkindi | gran. u caps. za otvaranje 50x2 mg | 2,3412 | 117,06 | RSRH92 | 5% |
| H02AB09 182 |  | hidrokortizon | 30 mg | 0,2229 | O | Pfizer Croatia d.o.o. | Pharmacia & Upjohn | Cortef | tbl. 100x10 mg | 0,0743 | 7,43 | R | 5% |
| H03AA01 051 | DS | levotiroksin | 0,15 mg |  | P |  |  |  |  |  |  |  | 5% |
| H03AA01 171 |  | levotiroksin | 0,15 mg | 0,0546 | O | Berlin Chemie AG | Berlin-Chemie AG | Letrox 50 | tbl. 100x50 mcg | 0,0182 | 1,82 | R | 5% |
| H03AA01 172 |  | levotiroksin | 0,15 mg | 0,0369 | O | Berlin Chemie AG | Berlin-Chemie AG | Letrox 100 | tbl. 100x100 mcg | 0,0246 | 2,46 | R | 5% |
| H03AA01 173 |  | levotiroksin | 0,15 mg | 0,0310 | O | Berlin Chemie AG | Berlin-Chemie AG | Letrox 150 | tbl. 100x150 mcg | 0,0310 | 3,10 | R | 5% |
| H03AA02 051 | DS | liotironin | 60 mcg |  | P |  |  |  |  |  |  |  | 5% |
| H03BA02 142 |  | propiltiouracil | 0,1 g | 0,3717 | O | Alkaloid d.o.o. | Alkaloid | Propiltiouracil Alkaloid | tbl. 60x50 mg | 0,1858 | 11,15 | R | 5% |
| H03BB02 051 | DS | tiamazol |  |  | P |  |  |  |  |  |  |  | 5% |
| H03BB02 111 |  | tiamazol | 10 mg | 0,1857 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Athyrazol | tbl. 30x10 mg | 0,1858 | 5,57 | R | 5% |
| H04AA01 061 | PR | glukagon | 1 mg | 14,3300 | P | Novo Nordisk A/S | Novo Nordisk | GlucaGen Hypokit | lio boč. 1x1 mg + štrcaljka | 14,3341 | 14,33 | R | 5% |
| H04AA01 761 |  | glukagon | 3 mg | 57,7700 | N | Eli Lilly Nederland B.V. | Lilly France S.A.S. | Baqsimi | praš. za nos, 3 mg (1 monodoza) | 57,7742 | 57,77 | RRH08 | 5% |
| H05AA02 001 | RL | teriparatid | 20 mcg | 6,6060 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V. | Teriparatid Pliva | otop. za inj., brizg. napunj. 1x600 mcg/2,4 ml (250 mcg/ml) | 198,1777 | 198,18 | RSRH07 | 5% |
| H05AA02 071 | RL | teriparatid | 20 mcg | 6,6060 | P | Eli Lilly Nederland B.V. | Lilly France | Forsteo | otop. za inj., brizg. napunj. 1x600 mcg/2,4 ml (250 mcg/ml) | 198,1777 | 198,18 | RSRH07 | 5% |
| H05AA02 072 | RL | teriparatid | 20 mcg | 5,9597 | P | STADA Arzneimittel AG | Gedeon Richter Plc. | Movymia | otop. za inj., uložak 1x600 mcg/2,4 ml (250 mcg/ml) | 178,7949 | 178,79 | RSRH07 | 5% |
| H05AA02 073 | RL | teriparatid | 20 mcg | 6,6060 | P | STADA Arzneimittel AG | Gedeon Richter Plc | Movymia starter kit | otop. za inj., brizgalica i uložak 1x600 mcg/2,4 ml (250 mcg/ml) | 198,1777 | 198,18 | RSRH07 | 5% |
| H05AA02 074 | RL | teriparatid | 20 mcg | 5,5954 | P | STADA Arzneimittel AG | Gedeon Richter Plc. | Movymia | otop. za inj., uložak 3x600 mcg/2,4 ml (250 mcg/ml) | 167,8638 | 503,59 | RSRH07 | 5% |
| H05AA02 081 | RL | teriparatid | 20 mcg | 6,6060 | P | Gedeon Richter Plc. | Richter-Helm BioLogics GmbH & Co. KG | Terrosa | otop. za inj., brizgalica Terrosa Pen i uložak 1x600 mcg/2,4 ml (250 mcg/ml) | 198,1777 | 198,18 | RSRH07 | 5% |
| H05AA02 082 | RL | teriparatid | 20 mcg | 5,9597 | P | Gedeon Richter Plc. | Richter-Helm BioLogics GmbH & Co. KG | Terrosa | otop. za inj., uložak 1x600 mcg/2,4 ml (250 mcg/ml) | 178,7949 | 178,79 | RSRH07 | 5% |
| H05AA02 083 | RL | teriparatid | 20 mcg | 6,6060 | P | Zentiva k.s. | GP Pharm S.A. | Teriparatid Zentiva | otop. za inj., brizg. napunj. 1x600 mcg/2,4 ml (250 mcg/ml) | 198,1777 | 198,18 | RSRH07 | 5% |
| H05AA02 084 | RL | teriparatid | 20 mcg | 6,6060 | P | Accord Healthcare S.L.U. | Accord Healthcare BV, Accord Healthcare Polska Sp. z o.o. | Sondelbay | otop. za inj., brizg. napunj. 1x600 mcg/2,4 ml (250 mcg/ml) | 198,1777 | 198,18 | RSRH07 | 5% |
| H05BX01 141 | DS | sinakalcetNH502 | 60 mg | 6,3571 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Laboratori Fundacio Dau | Cinakalcet Accordpharma | tbl. film obl. 28x30 mg | 3,1787 | 89,00 |  | 5% |
| H05BX01 142 | DS | sinakalcetNH502 | 60 mg | 6,3575 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Laboratori Fundacio Dau | Cinakalcet Accordpharma | tbl. film obl. 28x60 mg | 6,3574 | 178,01 |  | 5% |
| H05BX01 161 | DS | sinakalcetNH502 | 60 mg | 7,4436 | O | Amgen Europe B.V. | Amgen Europe B.V. | Mimpara | tbl. film obl. 28x30 mg | 3,7218 | 104,21 |  | 5% |
| H05BX01 162 | DS | sinakalcetNH502 | 60 mg | 6,9539 | O | Amgen Europe B.V. | Amgen Europe B.V. | Mimpara | tbl. film obl. 28x60 mg | 6,9538 | 194,71 |  | 5% |
| H05BX01 181 | DS | sinakalcetNH502 | 60 mg | 6,6993 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Cinet | tbl. film obl. 28x30 mg | 3,3496 | 93,79 |  | 5% |
| H05BX01 182 | DS | sinakalcetNH502 | 60 mg | 6,6993 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Cinet | tbl. film obl. 28x60 mg | 6,6993 | 187,58 |  | 5% |
| H05BX02 061 | DS | parikalcitolNH503 | 2 mcg | 5,4776 | P | AbbVie d.o.o. | AbbVie S.r.l. | Zemplar | boč. 5x5 mcg/ml | 13,6938 | 68,47 |  | 5% |
| H05BX02 161 |  | parikalcitol | 2 mcg | 5,1921 | O | AbbVie d.o.o. | Aesica Queenborough Limited, AbbVie Deutschland GmbH & Co.KG | Zemplar | caps. meke 28x1 mcg | 2,5961 | 72,69 | RSRH05 | 5% |
| H05BX02 162 |  | parikalcitol | 2 mcg | 5,4268 | O | AbbVie d.o.o. | Aesica Queenborough Limited, AbbVie Deutschland GmbH & Co.KG | Zemplar | caps. meke 28x2 mcg | 5,4268 | 151,95 | RSRH05 | 5% |
| H05BX02 171 |  | parikalcitol | 2 mcg | 3,6343 | O | ALPHA-MEDICAL d.o.o. | Yasenka d.o.o. | Parkol | caps. meke 28x1 mcg | 1,8173 | 50,88 | RSRH05 | 5% |
| H05BX02 172 |  | parikalcitol | 2 mcg | 3,7986 | O | ALPHA-MEDICAL d.o.o. | Yasenka d.o.o. | Parkol | caps. meke 28x2 mcg | 3,7987 | 106,36 | RSRH05 | 5% |
| H05BX04 061 | DS | etelkalcetidNH504 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Parsabiv | otop. za inj., boč. stakl. 6x2,5 mg/0,5 ml (5 mg/ml) | 16,2990 | 97,79 |  | 5% |
| H05BX04 062 | DS | etelkalcetidNH504 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Parsabiv | otop. za inj., boč. stakl. 6x5 mg/1 ml (5 mg/ml) | 32,5324 | 195,19 |  | 5% |
| J01AA02 112 |  | doksiciklin | 0,1 g | 0,1328 | O | Belupo d.d. | Belupo | Doksiciklin Belupo | caps. 25x100 mg | 0,1327 | 3,32 | R | 5% |
| J01AA12 061 | DS | tigeciklinNJ101 | 0,1 g | 77,6800 | P | Pfizer Europe MA EEIG | Wyeth | Tygacil | praš. za otop. za inf., boč. stakl. 10x50 mg (10 mg/ml) | 38,8400 | 388,40 |  | 5% |
| J01AA12 071 | DS | tigeciklinNJ101 | 0,1 g | 54,3740 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Tigeciklin Accord | praš. za otop. za inf., boč. stakl. 10x50 mg (10 mg/ml) | 27,1869 | 271,87 |  | 5% |
| J01BA01 052 | DS | kloramfenikolNJ101 | 3 g |  | P |  |  |  |  |  |  |  | 5% |
| J01CA01 051 | PR | ampicilin | 6 g |  | P |  |  |  | 500 mg |  |  |  | 5% |
| J01CA01 052 | DS | ampicilin | 6 g |  | P |  |  |  | 1 g |  |  |  | 5% |
| J01CA04 118 |  | amoksicilin | 1.5 g | 0,2269 | O | Belupo d.d. | Belupo | Amoksicilin Belupo | tbl. za oral. susp. 16x500 mg | 0,0757 | 1,21 | RRJ01 | 5% |
| J01CA04 119 |  | amoksicilin | 1.5 g | 0,2306 | O | Belupo d.d. | Belupo | Amoksicilin Belupo | tbl. za oral. susp. 16x1000 mg | 0,1535 | 2,46 | RRJ01 | 5% |
| J01CA04 121 |  | amoksicilin | 1.5 g | 0,2306 | O | Sandoz d.o.o. | Sandoz GmbH | Ospamox | tbl. za oral. susp. 16x1 g | 0,1535 | 2,46 | RRJ01 | 5% |
| J01CA04 141 |  | amoksicilin | 1.5 g | 0,2269 | O | Alkaloid d.o.o. | Alkaloid | Almacin | caps. 16x500 mg | 0,0757 | 1,21 | RRJ01 | 5% |
| J01CA04 311 |  | amoksicilin | 1.5 g | 0,4770 | O | Belupo d.d. | Belupo | Amoksicilin Belupo | sirup 1x100 ml (250 mg/5 ml) | 1,5927 | 1,59 | RRJ01 | 5% |
| J01CA04 342 |  | amoksicilin | 1.5 g | 0,4770 | O | Alkaloid d.o.o. | Alkaloid | Almacin | praš. za oral susp. 100 ml (250 mg/5 ml) | 1,5927 | 1,59 | RRJ01 | 5% |
| J01CE01 051 | PO | benzilpenicilin | 3,6 g |  | P |  |  |  |  |  |  |  | 5% |
| J01CE02 116 |  | fenoksimetilpenicilin | 2 g | 0,5793 | O | Belupo d.d. | Belupo d.d. | Silapen K | tbl. film obl. 30x1.500.000 i.j. | 0,2608 | 7,82 | RRJ02 | 5% |
| J01CE02 117 |  | fenoksimetilpenicilin | 2 g | 0,6044 | O | Sandoz d.o.o. | Sandoz | Ospen K | tbl. film obl. 30x1.000.000 i.j. | 0,1813 | 5,44 | RRJ02 | 5% |
| J01CE02 118 |  | fenoksimetilpenicilin | 2 g | 0,5793 | O | Sandoz d.o.o. | Sandoz | Ospen K | tbl. film obl. 30x1.500.000 i.j. | 0,2608 | 7,82 | RRJ02 | 5% |
| J01CE02 171 |  | fenoksimetilpenicilin | 2 g | 0,6150 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Penon | tbl. film obl. 30x800 mg | 0,2459 | 7,38 | RRJ02 | 5% |
| J01CE02 172 |  | fenoksimetilpenicilin | 2 g | 0,5893 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Penon | tbl. film obl. 30x1000 mg | 0,2946 | 8,84 | RRJ02 | 5% |
| J01CE02 313 |  | fenoksimetilpenicilin | 2 g | 5,4280 | O | Belupo d.d. | Belupo | Silapen K | praš. za oral. otop. 1x100 ml (250 mg/5 ml) | 13,5669 | 13,57 | RRJ02 | 5% |
| J01CE02 363 |  | fenoksimetilpenicilin | 2 g | 5,1560 | O | ALPHA-MEDICAL d.o.o. | Laboratorios Atral S.A. | Penon | praš. za oral. otop. 1x100 ml (250 mg/5 ml) | 12,8887 | 12,89 | RRJ02 | 5% |
| J01CE08 051 | PO | benzatin benzilpenicilin | 3,6 g |  | P |  |  |  |  |  |  |  | 5% |
| J01CE09 051 | PO | prokain benzilpenicilin |  |  | P |  |  |  |  |  |  |  | 5% |
| J01CE30 051 | PO | benzilpenicilin prokainpenicilin (depo-bipenicilin) |  |  | P |  |  |  |  |  |  |  | 5% |
| J01CF05 061 | DS | flukloksacilinnatrij | 2 g | 4,7400 | P | Altamedics d.o.o. | MITIM S.r.l. | Flukloksacilin Altamedics | praš. za otop. za inj./inf., boč. stakl. 10x1 g | 2,3704 | 23,70 |  | 5% |
| J01CF05 063 | DS | flukloksacilin | 2 g | 4,9610 | P | Altamedics d.o.o. | MITIM S.r.l. | Flukloksacilin Altamedics | praš. za otop. za inj. ili inf., boč. stakl. 10x2 g | 4,9612 | 49,61 |  | 5% |
| J01CF05 171 |  | flukloksacilin | 2 g | 2,0420 | O | Altamedics d.o.o. | Athlone Laboratories Limited, Co. Roscommon | Flukloksacilin Altamedics | caps. tvrda 20x500 mg | 0,5103 | 10,21 | R | 5% |
| J01CR01 051 | DS | ampicilin + sulbaktamNJ101 | 6 g |  | P |  |  |  |  |  |  |  | 5% |
| J01CR01 071 | DS | ampicilin + sulbaktamNJ101 | 6 g | 11,5078 | P | Apta Medica International d.o.o. | MITIM S.r.l. | Ampicilin/sulbaktam AptaPharma | praš. za otop. za inj./inf., boč. 10x(1 g + 0,5 g) | 1,9178 | 19,18 |  | 5% |
| J01CR01 072 | DS | ampicilin + sulbaktamNJ101 | 6 g | 11,5081 | P | Apta Medica International d.o.o. | MITIM S.r.l. | Ampicilin/sulbaktam AptaPharma | praš. za otop. za inj./inf., boč. 10x(2 g + 1 g) | 3,8357 | 38,36 |  | 5% |
| J01CR02 005 | PO | amoksicilin + klavulanska kiselina | 3 g | 19,9208 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Klavocin | boč. 5x(500 + 100 mg) | 3,3202 | 16,60 |  | 5% |
| J01CR02 006 | PR | amoksicilin + klavulanska kiselina | 3 g |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Klavocin | boč. 5x(1.000 + 200 mg) | 3,2708 | 16,35 |  | 5% |
| J01CR02 061 | PR | amoksicilin + klavulanska kiselina | 3 g | 6,8671 | P | Medochemie Ltd. | Medochemie Ltd. | Medoclav | boč. 10x(1.000 mg + 200 mg) | 2,2895 | 22,89 |  | 5% |
| J01CR02 071 | PR | amoksicilin + klavulanska kiselina | 3 g | 6,5071 | P | Apta Medica International d.o.o. | Laboratorio Reig Jofre S.A. | Amoksicilin/klavulanska kiselina AptaPharma | boč. 10x(1.000 mg + 200 mg) | 2,1687 | 21,69 |  | 5% |
| J01CR02 108 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,5363 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Klavocin bid | tbl. film obl. 14x1 g (875 mg + 125 mg) | 0,3128 | 4,38 | RRJ04 | 5% |
| J01CR02 111 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,4090 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Klavax bid | tbl. film obl. 14x1 g (875 mg + 125 mg) | 0,2389 | 3,34 | RRJ04 | 5% |
| J01CR02 115 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,5363 | O | Belupo d.d. | Belupo | Klavobel BID | tbl. film obl. 14x1 g (875 mg + 125 mg) | 0,3128 | 4,38 | RRJ04 | 5% |
| J01CR02 131 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,3686 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Betaklav | tbl. film obl. 14x1 g (875 mg + 125 mg) | 0,2150 | 3,01 | RRJ04 | 5% |
| J01CR02 141 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,3600 | O | PharmaS d.o.o. | PharmaS d.o.o. | KlavoPhar | tbl. film obl. 14x1 g (875 mg + 125 mg) | 0,2103 | 2,94 | RRJ04 | 5% |
| J01CR02 161 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,3600 | O | Medochemie Ltd. | Medochemie Ltd. | Medoclav | tbl. film obl. 14x1 g (875 mg + 125 mg) | 0,2102 | 2,94 | RRJ04 | 5% |
| J01CR02 171 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,5363 | O | GlaxoSmithKline Trading Services Limited | SmithKline Beecham Pharmaceuticals, Glaxo Wellcome Production | Augmentin | tbl. film obl. 14x1 g (875 mg + 125 mg) | 0,3128 | 4,38 | RRJ04 | 5% |
| J01CR02 209 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,7982 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Klavocin bid sirup | susp. 70 ml (400 mg + 57 mg)/5 ml | 2,9796 | 2,98 | RRJ04 | 5% |
| J01CR02 212 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,7982 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Klavax bid sirup | susp. 70 ml (400 mg + 57 mg)/5 ml | 2,9796 | 2,98 | RRJ04 | 5% |
| J01CR02 231 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,7179 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Betaklav | praš. za oral. susp. 1x70 ml (400 mg + 57 mg/5 ml) | 2,6823 | 2,68 | RRJ04 | 5% |
| J01CR02 273 |  | amoksicilin + klavulanska kiselina | 1.5 g | 0,7982 | O | GlaxoSmithKline Trading Services Limited | SmithKline Beecham Pharmaceuticals, Glaxo Wellcome Production | Augmentin | susp. 70 ml(400 mg + 57 mg)/5 ml | 2,9796 | 2,98 | RRJ04 | 5% |
| J01CR05 001 | DS | piperacilin + tazobaktamNJ101 | 14 g | 28,2489 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Acipirin | praš. za inj. ili inf. 10x4,5 g | 8,0709 | 80,71 |  | 5% |
| J01CR05 041 | DS | piperacilin + tazobaktamNJ101 | 14 g | 28,7179 | P | Sandoz d.o.o. | Sandoz | Piperacilin/tazobaktam Sandoz | praš. za otop. za inf., boč. 10x(4,0 g + 0,5 g)/100ml | 8,2053 | 82,05 |  | 5% |
| J01CR05 074 | DS | piperacilin + tazobaktamNJ101 | 14 g | 57,5600 | P | Fresenius Kabi d.o.o. | Laboratorio Farmaceutico, Labesfal-Laboratorios Almiro | Piperacilin/Tazobactam Fresenius Kabi | praš. za otop. za inf., boč. 10x(2,0 g + 0,25 g)/50 ml | 5,7555 | 57,56 |  | 5% |
| J01CR05 075 | DS | piperacilin + tazobaktamNJ101 | 14 g | 28,2489 | P | Fresenius Kabi d.o.o. | Laboratorio Farmaceutico, Labesfal-Laboratorios Almiro | Piperacilin/Tazobactam Fresenius Kabi | praš. za otop. za inf., boč. 10x(4,0 g + 0,5 g)/50 ml | 8,0709 | 80,71 |  | 5% |
| J01DB01 111 |  | cefaleksin | 2 g | 0,6950 | O | Belupo d.d. | Belupo | Cefaleksin Belupo | caps. 16x500 mg | 0,1739 | 2,78 | RRJ05 | 5% |
| J01DB01 142 |  | cefaleksin | 2 g | 0,6950 | O | Alkaloid d.o.o. | Alkaloid | Cefalexin Alkaloid | caps. 16x500 mg | 0,1739 | 2,78 | RRJ05 | 5% |
| J01DB01 313 |  | cefaleksin | 2 g | 1,0640 | O | Belupo d.d. | Belupo | Cefaleksin Belupo | praš. za oral. susp. 1x100 ml (250 mg/5 ml) | 2,6598 | 2,66 | RRJ05 | 5% |
| J01DB01 343 |  | cefaleksin | 2 g | 1,0640 | O | Alkaloid d.o.o. | Alkaloid | Cefalexin Alkaloid | praš. za oral. susp. 1x100 ml (250 mg/5 ml) | 2,6598 | 2,66 | RRJ05 | 5% |
| J01DB04 061 | PR | cefazolin | 3 g | 3,3800 | P | Medochemie Ltd. | Medochemie Ltd | Zepilen | praš. za otop. za inj. ili inf. boč. stakl. 10x1 g/10 ml | 1,0140 | 10,14 |  | 5% |
| J01DB04 082 | PR | cefazolin | 3 g | 2,8803 | P | ALPHA-MEDICAL d.o.o. | PJSC SIC Borshchahivskiy CPP | Cefazolin Alpha-Medical | praš. za otop. za inj. ili inf., boč. stakl. 1x1 g/10 ml | 0,9636 | 0,96 |  | 5% |
| J01DB04 083 | PR | cefazolin | 3 g | 2,7450 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefazolin AptaPharma | praš. za otop. za inj. ili inf. boč. 10x1 g/10 ml | 0,9154 | 9,15 |  | 5% |
| J01DC02 061 | DS | cefuroksim NJ102 | 3 g | 3,4520 | P | Medochemie Ltd. | Medochemie Ltd. | Axetine | praš. za otop. za inj. ili inf. boč. 10x750 mg | 0,8627 | 8,63 |  | 5% |
| J01DC02 062 | DS | cefuroksim NJ102 | 3 g | 2,6540 | P | Medochemie Ltd. | Medochemie Ltd. | Axetine | praš. za otop. za inj. ili inf. boč. 10x1,5 g | 1,3272 | 13,27 |  | 5% |
| J01DC02 076 | DS | cefuroksim NJ102 | 3 g | 3,4520 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefuroksim AptaPharma | praš. za otop. za inj. ili inf., boč. stakl. 10x750 mg | 0,8627 | 8,63 |  | 5% |
| J01DC02 077 | DS | cefuroksim NJ102 | 3 g | 2,5220 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefuroksim AptaPharma | praš. za otop. za inj. ili inf., boč. stakl. 10x1500 mg | 1,2609 | 12,61 |  | 5% |
| J01DC02 081 | DS | cefuroksim NJ102 | 3 g | 5,7920 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chemisch-pharmazeutische Fabrik GmbH | Cefuroxim-MIP | praš. za otop. za inj., boč. stakl. 10x750 mg | 1,4481 | 14,48 |  | 5% |
| J01DC02 082 | DS | cefuroksimNJ102 | 3 g | 3,4580 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chemisch-pharmazeutische Fabrik GmbH | Cefuroxim-MIP | praš. za otop. za inj. ili inf., boč. stakl. 10x1500 mg | 1,7287 | 17,29 |  | 5% |
| J01DC02 111 |  | cefuroksimNJ102 | 0,5 g | 0,3540 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Efox | tbl. film obl. 10x500 mg | 0,3544 | 3,54 | RRJ06 | 5% |
| J01DC02 113 |  | cefuroksimNJ102 | 0,5 g | 0,5540 | O | Belupo d.d. | Belupo d.d. | Beloxim | tbl. film obl. 10x250 mg | 0,2771 | 2,77 | RRJ06 | 5% |
| J01DC02 114 |  | cefuroksimNJ102 | 0,5 g | 0,3540 | O | Belupo d.d. | Belupo d.d. | Beloxim | tbl. film obl. 10x500 mg | 0,3544 | 3,54 | RRJ06 | 5% |
| J01DC02 123 |  | cefuroksimNJ102 | 0,5 g | 0,3540 | O | Sandoz d.o.o. | Sandoz | Xorimax | tbl. film obl. 10x500 mg | 0,3544 | 3,54 | RRJ06 | 5% |
| J01DC02 124 |  | cefuroksimNJ102 | 0,5 g | 0,3544 | O | Sandoz d.o.o. | Sandoz | Xorimax | tbl. film obl. 16x500 mg | 0,3544 | 5,67 | RRJ06 | 5% |
| J01DC02 144 |  | cefuroksimNJ102 | 0,5 g | 0,3543 | O | KRKA-FARMA d.o.o. | Krka d.d. | Furocef | tbl. film obl. 14x500 mg | 0,3544 | 4,96 | RRJ06 | 5% |
| J01DC02 162 |  | cefuroksimNJ102 | 0,5 g | 0,5540 | O | GlaxoSmithKline d.o.o. | Glaxo Operations UK Ltd., GlaxoSmithKline Trading Services Limited | Zinnat | tbl. film obl. 10x250 mg | 0,2771 | 2,77 | RRJ06 | 5% |
| J01DC02 163 |  | cefuroksimNJ102 | 0,5 g | 0,3540 | O | GlaxoSmithKline d.o.o. | Glaxo Operations UK Ltd., GlaxoSmithKline Trading Services Limited | Zinnat | tbl. film obl. 10x500 mg | 0,3544 | 3,54 | RRJ06 | 5% |
| J01DC02 262 |  | cefuroksimNJ102 | 0,5 g | 1,6460 | O | GlaxoSmithKline d.o.o. | Glaxo Operations UK Ltd., GlaxoSmithKline Trading Services Limited | Zinnat | suspenzija 1x100 ml (125 mg/5 ml) | 8,2288 | 8,23 | RRJ06 | 5% |
| J01DD01 051 | DS | cefotaksimNJ101 | 4 g |  | P |  |  |  |  |  |  |  | 5% |
| J01DD01 061 | DS | cefotaksimNJ101 | 4 g | 11,6040 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefotaksim AptaPharma | praš. za otop. za inj/inf., boč. 10x1 g | 2,9013 | 29,01 |  | 5% |
| J01DD01 062 | DS | cefotaksimNJ101 | 4 g | 11,5840 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefotaksim AptaPharma | praš. za otop. za inj/inf., boč. 10x2 g | 5,7922 | 57,92 |  | 5% |
| J01DD02 042 | DS | ceftazidimNJ101 | 4 g | 18,3200 | P | Alkaloid d.o.o. | Alkaloid | Cefaz | praš. za otop. za inj., boč. 5x1000 mg/10 ml | 4,5797 | 22,90 |  | 5% |
| J01DD02 043 | DS | ceftazidimNJ101 | 4 g | 15,5880 | P | Alkaloid d.o.o. | Alkaloid – INT d.o.o. | Cefaz | praš. za otop. za inj./inf., boč. 10x1000 mg/10 ml | 3,8974 | 38,97 |  | 5% |
| J01DD02 071 | DS | ceftazidimNJ101 | 4 g | 20,0000 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro S.A | Ceftazidim Kabi | praš. za otop. za inj., boč. 1x500 mg/10 ml | 2,5045 | 2,50 |  | 5% |
| J01DD02 072 | DS | ceftazidimNJ101 | 4 g | 20,0320 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro S.A | Ceftazidim Kabi | praš. za otop. za inj., boč. 10x500 mg/10 ml | 2,5045 | 25,04 |  | 5% |
| J01DD02 073 | DS | ceftazidimNJ101 | 4 g | 22,9600 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro S.A | Ceftazidim Kabi | praš. za otop. za inj., boč. 1x1000 mg/10 ml | 5,7363 | 5,74 |  | 5% |
| J01DD02 074 | DS | ceftazidimNJ101 | 4 g | 16,4080 | P | Fresenius Kabi d.o.o. | Labesfal-Laboratorios Almiro S.A | Ceftazidim Kabi | praš. za otop. za inj., boč. 10x1000 mg/10 ml | 4,1025 | 41,02 |  | 5% |
| J01DD02 077 | DS | ceftazidimNJ101 | 4 g | 16,4080 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Ceftazidim AptaPharma | praš. za otop. za inj./inf., boč. 10x1000 mg/10 ml | 4,1025 | 41,02 |  | 5% |
| J01DD02 078 | DS | ceftazidimNJ101 | 4 g | 15,5900 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Ceftazidim AptaPharma | praš. za otop. za inj./inf., boč. 10x2000 mg/10 ml | 7,7947 | 77,95 |  | 5% |
| J01DD04 065 | DSPO | ceftriakson NJ110 | 2 g | 4,7680 | P | Fresenius Kabi d.o.o. | Labesfal, Laboratorios Almiro, S.A. | Ceftriaxone Kabi | praš. za otop. za inj., boč 10x1 g | 2,3842 | 23,84 |  | 5% |
| J01DD04 066 | DSPO | ceftriaksonNJ110 | 2 g | 7,1670 | P | Fresenius Kabi d.o.o. | Labesfal, Laboratorios Almiro, S.A. | Ceftriaxone Kabi | praš. za otop. za inj., boč 10x2 g | 7,1670 | 71,67 |  | 5% |
| J01DD04 071 | DSPO | ceftriaksonNJ110 | 2 g | 3,1700 | P | Medochemie Ltd. | Medochemie Ltd. | Medaxone | praš. za otop. za inj. ili inf. boč. 10x1 g | 1,5854 | 15,85 |  | 5% |
| J01DD04 075 | DSPO | ceftriaksonNJ110 | 2 g | 4,7680 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Ceftriaxon MIP | praš. za otop. za inj. ili inf., boč. stakl. 10x1 g | 2,3842 | 23,84 |  | 5% |
| J01DD04 076 | DSPO | ceftriaksonNJ110 | 2 g | 5,0170 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Ceftriaxon MIP | praš. za otop. za inj. ili inf., boč. stakl. 10x2 g | 5,0169 | 50,17 |  | 5% |
| J01DD04 085 | DSPO | ceftriaksonNJ110 | 2 g | 3,1700 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A | Ceftriakson AptaPharma | praš. za otop. za inj./inf. boč. 10x1 g | 1,5854 | 15,85 |  | 5% |
| J01DD04 086 | DSPO | ceftriaksonNJ110 | 2 g | 4,7660 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A | Ceftriakson AptaPharma | praš. za otop. za inj./inf. boč. 5x2 g | 4,7661 | 23,83 |  | 5% |
| J01DD04 087 | DSPO | ceftriaksonNJ110 | 2 g | 4,5280 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A | Ceftriakson AptaPharma | praš. za otop. za inj./inf. boč. 10x2 g | 4,5278 | 45,28 |  | 5% |
| J01DD08 141 |  | cefiksim | 0,4 g | 0,5810 | O | ALPHA-MEDICAL d.o.o. | Medika d.d. | Cefiksim CLN | tbl. film obl. 10x400 mg | 0,5809 | 5,81 | RRJ07 | 5% |
| J01DD08 142 |  | cefiksim | 0,4 g | 0,5820 | O | ALPHA-MEDICAL d.o.o. | Medika d.d. | Cefiksim CLN | tbl. film obl. 5x400 mg | 0,5811 | 2,91 | RRJ07 | 5% |
| J01DD08 241 |  | cefiksim | 0,4 g | 2,0967 | O | Alkaloid d.o.o. | Alkaloid | Cefiksim Alkaloid | praš. za oral. susp. 1x60 ml (100 mg/5 ml) | 6,2911 | 6,29 | RRJ07 | 5% |
| J01DD08 242 |  | cefiksim | 0,4 g | 2,0980 | O | Alkaloid d.o.o. | Alkaloid | Cefiksim Alkaloid | praš. za oral. susp. 1x100 ml (100 mg/5 ml) | 10,4851 | 10,49 | RRJ07 | 5% |
| J01DD52 071 | DS | ceftazidim + avibaktamNJ107 |  |  | P | Pfizer Ireland Pharmaceuticals | GlaxoSmithKline Manufacturing S.p.A | Zavicefta | praš. za konc. za otop. za inf., boč. stakl. 10x(2 g + 0,5 g) | 104,0903 | 1.040,90 |  | 5% |
| J01DE01 041 | DS | cefepimNJ101 | 4 g | 13,5600 | P | Accord Healthcare Polska Sp. z o.o. | Laboratorio Farmaceutico C.T. S.r.l. | Cefepim Accord | praš. za otop. za inj. ili inf., boč. stakl. 1x1 g | 3,3871 | 3,39 |  | 5% |
| J01DE01 042 | DS | cefepimNJ101 | 4 g | 14,3000 | P | Accord Healthcare Polska Sp. z o.o. | Laboratorio Farmaceutico C.T. S.r.l. | Cefepim Accord | praš. za otop. za inj. ili inf., boč. stakl. 1x2 g | 7,1511 | 7,15 |  | 5% |
| J01DE01 071 | DS | cefepimNJ101 | 4 g | 19,3560 | P | Fresenius Kabi d.o.o. | Labesfal – Laboratorios Almiro S.A. | Cefepime Kabi | praš. za otop. za inj. ili inf., boč. stakl. 10x1 g | 4,8389 | 48,39 |  | 5% |
| J01DE01 072 | DS | cefepimNJ101 | 4 g | 20,4300 | P | Fresenius Kabi d.o.o. | Labesfal – Laboratorios Almiro S.A. | Cefepime Kabi | praš. za otop. za inj. ili inf., boč. stakl. 10x2 g | 10,2154 | 102,15 |  | 5% |
| J01DH02 073 | DS | meropenemNJ101 | 3 g | 34,9673 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Meropenem AptaPharma | praš. za otop. za inj. ili inf., boč. 10x500 mg | 5,8279 | 58,28 |  | 5% |
| J01DH02 074 | DS | meropenemNJ101 | 3 g | 31,9143 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Meropenem AptaPharma | praš. za otop. za inj. ili inf., boč. 10x1000 mg | 10,6377 | 106,38 |  | 5% |
| J01DH02 075 | DS | meropenemNJ101 | 3 g | 28,8000 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Meropenem AptaPharma | praš. za otop. za inf., boč. 6x2000 mg | 19,2006 | 115,20 |  | 5% |
| J01DH02 081 | DS | meropenemNJ101 | 3 g | 36,8033 | P | Fresenius Kabi d.o.o. | ACS Dobfar S.p.A. | Meropenem Kabi | praš. za otop. za inj. ili inf., boč. 10x500 mg/20 ml | 6,1343 | 61,34 |  | 5% |
| J01DH02 082 | DS | meropenemNJ101 | 3 g | 33,5943 | P | Fresenius Kabi d.o.o. | ACS Dobfar S.p.A. | Meropenem Kabi | praš. za otop. za inj. ili inf., boč. 10x1000 mg/20 ml | 11,1978 | 111,98 |  | 5% |
| J01DH02 083 | DS | meropenemNJ101 | 3 g | 36,8033 | P | Medochemie Ltd. | Medochemie Ltd | Archifar | praš. za otop. za inj. ili inf., boč. stakl. 10x500 mg/20 ml | 6,1343 | 61,34 |  | 5% |
| J01DH02 084 | DS | meropenemNJ101 | 3 g | 33,5943 | P | Medochemie Ltd. | Medochemie Ltd | Archifar | praš. za otop. za inj. ili inf., boč. stakl. 10x1000 mg/30 ml | 11,1978 | 111,98 |  | 5% |
| J01DH02 085 | DS | meropenemNJ101 | 3 g | 33,2153 | P | Ligula Pharma d.o.o. | Venus Pharma GmbH | Meropenem Ligula Pharma | praš. za otop. za inj. ili inf., boč. 10x500 mg | 5,5359 | 55,36 |  | 5% |
| J01DH02 086 | DS | meropenemNJ101 | 3 g | 30,3183 | P | Ligula Pharma d.o.o. | Venus Pharma GmbH | Meropenem Ligula Pharma | praš. za otop. za inj. ili inf., boč. 10x1000 mg | 10,1055 | 101,06 |  | 5% |
| J01DH03 061 | DS | ertapenemNJ101 | 1 g | 33,8400 | P | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | Invanz | praš. za konc.za otop. za inf., boč. stakl. 1x1g/20ml | 33,8403 | 33,84 |  | 5% |
| J01DH03 071 | DS | ertapenemNJ101 | 1 g | 30,3480 | P | Fresenius Kabi d.o.o. | ACS Dobfar S.p.A. | Ertapenem Fresenius Kabi | praš. za konc.za otop. za inf., boč. stakl. 10x1g/20 ml | 30,3484 | 303,48 |  | 5% |
| J01DH03 072 | DS | ertapenemNJ101 | 1 g | 27,3140 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Ertapenem AptaPharma | praš. za konc.za otop. za inf., boč. 10x1g | 27,3136 | 273,14 |  | 5% |
| J01DH51 068 | DS | imipenem + cilastatinNJ101 | 2 g | 18,2960 | P | Fresenius Kabi d.o.o. | Facta Farmaceutici | Imipenem/Cilastatin Kabi | praš. za otop. za inf., boč. stakl. 10x(500 mg + 500 mg) | 4,5744 | 45,74 |  | 5% |
| J01DH51 072 | DS | imipenem + cilastatinNJ101 | 2 g | 14,7600 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Imipenem/cilastatin AptaPharma | praš. za otop. za inf., boč. 10x(500 mg + 500 mg) | 3,6897 | 36,90 |  | 5% |
| J01DH56 061 | DS | imipenem + cilastatin + relebaktamNJ111 | 2 g | 693,1056 | P | Merck Sharp & Dohme B.V. | FAREVA Mirabel | Recarbrio | praš. za otop. za inf., boč. 25x(500 mg + 500 mg + 250 mg) | 173,2763 | 4.331,91 |  | 5% |
| J01DI02 061 | DS | ceftarolin fosamilNJ108 | 1,2 g | 107,9200 | P | Pfizer Ireland Pharmaceuticals | Facta Farmaceutici S.p.A | Zinforo | praš. za konc. za otop. za inf., boč. stakl. 10x600 mg | 53,9599 | 539,60 |  | 5% |
| J01DI54 061 | DS | ceftolozan + tazobaktamNJ712 |  |  | P | Merck Sharp & Dohme B.V. | Cubist Pharmaceuticals Italia s.r.l. | Zerbaxa | praš. za konc. za otop. za inf., boč. 10x1 g/0,5 g | 91,5840 | 915,84 |  | 5% |
| J01EA01 151 |  | trimetoprim | 0,4 g |  | O |  |  |  |  |  |  | R | 5% |
| J01EE01 051 | DS | sulfametoksazol + trimetoprim |  |  | P |  |  |  |  |  |  |  | 5% |
| J01EE01 111 |  | sulfametoksazol + trimetoprim |  |  | O | Belupo d.d. | Belupo | Sulotrim | tbl. 20x120 mg | 0,0372 | 0,74 | RRJ09 | 5% |
| J01EE01 112 |  | sulfametoksazol + trimetoprim |  |  | O | Belupo d.d. | Belupo | Sulotrim | tbl. 20x480 mg | 0,1116 | 2,23 | RRJ09 | 5% |
| J01EE01 114 |  | sulfametoksazol + trimetoprim |  |  | O | Belupo d.d. | Belupo | Sulotrim forte | tbl. 20x960 mg | 0,1690 | 3,38 | RRJ09 | 5% |
| J01FA01 051 | DS | eritromicin | 1 g |  | P |  |  |  |  |  |  |  | 5% |
| J01FA01 111 |  | eritromicin | 1 g | 0,9725 | O | Belupo d.d. | Belupo | Eritromicin | caps. 16x250 mg | 0,2429 | 3,89 | RRJ10 | 5% |
| J01FA09 112 |  | klaritromicin | 0,5 g | 0,4771 | O | Belupo d.d. | Belupo | Makcin SR | tbl. 7x500 mg | 0,4772 | 3,34 | RRJ11 | 5% |
| J01FA09 114 |  | klaritromicin | 0,5 g | 0,4771 | O | Belupo d.d. | Belupo | Makcin | tbl. 14x500 mg | 0,4772 | 6,68 | RRJ11 | 5% |
| J01FA09 131 |  | klaritromicin | 0,5 g | 0,4629 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid | tbl. film obl. 14x250 mg | 0,2314 | 3,24 | RRJ11 | 5% |
| J01FA09 132 |  | klaritromicin | 0,5 g | 0,4771 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid | tbl. film obl. 14x500 mg | 0,4772 | 6,68 | RRJ11 | 5% |
| J01FA09 133 |  | klaritromicin | 0,5 g | 0,4771 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid uno | tbl. s prod. otp. 7x500 mg | 0,4772 | 3,34 | RRJ11 | 5% |
| J01FA09 134 |  | klaritromicin | 0,5 g | 0,4771 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid uno | tbl. s prod. otp. 14x500 mg | 0,4772 | 6,68 | RRJ11 | 5% |
| J01FA09 143 |  | klaritromicin | 0,5 g | 0,4771 | O | Sandoz d.o.o. | Sandoz | Lekoklar XL | tbl. film obl. 7x500 mg | 0,4772 | 3,34 | RRJ11 | 5% |
| J01FA09 144 |  | klaritromicin | 0,5 g | 0,4771 | O | Sandoz d.o.o. | Sandoz | Lekoklar XL | tbl. film obl. 14x500 mg | 0,4772 | 6,68 | RRJ11 | 5% |
| J01FA09 335 |  | klaritromicin | 0,5 g | 1,0900 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fromilid | susp. oral. 60 ml (125 mg/5 ml) | 3,2716 | 3,27 | RRJ11 | 5% |
| J01FA10 007 | DS | azitromicinNJ103 | 0,5 g | 13,7620 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed | praš. za inf. otop. boč. 5x500 mg | 13,7618 | 68,81 |  | 5% |
| J01FA10 041 | DS | azitromicinNJ103 | 0,5 g | 9,6300 | P | PharmaS d.o.o. | Anfarm Hellas S.A. | Azitromicin PharmaS | praš. za konc. za inf. otop; boč. 1x500 mg | 9,6330 | 9,63 |  | 5% |
| J01FA10 101 |  | azitromicin | 0,3 g | 1,7560 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed | tbl. 6x125 mg | 0,7313 | 4,39 | RRJ12 | 5% |
| J01FA10 111 |  | azitromicin | 0,3 g | 0,3380 | O | Belupo d.d. | Belupo | Azitromicin Belupo | tbl. film obl. 6x250 mg | 0,2809 | 1,69 | RRJ12 | 5% |
| J01FA10 112 |  | azitromicin | 0,3 g | 0,3380 | O | Belupo d.d. | Belupo | Azitromicin Belupo | tbl. film obl. 3x500 mg | 0,5619 | 1,69 | RRJ12 | 5% |
| J01FA10 125 |  | azitromicin | 0,3 g | 0,3380 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Makromicin | tbl. film obl. 3x500 mg | 0,5619 | 1,69 | RRJ12 | 5% |
| J01FA10 131 |  | azitromicin | 0,3 g | 0,3380 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Azimed | caps. 6x250 mg | 0,2809 | 1,69 | RRJ12 | 5% |
| J01FA10 132 |  | azitromicin | 0,3 g | 0,3380 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Azimed | tbl. film obl. 3x500 mg | 0,5619 | 1,69 | RRJ12 | 5% |
| J01FA10 133 |  | azitromicin | 0,3 g | 0,3380 | O | KRKA-FARMA d.o.o. | Krka d.d. | Azibiot | tbl. film obl. 3x500 mg | 0,5619 | 1,69 | RRJ12 | 5% |
| J01FA10 141 |  | azitromicin | 0,3 g | 0,3380 | O | Sandoz d.o.o. | Sandoz | Azitromicin Sandoz | tbl. film obl. 6x250 mg | 0,2809 | 1,69 | RRJ12 | 5% |
| J01FA10 142 |  | azitromicin | 0,3 g | 0,3380 | O | Sandoz d.o.o. | Sandoz | Azitromicin Sandoz | tbl. film obl. 3x500 mg | 0,5619 | 1,69 | RRJ12 | 5% |
| J01FA10 143 |  | azitromicin | 0,3 g | 0,3380 | O | PharmaS d.o.o. | PharmaS d.o.o. | Azitromicin PharmaS | tbl. film obl. 3x500 mg | 0,5619 | 1,69 | RRJ12 | 5% |
| J01FA10 304 |  | azitromicin | 0,3 g | 2,1001 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed | praš. za oral. susp., 1x20 ml (100 mg/5 ml) | 2,8005 | 2,80 | RRJ18 | 5% |
| J01FA10 306 |  | azitromicin | 0,3 g | 1,4625 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed 1.200 | praš. za oral. susp., 1x30 ml (200 mg/5 ml) | 5,8531 | 5,85 | RRJ12 | 5% |
| J01FA10 308 |  | azitromicin | 0,3 g | 1,4650 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed forte | praš. za oral. susp., 1x15 ml (200 mg/5 ml) | 2,9265 | 2,93 | RRJ12 | 5% |
| J01FA10 309 |  | azitromicin | 0,3 g | 1,4640 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Sumamed 1.500 | praš. za oral. susp., 1x37,5 ml (200 mg/5 ml) | 7,3170 | 7,32 | RRJ12 | 5% |
| J01FA10 343 |  | azitromicin | 0,3 g | 1,3350 | O | Sandoz d.o.o. | Sandoz | Azitromicin Sandoz forte | praš. za oral. susp., boč. 1x15 ml (200 mg/5 ml) | 2,6730 | 2,67 | RRJ12 | 5% |
| J01FF01 022 | DS | klindamicin | 1,8 g | 7,9150 | P | Sandoz d.o.o. | Sandoz-Lek | Klimicin | amp. 10x300 mg/2 ml | 1,5831 | 15,83 |  | 5% |
| J01FF01 065 | DS | klindamicin | 1,8 g | 4,6200 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Clindamycin MIP/Klindamicin-MIP | otop. za inj., amp. 5x900 mg/6 ml | 2,3102 | 11,55 |  | 5% |
| J01FF01 071 | DS | klindamicin | 1,8 g | 5,4359 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-pharm. Fabrik GmbH | Clindamycin MIP/Klindamicin-MIP | otop. za inj., amp. 5x600 mg/4 ml | 1,8122 | 9,06 |  | 5% |
| J01FF01 081 | DS | klindamicin | 1,8 g | 9,0238 | P | hameln pharma gmbh | hameln rds, Siegfried Hameln GmbH | Klindamicin hameln | otop. za inj./inf., amp. 10x300 mg/2 ml | 1,5040 | 15,04 |  | 5% |
| J01FF01 082 | DS | klindamicin | 1,8 g | 5,1631 | P | hameln pharma gmbh | hameln rds, Siegfried Hameln GmbH | Klindamicin hameln | otop. za inj./inf., amp. 10x600 mg/4 ml | 1,7211 | 17,21 |  | 5% |
| J01FF01 121 |  | klindamicin | 1,2 g | 1,0900 | O | Sandoz d.o.o. | Sandoz-Lek | Klimicin | caps. 16x150 mg | 0,1363 | 2,18 | R | 5% |
| J01FF01 122 |  | klindamicin | 1,2 g | 0,7975 | O | Sandoz d.o.o. | Sandoz-Lek | Klimicin | caps. 16x300 mg | 0,1991 | 3,19 | R | 5% |
| J01FF01 162 |  | klindamicin | 1,2 g | 0,7975 | O | Pfizer Croatia d.o.o. | Pfizer | Dalacin C | caps. 16x300 mg | 0,1991 | 3,19 | R | 5% |
| J01GA01 051 | DS | streptomicin | 1 g |  | P |  |  |  |  |  |  |  | 5% |
| J01GB01 961 | DS | tobramicinNJ104 | 0,3 g | 30,1900 | I | Chiesi Pharmaceuticals GmbH | Chiesi | Bramitob | otop. za nebulizator, spremnik jednodozni, 56x300 mg/4 ml | 30,1900 | 1.690,64 |  | 5% |
| J01GB01 962 | DS | tobramicinNJ104 | 0.112g | 35,0307 | I | Mylan IRE Healthcare Ltd | Novartis Pharma GmbH | Tobi Podhaler | prašak inhalata, caps. tvrde 4x56x28 mg | 8,7577 | 1.961,72 |  | 5% |
| J01GB03 013 | PO | gentamicin | 0,24 g | 2,4810 | P | Belupo d.d. | Belupo | Gentamicin Belupo | amp. 10x80 mg | 0,8271 | 8,27 |  | 5% |
| J01GB03 014 | PO | gentamicin | 0,24 g | 2,2220 | P | Belupo d.d. | Belupo | Gentamicin Belupo | amp. 10x120 mg | 1,1109 | 11,11 |  | 5% |
| J01GB03 032 | PO | gentamicin | 0,24 g | #N/A | P | KRKA-FARMA d.o.o. | Krka d.d. | Garamycin | amp. 10x80 mg | #N/A | #N/A |  | 5% |
| J01GB03 033 | PO | gentamicin | 0,24 g | #N/A | P | KRKA-FARMA d.o.o. | Krka d.d. | Garamycin | amp. 10x120 mg | #N/A | #N/A |  | 5% |
| J01GB06 051 | DS | amikacinNJ101 | 1 g |  | P |  |  |  |  |  |  |  | 5% |
| J01GB07 051 | DS | netilmicin | 0,35 g |  | P |  |  |  |  |  |  |  | 5% |
| J01MA01 052 | DS | ofloksacin | 0,4 g |  | P |  |  |  |  |  |  |  | 5% |
| J01MA02 022 | DS | ciprofloksacinNJ105 | 0.8 g | 23,8320 | P | Sandoz d.o.o. | Sandoz-Salutas | Ciprofloksacin Lek | otop. za inf., boč. stakl. 5x200 mg/100 ml | 5,9582 | 29,79 |  | 5% |
| J01MA02 031 | DS | ciprofloksacinNJ105 | 0.8 g | 23,8400 | P | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | boč. inf. 1x200 mg/100 ml | 5,9579 | 5,96 |  | 5% |
| J01MA02 033 | DS | ciprofloksacinNJ105 | 0.8 g | 21,9840 | P | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | boč. inf. 5x10 ml (100 mg/10 ml) | 2,7482 | 13,74 |  | 5% |
| J01MA02 034 | DS | ciprofloksacinNJ105 | 0.8 g | 21,4600 | P | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | boč. inf. 1x400 mg/200 ml | 10,7253 | 10,73 |  | 5% |
| J01MA02 061 | DS | ciprofloksacinNJ105 | 0.8 g | 21,9840 | P | Alkaloid d.o.o. | Alkaloid | Citeral | konc. otop. za inf., amp. 5x10 ml (100 mg/10 ml) | 2,7482 | 13,74 |  | 5% |
| J01MA02 066 | DS | ciprofloksacin NJ105 | 0.8 g | 21,4400 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ciprofloxacin Kabi | otop. za inf., boč. 1x200 mg/100 ml | 5,3620 | 5,36 |  | 5% |
| J01MA02 067 | DS | ciprofloksacin NJ105 | 0.8 g | 19,3040 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ciprofloxacin Kabi | otop. za inf., boč. 10x200 mg/100 ml | 4,8258 | 48,26 |  | 5% |
| J01MA02 068 | DS | ciprofloksacin NJ105 | 0.8 g | 19,3000 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ciprofloxacin Kabi | otop. za inf., boč. 1x400 mg/200 ml | 9,6529 | 9,65 |  | 5% |
| J01MA02 069 | DS | ciprofloksacin NJ105 | 0.8 g | 17,3760 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Ciprofloxacin Kabi | otop. za inf., boč. 10x400 mg/200 ml | 8,6876 | 86,88 |  | 5% |
| J01MA02 102 |  | ciprofloksacin | 1 g | 1,1340 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Cipromed | tbl. 10x500 mg | 0,5671 | 5,67 | RSRV03 | 5% |
| J01MA02 111 |  | ciprofloksacin | 1 g | 1,0640 | O | Belupo d.d. | Belupo | Ciflox | tbl. film obl. 10x250 mg | 0,2664 | 2,66 | RSRV03 | 5% |
| J01MA02 112 |  | ciprofloksacin | 1 g | 1,1340 | O | Belupo d.d. | Belupo | Ciflox | tbl. film obl. 10x500 mg | 0,5671 | 5,67 | RSRV03 | 5% |
| J01MA02 116 |  | ciprofloksacin | 1 g | 1,1340 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ciprofloksacin JGL | tbl. film obl. 10x500 mg | 0,5671 | 5,67 | RSRV03 | 5% |
| J01MA02 122 |  | ciprofloksacin | 1 g | 1,1340 | O | Sandoz d.o.o. | Sandoz-Salutas | Ciprofloksacin Sandoz | tbl. film obl. 10x500 mg | 0,5671 | 5,67 | RSRV03 | 5% |
| J01MA02 131 |  | ciprofloksacin | 1 g | 1,0640 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | tbl. 10x250 mg | 0,2664 | 2,66 | RSRV03 | 5% |
| J01MA02 132 |  | ciprofloksacin | 1 g | 1,1340 | O | KRKA-FARMA d.o.o. | Krka d.d. | Ciprinol | tbl. 10x500 mg | 0,5671 | 5,67 | RSRV03 | 5% |
| J01MA02 161 |  | ciprofloksacin | 1 g | 1,0640 | O | Alkaloid d.o.o. | Alkaloid | Citeral | tbl. 10x250 mg | 0,2664 | 2,66 | RSRV03 | 5% |
| J01MA02 162 |  | ciprofloksacin | 1 g | 1,1340 | O | Alkaloid d.o.o. | Alkaloid | Citeral | tbl. 10x500 mg | 0,5671 | 5,67 | RSRV03 | 5% |
| J01MA03 051 | DS | pefloksacin | 0,8 mg |  | P |  |  |  |  |  |  |  | 5% |
| J01MA03 151 | DS | pefloksacin | 0,8 mg |  | O |  |  |  |  |  |  |  | 5% |
| J01MA06 111 |  | norfloksacin | 0,8 g | 0,4070 | O | Belupo d.d. | Belupo | Noflox | tbl. film obl. 20x400 mg | 0,2037 | 4,07 | RRJ14 | 5% |
| J01MA06 134 |  | norfloksacin | 0,8 g | 0,4070 | O | KRKA-FARMA d.o.o. | Krka d.d. | Nolicin | tbl. 20x400 mg | 0,2037 | 4,07 | RRJ14 | 5% |
| J01MA06 161 |  | norfloksacin | 0,8 g | 0,4070 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Trizolin URO | tbl. film obl. 20x400 mg | 0,2037 | 4,07 | RRJ14 | 5% |
| J01MA12 021 | DS | levofloksacinNJ105 | 0,5 g | 17,5900 | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Levofloksacin Sandoz | otop. za inf., vreć. 1x100 ml (5 mg/ml) | 17,5898 | 17,59 |  | 5% |
| J01MA12 031 | DS | levofloksacinNJ105 | 0,5 g | 12,3100 | P | KRKA-FARMA d.o.o. | Pharmathen S.A., Krka d.d., Anfarm Hellas S.A. | Levalox | otop. za inf., boč. 1x100 ml (5 mg/ml) | 12,3127 | 12,31 |  | 5% |
| J01MA12 032 | DS | levofloksacinNJ105 | 0,5 g | 12,3120 | P | KRKA-FARMA d.o.o. | Pharmathen S.A., Krka d.d., Anfarm Hellas S.A. | Levalox | otop. za inf., boč. 5x100 ml (5 mg/ml) | 12,3127 | 61,56 |  | 5% |
| J01MA12 132 |  | levofloksacin | 0,5 g | 0,6980 | O | KRKA-FARMA d.o.o. | Pharmathen S.A., Krka d.d. | Levalox | tbl. film obl. 10x500 mg | 0,6981 | 6,98 | RSRJ15 | 5% |
| J01MA12 133 |  | levofloksacin | 0,5 g | 0,6980 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Fovelid | tbl. film obl. 10x500 mg | 0,6981 | 6,98 | RSRJ15 | 5% |
| J01MA14 031 | DS | moksifloksacinNJ105 | 400 mg | 14,5200 | P | KRKA-FARMA d.o.o. | Krka dd, TAD Pharma GmbH | Moloxin | otop. za inf., boca 1x400 mg/250 ml | 14,5199 | 14,52 |  | 5% |
| J01MA14 044 | DS | moksifloksacinNJ105 | 400 mg | 16,1300 | P | PharmaS d.o.o. | Pharmathen S.A. | Moksifloksacin PharmaS | otop. za inf., boč. 1x400 mg/250 ml | 16,1338 | 16,13 |  | 5% |
| J01MA14 061 | DS | moksifloksacinNJ105 | 400 mg | 16,1340 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Moxifloxacin Kabi | otop. za inf., boč. (KabiPac) 10x400 mg/250 ml | 16,1338 | 161,34 |  | 5% |
| J01MA14 072 | DS | moksifloksacinNJ105 | 400 mg | 13,7900 | P | Zentiva k.s. | Pharmathen S.A. | Moksifloksacin Zentiva | otop. za inf., boč. 1x400 mg/250 ml | 13,7939 | 13,79 |  | 5% |
| J01MA14 131 |  | moksifloksacin | 0,4 g | 0,6980 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH, KRKA-FARMA d.o.o. | Moloxin | tbl. film obl. 5x400 mg | 0,6981 | 3,49 | RSRJ16 | 5% |
| J01MA14 132 |  | moksifloksacin | 0,4 g | 0,6986 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH, KRKA-FARMA d.o.o. | Moloxin | tbl. film obl. 7x400 mg | 0,6981 | 4,89 | RSRJ16 | 5% |
| J01XA01 021 | DS | vankomicinNJ101 | 2 g | 23,6400 | P | Sandoz d.o.o. | Sandoz-Lek | Edicin | boč. 1x500 mg | 5,9128 | 5,91 |  | 5% |
| J01XA01 022 | DS | vankomicinNJ101 | 2 g | 21,9600 | P | Sandoz d.o.o. | Sandoz-Lek | Edicin | boč. 1x1.000 mg | 10,9788 | 10,98 |  | 5% |
| J01XA01 071 | DS | vankomicinNJ101 | 2 g | 13,4000 | P | Fresenius Kabi d.o.o. | Xellia Pharmaceuticals ApS | Vancomycin Kabi | praš. za konc. za otop. za inf., boč. stakl. 1x500 mg | 3,3526 | 3,35 |  | 5% |
| J01XA01 072 | DS | vankomicinNJ101 | 2 g | 12,4400 | P | Fresenius Kabi d.o.o. | Xellia Pharmaceuticals ApS | Vancomycin Kabi | praš. za konc. za otop. za inf., boč. stakl. 1x1000 mg | 6,2247 | 6,22 |  | 5% |
| J01XA01 081 | DS | vankomicinNJ101 | 2 g | 12,7440 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-Pharm. Fabrik GmbH | Vankomicin MIP 500 mg | praš. za otop. za inf., boč. 5x500 mg | 3,1851 | 15,93 |  | 5% |
| J01XA01 082 | DS | vankomicinNJ101 | 2 g | 11,8280 | P | MIP Pharma Croatia d.o.o. | Chephasaar Chem.-Pharm. Fabrik GmbH | Vankomicin MIP 1000 mg | praš. za otop. za inf., boč. 5x1000 mg | 5,9136 | 29,57 |  | 5% |
| J01XA01 083 | DS | vankomicinNJ101 | 2 g | 12,1040 | P | Apta Medica International d.o.o. | Laboratorio Reig Jofre S.A. | Vankomicin AptaPharma | praš. za otop. za inf., boč. 10x500 mg | 3,0261 | 30,26 |  | 5% |
| J01XA01 084 | DS | vankomicinNJ101 | 2 g | 11,2360 | P | Apta Medica International d.o.o. | Laboratorio Reig Jofre S.A. | Vankomicin AptaPharma | praš. za otop. za inf., boč. 10x1000 mg | 5,6184 | 56,18 |  | 5% |
| J01XA01 151 | DS | vankomicinNJ101 | 2 g |  | O |  |  |  |  |  |  |  | 5% |
| J01XA02 061 | DS | teikoplaninNJ101 | 0,4g | 34,4400 | P | sanofi-aventis groupe | Gruppo Lepetit | Targocid | boč. 1x200 mg + otap. | 17,2155 | 17,22 |  | 5% |
| J01XA02 062 | DS | teikoplaninNJ101 | 0,4g | 33,7800 | P | sanofi-aventis groupe | Gruppo Lepetit | Targocid | boč. 1x400 mg + otap. | 33,7780 | 33,78 |  | 5% |
| J01XB01 001 | DS | kolistimetat-natrijNJ104 | 3 MU | 31,1511 | I | Teva B.V. | Penn Pharmaceutical Services Ltd, Forest-Tosara Ltd | Colobreathe | praš. za inh., caps. tvrda 56x125 mg (1,662,500 IU) + inhalator Turbospin | 17,2629 | 966,72 |  | 5% |
| J01XB01 071 | DS | kolistinNJ101 | 9 MU | 52,9775 | P | Altamedics d.o.o. | Xellia Pharmaceuticals ApS | Colixin | praš. za otop. za inj./inf., boč. stakl. 30x1.000.000 IU (80 mg) | 5,8863 | 176,59 |  | 5% |
| J01XB01 072 | DS | kolistinNJ101 | 9 MU | 52,9745 | P | Zentiva k.s. | Xellia Pharmaceuticals ApS | Kolistin Zentiva | praš. za otop. za inj., inf. ili inh., boč. 10x1.000.000 IU (80 mg) | 5,8863 | 58,86 |  | 5% |
| J01XB01 073 | DS | kolistinNJ101 | 9 MU | 52,9790 | P | Zentiva k.s. | Xellia Pharmaceuticals ApS | Kolistin Zentiva | praš. za otop. za inj., inf. ili inh., boč. 10x2.000.000 IU (160 mg) | 11,7725 | 117,73 |  | 5% |
| J01XB01 074 | DS | kolistinNJ101 | 9 MU | 50,3277 | P | Altamedics d.o.o. | Xellia Pharmaceuticals ApS | Colixin | praš. za otop. za inj./inf., boč. stakl. 30x2.000.000 IU (160 mg) | 11,1839 | 335,52 |  | 5% |
| J01XD01 031 | DS | metronidazol | 1,5 g |  | P | KRKA-FARMA d.o.o. | Krka d.d. | Efloran | boč. inf. 0,5% 100 ml | 2,1833 | 2,18 |  | 5% |
| J01XD01 065 | DS | metronidazol | 1.5 g | 4,8495 | P | B. Braun Adria d.o.o. | Braun Melsungen AG, Braun Medical S.A. | Metronidazol B. Braun 5 mg/ml | otop. za inf., 5 mg/ml, polietil. Ecoflac plus boca, 20x100 ml | 1,6166 | 32,33 |  | 5% |
| J01XD01 071 | DS | metronidazol | 1.5 g | 5,3071 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Metronidazol Fresenius | otop. za inf., boč. plast. (KabiPac) 10x100 ml (5 mg/ml) | 1,7691 | 17,69 |  | 5% |
| J01XE01 111 |  | nitrofurantoin | 0,2 g | 0,6533 | O | Belupo d.d. | Belupo | Ninur | caps. 30x50 mg | 0,1632 | 4,90 | R | 5% |
| J01XE01 171 |  | nitrofurantoin | 0,2 g | 0,4573 | O | Mylan Ireland Limited | IASIS Pharmaceticals Hellas S.A. | Prevuro | caps. 30x50 mg | 0,1143 | 3,43 | R | 5% |
| J01XX01 051 | DS | fosfomicinNJ101 | 8 g |  | P |  |  |  |  |  |  |  | 5% |
| J01XX08 041 | DS | linezolidNJ106 | 1,2 g | 40,0800 | P | KRKA-FARMA d.o.o. | Krka d.d. | Linezolid Krka | otop. za inf., vreć. 1x600 mg/300 ml | 20,0438 | 20,04 |  | 5% |
| J01XX08 060 | DS | linezolidNJ106 | 1,2 g | 49,4920 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Linezolid Kabi | otop. za inf., vreć. 10x600 mg/300 ml | 24,7456 | 247,46 |  | 5% |
| J01XX08 061 | DS | linezolidNJ106 | 1,2 g | 49,4920 | P | Pfizer Croatia d.o.o. | Fresenius Kabi | Zyvoxid | otop. za inf., vreć. plast. 10x600 mg/300 ml | 24,7456 | 247,46 |  | 5% |
| J01XX08 062 | DS | linezolidNJ106 | 1,2 g | 49,5000 | P | Sandoz d.o.o. | Synthon Hispania S.L., Synthon BV | Linezolid Sandoz | otop. za inf., vreć. 1x600 mg/300 ml | 24,7462 | 24,75 |  | 5% |
| J01XX08 063 | DS | linezolidNJ106 | 1,2 g | 49,4920 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Linezolid Kabi | otop. za inf., boč. 10x600 mg/300 ml | 24,7456 | 247,46 |  | 5% |
| J01XX08 091 | DS | linezolidNJ106 | 1,2 g | 36,0800 | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Demo S.A. Pharmaceutical Industry | Linezolid Accord | otop. za inf., vreć. plast. 10x600 mg/300 ml | 18,0397 | 180,40 |  | 5% |
| J01XX08 101 | DS | linezolidNJ106 | 1,2 g | 60,8440 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Linezolid Pliva | tbl. film obl. 10x600 mg | 30,4219 | 304,22 |  | 5% |
| J01XX08 121 | DS | linezolidNJ106 | 1,2 g | 65,3100 | O | Sandoz d.o.o. | Sandoz | Lynz | tbl. film obl. 10x600 mg | 32,6547 | 326,55 |  | 5% |
| J01XX08 131 | DS | linezolidNJ106 | 1,2 g | 54,7580 | O | KRKA-FARMA d.o.o. | Krka dd, TAD Pharma GmbH | Linezolid Krka | tbl. film obl. 10x600 mg | 27,3793 | 273,79 |  | 5% |
| J01XX08 161 | DS | linezolidNJ106 | 1,2 g | 65,3100 | O | Pfizer Croatia d.o.o. | Pharmacia & Upjohn | Zyvoxid | tbl. film obl. 10x600 mg | 32,6547 | 326,55 |  | 5% |
| J02AA01 051 | DS | amfotericin B | 35 mg |  | P |  |  |  |  |  |  |  | 5% |
| J02AC01 066 | DS | flukonazol | 0,2 g | 8,0930 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Flukonazol Kabi | otop. za inf., boč. 10x100 ml (2 mg/ml) | 8,0933 | 80,93 |  | 5% |
| J02AC01 113 |  | flukonazol | 0,2 g | 1,3143 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Fluconax | caps. 7x100 mg | 0,6570 | 4,60 | R | 5% |
| J02AC01 114 |  | flukonazol | 0,2 g | 3,0400 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Fluconax | caps. 1x150 mg | 2,2762 | 2,28 | R | 5% |
| J02AC01 161 |  | flukonazol | 0,2 g | 1,3314 | O | Pfizer Croatia d.o.o. | Pfizer | Diflucan | caps. 7x50 mg | 0,3328 | 2,33 | R | 5% |
| J02AC01 162 |  | flukonazol | 0,2 g | 1,3143 | O | Pfizer Croatia d.o.o. | Pfizer | Diflucan | caps. 7x100 mg | 0,6570 | 4,60 | R | 5% |
| J02AC01 163 |  | flukonazol | 0,2 g | 3,0400 | O | Pfizer Croatia d.o.o. | Pfizer | Diflucan | caps. 1x150 mg | 2,2762 | 2,28 | R | 5% |
| J02AC01 205 |  | flukonazol | 0,2 g | 4,7943 | O | Pfizer Croatia d.o.o. | Pfizer | Diflucan | sirup 1x35 ml (50 mg/5 ml) | 8,3881 | 8,39 | R | 5% |
| J02AC02 131 |  | itrakonazol | 0,2 g | 1,3950 | O | Belupo d.d. | Belupo | Itrac 3 | caps. 4x100 mg | 0,6971 | 2,79 | R | 5% |
| J02AC02 132 |  | itrakonazol | 0,2 g | 1,3143 | O | Belupo d.d. | Belupo | Itrac 3 | caps. 28x100 mg | 0,6570 | 18,40 | R | 5% |
| J02AC03 041 | DS | vorikonazolNJ201 | 0,4 g | 154,5000 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Vorikonazol Pliva | praš. za otop. za inf., boč. 1x200 mg | 77,2513 | 77,25 |  | 5% |
| J02AC03 042 | DS | vorikonazolNJ201 | 0,4 g | 154,5000 | P | PharmaS d.o.o. | Anfarm Hellas S.A., Pharmathen S.A. | Vorikonazol PharmaS | praš. za otop. za inf., boč. 1x200 mg | 77,2513 | 77,25 |  | 5% |
| J02AC03 061 | DS | vorikonazolNJ201 | 0,4 g | 154,5000 | P | Pfizer Europe MA EEIG | Pfizer | Vfend | praš. za otop. za inf. boč. 1x200 mg/20 ml (10 mg/1ml) | 77,2513 | 77,25 |  | 5% |
| J02AC03 071 | DS | vorikonazolNJ201 | 0,4 g | 139,0600 | P | Zentiva k.s. | Anfarm Hellas S.A., Pharmathen S.A., Pharmathen International S.A. | Voramol | praš. za otop. za inf., boč. 1x200 mg/20 ml (10 mg/ml) | 69,5268 | 69,53 |  | 5% |
| J02AC03 081 | DS | vorikonazolNJ201 | 0,4 g | 125,1400 | P | Fresenius Kabi d.o.o. | Fresenius Kabi Deutschland GmbH | Vorikonazol Fresenius Kabi | praš. za otop. za inf., boč. 1x200 mg | 62,5748 | 62,57 |  | 5% |
| J02AC03 101 | DS | vorikonazolNJ201 | 0,4 g | 38,9914 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Vorikonazol Pliva | tbl. film obl. 28x200 mg | 19,4957 | 545,88 |  | 5% |
| J02AC03 131 | DS | vorikonazolNJ201 | 0,4 g | 35,0921 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Vorikonazol Accord | tbl. film obl. 28x200 mg | 17,5461 | 491,29 |  | 5% |
| J02AC03 142 | DS | vorikonazolNJ201 | 0,4 g | 31,5829 | O | Medochemie Ltd. | Medochemie Ltd. | Verria | tbl. film obl. 28x200 mg | 15,7915 | 442,16 |  | 5% |
| J02AC03 161 | DS | vorikonazolNJ201 | 0,4 g | 35,6229 | O | Pfizer Europe MA EEIG | Pfizer | Vfend | tbl. film obl. 28x50 mg | 4,4529 | 124,68 |  | 5% |
| J02AC03 162 | DS | vorikonazolNJ201 | 0,4 g | 38,9914 | O | Pfizer Europe MA EEIG | Pfizer | Vfend | tbl. film obl. 28x200 mg | 19,4957 | 545,88 |  | 5% |
| J02AC03 171 | DS | vorikonazolNJ201 | 0,4 g | 38,9913 | O | Zentiva k.s. | Pharmathen S.A., Pharmathen International S.A. | Voramol | tbl. film obl. 30x200 mg | 19,4957 | 584,87 |  | 5% |
| J02AC03 361 | DS | vorikonazolNJ201 | 0,4 g | 68,7714 | O | Pfizer Europe MA EEIG | Pfizer | Vfend | praš. za oral. susp. 1x70 ml (40 mg/ml) | 481,4016 | 481,40 |  | 5% |
| J02AC04 101 | KS | posakonazolNJ202 | 0,3 g | 54,1863 | O | Teva B.V. | Delorbis Pharmaceuticals Ltd | Posakonazol Teva | tbl. žel. otp. 24x100 mg | 18,0619 | 433,49 |  | 5% |
| J02AC04 141 | KS | posakonazolNJ202 | 0,3 g | 54,1863 | O | Mylan Pharmaceuticals Limited | Medis International A.S., Delorbis Pharmaceuticals Ltd | Posakonazol Mylan | tbl. žel. otp. 24x100 mg | 18,0619 | 433,49 |  | 5% |
| J02AC04 171 | KS | posakonazolNJ202 | 0,3 g | 59,8513 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Delorbis Pharmaceutical Ltd. | Posakonazol Accord | tbl. žel. otp. 24x100 mg | 19,9505 | 478,81 |  | 5% |
| J02AC04 172 | KS | posakonazolNJ202 | 0,3 g | 51,4766 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Delorbis Pharmaceuticals Ltd. | Posakonazol Accord | tbl. žel. otp. 96x100 mg | 17,1588 | 1.647,25 |  | 5% |
| J02AC04 181 | KS | posakonazolNJ202 | 0,3 g | 57,0375 | O | Abdi Farma Unipessoal Ltd. | Interpharma Services Ltd. | Posakonazol Abdi | tbl. žel. otp. 24x100 mg | 19,0125 | 456,30 |  | 5% |
| J02AC04 191 | KS | posakonazolNJ202 | 0,3 g | 57,0375 | O | Zentiva k.s. | Delorbis Pharmaceuticals Ltd | Posakonazol Zentiva | tbl. žel. otp. 24x100 mg | 19,0125 | 456,30 |  | 5% |
| J02AC04 192 | KS | posakonazolNJ202 | 0,3 g | 51,4763 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Posakonazol STADA | tbl. žel. otp. 24x100 mg | 17,1588 | 411,81 |  | 5% |
| J02AC04 361 | KS | posakonazolNJ202 | 0,3 g | 32,0029 | O | Merck Sharp & Dohme B.V. | Schering – Plough | Noxafil | susp. oral., boč. stakl. 1x105 ml (40 mg/ml) | 448,0390 | 448,04 |  | 5% |
| J02AC05 071 | DS | izavukonazolNJ719 | 0,2 g | 357,3200 | P | Basilea Pharmaceutica Deutschland GmbH | Almac Pharma Services (Ireland) Limited | Cresemba | praš. za otop. za inf., boč. 1x200 mg | 357,3163 | 357,32 |  | 5% |
| J02AC05 171 | DS | izavukonazolNJ719 | 0,2 g | 87,3100 | O | Basilea Pharmaceutica Deutschland GmbH | Almac Pharma Services (Ireland) Limited | Cresemba | caps. tvrda 14x100 mg | 43,6552 | 611,17 |  | 5% |
| J02AX04 011 | DS | kaspofunginNJ201 | 50 mg | 241,8200 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kaspofungin Pliva | praš. za konc. za otop. za inf., boč. stakl. 1x50 mg | 241,8223 | 241,82 |  | 5% |
| J02AX04 012 | DS | kaspofunginNJ201 | 50 mg | 257,7929 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kaspofungin Pliva | praš. za konc. za otop. za inf., boč. stakl. 1x70 mg | 360,9078 | 360,91 |  | 5% |
| J02AX04 041 | DS | kaspofunginNJ201 | 50 mg | 241,8200 | P | PharmaS d.o.o. | Pharmadox Healthcare Ltd., Galenicum Health S.L. | Kaspofungin PharmaS | praš. za konc. za otop. za inf., boč. 1x50 mg | 241,8223 | 241,82 |  | 5% |
| J02AX04 042 | DS | kaspofunginNJ201 | 50 mg | 195,8700 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Xellia Pharmaceuticals ApS | Caspofungin Accord | praš. za konc. za otop. za inf., boč. 1x50 mg | 195,8750 | 195,87 |  | 5% |
| J02AX04 071 | DS | kaspofunginNJ201 | 50 mg | 217,6400 | P | Zentiva k.s. | Pharmaten S.A., Pharmadox Healthcare Ltd | Dalvocans | praš. za konc. za otop. za inf., boč. stakl. 1x50 mg | 217,6402 | 217,64 |  | 5% |
| J02AX04 072 | DS | kaspofunginNJ201 | 50 mg | 257,7929 | P | Zentiva k.s. | Pharmaten S.A., Pharmadox Healthcare Ltd | Dalvocans | praš. za konc. za otop. za inf., boč. stakl. 1x70 mg | 360,9078 | 360,91 |  | 5% |
| J02AX04 082 | DS | kaspofunginNJ201 | 50 mg | 257,7929 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Xellia Pharmaceuticals ApS | Caspofungin Accord | praš. za konc. za otop. za inf., boč. 1x70 mg | 360,9078 | 360,91 |  | 5% |
| J02AX05 001 | DS | mikafunginNJ201 | 0,1 g | 293,5200 | P | Teva B.V. | S.C. Sindan-Pharma S.R.L. | Mikafungin Teva | praš. za otop. za inf., boč. stakl. 1x50 mg | 146,7569 | 146,76 |  | 5% |
| J02AX05 002 | DS | mikafunginNJ201 | 0,1 g | 265,0200 | P | Teva B.V. | S.C. Sindan-Pharma S.R.L. | Mikafungin Teva | praš. za otop. za inf., boč. stakl. 1x100 mg | 265,0169 | 265,02 |  | 5% |
| J02AX05 021 | DS | mikafunginNJ201 | 0,1 g | 293,5200 | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Mikafungin Sandoz | praš. za otop. za inf., boč. stakl. 1x50 mg | 146,7569 | 146,76 |  | 5% |
| J02AX05 022 | DS | mikafunginNJ201 | 0,1 g | 251,7700 | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Mikafungin Sandoz | praš. za otop. za inf., boč. stakl. 1x100 mg | 251,7659 | 251,77 |  | 5% |
| J02AX05 061 | DS | mikafunginNJ201 | 0,1 g | 293,5200 | P | Astellas Pharma Europe B.V. | Astellas Ireland Co. Ltd | Mycamine | praš. za otop. za inf., boč. stakl. 1x50 mg | 146,7569 | 146,76 |  | 5% |
| J02AX05 062 | DS | mikafunginNJ201 | 0,1 g | 325,6400 | P | Astellas Pharma Europe B.V. | Astellas Ireland Co. Ltd | Mycamine | praš. za otop. za inf., boč. stakl. 1x100 mg | 325,6394 | 325,64 |  | 5% |
| J02AX06 001 | DS | anidulafunginNJ201 | 0,1 g | 265,0800 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Anidulafungin Pliva | praš. i otap. za konc. za otop. za inf., boč. 1×100 mg | 265,0846 | 265,08 |  | 5% |
| J02AX06 041 | DS | anidulafunginNJ201 | 0,1 g | 251,8300 | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Anidulafungin Accord | praš. za konc. za otop. za inf., stakl. boč. 1×100 mg | 251,8309 | 251,83 |  | 5% |
| J02AX06 061 | DS | anidulafunginNJ201 | 0,1 g | 9,9017 | P | Pfizer Europe MA EEIG | Pfizer | Ecalta | praš. i otap. za konc. za otop. za inf., boč. 1×100 mg/30 ml | 297,0469 | 297,05 |  | 5% |
| J02AX06 071 | DS | anidulafunginNJ201 | 0,1 g | 239,2400 | P | Fresenius Kabi d.o.o. | Laboratori Fundacio Dau | Anidulafungin Fresenius Kabi | praš. za konc. za otop. za inf., stakl. boč. 1×100 mg | 239,2395 | 239,24 |  | 5% |
| J04AB02 051 | DS | rifampicin | 0,6 g |  | P |  |  |  |  |  |  |  | 5% |
| J04AB02 101 |  | rifampicin | 0,6 g | 0,8438 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Rimactan | caps. 16x300 mg | 0,4221 | 6,75 | R | 5% |
| J04AB02 102 |  | rifampicin | 0,6 g | 0,7830 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Rimactan | caps. 100x300 mg | 0,3915 | 39,15 | R | 5% |
| J04AB04 151 | DS | rifabutinNJ401 | 0,15 g |  | O |  |  |  |  |  |  |  | 5% |
| J04AC51 052 | DS | izoniazid + piridoksin |  |  | P |  |  |  |  |  |  |  | 5% |
| J04AC51 151 |  | izoniazid + piridoksin |  |  | O |  |  |  |  |  |  | R | 5% |
| J04AD01 151 | DS | protionamidNJ401 | 0,75 g |  | O |  |  |  |  |  |  |  | 5% |
| J04AK01 131 |  | pirazinamid | 1,5 g | 0,7338 | O | KRKA-FARMA d.o.o. | Krka d.d. | Pyrazinamid | tbl. 100x500 mg | 0,2446 | 24,46 | R | 5% |
| J04AK02 051 | DS | etambutol | 1,2 g |  | P |  |  |  |  |  |  |  | 5% |
| J04AK02 151 |  | etambutol | 1,2 g |  | O |  |  |  |  |  |  | R | 5% |
| J05AB01 032 | DS | aciklovir | 4 g | 113,9200 | P | KRKA-FARMA d.o.o. | Krka d.d. | Virolex | boč. inf. 5x250 mg | 7,1200 | 35,60 |  | 5% |
| J05AB01 071 | DS | aciklovir | 4 g | 81,9520 | P | ALPHA-MEDICAL d.o.o. | Laboratorio Reig Jofre S.A., Alpha-Medical d.o.o. | Aciklovir Alpha-Medical | boč. inf. 5x250 mg | 5,1218 | 25,61 |  | 5% |
| J05AB01 113 |  | aciklovir | 4 g | 5,0029 | O | Belupo d.d. | Belupo | Herplexim | tbl. film obl. 35x400 mg | 0,5004 | 17,51 | R | 5% |
| J05AB01 131 |  | aciklovir | 4 g | 7,2500 | O | KRKA-FARMA d.o.o. | Krka d.d. | Virolex | tbl. film obl. 20x200 mg | 0,3623 | 7,25 | R | 5% |
| J05AB06 071 | KS | ganciklovir | 0,5 g | 29,9900 | P | Cheplapharm Arzneimittel GmbH | Cheplapharm Arzneimittel GmbH, Prestige Promotion Verkaufsförderung & Werbeservice GmbH | Cymevene | boč. 1x500 mg/10 ml | 29,9874 | 29,99 |  | 5% |
| J05AB14 101 |  | valganciklovir | 0,9 g | 22,0640 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Valganciklovir Pliva | tbl. film obl. 60x450 mg | 11,0319 | 661,92 | RRJ51 | 5% |
| J05AB14 181 |  | valganciklovir | 0,9 g | 22,0640 | O | Zentiva k.s. | Pharmadox Healthcare Ltd., SC Labormed – Pharma SA | Alvanocyt | tbl. film obl. 60x450 mg | 11,0319 | 661,92 | RRJ51 | 5% |
| J05AB14 182 |  | valganciklovir | 0,9 g | 20,0283 | O | STADA d.o.o. | Stada Arzneimittel AG, Pharmadox Healthcare Ltd, Centrafarm Services BV | Valganciklovir Stada | tbl. film obl. 60x450 mg | 10,0141 | 600,85 | RRJ51 | 5% |
| J05AE03 151 | KL | ritonavirNJ501 | 1,2 g |  | O |  |  |  |  |  |  |  | 5% |
| J05AE10 121 | KL | darunavirNJ501 | 1,2 g | 11,7070 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d., Salutas Pharma GmbH | Darunavir Sandoz | tbl. film obl. 30x800 mg | 7,8045 | 234,14 |  | 5% |
| J05AE10 131 | KL | darunavirNJ501 | 1,2 g | 10,8260 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma Gmbh | Darunavir Krka | tbl. film obl. 30x800 mg | 7,2172 | 216,52 |  | 5% |
| J05AE10 141 | KL | darunavirNJ501 | 1,2 g | 10,2845 | O | Accord Healthcare Polska Sp. z o.o. | Pharmathen International S.A. | Darunavir Accord | tbl. film obl. 30x800 mg | 6,8563 | 205,69 |  | 5% |
| J05AF01 252 | KL | zidovudinNJ501 | 0,6 g |  | O |  |  |  |  |  |  |  | 5% |
| J05AF05 101 | KL | lamivudinNJ501 | 0,3 g | 2,2933 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, TEVA UK Ltd | Lamivudin Teva Pharma B.V. | tbl. film obl. 30x300 mg | 2,2935 | 68,80 |  | 5% |
| J05AF05 161 | KL | lamivudinNJ501 | 0,3 g | 2,2473 | O | ViiV Healthcare B.V. | Glaxo Operations UK Ltd., GlaxoSmithKline Pharmaceuticals S.A. | Epivir | tbl. film obl. 60x150 mg | 1,1237 | 67,42 |  | 5% |
| J05AF05 163 | DS | lamivudinNJ503 | 0,3 g | 4,4818 | O | GlaxoSmithKline (Ireland) Limited | GlaxoWellcome Operations UK Limited, GlaxoSmithKline Pharmaceuticals S.A. | Zeffix | tbl. film obl. 28x100 mg | 1,4940 | 41,83 |  | 5% |
| J05AF05 165 | DS | lamivudinNJ503 | 0,3 g | 3,3118 | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Lamivudin Alpha-Medical | tbl. film obl. 28x100 mg | 1,1040 | 30,91 |  | 5% |
| J05AF05 262 | KL | lamivudinNJ501 | 0,3 g | 3,0088 | O | ViiV Healthcare B.V. | Aspen Bad Oldesloe GmbH, Glaxo Operations UK Ltd | Epivir | otop. za oral. primj. 240 ml (10 mg/1 ml) | 24,0666 | 24,07 |  | 5% |
| J05AF06 161 | KL | abakavirNJ501 | 0,6 g | 6,3743 | O | ViiV Healthcare B.V. | Glaxo Operations UK Ltd., GlaxoSmithKline Pharmaceuticals S.A. | Ziagen | tbl. film obl. 60x300 mg | 3,1871 | 191,23 |  | 5% |
| J05AF07 101 | DS | tenofovirNJ504 | 0,245 g | 4,9013 | O | PLIVA HRVATSKA d.o.o. | Teva Pharmaceutical Works, Teva UK Ltd., Pharmachemie B.V., Teva Operations, Merckle GmbH, Teva Pharma B.V. | Tenofovirdizoproksil Pliva | tbl. film obl. 30x245 mg | 4,9015 | 147,04 |  | 5% |
| J05AF07 161 | DS | tenofovirNJ504 | 0,245 g | 4,9013 | O | Gilead Sciences Ireland UC | Nycomed, Gilead | Viread | tbl. film obl. 30x245 mg | 4,9015 | 147,04 |  | 5% |
| J05AF07 171 | DS | tenofovirNJ504 | 0,245 g | 4,9013 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Tenofovirdizoproksil Alpha-Medical | tbl. film obl. 30x245 mg | 4,9015 | 147,04 |  | 5% |
| J05AF07 181 | DS | tenofovirNJ504 | 0,245 g | 4,9013 | O | Mylan Pharmaceuticals Limited | McDermott Laboratories Limited, Mylan Hungary Kft | Tenofovirdizoproksil Mylan | tbl. film obl. 30x245 mg | 4,9015 | 147,04 |  | 5% |
| J05AF10 171 | DS | entekavirNJ510 | 0,5 mg | 5,4367 | O | Mylan Pharmaceuticals Limited | Mylan Hungary Kft., McDermott Laboratories Limited trading as Gerard Laboratories | Entekavir Mylan | tbl. film obl. 30x0,5 mg | 5,4368 | 163,10 |  | 5% |
| J05AF10 172 | DS | entekavirNJ510 | 0,5 mg | 2,7183 | O | Mylan Pharmaceuticals Limited | Mylan Hungary Kft., McDermott Laboratories Limited trading as Gerard Laboratories | Entekavir Mylan | tbl. film obl. 30x1 mg | 5,4368 | 163,10 |  | 5% |
| J05AF10 181 | DS | entekavirNJ510 | 0,5 mg | 3,8050 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Entekavir Accord | tbl. film obl. 30x0,5 mg | 3,8052 | 114,15 |  | 5% |
| J05AF10 182 | DS | entekavirNJ510 | 0,5 mg | 1,9025 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Entekavir Accord | tbl. film obl. 30x1 mg | 3,8052 | 114,15 |  | 5% |
| J05AF13 161 | DS | tenofovir alafenamidNJ511 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Vemlidy | tbl. film obl. 30x25 mg | #N/A | #N/A |  | 5% |
| J05AG01 171 | KL | nevirapinNJ501 | 0,4 g | 2,5083 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Viramune | tbl. 60x200 mg | 1,2542 | 75,25 |  | 5% |
| J05AG03 101 | KL | efavirenzNJ501 | 0,6 g | 4,0817 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Efavirenz Teva | tbl. film obl. 30x600 mg | 4,0817 | 122,45 |  | 5% |
| J05AG03 171 | KL | efavirenzNJ501 | 0,6 g | 4,0817 | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Ltd. | Efavirenz Alpha-Medical | tbl. film obl. 30x600 mg | 4,0817 | 122,45 |  | 5% |
| J05AG24 161 | KL | doravirin + lamivudin + tenofovir dizoproksilNJ501 |  |  | O | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme B.V. | Delstrigo | tbl. film obl. 30 x (100 mg + 300 mg + 245 mg) | 19,3196 | 579,59 |  | 5% |
| J05AH01 771 | DS | zanamivirNJ506 | 20 mg | 3,0500 | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Limited | Relenza | praš. za inhal. 20x5 mg (5 rotadisk blist. po 4 doze + diskhaler) | 0,7627 | 15,25 |  | 5% |
| J05AH02 101 |  | oseltamivir | 0,15 g | 3,3600 | O | ACTAVIS GROUP PTC ehf. | Balkanpharma-Dupnitsa AD | Ebilfumin | tvrde caps. 10x30 mg | 0,6722 | 6,72 | R RJ52 | 5% |
| J05AH02 102 |  | oseltamivir | 0,15 g | 3,0800 | O | ACTAVIS GROUP PTC ehf. | Balkanpharma-Dupnitsa AD | Ebilfumin | tvrde caps. 10x45 mg | 0,9244 | 9,24 | R RJ52 | 5% |
| J05AH02 103 |  | oseltamivir | 0,15 g | 2,6860 | O | ACTAVIS GROUP PTC ehf. | Balkanpharma-Dupnitsa AD | Ebilfumin | tvrde caps. 10x75 mg | 1,3432 | 13,43 | R RJ52 | 5% |
| J05AH02 161 |  | oseltamivir | 0,15 g | 3,3960 | O | Roche Registration GmbH | Roche | Tamiflu | caps. 10x75 mg | 1,6979 | 16,98 | RRJ52 | 5% |
| J05AJ01 161 | KL | raltegravirNJ501 | 800 mg | 18,0413 | O | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | Isentress | tbl. film obl. 60x400 mg | 9,0207 | 541,24 |  | 5% |
| J05AJ01 162 | KL | raltegravirNJ501 | 800 mg | 12,0276 | O | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | Isentress | tbl. film obl. 60x600 mg | 9,0207 | 541,24 |  | 5% |
| J05AJ03 161 | KL | dolutegravirNJ501 | 50 mg | 19,1920 | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A., GlaxoSmithKline Pharmaceuticals S.A. | Tivicay | tbl. film obl. 30x50 mg | 19,1922 | 575,76 |  | 5% |
| J05AJ03 162 | KL | dolutegravirNJ501 | 50 mg | 18,6800 | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A., GlaxoSmithKline Pharmaceuticals S.A. | Tivicay | tbl. film obl. 30x10 mg | 3,7361 | 112,08 |  | 5% |
| J05AJ03 163 | KL | dolutegravirNJ501 | 50 mg | 18,5607 | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A., GlaxoSmithKline Pharmaceuticals S.A. | Tivicay | tbl. film obl. 30x25 mg | 9,2804 | 278,41 |  | 5% |
| J05AP51 161 | DS | ledipasvir + sofosbuvirNJ711 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ltd. | Harvoni | tbl. film obl. 28x(90 mg + 400 mg) | 529,8100 | 14.834,68 |  | 5% |
| J05AP51 162 | DS | ledipasvir + sofosbuvirNJ711 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ltd. | Harvoni | tbl. film obl. 28x(90 mg + 400 mg) | 529,8100 | 14.834,68 |  | 5% |
| J05AP54 161 | DS | elbasvir + grazoprevirNJ711 |  |  | O | Merck Sharp & Dohme B.V. | Schering-Plough Labo N.V. | Zepatier | tbl. film obl. 28x(50 mg + 100 mg) | 330,2944 | 9.248,24 |  | 5% |
| J05AP54 162 | DS | elbasvir + grazoprevirNJ711 |  |  | O | Merck Sharp & Dohme B.V. | Schering-Plough Labo N.V. | Zepatier | tbl. film obl. 28x(50 mg + 100 mg) | 330,2944 | 9.248,24 |  | 5% |
| J05AP55 161 | DS | sofosbuvir + velpatasvirNJ711 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Epclusa | tbl film obl. 28x(400 mg + 100 mg) | 395,1569 | 11.064,39 |  | 5% |
| J05AP55 162 | DS | sofosbuvir + velpatasvirNJ711 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Epclusa | tbl film obl. 28x(400 mg + 100 mg) | 395,1569 | 11.064,39 |  | 5% |
| J05AP56 161 | DS | sofosbuvir + velpatasvir + voksilaprevirNJ714 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Vosevi | tbl. film obl. 28x(400 mg + 100 mg + 100 mg) | 496,8138 | 13.910,79 |  | 5% |
| J05AP57 161 | DS | glekaprevir + pibrentasvirNJ711 |  |  | O | AbbVie Deutschland GmbH & Co. KG | Abbvie Deutschland GmBH & Co. KG | Maviret | tbl. film obl. 84x(100 mg + 40 mg) | 151,2876 | 12.708,16 |  | 5% |
| J05AP57 162 | DS | glekaprevir + pibrentasvirNJ711 |  |  | O | AbbVie Deutschland GmbH & Co. KG | Abbvie Deutschland GmBH & Co. KG | Maviret | tbl. film obl. 84x(100 mg + 40 mg) | 151,2876 | 12.708,16 |  | 5% |
| J05AR02 001 | KL | abakavir + lamivudinNJ501 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Merckle GmbH | Abakavir/lamivudin Pliva | tbl. film obl. 30x(600 mg + 300 mg) | 4,9952 | 149,86 |  | 5% |
| J05AR02 121 | KL | abakavir + lamivudinNJ501 |  |  | O | Sandoz d.o.o. | Lupin (Europe) Ltd | Abakavir/lamivudin Sandoz | tbl. film obl. 30x(600 mg + 300 mg) | 4,9952 | 149,86 |  | 5% |
| J05AR02 171 | KL | abakavir + lamivudinNJ501 |  |  | O | Remedica Ltd. | Remedica Ltd. | Abakavir/Lamivudin Remedica | tbl. film obl. 30x(600 mg + 300 mg) | 4,9952 | 149,86 |  | 5% |
| J05AR02 181 | KL | abakavir + lamivudinNJ501 |  |  | O | Mylan Pharmaceuticals Limited | Mylan S.A.S., Gerard Laboratories | Abakavir/Lamivudin Mylan | tbl. film obl. 30x(600 mg + 300 mg) | 4,9952 | 149,86 |  | 5% |
| J05AR03 101 | KL | emtricitabin + tenofovir NJ501 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Emtricitabin/tenofovirdizoproksil Pliva | tbl. film obl. 30x(200 mg + 245 mg) | 4,0534 | 121,60 |  | 5% |
| J05AR03 121 | KL | emtricitabin + tenofovir NJ501 |  |  | O | Krka d.d., Novo mesto | Krka d.d. | Emtricitabine/Tenofovir disoproxil Krka | tbl. film obl. 30x(200 mg + 245 mg) | 4,0534 | 121,60 |  | 5% |
| J05AR03 171 | KL | emtricitabin + tenofovir NJ501 |  |  | O | Remedica Ltd. | Remedica Ltd. | Emtricitabin/tenofovirdizoproksil Remedica | tbl. film obl. 30x(200 mg + 245 mg) | 4,0534 | 121,60 |  | 5% |
| J05AR03 181 | KL | emtricitabin + tenofovir NJ501 |  |  | O | Mylan Pharmaceuticals Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories t/a Mylan Dublin | Emtricitabin/tenofovirdizoproksil Mylan | tbl. film obl. 30x(200 mg + 245 mg) | 4,0534 | 121,60 |  | 5% |
| J05AR06 171 | KL | efavirenz + emtricitabin + tenofovir dizoproksilNJ501 |  |  | O | Mylan Pharmaceuticals Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories t/a Mylan Dublin | Efavirenz/emtricitabin/tenofovirdizoproksil Mylan | tbl. film obl. 30 x (600 mg + 200 mg + 245 mg) | 10,8676 | 326,03 |  | 5% |
| J05AR06 172 | KL | efavirenz + emtricitabin + tenofovir dizoproksilNJ501 |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Emtenef | tbl. film obl. 30 x (600 mg + 200 mg + 245 mg) | 7,6073 | 228,22 |  | 5% |
| J05AR10 141 | KL | lopinavir + ritonavirNJ501 |  |  | O | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lopinavir/Ritonavir Accord | tbl. film obl. 120x(200 mg + 50 mg) | 2,1498 | 257,98 |  | 5% |
| J05AR10 171 | KL | lopinavir + ritonavirNJ501 |  |  | O | Mylan Pharmaceuticals Limited | McDermott Laboratories Limited trading as Gerard Laboratories, Mylan Hungary Kft | Lopinavir/Ritonavir Mylan | tbl. film obl. 120x(200 mg + 50 mg) | 1,9349 | 232,18 |  | 5% |
| J05AR10 284 | KL | lopinavir + ritonavirNJ501 |  |  | O | AbbVie Deutschland GmbH & Co. KG | Aesica Queenborough Limited, AbbVie Logistics B.V. | Kaletra | otop. boč. plast. 5x60 ml + 5 štrc. 5 ml | 65,7243 | 328,62 |  | 5% |
| J05AR13 161 | KL | dolutegravir + abakavir + lamivudinNJ501 |  |  | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A., GlaxoSmithKline Pharmaceuticals S.A. | Triumeq | tbl. film obl. 30x(50 mg + 600 mg + 300 mg) | 24,7041 | 741,12 |  | 5% |
| J05AR14 161 | KL | darunavir + kobicistatNJ501 |  |  | O | Janssen-Cilag International N.V. | Janssen – Cilag SpA | Rezolsta | tbl. film obl. 30x(800 mg + 150 mg) | 15,2601 | 457,80 |  | 5% |
| J05AR17 161 | KL | emtricitabin + tenofovir alafenamidNJ713 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Descovy | tbl. film obl. 30x(200 mg + 10 mg) | 14,7013 | 441,04 |  | 5% |
| J05AR17 162 | KL | emtricitabin + tenofovir alafenamidNJ713 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Descovy | tbl. film obl. 30x(200 mg + 25 mg) | 14,7013 | 441,04 |  | 5% |
| J05AR19 161 | KL | emtricitabin + rilpivirin + tenofovir alafenamidNJ507 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Odefsey | tbl. film obl. 30x(200 mg + 25 mg + 25 mg) | 18,3905 | 551,72 |  | 5% |
| J05AR20 171 | KL | biktegravir + emtricitabin + tenofovir alafenamidNJ717 |  |  | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Biktarvy | tbl. film obl. 30x(50 mg + 200 mg + 25 mg) | 23,5822 | 707,47 |  | 5% |
| J05AR21 171 | KL | dolutegravir + rilpivirinNJ718 |  |  | O | ViiV Healthcare B.V. | Glaxo Wellcome S.A. | Juluca | tbl. film obl. 30x(50 mg + 25 mg) | 25,5589 | 766,77 |  | 5% |
| J05AR25 171 | KL | dolutegravir + lamivudinNJ501 |  |  | O | ViiV Healthcare B.V. | Glaxo Wellcome, S.A. | Dovato | tbl. film obl. 30x(50 mg + 300 mg) | 20,4114 | 612,34 |  | 5% |
| J05AX18 071 | KL | letermovirNJ720 | 480 mg | 334,6400 | P | Merck Sharp & Dohme B.V. | Schering-Plough Labo NV | Prevymis | konc. za otop. za inf., boč. 1x240 mg/12 ml | 167,3223 | 167,32 |  | 5% |
| J05AX18 171 | KL | letermovirNJ720 | 480 mg | 307,5764 | O | Merck Sharp & Dohme B.V. | Schering-Plough Labo NV | Prevymis | tbl. film obl. 28x240 mg | 153,7881 | 4.306,07 |  | 5% |
| J06AA03 013 | PO | imunoglobulin-antitoksin protiv otrova zmija (purificiran i koncentriran) |  |  | P | Imunološki zavod | Imunološki zavod | Antitoksin za otrov europskih zmija (konjski) | boč. 1x10 ml | 99,5421 | 99,54 |  | 5% |
| J06AA03 051 | PO | imunoglobulin-antitoksin protiv otrova zmija (purificiran i koncentriran) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06AA04 051 | DS | imunoglobulin-antitoksin botulinum |  |  | P |  |  |  |  |  |  |  | 5% |
| J06AA05 052 | DS | imunoglobulin-antitoksin protiv plinske gangrene |  |  | P |  |  |  |  |  |  |  | 5% |
| J06AA07 053 | PR | imunoglobulin-antitoksin protiv otrova pauka (crna udovica) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BA01 061 |  | imunoglobulin, ljudskiNJ708 |  |  | P | Jana Pharm d.o.o. | Octapharma AB | Gammanorm | otop. za inj., boč. 1x10 ml (165 mg/ml) | 96,5917 | 96,59 | RSRJ53 | 5% |
| J06BA01 063 |  | imunoglobulin, ljudskiNJ708 |  |  | P | Jana Pharm d.o.o. | Octapharma AB | Gammanorm | otop. za inj., boč. 1x12 ml (165 mg/ml) | 115,9068 | 115,91 | RSRJ53 | 5% |
| J06BA01 071 |  | imunoglobulin za subkutanu primjenu NJ715 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | HyQvia | otop. za inf. za potkožnu primjenu, boč. 1x25 ml (100 mg/ml) + 1,25 ml (rHuPH20) | 140,7114 | 140,71 | RSRJ54 | 5% |
| J06BA01 072 |  | imunoglobulin za subkutanu primjenu NJ715 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | HyQvia | otop. za inf. za potkožnu primjenu, boč. 1x50 ml (100 mg/ml) + 2,5 ml (rHuPH20) | 285,3779 | 285,38 | RSRJ54 | 5% |
| J06BA01 073 |  | imunoglobulin za subkutanu primjenu NJ715 |  |  | P | Baxalta Innovations GmbH | Baxalta Belgium Manufacturing SA | HyQvia | otop. za inf. za potkožnu primjenu, boč. 1x100 ml (100 mg/ml) + 5 ml (rHuPH20) | 561,2197 | 561,22 | RSRJ54 | 5% |
| J06BA01 081 |  | imunoglobulin, ljudskiNJ708 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Hizentra | otop. za inj., boč. 1x5 ml (200 mg/ml) | 53,4753 | 53,48 | RSRJ53 | 5% |
| J06BA01 082 |  | imunoglobulin, ljudskiNJ708 |  |  | P | CSL Behring GmbH | CSL Behring GmbH | Hizentra | otop. za inj., boč. 1x10 ml (200 mg/ml) | 106,9507 | 106,95 | RSRJ53 | 5% |
| J06BA02 016 | DS | imunoglobulin za intraven. primjenu 7 SNJ601 |  |  | P | Imunološki zavod | Imunološki zavod | IZ IVIG 50 mg/ml | boč. 1x2,5 g/50 ml | 84,1476 | 84,15 |  | 5% |
| J06BA02 017 | DS | imunoglobulin za intraven. primjenu 7 SNJ601 |  |  | P | Imunološki zavod | Imunološki zavod | IZ IVIG 50 mg/ml | boč. 1x5 g/100 ml | 159,2833 | 159,28 |  | 5% |
| J06BA02 018 | DS | imunoglobulin za intraven. primjenu7 SNJ601 |  |  | P | Imunološki zavod | Imunološki zavod | IZ IVIG 50 mg/ml | boč. 1x500 mg/10 ml | 13,6426 | 13,64 |  | 5% |
| J06BA02 051 | DS | imunoglobulin za intraven. primjenu 5 SNJ602 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BA02 060 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam (HR) | boč. 1x10 g/200 ml | 446,6255 | 446,63 |  | 5% |
| J06BA02 061 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam | boč. 1x2,5 g/50 ml | 120,4605 | 120,46 |  | 5% |
| J06BA02 062 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam (HR) | boč. 1x5 g/100 ml | 231,2164 | 231,22 |  | 5% |
| J06BA02 065 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Ig Vena | otop. za inf., boč. stakl. 1x20 ml (50 g/l) | 49,5653 | 49,57 |  | 5% |
| J06BA02 066 | DS | imunoglobulin za intraven. primjenu 7 S NJ716 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Ig Vena | otop. za inf., boč. stakl. 1x50 ml (50 g/l) | 146,3508 | 146,35 |  | 5% |
| J06BA02 067 | DS | imunoglobulin za intraven. primjenu 7 S NJ716 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Ig Vena | otop. za inf., boč. stakl. 1x100 ml (50 g/l) | 310,7970 | 310,80 |  | 5% |
| J06BA02 068 | DS | imunoglobulin za intraven. primjenu 7 S NJ716 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Ig Vena | otop. za inf., boč. stakl. 1x200 ml (50 g/l) | 573,9545 | 573,95 |  | 5% |
| J06BA02 076 | DS | imunoglobulin za intraven. primjenu 7 S NJ601 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Kiovig | otop. za inf., boč. 1x2,5 g/25 ml (100 mg/ml) | 122,4116 | 122,41 |  | 5% |
| J06BA02 077 | DS | imunoglobulin za intraven. primjenu 7 S NJ601 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Kiovig | otop. za inf., boč. 1x5 g/50 ml (100 mg/ml) | 252,4613 | 252,46 |  | 5% |
| J06BA02 078 | DS | imunoglobulin za intraven. primjenu 7 S NJ601 |  |  | P | Takeda Manufacturing Austria AG | Baxalta Belgium Manufacturing SA | Kiovig | otop. za inf., boč. 1x10 g/100 ml (100 mg/ml) | 480,0199 | 480,02 |  | 5% |
| J06BA02 091 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | CSL Behring GmbH | CSL Behring AG, CSL Behring GmbH | Privigen | otop. za inf., boč. stakl. 1x25 ml (100 mg/ml) | 146,3508 | 146,35 |  | 5% |
| J06BA02 092 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | CSL Behring GmbH | CSL Behring AG, CSL Behring GmbH | Privigen | otop. za inf., boč. stakl. 1x50 ml (100 mg/ml) | 284,5086 | 284,51 |  | 5% |
| J06BA02 093 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | CSL Behring GmbH | CSL Behring AG, CSL Behring GmbH | Privigen | otop. za inf., boč. stakl. 1x100 ml (100 mg/ml) | 559,3536 | 559,35 |  | 5% |
| J06BA02 094 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | CSL Behring GmbH | CSL Behring AG, CSL Behring GmbH | Privigen | otop. za inf., boč. stakl. 1x200 ml (100 mg/ml) | 1.107,8094 | 1.107,81 |  | 5% |
| J06BA02 960 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam (non HR) | boč. 1x10 g/200 ml | 621,5940 | 621,59 |  | 5% |
| J06BA02 962 | DS | imunoglobulin za intraven. primjenu 7 SNJ716 |  |  | P | Jana Pharm d.o.o. | Octapharma | Octagam (non HR) | boč. 1x5 g/100 ml | 310,7970 | 310,80 |  | 5% |
| J06BB01 081 | DS | imunoglobulin anti-D-(Rho) (ljudski)NJ603 |  |  | P | Jana Pharm d.o.o. | Octapharma | Rhesonativ | otop. za inj. amp. 1x2 ml (625 IU/125 mcg/ml) | 44,9293 | 44,93 |  | 5% |
| J06BB02 018 | PO | imunoglobulin antitetanus – TIG (ljudski) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Imunoglobulin protiv tetanusa, ljudski | otop. za inj. amp. 1x250 IU | 9,0198 | 9,02 |  | 5% |
| J06BB02 051 | PO | imunoglobulin antitetanus – TIG (ljudski)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB02 054 | DS | imunoglobulin antitetanus hiperimuni (5000i.j.) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB03 051 | DS | imunoglobulin Varicella/zosterNJ604 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB04 019 | DS | imunoglobulin anti-HBs (ljudski) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Imunoglobulin protiv hepatitisa B, ljudski | boč. stakl. 250 IU | 46,4530 | 46,45 |  | 5% |
| J06BB04 051 | DS | imunoglobulin anti-HBs (ljudski)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB04 061 | KL | imunoglobulin protiv hepatitisa B (ljudski)NJ606 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Venbig | praš. i otap. za otop. za inf., boč. stakl. 1x500 i.j. | 196,6952 | 196,70 |  | 5% |
| J06BB04 062 | KL | imunoglobulin protiv hepatitisa B (ljudski)NJ606 |  |  | P | Kedrion S.p.A. | Kedrion S.p.A. | Venbig | praš. i otap. za otop. za inf., boč. stakl. 1x2500 i.j. | 972,7971 | 972,80 |  | 5% |
| J06BB05 020 | PR | imunoglobulin protiv bjesnoće (ljudski) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | IZ HRIG 500 Imunoglobulin protiv bjesnoće, ljudski | otop. za inj., boč. stakl. 500 IU | 100,8481 | 100,85 |  | 5% |
| J06BB05 051 | PR | imunoglobulin protiv bjesnoće (ljudski)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB09 051 | KL | hiperimuni anti-citomegalo virus (ljudski) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BB12 051 | DS | imunoglobulin protiv krpeljnog meningoencefalitisa (ljudski) |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BD01 051 | DS | palivizumabNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J06BD01 084 | DS | palivizumabNJ707 |  |  | P | AstraZeneca AB | AbbVie S.r.l. | Synagis | otop. za inj., boč. stakl. 1x1 ml (100 mg/mL) | 805,4098 | 805,41 |  | 5% |
| J07AG01 051 | PR | cjepivo protiv Haemophilusa influenzae tipa BNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AG51 051 | PR | cjepivo protiv Haemophilus influenzae tipBNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AH04 051 |  | cjepivo protiv meningokokne bolesti, tetravalentno (A, C, W-135, Y)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AH08 051 |  | cjepivo protiv meningokokne bolesti, tetravalentno (A, C, W-135, Y)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AH09 051 |  | cjepivo protiv meningokoka grupe B (rDNK, komponentno, adsorbirano)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AJ51 051 | PR | cjepivo protiv difterije, tetanusa i pertusisa NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AJ52 051 | PR | cjepivo protiv difterije, tetanusa i pertusisa NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AL01 051 | PR | cjepivo protiv pneumokokne bolestiNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AL01 071 | PR | cjepivo protiv pneumokokne bolesti, polisaharidno, 23-valentnoNJ707 |  |  | P | Merck Sharp & Dohme d.o.o. | Merck Sharp & Dohme B.V. | Pneumovax 23 | štrc. napunj. 1x0,5 ml | 22,0798 | 22,08 |  | 5% |
| J07AL02 051 | PR | cjepivo protiv pneumokokne bolestiNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AL02 062 | PR | cjepivo protiv pneumokoka, polisaharidno, konjugirano, 13-valentno, adsorbiranoNJ707 |  |  | P | Pfizer Europe MA EEIG | John Wyeth & Brother Ltd. | Prevenar 13 | štrc. napunj. 1x1 doza (0,5 ml), susp. | 47,6196 | 47,62 |  | 5% |
| J07AL52 071 | PR | cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbiranoNJ707 |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Synflorix | štrc. napunj. 1x0,5 ml, susp. | 45,0687 | 45,07 |  | 5% |
| J07AL52 072 | PR | cjepivo protiv pneumokoka, polisaharidno, konjugirano, adsorbiranoNJ707 |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Synflorix | štrc. napunj. 10x0,5 ml, susp. | 45,0683 | 450,68 |  | 5% |
| J07AM01 013 | PO | tetanus anatoksin (ANA-TE) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv tetanusa, adsorbirano, Imunološki zavod | susp. za inj., boč. stakl. 1x10 doza | 2,9464 | 2,95 |  | 5% |
| J07AM01 014 | PO | tetanus anatoksin (ANA-TE) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv tetanusa, adsorbirano, Imunološki zavod | susp. za inj., amp 10x1 doza | 1,1524 | 11,52 |  | 5% |
| J07AM01 051 | PO | tetanus anatoksin NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AM51 015 | PR | cjepivo protiv difterije-tetanusa pro adultis (ANA-DI-TE pro adultis) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv difterije i tetanusa sa smanjenim sadržajem antigena, adsorbirano, Imunološki zavod | susp. za inj., amp. stakl. 10x1 doza | 1,0618 | 10,62 |  | 5% |
| J07AM51 016 | PR | cjepivo protiv difterije-tetanusa pro adultis (ANA-DI-TE pro adultis) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv difterije i tetanusa sa smanjenim sadržajem antigena, adsorbirano, Imunološki zavod | susp. za inj., boč. stakl. 1x10 doza | 7,2015 | 7,20 |  | 5% |
| J07AM51 051 | PR | cjepivo protiv difterije i tetanusa NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AN01 051 | PR | BCG-cjepivo protiv tuberkuloze-živo, atenuiranoNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07AP03 051 | PR | cjepivo protiv tifusa, polisaharidno |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BB01 051 | PR | cjepivo protiv gripeNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BB02 051 | PR | cjepivo protiv gripeNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BB03 051 | PR | cjepivo protiv gripeNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BC01 051 | DS | cjepivo protiv hepatitisa BNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BC01 074 | DS | cjepivo protiv hepatitisa B |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Engerix -B dosis adulta | 1x20 mcg/1 ml susp. za inj. u napunj. štrc. | 10,4678 | 10,47 |  | 5% |
| J07BC01 075 | DS | cjepivo protiv hepatitisa B |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Engerix -B dosis pediatrica | 1x10 mcg/0,5 ml susp. za inj. u napunj. štrc. | 6,3707 | 6,37 |  | 5% |
| J07BC02 051 |  | cjepivo protiv hepatitisa ANJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BD01 011 | PR | cjepivo protiv morbila (MO) |  |  | P | Imunološki zavod | Imunološki zavod | Cjepivo protiv morbila, živo, liofilizirano, Edmonston-Zagreb, HDS | praš. boč. + otap. za susp. za inj. boč. 0,5 ml | 3,0566 | 3,06 |  | 5% |
| J07BD01 051 | PR | cjepivo protiv ospicaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BD52 018 | PR | cjepivo protiv morbila-parotitisa-rubele (MO-PA-RU) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv morbila, rubele i parotitisa, živo, liofilizirano “Edmonston-Zgb” | lio boč. 1x1 doza | 8,9548 | 8,95 |  | 5% |
| J07BD52 051 | PR | cjepivo protiv ospica, mumpsa i rubeleNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BD52 061 | PR | cjepivo protiv morbila-parotitisa-rubele (MO-PA-RU) |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Priorix | cjepivo kombinirano, liof., boč. 1x1 doza + štrc. napunj. s 0,5 ml vode za injekcije + 2 igle sa zaštitom | 8,8022 | 8,80 |  | 5% |
| J07BD52 062 | PR | cjepivo protiv morbila-parotitisa-rubele, živo |  |  | P | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme | M-M-RVAXPRO | štrc. napunj. 1x0,5 ml + 1 boč. stakl. s praškom, + 2 priložene igle, susp. | 7,9182 | 7,92 |  | 5% |
| J07BE01 012 | PR | cjepivo protiv parotitisa (PA) |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Cjepivo protiv parotitisa živo, liofil. “L-Zgb” | lio boč. 1x1 doza | 4,9147 | 4,91 |  | 5% |
| J07BF03 051 | PR | cjepivo protiv dječje paralize, inaktiviranoNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BG01 051 | DS | cjepivo protiv bjesnoćeNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BH01 051 | PR | monovalentno cjepivo protiv rotavirusaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BH02 051 | PR | 5 – valentno cjepivo protiv rotavirusaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BJ01 019 | PR | cjepivo protiv rubele (RU ) |  |  | P | Imunološki zavod | Imunološki zavod | Cjepivo protiv rubele, živo, Imunološki zavod | praš. boč. + otap. za susp. za inj. boč. 0,5 ml | 3,2836 | 3,28 |  | 5% |
| J07BJ01 051 | PR | cjepivo protiv rubele NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BK01 051 |  | cjepivo protiv varičelaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BK01 061 |  | cjepivo protiv varičelaNJ707 |  |  | P | Merck Sharp & Dohme d.o.o. | Merck Sharp & Dohme B.V. | Varivax | štrc. napunj. 1x0,5 ml + 1 boč. s praškom | 42,9677 | 42,97 |  | 5% |
| J07BM01 051 |  | cjepivo protiv humanog papilomavirusaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BM02 051 |  | 2 – valentno cjepivo protiv humanog papilomavirusaNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BM03 051 |  | 9-valentno cjepivo protiv humanog papilomavirusa (rekombinantno, adsorbirano)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07BM03 061 |  | 9-valentno cjepivo protiv humanog papilomavirusa (rekombinantno, adsorbirano)NJ707 |  |  | P | Merck Sharp & Dohme B.V. | Merck Sharp & Dohme B.V. | Gardasil 9 | susp. za inj., štrc. napunj. 1×0,5 ml | 119,8593 | 119,86 |  | 5% |
| J07CA01 051 | PR | cjepivo protiv difterije, tetanusa i dječje paralize (Td-IPV)NJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07CA06 051 | PR | cjepivo protiv difterije, tetanusa, pertusisa, dječje paralize i Haemophilusa influenzae tipa BNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| J07CA06 071 | PR | cjepivo protiv difterije, tetanusa-DT, pertusisa-(acelularno), poliomijelitisa-IPV (inaktivirano), adsorbirano i Haemophilus influenzae tip b (konjugirano)NJ707 |  |  | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Infanrix-IPV + Hib | štrc. stakl. 1x0,5 ml + 1 stakl.boč. s praškom + 2 igle sa zaštitom, susp. | 18,7524 | 18,75 |  | 5% |
| J07CA09 051 | PR | cjepivo protiv difterije, tetanusa, pertusisa (acelularno), dječje paralize (inaktivirano),H. influenzae tipa B i hepatitisa BNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA01 051 | DS | ciklofosfamid |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA01 161 |  | ciklofosfamid |  |  | O | Baxter d.o.o. | Baxter Oncology GmbH | Endoxan | tbl. obl. 50x50 mg | 0,2163 | 10,82 | RSRL01 | 5% |
| L01AA02 151 |  | klorambucil |  |  | O |  |  |  |  |  |  | RSRL01 | 5% |
| L01AA03 051 | DS | melfalan |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA03 151 |  | melfalan |  |  | O |  |  |  |  |  |  | RSRL01 | 5% |
| L01AA05 052 | DS | klormetin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA06 051 | DS | ifosfamid |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AA09 001 | DS | bendamustinNL441 |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L. | Bendamustin Teva | praš. za konc. za otop. za inf., boč. 5x25 mg (2,5 mg/ml) | 36,5781 | 182,89 |  | 5% |
| L01AA09 002 | DS | bendamustinNL441 |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L. | Bendamustin Teva | praš. za konc. za otop. za inf., boč. 5x100 mg (2,5 mg/ml) | 161,7934 | 808,97 |  | 5% |
| L01AA09 040 | DS | bendamustinNL441 |  |  | P | PharmaS d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Bendamustin PharmaS | praš. za konc. za otop. za inf., boč. 5x25 mg (2,5 mg/ml) | 45,1579 | 225,79 |  | 5% |
| L01AA09 041 | DS | bendamustinNL441 |  |  | P | PharmaS d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Bendamustin PharmaS | praš. za konc. za otop. za inf., boč. 5x100 mg (2,5 mg/ml) | 199,7454 | 998,73 |  | 5% |
| L01AA09 061 | DS | bendamustinNL441 |  |  | P | Makpharm d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Benmak | praš. za konc. za otop. za inf., boč. 5x100 mg (2,5 mg/ml) | 199,7454 | 998,73 |  | 5% |
| L01AA09 062 | DS | bendamustinNL441 |  |  | P | Makpharm d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Benmak | praš. za konc. za otop. za inf., boč. 5x25 mg (2,5 mg/ml) | 45,1579 | 225,79 |  | 5% |
| L01AA09 071 | DS | bendamustinNL441 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc. | Bendamustin Kabi | praš. za konc. za otop. za inf., boč. 1x25 mg (2,5 mg/ml) | 40,6424 | 40,64 |  | 5% |
| L01AA09 072 | DS | bendamustinNL441 |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc. | Bendamustin Kabi | praš. za konc. za otop. za inf., boč. 1x100 mg (2,5 mg/ml) | 179,7704 | 179,77 |  | 5% |
| L01AB01 051 | DS | busulfan |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AB01 151 |  | busulfan |  |  | O |  |  |  |  |  |  | RSRL01 | 5% |
| L01AD01 051 | DS | karmustin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01AD02 151 | DS | lomustin |  |  | O |  |  |  |  |  |  |  | 5% |
| L01AX03 101 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x5 mg | 2,1217 | 10,61 |  | 5% |
| L01AX03 102 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x20 mg | 8,5805 | 42,90 |  | 5% |
| L01AX03 103 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x100 mg | 42,4514 | 212,26 |  | 5% |
| L01AX03 104 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x140 mg | 60,8003 | 304,00 |  | 5% |
| L01AX03 105 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x180 mg | 78,0604 | 390,30 |  | 5% |
| L01AX03 106 | DS | temozolomidNL101 |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Temazol | caps. tvrda 5x250 mg | 104,8112 | 524,06 |  | 5% |
| L01AX03 181 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x5 mg | 1,9096 | 9,55 |  | 5% |
| L01AX03 182 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x20 mg | 8,1579 | 40,79 |  | 5% |
| L01AX03 183 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x100 mg | 38,6770 | 193,39 |  | 5% |
| L01AX03 184 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x140 mg | 54,8238 | 274,12 |  | 5% |
| L01AX03 185 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x180 mg | 70,2539 | 351,27 |  | 5% |
| L01AX03 186 | DS | temozolomidNL101 |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Temozolomid Accord | caps. tvrda 5x250 mg | 97,9001 | 489,50 |  | 5% |
| L01AX04 051 | DS | dakarbazin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01BA01 006 | DS | metotreksat |  |  | P | Zentiva k.s. | Pliva Hrvatska d.o.o. | Metotreksat Zentiva | otop. za inj., boč. stakl. 1x50 mg/2 ml (25 mg/1 ml) | 3,5875 | 3,59 |  | 5% |
| L01BA01 007 | DS | metotreksat |  |  | P | Zentiva k.s. | Pliva Hrvatska d.o.o. | Metotreksat Zentiva | otop. za inj., boč. stakl. 1x1000 mg/10 ml (100 mg/1 ml) | 34,3526 | 34,35 |  | 5% |
| L01BA01 012 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x7,5 mg/0,30 ml | 4,0122 | 4,01 | RSRL50 | 5% |
| L01BA01 013 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x10 mg/0,40 ml | 7,4484 | 7,45 | RSRL50 | 5% |
| L01BA01 014 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x15 mg/0,38 ml | 11,1726 | 11,17 | RSRL50 | 5% |
| L01BA01 015 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x20 mg/0,50 ml | 13,3015 | 13,30 | RSRL50 | 5% |
| L01BA01 016 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x25 mg/0,63 ml | 15,1490 | 15,15 | RSRL50 | 5% |
| L01BA01 018 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A., S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x12,5 mg/0,31 ml | 9,3105 | 9,31 | RSRL50 | 5% |
| L01BA01 019 |  | metotreksat |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A.; S.C. Sindan-Pharma S.R.L. | Namaxir | otop. za inj., štrc. napunj. 1x17,5 mg/0,44 ml | 11,4606 | 11,46 | RSRL50 | 5% |
| L01BA01 081 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x7,5 mg/0,375 ml (20 mg/ml) | 4,0122 | 4,01 | RSRL50 | 5% |
| L01BA01 082 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x10 mg/0,5 ml (20 mg/ml) | 7,4484 | 7,45 | RSRL50 | 5% |
| L01BA01 083 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x15 mg/0,75 ml (20 mg/ml) | 11,1726 | 11,17 | RSRL50 | 5% |
| L01BA01 084 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x20 mg/1 ml (20 mg/ml) | 13,3015 | 13,30 | RSRL50 | 5% |
| L01BA01 085 |  | metotreksat |  |  | P | Sandoz d.o.o. | Sandoz-Salutas | Ebetrexat | otop. za inj., štrc. napunj. 1x25 mg/1,25 ml (20 mg/ml) | 15,1490 | 15,15 | RSRL50 | 5% |
| L01BA04 001 | DS | pemetreksedNL102 |  |  | P | PLIVA HRVATSKA d.o.o. | Pharmachemie B.V., Teva Pharmaceutical Works, Pliva Hrvatska d.o.o., Teva Operations | Pemetreksed Pliva | praš. za konc. za otop. za inf., boč. 1x500 mg | 407,1339 | 407,13 |  | 5% |
| L01BA04 002 | DS | pemetreksedNL102 |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharmaceutical Works | Pemetreksed Pliva | praš. za konc. za otop. za inf., boč. 1x1000 mg | 814,2677 | 814,27 |  | 5% |
| L01BA04 003 | DS | pemetreksedNL102 |  |  | P | ACTAVIS GROUP PTC ehf. | Pliva Hrvatska d.o.o., S.C. Sindan-Pharma S.R.L. | Armisarte | konc. za otop. za inf., boč. 1x20 ml (25 mg/ml) | 367,4391 | 367,44 |  | 5% |
| L01BA04 004 | DS | pemetreksedNL102 |  |  | P | ACTAVIS GROUP PTC ehf. | Pliva Hrvatska d.o.o., S.C. Sindan-Pharma S.R.L. | Armisarte | konc. za otop. za inf., boč. 1x40 ml (25 mg/ml) | 734,8769 | 734,88 |  | 5% |
| L01BA04 023 | DS | pemetreksedNL102 |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Pemetreksed Sandoz | konc. otop. za inf., boč. 1x20 ml (25 mg/ml) | 407,1339 | 407,13 |  | 5% |
| L01BA04 024 | DS | pemetreksedNL102 |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Pemetreksed Sandoz | konc. otop. za inf., boč. 1x40 ml (25 mg/ml) | 814,2677 | 814,27 |  | 5% |
| L01BA04 031 | DS | pemetreksedNL102 |  |  | P | Krka d.d., Novo mesto | KRKA d.d. | Pemetrexed Krka | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 81,4268 | 81,43 |  | 5% |
| L01BA04 032 | DS | pemetreksedNL102 |  |  | P | Krka d.d., Novo mesto | KRKA d.d. | Pemetrexed Krka | praš. za konc. za otop. za inf., boč. stakl. 1x500 mg | 407,1339 | 407,13 |  | 5% |
| L01BA04 041 | DS | pemetreksedNL102 |  |  | P | PharmaS d.o.o. | Synthon Hispania S.L., Synthon s.r.o., Adamed Sp. z.o.o. | Pemetreksed PharmaS | praš. za konc. za otop. za inf., boč. 1x500 mg | 407,1339 | 407,13 |  | 5% |
| L01BA04 044 | DS | pemetreksedNL102 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Wessling Hungary Kft. | Pemetrexed Accord | praš. za konc. za otop. za inf., boč. 1x500 mg | 386,7782 | 386,78 |  | 5% |
| L01BA04 045 | DS | pemetreksedNL102 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Wessling Hungary Kft | Pemetrexed Accord | konc. za otop. za inf., boč. 1x1000 mg | 773,5550 | 773,55 |  | 5% |
| L01BA04 071 | DS | pemetreksedNL102 |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Oncology Plc., Fresenius Kabi Deutschland GmbH | Pemetrexed Fresenius Kabi | praš. za konc. za otop. za inf., boč. 1x500 mg | 407,1339 | 407,13 |  | 5% |
| L01BA04 081 | DS | pemetreksedNL102 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Pemetrexed EVER Pharma | konc. za otop. za inf., boč. 1x4 ml (25 mg/ml) | 81,4268 | 81,43 |  | 5% |
| L01BA04 082 | DS | pemetreksedNL102 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Pemetrexed EVER Pharma | konc. za otop. za inf., boč. 1x20 ml (25 mg/ml) | 407,1339 | 407,13 |  | 5% |
| L01BA04 083 | DS | pemetreksedNL102 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Pemetrexed EVER Pharma | konc. za otop. za inf., boč. 1x40 ml (25 mg/ml) | 814,2677 | 814,27 |  | 5% |
| L01BB02 151 |  | merkaptopurin |  |  | O |  |  |  |  |  |  | RSRL92 | 5% |
| L01BB03 151 |  | tioguanin |  |  | O |  |  |  |  |  |  | RSRL92 | 5% |
| L01BB04 061 | DS | kladribinNL103 |  |  | P | Lipomed GmbH | Lipomed | Litak | otop. za inj. boč. 1x5 ml (2 mg /ml) | 295,8272 | 295,83 |  | 5% |
| L01BB05 071 | DS | fludarabinNL104 |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fludarabine Pliva | konc. otop. za inj. ili inf., boč. stakl. 1x2 ml | 75,0163 | 75,02 |  | 5% |
| L01BB05 081 | DS | fludarabinNL104 |  |  | P | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma S.R.L. | Sindarabin | praš. za otop. za inj. ili inf., boč. stakl. 1x50 mg | 72,0685 | 72,07 |  | 5% |
| L01BB05 091 | DS | fludarabinNL104 |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Fludarabin Accord | konc. za otop.za inj.ili inf., boč. stakl. 1x50 mg/2 mL | 64,8616 | 64,86 |  | 5% |
| L01BB05 092 | DS | fludarabinNL104 |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Fludarabin Accord | konc. za otop.za inj.ili inf., boč. stakl. 5x50 mg/2 mL | 64,8616 | 324,31 |  | 5% |
| L01BB06 061 | KL | klofarabinNL417 |  |  | P | Genzyme Europe B.V. | Pharmachemie B.V., Genzyme Limited | Evoltra | konc. za otop. za inf., boč. stakl. 1x20 mg/20 ml | 943,0141 | 943,01 |  | 5% |
| L01BB06 071 | KL | klofarabinNL417 |  |  | P | Makpharm d.o.o. | Synthon Hispania S.L., Synthon BV | Klofarabin Makpharm | konc. za otop. za inf., boč. stakl. 1x20 mg/20 ml | 943,0141 | 943,01 |  | 5% |
| L01BC01 063 | DS | citarabin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Cytosar | amp. 1x1.000 mg/10 ml | 22,0015 | 22,00 |  | 5% |
| L01BC02 002 | DS | 5-fluorouracil |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fluorouracil Pliva | otop. za inj./inf., boč. stak. 1x500 mg/10 ml (50 mg/ml) | 2,2258 | 2,23 |  | 5% |
| L01BC02 022 | DS | 5-fluorouracil |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Fluorouracil Sandoz | otop. za inj. ili inf., boč. stakl. 1x50 mg/ml (20 ml) | 4,8032 | 4,80 |  | 5% |
| L01BC02 023 | DS | 5-fluorouracil |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Fluorouracil Sandoz | otop. za inj. ili inf., boč. stakl. 1x50 mg/ml (100 ml) | 15,7967 | 15,80 |  | 5% |
| L01BC02 451 |  | 5-fluorouracil |  |  | L |  |  |  |  |  |  | R | 5% |
| L01BC05 011 | DS | gemcitabin |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Gitrabin | praš. za otop. za inf., boč. 1x2000 mg | 62,1382 | 62,14 |  | 5% |
| L01BC05 041 | DS | gemcitabin |  |  | P | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Gemcitabin Accord | konc. za otop. za inf., boč. 1x200 mg/2 ml | 5,9141 | 5,91 |  | 5% |
| L01BC05 042 | DS | gemcitabin |  |  | P | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Gemcitabin Accord | konc. za otop. za inf., boč. 1x1000 mg/10 ml | 31,0691 | 31,07 |  | 5% |
| L01BC05 043 | DS | gemcitabin |  |  | P | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Gemcitabin Accord | konc. za otop. za inf., boč. 1x2000 mg/20 ml | 59,0311 | 59,03 |  | 5% |
| L01BC05 068 | DS | gemcitabin |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH | Gemcitabin Sandoz | konc. za otop. za inf., boč. 1x200 mg/5 ml | 6,2260 | 6,23 |  | 5% |
| L01BC05 069 | DS | gemcitabin |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Gemcitabin Sandoz | konc. za otop. za inf., boč. 1x1000 mg/25 ml | 32,7042 | 32,70 |  | 5% |
| L01BC05 073 | DS | gemcitabin |  |  | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Gemcitabin Sandoz | konc. za otop. za inf., boč. 1x2000 mg/50 ml | 56,0794 | 56,08 |  | 5% |
| L01BC05 081 | DS | gemcitabin |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Gitrabin | praš. za otop. za inf., boč. 1x200 mg | 7,6860 | 7,69 |  | 5% |
| L01BC05 082 | DS | gemcitabin |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Gitrabin | praš. za otop. za inf., boč. 1x1 g | 36,3382 | 36,34 |  | 5% |
| L01BC05 083 | DS | gemcitabin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc. | Gemcitabin Kabi | praš. za otop. za inf., boč. 1x200 mg/10 ml | 7,6860 | 7,69 |  | 5% |
| L01BC05 084 | DS | gemcitabin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc. | Gemcitabin Kabi | praš. za otop. za inf., boč. 1x1000 mg/50 ml | 36,3382 | 36,34 |  | 5% |
| L01BC06 101 |  | kapecitabin |  |  | O | Teva B.V. | Teva Czech Industries s.r.o., Pharmachemie B.V., Merckle GmbH | Kapecitabin Teva | tbl. film obl. 60x150 mg | 0,2591 | 15,54 | RSRL02 | 5% |
| L01BC06 102 |  | kapecitabin |  |  | O | Teva B.V. | Teva Czech Industries s.r.o., Pharmachemie B.V., Merckle GmbH | Kapecitabin Teva | tbl. film obl. 120x500 mg | 0,6809 | 81,70 | RSRL02 | 5% |
| L01BC06 122 |  | kapecitabin |  |  | O | Sandoz d.o.o. | Sandoz-Salutas | Kapecitabin Sandoz | tbl. film obl. 120x500 mg | 0,6809 | 81,70 | RSRL02 | 5% |
| L01BC06 142 |  | kapecitabin |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Kapecitabin JGL | tbl. film obl. 120x500 mg | 0,6809 | 81,70 | RSRL02 | 5% |
| L01BC06 143 |  | kapecitabin |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmacare Premium Ltd | Kapecitabin Accord | tbl. film obl. 60x150 mg | 0,2591 | 15,54 | RSRL02 | 5% |
| L01BC06 144 |  | kapecitabin |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmacare Premium Ltd | Kapecitabin Accord | tbl. film obl. 60x300 mg | 0,5181 | 31,09 | RSRL02 | 5% |
| L01BC06 172 |  | kapecitabin |  |  | O | Zentiva k.s. | Remedica Ltd. | Xalvobin | tbl. film obl. 120x500 mg | 0,6809 | 81,70 | RSRL02 | 5% |
| L01BC06 173 |  | kapecitabin |  |  | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Kapetral | tbl. film obl. 60x150 mg | 0,2591 | 15,54 | RSRL02 | 5% |
| L01BC06 174 |  | kapecitabin |  |  | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Kapetral | tbl. film obl. 120x500 mg | 0,6809 | 81,70 | RSRL02 | 5% |
| L01BC06 175 |  | kapecitabin |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Kapecitabin Accord | tbl. film obl. 120x500 mg | 0,6809 | 81,70 | RSRL02 | 5% |
| L01BC06 176 |  | kapecitabin |  |  | O | Krka d.d., Novo mesto | Accord Healthcare Ltd., Pharmacare Premium Ltd | Ecansya | tbl. film obl. 120x500 mg | 0,6809 | 81,70 | RSRL02 | 5% |
| L01BC07 061 | DS | azacitidinNL106 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Celgene Distribution B.V. | Vidaza | praš. za susp. za inj., boč. stakl. 1x100 mg | 220,8454 | 220,85 |  | 5% |
| L01BC07 071 | DS | azacitidinNL106 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Azacitidin Accord | praš. za susp. za inj., boč. stakl. 1x100 mg | 220,8454 | 220,85 |  | 5% |
| L01BC07 081 | DS | azacitidinNL106 |  |  | P | Mylan Ireland Limited | Drehm Pharma GmbH | Azacitidin Mylan | praš. za susp. za inj., boč. stakl. 1x100 mg | 220,8454 | 220,85 |  | 5% |
| L01BC07 092 | DS | azacitidinNL106 |  |  | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Azacitidin Sandoz | praš. za susp. za inj., boč. stakl. 1x100 mg | 211,0319 | 211,03 |  | 5% |
| L01BC07 093 | DS | azacitidinNL106 |  |  | P | Zentiva k.s. | AqVida GmbH | Zassida | praš. za susp. za inj., boč. stakl. 1x100 mg | 200,4805 | 200,48 |  | 5% |
| L01BC59 161 | DS | trifluridin + tipiracilNL466 |  |  | O | Les Laboratoires Servier | Les Laboratoires Servier Industrie | Lonsurf | tbl. film obl. 20x(15 mg + 6,14 mg) | 29,5547 | 591,09 |  | 5% |
| L01BC59 162 | DS | trifluridin + tipiracilNL466 |  |  | O | Les Laboratoires Servier | Les Laboratoires Servier Industrie | Lonsurf | tbl. film obl. 20x(20 mg + 8,19 mg) | 35,0220 | 700,44 |  | 5% |
| L01CA01 051 | DS | vinblastin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01CA02 061 | DS | vinkristin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Vincristine | amp. 1x1 mg | 5,2824 | 5,28 |  | 5% |
| L01CA03 051 | KL | vindesin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01CA04 061 | DS | vinorelbin |  |  | P | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma | Vinorelsin | konc. za otop. za inf., boč. stakl. 10x1 ml (10 mg/ml) | 12,3830 | 123,83 |  | 5% |
| L01CA04 161 | DS | vinorelbin |  |  | O | Zentiva k.s. | Pharmadox Healthcare Limited | Lavib | caps. meka 4x20 mg | 15,6613 | 62,65 |  | 5% |
| L01CA04 162 | DS | vinorelbin |  |  | O | Zentiva k.s. | Pharmadox Healthcare Limited | Lavib | caps. meka 4x80 mg | 46,9839 | 187,94 |  | 5% |
| L01CB01 022 | DS | etopozid |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Etoposide Sandoz | konc. otop. za inf., boč. 1x100 mg/5 ml | 7,1763 | 7,18 |  | 5% |
| L01CB01 025 | DS | etopozid |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Etoposide Sandoz | konc. za otop. za inf., boč. stakl. 1x1000 mg/50 ml | 58,1352 | 58,14 |  | 5% |
| L01CB01 151 |  | etopozid |  |  | O |  |  |  |  |  |  | RSRL03 | 5% |
| L01CD01 006 | DS | paklitaksel |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paklitaksel Kabi | konc. za otop.za inf., boč. stakl. 1x5 ml (6 mg/ml) | 22,5761 | 22,58 |  | 5% |
| L01CD01 007 | DS | paklitaksel |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paklitaksel Kabi | konc. za otop. za inf., boč. stakl. 1x16,7 ml (6 mg/ml) | 71,4911 | 71,49 |  | 5% |
| L01CD01 008 | DS | paklitaksel |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paklitaksel Kabi | konc. za otop. za inf., boč. stakl. 1x25 ml (6 mg/ml) | 105,8650 | 105,87 |  | 5% |
| L01CD01 009 | DS | paklitaksel |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paklitaksel Kabi | konc. za otop. za inf., boč. stakl. 1x50 ml (6 mg/ml) | 207,5679 | 207,57 |  | 5% |
| L01CD01 071 | DS | paklitaksel |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Paklitaksel Sandoz | boč. 1x30 mg/5 ml | 31,1062 | 31,11 |  | 5% |
| L01CD01 072 | DS | paklitaksel |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Paklitaksel Sandoz | boč. 1x150 mg/25 ml | 145,2187 | 145,22 |  | 5% |
| L01CD01 074 | DS | paklitaksel |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Paklitaksel Sandoz | konc. za otop. za inf., boč. 1x100 mg/16,7 ml (6 mg/ml) | 98,8918 | 98,89 |  | 5% |
| L01CD01 075 | DS | paklitaksel |  |  | P | Sandoz d.o.o. | Ebewe Pharma | Paklitaksel Sandoz | konc. za otop. za inf., boč. 1x300 mg/50 ml (6 mg/ml) | 284,7302 | 284,73 |  | 5% |
| L01CD01 081 | DS | paklitaksel |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Paclitaxel Pliva | konc. za otop. za inf., boč. stakl. 1x30 mg/5 ml (6 mg/ml) | 50,3988 | 50,40 |  | 5% |
| L01CD01 082 | DS | paklitaksel |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Paclitaxel Pliva | konc. za otop. za inf., boč. stak. 1x100 mg/16,7 ml (6 mg/ml) | 161,9125 | 161,91 |  | 5% |
| L01CD01 083 | DS | paklitaksel |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Paclitaxel Pliva | konc. otop. za inf., boč. stakl. 1x150 mg/25 ml (6 mg/ml) | 290,4373 | 290,44 |  | 5% |
| L01CD01 084 | DS | paklitaksel |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Paclitaxel Pliva | konc. za otop. za inf., boč. stak. 1x300 mg/50 ml (6 mg/ml) | 504,8829 | 504,88 |  | 5% |
| L01CD01 086 | DS | paklitaksel |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis/ Sindan-Pharma | Sindaxel | konc. otop. za inf., boč. 1x5 ml (30 mg/5 ml) | 27,8718 | 27,87 |  | 5% |
| L01CD01 087 | DS | paklitaksel |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis/ Sindan-Pharma | Sindaxel | konc. otop. za inf., boč. 1x16,7 ml (100 mg/16,7 ml) | 88,2607 | 88,26 |  | 5% |
| L01CD01 088 | DS | paklitaksel |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis/ Sindan-Pharma | Sindaxel | konc. otop. za inf., boč. 1x25 ml (150 mg/25 ml) | 130,6975 | 130,70 |  | 5% |
| L01CD01 089 | DS | paklitaksel |  |  | P | ACTAVIS GROUP PTC ehf. | Actavis/ Sindan-Pharma | Sindaxel | konc. otop. za inf., boč. 1x50 ml (300 mg/50 ml) | 256,2572 | 256,26 |  | 5% |
| L01CD01 095 | DS | paklitaksel (nab)NL436 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Abraxane | praš. za susp. za inf., boč. stakl. 1x100 mg (5 mg/ml) | 259,8726 | 259,87 |  | 5% |
| L01CD01 096 | DS | paklitaksel (nab)NL436 |  |  | P | ratiopharm GmbH | Pharmachemie B.V., Merckle GmbH | Pazenir | praš. za disp. za inf., boč. stakl. 1x100 mg (5 mg/ml) | 195,0959 | 195,10 |  | 5% |
| L01CD02 031 | DS | docetaksel |  |  | P | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tolnexa | konc. za otop. za inf., boč. stakl. 1x20 mg/ml | 52,5702 | 52,57 |  | 5% |
| L01CD02 032 | DS | docetaksel |  |  | P | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tolnexa | konc. za otop. za inf., boč. stakl. 1x80 mg/4 ml | 183,3566 | 183,36 |  | 5% |
| L01CD02 033 | DS | docetaksel |  |  | P | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Tolnexa | konc. za otop. za inf., boč. stakl. 1x160 mg/8 ml | 330,2568 | 330,26 |  | 5% |
| L01CD02 061 | DS | docetaksel |  |  | P | Aventis Pharma S.A. | Aventis Pharma Dagenham | Taxotere | konc. otop. za inf., boč. 1x20 mg/1 ml | 52,5702 | 52,57 |  | 5% |
| L01CD02 062 | DS | docetaksel |  |  | P | Aventis Pharma S.A. | Aventis Pharma Dagenham | Taxotere | konc. za otop. za inf., boč. 1x80 mg/4 ml | 183,3566 | 183,36 |  | 5% |
| L01CD02 063 | DS | docetaksel |  |  | P | Aventis Pharma S.A. | Aventis Pharma Dagenham | Taxotere | konc. otop. za inf., boč. 1x160 mg/8 ml | 330,2568 | 330,26 |  | 5% |
| L01CD02 077 | DS | docetaksel |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Oncology Plc., Fresenius Kabi Deutschland GmbH | Docetaxel Kabi | konc. za otop. za inf., boč. stakl. 1x80 mg/4 ml | 183,3566 | 183,36 |  | 5% |
| L01CD02 078 | DS | docetaksel |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Oncology Plc., Fresenius Kabi Deutschland GmbH | Docetaxel Kabi | konc. za otop. za inf., boč. stakl. 1x160 mg/8 ml | 330,2568 | 330,26 |  | 5% |
| L01CD02 079 | DS | docetaksel |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Oncology Plc., Fresenius Kabi Deutschland GmbH | Docetaxel Kabi | konc. za otop. za inf., boč. stakl. 1x20 mg/ml | 52,5702 | 52,57 |  | 5% |
| L01CD02 081 | DS | docetaksel |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Docetaksel Teva | konc. za otop. za inf., boč. 1x20 mg/ml | 52,5702 | 52,57 |  | 5% |
| L01CD02 082 | DS | docetaksel |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Docetaksel Teva | konc. za otop. za inf., boč. 1x80 mg/4 ml | 183,3566 | 183,36 |  | 5% |
| L01CD02 083 | DS | docetaksel |  |  | P | Teva B.V. | S.C. Sindan-Pharma S.R.L., Actavis Italy S.p.A. | Docetaksel Teva | konc. za otop. za inf., boč. 1x140 mg/7 ml | 245,5425 | 245,54 |  | 5% |
| L01CD02 084 | DS | docetaksel |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Docetaxel Accord | konc. za otop. za inf., boč. stakl. 1x20 mg/ml | 42,5815 | 42,58 |  | 5% |
| L01CD02 085 | DS | docetaksel |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Docetaxel Accord | konc. za otop. za inf., boč. stakl. 1x80 mg/4 ml | 148,5195 | 148,52 |  | 5% |
| L01CD02 086 | DS | docetaksel |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Docetaxel Accord | konc. za otop. za inf., boč. stakl. 1x160 mg/8 ml | 267,5081 | 267,51 |  | 5% |
| L01CD04 011 | DS | kabazitakselNL438 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o., S.C. Sindan-Pharma S.R.L. | Kabazitaksel Teva | konc. za otop. za inf., boč. stakl. 1x60 mg | 2.275,9002 | 2.275,90 |  | 5% |
| L01CD04 061 | DS | kabazitakselNL438 |  |  | P | sanofi-aventis groupe | Aventis Pharma, Sanofi-Aventis Deutschland GmbH | Jevtana | konc. i otap. za otop. za inf., boč. stakl. 1x60 mg | 2.521,7718 | 2.521,77 |  | 5% |
| L01CD04 071 | DS | kabazitakselNL438 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Kabazitaksel Accord | konc. za otop. za inf., boč. stakl. 1x60 mg | 2.521,7718 | 2.521,77 |  | 5% |
| L01CD04 081 | DS | kabazitakselNL438 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Kabazitaksel EVER Pharma | konc. za otop. za inf., boč. stakl. 1x60 mg | 2.521,7718 | 2.521,77 |  | 5% |
| L01CD04 082 | DS | kabazitakselNL438 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Kabazitaksel EVER Pharma | konc. za otop. za inf., boč. stakl. 1x50 mg | 1.823,2132 | 1.823,21 |  | 5% |
| L01CD04 083 | DS | kabazitakselNL438 |  |  | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Kabazitaksel EVER Pharma | konc. za otop. za inf., boč. stakl. 1x45 mg | 1.640,9437 | 1.640,94 |  | 5% |
| L01CD04 084 | DS | kabazitakselNL438 |  |  | P | Zentiva k.s. | Pharmadox Healthcare Limited | Eleber | konc. i otap. za otop. za inf., boč. stakl. 1x60 mg | 2.521,7718 | 2.521,77 |  | 5% |
| L01CD04 085 | DS | kabazitakselNL438 |  |  | P | Viatris Limited | AqVida GmbH | Kabazitaksel Viatris | konc. za otop. za inf., boč. stakl. 1x60 mg | 2.395,6839 | 2.395,68 |  | 5% |
| L01CE01 061 | DS | topotekanNL123 |  |  | O | Novartis Europharm Limited Irska | GlaxoSmithKline Manufacturing S.p.A. | Hycamtin | caps. tvrda 10x0,25 mg | 9,2521 | 92,52 |  | 5% |
| L01CE01 062 | DS | topotekanNL123 |  |  | O | Novartis Europharm Limited Irska | GlaxoSmithKline Manufacturing S.p.A. | Hycamtin | caps. tvrda 10x1 mg | 35,5441 | 355,44 |  | 5% |
| L01CE01 081 | DS | topotekanNL124 |  |  | P | ALPHA-MEDICAL d.o.o. | Venus Pharma GmbH | Topotecan Alpha-medical | praš. za konc. za otop. za inf., boč. stakl. 5x4 mg | 131,4606 | 657,30 |  | 5% |
| L01CE01 083 | DS | topotekanNL124 |  |  | P | Pfizer Europe MA EEIG | Hospira UK Limited, Hospira Enterprises B.V. | Topotecan Hospira | konc. za otop. za inf., boč. stakl. 5x4 mg/4 ml | 109,7296 | 548,65 |  | 5% |
| L01CE01 091 | DS | topotekanNL425 |  |  | P | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma S.R.L. | Potactasol | praš. za konc. za otop. za inf., boč. stakl. 1x4 mg | 98,7564 | 98,76 |  | 5% |
| L01CE02 041 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Irinotekan Accord | konc. za otop. za inf., boč. 1x40 mg/2 ml | 23,1243 | 23,12 |  | 5% |
| L01CE02 042 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Irinotekan Accord | konc. za otop. za inf, boč. 1x1000 mg/50 ml | 471,4978 | 471,50 |  | 5% |
| L01CE02 063 | DS | irinotekan |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc, Fresenius Kabi Deutschland GmbH | Irinotekan Kabi | konc. za otop. za inf., boč. stakl. 1x40 mg/2 ml | 25,6938 | 25,69 |  | 5% |
| L01CE02 064 | DS | irinotekan |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc, Fresenius Kabi Deutschland GmbH | Irinotekan Kabi | konc. za otop. za inf, boč. stakl. 1x100 mg/5 ml | 58,0530 | 58,05 |  | 5% |
| L01CE02 065 | DS | irinotekan |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc, Fresenius Kabi Deutschland GmbH | Irinotekan Kabi | konc. za otop. za inf, boč. stakl. 1x300 mg/15 ml | 174,1589 | 174,16 |  | 5% |
| L01CE02 066 | DS | irinotekan |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Oncology Plc, Fresenius Kabi Deutschland GmbH | Irinotekan Kabi | konc. za otop. za inf, boč. stakl. 1x500 mg/25 ml | 290,2648 | 290,26 |  | 5% |
| L01CE02 067 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Irinotekan Accord | konc. za otop. za inf, boč. 1x100 mg/5 ml | 52,2477 | 52,25 |  | 5% |
| L01CE02 068 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Irinotekan Accord | konc. za otop. za inf, boč. 1x300 mg/15 ml | 156,7430 | 156,74 |  | 5% |
| L01CE02 069 | DS | irinotekan |  |  | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited | Irinotekan Accord | konc. za otop. za inf, boč. 1x500 mg/25 ml | 261,2383 | 261,24 |  | 5% |
| L01CE02 071 | DS | irinotekan |  |  | P | Teva B.V. | Actavis/ Sindan-Pharma | Irinotesin | konc. otop. za inf., boč. stakl. 1x2 ml (20 mg/ml) | 31,7208 | 31,72 |  | 5% |
| L01CE02 072 | DS | irinotekan |  |  | P | Teva B.V. | Actavis/ Sindan-Pharma | Irinotesin | konc. otop. za inf. boč. stakl. 1x5 ml (20 mg/ml) | 71,6703 | 71,67 |  | 5% |
| L01CE02 073 | DS | irinotekan |  |  | P | Teva B.V. | Actavis Italy S.p.A., S.C. Sindan-Pharma S.R.L. | Irinotesin | konc. za otop. za inf, boč. 1x300 mg/15 ml | 148,9057 | 148,91 |  | 5% |
| L01CE02 074 | DS | irinotekan |  |  | P | Teva B.V. | Actavis Italy S.p.A., S.C. Sindan-Pharma S.R.L. | Irinotesin | konc. za otop. za inf, boč. 1x500 mg/25 ml | 248,1771 | 248,18 |  | 5% |
| L01CE02 091 | DS | irinotekan |  |  | P | Pfizer Croatia d.o.o. | Aventis Pharma, Actavis , Pfizer | Campto | boč. inf. 1x100 mg/5 ml | 71,6703 | 71,67 |  | 5% |
| L01CX01 001 | KL | trabektedinNL418 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o. | Trabektedin Teva | praš. za konc. za otop. za inf., boč. stakl. 1x0,25 mg | 331,0094 | 331,01 |  | 5% |
| L01CX01 002 | KL | trabektedinNL418 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o. | Trabektedin Teva | praš. za konc. za otop. za inf., boč. stakl. 1x1 mg | 1.324,0388 | 1.324,04 |  | 5% |
| L01CX01 061 | KL | trabektedinNL418 |  |  | P | PHARMA MAR, S.A. | Pharma Mar S.A. | Yondelis | praš. za konc. za otop. za inf., boč. stakl. 1x0,25 mg | 509,8759 | 509,88 |  | 5% |
| L01CX01 062 | KL | trabektedinNL418 |  |  | P | PHARMA MAR, S.A. | Pharma Mar S.A. | Yondelis | praš. za konc. za otop. za inf., boč. stakl. 1x1 mg | 1.891,4845 | 1.891,48 |  | 5% |
| L01DA01 051 | KL | daktinomicin (aktinomicin-D) |  |  | P |  |  |  |  |  |  |  | 5% |
| L01DB01 008 | DS | doksorubicin liposomalniNL446 |  |  | P | Teva B.V. | GP-Pharm, Teva Operations Poland Sp. z o.o. | Myocet | praš., disp. i otap. za konc. za disp. za inf. 2x50 mg | 454,4117 | 908,82 |  | 5% |
| L01DB01 063 | DS | doksorubicin |  |  | P | ACTAVIS GROUP PTC ehf. | Sindan-Pharma | Sindroxocin | praš. za otop. za inj. ili inf., boč. 1x10 mg | 5,2253 | 5,23 |  | 5% |
| L01DB01 064 | DS | doksorubicin |  |  | P | ACTAVIS GROUP PTC ehf. | Sindan-Pharma | Sindroxocin | praš. za otop. za inj. ili inf., boč. 1x50 mg | 26,1238 | 26,12 |  | 5% |
| L01DB01 081 | DS | doksorubicin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Doxorubicin Pliva | boč. 1x10 mg/5 ml | 5,8053 | 5,81 |  | 5% |
| L01DB01 082 | DS | doksorubicin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Doxorubicin Pliva | boč. 1x50 mg/25 ml | 29,0265 | 29,03 |  | 5% |
| L01DB01 091 | DS | doksorubicin pegilirani liposomalni NL539 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z o.o. | Zolsketil | konc. za disp. za inf., boč. 1x25 ml (2 mg/ml) | 318,0888 | 318,09 |  | 5% |
| L01DB01 092 | DS | doksorubicin pegilirani liposomalni NL539 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z o.o. | Zolsketil | konc. za disp. za inf., boč. 1x10 ml (2 mg/ml) | 127,2360 | 127,24 |  | 5% |
| L01DB02 063 | DS | daunorubicin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Daunoblastina | amp. 1x20 mg | 9,4326 | 9,43 |  | 5% |
| L01DB03 064 | DS | epirubicin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Farmorubicin PFS | amp. 1x10 mg | 11,9849 | 11,98 |  | 5% |
| L01DB03 065 | DS | epirubicin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Farmorubicin PFS | amp. 1x50 mg | 50,4347 | 50,43 |  | 5% |
| L01DB03 081 | DS | epirubicin |  |  | P | Teva B.V. | Sindan-Pharma | Episindan | praš. za otop. za inj., boč. 1x10 mg | 10,6245 | 10,62 |  | 5% |
| L01DB03 082 | DS | epirubicin |  |  | P | Teva B.V. | Sindan-Pharma | Episindan | praš. za otop. za inj., boč. 1x50 mg | 58,1605 | 58,16 |  | 5% |
| L01DB06 067 | DS | idarubicin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Zavedos | lio amp. 1x10 mg | 116,1484 | 116,15 |  | 5% |
| L01DB07 051 | DS | mitoksantron |  |  | P |  |  |  |  |  |  |  | 5% |
| L01DB11 061 | DS | piksantronNL480 |  |  | P | Les Laboratoires Servier | Les Laboratoires Servier Industrie | Pixuvri | praš. za konc. za otop. za inf., boč. stakl. 1x29 mg | 693,0533 | 693,05 |  | 5% |
| L01DC01 051 | DS | bleomicin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01DC03 051 | DS | mitomicin-D |  |  | P |  |  |  |  |  |  |  | 5% |
| L01EA01 101 | DS | imatinibNL115 | 400 mg | 27,9853 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivatinib | tbl. film obl. 60x100 mg | 6,9963 | 419,78 |  | 5% |
| L01EA01 102 | DS | imatinibNL115 | 400 mg | 25,3440 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivatinib | tbl. film obl. 30x400 mg | 25,3439 | 760,32 |  | 5% |
| L01EA01 135 | DS | imatinib NL115 | 400 mg | 27,9853 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 60x100 mg | 6,9963 | 419,78 |  | 5% |
| L01EA01 136 | DS | imatinib NL115 | 400 mg | 28,5742 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 90x100 mg | 7,1436 | 642,92 |  | 5% |
| L01EA01 137 | DS | imatinibNL115 | 400 mg | 25,3440 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 30x400 mg | 25,3439 | 760,32 |  | 5% |
| L01EA01 138 | DS | imatinib NL115 | 400 mg | 24,8652 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 60x400 mg | 24,8652 | 1.491,91 |  | 5% |
| L01EA01 141 | DS | imatinibNL115 | 400 mg | 21,5900 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Imatinib Alkaloid-INT | tbl. film obl. 60x100 mg | 5,3976 | 323,85 |  | 5% |
| L01EA01 142 | DS | imatinibNL115 | 400 mg | 21,4167 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Imatinib Alkaloid-INT | tbl. film obl. 30x400 mg | 21,4167 | 642,50 |  | 5% |
| L01EA01 161 | DS | imatinibNL115 | 400 mg | 27,9853 | O | Zentiva k.s. | Remedica Ltd., Pharmadox Healthcare Ltd. | Imakrebin | tbl. film obl. 60x100 mg | 6,9963 | 419,78 |  | 5% |
| L01EA01 162 | DS | imatinibNL115 | 400 mg | 25,3440 | O | Zentiva k.s. | Remedica Ltd., Pharmadox Healthcare Ltd. | Imakrebin | tbl. film obl. 30x400 mg | 25,3439 | 760,32 |  | 5% |
| L01EA01 193 | DS | imatinibNL115 | 400 mg | 25,2520 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Imatinib Accord | tbl. film obl. 60x100 mg | 6,3130 | 378,78 |  | 5% |
| L01EA01 194 | DS | imatinibNL115 | 400 mg | 25,0487 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Imatinib Accord | tbl. film obl. 30x400 mg | 25,0488 | 751,46 |  | 5% |
| L01EA02 101 | DS | dasatinibNL119 | 100 mg | 84,0575 | O | Teva B.V. | Merckle GmbH, Pliva Hrvatska d.o.o. | Dasatinib Teva | tbl. film obl. 60x20 mg | 16,8114 | 1.008,69 |  | 5% |
| L01EA02 102 | DS | dasatinibNL119 | 100 mg | 50,5950 | O | Teva B.V. | Merckle GmbH, Pliva Hrvatska d.o.o. | Dasatinib Teva | tbl. film obl. 30x100 mg | 50,5949 | 1.517,85 |  | 5% |
| L01EA02 141 | DS | dasatinibNL119 | 100 mg | 88,4817 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Nodriga | tbl. film obl. 60x20 mg | 17,6963 | 1.061,78 |  | 5% |
| L01EA02 142 | DS | dasatinibNL119 | 100 mg | 53,2577 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Nodriga | tbl. film obl. 30x100 mg | 53,2578 | 1.597,73 |  | 5% |
| L01EA02 161 | DS | dasatinibNL119 | 100 mg | 133,0550 | O | Bristol-Myers Squibb Pharma EEIG | Bristol-Myers Squibb | Sprycel | tbl. film obl. 60x20 mg | 26,6109 | 1.596,66 |  | 5% |
| L01EA02 163 | DS | dasatinibNL119 | 100 mg | 80,0877 | O | Bristol-Myers Squibb Pharma EEIG | Bristol-Myers Squibb | Sprycel | tbl. film obl. 30x100 mg | 80,0876 | 2.402,63 |  | 5% |
| L01EA02 173 | DS | dasatinibNL119 | 100 mg | 79,8542 | O | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Dasatinib Zentiva | tbl. film obl. 60x20 mg | 15,9709 | 958,25 |  | 5% |
| L01EA02 174 | DS | dasatinibNL119 | 100 mg | 48,0650 | O | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Dasatinib Zentiva | tbl. film obl. 30x100 mg | 48,0651 | 1.441,95 |  | 5% |
| L01EA02 181 | DS | dasatinibNL119 | 100 mg | 84,0575 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Dasatinib Alpha-Medical | tbl. film obl. 60x20 mg | 16,8114 | 1.008,69 |  | 5% |
| L01EA02 182 | DS | dasatinibNL119 | 100 mg | 50,5950 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Dasatinib Alpha-Medical | tbl. film obl. 30x100 mg | 50,5949 | 1.517,85 |  | 5% |
| L01EA03 171 | DS | nilotinibNL121 | 600 mg | 87,0464 | O | Novartis Europharm Limited Irska | Lek d.d, PE PROIZVODNJA LENDAVA, Novartis Pharma GmbH | Tasigna | caps. tvrda 112x200 mg | 29,0154 | 3.249,73 |  | 5% |
| L01EA04 161 | DS | bosutinibNL119 | 400 mg | 93,5586 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Bosulif | tbl. film obl. 28x100 mg | 23,3896 | 654,91 |  | 5% |
| L01EA04 162 | DS | bosutinibNL119 | 400 mg | 93,7289 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Bosulif | tbl. film obl. 28x500 mg | 117,1611 | 3.280,51 |  | 5% |
| L01EA05 161 | DS | ponatinibNL526 | 45 mg | 277,9085 | O | Incyte Biosciences Distribution B.V. | Incyte Biosciences Distribution B.V. | Iclusig | tbl. film obl. 60x15 mg | 92,6361 | 5.558,17 |  | 5% |
| L01EA05 162 | DS | ponatinibNL526 | 45 mg | 168,8677 | O | Incyte Biosciences Distribution B.V. | Incyte Biosciences Distribution B.V. | Iclusig | tbl. film obl. 30x45 mg | 168,8677 | 5.066,03 |  | 5% |
| L01EB01 101 | DS | gefitinibNL419 | 250 mg | 32,9603 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gefitinib Pliva | tbl. film obl. 30x250 mg | 32,9604 | 988,81 |  | 5% |
| L01EB01 141 | DS | gefitinibNL419 | 250 mg | 31,3123 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Phrompo | tbl. film obl. 30x250 mg | 31,3124 | 939,37 |  | 5% |
| L01EB01 191 | DS | gefitinibNL419 | 250 mg | 36,6237 | O | Zentiva k.s. | Pharmadox Healthcare Limited, S.C Labormed – Pharma SA | Gefitinib Zentiva | tbl. film obl. 30x250 mg | 36,6235 | 1.098,71 |  | 5% |
| L01EB02 161 | DS | erlotinib | 150 mg | 26,1290 | O | Roche Registration GmbH | Roche | Tarceva | tbl. film obl. 30x150 mg | 26,1291 | 783,87 |  | 5% |
| L01EB02 162 | DS | erlotinib | 150 mg | 26,1290 | O | Zentiva k.s. | Remedica Ltd. | Varlota | tbl. film obl. 30x150 mg | 26,1291 | 783,87 |  | 5% |
| L01EB02 163 | DS | erlotinib | 150 mg | 26,1290 | O | Remedica Ltd. | Remedica Ltd. | Erlotinib Remedica | tbl. film obl. 30x150 mg | 26,1291 | 783,87 |  | 5% |
| L01EB02 164 | DS | erlotinib | 150 mg | 26,1290 | O | PharmaS d.o.o. | Remedica Ltd. | Erlotinib PharmaS | tbl. film obl. 30x150 mg | 26,1291 | 783,87 |  | 5% |
| L01EB02 165 | DS | erlotinib | 150 mg | 26,1290 | O | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma S.R.L. | Erlotinib Actavis | tbl. film obl. 30x150 mg | 26,1291 | 783,87 |  | 5% |
| L01EB02 166 | DS | erlotinib | 150 mg | 26,1290 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d., Remedica Ltd. | Erlotinib Sandoz | tbl. film obl. 30x150 mg | 26,1291 | 783,87 |  | 5% |
| L01EB02 167 | DS | erlotinib | 150 mg | 26,1290 | O | Mylan Pharmaceuticals Limited | Remedica Ltd. | Erlotinib Mylan | tbl. film obl. 30x150 mg | 26,1291 | 783,87 |  | 5% |
| L01EB02 168 | DS | erlotinib | 150 mg | 24,8227 | O | KRKA-FARMA d.o.o. | Krka d.d. | Erlotinib Krka | tbl. film obl. 30x150 mg | 24,8226 | 744,68 |  | 5% |
| L01EB02 169 | DS | erlotinib | 150 mg | 23,5813 | O | Alkaloid-INT d.o.o. | Alkaloid-INT d.o.o. | Fokleros | tbl. film obl. 30x150 mg | 23,5815 | 707,44 |  | 5% |
| L01EB03 161 | DS | afatinibNL419 | 40 mg | 132,4943 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Giotrif | tbl. film obl. 28x20 mg | 66,2473 | 1.854,92 |  | 5% |
| L01EB03 162 | DS | afatinibNL419 | 40 mg | 87,6367 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Giotrif | tbl. film obl. 28x30 mg | 65,7274 | 1.840,37 |  | 5% |
| L01EB03 163 | DS | afatinibNL419 | 40 mg | 65,7275 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Giotrif | tbl. film obl. 28x40 mg | 65,7274 | 1.840,37 |  | 5% |
| L01EB04 161 | KS | osimertinibNL473 | 80 mg | 403,1721 | O | AstraZeneca AB | AstraZeneca AB | Tagrisso | tbl. film obl. 28x40 mg | 201,5860 | 5.644,41 |  | 5% |
| L01EB04 162 | KS | osimertinibNL473 | 80 mg | 201,5861 | O | AstraZeneca AB | AstraZeneca AB | Tagrisso | tbl. film obl. 28x80 mg | 201,5860 | 5.644,41 |  | 5% |
| L01EC01 061 | KS | vemurafenibNL422 | 1920 mg | 227,1014 | O | Roche Registration GmbH | Roche Pharma AG | Zelboraf | tbl. film obl. 56x240 mg | 28,3876 | 1.589,71 |  | 5% |
| L01EC02 162 | KS | dabrafenibNL422 | 300 mg | 209,2055 | O | Novartis Europharm Limited Irska | Glaxo Wellcome S.A. | Tafinlar | caps. tvrda 120x50 mg | 34,8676 | 4.184,11 |  | 5% |
| L01EC02 163 | KS | dabrafenibNL422 | 300 mg | 210,2843 | O | Novartis Europharm Limited Irska | Glaxo Wellcome S.A. | Tafinlar | caps. tvrda 120x75 mg | 52,5711 | 6.308,53 |  | 5% |
| L01ED01 161 | DS | krizotinibNL444 | 500 mg | 181,3288 | O | Pfizer Europe MA EEIG | Pfizer | Xalkori | caps. tvrda 60x200 mg | 72,5314 | 4.351,89 |  | 5% |
| L01ED01 162 | DS | krizotinibNL444 | 500 mg | 145,0630 | O | Pfizer Europe MA EEIG | Pfizer | Xalkori | caps. tvrda 60x250 mg | 72,5314 | 4.351,89 |  | 5% |
| L01ED03 161 | DS | alektinibNL474 | 1200 mg | 188,3000 | O | Roche Registration GmbH | Roche Pharma AG | Alecensa | caps. tvrda 224x150 mg | 23,5375 | 5.272,40 |  | 5% |
| L01ED04 071 | DS | brigatinibNL501 | 180 mg | 182,8851 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. 28x30 mg | 30,4811 | 853,47 |  | 5% |
| L01ED04 072 | DS | brigatinibNL501 | 180 mg | 180,0114 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. 28x90 mg | 90,0055 | 2.520,16 |  | 5% |
| L01ED04 073 | DS | brigatinibNL501 | 180 mg | 149,2911 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. 28x180 mg | 149,2910 | 4.180,15 |  | 5% |
| L01ED04 074 | DS | brigatinibNL501 | 180 mg | 170,6184 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. (7x90 mg + 21x180 mg) | 149,2910 | 4.180,15 |  | 5% |
| L01ED05 161 | DS | lorlatinibNL511 | 100 mg | 188,7929 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Lorviqua | tbl. film obl. 90x25 mg | 47,1982 | 4.247,84 |  | 5% |
| L01ED05 162 | DS | lorlatinibNL511 | 100 mg | 188,9003 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Lorviqua | tbl. film obl. 120x25 mg | 47,2251 | 5.667,01 |  | 5% |
| L01ED05 163 | DS | lorlatinibNL511 | 100 mg | 139,8057 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Lorviqua | tbl. film obl. 30x100 mg | 139,8058 | 4.194,17 |  | 5% |
| L01EE01 161 | KS | trametinibNL422 | 2 mg | 143,1880 | O | Novartis Europharm Limited Irska | Lek Pharmaceuticals d.d., Novartis Pharma GmbH | Mekinist | tbl. film obl. 30x0,5 mg | 35,7971 | 1.073,91 |  | 5% |
| L01EE01 162 | KS | trametinibNL422 | 2 mg | 141,3140 | O | Novartis Europharm Limited Irska | Lek Pharmaceuticals d.d., Novartis Pharma GmbH | Mekinist | tbl. film obl. 30x2 mg | 141,3140 | 4.239,42 |  | 5% |
| L01EE02 161 | KS | kobimetinibNL422 | 45 mg | 180,8532 | O | Roche Registration GmbH | Roche Pharma AG | Cotellic | tbl. film obl. 63x20 mg | 80,3791 | 5.063,89 |  | 5% |
| L01EF01 161 | DS | palbociklibNL478 | 94 mg | 161,8007 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | caps. tvrda 21x75 mg | 129,0964 | 2.711,02 |  | 5% |
| L01EF01 162 | DS | palbociklibNL478 | 94 mg | 122,0345 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | caps. tvrda 21x100 mg | 129,8237 | 2.726,30 |  | 5% |
| L01EF01 163 | DS | palbociklibNL478 | 94 mg | 97,6276 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | caps. tvrda 21x125 mg | 129,8237 | 2.726,30 |  | 5% |
| L01EF01 164 | DS | palbociklibNL478 | 94 mg | 160,7927 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | tbl. film obl. 21x75 mg | 128,2921 | 2.694,13 |  | 5% |
| L01EF01 165 | DS | palbociklibNL478 | 94 mg | 120,5945 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | tbl. film obl. 21x100 mg | 128,2921 | 2.694,13 |  | 5% |
| L01EF01 166 | DS | palbociklibNL478 | 94 mg | 96,4756 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | tbl. film obl. 21x125 mg | 128,2921 | 2.694,13 |  | 5% |
| L01EF02 161 | DS | ribociklibNL479 | 450 mg | 106,9679 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Kisqali | tbl. film obl. 63x200 mg | 47,5413 | 2.995,10 |  | 5% |
| L01EF03 171 | DS | abemaciklibNL498 | 300 mg | 263,8931 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Verzenios | tbl. film obl. 28x50 mg | 43,9823 | 1.231,51 |  | 5% |
| L01EF03 172 | DS | abemaciklibNL498 | 300 mg | 131,9480 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Verzenios | tbl. film obl. 28x100 mg | 43,9823 | 1.231,51 |  | 5% |
| L01EF03 173 | DS | abemaciklibNL498 | 300 mg | 87,9650 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Verzenios | tbl. film obl. 28x150 mg | 43,9823 | 1.231,51 |  | 5% |
| L01EG01 071 | DS | temsirolimusNL122 | 3.57 mg | 101,4804 | P | Pfizer Europe MA EEIG | Wyeth | Torisel | konc. i otap. za inf. boč. stakl. 1x30 mg/1,2 ml + boč. stakl. 1x2,2 ml | 852,7772 | 852,78 |  | 5% |
| L01EG01 081 | DS | temsirolimusNL122 | 3.57 mg | 71,0355 | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Polska Sp. z o.o., Accord Healthcare B.V. | Temsirolimus Accord | konc. i otap. za otop. za inf. boč. stakl. 30 mg, 1 boč. s konc. i 1 boč. s otap. | 596,9447 | 596,94 |  | 5% |
| L01EG02 101 | DS | everolimusNL420 | 10 mg | 75,4520 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Everolimus Pliva | tbl. 30x5 mg | 37,7260 | 1.131,78 |  | 5% |
| L01EG02 102 | DS | everolimusNL420 | 10 mg | 51,5383 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Everolimus Pliva | tbl. 30x10 mg | 51,5383 | 1.546,15 |  | 5% |
| L01EG02 131 | DS | everolimusNL420 | 10 mg | 67,9067 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 30x2,5 mg | 16,9767 | 509,30 |  | 5% |
| L01EG02 132 | DS | everolimusNL420 | 10 mg | 61,1160 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 90x2,5 mg | 15,2790 | 1.375,11 |  | 5% |
| L01EG02 133 | DS | everolimusNL420 | 10 mg | 67,9067 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 30x5 mg | 33,9534 | 1.018,60 |  | 5% |
| L01EG02 134 | DS | everolimusNL420 | 10 mg | 61,1160 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 90x5 mg | 30,5580 | 2.750,22 |  | 5% |
| L01EG02 135 | DS | everolimusNL420 | 10 mg | 46,3843 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 30x10 mg | 46,3845 | 1.391,53 |  | 5% |
| L01EG02 136 | DS | everolimusNL420 | 10 mg | 41,7460 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 90x10 mg | 41,7460 | 3.757,14 |  | 5% |
| L01EG02 171 | DS | everolimusNL420 | 10 mg | 75,4520 | O | Zentiva k.s. | Genepharm S.A., Pharmadox Healthcare Limited | Everolimus Zentiva | tbl. 30x5 mg | 37,7260 | 1.131,78 |  | 5% |
| L01EG02 172 | DS | everolimusNL420 | 10 mg | 51,5383 | O | Zentiva k.s. | Genepharm S.A., Pharmadox Healthcare Limited | Everolimus Zentiva | tbl. 30x10 mg | 51,5383 | 1.546,15 |  | 5% |
| L01EG02 181 | DS | everolimusNL420 | 10 mg | 75,4520 | O | STADA d.o.o. | Stada Arzneimittel | Everolimus STADA | tbl. 30x5 mg | 37,7260 | 1.131,78 |  | 5% |
| L01EG02 182 | DS | everolimusNL420 | 10 mg | 51,5383 | O | STADA d.o.o. | Stada Arzneimittel | Everolimus STADA | tbl. 30x10 mg | 51,5383 | 1.546,15 |  | 5% |
| L01EG02 183 | DS | everolimusNL420 | 10 mg | 75,4520 | O | Mylan Pharmaceuticals Limited | Synthon Hispania S.L., Synthon BV | Everolimus Mylan | tbl. 30x5 mg | 37,7260 | 1.131,78 |  | 5% |
| L01EG02 184 | DS | everolimusNL420 | 10 mg | 51,5383 | O | Mylan Pharmaceuticals Limited | Synthon Hispania S.L., Synthon BV | Everolimus Mylan | tbl. 30x10 mg | 51,5383 | 1.546,15 |  | 5% |
| L01EG02 185 | DS | everolimusNL420 | 10 mg | 75,4520 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Alpha-Medical | tbl. 30x5 mg | 37,7260 | 1.131,78 |  | 5% |
| L01EG02 186 | DS | everolimusNL420 | 10 mg | 51,5383 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Alpha-Medical | tbl. 30x10 mg | 51,5383 | 1.546,15 |  | 5% |
| L01EH01 161 | DS | lapatinibNL120 | 1250 mg | 77,2179 | O | Novartis Europharm Limited Irska | Glaxo Wellcome S.A., Novartis Pharma GmbH | Tyverb | tbl. film obl. 70x250 mg | 15,4436 | 1.081,05 |  | 5% |
| L01EJ01 161 | DS | ruksolitinibNL453 | 30 mg | 195,2171 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Jakavi | tbl. 56x5 mg | 32,5361 | 1.822,02 |  | 5% |
| L01EJ01 162 | DS | ruksolitinibNL453 | 30 mg | 129,1382 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Jakavi | tbl. 56x15 mg | 64,5692 | 3.615,87 |  | 5% |
| L01EJ01 163 | DS | ruksolitinibNL453 | 30 mg | 96,8537 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Jakavi | tbl. 56x20 mg | 64,5692 | 3.615,87 |  | 5% |
| L01EK01 161 | DS | aksitinibNL430 | 10 mg | 106,0714 | O | Pfizer Europe MA EEIG | Pfizer | Inlyta | tbl. film obl. 56x1 mg | 10,6072 | 594,00 |  | 5% |
| L01EK01 162 | DS | aksitinibNL430 | 10 mg | 106,0721 | O | Pfizer Europe MA EEIG | Pfizer | Inlyta | tbl. film obl. 56x5 mg | 53,0360 | 2.970,02 |  | 5% |
| L01EL01 161 | DS | ibrutinibNL502 | 420 mg | 179,2277 | O | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Imbruvica | caps. tvrda 90x140 mg | 59,7425 | 5.376,83 |  | 5% |
| L01EL01 162 | DS | ibrutinibNL471 | 420 mg | 179,1493 | O | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Imbruvica | caps. tvrda 120x140 mg | 59,7164 | 7.165,97 |  | 5% |
| L01EL01 163 | DS | ibrutinibNL527 | 420 mg | 179,1499 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x140 mg | 59,7164 | 1.672,06 |  | 5% |
| L01EL01 164 | DS | ibrutinibNL527 | 420 mg | 179,1490 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x280 mg | 119,4328 | 3.344,12 |  | 5% |
| L01EL01 165 | DS | ibrutinibNL527 | 420 mg | 179,1493 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x420 mg | 179,1492 | 5.016,18 |  | 5% |
| L01EL01 166 | DS | ibrutinibNL471 | 420 mg | 179,1494 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x560 mg | 238,8656 | 6.688,24 |  | 5% |
| L01EL02 161 | DS | akalabrutinib NL533 | 0.2 g | 170,1918 | O | AstraZeneca AB | AstraZeneca AB | Calquence | caps. tvrda 56x100 mg | 85,0959 | 4.765,37 |  | 5% |
| L01EM01 161 | DS | idelalisibNL454 | 300 mg | 182,0265 | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Zydelig | tbl. film obl. 60x100 mg | 60,6756 | 3.640,53 |  | 5% |
| L01EM01 162 | DS | idelalisibNL454 | 300 mg | 121,3510 | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Zydelig | tbl. film obl. 60x150 mg | 60,6756 | 3.640,53 |  | 5% |
| L01EM03 171 | DS | alpelisibNL531 | 300 mg | 138,7412 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Piqray | tbl. film obl. 28x50 mg + 28x200 mg | 57,8087 | 3.237,29 |  | 5% |
| L01EM03 172 | DS | alpelisibNL531 | 300 mg | #N/A | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Piqray | tbl. film obl. 56x150 mg | #N/A | #N/A |  | 5% |
| L01EM03 173 | DS | alpelisibNL531 | 300 mg | 173,4259 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Piqray | tbl. film obl. 28x200 mg | 115,6175 | 3.237,29 |  | 5% |
| L01EX01 101 | DS | sunitinibNL117 | 33 mg | 63,4644 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sunitinib Pliva | caps. tvrda 28x12,5 mg | 24,0398 | 673,11 |  | 5% |
| L01EX01 102 | DS | sunitinibNL117 | 33 mg | 63,1748 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sunitinib Pliva | caps. tvrda 28x25 mg | 47,8598 | 1.340,07 |  | 5% |
| L01EX01 103 | DS | sunitinibNL117 | 33 mg | 62,9190 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sunitinib Pliva | caps. tvrda 28x50 mg | 95,3319 | 2.669,29 |  | 5% |
| L01EX01 131 | DS | sunitinibNL117 | 33 mg | 63,4658 | O | KRKA-FARMA d.o.o. | Krka d.d, Krka – farma d.o.o. | Sunitinib Krka | caps. tvrda 30x12,5 mg | 24,0401 | 721,20 |  | 5% |
| L01EX01 132 | DS | sunitinibNL117 | 33 mg | 63,1751 | O | KRKA-FARMA d.o.o. | Krka d.d, Krka – farma d.o.o. | Sunitinib Krka | caps. tvrda 30x25 mg | 47,8598 | 1.435,80 |  | 5% |
| L01EX01 133 | DS | sunitinibNL117 | 33 mg | 62,9192 | O | KRKA-FARMA d.o.o. | Krka d.d, Krka – farma d.o.o. | Sunitinib Krka | caps. tvrda 30x50 mg | 95,3321 | 2.859,96 |  | 5% |
| L01EX01 141 | DS | sunitinibNL117 | 33 mg | 60,2917 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Sunitinib Alkaloid-INT | caps. tvrda 28x12,5 mg | 22,8378 | 639,46 |  | 5% |
| L01EX01 142 | DS | sunitinibNL117 | 33 mg | 60,0162 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Sunitinib Alkaloid-INT | caps. tvrda 28x25 mg | 45,4668 | 1.273,07 |  | 5% |
| L01EX01 143 | DS | sunitinibNL117 | 33 mg | 59,7732 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Sunitinib Alkaloid-INT | caps. tvrda 28x50 mg | 90,5653 | 2.535,83 |  | 5% |
| L01EX01 164 | DS | sunitinibNL117 | 33 mg | 63,4644 | O | Pfizer Europe MA EEIG | Pfizer | Sutent | caps. tvrda 28x12,5 mg | 24,0398 | 673,11 |  | 5% |
| L01EX01 165 | DS | sunitinibNL117 | 33 mg | 63,1748 | O | Pfizer Europe MA EEIG | Pfizer | Sutent | caps. tvrda 28x25 mg | 47,8598 | 1.340,07 |  | 5% |
| L01EX01 166 | DS | sunitinibNL117 | 33 mg | 62,9190 | O | Pfizer Europe MA EEIG | Pfizer | Sutent | caps. tvrda 28x50 mg | 95,3319 | 2.669,29 |  | 5% |
| L01EX01 171 | DS | sunitinibNL117 | 33 mg | 63,4644 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sunitinib Stada | caps. tvrda 28x12,5 mg | 24,0398 | 673,11 |  | 5% |
| L01EX01 172 | DS | sunitinibNL117 | 33 mg | 63,1748 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sunitinib Stada | caps. tvrda 28x25 mg | 47,8598 | 1.340,07 |  | 5% |
| L01EX01 173 | DS | sunitinibNL117 | 33 mg | 62,9190 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sunitinib Stada | caps. tvrda 28x50 mg | 95,3319 | 2.669,29 |  | 5% |
| L01EX01 174 | DS | sunitinibNL117 | 33 mg | 63,4658 | O | Accord Healthcare S.L.U. | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Accord | caps. tvrda 30x12,5 mg | 24,0401 | 721,20 |  | 5% |
| L01EX01 175 | DS | sunitinibNL117 | 33 mg | 63,1751 | O | Accord Healthcare S.L.U. | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Accord | caps. tvrda 30x25 mg | 47,8598 | 1.435,80 |  | 5% |
| L01EX01 176 | DS | sunitinibNL117 | 33 mg | 62,9192 | O | Accord Healthcare S.L.U. | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Accord | caps. tvrda 30x50 mg | 95,3321 | 2.859,96 |  | 5% |
| L01EX01 177 | DS | sunitinibNL117 | 33 mg | 63,4644 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sunitinib Sandoz | caps. tvrda 28x12,5 mg | 24,0398 | 673,11 |  | 5% |
| L01EX01 178 | DS | sunitinibNL117 | 33 mg | 63,1748 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sunitinib Sandoz | caps. tvrda 28x25 mg | 47,8598 | 1.340,07 |  | 5% |
| L01EX01 179 | DS | sunitinibNL117 | 33 mg | 62,9190 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sunitinib Sandoz | caps. tvrda 28x50 mg | 95,3319 | 2.669,29 |  | 5% |
| L01EX01 181 | DS | sunitinibNL117 | 33 mg | 63,4644 | O | Mylan Ireland Limited | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Mylan | caps. tvrda 28x12,5 mg | 24,0398 | 673,11 |  | 5% |
| L01EX01 182 | DS | sunitinibNL117 | 33 mg | 63,1748 | O | Mylan Ireland Limited | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Mylan | caps. tvrda 28x25 mg | 47,8598 | 1.340,07 |  | 5% |
| L01EX01 183 | DS | sunitinibNL117 | 33 mg | 62,9190 | O | Mylan Ireland Limited | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Mylan | caps. tvrda 28x50 mg | 95,3319 | 2.669,29 |  | 5% |
| L01EX01 184 | DS | sunitinibNL117 | 33 mg | 63,4644 | O | ALPHA-MEDICAL d.o.o. | Synthon s.r.o., Synthon BV | Sunitinib Alpha-Medical | caps. tvrda 28x12,5 mg | 24,0398 | 673,11 |  | 5% |
| L01EX01 185 | DS | sunitinibNL117 | 33 mg | 63,1748 | O | ALPHA-MEDICAL d.o.o. | Synthon s.r.o., Synthon BV | Sunitinib Alpha-Medical | caps. tvrda 28x25 mg | 47,8598 | 1.340,07 |  | 5% |
| L01EX01 186 | DS | sunitinibNL117 | 33 mg | 62,9190 | O | ALPHA-MEDICAL d.o.o. | Synthon s.r.o., Synthon BV | Sunitinib Alpha-Medical | caps. tvrda 28x50 mg | 95,3319 | 2.669,29 |  | 5% |
| L01EX01 187 | DS | sunitinibNL117 | 33 mg | 63,4644 | O | Zentiva k.s. | Remedica Ltd., Pharmacare Premium Ltd. | Zesuva | caps. tvrda 28x12,5 mg | 24,0398 | 673,11 |  | 5% |
| L01EX01 188 | DS | sunitinibNL117 | 33 mg | 63,1748 | O | Zentiva k.s. | Remedica Ltd., Pharmacare Premium Ltd. | Zesuva | caps. tvrda 28x25 mg | 47,8598 | 1.340,07 |  | 5% |
| L01EX01 189 | DS | sunitinibNL117 | 33 mg | 62,9190 | O | Zentiva k.s. | Remedica Ltd., Pharmacare Premium Ltd. | Zesuva | caps. tvrda 28x50 mg | 95,3319 | 2.669,29 |  | 5% |
| L01EX01 191 | DS | sunitinibNL117 | 33 mg | 60,2917 | O | Pharmascience International Limited | Bluepharma Industria Farmaceutica S.A. | Sunitinib Pharmascience | caps. tvrda 28x12,5 mg | 22,8378 | 639,46 |  | 5% |
| L01EX01 192 | DS | sunitinibNL117 | 33 mg | 60,0162 | O | Pharmascience International Limited | Bluepharma Industria Farmaceutica S.A. | Sunitinib Pharmascience | caps. tvrda 28x25 mg | 45,4668 | 1.273,07 |  | 5% |
| L01EX01 193 | DS | sunitinibNL117 | 33 mg | 59,7732 | O | Pharmascience International Limited | Bluepharma Industria Farmaceutica S.A. | Sunitinib Pharmascience | caps. tvrda 28x50 mg | 90,5653 | 2.535,83 |  | 5% |
| L01EX01 194 | DS | sunitinibNL117 | 33 mg | 57,2765 | O | Farmex d.o.o. | Genepharm S.A., Pharmacare Premium Ltd. | Nibufar | caps. tvrda 28x12,5 mg | 21,6959 | 607,48 |  | 5% |
| L01EX01 195 | DS | sunitinibNL117 | 33 mg | 57,0151 | O | Farmex d.o.o. | Genepharm S.A., Pharmacare Premium Ltd. | Nibufar | caps. tvrda 28x25 mg | 43,1933 | 1.209,41 |  | 5% |
| L01EX01 196 | DS | sunitinibNL117 | 33 mg | 56,7839 | O | Farmex d.o.o. | Genepharm S.A., Pharmacare Premium Ltd. | Nibufar | caps. tvrda 28x50 mg | 86,0362 | 2.409,01 |  | 5% |
| L01EX02 171 | KLDS | sorafenibNL118 | 800 mg | 77,7832 | O | Bayer AG | Bayer AG | Nexavar | tbl. film obl. 112x200 mg | 19,4458 | 2.177,93 |  | 5% |
| L01EX02 172 | KLDS | sorafenibNL517 | 800 mg | 70,1996 | O | Mylan Ireland Limited | Remedica Ltd. | Sorafenib Mylan | tbl. film obl. 112x200 mg | 17,5499 | 1.965,59 |  | 5% |
| L01EX02 173 | KLDS | sorafenibNL517 | 800 mg | 77,7832 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sorafenib Stada | tbl. film obl. 112x200 mg | 19,4458 | 2.177,93 |  | 5% |
| L01EX02 174 | KLDS | sorafenibNL517 | 800 mg | 77,7832 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sorafenib Teva | tbl. film obl. 112x200 mg | 19,4458 | 2.177,93 |  | 5% |
| L01EX02 175 | KLDS | sorafenibNL517 | 800 mg | 73,8943 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sorafenib Sandoz | tbl. film obl. 112x200 mg | 18,4736 | 2.069,04 |  | 5% |
| L01EX02 176 | KLDS | sorafenibNL517 | 800 mg | 73,8943 | O | Zentiva k.s. | Remedica Ltd. | Fenesa | tbl. film obl. 112x200 mg | 18,4736 | 2.069,04 |  | 5% |
| L01EX02 177 | KLDS | sorafenibNL517 | 800 mg | 70,1996 | O | Pharmascience International Limited | Remedica Ltd., PharOS MT Ltd. | Sorafenib Pharmascience | tbl. film obl. 112x200 mg | 17,5499 | 1.965,59 |  | 5% |
| L01EX02 178 | KLDS | sorafenibNL517 | 800 mg | 70,1996 | O | STADA d.o.o. | STADA Arzneimittel AG | Sorafenib Stada | tbl. film obl. 56x400 mg | 35,0998 | 1.965,59 |  | 5% |
| L01EX03 101 | KLDS | pazopanibNL421 | 800 mg | 63,9947 | O | Teva B.V. | PharOS MT Ltd, Remedica Ltd. | Pazopanib Teva | tbl. film obl. 30x200 mg | 15,9986 | 479,96 |  | 5% |
| L01EX03 102 | KLDS | pazopanibNL421 | 800 mg | 63,9940 | O | Teva B.V. | PharOS MT Ltd, Remedica Ltd. | Pazopanib Teva | tbl. film obl. 30x400 mg | 31,9971 | 959,91 |  | 5% |
| L01EX03 161 | KLDS | pazopanibNL421 | 800 mg | 92,8667 | O | Novartis Europharm Limited Irska | Lek Pharmaceuticals d.d., Novartis Pharma GmbH | Votrient | tbl. film obl. 30x200 mg | 23,2168 | 696,50 |  | 5% |
| L01EX03 162 | KLDS | pazopanibNL421 | 800 mg | 91,4207 | O | Novartis Europharm Limited Irska | Lek Pharmaceuticals d.d., Novartis Pharma GmbH | Votrient | tbl. film obl. 30x400 mg | 45,7102 | 1.371,31 |  | 5% |
| L01EX03 171 | KLDS | pazopanibNL421 | 800 mg | 63,9947 | O | Zentiva k.s. | PharOS MT Ltd, Remedica Ltd. | Pazopanib Zentiva | tbl. film obl. 30x200 mg | 15,9986 | 479,96 |  | 5% |
| L01EX03 172 | KLDS | pazopanibNL421 | 800 mg | 63,9940 | O | Zentiva k.s. | PharOS MT Ltd, Remedica Ltd. | Pazopanib Zentiva | tbl. film obl. 30x400 mg | 31,9971 | 959,91 |  | 5% |
| L01EX03 181 | KLDS | pazopanibNL421 | 800 mg | 63,9947 | O | STADA d.o.o. | STADA Arzneimittel AG | Pyzypi | tbl. film obl. 30x200 mg | 15,9986 | 479,96 |  | 5% |
| L01EX03 182 | KLDS | pazopanibNL421 | 800 mg | 63,9940 | O | STADA d.o.o. | STADA Arzneimittel AG | Pyzypi | tbl. film obl. 30x400 mg | 31,9971 | 959,91 |  | 5% |
| L01EX03 191 | KLDS | pazopanibNL421 | 800 mg | 60,7947 | O | Pharmascience International Limited | Remedica Ltd., PharOS MT Ltd | Pazopanib Pharmascience | tbl. film obl. 30x200 mg | 15,1987 | 455,96 |  | 5% |
| L01EX03 192 | KLDS | pazopanibNL421 | 800 mg | 57,7547 | O | Pharmascience International Limited | Remedica Ltd., PharOS MT Ltd | Pazopanib Pharmascience | tbl. film obl. 60x400 mg | 28,8774 | 1.732,64 |  | 5% |
| L01EX04 161 | KS | vandetanibNL481 |  |  | O | Genzyme Europe B.V. | AstraZeneca UK Ltd. | Caprelsa | tbl. film obl. 30x100 mg | 55,0023 | 1.650,07 |  | 5% |
| L01EX04 162 | KS | vandetanibNL481 |  |  | O | Genzyme Europe B.V. | AstraZeneca UK Ltd. | Caprelsa | tbl. film obl. 30x300 mg | 156,2147 | 4.686,44 |  | 5% |
| L01EX05 161 | DS | regorafenibNL470 | 120 mg | 79,1771 | O | Bayer AG | Bayer AG | Stivarga | tbl. film obl. 84x40 mg | 26,3924 | 2.216,96 |  | 5% |
| L01EX08 161 | KL | lenvatinibNL542 | 18 mg | 222,9334 | O | Eisai GmbH | Eisai GmbH | Lenvima | caps. tvrda 30x4 mg | 49,5410 | 1.486,23 |  | 5% |
| L01EX08 162 | KL | lenvatinibNL542 | 18 mg | 92,2954 | O | Eisai GmbH | Eisai GmbH | Lenvima | caps. tvrda 30x10 mg | 51,2752 | 1.538,26 |  | 5% |
| L01EX09 161 | KS | nintedanibNL455 | 380 mg | 106,3080 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim Pharma GmbH | Ofev | caps. meka 60x100 mg | 27,9758 | 1.678,55 |  | 5% |
| L01EX09 162 | KS | nintedanibNL455 | 380 mg | 98,0574 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim Pharma GmbH | Ofev | caps. meka 60x150 mg | 38,7068 | 2.322,41 |  | 5% |
| L01EX09 171 | DS | nintedanibNL472 | 380 mg | 71,5218 | O | Boehringer Ingelheim International GmbH | Boerhinger Ingelheim | Vargatef | caps. meka 120x100 mg | 18,8215 | 2.258,58 |  | 5% |
| L01EX09 172 | DS | nintedanibNL472 | 380 mg | 95,3623 | O | Boehringer Ingelheim International GmbH | Boerhinger Ingelheim | Vargatef | caps. meka 60x150 mg | 37,6429 | 2.258,58 |  | 5% |
| L01EX10 171 | KL | midostaurinNL489 | 100 mg | 452,0275 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Rydapt | caps. meka 112x25 mg | 113,0068 | 12.656,77 |  | 5% |
| L01EX13 161 | DS | gilteritinibNL541 | 120 mg | 623,8011 | O | Astellas Pharma Europe B.V. | Astellas Pharma Europe B.V. | Xospata | tbl. film obl. 84x40 mg | 207,9337 | 17.466,43 |  | 5% |
| L01EX14 161 | DS | entrektinibNL528 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Rozlytrek | caps. tvrda 90x200 mg | 79,2085 | 7.128,77 |  | 5% |
| L01FA01 061 | DS | rituksimabNL518 |  |  | P | Roche Registration GmbH | Roche | Mabthera | boč. 2x100 mg/10 ml | 183,8510 | 367,70 |  | 5% |
| L01FA01 062 | DS | rituksimabNL518 |  |  | P | Roche Registration GmbH | Roche | Mabthera | boč. 1x500 mg/50 ml | 896,8651 | 896,87 |  | 5% |
| L01FA01 063 | DS | rituksimabNL429 |  |  | P | Roche Registration GmbH | Roche | Mabthera | otop. za supkut. inj., boč. 1x1400 mg | 1.394,1536 | 1.394,15 |  | 5% |
| L01FA01 071 | DS | rituksimabNL518 |  |  | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd. | Truxima | konc. za otop. za inf., boč. stakl. 1x500 mg/50 ml | 896,8651 | 896,87 |  | 5% |
| L01FA01 072 | DS | rituksimabNL518 |  |  | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd. | Truxima | konc. za otop. za inf., boč. stakl. 2x100 mg/10 ml | 183,8510 | 367,70 |  | 5% |
| L01FA01 081 | DS | rituksimabNL518 |  |  | P | Sandoz GmbH | Sandoz GmbH | Rixathon | konc. za otop. za inf., boč. stakl. 2x100 mg/10 ml | 181,5741 | 363,15 |  | 5% |
| L01FA01 082 | DS | rituksimabNL518 |  |  | P | Sandoz GmbH | Sandoz GmbH | Rixathon | konc. za otop. za inf., boč. stakl. 1x500 mg/50 ml | 891,5894 | 891,59 |  | 5% |
| L01FA01 083 | DS | rituksimabNL111 |  |  | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Ruxience | konc. za otop. za inf., boč. stakl. 1x100 mg/10 ml | 172,4959 | 172,50 |  | 5% |
| L01FA01 084 | DS | rituksimabNL111 |  |  | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Ruxience | konc. za otop. za inf., boč. stakl. 1x500 mg/50 ml | 847,0104 | 847,01 |  | 5% |
| L01FA03 061 | DS | obinutuzumabNL451 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Gazyvaro | konc. za otop. za inf., boč. stakl. 1x1000 mg/40 ml | 2.993,8616 | 2.993,86 |  | 5% |
| L01FC01 071 | KS | daratumumabNL492 |  |  | P | Janssen-Cilag International N.V. | Janssen Biologics B.V | Darzalex | konc. za otop. za inf., boč. stakl. 1x100 mg/5 ml | 421,1799 | 421,18 |  | 5% |
| L01FC01 072 | KS | daratumumabNL492 |  |  | P | Janssen-Cilag International N.V. | Janssen Biologics B.V | Darzalex | konc. za otop. za inf., boč. stakl. 1x400 mg/20 ml | 1.651,7592 | 1.651,76 |  | 5% |
| L01FC01 073 | KS | daratumumabNL492 |  |  | P | Janssen-Cilag International N.V. | Janssen Biologics B.V | Darzalex | otop. za supkut. inj., boč. 1x1800 mg/15 ml | 5.070,9802 | 5.070,98 |  | 5% |
| L01FD01 061 | DS | trastuzumab NL112 |  |  | P | Roche Registration GmbH | Roche | Herceptin | boč. 1x150 mg | 389,5959 | 389,60 |  | 5% |
| L01FD01 062 | DS | trastuzumab NL487 |  |  | P | Roche Registration GmbH | Roche | Herceptin | otop. za supkut. inj., boč. 1x600 mg/5 ml | 1.168,7876 | 1.168,79 |  | 5% |
| L01FD01 071 | DS | trastuzumab NL112 |  |  | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd | Herzuma | boč. 1x150 mg | 389,5959 | 389,60 |  | 5% |
| L01FD01 072 | DS | trastuzumab NL112 |  |  | P | Viatris Limited | McDermott Laboratories Limited T/A Mylan Dublin Biologics | Ogivri | boč. 1x150 mg | 370,1161 | 370,12 |  | 5% |
| L01FD01 081 | DS | trastuzumab NL112 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kanjinti | boč. 1x150 mg | 389,5959 | 389,60 |  | 5% |
| L01FD01 082 | DS | trastuzumab NL112 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kanjinti | boč. 1x420 mg | 1.055,6746 | 1.055,67 |  | 5% |
| L01FD01 083 | DS | trastuzumab NL112 |  |  | P | Pfizer Europe MA EEIG | Wyeth Pharmaceuticals, Pfizer Manufacturing Belgium NV | Trazimera | boč. 1x150 mg | 389,5959 | 389,60 |  | 5% |
| L01FD01 084 | DS | trastuzumab NL112 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Zercepac | boč. 1x150 mg | 351,6106 | 351,61 |  | 5% |
| L01FD01 085 | DS | trastuzumab NL112 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Zercepac | boč. 1x60 mg | 133,6121 | 133,61 |  | 5% |
| L01FD01 086 | DS | trastuzumab NL112 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Zercepac | boč. 1x420 mg | 970,4453 | 970,45 |  | 5% |
| L01FD02 061 | DS | pertuzumabNL443 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Perjeta | konc. za otop. za inf., boč. stakl. 1x420 mg | 2.538,0556 | 2.538,06 |  | 5% |
| L01FD03 061 | DS | trastuzumab emtanzinNL450 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Kadcyla | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 1.690,7559 | 1.690,76 |  | 5% |
| L01FD03 062 | DS | trastuzumab emtanzinNL450 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Kadcyla | praš. za konc. za otop. za inf., boč. stakl. 1x160 mg | 2.704,3599 | 2.704,36 |  | 5% |
| L01FE01 061 | DS | cetuksimabNL113 |  |  | P | Merck Europe B.V. | Merck Healthcare KGaA | Erbitux | otop. za inf., boč. 1x20 ml (5 mg/ml) | 178,3237 | 178,32 |  | 5% |
| L01FE02 061 | DS | panitumumabNL431 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Vectibix | konc. za otop. za inf., boč. 1x5 ml (20 mg/ml) | 366,7755 | 366,78 |  | 5% |
| L01FF01 061 | KS | nivolumabNL467 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Bristol – Myers Squibb S.r.l. | Opdivo | konc. za otop. za inf., boč. stakl. 1x4 ml (10 mg/ml) | 497,2234 | 497,22 |  | 5% |
| L01FF01 062 | KS | nivolumabNL467 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Bristol – Myers Squibb S.r.l. | Opdivo | konc. za otop. za inf., boč. stakl. 1x10 ml (10 mg/ml) | 1.225,2638 | 1.225,26 |  | 5% |
| L01FF01 063 | KS | nivolumabNL467 |  |  | P | Bristol-Myers Squibb Pharma EEIG | Bristol – Myers Squibb S.r.l. | Opdivo | konc. za otop. za inf., boč. stakl. 1x24 ml (10 mg/ml) | 2.925,3368 | 2.925,34 |  | 5% |
| L01FF02 062 | KS | pembrolizumabNL452 |  |  | P | Merck Sharp & Dohme B.V. | Schering – Plough Labo NV | Keytruda | konc. za otop. za inf., boč. stakl. 1x100 mg/4 ml (25 mg/ml) | 3.010,5727 | 3.010,57 |  | 5% |
| L01FF03 061 | KS | durvalumabNL515 |  |  | P | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | Imfinzi | konc. za otop. za inf., boč. stakl. 1x120 mg/2,4 ml (50mg/ml) | 653,9744 | 653,97 |  | 5% |
| L01FF03 062 | KS | durvalumabNL515 |  |  | P | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | Imfinzi | konc. za otop. za inf., boč. stakl. 1x500 mg/10 ml (50mg/ml) | 2.684,2471 | 2.684,25 |  | 5% |
| L01FF04 061 | KLKS | avelumabNL519 |  |  | P | Merck Europe B.V. | Merck Serono S.p.A. | Bavencio | konc. za otop. za inf. 10 ml, boč. stakl. 1x20 mg/ml | 882,8124 | 882,81 |  | 5% |
| L01FF05 071 | KS | atezolizumabNL529 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Tecentriq | konc. otop. za inf., boč. 1x1200 mg/20 ml | 4.049,7419 | 4.049,74 |  | 5% |
| L01FF05 072 | KS | atezolizumabNL529 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Tecentriq | konc. otop. za inf., boč. 1x840 mg/14 ml | 2.838,8068 | 2.838,81 |  | 5% |
| L01FF06 071 | KS | cemiplimabNL537 |  |  | P | Regeneron Ireland Designed Activity Company (DAC) | Regeneron Ireland DAC | Libtayo | konc. za otop. za inf., boč. 1x350 mg/7 ml | 6.010,9987 | 6.011,00 |  | 5% |
| L01FG01 061 | DS | bevacizumab NL128 |  |  | P | Roche Registration GmbH | Roche | Avastin | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 227,8041 | 227,80 |  | 5% |
| L01FG01 062 | DS | bevacizumabNL128 |  |  | P | Roche Registration GmbH | Roche | Avastin | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 859,2329 | 859,23 |  | 5% |
| L01FG01 071 | DS | bevacizumab NL128 |  |  | P | Amgen Technology (Ireland) UC | Amgen Technology (Ireland) UC | Mvasi | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 227,8041 | 227,80 |  | 5% |
| L01FG01 072 | DS | bevacizumab NL128 |  |  | P | Amgen Technology (Ireland) UC | Amgen Technology (Ireland) UC | Mvasi | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 859,2329 | 859,23 |  | 5% |
| L01FG01 073 | DS | bevacizumab NL128 |  |  | P | Mabxience Research S.L. | GH Genhelix S.A. | Alymsys | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 227,8041 | 227,80 |  | 5% |
| L01FG01 074 | DS | bevacizumab NL128 |  |  | P | Mabxience Research S.L. | GH Genhelix S.A. | Alymsys | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 859,2329 | 859,23 |  | 5% |
| L01FG01 075 | DS | bevacizumab NL128 |  |  | P | STADA Arzneimittel AG | GH GENHELIX S.A. | Oyavas | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 227,8041 | 227,80 |  | 5% |
| L01FG01 076 | DS | bevacizumab NL128 |  |  | P | STADA Arzneimittel AG | GH GENHELIX S.A. | Oyavas | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 859,2329 | 859,23 |  | 5% |
| L01FG01 077 | DS | bevacizumab NL128 |  |  | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Limited t/a Mylan Dublin Biologics, Mylan Germany GmbH | Abevmy | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 219,8805 | 219,88 |  | 5% |
| L01FG01 078 | DS | bevacizumab NL128 |  |  | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Limited t/a Mylan Dublin Biologics, Mylan Germany GmbH | Abevmy | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 840,3451 | 840,35 |  | 5% |
| L01FG02 061 | KS | ramucirumabNL469 |  |  | P | Eli Lilly Nederland B.V. | Lilly, S.A. | Cyramza | konc. za otop. za inf., boč. stakl. 2x10 ml (10 mg/ml) | 507,3582 | 1.014,72 |  | 5% |
| L01FX02 061 | KS | gemtuzumab ozogamicinNL525 |  |  | P | Pfizer Europe MA EEIG | Pfizer Ireland Pharmaceuticals | Mylotarg | praš. za konc. za otop. za inf., boč. stakl. 1x5 mg | 7.658,0875 | 7.658,09 |  | 5% |
| L01FX04 061 | KS | ipilimumabNL523 |  |  | P | Bristol-Myers Squibb Pharma EEIG | CATALENT ANAGNI S.R.L., Swords Laboratories T/A Bristol-Myers Squibb Cruiserath Biologics | Yervoy | konc. za otop. za inf., boč. stakl. 1x10 ml (5 mg/ml) | 3.448,3576 | 3.448,36 |  | 5% |
| L01FX05 061 | DS | brentuksimab vedotinNL442 |  |  | P | Takeda Pharma A/S | Takeda Italia S.p.A. | Adcetris | praš. za konc. za otop. za inf., boč. stakl. 1x50 mg | 2.939,0019 | 2.939,00 |  | 5% |
| L01FX06 061 | KL | dinutuksimab betaNL508 |  |  | P | EUSA Pharma (Netherlands) B.V. | Millmount Healthcare Ltd | Qarziba | konc. za otop. za inf., boč. stakl. 1x20 mg (4,5 mg/ml) | 9.219,4784 | 9.219,48 |  | 5% |
| L01XA01 001 | DS | cisplatin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Cisplatin | boč. 1x10 mg/20 ml | 3,0301 | 3,03 |  | 5% |
| L01XA01 002 | DS | cisplatin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Cisplatin | boč. 1x50 mg/100 ml | 14,6659 | 14,67 |  | 5% |
| L01XA01 063 | DS | cisplatin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Cisplatin | amp. 1x50 mg/50 ml | 14,0819 | 14,08 |  | 5% |
| L01XA02 072 | DS | karboplatin |  |  | P | Pfizer Croatia d.o.o. | Pfizer | Carboplatin | amp. 1x150 mg/15 ml | 25,2837 | 25,28 |  | 5% |
| L01XA03 066 | DS | oksaliplatin |  |  | P | ACTAVIS GROUP PTC ehf. | Sindan-Pharma | Sinoxal | praš. za otop. za inf., boč. 1x50 mg/10 ml | 89,1512 | 89,15 |  | 5% |
| L01XA03 067 | DS | oksaliplatin |  |  | P | ACTAVIS GROUP PTC ehf. | Sindan-Pharma | Sinoxal | praš. za otop. za inf., boč. 1x100 mg/20 ml | 187,0808 | 187,08 |  | 5% |
| L01XA03 075 | DS | oksaliplatin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Oxaliplatin Kabi | konc. za otop. za inf., boč. stakl. 1x10 ml (5 mg/ml) | 65,5677 | 65,57 |  | 5% |
| L01XA03 076 | DS | oksaliplatin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Oxaliplatin Kabi | konc. za otop. za inf., boč. stakl. 1x20 ml (5 mg/ml) | 128,6124 | 128,61 |  | 5% |
| L01XA03 077 | DS | oksaliplatin |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Oxaliplatin Kabi | konc. za otop. za inf., boč. stakl. 1x40 ml (5 mg/ml) | 257,2248 | 257,22 |  | 5% |
| L01XA03 081 | DS | oksaliplatin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Oxaliplatin Pliva | konc. otop. za inf., boč. stakl. 1x50 mg/10 ml | 97,8300 | 97,83 |  | 5% |
| L01XA03 082 | DS | oksaliplatin |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Oxaliplatin Pliva | konc. otop. za inf., boč. stakl. 1x100 mg/20 ml | 191,8973 | 191,90 |  | 5% |
| L01XB01 151 |  | prokarbazin |  |  | O |  |  |  |  |  |  | RSRL04 | 5% |
| L01XG01 002 | DS | bortezomibNL126 |  |  | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o., Teva Gyogyszergyar Zrt. | Bortezomib Pliva | praš. za otop. za inj., boč. 1x3,5 mg | 470,1029 | 470,10 |  | 5% |
| L01XG01 003 | DS | bortezomibNL126 |  |  | P | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma S.R.L. | Bortezomib Actavis | praš. za otop. za inj., boč. 1x3,5 mg | 423,0924 | 423,09 |  | 5% |
| L01XG01 032 | DS | bortezomibNL126 |  |  | P | KRKA-FARMA d.o.o. | Krka d.d. | Bortezomib Krka | praš. za otop. za inj., boč. 1x3,5 mg | 401,9378 | 401,94 |  | 5% |
| L01XG01 041 | DS | bortezomibNL126 |  |  | P | PharmaS d.o.o. | Synthon Hispania S.L., Synthon s.r.o. | Bortezomib PharmaS | praš. za otop. za inj., boč. 1x3,5 mg/10 ml | 470,1029 | 470,10 |  | 5% |
| L01XG01 042 | DS | bortezomibNL126 |  |  | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, WESSLING Hungary Kft. | Bortezomib Accord | praš. za otop. za inj., boč. 1x3,5 mg | 470,1029 | 470,10 |  | 5% |
| L01XG01 043 | DS | bortezomibNL126 |  |  | P | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Gloftrinid | praš. za otop. za inj., boč. 1x3,5 mg | 362,7487 | 362,75 |  | 5% |
| L01XG01 061 | DS | bortezomibNL126 |  |  | P | Zentiva k.s. | Synthon Hispania S.L., Synthon s.r.o. | Vortemyel | praš. za otop. za inj., boč. 1x3,5 mg/10 ml | 613,4833 | 613,48 |  | 5% |
| L01XG01 062 | DS | bortezomibNL126 |  |  | P | ALPHA-MEDICAL d.o.o. | Pharmidea LLC | Bortezomib Alpha-Medical | praš. za otop. za inj., boč. 1x3,5 mg | 470,1029 | 470,10 |  | 5% |
| L01XG01 081 | DS | bortezomibNL126 |  |  | P | Fresenius Kabi Deutschland GmbH | Fresenius Kabi Deutchland GmbH | Bortezomib Fresenius Kabi | praš. za otop. za inj., boč. 1x3,5 mg | 381,8409 | 381,84 |  | 5% |
| L01XG02 071 | KS | karfilzomibNL493 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kyprolis | praš. za otop. za inf., boč. stakl. 1x10 mg/5 ml (2 mg/ml) | 191,8429 | 191,84 |  | 5% |
| L01XG02 072 | KS | karfilzomibNL493 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kyprolis | praš. za otop. za inf., boč. stakl. 1x30 mg/15 ml (2 mg/ml) | 575,5286 | 575,53 |  | 5% |
| L01XG02 073 | KS | karfilzomibNL493 |  |  | P | Amgen Europe B.V. | Amgen Europe B.V. | Kyprolis | praš. za otop. za inf., boč. stakl. 1x60 mg/30 ml (2 mg/ml) | 1.073,5590 | 1.073,56 |  | 5% |
| L01XG03 171 | KS | iksazomibNL494 |  |  | O | Takeda Pharma A/S | Takeda Pharma A/S | Ninlaro | caps. tvrde 3x2,3 mg | 1.609,9843 | 4.829,95 |  | 5% |
| L01XG03 172 | KS | iksazomibNL494 |  |  | O | Takeda Pharma A/S | Takeda Pharma A/S | Ninlaro | caps. tvrde 3x3 mg | 1.609,9843 | 4.829,95 |  | 5% |
| L01XG03 173 | KS | iksazomibNL494 |  |  | O | Takeda Pharma A/S | Takeda Pharma A/S | Ninlaro | caps. tvrde 3x4 mg | 1.609,9843 | 4.829,95 |  | 5% |
| L01XK01 162 | KSDS | olaparibNL521 |  |  | O | AstraZeneca AB | AstraZeneca AB | Lynparza | tbl. film obl. 56x100 mg | 43,3933 | 2.430,02 |  | 5% |
| L01XK01 163 | KSDS | olaparibNL521 |  |  | O | AstraZeneca AB | AstraZeneca AB | Lynparza | tbl. film obl. 56x150 mg | 43,3933 | 2.430,02 |  | 5% |
| L01XK04 161 | DS | talazoparibNL530 |  |  | O | Pfizer Europe MA EEIG | Excella GmbH & Co. KG | Talzenna | caps. 30x0,25 mg | 55,9820 | 1.679,46 |  | 5% |
| L01XK04 162 | DS | talazoparibNL530 |  |  | O | Pfizer Europe MA EEIG | Excella GmbH & Co. KG | Talzenna | caps. 30x1 mg | 165,6535 | 4.969,61 |  | 5% |
| L01XX01 051 | KS | amsakrin |  |  | P |  |  |  |  |  |  |  | 5% |
| L01XX02 051 | KS | L-asparaginaza |  |  | P |  |  |  |  |  |  |  | 5% |
| L01XX05 183 |  | hidroksikarbamid |  |  | O | Cheplapharm Arzneimittel GmbH | Corden Pharma Latina S.p.A., | Litalir | caps. 100x500 mg | 0,3026 | 30,26 | RSRL04 | 5% |
| L01XX05 184 |  | hidroksikarbamid |  |  | O | Makpharm d.o.o. | PharmaS d.o.o. | Xybaid | caps. 100x500 mg | 0,3026 | 30,26 | RSRL04 | 5% |
| L01XX24 071 | KS | pegaspergazaNL497 |  |  | P | Les Laboratoires Servier | Les Laboratoires Servier Industrie | Oncaspar | praš. za otop. za inf., boč. stakl. 1x3750 U (750 U/ml) | 1.655,2751 | 1.655,28 |  | 5% |
| L01XX27 011 | DS | arsenov trioksidNL543 |  |  | P | Teva B.V. | Almac Pharma Services (Ireland) Limited, Almac Pharma Services Limited | Trisenox | konc. za otop. za inf., 10x6 ml (2 mg/ml) | 330,4798 | 3.304,80 |  | 5% |
| L01XX35 171 | DS | anagrelidNL459 |  |  | O | AOP Orphan Pharmaceuticals AG | AOP Orphan Pharmaceuticals AG | Thromboreductin | caps. tvrda 100x0,5 mg | 2,4244 | 242,44 |  | 5% |
| L01XX35 172 | DS | anagrelidNL459 |  |  | O | Zentiva k.s. | Synthon BV, Synthon Hispania S.L. | Grenalvon | caps. tvrda 100x0,5 mg | 2,4244 | 242,44 |  | 5% |
| L01XX35 173 | DS | anagrelidNL459 |  |  | O | PLIVA HRVATSKA d.o.o. | Synthon Hispania S.L. | Atremia | caps. tvrda 100x0,5 mg | 2,3062 | 230,62 |  | 5% |
| L01XX35 174 | DS | anagrelidNL459 |  |  | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania, Synthon BV | Anagrelid Alpha-Medical | caps. tvrda 100x0,5 mg | 2,4244 | 242,44 |  | 5% |
| L01XX35 175 | DS | anagrelidNL459 |  |  | O | STADA d.o.o. | Stada Arzneimittel AG | Anagrelid Stada | caps. tvrda 100x0,5 mg | 2,4244 | 242,44 |  | 5% |
| L01XX44 061 | DS | afliberceptNL475 |  |  | P | sanofi-aventis groupe | Sanofi – aventis Deutschland GmbH | Zaltrap | konc. za otop. za inf., boč. stakl. 1x100 mg/4 ml (25 mg/ml) | 337,8459 | 337,85 |  | 5% |
| L01XX44 062 | DS | afliberceptNL475 |  |  | P | sanofi-aventis groupe | Sanofi – aventis Deutschland GmbH | Zaltrap | konc. za otop. za inf., boč. stakl. 1x200 mg/8 ml (25 mg/ml) | 666,1265 | 666,13 |  | 5% |
| L01XX52 161 | DS | venetoklaksNL544 |  |  | O | AbbVie Deutschland GmbH & Co. KG | AbbVie Deutschland GmbH | Venclyxto | tbl. film obl. 14x10 mg | 5,2713 | 73,80 |  | 5% |
| L01XX52 162 | DS | venetoklaksNL544 |  |  | O | AbbVie Deutschland GmbH & Co. KG | AbbVie Deutschland GmbH | Venclyxto | tbl. film obl. 7x50 mg | 26,2114 | 183,48 |  | 5% |
| L01XX52 163 | DS | venetoklaksNL544 |  |  | O | AbbVie Deutschland GmbH & Co. KG | AbbVie Deutschland GmbH | Venclyxto | tbl. film obl. 7x100 mg | 51,7845 | 362,49 |  | 5% |
| L01XX52 164 | DS | venetoklaksNL544 |  |  | O | AbbVie Deutschland GmbH & Co. KG | AbbVie Deutschland GmbH | Venclyxto | tbl. film obl. 112x100 mg | 50,5400 | 5.660,48 |  | 5% |
| L01XX71 071 | KL | tisagenlekleucelNL499 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Kymriah | 1,2 x 106 – 6 x 108 stanica disperzija za infuziju, 1-3 vrećice za infuziju | ########### | 314.704,54 |  | 5% |
| L01XY02 061 | DS | pertuzumab + trastuzumabNL520 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Phesgo | otop. za inj., boč. stakl. 1x(600 mg + 600 mg)/10 ml | 3.848,3284 | 3.848,33 |  | 5% |
| L01XY02 062 | DS | pertuzumab + trastuzumabNL520 |  |  | P | Roche Registration GmbH | Roche Pharma AG | Phesgo | otop. za inj., boč. stakl. 1x(1200 mg + 600 mg)/15 ml | 6.527,8691 | 6.527,87 |  | 5% |
| L02AB01 161 |  | megestrol-acetat | 0,16 g | 1,3673 | O | Bausch Health Ireland Limited | Haupt Pharma Amareg GmbH | Megace | tbl. 30x160 mg | 1,3673 | 41,02 | RSRL02 | 5% |
| L02AE02 041 | DS | leuprorelinNL201 | 0,134 mg | 1,3072 | P | PharmaS d.o.o. | GP-PHARM, S.A. | Lutrate depo | praš. i otap. za susp. za inj. s prod. osl. 1x22,5 mg | 219,4877 | 219,49 |  | 5% |
| L02AE02 042 | DS | leuprorelinNL201 | 0,134 mg | 2,6664 | P | PharmaS d.o.o. | GP-PHARM, S.A. | Lutrate depo | praš. i otap. za susp. za inj. s prod. osl. 1x3,75 mg | 74,6168 | 74,62 |  | 5% |
| L02AE02 043 | DS | leuprorelinNL201 | 0,134 mg | 1,2418 | P | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp. z.o.o. | Camcevi | susp. za inj. s prod. osl., štrc. napunj. 1x42 mg | 389,2242 | 389,22 |  | 5% |
| L02AE02 062 | DS | leuprorelinNL201 | 0,134 mg | 1,4409 | P | Recordati Industria Chimica e Farmaceutica S.p.A. | Astellas Pharma Europe B.V. | Eligard | praš. i otap. za otop. za inj. štrc. 1x22,5 mg | 241,9484 | 241,95 |  | 5% |
| L02AE02 063 | DS | leuprorelinNL201 | 0,134 mg | 1,3521 | P | Recordati Industria Chimica e Farmaceutica S.p.A. | Astellas Pharma Europe B.V. | Eligard | praš. i otap. za otop. za inj., štrc. napunj. 1x45 mg | 454,0461 | 454,05 |  | 5% |
| L02AE02 802 | DS | leuprorelinNL201 | 60 mcg | 2,2432 | P | Sandoz d.o.o. | Sandoz – Ever Pharma | Lerin | implantat 1x5 mg | 186,9308 | 186,93 |  | 5% |
| L02AE03 061 | DS | goserelin | 0,129 mg | 3,0551 | P | AstraZeneca d.o.o. | AstraZeneca | Zoladex | implantat 1x3,6 mg, štap. u plast. aplik. | 85,2625 | 85,26 |  | 5% |
| L02AE03 062 | DS | goserelin | 0,129 mg | 3,1021 | P | AstraZeneca d.o.o. | AstraZeneca | Zoladex LA | implantat 1x10,8 mg, štap. u plast. aplik. | 259,7054 | 259,71 |  | 5% |
| L02AE03 071 | DS | goserelin | 0,129 mg | 2,7305 | P | Alvogen IPCo S.ar.l. | AMW GmbH | Reseligo | implantat u štrc. napunj. 1x3,6 mg | 76,1962 | 76,20 |  | 5% |
| L02AE03 072 | DS | goserelin | 0,129 mg | 2,7600 | P | Alvogen IPCo S.ar.l. | AMW GmbH | Reseligo | implantat u štrc. napunj. 1x10,8 mg | 231,0704 | 231,07 |  | 5% |
| L02AE04 072 | DS | triptorelin | 0,134 mg | 7,8720 | P | Ferring GmbH | Ferring | Decapeptyl | amp. 7x0,1 mg/ml | 5,6225 | 39,36 |  | 5% |
| L02AE04 073 | DS | triptorelin | 0,134 mg | 3,4336 | P | Ferring GmbH | Ferring | Decapeptyl Depot | prašak i otap. za susp. za inj., štrc. 1x3,75 mg/2 ml | 96,0887 | 96,09 |  | 5% |
| L02BA01 161 |  | tamoksifen | 20 mg | 0,1953 | O | AstraZeneca d.o.o. | AstraZeneca | Nolvadex | tbl. 30x10 mg | 0,0978 | 2,93 | RS RL02 | 5% |
| L02BA03 001 | DS | fulvestrantNL202 | 8,3 mg | 6,0255 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fulvestrant Pliva | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 181,4878 | 362,98 |  | 5% |
| L02BA03 022 | DS | fulvestrantNL202 | 8,3 mg | 6,0255 | P | Sandoz d.o.o. | Sandoz-Lek, Ebewe Pharma GmbH | Fulvestrant Sandoz | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 181,4878 | 362,98 |  | 5% |
| L02BA03 073 | DS | fulvestrantNL202 | 8,3 mg | 6,0255 | P | Mylan Pharmaceuticals Limited | Mylan Teoranta | Fulvestrant Mylan | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 181,4885 | 362,98 |  | 5% |
| L02BA03 081 | DS | fulvestrantNL202 | 8,3 mg | 5,7242 | P | Accord Healthcare Polska Sp. z o.o. | Actavis Italy S.p.A. | Fulvestrant Accord | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 172,4136 | 344,83 |  | 5% |
| L02BA03 082 | DS | fulvestrantNL202 | 8,3 mg | 5,1658 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Fulvestrant EVER Pharma | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 155,5936 | 311,19 |  | 5% |
| L02BA03 091 | DS | fulvestrantNL202 | 8,3 mg | 5,4377 | P | Apta Medica International d.o.o. | Laboratorios Farmalán | Fulvestrant AptaPharma | otop. za inj., štrc. napunj. 2x250 mg/5 ml | 163,7826 | 327,57 |  | 5% |
| L02BB01 101 |  | flutamid | 0,75 g | 1,0260 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prostandril | tbl. 100x250 mg | 0,3420 | 34,20 | RSRL05 | 5% |
| L02BB03 103 |  | bikalutamid | 50 mg | 0,7454 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Bilumid | tbl. film obl. 28x50 mg | 0,7455 | 20,87 | RSRL23 | 5% |
| L02BB03 104 |  | bikalutamid | 50 mg | 0,9313 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Bilumid | tbl. film obl. 28x150 mg | 2,7938 | 78,23 | RSRL23 | 5% |
| L02BB03 111 |  | bikalutamid | 50 mg | 0,7454 | O | Belupo d.d. | Belupo | Bixalan | tbl. film obl. 28x50 mg | 0,7455 | 20,87 | RSRL23 | 5% |
| L02BB03 112 |  | bikalutamid | 50 mg | 0,9313 | O | Belupo d.d. | Belupo | Bixalan | tbl. film obl. 28x150 mg | 2,7938 | 78,23 | RSRL23 | 5% |
| L02BB03 115 |  | bikalutamid | 50 mg | 0,7454 | O | Farmex d.o.o. | Genepharm S.A. | Kalufar | tbl. film obl. 28x50 mg | 0,7455 | 20,87 | RSRL23 | 5% |
| L02BB03 116 |  | bikalutamid | 50 mg | 0,9313 | O | Farmex d.o.o. | Genepharm S.A. | Kalufar | tbl. film obl. 28x150 mg | 2,7938 | 78,23 | RSRL23 | 5% |
| L02BB03 117 |  | bikalutamid | 50 mg | 0,7454 | O | STADA d.o.o. | Genepharm S.A. | Bikalis | tbl. film obl. 28x50 mg | 0,7455 | 20,87 | RSRL23 | 5% |
| L02BB03 118 |  | bikalutamid | 50 mg | 0,9313 | O | STADA d.o.o. | Genepharm S.A. | Bikalis | tbl. film obl. 28x150 mg | 2,7938 | 78,23 | RSRL23 | 5% |
| L02BB03 121 |  | bikalutamid | 50 mg | 0,7454 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Bikalutamid JGL | tbl. film obl. 28x50 mg | 0,7455 | 20,87 | RSRL23 | 5% |
| L02BB03 122 |  | bikalutamid | 50 mg | 0,9313 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Bikalutamid JGL | tbl. film obl. 28x150 mg | 2,7938 | 78,23 | RSRL23 | 5% |
| L02BB03 161 |  | bikalutamid | 50 mg | 0,7454 | O | Laboratoires Juvisé Pharmaceuticals | AstraZeneca | Casodex | tbl. 28x50 mg | 0,7455 | 20,87 | RSRL23 | 5% |
| L02BB03 162 |  | bikalutamid | 50 mg | 0,9313 | O | Laboratoires Juvisé Pharmaceuticals | AstraZeneca | Casodex | tbl. film obl. 28x150 mg | 2,7938 | 78,23 | RSRL23 | 5% |
| L02BB03 163 |  | bikalutamid | 50 mg | 0,7196 | O | Altamedics d.o.o. | Genepharm S.A. | Bicaprox | tbl. film obl. 28x50 mg | 0,7197 | 20,15 | RSRL23 | 5% |
| L02BB03 164 |  | bikalutamid | 50 mg | 0,8669 | O | Altamedics d.o.o. | Genepharm S.A. | Bicaprox | tbl. film obl. 28x150 mg | 2,6006 | 72,82 | RSRL23 | 5% |
| L02BB04 162 | DS | enzalutamidNL439 | 0,16 g | 109,9582 | O | Astellas Pharma Europe B.V. | Astellas Pharma Europe B.V. | Xtandi | tbl. film obl. 112x40 mg | 27,4895 | 3.078,83 |  | 5% |
| L02BB05 161 | DS | apalutamidNL532 | 0,24 g | 105,6864 | O | Janssen-Cilag International N.V. | Janssen-Cilag S.p.A. | Erleada | tbl. film obl. 112x60 mg | 26,4216 | 2.959,22 |  | 5% |
| L02BB06 161 | DS | darolutamidNL514 | 120 mg | 10,7023 | O | Bayer AG | Orion Corporation, Orion Pharma | Nubeqa | tbl. film obl. 112x300 mg | 26,7556 | 2.996,63 |  | 5% |
| L02BG03 101 |  | anastrozol | 1 mg | 0,6732 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Anastrozol Pliva | tbl. film obl. 28x1 mg | 0,6731 | 18,85 | RSRL24 | 5% |
| L02BG03 111 |  | anastrozol | 1 mg | 0,6732 | O | Farmex d.o.o. | Genepharm S.A., Rottendorf Pharma GmbH | Anastris | tbl. film obl. 28x1 mg | 0,6731 | 18,85 | RSRL24 | 5% |
| L02BG03 113 |  | anastrozol | 1 mg | 0,6732 | O | Belupo d.d. | Genepharm S.A. | Strazolan | tbl. film obl. 28x1 mg | 0,6731 | 18,85 | RSRL24 | 5% |
| L02BG03 121 |  | anastrozol | 1 mg | 0,6732 | O | Sandoz d.o.o. | Sandoz-Salutas | Anastrozol Sandoz | tbl. film obl. 28x1 mg | 0,6731 | 18,85 | RSRL24 | 5% |
| L02BG03 122 |  | anastrozol | 1 mg | 0,6732 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Anastrozol JGL | tbl. film obl. 28x1 mg | 0,6731 | 18,85 | RSRL24 | 5% |
| L02BG03 142 |  | anastrozol | 1 mg | 0,6732 | O | Mylan Hrvatska d.o.o. | McDermott Laboratories Limited t/a Gerard | Ivel | tbl. film obl. 28x1 mg | 0,6731 | 18,85 | RSRL24 | 5% |
| L02BG03 161 |  | anastrozol | 1 mg | 0,6480 | O | PharmaS d.o.o. | Cipla | Armotraz | tbl. film obl. 30x1 mg | 0,6481 | 19,44 | RSRL24 | 5% |
| L02BG03 163 |  | anastrozol | 1 mg | 0,6732 | O | STADA d.o.o. | Genepharm S.A. | Astralis | tbl. film obl. 28x1 mg | 0,6731 | 18,85 | RSRL24 | 5% |
| L02BG03 171 |  | anastrozol | 1 mg | 0,6732 | O | Laboratoires Juvisé Pharmaceuticals | AstraZeneca | Arimidex | tbl. film obl. 28x1 mg | 0,6731 | 18,85 | RSRL24 | 5% |
| L02BG03 181 |  | anastrozol | 1 mg | 0,6732 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Aremed | tbl. film obl. 28x1 mg | 0,6731 | 18,85 | RSRL24 | 5% |
| L02BG04 101 |  | letrozol | 2,5 mg | 0,6730 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Avomit | tbl. film obl. 30x2,5 mg | 0,6731 | 20,19 | RSRL25 | 5% |
| L02BG04 111 |  | letrozol | 2,5 mg | 0,6730 | O | Belupo d.d. | Genepharm S.A. | Letrilan | tbl. film obl. 30x2,5 mg | 0,6731 | 20,19 | RSRL25 | 5% |
| L02BG04 122 |  | letrozol | 2,5 mg | 0,6730 | O | Sandoz d.o.o. | Sandoz-Salutas | Letrozol Sandoz | tbl. film obl. 30x2,5 mg | 0,6731 | 20,19 | RSRL25 | 5% |
| L02BG04 124 |  | letrozol | 2,5 mg | 0,6730 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Letrozol JGL | tbl. film obl. 30x2,5 mg | 0,6731 | 20,19 | RSRL25 | 5% |
| L02BG04 161 |  | letrozol | 2,5 mg | 0,6730 | O | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Femara | tbl. film obl. 30x2,5 mg | 0,6731 | 20,19 | RSRL25 | 5% |
| L02BG04 164 |  | letrozol | 2,5 mg | 0,6730 | O | Zentiva k.s. | Vipharm S.A. | Lametta | tbl. film obl. 30x2,5 mg | 0,6731 | 20,19 | RSRL25 | 5% |
| L02BG04 165 |  | letrozol | 2,5 mg | 0,6730 | O | STADA d.o.o. | Genepharm S.A. | Siletris | tbl. film obl. 30x2,5 mg | 0,6731 | 20,19 | RSRL25 | 5% |
| L02BG04 171 |  | letrozol | 2,5 mg | 0,6730 | O | Farmex d.o.o. | Genepharm S.A. | Letrofar | tbl. film obl. 30x2,5 mg | 0,6731 | 20,19 | RSRL25 | 5% |
| L02BX03 111 | DS | abirateronNL440 | 1 g | 63,6523 | O | Teva B.V. | Teva Operations Poland Sp. z o.o., Merckle GmbH | Abirateron Teva | tbl. film obl. 60x500 mg | 31,8262 | 1.909,57 |  | 5% |
| L02BX03 121 | DS | abirateronNL440 | 1 g | 67,0027 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Abirateron Sandoz | tbl. film obl. 60x500 mg | 33,5013 | 2.010,08 |  | 5% |
| L02BX03 131 | DS | abirateronNL440 | 1 g | 67,0027 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, TAD Pharma GmbH | Abiraterone Krka | tbl. film obl. 60x500 mg | 33,5013 | 2.010,08 |  | 5% |
| L02BX03 141 | DS | abirateronNL440 | 1 g | 67,0027 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Abirateron Alpha-Medical | tbl. film obl. 60x500 mg | 33,5013 | 2.010,08 |  | 5% |
| L02BX03 142 | DS | abirateronNL440 | 1 g | 67,0027 | O | Accord Healthcare S.L.U. | Synthon Hispania S.L., Accord Healthcare Polska Sp. z.o.o. | Abiraterone Accord | tbl. film obl. 60x500 mg | 33,5013 | 2.010,08 |  | 5% |
| L02BX03 162 | DS | abirateronNL440 | 1 g | 67,0027 | O | Janssen-Cilag International N.V. | Janssen-Cilag S.p.A. | Zytiga | tbl. film obl. 60x500 mg | 33,5013 | 2.010,08 |  | 5% |
| L02BX03 171 | DS | abirateronNL440 | 1 g | 67,0027 | O | STADA d.o.o. | Remedica Ltd. | Abirateron STADA | tbl. film obl. 60x500 mg | 33,5013 | 2.010,08 |  | 5% |
| L02BX03 181 | DS | abirateronNL440 | 1 g | 67,0027 | O | Zentiva k.s. | Synthon BV, Synthon Hispania S.L. | Abirateron Zentiva | tbl. film obl. 60x500 mg | 33,5013 | 2.010,08 |  | 5% |
| L02BX03 191 | DS | abirateronNL440 | 1 g | 67,0027 | O | Mylan Ireland Limited | Remedica Ltd. | Abirateron Mylan | tbl. film obl. 60x500 mg | 33,5013 | 2.010,08 |  | 5% |
| L02BX03 192 | DS | abirateronNL440 | 1 g | 60,4700 | O | Pharmascience International Limited | Bluepharma Industria Farmaceutica S.A. | Abirateron Pharmascience | tbl. film obl. 60x500 mg | 30,2349 | 1.814,10 |  | 5% |
| L03AA02 001 | DS | filgrastim | 0,35 mg | 48,8974 | P | Teva GmbH | Pliva Hrvatska d.o.o. | Tevagrastim | otop. za inj. ili inf., štrc. stakl. napunj. 1x300 mcg/0,5 ml | 41,9099 | 41,91 |  | 5% |
| L03AA02 002 | DS | filgrastim | 0,35 mg | 49,6062 | P | Teva GmbH | Pliva Hrvatska d.o.o. | Tevagrastim | otop. za inj. ili inf., štrc. stakl. napunj. 1x480 mcg/0,8 ml | 68,0271 | 68,03 |  | 5% |
| L03AA02 071 | DS | filgrastim | 0,35 mg | 47,1621 | P | Pfizer Europe MA EEIG | Hospira Zagreb, Hospira Enterprises | Nivestim | otop. za inj. i inf., napunj. stakl. štrc. 12 MU, 5x0,2 ml (0,6 mg/ml) | 16,1702 | 80,85 |  | 5% |
| L03AA02 072 | DS | filgrastim | 0,35 mg | 48,8952 | P | Pfizer Europe MA EEIG | Hospira Zagreb d.o.o., Hospira Enterprises B.V. | Nivestim | otop. za inj. i inf., napunj. stakl. štrc. 30 MU, 5x0,5 ml (0,6 mg/ml) | 41,9101 | 209,55 |  | 5% |
| L03AA02 081 | DS | filgrastim | 0,35 mg | 48,8974 | P | Sandoz GmbH | Sandoz | Zarzio | otop. za inj. ili inf., štrc. stakl. napunj. 1x30 MU/0,5 ml | 41,9099 | 41,91 |  | 5% |
| L03AA02 082 | DS | filgrastim | 0,35 mg | 50,1094 | P | Sandoz GmbH | Sandoz | Zarzio | otop. za inj. ili inf., štrc. stakl. napunj. 1x48 MU/0,5 ml | 68,7186 | 68,72 |  | 5% |
| L03AA02 085 | DS | filgrastim | 0,35 mg | 40,5861 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Accofil | otop. za inj. ili inf., štrc. stakl. napunj. 5x30 MU/0,5 ml (0,6 mg/ml) | 34,7888 | 173,94 |  | 5% |
| L03AA02 086 | DS | filgrastim | 0,35 mg | 40,5871 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Accofil | otop. za inj. ili inf., štrc. stakl. napunj. 5x48 MU/0,5 ml (0,96 mg/ml) | 55,6621 | 278,31 |  | 5% |
| L03AA02 087 | DS | filgrastim | 0,35 mg | 47,1621 | P | Accord Healthcare S.L.U. | Accord Healthcare Ltd., Accord Healthcare Polska Sp.z o.o. | Accofil | otop. za inj. ili inf., štrc. stakl. napunj. 5x12 MU/0,2 ml (0,6 mg/ml) | 16,1702 | 80,85 |  | 5% |
| L03AA03 051 | DS | molgramostim | 0,35 mg |  | P |  |  |  |  |  |  |  | 5% |
| L03AA13 021 | DS | pegfilgrastimNL301 | 0,3 mg | 28,1805 | P | Sandoz GmbH | Sandoz GmbH | Ziextenzo | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 563,6101 | 563,61 |  | 5% |
| L03AA13 071 | DS | pegfilgrastimNL301 | 0,3 mg | 28,1805 | P | Amgen Europe B.V. | Amgen Europe B.V. | Neulasta | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 563,6101 | 563,61 |  | 5% |
| L03AA13 072 | DS | pegfilgrastimNL301 | 0,3 mg | 29,1320 | P | Amgen Europe B.V. | Amgen Europe B.V. | Neulasta | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml s on-body injektorom (Onpro pribor) | 582,6438 | 582,64 |  | 5% |
| L03AA13 073 | DS | pegfilgrastimNL301 | 0,3 mg | 28,1805 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Pelgraz | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 563,6101 | 563,61 |  | 5% |
| L03AA13 074 | DS | pegfilgrastimNL301 | 0,3 mg | 28,1805 | P | Viatris Limited | McDermott Laboratories t/a Mylan Dublin Biologics | Fulphila | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 563,6101 | 563,61 |  | 5% |
| L03AA13 075 | DS | pegfilgrastimNL301 | 0,3 mg | 27,6755 | P | Juta Pharma GmbH | Juta Pharma GmbH | Grasustek | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 553,5112 | 553,51 |  | 5% |
| L03AA13 081 | DS | pegfilgrastimNL301 | 0,3 mg | 28,1805 | P | Mundipharma Corporation (Ireland) Limited | 3P BIOPHARMACEUTICALS SL | Pelmeg | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 563,6101 | 563,61 |  | 5% |
| L03AA13 085 | DS | pegfilgrastimNL301 | 0,3 mg | 19,4085 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Pelgraz | otop. za inj., napunj. injektor 1x6 mg/0,6 ml | 388,1731 | 388,17 |  | 5% |
| L03AA14 001 | DS | lipegfilgrastimNL301 | 0,3 mg | 30,4035 | P | Teva Pharma B.V. | Merckle Biotec GmbH, Teva Pharmaceuticals Europe B.V. | Lonquex | otop. za inj., štrc. napunj. 1x6 mg/0,6 ml | 608,0722 | 608,07 |  | 5% |
| L03AA14 002 | DS | lipegfilgrastimNL301 | 0,3 mg | 28,8834 | P | Teva B.V. | Merckle GmbH, Teva Biotec GmbH | Lonquex | otop. za inj., boč. stakl. 6x6 mg/0,6 ml | 577,6685 | 3.466,01 |  | 5% |
| L03AB07 062 |  | interferon beta-1aNL303 | 4,3 mcg | 24,2767 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Avonex | otop. za inj., 4x0,5 ml (30 mcg/0,5 ml), štrc. napunj. i 4 igle | 169,3722 | 677,49 | RSRL94 | 5% |
| L03AB07 072 |  | interferon beta-1aNL303 | 4,3 mcg | 10,1291 | P | Merck Europe B.V. | Merck | Rebif | šprica 3x22 mcg (6 mil. i.j.)/0,5 ml | 51,8221 | 155,47 | RSRL94 | 5% |
| L03AB07 073 |  | interferon beta-1aNL303 | 4,3 mcg | 6,4931 | P | Merck Europe B.V. | Merck | Rebif | štrc. napunj. 12x44 mcg/0,5 ml | 66,4406 | 797,29 | RSRL94 | 5% |
| L03AB07 074 |  | interferon beta-1aNL303 | 4,3 mcg | 6,4543 | P | Merck Europe B.V. | Merck | Rebif | otop. za inj. u ulošku, 4x132 mcg/1,5 ml (44 mcg/0,5 ml) | 198,1319 | 792,53 | RSRL94 | 5% |
| L03AB08 092 |  | interferon beta-1bNL303 | 4 M i.j. |  | P | Bayer AG | Bayer AG | Betaferon | praš. i otap. štrc. napunj. 15x1,2 ml/300 mcg (250 mcg/ml) | 42,7894 | 641,84 | RSRL94 | 5% |
| L03AB11 061 | DS | peginterferon alfa-2aNL305 | 26 mcg | 25,8614 | P | Roche Registration GmbH | Roche | Pegasys | štrc. 1x135 mcg/0,5 ml i igla | 134,2770 | 134,28 |  | 5% |
| L03AB11 065 | DS | peginterferon alfa-2aNL305 | 26 mcg | 23,0980 | P | Roche Registration GmbH | Roche Pharma AG | Pegasys | štrc. 1x180 mcg/0,5 ml i igla | 159,9124 | 159,91 |  | 5% |
| L03AB13 071 |  | peginterferon beta-1aNL303 | 8.9 mcg | 15,5710 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Plegridy | otop. za inj., napunj. brizg. 1x63 mcg/0,5 ml + 1x94 mcg/0,5 ml | 274,6805 | 549,36 | RSRL94 | 5% |
| L03AB13 072 |  | peginterferon beta-1aNL303 | 8.9 mcg | 25,3134 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Plegridy | otop. za inj., napunj. brizg. 2x125 mcg/0,5 ml | 355,5226 | 711,05 | RSRL94 | 5% |
| L03AX03 051 | DS | BCG vaccinum | 1,8 mg |  | P |  |  |  |  |  |  |  | 5% |
| L03AX13 062 |  | glatiramer acetat (kopolimer-1)NL303 | 20 mg | 23,2007 | P | PLIVA HRVATSKA d.o.o. | Teva Pharmaceuticals Europe B.V. | Copaxone | otop. za inj., štrc. napunj. 28x20 mg/ml | 23,2008 | 649,62 | RSRL94 | 5% |
| L03AX13 063 |  | glatiramer acetat (kopolimer-1)NL303 | 20 mg | 23,3725 | P | PLIVA HRVATSKA d.o.o. | Teva Pharmaceuticals Europe B.V. | Copaxone | otop. za inj., štrc. napunj. 12x40 mg/ml | 46,7454 | 560,94 | RSRL94 | 5% |
| L03AX13 071 |  | glatirameracetatNL303 | 20 mg | 17,4575 | P | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Remurel | otop. za inj., štrc. napunj. 28x20 mg/ml | 17,4576 | 488,81 | RSRL94 | 5% |
| L03AX13 072 |  | glatirameracetatNL303 | 20 mg | 23,3725 | P | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Remurel | otop. za inj., štrc. napunj. 12x40 mg/ml | 46,7454 | 560,94 | RSRL94 | 5% |
| L03AX16 061 | KL | pleriksaforNL423 | 16,8 mg | 3.906,6219 | P | Genzyme Europe B.V. | Genzyme Ltd. | Mozobil | otop. za inj., boč. stakl. 1x24 mg/1,2 ml (20 mg/ml) | 5.581,0034 | 5.581,00 |  | 5% |
| L03AX21 051 | KL | elapegademaza-lvlrNL306 |  |  | P |  |  |  |  |  |  |  | 5% |
| L04AA02 051 | KL | muromonab (CD3) | 5 mg |  | P |  |  |  |  |  |  |  | 5% |
| L04AA03 051 | KL | imunoglobulin-antilimfocitniALGNL401 |  |  | P |  |  |  |  |  |  |  | 5% |
| L04AA04 073 | KL | imunoglobulin protiv T limfocita, kunićiji za humanu primj.NL402 |  |  | P | Neovii Biotech GmbH | Neovii Biotech GmbH | Grafalon | boč. 1x5 ml (20 mg/ml) | 256,6594 | 256,66 |  | 5% |
| L04AA04 074 | KL | imunoglobulin protiv T limfocita, kunićiji za humanu primj.NL402 |  |  | P | Neovii Biotech GmbH | Neovii Biotech GmbH | Grafalon | boč. 10x5 ml (20 mg/ml) | 256,6594 | 2.566,59 |  | 5% |
| L04AA04 161 | KL | kunićji imunoglobulin protiv timocita, za ljudeNL403 |  |  | P | sanofi-aventis groupe | Genzyme Polyclonals S.A.S. | Thymoglobuline | praš. za otop. za inf., boč. stakl. 1x25 mg | 182,5324 | 182,53 |  | 5% |
| L04AA06 062 | DS | mikofenolat mofetilNL404 | 2 g | 39,3100 | P | Roche Registration GmbH | Roche | CellCept | praš. za konc. za otop. za inf. boč. stakl. 4x500 mg/20 ml | 9,8275 | 39,31 |  | 5% |
| L04AA06 101 |  | mikofenolat mofetilNL404 | 2 g | 5,0272 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Trixin | tbl. film obl. 50x500 mg | 1,2569 | 62,84 | RSRL41 | 5% |
| L04AA06 102 |  | mikofenolat mofetilNL404 | 2 g | 5,2440 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Trixin | caps. tvrda 100x250 mg | 0,6555 | 65,55 | RSRL41 | 5% |
| L04AA06 161 |  | mikofenolat mofetilNL404 | 2 g | 5,6136 | O | Roche Registration GmbH | Roche | CellCept | caps. 100x250 mg | 0,7017 | 70,17 | RSRL41 | 5% |
| L04AA06 162 |  | mikofenolat mofetilNL404 | 2 g | 5,0272 | O | Roche Registration GmbH | Roche | CellCept | tbl. 50x500 mg | 1,2569 | 62,84 | RSRL41 | 5% |
| L04AA06 171 |  | mikofenolat-natrijNL405 | 2 g | 10,3028 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek d.d., PE PROIZVODNJA LENDAVA | Myfortic | tbl. žel. otp. 120x180 mg | 0,9273 | 111,27 | RSRL42 | 5% |
| L04AA06 172 |  | mikofenolat-natrijNL405 | 2 g | 9,9394 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek d.d., PE PROIZVODNJA LENDAVA | Myfortic | tbl. žel. otp. 120x360 mg | 1,7891 | 214,69 | RSRL42 | 5% |
| L04AA06 181 |  | mikofenolat-natrijNL405 | 2 g | 7,9676 | O | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Mikofenolatna kiselina Accord | tbl. žel. otp. 120x180 mg | 0,7171 | 86,05 | RSRL42 | 5% |
| L04AA06 182 |  | mikofenolat-natrijNL405 | 2 g | 7,9681 | O | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Mikofenolatna kiselina Accord | tbl. žel. otp. 120x360 mg | 1,4342 | 172,11 | RSRL42 | 5% |
| L04AA10 161 |  | sirolimus | 3 mg | 10,6990 | O | Pfizer Europe MA EEIG | Wyeth | Rapamune | tbl. obl. 30x1 mg | 3,5663 | 106,99 | RSRL43 | 5% |
| L04AA13 161 |  | leflunomid | 20 mg | 1,8607 | O | Sanofi-Aventis Deutschland GmbH | Aventis Intercontinental | Arava | tbl. film obl. 30x10 mg | 0,9304 | 27,91 | RSRL48 | 5% |
| L04AA13 162 |  | leflunomid | 20 mg | 1,1223 | O | Sanofi-Aventis Deutschland GmbH | Aventis Intercontinental | Arava | tbl. film obl. 30x20 mg | 1,1224 | 33,67 | RSRL48 | 5% |
| L04AA18 161 |  | everolimus | 1,5 mg | #N/A | O | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Certican | tbl. 60x0,25 mg | #N/A | #N/A | RSRL44 | 5% |
| L04AA18 162 |  | everolimus | 1,5 mg | 8,5130 | O | Novartis Hrvatska d.o.o. | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Certican | tbl. 60x0,50 mg | 2,8376 | 170,26 | RSRL44 | 5% |
| L04AA23 061 | DS | natalizumabNL406 | 10 mg | 49,5477 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Tysabri | konc. otop. za inf., boč. stakl. 1x15 ml (20 mg/1 ml) | 1.486,4251 | 1.486,43 |  | 5% |
| L04AA23 062 | DS | natalizumabNL406 | 10 mg | 50,5287 | P | Biogen Netherlands B.V. | FUJIFILM Diosynth Biotechnologies Denmark ApS, Biogen Netherlands B.V | Tysabri | otop. za inj., štrc. napunj. 2x150 mg | 757,9282 | 1.515,86 |  | 5% |
| L04AA25 061 | KL | ekulizumabNL482 | 64 mg | 917,6085 | P | Alexion Europe SAS | Almac Pharma Services, Patheon Italia S.p.A | Soliris | konc. za otop. za inf., boč. stakl. 1x300 mg (30 ml, 10 mg/ml) | 4.301,2901 | 4.301,29 |  | 5% |
| L04AA27 161 | DS | fingolimodNL457 | 0,5 mg | 35,4321 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Gilenya | caps. tvrda 28x0,5 mg | 35,4321 | 992,10 |  | 5% |
| L04AA27 162 | DS | fingolimodNL457 | 0,5 mg | 35,4321 | O | KRKA-FARMA d.o.o. | Idifarma Desarrollo Farmaceutico S.L., Krka d.d. | Efigalo | caps. tvrda 28x0,5 mg | 35,4321 | 992,10 |  | 5% |
| L04AA27 163 | DS | fingolimodNL457 | 0,5 mg | 35,4321 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Fingolimod Alpha-Medical | caps. tvrda 28x0,5 mg | 35,4321 | 992,10 |  | 5% |
| L04AA27 164 | DS | fingolimodNL457 | 0,5 mg | 35,4321 | O | Teva GmbH | Teva Operations Poland Sp. z o.o., Merckle GmbH | Fingolimod Teva | caps. tvrda 28x0,5 mg | 35,4321 | 992,10 |  | 5% |
| L04AA27 165 | DS | fingolimodNL457 | 0,5 mg | 35,4321 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Fingolimod Stada | caps. tvrda 28x0,5 mg | 35,4321 | 992,10 |  | 5% |
| L04AA27 166 | DS | fingolimodNL457 | 0,5 mg | 35,4321 | O | Sandoz d.o.o. | Novartis Pharma GmbH | Inzolfi | caps. tvrda 28x0,5 mg | 35,4321 | 992,10 |  | 5% |
| L04AA27 167 | DS | fingolimodNL457 | 0,5 mg | 35,4321 | O | Accord Healthcare S.L.U. | LABORATORI FUNDACIÓ DAU, Accord Healthcare Polska Sp. z.o.o. | Fingolimod Accord | caps. tvrda 28x0,5 mg | 35,4321 | 992,10 |  | 5% |
| L04AA27 168 | DS | fingolimodNL457 | 0,5 mg | 35,4321 | O | Mylan Ireland Limited | Mylan Hungary Kft | Fingolimod Mylan | caps. tvrda 28x0,5 mg | 35,4321 | 992,10 |  | 5% |
| L04AA27 169 | DS | fingolimodNL457 | 0,5 mg | 33,6604 | O | Pharmascience International Limited | Pharmascience International Limited | Fingolimod Pharmascience | caps. tvrda 28x0,5 mg | 33,6604 | 942,49 |  | 5% |
| L04AA27 171 | DS | fingolimodNL457 | 0,5 mg | 31,9775 | O | Jadran – Galenski Laboratorij d.d. | Genepharm S.A. | Arlesias | caps. tvrda 28x0,5 mg | 31,9774 | 895,37 |  | 5% |
| L04AA29 171 |  | tofacitinibNL506 | 10 mg | 1,2513 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Xeljanz | tbl. film obl. 56x5 mg | 12,5127 | 700,71 | RSRL105 | 5% |
| L04AA29 172 |  | tofacitinibNL507 | 10 mg | 1,1885 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Xeljanz | tbl. film obl. 56x10 mg | 23,7698 | 1.331,11 | RSRL106 | 5% |
| L04AA29 173 |  | tofacitinibNL509 | 10 mg | 1,1104 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Xeljanz | tbl. s prod. oslob. 28x11 mg | 24,4290 | 684,01 | RSRL109 | 5% |
| L04AA31 161 |  | teriflunomidNL538 | 14 mg | 23,7693 | O | sanofi-aventis groupe | Sanofi Winthrop Industrie | Aubagio | tbl. film obl. 28x14 mg | 23,7694 | 665,54 | RSRL114 | 5% |
| L04AA32 161 |  | apremilastNL505 |  |  | O | Amgen Europe B.V. | Celgene Distribution B.V. | Otezla | tbl. film obl. (4x10 mg) + (4x20 mg) + (19x30 mg) | 13,1338 | 354,61 | RSRL75 | 5% |
| L04AA32 162 |  | apremilastNL505 |  |  | O | Amgen Europe B.V. | Celgene Distribution B.V. | Otezla | tbl. film obl. 56x30 mg | 13,0834 | 732,67 | RSRL75 | 5% |
| L04AA33 061 | DS | vedolizumabNL437 |  |  | P | Takeda Pharma A/S | Takeda Italia S.p.A. | Entyvio | praš. za konc. za otop. za inf., boč. stakl. 1x300 mg | 1.897,2978 | 1.897,30 |  | 5% |
| L04AA33 064 |  | vedolizumabNL522 |  |  | P | Takeda Pharma A/S | Takeda Austria GmbH | Entyvio | otop. za inj., štrc. napunj. 2x108 mg | 441,8515 | 883,70 | RSRL110 | 5% |
| L04AA33 065 |  | vedolizumabNL522 |  |  | P | Takeda Pharma A/S | Takeda Austria GmbH | Entyvio | otop. za inj., brizg. napunj. 2x108 mg | 441,8515 | 883,70 | RSRL110 | 5% |
| L04AA34 061 | DS | alemtuzumabNL432 | 0,13 mg | 84,1506 | P | Sanofi Belgium | Genzyme Limited | Lemtrada | konc. za otop. za inf., boč. stakl. 1x12 mg/1,2 ml | 7.767,7484 | 7.767,75 |  | 5% |
| L04AA36 061 | DS | okrelizumabNL484 | 3.29 mg | 58,1965 | P | Roche Registration GmbH | Roche Pharma AG | Ocrevus | konc. za otop. za inf., boč. stakl. 1x300 mg/10 ml (30 mg/ml) | 5.306,6667 | 5.306,67 |  | 5% |
| L04AA37 161 |  | baricitinibNL503 | 4 mg | 54,0674 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Olumiant | tbl. film obl. 35x2 mg | 27,0339 | 946,18 | RSRL96 | 5% |
| L04AA37 162 |  | baricitinibNL504 | 4 mg | 24,7629 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Olumiant | tbl. film obl. 35x4 mg | 24,7630 | 866,70 | RSRL97 | 5% |
| L04AA40 161 | DS | kladribinNL308 | 0.34 mg | 61,9979 | O | Merck Europe B.V. | NerPharMa S.R.L., R-Pharm Germany GmbH | Mavenclad | tbl. 1x10 mg | 1.823,4720 | 1.823,47 |  | 5% |
| L04AA40 162 | DS | kladribinNL308 | 0.34 mg | 61,5591 | O | Merck Europe B.V. | NerPharMa S.R.L., R-Pharm Germany GmbH | Mavenclad | tbl. 4x10 mg | 1.810,5617 | 7.242,25 |  | 5% |
| L04AA42 161 | DS | siponimodNL513 |  |  | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Mayzent | tbl. film obl. 12x0,25 mg | 16,3594 | 196,31 |  | 5% |
| L04AA42 162 | DS | siponimodNL513 |  |  | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Mayzent | tbl. film obl. 120x0,25 mg | 12,4932 | 1.499,18 |  | 5% |
| L04AA42 163 | DS | siponimodNL513 |  |  | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Mayzent | tbl. film obl. 28x2 mg | 57,8729 | 1.620,44 |  | 5% |
| L04AA43 061 | KL | ravulizumab NL524 | 58.9 mg | #N/A | P | Alexion Europe SAS | Alexion Pharma International Operations Unlimited Company | Ultomiris | konc. za otop. za inf., boč. stakl. 1x300 mg (30 ml, 10 mg/ml) | #N/A | #N/A |  | 5% |
| L04AA43 062 | KL | ravulizumab NL524 | 58.9 mg | #N/A | P | Alexion Europe SAS | Alexion Pharma International Operations Unlimited Company | Ultomiris | konc. za otop. za inf., boč. stakl. 1x300 mg (3 ml, 100 mg/ml) | #N/A | #N/A |  | 5% |
| L04AA43 063 | KL | ravulizumab NL524 | 58.9 mg | #N/A | P | Alexion Europe SAS | Alexion Pharma International Operations Unlimited Company | Ultomiris | konc. za otop. za inf., boč. stakl. 1x1100 mg (11 ml, 100 mg/ml) | #N/A | #N/A |  | 5% |
| L04AA44 161 |  | upadacitinibNL512 | 15 mg | 23,9236 | O | AbbVie Deutschland GmbH & Co. KG | AbbVie S.r.l. | Rinvoq | tbl. s prod. oslob. 28x15 mg | 23,9237 | 669,86 | RSRL107 | 5% |
| L04AA44 162 |  | upadacitinibNL535 | 15 mg | 14,3543 | O | AbbVie Deutschland GmbH & Co. KG | AbbVie S.r.l. | Rinvoq | tbl. s prod. oslob. 28x30 mg | 28,7084 | 803,84 | RSRL112 | 5% |
| L04AA52 071 | DS | ofatumumabNL534 |  |  | P | Novartis Ireland Limited | Novartis Pharma GmbH | Kesimpta | otop. za inj., brizg. napunj. 1x20 mg | 1.342,5761 | 1.342,58 | RSRL111 | 5% |
| L04AB01 060 |  | etanerceptNL408 | 7 mg | 25,9455 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel | praš. i otap. za otop. za inj., boč. 4x25 mg + 4 napunj. štrc. s otap. | 92,6634 | 370,65 | RSRL93 | 5% |
| L04AB01 061 |  | etanerceptNL408 | 7 mg | 22,0171 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel | otop. za inj., štrc. napunj. 4x50 mg/ml + 4 jast. | 157,2656 | 629,06 | RSRL93 | 5% |
| L04AB01 063 |  | etanerceptNL408 | 7 mg | 21,8810 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel (MyClick) | otop. za inj., brizg. napunj. 4x50 mg/ml + 4 jast. natop. alkoholom | 156,2934 | 625,17 | RSRL93 | 5% |
| L04AB01 064 |  | etanerceptNL434 | 7 mg | 26,8764 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel | praš. i otap. za otop. za inj. za ped. upor., boč. 4x10 mg + 4 štrc. napunj. s otap. + 8 jast. | 38,3944 | 153,58 | RSRL93 | 5% |
| L04AB01 065 |  | etanerceptNL408 | 7 mg | 22,0171 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Benepali | otop. za inj., štrc. napunj. 4x50 mg/ml | 157,2656 | 629,06 | RSRL93 | 5% |
| L04AB01 066 |  | etanerceptNL408 | 7 mg | 21,8810 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Benepali | otop. za inj., brizg. napunj. 4x50 mg/ml | 156,2934 | 625,17 | RSRL93 | 5% |
| L04AB01 067 |  | etanerceptNL408 | 7 mg | 23,7734 | P | Pfizer Europe MA EEIG | Wyeth | Enbrel (MyClick) | otop. za inj., brizg. napunj. 4x25 mg/ml + 4 jast. natop. alkoholom | 84,9054 | 339,62 | RSRL93 | 5% |
| L04AB01 073 |  | etanerceptNL408 | 7 mg | 21,8810 | P | Sandoz GmbH | Sandoz GmbH | Erelzi | otop. za inj., brizg. napunj. 4x50 mg/ml | 156,2934 | 625,17 | RSRL93 | 5% |
| L04AB01 074 |  | etanerceptNL408 | 7 mg | 23,9568 | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Ltd T/A Mylan Dublin Biologics | Nepexto | otop. za inj., štrc. napunj. 4x25 mg/0.5 ml | 85,5608 | 342,24 | RSRL93 | 5% |
| L04AB01 075 |  | etanerceptNL408 | 7 mg | 22,0171 | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Ltd T/A Mylan Dublin Biologics | Nepexto | otop. za inj., štrc. napunj. 4x50 mg/ml | 157,2656 | 629,06 | RSRL93 | 5% |
| L04AB01 076 |  | etanerceptNL408 | 7 mg | 21,8810 | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Ltd T/A Mylan Dublin Biologics | Nepexto | otop. za inj., brizg. napunj. 4x50 mg/ml | 156,2934 | 625,17 | RSRL93 | 5% |
| L04AB02 021 | DS | infliksimabNL409 | 3,75 mg | 12,3495 | P | Sandoz GmbH | Sandoz GmbH | Zessly | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 329,3158 | 329,32 |  | 5% |
| L04AB02 061 | DS | infliksimabNL409 | 3,75 mg | 12,5111 | P | Janssen Biologics B.V. | Janssen Biologics B.V. | Remicade | lio boč. za inf. 1x100 mg | 333,6346 | 333,63 |  | 5% |
| L04AB02 071 | DS | infliksimabNL409 | 3,75 mg | 12,5111 | P | Pfizer Europe MA EEIG | HOSPIRA Enterprises B.V. | Inflectra | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 333,6346 | 333,63 |  | 5% |
| L04AB02 079 |  | infliksimabNL536 | 3,75 mg | 9,6431 | P | Celltrion Healthcare Hungary Kft. | Millmount Healthcare Ltd., Nuvisan GmbH | Remsima | otop. za inj., brizg. napunj. 2x120 mg | 308,5805 | 617,16 | RSRL113 | 5% |
| L04AB02 081 | DS | infliksimabNL409 | 3,75 mg | 12,5111 | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd. | Remsima | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 333,6346 | 333,63 |  | 5% |
| L04AB02 082 | DS | infliksimabNL409 | 3,75 mg | 12,5111 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Flixabi | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 333,6346 | 333,63 |  | 5% |
| L04AB04 063 |  | adalimumabNL510 | 2,9 mg | 21,0830 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie Biotechnology GmbH | Humira | otop. za inj., štrc. stakl. 2x40 mg/0,4 ml | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 064 |  | adalimumabNL510 | 2,9 mg | 21,0830 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie Biotechnology GmbH | Humira | otop. za inj., brizg. napunj. 2x40 mg/0,4 ml | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 066 |  | adalimumabNL411 | 2,9 mg | 21,0830 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie Biotechnology GmbH | Humira | otop. za inj., štrc. stakl. 2x20 mg/0,2 ml | 145,4005 | 290,80 | RSRL93 | 5% |
| L04AB04 067 |  | adalimumabNL510 | 2,9 mg | 21,0830 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie Biotechnology GmbH | Humira | otop. za inj., brizg. napunj. 1x80 mg/0,8 ml | 581,6006 | 581,60 | RSRL93 | 5% |
| L04AB04 071 |  | adalimumabNL411 | 2.9 mg | 21,0829 | P | Amgen Europe B.V. | Amgen Europe B.V. | Amgevita | otop. za inj. štrc. stakl., 1x20 mg/0,4 ml (50 mg/ml) | 145,4005 | 145,40 | RSRL93 | 5% |
| L04AB04 072 |  | adalimumabNL410 | 2,9 mg | 21,0830 | P | Amgen Europe B.V. | Amgen Europe B.V. | Amgevita | otop. za inj., štrc. stakl. 2x40 mg/0,8 ml (50 mg/ml) | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 073 |  | adalimumabNL410 | 2,9 mg | 21,0830 | P | Amgen Europe B.V. | Amgen Europe B.V. | Amgevita | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 074 |  | adalimumabNL410 | 2,9 mg | 21,0830 | P | Fresenius Kabi Deutschland GmbH | Merck Serono S.p.a. | Idacio | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 081 |  | adalimumabNL410 | 2,9 mg | 21,0830 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Imraldi | otop. za inj., štrc. stakl. 2x40 mg/0,8 ml (50 mg/ml) | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 082 |  | adalimumabNL410 | 2,9 mg | 21,0830 | P | Samsung Bioepis NL B.V. | Biogen Netherlands B.V. | Imraldi | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 085 |  | adalimumabNL410 | 2,9 mg | 21,0830 | P | Sandoz GmbH | Sandoz GmbH | Hyrimoz | otop. za inj., štrc. stakl. 2x40 mg/0,8 ml (50 mg/ml) | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 086 |  | adalimumabNL410 | 2,9 mg | 21,0830 | P | Sandoz GmbH | Sandoz GmbH | Hyrimoz | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 090 |  | adalimumabNL510 | 2,9 mg | 21,0830 | P | Viatris Limited | McDermott laboratories T/A Mylan Dublin Biologics, Mylan Germany GmbH | Hulio | otop. za inj., brizg. napunj. 2x40 mg/0,8 ml (50 mg/ml) | 290,8003 | 581,60 | RSRL93 | 5% |
| L04AB04 091 |  | adalimumabNL510 | 2,9 mg | 20,0289 | P | STADA Arzneimittel AG | Ivers-Lee CSM | Hukyndra | otop. za inj., brizg. napunj. 2x40 mg/0,4 ml | 276,2605 | 552,52 | RSRL93 | 5% |
| L04AB05 061 |  | certolizumab pegolNL428 | 14 mg | 28,9926 | P | UCB Pharma S.A. | UCB Pharma S.A. | Cimzia | otop. za inj., štrc. napunj. 2x200 mg/ml | 414,1814 | 828,36 | RSRL93 | 5% |
| L04AB06 061 |  | golimumabNL412 |  |  | P | Janssen Biologics B.V. | Janssen Biologics B.V. | Simponi | otop. za inj., brzig. napunj. 1x50 mg/0,5 ml | 859,2634 | 859,26 | RSRL93 | 5% |
| L04AB06 062 |  | golimumabNL412 |  |  | P | Janssen Biologics B.V. | Janssen Biologics B.V. | Simponi | otop. za inj., brizg. napunj. 1x100 mg/ml | 1.358,5507 | 1.358,55 | RSRL93 | 5% |
| L04AC02 061 | KS | baziliksimabNL413 | 40 mg | 2.174,7000 | P | Novartis Europharm Limited Irska | Novartis Farmacéutica S.A., Novartis Pharma GmbH | Simulect | praš. za inj. boč. 1x20 mg/5 ml | 1.087,3528 | 1.087,35 |  | 5% |
| L04AC05 061 |  | ustekinumabNL424 | 0,54 mg | 30,2587 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V. | Stelara | otop. za inj. štrc. napunj. 1x45 mg/0,5 ml | 2.521,5635 | 2.521,56 | RSRL99 | 5% |
| L04AC05 062 |  | ustekinumabNL463 | 0,54 mg | 15,1722 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V. | Stelara | otop. za inj. štrc. napunj. 1x90 mg/1 ml | 2.528,7040 | 2.528,70 | RSRL100 | 5% |
| L04AC05 063 | DS | ustekinumabNL464 | 0,54 mg | 10,5038 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V. | Stelara | konc. za otop. za inf., boč. stakl. 1x130 mg/26 ml | 2.528,7040 | 2.528,70 |  | 5% |
| L04AC07 061 | DS | tocilizumab NL414 |  |  | P | Roche Registration GmbH | Roche | RoActemra | konc. otop. za inf., boč. 1x80 mg/4 ml | 130,7864 | 130,79 |  | 5% |
| L04AC07 062 | DS | tocilizumabNL414 |  |  | P | Roche Registration GmbH | Roche | RoActemra | konc. otop. za inf., boč. 1x200 mg/10 ml | 327,0290 | 327,03 |  | 5% |
| L04AC07 063 | DS | tocilizumabNL414 |  |  | P | Roche Registration GmbH | Roche | RoActemra | konc. otop. za inf., boč. 1x400 mg/20 ml | 598,3197 | 598,32 |  | 5% |
| L04AC07 064 |  | tocilizumabNL486 | 20 mg | 26,1478 | P | Roche Registration GmbH | Roche | RoActemra | otop. za inj., štrc. napunj. 4x162 mg/0,9 ml | 211,7967 | 847,19 | RSRL93 | 5% |
| L04AC07 065 |  | tocilizumabNL485 | 20 mg | 26,1478 | P | Roche Registration GmbH | Roche Pharma AG | RoActemra | otop. za inj., brizg. napunj. 4x162 mg/0,9 ml (ACTPen) | 211,7967 | 847,19 | RSRL93 | 5% |
| L04AC10 061 |  | sekukinumabNL449 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Cosentyx | otop. za inj., brizg. napunj. 2x150 mg | 476,7529 | 953,51 | RSRL103 | 5% |
| L04AC10 062 |  | sekukinumabNL449 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Cosentyx | otop. za inj., brizg. napunj. 1x300 mg | 953,5059 | 953,51 | RSRL103 | 5% |
| L04AC13 061 |  | iksekizumabNL456 |  |  | P | Eli Lilly and Company (Ireland) Limited | Eli Lilly Italia S.p.A. | Taltz | otop. za inj., brizg. napunj. 1x80 mg/ml | 986,9441 | 986,94 | RSRL95 | 5% |
| L04AC14 071 |  | sarilumabNL433 | 14.3 mg | 42,0092 | P | sanofi-aventis groupe | Sanofi Winthrop Industrie | Kevzara | otop. za inj., štrc. napunj. 2x150 mg | 440,6563 | 881,31 | RSRL93 | 5% |
| L04AC14 072 |  | sarilumabNL433 | 14.3 mg | 40,7794 | P | sanofi-aventis groupe | Sanofi Winthrop Industrie | Kevzara | otop. za inj., brizg. napunj. 2x150 mg | 427,7557 | 855,51 | RSRL93 | 5% |
| L04AC14 073 |  | sarilumabNL433 | 14.3 mg | 31,0704 | P | sanofi-aventis groupe | Sanofi Winthrop Industrie | Kevzara | otop. za inj., štrc. napunj. 2x200 mg | 434,5484 | 869,10 | RSRL93 | 5% |
| L04AC14 074 |  | sarilumabNL433 | 14.3 mg | 30,5845 | P | sanofi-aventis groupe | Sanofi Winthrop Industrie | Kevzara | otop. za inj., brizg. napunj. 2x200 mg | 427,7557 | 855,51 | RSRL93 | 5% |
| L04AC16 062 |  | guselkumabNL483 | 1.79 mg | 34,0206 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V. | Tremfya | otop. za inj., brizg. napunj. 1x100 mg/ml | 1.900,5853 | 1.900,59 | RSRL102 | 5% |
| L04AC18 071 |  | risankizumabNL500 | 1,67 mg | 31,6759 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie S.r.l. | Skyrizi | otop. za inj., štrc. napunj. 2x75 mg/0,83 ml | 1.422,5695 | 2.845,14 | RSRL104 | 5% |
| L04AC18 072 |  | risankizumabNL500 | 1,67 mg | 31,6759 | P | AbbVie Deutschland GmbH & Co. KG | AbbVie S.r.l. | Skyrizi | otop. za inj., brizg. napunj. 1x150 mg | 2.845,1390 | 2.845,14 | RSRL104 | 5% |
| L04AD01 065 | KS | ciklosporinNL415 | 0,25 g | 8,7730 | P | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH | Sandimmun | amp. 10x250 mg/5 ml | 8,7734 | 87,73 |  | 5% |
| L04AD01 141 |  | ciklosporinNL415 | 0,25 g | 5,3040 | O | Alkaloid d.o.o. | Alkaloid | Ciklosporin Alkaloid | caps. meke 50x25 mg | 0,5304 | 26,52 | RSRL45 | 5% |
| L04AD01 142 |  | ciklosporinNL415 | 0,25 g | 4,7830 | O | Alkaloid d.o.o. | Alkaloid | Ciklosporin Alkaloid | caps. 50x50 mg | 0,9566 | 47,83 | RSRL45 | 5% |
| L04AD01 143 |  | ciklosporinNL415 | 0,25 g | 4,7450 | O | Alkaloid d.o.o. | Alkaloid | Ciklosporin Alkaloid | caps. meke 50x100 mg | 1,8979 | 94,90 | RSRL45 | 5% |
| L04AD01 161 |  | ciklosporinNL415 | 0,25 g | 5,3040 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek Pharmaceuticals d.d. | Sandimmun Neoral | caps. 50x25 mg | 0,5304 | 26,52 | RSRL45 | 5% |
| L04AD01 162 |  | ciklosporinNL415 | 0,25 g | 5,0790 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek Pharmaceuticals d.d. | Sandimmun Neoral | caps. 50x50 mg | 1,0158 | 50,79 | RSRL45 | 5% |
| L04AD01 163 |  | ciklosporinNL415 | 0,25 g | 4,7450 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Lek Pharmaceuticals d.d. | Sandimmun Neoral | caps. 50x100 mg | 1,8979 | 94,90 | RSRL45 | 5% |
| L04AD01 171 |  | ciklosporinNL415 | 0,25 g | 5,3040 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Equoral | caps. 50x25 mg | 0,5304 | 26,52 | RSRL45 | 5% |
| L04AD01 172 |  | ciklosporinNL415 | 0,25 g | 4,7830 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Equoral | caps. 50x50 mg | 0,9566 | 47,83 | RSRL45 | 5% |
| L04AD01 173 |  | ciklosporinNL415 | 0,25 g | 4,7450 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Equoral | caps. 50x100 mg | 1,8979 | 94,90 | RSRL45 | 5% |
| L04AD01 264 |  | ciklosporinNL415 | 0,25 g | 5,6265 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH | Sandimmun Neoral | otop. 10% 1x50 ml (100 mg/ml) | 112,5330 | 112,53 | RSRL45 | 5% |
| L04AD02 052 | KS | takrolimusNL416 | 5 mg |  | P |  |  |  |  |  |  |  | 5% |
| L04AD02 104 |  | takrolimusNL416 | 5 mg | 6,3267 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Tacforius | caps. s prod. oslob. tvrda 30x0,5 mg | 0,6327 | 18,98 | RSRL46 | 5% |
| L04AD02 105 |  | takrolimusNL416 | 5 mg | 6,5967 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Tacforius | caps. s prod. oslob. tvrda 30x1 mg | 1,3193 | 39,58 | RSRL46 | 5% |
| L04AD02 106 |  | takrolimusNL416 | 5 mg | 6,0039 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Tacforius | caps. s prod. oslob. tvrda 30x3 mg | 3,6023 | 108,07 | RSRL46 | 5% |
| L04AD02 107 |  | takrolimusNL416 | 5 mg | 5,8630 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company | Tacforius | caps. s prod. oslob. tvrda 30x5 mg | 5,8630 | 175,89 | RSRL46 | 5% |
| L04AD02 121 |  | takrolimusNL416 | 5 mg | 6,0400 | O | Sandoz d.o.o. | Sandoz-Lek | Tacrocel | caps. tvrda 30x0,5 mg | 0,6039 | 18,12 | RSRL46 | 5% |
| L04AD02 122 |  | takrolimusNL416 | 5 mg | 6,6492 | O | Sandoz d.o.o. | Sandoz-Lek | Tacrocel | caps. tvrda 60x1 mg | 1,3299 | 79,79 | RSRL46 | 5% |
| L04AD02 161 |  | takrolimusNL416 | 5 mg | 6,6492 | O | Astellas d.o.o. | Astellas Ireland Co. Ltd. | Prograf | caps. 60x1 mg | 1,3299 | 79,79 | RSRL46 | 5% |
| L04AD02 162 |  | takrolimusNL416 | 5 mg | 5,3987 | O | Astellas d.o.o. | Astellas Ireland Co. Ltd. | Prograf | caps. 30x5 mg | 5,3987 | 161,96 | RSRL46 | 5% |
| L04AD02 163 |  | takrolimusNL416 | 5 mg | 7,1200 | O | Astellas d.o.o. | Astellas Ireland Co. Ltd. | Prograf | caps. 30x0,5 mg | 0,7118 | 21,36 | RSRL46 | 5% |
| L04AD02 165 |  | takrolimusNL416 | 5 mg | 7,4133 | O | Astellas Pharma Europe B.V. | Astellas Ireland Co., Ltd. | Advagraf | caps. s prod. oslob. tvrda 30x0,5 mg | 0,7415 | 22,24 | RSRL46 | 5% |
| L04AD02 166 |  | takrolimusNL416 | 5 mg | 7,3083 | O | Astellas Pharma Europe B.V. | Astellas Ireland Co., Ltd. | Advagraf | caps. s prod. oslob. tvrda 30x1 mg | 1,4617 | 43,85 | RSRL46 | 5% |
| L04AD02 167 |  | takrolimusNL416 | 5 mg | 6,1878 | O | Astellas Pharma Europe B.V. | Astellas Ireland Co., Ltd. | Advagraf | caps. s prod. oslob. tvrda 30x3 mg | 3,7127 | 111,38 | RSRL46 | 5% |
| L04AD02 168 |  | takrolimusNL416 | 5 mg | 6,5180 | O | Astellas Pharma Europe B.V. | Astellas Ireland Co., Ltd. | Advagraf | caps. s prod. oslob. tvrda 30x5 mg | 6,5180 | 195,54 | RSRL46 | 5% |
| L04AD02 181 |  | takrolimusNL416 |  |  | O | Chiesi Faramaceutici S.p.A. | Chiesi Farmaceutici S.p.A. | Envarsus | tbl. s prod. oslob. 30x0,75 mg | 1,6232 | 48,70 | RSRL46 | 5% |
| L04AD02 182 |  | takrolimusNL416 |  |  | O | Chiesi Faramaceutici S.p.A. | Chiesi Farmaceutici S.p.A. | Envarsus | tbl. s prod. oslob. 60x1 mg | 2,0342 | 122,05 | RSRL46 | 5% |
| L04AD02 183 |  | takrolimusNL416 |  |  | O | Chiesi Faramaceutici S.p.A. | Chiesi Farmaceutici S.p.A. | Envarsus | tbl. s prod. oslob. 30x4 mg | 8,4876 | 254,63 | RSRL46 | 5% |
| L04AX01 195 |  | azatioprin | 0,15 g | 0,5190 | O | Aspen Pharma Trading Limited | Excella | Imuran | tbl. film obl. 100x50 mg | 0,1730 | 17,30 | R | 5% |
| L04AX03 131 |  | metotreksat | 2,5 mg | 0,1030 | O | Sandoz d.o.o. | Salutas Pharma GmbH | Metotreksat Sandoz | tbl. 30x2,5 mg | 0,1031 | 3,09 | RSRL48 | 5% |
| L04AX04 101 | DS | lenalidomidNL490 | 10 mg | 292,2705 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Lenalidomid Teva | caps. tvrda 21x5 mg | 146,1355 | 3.068,84 |  | 5% |
| L04AX04 102 | DS | lenalidomidNL490 | 10 mg | 151,1905 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Lenalidomid Teva | caps. tvrda 21x10 mg | 151,1902 | 3.175,00 |  | 5% |
| L04AX04 103 | DS | lenalidomidNL427 | 10 mg | 106,0943 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Lenalidomid Teva | caps. tvrda 21x15 mg | 159,1414 | 3.341,97 |  | 5% |
| L04AX04 104 | DS | lenalidomidNL427 | 10 mg | 69,7261 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Lenalidomid Teva | caps. tvrda 21x25 mg | 174,3150 | 3.660,62 |  | 5% |
| L04AX04 121 | DS | lenalidomidNL427 | 10 mg | 236,7390 | O | Sandoz d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Sandoz | caps. tvrda 21x5 mg | 118,3697 | 2.485,76 |  | 5% |
| L04AX04 122 | DS | lenalidomidNL427 | 10 mg | 122,4643 | O | Sandoz d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Sandoz | caps. tvrda 21x10 mg | 122,4641 | 2.571,75 |  | 5% |
| L04AX04 124 | DS | lenalidomidNL427 | 10 mg | 56,4781 | O | Sandoz d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Sandoz | caps. tvrda 21x25 mg | 141,1952 | 2.965,10 |  | 5% |
| L04AX04 141 | DS | lenalidomidNL490 | 10 mg | 202,9733 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Lenalidomid Alkaloid-INT | caps. tvrda 21x5 mg | 101,4868 | 2.131,22 |  | 5% |
| L04AX04 142 | DS | lenalidomidNL490 | 10 mg | 104,9971 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Lenalidomid Alkaloid-INT | caps. tvrda 21x10 mg | 104,9971 | 2.204,94 |  | 5% |
| L04AX04 143 | DS | lenalidomidNL427 | 10 mg | 73,6797 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Lenalidomid Alkaloid-INT | caps. tvrda 21x15 mg | 110,5195 | 2.320,91 |  | 5% |
| L04AX04 144 | DS | lenalidomidNL427 | 10 mg | 48,4223 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Lenalidomid Alkaloid-INT | caps. tvrda 21x25 mg | 121,0557 | 2.542,17 |  | 5% |
| L04AX04 161 | DS | lenalidomidNL490 | 10 mg | 297,5581 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Revlimid | caps. tvrda 21x5 mg | 148,7792 | 3.124,36 |  | 5% |
| L04AX04 162 | DS | lenalidomidNL490 | 10 mg | 154,5105 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Revlimid | caps. tvrda 21x10 mg | 154,5106 | 3.244,72 |  | 5% |
| L04AX04 163 | DS | lenalidomidNL427 | 10 mg | 108,8635 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Revlimid | caps. tvrda 21x15 mg | 163,2951 | 3.429,20 |  | 5% |
| L04AX04 164 | DS | lenalidomidNL427 | 10 mg | 71,5905 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Europe Limited | Revlimid | caps. tvrda 21x25 mg | 178,9763 | 3.758,50 |  | 5% |
| L04AX04 165 | DS | lenalidomidNL490 | 10 mg | 213,6562 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, KRKA – FARMA d.o.o. | Lenalidomid Krka | caps. tvrda 21x5 mg | 106,8282 | 2.243,39 |  | 5% |
| L04AX04 166 | DS | lenalidomidNL490 | 10 mg | 110,5238 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, KRKA – FARMA d.o.o. | Lenalidomid Krka | caps. tvrda 21x10 mg | 110,5238 | 2.321,00 |  | 5% |
| L04AX04 167 | DS | lenalidomidNL427 | 10 mg | 77,5575 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, KRKA – FARMA d.o.o. | Lenalidomid Krka | caps. tvrda 21x15 mg | 116,3363 | 2.443,06 |  | 5% |
| L04AX04 168 | DS | lenalidomidNL427 | 10 mg | 50,9709 | O | Krka d.d., Novo mesto | KRKA, d.d., Novo mesto, KRKA – FARMA d.o.o. | Lenalidomid Krka | caps. tvrda 21x25 mg | 127,4270 | 2.675,97 |  | 5% |
| L04AX04 171 | DS | lenalidomidNL427 | 10 mg | 297,5581 | O | Zentiva k.s. | Pharmadox Healthcare Limited, Pharmacare Premium Ltd. | Lenalidomid Zentiva | caps. tvrda 21x5 mg | 148,7792 | 3.124,36 |  | 5% |
| L04AX04 172 | DS | lenalidomidNL427 | 10 mg | 154,5105 | O | Zentiva k.s. | Pharmadox Healthcare Limited, Pharmacare Premium Ltd. | Lenalidomid Zentiva | caps. tvrda 21x10 mg | 154,5106 | 3.244,72 |  | 5% |
| L04AX04 173 | DS | lenalidomidNL427 | 10 mg | 108,8635 | O | Zentiva k.s. | Pharmadox Healthcare Limited, Pharmacare Premium Ltd. | Lenalidomid Zentiva | caps. tvrda 21x15 mg | 163,2951 | 3.429,20 |  | 5% |
| L04AX04 174 | DS | lenalidomidNL427 | 10 mg | 71,5905 | O | Zentiva k.s. | Pharmadox Healthcare Limited, Pharmacare Premium Ltd. | Lenalidomid Zentiva | caps. tvrda 21x25 mg | 178,9763 | 3.758,50 |  | 5% |
| L04AX04 175 | DS | lenalidomidNL427 | 10 mg | 224,9019 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x5 mg | 112,4507 | 2.361,47 |  | 5% |
| L04AX04 176 | DS | lenalidomidNL427 | 10 mg | 47,1644 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x7,5 mg | 35,3733 | 742,84 |  | 5% |
| L04AX04 177 | DS | lenalidomidNL427 | 10 mg | 116,3410 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x10 mg | 116,3408 | 2.443,16 |  | 5% |
| L04AX04 178 | DS | lenalidomidNL427 | 10 mg | 81,6397 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x15 mg | 122,4593 | 2.571,65 |  | 5% |
| L04AX04 179 | DS | lenalidomidNL427 | 10 mg | 64,1488 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x20 mg | 128,2974 | 2.694,25 |  | 5% |
| L04AX04 180 | DS | lenalidomidNL427 | 10 mg | 53,6535 | O | AS GRINDEKS | AS Grindeks | Lenalidomid Grindeks | caps. tvrda 21x25 mg | 134,1337 | 2.816,81 |  | 5% |
| L04AX04 181 | DS | lenalidomidNL427 | 10 mg | 136,0714 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Alpha-Medical | caps. tvrda 21x10 mg | 136,0712 | 2.857,50 |  | 5% |
| L04AX04 182 | DS | lenalidomidNL427 | 10 mg | 62,7533 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Lenalidomid Alpha-Medical | caps. tvrda 21x25 mg | 156,8835 | 3.294,55 |  | 5% |
| L04AX04 183 | DS | lenalidomidNL427 | 10 mg | 236,7390 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x2,5 mg | 59,1849 | 1.242,88 |  | 5% |
| L04AX04 184 | DS | lenalidomidNL490 | 10 mg | 236,7390 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x5 mg | 118,3697 | 2.485,76 |  | 5% |
| L04AX04 185 | DS | lenalidomidNL427 | 10 mg | 47,1644 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x7,5 mg | 35,3733 | 742,84 |  | 5% |
| L04AX04 186 | DS | lenalidomidNL490 | 10 mg | 122,4643 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x10 mg | 122,4641 | 2.571,75 |  | 5% |
| L04AX04 187 | DS | lenalidomidNL427 | 10 mg | 85,9362 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x15 mg | 128,9045 | 2.706,99 |  | 5% |
| L04AX04 188 | DS | lenalidomidNL427 | 10 mg | 67,5250 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x20 mg | 135,0499 | 2.836,05 |  | 5% |
| L04AX04 189 | DS | lenalidomidNL427 | 10 mg | 56,4781 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited, Pharmadox Healthcare Limited | Lenalidomid Accord | caps. tvrda 21x25 mg | 141,1952 | 2.965,10 |  | 5% |
| L04AX04 191 | DS | lenalidomidNL427 | 10 mg | 224,9029 | O | Pharmascience International Limited | Pharmadox Healthcare Limited, Alvogen Malta (Out-Licensing) Ltd. | Lenalidomid Pharmascience | caps. tvrda 21x5 mg | 112,4512 | 2.361,48 |  | 5% |
| L04AX04 192 | DS | lenalidomidNL427 | 10 mg | 116,3410 | O | Pharmascience International Limited | Pharmadox Healthcare Limited, Alvogen Malta (Out-Licensing) Ltd. | Lenalidomid Pharmascience | caps. tvrda 21x10 mg | 116,3409 | 2.443,16 |  | 5% |
| L04AX04 193 | DS | lenalidomidNL427 | 10 mg | 81,6397 | O | Pharmascience International Limited | Pharmadox Healthcare Limited, Alvogen Malta (Out-Licensing) Ltd. | Lenalidomid Pharmascience | caps. tvrda 21x15 mg | 122,4593 | 2.571,65 |  | 5% |
| L04AX04 194 | DS | lenalidomidNL427 | 10 mg | 53,6541 | O | Pharmascience International Limited | Pharmadox Healthcare Limited, Alvogen Malta (Out-Licensing) Ltd. | Lenalidomid Pharmascience | caps. tvrda 21x25 mg | 134,1354 | 2.816,84 |  | 5% |
| L04AX04 195 | DS | lenalidomidNL427 | 10 mg | 213,6571 | O | Mylan Ireland Limited | McDermott Laboratories Ltd trading as Gerard Laboratories, Mylan Hungary Kft | Lenalidomid Mylan | caps. tvrda 21x5 mg | 106,8287 | 2.243,40 |  | 5% |
| L04AX04 196 | DS | lenalidomidNL427 | 10 mg | 110,5238 | O | Mylan Ireland Limited | McDermott Laboratories Ltd trading as Gerard Laboratories, Mylan Hungary Kft | Lenalidomid Mylan | caps. tvrda 21x10 mg | 110,5238 | 2.321,00 |  | 5% |
| L04AX04 197 | DS | lenalidomidNL427 | 10 mg | 77,5575 | O | Mylan Ireland Limited | McDermott Laboratories Ltd trading as Gerard Laboratories, Mylan Hungary Kft | Lenalidomid Mylan | caps. tvrda 21x15 mg | 116,3363 | 2.443,06 |  | 5% |
| L04AX04 198 | DS | lenalidomidNL427 | 10 mg | 50,9714 | O | Mylan Ireland Limited | McDermott Laboratories Ltd trading as Gerard Laboratories, Mylan Hungary Kft | Lenalidomid Mylan | caps. tvrda 21x25 mg | 127,4286 | 2.676,00 |  | 5% |
| L04AX05 111 | KS | pirfenidonNL455 | 2,4 g | 50,2975 | O | Teva GmbH | Actavis Limited | Pirfenidon Teva | tbl. film obl. 252x267 mg | 5,5956 | 1.410,09 |  | 5% |
| L04AX05 112 | KS | pirfenidonNL455 | 2,4 g | 50,2975 | O | Teva GmbH | Actavis Limited | Pirfenidon Teva | tbl. film obl. 84x801 mg | 16,7868 | 1.410,09 |  | 5% |
| L04AX05 121 | KS | pirfenidonNL455 | 2,4 g | 52,9470 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Pirfenidon Sandoz | tbl. film obl. 252x267 mg | 5,8903 | 1.484,37 |  | 5% |
| L04AX05 122 | KS | pirfenidonNL455 | 2,4 g | 52,9470 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Pirfenidon Sandoz | tbl. film obl. 84x801 mg | 17,6710 | 1.484,37 |  | 5% |
| L04AX05 162 | KS | pirfenidonNL455 | 2,4 g | 75,6383 | O | Roche Registration GmbH | Roche Pharma AG | Esbriet | tbl. film obl. 252x267 mg | 8,4148 | 2.120,52 |  | 5% |
| L04AX05 163 | KS | pirfenidonNL455 | 2,4 g | 75,6383 | O | Roche Registration GmbH | Roche Pharma AG | Esbriet | tbl. film obl. 84x801 mg | 25,2443 | 2.120,52 |  | 5% |
| L04AX05 164 | KS | pirfenidonNL455 | 2,4 g | 50,2996 | O | Zentiva k.s. | PharOS MT Ltd, Rontis Hellas Medical and Pharmaceutical Products S.A. | Pirfenidon Zentiva | tbl. film obl. 252x267 mg | 5,5958 | 1.410,15 |  | 5% |
| L04AX05 165 | KS | pirfenidonNL455 | 2,4 g | 50,2996 | O | Zentiva k.s. | PharOS MT Ltd, Rontis Hellas Medical and Pharmaceutical Products S.A. | Pirfenidon Zentiva | tbl. film obl. 84x801 mg | 16,7875 | 1.410,15 |  | 5% |
| L04AX06 161 | KS | pomalidomidNL477 | 3 mg | 388,2362 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Distribution B.V. | Imnovid | caps. tvrda 21x3 mg | 388,2363 | 8.152,96 |  | 5% |
| L04AX06 162 | KS | pomalidomidNL477 | 3 mg | 294,7868 | O | Bristol-Myers Squibb Pharma EEIG | Celgene Distribution B.V. | Imnovid | caps. tvrda 21x4 mg | 393,0489 | 8.254,03 |  | 5% |
| L04AX07 161 | DS | dimetil fumaratNL538 | 0,48 g | 34,7057 | O | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Tecfidera | caps. žel. otp. tvrda 14x120 mg | 8,6766 | 121,47 |  | 5% |
| L04AX07 162 |  | dimetil fumaratNL538 | 0,48 g | 32,3279 | O | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Tecfidera | caps. žel. otp. tvrda 56x240 mg | 16,1639 | 905,18 | RSRL114 | 5% |
| L04AX07 171 | DS | dimetil fumaratNL538 | 0,48 g | 24,2943 | O | Mylan Ireland Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories | Dimetilfumarat Mylan | caps. žel. otp. tvrda 14x120 mg | 6,0736 | 85,03 |  | 5% |
| L04AX07 172 |  | dimetil fumaratNL538 | 0,48 g | 22,6293 | O | Mylan Ireland Limited | Mylan Hungary Kft, McDermott Laboratories Limited t/a Gerard Laboratories | Dimetilfumarat Mylan | caps. žel. otp. tvrda 56x240 mg | 11,3147 | 633,62 | RSRL114 | 5% |
| M01AB01 051 | DS | indometacin | 0,1 g |  | P |  |  |  |  |  |  |  | 5% |
| M01AB01 111 |  | indometacin | 0,1 g | 0,1840 | O | Belupo d.d. | Belupo | Indometacin Belupo | caps. tvrda 30x25 mg | 0,0460 | 1,38 | R | 5% |
| M01AB05 021 | PR | diklofenak | 0,1 g | 0,2533 | P | Sandoz d.o.o. | Sandoz-Salutas | Diclac | otop. za inj., amp. 5x75 mg/3 ml | 0,1906 | 0,95 |  | 5% |
| M01AB05 033 | PR | diklofenak | 0,1 g | 0,2650 | P | KRKA-FARMA d.o.o. | Krka d.d. | Naklofen | amp. 5x75 mg/3 ml | 0,2118 | 1,06 |  | 5% |
| M01AB05 111 |  | diklofenak | 0,1 g | 0,1030 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Diklofenak Mibe | tbl. retard 20x100 mg | 0,1031 | 2,06 | R | 5% |
| M01AB05 121 |  | diklofenak | 0,1 g | 0,1060 | O | Sandoz d.o.o. | Sandoz-Salutas | Diclac DUO | tbl. s prilag. oslob. 20x75 mg | 0,0796 | 1,59 | R | 5% |
| M01AB05 122 |  | diklofenak | 0,1 g | 0,1062 | O | Sandoz d.o.o. | Sandoz-Salutas | Diclac DUO | tbl. s prilag. oslob. 30x75 mg | 0,0796 | 2,39 | R | 5% |
| M01AB05 505 |  | diklofenak | 0,1 g | 2,1520 | R | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH | Voltaren | supp. 10x12,5 mg | 0,2694 | 2,69 | R | 5% |
| M01AB05 506 |  | diklofenak | 0,1 g | 1,4640 | R | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH | Voltaren | supp. 10x25 mg | 0,3662 | 3,66 | R | 5% |
| M01AC06 141 |  | meloksikam | 15 mg | 0,1030 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Meliam | tbl. 20x15 mg | 0,1031 | 2,06 | R | 5% |
| M01AE01 118 |  | ibuprofen | 1,2 g | 0,1060 | O | Belupo d.d. | Belupo | Ibuprofen Belupo | tbl. film obl. 30x800 mg | 0,0708 | 2,12 | R | 5% |
| M01AE01 274 |  | ibuprofen | 1,2 g | 0,9660 | O | Mylan Hrvatska d.o.o. | AbbVie S.r.L. | Dalsy | sirup 1x100 ml (100 mg/5 ml) | 1,6099 | 1,61 | R | 5% |
| M01AE01 314 |  | ibuprofen | 1,2 g | 0,9660 | O | Belupo d.d. | Belupo | Ibuprofen Belupo | oral. susp. 1x100 ml (20 mg/ml) | 1,6099 | 1,61 | R | 5% |
| M01AE01 342 |  | ibuprofen | 1,2 g | 0,7860 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Ibuprofen Alkaloid | oral. susp. 1x100 ml (20 mg/ml) | 1,3073 | 1,31 | R | 5% |
| M01AE01 361 |  | ibuprofen | 1,2 g | 0,7560 | O | Mylan Hrvatska d.o.o. | Farmasierra Manufacturing S.L. | Dalsy forte | oral. susp. 1x200 ml (40 mg/ml) | 5,0435 | 5,04 | R | 5% |
| M01AE01 371 |  | ibuprofen | 1,2 g | 0,8280 | O | Jadran – Galenski Laboratorij d.d. | Farmasierra Manufacturing S.L., JGL d.d. | Ibuprofen JGL | oral. susp. 1x100 ml (20 mg/ml) | 1,3763 | 1,38 | R | 5% |
| M01AE01 372 |  | ibuprofen | 1,2 g | 0,5310 | O | Jadran – Galenski Laboratorij d.d. | Farmasierra Manufacturing S.L., JGL d.d. | Ibuprofen JGL | oral. susp. 1x100 ml (40 mg/ml) | 1,7652 | 1,77 | R | 5% |
| M01AE03 021 | PR | ketoprofen | 0,15 g | 0,7200 | P | Sandoz d.o.o. | Sandoz-Lek | Ketonal | amp. 10x100 mg/2ml | 0,5043 | 5,04 |  | 5% |
| M01AE03 111 |  | ketoprofen | 0,15 g | 0,1080 | O | Belupo d.d. | Belupo | Knavon | caps. 25x50 mg | 0,0362 | 0,90 | R | 5% |
| M01AE03 112 |  | ketoprofen | 0,15 g | 0,1065 | O | Belupo d.d. | Belupo | Knavon forte | tbl. 20x100 mg | 0,0708 | 1,42 | R | 5% |
| M01AE03 113 |  | ketoprofen | 0,15 g | 0,1030 | O | Belupo d.d. | Belupo | Knavon | tbl. retard 20x150 mg | 0,1031 | 2,06 | R | 5% |
| M01AE03 122 |  | ketoprofen | 0,15 g | 0,1065 | O | Sandoz d.o.o. | Sandoz-Lek | Ketonal forte | tbl. film obl. 20x100 mg | 0,0708 | 1,42 | R | 5% |
| M01AE03 128 |  | ketoprofen | 0,15 g | 0,1030 | O | Sandoz d.o.o. | Sandoz-Lek | Ketonal DUO | caps. s prilag. oslob. tvrda 30x150 mg | 0,1031 | 3,09 | R | 5% |
| M01CB01 051 | DS | natrij-aurotiomalat | 2,4 mg |  | P |  |  |  |  |  |  |  | 5% |
| M01CC01 151 |  | penicilamin | 0,5 g |  | O |  |  |  |  |  |  | R | 5% |
| M03AB01 051 | DS | suksametonij |  |  | P |  |  |  |  |  |  |  | 5% |
| M03AC01 051 | DS | pankuronij |  |  | P |  |  |  |  |  |  |  | 5% |
| M03AC03 051 | DS | vekuronij |  |  | P |  |  |  |  |  |  |  | 5% |
| M03AC04 051 | DS | atrakurij |  |  | P |  |  |  |  |  |  |  | 5% |
| M03AC09 063 | DS | rokuronij |  |  | P | Merck Sharp & Dohme d.o.o. | Organon i Schering-Plough | Esmeron | boč. 10x50 mg/5 ml | 2,8397 | 28,40 |  | 5% |
| M03AC09 069 | DS | rokuronij |  |  | P | hameln pharma gmbh | Hameln rds, Siegfried Hameln GmbH | Rokuronijev bromid Hameln | otop za inj./inf., amp. 10x50 mg/5 ml | 2,4341 | 24,34 |  | 5% |
| M03AC09 071 | DS | rokuronij |  |  | P | hameln pharma gmbh | Hameln rds, Hameln Pharmaceuticals GmbH | Rokuronijev bromid Hameln | otop za inj./inf., boč. 10x50 mg/5 ml | 2,8397 | 28,40 |  | 5% |
| M03AC09 072 | DS | rokuronij |  |  | P | AS Kalceks | AS Kalceks | Rokuronijev bromid Kalceks 10 mg/ml | otop za inj./inf., boč. 10x50 mg/5 ml | 2,6977 | 26,98 |  | 5% |
| M03AC09 073 | DS | rokuronij |  |  | P | Mylan Pharmaceuticals Limited | Mylan S.A.S. | Rokuronijev bromid Mylan | otop za inj./inf., boč. 10x50 mg/5 ml | 2,6977 | 26,98 |  | 5% |
| M03AC09 074 | DS | rokuronij |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi Austria GmbH | Rokuronijev bromid Fresenius Kabi | otop za inj./inf., boč. 10x50 mg/5 ml | 2,5629 | 25,63 |  | 5% |
| M03AC09 075 | DS | rokuronij |  |  | P | B. Braun Melsungen AG | B. Braun Melsungen AG | Rokuronijev bromid B. Braun | otop za inj./inf., amp. 20x50 mg/5 ml | 2,4341 | 48,68 |  | 5% |
| M03AC11 061 | DS | cisatrakurij |  |  | P | Accord Healthcare Polska Sp. z o.o. | B. Braun Medical S.A. | Cisatrakurij Accordpharma | otop za inj./inf., boč. 5x5 ml (2 mg/ml) | 3,1057 | 15,53 |  | 5% |
| M03AC11 062 | DS | cisatrakurij |  |  | P | Accord Healthcare Polska Sp. z o.o. | B. Braun Medical S.A. | Cisatrakurij Accordpharma | otop za inj./inf., boč. 1x30 ml (5 mg/ml) | 46,5857 | 46,59 |  | 5% |
| M03AX01 061 | KSDS | C. botulinum toxin tip A-hemaglutinin kompleksNM301 |  |  | P | Allergan Pharm. Ireland | Allergan | Botox | lio. boč. 10 ml (1,4 mg/100 i.j.) | 185,3660 | 185,37 |  | 5% |
| M03AX01 071 | KS | clostridium botulinum neurotoksin tip A (150 kD)NM504 |  |  | P | Merz Pharmaceuticals Gmbh | Merz Pharma GmbH & Co. KgaA | Xeomin | praš. za otop. za inj., boč. 1x50 IU | 82,0015 | 82,00 |  | 5% |
| M03AX01 072 | KS | clostridium botulinum neurotoksin tip A (150 kD)NM504 |  |  | P | Merz Pharmaceuticals Gmbh | Merz Pharma GmbH & Co. KgaA | Xeomin | praš. za otop. za inj., boč. 1x100 IU | 164,0016 | 164,00 |  | 5% |
| M03BX01 051 | DS | baklofen | 0,55 mg |  | P |  |  |  |  |  |  |  | 5% |
| M03BX02 162 |  | tizanidin | 12 mg | 0,8160 | O | Altamedics d.o.o. | Niche Generics Ltd. | Tizanidin Altamedics | tbl 30x4 mg | 0,2721 | 8,16 | RSRM03 | 5% |
| M03CA01 151 | DS | dantrolenNM302 |  |  | OP |  |  |  |  |  |  |  | 5% |
| M04AA01 111 |  | alopurinol | 0,4 g | 0,1320 | O | Belupo d.d. | Belupo | Alopurinol Belupo | tbl. 100x100mg | 0,0330 | 3,30 | R | 5% |
| M04AA01 112 |  | alopurinol | 0,4 g | 0,1052 | O | Belupo d.d. | Belupo d.d. | Alopurinol Belupo | tbl. 100x200 mg | 0,0526 | 5,26 | R | 5% |
| M04AA01 121 |  | alopurinol | 0,4 g | 0,1320 | O | Sandoz d.o.o. | Sandoz-Salutas | Alopurinol Sandoz | tbl. 100x100 mg | 0,0330 | 3,30 | R | 5% |
| M04AA01 141 |  | alopurinol | 0,4 g | 0,1320 | O | PharmaS d.o.o. | PharmaS d.o.o. | Alopurinol PharmaS | tbl. 100x100 mg | 0,0330 | 3,30 | R | 5% |
| M04AC01 152 |  | kolhicin | 1 mg |  | O |  |  |  |  |  |  | R | 5% |
| M05BA04 121 |  | alendronat natrij | 10 mg | 0,2850 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma S.L.U., | Alendor | tbl. 4x70 mg | 1,9952 | 7,98 | RSRM02 | 5% |
| M05BA04 141 |  | alendronat natrij | 10 mg | 0,2850 | O | Sandoz d.o.o. | Sandoz-Lek | Forosa | tbl. film obl. 4x70 mg | 1,9952 | 7,98 | RSRM02 | 5% |
| M05BA04 162 |  | alendronat natrij | 10 mg | 0,2850 | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Fosamax T | tbl. 4x70 mg | 1,9952 | 7,98 | RSRM02 | 5% |
| M05BA06 121 |  | ibandronatna kiselina | 5 mg | 0,1947 | O | Sandoz d.o.o. | Sandoz-Pharmaten | Ibandronat Sandoz | tbl. film obl. 1x150 mg | 5,8398 | 5,84 | RSRM02 | 5% |
| M05BA06 122 |  | ibandronatna kiselina | 5 mg | 0,1980 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ostea | tbl. film obl. 1x150 mg | 5,9447 | 5,94 | RSRM02 | 5% |
| M05BA06 141 |  | ibandronatna kiselina | 5 mg | 0,1980 | O | PharmaS d.o.o. | PharmaS d.o.o. | Ibandronat PharmaS | tbl. film obl. 1x150 mg | 5,9447 | 5,94 | RSRM02 | 5% |
| M05BA06 161 |  | ibandronatna kiselina | 5 mg | 0,1980 | O | Atnahs Pharma Netherlands B.V. | Roche | Bonviva | tbl. film obl. 1x150 mg | 5,9447 | 5,94 | RSRM02 | 5% |
| M05BA06 162 |  | ibandronatna kiselinaNM502 | 5 mg | 0,3855 | O | Atnahs Pharma Netherlands B.V. | Roche | Bondronat | tbl. film obl. 28x50 mg | 3,8553 | 107,95 | RS RM01 | 5% |
| M05BA06 163 |  | ibandronatna kiselina | 5 mg | 0,1757 | O | Atnahs Pharma Netherlands B.V. | Waymade PLC | Bonviva | tbl. film obl. 3x150 mg | 5,2704 | 15,81 | RSRM02 | 5% |
| M05BA06 165 |  | ibandronatna kiselinaNM502 | 5 mg | 0,3855 | O | Makpharm d.o.o. | Synthon BV, Synthon Hispania | Ibadron | tbl. film obl. 30x50 mg | 3,8553 | 115,66 | RS RM01 | 5% |
| M05BA06 171 |  | ibandronatna kiselina | 5 mg | 0,1980 | O | Makpharm d.o.o. | Synthon BV, Synthon Hispania SL | Bonosta | tbl. film obl. 1x150 mg | 5,9447 | 5,94 | RSRM02 | 5% |
| M05BA06 172 |  | ibandronatna kiselinaNM502 | 5 mg | 0,3855 | O | Zentiva k.s. | Synthon Hispania, Synthon BV | Ibat | tbl. film obl. 30x50 mg | 3,8553 | 115,66 | RS RM01 | 5% |
| M05BA06 181 |  | ibandronatna kiselinaNM502 | 5 mg | 0,3855 | O | Pharmathen S.A. | Pharmathen S.A. | Iasibon | tbl. film obl. 28x50 mg | 3,8553 | 107,95 | RS RM01 | 5% |
| M05BA07 101 |  | risedronat natrij | 5 mg | 0,2483 | O | Accord Healthcare Polska Sp. z o.o. | Pliva Hrvatska d.o.o. | Risbon | tbl. film obl. 2x75 mg | 3,7249 | 7,45 | RSRM02 | 5% |
| M05BA07 112 |  | risedronat natrij | 5mg | 0,2850 | O | Belupo d.d. | Belupo | Bonna | tbl. film obl. 4x35 mg | 1,9952 | 7,98 | RSRM02 | 5% |
| M05BA07 113 |  | risedronat natrij | 5 mg | 0,2483 | O | Belupo d.d. | Belupo | Bonna | tbl. film obl. 2x75 mg | 3,7249 | 7,45 | RSRM02 | 5% |
| M05BA07 114 |  | risedronat natrij | 5 mg | 0,2236 | O | Belupo d.d. | Belupo | Bonna | tbl. film obl. 6x75 mg | 3,3526 | 20,12 | RSRM02 | 5% |
| M05BA07 145 |  | risedronat natrij | 5 mg | 0,2850 | O | PharmaS d.o.o. | PharmaS d.o.o. | Risedronat PharmaS | tbl. film obl. 4x35 mg | 1,9952 | 7,98 | RSRM02 | 5% |
| M05BA08 001 | DS | zoledronatna kiselina | 4 mg | 87,0700 | P | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Pharmachemie B.V., Teva Operations Poland Sp. Z.o.o. | Zoledronatna kiselina Teva | konc. za otop. za inf., boč. 1x4 mg/5 ml | 87,0675 | 87,07 |  | 5% |
| M05BA08 062 | DS | zoledronatna kiselina | 4 mg | 87,0700 | P | ALPHA-MEDICAL d.o.o. | Pharmidea LLC | Zolenat | konc. za otop. za inf., boč. 1x4 mg/5 ml | 87,0675 | 87,07 |  | 5% |
| M05BA08 071 | DS | zoledronatna kiselina | 4 mg | 86,8100 | P | Pfizer Europe MA EEIG | Hospira UK Limited, Hospira Enterprises B.V. | Zoledronatna kiselina Hospira | konc. za otop. za inf., boč. 1x4 mg/5 ml | 86,8074 | 86,81 |  | 5% |
| M05BA08 081 | DS | zoledronatna kiselina | 4 mg | 87,0700 | P | ACTAVIS GROUP PTC ehf. | Actavis Italy S.p.A | Zoledronatna kiselina Actavis | konc. za otop. za inf., boč. 1x4 mg/5 ml | 87,0675 | 87,07 |  | 5% |
| M05BA08 082 | DS | zoledronatna kiselina | 4 mg | 87,0700 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited | Zoledronatna kiselina Accord | konc. za otop. za inf., boč. 1x4 mg/5 ml | 87,0675 | 87,07 |  | 5% |
| M05BX04 071 | DS | denosumabNM503 | 0,33 mg | 0,7589 | P | Amgen Europe B.V. | Amgen Europe B.V. | Xgeva | otop. za inj., boč. stakl. 1x120 mg/1,7 ml (70 mg/ml) | 275,9506 | 275,95 |  | 5% |
| M05BX04 961 | DS/RL | denosumab | 0,33 mg | 1,0073 | P | Amgen Europe B.V. | Amgen Europe B.V. | Prolia | otop. za inj., štrc. napunj. 1x60 mg | 183,1362 | 183,14 | RSRM04 | 5% |
| M09AX03 171 | KL | atalurenNM601 | 2.8 g | 2,3398 | P | PTC Therapeutics International Limited | PTC Therapeutics International Limited, Almac Pharma Services Ltd. | Translarna | gran. za oral. susp., 30x125 mg | 104,4562 | 3.133,69 |  | 5% |
| M09AX03 172 | KL | atalurenNM601 | 2.8 g | 2,3336 | P | PTC Therapeutics International Limited | PTC Therapeutics International Limited, Almac Pharma Services Ltd. | Translarna | gran. za oral. susp., 30x250 mg | 208,3569 | 6.250,71 |  | 5% |
| M09AX03 173 | KL | atalurenNM601 | 2.8 g | 2,3289 | P | PTC Therapeutics International Limited | PTC Therapeutics International Limited, Almac Pharma Services Ltd. | Translarna | gran. za oral. susp., 30x1000 mg | 831,7433 | 24.952,30 |  | 5% |
| M09AX07 061 | KL | nusinersenNM600 | 0.1 mg | 586,2819 | P | Biogen Netherlands B.V. | Biogen (Denmark) Manufacturing ApS | Spinraza | otop. za inj., boč. stakl. 1x12 mg/5 ml (2,4 mg/ml) | 70.353,8310 | 70.353,83 |  | 5% |
| M09AX09 061 | KL | onasemnogen abeparvovekNM602 |  |  | P | Novartis Gene Therapies EU Limited | Almac Pharma Services (Ireland) Limited | Zolgensma | otop. za inf., 1 doza | ########### | 1.947.022,48 |  | 5% |
| M09AX10 371 | KL | risdiplamNM603 |  |  | O | Roche Registration GmbH | Roche Pharma AG | Evrysdi | praš. za oral. otop. 1x60 mg | 6.964,3865 | 6.964,39 |  | 5% |
| N01AB08 061 | DS | sevofluran |  |  | I | Piramal Critical Care B.V. | Piramal Healthcare UK Ltd. | Sojourn | para inhalata, tekućina, boca 1x250 ml | 114,3792 | 114,38 |  | 5% |
| N01AB08 063 | DS | sevofluran |  |  | P | Baxter d.o.o. | Baxter S.A. | Sevofluran Baxter | para inhalata, tekućina, boca 1x250 ml | 109,8945 | 109,89 |  | 5% |
| N01AB08 064 | DS | sevofluran |  |  | P | Baxter d.o.o. | Baxter S.A. | Sevofluran Baxter | para inhalata, tekućina, boca 6x250 ml | 98,9050 | 593,43 |  | 5% |
| N01AB08 072 | DS | sevofluran |  |  | P | AbbVie d.o.o. | AbbVie S.r.L. | Sevorane | boč. 1x250 ml | 114,3792 | 114,38 |  | 5% |
| N01AF03 051 | DS | tiopental-natrij |  |  | P |  |  |  |  |  |  |  | 5% |
| N01AH01 082 | DS | fentanil |  |  | P | Piramal Critical Care B.V. | Piramal Critical Care B.V. | Fentanyl | amp. 50x10 ml (0,05 mg/ml) | 1,3846 | 69,23 |  | 5% |
| N01AH02 051 | DS | alfentanil |  |  | P |  |  |  |  |  |  |  | 5% |
| N01AH03 061 | DS | sufentanil |  |  | P | Altamedics d.o.o. | Laboratoire Renaudin | Sufentanil Altamedics | otop. za inj./inf., 5 mcg/ml, amp., 10x10 ml | 1,1739 | 11,74 |  | 5% |
| N01AH03 071 | DS | sufentanil |  |  | P | hameln pharma gmbh | hameln rds a.s., Siegfried Hameln GmbH | Sufentanil hameln | otop. za inj./inf., 5 mcg/ml, amp., 10x10 ml | 0,8218 | 8,22 |  | 5% |
| N01AH51 051 | DS | fentanil + droperidol |  |  | P |  |  |  |  |  |  |  | 5% |
| N01AX03 051 | DS | ketamin-klorid |  |  | P |  |  |  |  |  |  |  | 5% |
| N01AX07 089 | DS | etomidat |  |  | P | Piramal Critical Care B.V. | Piramal Critical Care B.V. | Hypnomidate | amp. 5x10 ml | 0,9338 | 4,67 |  | 5% |
| N01AX10 071 | DS | propofol |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Propofol-Lipuro 10 mg/ml | emulz. za inj. ili inf., 10 mg/ml, amp., 5x20 ml | 2,5634 | 12,82 |  | 5% |
| N01AX10 072 | DS | propofol |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Propofol-Lipuro 10 mg/ml | emulz. za inj. ili inf., 10 mg/ml, boč., 10x50 ml | 6,4716 | 64,72 |  | 5% |
| N01AX10 074 | DS | propofol |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Propofol-Lipuro 20 mg/ml | emulz. za inj. ili inf., 20 mg/ml, boč., 10x50 ml | 10,4336 | 104,34 |  | 5% |
| N01AX10 083 | DS | propofol |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Propofol 1% MCT Fresenius | emulz. za inj./inf., amp. 1%, 5x20 ml (10 mg/ml) | 2,3070 | 11,53 |  | 5% |
| N01AX10 084 | DS | propofol |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Propofol 1% MCT Fresenius | emulz. za inj./inf., boč. 1%, 10x50 ml (10 mg/ml) | 6,4716 | 64,72 |  | 5% |
| N01AX10 085 | DS | propofol |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Propofol 1% MCT Fresenius | emulz. za inj./inf., boč. 1%, 10x100 ml (10 mg/ml) | 10,1566 | 101,57 |  | 5% |
| N01AX10 086 | DS | propofol |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Propofol 2% MCT Fresenius | emulz. za inj./inf., boč. 2%, 10x50 ml (20 mg/ml) | 9,3903 | 93,90 |  | 5% |
| N01AX13 951 | DS | dušik-oksidul |  |  | I |  |  |  |  |  |  |  | 5% |
| N01AX14 061 | DS | esketaminklorid |  |  | P | Makpharm d.o.o. | G.L. Pharma GmbH | Esgamda | otop. za inj. ili inf., amp., 10x25 mg/ml (2 ml) | 3,4242 | 34,24 |  | 5% |
| N01BB01 051 | DS | bupivakain |  |  | P |  |  |  |  |  |  |  | 5% |
| N01BB02 012 | PR | lidokain |  |  | P | Belupo d.d. | Belupo | Lidokainklorid Belupo | amp. 100x40 mg/2 ml | 0,2762 | 27,62 |  | 5% |
| N01BB02 013 | PR | lidokain |  |  | P | Belupo d.d. | Belupo | Lidokainklorid Belupo | amp. 5x100 mg/5 ml | 0,7833 | 3,92 |  | 5% |
| N01BB02 071 | PR | lidokain |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Lidokainklorid B. Braun 20 mg/ml | otop. za inj./inf., 20 mg/ml, polietil. amp. 20x5 ml | 0,3311 | 6,62 |  | 5% |
| N01BB02 072 | PR | lidokain |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Lidokainklorid B. Braun 20 mg/ml | otop. za inj./inf., 20 mg/ml, polietil. amp. 20x10 ml | 0,5840 | 11,68 |  | 5% |
| N01BB02 411 | DS | lidokain |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Dolokain gel | gel 1x25 g (20 mg/1 g) | 5,7243 | 5,72 |  | 5% |
| N01BB02 714 | PR | lidokain |  |  | L | Belupo d.d. | Belupo | Lidokain Belupo | otop. za rasprš. 50 ml (100 mg/1 ml) | 12,6087 | 12,61 |  | 5% |
| N01BB02 941 |  | lidokain |  |  | L | Grünenthal GmbH | Grünenthal GmbH | Versatis | flaster med. 5%, 5x(10 cmx14 cm)/700 mg | 2,3160 | 11,58 | RRN16 | 5% |
| N01BB02 942 |  | lidokain |  |  | L | Grünenthal GmbH | Grünenthal GmbH | Versatis | flaster med. 5%, 10x(10 cmx14 cm)/700 mg | 2,3160 | 23,16 | RRN16 | 5% |
| N01BB02 943 |  | lidokain |  |  | L | Grünenthal GmbH | Grünenthal GmbH | Versatis | flaster med. 5%, 30x(10 cmx14 cm)/700 mg | 2,3160 | 69,48 | RRN16 | 5% |
| N01BB08 051 | DS | artikain |  |  | P |  |  |  |  |  |  |  | 5% |
| N01BB09 061 | DS | ropivakain |  |  | P | L.Molteni & C. dei F.lli Alitti Soc. di Esercizio S.p.A. | L. Molteni | Ropivacaine Molteni | otop. za inf., 5x100 ml (2 mg/ml) | 9,0252 | 45,13 |  | 5% |
| N01BB09 062 | DS | ropivakain |  |  | P | L.Molteni & C. dei F.lli Alitti Soc. di Esercizio S.p.A. | L. Molteni | Ropivacaine Molteni | otop. za inj., amp. 5x10 ml (7,5 mg/ml) | 3,3446 | 16,72 |  | 5% |
| N01BB10 061 | DS | levobupivakain |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Levobupivakain Kabi | otop. za inj ili inf., amp. 5x10 ml (5 mg/ml) | 2,6014 | 13,01 |  | 5% |
| N01BB52 014 | PR | lidokain + adrenalin |  |  | P | Belupo d.d. | Belupo | Lidokainklorid – adrenalin Belupo | amp. 100x2 ml (40 mg + 0,025 mg) | 0,2762 | 27,62 |  | 5% |
| N01BB55 052 | DS | butanilkain + noradrenalin |  |  | P |  |  |  |  |  |  |  | 5% |
| N01BB58 053 | DS | artikain + adrenalin |  |  | P |  |  |  |  |  |  |  | 5% |
| N01BX01 454 | DS | kloretil (etil-klorid) |  |  | L |  |  |  |  |  |  |  | 5% |
| N02AA01 041 | PO | morfin | 30 mg | 1,1145 | P | Alkaloid d.o.o. | Alkaloid | Morfinklorid Alkaloid | otop. za inj./inf. 10x20 mg/ml | 0,7426 | 7,43 |  | 5% |
| N02AA01 161 |  | morfin | 0,1 g | 1,8917 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | Sevredol | tbl. film obl. 60x10 mg | 0,1891 | 11,35 | RRN01 | 5% |
| N02AA01 162 |  | morfin | 0,1 g | 1,7008 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | Sevredol | tbl. film obl. 60x20 mg | 0,3402 | 20,41 | RRN01 | 5% |
| N02AA01 173 |  | morfin | 0,1 g | 1,0906 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | MST Continus | tbl. obl. s post. oslob. 60x60 mg | 0,6543 | 39,26 | R | 5% |
| N02AA01 174 |  | morfin | 0,1 g | 1,0392 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | MST Continus | tbl. obl. s post. oslob. 60x100 mg | 1,0392 | 62,35 | R | 5% |
| N02AA05 173 |  | oksikodon | 75 mg | 1,5613 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | OxyContin | tbl. s prod. oslob. 60x10 mg | 0,2081 | 12,49 | RRN02 | 5% |
| N02AA05 174 |  | oksikodon | 75 mg | 1,9775 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | OxyContin | tbl. s prod. oslob. 60x20 mg | 0,5274 | 31,64 | RRN02 | 5% |
| N02AA05 181 |  | oksikodon | 75 mg | 1,5613 | O | ALPHA-MEDICAL d.o.o. | G.L. Pharma GmbH | Oxygerolan | tbl. s prod. oslob. 60x10 mg | 0,2081 | 12,49 | RRN02 | 5% |
| N02AA05 182 |  | oksikodon | 75 mg | 1,4619 | O | ALPHA-MEDICAL d.o.o. | G.L. Pharma GmbH | Oxygerolan | tbl. s prod. oslob. 60x20 mg | 0,3899 | 23,39 | RRN02 | 5% |
| N02AA55 101 |  | oksikodon + nalokson | 75 mg | 2,9850 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 50x(5 mg + 2,5 mg) | 0,1991 | 9,95 | R | 5% |
| N02AA55 102 |  | oksikodon + nalokson | 75 mg | 2,9865 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 50x(10 mg + 5 mg) | 0,3982 | 19,91 | R | 5% |
| N02AA55 103 |  | oksikodon + nalokson | 75 mg | 2,9910 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 50x(20 mg + 10 mg) | 0,7977 | 39,88 | R | 5% |
| N02AA55 104 | DS | oksikodon + nalokson | 75 mg | 2,9887 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 50x(40 mg + 20 mg) | 1,5940 | 79,70 |  | 5% |
| N02AA55 105 |  | oksikodon + nalokson | 75 mg | 2,5556 | O | PLIVA HRVATSKA d.o.o. | Develco Pharma GmbH | Oksikodon/nalokson Pliva | tbl. s prod. oslob. 30x(40 mg + 20 mg) | 1,3629 | 40,89 | R | 5% |
| N02AA55 163 |  | oksikodon + nalokson | 75 mg | 2,9913 | O | Mundipharma Gesellschaft m.b.H | Bard Pharmaceuticals Ltd., Mundipharma GmbH | Targinact | tbl. s prod. oslob. 30x(20 mg + 10 mg) | 0,7977 | 23,93 | R | 5% |
| N02AA55 164 |  | oksikodon + nalokson | 75 mg | 2,6900 | O | Mundipharma Gesellschaft m.b.H | Bard Pharmaceuticals Ltd., Mundipharma GmbH | Targinact | tbl. s prod. oslob. 30x(40 mg + 20 mg) | 1,4346 | 43,04 | R | 5% |
| N02AB02 051 | DS | petidin | 0,4 g |  | P |  |  |  |  |  |  |  | 5% |
| N02AB03 901 |  | fentanil | 1,2 mg | 1,4820 | TD | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fentagesic | flaster transd. 5x 4,125 mg (25 mcg/h) | 1,4812 | 7,41 | RRN02 | 5% |
| N02AB03 902 |  | fentanil | 1,2 mg | 2,9620 | TD | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fentagesic | flaster transd. 5x 8,25 mg (50 mcg/h) | 2,9624 | 14,81 | RRN02 | 5% |
| N02AB03 903 |  | fentanil | 1,2 mg | 5,9240 | TD | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fentagesic | flaster transd. 5x 16,50 mg (100 mcg/h) | 5,9247 | 29,62 | RRN02 | 5% |
| N02AB03 904 |  | fentanil | 1,2 mg | 0,4309 | TD | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Fentagesic | flaster transd. 5x 12,375 mg (75 mcg/h) | 4,4436 | 22,22 | RRN02 | 5% |
| N02AB03 961 |  | fentanil | 1,2 mg | 0,4234 | TD | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Durogesic | flaster transd. 5x4,2 mg (25 mcg/h) | 1,4812 | 7,41 | RRN02 | 5% |
| N02AB03 962 |  | fentanil | 1,2 mg | 0,4231 | TD | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Durogesic | flaster transd. 5x8,4 mg (50 mcg/h) | 2,9624 | 14,81 | RRN02 | 5% |
| N02AB03 963 |  | fentanil | 1,2 mg | 5,9240 | TD | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Durogesic | flaster transd. 5x16,8 mg (100 mcg/h) | 5,9247 | 29,62 | RRN02 | 5% |
| N02AB03 965 |  | fentanil | 1,2 mg | 4,4440 | TD | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Durogesic | flaster transd. 5x12,6 mg (75 mcg/h) | 4,4436 | 22,22 | RRN02 | 5% |
| N02AE01 901 |  | buprenorfin | 1,2 mg | 0,2202 | TD | PLIVA HRVATSKA d.o.o. | Tesa Labtec GmbH | Laribon | flaster transd. 4x20 mg (35 mcg/h) | 3,6688 | 14,68 | RRN02 | 5% |
| N02AE01 902 |  | buprenorfin | 1,2 mg | 0,2136 | TD | PLIVA HRVATSKA d.o.o. | Tesa Labtec GmbH | Laribon | flaster transd. 4x30 mg (52,50 mcg/h) | 5,3411 | 21,36 | RRN02 | 5% |
| N02AE01 903 |  | buprenorfin | 1,2 mg | 0,2016 | TD | PLIVA HRVATSKA d.o.o. | Tesa Labtec GmbH | Laribon | flaster transd. 4x40 mg (70 mcg/h) | 6,7194 | 26,88 | RRN02 | 5% |
| N02AE01 941 |  | buprenorfin | 1,2 mg | 0,2275 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 4x20 mg (35 mcg/h) | 3,7926 | 15,17 | RRN02 | 5% |
| N02AE01 942 |  | buprenorfin | 1,2 mg | 0,2276 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 8x20 mg (35 mcg/h) | 3,7927 | 30,34 | RRN02 | 5% |
| N02AE01 943 |  | buprenorfin | 1,2 mg | 0,2161 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 4x30 mg (52,50 mcg/h) | 5,4025 | 21,61 | RRN02 | 5% |
| N02AE01 944 |  | buprenorfin | 1,2 mg | 0,2161 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 8x30 mg (52,50 mcg/h) | 5,4023 | 43,22 | RRN02 | 5% |
| N02AE01 945 |  | buprenorfin | 1,2 mg | 0,2016 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 4x40 mg (70 mcg/h) | 6,7194 | 26,88 | RRN02 | 5% |
| N02AE01 946 |  | buprenorfin | 1,2 mg | 0,2016 | TD | Grünenthal GmbH | Grunenthal GmbH | Transtec | flaster transd. 8x40 mg (70 mcg/h) | 6,7193 | 53,75 | RRN02 | 5% |
| N02AJ13 102 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. film obl. 60x(37,5 mg + 325 mg) | 0,0525 | 3,15 | R | 5% |
| N02AJ13 103 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,0525 | 1,57 | R | 5% |
| N02AJ13 104 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. film obl. 50x(37,5 mg + 325 mg) | 0,0484 | 2,42 | R | 5% |
| N02AJ13 105 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. 30x(75 mg + 650 mg) | 0,1355 | 4,06 | R | 5% |
| N02AJ13 106 |  | tramadol + paracetamol |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Zotramid | tbl. 50x(75 mg + 650 mg) | 0,0989 | 4,95 | R | 5% |
| N02AJ13 111 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo | Zaracet | tbl. film obl. 10x(37,5 mg + 325 mg) | 0,0524 | 0,52 | R | 5% |
| N02AJ13 112 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo | Zaracet | tbl. film obl. 20x(37,5 mg + 325 mg) | 0,0525 | 1,05 | R | 5% |
| N02AJ13 113 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo | Zaracet | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,0525 | 1,57 | R | 5% |
| N02AJ13 114 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo | Zaracet | tbl. film obl. 100x(37,5 mg + 325 mg) | 0,0525 | 5,25 | R | 5% |
| N02AJ13 126 |  | tramadol + paracetamol |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Tramadox | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,0525 | 1,57 | R | 5% |
| N02AJ13 127 |  | tramadol + paracetamol |  |  | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Tramadox | tbl. film obl. 60x(37,5 mg + 325 mg) | 0,0525 | 3,15 | R | 5% |
| N02AJ13 132 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Doreta | tbl. film obl. 20x(37,5 mg + 325 mg) | 0,0525 | 1,05 | R | 5% |
| N02AJ13 133 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Doreta | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,0525 | 1,57 | R | 5% |
| N02AJ13 134 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Doreta | tbl. film obl. 50x(37,5 mg + 325 mg) | 0,0525 | 2,62 | R | 5% |
| N02AJ13 135 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Doreta | tbl. film obl. 30x(75 mg + 650 mg) | 0,1355 | 4,06 | R | 5% |
| N02AJ13 136 |  | tramadol + paracetamol |  |  | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Doreta | tbl. film obl. 50x(75 mg + 650 mg) | 0,1099 | 5,49 | R | 5% |
| N02AJ13 142 |  | tramadol + paracetamol |  |  | O | STADA d.o.o. | STADA Arzneimittel AG | Zaldiar | tbl. film obl. 30x(37,5 mg + 325 mg) | 0,0525 | 1,57 | R | 5% |
| N02AJ13 181 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo d.d. | Zaracet | tbl. film obl. 30x(75 mg + 650 mg) | 0,1355 | 4,06 | R | 5% |
| N02AJ13 182 |  | tramadol + paracetamol |  |  | O | Belupo d.d. | Belupo d.d. | Zaracet | tbl. film obl. 50x(75 mg + 650 mg) | 0,1099 | 5,49 | R | 5% |
| N02AX02 013 | PR | tramadol | 0,3 g | 1,9800 | P | Belupo d.d. | Belupo | Lumidol | amp. 5x50 mg/ml | 0,3960 | 1,98 |  | 5% |
| N02AX02 014 | PR | tramadol | 0,3 g | 1,2400 | P | Belupo d.d. | Belupo | Lumidol | amp. 5x100 mg/2 ml | 0,4953 | 2,48 |  | 5% |
| N02AX02 023 | PR | tramadol | 0,3 g | 1,7281 | P | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | amp. 5x50 mg/ml | 0,2880 | 1,44 |  | 5% |
| N02AX02 024 | PR | tramadol | 0,3 g | 1,0800 | P | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | amp. 5x100 mg/2 ml | 0,3597 | 1,80 |  | 5% |
| N02AX02 043 | PR | tramadol | 0,3 g | 1,9800 | P | STADA d.o.o. | STADA Arzneimittel AG | Tramal | amp. 5x50 mg/ml | 0,3960 | 1,98 |  | 5% |
| N02AX02 044 | PR | tramadol | 0,3 g | 1,2400 | P | STADA d.o.o. | STADA Arzneimittel AG | Tramal | amp. 5x100 mg/2 ml | 0,4953 | 2,48 |  | 5% |
| N02AX02 111 |  | tramadol | 0,3 g | 0,6540 | O | Belupo d.d. | Belupo | Lumidol | caps. 20x50 mg | 0,1088 | 2,18 | R | 5% |
| N02AX02 112 |  | tramadol | 0,3 g | 0,4750 | O | Belupo d.d. | Belupo | Lumidol retard | tbl. s prod. oslob. 30x100 mg | 0,1582 | 4,75 | R | 5% |
| N02AX02 113 |  | tramadol | 0,3 g | 0,4746 | O | Belupo d.d. | Belupo | Lumidol retard | tbl. s prod. oslob. 50x100 mg | 0,1582 | 7,91 | R | 5% |
| N02AX02 116 |  | tramadol | 0,3 g | 0,4845 | O | Belupo d.d. | Belupo | Lumidol retard | tbl. 30x200 mg | 0,3229 | 9,69 | R | 5% |
| N02AX02 117 |  | tramadol | 0,3 g | 0,4750 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH | Tramadol Mibe | tbl. s prod. oslob. 30x100 mg | 0,1582 | 4,75 | R | 5% |
| N02AX02 121 |  | tramadol | 0,3 g | 0,4750 | O | Sandoz d.o.o. | Sandoz-Salutas | Tramadolor retard | tbl. s prod. oslob. 30x100 mg | 0,1582 | 4,75 | R | 5% |
| N02AX02 123 |  | tramadol | 0,3 g | 0,4273 | O | Sandoz d.o.o. | Sandoz-Salutas | Tramadolor retard | tbl. s prod. oslob. 30x150 mg | 0,2137 | 6,41 | R | 5% |
| N02AX02 125 |  | tramadol | 0,3 g | 0,4845 | O | Sandoz d.o.o. | Sandoz-Salutas | Tramadolor retard | tbl. s prod. oslob. 30x200 mg | 0,3229 | 9,69 | R | 5% |
| N02AX02 131 |  | tramadol | 0,3 g | 0,4440 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | caps. tvrda 20x50 mg | 0,0741 | 1,48 | R | 5% |
| N02AX02 132 |  | tramadol | 0,3 g | 0,4510 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | tbl. s prod. oslob. 30x100 mg | 0,1503 | 4,51 | R | 5% |
| N02AX02 133 |  | tramadol | 0,3 g | 0,4060 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | tbl. s prod. oslob. 30x150 mg | 0,2030 | 6,09 | R | 5% |
| N02AX02 134 |  | tramadol | 0,3 g | 0,4600 | O | KRKA-FARMA d.o.o. | Krka d.d. | Tramadol Krka | tbl. s prod. oslob. 30x200 mg | 0,3067 | 9,20 | R | 5% |
| N02AX02 140 |  | tramadol | 0,3 g | 0,6540 | O | Mibe Pharmaceuticals d.o.o. | mibe GmbH Arzneimittel | Toram | caps. 20x50 mg | 0,1088 | 2,18 | R | 5% |
| N02AX02 141 |  | tramadol | 0,3 g | 0,6540 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal | caps. 20x50 mg | 0,1088 | 2,18 | R | 5% |
| N02AX02 142 |  | tramadol | 0,3 g | 0,4920 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 30x50 mg | 0,0818 | 2,46 | R | 5% |
| N02AX02 143 |  | tramadol | 0,3 g | 0,4908 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 50x50 mg | 0,0818 | 4,09 | R | 5% |
| N02AX02 146 |  | tramadol | 0,3 g | 0,4750 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 30x100 mg | 0,1582 | 4,75 | R | 5% |
| N02AX02 148 |  | tramadol | 0,3 g | 0,4746 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 50x100 mg | 0,1582 | 7,91 | R | 5% |
| N02AX02 149 |  | tramadol | 0,3 g | 0,4273 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 30x150 mg | 0,2137 | 6,41 | R | 5% |
| N02AX02 161 |  | tramadol | 0,3 g | 0,4746 | O | Mundipharma Gesellschaft m.b.H | Mundipharma | Tramundin retard | tbl. film obl. 50x100 mg | 0,1582 | 7,91 | R | 5% |
| N02AX02 162 |  | tramadol | 0,3 g | 0,4272 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 50x150 mg | 0,2137 | 10,68 | R | 5% |
| N02AX02 163 |  | tramadol | 0,3 g | 0,4845 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 30x200 mg | 0,3229 | 9,69 | R | 5% |
| N02AX02 164 |  | tramadol | 0,3 g | 0,4779 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal retard | tbl. film obl. 50x200 mg | 0,3186 | 15,93 | R | 5% |
| N02AX02 212 |  | tramadol | 0,3 g | 0,7230 | O | Belupo d.d. | Belupo | Lumidol | kapi, oralne, boč. 1x10 ml (100 mg/ml) | 2,4129 | 2,41 | R | 5% |
| N02AX02 242 |  | tramadol | 0,3 g | 0,7230 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal | kapi, oralne, boč. 1x10 ml (100 mg/ml) | 2,4129 | 2,41 | R | 5% |
| N02AX02 247 |  | tramadol | 0,3 g | 54,9375 | O | STADA d.o.o. | STADA Arzneimittel AG | Tramal | kapi, oralne,boč. 1x96 ml (100 mg/ml) | 17,5831 | 17,58 | R | 5% |
| N02AX06 164 |  | tapentadol | 0,4 g | 4,3040 | O | Grünenthal GmbH | Grünenthal GmbH | Palexia | tbl. film obl. 30x50 mg | 0,5379 | 16,14 | RRN02 | 5% |
| N02AX06 165 |  | tapentadol | 0,4 g | 3,9644 | O | Grünenthal GmbH | Grünenthal GmbH | Palexia | tbl. film obl. 30x75 mg | 0,7432 | 22,30 | RRN02 | 5% |
| N02AX06 166 |  | tapentadol | 0,4 g | 3,8053 | O | Grünenthal GmbH | Grünenthal GmbH | Palexia | tbl. film obl. 30x100 mg | 0,9512 | 28,54 | RRN02 | 5% |
| N02AX06 267 |  | tapentadol | 0,4 g | 3,9660 | O | Grünenthal GmbH | Grünenthal GmbH | Palexia | oralna otop., boč. 1x100 ml (20 mg/ml) | 19,8288 | 19,83 | RRN02 | 5% |
| N02BA01 151 | DS | acetilsalicilna kiselina | 3 g |  | O |  |  |  |  |  |  |  | 5% |
| N02BB02 042 | PR | metamizol | 3 g | 0,5055 | P | Alkaloid d.o.o. | Alkaloid | Alkagin | otop. za inj. 50x2,5 g/5 ml | 0,4245 | 21,23 |  | 5% |
| N02BE01 042 | DSPR | paracetamolNN101 | 3 g | 4,1205 | P | Accord Healthcare Polska Sp. z o.o. | Industria Farmaceutica Galenica Senese S.r.l. | Paracetamol Accord | otop. za inf., boč. stakl. 20x100 ml (10 mg/ml) | 1,3737 | 27,47 |  | 5% |
| N02BE01 061 | DSPR | paracetamolNN101 | 3 g | 5,0911 | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Paracetamol Kabi | otop. za inf., boč. stakl. 10x100 ml (10 mg/ml) | 1,6966 | 16,97 |  | 5% |
| N02BE01 071 | DSPR | paracetamolNN101 | 3 g | 4,5780 | P | B. Braun Adria d.o.o. | B. Braun Medical S.A. | Paracetamol B. Braun 10 mg/ml | otop. za inf., 10 mg/ml, polietil. Ecoflac plus boca, 10x100 ml | 1,5263 | 15,26 |  | 5% |
| N02BE01 151 | DS | paracetamol | 3 g |  | O |  |  |  |  |  |  |  | 5% |
| N02BE01 312 |  | paracetamol | 3 g | 1,8583 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Paracetamol JGL | sirup 1x150 ml (120 mg/5 ml) | 2,2297 | 2,23 | R | 5% |
| N02BE01 551 | DS | paracetamol | 3 g |  | R |  |  |  |  |  |  |  | 5% |
| N02CC01 122 |  | sumatriptan | 50 mg | 1,2417 | O | Sandoz d.o.o. | Sandoz-Salutas | Sumigra | tbl. 6x50 mg | 1,2414 | 7,45 | RSRN03 | 5% |
| N02CC01 162 |  | sumatriptan | 50 mg | 1,2400 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Imigran | tbl. 2x50 mg | 1,2416 | 2,48 | RSRN03 | 5% |
| N02CC04 171 |  | rizatriptan | 10 mg | 1,2417 | O | ALPHA-MEDICAL d.o.o. | Glenmark Pharmaceuticals s.r.o. | Emalt | tbl. rasp. za usta 6x10 mg | 1,2414 | 7,45 | RSRN03 | 5% |
| N03AA01 102 |  | metilfenobarbital | 0,5 g | 0,9545 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Phemiton | tbl. 50x200 mg | 0,3818 | 19,09 | R | 5% |
| N03AA02 051 | PR | fenobarbiton-natrij | 0,1 g |  | P |  |  |  |  |  |  |  | 5% |
| N03AA02 103 |  | fenobarbital | 0,1 g | 0,6111 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Phenobarbiton | tbl. 30x15 mg | 0,0917 | 2,75 | R | 5% |
| N03AA02 104 |  | fenobarbital | 0,1 g | 0,2720 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Phenobarbiton | tbl. 10x100 mg | 0,2725 | 2,72 | R | 5% |
| N03AA03 151 |  | primidon | 1,25 g |  | O |  |  |  |  |  |  | R | 5% |
| N03AB02 051 | DS | fenitoin | 0,3 g |  | P |  |  |  |  |  |  |  | 5% |
| N03AB02 151 |  | fenitoin | 0,3 g |  | O |  |  |  |  |  |  | R | 5% |
| N03AD01 351 |  | etosuksimid | 1,25 g |  | O |  |  |  |  |  |  | R | 5% |
| N03AE01 052 | PR | klonazepam | 8 mg |  | P |  |  |  |  |  |  |  | 5% |
| N03AE01 161 |  | klonazepam | 8 mg | 0,6496 | O | Cheplapharm Arzneimittel GmbH | Roche | Rivotril | tbl. 50x0,5 mg | 0,0407 | 2,03 | R | 5% |
| N03AE01 162 |  | klonazepam | 8 mg | 0,3507 | O | Cheplapharm Arzneimittel GmbH | Roche | Rivotril | tbl. 30x2 mg | 0,0876 | 2,63 | R | 5% |
| N03AF01 109 |  | karbamazepin | 1 g | 0,2530 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Novartis Farma S.p.A. | Tegretol | tbl. 50x200 mg | 0,0506 | 2,53 | R | 5% |
| N03AF01 110 |  | karbamazepin | 1 g | 0,2950 | O | Novartis Hrvatska d.o.o. | Novartis Pharma GmbH, Novartis Farma S.p.A. | Tegretol CR | tbl. 30x400 mg | 0,1180 | 3,54 | R | 5% |
| N03AF02 163 |  | okskarbazepin | 1g | 0,5073 | O | Novartis Hrvatska d.o.o. | Novartis Farma S.p.A., Novartis Pharma GmbH | Trileptal | tbl. film obl. 50x600 mg | 0,3044 | 15,22 | R | 5% |
| N03AF02 364 |  | okskarbazepin | 1g | 1,0473 | O | Novartis Hrvatska d.o.o. | Novartis Farmaceutica S.A., Novartis Pharma GmbH | Trileptal | boč. 1x250 ml (60 mg/ml), susp. | 15,7104 | 15,71 | R | 5% |
| N03AG01 121 |  | natrij-valproat | 1,5 g | 0,4140 | O | sanofi-aventis groupe | Sanofi Winthrop Ambares | Depakine Chrono | tbl. 100x300 mg | 0,0828 | 8,28 | R | 5% |
| N03AG01 122 |  | natrij-valproat | 1,5 g | 0,4830 | O | sanofi-aventis groupe | Sanofi Winthrop Ambares | Depakine Chrono | tbl. 30x500 mg | 0,1610 | 4,83 | R | 5% |
| N03AG01 251 |  | natrij-valproat | 1,5 g |  | O |  |  |  | oralna otopina/granule |  |  | R | 5% |
| N03AG04 151 |  | vigabatrin | 2 g |  | O |  |  |  |  |  |  | RSRN23 | 5% |
| N03AX09 111 |  | lamotrigin | 0,3 g | 0,9080 | O | Belupo d.d. | Belupo | Arvind | tbl. 30x25 mg | 0,0757 | 2,27 | RSRN22 | 5% |
| N03AX09 112 |  | lamotrigin | 0,3 g | 1,0060 | O | Belupo d.d. | Belupo | Arvind | tbl. 30x50 mg | 0,1677 | 5,03 | RSRN22 | 5% |
| N03AX09 113 |  | lamotrigin | 0,3 g | 0,8590 | O | Belupo d.d. | Belupo | Arvind | tbl. 30x100 mg | 0,2862 | 8,59 | RSRN22 | 5% |
| N03AX09 121 |  | lamotrigin | 0,3 g | 0,9080 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 30x25 mg | 0,0757 | 2,27 | RSRN22 | 5% |
| N03AX09 122 |  | lamotrigin | 0,3 g | 1,0060 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 30x50 mg | 0,1677 | 5,03 | RSRN22 | 5% |
| N03AX09 123 |  | lamotrigin | 0,3 g | 0,8590 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 30x100 mg | 0,2862 | 8,59 | RSRN22 | 5% |
| N03AX09 124 |  | lamotrigin | 0,3 g | 0,7320 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 30x200 mg | 0,4880 | 14,64 | RSRN22 | 5% |
| N03AX09 144 |  | lamotrigin | 0,3 g | 0,8890 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 60x50 mg | 0,1481 | 8,89 | RSRN22 | 5% |
| N03AX09 145 |  | lamotrigin | 0,3 g | 0,7765 | O | Alkaloid d.o.o. | Alkaloid | Lamal | tbl. 60x100 mg | 0,2588 | 15,53 | RSRN22 | 5% |
| N03AX09 162 |  | lamotrigin | 0,3 g | 0,9080 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, Specifar S.A. | Lamotrigin Genericon | tbl. za žvak./oral. susp. 30x50 mg | 0,1513 | 4,54 | RSRN22 | 5% |
| N03AX09 163 |  | lamotrigin | 0,3 g | 0,7765 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, Specifar S.A. | Lamotrigin Genericon | tbl. za žvak./oral. susp. 60x100 mg | 0,2588 | 15,53 | RSRN22 | 5% |
| N03AX09 175 |  | lamotrigin | 0,3 g | 0,5721 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. 56x25 mg | 0,0477 | 2,67 | RSRN22 | 5% |
| N03AX09 176 |  | lamotrigin | 0,3 g | 0,8893 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. 56x50 mg | 0,1481 | 8,30 | RSRN22 | 5% |
| N03AX09 177 |  | lamotrigin | 0,3 g | 0,7762 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. 56x100 mg | 0,2588 | 14,49 | RSRN22 | 5% |
| N03AX09 180 |  | lamotrigin | 0,3 g | 7,3300 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. za žvak./oral. susp. 60x5 mg | 0,1221 | 7,33 | RSRN22 | 5% |
| N03AX11 111 |  | topiramat | 0,3 g | 0,5720 | O | Belupo d.d. | Belupo | Tiramat | tbl. film obl. 60x25 mg | 0,0477 | 2,86 | RSRN15 | 5% |
| N03AX11 112 |  | topiramat | 0,3 g | 1,1950 | O | Belupo d.d. | Belupo | Tiramat | tbl. film obl. 60x50 mg | 0,1991 | 11,95 | RSRN15 | 5% |
| N03AX11 113 |  | topiramat | 0,3 g | 0,8625 | O | Belupo d.d. | Belupo | Tiramat | tbl. film obl. 60x100 mg | 0,2876 | 17,25 | RSRN15 | 5% |
| N03AX11 181 |  | topiramat | 0,3 g | 0,5720 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV, Lusomedicamenta-Sociedade Tecnica, Farmaceutica S.A. | Topamax | tbl. 60x25 mg | 0,0477 | 2,86 | RSRN15 | 5% |
| N03AX11 182 |  | topiramat | 0,3 g | 1,1950 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV, Lusomedicamenta-Sociedade Tecnica, Farmaceutica S.A. | Topamax | tbl. 60x50 mg | 0,1991 | 11,95 | RSRN15 | 5% |
| N03AX11 183 |  | topiramat | 0,3 g | 0,8625 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV, Lusomedicamenta-Sociedade Tecnica, Farmaceutica S.A. | Topamax | tbl. 60x100 mg | 0,2876 | 17,25 | RSRN15 | 5% |
| N03AX11 184 |  | topiramat | 0,3 g | 0,7320 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV, Lusomedicamenta-Sociedade Tecnica, Farmaceutica S.A. | Topamax | tbl. 60x200 mg | 0,4880 | 29,28 | RSRN15 | 5% |
| N03AX12 111 |  | gabapentin | 1,8 g | 1,0170 | O | Belupo d.d. | Belupo | Katena | caps. 20x100 mg | 0,0566 | 1,13 | RSRN04 | 5% |
| N03AX12 112 |  | gabapentin | 1,8 g | 1,1940 | O | Belupo d.d. | Belupo | Katena | caps. 50x300 mg | 0,1991 | 9,95 | RSRN04 | 5% |
| N03AX12 113 |  | gabapentin | 1,8 g | 0,9936 | O | Belupo d.d. | Belupo | Katena | caps. 50x400 mg | 0,2208 | 11,04 | RSRN04 | 5% |
| N03AX12 162 |  | gabapentin | 1,8 g | 1,1940 | O | Upjohn EESV | Pfizer Manufacturing Deutschland GmbH, Genera d.d. | Neurontin | caps. 50x300 mg | 0,1991 | 9,95 | RSRN04 | 5% |
| N03AX12 163 |  | gabapentin | 1,8 g | 0,9936 | O | Upjohn EESV | Pfizer Manufacturing Deutschland GmbH, Genera d.d. | Neurontin | caps. 50x400 mg | 0,2208 | 11,04 | RSRN04 | 5% |
| N03AX14 061 | DS | levetiracetam | 1,5 g | 21,9002 | P | Pharmathen S.A. | Pharmathen S.A. | Matever | konc. za otop. za inf., boč. 10x5 ml (100 mg/ml) | 7,2998 | 73,00 |  | 5% |
| N03AX14 071 | DS | levetiracetam | 1,5 g | 15,3302 | P | Sun Pharmaceutical Industries Europe BV | Sun Pharmaceutical Industries Europe B.V | Levetiracetam Sun | konc. za otop. za inf., boč. 10x5 ml (100 mg/ml) | 5,1098 | 51,10 |  | 5% |
| N03AX14 101 |  | levetiracetam | 1,5 g | 0,4980 | O | ACTAVIS GROUP PTC ehf. | Teva Operations Poland Sp. z o.o | Levetiracetam Actavis | tbl. film obl. 60x250 mg | 0,0830 | 4,98 | RSRN15 | 5% |
| N03AX14 102 |  | levetiracetam | 1,5 g | 0,4920 | O | ACTAVIS GROUP PTC ehf. | Teva Operations Poland Sp. z o.o | Levetiracetam Actavis | tbl. film obl. 60x500 mg | 0,1639 | 9,84 | RSRN15 | 5% |
| N03AX14 103 |  | levetiracetam | 1,5 g | 0,6080 | O | ACTAVIS GROUP PTC ehf. | Teva Operations Poland Sp. z o.o | Levetiracetam Actavis | tbl. film obl. 60x1000 mg | 0,4054 | 24,32 | RSRN15 | 5% |
| N03AX14 112 |  | levetiracetam | 1,5 g | 0,4920 | O | Belupo d.d. | Belupo d.d. | Levetiracetam Belupo | tbl. film obl. 60x500 mg | 0,1639 | 9,84 | RSRN15 | 5% |
| N03AX14 113 |  | levetiracetam | 1,5 g | 0,6755 | O | Belupo d.d. | Belupo d.d. | Levetiracetam Belupo | tbl. film obl. 60x1000 mg | 0,4504 | 27,02 | RSRN15 | 5% |
| N03AX14 121 |  | levetiracetam | 1,5 g | 0,4980 | O | Alkaloid d.o.o. | Alkaloid | Lyvam | tbl. film obl. 60x250 mg | 0,0830 | 4,98 | RSRN15 | 5% |
| N03AX14 123 |  | levetiracetam | 1,5 g | 0,7527 | O | Alkaloid d.o.o. | Alkaloid | Lyvam | tbl. film obl. 60x750 mg | 0,3763 | 22,58 | RSRN15 | 5% |
| N03AX14 124 |  | levetiracetam | 1,5 g | 0,6755 | O | Alkaloid d.o.o. | Alkaloid | Lyvam | tbl. film obl. 60x1000 mg | 0,4504 | 27,02 | RSRN15 | 5% |
| N03AX14 184 |  | levetiracetam | 1,5 g | 0,4980 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Levetiracetam Accord | tbl. film obl. 60x250 mg | 0,0830 | 4,98 | RSRN15 | 5% |
| N03AX14 185 |  | levetiracetam | 1,5 g | 0,4920 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Levetiracetam Accord | tbl. film obl. 60x500 mg | 0,1639 | 9,84 | RSRN15 | 5% |
| N03AX14 186 |  | levetiracetam | 1,5 g | 0,5473 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Levetiracetam Accord | tbl. film obl. 60x1000 mg | 0,3648 | 21,89 | RSRN15 | 5% |
| N03AX15 161 |  | zonisamid | 0,2 g | 1,6229 | O | Makpharm d.o.o. | Chanelle Medical | Zonisamid Makpharm | caps. tvrda 28x25 mg | 0,2028 | 5,68 | RSRN15 | 5% |
| N03AX15 162 |  | zonisamid | 0,2 g | 1,6229 | O | Makpharm d.o.o. | Chanelle Medical | Zonisamid Makpharm | caps. tvrda 28x50 mg | 0,4058 | 11,36 | RSRN15 | 5% |
| N03AX15 163 |  | zonisamid | 0,2 g | 1,3457 | O | Makpharm d.o.o. | Chanelle Medical | Zonisamid Makpharm | caps. tvrda 98x100 mg | 0,6729 | 65,94 | RSRN15 | 5% |
| N03AX16 101 |  | pregabalin | 0,3 g | 0,5721 | O | PLIVA HRVATSKA d.o.o. | Teva UK Ltd., Merckle GmbH, Pliva Hrvatska d.o.o. | Pregabalin Pliva | caps. tvrda 56x25 mg | 0,0477 | 2,67 | RSpn21 | 5% |
| N03AX16 102 |  | pregabalin | 0,3 g | 0,4564 | O | PLIVA HRVATSKA d.o.o. | Teva UK Ltd., Merckle GmbH, Pliva Hrvatska d.o.o. | Pregabalin Pliva | caps. tvrda 56x75 mg | 0,1141 | 6,39 | RSpn21 | 5% |
| N03AX16 103 |  | pregabalin | 0,3 g | 0,3504 | O | PLIVA HRVATSKA d.o.o. | Teva UK Ltd., Merckle GmbH, Pliva Hrvatska d.o.o. | Pregabalin Pliva | caps. tvrda 56x150 mg | 0,1751 | 9,81 | RSpn21 | 5% |
| N03AX16 104 |  | pregabalin | 0,3 g | 0,3891 | O | PLIVA HRVATSKA d.o.o. | Teva UK Ltd., Merckle GmbH, Pliva Hrvatska d.o.o. | Pregabalin Pliva | caps. tvrda 56x300 mg | 0,3892 | 21,79 | RSpn21 | 5% |
| N03AX16 121 |  | pregabalin | 0,3 g | 0,4564 | O | Sandoz GmbH | Sandoz-Kundl | Pregabalin Sandoz | caps. tvrda 56x75 mg | 0,1141 | 6,39 | RSpn21 | 5% |
| N03AX16 122 |  | pregabalin | 0,3 g | 0,3504 | O | Sandoz GmbH | Sandoz-Kundl | Pregabalin Sandoz | caps. tvrda 56x150 mg | 0,1751 | 9,81 | RSpn21 | 5% |
| N03AX16 125 |  | pregabalin | 0,3 g | 0,4564 | O | Belupo d.d. | Belupo | Pregabalin Belupo | caps. tvrda 56x75 mg | 0,1141 | 6,39 | RSpn21 | 5% |
| N03AX16 126 |  | pregabalin | 0,3 g | 0,3504 | O | Belupo d.d. | Belupo | Pregabalin Belupo | caps. tvrda 56x150 mg | 0,1751 | 9,81 | RSpn21 | 5% |
| N03AX16 127 |  | pregabalin | 0,3 g | 0,3891 | O | Belupo d.d. | Belupo | Pregabalin Belupo | caps. tvrda 56x300 mg | 0,3892 | 21,79 | RSpn21 | 5% |
| N03AX16 132 |  | pregabalin | 0,3 g | 0,4564 | O | KRKA-FARMA d.o.o. | KRKA d.d., TAD Pharma GmbH | Pragiola | caps. tvrda 56x75 mg | 0,1141 | 6,39 | RSpn21 | 5% |
| N03AX16 133 |  | pregabalin | 0,3 g | 0,3504 | O | KRKA-FARMA d.o.o. | KRKA d.d., TAD Pharma GmbH | Pragiola | caps. tvrda 56x150 mg | 0,1751 | 9,81 | RSpn21 | 5% |
| N03AX16 134 |  | pregabalin | 0,3 g | 0,3891 | O | KRKA-FARMA d.o.o. | KRKA d.d., TAD Pharma GmbH | Pragiola | caps. tvrda 56x300 mg | 0,3892 | 21,79 | RSpn21 | 5% |
| N03AX16 141 |  | pregabalin | 0,3 g | 0,4107 | O | Medochemie Ltd. | Medochemie Ltd. | Siranalen | caps. tvrda 56x75 mg | 0,1027 | 5,75 | RSpn21 | 5% |
| N03AX16 142 |  | pregabalin | 0,3 g | 0,3154 | O | Medochemie Ltd. | Medochemie Ltd. | Siranalen | caps. tvrda 56x150 mg | 0,1576 | 8,83 | RSpn21 | 5% |
| N03AX16 143 |  | pregabalin | 0,3 g | 0,3502 | O | Medochemie Ltd. | Medochemie Ltd. | Siranalen | caps. tvrda 56x300 mg | 0,3502 | 19,61 | RSpn21 | 5% |
| N03AX16 164 |  | pregabalin | 0,3 g | 0,3891 | O | Pfizer Europe MA EEIG | Pfizer | Lyrica | caps. 56x300 mg | 0,3892 | 21,79 | RSpn21 | 5% |
| N03AX16 182 |  | pregabalin | 0,3 g | 0,4087 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, GE Pharmaceuticals Ltd., Bluepharma Industria Farmaceutica S.A. | Pregabalin Genericon | caps. tvrda 60x75 mg | 0,1022 | 6,13 | RSpn21 | 5% |
| N03AX16 183 |  | pregabalin | 0,3 g | 0,3503 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, GE Pharmaceuticals Ltd., Bluepharma Industria Farmaceutica S.A. | Pregabalin Genericon | caps. tvrda 60x150 mg | 0,1751 | 10,51 | RSpn21 | 5% |
| N03AX16 184 |  | pregabalin | 0,3 g | 0,3892 | O | Genericon Pharma Gesellschaft m.b.H. | Genericon Pharma GmbH, GE Pharmaceuticals Ltd., Bluepharma Industria Farmaceutica S.A. | Pregabalin Genericon | caps. tvrda 60x300 mg | 0,3892 | 23,35 | RSpn21 | 5% |
| N03AX16 185 |  | pregabalin | 0,3 g | 0,3729 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Pregabalin Accord | caps. tvrda 56x25 mg | 0,0310 | 1,74 | RSpn21 | 5% |
| N03AX16 186 |  | pregabalin | 0,3 g | 0,4107 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Pregabalin Accord | caps. tvrda 56x75 mg | 0,1026 | 5,75 | RSpn21 | 5% |
| N03AX16 187 |  | pregabalin | 0,3 g | 0,3150 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Pregabalin Accord | caps. tvrda 56x150 mg | 0,1576 | 8,82 | RSpn21 | 5% |
| N03AX18 101 |  | lakozamid | 0,3 g | 0,8186 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Lakozamid Pliva | tbl. film obl. 56x50 mg | 0,1365 | 7,64 | RSpn22 | 5% |
| N03AX18 102 |  | lakozamid | 0,3 g | 0,9204 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Lakozamid Pliva | tbl. film obl. 56x100 mg | 0,3068 | 17,18 | RSpn22 | 5% |
| N03AX18 103 |  | lakozamid | 0,3 g | 0,9204 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Lakozamid Pliva | tbl. film obl. 56x150 mg | 0,4601 | 25,77 | RSpn22 | 5% |
| N03AX18 104 |  | lakozamid | 0,3 g | 0,9204 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Lakozamid Pliva | tbl. film obl. 56x200 mg | 0,6135 | 34,36 | RSpn22 | 5% |
| N03AX18 111 |  | lakozamid | 0,3 g | 0,8186 | O | Belupo d.d. | Belupo d.d. | Midza | tbl. film obl. 56x50 mg | 0,1365 | 7,64 | RSpn22 | 5% |
| N03AX18 112 |  | lakozamid | 0,3 g | 0,9204 | O | Belupo d.d. | Belupo d.d. | Midza | tbl. film obl. 56x100 mg | 0,3068 | 17,18 | RSpn22 | 5% |
| N03AX18 113 |  | lakozamid | 0,3 g | 0,9204 | O | Belupo d.d. | Belupo d.d. | Midza | tbl. film obl. 56x150 mg | 0,4601 | 25,77 | RSpn22 | 5% |
| N03AX18 114 |  | lakozamid | 0,3 g | 0,9204 | O | Belupo d.d. | Belupo d.d. | Midza | tbl. film obl. 56x200 mg | 0,6135 | 34,36 | RSpn22 | 5% |
| N03AX18 141 |  | lakozamid | 0,3 g | 0,8186 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd, Wessling Hungary Kft. | Lakozamid Accord | tbl. film obl. 56x50 mg | 0,1365 | 7,64 | RSpn22 | 5% |
| N03AX18 142 |  | lakozamid | 0,3 g | 0,9204 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd, Wessling Hungary Kft. | Lakozamid Accord | tbl. film obl. 56x100 mg | 0,3068 | 17,18 | RSpn22 | 5% |
| N03AX18 143 |  | lakozamid | 0,3 g | 0,9204 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd, Wessling Hungary Kft. | Lakozamid Accord | tbl. film obl. 56x150 mg | 0,4601 | 25,77 | RSpn22 | 5% |
| N03AX18 144 |  | lakozamid | 0,3 g | 0,9204 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd, Wessling Hungary Kft. | Lakozamid Accord | tbl. film obl. 56x200 mg | 0,6135 | 34,36 | RSpn22 | 5% |
| N03AX18 172 |  | lakozamid | 0,3 g | 0,9204 | O | Mylan Ireland Limited | HBM Pharma s.r.o., Mylan Hungary Kft | Seizpat | tbl. film obl. 56x100 mg | 0,3068 | 17,18 | RSpn22 | 5% |
| N03AX18 173 |  | lakozamid | 0,3 g | 0,9204 | O | Mylan Ireland Limited | HBM Pharma s.r.o., Mylan Hungary Kft | Seizpat | tbl. film obl. 56x200 mg | 0,6135 | 34,36 | RSpn22 | 5% |
| N03AX23 171 |  | brivaracetam | 0.1 g | 2,7918 | O | UCB Pharma S.A. | UCB Pharma S.A. | Briviact | tbl. film obl. 56x50 mg | 1,3960 | 78,17 | RSRN26 | 5% |
| N03AX23 172 |  | brivaracetam | 0.1 g | 1,3959 | O | UCB Pharma S.A. | UCB Pharma S.A. | Briviact | tbl. film obl. 56x100 mg | 1,3960 | 78,17 | RSRN26 | 5% |
| N03AX23 271 |  | brivaracetam | 0.1 g | 2,7907 | O | UCB Pharma S.A. | UCB Pharma S.A. | Briviact | otop. oral. 300 ml (10 mg/ml) | 83,7215 | 83,72 | RSRN26 | 5% |
| N04AA01 151 | DS | triheksifenidil | 10 mg |  | O |  |  |  |  |  |  |  | 5% |
| N04AA02 072 | PR | biperiden | 10 mg | 1,0080 | P | Desma GmbH | Sirton Pharmaceuticals S.p.A. | Akineton | amp. 5x5 mg/ml | 0,5036 | 2,52 |  | 5% |
| N04AA02 171 |  | biperiden | 10 mg | 0,1540 | O | Desma GmbH | Laboratorio Farmaceutico S.I.T. Srl | Akineton | tbl. 50x2 mg | 0,0308 | 1,54 | R | 5% |
| N04BA02 121 |  | levodopa + karbidopa | 0,6 g | 0,4322 | O | Sandoz d.o.o. | Sandoz-Lek | Nakom | tbl. 100x(250 mg + 25 mg) | 0,1801 | 18,01 | R | 5% |
| N04BA02 571 | DS | levodopa + karbidopaNN401 |  |  | P | AbbVie d.o.o. | Fresenius Kabi Norge AS, AbbVie Logistics B.V. | Duodopa intestinalni gel | vreć. plast., kazeta 7x100 ml (20 mg/ml levodope + 5 mg/ml karbidope) | 95,7830 | 670,48 |  | 5% |
| N04BA03 061 | DS | levodopa + karbidopa + entakaponNN401 |  |  | P | LobSor Pharmaceuticals AB | Bioglan AB | Lecigon | intestinalni gel u ulošku, 7x47 ml (20 mg/ml levodope + 5 mg/ml karbidope + 20mg/ml entakapona) | 96,3135 | 674,19 |  | 5% |
| N04BA03 161 |  | levodopa + karbidopa + entakapon | 0,45 g | 3,5793 | O | Orion Corporation | Orion Pharma | Stalevo | tbl. film obl. 100x(50 mg + 12,5 mg + 200 mg) | 0,3977 | 39,77 | Rpn05 | 5% |
| N04BA03 162 |  | levodopa + karbidopa + entakapon | 0,45 g | 1,7897 | O | Orion Corporation | Orion Pharma | Stalevo | tbl. film obl. 100x(100 mg + 25 mg + 200 mg) | 0,3977 | 39,77 | Rpn05 | 5% |
| N04BA03 163 |  | levodopa + karbidopa + entakapon | 0,45 g | 1,1931 | O | Orion Corporation | Orion Pharma | Stalevo | tbl. film obl. 100x(150 mg + 37,5 mg + 200 mg) | 0,3977 | 39,77 | Rpn05 | 5% |
| N04BA03 164 |  | levodopa + karbidopa + entakapon | 0,45 g | 0,8948 | O | Orion Corporation | Orion Pharma | Stalevo | tbl. film obl. 100x(200mg + 50 mg + 200 mg) | 0,3977 | 39,77 | Rpn05 | 5% |
| N04BB01 161 |  | amantadin | 200 mg | 0,2860 | O | Merz Pharmaceuticals Gmbh | Merz | PK-Merz | tbl. film obl. 30x100 mg | 0,1431 | 4,29 | R | 5% |
| N04BC04 101 |  | ropinirol | 6 mg | 0,9118 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Lirona XL | tbl. s prod. oslob. 28x2 mg | 0,3039 | 8,51 | R | 5% |
| N04BC04 102 |  | ropinirol | 6 mg | 0,8909 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Lirona XL | tbl. s prod. oslob. 28x4 mg | 0,5940 | 16,63 | R | 5% |
| N04BC04 103 |  | ropinirol | 6 mg | 0,8472 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Lirona XL | tbl. s prod. oslob. 28x8 mg | 1,1295 | 31,63 | R | 5% |
| N04BC04 115 |  | ropinirol | 6 mg | 0,9118 | O | Belupo d.d. | Belupo | Eminens SR | tbl. s prod. oslob. 28x2 mg | 0,3039 | 8,51 | R | 5% |
| N04BC04 116 |  | ropinirol | 6 mg | 0,8909 | O | Belupo d.d. | Belupo | Eminens SR | tbl. s prod. oslob. 28x4 mg | 0,5940 | 16,63 | R | 5% |
| N04BC04 117 |  | ropinirol | 6 mg | 0,8472 | O | Belupo d.d. | Belupo | Eminens SR | tbl. s prod. oslob. 28x8 mg | 1,1295 | 31,63 | R | 5% |
| N04BC04 131 |  | ropinirol | 6 mg | 0,9118 | O | KRKA-FARMA d.o.o. | KRKA d.d. | Rolpryna SR | tbl. s prod. oslob. 28x2 mg | 0,3039 | 8,51 | R | 5% |
| N04BC04 132 |  | ropinirol | 6 mg | 0,8909 | O | KRKA-FARMA d.o.o. | KRKA d.d. | Rolpryna SR | tbl. s prod. oslob. 28x4 mg | 0,5940 | 16,63 | R | 5% |
| N04BC04 133 |  | ropinirol | 6 mg | 0,8472 | O | KRKA-FARMA d.o.o. | KRKA d.d. | Rolpryna SR | tbl. s prod. oslob. 28x8 mg | 1,1295 | 31,63 | R | 5% |
| N04BC04 176 |  | ropinirol | 6 mg | 0,9118 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A., Glaxo Wellcome GmbH & Co.KG, Glaxo Wellcome S.A., SmithKline Beecham Plc | Requip Modutab | tbl. s prod. oslob. 28x2 mg | 0,3039 | 8,51 | R | 5% |
| N04BC04 177 |  | ropinirol | 6 mg | 0,8909 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A., Glaxo Wellcome GmbH & Co.KG, Glaxo Wellcome S.A., SmithKline Beecham Plc | Requip Modutab | tbl. s prod. oslob. 28x4 mg | 0,5940 | 16,63 | R | 5% |
| N04BC04 178 |  | ropinirol | 6 mg | 0,8472 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A., Glaxo Wellcome GmbH & Co.KG, Glaxo Wellcome S.A., SmithKline Beecham Plc | Requip Modutab | tbl. s prod. oslob. 28x8 mg | 1,1295 | 31,63 | R | 5% |
| N04BC05 103 |  | pramipeksol | 2,5 mg | 1,3141 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x0,26 mg | 0,1368 | 4,10 | R | 5% |
| N04BC05 104 |  | pramipeksol | 2,5 mg | 1,3157 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x0,52 mg | 0,2735 | 8,21 | R | 5% |
| N04BC05 105 |  | pramipeksol | 2,5 mg | 1,2730 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x1,05 mg | 0,5346 | 16,04 | R | 5% |
| N04BC05 106 |  | pramipeksol | 2,5 mg | 1,2103 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x2,1 mg | 1,0165 | 30,50 | R | 5% |
| N04BC05 107 |  | pramipeksol | 2,5 mg | 1,2101 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Pramipeksol Pliva | tbl. s prod. oslob. 30x3,15 mg | 1,5248 | 45,74 | R | 5% |
| N04BC05 187 |  | pramipeksol | 2,5 mg | 1,2726 | O | Krka d.d., Novo mesto | Krka d.d., TAD Pharma GmbH | Oprymea | tbl. 30x0,7 mg | 0,3564 | 10,69 | R | 5% |
| N04BD02 111 |  | razagilin | 1 mg | 0,7489 | O | Belupo d.d. | Belupo d.d. | Razagilin Belupo | tbl. 28x1 mg | 0,7489 | 20,97 | Rpn06 | 5% |
| N04BD02 112 |  | razagilin | 1 mg | 0,6782 | O | Belupo d.d. | Belupo d.d. | Razagilin Belupo | tbl. 56x1 mg | 0,6783 | 37,98 | Rpn06 | 5% |
| N04BD02 161 |  | razagilin | 1 mg | 0,7489 | O | Teva B.V. | Teva Pharmaceuticals | Azilect | tbl. 28x1 mg | 0,7489 | 20,97 | Rpn06 | 5% |
| N04BD02 162 |  | razagilin | 1 mg | 0,7489 | O | PLIVA HRVATSKA d.o.o. | Teva Pharmaceuticals Europe B.V. | Razagilin Teva | tbl. 28x1 mg | 0,7489 | 20,97 | Rpn06 | 5% |
| N04BD02 171 |  | razagilin | 1 mg | 0,7489 | O | Medochemie Ltd. | Medochemie Ltd. | Sagilia | tbl. 28x1 mg | 0,7489 | 20,97 | Rpn06 | 5% |
| N04BD02 181 |  | razagilin | 1 mg | 0,7489 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Azipron | tbl. 28x1 mg | 0,7489 | 20,97 | Rpn06 | 5% |
| N04BD02 191 |  | razagilin | 1 mg | 0,7489 | O | Makpharm d.o.o. | Synthon Hispania S.L., Synthon s.r.o., Synthon BV, | Razagilin Makpharm | tbl. 28x1 mg | 0,7489 | 20,97 | Rpn06 | 5% |
| N04BD02 192 |  | razagilin | 1 mg | 0,7489 | O | STADA d.o.o. | STADA Arzneimittel GmbH | Razagilin Stada | tbl. 28x1 mg | 0,7489 | 20,97 | Rpn06 | 5% |
| N04BX02 171 |  | entakapon | 1 g | 1,5183 | O | HEC Pharma GmbH | Formula Pharmazeutische und chemische Entwicklungs GmbH | Entakapon HEC | tbl. film obl. 30x200 mg | 0,3038 | 9,11 | Rpn05 | 5% |
| N05AA02 191 |  | levomepromazin | 0,3 g | 1,0200 | O | sanofi-aventis groupe | Sanofi S.p.A | Nozinan | tbl. film obl. 20x25 mg | 0,0849 | 1,70 | R | 5% |
| N05AA02 192 |  | levomepromazin | 0,3 g | 0,5400 | O | sanofi-aventis groupe | Sanofi S.p.A | Nozinan | tbl. film obl. 20x100 mg | 0,1800 | 3,60 | R | 5% |
| N05AA03 051 | PR | promazin | 0,1 g |  | P |  |  |  |  |  |  |  | 5% |
| N05AA03 101 |  | promazin | 0,3 g | 1,4808 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prazine | drag. 50x25 mg | 0,1234 | 6,17 | R | 5% |
| N05AA03 102 |  | promazin | 0,3 g | 0,6480 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Prazine | drag. 50x100 mg | 0,2161 | 10,80 | R | 5% |
| N05AA03 111 |  | promazin | 0,3 g | 1,4808 | O | Belupo d.d. | Belupo | Promazin Belupo | tbl. obl. 50x25 mg | 0,1234 | 6,17 | R | 5% |
| N05AA03 112 |  | promazin | 0,3 g | 0,6480 | O | Belupo d.d. | Belupo | Promazin Belupo | tbl. obl. 50x100 mg | 0,2161 | 10,80 | R | 5% |
| N05AB02 035 | PO | flufenazin-dekanoat | 1 mg | 0,1497 | P | KRKA-FARMA d.o.o. | Krka d.d. | Moditen depo | amp. 5x25 mg/ml | 3,7423 | 18,71 |  | 5% |
| N05AB02 131 |  | flufenazin | 10 mg | 1,2800 | O | KRKA-FARMA d.o.o. | Krka d.d. | Moditen | drag. 25x1 mg | 0,1281 | 3,20 | R | 5% |
| N05AB02 132 |  | flufenazin | 10 mg | 0,4460 | O | KRKA-FARMA d.o.o. | Krka d.d. | Moditen | drag. 100x2,5 mg | 0,1115 | 11,15 | R | 5% |
| N05AB02 133 |  | flufenazin | 10 mg | 0,4460 | O | KRKA-FARMA d.o.o. | Krka d.d. | Moditen | drag. 100x5 mg | 0,2230 | 22,30 | R | 5% |
| N05AD01 031 | PR | haloperidol | 8 mg | 0,8800 | P | KRKA-FARMA d.o.o. | Krka d.d. | Haldol/Haloperidol Krka | amp. 10x5 mg/ml / otop. za inj., 10x5 mg/ml | 0,5276 | 5,28 |  | 5% |
| N05AD01 032 | PO | haloperidol-dekanoat | 3,3 mg | 0,2703 | P | KRKA-FARMA d.o.o. | Krka d.d. | Haldol depo/Haloperidol depo Krka | amp. 5x50 mg/ml / otop. za inj. s prod. oslob., 5x50 mg/ml | 4,1072 | 20,54 |  | 5% |
| N05AD01 137 |  | haloperidol | 8 mg | 0,1515 | O | KRKA-FARMA d.o.o. | Krka d.d. | Haldol/Haloperidol Krka | tbl. 30x10 mg | 0,1895 | 5,68 | R | 5% |
| N05AD01 251 |  | haloperidol | 8 mg |  | O |  |  |  | oralne kapi |  |  | R | 5% |
| N05AE03 171 |  | sertindol | 16 mg | 2,7013 | O | Lundbeck Croatia d.o.o. | H. Lundbeck A/S | Serdolect | tbl. film obl. 30x4 mg | 0,6752 | 20,26 | RSRN06 | 5% |
| N05AE03 172 |  | sertindol | 16 mg | 2,7010 | O | Lundbeck Croatia d.o.o. | H. Lundbeck A/S | Serdolect | tbl. film obl. 28x12 mg | 2,0257 | 56,72 | RSRN06 | 5% |
| N05AE04 161 |  | ziprazidon | 80 mg | 1,8233 | O | Upjohn EESV | Pfizer | Zeldox | caps. 30x40 mg | 0,9118 | 27,35 | RSRN06 | 5% |
| N05AE04 162 |  | ziprazidon | 80 mg | 1,3520 | O | Upjohn EESV | Pfizer | Zeldox | caps. 30x60 mg | 1,0140 | 30,42 | RSRN06 | 5% |
| N05AE04 163 |  | ziprazidon | 80 mg | 1,6073 | O | Upjohn EESV | Pfizer | Zeldox | caps. 30x80 mg | 1,6072 | 48,22 | RSRN06 | 5% |
| N05AE05 161 |  | lurasidon | 60 mg | 2,8540 | O | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | Aziende Chimiche Riunite Angelini Francesco ACRAF SPA, Millmount Healthcare Ltd. | Latuda | tbl. film obl. 28x37 mg | 1,7599 | 49,28 | RSRN06 | 5% |
| N05AE05 162 |  | lurasidon | 60 mg | 1,4270 | O | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | Aziende Chimiche Riunite Angelini Francesco ACRAF SPA, Millmount Healthcare Ltd. | Latuda | tbl. film obl. 28x74 mg | 1,7599 | 49,28 | RSRN06 | 5% |
| N05AH02 051 | DS | klozapin | 0,3 g |  | P |  |  |  |  |  |  |  | 5% |
| N05AH02 101 |  | klozapin | 0,3 g | 0,9240 | O | PLIVA HRVATSKA d.o.o. | Accord Healthcare Limited | Sanosen | tbl. 50x25 mg | 0,0769 | 3,85 | RSRN06 | 5% |
| N05AH02 161 |  | klozapin | 0,3 g | 0,8208 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Klozapin Alpha-Medical | tbl. 50x100 mg | 0,2737 | 13,68 | RSRN06 | 5% |
| N05AH02 162 |  | klozapin | 0,3 g | 1,0248 | O | ALPHA-MEDICAL d.o.o. | Remedica Ltd. | Klozapin Alpha-Medical | tbl. 50x25 mg | 0,0855 | 4,27 | RSRN06 | 5% |
| N05AH02 163 |  | klozapin | 0,3 g | 0,8328 | O | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Wessling Hungary Kft. | Klozapin Accord | tbl. 50x25 mg | 0,0694 | 3,47 | RSRN06 | 5% |
| N05AH02 164 |  | klozapin | 0,3 g | 0,6660 | O | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Limited, Wessling Hungary Kft. | Klozapin Accord | tbl. 50x100 mg | 0,2219 | 11,10 | RSRN06 | 5% |
| N05AH02 171 |  | klozapin | 0,3 g | 0,9648 | O | Makpharm d.o.o. | Synthon Hispania S.L., Synthon BV | Zaniq | tbl. rasp. za usta 100x12,5 mg | 0,0402 | 4,02 | RSRN06 | 5% |
| N05AH02 172 |  | klozapin | 0,3 g | 0,8772 | O | Makpharm d.o.o. | Synthon Hispania S.L., Synthon BV | Zaniq | tbl. rasp. za usta 100x25 mg | 0,0731 | 7,31 | RSRN06 | 5% |
| N05AH02 173 |  | klozapin | 0,3 g | 0,7020 | O | Makpharm d.o.o. | Synthon Hispania S.L., Synthon BV | Zaniq | tbl. rasp. za usta 100x100 mg | 0,2340 | 23,40 | RSRN06 | 5% |
| N05AH02 174 |  | klozapin | 0,3 g | 1,0248 | O | Mylan Hrvatska d.o.o. | Novartis Pharma | Leponex | tbl. 50x25 mg | 0,0855 | 4,27 | RSRN06 | 5% |
| N05AH02 175 |  | klozapin | 0,3 g | 0,8208 | O | Mylan Hrvatska d.o.o. | Novartis Pharma | Leponex | tbl. 50x100 mg | 0,2737 | 13,68 | RSRN06 | 5% |
| N05AH03 061 | RL | olanzapinNN502 | 10 mg | 8,4676 | P | Eli Lilly Nederland B.V. | Lilly S.A. | Zypadhera | praš. i otap. za susp. za inj. s prod. osl. 1x210 mg | 177,8167 | 177,82 | RSRN08 | 5% |
| N05AH03 062 | RL | olanzapinNN502 | 10 mg | 7,4073 | P | Eli Lilly Nederland B.V. | Lilly S.A. | Zypadhera | praš. i otap. za susp. za inj. s prod. osl. 1x300 mg | 222,2151 | 222,22 | RSRN08 | 5% |
| N05AH03 063 | RL | olanzapinNN502 | 10 mg | 6,9215 | P | Eli Lilly Nederland B.V. | Lilly S.A. | Zypadhera | praš. i otap. za susp. za inj. s prod. osl. 1x405 mg | 280,3159 | 280,32 | RSRN08 | 5% |
| N05AH03 065 | DS | olanzapinNN503 | 10 mg | 3,4900 | P | Eli Lilly Nederland B.V. | Lilly S.A. | Zyprexa | praš. za otop. za inj. boč. 1x10 mg | 3,4906 | 3,49 |  | 5% |
| N05AH03 101 |  | olanzapin | 10 mg | 0,5364 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Olandix | tbl. rasp. za usta 28x5 mg | 0,2681 | 7,51 | RSRN06 | 5% |
| N05AH03 102 |  | olanzapin | 10 mg | 0,5175 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Olandix | tbl. rasp. za usta 28x10 mg | 0,5176 | 14,49 | RSRN06 | 5% |
| N05AH03 111 |  | olanzapin | 10 mg | 0,5364 | O | Belupo d.d. | Belupo | Vaira | tbl. film obl. 28x5 mg | 0,2681 | 7,51 | RSRN06 | 5% |
| N05AH03 112 |  | olanzapin | 10 mg | 0,5175 | O | Belupo d.d. | Belupo | Vaira | tbl. film obl. 28x10 mg | 0,5176 | 14,49 | RSRN06 | 5% |
| N05AH03 113 |  | olanzapin | 10 mg | 0,5364 | O | Belupo d.d. | Belupo | Vaira -V | tbl. rasp. za usta 28x5 mg | 0,2681 | 7,51 | RSRN06 | 5% |
| N05AH03 114 |  | olanzapin | 10 mg | 0,5175 | O | Belupo d.d. | Belupo | Vaira -V | tbl. rasp. za usta 28x10 mg | 0,5176 | 14,49 | RSRN06 | 5% |
| N05AH03 123 |  | olanzapin | 10 mg | 0,5333 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ziora | tbl. rasp. za usta 30x5 mg | 0,2668 | 8,00 | RSRN06 | 5% |
| N05AH03 124 |  | olanzapin | 10 mg | 0,5163 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Ziora | tbl. rasp. za usta 30x10 mg | 0,5163 | 15,49 | RSRN06 | 5% |
| N05AH03 126 |  | olanzapin | 10 mg | 0,5364 | O | Sandoz d.o.o. | Sandoz-Salutas | Olanzalux | tbl. film obl. 28x5 mg | 0,2681 | 7,51 | RSRN06 | 5% |
| N05AH03 127 |  | olanzapin | 10 mg | 0,5079 | O | Sandoz d.o.o. | Sandoz-Salutas | Olanzalux | tbl. film obl. 28x10 mg | 0,5079 | 14,22 | RSRN06 | 5% |
| N05AH03 131 |  | olanzapin | 10 mg | 0,5364 | O | Krka d.d., Novo mesto | Krka d.d. | Zalasta | tbl. rasp. za usta 28x5 mg | 0,2681 | 7,51 | RSRN06 | 5% |
| N05AH03 132 |  | olanzapin | 10 mg | 0,5175 | O | Krka d.d., Novo mesto | Krka d.d. | Zalasta | tbl. rasp. za usta 28x10 mg | 0,5176 | 14,49 | RSRN06 | 5% |
| N05AH03 133 |  | olanzapin | 10 mg | 0,9705 | O | Krka d.d., Novo mesto | Krka d.d. | Zalasta | tbl. rasp. za usta 28x15 mg | 1,4558 | 40,76 | RSRN06 | 5% |
| N05AH03 145 |  | olanzapin | 10 mg | 0,5279 | O | PharmaS d.o.o. | PharmaS d.o.o. | Olanzapin PharmaS | tbl. rasp. za usta 28x5 mg | 0,2639 | 7,39 | RSRN06 | 5% |
| N05AH03 146 |  | olanzapin | 10 mg | 0,4971 | O | PharmaS d.o.o. | PharmaS d.o.o. | Olanzapin PharmaS | tbl. rasp. za usta 28x10 mg | 0,4972 | 13,92 | RSRN06 | 5% |
| N05AH03 163 |  | olanzapin | 10 mg | 0,5364 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Zyprexa Velotab | tbl. rasp. za usta 28x5 mg | 0,2681 | 7,51 | RSRN06 | 5% |
| N05AH03 164 |  | olanzapin | 10 mg | 0,5175 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Zyprexa Velotab | tbl. rasp. za usta 28x10 mg | 0,5176 | 14,49 | RSRN06 | 5% |
| N05AH04 100 |  | kvetiapin | 0,4 g | 2,2427 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Loquen | tbl. film obl. 60x25 mg | 0,1402 | 8,41 | RSRN06 | 5% |
| N05AH04 101 |  | kvetiapin | 0,4 g | 0,8820 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Loquen | tbl. film obl. 60x100 mg | 0,2205 | 13,23 | RSRN06 | 5% |
| N05AH04 102 |  | kvetiapin | 0,4 g | 0,7713 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Loquen | tbl. film obl. 60x200 mg | 0,3857 | 23,14 | RSRN06 | 5% |
| N05AH04 103 |  | kvetiapin | 0,4 g | 1,0107 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Loquen XR | tbl. film obl. s prod. oslob. 60x200 mg | 0,5053 | 30,32 | RSRN06 | 5% |
| N05AH04 104 |  | kvetiapin | 0,4 g | 0,9498 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Loquen XR | tbl. film obl. s prod. oslob. 60x300 mg | 0,7123 | 42,74 | RSRN06 | 5% |
| N05AH04 105 |  | kvetiapin | 0,4 g | 0,9693 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Loquen XR | tbl. film obl. s prod. oslob. 60x400 mg | 0,9693 | 58,16 | RSRN06 | 5% |
| N05AH04 106 |  | kvetiapin | 0,4 g | 1,0636 | O | PLIVA HRVATSKA d.o.o. | Teva Pharma S.L.U. | Loquen XR | tbl. film obl. s prod. oslob. 60x150 mg | 0,3989 | 23,93 | RSRN06 | 5% |
| N05AH04 111 |  | kvetiapin | 0,4 g | 2,2427 | O | Belupo d.d. | Belupo | Q-pin | tbl. film obl. 60x25 mg | 0,1402 | 8,41 | RSRN06 | 5% |
| N05AH04 112 |  | kvetiapin | 0,4 g | 0,8820 | O | Belupo d.d. | Belupo | Q-pin | tbl. film obl. 60x100 mg | 0,2205 | 13,23 | RSRN06 | 5% |
| N05AH04 113 |  | kvetiapin | 0,4 g | 0,7713 | O | Belupo d.d. | Belupo | Q-pin | tbl. film obl. 60x200 mg | 0,3857 | 23,14 | RSRN06 | 5% |
| N05AH04 114 |  | kvetiapin | 0,4 g | 0,9013 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x50 mg | 0,1127 | 6,76 | RSRN06 | 5% |
| N05AH04 115 |  | kvetiapin | 0,4 g | 1,0636 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x150 mg | 0,3989 | 23,93 | RSRN06 | 5% |
| N05AH04 121 |  | kvetiapin | 0,4 g | 2,2427 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Quelapin | tbl. film obl. 60x25 mg | 0,1402 | 8,41 | RSRN06 | 5% |
| N05AH04 122 |  | kvetiapin | 0,4 g | 0,8820 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Quelapin | tbl. film obl. 60x100 mg | 0,2205 | 13,23 | RSRN06 | 5% |
| N05AH04 124 |  | kvetiapin | 0,4 g | 0,7713 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Quelapin | tbl. film obl. 60x200 mg | 0,3857 | 23,14 | RSRN06 | 5% |
| N05AH04 129 |  | kvetiapin | 0,4 g | 0,8800 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x400 mg | 0,8800 | 52,80 | RSRN06 | 5% |
| N05AH04 130 |  | kvetiapin | 0,4 g | 0,9013 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x50 mg | 0,1127 | 6,76 | RSRN06 | 5% |
| N05AH04 131 |  | kvetiapin | 0,4 g | 2,2427 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Kventiax | tbl. film obl. 60x25 mg | 0,1402 | 8,41 | RSRN06 | 5% |
| N05AH04 132 |  | kvetiapin | 0,4 g | 0,8820 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Kventiax | tbl. film obl. 60x100 mg | 0,2205 | 13,23 | RSRN06 | 5% |
| N05AH04 133 |  | kvetiapin | 0,4 g | 0,7713 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Kventiax | tbl. film obl. 60x200 mg | 0,3857 | 23,14 | RSRN06 | 5% |
| N05AH04 134 |  | kvetiapin | 0,4 g | 0,8836 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Kventiax | tbl. film obl. 60x300 mg | 0,6627 | 39,76 | RSRN06 | 5% |
| N05AH04 135 |  | kvetiapin | 0,4 g | 1,0107 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin XR PharmaS | tbl. s prod. oslob. 60x200 mg | 0,5053 | 30,32 | RSRN06 | 5% |
| N05AH04 136 |  | kvetiapin | 0,4 g | 0,9498 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin XR PharmaS | tbl. s prod. oslob. 60x300 mg | 0,7123 | 42,74 | RSRN06 | 5% |
| N05AH04 137 |  | kvetiapin | 0,4 g | 0,9693 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin XR PharmaS | tbl. s prod. oslob. 60x400 mg | 0,9693 | 58,16 | RSRN06 | 5% |
| N05AH04 138 |  | kvetiapin | 0,4 g | 0,9013 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin XR PharmaS | tbl. s prod. oslob. 60x50 mg | 0,1127 | 6,76 | RSRN06 | 5% |
| N05AH04 146 |  | kvetiapin | 0,4 g | 2,2427 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin PharmaS | tbl. film obl. 60x25 mg | 0,1402 | 8,41 | RSRN06 | 5% |
| N05AH04 147 |  | kvetiapin | 0,4 g | 0,8820 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin PharmaS | tbl. film obl. 60x100 mg | 0,2205 | 13,23 | RSRN06 | 5% |
| N05AH04 148 |  | kvetiapin | 0,4 g | 0,7713 | O | PharmaS d.o.o. | PharmaS d.o.o. | Kvetiapin PharmaS | tbl. film obl. 60x200 mg | 0,3857 | 23,14 | RSRN06 | 5% |
| N05AH04 164 |  | kvetiapin | 0,4 g | 0,9498 | O | AstraZeneca d.o.o. | AstraZeneca | Seroquel XR | tbl. s prod. oslob. 60x300 mg | 0,7123 | 42,74 | RSRN06 | 5% |
| N05AH04 165 |  | kvetiapin | 0,4 g | 0,9693 | O | AstraZeneca d.o.o. | AstraZeneca | Seroquel XR | tbl. s prod. oslob. 60x400 mg | 0,9693 | 58,16 | RSRN06 | 5% |
| N05AH04 181 |  | kvetiapin | 0,4 g | 1,0107 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x200 mg | 0,5053 | 30,32 | RSRN06 | 5% |
| N05AH04 182 |  | kvetiapin | 0,4 g | 0,9498 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x300 mg | 0,7123 | 42,74 | RSRN06 | 5% |
| N05AH04 183 |  | kvetiapin | 0,4 g | 0,9693 | O | Belupo d.d. | Belupo d.d. | Q-Pin SR | tbl. s prod. oslob. 60x400 mg | 0,9693 | 58,16 | RSRN06 | 5% |
| N05AH04 184 |  | kvetiapin | 0,4 g | 1,0636 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x150 mg | 0,3989 | 23,93 | RSRN06 | 5% |
| N05AH04 185 |  | kvetiapin | 0,4 g | 1,0107 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x200 mg | 0,5053 | 30,32 | RSRN06 | 5% |
| N05AH04 186 |  | kvetiapin | 0,4 g | 0,9498 | O | KRKA-FARMA d.o.o. | Krka d.d. | Kventiax SR | tbl. s prod. oslob. 60x300 mg | 0,7123 | 42,74 | RSRN06 | 5% |
| N05AL01 112 |  | sulpirid | 0,8 g | 0,8367 | O | Belupo d.d. | Belupo | Sulpirid Belupo | caps. tvrda 12x200 mg | 0,2094 | 2,51 | R | 5% |
| N05AL01 143 |  | sulpirid | 0,8 g | 0,8360 | O | Alkaloid d.o.o. | Alkaloid-int d.o.o. | Eglonyl forte | tbl. 10x200 mg | 0,2094 | 2,09 | R | 5% |
| N05AL01 144 |  | sulpirid | 0,8 g | 0,7360 | O | Alkaloid d.o.o. | Alkaloid-int d.o.o. | Eglonyl forte | tbl. 30x200 mg | 0,1840 | 5,52 | R | 5% |
| N05AL05 162 |  | amisulprid | 0,4 g | 0,8760 | O | sanofi-aventis groupe | Sanofi Winthrop Quetigny | Solian | tbl. 30x200 mg | 0,4382 | 13,14 | RSRN09 | 5% |
| N05AL05 172 |  | amisulprid | 0,4 g | 0,8760 | O | Medochemie Ltd. | Medochemie Ltd. | Aktiprol | tbl. 30x200 mg | 0,4382 | 13,14 | RSRN09 | 5% |
| N05AL05 173 |  | amisulprid | 0,4 g | 0,8763 | O | Medochemie Ltd. | Medochemie Ltd. | Aktiprol | tbl. 30x400 mg | 0,8763 | 26,29 | RSRN09 | 5% |
| N05AN01 115 |  | litij-karbonat | 24 mmol | 0,0080 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Litijev karbonat Jadran | tbl. 100x300 mg | 0,1000 | 10,00 | R | 5% |
| N05AX08 081 | RL | risperidonNN504 | 2,7 mg | 8,7328 | P | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Rispolept Consta | susp. s prod. djel. za i.m. primj. 1x25 mg | 80,8627 | 80,86 | RSRN10 | 5% |
| N05AX08 082 | RL | risperidonNN504 | 2,7 mg | 7,6846 | P | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Rispolept Consta | susp. s prod. djel. za i.m. primj. 1x37,5 mg | 106,7330 | 106,73 | RSRN10 | 5% |
| N05AX08 083 | RL | risperidonNN504 | 2,7 mg | 7,0756 | P | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Rispolept Consta | susp. s prod. djel. za i.m. primj. 1x50 mg | 131,0279 | 131,03 | RSRN10 | 5% |
| N05AX08 101 |  | risperidon | 5 mg | 0,8000 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Merckle GmbH | Risset | tbl. film obl. 20x1 mg | 0,1601 | 3,20 | RSRN06 | 5% |
| N05AX08 102 |  | risperidon | 5 mg | 0,6358 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Merckle GmbH | Risset | tbl. film obl. 60x2 mg | 0,2544 | 15,26 | RSRN06 | 5% |
| N05AX08 103 |  | risperidon | 5 mg | 0,6525 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Merckle GmbH | Risset | tbl. film obl. 60x3 mg | 0,3915 | 23,49 | RSRN06 | 5% |
| N05AX08 104 |  | risperidon | 5 mg | 0,8721 | O | Teva B.V. | Teva Pharmaceutical Works Private Limited Company, Merckle GmbH | Risset | tbl. film obl. 60x4 mg | 0,6977 | 41,86 | RSRN06 | 5% |
| N05AX08 111 |  | risperidon | 5 mg | 0,8000 | O | Belupo d.d. | Belupo | Prospera | tbl. film obl. 20x1 mg | 0,1601 | 3,20 | RSRN06 | 5% |
| N05AX08 112 |  | risperidon | 5 mg | 0,6358 | O | Belupo d.d. | Belupo | Prospera | tbl. film obl. 60x2 mg | 0,2544 | 15,26 | RSRN06 | 5% |
| N05AX08 122 |  | risperidon | 5 mg | 0,6358 | O | Sandoz d.o.o. | Sandoz-Lek | Rispolux | tbl. film obl. 60x2 mg | 0,2544 | 15,26 | RSRN06 | 5% |
| N05AX08 131 |  | risperidon | 5 mg | 0,8000 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Torendo | tbl. film obl. 20x1 mg | 0,1601 | 3,20 | RSRN06 | 5% |
| N05AX08 141 |  | risperidon | 5 mg | 0,8000 | O | Alkaloid d.o.o. | Alkaloid | Risdonal | tbl. film obl. 20x1 mg | 0,1601 | 3,20 | RSRN06 | 5% |
| N05AX08 142 |  | risperidon | 5 mg | 0,6358 | O | Alkaloid d.o.o. | Alkaloid | Risdonal | tbl. film obl. 60x2 mg | 0,2544 | 15,26 | RSRN06 | 5% |
| N05AX08 143 |  | risperidon | 5 mg | 0,6525 | O | Alkaloid d.o.o. | Alkaloid | Risdonal | tbl. film obl. 60x3 mg | 0,3915 | 23,49 | RSRN06 | 5% |
| N05AX08 185 |  | risperidon | 5 mg | 0,6358 | O | Johnson & Johnson S.E.d.o.o. | Janssen-Cilag S.p.A. | Rispolept | tbl. film obl. 60x2 mg | 0,2544 | 15,26 | RSRN06 | 5% |
| N05AX08 186 |  | risperidon | 5 mg | 0,6525 | O | Johnson & Johnson S.E.d.o.o. | Janssen-Cilag S.p.A. | Rispolept | tbl. film obl. 60x3 mg | 0,3915 | 23,49 | RSRN06 | 5% |
| N05AX08 187 |  | risperidon | 5 mg | 0,8721 | O | Johnson & Johnson S.E.d.o.o. | Janssen-Cilag S.p.A. | Rispolept | tbl. film obl. 60x4 mg | 0,6977 | 41,86 | RSRN06 | 5% |
| N05AX08 288 |  | risperidon | 5 mg | 1,2320 | O | Johnson & Johnson S.E.d.o.o. | Janssen Pharmaceutica NV | Rispolept | otop. oral. 100 ml (1 mg/ml) | 24,6426 | 24,64 | RSRN06 | 5% |
| N05AX12 061 | RL | aripiprazol | 15 mg | 9,7121 | P | Otsuka Pharmaceutical Netherlands B.V. | H. Lundbeck A/S | Abilify Maintena | praš. i otap. za susp. za inj. s prod. oslob. za i.m. primj. 1x400 mg | 258,9940 | 258,99 | RSRN17 | 5% |
| N05AX12 101 |  | aripiprazol | 15 mg | 1,0640 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Teva Operations Poland, Merckle GmbH | Aripiprazol Pliva | tbl. 30x5 mg | 0,3546 | 10,64 | RSRN06 | 5% |
| N05AX12 102 |  | aripiprazol | 15 mg | 0,8615 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Teva Operations Poland, Merckle GmbH | Aripiprazol Pliva | tbl. 30x10 mg | 0,5744 | 17,23 | RSRN06 | 5% |
| N05AX12 103 |  | aripiprazol | 15 mg | 0,9113 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Teva Operations Poland, Merckle GmbH | Aripiprazol Pliva | tbl. 30x15 mg | 0,9113 | 27,34 | RSRN06 | 5% |
| N05AX12 104 |  | aripiprazol | 15 mg | 0,6808 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V., Teva Operations Poland, Merckle GmbH | Aripiprazol Pliva | tbl. 30x30 mg | 1,3617 | 40,85 | RSRN06 | 5% |
| N05AX12 131 |  | aripiprazol | 15 mg | 0,8615 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Arisppa | tbl. 30x10 mg | 0,5744 | 17,23 | RSRN06 | 5% |
| N05AX12 132 |  | aripiprazol | 15 mg | 0,8203 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Arisppa | tbl. 30x15 mg | 0,8202 | 24,61 | RSRN06 | 5% |
| N05AX12 133 |  | aripiprazol | 15 mg | 0,6808 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Arisppa | tbl. 30x30 mg | 1,3617 | 40,85 | RSRN06 | 5% |
| N05AX12 141 |  | aripiprazol | 15 mg | 0,5662 | O | Mylan Pharmaceuticals Limited | Pharmathen | Aripiprazole Mylan Pharma | tbl. 28x10 mg | 0,3774 | 10,57 | RSRN06 | 5% |
| N05AX12 142 |  | aripiprazol | 15 mg | 0,5375 | O | Mylan Pharmaceuticals Limited | Pharmathen | Aripiprazole Mylan Pharma | tbl. 28x15 mg | 0,5375 | 15,05 | RSRN06 | 5% |
| N05AX12 143 |  | aripiprazol | 15 mg | 0,5513 | O | Mylan Pharmaceuticals Limited | Pharmathen | Aripiprazole Mylan Pharma | tbl. 28x30 mg | 1,1025 | 30,87 | RSRN06 | 5% |
| N05AX12 161 |  | aripiprazol | 15 mg | 0,6975 | O | Medochemie Ltd. | Medochemie Ltd. | Zykalor | tbl. 30x10 mg | 0,4651 | 13,95 | RSRN06 | 5% |
| N05AX12 162 |  | aripiprazol | 15 mg | 0,6630 | O | Medochemie Ltd. | Medochemie Ltd. | Zykalor | tbl. 30x15 mg | 0,6629 | 19,89 | RSRN06 | 5% |
| N05AX12 171 |  | aripiprazol | 15 mg | 0,6986 | O | STADA d.o.o. | STADA Arzneimittel AG, Centrafarm Services BV, STADA Arzneimittel GmbH | Aripiprazol STADA | tbl. 28x10 mg | 0,4659 | 13,04 | RSRN06 | 5% |
| N05AX12 172 |  | aripiprazol | 15 mg | 0,6643 | O | STADA d.o.o. | STADA Arzneimittel AG, Centrafarm Services BV, STADA Arzneimittel GmbH | Aripiprazol STADA | tbl. 28x15 mg | 0,6641 | 18,60 | RSRN06 | 5% |
| N05AX12 173 |  | aripiprazol | 15 mg | 0,6809 | O | STADA d.o.o. | STADA Arzneimittel AG, Centrafarm Services BV, STADA Arzneimittel GmbH | Aripiprazol STADA | tbl. 28x30 mg | 1,3617 | 38,13 | RSRN06 | 5% |
| N05AX12 181 |  | aripiprazol | 15 mg | 0,6289 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Aripiprazole Accord | tbl. 28x10 mg | 0,4193 | 11,74 | RSRN06 | 5% |
| N05AX12 183 |  | aripiprazol | 15 mg | 0,6129 | O | Accord Healthcare S.L.U. | Accord Healthcare Ltd | Aripiprazole Accord | tbl. 28x30 mg | 1,2256 | 34,32 | RSRN06 | 5% |
| N05AX13 001 | RL | paliperidon | 2,5 mg | 6,4260 | P | Teva B.V. | Actavis Group PTC ehf. | Paliperidon Teva | susp. za inj. s prod. oslob. za i.m. primj. 1x50 mg | 128,5248 | 128,52 | RSRN11 | 5% |
| N05AX13 002 | RL | paliperidon | 2,5 mg | 5,5027 | P | Teva B.V. | Actavis Group PTC ehf. | Paliperidon Teva | susp. za inj. s prod. oslob. za i.m. primj. 1x75 mg | 165,0806 | 165,08 | RSRN11 | 5% |
| N05AX13 003 | RL | paliperidon | 2,5 mg | 5,0880 | P | Teva B.V. | Actavis Group PTC ehf. | Paliperidon Teva | susp. za inj. s prod. oslob. za i.m. primj. 1x100 mg | 203,5211 | 203,52 | RSRN11 | 5% |
| N05AX13 004 | RL | paliperidon | 2,5 mg | 4,6780 | P | Teva B.V. | Actavis Group PTC ehf. | Paliperidon Teva | susp. za inj. s prod. oslob. za i.m. primj. 1x150 mg | 280,6835 | 280,68 | RSRN11 | 5% |
| N05AX13 061 | RL | paliperidon | 2,5 mg | 9,1805 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Xeplion | susp. za inj. s prod. oslob. za i.m. primj. 1x50 mg | 183,6074 | 183,61 | RSRN11 | 5% |
| N05AX13 062 | RL | paliperidon | 2,5 mg | 7,8610 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Xeplion | susp. za inj. s prod. oslob. za i.m. primj. 1x75 mg | 235,8298 | 235,83 | RSRN11 | 5% |
| N05AX13 063 | RL | paliperidon | 2,5 mg | 7,2688 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Xeplion | susp. za inj. s prod. oslob. za i.m. primj. 1x100 mg | 290,7452 | 290,75 | RSRN11 | 5% |
| N05AX13 064 | RL | paliperidon | 2,5 mg | 6,6830 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Xeplion | susp. za inj. s prod. oslob. za i.m. primj. 1x150 mg | 400,9755 | 400,98 | RSRN11 | 5% |
| N05AX13 065 | RL | paliperidon | 2,5 mg | 7,6526 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Trevicta | susp. za inj. s prod. oslob. za i.m. primj. 1x175 mg | 535,6759 | 535,68 | RSRN20 | 5% |
| N05AX13 066 | RL | paliperidon | 2,5 mg | 6,5673 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Trevicta | susp. za inj. s prod. oslob. za i.m. primj. 1x263 mg | 690,8780 | 690,88 | RSRN20 | 5% |
| N05AX13 067 | RL | paliperidon | 2,5 mg | 6,0977 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Trevicta | susp. za inj. s prod. oslob. za i.m. primj. 1x350 mg | 853,6837 | 853,68 | RSRN20 | 5% |
| N05AX13 068 | RL | paliperidon | 2,5 mg | 5,6285 | P | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Trevicta | susp. za inj. s prod. oslob. za i.m. primj. 1x525 mg | 1.181,9935 | 1.181,99 | RSRN20 | 5% |
| N05BA01 011 | PR | diazepam | 10 mg | 0,2470 | P | Belupo d.d. | Belupo | Normabel | amp. 10x10 mg/2 ml | 0,2474 | 2,47 |  | 5% |
| N05BA01 031 | PR | diazepam | 10 mg | 0,2470 | P | KRKA-FARMA d.o.o. | Krka d.d. | Apaurin | amp. 10x10 mg/2 ml | 0,2474 | 2,47 |  | 5% |
| N05BA01 043 | PR | diazepam | 10 mg | 0,2470 | P | Alkaloid d.o.o. | Alkaloid | Diazepam Alkaloid | otop. za inj. 10x10 mg/2 ml | 0,2474 | 2,47 |  | 5% |
| N05BA01 111 |  | diazepam | 10 mg | 0,1517 | O | Belupo d.d. | Belupo | Normabel | tbl. 30x2 mg | 0,0304 | 0,91 | R | 5% |
| N05BA01 113 |  | diazepam | 10 mg | 0,0740 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Diazepam JGL | tbl. 30x5 mg | 0,0372 | 1,11 | R | 5% |
| N05BA01 114 |  | diazepam | 10 mg | 0,0633 | O | Belupo d.d. | Belupo | Normabel | tbl. 30x10 mg | 0,0633 | 1,90 | R | 5% |
| N05BA01 117 |  | diazepam | 10 mg | 0,1517 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Diazepam JGL | tbl. 30x2 mg | 0,0304 | 0,91 | R | 5% |
| N05BA01 118 |  | diazepam | 10 mg | 0,0633 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Diazepam JGL | tbl. 30x10 mg | 0,0633 | 1,90 | R | 5% |
| N05BA01 141 |  | diazepam | 10 mg | 0,1517 | O | Alkaloid d.o.o. | Alkaloid | Diazepam Alkaloid | tbl. obl. 30x2 mg | 0,0304 | 0,91 | R | 5% |
| N05BA01 142 |  | diazepam | 10 mg | 0,0740 | O | Alkaloid d.o.o. | Alkaloid | Diazepam Alkaloid | tbl. obl. 30x5 mg | 0,0372 | 1,11 | R | 5% |
| N05BA01 551 |  | diazepam | 10 mg |  | R |  |  |  |  |  |  | R | 5% |
| N05BA06 071 | DS | lorazepam | 20 mg | 4,8200 | P | Medochemie Ltd. | Medochemie Ltd. | Temelor | otop. za inj., amp. 10 x 4 mg/ml | 0,9636 | 9,64 |  | 5% |
| N05BA09 151 | DS | klobazam | 20 mg |  | O |  |  |  |  |  |  |  | 5% |
| N05BA12 111 |  | alprazolam | 1 mg | 0,1013 | O | Belupo d.d. | Belupo | Misar | tbl. 30x0,25 mg | 0,0252 | 0,76 | R | 5% |
| N05BA12 132 |  | alprazolam | 1 mg | 0,1013 | O | KRKA-FARMA d.o.o. | Krka d.d. | Helex | tbl. 30x0,25 mg | 0,0252 | 0,76 | R | 5% |
| N05BA12 141 |  | alprazolam | 1 mg | 0,0907 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Maprazax | tbl. 30x0,25 mg | 0,0227 | 0,68 | R | 5% |
| N05BA12 142 |  | alprazolam | 1 mg | 0,0818 | O | Alkaloid-INT d.o.o. | Alkaloid – INT d.o.o. | Maprazax | tbl. 90x0,25 mg | 0,0204 | 1,84 | R | 5% |
| N05BC01 151 |  | meprobamat | 1,2 g |  | O |  |  |  |  |  |  | RRN91 | 5% |
| N05CD01 131 | DS | flurazepam | 30 mg | 0,4400 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fluzepam | caps. 10x15 mg | 0,2197 | 2,20 |  | 5% |
| N05CD01 132 | DS | flurazepam | 30 mg | 0,2580 | O | KRKA-FARMA d.o.o. | Krka d.d. | Fluzepam | caps. 10x30 mg | 0,2579 | 2,58 |  | 5% |
| N05CD02 111 |  | nitrazepam | 5 mg | 0,1170 | O | Belupo d.d. | Belupo | Cerson | tbl. 10x5 mg | 0,1171 | 1,17 | R | 5% |
| N05CD02 112 |  | nitrazepam | 5 mg | 0,1170 | O | Belupo d.d. | Belupo | Cerson | tbl. 30x5 mg | 0,1171 | 3,51 | R | 5% |
| N05CD02 161 |  | nitrazepam | 5 mg | 0,0820 | O | Accord Healthcare Polska Sp. z o.o. | PharmaS d.o.o., Accord Healthcare Polska Sp. z o.o. | Nitrazepam Accord | tbl. 30x5 mg | 0,0819 | 2,46 | R | 5% |
| N05CD08 062 | DS | midazolam | 15 mg | 1,6240 | P | Cheplapharm Arzneimittel GmbH | Cenexi | Dormicum | amp. 5x15 mg/3 ml | 1,6245 | 8,12 |  | 5% |
| N05CD08 075 | DS | midazolam | 15 mg | 1,1950 | P | AS Kalceks | AS Kalceks | Midazolam Kalceks 5 mg/ml | otop. za inj./inf., 5 mg/ml, amp., 10x3 ml | 1,1953 | 11,95 |  | 5% |
| N05CD08 076 | DS | midazolam | 15 mg | 1,1360 | P | hameln pharma gmbh | hameln rds a.s., Siegfried Hameln GmbH | Midazolam hameln | otop. za inj./inf., 5 mg/ml, amp., 10x3 ml | 1,1356 | 11,36 |  | 5% |
| N05CD08 077 | DS | midazolam | 15 mg | 1,0971 | P | hameln pharma gmbh | hameln rds a.s., Siegfried Hameln GmbH | Midazolam hameln | otop. za inj./inf., 5 mg/ml, amp., 10x10 ml | 3,6565 | 36,57 |  | 5% |
| N05CD08 081 | DS | midazolam | 15 mg | 1,0065 | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Midazolam B. Braun 1 mg/ml | otop. za inj./inf., 1 mg/ml, polietil. Ecoflac plus boca, 10x100 ml | 6,7105 | 67,10 |  | 5% |
| N05CD08 082 | DS | midazolam | 15 mg | 1,2580 | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Midazolam B. Braun 5 mg/ml | otop. za inj./inf., 5 mg/ml, amp., 10x3 ml | 1,2582 | 12,58 |  | 5% |
| N05CD08 083 | DS | midazolam | 15 mg | 1,1547 | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Midazolam B. Braun 5 mg/ml | otop. za inj./inf., 5 mg/ml, polietil. amp., 10x10 ml | 3,8490 | 38,49 |  | 5% |
| N05CD08 161 | DS | midazolam | 15 mg | 0,2520 | O | Cheplapharm Arzneimittel GmbH | Recipharm Leganés S.L.U. | Dormicum | tbl. 10x15 mg | 0,2519 | 2,52 |  | 5% |
| N05CF02 141 |  | zolpidem | 10 mg | 0,0720 | O | Alkaloid d.o.o. | Alkaloid | Lunata | tbl. film obl. 20x5 mg | 0,0358 | 0,72 | R | 5% |
| N05CF02 142 |  | zolpidem | 10 mg | 0,0665 | O | Alkaloid d.o.o. | Alkaloid | Lunata | tbl. film obl. 20x10 mg | 0,0664 | 1,33 | R | 5% |
| N05CF02 143 |  | zolpidem | 10 mg | 0,0720 | O | Alkaloid d.o.o. | ALKALOID-INT d.o.o. | Lunata | tbl. film obl. 30x5 mg | 0,0358 | 1,08 | R | 5% |
| N05CF02 144 |  | zolpidem | 10 mg | 0,0663 | O | Alkaloid d.o.o. | ALKALOID-INT d.o.o. | Lunata | tbl. film obl. 30x10 mg | 0,0664 | 1,99 | R | 5% |
| N05CM18 001 | DS | deksmedetomidinNN506 | 1 mg | 78,0260 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Deksmedetomidin Pliva | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 15,6054 | 390,13 |  | 5% |
| N05CM18 002 | DS | deksmedetomidinNN506 | 1 mg | 6,6900 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V. | Deksmedetomidin Pliva | konc. za otop. za inf., boč. 4x4 ml (100 mcg/ml) | 26,7592 | 107,04 |  | 5% |
| N05CM18 003 | DS | deksmedetomidinNN506 | 1 mg | 6,6898 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V. | Deksmedetomidin Pliva | konc. za otop. za inf., boč. 4x10 ml (100 mcg/ml) | 66,8986 | 267,59 |  | 5% |
| N05CM18 041 | DS | deksmedetomidinNN506 | 1 mg | 74,1260 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Dexmedetomidine Accord | konc. za otop. za inf., boč. 5x10 ml (100 mcg/ml) | 74,1257 | 370,63 |  | 5% |
| N05CM18 061 | DS | deksmedetomidin NN506 | 1 mg | 78,0260 | P | Mylan Ireland Limited | Mylan Teoranta | Deksmedetomidin Mylan | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 15,6054 | 390,13 |  | 5% |
| N05CM18 062 | DS | deksmedetomidinNN506 | 1 mg | 78,0260 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp.z.o.o. | Dexmedetomidine Accord | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 15,6054 | 390,13 |  | 5% |
| N05CM18 071 | DS | deksmedetomidin NN506 | 1 mg | 78,0260 | P | Orion Corporation | Orion Corporation | Dexdor | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 15,6054 | 390,13 |  | 5% |
| N05CM18 082 | DS | deksmedetomidinNN506 | 1 mg | 70,4200 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., amp. 25x2 ml (100 mcg/ml) | 14,0839 | 352,10 |  | 5% |
| N05CM18 083 | DS | deksmedetomidinNN506 | 1 mg | 70,4188 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., boč. 4x4 ml (100 mcg/ml) | 28,1678 | 112,67 |  | 5% |
| N05CM18 084 | DS | deksmedetomidinNN506 | 1 mg | 70,4200 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., boč. 4x10 ml (100 mcg/ml) | 70,4194 | 281,68 |  | 5% |
| N05CM18 085 | DS | deksmedetomidin NN506 | 1 mg | 63,5540 | P | AS Kalceks | AS Kalceks | Deksmedetomidin Kalceks | konc. za otop. za inf., boč. 25x2 ml (100 mcg/ml) | 12,7107 | 317,77 |  | 5% |
| N05CM18 086 | DS | deksmedetomidinNN506 | 1 mg | 60,3750 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., amp. 5x4 ml (100 mcg/ml) | 24,1502 | 120,75 |  | 5% |
| N05CM18 087 | DS | deksmedetomidinNN506 | 1 mg | 60,3760 | P | EVER Valinject GmbH | Ever Pharma Jena GmbH | Deksmedetomidin EVER Pharma | konc. za otop. za inf., amp. 5x10 ml (100 mcg/ml) | 60,3759 | 301,88 |  | 5% |
| N05CM18 088 | DS | deksmedetomidinNN506 | 1 mg | 60,3750 | P | Fresenius Kabi d.o.o. | Fresenius Kabi Austria GmbH | Deksmedetomidin Kabi | konc. za otop. za inf., boč. 10x2 ml (100 mcg/ml) | 12,0751 | 120,75 |  | 5% |
| N06AA04 051 | DS | klomipramin | 0,1 g |  | P |  |  |  |  |  |  |  | 5% |
| N06AA04 151 |  | klomipramin | 0,1 g |  | O |  |  |  |  |  |  | R | 5% |
| N06AA09 051 | DS | amitriptilin | 75 mg |  | P |  |  |  |  |  |  |  | 5% |
| N06AA21 103 |  | maprotilin | 0,1 g | 0,3880 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Ladiomil | tbl. 30x25 mg | 0,0969 | 2,91 | R | 5% |
| N06AB05 111 |  | paroksetin | 20 mg | 0,0853 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Seroxat | tbl. 30x20 mg | 0,0853 | 2,56 | R | 5% |
| N06AB05 115 |  | paroksetin | 20 mg | 0,0850 | O | PharmaS d.o.o. | PharmaS d.o.o. | Paroksetin PharmaS | tbl. film obl. 30x20 mg | 0,0852 | 2,55 | R | 5% |
| N06AB05 116 |  | paroksetin | 20 mg | 0,1700 | O | PharmaS d.o.o. | PharmaS d.o.o. | Paroksetin PharmaS | tbl. film obl. 30x30 mg | 0,2549 | 7,65 | R | 5% |
| N06AB06 102 |  | sertralin | 50 mg | 0,0853 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Luxeta | tbl. 30x50 mg | 0,0853 | 2,56 | R | 5% |
| N06AB06 121 |  | sertralin | 50 mg | 0,0854 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Sonalia | tbl. film obl. 28x50 mg | 0,0853 | 2,39 | R | 5% |
| N06AB06 131 |  | sertralin | 50 mg | 0,0854 | O | KRKA-FARMA d.o.o. | Krka d.d. | Asentra | tbl. 28x50 mg | 0,0853 | 2,39 | R | 5% |
| N06AB06 132 |  | sertralin | 50 mg | 0,1111 | O | KRKA-FARMA d.o.o. | Krka d.d. | Asentra | tbl. 28x100 mg | 0,2222 | 6,22 | R | 5% |
| N06AB06 171 |  | sertralin | 50 mg | 0,0854 | O | Upjohn EESV | Haupt Pharma | Zoloft | tbl. 28x50 mg | 0,0853 | 2,39 | R | 5% |
| N06AB10 101 |  | escitalopram | 10 mg | 0,0854 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Serpentil | tbl. film obl. 28x10 mg | 0,0853 | 2,39 | R | 5% |
| N06AB10 111 |  | escitalopram | 10 mg | 0,0854 | O | Belupo d.d. | Belupo | Citram | tbl. film obl. 28x10 mg | 0,0853 | 2,39 | R | 5% |
| N06AB10 128 |  | escitalopram | 10 mg | 0,0854 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Escital | tbl. rasp. za usta 28x10 mg | 0,0853 | 2,39 | R | 5% |
| N06AB10 132 |  | escitalopram | 10 mg | 0,0854 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea | tbl. film obl. 28x10 mg | 0,0853 | 2,39 | R | 5% |
| N06AB10 133 |  | escitalopram | 10 mg | 0,1111 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea | tbl. film obl. 28x20 mg | 0,2222 | 6,22 | R | 5% |
| N06AB10 136 |  | escitalopram | 10 mg | 0,1293 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea Q-Tab | tbl. rasp. za usta 28x5 mg | 0,0645 | 1,81 | R | 5% |
| N06AB10 137 |  | escitalopram | 10 mg | 0,0814 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea Q-Tab | tbl. rasp. za usta 28x10 mg | 0,0813 | 2,28 | R | 5% |
| N06AB10 138 |  | escitalopram | 10 mg | 0,1111 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Elicea Q-Tab | tbl. rasp. za usta. 28x20 mg | 0,2222 | 6,22 | R | 5% |
| N06AX11 111 |  | mirtazapin | 30 mg | 0,1807 | O | Belupo d.d. | Belupo | Calixta | tbl. film obl. 30x15 mg | 0,0903 | 2,71 | R | 5% |
| N06AX11 112 |  | mirtazapin | 30 mg | 0,2000 | O | Belupo d.d. | Belupo | Calixta | tbl. film obl. 30x30 mg | 0,2000 | 6,00 | R | 5% |
| N06AX11 113 |  | mirtazapin | 30 mg | 0,1807 | O | Belupo d.d. | Belupo | Calixta | tbl. film obl. 30x45 mg | 0,2709 | 8,13 | R | 5% |
| N06AX11 131 |  | mirtazapin | 30 mg | 0,2000 | O | KRKA-FARMA d.o.o. | Krka d.d. | Mirzaten | tbl. film obl. 30x30 mg | 0,2000 | 6,00 | R | 5% |
| N06AX11 132 |  | mirtazapin | 30 mg | 0,1807 | O | KRKA-FARMA d.o.o. | Krka d.d. | Mirzaten | tbl. film obl. 30x45 mg | 0,2709 | 8,13 | R | 5% |
| N06AX11 137 |  | mirtazapin | 30 mg | 0,1807 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Mirzaten Q-Tab | tbl. rasp. za usta 30x15 mg | 0,0903 | 2,71 | R | 5% |
| N06AX11 138 |  | mirtazapin | 30 mg | 0,2000 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Mirzaten Q-Tab | tbl. rasp. za usta 30x30 mg | 0,2000 | 6,00 | R | 5% |
| N06AX11 139 |  | mirtazapin | 30 mg | 0,1807 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Mirzaten Q-Tab | tbl. rasp. za usta 30x45 mg | 0,2709 | 8,13 | R | 5% |
| N06AX16 101 |  | venlafaksin | 0,1 g | 0,2010 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Velafax | tbl. 28x37,5 mg | 0,0753 | 2,11 | R | 5% |
| N06AX16 102 |  | venlafaksin | 0,1 g | 0,2005 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Velafax | tbl. 28x75 mg | 0,1505 | 4,21 | R | 5% |
| N06AX16 103 |  | venlafaksin | 0,1 g | 0,2357 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Velafax XL | caps. s prod. oslob. 28x75 mg | 0,1768 | 4,95 | R | 5% |
| N06AX16 104 |  | venlafaksin | 0,1 g | 0,1807 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Velafax XL | caps. s prod. oslob. 28x150 mg | 0,2709 | 7,59 | R | 5% |
| N06AX16 126 |  | venlafaksin | 0,1 g | 0,1807 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Faxiven | caps. s prod. oslob., tvrda 28x150 mg | 0,2709 | 7,59 | R | 5% |
| N06AX16 131 |  | venlafaksin | 0,1 g | 0,2610 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Alventa | caps. s prilag. oslob. 28x37,5 mg | 0,0979 | 2,74 | R | 5% |
| N06AX16 132 |  | venlafaksin | 0,1 g | 0,2357 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Alventa | caps. s prilag. oslob. 28x75 mg | 0,1768 | 4,95 | R | 5% |
| N06AX16 133 |  | venlafaksin | 0,1 g | 0,2358 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Alventa | caps. s prilag. oslob. 60x75 mg | 0,1768 | 10,61 | R | 5% |
| N06AX16 134 |  | venlafaksin | 0,1 g | 0,1807 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Alventa | caps. s prilag. oslob. 28x150 mg | 0,2709 | 7,59 | R | 5% |
| N06AX21 101 |  | duloksetin | 60 mg | 0,5457 | O | PLIVA HRVATSKA d.o.o. | Balkanpharma – Dupnitsa AD | Duloksetin Pliva | caps. žel. otp. tvrda 28x30 mg | 0,2728 | 7,64 | RRN18 | 5% |
| N06AX21 102 |  | duloksetin | 60 mg | 0,4954 | O | PLIVA HRVATSKA d.o.o. | Balkanpharma – Dupnitsa AD | Duloksetin Pliva | caps. žel. otp. tvrda 28x60 mg | 0,4955 | 13,87 | RRN18 | 5% |
| N06AX21 111 |  | duloksetin | 60 mg | 0,4200 | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Dolyxan | caps. žel. otp. tvrda 28x30 mg | 0,2099 | 5,88 | RRN18 | 5% |
| N06AX21 112 |  | duloksetin | 60 mg | 0,4200 | O | Belupo d.d. | Belupo lijekovi i kozmetika d.d. | Dolyxan | caps. žel. otp. tvrda 28x60 mg | 0,4198 | 11,76 | RRN18 | 5% |
| N06AX21 131 |  | duloksetin | 60 mg | 0,5457 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Dulsevia | caps. žel. otp. tvrda 28x30 mg | 0,2728 | 7,64 | RRN18 | 5% |
| N06AX21 132 |  | duloksetin | 60 mg | 0,4954 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Dulsevia | caps. žel. otp. tvrda 28x60 mg | 0,4955 | 13,87 | RRN18 | 5% |
| N06AX21 133 |  | duloksetin | 60 mg | 0,2821 | O | KRKA-FARMA d.o.o. | Krka d.d., TAD Pharma GmbH | Dulsevia | caps. žel. otp. tvrda 28x90 mg | 0,4234 | 11,85 | RRN18 | 5% |
| N06AX21 161 |  | duloksetin | 60 mg | 0,5457 | O | Mylan Pharmaceuticals Limited | McDermott Laboratories Ltd t/a Gerard Laboratories t/a Mylan, Mylan Hungary Kft | Duloxetine Mylan | caps. žel. otp. tvrda 28x30 mg | 0,2728 | 7,64 | RRN18 | 5% |
| N06AX21 162 |  | duloksetin | 60 mg | 0,4954 | O | Mylan Pharmaceuticals Limited | McDermott Laboratories Ltd t/a Gerard Laboratories t/a Mylan, Mylan Hungary Kft | Duloxetine Mylan | caps. žel. otp. tvrda 28x60 mg | 0,4955 | 13,87 | RRN18 | 5% |
| N06AX21 171 |  | duloksetin | 60 mg | 0,5457 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Cymbalta | caps. žel. otp. tvrda 28x30 mg | 0,2728 | 7,64 | RRN18 | 5% |
| N06AX21 172 |  | duloksetin | 60 mg | 0,4954 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Cymbalta | caps. žel. otp. tvrda 28x60 mg | 0,4955 | 13,87 | RRN18 | 5% |
| N06AX21 181 |  | duloksetin | 60 mg | 0,4914 | O | STADA d.o.o. | Stada Arzneimittel AG; Centrafarm Services BV, Stada Arzneimittel GmbH, Clonmel Healthcare Ltd., Stada Nordic ApS | Duloksetin STADA | caps. žel. otp. tvrda 28x30 mg | 0,2455 | 6,88 | RRN18 | 5% |
| N06AX21 182 |  | duloksetin | 60 mg | 0,4911 | O | STADA d.o.o. | Stada Arzneimittel AG; Centrafarm Services BV, Stada Arzneimittel GmbH, Clonmel Healthcare Ltd., Stada Nordic ApS | Duloksetin STADA | caps. žel. otp. tvrda 28x60 mg | 0,4910 | 13,75 | RRN18 | 5% |
| N06AX21 183 |  | duloksetin | 60 mg | 0,4421 | O | Medochemie Ltd. | Medochemie Ltd. | Onelar | caps. žel. otp. tvrda 28x30 mg | 0,2210 | 6,19 | RRN18 | 5% |
| N06AX21 184 |  | duloksetin | 60 mg | 0,4418 | O | Medochemie Ltd. | Medochemie Ltd. | Onelar | caps. žel. otp. tvrda 28x60 mg | 0,4419 | 12,37 | RRN18 | 5% |
| N06AX26 161 |  | vortioksetin | 10 mg | 0,8443 | O | H. Lundbeck A/S | H. Lundbeck A/S | Brintellix | tbl. film obl. 28x5 mg | 0,4221 | 11,82 | R | 5% |
| N06AX26 162 |  | vortioksetin | 10 mg | 0,8250 | O | H. Lundbeck A/S | H. Lundbeck A/S | Brintellix | tbl. film obl. 28x10 mg | 0,8251 | 23,10 | R | 5% |
| N06AX27 761 | DS | esketaminNN507 | 8 mg | 65,3457 | N | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Spravato | sprej za nos, 1x28 mg | 228,7106 | 228,71 |  | 5% |
| N06BA07 151 | DS | modafinilNN991 | 0,3 g |  | O |  |  |  |  |  |  |  | 5% |
| N06BA07 161 |  | modafinil | 0,3 g | 4,3970 | O | Makpharm d.o.o. | Chanelle Medical | Vigifinil | tbl. 30x100 mg | 1,4657 | 43,97 | RSRN21 | 5% |
| N06BC01 051 | DS | kofein citratNN992 | 0,4 g |  | P |  |  |  |  |  |  |  | 5% |
| N06BX13 161 | KL | idebenonNN300 | 900 mg | 139,8227 | O | Santhera Pharmaceuticals GmbH | Santhera Pharmaceuticals (Deutschland) GmbH | Raxone | tbl. film obl. 180x150 mg | 23,3038 | 4.194,68 |  | 5% |
| N07AA01 051 | DS | neostigminij | 2 mg |  | P |  |  |  |  |  |  |  | 5% |
| N07AA01 151 |  | neostigminij | 60 mg |  | O |  |  |  |  |  |  | R | 5% |
| N07AA02 052 | DS | piridostigminij | 10 mg |  | P |  |  |  |  |  |  |  | 5% |
| N07AA02 152 |  | piridostigminij | 0,18 g |  | O |  |  |  | 100x10 mg |  |  | R | 5% |
| N07AA02 161 |  | piridostigminij | 0,18 g | 0,6052 | O | Mylan Hrvatska d.o.o. | ICN Polfa Rzeszow S.A, Labiana Pharmaceuticals | Mestinon | tbl. obl. 150x60 mg | 0,2017 | 30,26 | R | 5% |
| N07BB01 151 |  | disulfiram | 0,2 g |  | O |  |  |  |  |  |  | R | 5% |
| N07BC01 121 |  | buprenorfin | 8 mg | 1,6800 | SL | Sandoz d.o.o. | Sandoz-Salutas | Buprenorfin Sandoz | tbl. sublingv. 7x2 mg | 0,4204 | 2,94 | RSRN13 | 5% |
| N07BC01 122 |  | buprenorfin | 8 mg | 1,4757 | SL | Sandoz d.o.o. | Sandoz-Salutas | Buprenorfin Sandoz | tbl. subllingv. 7x8 mg | 1,4763 | 10,33 | RSRN13 | 5% |
| N07BC01 142 |  | buprenorfin | 8 mg | 1,6800 | SL | Alkaloid d.o.o. | Alkaloid | Buprenorfin Alkaloid | tbl. sublingv. 7x2 mg | 0,4204 | 2,94 | RSRN13 | 5% |
| N07BC01 143 |  | buprenorfin | 8 mg | 1,4757 | SL | Alkaloid d.o.o. | Alkaloid | Buprenorfin Alkaloid | tbl. subllingv. 7x8 mg | 1,4763 | 10,33 | RSRN13 | 5% |
| N07BC01 162 |  | buprenorfin | 8 mg | 1,6800 | SL | INDIVIOR EUROPE LIMITED | RB | Subutex | tbl. sublingv. 7x2 mg | 0,4204 | 2,94 | RSRN13 | 5% |
| N07BC01 163 |  | buprenorfin | 8 mg | 1,4757 | SL | INDIVIOR EUROPE LIMITED | RB | Subutex | tbl. sublingv. 7x8 mg | 1,4763 | 10,33 | RSRN13 | 5% |
| N07BC02 101 | XX | metadon | 25 mg | 0,6425 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Heptanon | tbl. 20x5 mg | 0,1287 | 2,57 | RSRN14 | 5% |
| N07BC02 202 | XX | metadon | 25 mg | 0,5400 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Heptanon | otop. 1x10 ml (10 mg/ml) | 2,1634 | 2,16 | RSRN14 | 5% |
| N07BC02 241 | XX | metadon | 25 mg | 0,5400 | O | Alkaloid d.o.o. | Alkaloid | Metadon Alkaloid | otop. oral. 10 ml (10 mg/1ml) | 2,1634 | 2,16 | RSRN14 | 5% |
| N07BC02 242 | DS | metadon | 25 mg | 0,2868 | O | Alkaloid d.o.o. | Alkaloid | Metadon Alkaloid | otop. oral. 100 ml (10 mg/1ml) | 11,4686 | 11,47 |  | 5% |
| N07BC02 262 | XX | metadon | 25 mg | 0,5400 | O | L.Molteni & C. dei F.lli Alitti Soc. di Esercizio S.p.A. | L. Molteni | Metadon Molteni | otop. oral., boč. plast. 1x20 ml (5 mg/ml) | 2,1634 | 2,16 | RSRN14 | 5% |
| N07BC02 263 | DS | metadon | 25 mg |  | O | L.Molteni & C. dei F.lli Alitti Soc. di Esercizio S.p.A. | L. Molteni | Metadon Molteni | otop. oral., boca plast. 1x1000 ml (5 mg/ml) | 51,6093 | 51,61 |  | 5% |
| N07BC51 141 |  | buprenorfin + nalokson | 8 mg | 1,5543 | SL | Alkaloid-INT d.o.o. | Ethypharm | Bulnexo | tbl. sublingv. 7x(2 mg + 0,5 mg) | 0,3879 | 2,72 | RSRN13 | 5% |
| N07BC51 142 |  | buprenorfin + nalokson | 8 mg | 1,6314 | SL | Alkaloid-INT d.o.o. | Ethypharm | Bulnexo | tbl. sublingv. 7x(8 mg + 2 mg) | 1,6308 | 11,42 | RSRN13 | 5% |
| N07BC51 161 |  | buprenorfin + nalokson | 8 mg | 1,5543 | SL | INDIVIOR EUROPE LIMITED | RB | Suboxone | tbl. sublingv. 7x(2 mg + 0,5mg) | 0,3879 | 2,72 | RSRN13 | 5% |
| N07BC51 162 |  | buprenorfin + nalokson | 8 mg | 1,8871 | SL | INDIVIOR EUROPE LIMITED | RB | Suboxone | tbl. sublingv. 7x(8 mg + 2mg) | 1,8869 | 13,21 | RSRN13 | 5% |
| N07BC51 171 |  | buprenorfin + nalokson | 8 mg | 1,5543 | SL | G.L. Pharma GmbH | G.L. Pharma GmbH | Bupensanduo | tbl. sublingv. 7x(2 mg + 0,5mg) | 0,3879 | 2,72 | RSRN13 | 5% |
| N07BC51 172 |  | buprenorfin + nalokson | 8 mg | 1,5029 | SL | G.L. Pharma GmbH | G.L. Pharma GmbH | Bupensanduo | tbl. sublingv. 7x(4 mg + 1 mg) | 0,7514 | 5,26 | RSRN13 | 5% |
| N07BC51 173 |  | buprenorfin + nalokson | 8 mg | 1,3229 | SL | G.L. Pharma GmbH | G.L. Pharma GmbH | Bupensanduo | tbl. sublingv. 7x(8 mg + 2 mg) | 1,3223 | 9,26 | RSRN13 | 5% |
| N07XX02 171 | DS | riluzolNN994 | 100mg | 4,5054 | O | Makpharm d.o.o. | Glenmark Pharmaceuticals Europe Ltd., Glenmark Pharmaceuticals s.r.o. | Alsemol | tbl. film obl. 56x50 mg | 2,2528 | 126,15 | RSRN25 | 5% |
| N07XX02 181 | DS | riluzolNN994 | 100mg | 3,2561 | O | ALPHA-MEDICAL d.o.o. | Glenmark Pharmaceuticals s.r.o. | Yulir | tbl. film obl. 56x50 mg | 1,6280 | 91,17 | RSRN25 | 5% |
| N07XX04 361 | DS | natrijev oksibatNN700 | 7,5 g | 23,9833 | O | UCB Pharma S.A. | UCB Pharma Ltd. | Xyrem | otop. oral. 180 ml (500 mg/ml) | 287,7961 | 287,80 |  | 5% |
| N07XX08 161 | KL | tafamidisNN995 | 20 mg | 124,3447 | O | Pfizer Europe MA EEIG | Millmount Healthcare Limited | Vyndaqel | caps. meka 30x61 mg | 379,2514 | 11.377,54 |  | 5% |
| P01AB01 111 |  | metronidazol | 2 g | 1,2080 | O | Belupo d.d. | Belupo | Medazol | tbl. 20x250 mg | 0,1508 | 3,02 | R | 5% |
| P01AB01 112 |  | metronidazol | 2 g | 1,3300 | O | Belupo d.d. | Belupo | Medazol | tbl. 10x400 mg | 0,2664 | 2,66 | R | 5% |
| P01AB01 113 |  | metronidazol | 2 g | 1,3200 | O | Belupo d.d. | Belupo | Medazol | tbl. 20x400 mg | 0,2640 | 5,28 | R | 5% |
| P01BA01 151 |  | klorokin | 0,5 g |  | O |  |  |  |  |  |  | R | 5% |
| P01BA02 161 |  | hidroksiklorokin | 0,516 g | 0,5083 | O | Makpharm d.o.o. | PharmaS d.o.o. | Hyplaxy | tbl. film obl. 30x200 mg | 0,1969 | 5,91 | RSRV03 | 5% |
| P01BC01 151 |  | kinin-sulfat | 1,5 g |  | O |  |  |  |  |  |  | R | 5% |
| P01BD01 152 | DS | pirimetamin | 75 mg |  | O |  |  |  |  |  |  |  | 5% |
| P02BA01 151 | DS | prazikvantel | 3 g |  | O |  |  |  |  |  |  |  | 5% |
| P02CA01 151 |  | mebendazol | 0,2 g |  | O |  |  |  |  |  |  | R | 5% |
| P02CA03 151 |  | albendazol | 0,4 g |  | O |  |  |  |  |  |  | R | 5% |
| P03AC01 451 |  | piretrin |  |  | L |  |  |  |  |  |  | R | 5% |
| P03AX05 451 |  | krotamiton (krema) |  |  | L |  |  |  |  |  |  | R | 5% |
| P03AX05 752 |  | krotamiton (losion) |  |  | L |  |  |  |  |  |  | R | 5% |
| R02AA15 442 |  | povidon-jod |  |  | L | Alkaloid d.o.o. | Alkaloid | Betadine | grgljača 1%, 1x100 ml | 2,3067 | 2,31 | R | 5% |
| R03AC02 701 |  | salbutamol | 10 mg | 0,7900 | I | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Salbutamol Pliva | otop. 10 ml (5 mg/ml) | 3,9458 | 3,95 | R | 5% |
| R03AC02 705 |  | salbutamol | 0,8 mg | 0,2448 | I | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Ventolin | aerosol za inhal. 200x100 mcg | 0,0306 | 6,12 | R | 5% |
| R03AC12 763 |  | salmeterol | 0,1 mg | 0,6107 | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production | Serevent inhaler | stlač. inhalat, susp., 120x25 mcg | 0,1526 | 18,32 | R | 5% |
| R03AC18 771 |  | indakaterol | 0,15 mg | 0,6107 | I | Novartis Europharm Limited Irska | Novartis Pharma GmbH, Novartis Farmaceutica S.A. | Onbrez Breezhaler | prašak inhalata, caps. tvrde 30x150 mcg + 1 inhalator | 0,6105 | 18,32 | R | 5% |
| R03AK06 321 |  | salmeterol + flutikazon |  |  | I | Sandoz d.o.o. | Sandoz – Aeropharm | AirFluSal Forspiro | praš. za inhal. 60x(50 + 250 mcg)/doza | 0,3205 | 19,23 | RRR02 | 5% |
| R03AK06 322 |  | salmeterol + flutikazon |  |  | I | Sandoz d.o.o. | Sandoz – Aeropharm | AirFluSal Forspiro | praš. za inhal. 60x(50 + 500 mcg)/doza | 0,4218 | 25,31 | RRR03 | 5% |
| R03AK06 361 |  | salmeterol + flutikazon |  |  | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Seretide 100 Diskus | praš. za inhal. 60x(50 + 100 mcg)/doza | 0,2471 | 14,83 | RRR02 | 5% |
| R03AK06 362 |  | salmeterol + flutikazon |  |  | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Seretide 250 Diskus | praš. za inhal. 60x(50 + 250 mcg)/doza | 0,3205 | 19,23 | RRR02 | 5% |
| R03AK06 363 |  | salmeterol + flutikazon |  |  | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Seretide 500 Diskus | praš. za inhal. 60x(50 + 500 mcg)/doza | 0,4218 | 25,31 | RRR03 | 5% |
| R03AK06 371 |  | salmeterol + flutikazon |  |  | I | Salvus d.o.o. | Celon Pharma S.A. | Saldisk | praš. za inhal. 60x(50 + 100 mcg)/doza | 0,2471 | 14,83 | RRR02 | 5% |
| R03AK06 372 |  | salmeterol + flutikazon |  |  | I | Salvus d.o.o. | Celon Pharma S.A. | Saldisk | praš. za inhal. 60x(50 + 250 mcg)/doza | 0,3205 | 19,23 | RRR02 | 5% |
| R03AK06 373 |  | salmeterol + flutikazon |  |  | I | Salvus d.o.o. | Celon Pharma S.A. | Saldisk | praš. za inhal. 60x(50 + 500 mcg)/doza | 0,4218 | 25,31 | RRR03 | 5% |
| R03AK06 781 |  | salmeterol + flutikazon |  |  | I | Cipla Europe NV | S & D Pharma CZ, Cipla (EU) Limited | Salmeterol/flutikazon Cipla | inhalat stlač. susp. 120x(25 mcg + 125 mcg) | 0,1603 | 19,23 | RRR02 | 5% |
| R03AK06 782 |  | salmeterol + flutikazon |  |  | I | Cipla Europe NV | S & D Pharma CZ, Cipla (EU) Limited | Salmeterol/flutikazon Cipla | inhalat stlač. susp. 120x(25 mcg + 250 mcg) | 0,1898 | 22,78 | RRR02 | 5% |
| R03AK06 791 |  | salmeterol + flutikazon |  |  | I | Mylan Hrvatska d.o.o. | 3M Health Care Limited, McDermott Laboratories Limited trading as Gerard Laboratories | Serzyl | inhalat stlač. susp. 120x(25 mcg + 125 mcg) | 0,1467 | 17,60 | RRR02 | 5% |
| R03AK06 792 |  | salmeterol + flutikazon |  |  | I | Mylan Hrvatska d.o.o. | 3M Health Care Limited, McDermott Laboratories Limited trading as Gerard Laboratories | Serzyl | inhalat stlač. susp. 120x(25 mcg + 250 mcg) | 0,1898 | 22,78 | RRR02 | 5% |
| R03AK07 301 |  | budesonid + formoterol |  |  | I | Teva Pharma B.V. | Norton (Waterford) Limited T/A Teva Pharmaceuticals Ireland, Teva Pharmaceuticals Europe B.V. | DuoResp Spiromax | praš. za inhal. 120x(160 + 4,5 mcg)/doza | 0,2712 | 32,54 | RRR02 | 5% |
| R03AK07 302 |  | budesonid + formoterol |  |  | I | Teva Pharma B.V. | Norton (Waterford) Limited T/A Teva Pharmaceuticals Ireland, Teva Pharmaceuticals Europe B.V. | DuoResp Spiromax | praš. za inhal. 60x(320 + 9 mcg)/doza | 0,4788 | 28,73 | R RR05 | 5% |
| R03AK07 321 |  | budesonid + formoterol |  |  | I | Sandoz d.o.o. | Lek Pharmaceuticals d.d.; Salutas Pharma GmbH | AirBuFo Forspiro | praš. za inhal. 120x(160 + 4,5 mcg) | 0,2440 | 29,28 | RRR02 | 5% |
| R03AK07 322 |  | budesonid + formoterol |  |  | I | Sandoz d.o.o. | Lek Pharmaceuticals d.d., Salutas Pharma GmbH | AirBuFo Forspiro | praš. za inhal. 60x(320 + 9 mcg) | 0,4548 | 27,29 | R RR05 | 5% |
| R03AK07 373 |  | budesonid + formoterol |  |  | I | AstraZeneca d.o.o. | AstraZeneca | Symbicort Turbuhaler | praš. za inhal. 60x(320 + 9 mcg) + nastavak za usta | 0,4788 | 28,73 | R RR05 | 5% |
| R03AK07 375 |  | budesonid + formoterol |  |  | I | AstraZeneca d.o.o. | AstraZeneca | Symbicort Turbuhaler | praš. za inhal. 120x(160 + 4,5 mcg) + nastavak za usta | 0,2712 | 32,54 | RRR02 | 5% |
| R03AK07 376 |  | budesonid + formoterol |  |  | I | AstraZeneca d.o.o. | AstraZeneca | Symbicort | inhal. stlač., susp., 120x(160 + 4,5 mcg) | 0,2712 | 32,54 | RRR10 | 5% |
| R03AK08 362 |  | beklometazon + formoterol |  |  | I | Chiesi Pharmaceuticals GmbH | Chiesi | Foster | inhalat stlač. 180x(100 mcg + 6mcg) | 0,2394 | 43,09 | RRR05 | 5% |
| R03AK08 363 |  | beklometazon + formoterol |  |  | I | Chiesi Pharmaceuticals GmbH | Chiesi Pharmaceuticals GmbH | Foster NEXThaler | praš. inh. 180x(100 mcg + 6 mcg) | 0,2394 | 43,09 | RRR05 | 5% |
| R03AK10 362 |  | flutikazonfuorat + vilanterol |  |  | I | GlaxoSmithKline (Ireland) Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Relvar Ellipta | prašak inhalata 30x(184 + 22 mcg)/doza | 1,0846 | 32,54 | Rpr06 | 5% |
| R03AK11 761 |  | flutikazon + formoterol |  |  | I | Mundipharma Gesellschaft m.b.H | Bard Pharmaceuticals Ltd., Mundipharma DC B.V. | Flutiform | inhalat stlač. susp. 120x(50 mcg + 5 mcg) | 0,1838 | 22,06 | R | 5% |
| R03AL09 761 |  | beklometazon + formoterol + glikopironij |  |  | I | Chiesi Faramaceutici S.p.A. | Chiesi Farmaceutici S.p.A., Chiesi SAS | Trimbow | inhalat stlač., otop. 180x(87 mcg + 5 mcg + 9 mcg) | 0,3105 | 55,89 | RRR12 | 5% |
| R03BA01 704 |  | beklometazon | 1,5 mg | 1,0058 | I | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Qvar Autohaler | inhal. stlač. 1x10 ml, 200 doza (100 mcg/doza) | 0,0670 | 13,41 | R | 5% |
| R03BA02 761 |  | budesonid | 0,8 mg | 0,5392 | I | AstraZeneca d.o.o. | AstraZeneca | Pulmicort Respules | susp. za atomizator 0,5 mg/ml (20x2 ml) | 0,6742 | 13,48 | Rpr07 | 5% |
| R03BA05 773 |  | flutikazon | 0,6 mg | 0,7960 | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, GlaxoWellcome S.A. | Flixotide inhaler | stlač. inhalat, susp. 120x50 mcg | 0,0664 | 7,96 | RRR07 | 5% |
| R03BA08 362 |  | ciklezonid | 160 mcg | 0,2973 | I | Covis Pharma Europe B.V. | Takeda GmbH, AstraZeneca AB | Alvesco | aerosol za inhal. 120x160 mcg | 0,2973 | 35,68 | R | 5% |
| R03BB01 761 |  | ipratropij-bromid | 0,12 mg | 0,1155 | I | Boehringer Ingelheim Zagreb d.o.o. | Instituto De Angeli S.r.l. | Atrovent N | aerosol za inhal. 200x20 mcg | 0,0192 | 3,85 | R | 5% |
| R03BB01 962 |  | ipratropij-bromid | 0,3 mg | 0,1872 | I | Boehringer Ingelheim Zagreb d.o.o. | Instituto De Angeli S.r.l. | Atrovent | otop. za atomizator 1x20 ml (0,25 mg/1 ml) | 3,1150 | 3,12 | R | 5% |
| R03BB04 701 |  | tiotropij bromid | 10 mcg | 0,6773 | I | PLIVA HRVATSKA d.o.o. | Teva Pharma B.V. | Braltus | prašak inhal., caps. tvrda 30x10 mcg (isporučena doza) + Zonda uređaj za inhal. | 0,6773 | 20,32 | Rpr03 | 5% |
| R03BB04 764 |  | tiotropij bromid | 10 mcg | 0,3763 | I | Zentiva k.s. | Helm AG | Plubir | prašak za inhal. u caps. tvrdoj, 30x18 mcg + uređaj za inhal. | 0,6773 | 20,32 | Rpr03 | 5% |
| R03BB04 771 |  | tiotropij bromid | 10 mcg | 0,3763 | I | Viatris Limited | Ferrer Internacional S.A. | Acopair | prašak za inhal. u caps. tvrdoj, 30x18 mcg + uređaj za inhal. (NeumoHaler) | 0,6773 | 20,32 | Rpr03 | 5% |
| R03CB03 083 | PR | orciprenalinNR301 | 60 mg |  | P |  |  |  |  |  |  |  | 5% |
| R03CB04 952 | DS | kisik |  |  | N |  |  |  |  |  |  |  | 5% |
| R03DA05 051 | PO | aminofilin | 0,6 g |  | P |  |  |  |  |  |  |  | 5% |
| R03DC03 101 |  | montelukast | 10 mg | 0,2368 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Melarth | tbl. film obl. 28x10 mg | 0,2367 | 6,63 | RRR08 | 5% |
| R03DC03 102 |  | montelukast | 10 mg | 0,4550 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Melarth | tbl. za žvak. 28x5 mg | 0,2275 | 6,37 | RRR08 | 5% |
| R03DC03 103 |  | montelukast | 10 mg | 1,0429 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Melarth | vreć. alum. 28x4 mg (u 500 mg granula) | 0,4172 | 11,68 | RSRR09 | 5% |
| R03DC03 112 |  | montelukast | 10 mg | 0,2368 | O | Belupo d.d. | Belupo | Monlast | tbl. film obl. 28x10 mg | 0,2367 | 6,63 | RRR08 | 5% |
| R03DC03 122 |  | montelukast | 10 mg | 0,2368 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Montelux | tbl. film obl. 28x10 mg | 0,2367 | 6,63 | RRR08 | 5% |
| R03DC03 131 |  | montelukast | 10 mg | 0,7518 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Monkasta | tbl. za žvak. 28x4 mg | 0,3009 | 8,42 | RRR08 | 5% |
| R03DC03 133 |  | montelukast | 10 mg | 0,4550 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Monkasta | tbl. za žvak. 28x5 mg | 0,2275 | 6,37 | RRR08 | 5% |
| R03DC03 135 |  | montelukast | 10 mg | 0,2368 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o. | Monkasta | tbl. film obl. 28x10 mg | 0,2367 | 6,63 | RRR08 | 5% |
| R03DC03 183 |  | montelukast | 10 mg | 1,0429 | O | Organon Pharma d.o.o. | Merck Sharp & Dohme | Singulair mini | vreć. alum. 28x4 mg (u 500 mg granula) | 0,4172 | 11,68 | RSRR09 | 5% |
| R03DX05 061 | DS | omalizumabNR502 | 16 mg | 34,9195 | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Xolair | otop. za inj., štrc. napunj. 1x150 mg/ml | 327,3714 | 327,37 |  | 5% |
| R03DX08 061 | DS | reslizumabNR503 | 7.1 mg | 36,8351 | P | Teva B.V. | Sicor Biotech UAB | Cinqaero | konc. za otop. za inf., boč. stakl. 1x2,5 ml (10 mg/ml) | 129,7034 | 129,70 |  | 5% |
| R03DX08 062 | DS | reslizumabNR503 | 7.1 mg | 34,1105 | P | Teva B.V. | Sicor Biotech UAB | Cinqaero | konc. za otop. za inf., boč. stakl. 1x10 ml (10 mg/ml) | 480,4274 | 480,43 |  | 5% |
| R03DX09 071 | DS | mepolizumabNR504 | 3,6 mg | 36,6915 | P | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Manufacturing S.P.A., Glaxo Operations UK Ltd | Nucala | praš. za otop. za supkut. inj., boč. stakl. 1x100 mg | 1.019,2076 | 1.019,21 |  | 5% |
| R03DX09 072 | DS | mepolizumabNR505 | 3,6 mg | 35,4168 | P | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Manufacturing S.P.A | Nucala | otop. za inj., brizg. napunj. 1x100 mg | 983,8012 | 983,80 |  | 5% |
| R03DX10 061 | DS | benralizumabNR503 | 0.54 mg | 39,4799 | P | AstraZeneca AB | MedImmune UK Ltd, MedImmune Pharma B.V. | Fasenra | otop. za inj., štrc. napunj. 1x30 mg | 2.193,3280 | 2.193,33 |  | 5% |
| R03DX10 062 | DS | benralizumabNR503 | 0.54 mg | 39,4799 | P | AstraZeneca AB | MedImmune Pharma B.V. | Fasenra | otop. za inj., brizg. napunj. 1x30 mg | 2.193,3280 | 2.193,33 |  | 5% |
| R05CB13 961 |  | dornaze alfa (dezoksiribonukleaza)NR501 | 2,5 mg | 17,7067 | I | Roche d.o.o. | Roche | Pulmozyme | amp. za inhal. 6x2,5 mg/2,5 ml | 17,7063 | 106,24 | R | 5% |
| R05DA04 141 |  | kodein | 0,1 g | 0,9967 | O | Alkaloid d.o.o. | Alkaloid | Kodeinfosfat Alkaloid | tbl. 10x30 mg | 0,2994 | 2,99 | RSRR51 | 5% |
| R06AB03 271 |  | dimetinden | 4 mg | 0,4920 | O | GlaxoSmithKline Dungarvan Ltd. | GlaxoSmithKline Consumer Healtcare GmbH & Co. | Fenistil 0,1% | kapi za oral. primj. 1x20 ml (1mg/ml) | 2,4633 | 2,46 | R | 5% |
| R06AC03 003 | PO | kloropiramin | 20 mg | 1,2520 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Synopen | amp. 10x20mg/2 ml | 1,2524 | 12,52 |  | 5% |
| R06AD03 032 | PR | tietilperazin | 13 mg | 1,0300 | P | KRKA-FARMA d.o.o. | Krka d.d. | Torecan | amp. 50x6,5 mg | 0,5150 | 25,75 |  | 5% |
| R06AE07 132 |  | cetirizin | 10 mg | 0,0900 | O | KRKA-FARMA d.o.o. | Krka d.d. | Letizen | tbl. 20x10 mg | 0,0902 | 1,80 | R | 5% |
| R06AX13 102 |  | loratadin | 10 mg | 0,0900 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Rinolan | tbl. 30x10 mg | 0,0902 | 2,70 | R | 5% |
| R06AX13 111 |  | loratadin | 10 mg | 0,0900 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Contral | tbl. 10x10 mg | 0,0901 | 0,90 | R | 5% |
| R06AX13 112 |  | loratadin | 10 mg | 0,0900 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Contral | tbl. 30x10 mg | 0,0902 | 2,70 | R | 5% |
| R06AX13 116 |  | loratadin | 10 mg | 0,0900 | O | Belupo d.d. | Belupo | Belodin | tbl. 30x10 mg | 0,0902 | 2,70 | R | 5% |
| R06AX13 303 |  | loratadin | 10 mg | 0,1840 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Rinolan | sirup 1x100 ml (5 mg/5 ml) | 1,8382 | 1,84 | R | 5% |
| R06AX26 161 |  | feksofenadin | 0,12 g | 0,0600 | O | Cipla Europe NV | S & D Pharma CZ,spol. s.r.o., Cipla (EU) Limited | Feksofenadinklorid Cipla | tbl. film obl. 30x180 mg | 0,0902 | 2,70 | R | 5% |
| R06AX27 113 |  | desloratadin | 5 mg | 0,0900 | O | Belupo d.d. | Belupo | Alerdin | tbl. rasp. za usta 30x5 mg | 0,0902 | 2,70 | R | 5% |
| R06AX27 122 |  | desloratadin | 5 mg | 0,0900 | O | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Escontral direkt | tbl. rasp. za usta 30x5 mg | 0,0902 | 2,70 | R | 5% |
| R06AX27 123 |  | desloratadin | 5 mg | 0,0770 | O | Jadran – Galenski Laboratorij d.d. | Genepharm S.A., Jadran Galenski laboratorij d.d. | Escontral | tbl. film obl. 30x5 mg | 0,0769 | 2,31 | R | 5% |
| R06AX27 131 |  | desloratadin | 5 mg | 0,0900 | O | Krka d.d., Novo mesto | KRKA-FARMA d.o.o., Krka d.d. | Dasselta | tbl. film obl. 30x5 mg | 0,0902 | 2,70 | R | 5% |
| R06AX27 132 |  | desloratadin | 5 mg | 0,0900 | O | Krka d.d., Novo mesto | KRKA-FARMA d.o.o., Krka d.d. | Dasselta | tbl. film obl. 10x5 mg | 0,0901 | 0,90 | R | 5% |
| R06AX27 165 |  | desloratadin | 5 mg | 0,0810 | O | Teva B.V. | TEVA Pharmaceutical Works Private Limited Company | Desloratadin Teva | tbl. film obl. 10x5 mg | 0,0811 | 0,81 | R | 5% |
| R06AX27 171 |  | desloratadin | 5 mg | 0,0810 | O | Teva B.V. | TEVA Pharmaceutical Works Private Limited Company | Desloratadin Teva | tbl. film obl. 30x5 mg | 0,0811 | 2,43 | R | 5% |
| R07AA02 051 | DS | surfaktant, prirodni (goveđi) |  |  | I |  |  |  |  |  |  |  | 5% |
| R07AA02 361 | DS | surfaktant, prirodni (svinjski) | 0,16 g | 517,4600 | I | Chiesi Pharmaceuticals GmbH | Chiesi Farmaceutici S.p.A., Chiesi Pharmaceuticals GmbH | Curosurf | ukapna tekuć. za dušnik i pluća, susp., boč. stakl. 2x120 mg/1,5 ml | 388,0941 | 776,19 |  | 5% |
| R07AA02 362 | DS | surfaktant, prirodni (svinjski) | 0,16 g | 528,2933 | I | Chiesi Pharmaceuticals GmbH | Chiesi Farmaceutici S.p.A., Chiesi Pharmaceuticals GmbH | Curosurf | ukapna tekuć. za dušnik i pluća, susp., boč. stakl. 1x120 mg/1,5 ml | 396,2174 | 396,22 |  | 5% |
| R07AX02 171 | KS | ivakaftorNR508 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Kalydeco | film. obl. tbl., 28x150 mg | 264,9413 | 7.418,36 |  | 5% |
| R07AX30 171 | KS | lumakaftor + ivakaftorNR506 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Orkambi | granule 56x(100 mg + 125 mg) | 195,4680 | 10.946,21 |  | 5% |
| R07AX30 172 | KS | lumakaftor + ivakaftorNR506 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Orkambi | granule 56x(150 mg + 188 mg) | 195,4680 | 10.946,21 |  | 5% |
| R07AX30 173 | KS | lumakaftor + ivakaftorNR506 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Orkambi | film. obl. tbl., 112x(100 mg + 125 mg) | 109,4056 | 12.253,43 |  | 5% |
| R07AX30 174 | KS | lumakaftor + ivakaftorNR506 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Orkambi | film. obl. tbl., 112x(200 mg + 125 mg) | 97,7309 | 10.945,86 |  | 5% |
| R07AX32 171 | KS | ivakaftor + tezakaftor + eleksakaftorNR507 |  |  | O | Vertex Pharmaceuticals (Ireland) Limited | Almac Pharma Services Ltd. | Kaftrio | film. obl. tbl., 56 x (75 mg + 50 mg + 100 mg) | 182,8385 | 10.238,96 |  | 5% |
| S01BA01 071 | DS | deksametazonNS101 |  |  | P | AbbVie Deutschland GmbH & Co. KG | Allergan Pharmaceuticals Ireland | Ozurdex | intravitrealni implantat u aplikatoru 1x700 mcg | 916,1683 | 916,17 |  | 5% |
| S01EA05 772 |  | brimonidin |  |  | L | Allergan Pharm. Ireland | Allergan | Alphagan | kapi za oči 1x5 ml | 4,4462 | 4,45 | RSRS03 | 5% |
| S01EA05 775 |  | brimonidin |  |  | L | Bausch + Lomb Ireland Limited | Pharma Stulln GmbH, UAB Santonika | Luxfen | kapi za oči, otop. 1x5 ml (2 mg/ml) | 4,4462 | 4,45 | RSRS03 | 5% |
| S01EA05 777 |  | brimonidin |  |  | L | Jadran – Galenski Laboratorij d.d. | Jadran Galenski laboratorij d.d. | Bimanox | kapi za oči, otop. 1x5 ml (2 mg/ml) | 4,0016 | 4,00 | RSRS03 | 5% |
| S01EB02 751 | DS | karbakol |  |  | L |  |  |  |  |  |  |  | 5% |
| S01EC01 051 | DS | acetazolamid | 0,75 g |  | P |  |  |  |  |  |  |  | 5% |
| S01EC03 721 |  | dorzolamid | 0,3 ml | 0,8900 | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Dorzol | kapi za oči 1x5 ml (20 mg/ml) | 4,4462 | 4,45 | RSRS03 | 5% |
| S01EC03 761 |  | dorzolamid | 0,3 ml | 0,2670 | L | Santen Oy | Merck Sharp & Dohme B.V., Laboratories Merck Sharp & Dohme – Chibret | Trusopt | kapi za oči 1x5 ml (20 mg/ml) | 4,4462 | 4,45 | RSRS03 | 5% |
| S01EC03 771 |  | dorzolamid | 0,3 ml | 0,2670 | L | Bausch + Lomb Ireland Limited | S.C. Rompharm | Oftidor | kapi za oči 1x5 ml (20 mg/ml) | 4,4462 | 4,45 | RSRS03 | 5% |
| S01EC03 781 |  | dorzolamid | 0,3 ml | 0,2670 | L | Zentiva k.s. | Rafarm S.A. | Dorvis | kapi za oči 1x5 ml (20 mg/ml) | 4,4462 | 4,45 | RSRS03 | 5% |
| S01EC04 763 |  | brinzolamid |  |  | L | Zentiva k.s. | Famar S.A., Balkanpharma-Razgrad AD | Bravis | kapi za oči 1x5 ml | 4,3639 | 4,36 | RSRS03 | 5% |
| S01ED01 711 |  | timolol |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Timalen 0,25% | kapi za oči 1x5 ml (2,5 mg/ml) | 3,0155 | 3,02 | R | 5% |
| S01ED01 712 |  | timolol |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Timalen 0,5% | kapi za oči 1x5 ml (5 mg/ml) | 3,5158 | 3,52 | R | 5% |
| S01ED51 721 |  | timolol + dorzolamid |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Glaumax | kapi za oči 1x5 ml (5 mg + 20 mg/ml) | 4,8046 | 4,80 | RSRS03 | 5% |
| S01ED51 725 |  | timolol + dorzolamid |  |  | L | Bausch + Lomb Ireland Limited | FAMAR S.A., PHARMATHEN S.A. | Oftidorix | kapi za oči, otop. 1x5 ml (5 mg + 20 mg/ml) | 4,8046 | 4,80 | RSRS03 | 5% |
| S01ED51 771 |  | timolol + dorzolamid |  |  | L | Zentiva k.s. | Rafarm S.A. | Dorvis plus | kapi za oči, 1x5 ml (5 mg + 20 mg/ml) | 4,8046 | 4,80 | RSRS03 | 5% |
| S01ED51 772 |  | latanoprost + timolol |  |  | L | Bausch + Lomb Ireland Limited | S.C. Rompharm | Timlatan | kapi za oči boč. 1x2,5 ml (50 mcg/ml + 5 mg/ml) | 4,8099 | 4,81 | RSRS03 | 5% |
| S01ED51 782 |  | latanoprost + timolol |  |  | L | Zentiva k.s. | Rafarm S.A. | Lapovis plus | kapi za oči, boč. 1x2,5 ml (50 mcg/ml + 5 mg/ml) | 4,8099 | 4,81 | RSRS03 | 5% |
| S01ED51 783 |  | latanoprost + timolol |  |  | L | Upjohn EESV | Pfizer | Xalacom | kapi za oči boč. 1x2,5 ml (50 mcg/ml + 5 mg/ml) | 4,8099 | 4,81 | RSRS03 | 5% |
| S01EE01 721 |  | latanoprost |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Latanox | kapi za oči 1x2,5 ml (50 mcg/ml) | 5,3447 | 5,34 | RSRS03 | 5% |
| S01EE01 722 |  | latanoprost |  |  | L | Jadran – Galenski Laboratorij d.d. | JGL d.d. | Latanox | kapi za oči, boč. plast. 3x2,5 ml | 5,3447 | 16,03 | RSRS03 | 5% |
| S01EE01 761 |  | latanoprost |  |  | L | Upjohn EESV | Pfizer | Xalatan | kapi za oči 1x2,5 ml (50 mcg/ml) | 5,3447 | 5,34 | RSRS03 | 5% |
| S01EE01 771 |  | latanoprost |  |  | L | Bausch + Lomb Ireland Limited | S.C. Rompharm | Latapres | kapi za oči 1x2,5 ml (50 mcg/ml) | 5,3447 | 5,34 | RSRS03 | 5% |
| S01EE01 772 |  | latanoprost |  |  | L | Zentiva k.s. | Bruschettini S.R.L. | Lapovis | kapi za oči 1x2,5 ml (50 mcg/ml) | 5,0966 | 5,10 | RSRS03 | 5% |
| S01EE01 791 |  | latanoprost |  |  | L | UNIMED PHARMA spol s.r.o. | Unimed Pharma spol s.r.o. | Unilat | kapi za oči, boč. 1x2,5 ml (50 mcg/ml) | 4,5869 | 4,59 | RSRS03 | 5% |
| S01FB01 751 | DS | fenilefrin |  |  | L |  |  |  |  |  |  |  | 5% |
| S01JA01 751 | DS | fluorescein |  |  | L |  |  |  |  |  |  |  | 5% |
| S01KA02 751 | DS | hipromeloza |  |  | L |  |  |  |  |  |  |  | 5% |
| S01LA04 061 | DS | ranibizumabNS101 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Lucentis | otop. za inj., boč. stak. 1x2,3 mg/0,23 ml (10 mg/ml) | 630,5010 | 630,50 |  | 5% |
| S01LA04 062 | DS | ranibizumabNS101 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Lucentis | otop. za inj., štrc. napunj. 1x1,65 mg/0,165 ml (10 mg/ml) | 627,4351 | 627,44 |  | 5% |
| S01LA04 063 | DS | ranibizumabNS101 |  |  | P | Midas Pharma GmbH | Midas Pharma GmbH | Ranivisio | otop. za inj., boč. stak. 1x2,3 mg/0,23 ml (10 mg/ml) | 504,4011 | 504,40 |  | 5% |
| S01LA05 061 | DS | afliberceptNS101 |  |  | P | Bayer AG | Bayer AG | Eylea | otop. za inj., boč. stak. 1x40 mg/ml | 640,3822 | 640,38 |  | 5% |
| S01LA05 062 | DS | afliberceptNS101 |  |  | P | Bayer AG | Bayer AG | Eylea | otop. za inj., štrc. napunj. 1x40 mg/ml | 640,3822 | 640,38 |  | 5% |
| S01LA06 061 | DS | brolucizumabNS101 |  |  | P | Novartis Europharm Limited Irska | S.A. Alcon-Couvreur N.V. | Beovu | otop. za inj., štrc. napunj. 1x0,165 ml (120 mg/ml) | 616,1935 | 616,19 |  | 5% |
| S01XA20 762 |  | hipromeloza |  |  | L | Alcon Farmaceutika d.o.o. | Alcon | Isopto Tears | kapi za oči 1x15 ml (5 mg/ml) | 1,8050 | 1,81 | RRS02 | 5% |
| S01XA27 071 | KL | voretigen neparvovekNS104 |  |  | P | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Luxturna | 1x boč. konc. (5x1012 vg/ml) + 2x boč. otap. | ########### | 339.272,25 |  | 5% |
| V01AA01 011 | DS | alergeni za specifičnu imunoterapijuNV101 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za specifičnu imunoterapiju | boč. 1x10 ml | 8,8924 | 8,89 |  | 5% |
| V01AA01 012 | DS | alergeni za specifičnu imunoterapijuNV101 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za specifičnu imunoterapiju | boč. 1x10 ml | 8,8924 | 8,89 |  | 5% |
| V01AA01 013 | DS | alergeni za specifičnu imunoterapijuNV101 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za specifičnu imunoterapiju | boč. 1x10 ml | 8,8924 | 8,89 |  | 5% |
| V01AA01 014 | DS | alergeni za specifičnu imunoterapijuNV101 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za specifičnu imunoterapiju | boč. 1x10 ml | 12,4826 | 12,48 |  | 5% |
| V03AB03 052 | DS | natrij-kalcij-edetatNV301 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB04 054 | PR | pralidoksim NV301 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB04 153 | DS | pralidoksim NV301 |  |  | O |  |  |  |  |  |  |  | 5% |
| V03AB14 051 | DS | protamin-sulfatNV301 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB15 055 | PR | nalokson |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB23 051 | PR | acetilcisteinNV302 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AB25 061 | PR | flumazenilNV301 |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG | Flumazenil B. Braun 0,1 mg/ml | otopina za inj./inf., 0,1 mg/ml, amp. 5x5 ml | 5,4714 | 27,36 |  | 5% |
| V03AB25 062 | PR | flumazenilNV301 |  |  | P | Cheplapharm Arzneimittel GmbH | Cheplapharm Arzneimittel GmbH | Anexate | amp. 5x0,5 mg/5 ml | 7,8163 | 39,08 |  | 5% |
| V03AB35 001 | DS | sugamadeksNV303 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o. | Sugamadeks Teva | otop. za inj., boč. stakl. 10x200 mg/2 ml (100 mg/ml) | 50,7386 | 507,39 |  | 5% |
| V03AB35 002 | DS | sugamadeksNV303 |  |  | P | Teva B.V. | Pliva Hrvatska d.o.o. | Sugamadeks Teva | otop. za inj., boč. stakl. 10x500 mg/5 ml (100 mg/ml) | 126,8465 | 1.268,47 |  | 5% |
| V03AB35 041 | DS | sugamadeksNV303 |  |  | P | Pharmazac S.A. | Medichem S.A., Sant Joan Despí, Barcelona, Španjolska | Sugamadeks Pharmazac 100 mg/ml otopina za injekciju | otop. za inj., boč. stakl. 10x200 mg/2 ml (100 mg/ml) | 56,2199 | 562,20 |  | 5% |
| V03AB35 042 | DS | sugamadeksNV303 |  |  | P | Pharmazac S.A. | Medichem S.A., Sant Joan Despí, Barcelona, Španjolska | Sugamadeks Pharmazac 100 mg/ml otopina za injekciju | otop. za inj., boč. stakl. 10x500 mg/5 ml (100 mg/ml) | 140,5499 | 1.405,50 |  | 5% |
| V03AB35 081 | DS | sugamadeksNV303 |  |  | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Sugamadeks Sandoz | otop. za inj., boč. stakl. 10x200 mg/2 ml (100 mg/ml) | 53,4090 | 534,09 |  | 5% |
| V03AB37 061 | DS | idarucizumab |  |  | P | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Praxbind | otop. za inj./inf., boč. stakl. 2x2,5 g/50 ml | 1.319,9283 | 2.639,86 |  | 5% |
| V03AC01 051 | PR | deferoksaminNV301 |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AC03 101 |  | deferasiroks |  |  | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o | Deferasiroks Pliva | tbl. za oral. susp. 30x500 mg | 11,6572 | 349,72 | RSRV25 | 5% |
| V03AC03 161 |  | deferasiroks |  |  | O | Makpharm d.o.o. | Pharmascience International Limited | Zilart | tbl. za oral. susp. 28x125 mg | 3,2315 | 90,48 | RSRV25 | 5% |
| V03AC03 163 |  | deferasiroks |  |  | O | Makpharm d.o.o. | Pharmascience International Limited | Zilart | tbl. za oral. susp. 28x500 mg | 11,6572 | 326,40 | RSRV25 | 5% |
| V03AC03 171 |  | deferasiroks |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp.z.o.o., Pharmadox Healthcare Limited | Deferasiroks Accord | tbl. film obl. 30x90 mg | 3,0699 | 92,10 | RSRV25 | 5% |
| V03AC03 172 |  | deferasiroks |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp.z.o.o., Pharmadox Healthcare Limited | Deferasiroks Accord | tbl. film obl. 30x180 mg | 5,8250 | 174,75 | RSRV25 | 5% |
| V03AC03 173 |  | deferasiroks |  |  | O | Accord Healthcare S.L.U. | Accord Healthcare Polska Sp.z.o.o., Pharmadox Healthcare Limited | Deferasiroks Accord | tbl. film obl. 30x360 mg | 11,6557 | 349,67 | RSRV25 | 5% |
| V03AC03 174 |  | deferasiroks |  |  | O | PLIVA HRVATSKA d.o.o. | PharOS MT Ltd, Teva UK Ltd. | Deferasiroks Pliva | tbl. film obl. 30x180 mg | 5,8250 | 174,75 | RSRV25 | 5% |
| V03AC03 175 |  | deferasiroks |  |  | O | PLIVA HRVATSKA d.o.o. | PharOS MT Ltd, Teva UK Ltd. | Deferasiroks Pliva | tbl. film obl. 30x360 mg | 11,6572 | 349,72 | RSRV25 | 5% |
| V03AC03 181 |  | deferasiroks |  |  | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Deferasiroks Alpha-Medical | tbl. film obl. 30x180 mg | 5,8250 | 174,75 | RSRV25 | 5% |
| V03AC03 182 |  | deferasiroks |  |  | O | ALPHA-MEDICAL d.o.o. | Pharmadox Healthcare Limited | Deferasiroks Alpha-Medical | tbl. film obl. 30x360 mg | 11,6572 | 349,72 | RSRV25 | 5% |
| V03AC03 191 |  | deferasiroks |  |  | O | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Zeoks | tbl. film obl. 30x360 mg | 11,6572 | 349,72 | RSRV25 | 5% |
| V03AE01 361 |  | kalcijev polistirensulfonat | 45 g | 2,8981 | O | Makpharm d.o.o. | Laboratorios Rubió, S.A. | Xaviox | praš. za oral. susp., vreć. 26x14,96 g | 0,9636 | 25,05 | RSRV03 | 5% |
| V03AE02 101 |  | sevelamer-karbonat | 6,4 g | 3,2702 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o.; Synthon Hispania S.L.; Merckle GmbH | Sevelamerkarbonat Pliva | tbl. film obl. 180x800 mg | 0,4088 | 73,58 | RSRV01 | 5% |
| V03AE02 121 |  | sevelamer-karbonat | 6,4 g | 3,2702 | O | Sandoz d.o.o. | Synthon Hispania S.L. | Sevelamer Sandoz | tbl. film obl. 180x800 mg | 0,4088 | 73,58 | RSRV01 | 5% |
| V03AE02 162 |  | sevelamer-karbonat | 6,4 g | 3,2702 | O | Genzyme Europe B.V. | Genzyme | Renvela | tbl. film obl. 180x800 mg | 0,4088 | 73,58 | RSRV01 | 5% |
| V03AE02 163 |  | sevelamer-karbonat | 6,4 g | 4,2436 | O | Genzyme Europe B.V. | Genzyme | Renvela | praš. za oral. susp. 60x2,4 g | 1,5913 | 95,48 | RSRV01 | 5% |
| V03AE03 171 |  | lantan | 2,25 g | 3,2705 | O | Mylan Ireland Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Mylan Hungary Kft | Lantan Mylan | tbl. za žvak. 90x500 mg | 0,7267 | 65,41 | RSRV01 | 5% |
| V03AE03 172 |  | lantan | 2,25 g | 3,2703 | O | Mylan Ireland Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Mylan Hungary Kft | Lantan Mylan | tbl. za žvak. 90x750 mg | 1,0901 | 98,11 | RSRV01 | 5% |
| V03AE03 173 |  | lantan | 2,25 g | 3,2703 | O | Mylan Ireland Limited | McDermott Laboratories Limited, t/a Gerard Laboratories, Mylan Hungary Kft | Lantan Mylan | tbl. za žvak. 90x1000 mg | 1,4535 | 130,81 | RSRV01 | 5% |
| V03AE04 161 |  | kalcijev acetat + magnezijev subkarbonat teški |  |  | O | Fresenius Medical Care Hrvatska d.o.o. | Fresenius Medical Care Deutschland GmbH | OsvaRen | tbl. film obl. 180x(435 mg + 235 mg) | 0,1155 | 20,78 | RSRV12 | 5% |
| V03AE05 171 |  | saharoželjezov (III) oksihidroksid | 1.5 g | 5,1803 | O | Vifor Fresenius Medical Care Renal Pharma France | Vifor France | Velphoro | tbl. za žvak. 90x500 mg | 1,7267 | 155,41 | RSRV24 | 5% |
| V03AF01 051 | DS | mesna (merkaptoetan-sulfonska kiselina) |  |  | P |  |  |  |  |  |  |  | 5% |
| V03AF03 001 | DS | kalcij-folinat | 60 mg | 4,2850 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kalcijev folinat Pliva | otop. za inj./inf., boč. stakl. 1x100 mg/10 ml (10 mg/ml) | 8,5659 | 8,57 |  | 5% |
| V03AF03 003 | DS | kalcij-folinat | 60 mg | 3,4325 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kalcijev folinat Pliva | otop. za inj./inf., boč. stakl. 1x500 mg/50 ml (10 mg/1 ml) | 27,4564 | 27,46 |  | 5% |
| V03AF03 004 | DS | kalcij-folinat | 60 mg | 4,9682 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kalcijev folinat Pliva | otop. za inj., boč. stakl. 1x50 mg/5 ml (10 mg/1 ml) | 4,1423 | 4,14 |  | 5% |
| V03AF03 005 | DS | kalcij-folinat | 60 mg | 3,5600 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Kalcijev folinat Pliva | otop. za inj., boč. stakl. boč. 1x300 mg/30 ml (10 mg/1 ml) | 17,8008 | 17,80 |  | 5% |
| V03AF03 064 | DS | kalcij-folinat | 60 mg | 4,5030 | P | Sandoz d.o.o. | Ebewe Pharma | Kalcijev folinat Sandoz | otop. za inj. ili inf., boč. stakl. 1x20 ml (10 mg/ml) | 15,0136 | 15,01 |  | 5% |
| V03AF03 065 | DS | kalcij-folinat | 60 mg | 3,5469 | P | Sandoz d.o.o. | Ebewe Pharma | Kalcijev folinat Sandoz | otop. za inj. ili inf., boč. stakl. 1x35 ml (10 mg/ml) | 20,6888 | 20,69 |  | 5% |
| V03AF03 067 | DS | kalcij-folinat | 60 mg | 5,1419 | P | Sandoz d.o.o. | Ebewe Pharma | Kalcijev folinat Sandoz | otop. za inj. ili inf., boč. stakl. 1x10 ml (10 mg/ml) | 8,5659 | 8,57 |  | 5% |
| V03AF03 069 | DS | kalcij-folinat | 60 mg | 6,7044 | P | Sandoz d.o.o. | Ebewe Pharma GmbH Nfg. KG | Kalcijev folinat Sandoz | otop. za inj./inf., boč. stakl. 1x1000 mg/100 ml (10 mg/1 ml) | 111,7407 | 111,74 |  | 5% |
| V03AF03 151 | DS | kalcij-folinat | 60 mg |  | O |  |  |  |  |  |  |  | 5% |
| V04CD01 051 | KL | metirapon |  |  | P |  |  |  |  |  |  |  | 5% |
| V04CF01 051 | PR | tuberkulinNJ707 |  |  | P |  |  |  |  |  |  |  | 5% |
| V04CJ02 051 | KL | protirelin (TRH) |  |  | P |  |  |  |  |  |  |  | 5% |
| V04CL01 011 | DS | alergeni grupni za testiranje |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za PRICK test | boč. 1x2 ml | 7,0940 | 7,09 |  | 5% |
| V04CL01 012 | DS | alergeni grupni za testiranje |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za intradermalno testiranje-ID test | boč. 1x10 ml | 7,0940 | 7,09 |  | 5% |
| V04CL02 011 | DS | alergeni pojedinačni za testiranje |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za PRICK test | boč. 1x2 ml | 7,0940 | 7,09 |  | 5% |
| V04CL02 012 | DS | alergeni pojedinačni za testiranje |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Alergeni za intradermalno testiranje-ID test | boč. 1x10 ml | 7,0940 | 7,09 |  | 5% |
| V06DC01 024 | PR | glukoza |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Glukoza 20% HZTM otopina za infuziju | otop. za inf., boca stakl. 10x500 ml (200 mg/ml) | 1,3418 | 13,42 |  | 5% |
| V06DC01 051 | PR | glukoza (amp. 37 %) |  |  | P |  |  |  |  |  |  |  | 5% |
| V06DC01 052 | PR | glukoza (amp. 50 %) |  |  | P |  |  |  |  |  |  |  | 5% |
| V07AB01 911 | PR | voda redestilirana |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Aqua pro injectione HZTM | otap. za parent. upor., boca stakl. 20x100 ml | 0,7459 | 14,92 |  | 5% |
| V07AB01 912 | PR | voda redestilirana |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. | Aqua pro injectione HZTM | otap. za parent. upor., boca stakl. 10x500 ml | 0,8600 | 8,60 |  | 5% |
| V07AB01 941 | PR | voda redestilirana |  |  | P | Alkaloid d.o.o. | Alkaloid | Voda za injekcije Alkaloid | otap. za parent. upor., amp. stakl. 50x5 ml | 0,1354 | 6,77 |  | 5% |
| V07AB01 962 | PR | voda redestilirana |  |  | P | Baxter d.o.o. | Baxter, Bieffe Medital | Voda za injekcije Viaflo | otop. za parent. prim., vreć. plast. 20x500 ml | 0,9043 | 18,09 |  | 5% |
| V07AB01 963 | PR | voda redestilirana |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Voda za injekcije B.Braun | otap. za parent. prim., polietil. Ecoflac plus boca, 20x100 ml | 0,7459 | 14,92 |  | 5% |
| V07AB01 964 | PR | voda redestilirana |  |  | P | B. Braun Adria d.o.o. | B. Braun Melsungen AG, B. Braun Medical S.A. | Voda za injekcije B. Braun | otap. za parent. prim., polietil. Ecoflac plus boca, 10x500 ml | 0,8623 | 8,62 |  | 5% |
| V07AB01 965 | PR | voda redestilirana |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Voda za injekcije Fresenius Kabi | otap. za parent. upor., amp. polietil. 20x5 ml | 0,1679 | 3,36 |  | 5% |
| V07AB01 966 | PR | voda redestilirana |  |  | P | Fresenius Kabi d.o.o. | Fresenius Kabi | Voda za injekcije Fresenius Kabi | otap. za parent. upor., amp. polietil. 20x10 ml | 0,1664 | 3,33 |  | 5% |
| V07AB02 971 | DS | irigacijske otopine |  |  | L | B. Braun Adria d.o.o. | B.Braun | Izotonična otopina NaCl 0,9% B.Braun | ecotainer 1x1.000 ml |  |  |  | 5% |
| V07AB02 972 | DS | irigacijske otopine |  |  | L | B. Braun Adria d.o.o. | B.Braun | Izotonična otopina NaCl 0,9% B.Braun | ecobag 1x3.000 ml |  |  |  | 5% |
| V07AB02 973 | DS | irigacijske otopine |  |  | L | Agmar d.o.o. | Baxter S.A. | Natrijev klorid 0,9 % | otop. za ispir., vreć. Clear-Flex 4x3.000 ml | 4,3384 | 17,35 |  | 5% |
| V07AB02 974 | DS | irigacijske otopine |  |  | L | Fresenius Kabi d.o.o. | Fresenius Kabi France S.A.S. | NaCl 0,9% Fresenius 1000 ml | boca plast. Plastipur 6x1000 ml | 1,5181 | 9,11 |  | 5% |
| V07AB02 975 | DS | irigacijske otopine |  |  | L | Fresenius Kabi d.o.o. | Fresenius Kabi AG | NaCl 0,9% Fresenius 3000 ml | vreć. plast. 4x3000 ml | 3,9047 | 15,62 |  | 5% |
| V07AZ01 421 | DS | gel za ultrazvuk |  |  | L | CERACARTA S.p.a. | CERACARTA | Eko gel | boca plast. 1x250 ml | 1,0618 | 1,06 |  | 5% |
| V07AZ01 422 | DS | gel za EKG, EEG, EMG i defibrilator |  |  | L | CERACARTA S.p.a. | CERACARTA | Zero gel | boca plast. 1x260 g, gel | 1,0618 | 1,06 |  | 5% |
| V07AZ01 423 | DS | gel za ultrazvuk |  |  | L | CERACARTA S.p.a. | CERACARTA | Eko gel | ecotainer 1x5.000 ml | 11,2814 | 11,28 |  | 5% |
| V07AZ01 424 | DS | gel za ultrazvuk |  |  | L | CERACARTA S.p.a. | CERACARTA | Eko gel | boč. plast. 1x300 ml | 1,1945 | 1,19 |  | 5% |
| V08AA11 051 | DS | meglumin-amidotrizoat-65%NV801 |  |  | P |  |  |  |  |  |  |  | 5% |
| V08AA12 076 | DS | natrijev amidotrizoat + meglumin amidotrizoat |  |  | P | Bayer d.o.o. | Berlimed S.A. | Gastrografin 0,1 g/ml + 0,66 g/ml oralna/rektalna otopina | oralna/rektalna otopina, boč. stakl. 1x100 ml (10 g natrijevog amidotrizoata + 66 g meglumin amidotrizoata) | 8,1266 | 8,13 |  | 5% |
| V08AB02 089 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 300 | boč. polipropil. 10x50 ml (300 mg I/ml) | 12,7324 | 127,32 |  | 5% |
| V08AB02 090 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 300 | boč. polipropil. 10x100 ml (300 mg I/ml) | 27,9765 | 279,77 |  | 5% |
| V08AB02 092 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 350 | boč. polipropil. 10x50 ml (350 mg I/ml) | 16,1124 | 161,12 |  | 5% |
| V08AB02 093 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 350 | boč. polipropil. 10x100 ml (350 mg I/ml) | 28,2820 | 282,82 |  | 5% |
| V08AB02 094 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 350 | boč. polipropil. 10x200 ml (350 mg I/ml) | 50,0737 | 500,74 |  | 5% |
| V08AB02 095 | DS | joheksolNV802 |  |  | P | GE HEALTHCARE AS | GE Healthcare | Omnipaque 350 | boč. polipropil. 6x500 ml (350 mg I/ml) | 128,1346 | 768,81 |  | 5% |
| V08AB03 052 | DS | joksaglikanska kiselinaNV803 |  |  | P |  |  |  |  |  |  |  | 5% |
| V08AB04 063 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 300 | boč. 1x30 ml | 9,8865 | 9,89 |  | 5% |
| V08AB04 064 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 300 | boč. 1x50 ml (300 mg I/ml) | 14,7375 | 14,74 |  | 5% |
| V08AB04 065 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 300 | boč. 1x100 ml (300 mg I/ml) | 30,3497 | 30,35 |  | 5% |
| V08AB04 066 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 370 | boč. 1x30 ml (370 mg/ml) | 9,8427 | 9,84 |  | 5% |
| V08AB04 067 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 370 | boč. 1x50 ml (370 mg/ml) | 16,8067 | 16,81 |  | 5% |
| V08AB04 068 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 370 | boč. 1x100 ml (370 mg/ml) | 32,7547 | 32,75 |  | 5% |
| V08AB04 069 | DS | jopamidolNV804 |  |  | P | Bracco Imaging s.p.a. | Bracco | Iopamiro 370 | boč. 1x200 ml (370 mg/ml) | 62,3664 | 62,37 |  | 5% |
| V08AB05 073 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 300 | amp. 10x50 ml | 16,8980 | 168,98 |  | 5% |
| V08AB05 074 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 300 | amp. 10x100 ml | 33,1915 | 331,91 |  | 5% |
| V08AB05 076 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 370 | amp. 10x50 ml | 18,9507 | 189,51 |  | 5% |
| V08AB05 077 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 370 | amp. 10x100 ml | 37,8022 | 378,02 |  | 5% |
| V08AB05 078 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 370 | amp. 10x200 ml | 73,1348 | 731,35 |  | 5% |
| V08AB05 079 | DS | jopromid |  |  | P | Bayer d.o.o. | Bayer AG | Ultravist 370 | boca 8x500 ml | 184,6339 | 1.477,07 |  | 5% |
| V08AB07 061 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf., boč. stakl. 10x50 ml (300 mg/ml) | 12,8965 | 128,97 |  | 5% |
| V08AB07 062 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x100 ml (300 mg/ml) | 25,2386 | 252,39 |  | 5% |
| V08AB07 063 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x100 ml (320 mg/ml) | 31,3355 | 313,35 |  | 5% |
| V08AB07 064 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf., boč. stakl. 10x50 ml (350 mg/ml) | 14,8727 | 148,73 |  | 5% |
| V08AB07 065 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x100 ml (350 mg/ml) | 28,7325 | 287,32 |  | 5% |
| V08AB07 066 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x200 ml (350 mg/ml) | 45,9991 | 459,99 |  | 5% |
| V08AB07 067 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 5x500 ml (350 mg/ml) | 138,9236 | 694,62 |  | 5% |
| V08AB07 069 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf., boč. stakl. 25x50 ml (350 mg/ml) | 14,8729 | 371,82 |  | 5% |
| V08AB07 070 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x500 ml (350 mg/ml) | 138,9236 | 1.389,24 |  | 5% |
| V08AB07 071 | DS | joversol |  |  | P | Pharmacol d.o.o. | Guerbet Ireland ULC | Optiray | otop. za inj. ili inf. boč. stakl. 10x500 ml (320 mg/ml) | 140,9516 | 1.409,52 |  | 5% |
| V08AB09 082 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 270 | boč. plast. 10x100 ml (270 mgI/ml) | 30,8672 | 308,67 |  | 5% |
| V08AB09 083 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 320 | boč. plast. 10x50 ml (320 mgI/ml) | 18,7637 | 187,64 |  | 5% |
| V08AB09 084 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 320 | boč. plast. 10x100 ml (320 mgI/ml) | 37,5226 | 375,23 |  | 5% |
| V08AB09 085 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 320 | boč. 10x200 ml (320 mgI/ml) | 70,6218 | 706,22 |  | 5% |
| V08AB09 087 | DS | jodiksanol |  |  | P | GE HEALTHCARE AS | GE Healthcare | Visipaque 320 | boč. plast. 6x500 ml (320 mgI/ml) | 167,5243 | 1.005,15 |  | 5% |
| V08AB10 061 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 300 | otop. za inj., stakl. boca 1x50 ml (300 mg I/ml) | 13,8456 | 13,85 |  | 5% |
| V08AB10 062 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 300 | otop. za inj., boca stakl. 1x100 ml (300 mg I/ml) | 27,3144 | 27,31 |  | 5% |
| V08AB10 063 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 300 | otop. za inj., stakl. boca 1x200 ml (300 mg I/ml) | 49,7392 | 49,74 |  | 5% |
| V08AB10 064 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 300 | otop. za inj., stakl. boca 1x500 ml (300 mg I/ml) | 126,7928 | 126,79 |  | 5% |
| V08AB10 065 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 350 | otop. za inj., stakl. boca 1x50 ml (350 mg I/ml) | 16,1258 | 16,13 |  | 5% |
| V08AB10 066 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 350 | otop. za inj., boca stakl. 1x100 ml (350 mg I/ml) | 31,6544 | 31,65 |  | 5% |
| V08AB10 067 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 350 | otop. za inj., stakl. boca 1x200 ml (350 mg I/ml) | 55,7117 | 55,71 |  | 5% |
| V08AB10 068 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 350 | otop. za inj., stakl. boca 1x500 ml (350 mg I/ml) | 143,0778 | 143,08 |  | 5% |
| V08AB10 069 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 400 | otop. za inj., stakl. boca 1x50 ml (400 mg I/ml) | 19,7757 | 19,78 |  | 5% |
| V08AB10 070 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 400 | otop. za inj., stakl. boca 1x100 ml (400 mg I/ml) | 37,4278 | 37,43 |  | 5% |
| V08AB10 071 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 400 | otop. za inj., stakl. boca 1x200 ml (400 mg I/ml) | 74,3248 | 74,32 |  | 5% |
| V08AB10 072 | DS | iomeprol |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | Iomeron 400 | otop. za inj., stakl. boca 1x500 ml (400 mg I/ml) | 184,4847 | 184,48 |  | 5% |
| V08AB11 062 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 300 | boč. 1x50 ml (300 mgI/ml) | 14,1854 | 14,19 |  | 5% |
| V08AB11 063 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 300 | boč. 1x100 ml (300 mgI/ml) | 28,7292 | 28,73 |  | 5% |
| V08AB11 064 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 350 | boč. 1x50 ml (350 mgI/ml) | 15,3189 | 15,32 |  | 5% |
| V08AB11 065 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 350 | boč. 1x100 ml (350 mgI/ml) | 30,0710 | 30,07 |  | 5% |
| V08AB11 066 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 300 | otop. za inj., boč. 1x200 ml (300 mgI/ml) | 55,2658 | 55,27 |  | 5% |
| V08AB11 067 | DS | jobitridol |  |  | P | Pharmacol d.o.o. | Guerbet | Xenetix 350 | otop. za inj., boč. 1x200 ml (350 mgI/ml) | 61,9019 | 61,90 |  | 5% |
| V08AC01 053 | DS | jodoksaminska kiselina meglumin-jodoksamat |  |  | P |  |  |  |  |  |  |  | 5% |
| V08AD02 055 | DS | smjesa etilnih estera jodiranih masnih kiselina (lipiodol-ultrafluid) |  |  | P |  |  |  |  |  |  |  | 5% |
| V08BA01 251 | DS | barij-sulfat |  |  | O |  |  |  |  |  |  |  | 5% |
| V08CA02 061 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč.stakl. 1x15 ml (279,32 mg/ml) | 33,1462 | 33,15 |  | 5% |
| V08CA02 062 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč.stakl. 1x20 ml (279,32 mg/ml) | 41,4042 | 41,40 |  | 5% |
| V08CA02 063 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., štrc. napunj. 1x10 ml (279,32 mg/ml) | 21,4334 | 21,43 |  | 5% |
| V08CA02 064 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., štrc. napunj. 1x15 ml (279,32 mg/ml) | 31,9756 | 31,98 |  | 5% |
| V08CA02 065 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., štrc. napunj. 1x20 ml (279,32 mg/ml) | 41,4042 | 41,40 |  | 5% |
| V08CA02 066 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč. stakl. 1x10 ml (279,32 mg/ml) | 21,4334 | 21,43 |  | 5% |
| V08CA02 067 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč. stakl. 1x60 ml (279,32 mg/ml) | 82,6014 | 82,60 |  | 5% |
| V08CA02 068 | DS | gadoteratna kiselina |  |  | P | Pharmacol d.o.o. | Guerbet | Dotarem | otop. za inj., boč. stakl. 1x100 ml (279,32 mg/ml) | 137,6694 | 137,67 |  | 5% |
| V08CA02 071 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x10 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 15,0030 | 150,03 |  | 5% |
| V08CA02 072 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x15 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 23,2023 | 232,02 |  | 5% |
| V08CA02 073 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x20 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 28,9829 | 289,83 |  | 5% |
| V08CA02 074 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x50 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 72,4574 | 724,57 |  | 5% |
| V08CA02 075 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., boč. 10x100 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 144,9147 | 1.449,15 |  | 5% |
| V08CA02 076 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., štrc. napunj. 10x10 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 15,0030 | 150,03 |  | 5% |
| V08CA02 077 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., štrc. napunj. 10x15 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 22,3829 | 223,83 |  | 5% |
| V08CA02 078 | DS | gadoteratna kiselina |  |  | P | GE HEALTHCARE AS | GE Healthcare AS | Clariscan | otop. za inj., štrc. napunj. 10x20 ml (1 ml otopine za injekciju sadrži 279,3 mg gadoteratne kiseline što odgovara 0,5 mmol) | 28,9829 | 289,83 |  | 5% |
| V08CA02 081 | DS | gadoteratna kiselina |  |  | P | Bayer d.o.o. | Sanochemia Pharmazeutika GmbH | Dotagraf | otop. za inj., boč. 1x10 ml (0,5 mmol/ml) | 13,5032 | 13,50 |  | 5% |
| V08CA02 082 | DS | gadoteratna kiselina |  |  | P | Bayer d.o.o. | Sanochemia Pharmazeutika GmbH | Dotagraf | otop. za inj., boč.1x15 ml (0,5 mmol/ml) | 20,8826 | 20,88 |  | 5% |
| V08CA02 083 | DS | gadoteratna kiselina |  |  | P | Bayer d.o.o. | Sanochemia Pharmazeutika GmbH | Dotagraf | otop. za inj., boč. 1x20 ml (0,5 mmol/ml) | 26,0840 | 26,08 |  | 5% |
| V08CA04 061 | DS | gadoteridol |  |  | P | Bracco Imaging s.p.a. | Bipso GmbH, Bracco Imaging s.p.a. | ProHance | otop. za inj., boč. stakl. 1x20 ml (0,5 mmol/ml) | 39,1532 | 39,15 |  | 5% |
| V08CA08 061 | DS | gadobenična kiselina |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | MultiHance | otop. za inj., boč. stakl. 1x10 ml (0,5 mmol/ml) | 32,5410 | 32,54 |  | 5% |
| V08CA08 062 | DS | gadobenična kiselina |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | MultiHance | otop. za inj., boč. stakl. 1x15 ml (0,5 mmol/ml) | 44,2418 | 44,24 |  | 5% |
| V08CA08 063 | DS | gadobenična kiselina |  |  | P | Bracco Imaging s.p.a. | Patheon Italia S.p.A. | MultiHance | otop. za inj., boč. stakl. 1x20 ml (0,5 mmol/ml) | 53,3201 | 53,32 |  | 5% |
| V08CA09 071 | DS | gadobutrol |  |  | P | Bayer d.o.o. | Bayer AG | Gadovist | otop. za inj. u napunj. štrc./ulošku 5x7,5 ml (604,72 mg/1 mmol/ml) | 48,9529 | 244,76 |  | 5% |
| V08CA09 073 | DS | gadobutrol |  |  | P | Bayer d.o.o. | Bayer AG | Gadovist | otop. za inj., boč. 1x15 ml (604,72 mg/1 mmol/ml) | 95,8259 | 95,83 |  | 5% |
| V08CA10 074 | DS | gadoksetična kiselinaNV805 |  |  | P | Bayer d.o.o. | Bayer AG | Primovist | otop. za inj., štrc. napunj. 1x10 ml (0,25 mmol/ml) | 167,9488 | 167,95 |  | 5% |
| V09AB03 061 | DS | ioflupanNV806 |  |  | P | GE Healthcare B.V. | GE Healthcare B.V. | DaTSCAN | otop. za inj., boč. stakl. 1x10 ml s 2,5 ml otop. (74 MBq/ml) | 813,3970 | 813,40 |  | 5% |
| V09AB03 062 | DS | ioflupanNV806 |  |  | P | GE Healthcare B.V. | GE Healthcare B.V. | DaTSCAN | otop. za inj., boč. stakl. 1x10 ml s 5 ml otop. (74 MBq/ml) | 849,4180 | 849,42 |  | 5% |
| V09IX04 051 | DS | fludeoksiglukoza (18F) |  |  | P |  |  |  |  | #N/A | #N/A |  | 5% |
| V10XX03 061 | KL | radij-223 dikloridNV808 |  |  | P | Bayer AG | Bayer AS | Xofigo | otop. za inj., boč. stakl. 1x6 ml (1000 kBq/ml) | 4.509,1074 | 4.509,11 |  | 5% |

Osnovna lista lijekova s cijenama u eurima – 2. dio

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena u EUR za DDD (bez PDV-a) | Način primjene | Nositelj  odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena u EUR za jed. obl. (bez PDV-a) | Cijena u EUR za orig. pak. (bez PDV-a) | R/RS | Stopa PDV-a |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. |
| V06CA01 362 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Anamix Infant | prašak 1x400 g | 33,0931 | 33,09 | RSRV02 | 5% |
| V06CA01 363 |  | dijetetski preparat |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Start | prašak 4x400 g | 34,3148 | 137,26 | RSRV02 | 5% |
| V06CA01 371 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Cooler 10 | napitak, 30 vreć.x87 ml/kutija | 5,8031 | 174,09 | RSfRV17 | 5% |
| V06CA01 372 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Cooler 15 | napitak, 30 vreć.x130 ml/kutija | 8,7047 | 261,14 | RSfRV17 | 5% |
| V06CA01 373 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Cooler 20 | napitak, 30 vreć.x174 ml/kutija | 11,6063 | 348,19 | RSfRV17 | 5% |
| V06CA01 383 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Express | prah, 30x25 g | 7,8240 | 234,72 | RSfRV17 | 5% |
| V06CA01 384 |  | dijetetski preparatNV601 |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Express | prah, 30x34 g | 10,4320 | 312,96 | RSfRV17 | 5% |
| V06CA01 391 |  | dijetetski preparatNV601 |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Lophlex LQ 20 | tetrapak 30x125 ml | 12,2171 | 366,51 | RSfRV17 | 5% |
| V06CA01 392 |  | dijetetski preparatNV601 |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Lophlex | prah, vreć. 30x27,8 g | 10,9954 | 329,86 | RSfRV17 | 5% |
| V06CA01 394 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Nutri 2 | prašak 1x500 g | 99,7717 | 99,77 | RSRV21 | 5% |
| V06CA01 395 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Nutri 3 | prašak 1x500 g | 116,3992 | 116,40 | RSRV22 | 5% |
| V06CA01 396 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Anamix First Spoon | prašak 30x12,5 g | 3,1577 | 94,73 | RSRV18 | 5% |
| V06CA01 397 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | PKU Anamix Junior | prašak 30x36 g | 6,3155 | 189,46 | RSRV19 | 5% |
| V06CA01 398 |  | dijetetski preparat |  |  | O | INSPHARMA d.o.o. | Vitaflo International Ltd | PKU Gel | prašak 30x24 g | 5,9991 | 179,97 | RSRV28 | 5% |
| V06DX01 381 |  | dijetetski preparat |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | Neocate LCP | limenka 1x400 g | 27,5599 | 27,56 | RSVP02 | 5% |
| V06DX01 383 |  | dijetetski preparatNV611 |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | Zamjena za mlijeko PKU Loprofin | tetrepak 1x200 ml | 0,9423 | 0,94 | RSfRV17 | 5% |
| V06DX01 389 |  | dijetetski preparatNV611 |  |  | O | G-M Pharma Zagreb d.o.o. | SHS International Ltd. | Zamjena za rižu Loprofin | kutija 1x500 g | 7,1670 | 7,17 | RSfRV17 | 5% |
| V06DX01 391 |  | dijetetski preparat |  |  | O | Medis Adria d.o.o. | UP Medi-Europa SA | Novalac Aminova | limenka 1x400 g | 27,2812 | 27,28 | RSVP02 | 5% |
| V06DX01 392 |  | dijetetski preparat |  |  | O | Abbott Laboratories d.o.o. | Abbott | Similac Elecare | limenka 1x400 g | 26,5539 | 26,55 | RSVP02 | 5% |
| V06DX01 466 |  | dijetetski preparat |  |  | O | Oktal Pharma d.o.o. | Nestle Suisse S.A. | Alfamino | limenka 1x400 g | 27,9514 | 27,95 | RSVP02 | 5% |
| V06DX03 345 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Two Cal | boca 1x200 ml | 1,1693 | 1,17 | RSVO06a | 5% |
| V06DX03 350 | DS | namirnice za enteralnu primjenuNV605 |  |  | O | Abbott Laboratories d.o.o. | Abbott | Oxepa | boca 1x500 ml | 9,9542 | 9,95 |  | 5% |
| V06DX03 357 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Nutrison | vreć. plast./kolapsibilna boca 1x1000 ml | 4,2312 | 4,23 | RSVO01b | 5% |
| V06DX03 360 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle | Modulen IBD | kutija 1x400 g/1800 ml | 14,2929 | 14,29 | RSVS10a | 5% |
| V06DX03 361 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Glucerna | limenka 1x250 ml | 1,1295 | 1,13 | RSVS13b | 5% |
| V06DX03 362 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Glucerna SR | tetrapak 1x230 ml | 1,2144 | 1,21 | RSVS12a | 5% |
| V06DX03 372 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Diben | vreć. plast. 1x500 ml | 2,3492 | 2,35 | RSVS13b | 5% |
| V06DX03 380 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle | Peptamen Junior | kutija 1x400 g/1800 ml | 8,5168 | 8,52 | RSVP12 | 5% |
| V06DX03 384 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Nutrini Drink Multi Fibre | boca. plast. 1x200 ml | 1,0936 | 1,09 | RSVP11 | 5% |
| V06DX03 387 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Plus Fiber | boca 1x200 ml | 1,0817 | 1,08 | RSVO04a | 5% |
| V06DX03 389 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Jevity | spremnik plast. 1x1.000 ml | 3,2517 | 3,25 | RSVO02b | 5% |
| V06DX03 390 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Osmolite | spremnik plast. 1x1.000 ml | 3,2517 | 3,25 | RSVO01b | 5% |
| V06DX03 391 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Pulmocare RTH | boca 1x250 ml | 1,1839 | 1,18 | RSVS11a | 5% |
| V06DX03 394 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Fresubin HP Energy | vreć. plast. 1x500 ml | 2,3890 | 2,39 | RSVO03b | 5% |
| V06DX03 395 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Supportan | vreć. plast. 1x500 ml | 3,9790 | 3,98 | RSVS01b | 5% |
| V06DX03 396 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Pediasure | tetrapak/boca 1x200 ml | 0,8720 | 0,87 | RSVP10 | 5% |
| V06DX03 399 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Survimed OPD | vreć. plast. 1x500 ml | 3,5809 | 3,58 | RSVS09b | 5% |
| V06DX03 400 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutrison Energy Multi Fibre | vreć. plast. 1x1000 ml | 4,8683 | 4,87 | RSVO04b | 5% |
| V06DX03 421 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Nutrison Advanced Diason | vreć. plast. 1x1000 ml | 4,8975 | 4,90 | RSVS12b | 5% |
| V06DX03 432 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Nepro HP | boca 1x220 ml | 2,2682 | 2,27 | RSVS08a | 5% |
| V06DX03 437 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Nepro LP | boč. 1x220 ml | 2,0413 | 2,04 | RSVS07a | 5% |
| V06DX03 438 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi Deutschland GmbH | FRESUBIN 2 kcal HP | vreć. plast. 1x500 ml | 2,5536 | 2,55 | RSVO05b | 5% |
| V06DX03 439 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi Deutschland GmbH | FRESUBIN 2 kcal HP fibre | vreć. plast. 1x500 ml | 2,6412 | 2,64 | RSVO06b | 5% |
| V06DX03 440 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Intestamin | vreć. plast. 1x500 ml | 24,9519 | 24,95 | RSVS02b | 5% |
| V06DX03 443 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Vital 1,5 kcal | boč. 1x200 ml | 1,8382 | 1,84 | RSVS09a | 5% |
| V06DX03 444 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutridrink Multi Fibre | boca plast. 4x200 ml | 1,0817 | 4,33 | RSVO04a | 5% |
| V06DX03 445 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Renilon 7,5 | boč. 4x125 ml | 1,4248 | 5,70 | RSVS08a | 5% |
| V06DX03 446 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N. V. Nutricia | Forticare | boč. 4x125 ml | 1,4955 | 5,98 | RSVS01a | 5% |
| V06DX03 447 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | N.V. Nutricia | Diasip | boca plast. 4x200 ml | 1,0034 | 4,01 | RSVS12a | 5% |
| V06DX03 451 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Fresubin Protein Energy Drink | boč. plast. 4x200 ml | 1,0459 | 4,18 | RSVO03a | 5% |
| V06DX03 452 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Diben drink | boč. plast. 4x200 ml | 0,9510 | 3,80 | RSVS13a | 5% |
| V06DX03 453 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Fresubin Energy Drink | boč. plast. 4x200 ml | 1,0459 | 4,18 | RSVO03a | 5% |
| V06DX03 454 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Supportan | boč. plast. 4x200 ml | 2,2430 | 8,97 | RSVS01a | 5% |
| V06DX03 455 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Frebini Energy Drink | plast. boč. 4x200 ml | 1,0794 | 4,32 | RSVP11 | 5% |
| V06DX03 456 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN 2 kcal fibre DRINK | boč. plast. 4x200 ml | 1,1719 | 4,69 | RSVO06a | 5% |
| V06DX03 457 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN 2 kcal DRINK | boč. plast. 4x200 ml | 1,1348 | 4,54 | RSVO05a | 5% |
| V06DX03 458 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN HEPA DRINK | boč. plast. 4x200 ml | 1,4321 | 5,73 | RSVS06a | 5% |
| V06DX03 460 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN RENAL | boč. plast. 4x200 ml | 2,0618 | 8,25 | RSVS07a | 5% |
| V06DX03 461 | DS | namirnice za enteralnu primjenu NV612 |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | ProvideXtra Drink | plast. boč. 4x200 ml | 1,7918 | 7,17 |  | 5% |
| V06DX03 462 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Frebini Energy fibre Drink | plast. boč. 4x200 ml | 1,0721 | 4,29 | RSVP11 | 5% |
| V06DX03 463 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN 2 kcal CREME | krema, plast. posudica 4x125 g | 1,6438 | 6,58 | RSVS15 | 5% |
| V06DX03 464 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | Fresubin DB Creme | krema, plast. posudica 4x125 g | 1,6438 | 6,58 | RSVS15 | 5% |
| V06DX03 465 |  | namirnice za enteralnu primjenu |  |  | O | Belupo d.d. | Belupo d.d. | Nutrixa | tetrapak 1x200 ml | 0,9742 | 0,97 | RSVO01a | 5% |
| V06DX03 467 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Plus Advance | boca 4x220 ml | 2,2696 | 9,08 | RSVS04a | 5% |
| V06DX03 469 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Milupa GmbH | FortiFit | limenka, prah 1x280 g | 15,8869 | 15,89 | RSVS04a | 5% |
| V06DX03 470 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Prosure | boca 4x220 ml | 2,2430 | 8,97 | RSVS01a | 5% |
| V06DX03 472 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi | FRESUBIN 3,2 kcal DRINK | boč. plast. 4x125 ml | 2,2696 | 9,08 | RSVS04a | 5% |
| V06DX03 473 |  | namirnice za enteralnu primjenu |  |  | O | Belupo d.d. | Immergut GmbH&Co.KG | Nutribel Complex | tetrapak 1x200 ml | 2,2430 | 2,24 | RSVS01a | 5% |
| V06DX03 474 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Compact | boca 4x125 ml | 1,1690 | 4,68 | RSVO07a | 5% |
| V06DX03 475 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle Health Science | Resource Senior Active/Resource Active | boca 4x200 ml | 2,2696 | 9,08 | RSVS04a | 5% |
| V06DX03 476 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle Clinical Nutrition France | Nestle Resource 2.0.+fibre | boč. 4x200 ml | 1,1719 | 4,69 | RSVO06a | 5% |
| V06DX03 478 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Even Sante Industrie | Nestle Resource Junior | boč. 4x200 ml | 1,0936 | 4,37 | RSVP11 | 5% |
| V06DX03 479 |  | namirnice za enteralnu primjenu |  |  | O | Oktal Pharma d.o.o. | Nestle Clinical Nutrition France | Nestle Resource 2.0. | boč. 4x200 ml | 1,1348 | 4,54 | RSVO05a | 5% |
| V06DX03 480 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Plus Advance RTH | spremnik plast. 1x500 ml | 5,1576 | 5,16 | RSVS04b | 5% |
| V06DX03 481 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Glucerna 1,5 kcal/500 ml | spremnik plast. 1x500 ml | 3,3552 | 3,36 | RSVS13b | 5% |
| V06DX03 483 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Jevity Plus HP | spremnik plast. 1x500 ml | 1,9908 | 1,99 | RSVO02b | 5% |
| V06DX03 484 |  | namirnice za enteralnu primjenu |  |  | O | Belupo d.d. | Belupo d.d. | Nutribel Diabet | tetrapak 1x200 ml | 1,0034 | 1,00 | RSVS12a | 5% |
| V06DX03 485 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutrison Advanced Cubison | vreć. plast./ kolapsibilna boca 1x1000 ml | 6,3826 | 6,38 | RSVS05b | 5% |
| V06DX03 486 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Cubitan | boca plast. 4x200 mL | 2,0585 | 8,23 | RSVS05a | 5% |
| V06DX03 487 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Abound | kutija 30x24 g | 2,0585 | 61,76 | RSVS05a | 5% |
| V06DX03 488 |  | namirnice za enteralnu primjenu |  |  | O | PROXIMUM d.o.o. | Biodue S.p.A. | PRONUTIM | vrećice, 30x20g | 2,2316 | 66,95 | RSVS04a | 5% |
| V06DX03 490 |  | namirnice za enteralnu primjenu |  |  | O | Fresenius Kabi d.o.o. | Fresenius Kabi Deutschland GmbH | Survimed OPD 1.5 kcal DRINK | plast. boč. 4x200 ml | 1,8382 | 7,35 | RSVS09a | 5% |
| V06DX03 491 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Plus | boca 4x220 ml | 1,1507 | 4,60 | RSVO03a | 5% |
| V06DX03 492 |  | namirnice za enteralnu primjenu |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutridrink Compact Protein | boca 4x125 ml | 2,1567 | 8,63 | RSVS04a | 5% |
| V06DX03 493 |  | namirnice za enteralnu primjenu |  |  | O | Abbott Laboratories d.o.o. | Abbott | Ensure Compact Protein HMB | boca 4x125 ml | 2,1561 | 8,62 | RSVS04a | 5% |
| V06DX03 494 | DS | namirnica za enteralnu primjenuNV613 |  |  | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutrison Protein Intense | kolapsibilna boca 1x500 ml | 8,3177 | 8,32 |  | 5% |

Osnovna lista lijekova s cijenama u eurima – 3. dio

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena u EUR za DDD (bez PDV-a) | Način primjene | Nositelj  odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena u EUR za jed. obl. (bez PDV-a) | Cijena u EUR za orig. pak. (bez PDV-a) | R/RS | Stopa PDV-a |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. |
| V20AA01 916 | RZ | sterilna gaza |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care sterilna gaza 1/4 m | 1 x 1/4 m | 0,1845 | 0,18 | RRZ01 | 5% |
| V20AA01 925 | RZ | sterilna gaza |  |  | L | Lohmann & Rauscher d.o.o. | Lohmann&Rauscher | Gaza Swab 1/2 m L&R | 1 x 1/2 m | 0,2442 | 0,24 | RRZ01 | 5% |
| V20AA01 926 | RZ | sterilna gaza |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care sterilna gaza 1/2 m | 1 x 1/2 m | 0,2442 | 0,24 | RRZ01 | 5% |
| V20AA01 935 | RZ | sterilna gaza |  |  | L | Lohmann & Rauscher d.o.o. | Lohmann&Rauscher | Gaza Swab 1/1 m L&R | 1 x 1 m | 0,4101 | 0,41 | RRZ01 | 5% |
| V20AA01 936 | RZ | sterilna gaza |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care sterilna gaza 1 m | 1 x 1 m | 0,4101 | 0,41 | RRZ01 | 5% |
| V20AA01 947 | RZ | sterilna gaza |  |  | L | InMEDIC d.o.o. | Tosama | Upojna gaza 1/4 m Tosama | 1 x 1/4 m | 0,1858 | 0,19 | RRZ01 | 5% |
| V20AA01 957 | RZ | sterilna gaza |  |  | L | InMEDIC d.o.o. | Tosama | Upojna gaza 1/2 m Tosama | 1 x 1/2 m | 0,2442 | 0,24 | RRZ01 | 5% |
| V20AA01 967 | RZ | sterilna gaza |  |  | L | InMEDIC d.o.o. | Tosama | Upojna gaza 1/1 m Tosama | 1 x 1 m | 0,4101 | 0,41 | RRZ01 | 5% |
| V20AB02 926 | RZ | komprese |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care Loli gauze komprese sterilne 5 cm x 8 cm, 16 sl a1 | 1 vr. (8 x 5) cm, 1 kom., 16 sl. | 0,0531 | 0,05 | RRZ01 | 5% |
| V20AB02 928 | RZ | komprese |  |  | L | Lola Ribar d.d. | Lola Ribar d.d. | Lola care Loli gauze komprese sterilne 5 cm x 8 cm, 16 sl a5 | 1 vr. (8 x 5) cm, 5 kom., 16 sl. | 0,0478 | 0,24 | RRZ01 | 5% |
| V20AB02 935 | RZ | komprese |  |  | L | Lohmann & Rauscher d.o.o. | Lohmann&Rauscher | Gazin | 1 vr. x (7,5 x 7,5) cm, 2 kom., 8 sl. | 0,0544 | 0,05 | RRZ01 | 5% |
| V20AB02 936 | RZ | komprese |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care Loli gauze komprese sterilne 7,5 cm x 7,5 cm, 8 sl a2 | 1 vr. x (7,5 x 7,5) cm, 2 kom., 8 sl. | 0,0544 | 0,05 | RRZ01 | 5% |
| V20AB02 945 | RZ | komprese |  |  | L | Lohmann & Rauscher d.o.o. | Lohmann&Rauscher | Gazin | 1 vr. x (10 x 10) cm, 2 kom., 8 sl. | 0,0995 | 0,10 | RRZ01 | 5% |
| V20AB02 946 | RZ | komprese |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care Loli gauze komprese sterilne 10 cm x 10 cm, 8 sl a2 | 1 vr. x (10 x 10) cm, 2 kom., 8 sl. | 0,0995 | 0,10 | RRZ01 | 5% |
| V20AD04 916 | RZ | mikropore |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care lolapora medicinska / kirurška traka 1,25 cm x 9,1 m | 1x (1,25 cm x 9,1 m) | 0,1845 | 0,18 | RRZ01 | 5% |
| V20AD04 917 | RZ | mikropore |  |  | L | InMEDIC d.o.o. | Tosama | Microtape | 1x (2,5 cm x 9,1m) | 0,3411 | 0,34 | RRZ01 | 5% |
| V20AD04 926 | RZ | mikropore |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care lolapora medicinska / kirurška traka 2,5 cm x 9,1 m | 1x (2,5 cm x 9,1m) | 0,3398 | 0,34 | RRZ01 | 5% |
| V20AD04 936 | RZ | mikropore |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola care lolapora medicinska / kirurška traka 5 cm x 9,1 m | 1x (5 cm x 9,1 m) | 0,6663 | 0,67 | RRZ01 | 5% |
| V20AD04 947 | RZ | mikropore |  |  | L | InMEDIC d.o.o. | Tosama | Microtape | 1x (5 cm x 9,1 m) | 0,6676 | 0,67 | RRZ01 | 5% |
| V20AD04 949 | RZ | mikropore |  |  | L | Lohmann & Rauscher d.o.o. | Jiangsu Nanfang Medical Co., Ltd. | Microporous Tape | 1x (1,25 cm x 9,15 m) | 0,1845 | 0,18 | RRZ01 | 5% |
| V20AD04 959 | RZ | mikropore |  |  | L | Lohmann & Rauscher d.o.o. | Jiangsu Nanfang Medical Co., Ltd. | Microporous Tape | 1x (2,5 cm x 9,15m) | 0,3424 | 0,34 | RRZ01 | 5% |
| V20AD04 969 | RZ | mikropore |  |  | L | Lohmann & Rauscher d.o.o. | Jiangsu Nanfang Medical Co., Ltd. | Microporous Tape | 1x (5 cm x 9,15 m) | 0,6676 | 0,67 | RRZ01 | 5% |
| V20AE05 916 | RZ | staničevina |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola celulozna vata 1 kg | 1 x 1 kg | 2,9199 | 2,92 | RRZ01 | 5% |
| V20AF06 916 | RZ | vata |  |  | L | Lola Ribar d.d. | Lola Ribar | Lola sensitive vata za osjetljivu kožu 50 g | 1 x 50 g | 0,4446 | 0,44 | RRZ01 | 5% |
| V20AF06 917 | RZ | vata |  |  | L | InMEDIC d.o.o. | Tosama | Cik cak vata Tosama | 1 x 50 g | 0,4446 | 0,44 | RRZ01 | 5% |

Osnovna lista lijekova s cijenama u eurima – 4. dio

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena u EUR za DDD (bez PDV-a) | Način primjene | Nositelj  odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena u EUR za jed. obl. (bez PDV-a) | Cijena u EUR za orig. pak. (bez PDV-a) | R/RS | Stopa PDV-a |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. |
| V07AC01 911 | DS | puna krv NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (525 ml) | 42,5045 | 42,50 |  | 0% |
| V07AC01 912 | DS | + puna krv za autolognu transfuzijuNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 69,2773 | 69,28 |  | 0% |
| V07AC03 912 | DS | puna krv sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (500 ml) | 72,3339 | 72,33 |  | 5% |
| V07AC04 913 | DS | svježe zamrznuta plazmaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (260 ml) | 24,5006 | 24,50 |  | 5% |
| V07AC04 915 | DS | Svježe zamrznuta plazma – COVID-19 kovalenscentna plazmaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 24,5006 | 24,50 |  | 5% |
| V07AC04 930 | DS | svježe zamrznuta plazma dobivena aferezom NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (480 ml) | 70,0776 | 70,08 |  | 5% |
| V07AC04 931 | DS | + svježe zamrznuta plazma – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 75,4622 | 75,46 |  | 5% |
| V07AC04 932 | DS | + svježe zamrznuta plazma dobivena aferezom – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 121,0392 | 121,04 |  | 5% |
| V07AC04 933 | DS | + svježe zamrznuta plazma dobivena aferezom sa smanjenim sadržajem krioprecipitataNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 100,2933 | 100,29 |  | 5% |
| V07AC04 934 | DS | + svježe zamrznuta plazma sa smanjenim brojem leukocita – filtrirana plazmaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 66,2406 | 66,24 |  | 5% |
| V07AC04 935 | DS | + svježe zamrznuta plazma za autolognu transfuzijuNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 56,8545 | 56,85 |  | 5% |
| V07AC04 936 | DS | + svježe zamrznuta plazma dobivena aferezom – COVID-19 kovalenscentna plazmaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 70,0776 | 70,08 |  | 5% |
| V07AC04 937 | DS | + svježe zamrznuta plazma sa smanjenim sadržajem krioprecipitataNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 54,7163 | 54,72 |  | 5% |
| V07AC06 915 | DS | koncentrat eritrocitaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 48,4996 | 48,50 |  | 5% |
| V07AC06 931 | DS | koncentrat eritrocita u hranjivoj otopiniNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 48,4996 | 48,50 |  | 5% |
| V07AC06 932 | DS | koncentrat eritrocita bez sloja leukocita i trombocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 48,4996 | 48,50 |  | 5% |
| V07AC06 933 | DS | koncentrat eritrocita bez sloja leukocita i trombocita, u hranjivoj otopiniNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 48,4996 | 48,50 |  | 5% |
| V07AC06 934 | DS | + koncentrat eritrocita bez sloja leukocita i trombocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 60,6185 | 60,62 |  | 5% |
| V07AC06 935 | DS | +koncentrat eritrocita za autolognu transfuzijuNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 74,2226 | 74,22 |  | 5% |
| V07AC07 916 | DS | koncentrat eritrocita sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (265 ml) | 76,2386 | 76,24 |  | 5% |
| V07AC07 934 | DS | koncentrat eritrocita sa smanjenim brojem leukocita, u hranjivoj otopini NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (265 ml) | 76,2386 | 76,24 |  | 5% |
| V07AC07 935 | DS | koncentrat eritocita sa smanjenim brojem leukocita, u hranjivoj otopini – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 88,3576 | 88,36 |  | 5% |
| V07AC07 936 | DS | + koncentrat eritrocita sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 88,3576 | 88,36 |  | 5% |
| V07AC08 917 | DS | koncentrat opranih eritrocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (280 ml) | 42,3651 | 42,37 |  | 5% |
| V07AC09 918 | DS | koncentrat opranih eritrocita sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (250 ml) | 72,3339 | 72,33 |  | 5% |
| V07AC09 919 | DS | + koncentrat opranih eritrocita sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 84,4529 | 84,45 |  | 5% |
| V07AC10 919 | DS | koncentrat eritrocita u plazmi NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (550 ml) | 57,6681 | 57,67 |  | 5% |
| V07AC10 920 | DS | + koncentrat eritrocita u plazmi sa smanjenim brijem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 125,8464 | 125,85 |  | 5% |
| V07AC10 921 | DS | + koncentrat eritrocita u plazmi sa smanjenim brojem leukocitaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 113,7275 | 113,73 |  | 5% |
| V07AC11 920 | DS | koncentrat trombocita dobiven trombaferezom NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 45,0421 | 45,04 |  | 5% |
| V07AC12 922 | DS | koncentrat trombocita dobiven tromboferezom, sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 64,4741 | 64,47 |  | 5% |
| V07AC12 923 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 81,1746 | 81,17 |  | 5% |
| V07AC12 924 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita u smanjenom volumenu plazme – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 82,2205 | 82,22 |  | 5% |
| V07AC12 925 | DS | + koncentrat opranih trombocita dobiven trombaferezom sa smanjenim brojem leukocita – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 86,8764 | 86,88 |  | 5% |
| V07AC12 926 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 66,4941 | 66,49 |  | 5% |
| V07AC12 927 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita u smanjenom volumenu plazme – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 67,5400 | 67,54 |  | 5% |
| V07AC12 928 | DS | + koncentrat opranih trombocita dobiven trombaferezom sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 72,1959 | 72,20 |  | 5% |
| V07AC12 929 | DS | + koncentrat trombocita dobiven trombaferezom sa smanjenim brojem leukocita u smanjenom volumenu plazmeNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 65,5199 | 65,52 |  | 5% |
| V07AC12 930 | DS | + koncentrat opranih trombocita sa smanjenim brojem leukocita – trombaferezaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 70,1772 | 70,18 |  | 5% |
| V07AC12 931 | DS | koncentrat trombocita dobiven tromboferezom u hranjivoj otopini sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 64,4741 | 64,47 |  | 5% |
| V07AC12 932 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 66,4941 | 66,49 |  | 5% |
| V07AC12 934 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 81,1746 | 81,17 |  | 5% |
| V07AC12 935 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita u smanjenom volumenu – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 67,5400 | 67,54 |  | 5% |
| V07AC12 936 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita u smanjenom volumenuNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 65,5199 | 65,52 |  | 5% |
| V07AC12 937 | DS | + koncentrat trombocita dobiven trombaferezom u hranjivoj otopini sa smanjenim brojem leukocita u smanjenom volumenu – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 81,1746 | 81,17 |  | 5% |
| V07AC13 923 | DS | koncentrat trombocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 29,6543 | 29,65 |  | 5% |
| V07AC13 935 | DS | koncentrat trombocita-više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 33,6160 | 33,62 |  | 5% |
| V07AC13 936 | DS | koncentrat trombocita iz sloja leukocita i trombocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 29,6543 | 29,65 |  | 5% |
| V07AC13 937 | DS | koncentrat trombocita iz sloja leukocita i trombocita-više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 33,6160 | 33,62 |  | 5% |
| V07AC13 938 | DS | + koncentrat trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza u smanjenom volumenu plazme – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 68,5301 | 68,53 |  | 5% |
| V07AC13 939 | DS | +koncentrat trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza u smanjenom volumenu plazme – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 46,5101 | 46,51 |  | 5% |
| V07AC13 940 | DS | + koncentrat trombocita u smanjenom volumenu plazme – 1 dozaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 35,9320 | 35,93 |  | 5% |
| V07AC13 941 | DS | + koncentrat trombocita u smanjenom volumenu plazme – više dozaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 35,9347 | 35,93 |  | 5% |
| V07AC13 942 | DS | + koncentrat trombocita sa smanjenim brojem leukocita u smanjenom volumenu plazme – više davateljaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 43,4800 | 43,48 |  | 5% |
| V07AC13 943 | DS | +koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita pool više doza u smanjenom volumenu – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 46,5101 | 46,51 |  | 5% |
| V07AC13 944 | DS | + koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita, pool više doza u smanjenom volumenu NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 43,4800 | 43,48 |  | 5% |
| V07AC14 925 | DS | koncentrat trombocita sa smanjenim brojem leukocita više davatelja NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 41,9099 | 41,91 |  | 5% |
| V07AC14 938 | DS | koncentrat trombocita sa smanjenim brojem leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 75,0375 | 75,04 |  | 5% |
| V07AC14 940 | DS | + koncentrat trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 66,9600 | 66,96 |  | 5% |
| V07AC14 941 | DS | + koncentrat opranih trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 75,5140 | 75,51 |  | 5% |
| V07AC14 942 | DS | + koncentrat trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više davatelja – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 54,0288 | 54,03 |  | 5% |
| V07AC14 943 | DS | + koncentrat opranih trombocita iz sloja leukocita i trombocita sa smanjenim brojem leukocita pool više doza – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 59,0179 | 59,02 |  | 5% |
| V07AC14 944 | DS | + koncentrat opranih trombocita sa smanjenim brojem leukocita – više dozaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 50,4639 | 50,46 |  | 5% |
| V07AC14 945 | DS | koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita, pool više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 41,9099 | 41,91 |  | 5% |
| V07AC14 946 | DS | + koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita pool više doza – inaktivacija patogena NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 66,9600 | 66,96 |  | 5% |
| V07AC14 947 | DS | + koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita pool više davatelja – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 54,0288 | 54,03 |  | 5% |
| V07AC14 948 | DS | + koncentrat trombocita iz sloja leukocita i trombocita u hranjivoj otopini sa smanjenim brojem leukocita pool više doza u smanjenom volumenu – inaktivacija patogenaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 66,9600 | 66,96 |  | 5% |
| V07AC15 926 | DS | koncentrat leukocita dobiven leukoforezom NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 45,0421 | 45,04 |  | 5% |
| V07AC16 927 | DS | koncentrat leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 29,6543 | 29,65 |  | 5% |
| V07AC16 939 | DS | koncentrat leukocitia-više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 33,6160 | 33,62 |  | 5% |
| V07AC16 940 | DS | koncentrat trombocita i leukocita NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 29,6543 | 29,65 |  | 5% |
| V07AC16 941 | DS | koncentrat trombocita i leukocita-više doza NV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 33,6160 | 33,62 |  | 5% |
| V07AC16 942 | DS | + koncentrat leukocita i trombocita pool više doza – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 45,7350 | 45,73 |  | 5% |
| V07AC16 943 | DS | + koncentrat leukocita i trombocita – ozračenNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza | 41,7732 | 41,77 |  | 5% |
| V07AC17 928 | DS | krioprecipitat univerzalni-deset dozaNV701 |  |  | P | Hrvatski zavod za transfuzijsku medicinu | Hrvatski zavod za transf. med. |  | doza (200 ml) | 333,8297 | 333,83 |  | 5% |
| V07AC17 929 | DS | krioprecipitat liofiliziran iz 1500 ml plazme NV701 |  |  | P | Imunološki zavod d.d. | Imunološki zavod | Krioprecipitat | boč. 1x50 ml (550-650 i.j F-VIII) s priborom za infuziju | 143,3406 | 143,34 |  | 5% |

Legenda

|  |  |
| --- | --- |
| Oznake skraćenica: | |
| g | gram |
| mg | miligram |
| mcg | mikrogram |
| UI (i.j.) | internacionalna jedinica |
| TUI (Ti.j.) | tisuću internacionalnih jedinica |
| MUI (Mi.j.) | milijun internacionalnih jedinica |
| mmol | milimol |
| ml | mililitar |
| l | litra |
|  |  |
| Oznaka ograničenja primjene lijeka: | |
| KL | Lijekovi koji se primjenjuju samo u visoko specijaliziranim zdravstvenim ustanovama (klinikama). |
| KS | Lijekovi koji se mogu u nastavku obrade i liječenja u klinici primjenjivati u drugim stacionarnim zdravstvenim ustanovama. |
| DS | Lijekovi koji se primjenjuju u drugim stacionarnim ustanovama. |
| PR | Lijekovi koji se mogu primjenjivati i na razini primarne zdravstvene zaštite. |
| PO | Lijekovi koji se mogu upotrebljavati na razini primarne zdravstvene zaštite i koji se mogu posebice obračunavati Hrvatskom zavodu za zdravstveno osiguranje. |
| RL | Izdaje se isključivo na ruke liječnika. |
| XX | Izdaje se na ruke liječnika ovisno o indikaciji. |
| RZ | Isključivo za zavojni materijal koji se može propisati na recept Zavoda za potrebe kućnog liječenja i zdravstvene njege u kući osigurane osobe. |
| DSPO | Lijekovi koji se primjenjuju u drugim stacionarnim ustanovama, a koji se mogu upotrebljavati i na razini primarne zdravstvene zaštite i koji se mogu posebice obračunavati Hrvatskom zavodu za zdravstveno osiguranje |
| DSPR | Lijekovi koji se primjenjuju u drugim stacionarnim ustanovama, a koji se mogu upotrebljavati i na razini primarne zdravstvene zaštite. |
|  |  |
| Oznaka načina primjene lijeka: | |
| O | oralno |
| P | parenteralno |
| R | rektalno |
| N | nazalno |
| L | lokalno |
| SL | sublingvalno |
| TD | transdermalno |
| V | vaginalno |
| I | inhalacija |
|  |  |
| Oznaka izdavanja lijeka: | |
| R | izdavanje na recept |
| RS | izdavanje na recept po preporuci specijalista |
| RSf | izdavanje pripravaka za potrebe liječenja fenilketonurije, po preporuci bolničkog specijalista |

Indikacije i smjernice

|  |  |
| --- | --- |
| Oznaka indikacije | Indikacija |
| mv601 | Za bolesnike s fenilketonurijom. |
| NA101 | Stomatitis stupnja III i IV uzrokovan sistemnom ili lokalnom onkološkom terapijom. |
| NA201 | Samo u jedinicama intenzivnog liječenja te u jedinicama koje zbrinjavaju akutna krvarenja iz gornjeg gastrointestinalnog sustava, u uvjetima akutnog krvarenja iz ulkusa i erozija gornjeg probavnog sustava kada nije moguća oralna primjena. |
| NA401 | Samo za suzbijanje povraćanja uzrokovanog emetogenim lijekovima (citostaticima). |
| NA402 | Samo za suzbijanje povraćanja uzrokovanog visokoemetogenom kemoterapijom. |
| NA501 | Za liječenje hiperamonijemije uzrokovane primarnom deficijencijom N-acetilglutamat sintaze (NAGS), izovaleričnom acidemijom (IVA), metilmaloničnom acidemijom (MMA) ili propionskom acidemijom (PA). Uz laboratorijski potvrđenu hiperamonijemu, uzročna bolest mora biti potvrđena na temelju kliničke slike i odgovarajućih laboratorijskih nalaza. Početak liječenja i nastavak liječenja za razdoblje od 6 mjeseci odobrava Bolničko povjerenstvo za lijekove na prijedlog bolničkog specijaliste pedijatra iz ugovorne bolničke zdravstvene ustanove. Učinak liječenja se procjenjuje najmanje svaka 3 mjeseca. Liječenje se može nastaviti ako je došlo do laboratorijski potvrđene metaboličke stabilizacije bolesti te do značajnog smanjenja broja i intenziteta hiperamonijemijskih kriza. Liječenje se prekida ako je došlo do teških i ireverzibilnih multiorganskih oštećenja. |
| NA700 | Kod rekurirajućeg kolitisa uzrokovanog Clostridium difficile (više od 2 recidiva) kod kojeg je prethodno provedena terapija peroralnim metronidazolom i/ili peroralnim vankomicinom. Propisuje se kao rezervni antibiotik. |
| NA901 | Samo za kongenitalnu kolestazu u djece. |
| NA903 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika kojima je potvrđena dijagnoza Gaucherove bolesti. Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA904 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika kojima je potvrđena dijagnoza Fabry-eve bolesti. Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA905 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika kojima je potvrđena dijagnoza nasljedne tirozinemije tip I. Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA906 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika kojima je potvrđena dijagnoza mukopolisaharidoze tipa I. Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA907 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika kojima je potvrđena dijagnoza Pompeove bolesti. Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA908 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika kojima je potvrđena dijagnoza mukopolisaharidoze tipa VI (Maroteaux-Lamy sindrom). Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA909 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika kojima je potvrđena dijagnoza mukopolisaharidoze tipa II (Hunterov sindrom). Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA910 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika kojima je potvrđena dijagnoza Gaucherove bolesti tipa 1 koji su spori metabolizatori (SM), intermedijarni metabolizatori (IM) ili ekstenzivni metabolizatori (EM) CYP2D6. Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA911 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika odraslih i adolescenata u dobi od 16 godina i starijih kojima je potvrđena dijagnoza Fabryeve bolesti (nedostatak alfa-galaktozidaze A) koji imaju određene genske mutacije koje omogućuju odgovor na liječenje. Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA912 | Za liječenje šećerne bolesti u odraslih, adolescenata i djece u dobi od jedne i više godina. |
| NA913 | Za dugotrajno liječenje (enzimska nadomjesna terapija) kod bolesnika kojima je potvrđena dijagnoza mukopolisaharidoze tip IV (Morquio A sindrom). Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NA914 | 1. Za liječenje djece sa sindromom kratkog crijeva od navršene 1 godine po preporuci specijalista pedijatra. Procjena učinka liječenja i prekidanje liječenja – preporučuje se liječenje u trajanju od 12 tjedana, a nakon toga je potrebno procijeniti učinak liječenja. Ukoliko klinički učinak u smislu povišenja enteralnog unosa i/ili smanjenja parenteralnog izostane, potrebno je razmotriti primjenu daljnje terapije. Započinjanje liječenja moguće je samo u Klinici za dječje bolesti Zagreb – u Referentnom centru Ministarstva zdravstva Republike Hrvatske za dječju gastroenterologiju i poremećaje prehrane. 2. Za liječenje odraslih sa sindromom kratkog crijeva koji su stabilni nakon razdoblja adaptacije crijeva poslije operacije, po poreporuci specijalista gastroenterologa. Procjena učinka terapije treba biti učinjena nakon 6 mjeseci te ponovno nakon 12 mjeseci od započinjanja liječenja. Nastavak liječenja nakon 12 mjeseci moguć je isključivo ukoliko je postignuta poboljšana adaptacija crijevne sluznice na način da je smanjena potreba za parenteralnom prehranom (PP redukcija volumena ≥ 20% bazalnog PP\* volumena) ili je ona potpuno ukinuta. Započinjanje terapije moguće je samo u Klinici za unutarnje bolesti KBC Zagreb, Zavodu za gastroenterologiju, Jedinica za liječenje kroničnog intestinalnog zatajenja. \*PP= parenteralna prehrana. |
| NA915 | Za dugotrajnu enzimsku nadomjesnu terapiju u bolesnika s potvrđenom dijagnozom neuronalne ceroidne lipofuscinoze tipa 2 (CLN2), bolesti poznate i kao nedostatak tripeptidil-peptidaze 1 (TPP1) – Battenova bolest. Kriteriji za početak primjene lijeka – a) Prije početka liječenja, bolesnik mora imati potvrđenu dijagnozu CLN2 na temelju kliničkih pokazatelja i snižene enzimatske aktivnosti enzima tripeptidil-peptidaze 1 (TPP1), a dijagnozu je tijekom liječenja potrebno dodatno potvrditi genskim testiranjem, odnosno mutacijom CLN2 gena. b) Bolesnik ne smije bolovati od drugih progresivno životno ugrožavajućih bolesti. c) Prije početka liječenja, bolesnik mora imati klinički stupanj bolesti veći ili jednak 2 boda prema CLN2 ljestvici kliničke procjene motoričke (M) i govorne (G) domene-M/G. Početak i nastavak liječenja odobrava svakih 6 mjeseci Bolničko povjerenstvo za lijekove KBC Rijeka, gdje se liječenje i provodi, temeljem preporuke Referentnog centra Ministarstva zdravstva Republike Hrvatske za epilepsije i konvulzivne bolesti razvojne dobi, Klinike za pedijatriju, KBC Rijeka. Prva reevaluacija primjene se provodi nakon prvih 18 mjeseci primjene lijeka, a potom se svaka sljedeća reevaluacija provodi nakon završene 12-mjesečne primjene lijeka. Svaka procjena progresije odnosno zaustavljanja progresije bolesti provodi se bodovanjem prema CLN2 ljestvici kliničke procjene motoričke (M) i govorne (G) domene-M/G u odnosu na početne vrijednosti prije i nakon započinjanja terapije. Kriteriji za prekid liječenja – a) Bolesnik ne surađuje u svezi potrebe primjene kontinuirane terapije (nesuradljivost se definira kao najviše dva izostanka za primjenu i/ili procjenu u bilo kojem 12 mjesečnom razdoblju, isključujući medicinske razloge za propuštene doze). b) Bolesnik ne podnosi intracerebroventrikularne infuzije zbog nuspojava (ozbiljnih štetnih događaja povezanih s infuzijom) ili drugih kliničkih problema koji se ne mogu otkloniti. c) Bolesniku se tijekom liječenja i primjene ovog lijeka dijagnosticira dodatna progresivna bolest ili stanje koje mu ograničava život. d) Liječenje se prekida zbog neučinkovitosti kod bolesnika koji su započeli liječenje u dobi od 3 ili više godina ako je utvrđen gubitak za više od dva boda (tj. 3 ili više bodova) prema CNL2 kliničkoj M/G ljestvici u odnosu na početne vrijednosti tijekom prvih 18 mjeseci liječenja, a koje perzistira tijekom minimalno 3 infuzije (tj. i nakon 6 tjedana). (U slučaju privremene bolesti, bolesnike treba ponovno testirati 2x u roku od 12 tjedana kako bi se osiguralo da gubitak na ljestvici nije posljedica privremene i prolazne bolesti). e) Kod bolesnika koji se već liječe (i oni koji se liječe duže od 18 mjeseci), liječenje se prekida zbog neučinkovitosti ako je utvrđen gubitak za više od jednog boda (tj. 2 ili više bodova) prema CNL2 kliničkoj M/G ljestvici u odnosu na procjenu u prethodnom dvanaestomjesečnom razdoblju liječenja, a koje perzistira tijekom minimalno 3 infuzije (tj. i nakon 6 tjedana). f) Liječenje se prekida ukoliko se utvrdi napredovanje bolesti do ireverzibilne procjene 0 prema CLN2 kliničkoj M/G ljestvici. Pacijenti s ocjenom 0 trebaju se ponovno procijeniti 2x u roku od 12 tjedana kako bi se osiguralo da pad nije posljedica privremene bolesti. |
| NB101 | Samo kod izmjerenog manjka (manje od 70% antitrombina III), po preporuci specijalista hematologa ili transfuziologa. |
| NB102 | 1. Prije i poslijeoperacijska profilaksa tromboembolije u visokorizičnih bolesnika u općoj kirurgiji te kod operacije kuka i totalne zamjene koljena u ortopediji (svi niskomolekularni heparini), 2. Liječenje tromboembolijskih incidenata i prevencija zgrušavanja tijekom hemodijalize (nadroparin, dalteparin i enoksaparin), 3. Liječenje nestabilne angine pektoris i ne-Q infarkta miokarda (enoksaparin, dalteparin i nadroparin), 4. PO Za ambulantne bolesnike kojima je postavljena dijagnoza tromboze potkoljeničnih dubokih vena, a nisu hospitalizirani, s najdužom primjenom do sedam dana. Istovremeno s primjenom niskomolekularnih heparina započeti s primjenom peroralnih antikoagulantnih lijekova. |
| NB103 | Za bolesnike poslije ugradnje premosnice ili stenta, po preporuci bolničkog specijalista. |
| NB104 | Za postavljanje dijagnoze koronarne bolesti. |
| NB105 | Za liječenje bolesnika s primarnom plućnom hipertenzijom u kojih postoji insuficijencija srca stupnja III prema NYHA/WHO klasifikaciji, a koji više ne reagiraju na dotadašnju terapiju, koja je uključivala blokatore kalcijevih kanala i sildenafil. Obavezno se primjenjuje u kombinaciji sa sildenafilom. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NB106 | Za bolesnike nakon dilatacije i uvođenja stenta. |
| NB107 | Za liječenje akutnog ishemijskog moždanog udara ako su zadovoljeni propisani kriteriji (indikacije i kontraindikacije prema preporukama) i ukoliko se liječenje započne unutar tri sata od nastupa simptoma moždanog udara i nakon prethodnog isključivanja intrakranijalnog krvarenja odgovarajućim dijagnostičkim tehnikama. |
| NB108 | Prije i poslijeoperacijska profilaksa tromboembolije u visokorizičnih bolesnika kod operacije kuka i totalne zamjene koljena u ortopediji. |
| NB109 | 1. Liječenje nestabilne angine pektoris ili infarkta miokarda bez elevacije ST-segmenta (UA/NSTEMI) u bolesnika u kojih nije indicirano hitno (<120 minuta) invazivno liječenje perkutanom koronarnom intervencijom, 2. Liječenje infarkta miokarda s elevacijom ST-segmenta (STEMI) u bolesnika koji se liječe tromboliticima ili u onih koji u početku neće primati nijedan drugi oblik reperfuzijskog liječenja, 3. Prije i poslijeoperacijska profilaksa tromboembolije u visokorizičnih bolesnika kod operacije kuka i totalne zamjene koljena u ortopediji te kod abdominalnih kirurških zahvata. |
| NB201 | Za liječenje bolesnika s hemofilijom A i B, s von Willenbrandovom bolesti i bolesnika s drugim nasljednim koagulopatijama. |
| NB202 | Samo kirurška indikacija kao antifibrinolitik, ne za akutni pankreatitis. |
| NB203 | Za bolničko liječenje po preporuci specijalista hematologa. |
| NB204 | 1. Za bolničko liječenje po preporuci specijalista hematologa. 2. Za kućno liječenje kroničnih bolesnika liječenje odobrava Zavod na prijedlog Centra za hemofiliju i uz suglasnost Bolničkog povjerenstva za lijekove KBC Zagreb. |
| NB205 | Hemofilija HBV i HCV negativna, 1. Za bolničko liječenje po preporuci specijalista hematologa. 2. Za kućno liječenje kroničnih bolesnika liječenje odobrava Zavod na prijedlog Centra za hemofiliju i Klinike za pedijatriju Zavoda za hematologiju uz suglasnost Bolničkog povjerenstva za lijekove KBC Zagreb. |
| NB206 | 1. Za bolničko liječenje oboljelih od von Willebrandove bolesti po preporuci specijalista hematologa. 2. Za kućno liječenje kroničnih bolesnika liječenje odobrava Zavod na prijedlog Centra za hemofiliju i uz suglasnost Bolničkog povjerenstva za lijekove KBC Zagreb. |
| NB207 | Liječenje i profilaksa krvarenja u bolesnika s hemofilijom A koji imaju 12 i više godina. Hemofilija HBV i HCV negativna, 1. Za bolničko liječenje po preporuci specijalista hematologa. 2. Za kućno liječenje kroničnih bolesnika liječenje odobrava Zavod na prijedlog Centra za hemofiliju i Klinike za pedijatriju Zavoda za hematologiju uz suglasnost Bolničkog povjerenstva za lijekove KBC Zagreb. |
| NB301 | 1. Primjenjuje se u svim centrima gdje se provodi dijaliza za bubrežnu anemiju s hemoglobinom nižim od 90 g/L za početak terapije, a za održavanje 110g/L, 2. Oznaka PO samo za bolesnike na peritonejskoj dijalizi. |
| NB400 | Za parenteralnu prehranu odraslih i djece starije od 2 godine kod kojih oralna ili enteralna prehrana nije moguća, nije dovoljna ili je kontraindicirana, tijekom kataboličke faze kritičnog stanja (od 2. do 5. dana u jedinicama intenzivnog liječenja). |
| NB501 | Nadoknada volumena, druga linija terapije (kada je primjena artificijelnih koloida kontraindicirana ili kada je postignuta maksimalna doza za koloide), opekline, hiperbilirubinemija u neonatusa i terapijska izmjena plazme. |
| NB502 | Hipoalbuminemija <20 g/L uz generalizirane edeme. |
| NB504 | Za liječenje odraslih splenektomiranih bolesnika s kroničnom imunom (idiopatskom) trombocitopeničnom purpurom (ITP), koji ne reagiraju na uobičajenu terapiju (primjerice – kortikosteroide, imunoglobuline), kao i u drugoj liniji liječenja odraslih nesplenektomiranih bolesnika kod kojih je splenektomija kontraindicirana. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista internista hematologa. |
| NB506 | 1. Prije i poslijeoperacijska profilaksa tromboembolije u visokorizičnih bolesnika u općoj kirurgiji te kod operacije kuka i totalne zamjene koljena u ortopediji (svi niskomolekularni heparini), 2. Liječenje tromboembolijskih incidenata i prevencija zgrušavanja tijekom hemodijalize (nadroparin, dalteparin i enoksaparin), 3. Liječenje nestabilne angine pektoris i ne-Q infarkta miokarda (enoksaparin, dalteparin i nadroparin), 4. Za profilaksu venske tromboembolijske bolesti u trajanju do 4 tjedna kod umjerenorizičnih i visokorizičnih bolesnika koji se podvrgavaju onkološkom kirurškom zahvatu gastrointestinalnih i genitourinarnih tumora, 5. PO Za ambulantne bolesnike kojima je postavljena dijagnoza tromboze potkoljeničnih dubokih vena, a nisu hospitalizirani, s najdužom primjenom do sedam dana. Istovremeno s primjenom niskomolekularnih heparina započeti s primjenom peroralnih antikoagulantnih lijekova. |
| NB507 | Za kućno liječenje kroničnih bolesnika s hemofilijom A i inhibitorima faktora VIII. Liječenje odobrava Zavod na prijedlog Centra za hemofiliju i uz suglasnost Bolničkog povjerenstva za lijekove KBC Zagreb. |
| NB509 | Za liječenje akutnih napada angioedema u odraslih bolesnika, adolescenata i djece od navršene 2. godine, s nasljednim angioedemom (HAE) zbog nedostatka inhibitora C1 esteraze, po preporuci specijalista. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NB510 | Za kućno liječenje kroničnih bolesnika s teškom hemofilijom A bez inhibitora faktora VIII. Liječenje odobrava Zavod na prijedlog Centra za hemofiliju i uz suglasnost Bolničkog povjerenstva za lijekove KBC Zagreb. |
| NC101 | Za hipotenziju tijekom epiduralne i subduralne anestezije. |
| NC102 | Samo za bolesnike s akutnim srčanim zatajenjem koji nisu hipotenzivni (sistolički arterijski tlak >= 100 mm Hg), u kojih se ne može postići dovoljan terapijski učinak primjenom adekvatnih doza diuretika i vazodilatatora i za bolesnike s kontraindikacijom za primjenu beta-1 agonista, a uz to imaju hemodinamske kriterije LOS-a (CI<1,7 L/min/m2, PCWP>20 mmHg), u jedinicama intenzivnog liječenja. Trajanje liječenja najviše do 24 sata. |
| NC103 | Samo za održavanje prohodnosti Ductus Botalli u novorođenčadi s urođenom srčanom greškom prije operacije. |
| NC201 | Za liječenje bolesnika s primarnom plućnom hipertenzijom u kojih postoji insuficijencija srca stupnja III prema NYHA/WHO klasifikaciji, a koji više ne reagiraju na dotadašnju terapiju koja je uključivala blokatore kalcijevih kanala i sildenafil. Liječenje se provodi u bolnici na temelju odobrenja Bolničkog Povjerenstva za lijekove. |
| NC801 | Samo za liječenje bolesnika sa subarahnoidalnim krvarenjem. |
| NC991 | Samo za izrazito refrakternu hipertenziju, po preporuci specijalista internista. |
| ND991 | Za bolesnike na PUVA terapiji. |
| NG201 | Za odgađanje prijetećeg prijevremenog poroda u rizičnih skupina trudnica koje boluju od šećerne bolesti, kardiovaskularnih bolesti i bolesti štitnjače. |
| NG301 | Terapija menoragije, preobilna menstrualna krvarenja u više uzastopnih ciklusa u žena starijih od 35 godina. Odobrava se 1 puta u 5 godina. |
| NG302 | Samo za bolesnike s kliničkim simptomima muškog hipogonadizma kod kojih je izmjeren manjak testosterona u krvi (koncentracija ukupnog testosterona manja od 12 nmol/L), po preporuci specijalista endokrinologa ili pedijatra. |
| NG303 | Po preporuci specijalista ginekologa ili endokrinologa. |
| NG304 | Do šest pokušaja stimulacije, a nakon svakog poroda ostvaruje se pravo na dodatnih 6 pokušaja. |
| NG305 | Stimuliranje razvoja folikula u odraslih žena s teškim nedostatkom LH i FSH. Do šest pokušaja stimulacije, a nakon svakog poroda ostvaruje se pravo na dodatnih 6 pokušaja. |
| NG306 | Poticanje zrenja cerviksa u trudnica koje su iznijele trudnoću do termina (nakon 37. tjedna trudnoće). |
| NG307 | Za poticanje porođaja. |
| NG401 | Za liječenje bolesnika s uznapredovalom plućnom hipertenzijom u kojih postoji insuficijencija srca stupnja III prema NYHA/WHO klasifikaciji, a koji više ne reagiraju na dotadašnju terapiju koja je uključivala blokatore kalcijevih kanala, po preporuci specijalista pulmologa. |
| NH101 | 1. U bolesnika kod kojih se endogenom stimulacijom ne može postići zadovoljavajući nivo TSH čiji je porast potreban za dijagnostiku i terapiju pomoću J-131, te određivanje tumorskog biljega tireoglobulina u serumu – 2. U bolesnika kod kojih ukidanje hormonske supresijske terapije tiroksinom može izazvati teže komplikacije i na taj način ugroziti život bolesnika – 3. U bolesnika kod kojih ukidanje hormonske supresijske terapije tiroksinom može uzrokovati kompresiju zbog pritiska metastaza tumora na vitalne strukture. Liječenje indicira specijalist nuklearne medicine, a provodi se u kliničkim zavodima ili klinikama za nuklearnu medicinu. |
| NH104 | Karcinoid i endokrini tumori ili za krvarenja iz gornjeg dijela probavnog trakta, koja ne reagiraju na endoskopsku hemostazu. |
| NH105 | 1. Za neuroendokrine tumore, po preporuci bolničkog specijalista, 2. Za akromegaliju, po preporuci bolničkog specijalista internista endokrinologa. |
| NH106 | Za krvarenja iz gornjeg dijela probavnog trakta, koja nisu adekvatno kontrolirana dostupnim endoskopskim tehnikama hemostaze. |
| NH502 | Liječenje sekundarnog hiperparatireoidizma u bolesnika s kroničnim zatajenjem bubrega na intermitentnoj dijalizi. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NH503 | Samo za liječenje sekundarog hiperparatireoidizma u bolesnika na hemodijalizi. |
| NH504 | Za liječenje sekundarnog hiperparatireoidizma (SHPT) u odraslih bolesnika s kroničnom bubrežnom bolesti na terapiji hemodijalizom. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijalista nefrologa bolničke zdravstvene ustanove koja provodi hemodijalizu. Liječenje se može provoditi i u dijaliznim središtima. |
| NH505 | 1. Poremećaj u rastu niske djece rođene premale za gestacijsku dob (SGA), tjelesne težine i/ili dužine ispod -2 SD, koja zaostajanje u rastu nisu nadoknadila do dobi od 4 godine ili kasnije, a po preporuci pedijatra endokrinologa, 2. Za liječenje Prader-Willi sindroma. Liječenje pod točkom 1. i 2. odobrava se iz sredstava bolničkog proračuna. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NH506 | Poremećaj u rastu niske djece rođene premale za gestacijsku dob (SGA), tjelesne težine i/ili dužine ispod -2 SD, koja zaostajanje u rastu nisu nadoknadila do dobi od 4 godine ili kasnije, a po preporuci pedijatra endokrinologa, Liječenje se odobrava iz sredstava bolničkog proračuna. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NH507 | Za liječenje bolesnika s akromegalijom – 1. Ako remisija bolesti nije postignuta nakon kirurškog liječenja i primjene lijeka prve linije farmakoterapije (analog somatostatina prve generacije). 2. Ako je kirurški zahvat kontraindiciran, a uz primjenu lijeka prve linije farmakoterapije (analog somatostatina prve generacije) nije postignuta remisija bolesti. 3. Ako je primjena lijeka prve linije farmakoterapije (analog somatostatina prve generacije) izazvala nuspojave koje su zahtijevale prekid liječenja. |
| NJ101 | Samo kao rezervni antibiotik. |
| NJ102 | Druga linija liječenja infekcija respiratornog i genitourinarnog sustava te kože i mekih tkiva izazvane uzročnicima koji ne reagiraju na polusintetske peniciline (E.coli, H. influenzae, Proteus). |
| NJ103 | Atipična pneumonija i urogenitalne infekcije s Chlamydia trachomatis ili N. gonorrhoeae u bolesnika koji zahtijevaju inicijalno parenteralno liječenje. |
| NJ104 | Kronična plućna infekcija uzrokovana s Pseudomonas aeruginosa u bolesnika s cističnom fibrozom u dobi od 6 godina i starijih, po preporuci specijalista pedijatra ili pulmologa. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ105 | Isključivo kod bolesnika koji ne mogu uzimati lijek na usta i dokazane infekcije osjetljivim uzročnicima. |
| NJ106 | Samo kao rezervni antibiotik u slučaju nepodnošenja ili rezistencije na glikopeptide. |
| NJ107 | Samo kao rezervni antibiotik, za liječenje bolesnika s dokazanim multiplorezistentnim uzročnicima kada primjena drugih antibiotika nije moguća niti opravdana. |
| NJ108 | Rezervni antibiotik kao terapija spašavanja u liječenju teških infekcija uzrokovanih rezistentnim gram-pozitivnim bakterijama (MRSA, penicilin rezistentni pneumokoki), nakon neuspjeha liječenja vankomicinom, teikoplaninom i/ili linezolidom. |
| NJ110 | Samo kao rezervni antibiotik. PO jednokratna profilaksa kod meningokokne sepse prema Provedbenom Programu imunizacije, seroprofilakse i kemoprofilakse za posebne skupine stanovništva i pojedince. |
| NJ111 | Rezervni antibiotik za liječenje teških bolničkih infekcija uzrokovanih gram-negativnim bakterijama koje produciraju beta-laktamaze (KPC, ESBL-producirajuće bakterije, PDC) i koje su rezistentne na sve druge antibiotike. Liječenje odobrava Bolničko povjerenstvo za lijekove po uvidu u antibiogram izolata. |
| NJ201 | Za sustavne gljivične infekcije u imunokompromitiranih bolesnika u stacionarnim ustanovama. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ202 | Za liječenje refraktornih invazivnih gljivičnih infekcija te profilaksu invazivnih gljivičnih infekcija u bolesnika s AML/MDS i u bolesnika s GVHD nakon transplantacije alogenih matičnih stanica. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ401 | Za rezistentnu TBC. |
| NJ501 | Za liječenje oboljelih od HIV-infekcija. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ503 | Indikacije za primjenu – 1. Kronični B hepatitis, HBsAg poz (bez obzira na HBeAg status), uz slijedeće kriterije – HBV DNA veći od 2000 IU/ml (10000 kopija/ml seruma), povišene vrijednosti ALT u dva uzastopna mjerenja – uz dokaz histološke aktivnosti fibroza >= od F2 ( po Ishak Knodellovom indexu) ili vrijednosti fibroelastografskog mjerenja (fibroscan) više od 8 kPa. Bolesnici s viremijom manjom od 2000 IU/ml i normalnim vrijednostima ALT liječe se ukoliko imaju histološki ili fibroelastografski pokazatelj uznapredovale fibroze (F >= od 4, odnosno fibroscan veći od 14 kPa). Terapija uključuje i bolesnike s dekompenziranom cirozom i transplantiranom jetrom. Terapija se provodi u dozi od 100 mg dnevno, do nastanka konverzije HBsAg u anti HBs ili do pojave rezistencije na lijek (povišenje viremije nakon prethodnog dobrog učinka). Učinak terapije procjenjuje se svakih 6 mjeseci određivanjem HBV DNA u serumu te HBV markera 1x godišnje. Terapiju odobrava Bolničko povjerenstvo uz reevaluaciju 1x godišnje. 2. Akutni fulminantni hepatitis B. Terapija se provodi u dozi od 100 mg dnevno još tri mjeseca nakon postignute HBsAg serokonverzije. 3. Prevencija vertikalne transmisije. Terapija se provodi u dozi od 100 mg dnevno u zadnjem trimestru trudnoće ako je viremija veća od 106 kopija/ml, te 3 mjeseca nakon poroda, a tada slijedi evaluacija kronične bolesti trudnice. 4. Prevencija reaktivacije bolesti u HBsAg pozitivnih bolesnika na imunosupresivnoj ili antitumorskoj terapiji. Terapija se započinje 2 tjedna prije planiranog liječenja osnovne bolesti u dozi od 100 mg dnevno, te nastavlja najmanje 12 mjeseci po prekidu, ili duže ako je riječ o aktivnosti hepatitisa B. Kod HBsAg negativnih, a anti HBc pozitivnih bolesnika terapije se započinje ako imaju mjerljivu HBV DNA u serumu. |
| NJ504 | Indikacije za primjenu – 1. Kronični B hepatitis, HBsAg poz (bez obzira na HBeAg status), uz HBV DNA veći od 2000 IU/ml (10000 kopija/ml seruma), povišene vrijednosti ALT u dva uzastopna mjerenja te dokaz histološke aktivnosti – fibroza >= od F2 ( po Ishak Knodellovom indexu) ili vrijednosti fibroelastografskog mjerenja (fibroscan) više od 8 kPa. Bolesnici s viremijom manjom od 2000 IU/ml i normalnim vrijednostima ALT liječe se ukoliko imaju histološki ili fibroelastografski pokazatelj uznapredovale fibroze po Ishak Knodellu >= od F4, odnosno fibroscan veći od 14 kPa). Liječenje se provodi u bolesnika starijih od 12 godina. Uključuje i bolesnike s dekompenziranom cirozom i transplantiranom jetrom. Terapija se provodi do nastanka konverzije HBsAg u anti HBs ili do pojave rezistencije na lijek (povišenje viremije nakon prethodnog dobrog učinka). Učinak terapije procjenjuje se svakih 6 mjeseci određivanjem HBV DNA u serumu te HBV markera 1x godišnje. Terapiju odobrava Bolničko povjerenstvo uz reevaluaciju 1x godišnje. Tenofovir je lijek izbora za liječenje bolesnika s kroničnim hepatitisom B koji nisu prikladni za liječenje pegiliranim interferonom alfa-2a, kao i bolesnika koji su prethodno liječeni drugim analozima nukleozida uz razvoj rezistencije. 2. Akutni fulminantni hepatitis B. Terapija se provodi u dozi od 100 mg dnevno još tri mjeseca nakon postignute HBsAg serokonverzije. 3. Prevencija vertikalne transmisije. Terapija se provodi u dozi od 100 mg dnevno u zadnjem trimestru trudnoće ako je viremija veća od (10)6 kopija/ml te 3 mjeseca nakon poroda, a tada slijedi evaluacija kronične bolesti trudnice. 4. Prevencija reaktivacije bolesti u HBsAg pozitivnih bolesnika na imunosupresivnoj ili antitumorskoj terapiji može se provoditi tenofovirom u slučaju razvoja ili postojanja rezistencije na lamivudin. Terapija se započinje 2 tjedna prije planiranog liječenja osnovne bolesti u dozi od 100 mg dnevno te nastaviti najmanje 12 mj po prekidu ili duže ako je riječ o aktivnosti hepatitisa B. Kod HBsAg negativnih, a anti HBc pozitivnih bolesnika terapija se započinje ako imaju mjerljivu HBV DNA u serumu. |
| NJ506 | Koristi se u slučaju pandemije gripe, ako je ista proglašena po odluci Kriznog stožera Ministarstva zdravstva i socijalne skrbi. |
| NJ507 | Za liječenje oboljelih od HIV-infekcija koji su rezistentni ili razvijaju nuspojave na standardnu antivirusnu terapiju. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ510 | 1. Kronični B hepatitis, HBsAg poz (bez obzira na HBeAg status), uz HBV DNA veći od 2000 IU/ml (10000 kopija/ml seruma), povišene vrijednosti ALT u dva uzastopna mjerenja te dokaz histološke aktivnosti – fibroza >= od F2 po Ishak Knodellovom indexu, (što odgovara F1 stadiju po Metaviru) ili vrijednosti fibroelastografskog mjerenja (fibroscan) adekvatan tom stadiju fibroze. Bolesnici s viremijom manjom od 2000 IU/ml i normalnim vrijednostima ALT liječe se ukoliko imaju histološki ili fibroelastografski pokazatelj uznapredovale fibroze po Ishak Knodellu >= od F4 (ili po Metavir skali F3 stadij fibroze) ili nalaz elastografije adekvatan tom stadiju fibroze. Liječenje se provodi u bolesnika starijih od 2 godina. Uključuje i bolesnike s dekompenziranom cirozom i transplantiranom jetrom. Terapija se provodi do nastanka konverzije HBsAg u anti HBs ili do pojave rezistencije na lijek (povišenje viremije nakon prethodnog dobrog učinka). Učinak terapije procjenjuje se svakih 6 mjeseci određivanjem HBV DNA u serumu te HBV markera 1x godišnje. Terapiju odobrava Bolničko povjerenstvo. 2. Entekavir je preporučena terapija za bolesnike s kroničnim hepatitisom B koji su stariji od 60 godina, bolesnike s osteoporozom, patološkim frakturama ili one na kroničnoj terapiji kortikosteroidima, za bolesnike s glomerularnom filtracijom <60 ml/min/1.73m2, albuminurijom >30 mg, bolesnike na dijalizi ili nakon transplantacije bubrega, za bolesnike s konkomitantnom nefrotoksičnom kroničnom terapijom te nekontroloranim dijabetesom i hipertenzijom kao potencijalnim čimbenicima razvoja bubrežne bolesti. 3. Prevencija reaktivacije bolesti u HBsAg pozitivnih bolesnika na imunosupresivnoj ili antitumorskoj terapiji može se provoditi entekavirom, osim u slučaju razvoja ili postojanja rezistencije na lamivudin. |
| NJ511 | Za bolesnike s kroničnim hepatitisom B, koji ispunjavaju jedan ili više slijedećih kriterija, a kod kojih je kontraindicirana upotreba entekavira, 1) osobe starije od 60 godina, 2) osobe koje imaju bolesti kostiju a. Kronična uporaba steroida ili drugih lijekova koji smanjuju gustoću kostiju, b. Povijest fraktura zbog slabosti koštane strukture, c. Osteoporoza, 3) osobe s oštećenom bubrežnom funkcijom – a. eGFR<60 ml/min/1.73 m2, b. Albuminurija >30 mg/24 h ili umjerenom dipstick proteinurijom, c. Smanjeni fosfati (<2.5 mg/dl), d. Kod dijaliziranih pacijenata (hemodijaliza). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ601 | Primarna imunodeficijencija, sekundarna imunodeficijencija u bolesnika s kroničnom limfatičnom leukemijom i rekurentnim bakterijskim infekcijama, imunotrombocitopenija refrakterna na kortikosteroide, Kawasaki sindrom, HIV infekcija u djece s rekurentnim bakterijskim infekcijama. |
| NJ602 | Sepsa uz sniženu koncentraciju imunoglobulina. |
| NJ603 | Prevencija Rh(D) imunizacije u Rh(D) negativnih trudnica, u kojih nisu dokazana anti-Rh(D) protutijela nakon poroda, nakon prekida trudnoće i tijekom trudnoće nakon medicinskog zahvata koji može uzrokovati krvarenje. |
| NJ604 | Samo na odjelima s imunokompromitiranim bolesnicima (ako postoji zaraza s dokazanom infekcijom varicellom-zoster). |
| NJ606 | Samo za reinfekcije virusom hepatitisa B nakon transplantacije jetre zbog zatajenja jetre uzrokovanog virusom hepatitisa B. |
| NJ707 | Prema važećem Provedbenom programu obveznog cijepljenja i Programu imunizacije, seroprofilakse i kemoprofilakse za posebne skupine stanovništva i pojedince pod povećanim rizikom Ministarstva zdravstva Republike Hrvatske. |
| NJ708 | Za liječenje primarne kongenitalne agamaglobulinemije i teške kombinirane imunodeficijencije, kod bolesnika s ranije klinički značajnom preosjetljivosti pri primjeni IVIG-a, uz odobrenje Bolničkog povjerenstva za lijekove koje se može izdati za razdoblje liječenja do najviše 12 mjeseci, nakon čega Bolničko povjerenstvo za lijekove mora donijeti svoju novu odluku. |
| NJ711 | Za liječenje kroničnog hepatitisa C kod bolesnika u dobi >=18 godina, kojima je potvrđena dijagnoza kroničnog hepatitisa C i koji imaju pozitivan nalaz HCV RNA. Potrebna je apstinencija od i.v. droga i abuzusa alkohola unatrag 6 mjeseci. Bolesnici koji su ovisnici o drogama moraju imati dokaz da apstiniraju najmanje 6 mjeseci, a dokaz su dokumentirani nalaz psihijatra i rezultati toksikoloških ispitivanja tijekom tretmana svaka 3 mjeseca. Na prijedlog Bolničkog povjerenstva za lijekove, bolesnicima koji zadovoljavaju kriterije i kojima je terapija preporučena u skladu sa smjernicama Referentnog centra za dijagnostiku i liječenje virusnih hepatitisa Ministarstva zdravstva, terapijski protokol i trajanje liječenja odobrava Stručno povjerenstvo Zavoda. Na teret sredstava namijenjenih za financiranje posebno skupih lijekova mogu se odobriti lijekovi za liječenje kroničnog C hepatitisa za potrebe liječenja bolesnika koji do sada nisu liječeni ili je prethodno liječenje bilo neuspješno 1) za G1 i G4 – ledipasvir + sofosbuvir, elbasvir + grazoprevir, glekaprevir + pibrentasvir, sofosbuvir + velpatasvir 2) za G2 i G3 – sofosbuvir + velpatasvir, glekaprevir + pibrentasvir 3) za HCV s dekompenziranom cirozom – sofosbuvir + velpatasvir. 4) za bolesnike u dobi od 6 i više godina i tjelesne težine ≥ 30 kg lijek sofosbuvir + velpatasvir. |
| NJ712 | Za liječenje komplicirane intraabdominalne infekcije i komplicirane infekcije mokraćnog sustava (uključujući pijelonefritis) uzrokovane osjetljivim gram negativnim uzročnicima koji prema antibiogramu ne reagiraju na druge antibiotike. Samo kao rezervni antibiotik. |
| NJ713 | Za liječenje HIV-infekcija u osoba koje imaju procjenjenu glomerularnu filtraciju <60 ml/min/1.73 m2. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ714 | Za liječenje kroničnog hepatitisa C kod bolesnika u dobi >=18 godina bez ciroze ili s kompenziranom cirozom koji su prethodno bili liječeni direktno djelujućim antivirusnim lijekovima. Potrebna je apstinencija od i.v. droga i abuzusa alkohola unatrag 6 mjeseci. Bolesnici koji su ovisnici o drogama moraju imati dokaz da apstiniraju najmanje 6 mjeseci, a dokaz su dokumentirani nalaz psihijatra i rezultati toksikoloških ispitivanja tijekom tretmana svaka 3 mjeseca. Na prijedlog Bolničkog povjerenstva za lijekove, bolesnicima koji zadovoljavaju kriterije i kojima je terapija preporučena u skladu sa smjernicama Referentnog centra za dijagnostiku i liječenje virusnih hepatitisa Ministarstva zdravstva, terapijski protokol i trajanje liječenja odobrava Stručno povjerenstvo Zavoda. |
| NJ715 | Kod sindroma primarnih imunodeficijencija s nedovoljnom proizvodnjom antitijela. |
| NJ716 | Primarna imunodeficijencija, sekundarna imunodeficijencija u bolesnika s kroničnom limfatičnom leukemijom i rekurentnim bakterijskim infekcijama, imunotrombocitopenija refrakterna na kortikosteroide, Kawasaki sindrom, HIV infekcija u djece s rekurentnim bakterijskim infekcijama, Guillian-Barre sindrom, kronične upalne demijelinizirajuće poliradikuloneuropatije (KUDP). |
| NJ717 | Za liječenje odraslih osoba zaraženih virusom humane imunodeficijencije tipa 1 (HIV-1) bez dokaza o sadašnjoj ili prošloj rezistenciji virusa na skupinu inhibitora integraze, emtricitabin ili tenofovir. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ718 | Za liječenje oboljelih od HIV-infekcija u kojih je postignuta virološka supresija (HIV 1 RNK <50 kopija/ml). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ719 | Invazivna aspergiloza u odraslih bolesnika. Mukormikoza u odraslih bolesnika koji ne mogu uzimati amfotericin B. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NJ720 | Za profilaksu reaktivacije citomegalovirusa (CMV) i CMV bolesti u odraslih CMV-seropozitivnih primatelja [R+] alogenih transplantata hematopoetskih matičnih stanica. Liječenje treba početi unutar 28 dana od dana transplantacije. Primjena lijeka se odobrava za razdoblje od 100 dana od dana transplantacije. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima specijaliziranog za transplantacije krvotvornih matičnih stanica. Liječenje se provodi u Kliničkim bolničkim centrima ili kliničkim bolnicama u kojima se provode transplantacije alogenih krvotvornih matičnih stanica. |
| NL101 | Novo dijagnosticirani glioblastoma multiforme u prvoj liniji liječenja – konkomitantna primjena sa zračenjem. Nastavak liječenja u monoterapiji moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). Po preporuci interniste onkologa ili specijalista radioterapije i onkologije. |
| NL102 | 1. Za liječenje bolesnika s inoperabilnim IIIB ili IV stadijem neskvamoznog karcinoma pluća nemalih stanica, kao monoterapija u drugoj kemoterapijskoj liniji, do pojave neprihvatljive toksičnosti ili progresije bolesti. 2. Za liječenje bolesnika s inoperabilnim zloćudnim pleuralnim mezoteliomom u kombinaciji sa cisplatinom, a koji prethodno nisu primali drugu kemoterapiju, do pojave neprihvatljive toksičnosti ili progresije bolesti. Liječenje lijekom pemetreksed dozvoljeno je ukoliko su ispunjeni sljedeći kriteriji – a. opće stanje ECOG 0-2, b. razina bilirubina, AST, ALT < 5x gornja granica uredne vrijednosti, kreatinin < 1.5x gornja granica urednih vrijednosti, razina neutrofila > 1.5x(10)9/L, razina trombocita >100x(10)9/L. Odobravaju se dva ciklusa liječenja lijekom pemetreksed , nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora i podnošljivosti liječenja. Nastavak liječenja je moguć isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest). |
| NL103 | Samo za leukemiju vlasastih stanica. |
| NL104 | Za B-kroničnu limfocitnu leukemiju rezistentnu na prvu liniju terapije (klorambucil). |
| NL106 | Za liječenje odraslih bolesnika kod kojih nije moguće transplantirati hematopoetsku matičnu stanicu, a koji boluju od – 1. mijelodisplastičnog sindroma (MDS), srednjeg 2 ili visokog rizika prema međunarodnome prognostičkom numeričkom sustavu rangiranja (IPSS), 2. kronične mijelomonocitne leukemije (CMML) s 10-29% blasta u koštanoj srži bez mijeloproliferativnog poremećaja, 3. akutne mijeloidne leukemije (AML) s 20-30% blasta i displazije više loza, prema klasifikaciji Svjetske zdravstvene organizacije (WHO). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL111 | 1. Prva linija liječenja agresivnih non-Hodgkin limfoma, koji su prema nalazu imunohistokemije, imunocitokemije ili protočne citometrije CD20 pozitivni, u kliničkom stadiju II-IV ili stadiju I s povišenim LDH ili velikom tumorskom masom, odobrava se 4 ciklusa liječenja u kombinaciji s kemoterapijom u dozi od 375 mg/(m)2 po ciklusu. U slučaju povoljnog učinka odobrava se primjena još 4 ciklusa terapije. 2. Prva linija liječenja bolesnika s neliječenim CD20 pozitivnim indolentnim non-Hodgkin limfomom. Odobrava se primjena osam ciklusa liječenja u dozi od 375 mg/(m)2 po ciklusu. 3. Liječenje bolesnika sa indolentnim B-staničnim non-Hodgkinovim limfomom u relapsu odnosno u bolesnika sa kemorezistentnim tipom B-staničnog non-Hodgkinovog limfoma niskog stupnja malignosti u kojih je imunohistokemijski i/ili protočnom citometrijom dokazano da stanice na sebi imaju CD20 biljeg. Odobrava se primjena tri ciklusa liječenja uz obveznu reevaluaciju učinka nakon trećeg ciklusa terapije. U slučaju povoljnog učinka odobrava se primjena još tri ciklusa terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista internista hematologa. 4. Za liječenje reumatoidnog artritisa 4.a. Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >= 5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status – HAQ 0,5-2,5. 4.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno i jedan TNF blokator ili lijek tocilizumab kroz 12 tjedana. 4.c. Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. 4.d. Zadani učinak liječenja nakon 16 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >= 1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 4.e. Trajanje liječenja, reekspozicija lijeku rituksimab nakon dvije infuzije dolazi u obzir nakon 24 tjedna ukoliko je prisutna rezidualna upalna aktivnost DAS28 >= 3,2 ili je došlo do egzacerbacije RA s porastom DAS28 za >= 0.6. 4.f. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. Liječenje odobrava Bolničko povjerenstvo za lijekove, po preporuci reumatologa, za prve dvije infuzije, a kasnije najranije 24 tjedna od prve aplikacije s dokumentiranim ishodom kao što je navedeno u točki 4.d. Liječenje pod 1., 2. i 4. odobrava se iz sredstava posebno skupih lijekova, a liječenje pod 3. iz sredstava bolničkog proračuna. |
| NL112 | I. Za liječenje HER2-pozitivnog raka dojke (IHC 3+ ili CISH/FISH+) u slijedećim indikacijama 1. adjuvantno liječenje – 1.1 rani stadij raka dojke nakon provedenog primarnog liječenja (operacija). Liječenje se provodi sekvencijski ili konkomitantno s primjenom taksana i/ili zračenja, ukupno do godinu dana. 1.2 neoadjuvantno liječenje, prije operativnog zahvata, ukoliko je indicirana neoadjuvantna sistemska terapija, s adjuvantnim liječenjem do ukupno godinu dana. Način primjene – a) i.v. primjena – početna doza je 8 mg/kg tjelesne težine, a zatim 6 mg/kg tjelesne težine za trotjedni ciklus. b) s.c. primjena – 600 mg za trotjedni ciklus. Adjuvantno liječenje se može provoditi i sa hormonskom terapijom. Kriteriji za primjenu – ECOG 0-1, EFLV (ejekciona frakcija lijevog ventrikla) >50%, uredni laboratorijski nalazi (AST, ALT do 5x gornje granice, bilirubin do 3x gornje granice referentne vrijednosti). 2. metastatski rak dojke – 2.1. prva linija kemoterapije – 2.1.1. u kombinaciji s taksanima, 2.1.2. u kombinaciji s hormonskom terapijom kod istovremeno HER2+ i hormonski pozitivnih tumora (HER2+++, ER+). Liječenje se provodi do progresije bolesti. 2.2. u monoterapiji kao treća linija nakon prethodno provedene najmanje dvije linije kemoterapije za metastatsku bolesti, koja je sadržavala antracikline i taksane. Kriteriji za primjenu – ECOG 0-1, nepostojanje presadnica u CNS-u (ili postojanje stabilnih/kontroliranih moždanih presadnica, uz očekivano trajanje života više od godine dana), uredni laboratorijski nalazi (AST, ALT do 5x gornje granice, bilirubin do 3x gornje granice referentne vrijednosti. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu reevaluaciju učinka nakon četiri ciklusa liječenja. Svaka slijedeća evaluacija učinka liječenja se radi nakon provedenih šest ciklusa liječenja. II. U kombinaciji s kemoterapijom za liječenje odraslih bolesnika s HER2 pozitivnim metastatskim adenokarcinomom želuca ili gastroezofagealnog spoja, koji nisu prethodno primali kemoterapiju za metastatsku bolest. Liječenje pod 1. i 2.1. odobrava se iz sredstava posebno skupih lijekova, a liječenje pod 2.2. i II. iz sredstava bolničkog proračuna. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL113 | 1. Prva linija liječenja bolesnika s metastatskim rakom debelog crijeva kod kojih je potvrđeno nepostojanje RAS mutacija (‘divlji tip’ RAS statusa 2, 3 i 4 ekson KRAS-a, odnosno NRAS-a) što se određuje u laboratorijjima sa validiranom metodom određivanja. Primjenjuje se u kombinaciji sa kemoterapijom na bazi irinotekana ili u prvoj liniji u kemoterapiji sa FOLFOX kemoterapijskim protokolom, kao monoterapija nakon neuspjeha terapije na bazi irinotekana i oksaliplatine i kod onih koji ne podnose irinotekan. Kriteriji za primjenu – 1. tjelesni status 0 i 1 po ECOG (Karnofsky 80-100), 2. nepostojanje presadnica u CNS-u, 3. razina bilirubina <1,5 x gornja granica normalne vrijednosti, 4. razina AST i ALT <5x gornja granica normalne vrijednosti, 5. razina kreatinina <1.25x gornja granica normalne vrijednosti, 6. razina granulocita > 1.5x(10)9/L, 7. razina trombocita >100x(10)9/L. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista onkologa (specijalista radioterapije i onkologije, specijalista radioterapije ili subspecijalista internističke onkologije). Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). 2. Za liječenje bolesnika s karcinomom pločastih stanica glave i vrata (osim karcinoma epifarinksa) u kombinaciji sa zračenjem za lokalno uznapredovalu bolest koji ne podnose preporučene visoke doze platine (punu terapijsku dozu) ili je njena primjena kontraindicirana. Liječenje odobrava Bolničko povjerenstvo za lijekove u trajanju do najviše 8 tjedana. 3. Za liječenje bolesnika s karcinomom pločastih stanica glave i vrata, u kombinaciji s kemoterapijom na bazi platine za recidivirajuću i/ili metastatsku bolest, koju slijedi terapija održavanja do progresije bolesti ili neprihvatljive toksičnosti. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL115 | Kronična mijeloična leukemija s pozitivnim Philadelphia(Ph+) kromosomom i/ili bcr-abl1 prijepisom. Potrebna je citogenetska potvrda postojanja Ph+ kromosoma i/ili nalaz molekularnog bcr-abl1 prijepisa. I. Bolesnici u prvoj kroničnoj fazi bolesti – 1. Kriteriji za prekid liječenja zbog primarne rezistencije – a) nakon 3 mjeseca liječenja – nije postignut kompletan hematološki odgovori/ili Ph+ >95% b) nakon 3 mjeseca liječenja – bcr-abl1 >10% i/ili Ph+ >35% c) nakon 12 mjeseci liječenja – bcr-abl1 >1% i/ili Ph+ >0 2. Kriteriji za prekid liječenja zbog sekundarne rezistencije, zbog jednog ili više od navedenog bilo kada tijekom liječenja – a) gubitak kompletnog hematološkog odgovora b) gubitak kompletnog citogenetskog odgovora c) potvrđen gubitak velikog molekularnog odgovora u dva uzastopna testa, od kojih je u jednom bcr-abl1 >=1% d) pojava mutacije 3. Kriteriji za prekid liječenja zbog nuspojava – a) teške nuspojave gradusa 3 ili 4 b) perzistentne nuspojave gradusa 2, koje nereagiraju na terapiju (citopenija u prva tri mjeseca liječenja ne smatra se razlogom za promjenu terapije). Po preporuci specijalista internista hematologa za početak i nastavak liječenja. II. Bolesnici kojima je dijagnoza postavljena u ubrzanoj fazi ili blastičnoj transformaciji – a) ubrzana faza se definira prisutnošću bilo kojeg od sljedećih kriterija – blasti >=15%, ali <30% u krvi ili koštanoj srži, blasti plus promijelociti >=30% u krvi ili koštanoj srži (od čega blasta <30%), bazofili u perifernoj krvi >=20%, trombociti <100x(10)9/L (osim ukoliko trombocitopenija nije uzrokovana prethodnom terapijom) b) blastična transformacija se definira kao – blasti >=30% u krvi ili koštanoj srži ili postojanje ekstramedularne bolesti, osim splenomegalije Kriteriji za prekid liječenja – a) nakon 3 mjeseca liječenja nije postignut hematološki odgovor (L>10x(10)12/L ili prisustvo blasta u perifernoj krvi Po preporuci specijalista internista hematologa za početak i nastavak liječenja. 2. Za liječenje odraslih bolesnika s neoperabilnim i/ili metastazirajućim malignim gastrointestinalnim stromalnim tumorima (GIST). Po preporuci internističkog onkologa ili specijalista radioterapije i onkologije u KBC i KB do najdulje 6 mjeseci (ova indikacija ne odnosi se na lijek Imatinib Sandoz). |
| NL117 | 1. Prva linija liječenja metastatskog raka bubrega svijetlih stanica, primijenjen kao monoterapija. Kriteriji za primjenu – ECOG 0-1, nepostojanje CNS presadnica, AST i ALT <5x gornja granica normalne vrijednosti, klirens kreatinina >= 30 ml/min. Odobrava se primjena dva ciklusa liječenja, nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora i podnošljivosti liječenja. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija ili stabilna bolest) do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. 2. Za liječenje bolesnika s inoperabilnim i/ili metastatskim gastrointestinalnim stromalnim tumorom nakon prethodnog liječenja imatinibom u dozi od 800 mg dnevno u slučaju progresije bolesti ili nepodnošenja lijeka. Kriteriji za primjenu – 1. funkcija bubrega – klirens kreatinina >30 ml/min. 2. nepostojanje CNS presadnica 3. AST i ALT <5x gornja granica normalne vrijednosti 4. status ECOG 0-2. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Odobrava se primjena terapije za 3 mjeseca, nakon kojih se provodi provjera učinka terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (remisija kompletna ili parcijalna ili stabilna bolest). |
| NL118 | 1. Za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom bubrega u drugoj liniji liječenja. Kriteriji za primjenu – 1. nepostojanje CNS presadnica. 2. status ECOG 0-2. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Odobrava se primjena terapije za 3 mjeseca, nakon kojih se provodi provjera učinka terapije. 2. Za liječenje uznapredovalog hepatocelularnog karcinoma jetre. Kriteriji za primjenu – 1. Child-Pugh stadij jetrene bolesti A. 2. Uredna bubrežna funkcija (kreatinin klirens > 50 ml/min). 3. Uredna funkcija hematopoetskog sustava (trombociti > 1000 000, neutrofili > 1500, hemoglobin > 110 g/l. 4. Nepostojanje CNS presadnica. 5. ECOG 0-1. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Odobrava se primjena terapije za 2 mjeseca, nakon kojih se provodi provjera učinka terapije. 3. Za liječenje brzoprogredirajućeg (progresija bolesti prema RECIST-kriterijima u manje od 12 mjeseci) ili agresivnog simptomatskog diferenciranog karcinoma štitnjače refraktornog na radioaktivni jod u bolesnika s metastatskom ili lokalno/lokoregionalno uznapredovalom neresektabilnom bolešću. Liječenje odobrava Bolničko povjerenstvo za lijekove KBC-a, po preporuci specijalista internističkog onkologa ili specijalista radioterapije i onkologije. Liječenje se odobrava iz sredstava bolničkog proračuna. Oznaka KL samo za liječenje pod 2. i 3. |
| NL119 | Za liječenje bolesnika s Philadelphia pozitivnom kroničnom mijeloičnom leukemijom, u kojih se razvila rezistencija ili intolerancija na lijek imatinib. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL120 | Druga linija liječenja bolesnika s lokalno uznapredovalim ili metastatskim rakom dojke, koji pokazuje prekomjernu ekspresiju ErbB2 (HER2) kod progresije bolesti nakon ranijeg liječenja taksanima, antraciklinima i lijekom trastuzumab, a u kombinaciji s lijekom kapecitabin. Kriteriji za primjenu – 1. EFLV (ejekciona frakcija lijevog ventrikla) >50%. 2 Uredna jetrena funkcija (razina AST, ALT < 5 x gornja granica uredne vrijednosti). 3. Uredna bubrežna funkcija (kreatinin klirens >50 ml/min). 4. Uredna funkcija hematopoetskog sustava (trombociti >100 000, neutrofili >1500). 5. ECOG status bolesnika 0-2. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL121 | Za terapiju kronične mijeloične leukemije u bolesnika u kojih se razvila rezistencija ili intolerancija na lijek imatinib. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL122 | Za terapiju metastatskog karcinoma bubrega (neovisno o histološkom podtipu). Kriteriji primjene, prva linija liječenja metastatskog karcinoma bubrega ukoliko su prisutna 3 ili više nepovoljna prognostička čimbenika (koji uključuju – 1. vrijeme od dijagnoze raka bubrega manje od 1 godine, 2. Karnoffsky status 60-70%, 3. hemoglobin niži od donje granice, 4. koncentracija kalcija >2.5 mmol/L, 5. LDH >1.5x gornja granica normale, 6. prisutnost 2 ili više sijela metastaza) te ukoliko su laboratorijski parametri – AST i ALT <= 3x gornja granica normale, bilirubin <= 2x gornja granica normale. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Odobrava se primjena terapije za 2 mjeseca, nakon čega se provodi provjera učinka terapije. |
| NL123 | Indiciran je u monoterapiji kao II. linija kemoterapije karcinoma malih stanica pluća. Liječenje lijekom topotekan dozvoljeno je ukoliko su ispunjeni kriteriji – 1. rezistencija/refrakternost na derivate platine (tj. slobodni interval kraći od 6 mjeseci), 2. ECOG status 0-2, 3. razina bilirubina, AST, ALT <5x iznad gornje granice urednih vrijednosti, 4. kreatinin < 1.5x gornja granica urednih vrijednosti, 5. razina neutrofila >1.5 x (10)9/L, razina trombocita >100 x (10)9/L. Odobrava se primjena dva ciklusa terapije, nakon čega je obvezna klinička i dijagnostička obrada u cilju provjere stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL124 | 1. U monoterapiji kao II. linija kemoterapije karcinoma malih stanica pluća. Liječenje lijekom topotekan dozvoljeno je ukoliko su ispunjeni kriteriji – 1. rezistencija/refrakternost na derivate platine (tj. slobodni interval kraći od 6 mjeseci), 2. ECOG status 0-2, 3. razina bilirubina, AST, ALT <5x iznad gornje granice urednih vrijednosti, 4. kreatinin < 1.5x gornja granica urednih vrijednosti, 5. razina neutrofila >1.5 x (10)9/L, razina trombocita >100 x (10)9/L. Odobrava se primjena dva ciklusa terapije, nakon čega je obvezna klinička i dijagnostička obrada u cilju provjere stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. U I. liniji liječenja uznapredovalog, metastatskog i recidivirajućeg karcinoma vrata maternice. 3. U monoterapiji kao II. linija kemoterapije metastatskog raka jajnika nakon neuspjeha I. linije liječenja. Liječenje lijekom topotekan u indikacijama pod 2. i 3. dozvoljeno je ukoliko su ispunjeni kriteriji – 1. rezistencija na derivate platine (tj. slobodni interval kraći od 6 mjeseci), 2. ECOG status 0-2, 3. nepostojanje presadnica u CNS-u, 4. očekivano trajanje života dulje od 3 mjeseca, 5. zadovoljavajuća bubrežna i jetrena funkcija (AST, ALT <5x iznad gornje granice urednih vrijednosti, kreatinin klirens >20 ml/min), 6. zadovoljavajuća funkcija hematopoetskog sustava (trombociti >100 x(10)9/L, neutrofili >1.5 x (10)9/L, hemoglobin >100g/L). Odobrava se primjena dva ciklusa kemoterapije, nakon kojih je obvezna klinička i dijagnostička obrada u cilju provjere stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz odobrenje Bolničkog povjerenstva za lijekove. |
| NL126 | Za bolesnike sa diseminiranim multiplim mijelomom. Odobrava se 4 ciklusa liječenja te, u slučaju povoljnog učinka, odobrava se primjena još 4 ciklusa terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). |
| NL128 | 1. Prva linija liječenja bolesnika s metastatskim rakom debelog crijeva u kombinaciji s kemoterapijom kod bolesnika općeg tjelesnog statusa ECOG 0-1. Liječenje bevacizumabom se provodi dok traje pozitivni tumorski odgovor (kompletna remisija, parcijalna remisija ili stabilna bolest) uz odobrenje Bolničkog povjerenstva za lijekove. 2. Za liječenje odraslih bolesnica s uznapredovalim (stadiji IIIB, IIIC i IV) epitelnim karcinomom jajnika, karcinomom jajovoda i primarnim peritonealnim karcinomom, koje prethodno nisu bile liječene lijekom bevacizumab drugim VEGF inhibitorima niti lijekovima koji djeluju na VEGF receptore i to – a. Prva linija liječenja visokorizičnih bolesnica (FIGO IIIB i IIIC s rezidualnom bolešću i sve FIGO IV bolesnice) u kombinaciji s odgovarajućom kemoterapijom. b. Druga linija liječenja bolesnica s karcinomom osjetljivim na platinu u kombinaciji s odgovarajućom kemoterapijom. c. Druga linija liječenja bolesnica s karcinomom rezistentnim na platinu u kombinaciji s odgovarajućom kemoterapijom. Odobrava se primjena 3 ciklusa liječenja, nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora i podnošljivosti liječenja. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija ili stabilna bolest) do progresije bolesti. Početnih 6-8 ciklusa bevacizumabom se provodi u kombinaciji s navedenom kemoterapijom, dok se ostatak liječenja provodi kao monoterapija bevacizumabom. Liječenje bevacizumabom iz točke 2.a ove smjernice se treba prekinuti nakon 15 mjeseci. Liječenje odobrava Bolničko povjerenstvo za lijekove. 3. Za liječenje odraslih bolesnica s perzistentnim, recidivirajućim ili metastatskim karcinomom cerviksa u kombinaciji s odgovarajućom kemoterapijom. Odobrava se primjena 3 ciklusa liječenja, nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora i podnošljivosti liječenja. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija ili stabilna bolest) do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove. 4. a. U kombinaciji sa standardnom kemoterapijom, u 2. liniji liječenja metastatskog kolorektalnog karcinoma, a nakon progresije bolesti u 1. liniji liječenja gdje je već primjenjen s odgovarajućom kemoterapijom. b. U kombinaciji sa standardnom kemoterapijom, u 2. liniji liječenja metastatskog kolorektalnog karcinoma, a nakon progresije bolesti u 1. liniji liječenja koje nije sadržavalo bevacizumab. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL201 | Karcinom prostate, po preporuci specijalista urologa ili onkologa. |
| NL202 | Za liječenje raka dojke u žena s pozitivnim estrogenskim receptorima u postmenopauzi, lokalno uznapredovalog ili s metastazama i to zbog recidiva bolesti tijekom ili nakon adjuvantne antiestrogenske terapije, odnosno zbog napredovanja bolesti tijekom antiestrogenske terapije. Po preporuci internističkog onkologa ili specijalista radioterapije i onkologije, na period od 3 mjeseca, nakon čega slijedi provjera rezultata liječenja. |
| NL203 | Za liječenje postmenopauzalnih bolesnica s hormonski ovisnim metastatskim karcinomom dojke, u kojih je došlo do progresije bolesti nakon liječenja antiestrogenom i inhibitorom aromataze, uz dokazanu prisutnost presadnica. Po preporuci specijalista radioterapije i onkologije ili specijalista internista onkologa, na period od 3 mjeseca, nakon kojega slijedi provjera rezultata liječenja. |
| NL301 | Za skraćenje trajanja neutropenije i smanjenje učestalosti febrilne neutropenije u bolesnika s malignom bolesti, koji se liječe citiotoksičnom kemoterapijom (izuzev kronične mijeloične leukemije i mijelodisplastičkih sindroma). |
| NL303 | Za prvu liniju liječenja bolesnika s relaps remitentnim oblikom multiple skleroze. Indikacije za početak liječenja – a. 2 relapsa (u relaps se ubraja i anamnestički relaps za kojega se naknadno ustanovi da je posljedica demijelinizacijskih lezija, a zbog kojega se bolesnik javio svom liječniku obiteljske medicine ili neurologu te kod kojega je došlo do spontanog oporavka. Relaps ne mora biti liječen pulsnom kortikosteroidnom terapijom ako dođe do spontanog oporavka simptoma) ili b. 1 relaps uz dokaz diseminacije u prostoru – ≥1 T2 lezije u 2 od 4 tipične regije za multiplu sklerozu unutar središnjeg živčanog sustava (periventrikularna, jukstakortikalna, infratentorijska ili leđna moždina) te diseminacija u vremenu – istovremena prisutnost demijelinizacijske lezije koja se imbibira kontrastom i neimbibirajuće demijelinizacijske lezije ili nova T2 i/ili gadolinijumom imbibirana demijelinizacijska lezija na kontrolnom MR-u bez obzira u kojem vremenskom razmaku se učini ili pozitivne oligoklonske IgG vrpce u likvoru. c. EDSS ≤6 Prvo odobrenje Bolničkog povjerenstva za lijekove izdaje se za razdoblje od 6 mjeseci od kojih se prvih mjesec dana lijek primjenjuje na teret sredstva bolničkog proračuna, a u nastavku se za preostalih 5 odobrenih mjeseci liječenja lijek može propisivati na recept Zavoda. Svako sljedeće odobrenje za nastavak liječenja, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijalista neurologa, Bolničko povjerenstvo za lijekove može izdati za razdoblje od najviše 12 mjeseci. Lijek se može propisivati na recept Zavoda isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Kriteriji za promjenu lijeka ili prekid 1. linije terapije relapsno-remitirajuće multiple skleroze – a. ≥4 nove T2 lezije na MR-u nakon početka liječenja ili b. ≥2 relapsa nakon početka liječenja c. Ozbiljne nuspojave (dokumentirane i prijavljene). |
| NL305 | I. Kronični hepatitis C kod bolesnika u dobi >=18 godina, uz pozitivan nalaz anti-HCV protutijela, te pozitivne HCV RNK u serumu u 2 navrata unutar 3 mjeseca, apstinenciju od iv uzimanja psihoaktivnih droga dulje od 6 mjeseci, apstinenciju od abuzusa alkohola dulje od 6 mjeseci. Za osobe koje u anamnezi imaju ovisnost o psihoaktivnim drogama i/ili alkoholu potrebno je mišljenje psihijatara o podobnosti za liječenje. Liječenje se provodi prema preporuci liječnika specijalista infektologa ili gastroenterologa uz odobrenje Bolničkog povjerenstva za lijekove u skladu s preporukama Referentnog centra za dijagnostiku i liječenje virusnih hepatitisa Ministarstva zdravstva. II. Kronični HEPATITIS B – peginterferon alfa-2a HBsAg poz (bez obzira na HBeAg status), uz slijedeće kriterije – HBV DNA veći od 2000 IU/ml (10000 kopija/ml seruma), povišene vrijednosti ALT u dva uzastopna mjerenja, uz dokaz histološke aktivnosti fibroza >= od F2 (po Ishak Knodellovom indexu) ili vrijednosti fibroelastografskog mjerenja (fibroscan) više od 8 kPa. Bolesnici s viremijom manjom od 2000 IU/ml i normalnim vrijednostima ALT liječe se ukoliko imaju histološki ili fibroelastografski pokazatelj uznapredovale fibroze pod Ishak Knodellu F >= od 4, odnosno fibroscan veći od 14 kPa. Terapija se primjenjuje u bolesnika koji 12 mjeseci apstiniraju od i.v. droga i abuzusa alkohola te nemaju dekompenziranu cirozu i druge poznate kontraindikacije za primjenu pegiliranog interferona. Bolesnici koji su ovisnici o drogama moraju imati dokaz da apstiniraju najmanje 1 godinu, a dokaz su dokumentirani nalaz psihijatra i rezultati toksikoloških ispitivanja tijekom tretmana svaka 3 mjeseca. Terapija uključuje bolesnike u dobi od 18 do 70 godina. Terapijske smjernice – Liječenje se provodi u dozi 180 mcg 1x tjedno sc. kroz 48 tjedana uz provjeru HBV DNA nakon 24 tjedna (ukoliko se ne postigne redukcija viremije za 100x od početne vrijednosti terapija se prekida). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL306 | Lijek je indiciran za dugotrajno enzimsko nadomjesno liječenje bolesti povezanih s potvrđenim nedostatkom adenozin deaminaze. Početak i svaki nastavak liječenja odobrava Bolničko povjerenstvo za lijekove KBC ili Bolničko povjerenstvo za lijekove Klinike za dječje bolesti Zagreb na prijedlog bolničkog specijaliste koji liječi oboljelog uz prethodno pribavljenu pisanu suglasnost odgovarajućeg Referentnog centra Ministarstva zdravstva. Prvo odobrenje za početak liječenja se izdaje na 6 mjeseci, a svako sljedeće, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i uz suglasnost Referentnog centra, najmanje jedanput godišnje. |
| NL308 | Za liječenje odraslih bolesnika s relapsno-remitentnom multiplom sklerozom uz EDSS <=6 i odsutnost trudnoće – I. kod bolesnika kod kojih je bolest aktivna i koji nisu odgovorili na potpuni i odgovarajući režim liječenja barem jednom terapijom koja modificira tijek bolesti (interferon beta, glatiramer acetat, teriflunomid, dimetil fumarat), odnosno kada su ispunjeni kriteriji za prekid navedene terapije prema važećim smjernicama u listi lijekova. Bolest se smatra aktivnom usprkos provedenoj prethodnoj terapiji uz – a) >= 4 nove T2 hiperintenzivne lezije na MR-u ili b) >= 2 relapsa. II. Bolesnici s teškom, visokoaktivnom RRMS – definiranom s 2 ili više onesposobljavajućih relapsa u 1 godini (onesposobljavajući relaps definira se kao porast EDSS-a u relapsu za jednako ili više od 2 boda). Liječenje odobrava Bolničko povjerenstvo za lijekove. Prvi ciklus liječenja sastoji se od 2 tjedna liječenja, jednog na početku prvog mjeseca i jednog na početku drugog mjeseca prve godine liječenja, a drugi ciklus jednako je raspodijeljen 12 mjeseci nakon prvog ciklusa liječenja. Nije potrebno daljnje liječenje lijekom tijekom 3 i 4. godine. Na preporuku specijalista neurologa, u bolesnika sa znakovima umjerene aktivnosti bolesti (1 relaps ili 2-4 nove lezije na kontrolnim MR-ima mozga i vratne kralježnice), po završetku četverogodišnjeg ciklusa liječenja (dva ciklusa liječenja kladribin tabletama) može se nastaviti liječenje novim ciklusom kladribin tableta. Doziranje lijeka sukladno je važećem Sažetku opisa svojstava lijeka. |
| NL401 | Za prvu liniju koristi se konjski serum, a za drugu liniju zečji serum. |
| NL402 | Samo za liječenje aplastične anemije, po preporuci specijalista internista hematologa. |
| NL403 | Profilaksa akutnog odbacivanja srca nakon transplantacije. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL404 | Za bolesnike s transplantiranim organima. |
| NL405 | Za bolesnike sa transplantiranim bubregom. |
| NL406 | Kao monoterapija u visoko aktivnoj relapsno-remitentnoj multiploj sklerozi s fazama relapsa i remisije uz EDSS <=6 i odsutnost trudnoće (samo bolesnici s negativnim protutijelima na JCV ili niskim titrom JCV protutijela (indeks < 0.9) mogu biti kandidati za terapiju natalizumabom):  I. kod bolesnika kod kojih je bolest aktivna i koji nisu odgovorili na potpuni i odgovarajući režim liječenja barem jednom terapijom koja modificira tijek bolesti (interferon beta, glatiramer acetat, teriflunomid, dimetil fumarat), odnosno kada su ispunjeni kriteriji za prekid navedene terapije prema važećim smjernicama u listi lijekova.  Bolest se smatra aktivnom usprkos provedenoj prethodnoj terapiji uz:  a) >= 4 nove T2 hiperintenzivne lezije na MR-u ili  b) >= 2 relapsa.  Liječenje odobrava Bolničko povjerenstvo za lijekove.  II. kod bolesnika kod kojih se očituje teška brzonapredujuća relapsno-remitentna multipla skleroza.  Liječenje odobrava Bolničko povjerenstvo za lijekove na teret sredstava bolničkog proračuna. |
| NL408 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa, dermatovenerologa, pedijatra odgovarajuće subspecijalizacije), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda.) 1. Za bolesnike kojima je postavljena dijagnoza juvenilnog idiopatskog artritisa. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje reumatoidnog artritisa, 2.a. Indikacija za primjenu (u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest – DAS28 >=5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 2.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno (ili zbog nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka lijeka tocilizumab ili drugog TNF blokatora. 2.c. Prije primjene probir na hepatitis B i C i latentnu TBC prema preporukama HRD. 2.d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 2.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. e. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 2.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.d. 3. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa – 3.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 3.b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 3.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 3.d. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 3.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 3.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 3.d. 4. Za liječenje aktivnog psorijatičnog artritisa – 4.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primijenjena u punoj dnevnoj dozi kroz 2 mjeseca. 4.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. 4.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 4.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 4.e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 4.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka kao što je navedeno u 4.e. 4.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 4.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 4.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 4.e. 5. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Preporučena doza je 25 mg s.c. 2x tjedno ili 50 mg 1x tjedno. Liječenje se mora nastaviti dok se ne postigne remisija, najdulje do 24 tjedna. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu 12. i 24., izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 12 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijednosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL409 | 1. a. Liječenje fistulirajućeg oblika Crohnove bolesti, b. Liječenje umjerenog do teškog oblika aktivne Crohnove bolesti koja je refraktorna na terapiju kortikosteroidima i imunomodulatorima, odnosno u slučaju nepodnošenja ili kontraindikacija za njihovu primjenu, c. Liječenje Crohnove bolesti u djece (6-17 godina) koji nisu reagirali na konvencionalnu terapiju kortikosteroidima i imunomdulatorima odnosno u slučaju nepodnošenja ili kontraidikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Liječenje umjerenog do teškog oblika ulceroznog kolitisa u bolesnika koji nisu adekvatno odgovorili na konvencionalno liječene kortikosteroidima i 6-merkatopurinom ili azatioprinom odnosno u slučaju nepodnošenja ili kontraindikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. 3. Za liječenje reumatoidnog artritisa 3.a. Indikacija za primjenu (u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest, DAS28 >=5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 3.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno (ili zbog nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka lijeka tocilizumab ili drugog TNF blokatora. 3.c. Prije primjene probir na hepatitis B i C i latentnu TBC prema preporukama HRD. 3.d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 3.e. |
|  | Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 3.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 3 mjeseca, a kasnije za period od 6 mjeseci i dokumentiranim ishodom kao što je navedeno u točki 3.d. 4. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa 4.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 4.b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 4.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 4.d. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 4.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 4.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 3 mjeseca, a kasnije za period od 6 mjeseci i dokumentiranim ishodom kao što je navedeno u točki 4.d. 5. Za liječenje aktivnog psorijatičnog artritisa 5.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primijenjena u punoj dnevnoj dozi kroz 2 mjeseca. 5.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka, lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi 5.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 5.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 5.e. Nakon najmanje 12 tjedana primjene očekivani učinak je 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 5.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 5.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 5.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 5.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 3 mjeseca, a kasnije za period od 6 mjeseci i dokumentiranim ishodom kao što je navedeno u točki 5.e. 6. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Liječenje započinje primjenom doze od 5 mg/kg u tjednu 0 (nultom), nakon čega slijedi doza od 5 mg/kg u tjednu 2 i 6, a nakon toga doza od 5 mg/kg svakih 8 tjedana. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu 14., izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 14 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijednosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL410 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa, gastroenterologa, dermatovenerologa, pedijatra odgovarajuće subspecijalizacije, oftalmologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda.) 1. Za bolesnike kojima je postavljena dijagnoza juvenilnog idiopatskog artritisa. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje reumatoidnog artritisa 2.a. Indikacija za primjenu (u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest – DAS28 >=5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 2.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno (ili zbog nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka lijeka tocilizumab ili drugog TNF blokatora. 2.c. Prije primjene probir na hepatitis B i C i latentnu TBC prema preporukama HRD. 2.d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 2.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 2.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.d. 3. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa 3.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 3.b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 3.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 3.d. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 3.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 3.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 3.d. 4. Za liječenje aktivnog psorijatičnog artritisa 4.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 4.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. 4.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 4.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 4.e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 4.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 4.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 4.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 4.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 4.e. 5. a. Liječenje fistulirajućeg oblika Crohnove bolesti, b. Liječenje teške aktivne Cronhove bolesti koja je refraktorna na terapiju kortikosteroidima i imunomodulatorima, odnosno u slučaju nepodnošenja ili kontraidikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. 6. Liječenje teškog oblika ulceroznog kolitisa u odraslih bolesnika koji nisu adekvatno odgovorili na knovencionalno liječene kortikosteroidima i 6-merkatopurinom ili azatioprinom odnosno u slučaju nepodnošenja ili kontraidikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. 7. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Liječenje započinje primjenom doze od 80 mg s.c. u tjednu 0 (nultom), nakon čega slijedi doza od 40 mg u tjednu 1, a nakon toga doza od 40 mg svaka 2 tjedana. Primjena adalimumaba odnosno procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu 4., 12. i 28., izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 12 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijedosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. 8. Za liječenje umjerenog do teškog oblika aktivnog gnojnog hidradenitisa (acne inversa) u odraslih bolesnika u kojih nije postignut zadovoljavajući odgovor na konvencionalno sistemsko liječenje gnojnog hidradenitisa. Prije uvođenja lijeka u terapiju, potrebno je zbrojiti apscese, upalne nodule i drenirajuće fistule. Liječenje započinje primjenom početne doze lijeka od 160 mg (ili 4x40 mg u 1 danu ili 2x80 mg u 1 danu ili 80 mg dnevno kroz 2 uzastopna dana). Liječenje se nastavlja 15. dan s dozom od 80 mg (ili 2x40 mg ili 1x80 mg), a 2 tjedna kasnije (29. dan) liječenje se nastavlja s dozom od 40 mg tjedno ili 80 mg svaki drugi tjedan. Primjena adalimumaba odnosno procjena učinka terapije i aktivnosti bolesti treba biti evaluirana nakon 12 tjedana. Nastavak liječenja moguć je isključivo kod pozitivnog kliničkog odgovora , odnosno ukoliko je nakon 12 tjedana postignut HiSCR (engl. Hidradenitis Suppurativa Clinical Response) tj. smanjenje ukupnog broja apscesa i upalnih nodula za 50%, bez povećanja broja apscesa i bez povećanja broja drenirajućih fistula u odnosu na vrijednost prije početka liječenja. Ukoliko je postignut djelomični klinički odgovor (najmanje AN >= 25, odnosno ako je nakon 12 tjedana liječenja zbroj apscesa i upalnih nodula manji za 25% u odnosu na početnu vrijednost prije početka liječenja), liječenje se nastavlja još dodatnih 24. tjedana (ukupno 36 tjedana). Liječenje se nastavlja ukoliko je tada postignut HiSCR u odnosu na početne vrijednosti prije početka liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove. 9. Za liječenje neifekcijskog intermedijarnog i stražnjeg uveitisa i panuveitisa kod odraslih bolesnika kod kojih nije postignut zadovoljavajući učinak liječenjem konvencionalnom imunosupresijskom terapijom ako – a) nema smanjenja upale unatoč 6 mjeseci liječenjem imunosupresivima (bez aktivnih upalnih lezija na fundusu oka, stanice u prednjoj sobici 0,5+ ili manje, zamućenje staklovine 0,5+ ili manje po kriterijima SUN working group) ili b) kod pogoršanja bolesti koje se po kriterijima SUN working group manifestira povećanjem razine inflamacije (stanice u prednjoj očnoj sobici i zamućenja staklovine) za dva stupnja ili sa stupnja 3+ na 4+, perzistiranje aktivne inflamacije i nastanak novih upalnih lezija na fundusu te smanjenje vidne oštrine za >=15 znakova od najbolje dostignute po ETDRS sustavu ili c) kronična supresija uz imunosupresive zahtijeva dnevnu dozu kortikosteroida više od 10 mg prednisona. Prije uvođenja lijeka potrebno je klasificirati uveitis po klasifikaciji međunarodne skupine za proučavanje uveitisa (IUSG) te radne skupine za uveitis (SUN working group). Procjena učinka terapije i aktivnosti bolesti evaluira se nakon 16 tjedana. Nastavak liječenja je isključivo kod pozitivnog kliničkog odgovora. Liječenje započinje primjenom doze od 80 mg s.c. kao početne doze te dalje 40 mg s.c. svaka 2 tjedna počevši od prvog tjedna nakon inicijalne doze. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL411 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu na prijedlog bolničkog specijaliste pedijatra odgovarajuće subspecijalizacije odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda.) 1. Liječenje aktivnog poliartikularnog juvenilnog idiopatskog artritisa, u kombinaciji s lijekom metotreksat, kod djece i adolescenata u dobi od 2 do 17 godina u kojih prethodnim liječenjem jednim ili više antireumatika koji modificiraju tijek bolesti nije postignut zadovoljavajući odgovor, te kao monoterapija u slučajevima nepodnošenja lijeka metotreksat ili kada nastavak terapije lijekom metotreksat nije prikladan. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. a. Liječenje fistulirajućeg oblika Crohnove bolesti, b. Liječenje teške aktivne Cronhove bolesti koja je refraktorna na terapiju kortikosteroidima i imunomodulatorima, odnosno u slučaju nepodnošenja ili kontraidikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. 3. Za liječenje teške kronične plak psorijaze u djece i adolescenata u dobi od 4 ili više godina u kojih nije postignut zadovoljavajući odgovor ili koji nisu prikladni kandidati za topikalnu terapiju i fototerapije, po preporuci specijalista dermatovenerologa. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL412 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa, gastroenterologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za liječenje reumatoidnog artritisa, 1.a. Indikacija za primjenu (u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest, DAS28 >=5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 1.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno (ili zbog nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka lijeka tocilizumab ili drugog TNF blokatora. 1.c. Prije primjene probir na hepatitis B i C i latentnu TBC prema preporukama HRD. 1.d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 1.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 1.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 1.d. 2. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa – 2.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 2.b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 2.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 2.d. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 2.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 2.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.d. 3. Za liječenje aktivnog psorijatičnog artritisa, 3.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 3.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. 3.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 3.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 3.e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 3.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 3.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 3.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 3.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 3.e. 4. Za liječenje teškog oblika ulceroznog kolitisa u odraslih bolesnika koji nisu adekvatno odgovorili na konvencionalno liječenje kortikosteroidima i 6-merkatopurinom ili azatioprinom odnosno u slučaju nepodnošenja ili kontraidikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL413 | Prevencija akutnog odbacivanja organa u de novo alogeničnoj transplantaciji bubrega u odraslih i pedijatrijskih bolesnika. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL414 | 1. Za liječenje sistemskog juvenilnog idiopatskog artritisa u dobi od dvije godine i više. Liječenje odobrava Bolničko Povjerenstvo za lijekove. 2. Za liječenje juvenilnog idiopatskog poliartritisa. Liječenje odobrava Bolničko Povjerenstvo za lijekove. 3. Za liječenje reumatoidnog artritisa 3.a. Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >=5,1 ili DAS28 >=3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 3.b. Prethodna terapija, najmanje 2 lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primjenjen najmanje kroz 2 mjeseca 20 mg tjedno (u slučaju nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka nekog drugog biološkog lijeka. 3.c. Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. 3.d.Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >=5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <=3,2, ako je započeto s DAS28 >=3,2 + 6 otečenih zglobova (od 44), pad DAS28 >=1,2 + 50% manje otečenih zglobova. 3.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 3.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 3 mjeseca, a kasnije za period od 6 mjeseci i dokumentiranim ishodom kao što je navedeno u točki 3.d. |
| NL415 | 1. Samo za bolesnike nakon transplantacije i isključivo za najteže bolesnike s reumatoidnim artritisom, rezistentne na sve načine liječenja u nadležnosti Klinike za reumatske bolesti i rehabilitaciju i Zavoda za kliničku imunologiju KBC i KB te u bolesnika s idiopatskim nefrotskim sindromom nakon započetog bolničkog liječenja. 2. Za liječenje endogenog uveitisa po preporuci specijalista oftalmologa. |
| NL416 | 1. Primarna imunosupresija kod primatelja presatka jetre, 2. prva linija imunosupresivnog liječenja nakon transplantacije bubrega, po preporuci specijalista internista, kirurga ili urologa u KBC i KB nakon započetog bolničkog liječenja, 3. Primarna imunosupresija kod primatelja presatka srca. |
| NL417 | Za liječenje akutne limfoblastične leukemije (ALL) u pedijatrijskih bolesnika kod kojih je bolest u relapsu ili je refraktorna nakon najmanje dva prethodna liječenje i kod kojih nema druge mogućnosti liječenja koje bi dovelo do trajnijeg odgovora. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL418 | Za liječenje odraslih bolesnika s uznapredovalim sarkomom mekih tkiva, nakon neuspješnog liječenja antraciklinima i ifosfamidom ili za liječenje bolesnika, koji ne mogu primiti te lijekove. Liječenje uznapredovalog sarkoma mekih tkiva potrebno je provesti u skladu sa podacima navedenim u Sažetku opisa svojstava lijeka. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL419 | Prva i druga linija liječenja lokalno uznapredovalog ili metastatskog raka pluća ne-malih stanica s aktivirajućom mutacijom tirozin kinaze receptora za epidermalni faktor rasta (EGFR-TK). Kriteriji za primjenu, 1. dokazan lokalno uznapredovali ili metastatski rak pluća ne-malih stanica, 2. dokazana EGFR-TK mutacija u stanicama tumora ili presadnica, 3. odobrava se primjena terapije za dva mjeseca nakon koje slijedi provjera rezultata liječenja. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija, stabilna bolest) do progresije bolesti, 4. liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL420 | 1. Za liječenje bolesnika s uznapredovalim karcinomom bubrežnih stanica u 2. liniji liječenja u kojih je bolest napredovala tijekom ili nakon liječenja lijekovima koji ciljano djeluju protiv čimbenika rasta vaskularnog endotela (VEGF-ciljana terapija). Kriteriji za primjenu – 1. ECOG 0-2, 2. Nepostojanje CNS presadnica, 3. AST i ALT <5x gornja granica normalne vrijednosti, 4. Klirens kreatinina >= 30 ml/min. Odobrava se primjena terapije za 3 mjeseca nakon kojih se provodi provjera učinka terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija ili stabilna bolest) do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. 2. Za liječenje neresektabilnih ili metastatskih, dobro ili umjereno diferenciranih neuroendokrinih tumora s primarnim sijelom u gušterači, u odraslih bolesnika s progresivnom bolešću. Odobrava se 3 mjeseca liječenja, nakon čega se temeljem dijagnostičke obrade ocjenjuje učinak terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti po RECIST kriterijima. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL421 | 1. Prva linija liječenja metastatskog raka bubrega svijetlih stanica, primijenjen kao monoterapija. Kriteriji za primjenu – 1. ECOG 0-1, 2. Nepostojanje CNS presadnica, 3. AST i ALT <5x gornja granica normalne vrijednosti, 4. Klirens kreatinina >= 30 ml/min. Odobrava se primjena terapije za 3 mjeseca nakon kojih se provodi provjera učinka terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija ili stabilna bolest) do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. 2. Za liječenje odraslih bolesnika s određenim podtipovima uznapredovalog sarkoma mekih tkiva koji su prethodno primili kemoterapiju za metastatsku bolest ili kod kojih je došlo do progresije bolesti u roku od 12 mjeseci nakon (neo) adjuvantne terapije. Liječenje uznapredovalog sarkoma mekih tkiva potrebno je provesti u skladu sa podacima navedenim u Sažetku opisa svojstava lijeka. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Oznaka KL samo za liječenje pod 2. |
| NL422 | 1. Za liječenje bolesnika s metastatskim ili neoperabilnim melanomom stadija IIIc u kojih je dokazana BRAF V600 mutacija. ECOG 0-2. Odobrava se primjena dva ciklusa liječenja, nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora i podnošljivosti liječenja. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. Klinička i dijagnostička obrada u cilju procjene uspješnosti liječenja obvezna je svaka 2 mjeseca. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima u čijem je sastavu obvezno internistički onkolog. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. 2. Trametinib u kombinaciji s dabrafenibom za adjuvantno liječenje odraslih bolesnika s melanomom stadija III u kojih je dokazana BRAF V600 mutacija, nakon potpune resekcije. ECOG 0-1. Odobrava se primjena tri ciklusa liječenja, nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene postojanja recidiva bolesti i podnošljivosti liječenja. Liječenje se provodi do znakova recidiva bolesti ili nepodnošenja liječenja a najviše u trajanju od godinu dana. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima u čijem je sastavu obvezno internistički onkolog. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. |
| NL423 | Za mobilizaciju matičnih stanica u bolesnika s limfomima i multiplim mijelomom u kojih se nije uspjelo konvencionalnim načinom mobilizacije sakupiti dovoljan broj matičnih stanica za transplantaciju. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL424 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa, dermatovenerologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Liječenje započinje primjenom doze od 45 mg u tjednu 0 (nultom), nakon čega slijedi doza od 45 mg u tjednu 4, a nakon toga doza od 45 mg svakih 12 tjedana. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu 4., 12. i 28., izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 12 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijedosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje aktivnog psorijatičnog artritisa 2.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primijenjena u punoj dnevnoj dozi kroz 2 mjeseca. 2.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka, lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi 2.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 2.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 2.e. Nakon najmanje 12 tjedana primjene očekivani učinak je 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 2.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 2.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 2.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 2.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.e. |
| NL425 | 1. U monoterapiji kao II. linija kemoterapije karcinoma malih stanica pluća. Liječenje lijekom topotekan dozvoljeno je ukoliko su ispunjeni kriteriji – 1. rezistencija/refrakternost na derivate platine (tj. slobodni interval kraći od 6 mjeseci), 2. ECOG status 0-2, 3. razina bilirubina, AST, ALT <5x iznad gornje granice urednih vrijednosti, 4. kreatinin < 1.5x gornja granica urednih vrijednosti, 5. razina neutrofila >1.5 x (10)9/L, razina trombocita >100 x (10)9/L. Odobrava se primjena dva ciklusa terapije, nakon čega je obvezna klinička i dijagnostička obrada u cilju provjere stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. U I. liniji liječenja uznapredovalog, metastatskog i recidivirajućeg karcinoma vrata maternice. Liječenje lijekom topotekan dozvoljeno je ukoliko su ispunjeni kriteriji – 1. rezistencija na derivate platine (tj. slobodni interval kraći od 6 mjeseci), 2. ECOG status 0-2, 3. nepostojanje presadnica u CNS-u, 4. očekivano trajanje života dulje od 3 mjeseca, 5. zadovoljavajuća bubrežna i jetrena funkcija (AST, ALT <5x iznad gornje granice urednih vrijednosti, kreatinin klirens >20 ml/min), 6. zadovoljavajuća funkcija hematopoetskog sustava (trombociti >100 x(10)9/L, neutrofili >1.5 x (10)9/L, hemoglobin >100g/L). Odobrava se primjena dva ciklusa kemoterapije, nakon kojih je obvezna klinička i dijagnostička obrada u cilju provjere stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz odobrenje Bolničkog povjerenstva za lijekove. |
| NL427 | Za liječenje multiplog mijeloma, u 2. i 3. liniji liječenja, u kombinaciji s deksametazonom u odraslih bolesnika koji su prethodno liječeni lijekom bortezomib. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL428 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti, odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za liječenje reumatoidnog artritisa 1.a. Indikacija za primjenu (u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest – DAS28 >=5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 1.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno (ili zbog nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka lijeka tocilizumab ili drugog TNF blokatora. 1.c. Prije primjene probir na hepatitis B i C i latentnu TBC prema preporukama HRD. 1.d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 1.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje, e. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 1.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 1.d. 2. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa 2.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 2.b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 2.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 2.d. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 2.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 2.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.d. 3. |
|  | Za liječenje aktivnog psorijatičnog artritisa 3.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 3.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. 3.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 3.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 3.e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 3.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 3.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 3.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 3.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 3.e. |
| NL429 | 1. Prva linija liječenja agresivnih non-Hodgkin limfoma, koji su prema nalazu imunohistokemije, imunocitokemije ili protočne citometrije CD20 pozitivni, u kliničkom stadiju II-IV ili stadiju I s povišenim LDH ili velikom tumorskom masom, odobrava se 4 ciklusa liječenja (1 i.v. + 3 s.c.) u kombinaciji s kemoterapijom. U slučaju povoljnog učinka odobrava se primjena još 4 ciklusa terapije (s.c.). 2. Prva linija liječenja bolesnika s neliječenim CD20 pozitivnim indolentnim non-Hodgkin limfomom. Odobrava se primjena 8 ciklusa liječenja (1 i.v. + 7 s.c.). 3. Liječenje bolesnika sa indolentnim B-staničnim non-Hodgkinovim limfomom u relapsu odnosno u bolesnika sa kemorezistentnim tipom B-staničnog non-Hodgkinovog limfoma niskog stupnja malignosti u kojih je imunohistokemijski i/ili protočnom citometrijom dokazano da stanice na sebi imaju CD20 biljeg. Odobrava se primjena 3 ciklusa liječenja (1 i.v. + 2 s.c.) uz obveznu reevaluaciju učinka nakon trećeg ciklusa terapije. U slučaju povoljnog učinka odobrava se primjena još 3 ciklusa terapije (s.c.). Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista internista hematologa. Lijek se primjenjuje u fiksnoj dozi od 1400 mg po ciklusu. Prije početka primjene s.c. injekcija, svi bolesnici uvijek moraju najprije intravenskom infuzijom primiti cijelu dozu lijeka rituksimab u formulaciji za intravensku primjenu u 1. ciklusu liječenja. Liječenje pod 1. i 2. odobrava se iz sredstava posebno skupih lijekova, a liječenje pod 3. iz sredstava bolničkog proračuna. |
| NL430 | Za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom bubrega u drugoj liniji, nakon prethodnog neuspješnog liječenja tirozin kinaznim inhibitorom ili citokinom. Kriteriji za primjenu – 1. funkcija bubrega – klirens kreatinina >30 ml/min, 2. nepostojanje CNS presadnica, 3. status ECOG 0-2. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista onkologije i radioterapije ili inetrnističke onkologije. Odobrava se primjena terapije na 3 mjeseca, nakon kojih se provodi provjera učinka terapije. Nastavak liječenja moguć je samo u slučaju postojanja kliničkog odgovora (kompletan odgovor, parcijalna remisija ili stabilna bolest). |
| NL431 | Prva linija liječenja bolesnika s metastatskim rakom debelog crijeva kod kojih je potvrđeno nepostojanje RAS mutacija (‘divlji tip’ RAS statusa 2, 3 i 4 ekson KRAS-a, odnosno NRAS-a) što se određuje u laboratorijjima sa validiranom metodom određivanja. Primjenjuje se u prvoj liniji liječenja u kombinaciji sa kemoterapijom po FOLFOX ili FOLFIRI-protokolu ili kao monoterapija nakon progresije bolesti, a nakon prethodnog liječenja kemoterapijom irinotekanom, oksaliplatinom i fluoropirimidinima. Kriteriji za primjenu – 1. tjelesni status 0 i 1 po ECOG (Karnofsky 80-100), 2. nepostojanje presadnica u CNS-u, 3. razina bilirubina <1,5 x gornja granica normalne vrijednosti, 4. razina AST i ALT <5x gornja granica normalne vrijednosti, 5. Klirens kreatinina >50 ml/min, 6. razina granulocita > 1.5x(10)9/L, 7. razina trombocita >100x(10)9/L. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista onkologa (specijalista radioterapije i onkologije, specijalista radioterapije ili subspecijalista internističke onkologije). Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). |
| NL432 | Za liječenje odraslih bolesnika s relapsno-remitentnom multiplom sklerozom uz EDSS <=6 i odsutnost trudnoće – I. kod bolesnika kod kojih je bolest aktivna i koji nisu odgovorili na potpuni i odgovarajući režim liječenja barem jednom terapijom koja modificira tijek bolesti (interferon beta, glatiramer acetat, teriflunomid, dimetil fumarat), odnosno kada su ispunjeni kriteriji za prekid navedene terapije prema važećim smjernicama u listi lijekova. Bolest se smatra aktivnom usprkos provedenoj prethodnoj terapiji uz – a) >= 4 nove T2 hiperintenzivne lezije na MR-u ili b) >= 2 relapsa. II. Bolesnici s teškom, visokoaktivnom RRMS – definiranom s 2 ili više onesposobljavajućih relapsa u 1 godini (onesposobljavajući relaps definira se kao porast EDSS-a u relapsu za jednako ili više od 2 boda), Liječenje odobrava Bolničko povjerenstvo za lijekove. Odobravaju se ukupno dva ciklusa liječenja – prvi ciklus tijekom 5 uzastopnih dana prve godine, a drugi ciklus 3 uzastopna dana 12 mjeseci nakon prvog ciklusa liječenja. |
| NL433 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za liječenje reumatoidnog artritisa 1.a. Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >=5,1 ili DAS28 >=3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 1.b. Prethodna terapija, najmanje 2 lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primjenjen najmanje kroz 2 mjeseca 20 mg tjedno (u slučaju nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka nekog drugog biološkog lijeka. 1.c. Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. 1.d.Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >=5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <=3,2, ako je započeto s DAS28 >=3,2 + 6 otečenih zglobova (od 44), pad DAS28 >=1,2 + 50% manje otečenih zglobova. 1.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 1.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa/kliničkog imunologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 1.d. |
| NL434 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu na prijedlog bolničkog specijaliste pedijatra odgovarajuće subspecijalizacije odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda.) Za liječenje 1. Juvenilnog idiopatskog artritisa. 2. Poliartritisa (s pozitivnim i negativnim reumatoidnim faktorom) i produljenog oligoartritisa u djece i adolescenata starijih od 2 godine u kojih postoji neadekvatan odgovor na metotreksat ili ga dokazano ne podnose. 3. Psorijatičnog artritisa u adolescenata starijih od 12 godina u kojih postoji neadekvatan odgovor na metotreksat ili ga dokazano ne podnose. 4. Artritisa povezanog s entezitisom u adolescenata starijih od 12 godina u kojih postoji neadekvatan odgovor na konvencionalnu terapiju ili je dokazano ne podnose. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL436 | Prva linija liječenja odraslih bolesnika s metastatskim adenokarcinomom gušterače, u kombinaciji s gemcitabinom. Kriteriji za primjenu – 1. ECOG 0-1, 2. razina bilirubina <1,5x gornja granica normalne vrijednosti, 3. AST i ALT <3x gornja granica normalne vrijednosti, 4. Klirens kreatinina >50 ml/min. 5. razina granulocita >1,5 X(10)9/L, razina trombocita >100X (10)9/L. Odobrava se primjena terapije za 3 mjeseca nakon kojih se provodi provjera učinka terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija ili stabilna bolest) do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL437 | 1. Za liječenje odraslih bolesnika s umjereno do izrazito aktivnom Crohnovom bolesti koji nisu postigli odgovarajući odgovor ili su izgubili odgovor ili na standardnu terapiju ili na antagoniste faktora nekroze tumora alfa (TNFα), te u slučaju dokumentiranog nepodnošenja takve terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje odraslih bolesnika s umjereno do izrazito aktivnim ulceroznim kolitisom koji nisu postigli odgovarajući odgovor ili su izgubili odgovor ili na standardnu terapiju ili na antagoniste faktora nekroze tumora alfa (TNFα), te u slučaju dokumentiranog nepodnošenja takve terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL438 | Za drugu liniju liječenja bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju (kod bolesnika kod kojih je bolest napredovala tijekom ili nakon kemoterapijskog protokola temeljenog na docetakselu, u kumulativnoj/ukupnoj dozi od barem 225 mg/m2). Lijek se primjenjuje u kombinaciji s prednizonom ili prednizolonom, kod bolesnika koji imaju tjelesni status 0 ili 1 po ECOG. Odobravaju se 3 ciklusa liječenja, nakon čega se temeljem dijagnostičke obrade ocjenjuje učinak terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti. Progresijom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL439 | 1. Za liječenje bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju koji su asimptomatski ili imaju blage simptome nakon neuspješnog liječenja androgenom deprivacijom te u kojih kemoterapija još nije klinički indicirana. Odobravaju se 3 ciklusa liječenja, nakon čega se temeljem dijagnostičke obrade ocjenjuje učinak terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti. Progresijom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. Liječenje se odobrava iz sredstava bolničkog proračuna. 2. Za drugu liniju liječenja bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju, kod kojih je bolest napredovala tijekom ili nakon kemoterapijskog protokola temeljenog na docetakselu u kumulativnoj/ukupnoj dozi od barem 225 mg/m2. Odobravaju se 3 ciklusa liječenja, nakon čega se temeljem dijagnostičke obrade ocjenjuje učinak terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti. Progresijom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. Liječenje se odobrava iz sredstava bolničkog proračuna. 3. Za liječenje bolesnika s nemetastatskim, kastracijski rezistentnim karcinomom prostate (nmCRPC) koji zadovoljavaju kriterij definicije visokog rizika odnosno u kojih je vrijeme udvostručenja PSA ≤ 10 mjeseci (PSA-DT ≤10 mjeseci), ECOG statusa 0-1. Potrebna je klinička i dijagnostička obrada svaka 3 mjeseca radi procjene učinka terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti, a kojom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. Liječenje se odobrava iz sredstava posebno skupih lijekova. 4. Za liječenje odraslih muškaraca s hormonski osjetljivim metastatskim karcinomom prostate u kombinaciji s terapijom deprivacije androgena. Odobravaju se 3 ciklusa liječenja, nakon čega se temeljem dijagnostičke obrade ocjenjuje učinak terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti. Progresijom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. Liječenje se odobrava iz sredstava bolničkog proračuna. |
| NL440 | 1. Za liječenje bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju koji su asimptomatski ili imaju blage simptome nakon neuspješnog liječenja androgenom deprivacijom te u kojih kemoterapija još nije klinički indicirana. Lijek se primjenjuje u kombinaciji s prednizonom ili prednizolonom. Odobravaju se 3 ciklusa liječenja, nakon čega se temeljem dijagnostičke obrade ocjenjuje učinak terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti. Progresijom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za drugu liniju liječenja bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju, kod kojih je bolest napredovala tijekom ili nakon kemoterapijskog protokola temeljenog na docetakselu u kumulativnoj/ukupnoj dozi od barem 225 mg/m2. Lijek se primjenjuje u kombinaciji s prednizonom ili prednizolonom. Odobravaju se 3 ciklusa liječenja, nakon čega se temeljem dijagnostičke obrade ocjenjuje učinak terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti. Progresijom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. 3. Za liječenje odraslih muškaraca s novodijagnosticiranim hormonski osjetljivim metastatskim karcinomom prostate visokog rizika u kombinaciji s terapijom deprivacije androgena, koji nisu kandidati za primjenu kemoterapije ili koji nisu odgovorili ili ne podnose započetu terapiju docetakselom. Lijek se primjenjuje u kombinaciji s prednizonom ili prednizolonom. Odobravaju se 3 ciklusa liječenja, nakon čega se temeljem dijagnostičke obrade ocjenjuje učinak terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti. Progresijom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL441 | Za liječenje kronične limfocitne leukemije i indolentnih non-Hodgkin limfoma po preporuci specijalista internista hematologa. |
| NL442 | 1. Za liječenje odraslih bolesnika s relapsom ili refraktornim oblikom CD30+ Hodgkinovog limfoma, nakon transplantacije autolognih matičnih stanica (ASCT). 2. Za liječenje odraslih bolesnika s relapsom ili refraktornim oblikom CD30+ Hodgkinovog limfoma nakon najmanje dvije prethodne linije liječenja, kad transplantacija autolognih matičnih stanica (ASCT) ili kombinirana kemoterapija nisu terapijska opcija. 3. Za liječenje odraslih bolesnika s relapsom ili refraktornim oblikom sistemskog anaplastičnog velikostaničnog limfoma (sALCL). 4. Za liječenje odraslih bolesnika sa CD30+ Hodgkinovim limfomom s povećanim rizikom relapsa ili progresije bolesti nakon ASCT. 5. Za liječenje odraslih bolesnika sa CD30+ kožnim limfomom T-stanica nakon najmanje 1 prethodne sistemske terapije. 6. Za liječenje odraslih bolesnika s prethodno neliječenim CD30+ Hodgkinovim limfomom u četvrtom stadiju, u kombinaciji s doksorubicinom, vinblastinom i dakarbazinom (AVD). Odobrava se šest ciklusa liječenja uz obveznu procjenu učinka nakon četvrtog ciklusa terapije. Liječenje se prekida ako se pri procjeni učinka zabilježi progresija bolesti ili izostanak odgovora, u slučaju nepodnošljive toksičnosti ili preosjetljivosti na djelatnu tvar. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista hematologa. Liječenje se odobrava iz sredstava posebno skupih lijekova. 7. Za liječenje odraslih bolesnika s prethodno neliječenim sistemskim anaplastičnim velikostaničnim limfomom u kombinaciji s ciklofosfamidom, doksorubicinom i prednizonom (CHP). Odobrava se šest do osam ciklusa liječenja uz obveznu procjenu učinka nakon četvrtog ciklusa terapije. Liječenje se prekida ako se pri procjeni učinka zabilježi progresija bolesti ili izostanak odgovora, u slučaju nepodnošljive toksičnosti ili preosjetljivosti na djelatnu tvar. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista hematologa. Liječenje se odobrava iz sredstava posebno skupih lijekova. |
| NL443 | 1. Za liječenje u kombinaciji s trastuzumabom i kemoterapijom odraslih bolesnika s HER2 pozitivnim lokalno recidivirajućim, neresektabilnim ili metastatskim rakom dojke koji prethodno za liječenje metastatske bolesti nisu primali anti – HER2 terapiju ni kemoterapiju. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu reevaluaciju učinka nakon četiri ciklusa liječenja. Nakon prestanka kemoterapije, a prema odluci nadležnog onkologa, liječenje kombinacijom pertuzumaba i trastuzumaba (s ili bez hormonske terapije) se nastavlja do progresije bolesti ili do pojave neprihvatljive toksičnosti. Svaka slijedeća evaluacija učinka liječenja se radi nakon provedenih šest ciklusa liječenja. 2. Za neoadjuvantno liječenje u kombinaciji s trastuzumabom i kemoterapijom odraslih bolesnika s HER2 pozitivnim, lokalno uznapredovalim, upalnim ili rakom dojke u ranom stadiju s velikim rizikom od recidiva. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. 3. Za adjuvantno liječenje bolesnica s HER2 pozitivnim rakom dojke s visokim rizikom povrata bolesti, u kombinaciji s lijekom trastuzumab, a koje imaju barem jedno od obilježja – 1. Pozitivni limfni čvorovi, 2. Negativni hormonski receptori (tumori veličine T2 i veći). Lijek pertuzumab treba primjenjivati u kombinaciji s lijekom trastuzumab (supkutano ili intravenski) tijekom ukupno godinu dana, odnosno do recidiva bolesti ili do pojave toksičnosti koja se ne može zbrinuti, kao dio cjelovitog protokola za liječenje ranog raka dojke, neovisno o vremenu kirurškog zahvata. Ukupno trajanje liječenja (neoadjuvantno+adjuvantno) može trajati ukupno do godinu dana. Liječenje odobrava Bolničko povjerenstvo za lijekove na teret sredstava posebno skupih lijekova na prijedlog multidisciplinarnog tima za tumore dojke. |
| NL444 | Za liječenje bolesnika s uznapredovalim rakom pluća nemalih stanica pozitivnim na kinazu anaplastičnog limfoma (ALK) u prvoj ili drugoj liniji liječenja i za liječenje bolesnika s ROS1-pozitivnim uznapredovalim rakom pluća nemalih stanica (NSCLC). Liječenje odobrava Bolničko povjerenstvo za lijekove. Odobravaju se dva ciklusa liječenja, nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora i podnošljivosti liječenja, od kojih 2. ciklus liječenja može teretiti sredstva posebno skupih lijekova. Nastavak liječenja je moguć na teret sredstava posebno skupih lijekova isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. |
| NL446 | Prva linija liječenja metastatskog karcinoma dojke u odraslih žena, u kombinaciji s ciklofosfamidom. |
| NL449 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa, dermatovenerologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa – 1.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 1.b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 1.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 1.d. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 1.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 1.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 1.d. 2. Za liječenje aktivnog psorijatičnog artritisa 2.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 2.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. 2.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 2.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 2.e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 2.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 2.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 2.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 2.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.e. 3. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sistemska lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebno je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Liječenje započinje primjenom doze od 300 mg u tjednu 0 (nultom), 1., 2. i 3. tjednu, nakon čega slijedi mjesečna doza održavanja počevši od 4. tjedna u dozi od 300 mg (15 aplikacija u prvoj godini liječenja i 12 aplikacija u drugoj i svakoj slijedećoj godini). Procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu 4., 12. i 28., izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 12 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijednosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL450 | 1. Adjuvantno liječenje odraslih bolesnika s HER2 pozitivnim ranim rakom dojke koji imaju rezidualnu invazivnu bolest u dojci i/ili limfnim čvorovima nakon neoadjuvantne terapije utemeljene na taksanu i ciljanoj HER2 terapiji. Liječenje lijekom Kacyla traje 14 ciklusa, osim u slučaju nepodnošljive toksičnosti kada se bolesnici mogu vratiti na liječenje ciljanom antiHER2 terapijom, monoterapijom trastuzumabom ili kombinacijom lijekova trastuzumab i pertuzumab. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. 2. Druga linija liječenja odraslih bolesnika s HER2 pozitivnim, neoperabilnim lokalno uznapredovalim ili metastatskim rakom dojke, u monoterapiji, koji su prethodno primali trastuzumab i taksan, odvojeno ili u kombinaciji. Bolesnici su trebali ili a. prethodno primati terapiju za lokalno uznapredovalu ili metastatsku bolest, ili b. imati povrat bolesti tijekom ili unutar 6 mjeseci od završetka adjuvantne terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). uz obveznu prvu procjenu terapijskog učinka liječenja nakon 4 ciklusa liječenja. Svaka slijedeća procjena se radi nakon provedenih 6 ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL451 | 1. U kombinaciji s klorambucilom za liječenje odraslih bolesnika s prethodno neliječenom kroničnom limfocitnom leukemijom (KLL) i komorbiditetima, zbog kojih kod istih nije prikladno liječenje temeljeno na punoj dozi fludarabina. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa, ukupno do najviše 6 ciklusa. 2. U kombinaciji s bendamustinom, nakon čega slijedi terapija održavanja lijekom obinutuzumab, za liječenje bolesnika s folikularnim limfomom (FL) koji nisu odgovorili na liječenje rituksimabom ili protokolom koji sadrži rituksimab ili su doživjeli progresiju tijekom ili do 6 mjeseci nakon takvog liječenja. Odobrava se primjena tri ciklusa liječenja uz obveznu reevaluaciju učinka nakon trećeg ciklusa terapije. U slučaju povoljnog učinka odobrava se primjena još tri ciklusa terapije. Nakon 6 ciklusa liječenja potrebno je učiniti reevaluaciju učinka terapije. Ukoliko je postignuta kompletna remisija bolesti slijedi terapija održavanja lijekom obinutuzumab do najviše 24 mjeseca uz obveznu reevaluaciju učinka terapije nakon 12 mjeseci liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista internista hematologa. 3. Obintuzumab je u kombinaciji s kemoterapijom ili kao monoterapija indiciran za liječenje bolesnika s prethodno neliječenim uznapredovalim folikularnim limfomom stadija II-IV i jednom od slijedećih karakteristika bolesti – masivna bolest, simptomatska bolest, vrijeme podvostručenja tumorske mase <1 godine, citopenija, uz napomenu za provođenje terapije – a.) Uvodno liječenje obintuzumabom u kombinaciji s bendamustinom (6 ciklusa uz kemoterapiju + 2 ciklusa monoterapija) ili alternativno osobito za FL stadija 3a CHOP-om (6 ciklusa uz kemoterapiju + 2 ciklusa monoterapija). Za bolesnike kod kojih je važno smanjiti toksičnost obintuzumab se kombinira s CVP ili Clb (8 ciklusa). b.) Terapija održavanja obIntuzumabom kao monoterapijom svaka 2 mjeseca, tijekom dvije godine ukoliko je postignut potpun ili djelomičan odgovor nakon provedenog uvodnog liječenje. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista internista hematologa. |
| NL452 | 1.1 Za liječenje bolesnika s metastatskim ili neoperabilnim melanomom stadija IIIc, osim uvealnog melanoma. ECOG status 0-1. Procjena uspješnosti liječenja primjenom RECIST i irRC kriterija obvezna je svaka 3 mjeseca. Ukoliko se nakon prve procjene utvrdi da je došlo do progresije bolesti terapija se do sljedeće procjene može nastaviti u bolesnika koji zadovoljavaju slijedeće kriterije – 1. odsutnost simptoma koji ukazuju na progresiju bolesti, 2. nema pogoršanja ECOG statusa, 3. odsutnost brze progresije bolesti ili progresije bolesti na kritičnim anatomskim mjestima koja bi zahtijevala hitnu medicinsku intervenciju. Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti.  Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima u čijem je sastavu obvezno internistički onkolog. Liječenje se može započeti u Kliničkim bolničkim centrima.  Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. 1.2 Za adjuvantno liječenje operabilnog melanoma stadija III u odraslih kod kojih je bolest zahvatila limfne čvorove i koji su podvrgnuti potpunoj resekciji. ECOG status 0-1. Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca. Liječenje se provodi do znakova recidiva bolesti ili nepodnošenja liječenja, a najviše u trajanju od godinu dana. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima u čijem je sastavu obvezno internistički onkolog. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje.  2.1 Prva linija liječenja metastatskog karcinoma pluća nemalih stanica u odraslih čiji tumori eksprimiraju PD-L1 uz udio tumorskih stanica s ekspresijom >=50% i koji nisu pozitivni na tumorske mutacije gena EGFR ili ALK ili ROS1 (napomena: mutacije je potrebno isključiti samo u neskvamoznom karcinomu pluća nemalih stanica), a imaju ECOG status 0-1. 2.2. Prva linija liječenja metatastatskog neskvamoznog karcinoma pluća nemalih stanica u kombinaciji s kemoterapijom koja sadrži platinu za liječenje odraslih čiji tumori eksprimiraju PD-L1 uz udio tumorskih stanica s ekspresijom 1-49% i koji nisu pozitivni na tumorske mutacije gena EGFR ili ALK ili ROS1, a imaju ECOG status 0-1. 2.3 U l. liniji liječenja metastatskog skvamoznog karcinoma pluća nemalih stanica u kombinaciji sa karboplatinom i paklitakselom za liječenje odraslih čiji tumori eksprimiraju PD-L1 uz udio tumorskih stanica s ekspresijom 1-49%, a imaju ECOG status 0-l.  2.4. Prva linija liječenja metatastatskog neskvamoznog karcinoma pluća nemalih stanica u kombinaciji s kemoterapijom koja sadrži platinu za liječenje odraslih čiji tumori eksprimiraju PD-L1 <1% i koji nisu pozitivni na tumorske mutacije gena EGFR ili ALK ili ROS1, a imaju ECOG status 0-1.  2.5. U l. liniji liječenja metastatskog skvamoznog karcinoma pluća nemalih stanica u kombinaciji sa karboplatinom i paklitakselom za liječenje odraslih čiji tumori eksprimiraju PD-L1 <1%, a imaju ECOG status 0-l.  Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja pod točkom 2.1, 2.2, 2.3, 2.4 i 2.5 obvezna je svaka 2 mjeseca, a nakon provedenih 6 mjeseci liječenja klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima za tumore torakalnih organa iz Kliničkog bolničkog centra. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje.  3.1. Monoterapija u prvoj liniji liječenja odraslih bolesnika sa lokalno uznapredovalim ili metastatskim urotelnim karcinomom, koji se ne smatraju pogodnima za liječenje cisplatinom (što podrazumijeva – WHO ili ECOG status >=2 ili klirens kreatinina <55 ml/min ili zatajenje srca NYHA III ili perifernu neuropatiju stupnja >=2) i čiji tumor pokazuju razinu ekspresije CPS >=10 potvrđene validiranim testom, samo ako su ECOG-statusa 0-1, uz laboratorijske nalaze AST, ALT < 2,5x GGN, odnosno bilirubin do 1,5x GGN, klirens kreatinina >30 ml/min, a očekivano preživljenje najmanje 6 mjeseci,  3.2. Druga linija liječenja odraslih bolesnika sa lokalno uznapredovalim ili metastatskim urotelnim karcinomom koji su prethodno primali kemoterapiju koja je sadržavala platinu, samo ako su ECOG-statusa 0-1, uz laboratorijske nalaze AST, ALT < 2,5x GGN, bilirubin do 1,5x GGN, odnosno klirens kreatinina >30 ml/min, a očekivano preživljenje najmanje 6 mjeseci.  Klinička i dijagnostička obrada radi procjene uspješnosti liječenja primjenom RECIST i irRC kriterija obvezna je svaka 3 mjeseca, a nastavak liječenja moguće je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), a sve do progresije bolesti ili pojave nepodnošljive toksičnosti. Ukoliko se nakon prve procjene utvrdi da je došlo do progresije bolesti terapija se do slijedeće procjene može nastaviti u bolesnika koji zadovoljavaju slijedeće kriterije – 1. odsutnost simptoma koji ukazuju na neupitnu progresiju bolesti, 2. nema daljnjeg pogoršanja ECOG-statusa, 3. izostanak tumorske progresije na kritičnim anatomskim mjestima koja se ne može jednostavno zbrinuti i stabilizirati medicinskim intervencijama dopuštenima prema protokolu prije ponovljenog doziranja. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima za urogenitalne tumore. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje.  4. Prva linija liječenja metastatskog kolorektalnog karcinoma s visokom mikrosatelitskom nestabilnosti ili s nedostatkom mehanizma popravka pogrešno spojenih baza u odraslih s ECOG statusom 0-1. Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca. Liječenje se provodi do potvrđenog recidiva bolesti ili znakova nepodnošenja liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima. Liječenje je potrebno započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. |
| NL453 | Za liječenje splenomegalije kod odraslih bolesnika s primarnom mijelofibrozom (koja se naziva i kronična idiopatska mijelofibroza) i sekundarne mijelofibroze nakon policitemije rubre vere ili nakon esencijalne trombocitemije. Kriteriji za primjenu lijeka – Liječe se bolesnici koji imaju bolest srednjeg i visokog rizika (International prognostic scoring system IPSS 2 i viši ) Liječenje se odobrava inicijalno na 3 mjeseca. Reevaluacija liječenja se inicijalno vrši nakon 3 mjeseca kliničkim pregledom i dijagnostičkom obradom s ciljem provjere duljine slezene. Liječenje se prekida – a) ako nakon 3 mjeseca od početka liječenja nije UZV-om dokazano smanjenje slezene ili kliničkim pregledom nije došlo do poboljšanja statusa b) ako nakon 6 mjeseci od početka liječenja mjereno MR-om ili CT-om nije došlo do smanjenja volumena slezene od 25 % u odnosu na početni volumen ili 30 % smanjenja duljine slezene mjereno UZV-om ili CT-om ili MR-om (dovoljno je da je zadovoljen jedan od navedena dva kriterija) te ako nije postignuto daljnje poboljšanje simptoma bolesti uz terapiju (kliničkim pregledom nije došlo do poboljšanja statusa bolesnika od >= 20% po Karnofsky skali u usporedbi s početnom vrijednosti) Daljnje se reevaluacije vrše svakih 6 mjeseci, a liječene se prekida ako je u nekoj od sljedećih reevaluacija utvrđeno povećanje slezene. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijaliste hematologa. |
| NL454 | 1. Za liječenje odraslih bolesnika s kroničnom limfocitnom leukemijom (KLL) s delecijom kromosoma 17p odnosno mutacijom p53 ili kod prethodno liječenih bolesnika koji su refrakterni na terapiju ili su u ranom relapsu, a koji se definira kao relaps unutar 24 mjeseca od završetka prethodne terapije. Kriteriji za primjenu lijeka – Prije početka terapije obvezno je učiniti citogenetsko testiranje, FISH iz koštane srži/periferne krvi te radiološki procijeniti veličinu limfnih čvorova, jetre i slezene, odnosno infiltraciju organa. Liječe se bolesnici s prisutnim simptomima bolesti koji imaju jedan od kriterija – a) visok rizik – po RAI-u III-IV b) TTM veći ili jednako 15 c) masivnu tumorsku bolest (jedan čvor ili konglomerat > 10 cm ili progresivna ili simptomatska limfadenopetija) d) imaju značajne B simptome koji ometaju kvalitetu života (jedan ili više navedenih simptoma – nenamjerni gubitak tjelesne težine >= 10% u zadnjih 6 mjeseci, temperatura > 38 stupnjeva C u trajanju 2 ili više tjedna bez dokaza infekcije, noćno znojenje duže od mjesec dana bez dokaza infekcije). ECOG 0-2. (Lijek idelalisib se odobrava u kombinaciji s lijekom rituksimab). Procjenu terapijskog učinka prvi puta obvezno je provesti najkasnije 6 mjeseci od početka liječenja, a nastavak liječenja je moguć ako bolesnici zadovoljavaju jedan od kriterija a) ako je došlo do smanjenja tumorske mase >=50% u odnosu na početne vrijednosti mjerenja po TTM-u (u reevaluaciji obavezno učiniti UZV ili CT koji potvrđuje smanjenje >=50%) b) ako je došlo do poboljšanja RAI statusa sa stupnja III-IV na I-II-III (učiniti laboratorijsku obradu koja potvrđuje smanjenje RAI-a III-IV na RAI I-II-III) c) ako je došlo do poboljšanja anemije (ako inicijalno hemoglobin 80-100 g/l porast >100 g/l, ako inicijalno <80 g/l bolesnik je postao neovisan o transfuzijama) ili trombocitopenije (trombociti iznad 100x109/L ili porast za >50% od inicijalne vrijednosti ili neovisnost bolesnika o transfuzijama) d) značajno smanjenje B simptoma. Nakon toga liječenje se prekida u slučaju progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. |
| NL455 | Lijek se može primijeniti kod bolesnika koji boluju od idiopatske plućne fibroze ukoliko im FVC iznosi između 50% i 80% od očekivane vrijednosti. Terapija lijekom se treba ukinuti ukoliko je pogoršanje FVC >=10% u bilo kojem 12-mjesečnom razdoblju. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista pulmologa. |
| NL456 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa, dermatovenerologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Nakon početne titracije lijeka dozom od 160 mg supkutanom injekcijom u 0. tjednu, potom 80 mg u 2., 4., 6., 8., 10. i 12. tjednu, slijedi doza od 80 mg svaka 4 tjedna. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu nakon 12 tjedana izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 12 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijednosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje aktivnog psorijatičnog artritisa 2.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 2.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. 2.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 2.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 2.e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 2.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 2.g. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 2.h. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.e. 3. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa. 3.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 3.b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 3.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 3.d. Nakon najmanje 12 tjedana primjene očekivani učinak je -50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 3.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 3.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 3.d. |
| NL457 | Kao monoterapija u visoko aktivnoj relapsno-remitentnoj multiploj sklerozi s fazama relapsa i remisije uz EDSS <=6 i odsutnost trudnoće – I. kod bolesnika kod kojih je bolest aktivna i koji nisu odgovorili na potpuni i odgovarajući režim liječenja barem jednom terapijom koja modificira tijek bolesti (interferon beta, glatiramer acetat, teriflunomid, dimetil fumarat), odnosno kada su ispunjeni kriteriji za prekid navedene terapije prema važećim smjernicama u listi lijekova. Bolest se smatra aktivnom usprkos provedenoj prethodnoj terapiji uz – a) >= 4 nove T2 hiperintenzivne lezije na MR-u ili b) >= 2 relapsa. Liječenje odobrava Bolničko povjerenstvo za lijekove. II. kod bolesnika kod kojih se očituje teška brzonapredujuća relapsno-remitentna multipla skleroza. Liječenje odobrava Bolničko povjerenstvo za lijekove na teret sredstava bolničkog proračuna. |
| NL459 | Kod bolesnika sa esencijalnom trombocitemijom u stanjima nepotpunog odgovora na hidroksikarbamid te kod bolesnika bez simptoma koji su mlađi od 60 godina, a trombociti >1000x(10)9/L. Po preporuci specijalista hematologa. |
| NL463 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa, gastroenterologa, dermatovenerologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Liječenje započinje primjenom doze od 90 mg u tjednu 0 (nultom), nakon čega slijedi doza od 90 mg u tjednu 4, a nakon toga doza od 90 mg svakih 12 tjedana (kod bolesnika TT > 100 kg). Procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu 4., 12. i 28., izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 12 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijedosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje aktivnog psorijatičnog artritisa 2.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primijenjena u punoj dnevnoj dozi kroz 2 mjeseca. 2.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka, lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi 2.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 2.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 2.e. Nakon najmanje 12 tjedana primjene očekivani učinak je 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 2.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 2.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 2.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 2.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.e. 3. Za liječenje odraslih bolesnika s umjerenim do teškim oblikom aktivne Crohnove bolesti, koji su imali neadekvatan odgovor ili su izgubili odgovor ili nisu podnosili bilo konvencionalnu terapiju ili terapiju antagonistom TNF-a ili su imali medicinske kontraindikacije za takve terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove. 4. Za liječenje odraslih bolesnika s umjerenim do teškim oblikom ulceroznog kolitisa, koji nisu postigli odgovarajući odgovor ili su izgubili odgovor ili nisu podnosili konvencionalnu terapiju ili biološku terapiju ili koji imaju medicinske kontraindikacije za takve terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL464 | 1. Za liječenje odraslih bolesnika s umjerenim do teškim oblikom aktivne Crohnove bolesti, koji su imali neadekvatan odgovor ili su izgubili odgovor ili nisu podnosili bilo konvencionalnu terapiju ili terapiju antagonistom TNF-a ili su imali medicinske kontraindikacije za takve terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje odraslih bolesnika s umjerenim do teškim oblikom ulceroznog kolitisa, koji nisu postigli odgovarajući odgovor ili su izgubili odgovor ili nisu podnosili konvencionalnu terapiju ili biološku terapiju ili koji imaju medicinske kontraindikacije za takve terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL466 | 1. Za liječenje bolesnika s metastatskim rakom debelog crijeva nakon neuspjeha prethodne terapije (na bazi fluoropirimidina, s irinotekanom i/oksaliplatinom, te anti-VEGF terapije ili anti-EGFR terapije (ili se ne smatraju kandidatima za liječenje dostupnim terapijama), a koji su još uvijek dobrog stanja (ECOG 0-2). Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista onkologa. Odobrava se primjena terapije za 3 mjeseca, nakon kojih se provodi provjera učinka terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest). 2. Kao monoterapija za liječenje odraslih bolesnika s metastatskim karcinomom želuca uključujući adenokarcinom gastroezofagealnog spoja koji su prethodno bili liječeni s najmanje dva režima sistemskog liječenja uznapredovale bolesti, a koji su još uvijek dobrog stanja (ECOG 0-2). Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista onkologa. Odobrava se primjena terapije za 3 mjeseca, nakon kojih se provodi provjera učinka terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest). |
| NL467 | 1. Za liječenje bolesnika s metastatskim ili neoperabilnim melanomom stadija IIIc, osim uvealnog melanoma. ECOG status 0-1. Procjena uspješnosti liječenja primjenom RECIST i irRC kriterija obvezna je svaka 3 mjeseca. Ukoliko se nakon prve procjene utvrdi da je došlo do progresije bolesti terapija se do sljedeće procjene može nastaviti u bolesnika koji zadovoljavaju slijedeće kriterije – 1. odsutnost simptoma koji ukazuju na progresiju bolesti, 2. nema pogoršanja ECOG statusa, 3. odsutnost brze progresije bolesti ili progresije bolesti na kritičnim anatomskim mjestima koja bi zahtijevala hitnu medicinsku intervenciju. Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima u čijem je sastavu obvezno internistički onkolog. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. 2. Druga linija liječenja uznapredovalog karcinoma bubrežnih stanica (RCC), u monoterapiji, u odraslih osoba nakon prethodne terapije. Kriteriji za primjenu – a. ECOG status 0-1, b. nepostojanje stanja koje zahtjeva sistemsko liječenje kortikosteroidima (ekvivalentno dozi prednizona > 10 mg dnevno) ili drugim imunosupresivnim lijekovima unutar 14 dana prije prve doze lijeka. Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima za urogenitalne tumore. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. 3. Druga linija liječenja odraslih bolesnika sa lokalno uznapredovalim ili metastatskim urotelnim karcinomom koji su prethodno primali kemoterapiju koja je sadržavala platinu, samo ako su ECOG-statusa 0-1, uz laboratorijske nalaze AST, ALT do 5x GGN, bilirubin do 3x GGN, odnosno klirens kreatinina >30 ml/min, a očekivano preživljenje najmanje 6 mjeseci. Klinička i dijagnostička obrada radi procjene uspješnosti liječenja primjenom RECIST i irRC kriterija obvezna je svaka 3 mjeseca, a nastavak liječenja moguće je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), a sve do progresije bolesti ili pojave nepodnošljive toksičnosti. Ukoliko se nakon prve procjene utvrdi da je došlo do progresije bolesti terapija se do slijedeće procjene može nastaviti u bolesnika koji zadovoljavaju slijedeće kriterije – 1. odsutnost simptoma koji ukazuju na neupitnu progresiju bolesti, 2. nema daljnjeg pogoršanja ECOG-statusa, 3. izostanak tumorske progresije na kritičnim anatomskim mjestima koja se ne može jednostavno zbrinuti i stabilizirati medicinskim intervencijama dopuštenima prema protokolu prije ponovljenog doziranja. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima za urogenitalne tumore. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. 4. U monoterapiji za drugu liniju liječenja odraslih bolesnika s lokalno uznapredovalim ili metastatskim rakom pluća nemalih stanica nakon prethodno provedene kemoterapije. Kriteriji za primjenu – a. histološki ili citološki dokazan lokalno uznapredovali ili metastatski rak pluća nemalih stanica (neskvamozni tumori koji nisu pozitivni na tumorske mutacije gena EGFR ili ALK) b. ECOG status 0-1 c. nepostojanje stanja koje zahtijeva sistemsko liječenje kortikosteroidima (ekvivalentno dozi prednizona >10mg dnevno) ili drugim imunosupresivnim lijekovima unutar 14 dana prije prve doze lijeka. d) nepostojanje bilo koje aktivne poznate autoimune bolesti ili sumnje na istu. Diabetes mellitus Tip I, rezidualni hipotireoidizam zbog autoimunog stanja koje zahtijeva HNT, psorijaza za koju nije potrebna sistemska terapija, ili stanja za koja se ne očekuje da se ponovno pojavljuju u odsutnosti vanjskoj aktivatora, mogu se uključiti e) Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obavezna je svaka 2 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti ili pojave nepodnošljive toksičnosti. Ukoliko se nakon prve procjene utvrdi da je došlo do radiološke progresije bolesti terapija se do slijedeće procjene može nastaviti u bolesnika koji nemaju simptoma koji ukazuju na progresiju bolesti i nemaju daljnjeg pogoršanja ECOG statusa. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima za tumore torakalnih organa. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. 5. U kombinaciji s ipilimumabom za prvu liniju liječenja odraslih bolesnika s uznapredovalim karcinomom bubrežnih stanica umjerenog/visokog rizika. Kriteriji za primjenu – a. Histološki potvrđen uznapredovali karcinom bubrega svijetlih stanica bez prethodne sistemske terapije, uz iznimku jedne prethodne adjuvantne ili neoadjuvantne terapije (koja ne uključuje VEGF-ciljane lijekove) za potpuno odstranjen karcinom bubrežnih stanica, ukoliko je povrat bolesti uslijedio najmanje šest mjeseci nakon posljednje doze, b. ECOG status 0-1, c. Nepostojanje stanja koje zahtjeva sistemsko liječenje kortikosteroidima (ekvivalentno dozi prednizona > 10 mg dnevno) ili drugim imunosupresivnim lijekovima unutar 14 dana prije prve doze lijeka, d. Uredna funkcija hematopoetskog sustava (leukociti > 2.000 stanica/mm3, neutrofili > 1.500 stanica/mm3, trombociti > 100.000/mm3), e. Uredna funkcija jetre (razina AST ili ALT < 3 x gornja granica uredne vrijednosti (ili < 5 x gornja granica uredne vrijednosti ukoliko su prisutne presadnice u jetri), ukupni bilirubin < 1,5 x gornja granica uredne vrijednosti (osim u bolesnika s Gilbertovim sindromom u kojih je dozvoljena razina ukupnog bilirubina <3,0 mg/dL), f. Uredna funkcija bubrega (razina serumskog kreatinina < 1,5 x gornje granice uredne vrijednosti, ili klirens kreatinina > 40 mL/min). Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog multidisciplinarnog tima specijaliziranog za liječenje urogenitalnih tumora. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. 6. U monoterapiji, kao druga linija liječenja, za liječenje planocelularnog raka glave i vrata (SCCHN) u odraslih bolesnika u kojih je došlo do progresije bolesti tijekom ili nakon terapije na bazi platine.  Kriteriji za primjenu:  a. Histološki dokazan rekurentan ili metastatski planocelularni rak glave i vrata  b. Progresija bolesti tijekom ili nakon terapije na bazi platine (neovisno da li je bila primijenjena u adjuvantnom, neoadjuvantnom, primarnom, rekurentnom ili metastatskom setingu) uključujući progresiju unutar šest mjeseci nakon završetka liječenja režimom EXTREME  c. ECOG status 0-1;  d. Nepostojanje aktivnih moždanih metastaza  e. Nepostojanje medicinskog stanja koje zahtijeva dugotrajnu imunosupresivnu terapiju  f. Nepostojanje druge aktivne maligne bolesti koja zahtijeva istovremenu intervenciju  g. Nepostojanje rekurentnog ili metastatskog karcinoma epifarinksa  h. Liječnici trebaju uzeti u obzir odgođeni odgovor na učinak nivolumaba prije započinjanja liječenja u bolesnika s lošijim prognostičkim obilježjima i/ili agresivnom bolesti.  Odobrava se primjena terapije za tri mjeseca nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest) do progresije bolesti.  Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. |
| NL469 | Liječenje uznapredovalog raka želuca ili adenokarcinoma gastroezofagealnog spoja u odraslih bolesnika kod kojih je došlo do progresije bolesti nakon prethodne kemoterapije platinom ili fluoropirimidinom. Cyramza se primjenjuje u kombinaciji s paklitakselom. Lijek se primjenjuje kod bolesnika koji imaju ECOG status 0-1. Nastavak liječenja moguć je kod pozitivnog odgovora na provedeno liječenje nakon 3 mjeseca terapije do progresije bolesti ili do klinički neprihvatljive toksičnosti ramucirumaba. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL470 | 1. Za liječenje bolesnika s metastatskim rakom debelog crijeva nakon neuspjeha prethodne terapije (na bazi fluoropirimidina, s irinotekanom i/oksaliplatinom, te anti-VEGF terapije ili anti-EGFR terapije (ili se ne smatraju kandidatima za liječenje dostupnim terapijama). Kriteriji za primjenu – 1. ECOG 0-2, 2. Bez teškog oštećenja funkcije jetre (Child-Pugh C), 3. Klirens kreatinina >30 ml/min/1,73 m2. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista onkologa. Odobrava se primjena terapije za 3 mjeseca, nakon kojih se provodi provjera učinka terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili parcijalna remisija, stabilna bolest). 2. Za liječenje bolesnika s inoperabilnim ili metastatskim gastrointestinalnim stromalnim tumorima nakon prethodne dvije linije liječenja. Kriteriji za primjenu – 1. tjelesni status 0-2 po ECOG-u, 2. bez teškog oštećenja funkcije jetre (Child-Pugh C), 3. Klirens kreatinina >30 ml/min/1,73m2. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista onkologa. Odobrava se primjena terapije za 3 mjeseca, nakon kojih se provodi provjera učinka terapije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). 3. Za liječenje odraslih bolesnika s hepatocelularnim karcinomom (HCC) u drugoj liniji, nakon prethodno neuspješnog liječenja sorafenibom. Kriteriji za primjenu – 1. ECOG 0-2, 2. Child-Pugh stadij jetrene bolesti A, 3. klirens kreatinina > 30 ml/min/1,73 m2. Obvezna procjena učinka nakon 3 mjeseca. Liječenje se provodi dok traje pozitivni tumorski odgovor (kompletna remisija, parcijalna remisija ili stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista onkologa. |
| NL471 | Za bolesnike s limfomom plaštenih stanica (MCL) koji su refraktorni ili u relapsu nakon terapije koja je uključivala bendamustin i monoklonsko protu – CD 20 protutijelo. Kriterij za primjenu lijeka – Prije započinjanja liječenja potrebno je radiološki procijeniti veličinu limfnih čvorova, jetre i slezene, odnosno postojanje infiltracije organa. Procjenu terapijskog učinka prvi puta obvezno je provesti najkasnije 6 mjeseci od početka liječenja. Liječenje se prekida u slučaju progresije bolesti ili pojave neprihvatljive toksičnosti. Nastavak liječenja je moguć ako bolesnici zadovoljavaju jedan od kriterija, a) smanjenje veličine limfnih čvorova ili infiltracije organa u odnosu na nalaz prije početka liječenja, ili b) klinički, radiološki i laboratorijski nema znakova progresije. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista hematologa. |
| NL472 | U kombinaciji s docetakselom za liječenje odraslih bolesnika s lokalno uznapredovalim, metastatskim ili lokalno rekurentnim karcinomom pluća ne-malih stanica (NSCLC) s histološkim nalazom adenokarcinoma, nakon kemoterapije kao prve linije liječenja. Odobrava se primjena tri ciklusa terapije, nakon čega je obvezna klinička i dijagnostička obrada u cilju provjere stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL473 | Za liječenje odraslih bolesnika s lokalno uznapredovalim ili metastatskim rakom pluća ne-malih stanica s pozitivnim T790M mutacijom receptora epidermalnog faktora rasta, koji su prethodno liječeni i razvili su progresiju na inhibitore tirozin kinaze (EGFR-TKI – erlotinib, gefitinib, afatinib). Liječenje se može započeti u Kliničkim bolničkim centrima. Liječenje na teret sredstava posebno skupih lijekova odobrava Bolničko povjerenstvo za lijekove na period od 3 mjeseca, nakon čega slijedi provjera rezultata liječenja. U slučaju pozitivnog odgovora na liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest), liječenje se, do progresije bolesti, može nastaviti u drugim bolničkim zdravstvenim ustanovama, uz odobrenje Bolničkog povjerenstva za lijekove ustanove u kojoj se liječenje nastavlja. |
| NL474 | Kao monoterapija za liječenje odraslih bolesnika s uznapredovalim rakom pluća nemalih stanica pozitivnim na kinazu anaplastičnog limfoma u prvoj liniji liječenja ili u drugoj liniji liječenja kod bolesnika prethodno liječenih krizotinibom. Liječenje odobrava Bolničko povjerenstvo za lijekove. Odobravaju se dva ciklusa liječenja, nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora i podnošljivosti liječenja, od kojih 2. ciklus liječenja može teretiti sredstva posebno skupih lijekova. Nastavak liječenja je moguć na teret sredstava posebno skupih lijekova isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. |
| NL475 | Za liječenje odraslih osoba s metastatskim kolorektalnim karcinomom (MKRK), u kombinaciji s kemoterapijom irinotekanom/5-fluorouracilom/folnom kiselinom (FOLFIRI) kod kojih je bolest rezistentna na ili je napredovala nakon liječenja protokolom koji sadrži oksaliplatin, u bolesnika dobrog općeg stanja (ECOG 0-1), do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista onkologa. |
| NL476 | I. Venetoklaks je indiciran u kombinaciji s obinutuzumabom za liječenje prethodno neliječenih bolesnika s kroničnom limfocitnom leukemijom bez del 17p ili mutacije TP53 kod kojih nije prikladno liječenje temeljeno na punoj dozi fludarabina. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. II. Venetoklaks je indiciran u kombinaciji s rituksimabom za liječenje odraslih bolesnika s kroničnom limfocitnom leukemijom koji su primili najmanje jednu prethodnu terapiju, a koji su refraktorni na terapiju ili su u ranom relapsu. Rani relaps se definira kao relaps unutar 24 mjeseca od završetka prethodne terapije. U kombinaciji s rituksimabom venetoklaks je potrebno uzimati tijekom 24 mjeseca od 1. dana 1. ciklusa primjene rituksimaba. III. Kao monoterapija – 1. Za liječenje KLL s delecijom 17p ili mutacijom gena TP53 u bolesnika koji nisu pogodni za liječenje inhibitorom signalnog puta B staničnog receptora ili nisu na njega odgovorili. 2. Za liječenje KLL u bolesnika u ranom relapsu ili refraktornih na kemoimunoterapiju i inhibitor signalnog puta B-staničnog receptora. Kriteriji za primjenu lijeka – Prije početka terapije obvezno je učiniti citogenetsko testiranje, FISH iz koštane srži/periferne krvi te radiološki procijeniti veličinu limfnih čvorova, jetre i slezene, odnosno infiltraciju organa. Liječe se bolesnici s prisutnim simptomima bolesti koji imaju jedan od kriterija – a) visok rizik po Rai-u (III-IV) b) TTM veći ili jednako 15 c) masivnu tumorsku bolest (jedan čvor ili konglomerat > 10 cm ili progresivnu ili simptomatsku limfadenopatiju) d) imaju značajne B simptome koji ometaju kvalitetu života (jedan ili više navedenih simptoma – nenamjerni gubitak tjelesne težine ≥10% u zadnjih 6 mjeseci, temperatura > 38 stupnjeva C u trajanju 2 ili više tjedna bez dokaza infekcije, noćno znojenje duže od mjesec dana bez dokaza infekcije). ECOG 0-2. Procjenu terapijskog učinka prvi puta obvezno je provesti najkasnije 6 mjeseci od početka liječenja, a nastavak liječenja je moguć ako bolesnici zadovoljavaju jedan od kriterija. a) ako je došlo do smanjenja tumorske mase ≥50% u odnosu na početne vrijednosti mjerenja po TTM-u (u reevaluaciji obavezno učiniti UZV ili CT koji potvrđuje smanjenje ≥50%). b) ako je došlo do poboljšanja RAI statusa sa stupnja III-IV na I-II-III (učiniti laboratorijsku obradu koja potvrđuje smanjenje RAI-a III-IV na RAI I-II-III) c) ako je došlo do poboljšanja anemije (ako inicijalno hemoglobin 80-100 g/l porast >100 g/l, ako inicijalno <80 g/l bolesnik je postao neovisan o transfuzijama) ili trombocitopenije (trombociti iznad 100x109/L ili porast za >50% od inicijalne vrijednosti ili neovisnost bolesnika o transfuzijama) d) značajno smanjenje B simptoma. Liječenje se prekida u slučaju progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. IV Venetoklaks je u kombinaciji s hipometilirajućim lijekom indiciran za liječenje novodijagnosticirane akutne mijeloične leukemije (AML) u odraslih bolesnika koji nisu podobni za intenzivnu kemoterapiju. Predviđena reevalaucija je najviše nakon 3 mjeseca od početka primjene terapije. Uspješnost terapije utvrđuje se procjenom odgovora na terapiju ( CR, CRi i SD) iz koštane srži. Liječenje se prekida u slučaju progresije bolesti ili neprihvatljive toksičnosti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. |
| NL477 | Za treću liniju liječenja odraslih bolesnika s relapsim ili refraktornim oblikom multiplog mijeloma koji su prije toga primili barem dvije linije liječenja, uključujući i lenalidomid i bortezomib, a kod kojih je bolest uznapredovala tijekom zadnje terapije, u kombinaciji s deksametazonom. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL478 | Za liječenje lokalno uznapredovalog ili metastatskog raka dojke pozitivnog na hormonski receptor (HR), negativnog na receptor humanog epidermalnog faktora rasta 2 (HER2) – a. u kombinaciji s inhibitorom aromataze u bolesnica koje prethodno nisu primile sistemsko liječenje za svoju uznapredovalu bolest, b. u kombinaciji s fulvestrantom u žena kod kojih je bolest napredovala tijekom ili unutar 12 mjeseci od završetka adjuvantne endokrine terapije, ili tijekom ili unutar 1 mjesec od prethodne endokrine terapije za uznapredovalu bolest. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu procjenu terapijskog učinka liječenja nakon 3 ciklusa liječenja. Svaka slijedeća procjena se radi nakon provedenih 3 ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL479 | Za liječenje lokalno uznapredovalog ili metastatskog raka dojke pozitivnog na hormonski receptor (HR), negativnog na receptor humanog epidermalnog faktora rasta 2 (HER2) – a. u kombinaciji s inhibitorom aromataze ili fulvestrantom u bolesnika kao početna endokrina terapija za uznapredovalu bolest, b. u kombinaciji s fulvestrantom u bolesnika kod kojih je bolest napredovala tijekom ili unutar 12 mjeseci od završetka adjuvantne endokrine terapije, ili tijekom ili unutar 1 mjesec od prethodne endokrine terapije za uznapredovalu bolest. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu procjenu terapijskog učinka liječenja nakon 3 ciklusa liječenja. Svaka slijedeća procjena se radi nakon provedenih 3 ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL480 | Kao monoterapija za liječenje odraslih bolesnika s histološki potvrđenim višekratno relapsirajućim ili refraktornim agresivnim B-staničnim ne-Hodgkinovim limfomom koji je u relapsu nakon 2 ili više linija kemoterapije, općeg tjelesnog stanja prema ECOG ljestvici od 0 do 2. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci specijalista hematologa. |
| NL481 | Za liječenje agresivnog i simptomatskog medularnog karcinoma štitnjače u bolesnika (odrasli, djeca i adolescenti u dobi od 5 godina i stariji) s neoperabilnom lokalno uznapredovalom ili metastatskom bolešću. Liječenje mora započeti i nadzirati liječnik specijalist internističke onkologije ili specijalist radioterapije i onkologije ili specijalist nuklearne medicine s iskustvom u liječenju medularnog karcinoma štitnjače i/ili primjeni lijekova protiv raka. Liječenje odobrava Bolničko povjerenstvo za lijekove. Procjenu terapijskog učinka prvi puta obvezno je provesti najkasnije 3 mjeseca od početka liječenja, a nadalje svakih 6 mjeseci. Nastavak liječenja nije moguć ukoliko je došlo do – 1. podvostručenja vrijednosti karcinoembrionskog antigena (CEA) i/ili kalcitonina (CTN) i/ili 2. progresije bolesti po RECIST kriterijima. |
| NL482 | 1. Za bolesnike s dokazanim aHUS-om ili s opravdanom kliničkom sumnjom na aHUS, a koji su životno ugroženi i/ili im prijeti ili je nastupilo bubrežno zatajenje koje zahtijeva nadomještanje bubrežne funkcije. Za nastavak terapije potrebno je dokazati klinički značajno poboljšanje (hemolize – normalizacija broja trombocita, laktatdehidrogenaze, i ev. poboljšanje bubrežne funkcije) i imati dokazanu bolest (genski). Evaluacija je potrebna nakon prva 2 mjeseca (klinički i genski) liječenja te nakon svaka 3 mjeseca (klinički). Ukoliko se bolest ne dokaže genski, liječenje treba prekinuti, ali i ponovo uvesti u slučaju prethodnog klinički dobrog odgovora, a recidiva nakon ukidanja ekulizumaba. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog pedijatra nefrologa ili bolničkog nefrologa. 2. Za bolesnike s dokazanom PNH i intravaskularnom hemolizom, s velikom aktivnošću bolesti (laktatdehidrogenaza više od 1,5 x iznad gornje referentne vrijednosti). Za nastavak terapije potrebno je imati klinički značajno poboljšanje (hemolize, uz smanjenje incidencije ili nestanak trombotičkih događaja), a isto je potrebno evaluirati nakon mjesec dana terapije pa nakon svaka 3 mjeseca. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog hematologa ili bolničkog nefrologa. |
| NL483 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – dermatovenerologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Liječenje započinje primjenom doza lijeka Tremfya od 100 mg supkutanom injekcijom u 0. i 4. tjednu, nakon čega se primjenjuje doza održavanja svakih 8 tjedana. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 16 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijedosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje aktivnog psorijatičnog artritisa 2.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primijenjena u punoj dnevnoj dozi kroz 2 mjeseca. 2.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka, lijek metotreksat (20 mg/tjedan) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi 2.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 2.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 2.e. Nakon najmanje 12 tjedana primjene očekivani učinak je 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 2.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 2.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 2.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 2.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.e. |
| NL484 | I. Kao monoterapija u visoko aktivnoj relapsno-remitentnoj multiploj sklerozi s fazama relapsa i remisije uz EDSS <=6 i odsutnost trudnoće – 1. kod bolesnika kod kojih je bolest aktivna i koji nisu odgovorili na potpuni i odgovarajući režim liječenja barem jednom terapijom koja modificira tijek bolesti (interferon beta, glatiramer acetat, teriflunomid, dimetil fumarat), odnosno kada su ispunjeni kriteriji za prekid navedene terapije prema važećim smjernicama u listi lijekova. Bolest se smatra aktivnom usprkos provedenoj prethodnoj terapiji uz – a) >= 4 nove T2 hiperintenzivne lezije na MR-u ili b) >= 2 relapsa. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. kod bolesnika kod kojih se očituje teška brzonapredujuća relapsno-remitentna multipla skleroza. Liječenje odobrava Bolničko povjerenstvo za lijekove na teret sredstava bolničkog proračuna. II. Za liječenje odraslih bolesnika s ranom primarno progresivnom multiplom sklerozom (PPMS). Kriteriji za primjenu – a. progresija onesposobljenosti u trajanju od 1 godine (utvrđena retrospektivno ili prospektivno) neovisno o kliničkim relapsima, ukoliko su zadovoljena još 2 od slijedećih 3 kriterija – b. jedna ili više T2-hiperintenzivnih lezija karakterističnih za MS u jednoj ili više slijedećih struktura – periventrikularno, kortikalno ili jukstakortikalno ili infratentorijalna, c. dvije ili više T2 – hiperintenzivne lezije u kralježničnoj moždini, d. prisutnost specifičnih oligoklonalnih traka u cerebrospinalnom likvoru. e. EDSS manje ili jednako 6, f. odsutnost trudnoće. Kriterij za isključivanje iz terapijskog postupka lijekom je porast EDSS za 2 ili više. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL485 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za liječenje reumatoidnog artritisa 1.a. Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >=5,1 ili DAS28 >=3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 1.b. Prethodna terapija, najmanje 2 lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primjenjen najmanje kroz 2 mjeseca 20 mg tjedno (u slučaju nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka nekog drugog biološkog lijeka. 1.c. Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. 1.d.Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >=5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <=3,2, ako je započeto s DAS28 >=3,2 + 6 otečenih zglobova (od 44), pad DAS28 >=1,2 + 50% manje otečenih zglobova. 1.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 1.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 1.d. 2. Za liječenje arteritisa divovskih stanica (engl. giant cell arteritis, GCA) u odraslih bolesnika – 2.a. Evidentirane ozbiljne nuspojave na primjenu glukokortikoida. 2.b. Liječenje bolesnika s refraktornom bolešću kod kojih se nakon 4 – 6 tjedana ne može sniziti inicijalna doza glukokortikoida, u bolesnika kod kojih je nakon 6 mjeseci liječenja potrebna doza prednizona > 0,2 mg/kg/dan, u bolesnika kod kojih je nakon 12 mjeseci liječenja potrebna doza prednizona > 0,1 mg/kg/dan. 2.c. Liječenje bolesnika s pogoršanjem kliničke slike i/ili upalnih parametara nakon postignute remisije sukladno liječnikovoj prosudbi. Preporučena doza iznosi 162 mg supkutano jedanput tjedno u kombinaciji s glukokortikoidom čija se doza postupno smanjuje. RoActemra se nakon prekida primjene glukokortikoida može primjenjivati u monoterapiji, ali se kao monoterapija ne smije primjenjivati za liječenje bolesnika s akutnim relapsima. S obzirom na kroničnu prirodu GCA, liječenje lijekom Roactemra je dugotrajno, a može se prekinuti nakon potpunog prestanka liječenja glukokortikoidima (postignuto postupnim smanjenjem doze glukokortikoida), ali samo ukoliko je postignuta trajna i potpuna remisija koja se prema kliničkoj procjeni liječnika definira kao odsutnost svih simptoma i pogoršanja u posljednjih najmanje tri mjeseca aktivnog liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, a traje do pojave toksičnosti koja se ne može zbrinuti ili do gubitka kliničke koristi. 3. Za liječenje juvenilnog idiopatskog poliartritisa. Liječenje odobrava Bolničko Povjerenstvo za lijekove. |
| NL486 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa, pedijatra odgovarajuće subspecijalizacije), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za liječenje juvenilnog idiopatskog poliartritisa. Liječenje odobrava Bolničko Povjerenstvo za lijekove. 2. Za liječenje reumatoidnog artritisa 2.a. Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >=5,1 ili DAS28 >=3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 2.b. Prethodna terapija, najmanje 2 lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primjenjen najmanje kroz 2 mjeseca 20 mg tjedno (u slučaju nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka nekog drugog biološkog lijeka. 2.c. Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. 2.d.Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >=5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <=3,2, ako je započeto s DAS28 >=3,2 + 6 otečenih zglobova (od 44), pad DAS28 >=1,2 + 50% manje otečenih zglobova. 2.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 2.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.d. 3. Za liječenje arteritisa divovskih stanica (engl. giant cell arteritis, GCA) u odraslih bolesnika – 3.a. Evidentirane ozbiljne nuspojave na primjenu glukokortikoida. 3.b. Liječenje bolesnika s refraktornom bolešću kod kojih se nakon 4 – 6 tjedana ne može sniziti inicijalna doza glukokortikoida, u bolesnika kod kojih je nakon 6 mjeseci liječenja potrebna doza prednizona > 0,2 mg/kg/dan, u bolesnika kod kojih je nakon 12 mjeseci liječenja potrebna doza prednizona > 0,1 mg/kg/dan. 3.c. Liječenje bolesnika s pogoršanjem kliničke slike i/ili upalnih parametara nakon postignute remisije sukladno liječnikovoj prosudbi. Preporučena doza iznosi 162 mg supkutano jedanput tjedno u kombinaciji s glukokortikoidom čija se doza postupno smanjuje. RoActemra se nakon prekida primjene glukokortikoida može primjenjivati u monoterapiji, ali se kao monoterapija ne smije primjenjivati za liječenje bolesnika s akutnim relapsima. S obzirom na kroničnu prirodu GCA, liječenje lijekom Roactemra je dugotrajno, a može se prekinuti nakon potpunog prestanka liječenja glukokortikoidima (postignuto postupnim smanjenjem doze glukokortikoida), ali samo ukoliko je postignuta trajna i potpuna remisija koja se prema kliničkoj procjeni liječnika definira kao odsutnost svih simptoma i pogoršanja u posljednjih najmanje tri mjeseca aktivnog liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove, prvo za period od 4 mjeseca, a kasnije za period od 6 mjeseci, odnosno u nastavku 12 mjeseci, a traje do pojave toksičnosti koja se ne može zbrinuti ili do gubitka kliničke koristi. 4. Za liječenje sistemskog juvenilnog idiopatskog artritisa u dobi od 1 godine ili više. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL487 | Za liječenje HER2-pozitivnog raka dojke (IHC 3+ ili CISH/FISH+) u slijedećim indikacijama 1. adjuvantno liječenje – 1.1 rani stadij raka dojke nakon provedenog primarnog liječenja (operacija). Liječenje se provodi sekvencijski ili konkomitantno s primjenom taksana i/ili zračenja, ukupno do godinu dana. 1.2 neoadjuvantno liječenje, prije operativnog zahvata, ukoliko je indicirana neoadjuvantna sistemska terapija, s adjuvantnim liječenjem do ukupno godinu dana. Način primjene s.c. primjena – 600 mg za trotjedni ciklus. Adjuvantno liječenje se može provoditi i sa hormonskom terapijom. Kriteriji za primjenu – ECOG 0-1, EFLV (ejekciona frakcija lijevog ventrikla) >50%, uredni laboratorijski nalazi (AST, ALT do 5x gornje granice, bilirubin do 3x gornje granice referentne vrijednosti). 2. metastatski rak dojke – 2.1. prva linija kemoterapije – 2.1.1. u kombinaciji s taksanima, 2.1.2. u kombinaciji s hormonskom terapijom kod istovremeno HER2+ i hormonski pozitivnih tumora (HER2+++, ER+). Liječenje se provodi do progresije bolesti. 2.2. u monoterapiji kao treća linija nakon prethodno provedene najmanje dvije linije kemoterapije za metastatsku bolesti, koja je sadržavala antracikline i taksane. Kriteriji za primjenu – ECOG 0-1, nepostojanje presadnica u CNS-u (ili postojanje stabilnih/kontroliranih moždanih presadnica, uz očekivano trajanje života više od godine dana), uredni laboratorijski nalazi (AST, ALT do 5x gornje granice, bilirubin do 3x gornje granice referentne vrijednosti. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu reevaluaciju učinka nakon četiri ciklusa liječenja. Svaka slijedeća evaluacija učinka liječenja se radi nakon provedenih šest ciklusa liječenja. Liječenje pod 1. i 2.1. odobrava se iz sredstava posebno skupih lijekova, a liječenje pod 2.2. iz sredstava bolničkog proračuna. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL489 | Za odrasle bolesnike s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML) koji su pozitivni na FLT3 mutaciju, u kombinaciji sa standardnom indukcijskom kemoterapijom daunorubicinom i citarabinom i konsolidacijskom kemoterapijom visokom dozom citarabina te za bolesnike s potpunim terapijskim odgovorom na te kombinacije nakon kojih se midostaurin koristi kao monoterapija održavanja. Za početak liječenja potreban je dokaz o dijagnozi akutne mijeloične leukemije i FLT3 mutacije. Odobrava se kao dodatak citostatskoj terapiji tijekom ciklusa indukcije i konsolidacije te kao monoterapija u terapiji održavanja, uz sljedeće uvjete – Liječenje započinje indukcijskom kemoterapijom uz dodatak midostaurina od 8. do 21. dana cikusa u dozi 2 x 50 mg na dan (jedan do dva ciklusa indukcijske terapije). U slučaju postizanja remisije nastavlja se terapija konsolidacijama (2 do 4 ciklusa kemoterapije u dodatak midostaurina 2 x 50 mg na dan od 8. do 21. dana ciklusa). Ako je terapijski učinak povoljan, nastavlja se terapija održavanja u trajanju od 12 mjeseci u kontinuitetu. Evaluacija odgovora na liječenje provodi se citomorfološkom analizom koštane srži nakon svakog ciklusa intenzivne terapije, a tijekom terapije održavanja svaka 2 mjeseca. Nepovoljni terapijski odgovor podrazumijeva prisustvo >5% blasta u koštanoj srži nakon 2 ciklusa indukcijske terapije, tijekom terapije konsolidacije ili terapije održavanja. Kod nepovoljnog terapijskog odgovora terapiju midostaurinom treba prekinuti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. |
| NL490 | 1. Za liječenje multiplog mijeloma, u 2. i 3. liniji liječenja, u kombinaciji s deksametazonom u odraslih bolesnika koji su prethodno liječeni lijekom bortezomib. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje bolesnika s MDS-om (niskog i intermedijarnog rizika) koji imaju sindrom 5q – te koji imaju vrijednost serumskog eritropoetina 500 mU/ml ili više i koji zahtijevaju više od dvije transfuzije na mjesec. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL491 | 1. Za bolesnike kojima je postavljena dijagnoza juvenilnog idiopatskog artritisa. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje reumatoidnog artritisa, 2.a. Indikacija za primjenu (u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest – DAS28 >=5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 2.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno (ili zbog nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka lijeka tocilizumab ili drugog TNF blokatora. 2.c. Prije primjene probir na hepatitis B i C i latentnu TBC prema preporukama HRD. 2.d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 2.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. e. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 2.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 3 mjeseca, a kasnije za period od 6 mjeseci i dokumentiranim ishodom kao što je navedeno u točki 2.d. 3. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa – 3.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 3.b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 3.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 3.d. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 3.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 3.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 3 mjeseca, a kasnije za period od 6 mjeseci i dokumentiranim ishodom kao što je navedeno u točki 3.d. 4. Za liječenje aktivnog psorijatičnog artritisa – 4.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primijenjena u punoj dnevnoj dozi kroz 2 mjeseca. 4.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. 4.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 4.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 4.e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 4.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka kao što je navedeno u 4.e. 4.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 4.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 4.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 3 mjeseca, a kasnije za period od 6 mjeseci i dokumentiranim ishodom kao što je navedeno u točki 4.e. 5. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Preporučena doza je 25 mg s.c. 2x tjedno ili 50 mg 1x tjedno. Liječenje se mora nastaviti dok se ne postigne remisija, najdulje do 24 tjedna. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu 12. i 24., izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 12 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijednosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL492 | U kombinaciji s lenalidomidom i deksametazonom ili bortezomibom i deksametazonom, za liječenje odraslih bolesnika s multiplim mijelomom koji su primili barem jednu prethodnu terapiju. Odobrava se 4 ciklusa liječenja. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (potpuni odgovor, vrlo dobar djelomičan odgovor, djelomičan odgovor ili stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog hematologa. |
| NL493 | U kombinaciji s lenalidomidom i deksametazonom ili samo s deksametazonom za liječenje odraslih bolesnika s multiplim mijelomom koji su prethodno primili najmanje jednu liniju liječenja. a) u kombinaciji s deksametazonom u odraslih bolesnika s multiplim mijelomom u kojih je došlo do relapsa nakon prethodne linije liječenja ili nije postignut zadovoljavajući terapijski odgovor. Odobrava se 4 ciklusa liječenja. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (potpuni odgovor, vrlo dobar djelomičan odgovor, djelomičan odgovor ili stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog hematologa. b) u kombinaciji s lenadilomidom i deksametazonom u odraslih osoba koje imaju recidivirajući ili refraktorni oblik bolesti unatoč standardnom liječenju. Odobrava se 4 ciklusa liječenja. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (potpuni odgovor, vrlo dobar djelomičan odgovor, djelomičan odgovor ili stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog hematologa. |
| NL494 | U kombinaciji s lenalidomidom i deksametazonom za liječenje odraslih bolesnika s multiplim mijelomom koji su primili barem jednu prethodnu terapiju. Odobrava se četiri ciklusa liječenja. Nastavak liječenja moguć isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (potpuni odgovor, vrlo dobar djelomičan odgovor, djelomičan odgovor ili stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog hematologa. |
| NL497 | Indiciran kao dio antineoplastične kombinirane terapije u akutnoj limfoblastičnoj leukemiji (ALL). |
| NL498 | 1. Za liječenje lokalno uznapredovalog ili metastatskog raka dojke pozitivnog na hormonski receptor (HR), negativnog na receptor humanog epidermalnog faktora rasta 2 (HER2) – a. u kombinaciji s inhibitorom aromataze u bolesnica koje prethodno nisu primile sistemsko liječenje za svoju uznapredovalu bolest, b. u kombinaciji s fulvestrantom u žena kod kojih je bolest napredovala tijekom neo(adjuvantne) endokrine terapije ili unutar 12 mjeseci od završetka adjuvantne endokrine terapije, ili tijekom prethodne endokrine terapije za uznapredovalu bolest. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu procjenu terapijskog učinka liječenja nakon 3 ciklusa liječenja. Svaka slijedeća procjena se radi nakon provedenih 3 ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. 2. Za adjuvantno liječenje odraslih bolesnika s ranim rakom dojke pozitivnim na hormonski receptor (HR) i negativnim na receptor humanog epidermalnog faktora rasta 2 (HER2) s visokim rizikom povrata bolesti, a koje imaju jedno od obilježja – a. ≥4 pozitivna pazušna limfna čvora ili b. 1-3 pozitivna pazušna limfna čvora uz najmanje jedan od sljedećih kriterija – veličina tumora ≥5 cm ili histološki gradus 3. Liječenje se provodi u kombinaciji s hormonskom terapijom, do ukupno 2 godine, odnosno do povrata bolesti ili do pojave toksičnosti koja se ne može zbrinuti. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL499 | Za liječenje pedijatrijskih i mladih odraslih bolesnika u dobi do 25 godina s akutnom limfoblastičnom leukemijom B stanica (ALL) koja je refraktorna, u recidivu nakon transplantacije ili u drugom ili kasnijem recidivu. Za liječenje odraslih bolesnika s difuznim B-velikostaničnim limfomom koji zadovoljavaju sljedeće kriterije – • histološki ili citološki dokazan DLBCL, • aktivna bolest nakon najmanje dvije linije sustavnog liječenja standardnim protokolima od kojih je najmanje jedna sadržavala polikemoterapiju i protu-CD20 monoklonsko protutijelo, • opće stanje po ECOG skali 0-2 (ECOG, Eastern Cooperative Oncology Group), • bez medicinskih kontraindikacija za intenzivno liječenje. Liječenje se provodi u KBC Zagreb. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima u čijem je sastavu obvezno hematolog/pedijatar hematolog, iz sredstava posebno skupih lijekova. |
| NL500 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – dermatovenerologa, reumatologa/kliničkog imunologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Liječenje započinje primjenom doza lijeka Skyrizi od 150 mg supkutanom injekcijom (dvije injekcije od 75 mg) u 0. i 4. tjednu, nakon čega se primjenjuje doza održavanja od 150 mg supkutanom injekcijom (dvije injekcije od 75 mg) svakih 12 tjedana. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 16 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijedosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje aktivnog psorijatičnog artritisa 2.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primijenjena u punoj dnevnoj dozi kroz 2 mjeseca. 2.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka, lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi 2.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 2.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 2.e. Nakon najmanje 16 tjedana primjene očekivani učinak je 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 2.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 2.g. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 2.h. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6 mjesec odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.e. |
| NL501 | Za liječenje odraslih bolesnika s uznapredovalim rakom pluća nemalih stanica pozitivnim na kinazu anaplastičnog limfoma kao monoterapija u prvoj liniji liječenja ili kao monoterapija u drugoj liniji liječenja (prethodno liječenih krizotinibom). Liječenje odobrava Bolničko povjerenstvo za lijekove. Odobravaju se dva ciklusa liječenja, nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora i podnošljivosti liječenja, od kojih 2. ciklus liječenja može teretiti sredstva posebno skupih lijekova. Nastavak liječenja je moguć na teret sredstava posebno skupih lijekova isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. |
| NL502 | 1. Za liječenje odraslih bolesnika s kroničnim limfocitnom leukemijom (KLL) – a) s delecijom kromosoma 17p odnosno mutacijom p53 b) kod prethodno neliječenih bolesnika dobrog općeg stanja (ECOG 0-2), visokog rizika, a koji se definira prisustvom nemutiranih gena za teški lanac imunoglubulina (uIGHV) ili delecijom kromosoma 11q kao i za liječenje prethodno neliječenih bolesnika kod kojih nije prikladno liječenje temeljeno na punoj dozi fludarabina c) kod prethodno liječenih bolesnika koji su refrakterni na terapiju ili su u ranom relapsu, a koji se definira kao relaps unutar 24 mjeseca od završetka prethodne terapije Kriteriji za primjenu lijeka – Prije početka terapije obvezno je učiniti citogenetsko testiranje, FISH iz koštane srži/periferne krvi te radiološki procijeniti veličinu limfnih čvorova, jetre i slezene, odnosno infiltraciju organa. Liječe se bolesnici s prisutnim simptomima bolesti koji imaju jedan od kriterija – a) visok rizik – po RAI-u III-IV b) TTM veći ili jednako 15 c) masivnu tumorsku bolest (jedan čvor ili konglomerat > 10 cm ili progresivna ili simptomatska limfadenopatija) d) imaju značajne B simptome koji ometaju kvalitetu života (jedan ili više navedenih simptoma – nenamjerni gubitak tjelesne težine >= 10% u zadnjih 6 mjeseci, temperatura > 38 stupnjeva C u trajanju 2 ili više tjedna bez dokaza infekcije, noćno znojenje duže od mjesec dana bez dokaza infekcije). ECOG 0-2. Procjenu terapijskog učinka prvi puta obvezno je provesti najkasnije 6 mjeseci od početka liječenja, a nastavak liječenja je moguć ako bolesnici zadovoljavaju jedan od kriterija a) ako je došlo do smanjenja tumorske mase >=50% u odnosu na početne vrijednosti mjerenja po TTM-u (u reevaluaciji obavezno učiniti UZV ili CT koji potvrđuje smanjenje >=50%) b) ako je došlo do poboljšanja RAI statusa sa stupnja III-IV na I-II-III (učiniti laboratorijsku obradu koja potvrđuje smanjenje RAI-a III-IV na RAI I-II-III) c) ako je došlo do poboljšanja anemije (ako inicijalno hemoglobin 80-100 g/l porast >100 g/l, ako inicijalno <80 g/l bolesnik je postao neovisan o transfuzijama) ili trombocitopenije (trombociti iznad 100x109/L ili porast za >50% od inicijalne vrijednosti ili neovisnost bolesnika o transfuzijama) d) značajno smanjenje B simptoma. Nakon toga liječenje se prekida u slučaju progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. 2. Za liječenje odraslih bolesnika s Waldenströmovom makroglobulinemijom (WM) koji su prethodno primili najmanje jednu terapiju. Kriteriji za primjenu lijeka – Liječe se bolesnici s povišenom koncentracijom imunoglobulina IgM, koji imaju jedan ili više simptoma ili znakova bolesti – hemoglobin ≤ 100g/l, trombociti ≤ 100 x 109 /l, simptomatska limfadenopatija, simptomatska organomegalija, amiloidoza uzrokovana Waldenstromovom makroglobulinemijom, nefropatija uzrokovana Waldenstromovom makroglobulinemijom, simptomatska krioglobulinemija, hiperviskoznost, ponavljajuće povišene temperature, noćno znojenje, gubitak tjelesne težine, umor. Prvu procjenu terapijskog učinka je potrebno provesti najkasnije 6 mjeseci od početka liječenja, a nastavak liječenja je moguć ako je došlo do smanjenja koncentracije IgM u odnosu na nalaz prije početka liječenja i poboljšanja simptoma ili znaka zbog kojeg je liječenje započeto. Nakon toga se liječenje nastavlja do progresije bolesti ili pojave neprihvatljive toksičnosti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. |
| NL503 | 1. Za liječenje umjerenog do teškog oblika aktivnog reumatoidnog artritisa u odraslih bolesnika koji nisu dovoljno dobro odgovorili na jedan ili više anti-reumatskih lijekova koji modificiraju tijek bolesti ili koji ne podnose takve lijekove. Olumiant se može primjenjivati u monoterapiji ili u kombinaciji s metotreksatom. 1. Za liječenje reumatoidnog artritisa 1.a Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >=5,1 ili DAS28 >=3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 1.b Prethodna terapija, najmanje 2 lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek meto-treksat primjenjen najmanje kroz 2 mjeseca 20 mg tjedno (u slučaju nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka nekog drugog biološkog lijeka. 1.c Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. 1.d Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >=5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <=3,2, ako je započeto s DAS28 >=3,2 + 6 otečenih zglobova (od 44), pad DAS28 >=1,2 + 50% manje otečenih zglobova. 1.e Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz JAK inhibitor. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija JAK inhibitoru bez obzira na vrijednost DAS28. Bolesnici koji se JAK inhibitorom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju liječenje JAK inhibitorom. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 1.f Olumiant 2 mg smije se primijenjivati isključivo kod bolesnika kod kojih je preporučena dnevna doza maksimalno 2 mg, odnosno za bolesnike u dobi od ≥ 75 godina ili za bolesnike koji u anamnezi imaju kronične ili rekurentne infekcije ili u bolesnika koji su kandidati za postupno smanjivanje doze nakon što su dozom od 4 mg jedanput na dan postigli održanu kontrolu aktivnosti bolesti. 1.g Procjena učinka lijeka obavezna je nakon 12 tjedana od početka liječenja, a kasnije najmanje jedanput tijekom godine. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka specijalista reumatologa/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje teškog atopijskog dermatitisa (EASI >=21 i/ili SCORAD >50 i DLQI>13) u odraslih bolesnika u kojih nije postignut zadovoljavajući terapijski odgovor nakon najmanje 12 tjedana primjene barem jednog imunosupresivnog lijeka (uključujući ciklosporin, metotreksat, azatioprin i mikofenolat mofetil) ili su na isti razvili nuspojave koje zahtijevaju prekid terapije ili imaju kontraindikacije za uvođenje gore navedenih imunosupresivnih lijekova. Liječenje može započeti i provoditi samo liječnik specijalist dermatovenereologije. Prije uvođenja lijeka potrebno je odrediti EASI i/ili SCORAD i DLQI te probir na latentnu TBC i određivanje markera hepatitisa B i C. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana nakon 8 tjedana od početka liječenja, određivanjem vrijednosti EASI i/ili SCORAD te DLQI. Nastavak liječenja moguć je ukoliko je nakon 8 tjedana postignuto najmanje 50 % poboljšanje EASI i/ili SCORAD vrijednosti i poboljšanje DLQI vrijednosti više od 4 boda, prema procjeni nadležnog liječnika. Procjena učinka terapije se potom evaluira najmanje jedanput tijekom godine izračunavanjem vrijednosti EASI i/ili SCORAD i DLQI prema procjeni nadležnog liječnika – održavanje postignutog učinka liječenja. Liječenje se prekida kod izostanka očekivanog učinka prema zadanim kriterijima – a) nakon 8 tjedana ukoliko nije postignuto najmanje 50 % poboljšanje EASI i/ili SCORAD vrijednosti i poboljšanje DLQI vrijednosti više od 4 boda ili b) ukoliko nakon svake naknadne evaluacije (najmanje jedanput tijekom godine) nije postignut očekivan učinak održavanja terapijskog odgovora prema procjeni nadležnog liječnika ili c) u slučaju ozbiljnih nuspojava, teške interkurentne infekcije (privremeni/trajni prekid), trudnoće. Olumiant 2 mg smije se prim-jenjivati isključivo kod bolesnika kod kojih je preporučena dnevna doza maksimalno 2 mg, odnosno za bolesnike u dobi od ≥ 75 godina ili za bolesnike koji u anamnezi imaju kronične ili rekurentne infekcije ili u bolesnika koji su kandidati za postupno smanjivanje doze nakon što su dozom od 4 mg jedanput na dan postigli održanu kontrolu aktivnosti bolesti. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. |
| NL504 | 1. Liječenje umjerenog do teškog oblika aktivnog reumatoidnog artritisa u odraslih bolesnika koji nisu dovoljno dobro odgovorili na jedan ili više antireumatskih lijekova koji modificiraju tijek bolesti ili koji ne podnose takve lijekove. Olumiant se primjenjuje u monoterapiji ili u kombinaciji s metotreksatom. 1. Za liječenje reumatoidnog artritisa 1.a Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >=5,1 ili DAS28 >=3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 1.b Prethodna terapija, najmanje 2 lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek meto-treksat primjenjen najmanje kroz 2 mjeseca 20 mg tjedno (u slučaju nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka nekog drugog biološkog lijeka. 1.c Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. 1.d Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >=5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <=3,2, ako je započeto s DAS28 >=3,2 + 6 otečenih zglobova (od 44), pad DAS28 >=1,2 + 50% manje otečenih zglobova. 1.e Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz JAK inhibitor. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija JAK inhibitoru bez obzira na vrijednost DAS28. Bolesnici koji se JAK inhibitorom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju liječenje JAK inhibitorom. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 1.f Procjena učinka lijeka obavezna je nakon 12 tjedana od početka liječenja, a kasnije najmanje jedanput tijekom godine. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka specijalista reumatologa/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje teškog atopijskog dermatitisa (EASI >=21 i/ili SCORAD >50 i DLQI>13) u odraslih bolesnika u kojih nije postignut zadovoljavajući terapijski odgovor nakon najmanje 12 tjedana primjene barem jednog imunosupresivnog lijeka (uključujući ciklosporin, metotreksat, azatioprin i mikofenolat mofetil) ili su na isti razvili nuspojave koje zahtijevaju prekid terapije ili imaju kontraindikacije za uvođenje gore navedenih imunosupresivnih lijekova. Liječenje može započeti i provoditi samo liječnik specijalist dermatovenereologije. Prije uvođenja lijeka potrebno je odrediti EASI i/ili SCORAD i DLQI te probir na latentnu TBC i određivanje markera hepatitisa B i C. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana nakon 8 tjedana od početka liječenja, određivanjem vrijednosti EASI i/ili SCORAD te DLQI. Nastavak liječenja moguć je ukoliko je nakon 8 tjedana postignuto najmanje 50 % poboljšanje EASI i/ili SCORAD vrijednosti i poboljšanje DLQI vrijednosti više od 4 boda, prema procjeni nadležnog liječnika. Procjena učinka terapije se potom evaluira najmanje jedanput tijekom godine izračunavanjem vrijednosti EASI i/ili SCORAD i DLQI prema procjeni nadležnog liječnika – održavanje postignutog učinka liječenja. Liječenje se prekida kod izostanka očekivanog učinka prema zadanim kriterijima – a) nakon 8 tjedana ukoliko nije postignuto najmanje 50 % poboljšanje EASI i/ili SCORAD vrijednosti i poboljšanje DLQI vrijednosti više od 4 boda ili b) ukoliko nakon svake naknadne evaluacije (najmanje jedanput tijekom godine) nije postignut očekivan učinak održavanja terapijskog odgovora prema procjeni nadležnog liječnika ili c) u slučaju ozbiljnih nuspojava, teške interkurentne infekcije (privremeni/trajni prekid), trudnoće. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. |
| NL505 | 1. Za liječenje aktivnog psorijatičnog artritisa. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa iz ugovorne zdravstvene ustanove Zavoda, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). Nakon najmanje 16 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa iz ugovorne zdravstvene ustanove Zavoda (skala 0-10). Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. Procjena učinka lijeka obavezna je nakon 16 tjedana od početka liječenja, a kasnije najmanje jedanput tijekom godine. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka subspecijalista reumatologa iz ugovorne zdravstvene ustanove Zavoda. 2. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa iz ugovorne zdravstvene ustanove Zavoda. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze iz ugovorne zdravstvene ustanove Zavoda. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Nakon početne titracije lijeka preporučena doza je 30 mg dvaput na dan. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana nakon 16 tjedana izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 16 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijednosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Procjena učinka lijeka obavezna je nakon 16 tjedana od početka liječenja, a kasnije najmanje jedanput tijekom godine. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka specijalista dermatovenerologa iz ugovorne zdravstvene ustanove Zavoda. Početak i nastavak liječenja pod točkom 1. i pod točkom 2. odobrava Bolničko povjerenstvo za lijekove. |
| NL506 | 1. Za liječenje reumatoidnog artritisa 1.a. Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >=5,1 ili DAS28 >=3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 1.b. Prethodna terapija, najmanje 2 lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primjenjen najmanje kroz 2 mjeseca 20 mg tjedno (u slučaju nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka nekog drugog biološkog lijeka. 1.c. Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. 1.d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >=5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <=3,2, ako je započeto s DAS28 >=3,2 + 6 otečenih zglobova (od 44), pad DAS28 >=1,2 + 50% manje otečenih zglobova. 1.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz JAK inhibitor. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija JAK inhibitoru bez obzira na vrijednost DAS28. Bolesnici koji se JAK inhibitorom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju liječenje JAK inhibitorom. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 1.f. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka reumatologa ili kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. 2. Za liječenje aktivnog psorijatičnog artritisa 2.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 2.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. 2.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 2.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa iz ugovorne zdravstvene ustanove Zavoda, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 2.e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa iz ugovorne zdravstvene ustanove Zavoda (skala 0-10). 2.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 2.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 2.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 2.i. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka reumatologa ili kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. 3. Liječenje umjerenog do teškog oblika aktivnog ulceroznog kolitisa u odraslih bolesnika koji su na liječenje konvencionalnom terapijom ili biološkim lijekom imali neadekvatan odgovor, izgubili odgovor ili ta liječenja nisu podnosili. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka gastroenterologa iz ugovorne zdravstvene ustanove Zavoda. Početak i nastavak liječenja pod točkom 1., pod točkom 2. i pod točkom 3. odobrava Bolničko povjerenstvo za lijekove. |
| NL507 | Liječenje umjerenog do teškog oblika aktivnog ulceroznog kolitisa u odraslih bolesnika koji su na liječenje konvencionalnom terapijom ili biološkim lijekom imali neadekvatan odgovor, izgubili odgovor ili ta liječenja nisu podnosili. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka gastroenterologa iz ugovorne zdravstvene ustanove Zavoda. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. |
| NL508 | Za liječenje bolesnika s neuroblastomom visokog rizika u dobi od 12 mjeseci i starijih, koji su prethodno primali indukcijsku kemoterapiju i postigli barem djelomični odgovor, nakon čega su slijedile mijeloablacijska terapija i transplantacija matičnih stanica te bolesnika koji imaju povijest recidiva neuroblastoma ili refraktornog neuroblastoma, sa ili bez rezidualne bolesti. Prije liječenja recidiva neuroblastoma svaku bolest koja aktivno napreduje potrebno je stabilizirati primjenom drugih odgovarajućih mjera. Odobrava se liječenje kroz 5 ciklusa. Liječenje se provodi u Kliničkim bolničkim centrima te Klinici za dječje bolesti Zagreb. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima. |
| NL509 | Za liječenje reumatoidnog artritisa a. Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >=5,1 ili DAS28 >=3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. b. Prethodna terapija, najmanje 2 lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primjenjen najmanje kroz 2 mjeseca 20 mg tjedno (u slučaju nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka nekog drugog biološkog lijeka. c. Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >=5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <=3,2, ako je započeto s DAS28 >=3,2 + 6 otečenih zglobova (od 44), pad DAS28 >=1,2 + 50% manje otečenih zglobova. e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz JAK inhibitor. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija JAK inhibitoru bez obzira na vrijednost DAS28. Bolesnici koji se JAK inhibitorom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju liječenje JAK inhibitorom. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. f. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka reumatologa ili kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. |
| NL510 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – reumatologa/kliničkog imunologa, gastroenterologa, dermatovenerologa, pedijatra odgovarajuće subspecijalizacije, oftalmologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda.) 1. Za bolesnike kojima je postavljena dijagnoza juvenilnog idiopatskog artritisa. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje reumatoidnog artritisa 2.a. Indikacija za primjenu (u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest – DAS28 >=5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 2.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno (ili zbog nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka lijeka tocilizumab ili drugog TNF blokatora. 2.c. Prije primjene probir na hepatitis B i C i latentnu TBC prema preporukama HRD. 2.d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 2.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 2.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 2.d. 3. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa 3.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 3.b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 3.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 3.d. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 3.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 3.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 3.d. 4. Za liječenje aktivnog psorijatičnog artritisa 4.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 4.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. 4.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 4.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 4.e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 4.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 4.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 4.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 4.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 4.e. 5. a. Liječenje fistulirajućeg oblika Crohnove bolesti, b. Liječenje teške aktivne Cronhove bolesti koja je refraktorna na terapiju kortikosteroidima i imunomodulatorima, odnosno u slučaju nepodnošenja ili kontraidikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. 6. Liječenje teškog oblika ulceroznog kolitisa u odraslih bolesnika koji nisu adekvatno odgovorili na knovencionalno liječene kortikosteroidima i 6-merkatopurinom ili azatioprinom odnosno u slučaju nepodnošenja ili kontraidikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. 7. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Liječenje započinje primjenom doze od 80 mg s.c. u tjednu 0 (nultom), nakon čega slijedi doza od 40 mg u tjednu 1, a nakon toga doza od 40 mg svaka 2 tjedana. Primjena adalimumaba odnosno procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu 4., 12. i 28., izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 12 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijedosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. 8. Za liječenje umjerenog do teškog oblika aktivnog gnojnog hidradenitisa (acne inversa) u odraslih i adolescenata u dobi od 12 godina i starijih u kojih nije postignut zadovoljavajući odgovor na konvencionalno sistemsko liječenje gnojnog hidradenitisa. Prije uvođenja lijeka u terapiju, potrebno je zbrojiti apscese, upalne nodule i drenirajuće fistule. Liječenje započinje primjenom početne doze lijeka od 160 mg (ili 4x40 mg u 1 danu ili 2x80 mg u 1 danu ili 80 mg dnevno kroz 2 uzastopna dana). Liječenje se nastavlja 15. dan s dozom od 80 mg (ili 2x40 mg ili 1x80 mg), a 2 tjedna kasnije (29. dan) liječenje se nastavlja s dozom od 40 mg tjedno ili 80 mg svaki drugi tjedan. Primjena adalimumaba odnosno procjena učinka terapije i aktivnosti bolesti treba biti evaluirana nakon 12 tjedana. Nastavak liječenja moguć je isključivo kod pozitivnog kliničkog odgovora , odnosno ukoliko je nakon 12 tjedana postignut HiSCR (engl. Hidradenitis Suppurativa Clinical Response) tj. smanjenje ukupnog broja apscesa i upalnih nodula za 50%, bez povećanja broja apscesa i bez povećanja broja drenirajućih fistula u odnosu na vrijednost prije početka liječenja. Ukoliko je postignut djelomični klinički odgovor (najmanje AN >= 25, odnosno ako je nakon 12 tjedana liječenja zbroj apscesa i upalnih nodula manji za 25% u odnosu na početnu vrijednost prije početka liječenja), liječenje se nastavlja još dodatnih 24. tjedana (ukupno 36 tjedana). Liječenje se nastavlja ukoliko je tada postignut HiSCR u odnosu na početne vrijednosti prije početka liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove. 9. Za liječenje neifekcijskog intermedijarnog i stražnjeg uveitisa i panuveitisa kod odraslih bolesnika kod kojih nije postignut zadovoljavajući učinak liječenjem konvencionalnom imunosupresijskom terapijom ako – a) nema smanjenja upale unatoč 6 mjeseci liječenjem imunosupresivima (bez aktivnih upalnih lezija na fundusu oka, stanice u prednjoj sobici 0,5+ ili manje, zamućenje staklovine 0,5+ ili manje po kriterijima SUN working group) ili b) kod pogoršanja bolesti koje se po kriterijima SUN working group manifestira povećanjem razine inflamacije (stanice u prednjoj očnoj sobici i zamućenja staklovine) za dva stupnja ili sa stupnja 3+ na 4+, perzistiranje aktivne inflamacije i nastanak novih upalnih lezija na fundusu te smanjenje vidne oštrine za >=15 znakova od najbolje dostignute po ETDRS sustavu ili c) kronična supresija uz imunosupresive zahtijeva dnevnu dozu kortikosteroida više od 10 mg prednisona. Prije uvođenja lijeka potrebno je klasificirati uveitis po klasifikaciji međunarodne skupine za proučavanje uveitisa (IUSG) te radne skupine za uveitis (SUN working group). Procjena učinka terapije i aktivnosti bolesti evaluira se nakon 16 tjedana. Nastavak liječenja je isključivo kod pozitivnog kliničkog odgovora. Liječenje započinje primjenom doze od 80 mg s.c. kao početne doze te dalje 40 mg s.c. svaka 2 tjedna počevši od prvog tjedna nakon inicijalne doze. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL511 | Kao monoterapija u drugoj liniji liječenja odraslih bolesnika s uznapredovalim rakom pluća nemalih stanica pozitivnim na kinazu anaplastičnog limfoma. Liječenje odobrava Bolničko povjerenstvo za lijekove. Odobravaju se dva ciklusa liječenja, nakon čega je obvezna klinička i dijagnostička obrada u cilju ocjene stupnja tumorskog odgovora i podnošljivosti liječenja, od kojih 2. ciklus liječenja može teretiti sredstva posebno skupih lijekova. Nastavak liječenja je moguć na teret sredstava posebno skupih lijekova isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. |
| NL512 | 1. Liječenje umjerenog do teškog oblika aktivnog reumatoidnog artritisa u odraslih bolesnika koji nisu dovoljno dobro odgovorili na jedan ili više antireumatskih lijekova koji modificiraju tijek bolesti ili koji ne podnose takve lijekove. Primjenjuje se u monoterapiji ili u kombinaciji s metotreksatom. a. Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >=5,1 ili DAS28 >=3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. b. Prethodna terapija, najmanje 2 lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primjenjen najmanje kroz 2 mjeseca 20 mg tjedno (u slučaju nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka nekog drugog biološkog lijeka. c. Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >=5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <=3,2, ako je započeto s DAS28 >=3,2 + 6 otečenih zglobova (od 44), pad DAS28 >=1,2 + 50% manje otečenih zglobova. e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz JAK inhibitor. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija JAK inhibitoru bez obzira na vrijednost DAS28. Bolesnici koji se JAK inhibitorom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju liječenje JAK inhibitorom. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. f. Procjena učinka lijeka obavezna je nakon 12 tjedana od početka liječenja, a kasnije najmanje jedanput tijekom godine. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka specijalista reumatologa/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje aktivnog psorijatičnog artritisa. Primjenjuje se u monoterapiji ili kombinaciji s metotreksatom. a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka – lijek metotreksat (20 mg/tjedno) |
|  | ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi. c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa iz ugovorne zdravstvene ustanove Zavoda, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena) e. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa iz ugovorne zdravstvene ustanove Zavoda (skala 0-10). f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. i. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka specijalista reumatologa/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. 3. Za liječenje aktivnog ankilozantnog spondilitisa. a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. b. Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu (0-10) >= 4 ili prema ASDAS indeksu >=1,1. c. Prema procjeni reumatologa ukupna težina bolesti (na ljestvici 0-10) >= 4, a koja respektira – aktivni koksitis, sinovitis/entezitis i/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). d. Nakon najmanje 16 tjedana primjene očekivani učinak je -50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog cilja. f. Procjena učinka lijeka obavezna je nakon 16 tjedana od početka liječenja, a kasnije najmanje jedanput tijekom godine. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka specijalista reumatologa/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. 4. Za liječenje teškog atopijskog dermatitisa (EASI >=21 i/ili SCORAD >50 i DLQI>13) u bolesnika starijih od 12 godina u kojih nije postignut zadovoljavajući terapijski odgovor nakon najmanje 12 tjedana primjene barem jednog imunosupresivnog lijeka (uključujući ciklosporin, metotreksat, azatioprin i mikofenolat mofetil) ili su na isti razvili nuspojave koje zahtijevaju prekid terapije ili imaju kontraindikacije za uvođenje gore navedenih imunosupresivnih lijekova. Liječenje može započeti i provoditi samo liječnik specijalist dermatovenerologije. Prije uvođenja lijeka potrebno je odrediti EASI i/ili SCORAD i DLQI te probir na latentnu TBC i određivanje markera hepatitisa B i C. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana nakon 12 tjedana od početka liječenja, određivanjem vrijednosti EASI i/ili SCORAD te DLQI. Nastavak liječenja moguć je ukoliko je nakon 12 tjedana postignuto najmanje 50 % poboljšanje EASI i/ili SCORAD vrijednosti i poboljšanje DLQI vrijednosti više od 4 boda, prema procjeni nadležnog liječnika. Procjena učinka terapije se potom evaluira najmanje jedanput tijekom godine izračunavanjem vrijednosti EASI i/ili SCORAD i DLQI prema procjeni nadležnog liječnika – održavanje postignutog učinka liječenja. Liječenje se prekida kod izostanka očekivanog učinka prema zadanim kriterijima – a) nakon 12 tjedana ukoliko nije postignuto najmanje 50 % poboljšanje EASI i/ili SCORAD vrijednosti i poboljšanje DLQI vrijednosti više od 4 boda ili b) ukoliko nakon svake naknadne evaluacije (najmanje jedanput tijekom godine) nije postignut očekivan učinak održavanja terapijskog odgovora prema procjeni nadležnog liječnika ili c) u slučaju ozbiljnih nuspojava, teške interkurentne infekcije (privremeni/trajni prekid), trudnoće. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. Preporučena doza upadacitiniba je 15 mg ili 30 mg jedanput na dan na temelju kliničke slike pojedinog bolesnika. Doza od 30 mg jedanput na dan može biti prikladna za bolesnike s visokim opterećenjem bolešću (engl. disease burden). Doza od 30 mg jedanput na dan može biti prikladna za bolesnike s neadekvatnim odgovorom na liječenje dozom od 15 mg jedanput na dan. Za bolesnike u dobi od ≥ 65 godina, preporučena doza je 15 mg jedanput na dan. Adolescentima (u dobi od 12 do 17 godina) je preporučena doza upadacitiniba je 15 mg jedanput na dan za adolescente tjelesne težine od najmanje 30 kg. |
| NL513 | Kao monoterapija za liječenje odraslih bolesnika sa sekundarno progresivnom multiplom sklerozom uz zadovoljene navedene kriterije – a. Zadovoljeni Lublinovi kriteriji za sekundarno progresivnu multiplu sklerozu – progresivno nakupljanje onesposobljenosti nakon inicijalnog relapsnog remitirajućeg tijeka bolesti. b. Progresija EDSS-a za 1 za EDSS do 5.5, a za 0.5 za EDSS veći ili jednako od 5.5, u odsustvu relapsa. c. EDSS 3,0 – 7,5. d. Broj bodova na skali piramidnog funkcionalnog sustava (FS) veći ili jednak od 2. e. Odsutnost trudnoće. Kriterij za isključivanje iz terapijskog postupka lijekom je porast EDSS vrijednosti ≥ 3 u odnosu na početnu vrijednost u trenutku početka liječenja siponimodom. Liječenje odobrava bolničko povjerenstvo za lijekove iz sredstava posebno skupih lijekova. |
| NL514 | Za liječenje bolesnika s nemetastatskim, kastracijski rezistentnim karcinomom prostate (nmCRPC) koji zadovoljavaju kriterij definicije visokog rizika odnosno u kojih je vrijeme udvostručenja PSA ≤ 10 mjeseci (PSA-DT ≤10 mjeseci), ECOG statusa 0-1. Potrebna je klinička i dijagnostička obrada svaka 3 mjeseca radi procjene učinka terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti, a kojom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. Liječenje se odobrava iz sredstava posebno skupih lijekova. |
| NL515 | Monoterapija za liječenje lokalno uznapredovalog, neresektabilnog raka pluća nemalih stanica (engl. non small cell lung cancer, NSCLC) kod odraslih osoba čiji tumori pokazuju ekspresiju PD L1 na ≥ 1% tumorskih stanica i kojima bolest nije uznapredovala nakon kemoradioterapije temeljene na platini. Kriteriji za primjenu lijeka durvalumaba su – a. ECOG status 0-1, b. bolesnici nisu prethodno bili izloženi bilo kojem protutijelu na PD 1 ili PD L1. Liječenje treba započeti unutar 6 tjedana nakon što su dovršena najmanje dva ciklusa definitivne kemoterapije temeljene na platini u kombinaciji s radioterapijom. Procjena uspješnosti liječenja primjenom RECIST i irRC kriterija obvezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti, pojave neprihvatljive toksičnosti ili do najduže 12 mjeseci. Ukoliko se nakon prve procjene utvrdi da je došlo do progresije bolesti terapija se do sljedeće procjene može nastaviti u bolesnika koji zadovoljavaju slijedeće kriterije – 1. odsutnost simptoma koji ukazuju na progresiju bolesti, 2. nema pogoršanja ECOG statusa, 3. odsutnost brze progresije bolesti ili progresije bolesti na kritičnim anatomskim mjestima koja bi zahtijevala hitnu medicinsku intervenciju. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima specijaliziranog za tumore torakalnih organa. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. |
| NL517 | 1. Za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom bubrega u drugoj liniji liječenja. Kriteriji za primjenu – 1. nepostojanje CNS presadnica. 2. status ECOG 0-2. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Odobrava se primjena terapije za 3 mjeseca, nakon kojih se provodi provjera učinka terapije. 2. Za liječenje uznapredovalog hepatocelularnog karcinoma jetre. Kriteriji za primjenu – 1. Child-Pugh stadij jetrene bolesti A. 2. Uredna bubrežna funkcija (kreatinin klirens > 50 ml/min). 3. Uredna funkcija hematopoetskog sustava (trombociti > 1000 000, neutrofili > 1500, hemoglobin > 110 g/l. 4. Nepostojanje CNS presadnica. 5. ECOG 0-1. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Odobrava se primjena terapije za 2 mjeseca, nakon kojih se provodi provjera učinka terapije. Oznaka KL samo za liječenje pod 2. |
| NL518 | 1. Prva linija liječenja agresivnih non-Hodgkin limfoma, koji su prema nalazu imunohistokemije, imunocitokemije ili protočne citometrije CD20 pozitivni, u kliničkom stadiju II-IV ili stadiju I s povišenim LDH ili velikom tumorskom masom, odobrava se 4 ciklusa liječenja u kombinaciji s kemoterapijom u dozi od 375 mg/(m)2 po ciklusu. U slučaju povoljnog učinka odobrava se primjena još 4 ciklusa terapije. 2. Prva linija liječenja bolesnika s neliječenim CD20 pozitivnim indolentnim non-Hodgkin limfomom. Odobrava se primjena osam ciklusa liječenja u dozi od 375 mg/(m)2 po ciklusu. 3. Liječenje bolesnika sa indolentnim B-staničnim non-Hodgkinovim limfomom u relapsu odnosno u bolesnika sa kemorezistentnim tipom B-staničnog non-Hodgkinovog limfoma niskog stupnja malignosti u kojih je imunohistokemijski i/ili protočnom citometrijom dokazano da stanice na sebi imaju CD20 biljeg. Odobrava se primjena tri ciklusa liječenja uz obveznu reevaluaciju učinka nakon trećeg ciklusa terapije. U slučaju povoljnog učinka odobrava se primjena još tri ciklusa terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista internista hematologa. 4. Za liječenje reumatoidnog artritisa 4.a. Indikacija za primjenu (kao monoterapija te u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest DAS28 >= 5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status – HAQ 0,5-2,5. 4.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno i jedan TNF blokator ili lijek tocilizumab kroz 12 tjedana. 4.c. Prije primjene probir na latentnu TBC prema preporukama HRD i određivanje markera hepatitisa B i C. 4.d. Zadani učinak liječenja nakon 16 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >= 1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 4.e. Trajanje liječenja, reekspozicija lijeku rituksimab nakon dvije infuzije dolazi u obzir nakon 24 tjedna ukoliko je prisutna rezidualna upalna aktivnost DAS28 >= 3,2 ili je došlo do egzacerbacije RA s porastom DAS28 za >= 0.6. 4.f. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. Liječenje odobrava Bolničko povjerenstvo za lijekove, po preporuci reumatologa, za prve dvije infuzije, a kasnije najranije 24 tjedna od prve aplikacije s dokumentiranim ishodom kao što je navedeno u točki 4.d. 5. Za liječenje bolesnika s umjerenim do teškim oblikom običnog pemfigusa (PV). Liječenje odobrava Bolničko povjerenstvo za lijekove. Liječenje pod 1., 2. i 4. odobrava se iz sredstava posebno skupih lijekova, a liječenje pod 3. i 5. iz sredstava bolničkog proračuna. |
| NL519 | I. Za liječenje odraslih bolesnika s metastatskim karcinomom Merkelovih stanica.  Kriteriji za primjenu: a. ECOG status 0-1, b. Procjena uspješnosti liječenja primjenom RECIST i irRC kriterija obvezna je svaka 3 mjeseca. Ukoliko se nakon prve procjene utvrdi da je došlo do progresije bolesti terapija se do sljedeće procjene može nastaviti u bolesnika koji zadovoljavaju sljedeće kriterije – 1. odsutnost simptoma koji ukazuju na progresiju bolesti, 2. nema pogoršanja ECOG statusa, 3. odsutnost brze progresije bolesti ili progresije bolesti na kritičnim anatomskim mjestima koja bi zahtijevala hitnu medicinsku intervenciju. c. Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. d. Liječenje se provodi u Kliničkim bolničkim centrima. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije.  II. Monoterapija u prvoj liniji liječenja terapijom održavanja kod odraslih bolesnika s lokalno uznapredovalim ili metastatskim urotelnim karcinomom u kojih nije došlo do progresije nakon kemoterapije na bazi platine. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima za urogenitalne tumore na period od 3 mjeseca, nakon čega slijedi provjera rezultata liječenja – nastavak liječenja samo u slučaju pozitivnog odgovora na liječenje (kompletna remisija, parcijalna remisija, stabilna bolest) do progresije bolesti. Liječenje se može započeti u Kliničkim bolničkim centrima.  Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. Oznaka KL samo za liječenje pod I. |
| NL520 | 1. Za liječenje u kombinaciji s kemoterapijom odraslih bolesnika s HER2 pozitivnim lokalno recidivirajućim, neresektabilnim ili metastatskim rakom dojke koji prethodno za liječenje metastatske bolesti nisu primali anti – HER2 terapiju ni kemoterapiju. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu reevaluaciju učinka nakon četiri ciklusa liječenja. Nakon prestanka kemoterapije, a prema odluci nadležnog onkologa, liječenje se nastavlja (s ili bez hormonske terapije) do progresije bolesti ili do pojave neprihvatljive toksičnosti. Svaka slijedeća evaluacija učinka liječenja se radi nakon provedenih šest ciklusa liječenja. 2. Za neoadjuvantno liječenje u kombinaciji s kemoterapijom odraslih bolesnika s HER2 pozitivnim, lokalno uznapredovalim, upalnim ili rakom dojke u ranom stadiju s velikim rizikom od recidiva. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. 3. Za adjuvantno liječenje bolesnica s HER2 pozitivnim rakom dojke s visokim rizikom povrata bolesti, a koje imaju barem jedno od obilježja – 1. Pozitivni limfni čvorovi, 2. Negativni hormonski receptori (tumori veličine T2 i veći). Fiksnu supkutanu kombinaciju lijekova pertuzumab+trastuzumab treba primjenjivati tijekom ukupno godinu dana ili 18 ciklusa, odnosno do recidiva bolesti ili do pojave toksičnosti koja se ne može zbrinuti, kao dio cjelovitog protokola za liječenje ranog raka dojke, neovisno o vremenu kirurškog zahvata. Ukupno trajanje liječenja (neoadjuvantno+adjuvantno) može trajati ukupno do godinu dana ili 18 ciklusa. Liječenje odobrava Bolničko povjerenstvo za lijekove na teret sredstava posebno skupih lijekova na prijedlog multidisciplinarnog tima za tumore dojke. |
| NL521 | 1. Monoterapija u terapiji održavanja kod odraslih bolesnica s recidivom na platinu osjetljivog seroznog epitelnog karcinoma jajnika visokog stupnja nediferenciranosti, karcinoma jajovoda ili primarnog peritonealnog karcinoma s mutacijom (germinativnom i/ili somatskom) BRCA gena koje su ostvarile odgovor (potpun ili djelomičan) na kemoterapiju temeljenu na platini. Liječenje odobrava Bolničko povjerenstvo za lijekove na period od 3 mjeseca, nakon čega slijedi provjera rezultata liječenja – nastavak liječenja samo u slučaju pozitivnog odgovora na liječenje (kompletna remisija, parcijalna remisija, stabilna bolest) do progresije bolesti. 2. Monoterapija za terapiju održavanja kod odraslih bolesnica s uznapredovalim (stadiji III i IV prema FIGO klasifikaciji) epitelnim karcinomom jajnika visokog stupnja nediferenciranosti, karcinomom jajovoda ili primarnim peritonealnim karcinomom pozitivnim na mutacije gena BRCA1/2 (germinativne i/ili somatske) koje su ostvarile odgovor (potpun ili djelomičan) nakon završetka prve linije kemoterapije temeljene na platini. Kriteriji za primjenu lijeka su a. dokazane mutacije gena BRCA1 i/ili BRCA2 (germinativne i/ili somatske), b. ostvaren odgovor (potpun ili djelomičan) na prvu liniju kemoterapije temeljene na platini. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima specijaliziranog za ginekološke karcinome, na period od 3 mjeseca, nakon čega slijedi provjera rezultata liječenja – nastavak liječenja samo u slučaju pozitivnog odgovora na liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) do radiološke progresije bolesti, pojave neprihvatljive toksičnosti ili do 2 godine. Kod bolesnica koje nakon 2 godine liječenja nemaju radioloških dokaza progresije bolesti, ali je bolest i dalje prisutna, i koje prema mišljenju nadležnog onkologa mogu ostvariti daljnju korist od nastavka liječenja, mogu nastaviti liječenje i dulje od 2 godine. 3. Monoterapija za liječenje odraslih bolesnika sa zametnim mutacijama gena BRCA1 i BRCA2 koji boluju od lokalno uznapredovalog ili metastatskog trostruko-negativnog raka dojke. Bolesnici su prethodno trebali biti liječeni antraciklinom i/ili taksanom u (neo)adjuvantnom, lokalno uznapredovalom ili metastatskom okruženju osim ako ta liječenja nisu bila prikladna za bolesnike. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu procjenu terapijskog učinka liječenja nakon 3 ciklusa liječenja. Svaka sljedeća procjena se radi nakon provedenih 3 ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. Oznaka DS samo za liječenje pod točkom 3. |
| NL522 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste gastroenterologa, odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek vedolizumab se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ako nakon prvih 4 mjeseca primjene lijeka vedolizumab (prije početka primjene lijeka supkutanim oblikom, a sve sukladno odobrenom sažetku opisa svojstava lijeka, primjenjuju se najmanje 2 doze intravenskim putem, a dalje svaka 2 tjedna se lijek primjenjuje supkutanim putem), bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka supkutanim putem za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. Za liječenje odraslih bolesnika s umjereno do izrazito aktivnom Crohnovom bolesti koji nisu postigli odgovarajući odgovor ili su izgubili odgovor ili na standardnu terapiju ili na antagoniste faktora nekroze tumora alfa (TNFα), te u slučaju dokumentiranog nepodnošenja takve terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Za liječenje odraslih bolesnika s umjereno do izrazito aktivnim ulceroznim kolitisom koji nisu postigli odgovarajući odgovor ili su izgubili odgovor ili na standardnu terapiju ili na antagoniste faktora nekroze tumora alfa (TNFα), te u slučaju dokumentiranog nepodnošenja takve terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove. Prije početka primjene lijeka supkutanim oblikom, a sve sukladno odobrenom sažetku opisa svojstava lijeka, primjenjuju se najmanje 2 doze intravenskim putem, a dalje svaka 2 tjedna se lijek primjenjuje supkutanim putem. |
| NL523 | U kombinaciji s nivolumabom za prvu liniju liječenja odraslih bolesnika s uznapredovalim karcinomom bubrežnih stanica umjerenog/visokog rizika. Kriteriji za primjenu – a. Histološki potvrđen uznapredovali karcinom bubrega svijetlih stanica bez prethodne sistemske terapije, uz iznimku jedne prethodne adjuvantne ili neoadjuvantne terapije (koja ne uključuje VEGF-ciljane lijekove) za potpuno odstranjen karcinom bubrežnih stanica, ukoliko je povrat bolesti uslijedio najmanje šest mjeseci nakon posljednje doze, b. ECOG status 0-1, c. Nepostojanje stanja koje zahtjeva sistemsko liječenje kortikosteroidima (ekvivalentno dozi prednizona > 10 mg dnevno) ili drugim imunosupresivnim lijekovima unutar 14 dana prije prve doze lijeka, d. Uredna funkcija hematopoetskog sustava (leukociti > 2.000 stanica/mm3, neutrofili > 1.500 stanica/mm3, trombociti > 100.000/mm3), e. Uredna funkcija jetre (razina AST ili ALT < 3 x gornja granica uredne vrijednosti (ili < 5 x gornja granica uredne vrijednosti ukoliko su prisutne presadnice u jetri), ukupni bilirubin < 1,5 x gornja granica uredne vrijednosti (osim u bolesnika s Gilbertovim sindromom u kojih je dozvoljena razina ukupnog bilirubina <3,0 mg/dL), f. Uredna funkcija bubrega (razina serumskog kreatinina < 1,5 x gornje granice uredne vrijednosti, ili klirens kreatinina > 40 mL/min). Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog multidisciplinarnog tima specijaliziranog za liječenje urogenitalnih tumora. Liječenje se može započeti u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. |
| NL524 | 1. Za bolesnike s dokazanim aHUS-om ili s opravdanom kliničkom sumnjom na aHUS, a koji su životno ugroženi i/ili im prijeti ili je nastupilo bubrežno zatajenje koje zahtijeva nadomještanje bubrežne funkcije. Za nastavak terapije potrebno je dokazati klinički značajno poboljšanje (hemolize – normalizacija broja trombocita, laktatdehidrogenaze, i ev. poboljšanje bubrežne funkcije) i imati dokazanu bolest (genski). Evaluacija je potrebna nakon prva 2 mjeseca (klinički i genski) liječenja te nakon svaka 3 mjeseca (klinički). Ukoliko se bolest ne dokaže genski, liječenje treba prekinuti, ali i ponovo uvesti u slučaju prethodnog klinički dobrog odgovora, a recidiva nakon ukidanja ekulizumaba. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog pedijatra nefrologa ili bolničkog nefrologa. 2. Za liječenje odraslih bolesnika s PNH. Kriteriji za primjenu u bolesnika s hemolizom s jednim ili više kliničkih simptoma koji ukazuju na bolest visoke aktivnosti – a) bolesnici starosti ≥ 18 godina koji prethodno nisu primali inhibitor sustava komplementa, b) dijagnosticirana PNH dokumentirana protočnom (flow) citometrijom, c) veličina klona bijelih krvnih stanica ≥ 5%, LDH ≥ 1,5 gornje granice normale, d) prisutnost ≥ 1 znaka ili simptoma povezanih s PNH unutar 3 mjeseca, e) primljeno meningokokno cjepivo barem 2 tjedna prije početka liječenja, ako je cjepivo primljeno unutar 2 tjedna od početka liječenja obavezna je antibiotska profilaksa do dva tjedna nakon cijepljenja, f) Za nastavak terapije potrebno je imati klinički značajno poboljšanje (hemolize, uz smanjenje incidencije ili nestanak trombotičkih događaja), a isto je potrebno evaluirati nakon mjesec dana terapije pa nakon svaka 3 mjeseca. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog hematologa ili bolničkog nefrologa. Kriteriji za primjenu u bolesnika koji su klinički stabilni nakon liječenja ekulizumabom najmanje proteklih 6 mjeseci – a) bolesnici starosti ≥ 18 godina koji su prethodno najmanje 6 mjeseci primali ekulizumab za liječenje PNH, b) dijagnosticirana PNH dokumentirana visoko senzitivnom protočnom (flow) citometrijom, c) veličina klona bijelih krvnih stanica ≥ 5%, LDL ≤ 1,5 gornje referentne vrijednosti, d) primljeno meningokokno cjepivo barem 2 tjedna prije početka liječenja, ako je cjepivo primljeno unutar 2 tjedna od početka liječenja obavezna je antibiotska profilaksa do dva tjedna nakon cijepljenja, e) Za nastavak terapije potrebno je barem ostati klinički stabilno, a isto je potrebno evaluirati nakon mjesec dana terapije pa nakon svaka 3 mjeseca. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog hematologa ili bolničkog nefrologa. |
| NL525 | Liječenje u kombinaciji sa standardnom uvodnom terapijom i terapijom konsolidacije daunorubicinom (DNR) i citarabinom (AraC) bolesnika starijih od 15 godina s prethodno neliječenom, de novo CD-33 pozitivnom akutnom mijeloičnom leukemijom (AML), povoljnog i intermedijarnog rizika po ELN kriterijima, osim akutne promijelocitne leukemije (APL). Liječenje se odobrava za 1 ciklus uvodne terapije i do 2 ciklusa konsolidacije. Liječenje se provodi u Kliničkim bolničkim zdravstvenim ustanovama. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL526 | 1. liječenje odraslih bolesnika s kroničnom mijeloičnom leukemijom u kroničnoj, ubrzanoj ili blastičnoj fazi bolesti koji su rezistentni na 2 inhibitora tirozin kinaze (imatinib i jedan inhibitor tirozin kinaze 2. generacije), 2. liječenje odraslih bolesnika s kroničnom mijeloičnom leukemijom u kroničnoj, ubrzanoj ili blastičnoj fazi bolesti koji imaju T315I mutaciju. Liječenje pod 1. i 2. odobrava Bolničko povjerenstvo za lijekove. |
| NL527 | 1. Za liječenje odraslih bolesnika s kroničnim limfocitnom leukemijom (KLL) – a) s delecijom kromosoma 17p odnosno mutacijom p53 b) kod prethodno neliječenih bolesnika dobrog općeg stanja (ECOG 0-2), visokog rizika, a koji se definira prisustvom nemutiranih gena za teški lanac imunoglubulina (uIGHV) ili delecijom kromosoma 11q kao i za liječenje prethodno neliječenih bolesnika kod kojih nije prikladno liječenje temeljeno na punoj dozi fludarabina c) kod prethodno liječenih bolesnika koji su refrakterni na terapiju ili su u ranom relapsu, a koji se definira kao relaps unutar 24 mjeseca od završetka prethodne terapije Kriteriji za primjenu lijeka – Prije početka terapije obvezno je učiniti citogenetsko testiranje, FISH iz koštane srži/periferne krvi te radiološki procijeniti veličinu limfnih čvorova, jetre i slezene, odnosno infiltraciju organa. Liječe se bolesnici s prisutnim simptomima bolesti koji imaju jedan od kriterija – a) visok rizik – po RAI-u III-IV b) TTM veći ili jednako 15 c) masivnu tumorsku bolest (jedan čvor ili konglomerat > 10 cm ili progresivna ili simptomatska limfadenopatija) d) imaju značajne B simptome koji ometaju kvalitetu života (jedan ili više navedenih simptoma – nenamjerni gubitak tjelesne težine >= 10% u zadnjih 6 mjeseci, temperatura > 38 stupnjeva C u trajanju 2 ili više tjedna bez dokaza infekcije, noćno znojenje duže od mjesec dana bez dokaza infekcije). ECOG 0-2. Procjenu terapijskog učinka prvi puta obvezno je provesti najkasnije 6 mjeseci od početka liječenja, a nastavak liječenja je moguć ako bolesnici zadovoljavaju jedan od kriterija a) ako je došlo do smanjenja tumorske mase >=50% u odnosu na početne vrijednosti mjerenja po TTM-u (u reevaluaciji obavezno učiniti UZV ili CT koji potvrđuje smanjenje >=50%) b) ako je došlo do poboljšanja RAI statusa sa stupnja III-IV na I-II-III (učiniti laboratorijsku obradu koja potvrđuje smanjenje RAI-a III-IV na RAI I-II-III) c) ako je došlo do poboljšanja anemije (ako inicijalno hemoglobin 80-100 g/l porast >100 g/l, ako inicijalno <80 g/l bolesnik je postao neovisan o transfuzijama) ili trombocitopenije (trombociti iznad 100x109/L ili porast za >50% od inicijalne vrijednosti ili neovisnost bolesnika o transfuzijama) d) značajno smanjenje B simptoma. Nakon toga liječenje se prekida u slučaju progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. 2. Za liječenje odraslih bolesnika s Waldenströmovom makroglobulinemijom (WM) koji su prethodno primili najmanje jednu terapiju. Kriteriji za primjenu lijeka – Liječe se bolesnici s povišenom koncentracijom imunoglobulina IgM, koji imaju jedan ili više simptoma ili znakova bolesti – hemoglobin ≤ 100g/l, trombociti ≤ 100 x 109 /l, simptomatska limfadenopatija, simptomatska organomegalija, amiloidoza uzrokovana Waldenstromovom makroglobulinemijom, nefropatija uzrokovana Waldenstromovom makroglobulinemijom, simptomatska krioglobulinemija, hiperviskoznost, ponavljajuće povišene temperature, noćno znojenje, gubitak tjelesne težine, umor. Prvu procjenu terapijskog učinka je potrebno provesti najkasnije 6 mjeseci od početka liječenja, a nastavak liječenja je moguć ako je došlo do smanjenja koncentracije IgM u odnosu na nalaz prije početka liječenja i poboljšanja simptoma ili znaka zbog kojeg je liječenje započeto. Nakon toga se liječenje nastavlja do progresije bolesti ili pojave neprihvatljive toksičnosti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. 3. Za bolesnike s limfomom plaštenih stanica (MCL) koji su refraktorni ili u relapsu nakon terapije koja je uključivala bendamustin i monoklonsko protu – CD 20 protutijelo. Kriterij za primjenu lijeka – Prije započinjanja liječenja potrebno je radiološki procijeniti veličinu limfnih čvorova, jetre i slezene, odnosno postojanje infiltracije organa. Procjenu terapijskog učinka prvi puta obvezno je provesti najkasnije 6 mjeseci od početka liječenja. Liječenje se prekida u slučaju progresije bolesti ili pojave neprihvatljive toksičnosti. Nastavak liječenja je moguć ako bolesnici zadovoljavaju jedan od kriterija, a) smanjenje veličine limfnih čvorova ili infiltracije organa u odnosu na nalaz prije početka liječenja, ili b) klinički, radiološki i laboratorijski nema znakova progresije. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista hematologa. |
| NL528 | Lijek je u monoterapiji indiciran za liječenje odraslih bolesnika s ROS1-pozitivnim uznapredovalim rakom pluća nemalih stanica (engl. non-small cell lung cancer, NSCLC) koji prethodno nisu bili liječeni inhibitorima ROS1. Prije početka liječenja lijekom Rozlytrek mora se utvrditi pozitivan nalaz na ROS1 validiranim testom. Bolesnici moraju biti ECOG statusa 0-1 s očekivanim preživljenjem od najmanje 6 (šest) mjeseci. Klinička i dijagnostička obrada radi procjene uspješnosti liječenja obvezna je svaka 2 (dva) mjeseca. Uspješnost terapije se utvrđuje odgovorom bolesnika na liječenje (kompletna ili djelomična remisija te stabilna bolest). Prekid liječenja entrektinibom indiciran je u slučaju pojave neprihvatljive toksičnosti ili neupitne progresije bolesti i pogoršanja općeg stanja bolesnika prema ocjeni specijalista onkologa ili pulmoonkologa. Terapiju indicira nadležni specijalist onkolog/pulmolog, a odobrava Bolničko povjerenstvo za lijekove. |
| NL529 | 1. Monoterapija u prvoj liniji liječenja odraslih bolesnika sa lokalno uznapredovalim ili metastatskim urotelnim karcinomom, koji se ne smatraju pogodnima za liječenje cisplatinom (što podrazumijeva: WHO ili ECOG status >=2 ili klirens kreatinina <55 ml/min ili zatajenje srca NYHA III ili perifernu neuropatiju stupnja >=2) i čiji tumor pokazuju razinu ekspresije PD-L1 >=5%, potvrđene validiranim testom, samo ako su ECOG-statusa 0-1, uz laboratorijske nalaze AST, ALT < 5x GGN, odnosno bilirubin do 3x GGN, klirens kreatinina >30 ml/min, a očekivano preživljenje najmanje 6 mjeseci,  2. Druga linija liječenja odraslih bolesnika sa lokalno uznapredovalim ili metastatskim urotelnim karcinomom koji su prethodno primali kemoterapiju koja je sadržavala platinu, samo ako su ECOG-statusa 0-1, uz laboratorijske nalaze AST, ALT < 5x GGN, bilirubin do 3x GGN, odnosno klirens kreatinina >30 ml/min, a očekivano preživljenje najmanje 6 mjeseci.  Klinička i dijagnostička obrada radi procjene uspješnosti liječenja primjenom RECIST i irRC kriterija obvezna je svaka 3 mjeseca, a nastavak liječenja moguće je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), a sve do progresije bolesti ili pojave nepodnošljive toksičnosti. Ukoliko se nakon prve procjene utvrdi da je došlo do progresije bolesti terapija se do slijedeće procjene može nastaviti u bolesnika koji zadovoljavaju slijedeće kriterije: 1. odsutnost simptoma koji ukazuju na neupitnu progresiju bolesti, 2. nema daljnjeg pogoršanja ECOG-statusa, 3. izostanak tumorske progresije na kritičnim anatomskim mjestima koja se ne može jednostavno zbrinuti i stabilizirati medicinskim intervencijama dopuštenima prema protokolu prije ponovljenog doziranja. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima za urogenitalne tumore. Liječenje se može započeti isključivo u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje.  3. U monoterapiji za drugu liniju liječenja odraslih bolesnika s lokalno uznapredovalim ili metastatskim rakom pluća nemalih stanica nakon prethodno provedene kemoterapije. Kriteriji za primjenu: a. histološki ili citološki dokazan lokalno uznapredovali ili metastatski rak pluća nemalih stanica (neskvamozni tumori koji nisu pozitivni na tumorske mutacije gena EGFR ili ALK) b. ECOG status 0-1 c. nepostojanje stanja koje zahtijeva sistemsko liječenje kortikosteroidima (ekvivalentno dozi prednizona >10mg dnevno) ili drugim imunosupresivnim lijekovima unutar 14 dana prije prve doze lijeka. d) nepostojanje bilo koje aktivne poznate autoimune bolesti ili sumnje na istu. Diabetes mellitus Tip I, rezidualni hipotireoidizam zbog autoimunog stanja koje zahtijeva HNT, psorijaza za koju nije potrebna sistemska terapija, ili stanja za koja se ne očekuje da se ponovno pojavljuju u odsutnosti vanjskoj aktivatora, mogu se uključiti e) Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obavezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti ili pojave nepodnošljive toksičnosti. Ukoliko se nakon prve procjene utvrdi da je došlo do radiološke progresije bolesti terapija se do slijedeće procjene može nastaviti u bolesnika koji nemaju simptoma koji ukazuju na progresiju bolesti i nemaju daljnjeg pogoršanja ECOG statusa. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima za tumore torakalnih organa. Liječenje se može započeti isključivo u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje.  4. Prva linija liječenja metastatskog karcinoma pluća nemalih stanica u odraslih čiji tumori eksprimiraju PD-L1 uz udio tumorskih stanica s ekspresijom >=50% i koji nisu pozitivni na tumorske mutacije gena EGFR, ALK ili ROS1 (napomena – mutacije je potrebno isključiti samo u neskvamoznom karcinomu pluća nemalih stanica), a imaju ECOG status 0-1.  5. U kombinaciji s kemoterapijom koja sadrži platinu kao l. linija liječenja odraslih bolesnika s metastatskim neplanocelularnim rakom pluća nemalih stanica s negativnim nalazom EGFR, ALK i ROS1 promjena, te imaju ECOG status 0-1, a pokazuju izraženost PD-L1 1-49%.  6. U kombinaciji s bevacizumabom, paklitakselom i karboplatinom indiciran je u l. liniji liječenja odraslih bolesnika s metastatskim (stadij IV) neplanocelularnim rakom pluća nemalih stanica s jetrenim presadnicama u trenutku postavljanja dijagnoze, a s negativnim nalazom EGFR , ALK i ROS1 promjena, te imaju ECOG status 0-1.  Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja pod točkama 4., 5. i 6. obvezna je svaka 2 mjeseca, a nakon 6 mjeseci klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima za tumore torakalnih organa iz Kliničkog bolničkog centra. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje.  7. U kombinaciji s bevacizumabom za prvu liniju sustavnog liječenja odraslih bolesnika s lokalno uznapredovalim, neresektabilnim ili metastatskim hepatocelularnim karcinomom, a koji zadovoljavaju sljedeće kriterije: a) bolesnici sa lokalno uznapredovalim ili metastatskim HCC-om čija bolest nije pogodna za kirurške ili lokoregionalne metode liječenja ili je došlo do progresije bolesti nakon primjene neke od tih metoda liječenja, b) ECOG funkcionalni status 0 – 1, c) jetrena bolest stadija A prema Child-Pugh klasifikaciji. Klinička i dijagnostička obrada radi procjene uspješnosti liječenja obvezna je nakon 3 mjeseca od početka liječenja te potom svaka 3 mjeseca tijekom trajanja liječenja. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest). Klinička i dijagnostička obrada radi se prema RECIST1.1, mRECIST ili iRECIST kriterijima. Prekid liječenja kombinacijom atezolizumaba s bevacizumabom indicirano je u slučaju gubitka kliničke koristi (neupitna progresija bolesti) ili pojave neprihvatljive toksičnosti koja se ne može zbrinuti, prema procjeni specijaliste internističkog onkologa odnosno onkologa i radioterapeuta. Liječenje atezolizumabom ili bevacizumabom se može prekinuti (npr. zbog štetnih događaja) i nastaviti liječenje samo jednim lijekom do gubitka kliničke koristi ili pojave neprihvatljive toksičnosti povezane s lijekom koji se nastavio primjenjivati. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima. Liječenje se može započeti isključivo u Kliničkim bolničkim centrima. Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje.  8. U kombinaciji s nab-paklitakselom za liječenje neresektabilnog lokalno uznapredovalog ili metastatskog trostruko negativnog raka dojke u odraslih bolesnika čiji tumori pokazuju razinu ekspresije PD-L1 ≥ 1% i koji prethodno nisu primali kemoterapiju za metastatsku bolest, ako zadovoljavaju slijedeće kriterije: a) ECOG 0-2, b) nepostojanje simptomatskih ili o kortikosteroidima ovisnih presadnica c) nepostojanje autoimune bolesti u anamnezi. Klinička i dijagnostička obrada radi procjene uspješnosti liječenja primjenom RECIST i/ili irRECIST kriterija obvezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest). Liječenje odobrava Bolničko povjerenstvo za lijekove, a na prijedlog specijalista internističke onkologije ili specijalista radioterapije i onkologije. |
| NL530 | Monoterapija za liječenje odraslih bolesnika sa zametnim mutacijama gena BRCA1 i BRCA2 koji boluju od lokalno uznapredovalog ili metastatskog trostruko-negativnog raka dojke. Bolesnici su prethodno trebali biti liječeni antraciklinom i/ili taksanom u (neo)adjuvantnom, lokalno uznapredovalom ili metastatskom okruženju osim ako ta liječenja nisu bila prikladna za bolesnike. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu procjenu terapijskog učinka liječenja nakon 3 ciklusa liječenja. Svaka sljedeća procjena se radi nakon provedenih 3 ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije. |
| NL531 | U kombinaciji s fulvestrantom za liječenje odraslih bolesnika s uznapredovalim ili metastatskim rakom dojke pozitivnim na hormonski receptor (HR) i negativnim na receptor za humani epidermalni čimbenik rasta 2 (HER2) i potvrđenom PIK3CA mutacijom, u liječenju – 1. kao početna terapija u metastatskoj bolesti kod bolesnika koji su progredirali tijekom adjuvantnog liječenja baziranog na endokrinoj terapiji ili unutar godine dana od završetka istog, 2. kao 2. linija liječenja, neposredno nakon progresije bolesti na prvu liniju liječenja endokrinom terapijom (koja se primjenjivala kao monoterapija) ili u kombinaciji s CDK4/6 inhibitorom. Kriteriji za propisivanje – – Potvrđena PIK3CA mutacija u tumorskom tkivu ili plazmi – Progresija nakon endokrine terapije i/ili CDK4/6 inhibitora – ECOG status ≤ 2 Procjena prvog terapijskog odgovora liječenja nakon tri ciklusa liječenja kod pozitivnog tumorskog odgovora na liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). Svaka sljedeća procjena se radi nakon provedena tri ciklusa liječenja. Odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista internističke onkologije ili specijalista radioterapije i onkologije. |
| NL532 | 1. Za liječenje bolesnika s nemetastatskim, kastracijski rezistentnim karcinomom prostate (nmCRPC) koji zadovoljavaju kriterij definicije visokog rizika odnosno u kojih je vrijeme udvostručenja PSA ≤ 10 mjeseci (PSA-DT ≤10 mjeseci), ECOG statusa 0-1. Potrebna je klinička i dijagnostička obrada svaka 3 mjeseca radi procjene učinka terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti, a kojom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. Liječenje se odobrava iz sredstava posebno skupih lijekova. 2. Za liječenje odraslih muškaraca s hormonski osjetljivim metastatskim karcinomom prostate u kombinaciji s terapijom deprivacije androgena. Odobravaju se 3 ciklusa liječenja, nakon čega se temeljem dijagnostičke obrade ocjenjuje učinak terapije i podnošljivost liječenja. Liječenje se provodi do progresije bolesti. Progresijom se smatra značajno pogoršanje bolesti temeljeno na procjeni kliničke progresije i najmanje jednog od dva dodatna kriterija (vrijednost PSA i/ili radiološka progresija). Liječenje odobrava Bolničko povjerenstvo za lijekove. Liječenje se odobrava iz sredstava bolničkog proračuna. |
| NL533 | Za liječenje odraslih bolesnika s kroničnim limfocitnom leukemijom (KLL) – a) s delecijom kromosoma 17p odnosno mutacijom p53 b) kod prethodno neliječenih bolesnika dobrog općeg stanja (ECOG 0-2), visokog rizika, a koji se definira prisustvom nemutiranih gena za teški lanac imunoglubulina (uIGHV) ili delecijom kromosoma 11q kao i za liječenje prethodno neliječenih bolesnika kod kojih nije prikladno liječenje temeljeno na punoj dozi fludarabina c) kod prethodno liječenih bolesnika koji su refrakterni na terapiju ili su u ranom relapsu, a koji se definira kao relaps unutar 24 mjeseca od završetka prethodne terapije. Kriteriji za primjenu lijeka – Prije početka terapije obvezno je učiniti citogenetsko testiranje, FISH iz koštane srži/periferne krvi te radiološki procijeniti veličinu limfnih čvorova, jetre i slezene, odnosno infiltraciju organa. Liječe se bolesnici s prisutnim simptomima bolesti koji imaju jedan od kriterija – a) visok rizik – po RAI-u III-IV b) TTM veći ili jednako 15 c) masivnu tumorsku bolest (jedan čvor ili konglomerat > 10 cm ili progresivna ili simptomatska limfadenopatija) d) imaju značajne B simptome koji ometaju kvalitetu života (jedan ili više navedenih simptoma – nenamjerni gubitak tjelesne težine >= 10% u zadnjih 6 mjeseci, temperatura > 38 stupnjeva C u trajanju 2 ili više tjedna bez dokaza infekcije, noćno znojenje duže od mjesec dana bez dokaza infekcije). ECOG 0-2. Procjenu terapijskog učinka prvi puta obvezno je provesti najkasnije 6 mjeseci od početka liječenja, a nastavak liječenja je moguć ako bolesnici zadovoljavaju jedan od kriterija a) ako je došlo do smanjenja tumorske mase >=50% u odnosu na početne vrijednosti mjerenja po TTM-u (u reevaluaciji obavezno učiniti UZV ili CT koji potvrđuje smanjenje >=50%) b) ako je došlo do poboljšanja RAI statusa sa stupnja III-IV na I-II-III (učiniti laboratorijsku obradu koja potvrđuje smanjenje RAI-a III-IV na RAI I-II-III) c) ako je došlo do poboljšanja anemije (ako inicijalno hemoglobin 80-100 g/l porast >100 g/l, ako inicijalno <80 g/l bolesnik je postao neovisan o transfuzijama) ili trombocitopenije (trombociti iznad 100x109/L ili porast za >50% od inicijalne vrijednosti ili neovisnost bolesnika o transfuzijama) d) značajno smanjenje B simptoma. Nakon toga liječenje se prekida u slučaju progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. |
| NL534 | 1. Prva linija liječenja osoba s RRMS-om s visokim rizikom od napredovanja neurološke onesposobljenosti kod postavljanja dijagnoze RRMS-e. Kriteriji započinjanja terapije – Zadovoljeni revidirani McDonaldovi dijagnostički kriteriji za RRMS-u, uz još jedan od dolje navedenih kriterija – a. ≥ 9 T2 ili FLAIR lezija na inicijalnom MR-u mozga i vratne kralježnice b. ≥ 3 lezija koje se imbibiraju na primjenu kontrastnog sredstva na inicijalnom MR-u mozga i vratne kralježnice c. EDSS nakon liječenja prvog simptoma ≥ 3 Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijalista neurologa. Prvo odobrenje Bolničkog povjerenstva za lijekove izdaje se za razdoblje od 6 mjeseci od kojih se prvih mjesec dana lijek primjenjuje na teret sredstva bolničkog proračuna, a u nastavku se za preostalih 5 odobrenih mjeseci liječenja lijek može propisivati na recept Zavoda. Svako sljedeće odobrenje za nastavak liječenja, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijalista neurologa, Bolničko povjerenstvo za lijekove može izdati za razdoblje od najviše 12 mjeseci. Lijek se može propisivati na recept Zavoda isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. 2. Druga linija liječenja osoba s RRMS. Kriteriji započinjanja terapije – 1. Bolesnici kod kojih je bolest aktivna usprkos 1. liniji liječenja – a. ≥4 nove T2 ili T1 lezije koje se imbibiraju na primjenu kontrasta na MR-u nakon početka liječenja lijekovima 1. linije ili b. ≥2 relapsa nakon početka liječenja lijekovima 1. linije 2. EDSS ≤ 6,0 3. Odsutnost trudnoće 4. Odobrenje Bolničkog povjerenstva za lijekove na prijedlog specijalista neurologa. Liječenje odobrava Bolničko povjerenstvo za lijekove na teret sredstava namijenjenih za posebno skupe lijekove. 3. Liječenje teške brzonapredujuće multiple skleroze. Kriteriji započinjanja terapije – a. Bolesnici s teškom brzonapredujućom relapsno-remitirajućom multiplom sklerozom definiranom s 2 ili više onesposobljavajućih relapsa (motorički relaps, ataksija, moždano deblo) u trajanju manje od jedne godine neovisno o trajanju bolesti i prethodnoj terapiji b. EDSS ≤ 6,0 c. Odsutnost trudnoće d. Odobrenje Bolničkog povjerenstva za lijekove na prijedlog specijalista neurologa. Liječenje odobrava Bolničko povjerenstvo za lijekove na teret sredstava bolničkog proračuna. |
| NL535 | Za liječenje teškog atopijskog dermatitisa (EASI >=21 i/ili SCORAD >50 i DLQI>13) u bolesnika starijih od 12 godina u kojih nije postignut zadovoljavajući terapijski odgovor nakon najmanje 12 tjedana primjene barem jednog imunosupresivnog lijeka (uključujući ciklosporin, metotreksat, azatioprin i mikofenolat mofetil) ili su na isti razvili nuspojave koje zahtijevaju prekid terapije ili imaju kontraindikacije za uvođenje gore navedenih imunosupresivnih lijekova. Liječenje može započeti i provoditi samo liječnik specijalist dermatovenerologije. Prije uvođenja lijeka potrebno je odrediti EASI i/ili SCORAD i DLQI te probir na latentnu TBC i određivanje markera hepatitisa B i C. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana nakon 12 tjedana od početka liječenja, određivanjem vrijednosti EASI i/ili SCORAD te DLQI. Nastavak liječenja moguć je ukoliko je nakon 12 tjedana postignuto najmanje 50 % poboljšanje EASI i/ili SCORAD vrijednosti i poboljšanje DLQI vrijednosti više od 4 boda, prema procjeni nadležnog liječnika. Procjena učinka terapije se potom evaluira najmanje jedanput tijekom godine izračunavanjem vrijednosti EASI i/ili SCORAD i DLQI prema procjeni nadležnog liječnika – održavanje postignutog učinka liječenja. Liječenje se prekida kod izostanka očekivanog učinka prema zadanim kriterijima – a) nakon 12 tjedana ukoliko nije postignuto najmanje 50 % poboljšanje EASI i/ili SCORAD vrijednosti i poboljšanje DLQI vrijednosti više od 4 boda ili b) ukoliko nakon svake naknadne evaluacije (najmanje jedanput tijekom godine) nije postignut očekivan učinak održavanja terapijskog odgovora prema procjeni nadležnog liječnika ili c) u slučaju ozbiljnih nuspojava, teške interkurentne infekcije (privremeni/trajni prekid), trudnoće. Početak i nastavak liječenja odobrava Bolničko povjerenstvo za lijekove. Preporučena doza upadacitiniba je 15 mg ili 30 mg jedanput na dan na temelju kliničke slike pojedinog bolesnika. Doza od 30 mg jedanput na dan može biti prikladna za bolesnike s visokim opterećenjem bolešću (engl. disease burden). Doza od 30 mg jedanput na dan može biti prikladna za bolesnike s neadekvatnim odgovorom na liječenje dozom od 15 mg jedanput na dan. Za bolesnike u dobi od ≥ 65 godina, preporučena doza je 15 mg jedanput na dan. Adolescentima (u dobi od 12 do 17 godina) je preporučena doza upadacitiniba je 15 mg jedanput na dan za adolescente tjelesne težine od najmanje 30 kg. |
| NL536 | Primjenu lijeka prema dolje pojedinačno navedenim indikacijama i kriterijima za primjenu, na prijedlog bolničkog specijaliste odgovarajuće specijalnosti (ovisno o indikaciji – gastroenterologa, reumatologa/kliničkog imunologa i dermatovenerologa), odobrava Bolničko povjerenstvo za lijekove. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek Remsima (i.v. ili s.c.) se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna. Ukoliko nakon prva 4 mjeseca primjene novog lijeka bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, primjenu lijeka za nastavak liječenja Bolničko povjerenstvo za lijekove može odobriti za sljedećih 6 mjeseci, a lijek se može propisivati na recept Zavoda. U slučaju da nakon 6 mjeseci liječenja bolesnik i dalje ima indikaciju za nastavak liječenja istim lijekom te zadovoljava kriterije za nastavak liječenja uz pripadajuću indikaciju iz dolje navedene smjernice, svako sljedeće odobrenje Bolničkog povjerenstva se može izdati za razdoblje od najviše 12 mjeseci, a lijek se na recept Zavoda može propisivati isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Iznimno, u slučaju uvođenja novog lijeka (prebacivanje na drugi biološki/bioslični lijek), u liječenje, gore navedena procedura se ponavlja (bolničko povjerenstvo za lijekove ponovno izdaje odobrenje prvo za 4 mjeseca primjene lijeka na teret sredstava bolničkog proračuna, a u nastavku se lijek može propisivati na recept Zavoda). 1. a. Liječenje fistulirajućeg oblika Crohnove bolesti, b. Liječenje umjerene do teške aktivne Crohnove bolesti koja je refraktorna na terapiju kortikosteroidima i imunomodulatorima, odnosno u slučaju nepodnošenja ili kontraindikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Liječenje umjerenog do teškog oblika ulceroznog kolitisa u bolesnika koji nisu adekvatno odgovorili na konvencionalno liječene kortikosteroidima i 6-merkatopurinom ili azatioprinom odnosno u slučaju nepodnošenja ili kontraindikacija za njihovu primjenu. Liječenje odobrava Bolničko povjerenstvo za lijekove. 3. Za liječenje reumatoidnog artritisa 3.a. Indikacija za primjenu (u kombinaciji s lijekom metotreksat ili nekim drugim sintetskim DMARD), sigurna dijagnoza RA i aktivna bolest, DAS28 >=5,1 ili DAS28 >= 3,2 + 6 otečenih zglobova (od 44), funkcionalni status, HAQ 0,5-2,5. 3.b. Prethodna terapija, najmanje dva lijeka iz skupine lijekova koji modificiraju bolest (DMARD) u razdoblju od 6 mjeseci od kojih jedan obavezno treba biti lijek metotreksat primijenjen najmanje kroz 2 mjeseca 20 mg tjedno (ili zbog nepodnošljivosti u nižoj dozi) ili nakon izostanka učinka lijeka tocilizumab ili drugog TNF blokatora. 3.c. Prije primjene probir na hepatitis B i C i latentnu TBC prema preporukama HRD. 3.d. Zadani učinak liječenja nakon 12 tjedana primjene, ako je započeto s DAS28 >= 5,1, pad DAS28 >=1,2 u odnosu na početno stanje ili postignuće DAS28 <= 3,2, ako je započeto s DAS28 >= 3,2 + 6 otečenih zglobova (od 44), pad DAS28 >= 1,2 + 50% manje otečenih zglobova. 3.e. Kriteriji za prekid terapije, a. stabilna klinička remisija u trajanju od 6 mjeseci (a. CRP <=1 mg/dL, b. broj bolnih zglobova/28<=1, c. broj otečenih zglobova/28<=1, d. bolesnikova ocjena (0-10) <=1) pod uvjetom da kroz to vrijeme nije bilo nikakvih epizoda pogoršanja aktivnosti RA, a obavezno se nastavlja sintetskim lijekovima koji mijenjaju tijek bolesti (DMARD) i koje je bolesnik uzimao uz biološki lijek. U slučaju apsolutnog pogoršanja DAS28 za 1,2 neophodna je reekspozicija biološkom lijeku bez obzira na vrijednost DAS28. Bolesnici koji se biološkom terapijom liječe po monoterapijskom načelu isključeni su iz navedenih kriterija i nastavljaju biološko liječenje. b. ozbiljne nuspojave, teška interkurentna infekcija (privremeni/trajni prekid), trudnoća i izostanak zadanog učinka. 3.f. Liječenje odobrava Bolničko povjerenstvo po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 3.d. 4. Za liječenje aktivnog ankilozantnog spondilitisa i aksijalnog spondiloartritisa 4.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primjenjena u punoj dnevnoj dozi kroz 2 mjeseca. 4.b. |
|  | Kod aktivne bolesti trajanja >= 4 tjedna prema BASDAI indeksu >= 4. 4.c. Prema procjeni reumatologa ukupna težina bolesti >= 4 na skali 0-10, a koja respektira – aktivni koksitis, sinovitis/entezitisi/ili recidivirajući uveitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 4.d. Nakon najmanje 12 tjedana primjene očekivani učinak je – 50% poboljšanje BASDAI indeksa ili apsolutno poboljšanje BASDAI indeksa za >=2. 4.e. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog efekta. 4.f. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 4.d. 5. Za liječenje aktivnog psorijatičnog artritisa 5.a. Nakon izostanka učinka ili kontraindikacija na najmanje 2 nesteroidna antireumatika primijenjena u punoj dnevnoj dozi kroz 2 mjeseca. 5.b. Nakon izostanka učinka najmanje 2 od 3 diferentna lijeka, lijek metotreksat (20 mg/tjedno) ili lijek leflunomid (20 mg/dan) ili lijek sulfasalazin (2 g/dan) ukupno kroz 6 mjeseci, a jedan od njih primijenjen najmanje 2 mjeseca u punoj dnevnoj dozi 5.c. Kod afekcije perifernih zglobova trajanje aktivne bolesti >= 4 tjedna s >= 3 bolna i >= 3 otečena zgloba. 5.d. Ukupna težina bolesti >= 4 prema skali 0-10 prema procjeni reumatologa, a koja respektira – aktivni koksitis, sinovitis/entezitisi/daktilitis i/ili psorijatični spondilitis i/ili SE, CRP i/ili radiološki nalaz (klasični radiogrami, kompjutorizirana tomografija, magnetska rezonancija, progresija strukturnih promjena). 5.e. Nakon najmanje 12 tjedana primjene očekivani učinak je 50% poboljšanje bolnih i otečenih zglobova i 50% ukupno poboljšanje prema procjeni subspecijalista reumatologa (skala 0-10). 5.f. Terapija se prekida kod izostanka očekivanog učinka ili razvoja nuspojava, a nastavlja kod postignuća zadanog učinka. 5.g. Za izolirani psorijatični spondilitis primjenjuju se kriteriji za ankilozantni spondilitis. 5.h. Težina zglobne bolesti ocjenjuje se neovisno o težini kožne bolesti. 5.i. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci reumatologa, prvo za period od 4 mjeseca, a kasnije za period od 6, odnosno u nastavku 12 mjeseci, i dokumentiranim ishodom kao što je navedeno u točki 5.e. 6. Za bolesnike s umjereno-teškom do teškom psorijazom (PASI i/ili BSA>15% i/ili DLQI>15), iznimno u slučajevima zahvaćenosti posebnih dijelova kože kao npr – lice i/ili vlasište i/ili dlanovi i/ili stopala i/ili genitalna regija i/ili jaka zahvaćenost noktiju, i to onima koji nisu odgovorili ili ne podnose ili imaju kontraindikacije na najmanje dva različita ranije primijenjena sustavna lijeka uključujući PUVA terapiju, retinoide, ciklosporin i metotreksat, po preporuci specijalista dermatovenerologa. Liječenje treba započinjati i nadzirati liječnik koji ima iskustva s dijagnozom i liječenjem psorijaze. Prije uvođenja lijeka u terapiju, potrebo je izračunati PASI i/ili BSA vrijednost te index kvalitete života DLQI. Liječenje započinje primjenom doze od 5 mg/kg u tjednu 0 (nultom), nakon čega slijedi doza od 5 mg/kg u tjednu 2 i 6, a nakon toga doza od 5 mg/kg svakih 8 tjedana. Procjena učinka terapije i aktivnost bolesti treba biti evaluirana u tjednu 14., izračunavanjem vrijednosti PASI, BSA i DLQI. Nastavak liječenja moguć je isključivo kod pozitivnog odgovora na započeto liječenje, odnosno ukoliko je nakon 14 tjedana postignuto najmanje 50% poboljšanje PASI vrijednosti te poboljšanje DLQI vrijednosti veće od 5 bodova te ukoliko je nakon 28 tjedana postignuto najmanje 75% poboljšanje PASI vrijedosti ili najmanje 50% poboljšanje PASI vrijednosti uz pad DLQI vrijednosti ispod 5). Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NL537 | Za liječenje bolesnika s metastatskim ili lokalno uznapredovalim planocelularnim karcinomom kože koji nisu kandidati za kurativno kirurško liječenje ili kurativnu radioterapiju. Lijek se primjenjuje do progresije bolesti ili do pojave neprihvatljivih nuspojava. ECOG status 0-1. Procjena uspješnosti liječenja primjenom RECIST i irRC kriterija obvezna je svaka 3 mjeseca. Klinička i dijagnostička obrada zbog procjene uspješnosti liječenja obvezna je svaka 3 mjeseca, a nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna ili djelomična remisija, stabilna bolest), do progresije bolesti. Liječenje se provodi u Kliničkim bolničkim centrima. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog internističkog onkologa ili radioterapijskog onkologa i uz suglasnost multidisplinarnog tima za kožne tumore.  Nastavak obrade i liječenja, samo kod pozitivnog tumorskog odgovora na provedeno liječenje, moguć je i u drugim bolničkim zdravstvenim ustanovama uz uvjet da je nakon kontrolne obrade, a radi nastavka liječenja, prethodno pribavljena pisana suglasnost multidisciplinarnog tima iz onog kliničkog bolničkog centra gdje je liječenje započelo, temeljem čega nastavak liječenja odobrava Bolničko povjerenstvo za lijekove bolničke zdravstvene ustanove u kojoj se nastavlja liječenje. |
| NL538 | Za prvu liniju liječenja bolesnika s relaps remitentnim oblikom multiple skleroze. Indikacije za početak liječenja – a. 2 relapsa (u relaps se ubraja i anamnestički relaps za kojega se naknadno ustanovi da je posljedica demijelinizacijskih lezija, a zbog kojega se bolesnik javio svom liječniku obiteljske medicine ili neurologu te kod kojega je došlo do spontanog oporavka. Relaps ne mora biti liječen pulsnom kortikosteroidnom terapijom ako dođe do spontanog oporavka simptoma) ili b. 1 relaps uz dokaz diseminacije u prostoru – ≥1 T2 lezije u 2 od 4 tipične regije za multiplu sklerozu unutar središnjeg živčanog sustava (periventrikularna, jukstakortikalna, infratentorijska ili leđna moždina) te diseminacija u vremenu – istovremena prisutnost demijelinizacijske lezije koja se imbibira kontrastom i neimbibirajuće demijelinizacijske lezije ili nova T2 i/ili gadolinijumom imbibirana demijelinizacijska lezija na kontrolnom MR-u bez obzira u kojem vremenskom razmaku se učini ili pozitivne oligoklonske IgG vrpce u likvoru. c. EDSS ≤6 d. Odsutnost trudnoće kod primjene teriflunomida i dimetilfumarata Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste neurologa. Prvo odobrenje za primjenu lijeka izdaje se za razdoblje od 6 mjeseci, a svako sljedeće odobrenje za nastavak liječenja, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste neurologa, Bolničko povjerenstvo za lijekove može izdati za razdoblje od najviše 12 mjeseci. Kriteriji za promjenu lijeka ili prekid 1. linije terapije relapsno-remitirajuće multiple skleroze – a. ≥4 nove T2 lezije na MR-u nakon početka liječenja ili b. ≥2 relapsa nakon početka liječenja c. Trudnoća\* d. Ozbiljne nuspojave (dokumentirane i prijavljene). |
| NL539 | Kao monoterapija u bolesnika s metastatskim karcinomom dojke kod kojih postoji povećani rizik od srčanih poremećaja. |
| NL541 | Lijek je indiciran kao monoterapija za liječenje odraslih bolesnika s relapsnom ili refraktornom akutnom mijeloičnom leukemijom (AML) koja je pozitivna na FLT3 mutaciju. Za početak liječenja potreban je dokaz o dijagnozi relapsne ili refraktorne AML i mutacije FLT3. Liječenje se započinje u dozi od 120 mg, a u slučaju izostanka odgovora nakon 4 tjedna doza se može povećati na 200 mg ako je bolesnik podnosi. Evaluacija odgovora na liječenje provodi se citomorfološkom analizom koštane srži nakon 4 tjedana terapije, potom najmanje nakon svakih 8 tjedana terapije. Liječenje treba nastaviti sve dok bolesnik ima povoljan terapijski odgovor ili do pojave neprihvatljive toksičnosti. Liječenje treba obustaviti ukoliko imamo nepovoljan terapijski odgovor što podrazumijeva porast postotka blasta u koštanoj srži u odnosu na vrijednosti prije početka terapije ili prisustvo više od 5% blasta u koštanoj srži nakon 6 mjeseci terapije. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista hematologa. |
| NL542 | Za liječenje brzoprogredirajućeg (progresija bolesti prema RECIST-kriterijima u manje od 12 mjeseci) ili agresivnog simptomatskog diferenciranog karcinoma štitnjače refraktornog na radioaktivni jod u bolesnika s metastatskom ili lokalno/lokoregionalno uznapredovalom neresektabilnom bolešću. Liječenje odobrava Bolničko povjerenstvo za lijekove KBC-a, po preporuci specijalista internističkog onkologa ili specijalista radioterapije i onkologije. Liječenje se odobrava iz sredstava bolničkog proračuna. |
| NL543 | Lijek je indiciran za indukciju remisije i konsolidaciju u odraslih bolesnika s novodijagnosticiranom akutnom promijelocitnom leukemijom (APL) niskog do srednjeg rizika (broj bijelih krvnih stanica ≤ 10 x 103/µl) u kombinaciji sa sve-trans-retinoatnom kiselinom (engl. all-trans-retinoic acid, ATRA). |
| NL544 | I. Venetoklaks je indiciran u kombinaciji s obinutuzumabom za liječenje prethodno neliječenih bolesnika s kroničnom limfocitnom leukemijom bez del 17p ili mutacije TP53 kod kojih nije prikladno liječenje temeljeno na punoj dozi fludarabina. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. II. Venetoklaks je indiciran u kombinaciji s rituksimabom za liječenje odraslih bolesnika s kroničnom limfocitnom leukemijom koji su primili najmanje jednu prethodnu terapiju, a koji su refraktorni na terapiju ili su u ranom relapsu. Rani relaps se definira kao relaps unutar 24 mjeseca od završetka prethodne terapije. U kombinaciji s rituksimabom venetoklaks je potrebno uzimati tijekom 24 mjeseca od 1. dana 1. ciklusa primjene rituksimaba. III. Kao monoterapija – 1. Za liječenje KLL s delecijom 17p ili mutacijom gena TP53 u bolesnika koji nisu pogodni za liječenje inhibitorom signalnog puta B staničnog receptora ili nisu na njega odgovorili. 2. Za liječenje KLL u bolesnika u ranom relapsu ili refraktornih na kemoimunoterapiju i inhibitor signalnog puta B-staničnog receptora. Kriteriji za primjenu lijeka – Prije početka terapije obvezno je učiniti citogenetsko testiranje, FISH iz koštane srži/periferne krvi te radiološki procijeniti veličinu limfnih čvorova, jetre i slezene, odnosno infiltraciju organa. Liječe se bolesnici s prisutnim simptomima bolesti koji imaju jedan od kriterija – a) visok rizik po Rai-u (III-IV) b) TTM veći ili jednako 15 c) masivnu tumorsku bolest (jedan čvor ili konglomerat > 10 cm ili progresivnu ili simptomatsku limfadenopatiju) d) imaju značajne B simptome koji ometaju kvalitetu života (jedan ili više navedenih simptoma – nenamjerni gubitak tjelesne težine ≥10% u zadnjih 6 mjeseci, temperatura > 38 stupnjeva C u trajanju 2 ili više tjedna bez dokaza infekcije, noćno znojenje duže od mjesec dana bez dokaza infekcije). ECOG 0-2. Procjenu terapijskog učinka prvi puta obvezno je provesti najkasnije 6 mjeseci od početka liječenja, a nastavak liječenja je moguć ako bolesnici zadovoljavaju jedan od kriterija. a) ako je došlo do smanjenja tumorske mase ≥50% u odnosu na početne vrijednosti mjerenja po TTM-u (u reevaluaciji obavezno učiniti UZV ili CT koji potvrđuje smanjenje ≥50%). b) ako je došlo do poboljšanja RAI statusa sa stupnja III-IV na I-II-III (učiniti laboratorijsku obradu koja potvrđuje smanjenje RAI-a III-IV na RAI I-II-III) c) ako je došlo do poboljšanja anemije (ako inicijalno hemoglobin 80-100 g/l porast >100 g/l, ako inicijalno <80 g/l bolesnik je postao neovisan o transfuzijama) ili trombocitopenije (trombociti iznad 100x109/L ili porast za >50% od inicijalne vrijednosti ili neovisnost bolesnika o transfuzijama) d) značajno smanjenje B simptoma. Liječenje se prekida u slučaju progresije bolesti. Liječenje odobrava Bolničko povjerenstvo za lijekove, na prijedlog specijalista hematologa. |
| NM301 | 1. Samo za blefarospazam, hemifacijalni spazam i cervikalnu distoniju (tortikolis) po preporuci specijalista neurologa uz odobrenje Bolničkog povjerenstva za lijekove te za cerebralnu paralizu u djece s dinamičkim ekvinusom i urednim mentalnim statusom, uz odobrenje Bolničkog povjerenstva za lijekove, a na prijedlog stručne skupine koju sačinjavaju specijalista neuropedijatar, ortoped, fizijatar i psiholog. 2. Za liječenje spasticiteta (ako nisu nastale kontrakture) kao posljedica moždanog udara koji je uzrokovao teški invaliditet, sa posljedičnim spasticitetom ručnog zgloba i šake i/ili gležnja kod bolesnika sa MAS (eng. Modified Ashford Scale) rezultatom 3 ili 4. Liječenje odobrava Bolničko povjerenstvo za lijekove, po preporuci specijalista neurologa ili fizijatra, do ukupno 3 puta godišnje. 3. Profilaktičko liječenje migrene u odraslih osoba koji ispunjavaju kriterije za kroničnu migrenu (glavobolje ≥ 15 dana u mjesecu, od kojih je najmanje 8 dana s migrenom), a u kojih nema adekvatnog odgovora na prethodne lijekove za profilaksu migrene ili koji ne podnose takve lijekove (u slučaju neučinkovitosti ili nepodnošljivosti najmanje dva profilaktička lijeka ili je uporaba drugih profilaktičkih terapija kontraindicirana zbog komorbiditeta). Nakon evaluacije od najmanje dva ciklusa od tri mjeseca, liječenje se provodi dok se ne postigne frekvencija glavobolja manje od 10 dana mjesečno tijekom 3 mjeseca. Lijek se primjenjuje u bolničkim ustanovama pod nadzorom neurologa koji se bavi užim područjem liječenja glavobolja. Liječenje odobrava Bolničko povjerenstvo za lijekove. Oznaka DS samo za liječenje pod točkom 3. |
| NM302 | Samo za malignu hipertermiju i maligni neuroleptički sindrom. |
| NM502 | Po preporuci specijalista onkologa ili hematologa. |
| NM503 | 1. Za liječenje odraslih i koštano sazrelih adolescenata s gigantocelularnim tumorom kosti koji je neresektabilan ili gdje kirurška resekcija može rezultirati teškim morbiditetom. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Prevencija koštanih događaja (patološke frakture, zračenje kosti, kompresija leđne moždine ili operacija kosti) u odraslih s a) koštanim metastazama solidnih tumora ili b) koštanim lezijama multiplog mijeloma. Liječenje denosumabom je dozvoljeno za bolesnike s – oštećenom bubrežnom funkcijom (klirens kreatinina <=50 ml/min) ili akutnim reakcijama preosjetljivosti na prethodnu primjenu bisfosfonata uz ECOG status 0-2 i očekivano preživljenje duže od 6 mjeseci. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NM504 | 1. Za simptomatsko liječenje blefarospazma i prevladavajuće rotacijskog oblika cervikalne distonije (spazmodični tortikolis) po preporuci specijalista neurologa uz odobrenje Bolničkog povjerenstva za lijekove. 2. Za liječenje spasticiteta (ako nisu nastale kontrakture) kao posljedica moždanog udara koji je uzrokovao teški invaliditet, sa posljedičnim spasticitetom ručnog zgloba i šake kod bolesnika sa MAS (eng. Modified Ashford Scale) rezultatom 3 ili 4. Liječenje odobrava Bolničko povjerenstvo za lijekove, po preporuci specijalista neurologa ili fizijatra, do ukupno 3 puta godišnje. |
| NM600 | Za liječenje spinalne mišićne atrofije uzrokovane mutacijom na kromosomu 5q uz minimalno dvije kopije gena, kod bolesnika s potvrđenom dijagnozom SMA tipa 1, 2 ili 3. Liječenje se može započeti samo u Kliničkom bolničkom centru Zagreb. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog Povjerenstva Referentnih centara Ministarstva zdravstva za neuromuskularne bolesti (za djecu – Referentni centar za pedijatrijske neuromuskularne bolesti Klinike za pedijatriju KBC Zagreb, za odrasle – Referentni centar za neuromuskularne bolesti Klinike za neurologiju KBC Zagreb). Povjerenstvo Referentnih centara postavlja medicinsku indikaciju za početak primjene lijeka te provodi prvu procjenu učinka primijenjenog lijeka obavezno nakon 6 mjeseci liječenja (prije 5. doze) i dalje svaka 4 mjeseca odnosno prije primjene iduće doze lijeka, temeljem čega donosi ocjenu i daje preporuku za nastavak ili prekid primjene lijeka, a sve sukladno smjernicama Nacionalnog povjerenstva za evaluaciju učinka lijeka nusinersen i Referentnih centara. Liječenje se odobrava iz sredstava namijenjenih za posebno skupe lijekove. |
| NM601 | Za bolesnike s Duchennovom mišićnom distrofijom (DMD) uzrokovanom besmislenom (nonsense) mutacijom gena za distrofin, u dobi od 2 godine i starija, samostalno pokretna, na terapiji kortikosteroidnom terapijom najmanje 6 mjeseci prije uvođenja terapije atalurenom. Dijagnoza postavljena temeljem rezultata molekularne genetike. Procjena uspjeha liječenja provodi se svakih 12 mjeseci, 6-minutnim testom hoda. Indikacije za prekid liječenja su – 1. prestanak samostalne pokretnosti – nemogućnost samostalnog stajanja i hodanja, uz izuzetak interkurentnih bolesti koje mogu uzrokovati motoričko pogoršanje ili nesretnog slučaja, 2. potpuna ovisnost o invalidskim kolicima 3. liječenje se provodi maksimalno 6 mjeseci nakon potpunog prestanka samostalne pokretljivosti. Po prekidu liječenja bolesnici će biti uključeni u postupak uobičajenih za standarde zbrinjavanja bolesnika sa DMD. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NM602 | Za primjenu u liječenju djece, u dobi do dvije godine života i tjelesne težine od 2,6 do 13,5 kg, kod bolesnika s 5q spinalnom mišićnom atrofijom (SMA) s utvrđenom bialelnom mutacijom gena SMN1 i s kliničkom dijagnozom SMA tipa 1 ili kod bolesnika s 5q SMA s utvrđenom bialelnom mutacijom gena SMN1 i do 2 kopije gena SMN2. Lijek se primjenjuje jednokratno (jedna doza) i može se primijeniti isključivo u Kliničkom bolničkom centru Zagreb, pod nadzorom liječnika s iskustvom u liječenju bolesnika s SMA. Prije infuzije lijeka potrebno je dokazati odsutnost protutijela na AA9 virus. Liječenje odobrava Bolničko povjerenstvo za lijekove na temelju prijedloga Povjerenstva Referentnog centra za pedijatrijske neuromuskularne bolesti Klinike za pedijatriju KBC Zagreb, koje postavlja medicinsku indikaciju za primjenu lijeka i provodi procjenu učinka primijenjenog lijeka najmanje jednom godišnje te o učinku lijeka jednom godišnje izvješćuje Zavod. Nakon jednokratne primjene lijeka onasemnogen abeparvovek nije primjenjiva druga ciljana terapija za SMA na teret sredstava za posebno skupe lijekove. |
| NM603 | Za liječenje spinalne mišićne atrofije uzrokovane mutacijom na kromosomu 5q u bolesnika u dobi od 2 mjeseca i starijih bolesnika, uz minimalno dvije kopije gena kod bolesnika s potvrđenom dijagnozom SMA tipa 1, 2 ili 3. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog Povjerenstva Referentnih centara za neuromuskularne bolesti (za djecu – Referentni centar za pedijatrijske neuromuskularne bolesti Klinike za pedijatriju KBC Zagreb, za odrasle – Referentni centar za neuromuskularne bolesti Klinike za neurologiju KBC Zagreb). Povjerenstvo Referentnih centara postavlja medicinsku indikaciju za početak primjene lijeka i daje preporuku za nastavak ili prekid primjene lijeka, a sve sukladno smjernicama Nacionalnog povjerenstva za evaluaciju učinka lijeka i Referentnih centara. Lijek se odobrava na razdoblje od 6 (šest) mjeseci kada se radi reevaluacija radi nastavka liječenja. Liječenje se odobrava iz sredstava namijenjenih za posebno skupe lijekove. |
| NN101 | Samo za bolesnike koji ne mogu uzimati peroralnu terapiju, uz uvjet da vrijednosti ALT i AST ne smiju biti > 3x u odnosu na normalne vrijednosti. PR Za bolesnike u izvanbolničkoj hitnoj medicinskoj službi. |
| NN300 | Za liječenje genetski dokazane Leberove hereditarne optičke neuropatije (LHON) u adolescenata i odraslih bolesnika. Kriteriji za početak terapije – liječenje započeti za vrijeme subakutne/dinamičke faze u roku do maksimalno 2 godine od početka simptoma. Procjena uspješnosti liječenja provodi se svakih 6 mjeseci, a nastavak liječenja moguć je isključivo kod pozitivnog odgovora na provedeno liječenje (klinički značajan odgovor – poboljšanje vida/stabilna bolest), do maksimalno 2 godine. Liječenje se provodi u Kliničkim bolničkim centrima. Liječenje odobrava Bolničko povjerenstvo za lijekove, po preporuci specijalista oftalmologa i/ili neurologa. |
| NN401 | Samo za liječenje uznapredovalog stadija Parkinsonove bolesti, kad više nije moguće stabilizirati klinički status dostupnom kombiniranom peroralnom terapijom. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NN502 | Samo za poboljšanje terapijske suradljivosti u shizofenih bolesnika, nakon prethodne terapije s oralnim olanzapinom, po preporuci specijalista psihijatra, a izdaje se na ruke liječnika. |
| NN503 | Samo za akutno psihotične bolesnike. |
| NN504 | Samo za poboljšanje terapijske suradljivosti u shizofenih bolesnika, nakon prethodne terapije s oralnim risperidonom, po preporuci specijalista psihijatra, a izdaje se na ruke liječnika. |
| NN506 | Za sedaciju u jedinicama intenzivnog liječenja odraslih bolesnika kojima je potrebna sedacija ne dublja od one za buđenje verbalnom stimulacijom, što odgovara stupnju 0-3 po RASS (Richmond Agitation-Sedation Scale) skali, za liječenje najduljeg trajanja 14 dana. |
| NN507 | Za liječenje odraslih bolesnika s velikim depresivnim poremećajem rezistentnim na liječenje u kombinaciji sa selektivnim inhibitorima ponovne pohrane serotonina (SSRI) ili inhibitorima ponovne pohrane serotonina i noradrenalina (SNRI) koji nisu odgovorili na najmanje dvije različite terapije antidepresivima tijekom trenutne teške depresivne epizode s rezultatom na MADRS skali ≥ 34 i rezultatom na CGI-S skali ≥ 5. Uspješnost terapije utvrđuje se nakon 4 tjedna uvodnog liječenja, a liječenje se nastavlja u slučaju postizanja pozitivnog terapijskog odgovora definiranog kao smanjenje rezultata na MADRS skali za ≥ 50% od inicijalne vrijednosti. Daljnje evaluacije uspješnosti liječenja utvrđuju se u 8. i 24. tjednu liječenja. Liječenje se nastavlja u slučaju postizanja kliničkog poboljšanja, a koje se definira kao rezultat na CGI-I skali 1-3 u odnosu na inicijalno stanje. Liječenje se prekida zbog pogoršanja simptoma depresije potvrđenim rezultatom na MADRS skali >22 na dva uzastopna mjerenja u razmaku 5 do 15 dana ili zbog hospitalizacije uslijed pogoršanja simptoma depresije ili pokušaja suicida. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog specijalista psihijatra. |
| NN700 | Za liječenje narkolepsije s katapleksijom. Lijek se primjenjuje u bolničkim zdravstvenim ustanovama, po preporuci specijalista neurologa iz Klinike, nakon dijagnostičke obrade (polisomnografija, MSLT, HLA tipizacija). |
| NN991 | Lijek se primjenjuje u bolničkim zdravstvenim ustanovama, po preporuci specijalista u centrima za poremećaj spavanja (narkolepsija), nakon dijagnostičke obrade (polisomnografija, MSLT, HLA tipizacija). |
| NN992 | Za liječenje apneje nedonoščadi. |
| NN994 | Za bolesnike s amiotrofičnom lateralnom sklerozom, za produljenje razdoblja bez intubacije za mehaničku ventilaciju i bez traheotomije. Po preporuci specijalista neurologa. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NN995 | Liječenje odraslih bolesnika s kardiomiopatijom uzrokovanom transtiretinskom amiloidozom (ATTR-CM), divljeg tipa ili nasljednom, dokazanom scintigrafijom kostiju uz SPECT primjenom jednog od radiofarmaka – 99mTc-PYP, 99mTc-DPD ili 99mTc-HMDP (ocjena nakupljanja 2 ili 3) uz isključivanje amiloidoze lakih lanaca (AL) metodom određivanja slobodnih lakih lanaca u serumu te elektroforezom serumskih i urinskih proteina uz imunofiksaciju, u slučaju nejasnog nalaza scintigrafije (ocjena nakupljanja 1) za dokazivanje bolesti radi se histološka potvrda biopsijom, anamneza zatajivanja srca klase NYHA l ili ll, ≥1 hospitalizacija zbog zatajivanja srca ili klinički dokazano zatajivanje srca (simptomi ili znakovi kongestije ili potreba za diuretskom terapijom), zahvaćanje srca potvrđeno ehokardiografijom (debljina stijenke lijeve klijetke ≥ 12 mm), eGFR>25ml/min, povišene vrijednosti NT-proBNP ≥600 pg/mL i udaljenost prijeđena 6-minutnim testom hoda >100 m. Liječenje se odobrava na period od 6 mjeseci, nakon čega slijedi reevaluacija primjene lijeka. Klinička i dijagnostička kontrolna obrada obvezna je svakih 6 mjeseci. Nastavak liječenja odobrava se samo u slučaju povoljnog odgovora na liječenje utvrđenog od strane ekspertnog tima na temelju procjene funkcijskih testova te kliničkih, slikovnih i laboratorijskih parametara. Liječenje se prekida u slučaju progresije bolesti u zatajivanje srca NYHA klase IV. Liječenje se provodi u Kliničkom bolničkom centru Zagreb. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog kardiologa. |
| NR301 | Za medikamentozno liječenje bradikardije, ne kao bronhodilatator, jer je neselektivan – izaziva tahikardiju! |
| NR501 | Samo za cističnu fibrozu s forsiranim vitalnim kapacitetom većim od 40%. |
| NR502 | 1. Za liječenje teške perzistentne IgE-om posredovane alergijske astme u bolesnika starijih od 6 godina koji trebaju trajnu ili čestu terapiju peroralnim kortkosteroidima (definirano kao 4 ili više ciklusa tijekom prethodne godine) uz optimalnu standardnu terapiju (visoke doze inhalacijskih kortikosteroida, dugodjelujućih beta-2 agonista, antagonista leukotrijenskih receptora, teofilina. Bolesnici trebaju ispuniti slijedeće uvjete – pozitivan kožni ili laboratorijski test na bar jedan od inhalacijskih alergena, povišena razina IgE, FEV1 <60%, dnevni simptomi unatoč optimalnoj standardnoj terapiji. Obvezna je reevaluacija učinka nakon 12 tjedana liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove. 2. Dodatna terapija za liječenje teške kronične spontane urtikarije (UAS7>=28) u odraslih bolesnika i adolescenata (12 godina starosti i više), s neodgovarajućim odgovorom na liječenje antagonistima leukotrienskih receptora i antagonistima H1 histaminskih receptora u standardnim i povišenim dozama. Odobrava se 4 ciklusa liječenja (300 mg supkutanom injekcijom svaka četiri) uz 2 dodatna ciklusa liječenja samo u bolesnika koji su postigli terapijski odgovor (UAS7<16). Nakon toga terapija se ukida. Za bolesnike sa odgovorom na omalizumab koji dožive relaps (UAS7>=28) nakon završetka prethodnog ciklusa liječenja, odobrava se dodatnih 6 ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NR503 | Za liječenje teške perzistentne refraktorne eozinofilne astme u bolesnika starijih od 18 godina koji trebaju trajnu ili čestu terapiju kortikosteroidima uz optimalnu standardnu terapiju (visoke doze inhalacijskih kortikosteroida, dugodjelujućih beta-2 agonista, antagonista leukotrijenskih receptora, teofilina). Bolesnici trebaju ispuniti slijedeće uvjete – 1. vrijednost eozinofila u perifernoj krvi je >150 stanica/μl na početku terapije te >300 stanica/μl u zadnjih 12 mjeseci, 2. FEV1<60%, 3. bolesnici su imali >=4 egzacerbacija koje su zahtijevale primjenu sistemskih kortikosteroida ili su tijekom posljednjih 6 mjeseci kontinuirano liječeni oralnim kortikosteroidima u dozi ekvivalentnoj >=5 mg prednizolona. Liječenje se odobrava na 12 mjeseci nakon čega je obvezna procjena terapijskog odgovora, a nastavak terapije moguć je samo uz pozitivan terapijski odgovor koji se definira kao redukcija od najmanje 50% u broju astmatskih napadaja (u bolesnika koji su imali >=4 egzacerbacije u 12 mjeseci prije početka liječenja) ili klinički značajno smanjenje razdoblja uzimanja peroralnih kortikosteroida uz održavanje ili poboljšanje simptoma astme. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NR504 | Za liječenje teške perzistentne refraktorne eozinofilne astme u djece u dobi 6 i više godina, adolescenata te odraslih bolesnika starijih od 18 godina koji trebaju trajnu ili čestu terapiju kortikosteroidima uz optimalnu standardnu terapiju (visoke doze inhalacijskih kortikosteroida, dugodjelujućih beta-2 agonista, antagonista leukotrijenskih receptora, teofilina – GINA stupanj težine IV i V). Bolesnici trebaju ispuniti slijedeće uvjete – 1. vrijednost eozinofila u perifernoj krvi je >150 stanica/μl na početku terapije te >300 stanica/μl u zadnjih 12 mjeseci, 2. FEV1 <60% (za odrasle) te FEV1 <90% (za djecu i adolescente), 3. bolesnici su imali >=4 pogoršanja koja su zahtijevala primjenu sistemskih kortikosteroida ili su tijekom posljednjih 6 mjeseci kontinuirano liječeni oralnim kortikosteroidima u dozi ekvivalentnoj >=5 mg prednizolona. Liječenje se odobrava na 12 mjeseci nakon čega je obvezna procjena terapijskog odgovora, a nastavak terapije moguć je samo uz pozitivan terapijski odgovor koji se definira kao redukcija od najmanje 50% u broju astmatskih napadaja (u bolesnika koji su imali >=4 pogoršanja u 12 mjeseci prije početka liječenja) ili klinički značajno smanjenje razdoblja uzimanja peroralnih kortikosteroida uz održavanje ili poboljšanje simptoma astme. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NR505 | Za liječenje teške perzistentne refraktorne eozinofilne astme u bolesnika starijih od 12 godina koji trebaju trajnu ili čestu terapiju kortikosteroidima uz optimalnu standardnu terapiju (visoke doze inhalacijskih kortikosteroida, dugodjelujućih beta-2 agonista, antikolinergika, antagonista leukotrijenskih receptora, teofilina). Bolesnici trebaju ispuniti sljedeće uvjete – 1. vrijednost eozinofila u perifernoj krvi je >150 stanica/μl na početku terapije te >300 stanica/μl u zadnjih 12 mjeseci, 2. FEV1 <90% kod bolesnika starosti >= 12 do 18 godina, te FEV1<60% u bolesnika starosti >= 18 godina, 3. bolesnici su imali >=4 egzacerbacija koje su zahtijevale primjenu sistemskih kortikosteroida ili su tijekom posljednjih 6 mjeseci kontinuirano liječeni oralnim kortikosteroidima u dozi ekvivalentnoj >=5 mg prednizolona. Liječenje se odobrava na 12 mjeseci nakon čega je obvezna procjena terapijskog odgovora, a nastavak terapije moguć je samo uz pozitivan terapijski odgovor koji se definira kao redukcija od najmanje 50% u broju astmatskih napadaja (u bolesnika koji su imali >=4 egzacerbacije u 12 mjeseci prije početka liječenja) ili klinički značajno smanjenje razdoblja uzimanja peroralnih kortikosteroida uz održavanje ili poboljšanje simptoma astme. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NR506 | Za liječenje cistične fibroze (CF) kod bolesnika, u obliku granula za dob od 2 i više godina, u obliku tableta za dob od 6 i više godina, koji su homozigoti za mutaciju F508del gena koji je transmembranski regulator provodljivosti za ione klora u cističnoj fibrozi (engl. Cystic Fibrosis Transmembrane Conductance Regulator, CFTR). Indikacija za početak liječenja postavlja se timski nakon što se uvidom u dokumentaciju, nalaze genskog testiranja (potvrda mutacija) i drugih učinjenih pretraga i testova te klinički status bolesnika definitivno potvrdi dijagnoza cistične fibroze. Prije postavljanja indikacije odnosno početka liječenja, ali isto i tako kod svake procjene djelotvornosti primijenjenog lijeka, potrebno je procijeniti plućnu funkciju (spirometrija, ppFEV1), izmjeriti koncentraciju klorida u znoju i parametre važne za praćenje funkcije jetre i gušterače. Radi praćenja učinka lijeka mora se bilježiti broj plućnih egzacerbacija (PE) i vrijeme između dvije PE, zatim broj hospitalizacija (broj dana bolničkog liječenja) i potrošnja antibiotske terapije zbog PE (stopa kolonizacije s karakterističnim bakterijama). Potrebno je pratiti i bilježiti nutritivni status bolesnika (Indeks tjelesne mase) te sve neželjene događaje i eventualne nuspojave lijeka ili razloge i vrijeme zbog kojih je terapija bila prekinuta. Liječenje se može započeti isključivo u stabilnoj fazi bolesti (izvan PE odnosno barem tjedan dana po završetku antibiotske terapije zbog PE). Liječenje se može započeti samo u Kliničkom bolničkom centru Zagreb (KBC Zagreb). Početak liječenja odobrava Bolničko povjerenstvo za lijekove KBC Zagreb na prijedlog Multidisciplinarnog tima iz Centra za cističnu fibrozu djece i odraslih s Klinike za plućne bolesti Jordanovac KBC Zagreb (CF Centar) za one bolesnike koji zadovoljavaju kriterije za primjenu lijeka i kojima je terapija preporučena u skladu sa stručnim smjernicama. Prva dva odobrenja se izdaju za liječenje u trajanju od po 6 mjeseci. Prvih 12 mjeseci terapije se u CF Centru nadziru provedba i učinci terapije te se centralizirano prate moguće nuspojave temeljem čega se timski donosi ocjena i daje preporuka za nastavak ili prekid primjene lijeka. Nakon toga redoviti nadzor nad terapijom može preuzeti liječnik koji inače skrbi za bolesnika, a najmanje jedanput godišnje bolesnik obvezno mora obaviti kontrolu u CF Centru. Za one bolesnike kojima je Multidisciplinarni tim CF Centra, nakon kontrolne obrade nakon 12 mjeseci liječenja preporučio nastavak liječenja u skladu sa stručnim smjernicama, nastavak liječenja odobrava Bolničko povjerenstvo za lijekove one bolničke zdravstvene ustanove u kojoj bolesnik nastavlja liječenje. Odobrenje za nastavak liječenja se mora obnoviti svakih 12 mjeseci uz prethodno pribavljenu preporuku Multidisciplinarnog tima CF Centra. Liječenje se odobrava iz sredstava namijenjenih za posebno skupe lijekove. |
| NR507 | U kombiniranom režimu s tabletama ivakaftor za liječenje cistične fibroze (CF) u bolesnika u dobi od 12 i više godina koji su homozigoti za mutaciju F508del gena koji je transmembranski regulator provodljivosti za ione klora u cističnoj fibrozi (engl. Cystic Fibrosis Transmembrane Conductance Regulator, CFTR) ili heterozigoti za mutaciju F508del u genu CFTR s mutacijom koja dovodi do minimalne funkcije (MF) gena. Indikacija za početak liječenja postavlja se timski nakon što se uvidom u dokumentaciju, nalaze genskog testiranja (potvrda mutacija) i drugih učinjenih pretraga i testova te klinički status bolesnika definitivno potvrdi dijagnoza cistične fibroze. Prije postavljanja indikacije odnosno početka liječenja, ali isto i tako kod svake procjene djelotvornosti primijenjenog lijeka, potrebno je procijeniti plućnu funkciju (spirometrija, ppFEV1), izmjeriti koncentraciju klorida u znoju i parametre važne za praćenje funkcije jetre i gušterače. Radi praćenja učinka lijeka mora se bilježiti broj plućnih egzacerbacija (PE) i vrijeme između dvije PE, zatim broj hospitalizacija (broj dana bolničkog liječenja) i potrošnja antibiotske terapije zbog PE (stopa kolonizacije s karakterističnim bakterijama). Potrebno je pratiti i bilježiti nutritivni status bolesnika (Indeks tjelesne mase) te sve neželjene događaje i eventualne nuspojave lijeka ili razloge i vrijeme zbog kojih je terapija bila prekinuta. Liječenje se može započeti isključivo u stabilnoj fazi bolesti (izvan PE odnosno barem tjedan dana po završetku antibiotske terapije zbog PE). Liječenje se može započeti samo u Kliničkom bolničkom centru Zagreb (KBC Zagreb). Početak liječenja odobrava Bolničko povjerenstvo za lijekove KBC Zagreb na prijedlog Multidisciplinarnog tima iz Centra za cističnu fibrozu djece i odraslih s Klinike za plućne bolesti Jordanovac KBC Zagreb (CF Centar) za one bolesnike koji zadovoljavaju kriterije za primjenu lijeka i kojima je terapija preporučena u skladu sa stručnim smjernicama. Prva dva odobrenja se izdaju za liječenje u trajanju od po 6 mjeseci. Prvih 12 mjeseci terapije se u CF Centru nadziru provedba i učinci terapije te se centralizirano prate moguće nuspojave temeljem čega se timski donosi ocjena i daje preporuka za nastavak ili prekid primjene lijeka. Nakon toga redoviti nadzor nad terapijom može preuzeti liječnik koji inače skrbi za bolesnika, a najmanje jedanput godišnje bolesnik obvezno mora obaviti kontrolu u CF Centru. Za one bolesnike kojima je Multidisciplinarni tim CF Centra, nakon kontrolne obrade nakon 12 mjeseci liječenja preporučio nastavak liječenja u skladu sa stručnim smjernicama, nastavak liječenja odobrava Bolničko povjerenstvo za lijekove one bolničke zdravstvene ustanove u kojoj bolesnik nastavlja liječenje. Odobrenje za nastavak liječenja se mora obnoviti svakih 12 mjeseci uz prethodno pribavljenu preporuku Multidisciplinarnog tima CF Centra. Liječenje se odobrava iz sredstava namijenjenih za posebno skupe lijekove. |
| NR508 | U kombiniranom režimu s tabletama ivakaftor/tezakaftor/eleksakaftor za liječenje cistične fibroze (CF) u bolesnika u dobi od 12 i više godina koji su homozigoti za mutaciju F508del gena koji je transmembranski regulator provodljivosti za ione klora u cističnoj fibrozi (engl. Cystic Fibrosis Transmembrane Conductance Regulator, CFTR) ili heterozigoti za F508del u genu CFTR s mutacijom koja dovodi do minimalne funkcije (MF) gena. Indikacija za početak liječenja postavlja se timski nakon što se uvidom u dokumentaciju, nalaze genskog testiranja (potvrda mutacija) i drugih učinjenih pretraga i testova te klinički status bolesnika definitivno potvrdi dijagnoza cistične fibroze. Prije postavljanja indikacije odnosno početka liječenja, ali isto i tako kod svake procjene djelotvornosti primijenjenog lijeka, potrebno je procijeniti plućnu funkciju (spirometrija, ppFEV1), izmjeriti koncentraciju klorida u znoju i parametre važne za praćenje funkcije jetre i gušterače. Radi praćenja učinka lijeka mora se bilježiti broj plućnih egzacerbacija (PE) i vrijeme između dvije PE, zatim broj hospitalizacija (broj dana bolničkog liječenja) i potrošnja antibiotske terapije zbog PE (stopa kolonizacije s karakterističnim bakterijama). Potrebno je pratiti i bilježiti nutritivni status bolesnika (Indeks tjelesne mase) te sve neželjene događaje i eventualne nuspojave lijeka ili razloge i vrijeme zbog kojih je terapija bila prekinuta. Liječenje se može započeti isključivo u stabilnoj fazi bolesti (izvan PE odnosno barem tjedan dana po završetku antibiotske terapije zbog PE). Liječenje se može započeti samo u Kliničkom bolničkom centru Zagreb (KBC Zagreb). Početak liječenja odobrava Bolničko povjerenstvo za lijekove KBC Zagreb na prijedlog Multidisciplinarnog tima iz Centra za cističnu fibrozu djece i odraslih s Klinike za plućne bolesti Jordanovac KBC Zagreb (CF Centar) za one bolesnike koji zadovoljavaju kriterije za primjenu lijeka i kojima je terapija preporučena u skladu sa stručnim smjernicama. Prva dva odobrenja se izdaju za liječenje u trajanju od po 6 mjeseci. Prvih 12 mjeseci terapije se u CF Centru nadziru provedba i učinci terapije te se centralizirano prate moguće nuspojave temeljem čega se timski donosi ocjena i daje preporuka za nastavak ili prekid primjene lijeka. Nakon toga redoviti nadzor nad terapijom može preuzeti liječnik koji inače skrbi za bolesnika, a najmanje jedanput godišnje bolesnik obvezno mora obaviti kontrolu u CF Centru. Za one bolesnike kojima je Multidisciplinarni tim CF Centra, nakon kontrolne obrade nakon 12 mjeseci liječenja preporučio nastavak liječenja u skladu sa stručnim smjernicama, nastavak liječenja odobrava Bolničko povjerenstvo za lijekove one bolničke zdravstvene ustanove u kojoj bolesnik nastavlja liječenje. Odobrenje za nastavak liječenja se mora obnoviti svakih 12 mjeseci uz prethodno pribavljenu preporuku Multidisciplinarnog tima CF Centra. Liječenje se odobrava iz sredstava namijenjenih za posebno skupe lijekove. |
| NR509 | Za liječenje teške perzistentne astme s upalom tipa 2 u bolesnika starijih od 12 godina koji trebaju trajnu ili čestu terapiju kortikosteroidima uz optimalnu standardnu terapiju (visoke doze inhalacijskih kortikosteroida, dugodjelujućih beta-2 agonista, antagonista leukotrijenskih receptora, teofilina). Bolesnici trebaju ispuniti slijedeće uvjete – 1. vrijednost eozinofila u perifernoj krvi je >150 stanica/μl na početku terapije te >300 stanica/μl u zadnjih 12 mjeseci i/ili povišene razine FeNO (frakcija izdahnutog dušikovog oksida) > 25 ppb , 2. FEV1<60% za bolesnike iznad 18 godina, te FEV1<90% za bolesnike od 12 do 18 godina, 3. bolesnici su imali >=4 egzacerbacija koje su zahtijevale primjenu sistemskih kortikosteroida ili su tijekom posljednjih 6 mjeseci kontinuirano liječeni oralnim kortikosteroidima u dozi ekvivalentnoj >=5 mg prednizolona. Liječenje se odobrava na 12 mjeseci nakon čega je obvezna procjena terapijskog odgovora, a nastavak terapije moguć je samo uz pozitivan terapijski odgovor koji se definira kao redukcija od najmanje 50% u broju astmatskih napadaja (u bolesnika koji su imali >=4 egzacerbacije u 12 mjeseci prije početka liječenja) ili klinički značajno smanjenje razdoblja uzimanja peroralnih kortikosteroida uz održavanje ili poboljšanje simptoma astme. Liječenje odobrava Bolničko povjerenstvo za lijekove. |
| NS101 | Lijek odobrava Bolničko povjerenstvo za lijekove po preporuci specijaliste oftalmologa. |
| NS104 | Za liječenje odraslih i pedijatrijskih bolesnika s gubitkom vida zbog naslijeđene distrofije mrežnice uzrokovane potvrđenim bialelnim RPE65 mutacijama, koji imaju dovoljno vijabilnih stanica mrežnice. Lijek se može primijeniti isključivo u osposobljenom centru KB ‘’Sveti Duh’’. Liječenje odobrava Bolničko povjerenstvo za lijekove na prijedlog multidisciplinarnog tima u čijem je sastavu obvezno subspecijalista retinolog oftalmolog ili dječji oftalmolog. |
| NV101 | Za dermatophagoides pteronyssinus, peludi trave i stabala te otrov insekata. |
| NV301 | U slučaju potrebe broj lijekova se može proširiti. |
| NV302 | Samo za liječenje otrovanja s paracetamolom. |
| NV303 | 1. Neposredna reverzija blokade izazvane lijekom rokuronij. 2. Rutinska reverzija duboke ili umjerene blokade izazvane lijekovima rokuronij ili vekuronij u bolesnika u kojih je kontraindicirana primjena lijekova neostigmin i atropin. |
| NV601 | Za bolesnike s fenilketonurijom. |
| NV605 | Za dijetalnu prehranu bolesnika na umjetnoj ventilaciji, kojima je potrebna enteralna prehrana. |
| NV611 | Za liječenje 1. fenilketonurije, 2. organske acidurije, 3. bolesti iz skupine poremećaja ciklusa ureje, 4. leucinoze, 4. tirozinemije, 5. klasične homocistinurije i ostalih poremećaja metabolizma metionina, 6. sindroma hiperamonijemija/hiperinzulinizam. |
| NV612 | Za preoperativnu primjenu. |
| NV613 | Za enteralno hranjenje putem sonde postoperativnih i posttraumatskih bolesnika u kritičnom stanju kod kojih se normalnim putem ne mogu zadovoljiti energetske i nutritivne dnevne potrebe te je potrebno postići anabolički učinak primjenom specifičnih farmakonutrijenata, a po preporuci specijalista iz ugovorne zdravstvene ustanove kada na osnovu medicinske dokumentacije ustanovi potrebu za enteralnom nutritivnom potporom. |
| NV701 | Prema preporukama za primjenu krvi i krvnih pripravaka u kliničkoj medicini. |
| NV801 | Za dijagnostiku perforacije, ileus, poslijeoperativnu kontrolu nakon zahvata na probavnom traktu, CT pretrage. |
| NV802 | Za mijelografiju za rizične skupine – a) alergija u anamnezi (posebno na RTG kontraste), b) mala djeca, c) dijabetičari. |
| NV803 | Za angiografiju udova i selektivnu angiografiju malih krvnih žila. |
| NV804 | Za rizične skupine – a) alergija u anamnezi (posebno na RTG kontraste), b) mala djeca, c) dijabetičari. |
| NV805 | Samo za dijagnostiku karcinoma jetre. |
| NV806 | Za detekciju gubitka funkcije završetaka dopaminergičkih neurona u striatumu – kao pomoć u diferencijaciji esencijalnog tremora od Parkinsonovih sindroma povezanih s idopatskom Parkinsonovom bolešću, multiplom sistemskom atrofijom i progresivnom supranuklearnom paralizom. |
| NV808 | 1. Za liječenje odraslih bolesnika s metastatskim rakom prostate rezistentnim na kastraciju u monoterapiji ili u kombinaciji s analogom hormona koji oslobađa luteinizirajući hormon (LHRH), a sa simptomatskim koštanim metastazama i bez poznatih visceralnih metastaza, koji je u progresiji nakon najmanje dvije prethodne linije sistemske terapije za metastatski kastracijski rezistentni rak prostate (osim analoga LHRH) s ECOG statusom 0-2. Odobrava se šest ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove KBC-a uz prethodno mišljenje multidisciplinarnog tima. 2. Kod bolesnika s metastatskim rakom prostate rezistentnim na kastraciju u monoterapiji ili u kombinaciji s analogom hormona koji oslobađa luteinizirajući hormon (LHRH), sa simptomatskim koštanim metastazama i bez poznatih visceralnih metastaza, a koji nisu pogodni za liječenje dostupnom sistemskom terapijom (kemoterapijski protokol temeljen na docetakselu / kabazitakselu ili novom hormonskom terapijom abirateron acetat / enzalutamid protokol) s ECOG statusom 0-2. Odobrava se šest ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekove KBC-a uz prethodno mišljenje multidisciplinarnog tima. |
| Oznaka smjernice | Smjernica |
| GO01 | Samo za bolesnike koji su na terapiji inzulina i kućnoj dijalizi. |
| pa02 | 1. Indukcija remisije u bolesnika s blagom do umjerenom Crohnovom bolešću koja zahvaća ileum i/ili uzlazni kolon, po preporuci specijalista internista ili pedijatra. 2. Indukcija remisije u bolesnika s mikroskopskim kolitisom po preporuci specijalista internista ili pedijatra. 3. Za liječenje autoimunog hepatitisa kod ne-cirotičnih bolesnika s novodijagnosticiranom bolešću i/ili u bolesnika kod kojih treba izbjegavati kortikosteroidne nuspojave, po preporuci specijalista gastroenterologa. |
| pa03 | Za liječenje ulceroznog kolitisa ili Crohnove bolesti po preporuci specijalista internista ili pedijatra. |
| pa04 | Samo za pretile bolesnike sa šećernom bolesti tipa 2, s ITM >35 kg/m2, po preporuci specijalista endokrinologa ili dijabetologa. |
| pa05 | Kod dokazane insuficijencije gušterače, po preporuci specijalista internista gastroenterologa te po preporuci specijalista abdominalnog kirurga. |
| pa09 | Za liječenje šećerne bolesti tipa 2. |
| pa10 | Za bolesnike s hipokalcemijom u kojih terapija kolekalciferolom nema terapijski učinak, po preporuci specijalista internista. |
| pa14 | Dopunsko, simptomatsko liječenje akutnog proljeva u dojenčadi (starije od 3 mjeseca) i djece do 30 mjeseci starosti, zajedno s oralnom rehidracijom i uobičajenim potpornim mjerama kada te mjere same nisu dovoljne za nadzor kliničkog stanja. |
| pa17 | Za simptomatsko liječenje kronične konstipacije u odraslih koji su prethodno bili neuspješno liječeni s barem dvije različite vrste laksativa u najvećim preporučenim dozama i u periodu od najmanje 6 mjeseci, po preporuci specijalista gastroenterologa. Nakon 4 tjedna terapije potrebno je napraviti procjenu učinka terapije. Nastavak liječenja moguć je isključivo kod pozitivnog terapijskog odgovora na započeto liječenje. |
| pa20 | U kombinaciji s oralnim hipoglikemizantnim lijekovima za skupinu bolesnika sa šećernom bolesti tipa 2, koji nakon 6 mjeseci kombinirane terapije maksimalnim dozama oralnih hipoglikemizantnih lijekova nisu postigli ciljne vrijednosti HbA1c < 7 %. |
| pa21 | Za liječenje osteoporoze u postmenopauzi i osteoporoze povezane s liječenjem glukokortikoidima. |
| pa22 | Dopunsko, simptomatsko liječenje akutnog proljeva u djece od 30 mjeseci do 5 godina starosti, zajedno s oralnom rehidracijom i uobičajenim potpornim mjerama kada te mjere same nisu dovoljne za nadzor kliničkog stanja. |
| pa24 | Za liječenje akutnih epizoda ulceroznog kolitisa koji je ograničen na rektum i sigmoidni kolon, po preporuci specijalista internista ili pedijatra. |
| pa25 | 1. Za indukciju remisije u odraslih bolesnika s blagim do umjereno aktivnim ulceroznim kolitisom (UC) u slučajevima kada liječenje 5-aminosalicilatima (5-ASA) nije dovoljno, u trajanju do osam tjedana, po preporuci specijalista internista. 2. Za indukciju remisije u pacijenata s aktivnim mikroskopskim kolitisom (MC), po preporuci specijalista internista. |
| pa26 | Za liječenje ulceroznog kolitisa po preporuci specijalista internista. |
| PA29 | Za liječenje šećerne bolesti u odraslih, adolescenata i djece u dobi od jedne i više godina koji koriste inzulinske pumpe. |
| pa30 | Za bolesnike sa šećernom bolešću tipa 2 s nereguliranom glikemijom nakon primjene kombinirane terapije s oralnim antidijabeticima i inzulinom ili kombinirane terapije sa oralnim antidijabeticima i agonista GLP-1 receptora, koji ne uspijevaju postići HbA1c<7%, te koji uz to imaju indeks tjelesne mase ≥30 kg/m2. Po preporuci specijalista internista ili endokrinologa. Nakon šestomjesečnog liječenja potrebno je procijeniti učinak liječenja, a nastavak liječenja moguć je isključivo ukoliko postoji pozitivan odgovor na liječenje (smanjenje HbA1c za najmanje 0,5%) i/ili gubitak na tjelesnoj težini od 3%. |
| pa32 | Za liječenje patohistološki potvrđenog eozinofilnog ezofagitisa u odraslih osoba. Preporučena dnevna doza je 2 mg dnevno u obliku jedne tablete od 1 mg ujutro i jedne tablete od 1 mg navečer u trajanju od 6 tjedana. Kod bolesnika bez odgovarajućeg terapijskog odgovora sa nadalje prisutnim simptomima bolesti tijekom prvih 6 tjedana, liječenje se može produžiti još 6 tjedana do ukupno 12 tjedana. Po preporuci specijaliste gastroenterologa. |
| pb04 | Primijenjen istodobno s acetilsalicilnom kiselinom (ASA), za prevenciju aterotrombotičnih događaja, u trajanju do 12 mjeseci – – kod odraslih bolesnika s akutnim koronarnim sindromima (nestabilnom anginom, infarktom miokarda bez ST elevacije (NSTEMI) ili – infarktom miokarda sa ST elevacijom (STEMI), uključujući bolesnike koji su medikamentozno tretirani kao i one koji su liječeni perkutanom koronarnom intervencijom (PCI) ili aortokoronarnom premosnicom (CABG). |
| pb05 | Za liječenje bolesnika poslije ugradnje premosnice ili stenta, koji već uzimaju klopidogrel i acetilsalicilnu kiselinu, po preporuci bolničkog specijalista, u trajanju od 3 do najviše 12 mjeseci, ovisno o vrsti stenta. |
| pb07 | 1. Prevencija moždanog udara i sistemske embolije u odraslih osoba s nevalvularnom atrijskom fibrilacijom s jednim ili više sljedećih čimbenika rizika – 1. prethodni moždani udar, tranzitorna ishemična ataka ili sistemska embolija, 2. ejekcijska frakcija lijevog ventrikula < 40%, 3. simptomatsko zatajenje srca, stupanj ≥ 2 prema klasifikaciji NYHA, 4. dob ≥ 75 godina, 5. dob ≥ 65 godina povezana s jednim od sljedećeg – dijabetes melitus, koronarna bolest srca ili hipertenzija, a koji ne postižu s varfarinom ciljnu vrijednost INR-a (INR 2-3). 2. a. za liječenje duboke venske tromboze najduže do 6 mjeseci i liječenje plućne embolije najduže do 12 mjeseci. b. za prevenciju kod bolesnika nakon ponovljene epizode (nakon druge ili više epizoda) duboke venske tromboze i/ili plućne embolije. c. Za prevenciju kod bolesnika s prvom epizodom duboke venske tromboze i/ili plućne embolije kojima je dijagnosticirana trombofilija. |
| pb08 | Za prevenciju aterotrombotičnih događaja kod odraslih bolesnika s infarktom miokarda u anamnezi i visokim rizikom za razvoj aterotrombotskog događaja (dijabetes, višežilna koronarna bolest, dva prethodna infarkta miokarda u anamnezi, kronična bolest bubrega), primijenjen istodobno s acetilsalicilnom kiselinom (ASA) kao nastavak terapije nakon početnog jednogodišnjeg liječenja lijekom tikagrelor od 90 mg ili drugim inhibitorom receptora adenozin difosfata (ADP), bez prekida ili unutar jedne godine nakon prekida prethodnog liječenja inhibitorom ADP, po preporuci specijalista kardiologa, a u trajanju do najviše 12 mjeseci. |
| pb09 | Produljena prevencija nakon završetka liječenja ponovljene epizode (nakon druge ili više epizoda) duboke venske tromboze i/ili plućne embolije u odraslih bolesnika. |
| pb11 | Za prevenciju, primijenjen istodobno s acetilsalicilatnom kiselinom (ASK), aterotrombotskih događaja u odraslih bolesnika koji imaju – •simptomatsku bolest perifernih arterija (BPA) ili •bolest koronarnih arterija (BKA) uz 1 ili više sljedećih čimbenika ishemijskog rizika – 1. Ateroskleroza prisutna u dvije ili više koronarnih arterija, 2. Šećerna bolest, 3. Preboljeli srčani udar, 4. Bolest perifernih arterija, 5. Srčano zatajivanje (NYHA 1-2, uz LVEF >30%), 6. Kroničnu bubrežnu bolest s eGFR 15-59 ml/min po tjelesnoj površini. |
| pc01 | Za bolesnike s koronarografski dokazanom koronarnom arterijskom bolešću kod kojih nije moguć revaskularizacijski ili ponovni revaskularizacijski postupak, a kod kojih nije postignuta stabilizacija koronarne bolesti drugom medikamentoznom terapijom, po preporuci specijalista internista kardiologa. |
| pc02 | 1. Za bolesnike sa stabilnom anginom pektoris nakon revaskularizacije u slučaju nepodnošljivosti ili kontraindikacije za blokatore beta-adrenergičkih receptora i srčane frekvencije više od 70 otkucaja u minuti, po preporuci specijalista internista kardiologa. 2. Za liječenje kroničnog zatajenja srca stupnja III do IV NYHA klasifikacije sa sistoličkom disfunkcijom (LVEF<35%), kod bolesnika u sinusnom ritmu sa srčanom fekvencijom >= 75 otkucaja u minuti u mirovanju u kombinaciji sa standardnom terapijom uključujući terapiju s beta-blokatorom ili kada je primjena beta-blokatora kontraindicirana ili se ne podnosi, po preporuci specijalista internista kardiologa. |
| pc08 | Za liječenje primarne hiperkolesterolemije umjesto statina u bolesnika s vrlo visokim ili visokim kardiovaskularnim rizikom u kojih je, na terapiju statinom, razina LDL-kolesterola >= 2,5 mmol/L, po preporuci specijalista internista, kardiologa ili endokrinologa. |
| pc09 | Za bolesnike s paroksizmalnom ili perzistentnom fibrilacijom atrija koji imaju očuvanu sistoličku funkciju lijevog ventrikula, nemaju akutno ili srčano zatajivanje u povijesti bolesti i imaju barem jedan od navedenih rizičnih faktora – 1. hipertenziju koja zahtijeva barem dva antihipertenzivna lijeka, 2. dijabetes, 3. prethodna TIA, moždani udar ili sistemska embolija, 4. >70 godina starosti bolesnika, nakon nezadovoljavajućeg liječenja (nedovoljna učinkovitost/nepodnošljivost terapije) beta blokatorima i/ili ostalim antiaritmicima, po preporuci specijalista internista kardiologa uz priloženu dokumentaciju. |
| pc11 | Druga linija liječenja simptomatskog kroničnog zatajenja srca u bolesnika sa smanjenom ejekcijskom frakcijom EF<=35%, NYHA klasa II ili III, koji imaju razine BNP ≥150 pg/ml (ili pro-BNP ≥ 600 pg/ml) odnosno razine BNP >=100 pg/ml (ili pro-BNP >=400 pg/ml) ako su zbog zatajenja srca bili hospitalizirani zadnjih 12 mjeseci. Temeljem preporuke specijaliste kardiologa, lijek se može propisati samo u bolesnika koji su bez simptomatskog poboljšanja liječeni >=3 mjeseca maksimalno podnošljivom dozom ACE inhbitora ili blokatora angiotenzinskih receptora te primaju ostalu standardnu terapiju koja uključuje beta-blokator, diuretik i blokator mineralokortikoidnih receptora. Lijek se propisuje na 6 mjeseci. Nastavak liječenja moguć je samo uz dokumentirano simptomatsko poboljšanje. |
| pc13 | Za sekundarnu prevenciju u bolesnika koji su preboljeli infarkt miokarda, ishemični cerebralni infarkt, tranzitornu ishemičnu ataku, ultrazvučno dokazani plak na karotidi ili ultrazvučno dokazanu perifernu arterijsku okluzivnu bolest ili boluju od koronarne bolesti dokazane koronarografijom ili testom opterećenja te za bolesnike koji boluju od šećerne bolesti uz vrijednosti ukupnog kolesterola iznad 5 mmol/L. |
| pc14 | Liječenje simptomatskog kroničnog zatajivanja srca u bolesnika sa smanjenom ejekcijskom frakcijom (EF 40% ili niža), NYHA klasa II ili III. Temeljem preporuke specijalista kardiologa, lijek se može propisati samo u bolesnika koji su bez simptomatskog poboljšanja liječeni barem tri mjeseca maksimalno podnošljivom dozom ACE inhibitora ili blokatora angiotenzinskih receptora ili sakubitril-valsartana te primaju ostalu standardnu terapiju koja uključuje beta-blokator, diuretik i blokator mineralokortikoidnih receptora. |
| pd01 | Onihomikoze, mikoze vlasišta i dermatomikoze stopala, a što mora biti utvrđeno dokazom uzročnika u nativnom preparatu ili u kulturi na gljive. |
| pd03 | Samo po preporuci specijalista dermatologa. |
| pd04 | Rozacea, dermatitis rosaceiformis steroidica i tumori s neugodnim mirisom. |
| pd05 | 1. Za topikalno liječenje vanjskih genitalnih i perianalnih bradavica (condylomata acuminata) u odraslih bolesnika. |
| pd09 | Dodatno liječenje blagih do umjerenih oblika atopijskog dermatitisa u subakutnoj i u kroničnoj fazi bolesti kod djece do 6 godina života u čijem je liječenju indicirana primjena lokalnih kortikosteroida ili lokalnih imunomodulatora. Po preporuci specijaliste dermatovenerologa ili specijalist pedijatar. |
| pg01 | U bolesnika nakon osteoporotične frakture i za liječenje osteoporoze (DXA T vrijednosti u L1-4 <= – 2,5 ili <= od -2,5 u Total/Neck), po preporuci specijalista internista, fizijatra, ortopeda ili ginekologa. |
| pg02 | Za liječenje funkcionalnih simptoma donjeg urinaranog trakta kod dokazanog postojanja benigne hiperplazije prostate, po preporuci specijalista urologa. |
| pg03 | Kod pacijenata s kliničkom dijagnozom benigne hiperplazije prostate, IPSS (International Prostate Symptom Score) s kliničkim zbrojem ≥ 12, volumenom prostate ≥ 30 cm(3), PSA (prostatični specifični antigen) vrijednošću 1,5 – 10 ug/L, po preporuci specijaliste urologa. |
| pg04 | Za liječenje funkcionalnih simptoma donjeg urinaranog trakta kod dokazanog postojanja benigne hiperplazije prostate, po preporuci specijalista urologa. Ne može se propisivati nakon prostatektomije. |
| pg05 | Za liječenje endometrioze po preporuci bolničkog specijalista ginekologa. |
| pg07 | Za liječenje dokazane vulvovaginalne miješane infekcije. |
| pg08 | Lijek je indiciran za intermitentno liječenje umjerenih do teških simptoma fibroida maternice u odraslih žena koje nisu u menopauzi, kada embolizacija fibroida maternice i/ili kirurško liječenje nisu prikladni ili nisu bili uspješni. Po preporuci bolničkog specijalista ginekologa iz ugovorne zdravstvene ustanove. Primjenjuje se u terapijskim ciklusima u trajanju od 3 mjeseca. Nakon 1. ciklusa se prekida ukoliko izostane smanjenje krvarenja. Nakon 2. ciklusa se prekida ukoliko izostane smanjenje veličine mioma. Može se primijeniti u najviše 4 ciklusa tijekom dvije godine. Između tih ciklusa su pauze u trajanju od po 2 mjeseca. Nakon 4. ciklusa potrebna je pauza od najmanje 6 mjeseci. |
| pg09 | Za liječenje simptoma donjeg urinarnog trakta udruženih s benignom hiperplazijom prostate, kod muškaraca koji nemaju adekvatan odgovor na monoterapiju. |
| ph02 | Za liječenje idiopatske noćne poliurije u odraslih žena. Najmanje 2 dana prije početka liječenja mora se odrediti odnos učestalosti mokrenja i volumena urina. Količina urina proizvedenog tijekom noći treba iznositi više od 1/3 mokraće proizvedene u razdoblju od 24 sata. Odobrava se primjena terapije za 3 mjeseca nakon čega je obvezna klinička ocjena odgovora. Nastavak liječenja moguć je kod pozitivnog odgovora na provedeno liječenje, po preporuci specijalista internista, urologa ili ginekologa. |
| ph03 | Za liječenje idiopatske noćne poliurije u odraslih muškaraca. Najmanje 2 dana prije početka liječenja mora se odrediti odnos učestalosti mokrenja i volumena urina. Količina urina proizvedenog tijekom noći treba iznositi više od 1/3 mokraće proizvedene u razdoblju od 24 sata. Odobrava se primjena terapije za 3 mjeseca nakon čega je obvezna klinička ocjena odgovora. Nastavak liječenja moguć je kod pozitivnog odgovora na provedeno liječenje, po preporuci specijalista internista ili urologa. |
| pm02 | Za liječenje bolesnika s kroničnom hiperuricemijom, u stanjima kada je već došlo do taloženja urata (uključujući prisutnost tofa i/ili uložnog artritisa, trenutačno ili u anamnezi), a kod kojih prethodno provedena terapija lijekom alopurinol nije dovoljno učinkovita ili se razvila intoleracije na lijek alopurinol te kod oštećene bubrežne funkcije. |
| pn04 | 1. Za liječenje Parkinsonove bolesti. 2. Za simptomatsko liječenje sindroma nemirnih nogu. |
| pn05 | Samo za liječenje uznapredovalog stadija Parkinsonove bolesti sa razvojem jenjavanja učinka levodope i/ili pojave oscilacija. |
| pn06 | 1. Kao monoterapija u ranoj fazi Parkinsonove bolesti, 2. Za liječenje uznapredovalog stadija Parkinsonove bolesti sa razvojem jenjavanja učinka levodope i/ili pojave oscilacija. |
| pn10 | Za liječenje velikih depresivnih epizoda u odraslih. |
| pn11 | Za liječenje bolesnika s blagom do umjerenom Alzheimerovom bolesti, po preporuci specijalista neurologa ili psihijatra. |
| pn12 | Za liječenje bolesnika s umjerenom ili teškom Alzheimerovom bolesti, po preporuci specijalista neurologa ili psihijatra. |
| pn17 | Samo za liječenje dijagnosticirane Menierove bolesti, po preporuci specijalista neurologa ili otorinolaringologa, najviše do 3 mjeseca. |
| pn19 | Samo za liječenje bolesnika s uznapredovalom Huntingtonovom bolesti, refrakterne na prethodnu terapiju antipsihoticima i dopaminergicima, po preporuci specijalista neurologa. |
| pn21 | 1. Druga ili kasnija linija liječenja epilepsije, po preporuci specijaliste neurologa ili psihijatra. 2. Za liječenje generaliziranog anksioznog poremećaja (GAP) u odraslih osoba. |
| pn22 | Druga ili kasnija linija liječenja epilepsija kao dodatna ili monoterapija u liječenju žarišnih napada sa ili bez sekundarne generalizacije kod bolesnika s epilepsijom starijih od 4 godine, po preporuci specijaliste neurologa ili pedijatra. |
| pn25 | Za kratkotrajno liječenje jake boli različitog podrijetla i za snižavanje povišene tjelesne temperature kada ostale terapijske mjere ne pomažu. |
| pr01 | 1. Za liječenje bolesnika s astmom kojima je indicirana kombinacija inhalacijskog kortikosteroida i beta 2-agonista dugog djelovanja/bronhodilatatora, 1.a. u bolesnika u kojih astma nije na odgovarajući način kontrolirana monoterapijom inhalatornim kortikosteroidom i po potrebi beta-2-agonistima kratkog djelovanja ili 1.b. u bolesnika koji su već postigli kontrolu astme kombinacijom inhalacijskog kortikosteroida i beta-2-agonista dugog djelovanja, radi održavanja kontrole bolesti. |
| pr02 | Kod prvog propisivanja odobrava se inhalator, a zatim po potrebi 1 puta godišnje. |
| pr03 | Za bolesnike s umjerenom, teškom i vrlo teškom KOPB. |
| pr04 | Za liječenje bolesnika s teškom i vrlo teškom kroničnom opstruktivnom plućnom bolesti (FEV1<50%) povezane s kroničnim bronhitisom i čestim egzacerbacijama (dvije ili više godišnje), kao dodatak bronhodilatatorima, inhalacijskim kortikosteroidima i dugodjelujućim antagonistima muskarinskih receptora, po preporuci specijalista pulmologa. |
| pr05 | 1. Za liječenje bolesnika s astmom kojima je indicirana kombinacija inhalacijskog kortikosteroida i beta 2-agonista dugog djelovanja/bronhodilatatora, 1.a. u bolesnika u kojih astma nije na odgovarajući način kontrolirana monoterapijom inhalatornim kortikosteroidom i po potrebi beta-2-agonistima kratkog djelovanja. 2. Za liječenje bolesnika s kroničnom opstruktivnom plućnom bolesti (KOPB) s FEV1<60% i učestalim egzacerbacijama bolesti unatoč terapiji bronhodilatatorima. |
| pr06 | 1. Za liječenje bolesnika s astmom kojima je indicirana kombinacija inhalacijskog kortikosteroida i beta 2-agonista dugog djelovanja/bronhodilatatora, 1.a. u bolesnika u kojih astma nije na odgovarajući način kontrolirana monoterapijom inhalatornim kortikosteroidom i po potrebi beta-2-agonistima kratkog djelovanja. |
| pr07 | Za liječenje djece s bronhijalnom astmom od 6 mjeseci do navršenih 6 godina. |
| pr08 | Za bolesnike s umjerenom, teškom i vrlo teškom KOPB kod kojih terapija jednim bronhodilatatorom ne daje zadovoljavajući učinak. |
| pr09 | Kao dodatni bronhodilatator u liječenju održavanja kod odraslih bolesnika s astmom, kod kojih se primjenjuje liječenje održavanja kombinacijom inhalacijskih kortikosteroida (>=800 μg budesonida dnevno ili ekvivalentna terapija) i ß2 agonista dugog djelovanja, te koji su u protekloj godini doživjeli jednu ili više ozbiljnjih egzacerbacija. |
| pr11 | Za profilaksu migrene u odraslih osoba koje imaju migrenu najmanje 4 dana mjesečno, po preporuci specijalista neurologa. |
| ps02 | Za pacijente sa stupnjem 4 bolesti suhog oka, određenim prema DEWS smjernicama iz 2007. koje uključuje određivanje stupnja bolesti pomoću TBUT (Tear break up test), Schimmerovog testa i bojanja površine oka flouresceinom (CFS). Odobrava se primjena terapije za 6 mjeseci, po preporuci oftalmologa. |
| pv01 | Po preporuci bolničkog specijalista pedijatra ili internista u bolnici. |
| RA01 | Stomatitis stupnja III i IV uzrokovan sistemnom ili lokalnom onkološkom terapijom. |
| RA02 | Gastroezofagealna refluksna bolest i prateći simptomi, želučani i duodenalni vrijed, profilaksa gastropatije u bolesnika na kontinuiranoj terapiji s NSAR i povišenim rizikom GI komplikacija, Zollinger-Ellisonov sindrom i druga patološka hipersekretorna stanja te za eradikaciju Helicobacter pylori, pri čemu se terapija može provoditi samo ako je učinjen jedan od tri testa – urea-izdisajni test, test Helicobacter pylori na stolicu ili dokaz u tijeku biopsije. Nakon neuspješne primarne terapije obvezna je mikrobiološka analiza s antibiogramom. |
| RA03 | Primarna bilijarna ciroza, primarni sklerozirajući kolangitis, intrahepatalna kolestaza u trudnoći, graft versus host bolest jetre, bolesnici s totalnom parenteralnom terapijom i kolestazom, progresivna intrahepatalna familijarna kolestaza, bolest jetre u sklopu cistične fibroze, po preporuci specijalista internista ili pedijatra. |
| RA08 | Za bolesnike na intenziviranoj terapiji inzulinom (dnevno 1 ili 2 injekcije bazalnog inzulina +3 injekcije kratkodjelujućeg inzulina uz glavne obroke), koji tijekom posljednjih 6 mjeseci, unatoč promjenama terapijske sheme, ne uspijevaju postići zadovoljavajuću glukoregulaciju (HbA1c <6,5%), koji imaju više od jedne hipoglikemije tjedno, a kod kojih se s ostalim vrstama inzulina ne može postići dobra regulacija glikemije. |
| RA11 | Za bolesnike sa šećernom bolešću tipa 2 s nereguliranom glikemijom nakon primjene dva oralna antidijabetika ili kombinirane terapije oralnim antidijabeticima i inzulinom, koji ne uspijevaju postići HbA1c<7%, te koji uz to imaju – a) indeks tjelesne mase ≥30 kg/m2 (odnosi se na sve lijekove obuhvaćene smjernicom) ili b) indeks tjelesne mase ≥28 kg/m2 i dokazanu kardiovaskularnu bolest (odnosi se samo za primjenu liraglutida, dulaglutida i semaglutida). Po preporuci specijalista internista ili endokrinologa. Nakon šestomjesečnog liječenja potrebno je procijeniti učinak liječenja, a nastavak liječenja moguć je isključivo ukoliko postoji pozitivan odgovor na liječenje (smanjenje HbA1c za najmanje 0,5%) i/ili gubitak na tjelesnoj težini od 3%. |
| RA12 | 1. Prevencija i liječenje hepatičke encefalopatije, 2. Za liječenje opstipacije uzrokovane opijatima kod onkoloških bolesnika, 3. Za liječenje djece u dobi do 7 godina koja dokazano boluju od Mb Hirschprung. |
| RA15 | 1. Za bolesnike s cističnom fibrozom, po preporuci bolničkog specijalista. 2. Za bolesnike nakon pankreatektomije uslijed karcinoma gušterače, po preporuci bolničkog specijalista. |
| RA16 | Samo kao druga linija liječenja Helicobacter pylori infekcije u sklopu četverostruke terapije s bizmutom u slučaju neuspjeha liječenja prvom linijom terapije. |
| RA17 | Za suzbijanje povraćanja uzrokovanog visoko i srednje emetogenim lijekovima za vrijeme trajanja terapije i 5 dana nakon zadnje doze ciklusa terapije, po preporuci bolničkog specijaliste koji sudjeluje u onkološkom liječenju bolesnika. |
| RA31 | Liječenje manjka vitamina D po preporuci bolničkog specijaliste. Nakon početka terapije potrebno je pratiti razine 25(OH)D i kalcija u serumu. |
| RB01 | Za liječenje bolesnika poslije ugradnje premosnice ili stenta, po preporuci bolničkog specijalista, u trajanju od 3 do najviše 12 mjeseci, ovisno o vrsti stenta. |
| RB02 | 1. Za liječenje bolesnika s akutnim infarktom miokarda sa ST elevacijom (STEMI) kod kojih je učinjena primarna (urgentna) PCI s implantacijom stenta, po preporuci nadležnog kardiologa, a u trajanju do 12 mjeseci. 2. Za liječenje bolesnika s akutnim infarktom miokarda bez ST elevacije (NSTEMI) koji su u nastavku koronarografije liječeni perkutanom koronarnom intervencijom (PCI) s implantacijom stenta tijekom inicijalne hospitalizacije, po preporuci nadležnog kardiologa, a u trajanju do 12 mjeseci. |
| RB10 | Za liječenje akutne duboke venske tromboze i plućne embolije te za produljenu sekundarnu tromboprofilaksu kod bolesnika s karcinomom, a u trajanju do najviše 6 mjeseci, po preporuci specijalista internista. |
| RB11 | Za profilaksu venske tromboembolijske bolesti u trajanju do najviše 35 dana kod operacije kuka i totalne zamjene koljena u ortopediji, po preporuci specijalista ortopeda. |
| RB13 | Liječenje venske tromboembolije (VTE) i prevencija ponavljajućeg VTE-a u donošene novorođenčadi, dojenčadi i male djece te djece i adolescenata u dobi manjoj od 18 godina nakon najmanje 5 dana početnog liječenja parenteralnim antikoagulansima. |
| RB14 | Liječenje venske tromboembolije (VTE) i prevencija ponavljajućeg VTE-a u djece i adolescenata u dobi manjoj od 18 godina i tjelesne težine od 30 kg do 50 kg nakon najmanje 5 dana početnog liječenja parenteralnim antikoagulansom. |
| RB15 | Liječenje venske tromboembolije (VTE) i prevencija ponavljajućeg VTE-a u djece i adolescenata u dobi manjoj od 18 godina i tjelesne težine veće od 50 kg nakon najmanje 5 dana početnog liječenja parenteralnim antikoagulansom. |
| RC01 | Samo kao antiaritmik, po preporuci specijalista internista. |
| RC02 | Samo za bolesnike koji ne podnose ACE-inhibitore nakon 4 mjeseca primjene terapije. |
| RC03 | 1. Za sekundarnu prevenciju u bolesnika koji su preboljeli infarkt miokarda, ishemični cerebralni infarkt, tranzitornu ishemičnu ataku, ultrazvučno dokazani plak na karotidi ili ultrazvučno dokazanu perifernu arterijsku okluzivnu bolest ili boluju od koronarne bolesti dokazane koronarografijom ili testom opterećenja te za bolesnike koji boluju od šećerne bolesti uz vrijednosti ukupnog kolesterola iznad 5 mmol/L. 2. U primarnoj prevenciji u bolesnika kojima je, nakon tromjesečnog pridržavanja dijete, vrijednost ukupnog kolesterola iznad 7 mmol/L i to u dva laboratorijska nalaza u razmaku od tri mjeseca. Primarna prevencija bolesnika može se započeti u bolesnika mlađih od 70 godina. |
| RC04 | Propisuje se samo ako, nakon tri mjeseca dijete, trigliceridi u krvi nisu manji od 2 mmol/L. |
| RC06 | Kao dodatna terapija dijeti i tjelovježbi, odraslim bolesnicima s miješanom dislipidemijom i visokim kardiovaskularnim rizikom (bolesnici koji su preboljeli infarkt miokarda, ishemični cerebralni inafrkt, tranzitornu ishemičnu ataku, ultrazvučno dokazani plak na karotidi ili ultrazvučno dokazanu perifernu arterijsku okluzivnu bolest ili boluju od koronarne bolesti dokazane koronarografijom ili testom opterećenja te za bolesnike koji boluju od šećerne bolesti) radi smanjivanja razina triglicerida ispod 2,0 mmol/l i povećavanja razine HDL-kolesterola iznad 1,0 mmol/l kod muškaraca i iznad 1,2 mmol/l kod žena, kada su razine LDL-kolesterola odgovarajuće kontrolirane. |
| RC07 | Za bolesnike s hipertenzijom u kojih, uz primjenu bar jedne glavne skupine antihipertenziva nije postignuta odgovarajuća kontrola arterijskog tlaka. |
| RC08 | Za liječenje primarne hiperkolesterolemije uz statine u bolesnika s vrlo visokim ili visokim kardiovaskularnim rizikom u kojih je, na terapiju statinom, razina LDL-kolesterola >= 2,5 mmol/L, po preporuci specijalista internista, kardiologa ili endokrinologa. |
| RC09 | Za bolesnike s prethodno dokumentiranim anafilaktičkim šokom ili teškom alergijskom reakcijom na alergene, npr. ubode ili ugrize kukaca, hranu ili lijekove, po preporuci bolničkog specijalista. |
| RC10 | Za liječenje proliferirajućeg infantilnog hemangioma koji zahtijeva sistemsku terapiju – 1. hemangiom koji ugrožava život ili funkciju, 2. ulcerirani hemangiom s bolovima i/ili izostankom odgovora na jednostavne mjere njege rane, 3. hemangiom s opasnošću od trajnih ožiljaka ili izobličavanja. Primjenu treba započeti kod dojenčadi u dobi od 5 tjedana do 5 mjeseci, po preporuci bolničkog specijaliste pedijatra. |
| RC11 | 1. Za bolesnike s heterozigotnom porodičnom hiperkolesterolemijom (koji imaju 6 ili više bodova prema kriterijima za postavljanje kliničke dijagnoze porodične hiperkolesterolemije prema »Dutch Lipid Clinic Network«) bez aterosklerotske KVB kod kojih su vrijednosti LDL-K više od 5 mmol/l unatoč liječenju maksimalno podnošljivom dozom potentnog statina (rosuvastatin/ atorvastatin) i ezetimibom u dozi od 10 mg, i za bolesnike s heterozigotnom porodičnom hiperkolesterolemijom, koji imaju aterosklerotsku KV bolest koji unatoč liječenju maksimalno podnošljivom dozom potentnog statina (rosuvastatina/ atorvastatina) i ezetimibom u dozi od 10 mg imaju vrijednosti LDL-K više od 2,6 mmol/l po preporuci specijalista endokrinologa, kardiologa ili internista. Liječenje odobrava Bolničko povjerenstvo za lijekove svakih 6 mjeseci kroz prvu godinu dana, a nakon toga svakih 12 mjeseci liječenja. 2. Za bolesnike s preboljenim akutnim koronarnim sindromom kod kojih su vrijednosti LDL kolesterola više od 2,6 mmol/l unatoč liječenju maksimalno podnošljivom dozom potentnog statina (rosuvastatin/ atorvastatin) i ezetimibom u dozi od 10 mg, po preporuci specijalista, kardiologa, internista ili endokrinologa. Liječenje se može započeti unutar 12 mjeseci od akutnog događaja. Liječenje odobrava Bolničko povjerenstvo za lijekove svakih 6 mjeseci kroz prvu godinu dana, a nakon toga svakih 12 mjeseci liječenja. |
| RC91 | Samo za izrazito refrakternu hipertenziju, po preporuci specijalista internista. |
| RD01 | Onihomikoze, mikoze vlasišta i dermatomikoze stopala, a što prethodno mora biti utvrđeno dokazom uzročnika u nativnom preparatu ili u kulturi na gljive. |
| RD02 | Za nastavak liječenja atopijskog dermatitisa zbog sprječavanje rasplamsavanja i produljenja razdoblja bez rasplamsavanja u djece do navršenih šest godina života koji su imali početni odgovor na liječenje lokalnim metilprednizolonaceponatom. Terapija održavanja u trajanju od 12 mjeseci, primjena jedanput na dan dvaput tjedno. Po preporuci specijalista dermatovenerologa ili specijalista pedijatra. |
| RD03 | Za bolesnike s umjereno-teškom do teškom psorijazom koji se liječe sustavnim lijekovima uključujući PUVA terapiju, ciklosporin, metotreksat i retinoide, a na iste nisu zadovoljavajuće odgovorili (što znači da nakon najmanje 16 tjedana terapije nije postignut PASI 75 i DLQI manji od 5), dodatno se uvodi topička terapija s lijekom Enstilar u svrhu kombinacijskog liječenja, te za bolesnike s umjereno-teškom do teškom psorijazom koji na liječenje apremilastom nisu zadovoljavajuće odgovorili (što znači da nakon najmanje 16 tjedana terapije nije postignut PASI 75 i DLQI manji od 5), dodatno se uvodi topička terapija s lijekom Enstilar u svrhu kombinacijskog liječenja, po preporuci specijalista dermatovenerologa. Procjena učinka lijeka obavezna je nakon 4 tjedana od početka liječenja, a nakon toga najmanje dvaput tijekom godine. Kod pozitivnog odgovora na liječenje za nastavak terapije potrebna je preporuka specijalista dermatovenerologa. U slučaju negativnog odgovora na liječenje ili u slučaju uključivanja sljedećih bioloških lijekova-ustekinumab, sekukinumab, iksekizumab, guselkumab i risankizumab u liječenje bolesnika, lijek Enstilar ne može se više primjenjivati prema ovoj smjernici za Osnovnu listu lijekova. |
| RG01 | Samo za bolesnike s kliničkim simptomima muškog hipogonadizma u kojih je izmjeren manjak testosterona u krvi (koncentracija ukupnog testosterona manja od 12 nmol/L), po preporuci specijalista endokrinologa ili urologa. |
| RG02 | 1. Idiopatski hirzutizam uz dismenoreju u žena generativne dobi, po preporuci specijalista endokrinologa i ginekologa, 2. Ozbiljne akne koje ne reagiraju na antimikrobnu terapiju, po preporuci specijalista dermatologa. |
| RG03 | U prevenciji i liječenju osteoporoze u bolesnica s povećanim rizikom za razvoj karcinoma dojke (obiteljska opterećenost, mastopatija), po preporuci specijalista endokrinologa, ginekologa ili onkologa. |
| RG04 | Samo za bolesnike s urinarnom inkontinencijom i neurogenim mokraćnim mjehurom. |
| RG05 | Za liječenje funkcionalnih simptoma donjeg urinarnog trakta kod dokazanog postojanja benigne hiperplazije prostate, po preporuci specijalista urologa. |
| RG06 | Za liječenje funkcionalnih simptoma donjeg urinaranog trakta kod dokazanog postojanja benigne hiperplazije prostate. Ne može se propisivati nakon prostatektomije, po preporuci specijalista urologa. |
| RG07 | Druga linija liječenja sindroma prekomjerno aktivnog mokraćnog mjehura (PAMM) samo u bolesnika u kojih su antimuskarinski lijekovi kontraindicirani ili klinički neučinkoviti nakon 3 mjeseca primjene, po preporuci specijalista urologa ili ginekologa. |
| RG08 | Liječenje adenoma hipofize u kojih dolazi do sekrecije prolaktina (mikroprolaktinomi i makroprolaktinomi), idiopatske hiperprolaktinemije ili sindroma praznog turskog sedla s popratnom hiperprolaktinemijom. Po preporuci specijalista endokrinologa. |
| RG09 | Samo za djecu s urinarnom inkontinencijom i neurogenim mokraćnim mjehurom. |
| RG91 | Za liječenje hereditarnog angioedema, po preporuci bolničkog specijalista. |
| RH01 | 1. U slučajevima kongestije nosne sluznice, ozljede ili anomalija nosa, nakon operativnog zahvata tumora hipotalamo-hipofizne regije ili epistakse, 2. Za liječenje primarnog noćnog mokrenja. Po preporuci specijalista internista endokrinologa ili pedijatra. |
| RH02 | Samo za liječenje centralnog dijabetes insipidusa, po preporuci specijalista internista endokrinologa ili pedijatra. |
| RH05 | Za liječenje sekundarnog hiperparatireoidizma u bolesnika s kroničnom bubrežnom bolesti koji se liječe dijalizom (hemodijalizom ili peritonejskom dijalizom) te u bolesnika s kroničnom bubrežnom bolesti od stupnja 3b do stupnja 5 koji se još ne liječe dijalizom, sa serumskom koncentracijom PTH > 2 x iznad referentnih vrijednosti, po preporuci bolničkog liječnika specijalista nefrologa. |
| RH06 | Lijek je indiciran za primjenu u liječenju utvrđenog deficita hormona rasta i Turnerovog sindroma, samo za djecu do navršenih 18 godina života. Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste endokrinologa. Lijek se može započeti propisivati na recept Zavoda samo temeljem odobrenja Bolničkog povjerenstva za lijekove, a u nastavku liječenja se lijek može propisivati na recept temeljem preporuke bolničkog specijaliste endokrinologa. |
| RH07 | Za liječenje žena u postmenopauzi sa multiplim osteoporotičnim frakturama i za liječenje muškaraca sa multiplim osteoporotičnim frakturama, po preporuci specijalista internista ili fizijatra, a izdaje se na ruke liječnika. |
| RH08 | Za liječenje teške hipoglikemije u odraslih, adolescenata i djece u dobi od 4 ili više godina sa šećernom bolešću. |
| RH91 | Retencija testisa u djece do navršene 3 godine života pod kontrolom Klinike za pedijatriju. |
| RH92 | Za liječenje adrenalne insuficijencije u dojenčadi i djece kao nadomjesna terapija kad ukupna propisana dnevna doza hidrokortizona ne prelazi 10 mg. Po preporuci specijalista pedijatra endokrinologa. |
| RJ01 | Infekcije dišnog sustava (akutni i recidivirajući bronhitis, bronhopneumonija), sinusitis, otitis i urinarne infekcije te infekcije želuca i dvanaesnika s Helicobacter pylori. |
| RJ02 | Liječenje streptokoknih i odontogenih (aerobnih i anaerobnih) infekcija i profilaksa reumatske groznice. |
| RJ04 | Infekcije uzrokovane H. influenzae, M. catarrhalis, E. coli i S. aureus koji stvaraju beta-laktamaze, a empirijski samo u sredinama gdje je njihova rezistencija prema aminopenicilinima > 20% i za blaže oblike dijabetičkog stopala. |
| RJ05 | Infekcije respiratornog i urinarnog sustava, s uzročnicima koji ne reagiraju na polusintetske peniciline (E. coli, H. influenze, Proteus). |
| RJ06 | Druga linija liječenja infekcija respiratornog i genitourinarnog sustava te kože i mekih tkiva izazvane uzročnicima koji ne reagiraju na polusintetske peniciline (E. coli, H. influenze, Proteus). |
| RJ07 | Druga linija liječenja infekcija respiratornog, urinarnog i bilijarnog sustava uzročnicima koji ne reagiraju na polusintetske peniciline (E. coli, H. influenze, Proteus). |
| RJ09 | Nekomplicirane infekcije urinarnog ili respiratornog sustava, profilaksa i liječenje infekcija s Pneumocystis carinii u imunosuprimiranih. |
| RJ10 | Infekcije respiratornog sustava atipičnim uzročnima, infekcije gram + uzročnicima u bolesnika preosjetljivih na penicilin, profilaksa reumatske groznice u preosjetljivih na penicilin. |
| RJ11 | Infekcije respiratornog sustava atipičnim uzročnicima ili gram+ uzročnicima u bolesnika preosjetljivih na penicilin i kao dio trojne terapije za eradikaciju Helicobacter pylori. |
| RJ12 | Infekcije respiratornog sustava atipičnim uzročnicima, nespecifični uretritis, infekcije Chlamydiom, infekcije gram+ uzročnicima u bolesnika preosjetljivih na penicilin. |
| RJ14 | Druga linija liječenja infekcija mokraćnog sustava. |
| RJ15 | Druga linija liječenja infekcija mokraćnog i respiratornog sustava, po preporuci specijalista ili nastavak bolnički započetog liječenja parenteralnim oblikom lijeka levofloksacin, po preporuci bolničkog specijalista. |
| RJ16 | Druga linija liječenja infekcija respiratornog sustava, po preporuci specijalista. |
| RJ18 | Infekcije respiratornog sustava atipičnim uzročnicima, nespecifični uretritis, infekcije Chlamydiom, infekcije gram+ uzročnicima u bolesnika preosjetljivih na penicilin. Primjena samo kod djece do 14 kg tjelesne težine. |
| RJ19 | Druga linija liječenja infekcija respiratornog i urinarnog sustava, uzročnicima koji ne reagiraju na polusintetske peniciline (E. coli, H. influenzae, P. mirabilis), kao i u slučaju neuspjeha terapije amoksicilinom ili nekim drugim antibiotikom koji je korišten kao prvi lijek izbora. Primjena cefpodoksima kao izbora prve linije liječenja je moguća i u bolesnika u sljedećim indikacijama – 1. u djece i odraslih kod preosjetljivosti na penicilin koja nije anafilaktičkog tipa, 2. rekurentne infekcije i/ili sumnje na antibiotsku rezistenciju, 3. kao nastavak terapije nakon bolničkog liječenja parenteralnim antibiotikom. |
| RJ51 | 1. Za prevenciju CMV bolesti u osoba rizičnih za razvoj CMV bolesti, osoba u kojih je izvršena transplantacija solidnog organa te osoba oboljelih od HIV-infekcije. 2. Za održavanje liječenja CMV bolesti nakon, parenteralnom terapijom postignute, stabilizacije bolesti. |
| RJ52 | 1. Za liječenje skupina s povećanim rizikom od komplikacija gripe koje obuhvaćaju slijedeće osobe – a) osobe starije od 65 godina, b) trudnice te žene unutar 2 tjedna po porodu, c) osobe s kroničnim plućnim, kardiovaskularnim, jetrenim, bubrežnim metaboličkim, neurološkim, mišićnim bolestima neovisno o dobi, e) imunosuprimirane osobe te d) osobe smještene u domovima za starije i nemoćne i sličnim ustanovama. Lijek treba primijeniti odmah pri postavljanju kliničke sumnje na gripu, najbolje u prvih 48 sati bolesti. 2. Postekspozicijska profilaksa oseltamivirom provodi se u slučaju izbijanja epidemije u domovima za starije i nemoćne, bolničkim odjelima i sličnim kolektivima. |
| RJ53 | Liječenje odobrava Bolničko povjerenstvo za lijekove, prema kriterijima navedenim u tekstu indikacije »NJ708«. Prije prvog propisivanja lijeka na recept Zavoda, bolesnik mora lijek dobivati najmanje 3 mjeseca na teret sredstava bolničkog proračuna. Lijek se može propisivati na recept Zavoda samo temeljem odobrenja Bolničkog povjerenstva za lijekove za razdoblje na koje je odobren. |
| RJ54 | Liječenje odobrava Bolničko povjerenstvo za lijekove, prema kriterijima navedenim u tekstu indikacije »NJ715«. Prije prvog propisivanja lijeka na recept Zavoda, bolesnik mora lijek dobivati najmanje 3 mjeseca na teret sredstava bolničkog proračuna. Lijek se može propisivati na recept Zavoda samo temeljem odobrenja Bolničkog povjerenstva za lijekove za razdoblje na koje je odobren. |
| RL01 | Po preporuci bolničkog specijalista hematologa, internista reumatologa ili onkologa. |
| RL02 | Po preporuci specijalista onkologa. |
| RL03 | Po preporuci specijalista hematologa, onkologa (specijalist radioterapije i onkologije, specijalist radioterapije ili subspecijalist internističke onkologije) ili pulmologa. |
| RL04 | Po preporuci specijalista hematologa ili onkologa. |
| RL05 | Po preporuci specijalista urologa ili onkologa. |
| RL22 | Po preporuci bolničkog specijalista, očekivano preživljenje više od 6 mjeseci, mogućnost peroralne prehrane (isključuju se bolesnici s tumorima jednjaka ili želuca kod kojih je peroralna prehrana nemoguća), dijagnoza kaheksije u bolesnika sa zloćudnom bolesti, primjena terapije tijekom 8 tjedana te nakon navedenog perioda obvezatna reevaluacija statusa težine bolesnika. Samo bolesnici sa zaustavljenim gubitkom ili porastom tjelesne mase smiju nastaviti započeto liječenje, primjena nije dozvoljena u bolesnika s presadnicama u CNS-u. |
| RL23 | 1. Za liječenje bolesnika s metastatskim karcinomom prostate, u dozi od 50 mg/dnevno, u kombinaciji s LHRH analogom ili orhidektomijom u kompletnoj androgenoj blokadi, 2. Kod oštećenja jetre uzrokovanog preegzistentnom jetrenom bolešću ili prethodnim uzimanjem drugih antiandrogena, s time da vrijednost AST i ALT bude >2-4x normalne vrijednosti, a bilirubin >2x normalne vrijednosti, 3. U dozi od 150 mg/dnevno (samo jačina od 150 mg), umjesto kastracije, kod lokalno uznapredovale bolesti (obradom moraju biti isključene udaljene metastaze, koštane ili visceralne). Po preporuci specijalista internista onkologa ili specijalista radioterapije i onkologije ili urologije. |
| RL24 | 1. Adjuvantno hormonsko liječenje raka dojke postmenopauzalnih bolesnica s pozitivnim hormonskim receptorima. 2. Prva linija hormonskog liječenja metastatskog raka dojke postmenopauzalnih bolesnica. 3. Druga linija hormonskog liječenja raka dojke postmenopauzalnih bolesnica, u kojih je bolest napredovala tijekom ili nakon provedenog liječenja tamoksifenom (Nolvadexom) u prvoj liniji hormonskog liječenja. Liječenje je dozvoljeno ukoliko su ispunjeni kriteriji za hormonski ovisnu bolest – ECOG 0-3 i nepostojanje CNS presadnica. U bolesnica s metastatskom bolesti odobrava se dvomjesečno liječenje, a po završetku liječenja onkolog je dužan izvršiti dijagnostičku obradu u cilju provjere stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). Liječenje preporučuje specijalost internistički onkolog ili specijalist radioterapije i onkologije. |
| RL25 | 1. Adjuvantno hormonsko liječenje raka dojke postmenopauzalnih bolesnica s pozitivnim hormonskim receptorima. 2. Produženo adjuvantno hormonsko liječenje raka dojke postmenopauzalnih bolesnica pozitivnih hormonskih receptora nakon 5 godina adjuvantne primjene tamoksifena. 3. Metastatski rak dojke postmenopauzalnih bolesnica, pozitivnih hormonskih receptora. Liječenje je dozvoljeno ukoliko su ispunjeni kriteriji – hormonski ovisna bolest, ECOG 0-3, nepostojanje CNS presadnica. U bolesnica s metastatskom bolesti odobrava se dvomjesečno liječenje, a po završetku liječenja onkolog je dužan izvršiti dijagnostičku obradu u cilju provjere stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). Liječenje preporuča specijalist internistički onkolog ili specijalist radioterapije i onkologije. |
| RL26 | 1. Adjuvantno hormonsko liječenje postmenopauzalnih bolesnica s estrogen-receptor pozitivnim ranim rakom dojke, nakon 2-3 godine početnog adjuvantnog liječenja tamoksifenom, do ukupno 5 godina adjuvantnog hormonskog liječenja, 2. Metastatski/uznapredovali rak dojke postmenopauzalnih bolesnica hormonski pozitivnih receptora, nakon neuspjeha liječenja lijekom tamoksifen. Liječenje je dozvoljeno ukoliko su ispunjeni kriteriji – hormonski ovisna bolest, ECOG 0-3, nepostojanje CNS presadnica. U bolesnica s metastatskom bolesti odobrava se dvomjesečno liječenje, a po završetku liječenja onkolog je dužan izvršiti dijagnostičku obradu u cilju provjere stupnja tumorskog odgovora. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest). Liječenje preporuča specijalist internistički onkolog ili specijalist radioterapije i onkologije. |
| RL41 | Za bolesnike s transplantiranim organima. |
| RL42 | Za bolesnike s transplantiranim bubregom. |
| RL43 | Samo za bolesnike nakon transplantacije bubrega, po preporuci specijalista internista ili specijalista pedijatra u transplantacijskim centrima. |
| RL44 | Prevencija odbacivanja organa u alogenoj transplantaciji bubrega ili srca u odraslih bolesnika s niskim do umjerenim imunološkim rizikom, po preporuci specijalista. |
| RL45 | 1. Samo za bolesnike nakon transplantacije i isključivo za najteže bolesnike s reumatoidnim artritisom rezistentne na sve načine liječenja u nadležnosti Klinike za reumatske bolesti i rehabilitaciju i Zavoda za kliničku imunologiju KBC i KB i u bolesnika s idiopatskim nefrotskim sindromom nakon započetog bolničkog liječenja. 2. Za liječenje endogenog uveitisa po preporuci specijalista oftalmologa. |
| RL46 | 1. Primarna imunosupresija kod primatelja presatka jetre, 2. prva linija imunosupresivnog liječenja nakon transplantacije bubrega, po preporuci specijalista internista, kirurga ili urologa u KBC i KB nakon započetog bolničkog liječenja, 3. Primarna imunosupresija kod primatelja presatka srca. |
| RL48 | Po preporuci specijaliste odgovarajuće specijalnosti. |
| RL50 | Za liječenje bolesnika koji nisu u mogućnosti primijeniti lijek oralnim putem, koji zbog nuspojava na peroralni oblik odustaju od terapije ili kod kojih je peroralna primjena pokazala manjak učinkovitosti, po preporuci specijalista. |
| RL75 | 1. Za liječenje aktivnog psorijatičnog artritisa, prema kriterijima navedenim u tekstu indikacije NL 505, po preporuci subspecijalista reumatologa iz ugovorne zdravstvene ustanove Zavoda, 2. Za liječenje umjereno-teške do teške psorijaze, prema kriterijima navedenim u tekstu indikacije NL 505, po preporuci specijalista dermatovenerologa iz ugovorne zdravstvene ustanove Zavoda. |
| RL92 | Po preporuci specijalista hematologa. |
| RL93 | Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste, prema kriterijima navedenim u tekstu indikacije (ovisno o obliku i pakiranju lijeka – za lijek etanercept NL408 ili NL434, za lijek adalimumab NL410, NL411 ili NL510, za lijek certolizumab pegol NL428, za lijek golimumab NL412, za lijek tocilizumab NL485 ili NL486, a za lijek sarilumab NL433). Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna, a tek se nakon isteka tog perioda može početi propisivati na recept Zavoda, isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. U slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste ovisno o indikaciji u kojoj se lijek primjenjuje, Bolničko povjerenstvo za lijekove može izdati odobrenje za nastavak primjene lijeka – drugo odobrenje Bolničko povjerenstvo za lijekove može dati za razdoblje od 6 mjeseci, a svako sljedeće odobrenje Bolničkog povjerenstva za lijekove se može izdati za razdoblje od najviše 12 mjeseci. |
| RL94 | Lijek je indiciran za primjenu u 1. liniji liječenja kod bolesnika s relapsno-remitirajućom multiplom sklerozom. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste neurologa, prema kriterijima navedenim u tekstu indikacije »NL303«. Prvo odobrenje za primjenu lijeka izdaje se za razdoblje od 6 mjeseci, od kojih se prvih mjesec dana lijek primjenjuje na teret sredstva bolničkog proračuna, a u nastavku se za preostalih 5 odobrenih mjeseci liječenja lijek može propisivati na recept Zavoda. Svako sljedeće odobrenje za nastavak liječenja, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste neurologa, Bolničko povjerenstvo za lijekove može izdati za razdoblje od najviše 12 mjeseci. Lijek se može propisivati na recept Zavoda samo temeljem odobrenja Bolničkog povjerenstva za lijekove za razdoblje na koje je odobren. |
| RL95 | Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste, prema kriterijima navedenim u tekstu indikacije (NL456). Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna, a tek se nakon isteka tog perioda može početi propisivati na recept Zavoda, isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. U slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste ovisno o indikaciji u kojoj se lijek primjenjuje, Bolničko povjerenstvo za lijekove može izdati odobrenje za nastavak primjene lijeka – drugo odobrenje Bolničko povjerenstvo za lijekove može dati za razdoblje od 6 mjeseci, a svako sljedeće odobrenje Bolničkog povjerenstva za lijekove se može izdati za razdoblje od najviše 12 mjeseci. |
| RL96 | 1. Za liječenje umjerenog do teškog oblika aktivnog reumatoidnog artritisa prema kriterijima navedenim u tekstu indikacije NL 503, po preporuci specijalista reumatolo-ga/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. 2. Za liječenje teškog atopijskog dermatitisa, prema kriterijima navedenim u tekstu indikacije NL 503, po preporuci specijalista dermatovener-ologa iz ugovorne zdravstvene ustanove Zavoda. |
| RL97 | 1. Za liječenja umjerenog do teškog oblika aktivnog reumatoidnog artritisa prema kriterijima navedenim u tekstu indikacije NL 504, po preporuci specijalista reumatolo-ga/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. 2. Za liječenje teškog atopijskog dermatitisa, prema kriterijima navedenim u tekstu indikacije NL 504, po preporuci specijalista dermatovener-ologa iz ugovorne zdravstvene ustanove Zavoda. |
| RL99 | Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste, prema kriterijima navedenim u tekstu indikacije (NL424). Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna, a tek se nakon isteka tog perioda može početi propisivati na recept Zavoda, isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. U slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste ovisno o indikaciji u kojoj se lijek primjenjuje, Bolničko povjerenstvo za lijekove može izdati odobrenje za nastavak primjene lijeka – drugo odobrenje Bolničko povjerenstvo za lijekove može dati za razdoblje od 6 mjeseci, a svako sljedeće odobrenje Bolničkog povjerenstva za lijekove se može izdati za razdoblje od najviše 12 mjeseci. |
| RL100 | Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste, prema kriterijima navedenim u tekstu indikacije (NL463). Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna, a tek se nakon isteka tog perioda može početi propisivati na recept Zavoda, isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. U slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste ovisno o indikaciji u kojoj se lijek primjenjuje, Bolničko povjerenstvo za lijekove može izdati odobrenje za nastavak primjene lijeka – drugo odobrenje Bolničko povjerenstvo za lijekove može dati za razdoblje od 6 mjeseci, a svako sljedeće odobrenje Bolničkog povjerenstva za lijekove se može izdati za razdoblje od najviše 12 mjeseci. |
| RL102 | Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste, prema kriterijima navedenim u tekstu indikacije (NL483). Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna, a tek se nakon isteka tog perioda može početi propisivati na recept Zavoda, isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. U slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste ovisno o indikaciji u kojoj se lijek primjenjuje, Bolničko povjerenstvo za lijekove može izdati odobrenje za nastavak primjene lijeka – drugo odobrenje Bolničko povjerenstvo za lijekove može dati za razdoblje od 6 mjeseci, a svako sljedeće odobrenje Bolničkog povjerenstva za lijekove se može izdati za razdoblje od najviše 12 mjeseci. |
| RL103 | Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste, prema kriterijima navedenim u tekstu indikacije (NL449). Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna, a tek se nakon isteka tog perioda može početi propisivati na recept Zavoda, isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. U slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste ovisno o indikaciji u kojoj se lijek primjenjuje, Bolničko povjerenstvo za lijekove može izdati odobrenje za nastavak primjene lijeka – drugo odobrenje Bolničko povjerenstvo za lijekove može dati za razdoblje od 6 mjeseci, a svako sljedeće odobrenje Bolničkog povjerenstva za lijekove se može izdati za razdoblje od najviše 12 mjeseci. |
| RL104 | Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste, prema kriterijima navedenim u tekstu indikacije (NL500). Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna, a tek se nakon isteka tog perioda može početi propisivati na recept Zavoda, isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. U slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste ovisno o indikaciji u kojoj se lijek primjenjuje, Bolničko povjerenstvo za lijekove može izdati odobrenje za nastavak primjene lijeka – drugo odobrenje Bolničko povjerenstvo za lijekove može dati za razdoblje od 6 mjeseci, a svako sljedeće odobrenje Bolničkog povjerenstva za lijekove se može izdati za razdoblje od najviše 12 mjeseci. |
| RL105 | 1. Za liječenje reumatoidnog artritisa i aktivnog psorijatičnog artritisa, prema kriterijima navedenim u tekstu indikacije NL 506, po preporuci specijalista reumatologa/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda, 2. Za liječenje umjerenog do teškog oblika ulceroznog kolitisa, prema kriterijima navedenim u tekstu indikacije NL 506, po preporuci specijalista gastroenterologa iz ugovorne zdravstvene ustanove Zavoda. |
| RL106 | Za liječenje umjerenog do teškog oblika ulceroznog kolitisa, prema kriterijima navedenim u tekstu indikacije NL 507, po preporuci specijalista gastroenterologa iz ugovorne zdravstvene ustanove Zavoda. |
| RL107 | 1. Za liječenje umjerenog do teškog oblika aktivnog reumatoidnog artritisa, aktivnog psorijatičnog artritisa i aktivnog ankilozantnog spondilitisa, prema kriterijima navedenim u tekstu indikacije NL 512, po preporuci specijalista reumatologa/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. 2. Za liječenje teškog atopijskog dermatitisa, prema kriterijima navedenim u tekstu indikacije NL 512, po preporuci specijalista dermatovenerologa iz ugovorne zdravstvene ustanove Zavoda. |
| RL109 | Za liječenje reumatoidnog artritisa, prema kriterijima navedenim u tekstu indikacije NL509, po preporuci specijalista reumatologa/kliničkog imunologa iz ugovorne zdravstvene ustanove Zavoda. |
| RL110 | Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste, prema kriterijima navedenim u tekstu indikacije NL522. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek se do 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna (prije početka primjene lijeka supkutanim oblikom, a sve sukladno odobrenom sažetku opisa svojstava lijeka, primjenjuju se najmanje 2 doze intravenskim putem, a dalje svaka 2 tjedna se lijek primjenjuje supkutanim putem), a tek se nakon isteka tog perioda može početi propisivati na recept Zavoda, isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. U slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste ovisno o indikaciji u kojoj se lijek primjenjuje, Bolničko povjerenstvo za lijekove može izdati odobrenje za nastavak primjene lijeka – drugo odobrenje Bolničko povjerenstvo za lijekove može dati za razdoblje od 6 mjeseci, a svako sljedeće odobrenje Bolničkog povjerenstva za lijekove se može izdati za razdoblje od najviše 12 mjeseci. |
| RL111 | Prva linija liječenja bolesnika s relapsno-remitirajućom multiplom sklerozom (RRMS) s visokim rizikom od napredovanja neurološke onesposobljenosti kod postavljanja dijagnoze RRMS-e. Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijalista neurologa, prema kriterijima navedenim u tekstu indikacije »NL534«. Prvo odobrenje Bolničkog povjerenstva za lijekove izdaje se za razdoblje od 6 mjeseci od kojih se prvih mjesec dana lijek primjenjuje na teret sredstva bolničkog proračuna, a u nastavku se za preostalih 5 odobrenih mjeseci liječenja lijek može propisivati na recept Zavoda. Svako sljedeće odobrenje za nastavak liječenja, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijalista neurologa, Bolničko povjerenstvo za lijekove može izdati za razdoblje od najviše 12 mjeseci. Lijek se može propisivati na recept Zavoda isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. Lijek se, nakon početnog doziranja koje tereti bolnički proračun primjenjuje jedanput mjesečno. Za razdoblje od 12 mjeseci liječenja može se propisati najviše 12 pakiranja lijeka. |
| RL112 | Za liječenje teškog atopijskog dermatitisa, prema kriterijima navedenim u tekstu indikacije NL 535, po preporuci specijalista dermatovenerologa iz ugovorne zdravstvene ustanove Zavoda. |
| RL113 | Početak liječenja odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste, prema kriterijima navedenim u tekstu indikacije NL536. Temeljem prvog odobrenja Bolničkog povjerenstva za lijekove, lijek Remsima (i.v. ili s.c.) se prva 4 mjeseca primjenjuje na teret sredstava bolničkog proračuna, a tek se nakon isteka tog perioda može početi propisivati na recept Zavoda, isključivo temeljem važećeg odobrenja Bolničkog povjerenstva za lijekove. U slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste ovisno o indikaciji u kojoj se lijek primjenjuje, Bolničko povjerenstvo za lijekove može izdati odobrenje za nastavak primjene lijeka – drugo odobrenje Bolničko povjerenstvo za lijekove može dati za razdoblje od 6 mjeseci, a svako sljedeće odobrenje Bolničkog povjerenstva za lijekove se može izdati za razdoblje od najviše 12 mjeseci. |
| RL114 | Lijek je indiciran za primjenu u 1. liniji liječenja kod bolesnika s relapsno-remitirajućom multiplom sklerozom. Liječenje odobrava Bolničko povjerenstvo za lijekove po preporuci bolničkog specijaliste neurologa, prema kriterijima navedenim u tekstu indikacije »NL538«. Prvo odobrenje za primjenu lijeka izdaje se za razdoblje od 6 mjeseci, a svako sljedeće odobrenje za nastavak liječenja, u slučaju dokumentiranog pozitivnog odgovora na primjenu lijeka i na preporuku bolničkog specijaliste neurologa, Bolničko povjerenstvo za lijekove može izdati za razdoblje od najviše 12 mjeseci. Lijek se može propisivati na recept Zavoda samo temeljem odobrenja Bolničkog povjerenstva za lijekove za razdoblje na koje je odobren. |
| RM01 | Po preporuci specijalista onkologa ili hematologa. |
| RM02 | 1. U bolesnika nakon osteoporotične frakture, 2. Za liječenje osteoporoze (DXA T vrijednosti u L1-4 <= – 2,5 ili <= od -2,5 u Total/Neck), po preporuci specijalista internista, fizijatra, ortopeda ili ginekologa. |
| RM03 | Samo po preporuci specijalista neurologa. |
| RM04 | Za liječenje žena u postmenopauzi sa multiplim osteoporotičnim frakturama i za liječenje muškaraca sa multiplim osteoporotičnim frakturama, po preporuci specijalista internista ili fizijatra. Liječenje prvih šest mjeseci tereti sredstva bolničkog proračuna, a u nastavku liječenja lijek se izdaje na ruke liječnika. |
| RN01 | Samo za titriranje doze opijata. |
| RN02 | Samo za liječenje boli kod bolesnika s malignom bolesti. |
| RN03 | Za liječenje migrene, po preporuci specijalista neurologa. |
| RN04 | Druga ili kasnija linija liječenja epilepsije, po preporuci specijaliste neurologa ili psihijatra. |
| RN06 | Samo za shizofrene i bolesnike s psihotičnim poremećajima, po preporuci specijalista psihijatra. |
| RN08 | Samo za poboljšanje terapijske suradljivosti u shizofenih bolesnika, nakon prethodne terapije s oralnim olanzapinom, po preporuci specijalista psihijatra, a izdaje se na ruke liječnika. |
| RN09 | Samo za shizofrene i bolesnike s psihotičnim poremećajima i poremećajima raspoloženja, po preporuci specijalista psihijatra. |
| RN10 | Samo za poboljšanje terapijske suradljivosti u shizofenih bolesnika, nakon prethodne terapije s oralnim risperidonom, po preporuci specijalista psihijatra, a izdaje se na ruke liječnika. |
| RN11 | Samo za poboljšanje terapijske suradljivosti u shizofrenih bolesnika, nakon prethodne terapije s oralnim risperidonom ili paliperidonom, po preporuci specijalista psihijatra, a izdaje se na ruke liječnika. |
| RN13 | Za primjenu u farmakoterapiji opijatskih ovisnika na preporuku ovlaštenih specijalista psihijatrije ili ovlaštenog liječnika službe za prevenciju i liječenje ovisnosti Zavoda za javno zdravstvo, a izdaje se na recept, na ruke pacijenta u količini dostatnoj za 7 dana terapije. |
| RN14 | 1. Za liječenje kronične boli u terminalnih bolesnika, 2. Za primjenu u farmakoterapiji opijatskih ovisnika na preporuku ovlaštenih specijalista psihijatrije ili ovlaštenog liječnika službe za prevenciju i liječenje ovisnosti Zavoda za javno zdravstvo, a izdaje se na ruke liječnika. |
| RN15 | Za liječenje epilepsije, po preporuci specijaliste neurologa ili pedijatra. |
| RN16 | Za liječenje bolesnika u postherpetičnoj neuralgiji. |
| RN17 | Samo za poboljšanje terapijske suradljivosti u shizofenih bolesnika, nakon prethodne terapije s oralnim aripiprazolom, po preporuci specijalista psihijatra, a izdaje se na ruke liječnika. |
| RN18 | Za liječenje velikih depresivnih epizoda i generaliziranog anksioznog poremećaja. |
| RN20 | 3-mjesečna injekcija, za terapiju održavanja u liječenju shizofrenije kod odraslih bolesnika koji su klinički stabilni na paliperidonpalmitatu u obliku 1-mjesečne injekcije, po preporuci specijalista psihijatra, a izdaje se na ruke liječnika. |
| RN21 | Za liječenje prekomjerne pospanosti u odraslih udružene s narkolepsijom sa ili bez katapleksije, po preporuci specijalista neurologa ili psihijatra s Klinike. |
| RN22 | 1. Za liječenje epilepsije, po preporuci specijalista neurologa ili pedijatra, 2. Za bipolarni afektivni poremećaj u bolesnika kod kojih su dominantne depresivne epizode, po preporuci specijalista psihijatra. |
| RN23 | Samo za bolesnike s epilepsijom refrakternom na druge antiepileptike (N03AA, N03AB, N03AD, N03AE, N03AF i N03AG), po preporuci specijalista neurologa ili pedijatra. |
| RN25 | Za bolesnike s amiotrofičnom lateralnom sklerozom. Lijek se može propisivati na recept Zavoda samo temeljem odobrenja Bolničkog povjerenstva za lijekove za razdoblje na koje je odobren, a nakon što je liječenje započeto u bolnici. |
| RN26 | Treća linija liječenja epilepsije, kod liječenja žarišnih napada sa ili bez sekundarne generalizacije kod bolesnika s epilepsijom starijih od 4 godine, po preporuci specijalista neurologa ili pedijatra. |
| RN27 | Za liječenje poremećaja hiperaktivnosti i deficita pažnje (ADHD) u djece i odraslih koji su započeli s primjenom lijeka u dobi između 6 i 18 godina, nakon pokušaja liječenja koji uključuje nefarmakološke mjere (poput savjetovanja ili bihevioralnog liječenja). Bolesnici moraju imati 6 ili više simptoma iz područja nepažnje i/ili hiperaktivnosti i impulzivnosti sukladno DSM-V kriterijima, tijekom posljednjih 6 mjeseci te moraju uzrokovati probleme u funkcioniranju na barem dva polja (škola, rekreacija, posao, obitelj i dr.). Terapija se odobrava na inicijalni period od 3 mjeseca, nakon kojeg se vrši procjena učinkovitosti. Nastavak liječenja odobrava se u bolesnika s poboljšanjem simptoma u domenama hiperaktivnosti/impulzivnosti ili nepažnje. Po preporuci specijalista dječje i adolescentne psihijatrije, specijalista psihijatra ili pedijatra s užom subspecijalizacijom iz neuropedijatrije, a nakon isključenja psihijatrijskih te cerebrovaskularnih i kardiovaskularnih rizika. |
| RN28 | Za liječenje poremećaja hiperaktivnosti i deficita pažnje (ADHD) u djece dobi 6 godina i više, u adolescenata te u odraslih, nakon pokušaja liječenja koji uključuje nefarmakološke mjere (poput savjetovanja ili bihevioralnog liječenja) te primjene metilfenidata, osim u posebnim skupinama bolesnika kod kojih atomoksetin ima prednost, poput bolesnika s tikovima, Touretteovim sindromom, epilepsijom, bipolarno afektivnim poremećajem, anskioznošću ili kada postoji opasnost od zlouporabe stimulansa te u odraslih bolesnika. Bolesnici moraju imati 6 ili više simptoma iz područja nepažnje i/ili hiperaktivnosti i impulzivnosti sukladno DSM-V kriterijima, tijekom posljednjih 6 mjeseci te moraju uzrokovati probleme u funkcioniranju na barem dva polja (škola, rekreacija, posao, obitelj i dr.). Terapija se odobrava na inicijalni period od 3 mjeseca, nakon kojeg se vrši procjena učinkovitosti. Nastavak liječenja odobrava se u bolesnika s poboljšanjem simptoma u domenama hiperaktivnosti/impulzivnosti ili nepažnje. Po preporuci specijalista dječje i adolescentne psihijatrije, specijalista psihijatra ili pedijatra s užom subspecijalizacijom iz neuropedijatrije. |
| RN91 | Samo za liječenje alkoholizma (delirantna i predelirantna stanja). |
| RR02 | 1. Za liječenje bolesnika s astmom kojima je indicirana kombinacija inhalacijskog kortikosteroida i beta 2-agonista dugog djelovanja/bronhodilatatora, 1.a. u bolesnika u kojih astma nije na odgovarajući način kontrolirana monoterapijom inhalatornim kortikosteroidom i po potrebi beta-2-agonistima kratkog djelovanja ili 1.b. u bolesnika koji su već postigli kontrolu astme kombinacijom inhalacijskog kortikosteroida i beta-2-agonista dugog djelovanja, radi održavanja kontrole bolesti. |
| RR03 | 1. Za liječenje bolesnika s astmom kojima je indicirana kombinacija inhalacijskog kortikosteroida i beta 2-agonista dugog djelovanja/bronhodilatatora, 1.a. u bolesnika u kojih astma nije na odgovarajući način kontrolirana monoterapijom inhalatornim kortikosteroidom i po potrebi beta-2-agonistima kratkog djelovanja ili 1.b. u bolesnika koji su već postigli kontrolu astme kombinacijom inhalacijskog kortikosteroida i beta-2-agonista dugog djelovanja, radi održavanja kontrole bolesti. 2. Za liječenje bolesnika s kroničnom opstruktivnom plućnom bolesti (KOPB) s FEV1<60% i učestalim egzacerbacijama bolesti unatoč terapiji bronhodilatatorima. |
| RR05 | 1. Za liječenje bolesnika s astmom kojima je indicirana kombinacija inhalacijskog kortikosteroida i beta 2-agonista dugog djelovanja/bronhodilatatora, 1.a. u bolesnika u kojih astma nije na odgovarajući način kontrolirana monoterapijom inhalatornim kortikosteroidom i po potrebi beta-2-agonistima kratkog djelovanja ili 1.b. u bolesnika koji su već postigli kontrolu astme kombinacijom inhalacijskog kortikosteroida i beta-2-agonista dugog djelovanja, radi održavanja kontrole bolesti. 2. Za liječenje bolesnika s kroničnom opstruktivnom plućnom bolesti (KOPB) s FEV1<50% i učestalim egzacerbacijama bolesti unatoč terapiji bronhodilatatorima. |
| RR07 | Samo za djecu do navršenih 6 godina života. |
| RR08 | Kao dodatna terapija inhalacijskim kortikosteroidima ili beta-2 agonistima u blagoj ili umjereno teškoj astmi, aspirinskoj astmi i naporom uzrokovanoj astmi, 4 mg tablete za žvakanje za djecu u dobi od 2 do 5 godina, 5 mg tablete za žvakanje za djecu u dobi od 6 do 14 godina, 10 mg tableta ili 10 mg filmom obložena tableta za odrasle bolesnike i adolescente u dobi od 15 godina nadalje. |
| RR09 | Kao dodatna terapija inhalacijskim kortikosteroidima ili beta-2 agonistima u blagoj ili umjereno teškoj astmi, aspirinskoj astmi i naporom uzrokovanoj astmi, za djecu od 6 mjeseci do 5 godina, po preporuci specijalista pedijatra. |
| RR10 | Za liječenje odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (KOPB), koji imaju forsirani ekspiracijski volumen u prvoj sekundi FEV1<60% od predviđene normale (nakon primjene bronhodilatatora) i anamnezom egzacerbacija bolesti unatoč redovitoj terapiji bronhodilatatorima. |
| RR11 | Za liječenje bolesnika s kroničnom opstruktivnom plućnom bolešću (KOPB) s FEV1<60% i učestalim egzacerbacijama, koji nisu odgovarajuće liječeni kombinacijom inhalacijskog kortikosteroida i dugodjelujućeg beta-2 agonista. |
| RR12 | 1. Za liječenje bolesnika s kroničnom opstruktivnom plućnom bolešću (KOPB) s FEV1<60% i učestalim egzacerbacijama, koji nisu odgovarajuće liječeni kombinacijom inhalacijskog kortikosteroida i dugodjelujućeg beta-2 agonista.  2. Terapija održavanja u odraslih s astmom koja nije odgovarajuće kontrolirana kombiniranom terapijom  održavanja dugodjelujućim beta-2 agonistom i srednjom dozom inhalacijskog kortikosteroida i koji su  u prethodnih godinu dana imali jednu ili više egzacerbacija astme. |
| RR51 | Umjereno jaka bol kod malignih bolesti u kombinaciji sa blagim analgeticima, supresija podražajnog kašlja kod zloćudnih bolesti dišnih organa po preporuci specijalista. |
| RS02 | Samo za najteži oblik suhog oka. |
| RS03 | 1. Druga linija liječenja – Za slučajeve refrakterne na uobičajenu antiglaukomsku terapiju, po preporuci specijalista oftalmologa. Nije opravdano mijenjati terapiju beta blokatora kada se postigao ciljni očni tlak te zaustavilo napredovanje bolesti (stabilno vidno polje) kod primarnog glaukoma otvorenog kuta i okularne hipertenzije. 2. Prva linija liječenja isključivo za – a) primarni glaukom otvorenog kuta s početnom vrijednosti očnog tlaka > = od 30 mm Hg izmjerenog Goldmannovom aplanacijskom metodom, b) hitnog stanja, kao što je akutno stanje glaukoma zatvorenog kuta, c) sekundarni refraktorni glaukomi, d) pacijenti kod kojih su beta blokatori kontraindicirani zbog komorbiditetnih kardiorespiratornih bolesti, e) uznapredovali stadij glaukoma (oštećenje vidnog polja i/ili živčanih niti vidnog živca) u trenutku postavljanja dijagnoze zbog postizanja nižeg ciljnog tlaka. |
| RV01 | Regulacija/sniženje hiperfosfatemije u bolesnika s uremijskim sindromom koji su liječeni dijalizom (hemodijaliza i peritonejska dijaliza), u kojih se i drugim mjerama, koje uključuju dijetu siromašnu fosfatima, dijalizu pomoću otopine s niskom koncentracijom kalcija (1,25 mmol/L) i maksimalno moguću primjenu vezača s kalcijem (kalcijev karbonat), nije postigla zadovoljavajuća razina fosfata u serumu (umnožak kalcija i fosfata veći od 4,4 mmol2/L2), ili u slučaju dokazanih izvankoštanih kalcifikacija, po preporuci specijalista internista nefrologa. |
| RV02 | Po preporuci bolničkog specijalista pedijatra ili internista u bolnici. |
| RV03 | Po preporuci bolničkog specijalista. |
| RV12 | Za liječenje hiperfosfatemije povezane s kroničnom bubrežnom insuficijencijom, u bolesnika na dijalizi (hemodijalizi, peritonejskoj dijalizi) po preporuci bolničkog specijalista. |
| RV17 | Izdaje se na recept Zavoda po preporuci bolničkog specijalista za potrebe liječenja fenilketonurije. |
| RV18 | Za dijetalnu prehranu djece u dobi od 6 mjeseci do 5 godina, po preporuci bolničkog specijalista pedijatra ili internista u bolnici. |
| RV19 | Za dijetalnu prehranu djece u dobi od 1 do 10 godina, po preporuci bolničkog specijalista pedijatra ili internista u bolnici. |
| RV20 | Za dijetalnu prehranu dojenčadi oboljelih od fenilketonurije, po preporuci bolničkog specijalista pedijatra ili internista. |
| RV21 | Za dijetalnu prehranu djece iznad 1 godine starosti oboljelih od fenilketonurije, po preporuci bolničkog specijalista pedijatra ili internista. |
| RV22 | Za dijetalnu prehranu djece iznad 8 godina, adolescenata i odraslih oboljelih od fenilketonurije, po preporuci bolničkog specijalista pedijatra ili internista. |
| RV24 | Regulacija/sniženje hiperfosfatemije u bolesnika na dijalizi kod kojih prethodno liječenje sevelamerom nije dalo željene rezultate nakon najmanje 3 mjeseca primjene ili u bolesnika koji sevelamer ne podnose, po preporuci specijalista internista nefrologa. |
| RV25 | Za bolesnike s preopterećenjem željezom koje zbog anemije nije moguće liječiti venepunkcijama kada razina serumskog feritina iznosi više od 1000 mikrograma/L te u bolesnika ovisnih o transfuzijama eritrocita za koje se očekuje da će primati 2 ili više doza eritrocita mjesečno tijekom najmanje 1 godine. Liječenje treba prekinuti kada razina serumskog feritina padne ispod 1000 mikrograma/L i više nije potrebno liječenje transfuzijama eritrocita ili ako feritin padne ispod 500 mikrograma/L neovisno o tome hoće li se bolesnik u budućnosti transfuzijski liječiti. Po preporuci specijalista hematologa. |
| RV28 | Za dijetalnu prehranu djece u dobi od 6 mjeseci do 10 godina, po preporuci bolničkog specijalista pedijatra ili internista u bolnici. |
| RZ01 | U slučaju kućnog liječenja i zdravstvene njege u kući osigurane osobe, doktor primarne zdravstvene zaštite može na jedan recept propisati zavojni materijal najviše za potrebe liječenja do 7 dana. |
| VO01a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna hiperkalorijska (1,25 kcal/ml) enteralna prehrana s vlaknima. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. |
| VO01b | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna izokalorijska enteralna prehrana bez vlakana. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. Isključivo za primjenu putem enteralne sonde. |
| VO02b | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna izokalorijska enteralna prehrana s vlaknima. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. Isključivo za primjenu putem enteralne sonde. |
| VO03a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna hiperkalorijska (1,5 kcal/ml) enteralna prehrana bez vlakana. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. |
| VO03b | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna hiperkalorijska (1,5 kcal/ml) enteralna prehrana bez vlakana. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. Isključivo za primjenu putem enteralne sonde. |
| VO04a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna hiperkalorijska (1,5 kcal/ml) enteralna prehrana s vlaknima. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. |
| VO04b | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna hiperkalorijska (1,5 kcal/ml) enteralna prehrana s vlaknima. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. Isključivo za primjenu putem enteralne sonde. |
| VO05a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna enteralna prehrana bez vlakana s 2,0 kcal/ml. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. |
| VO05b | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna enteralna prehrana bez vlakana s 2,0 kcal/ml. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. Isključivo za primjenu putem enteralne sonde. |
| VO06a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna enteralna prehrana s vlaknima s 2,0 kcal/ml. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. |
| VO06b | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kojima je potrebna enteralna prehrana s vlaknima s 2,0 kcal/ml. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. Isključivo za primjenu putem enteralne sonde. |
| VO07a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s pothranjenošću kod kojih je zbog bolesti došlo do nenamjernog gubitka tjelesne težine većeg od 5% u mjesec dana ili većeg od 10% u tri mjeseca ili koji zbog bolesti normalnim putem ne mogu zadovoljiti energetske i nutritivne potrebe, a kod kojih je indiciran unos energije i proteina u malom volumenu, odnosno kojima je potrebna enteralna prehrana bez vlakana koja sadrži cjeloviti dnevni unos makro i mikronutrijenata u smanjenom volumenu. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje izabrani doktor medicine koji je obvezan svaka 3 mjeseca procijeniti učinak i potrebu za nastavkom njene primjene te navedeno upisati u osobni zdravstveni karton bolesnika. |
| VP02 | Elementarne se formule mogu primjenjivati za dijetalnu prehranu dojenčadi i male djece (do 3 godine starosti) – 1. kao primarno nutritivno liječenje teških oblika alergije na bjelančevine kravljeg mlijeka koje su zahtijevale bolničko liječenje, kao što su eozinofilni ezofagitis, anafilaksija, životno ugrožavajuća alergijska reakcija, protein gubeća enteropatija, teški malapsorpcijski sindrom. 2. kao druga linija nutritivnog liječenja kada semielementarni mliječni pripravak nije bio terapijski uspješan, u sljedećim indikacijama – alergija na bjelančevine kravljeg mlijeka, teške multiple nutritivne alergije, teški malapsorpcijski sindrom. Za prvu i drugu liniju liječenja potrebna je preporuka specijalista pedijatra ili dermatologa iz ugovorne bolničke ustanove. Vremensko ograničenje preporuke je 6 mjeseci. |
| VP03 | Semielementarne formule bez laktoze mogu se primjenjivati za dijetalnu prehranu kod dojenčadi (0-12 mjeseci, sve namirnice) i kod male djece (1-3 godine, sve namirnice, osim namirnice Aptamil Pregomin Allergy Digestive Care) kod alergija na bjelančevine kravljeg mlijeka i kod malapsorpcijskog sindroma (kronični dojenački proljev). Potrebna je preporuka specijalista pedijatra ili dermatologa iz ugovorne bolničke ustanove. Vremensko ograničenje preporuke je 6 mjeseci. Iznimno, s primjenom ove namirnice može započeti i liječnik specijalist iz primarne zdravstvene zaštite u svrhu provođenja eliminacijskog dijagnostičkog testa kod dojenčadi, s time da trajanje takve primjene namirnice ne smije biti dulje od 4 tjedna. |
| VP05 | Semielementarne formule s laktozom mogu se primjenjivati za dijetalnu prehranu kod dojenčadi (0-12 mjeseci) i kod male djece (1-3 godine) kod alergije na bjelančevine kravljeg mlijeka. Potrebna je preporuka specijalista pedijatra ili dermatologa iz ugovorne bolničke ustanove. Vremensko ograničenje preporuke je 6 mjeseci. Iznimno, s primjenom ove namirnice može započeti i liječnik specijalist iz primarne zdravstvene zaštite u svrhu provođenja eliminacijskog dijagnostičkog testa kod dojenčadi, s time da trajanje takve primjene namirnice ne smije biti dulje od 4 tjedna. |
| VP08 | Elementarne se formule mogu primjenjivati za dijetalnu prehranu djece starije od 1 godine – 1. kao primarno nutritivno liječenje teških oblika alergije na bjelančevine kravljeg mlijeka koje su zahtijevale bolničko liječenje, kao što su eozinofilni ezofagitis, anafilaksija, životno ugrožavajuća alergijska reakcija, protein gubeća enteropatija, teški malapsorpcijski sindrom. 2. kao druga linija nutritivnog liječenja kada semielementarni mliječni pripravak nije bio terapijski uspješan, u sljedećim indikacijama – alergija na bjelančevine kravljeg mlijeka, teške multiple nutritivne alergije, teški malapsorpcijski sindrom. Za prvu i drugu liniju liječenja potrebna je preporuka specijalista pedijatra ili dermatologa iz ugovorne bolničke ustanove. Vremensko ograničenje preporuke je 6 mjeseci. |
| VP09 | Za liječenje dojenčadi od rođenja do 18 mjeseci (ili do 9 kg tjelesne mase) koja normalnom prehranom i/ili peroralnim unosom ne mogu zadovoljiti ili nadoknaditi energetske i nutritivne potrebe. Po preporuci specijalista pedijatra iz ugovorne bolničke ustanove. Vremensko ograničenje preporuke je 6 mjeseci. |
| VP10 | Za djecu stariju od 1 godine koja normalnom prehranom i/ili peroralnim unosom ne mogu zadovoljiti ili nadoknaditi energetske i nutritivne potrebe, u liječenju Crohnove bolesti i kao potpora prehrani prije ili nakon operativnih zahvata. Po preporuci specijalista pedijatra iz ugovorne bolničke ustanove. Vremensko ograničenje preporuke je 6 mjeseci. |
| VP11 | Za djecu stariju od 1 godine s povećanim energijskim potrebama i/ili ograničenim unosom ili ograničenim volumenom tekućine kod koje se normalnom prehranom i/ili peroralnim unosom ne mogu zadovoljiti ili nadoknaditi energetske i nutritivne potrebe, kao pripravak za enteralnu prehranu u liječenju Crohnove bolesti i kao potpora prehrani prije ili nakon operativnih zahvata. Po preporuci specijalista pedijatra iz ugovorne bolničke ustanove. Vremensko ograničenje preporuke je 6 mjeseci. |
| VP12 | Za djecu stariju od 1 godine za primjenu preko sonde ili peroralno u sljedećim indikacijama – – malapsorpcijski sindrom – za pedijatrijske bolesnike u kojih je poželjno unošenje dijela masnoća u formi srednjelančanih triglicerida (MCT) – Crohnova bolest. Po preporuci specijalista pedijatra iz ugovorne bolničke ustanove. Vremensko ograničenje preporuke je 6 mjeseci. |
| VS01a | Namirnica za enteralnu primjenu namijenjena je za liječenje onkoloških bolesnika s tumorskom kaheksijom u kojih je indicirana primjena EPA (eikozapentaenske kiseline) u učinkovitoj dozi od 2g/dan. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist koji sudjeluje u onkološkom liječenju iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene utvrđuje specijalist koji sudjeluje u onkološkom liječenju iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS01b | Namirnica za enteralnu primjenu namijenjena je za liječenje onkoloških bolesnika s tumorskom kaheksijom u kojih je indicirana primjena EPA (eikozapentaenske kiseline) u učinkovitoj dozi od 2g/dan. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist koji sudjeluje u onkološkom liječenju iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene utvrđuje specijalist koji sudjeluje u onkološkom liječenju iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. Isključivo za primjenu putem enteralne sonde. |
| VS02b | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika u kritičnom stanju s ograničenom tolerancijom enteralnog volumena i velikom potrebom za glutaminom i antioksidansima. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene duljem od 3 mjeseca utvrđuje specijalist iz ugovorne bolničke zdravstvene ustanove. Isključivo za primjenu putem enteralne sonde. |
| VS03b | Namirnica za enteralnu primjenu namijenjena je za prehranu bolesnika s povećanim rizikom od infekcija u postoperativnim i posttraumatskim stanjima. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene duljem od 3 mjeseca utvrđuje specijalist iz ugovorne bolničke zdravstvene ustanove. Isključivo za primjenu putem enteralne sonde. |
| VS04a | Kao hrana za posebne medicinske potrebe za liječenje bolesnika s gubitkom mase, snage i funkcije mišića kod kojih se normalnim putem ne mogu zadovoljiti energetske i nutritivne dnevne potrebe te je potrebno postići anabolički učinak primjenom specifičnih farmakonutrijenata, a po preporuci specijalista iz ugovorne bolničke zdravstvene ustanove kada na osnovu medicinske dokumentacije ustanovi potrebu za enteralnom nutritivnom potporom. Za pokretne bolesnike potrebno je provesti procjenu funkcionalne sposobnosti bolesnika korištenjem jednostavnih validiranih testova (test brzine hoda ili test ustajanja sa stolca ili SARC-F upitnik) te propisati nutritivnu potporu ako rezultati ukazuju na smanjenu funkcionalnu sposobnost. Za nepokretne bolesnike dovoljna je klinička procjena. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan u nalazu jasno utvrditi medicinske razloge (ovisno o tome radi li se o pokretnom ili nepokretnom bolesniku) zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore . Potrebu za nastavkom primjene utvrđuje specijalist iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS04b | Kao hrana za posebne medicinske potrebe za liječenje bolesnika s gubitkom mase, snage i funkcije mišića kod kojih se normalnim putem ne mogu zadovoljiti energetske i nutritivne dnevne potrebe te je potrebno postići anabolički učinak primjenom specifičnih farmakonutrijenata, a po preporuci specijalista iz ugovorne bolničke zdravstvene ustanove kada na osnovu medicinske dokumentacije ustanovi potrebu za enteralnom nutritivnom potporom. Za pokretne bolesnike potrebno je provesti procjenu funkcionalne sposobnosti bolesnika korištenjem jednostavnih validiranih testova (test brzine hoda ili test ustajanja sa stolca ili SARC-F upitnik) te propisati nutritivnu potporu ako rezultati ukazuju na smanjenu funkcionalnu sposobnost. Za nepokretne bolesnike dovoljna je klinička procjena. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan u nalazu jasno utvrditi medicinske razloge (ovisno o tome radi li se o pokretnom ili nepokretnom bolesniku) zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore . Potrebu za nastavkom primjene utvrđuje specijalist iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. Isključivo za primjenu putem enteralne sonde. |
| VS05a | Namirnica za enteralnu primjenu namijenjena je za nadopunu dijetalnoj prehrani kod bolesnika s proteinsko-energetskom malnutricijom uz NRS 2002 3 ili više, a koji imaju kronične rane različite etiologije. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist koji sudjeluje u liječenju kroničnih rana iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan u nalazu jasno klinički opisati kroničnu ranu ili dekubitalni ulkus. Za nastavak propisivanja na recept Zavoda mora postojati dokumentirani nalaz tijeka cijeljenja rane. Potrebu za nastavkom primjene duljem od 3 mjeseca utvrđuje specijalist koji sudjeluje u liječenju kroničnih rana iz ugovorne bolničke zdravstvene ustanove. |
| VS05b | Namirnica za enteralnu primjenu namijenjena je za nadopunu dijetalnoj prehrani kod bolesnika s proteinsko-energetskom malnutricijom uz NRS 2002 3 ili više, a koji imaju kronične rane različite etiologije. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist koji sudjeluje u liječenju kroničnih rana iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan u nalazu jasno klinički opisati kroničnu ranu ili dekubitalni ulkus. Za nastavak propisivanja na recept Zavoda mora postojati dokumentirani nalaz tijeka cijeljena rane. Potrebu za nastavkom primjene duljem od 3 mjeseca utvrđuje bolnički specijalist koji sudjeluje u liječenju kroničnih rana iz ugovorne bolničke zdravstvene ustanove. Isključivo za primjenu putem enteralne sonde. |
| VS06a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s kroničnim zatajenjem jetre kod kojih se normalnim putem ne mogu zadovoljiti energetske i nutritivne dnevne potrebe kada se na osnovu medicinske dokumentacije ustanovi potreba za enteralnom nutritivnom potporom (primjerice, kod bolesnika s nenamjernim gubitkom tjelesne težine većim od 5% u mjesec dana ili većim od 10% u tri mjeseca). Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist gastroenterolog iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje specijalist gastroenterolog iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS07a | Namirnica za enteralnu primjenu namijenjena je za liječenje proteinsko-energetske pothranjenosti u bolesnika s renalnom insuficijencijom (KBB stadij 3-5) koji nisu na dijalizi i koji normalnom prehranom ne mogu unijeti zadovoljavajuću preporučenu količinu proteina i energije. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist nefrolog i/ili urolog i/ili endokrinolog iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje specijalist nefrolog i/ili urolog i/ili endokrinolog iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS08a | Namirnica za enteralnu primjenu namijenjena je za liječenje proteinsko-energetske pothranjenosti u bolesnika s renalnom insuficijencijom koji su na dijalizi i koji normalnom prehranom ne mogu unijeti zadovoljavajuću preporučenu količinu proteina i energije. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist nefrolog i/ili urolog i/ili endokrinolog iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje specijalist nefrolog i/ili urolog i/ili endokrinolog iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS09a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s malapsorpcijskim sindromom, teškim oblicima Crohnove bolesti, sindromom kratkog crijeva, teškom insuficijencijom funkcije gušterače i jetre, enteropatijama te svim oblicima zatajenja crijevne funkcije, a kod kojih se normalnim putem ne mogu zadovoljiti energetske i nutritivne dnevne potrebe. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati bolnički specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje bolnički specijalist iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS09b | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s malapsorpcijskim sindromom, teškim oblicima Crohnove bolesti, sindromom kratkog crijeva, teškom insuficijencijom funkcije gušterače i jetre, enteropatijama te svim oblicima zatajenja crijevne funkcije, a kod kojih se normalnim putem ne mogu zadovoljiti energetske i nutritivne dnevne potrebe. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati bolnički specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje bolnički specijalist iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. Isključivo za primjenu putem enteralne sonde. |
| VS10a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s upalnim bolestima crijeva kod kojih se normalnim putem ne mogu zadovoljiti energetske i nutritivne dnevne potrebe. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist gastroenterolog iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje specijalist gastroenterolog iz ugovorne bolničke zdravstvene ustanove, koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS11a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s teškom kroničnom respiracijskom insuficijencijom kod kojih se normalnim putem ne mogu zadovoljiti energetske i nutritivne dnevne potrebe i kojima je potrebna enteralna prehrana s visokim udjelom masti. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist pulmolog iz ugovorne bolničke zdravstvene ustanove koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore (primjerice, nenamjerni gubitak tjelesne težine veći od 5% u mjesec dana ili veći od 10% u tri mjeseca). Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje specijalist pulmolog iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS12a | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s dijabetesom koji uz redovitu terapiju nemaju uredno reguliranu šećernu bolest (HbA1c>7,5%) i kod kojih postoji rizik za razvoj komplikacija, u svrhu poboljšanja glikemijske kontrole, glikiranog hemoglobina i metaboličkih parametara. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist endokrinolog iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje specijalist endokrinolog iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS12b | Namirnica za enteralnu primjenu namijenjena je za liječenje bolesnika s dijabetesom koji uz redovitu terapiju nemaju uredno reguliranu šećernu bolest (HbA1c>7,5%) i kod kojih postoji rizik za razvoj komplikacija, u svrhu poboljšanja glikemijske kontrole, glikiranog hemoglobina i metaboličkih parametara. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist endokrinolog iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje specijalist endokrinolog iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. Isključivo za primjenu putem enteralne sonde. |
| VS13a | Namirnica za enteralnu primjenu namijenjena je za liječenje pothranjenosti bolesnika s dijabetesom kod kojih se normalnim putem zbog bolesti ne mogu zadovoljiti energetske i nutritivne dnevne potrebe. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist endokrinolog iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore (primjerice, nenamjerni gubitak tjelesne težine veći od 5% u mjesec dana ili veći od 10% u tri mjeseca). Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje specijalist endokrinolog iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS13b | Namirnica za enteralnu primjenu namijenjena je za liječenje pothranjenosti bolesnika s dijabetesom kod kojih se normalnim putem zbog bolesti ne mogu zadovoljiti energetske i nutritivne dnevne potrebe. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati specijalist endokrinolog iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika i navođenje tjelesne težine bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore (primjerice, nenamjerni gubitak tjelesne težine veći od 5% u mjesec dana ili veći od 10% u tri mjeseca). Potrebu za nastavkom primjene enteralne nutritivne potpore utvrđuje specijalist endokrinolog iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. Isključivo za primjenu putem enteralne sonde. |
| VS14 | Za ugušćivanje tekućina i hrane kod bolesnika s disfagijom. Za propisivanje na recept Zavoda preporuku za primjenu mora dati bolnički specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom nutritivne potpore. Potrebu za nastavkom primjene utvrđuje bolnički specijalist iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS15 | Namirnica za enteralnu primjenu namijenjena je za bolesnike s disfagijom kojima je indicirana dijeta promijenjene konzistencije. Za propisivanje na recept Zavoda preporuku za primjenu namirnice za enteralnu primjenu mora dati bolnički specijalist iz ugovorne bolničke zdravstvene ustanove, a koji je obvezan, uz status bolesnika, u nalazu jasno utvrditi medicinske razloge zbog kojih postoji potreba za ovom vrstom enteralne nutritivne potpore. Potrebu za nastavkom primjene utvrđuje bolnički specijalist iz ugovorne bolničke zdravstvene ustanove koji je obvezan svakih 6 mjeseci procijeniti učinak i potrebu za nastavkom njene primjene. |
| VS16 | Za bolesnike s celijakijom. |

Osnovna lista magistralnih pripravaka s cijenama u kunama

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Šifra ATK | Naziv pripravka | Cijena u kn za orig. pak. (bez PDV-a) | Stopa PDV-a | R/RS  DS |
| 1. | 2. | 3. |  | 5. |
| A09AB04 101 | Kalii citras 100,0 Natrii citras 100,0 Aqua purificata ad 1000,0 M.D.S. solutio DS. Na usta | 44,88 | 5% | RSRV03 |
| B05BA10 021 | Pedijatrijska parenteralna prehrana (TPN) vrećica 1x250 ml s priborom | 230,87 | 5% | DS |
| B05BA10 022 | Pedijatrijska parenteralna prehrana (TPN) vrećica 1x500 ml s priborom | 206,69 | 5% | DS |
| B05BA10 023 | Pedijatrijska parenteralna prehrana (TPN) vrećica 1x1.000 ml s priborom | 229,25 | 5% | DS |
| B05BA10 024 | Pedijatrijska parenteralna prehrana (TPN) vrećica 1x2.000 ml s priborom | 295,5 | 5% | DS |
| D01AE12 411 | Rp. Acidi salicilici 1,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 10,61 | 5% | R |
| D01AE12 412 | Rp. Acidi salicilici 2,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 10,7 | 5% | R |
| D01AE12 413 | Rp. Acidi salicilici 3,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 10,8 | 5% | R |
| D01AE12 414 | Rp. Acidi salicilici 2,0 Resorcioli 1,0 Aethanoli diluti ad 100,0 M.D.S. solutio | 11,3 | 5% | R |
| D01AE12 415 | Rp. Acidi salicilici 3,0 Resorcini 1,0 Aethanoli diluti ad 100,0 M.D.S. solutio | 11,4 | 5% | R |
| D02AB01 411 | Rp. Zinci oxydi pasta 25 g | 4,53 | 5% | R |
| D02AF01 421 | Rp. Acidi salicilici 0,5 Mentholi 0,2 Phenoli 0,3 Camphorae 0,5 Amigdalae olei 5,0 Zinci oxydi pastae ad 50,0 M.D.S. pasta | 23,53 | 5% | R |
| D02AX01 422 | Rp. Talci Zinci oxydi Glyceroli Aquae purificatae aa ad 100,0 M.D.S. izvana tekući puder bez anestezina | 22,61 | 5% | R |
| D04AA40 423 | Rp. Balsami peruviani 5,0 Vaselini ad 100,0 M.D.S. mast | 25,75 | 5% | R |
| D04AA40 424 | Rp. Balsami peruviani 10,0 Vaselini ad 100,0 M.D.S. mast | 28,65 | 5% | R |
| D04AA40 425 | Rp. Balsami peruviani 15,0 Vaselini ad 100,0 M.D.S. mast | 31,54 | 5% | R |
| D04AA40 426 | Rp. Balsami peruviani 20,0 Vaselini ad 100,0 M.D.S. mast | 34,44 | 5% | R |
| D04AX01 427 | Rp. Aethili aminobenzoatis (Anaesthesini) 5,0 Talci 20,0 Zinci oxydi 20,0 Glyceroli 20,0 Aquae purificatae 15,0 Aethanol. dil. 20,0 M.D.S. izvana tekući puder s anestezinom | 23,86 | 5% | R |
| D06BB04 411 | Rp. Podophylini 20,0 Aethanoli diluti ad 100,0 M.D.S. solutio | 266,96 | 5% | R |
| D06BB04 412 | Rp. Podophylini 5,0 Aethanoli diluti ad 25,0 M.D.S. solutio | 73,32 | 5% | R |
| D08AA01 411 | Rp. Rivanoli solutioae 0,1% (Aethacridini lactatis 0,1%) 300,0 D.S. za obloge | 11,34 | 5% | R |
| D08AA01 412 | Rp. Rivanoli (Aethacridini lactatis) 1,0 Talci Zinci oxydi Glyceroli aa 15,0 Aquae purificatae ad 100,0 M.D.S. mikstura | 24,27 | 5% | R |
| D08AX01 413 | Hydrogenii peroxydi solutio diluta 3% 100 g | 4,68 | 5% | R |
| D08AX08 411 | Aethanolum dilutum (70 vol.%) 200,0 M.D.S. izvana | 7,43 | 5% | RGO01 |
| D10AB02 414 | Rp. Ichtyoli (Ammonii sulfogirodalatis, Girodali) 5,0 Sulfuri praecipitati 2,5 Talci Zinci oxydi Glyceroli aa 15,0 Aquae purificatae ad 100,0 M.D.S. mikstura | 24,92 | 5% | R |
| D10AB02 415 | Rp. Ichtyoli (Ammonii sulfogirodalatis, Girodali) 10,0 Sulfuri praeciptati 5,0 Talci Zinci oxydi Glyceroli aa 15,0 Aquae purificatae ad 100,0 M.D.S. mikstura | 28,07 | 5% | R |
| D10AB02 421 | Rp. Sulfuri pracepitati 5,0 Vaselini ad 100,0 M.D.S. izvana | 23,31 | 5% | R |
| D10AB02 422 | Rp. Sulfuri pracepitati 10, 0 Vaselini ad 100,0 M.D.S. izvana | 23,78 | 5% | R |
| D10AB02 423 | Rp. Sulfuri pracepitati 15,0 Vaselini ad 100,0 M.D.S. izvana | 24,24 | 5% | R |
| D10AB02 424 | Rp. Sulfuri pracepitati 20, 0 Vaselini ad 100,0 M.D.S. izvana | 24,71 | 5% | R |
| D10AB08 425 | Rp. Sulfuri praecipitati Girodali (Ammonii sulfogyrodalatis, Ichtyoli) aa 0,6 Zinci oxydi pastae ad 50,0 M.D.S. pasta | 23,46 | 5% | R |
| D10AD02 426 | Rp. A vitaminae (Retinoli acetetati solutioae oleosae) 1000-10000 i.j./ g Cerae lanae 20, 0 Vaselini ad 100,0 M.D.S. mast | 32,52 | 5% | R |
| D10AF01 421 | Rp. Clindamycini 600 mg Propilenglycoli 10,0 -15,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 13,85 | 5% | R |
| D10AF02 422 | Rp. Erythromycini 2,0 Propilenglycoli 10,0 -15,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 25,4 | 5% | R |
| D11AX03 423 | Rp. Calcii gluconatis 2,0 Talci 40,0 Olivae olei ad 100,0 M.D.S. mikstura | 26,82 | 5% | R |
| M05BB02 311 | Rp. Natrii phosphati monobasicae 54,7 Natrii phosphati dibasicae anhydricae 9,4 M.f. pulvis Divide in doses aequales No L (quinquaginta) D.S. 4x1 prašak | 56,38 | 5% | R |
| P03AC04 411 | Permethrin 2,5 Simulgel (Carbopol 940) 47,45 Pulvis conservans ad 50,0 M.D.S. gel | 46,33 | 5% | R |
| P03AC04 412 | Permethrin 0,5 Simulgel (Carbopol 940) 49,45 Pulvis conservans ad 50,0 M.D.S. gel | 36,04 | 5% | R |
| P03AX01 411 | Rp. Lanacoli 7,5 g Polysorbatum 80 7,5 g Benzyli benzoatis 37,5 g Aquae purificatae ad 150,0 g M.D.S. izvana | 37,51 | 5% | R |
| R01AA03 711 | Ephedrini rhinoguttae 0,25% 10 g | 8,39 | 5% | R |
| R01AA03 712 | Ephedrini rhinoguttae 0,50% 10 g | 8,43 | 5% | R |
| R01AA03 713 | Ephedrini rhinoguttae 1,00% 10 g | 9,91 | 5% | R |
| R05CA04 311 | Sirupi Ipecacuanhae 100 g | 19,6 | 5% | R |
| S01AX20 411 | Acidi borici solutio 1 % (p.o.) 10 g | 32,8 | 5% | R |
| S01AX20 412 | Acidi borici solutio 2 % (p.o.) 10 g | 32,81 | 5% | R |
| S01AX20 413 | Acidi borici solutio 3 % (p.o.) 10 g | 32,81 | 5% | R |
| S01EB01 711 | Pilocarpini solutio 1 % 10 ml | 37,04 | 5% | R |
| S01EB01 712 | Pilocarpini solutio 2 % 10 ml | 41,28 | 5% | R |
| S01FA01 711 | Atropini sulfati solutio 0,5% 10 ml | 34,3 | 5% | R |
| S01FA01 712 | Atropini sulfati solutio 1%, 10 ml | 35,79 | 5% | R |
| S01HA03 711 | Tetracaini hydrochloridi solutio 0,5 % 10 ml | 33,22 | 5% | R |
| S01XA04 711 | Natrij jodid 1% 5 ml | 32,93 | 5% | R |
| S02AA06 411 | Hydrogenii peroxydi solutio diluta 3% 20 g | 3,61 | 5% | R |
| S02AA31 712 | Resorcinoli 2% otoguttae 30 g | 8,6 | 5% | R |
| S02DC01 713 | Glyceroli otoguttae 30 g | 3,61 | 5% | R |

Osnovna lista magistralnih pripravaka s cijenama u eurima

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Šifra ATK | Naziv pripravka | Cijena u EUR za orig. pak. (bez PDV-a) | Stopa PDV-a | R/RS  DS |
| 1. | 2. | 3. | 4. | 5. |
| A09AB04 101 | Kalii citras 100,0 Natrii citras 100,0 Aqua purificata ad 1000,0 M.D.S. solutio DS. Na usta | 5,96 | 5% | RS |
| B05BA10 021 | Pedijatrijska parenteralna prehrana (TPN) vrećica 1x250 ml s priborom | 30,64 | 5% |  |
| B05BA10 022 | Pedijatrijska parenteralna prehrana (TPN) vrećica 1x500 ml s priborom | 27,43 | 5% |  |
| B05BA10 023 | Pedijatrijska parenteralna prehrana (TPN) vrećica 1x1.000 ml s priborom | 30,43 | 5% |  |
| B05BA10 024 | Pedijatrijska parenteralna prehrana (TPN) vrećica 1x2.000 ml s priborom | 39,22 | 5% |  |
| D01AE12 411 | Rp. Acidi salicilici 1,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 1,41 | 5% | R |
| D01AE12 412 | Rp. Acidi salicilici 2,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 1,42 | 5% | R |
| D01AE12 413 | Rp. Acidi salicilici 3,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 1,43 | 5% | R |
| D01AE12 414 | Rp. Acidi salicilici 2,0 Resorcioli 1,0 Aethanoli diluti ad 100,0 M.D.S. solutio | 1,50 | 5% | R |
| D01AE12 415 | Rp. Acidi salicilici 3,0 Resorcini 1,0 Aethanoli diluti ad 100,0 M.D.S. solutio | 1,51 | 5% | R |
| D02AB01 411 | Rp. Zinci oxydi pasta 25 g | 0,60 | 5% | R |
| D02AF01 421 | Rp. Acidi salicilici 0,5 Mentholi 0,2 Phenoli 0,3 Camphorae 0,5 Amigdalae olei 5,0 Zinci oxydi pastae ad 50,0 M.D.S. pasta | 3,12 | 5% | R |
| D02AX01 422 | Rp. Talci Zinci oxydi Glyceroli Aquae purificatae aa ad 100,0 M.D.S. izvana tekući puder bez anestezina | 3,00 | 5% | R |
| D04AA40 423 | Rp. Balsami peruviani 5,0 Vaselini ad 100,0 M.D.S. mast | 3,42 | 5% | R |
| D04AA40 424 | Rp. Balsami peruviani 10,0 Vaselini ad 100,0 M.D.S. mast | 3,80 | 5% | R |
| D04AA40 425 | Rp. Balsami peruviani 15,0 Vaselini ad 100,0 M.D.S. mast | 4,19 | 5% | R |
| D04AA40 426 | Rp. Balsami peruviani 20,0 Vaselini ad 100,0 M.D.S. mast | 4,57 | 5% | R |
| D04AX01 427 | Rp. Aethili aminobenzoatis (Anaesthesini) 5,0 Talci 20,0 Zinci oxydi 20,0 Glyceroli 20,0 Aquae purificatae 15,0 Aethanol. dil. 20,0 M.D.S. izvana tekući puder s anestezinom | 3,17 | 5% | R |
| D06BB04 411 | Rp. Podophylini 20,0 Aethanoli diluti ad 100,0 M.D.S. solutio | 35,43 | 5% | R |
| D06BB04 412 | Rp. Podophylini 5,0 Aethanoli diluti ad 25,0 M.D.S. solutio | 9,73 | 5% | R |
| D08AA01 411 | Rp. Rivanoli solutioae 0,1% (Aethacridini lactatis 0,1%) 300,0 D.S. za obloge | 1,51 | 5% | R |
| D08AA01 412 | Rp. Rivanoli (Aethacridini lactatis) 1,0 Talci Zinci oxydi Glyceroli aa 15,0 Aquae purificatae ad 100,0 M.D.S. mikstura | 3,22 | 5% | R |
| D08AX01 413 | Hydrogenii peroxydi solutio diluta 3% 100 g | 0,62 | 5% | R |
| D08AX08 411 | Aethanolum dilutum (70 vol.%) 200,0 M.D.S. izvana | 0,99 | 5% | R |
| D10AB02 414 | Rp. Ichtyoli (Ammonii sulfogirodalatis, Girodali) 5,0 Sulfuri praecipitati 2,5 Talci Zinci oxydi Glyceroli aa 15,0 Aquae purificatae ad 100,0 M.D.S. mikstura | 3,31 | 5% | R |
| D10AB02 415 | Rp. Ichtyoli (Ammonii sulfogirodalatis, Girodali) 10,0 Sulfuri praeciptati 5,0 Talci Zinci oxydi Glyceroli aa 15,0 Aquae purificatae ad 100,0 M.D.S. mikstura | 3,73 | 5% | R |
| D10AB02 421 | Rp. Sulfuri pracepitati 5,0 Vaselini ad 100,0 M.D.S. izvana | 3,09 | 5% | R |
| D10AB02 422 | Rp. Sulfuri pracepitati 10, 0 Vaselini ad 100,0 M.D.S. izvana | 3,16 | 5% | R |
| D10AB02 423 | Rp. Sulfuri pracepitati 15,0 Vaselini ad 100,0 M.D.S. izvana | 3,22 | 5% | R |
| D10AB02 424 | Rp. Sulfuri pracepitati 20, 0 Vaselini ad 100,0 M.D.S. izvana | 3,28 | 5% | R |
| D10AB08 425 | Rp. Sulfuri praecipitati Girodali (Ammonii sulfogyrodalatis, Ichtyoli) aa 0,6 Zinci oxydi pastae ad 50,0 M.D.S. pasta | 3,11 | 5% | R |
| D10AD02 426 | Rp. A vitaminae (Retinoli acetetati solutioae oleosae) 1000-10000 i.j./ g Cerae lanae 20, 0 Vaselini ad 100,0 M.D.S. mast | 4,32 | 5% | R |
| D10AF01 421 | Rp. Clindamycini 600 mg Propilenglycoli 10,0 -15,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 1,84 | 5% | R |
| D10AF02 422 | Rp. Erythromycini 2,0 Propilenglycoli 10,0 -15,0 Aethanoli diluti ad 100,0 M.D.S. izvana | 3,37 | 5% | R |
| D11AX03 423 | Rp. Calcii gluconatis 2,0 Talci 40,0 Olivae olei ad 100,0 M.D.S. mikstura | 3,56 | 5% | R |
| M05BB02 311 | Rp. Natrii phosphati monobasicae 54,7 Natrii phosphati dibasicae anhydricae 9,4 M.f. pulvis Divide in doses aequales No L (quinquaginta) D.S. 4x1 prašak | 7,48 | 5% | R |
| P03AC04 411 | Permethrin 2,5 Simulgel (Carbopol 940) 47,45 Pulvis conservans ad 50,0 M.D.S. gel | 6,15 | 5% | R |
| P03AC04 412 | Permethrin 0,5 Simulgel (Carbopol 940) 49,45 Pulvis conservans ad 50,0 M.D.S. gel | 4,78 | 5% | R |
| P03AX01 411 | Rp. Lanacoli 7,5 g Polysorbatum 80 7,5 g Benzyli benzoatis 37,5 g Aquae purificatae ad 150,0 g M.D.S. izvana | 4,98 | 5% | R |
| R01AA03 711 | Ephedrini rhinoguttae 0,25% 10 g | 1,11 | 5% | R |
| R01AA03 712 | Ephedrini rhinoguttae 0,50% 10 g | 1,12 | 5% | R |
| R01AA03 713 | Ephedrini rhinoguttae 1,00% 10 g | 1,32 | 5% | R |
| R05CA04 311 | Sirupi Ipecacuanhae 100 g | 2,60 | 5% | R |
| S01AX20 411 | Acidi borici solutio 1 % (p.o.) 10 g | 4,35 | 5% | R |
| S01AX20 412 | Acidi borici solutio 2 % (p.o.) 10 g | 4,35 | 5% | R |
| S01AX20 413 | Acidi borici solutio 3 % (p.o.) 10 g | 4,35 | 5% | R |
| S01EB01 711 | Pilocarpini solutio 1 % 10 ml | 4,92 | 5% | R |
| S01EB01 712 | Pilocarpini solutio 2 % 10 ml | 5,48 | 5% | R |
| S01FA01 711 | Atropini sulfati solutio 0,5% 10 ml | 4,55 | 5% | R |
| S01FA01 712 | Atropini sulfati solutio 1%, 10 ml | 4,75 | 5% | R |
| S01HA03 711 | Tetracaini hydrochloridi solutio 0,5 % 10 ml | 4,41 | 5% | R |
| S01XA04 711 | Natrij jodid 1% 5 ml | 4,37 | 5% | R |
| S02AA06 411 | Hydrogenii peroxydi solutio diluta 3% 20 g | 0,48 | 5% | R |
| S02AA31 712 | Resorcinoli 2% otoguttae 30 g | 1,14 | 5% | R |
| S02DC01 713 | Glyceroli otoguttae 30 g | 0,48 | 5% | R |